

NOVEL POLYPEPTIDES AND NUCLEIC ACIDS ENCODED THEREBY

RELATED APPLICATIONS

This application claims priority to U.S.S.N. 60/262,892, filed January 19, 2001; U.S.S.N. 60/263,598, filed January 23, 2001; U.S.S.N. 60/263,799, filed January 24, 2001; U.S.S.N. 60/264,117, filed January 25, 2001; U.S.S.N. 60/264,139, filed January 25, 2001; U.S.S.N. 60/264,478, filed January 26, 2001; U.S.S.N. 60/263,351, filed January 30, 2001; U.S.S.N. 60/272,870, filed March 2, 2001; U.S.S.N. 60/275,990, filed March 14, 2001; U.S.S.N. 60/275,927, filed March 14, 2001; U.S.S.N. 60/276,449, filed March 15, 2001; U.S.S.N. 60/277,358, filed March 20, 2001; U.S.S.N. 60/278,151, filed March 23, 2001; U.S.S.N. 60/279,857, filed March 29, 2001; U.S.S.N. 60/285,140, filed April 20, 2001; U.S.S.N. 60/285,141, filed April 20, 2001; U.S.S.N. 60/287,484, filed April 30, 2001; U.S.S.N. 60/291,701, filed May 17, 2001; U.S.S.N. 60/296,960, filed June 8, 2001; U.S.S.N. 60/304,353, filed July 10, 2001; U.S.S.N. 60/304,355, filed July 10, 2001; U.S.S.N. 60/304,886, filed July 12, 2001; U.S.S.N. 60/311,289, filed August 9, 2001; U.S.S.N. 60/311,975, filed August 13, 2001; U.S.S.N. 60/312,937, filed August 16, 2001; U.S.S.N. 60/330,227, filed October 18, 2001; and U.S.S.N. 60/334,198, filed November 29, 2001 each of which is incorporated by reference in its entirety.

BACKGROUND OF THE INVENTION

The invention relates to polynucleotides and the polypeptides encoded by such polynucleotides, as well as vectors, host cells, antibodies and recombinant methods for producing the polypeptides and polynucleotides, as well as methods for using the same.

SUMMARY OF THE INVENTION

The invention is based in part upon the discovery of nucleic acid sequences encoding novel polypeptides. The novel nucleic acids and polypeptides are referred to herein as NOVX, or NOV1, NOV2, NOV3, NOV4, NOV5, NOV6, NOV7, NOV8, NOV9, NOV10, NOV11, NOV12, NOV13, NOV14, NOV15, NOV16, NOV17, NOV18, NOV19, NOV20, NOV21,

NOV22, NOV23, NOV24, NOV25, NOV26, NOV27, NOV28, NOV29, NOV30, NOV31, NOV32, and NOV33 nucleic acids and polypeptides. These nucleic acids and polypeptides, as well as derivatives, homologs, analogs and fragments thereof, will hereinafter be collectively designated as “NOVX” nucleic acid or polypeptide sequences.

5 In one aspect, the invention provides an isolated NOVX nucleic acid molecule encoding a NOVX polypeptide that includes a nucleic acid sequence that has identity to the nucleic acids disclosed in SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, and 122. In
10 some embodiments, the NOVX nucleic acid molecule will hybridize under stringent conditions to a nucleic acid sequence complementary to a nucleic acid molecule that includes a protein-coding sequence of a NOVX nucleic acid sequence. The invention also includes an isolated nucleic acid that encodes a NOVX polypeptide, or a fragment, homolog, analog or derivative thereof. For example, the nucleic acid can encode a polypeptide at least 80% identical to a
15 polypeptide comprising the amino acid sequences of SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, and 123. The nucleic acid can be, for example, a genomic DNA fragment or a cDNA molecule that includes the nucleic acid sequence of any of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15,
20 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, and 122.

Also included in the invention is an oligonucleotide, *e.g.*, an oligonucleotide which includes at least 6 contiguous nucleotides of a NOVX nucleic acid (*e.g.*, SEQ ID NOS:1, 3, 5, 7,
25 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, and 122) or a complement of said oligonucleotide. Also included in the invention are substantially purified NOVX polypeptides (SEQ ID NOS:2, 4, 6, 8,
30 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, and 123). In certain embodiments, the NOVX polypeptides

include an amino acid sequence that is substantially identical to the amino acid sequence of a human NOVX polypeptide.

The invention also features antibodies that immunoselectively bind to NOVX polypeptides, or fragments, homologs, analogs or derivatives thereof.

5 In another aspect, the invention includes pharmaceutical compositions that include therapeutically- or prophylactically-effective amounts of a therapeutic and a pharmaceutically-acceptable carrier. The therapeutic can be, *e.g.*, a NOVX nucleic acid, a NOVX polypeptide, or an antibody specific for a NOVX polypeptide. In a further aspect, the invention includes, in one or more containers, a therapeutically- or prophylactically-effective amount of this
10 pharmaceutical composition.

In a further aspect, the invention includes a method of producing a polypeptide by culturing a cell that includes a NOVX nucleic acid, under conditions allowing for expression of the NOVX polypeptide encoded by the DNA. If desired, the NOVX polypeptide can then be recovered.

15 In another aspect, the invention includes a method of detecting the presence of a NOVX polypeptide in a sample. In the method, a sample is contacted with a compound that selectively binds to the polypeptide under conditions allowing for formation of a complex between the polypeptide and the compound. The complex is detected, if present, thereby identifying the NOVX polypeptide within the sample.

20 The invention also includes methods to identify specific cell or tissue types based on their expression of a NOVX.

Also included in the invention is a method of detecting the presence of a NOVX nucleic acid molecule in a sample by contacting the sample with a NOVX nucleic acid probe or primer, and detecting whether the nucleic acid probe or primer bound to a NOVX nucleic acid molecule
25 in the sample.

In a further aspect, the invention provides a method for modulating the activity of a NOVX polypeptide by contacting a cell sample that includes the NOVX polypeptide with a compound that binds to the NOVX polypeptide in an amount sufficient to modulate the activity of said polypeptide. The compound can be, *e.g.*, a small molecule, such as a nucleic acid,
30 peptide, polypeptide, peptidomimetic, carbohydrate, lipid or other organic (carbon containing) or inorganic molecule, as further described herein.

Also within the scope of the invention is the use of a therapeutic in the manufacture of a medicament for treating or preventing disorders or syndromes including, *e.g.*, trauma, regeneration (in vitro and in vivo), viral/bacterial/parasitic infections, Von Hippel-Lindau (VHL) syndrome, Alzheimer's disease, stroke, tuberous sclerosis, hypercalcaemia, Parkinson's disease, Huntington's disease, cerebral palsy, epilepsy, Lesch-Nyhan syndrome, multiple sclerosis, ataxia-telangiectasia, leukodystrophies, behavioral disorders, addiction, anxiety, pain, actinic keratosis, acne, hair growth diseases, alopecia, pigmentation disorders, endocrine disorders, connective tissue disorders, such as severe neonatal Marfan syndrome, dominant ectopia lentis, familial ascending aortic aneurysm, inflammatory disorders such as osteo- and rheumatoid-arthritis, inflammatory bowel disease, Crohn's disease, immunological disorders, AIDS, cancers including but not limited to lung cancer, colon cancer, neoplasm, adenocarcinoma, lymphoma, prostate cancer, uterus cancer, leukemia or pancreatic cancer, blood disorders, asthma, psoriasis, vascular disorders, hypertension, skin disorders, renal disorders including Alport syndrome, immunological disorders, tissue injury, fibrosis disorders, bone diseases, osteogenesis imperfecta, Neurologic diseases, brain and/or autoimmune disorders like encephalomyelitis, neurodegenerative disorders, immune disorders, hematopoietic disorders, muscle disorders, inflammation and wound repair, bacterial, fungal, protozoal and viral infections (particularly infections caused by HIV-1 or HIV-2), pain, acute heart failure, hypotension, hypertension, urinary retention, osteoporosis, angina pectoris, myocardial infarction, ulcers, benign prostatic hypertrophy, arthrogryposis multiplex congenita, keratoconus, scoliosis, pancreatitis, obesity systemic lupus erythematosus, emphysema, scleroderma, allergy, ards, neuroprotection, fertility myasthenia gravis, diabetes, obesity, growth and reproductive disorders, hemophilia, hypercoagulation, immunodeficiencies, graft versus host, congenital adrenal hyperplasia, endometriosis, xerostomia, ulcers, cirrhosis, transplantation, diverticular disease, hirschsprung's disease, appendicitis, tendinitis, renal artery stenosis, interstitial nephritis, glomerulonephritis, polycystic kidney disease, erythematosus, renal tubular acidosis, IgA nephropathy, anorexia, bulimia, psychotic disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease and/or other pathologies and disorders of the like.

The therapeutic can be, *e.g.*, a NOVX nucleic acid, a NOVX polypeptide, or a NOVX-specific antibody, or biologically-active derivatives or fragments thereof.

For example, the compositions of the present invention will have efficacy for treatment of patients suffering from the diseases and disorders disclosed above and/or other pathologies and disorders of the like. The polypeptides can be used as immunogens to produce antibodies specific for the invention, and as vaccines. They can also be used to screen for potential agonist and antagonist compounds. For example, a cDNA encoding NOVX may be useful in gene therapy, and NOVX may be useful when administered to a subject in need thereof. By way of non-limiting example, the compositions of the present invention will have efficacy for treatment of patients suffering from the diseases and disorders disclosed above and/or other pathologies and disorders of the like.

The invention further includes a method for screening for a modulator of disorders or syndromes including, *e.g.*, the diseases and disorders disclosed above and/or other pathologies and disorders of the like. The method includes contacting a test compound with a NOVX polypeptide and determining if the test compound binds to said NOVX polypeptide. Binding of the test compound to the NOVX polypeptide indicates the test compound is a modulator of activity, or of latency or predisposition to the aforementioned disorders or syndromes.

Also within the scope of the invention is a method for screening for a modulator of activity, or of latency or predisposition to disorders or syndromes including, *e.g.*, the diseases and disorders disclosed above and/or other pathologies and disorders of the like by administering a test compound to a test animal at increased risk for the aforementioned disorders or syndromes.

The test animal expresses a recombinant polypeptide encoded by a NOVX nucleic acid. Expression or activity of NOVX polypeptide is then measured in the test animal, as is expression or activity of the protein in a control animal which recombinantly-expresses NOVX polypeptide and is not at increased risk for the disorder or syndrome. Next, the expression of NOVX polypeptide in both the test animal and the control animal is compared. A change in the activity of NOVX polypeptide in the test animal relative to the control animal indicates the test compound is a modulator of latency of the disorder or syndrome.

In yet another aspect, the invention includes a method for determining the presence of or predisposition to a disease associated with altered levels of a NOVX polypeptide, a NOVX nucleic acid, or both, in a subject (*e.g.*, a human subject). The method includes measuring the amount of the NOVX polypeptide in a test sample from the subject and comparing the amount of the polypeptide in the test sample to the amount of the NOVX polypeptide present in a control

sample. An alteration in the level of the NOVX polypeptide in the test sample as compared to the control sample indicates the presence of or predisposition to a disease in the subject. Preferably, the predisposition includes, *e.g.*, the diseases and disorders disclosed above and/or other pathologies and disorders of the like. Also, the expression levels of the new polypeptides of the invention can be used in a method to screen for various cancers as well as to determine the stage of cancers.

In a further aspect, the invention includes a method of treating or preventing a pathological condition associated with a disorder in a mammal by administering to the subject a NOVX polypeptide, a NOVX nucleic acid, or a NOVX-specific antibody to a subject (*e.g.*, a human subject), in an amount sufficient to alleviate or prevent the pathological condition. In preferred embodiments, the disorder, includes, *e.g.*, the diseases and disorders disclosed above and/or other pathologies and disorders of the like.

In yet another aspect, the invention can be used in a method to identify the cellular receptors and downstream effectors of the invention by any one of a number of techniques commonly employed in the art. These include but are not limited to the two-hybrid system, affinity purification, co-precipitation with antibodies or other specific-interacting molecules.

NOVX nucleic acids and polypeptides are further useful in the generation of antibodies that bind immuno-specifically to the novel NOVX substances for use in therapeutic or diagnostic methods. These NOVX antibodies may be generated according to methods known in the art, using prediction from hydrophobicity charts, as described in the "Anti-NOVX Antibodies" section below. The disclosed NOVX proteins have multiple hydrophilic regions, each of which can be used as an immunogen. These NOVX proteins can be used in assay systems for functional analysis of various human disorders, which will help in understanding of pathology of the disease and development of new drug targets for various disorders.

The NOVX nucleic acids and proteins identified here may be useful in potential therapeutic applications implicated in (but not limited to) various pathologies and disorders as indicated below. The potential therapeutic applications for this invention include, but are not limited to: protein therapeutic, small molecule drug target, antibody target (therapeutic, diagnostic, drug targeting/cytotoxic antibody), diagnostic and/or prognostic marker, gene therapy (gene delivery/gene ablation), research tools, tissue regeneration in vivo and in vitro of all tissues and cell types composing (but not limited to) those defined here.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In the case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

Other features and advantages of the invention will be apparent from the following detailed description and claims.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides novel nucleotides and polypeptides encoded thereby. Included in the invention are the novel nucleic acid sequences and their encoded polypeptides. The sequences are collectively referred to herein as "NOVX nucleic acids" or "NOVX polynucleotides" and the corresponding encoded polypeptides are referred to as "NOVX polypeptides" or "NOVX proteins." Unless indicated otherwise, "NOVX" is meant to refer to any of the novel sequences disclosed herein. Table A provides a summary of the NOVX nucleic acids and their encoded polypeptides.

TABLE A. Sequences and Corresponding SEQ ID Numbers

NOVX Assignment	Internal Identification	SEQ ID NO (nucleic acid)	SEQ ID NO (polypeptide)	Homology
1	CG56181-01	1	2	Neurotrophin-6 alpha
2	CG56275-01	3	4	Guanylate kinase
3	CG53400-01	5	6	85.6 kDa protein
4a	CG56209-01	7	8	Myotonic dystrophy kinase-related CDC42-binding kinase
4b	CG56209-02	9	10	Myotonic dystrophy kinase-related CDC42-binding kinase
5	CG56288-01	11	12	S100 Calcium binding protein
6	CG56048-01	13	14	Olfactory receptor/GPCR
7a	CG50365-01	15	16	Carbonate dehydratase
7b	CG50365-02	17	18	Carbonate dehydratase
8a	CG55794-01	19	20	carboxypeptidase
8b	CG55794-03	21	22	carboxypeptidase
8c	CG55794-06	23	24	carboxypeptidase-B
8d	CG55794-07	25	26	carboxypeptidase-B

9	CG56463-01	27	28	Neurotransmitter receptor
10	CG56321-01	29	30	Proto-oncogene MAF
11a	CG56381-01	31	32	Lysyl oxidase
11b	CG56381-02	33	34	Lysyl oxidase
12a	CG56436-01	35	36	phosphatase
12b	CG56436-02	37	38	phosphatase
13	CG56441-01	39	40	Chloride Channel protein CLC-KA
14	CG56442-01	41	42	Mast cell function associated antigen (MAFA)
15a	CG56449-01	43	44	MEGF6
15b	CG56449-02	45	46	MEGF6
15c	CG56449-03	47	48	MEGF6
15d	CG56449-04	49	50	MEGF6
15e	CG56449-06	51	52	MEGF6
15f	CG56449-08	53	54	MEGF6
16	AL359846 A da1	55	56	GPCR
17a	CG56459-01	57	58	PEST-containing transporter
17b	CG56459-02	59	60	Na ⁺ independent aromatic amino acid transporter
18a	CG56510-01	61	62	Olfactory receptor/GPCR
18b	CG56510-02	63	“	Olfactory receptor/GPCR
19a	CG56574-01	64	65	Major Duchenne muscular dystrophy protein (DP71)
19b	CG56574-02	66	67	Major Duchenne muscular dystrophy protein (DP71)
20a	CG56517-01	68	69	GPCR RTA
20b	CG56517-02	70	71	GPCR RTA
21	CG56500-01	72	73	TFIIIC box B-binding subunit
22	CG56475-01	74	75	Nucleosidediphosphate kinase B
23	CG56352-02	76	77	T-cell
24a	CG56062-01	78	79	Organic anion transporter 3
24b	CG56062-01	80	81	Renal organic anion transporter
25a	152736829	82	83	Ficolin
25b	CG56653-02	84	85	Ficolin
25c	CG56653-03	86	87	Ficolin
25d	CG56653-04	88	89	Ficolin
25e	CG56653-06	90	91	Ficolin
25f	CG56653-01	92	93	Ficolin
25g	CG56653-09	94	95	Ficolin
25h	169319361	96	97	Ficolin
26	152736833	98	99	Ficolin
27	CG56262-01	100	101	Peroxisomal Ca-dependent solute carrier
28	CG56559-01	102	103	Na ⁺ /glucose cotransporter
29a	CG56557-01	104	105	Na ⁺ /glucose cotransporter
29b	CG56557-02	106	107	Na ⁺ /glucose cotransporter
29c	CG56557-03	108	109	Na ⁺ /glucose cotransporter
29d	CG56557-04	110	111	Na ⁺ /glucose cotransporter
29e	CG56557-05	112	113	Na ⁺ /glucose cotransporter
29f	CG56557-06	114	115	Na ⁺ /glucose cotransporter
30	CG56398-01	116	117	Na ⁺ /glucose cotransporter
31	CG56616-01	118	119	Olfactory receptor/GPCR
32	153065222 (or CG56234-02)	120	121	Phosphoenolpyruvate Carboxykinase

33	CG56610-01	122	123	Olfactory receptor/GPCR
----	------------	-----	-----	-------------------------

NOVX nucleic acids and their encoded polypeptides are useful in a variety of applications and contexts. The various NOVX nucleic acids and polypeptides according to the invention are useful as novel members of the protein families according to the presence of domains and sequence relatedness to previously described proteins. Additionally, NOVX nucleic acids and polypeptides can also be used to identify proteins that are members of the family to which the NOVX polypeptides belong.

NOV1 is homologous to members of the neurotrophin-6 alpha family of proteins. Thus, the NOV1 nucleic acid and polypeptide, antibodies and related compounds according to the invention may be used to treat immune and nervous system disorders, *e.g.*, proinflammatory disorder, immune disorder, inflammatory disease, septic shock, arthritis, bone pain, or bone deformity.

NOV2 is homologous to members of the guanylate kinase family of proteins. Thus, the NOV2 nucleic acid and polypeptide, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications in the mediation of biosynthesis and nucleotide metabolism. As such the NOV2 nucleic acid and polypeptide, antibodies and related compounds according to the invention may be used to treat genetic conditions, *e.g.*, Von Hippel-Lindau (VHL) syndrome, diabetes, or tuberous sclerosis.

NOV3 is homologous to members of a family of the 85.6 kDa-like proteins that contain ankyrin domains. Thus NOV3 nucleic acid and polypeptide, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications in the mediation of signal transduction or cell activation. As such the NOV3 nucleic acid and polypeptide, antibodies and related compounds according to the invention may be used to treat genetic conditions, *e.g.*, endometriosis, fertility, adrenoleukodystrophy, congenital adrenal hyperplasia, diabetes, Von Hippel-Lindau (vhl) syndrome, pancreatitis, obesity, hyperparathyroidism, hypoparathyroidism, hyperthyroidism, hypothyroidism, SIDS, xerostomia, scleroderma, hypercalcaemia, ulcers, cirrhosis, transplantation, inflammatory bowel disease, diverticular disease, hirschsprung's disease, crohn's disease, appendicitis, hemophilia, hypercoagulation, idiopathic thrombocytopenic purpura, autoimmune disease, allergies, immunodeficiencies, graft versus host, anemia, ataxia-telangiectasia, lymphedema, tonsillitis, osteoporosis, hypercalcaemia, arthritis, ankylosing spondylitis, scoliosis, tendinitis, muscular

dystrophy, lesch-nyhan syndrome, myasthenia gravis, dental disease and infection, cardiomyopathy, atherosclerosis, hypertension, congenital heart defects, aortic stenosis, atrial septal defect (asd), atrioventricular (a-v) canal defect, ductus arteriosus, pulmonary stenosis, subaortic stenosis, ventricular septal defect (vsd), valve diseases, tuberous sclerosis, aneurysm, fibromuscular dysplasia, stroke, bleeding disorders, alzheimer's disease, parkinson's disease, huntington's disease, cerebral palsy, epilepsy, multiple sclerosis, ataxia-telangiectasia, leukodystrophies, behavioral disorders, addiction, anxiety, pain, neuroprotection, endocrine dysfunctions, growth and reproductive disorders, cystitis, incontinence, renal artery stenosis, interstitial nephritis, glomerulonephritis, polycystic kidney disease, systemic lupus erythematosus, renal tubular acidosis, iga nephropathy, or vesicoureteral reflux.

NOV4 is homologous to members of the myotonic dystrophy kinase-related CDC42-binding kinase family of proteins. Thus, the NOV4 nucleic acids and polypeptides, antibodies and related compounds according to the invention may be used to treat muscle, or cell migration disorders, *e.g.*, myotonic dystrophy, myotonic dystrophy type 2, proximal myotonic myopathy, proximal myotonic dystrophy, neuromuscular diseases associated with cardiomyopathy, multiple endocrine neoplasia type 1(MEN1), insulin dependent diabetes mellitus, familial paraganglioma type 2, spinocerebellar ataxia type 5, Bardet-Biedl syndrome, non-hodgkins lymphoma, cancers such as breast cancer, liver, lung, pancreas, and prostate cancers.

NOV5 is homologous to members of the S100 Calcium binding protein family. Thus, the NOV5 nucleic acid and polypeptide, antibodies and related compounds according to the invention may be used to treat genetic conditions, *e.g.*, various cancers like breast, lung, and colorectal, as well as heart disease such as myocardial ischemia.

NOV6, NOV16, NOV18, NOV31, and NOV33 are homologous to the olfactory receptor/GPCR-like family of proteins. G-Protein Coupled Receptor (GPCRs) have been identified as an extremely large family of protein receptors in a number of species. Thus, the NOV6 nucleic acid and polypeptide, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications in the mediation of signal transduction. As such the NOV6 nucleic acid and polypeptide, antibodies and related compounds according to the invention may be used to treat, *e.g.*, developmental diseases, MHC II and III diseases (immune diseases), taste and scent detectability disorders, Burkitt's lymphoma, corticoneurogenic disease, signal transduction pathway disorders, retinal diseases including those

involving photoreception, cell growth rate disorders, cell shape disorders, feeding disorders, control of feeding, potential obesity due to over-eating, potential disorders due to starvation (lack of appetite), noninsulin-dependent diabetes mellitus (NIDDM1), bacterial, fungal, protozoal and viral infections (particularly infections caused by HIV-1 or HIV-2), pain, cancer (including but not limited to neoplasm, adenocarcinoma, lymphoma, prostate cancer, uterus cancer), anorexia, bulimia, asthma, parkinson's disease, acute heart failure, hypotension, hypertension, urinary retention, osteoporosis, crohn's disease, multiple sclerosis, and treatment of albright hereditary osteodystrophy, angina pectoris, myocardial infarction, ulcers, asthma, allergies, benign prostatic hypertrophy, and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation, dentatorubro-pallidolusian atrophy(DRPLA) hypophosphatemic rickets, autosomal dominant (2) acrocallosal syndrome and dyskinesias, such as huntington's disease or gilles de la tourette syndrome.

NOV7 is homologous to members of the carbonate dehydratase/anhydrase family of proteins. As such the NOV7 nucleic acids and polypeptides, antibodies and related compounds according to the invention may be used to treat respiratory or CO2 transport disorders, *e.g.*, lung cancer, hypertension, asthma, emphysema, or diabetes.

NOV8 is homologous to members of the carboxypeptidase family of proteins. Thus, the NOV8 nucleic acids and polypeptides, antibodies and related compounds according to the invention may be used to treat digestive disorders, *e.g.*, xerostomia, hypercalceimia, ulcers, Von Hippel-Lindau (VHL) syndrome, cirrhosis, transplantation, inflammatory bowel disease, diverticular disease, hirschsprung's disease, crohn's disease, appendicitis, stroke, tuberous sclerosis, anxiety, pain, endocrine dysfunctions, nueroprotection, diabetes, obesity, growth and reproductive disorders, myasthenia gravis.

NOV9 is homologous to members of the neurotransmitter receptor family of proteins. Thus, the NOV9 nucleic acid and polypeptide, antibodies and related compounds according to the invention may be used to treat, *e.g.*, leukemia, acute nonlymphocytic, spinocerebellar ataxia-1, or neurological disorders.

NOV10 is homologous to members of the proto-oncogene MAF-like family of proteins. Thus, the NOV10 nucleic acid and polypeptide, antibodies and related compounds according to the invention may be used to treat, *e.g.*, anemia, ataxia-telangiectasia, autoimmune disease, cancer, immunodeficiencies, hemophilia, hypercoagulation, idiopathic thrombocytopenic

purpura, allergies, transplantation, graft versus host disease (GVHD), lymphoedema, systemic lupus erythematosus, asthma, emphysema, scleroderma, ARDS, diabetes, renal artery stenosis, interstitial nephritis, glomerulonephritis, polycystic kidney disease, systemic lupus erythematosus, renal tubular acidosis, IgA nephropathy, hypercalcaemia, or Lesch-Nyhan syndrome.

NOV11 is homologous to members of the lysyl oxidase family of proteins. Thus, the NOV11 nucleic acids and polypeptides, antibodies and related compounds according to the invention may be used to treat digestive disorders, *e.g.*, diabetes, Von Hippel-Lindau (VHL) syndrome, pancreatitis, obesity, endometriosis, fertility, hemophilia, hypercoagulation, idiopathic thrombocytopenic purpura, autoimmune disease, allergies, immunodeficiencies, transplantation, graft versus host disease (GVHD), lymphoedema, osteoporosis, hypercalcaemia, arthritis, ankylosing spondylitis, scoliosis, systemic lupus erythematosus, asthma, emphysema, scleroderma, allergy, ARDS, renal artery stenosis, interstitial nephritis, glomerulonephritis, polycystic kidney disease, systemic lupus erythematosus, renal tubular acidosis, IgA nephropathy, Lesch-Nyhan syndrome, psoriasis, actinic keratosis, tuberous sclerosis, acne, hair growth/loss, alopecia, pigmentation disorders, and endocrine disorders.

NOV12 is homologous to members of the phosphatase family of proteins. Thus, the NOV12 nucleic acids and polypeptides, antibodies and related compounds according to the invention may be used to treat, *e.g.*, hyperthyroidism, hypothyroidism, endometriosis, fertility, Von Hippel-Lindau (VHL) syndrome, cirrhosis, transplantation, hypogonadism, Alzheimer's disease, stroke, tuberous sclerosis, hypercalcaemia, Parkinson's disease, Huntington's disease, cerebral palsy, epilepsy, Lesch-Nyhan syndrome, multiple sclerosis, ataxia-telangiectasia, leukodystrophies, behavioral disorders, addiction, anxiety, pain, neurodegeneration, endocrine dysfunctions, diabetes, obesity, growth and reproductive disorders, systemic lupus erythematosus, autoimmune disease, asthma, emphysema, scleroderma, allergy, ARDS, renal artery stenosis, interstitial nephritis, glomerulonephritis, polycystic kidney disease, renal tubular acidosis, IgA nephropathy, hemophilia, hypercoagulation, idiopathic thrombocytopenic purpura, immunodeficiencies, and graft versus host disease.

NOV13 is homologous to members of the chloride channel CLC-KA family of proteins. Thus, the NOV13 nucleic acid and polypeptide, antibodies and related compounds according to the invention may be used to treat, *e.g.*, diabetes, autoimmune disease, renal artery stenosis,

interstitial nephritis, glomerulonephritis, polycystic kidney disease, systemic lupus erythematosus, renal tubular acidosis, IgA nephropathy, hypercalcaemia, or Lesch-Nyhan syndrome.

NOV14 is homologous to members of the mast cell function-associated antigen (MAFA) family of proteins. Thus, the NOV14 nucleic acid and polypeptide, antibodies and related compounds according to the invention may be used to treat, *e.g.*, cancer, autoimmune disease, allergies, immunodeficiencies, transplantation, graft versus host disease (GVHD), or lymphoedema.

NOV15 is homologous to members of the murine epithelial growth factor (MEGF) family of proteins. Thus, the NOV15 nucleic acids and polypeptides, antibodies and related compounds according to the invention may be used to treat, *e.g.*, cancer, trauma, bacterial and viral infections, regeneration (in vitro and in vivo), fertility, endometriosis, cardiomyopathy, atherosclerosis, hypertension, congenital heart defects, aortic stenosis, atrial septal defect (ASD), atrioventricular (A-V) canal defect, ductus arteriosus, pulmonary stenosis, subaortic stenosis, ventricular septal defect (VSD), valve diseases, tuberous sclerosis, scleroderma, obesity, transplantation, anemia, bleeding disorders, transplantation, diabetes, autoimmune disease, renal artery stenosis, interstitial nephritis, glomerulonephritis, polycystic kidney disease, systemic lupus erythematosus, renal tubular acidosis, IgA nephropathy, hypercalcaemia, Lesch-Nyhan syndrome, systemic lupus erythematosus, autoimmune disease, asthma, emphysema, allergy, ARDS, von Hippel-Lindau (VHL) syndrome, Alzheimer's disease, stroke, hypercalcaemia, Parkinson's disease, Huntington's disease, cerebral palsy, epilepsy, Lesch-Nyhan syndrome, multiple sclerosis, ataxia-telangiectasia, leukodystrophies, behavioral disorders, addiction, anxiety, pain, neurodegeneration, Hirschsprung's disease, Crohn's Disease, and appendicitis.

NOV17 is homologous to members of the monocarboxylate transporter (MCT)-like family of proteins. Thus, the NOV17 nucleic acids and polypeptides, antibodies and related compounds according to the invention may be used to treat, *e.g.*, Salla disease, infantile sialic acid storage disease, cystinosis, or streptozotocin-induced diabetes.

NOV19 is homologous to members of the major Duchenne muscular dystrophy (DP71) family of proteins. Thus, the NOV19 nucleic acids and polypeptides, antibodies and related compounds according to the invention may be used to treat muscle and nervous system

disorders, *e.g.*, Duchenne muscular dystrophy, Becker muscular dystroph, cardiomyopathy, dilated, X-linked, McLeod phenotype, Lesch-Nyhan syndrome, myasthenia gravis.

NOV20 is homologous to members of the GPCR RTA family of proteins. Thus, the NOV20 nucleic acids and polypeptides, antibodies and related compounds according to the invention may be used to treat a wide range of disorders such as cancer, immune disorders, endocrine disorders and other diseases, *e.g.*, developmental diseases; MHCII and III diseases (immune diseases); taste and scent detectability disorders; Burkitt's lymphoma; corticoneurogenic disease; signal transduction pathway disorders; metabolic pathway disorders; retinal diseases including those involving photoreception; cell growth rate disorders; cell shape disorders; metabolic disorders; feeding disorders; control of feeding; the metabolic syndrome X; wasting disorders associated with chronic diseases; obesity; potential obesity due to over-eating or metabolic disturbances; potential disorders due to starvation (lack of appetite); diabetes; noninsulin-dependent diabetes mellitus (NIDDM); infectious disease; bacterial, fungal, protozoal and viral infections (particularly infections caused by HIV-1 or HIV-2); pain; cancer (including but not limited to neoplasm; adenocarcinoma; lymphoma; prostate cancer; uterus cancer); cancer-associated cachexia; anorexia; bulimia; asthma; Parkinson's disease; acute heart failure; hypotension; hypertension; urinary retention; osteoporosis; Crohn's disease; multiple sclerosis; Albright Hereditary Osteodystrophy; angina pectoris; myocardial infarction; ulcers; allergies; benign prostatic hypertrophy; and psychotic and neurological disorders; including anxiety; schizophrenia; manic depression; delirium; dementia; neurodegenerative disorders; Alzheimer's disease; severe mental retardation; Dentatorubro-pallidoluysian atrophy (DRPLA); Hypophosphatemic rickets; autosomal dominant (2) Acrocallosal syndrome and dyskinesias, such as Huntington's disease or Gilles de la Tourette syndrome; immune disorders; Adrenoleukodystrophy; Congenital Adrenal Hyperplasia; Hemophilia; Hypercoagulation; Idiopathic thrombocytopenic purpura; autoimmune disease; immunodeficiencies; transplantation; Von Hippel-Lindau (VHL) syndrome; Stroke; Tuberous sclerosis; hypercalcaemia; Cerebral palsy; Epilepsy; Lesch-Nyhan syndrome; Ataxia-telangiectasia; Leukodystrophies; Behavioral disorders; Addiction; Neuroprotection; Cirrhosis; Transplantation; Systemic lupus erythematosus; Emphysema; Scleroderma; ARDS; Renal artery stenosis; Interstitial nephritis; Glomerulonephritis; Polycystic kidney disease; Systemic lupus erythematosus; Renal tubular acidosis; IgA nephropathy; Cardiomyopathy; Atherosclerosis;

Congenital heart defects; Aortic stenosis ; Atrial septal defect (ASD); Atrioventricular (A-V) canal defect; Ductus arteriosus; Pulmonary stenosis ; Subaortic stenosis; Ventricular septal defect (VSD); valve diseases; Scleroderma; fertility; Pancreatitis; Endocrine dysfunctions; Growth and reproductive disorders; Inflammatory bowel disease; Diverticular disease;
5 Leukodystrophies; Graft vesus host; Hyperthyroidism; Endometriosis; and hematopoietic disorders.

NOV21 is homologous to members of the TFIIC box B-binding subunit family of proteins. Thus, the NOV21 nucleic acids and polypeptides, antibodies and related compounds according to the invention may be used to treat cancer and viral infections, *e.g.*, TFIIC box B-
10 binding subunit protein is cleaved and inactivated by the poliovirus-encoded 3C protease during poliovirus infection (Shen *et al.*, Mol. Cell. Biol, 16: 4163-71 (1996)).

NOV22 is homologous to members of the nucleoside diphosphate kinase B family of proteins. Thus, the NOV22 nucleic acids and polypeptides, antibodies and related compounds according to the invention may be used to treat cancer, *e.g.*, atherosclerosis, aneurysm,
15 hypertension, fibromuscular dysplasia, stroke, scleroderma, obesity, transplantation, myocardial infarction, embolism, cardiovascular disorders, bypass surgery, fertility disorders, myasthenia gravis, leukodystrophies, pain, neuroprotection, systemic lupus erythematosus, autoimmune disease, asthma, emphysema, scleroderma, allergy, ARDS and other diseases, disorders and conditions of the like.

NOV23 is homologous to members of the T-cell family of proteins. Thus, the NOV23 nucleic acids and polypeptides, antibodies and related compounds according to the invention may be used to immune disorders, *e.g.*, inflammation, allergies, autoimmune disease, and
20 asthma.

NOV24 is homologous to members of the organic anion transporter (OAT) 3 family of
25 proteins. Thus, the NOV24 nucleic acids and polypeptides, antibodies and related compounds according to the invention may be used to treat a wide range of disorders such as cancer, kidney disorders, immune disorders and other diseases, *e.g.*, Von Hippel-Lindau (VHL) syndrome, Cirrhosis, Transplantation, Osteoporosis, Hypercalceimia, Arthritis, Ankylosing spondylitis, Scoliosis, Diabetes, Autoimmune disease, Renal artery stenosis, Interstitial nephritis,
30 Glomerulonephritis, Polycystic kidney disease, Systemic lupus erythematosus, Renal tubular acidosis, IgA nephropathy, Lesch-Nyhan syndrome renal malfunction, nephrotoxicity, disease

associated with cytotoxic drug, osteoporosis, osteopetrosis resistance, liver diseases, and heart diseases.

NOV25 and NOV26 are homologous to members of the ficolin family of proteins. Thus, such nucleic acid or protein therapeutics designed with the protein encoded for by NOV26 could function as an opsinin to target and eliminate bacteria by complement –mediated destruction. These proteins could be important for the treatment of bacterial septicemia. Ficolins may also have the ability to bind to elastins. Elastins are functionally important for lung alveolar development and inactivation of these proteins can lead to emphysema-like disease. Antibodies against NOV25 and NOV26 may prevent tissue destruction mediated by ficolin activity during emphysema, asthma and arthritis.

NOV27 is homologous to members of the peroxisomal Ca^{2+} -dependent solute carrier family of proteins. Thus, the NOV27 nucleic acids and polypeptides, antibodies and related compounds according to the invention may be used to treat metabolic disorders, *e.g.*, cancer, trauma, regeneration (*in vitro* and *in vivo*), viral/bacterial/parasitic infections, atherosclerosis, aneurysm, hypertension, fibromuscular dysplasia, stroke, scleroderma, obesity, Von Hippel-Lindau (VHL) syndrome, Alzheimer's disease, stroke, tuberous sclerosis, hypercalceimia, Parkinson's disease, Huntington's disease, cerebral palsy, epilepsy, Lesch-Nyhan syndrome, multiple sclerosis, ataxia-telangiectasia, leukodystrophies, behavioral disorders, addiction, anxiety, pain, diabetes, autoimmune disease, renal artery stenosis, interstitial nephritis, glomerulonephritis, polycystic kidney disease, systemic lupus erythematosus, renal tubular acidosis, IgA nephropathy, hypercalceimia, muscular dystrophy, Lesch-Nyhan syndrome, and myasthenia gravis.

NOV28, NOV29, and NOV30 are homologous to members of the Na^+ /glucose cotransporter family of proteins. Thus, the NOV28 nucleic acids and polypeptides, antibodies and related compounds according to the invention may be used to treat metabolic, immune and renal disorders, *e.g.*, metabolic diseases such as diabetes and hypertension, or cancer, trauma, regeneration (*in vitro* and *in vivo*), viral/bacterial/parasitic infections, diabetes, autoimmune disease, renal artery stenosis, interstitial nephritis, glomerulonephritis, polycystic kidney disease, systemic lupus erythematosus, renal tubular acidosis, IgA nephropathy, hypercalceimia, Lesch-Nyhan syndrome, cardiomyopathy, atherosclerosis, hypertension, congenital heart defects, aortic stenosis, atrial septal defect (ASD), atrioventricular (A-V) canal defect, ductus arteriosus,

pulmonary stenosis, subaortic stenosis, ventricular septal defect (VSD), valve diseases, tuberous sclerosis, scleroderma, obesity, transplantation and other diseases, disorders and conditions of the like.

NOV32 is homologous to members of the phosphoenolpyruvate carboxykinase family of proteins. Thus, the NOV32 nucleic acids and polypeptides, antibodies and related compounds according to the invention may be used to treat metabolic disorders, *e.g.*, hypoglycemia.

The NOVX nucleic acids and proteins of the invention, therefore, are useful in potential therapeutic applications implicated, for example but not limited to, in various pathologies /disorders as described herein and/or other pathologies/disorders. Potential therapeutic uses for the invention(s) are, for example but not limited to, the following: (i) a protein therapeutic, (ii) a small molecule drug target, (iii) an antibody target (therapeutic, diagnostic, drug targeting/cytotoxic antibody), (iv) a nucleic acid useful in gene therapy (gene delivery/gene ablation), (v) an agent promoting tissue regeneration in vitro and in vivo, and (vi) a biological defense weapon.

NOV1

The disclosed NOV1 nucleic acid (alternatively referred to herein as CG56181-01) encodes a novel neutrophin-6 alpha-like protein and includes the 796 nucleotide sequence (SEQ ID NO:1) shown in Table 1A. The novel NOV1 nucleic acid of the invention maps to chromosome 19.

An open reading frame for the mature protein was identified beginning with an AGC, but no start codon, and ending with a TGA stop codon at nucleotides 775-777. Putative untranslated regions, if any, are found upstream from the initiation codon and downstream from the termination codon. The start and stop codons are in bold letters.

Table 1A. NOV1 Nucleotide Sequence (SEQ ID NO:1)

AGCAAGGGCTTCCCCATAATCCTGGCAGGCAGGCCTCCCCTGGGGTTTCCAACCTCTGACCCCACTGAAGTGTTT ATCCTCTTCTCTAACCCAGCCTCCTTTTCCCTGTCTCCATGTGCTCTGAGAGATGCTCTGAGAGATGCTCCAC TCCCCAGGCTCCCTCTGCATCCCCCTCATTTTCTTCTCCCAAGTGTGTCAATGGAGTCCTGGCCCCACCCCTC TCGACATTGTACCTTTTCTGATCCAAAGTGGGACCTTCTTTTCCCCAAGTGGTCCTGTCTAGGGGTGCCGCT GCCGGGCCCCCTCTGGTCTTCTGCTGCAGACTGGGGCCTTTTGGGAGTCAGCAGGCGCCCGGGCCAAACCGCAGC CAGCGTGAGGCGAGCGATGCTTCACCGGCGAGTCATCAGGGTGAGCTGGCCGTGTGCGATGCAGTCAGTGTCTGG GTGACAGATCCCGGGACTGCTGTGGACTTGGTTGTGCTCGAGGTGGAGGTGTTGGGCGAGGTGCCTGCAGCTGTC GGCAGTTCCCTCCACCAACACTTCTTTGTTGCCCACTTCGAGGCCGATAACTCTGAGGAAGGTGGCCCCGGGGTA GGTGGAGGGGCTGCCCGGGGGTGTGGACCGGGGGGCACTGGGTGTCTGAGTGCAAGGCCAAGCAGTCCTATGTG

CGGGCATTGACCGCTGATGCCCAGGGCCGTGTGGACTGGCGATGGATTCAAATTGGCACTGCCTGTGTCTGCACA
CTCCTCAGCCGACTGGCCGGGCTGAGACCCATGCCCAGGAAGT

The NOV1 protein (SEQ ID NO:2) encoded by SEQ ID NO:1 is 258 amino acid residues in length and is presented using the one-letter amino acid code in Table 1B. The SignalP, Psort and/or Hydropathy results indicate that NOV1 has a signal peptide and is likely to be localized in the microbody (peroxisome) with a certainty of 0.5952. Alternatively, a NOV1 polypeptide is located to the cytoplasm with a certainty of 0.4500, the lysosome (lumen) with a certainty of 0.2100, or the mitochondrial matrix space with a certainty of 0.1000.

Table 1B. Encoded NOV1 Protein Sequence (SEQ ID NO:2)

SKGFPIILAGRPPLGFPTSDPTEVFILFSNPSSLFPVSMCSERCSERCSPRLPLHPPHFLPPQCVNGVLAPTL
STLSPPDPKWDLLFPQVLSRGAAAGPPLVFLLOTGAFWESAGARANRSQREASDASPASHQGELAVCDVSVW
VTDPGTAVDLVVLEVEVLGEVPAAVGSSSLHQHFFVAHFEADNSEEKGGPGVGGGAAAGVWTGGHWVSECKAKQSYV
RALTADAQGRVDWRWIIQIGTACVCTLLSRTGRA

A search against the Patp database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 1C.

Table 1C. PatP Results for NOV1

		High Score	Smallest Sum Prob P (N)
Sequences Producing High-Scoring Segment Pairs:			
patp:AAR22467	Neurotrophic factor 4-gamma - Homo sapiens	1175	3.8e-119
patp:AAR22466	Neurotrophic factor 4-beta - Homo sapiens	1047	1.4e-105
patp:AAR22468	Neurotrophic factor 4-delta - Homo sapiens	864	3.4e-86
patp:AAR29735	Human NT-4, encoded by clone 7-2	680	1.1e-66
patp:AAR30691	Human neurotrophin-4	678	1.8e-66

In a BLAST search of public sequence databases, it was found, for example, that the NOV1 nucleic acid sequence of this invention has 762 of 796 bases (95%) identical to a gb:GENBANK-ID:HUMNT4PSG|acc:M86529.1 mRNA from Human neurotrophin-4 pseudogene sequence. Further, the full amino acid sequence of the disclosed protein of the invention has 239 of 258 amino acid residues (92%) identical to, and 244 of 258 amino acid

residues (94%) similar to, the 257 amino acid residue ptmr:SWISSPROT-ACC:P34132 protein from Human (NEUROTROPHIN-6 ALPHA (NT-6 ALPHA)).

In all BLAST alignments herein, the "E-value" or "Expect" value is a numeric indication of the probability that the aligned sequences could have achieved their similarity to the BLAST query sequence by chance alone, within the database that was searched. For example, the probability that the subject ("Sbjct") retrieved from the IIT BLAST analysis, matched the Query IIT sequence purely by chance is the E value. The Expect value (E) is a parameter that describes the number of hits one can "expect" to see just by chance when searching a database of a particular size. It decreases exponentially with the Score (S) that is assigned to a match between two sequences. Essentially, the E value describes the random background noise that exists for matches between sequences. Blasting is performed against public nucleotide databases such as GenBank databases and the GeneSeq patent database. For example, BLASTX searching is performed against public protein databases, which include GenBank databases, SwissProt, PDB and PIR.

The Expect value is used as a convenient way to create a significance threshold for reporting results. The default value used for blasting is typically set to 0.0001. In BLAST 2.0, the Expect value is also used instead of the P value (probability) to report the significance of matches. For example, an E value of one assigned to a hit can be interpreted as meaning that in a database of the current size one might expect to see one match with a similar score simply by chance. An E value of zero means that one would not expect to see any matches with a similar score simply by chance. See, e.g., <http://www.ncbi.nlm.nih.gov/Education/BLASTinfo/>. Occasionally, a string of X's or N's will result from a BLAST search. This is a result of automatic filtering of the query for low-complexity sequence that is performed to prevent artifactual hits. The filter substitutes any low-complexity sequence that it finds with the letter "N" in nucleotide sequence (e.g., "NNNNNNNNNNNNNN") or the letter "X" in protein sequences (e.g., "XXXXXXXXXX"). Low-complexity regions can result in high scores that reflect compositional bias rather than significant position-by-position alignment. Wootton and Federhen, *Methods Enzymol* 266:554-571, 1996.

The NOV1 protein of the invention also has homolgy to the proteins shown in the BLASTP data in Table 1D.

		130	140	150	160	170	180				
	NOV1	GPPLVFLLOTGAFWESAGARANRSQREASDASPASHQ	GELAVC	-----	DAVSV	149					
5	Q96K94	DEKFNLLKLVIKPAKVTP	---APT	LQDF	TAAFP	RLMTTRGHGP	-----	AETQT	164		
	AAL35776	DKKLELKLDIKAAKVTP	---AQ	TAHGD	STTAS	PRTL	TERNG	-----	SETQT	164	
	AAL35774	DQKVTFSLQVKPEIPT	TRPPT	TRPT	ITRPT	ATGRPTT	ISTR	STHVPTS	SIRVSTSTPPT	STHT	177
	AAL35775	DQKVTFSLQVKPEIPT	TRPPR	PTT	TRPT	ATGRPTT	ISTR	STHVPT	STRVSTSTPPT	STHT	177
	O54947	DQKMTFSLQVKPEIPT	SPPT	TRPT	ITRPTT	-RETT	ISTR	STHVPT	STRVSTSTP	-IPEQT	175
10		190	200	210	220	230	240				
	NOV1	WVTDPG	-----	TAVDL	VVLE	VEVL	GEVPA	AVGSSLHCHFFVAH	187		
	Q96K94	LGSLPD	-----	INLTQ	ISTL	ANEL	RDSRL	ANDLRDSGATIRIG	202		
15	AAL35776	LVTLHN	-----	NNGTK	ISTW	ADEIK	DS	-----	GETIRTA	193	
	AAL35774	WTHKPEPTTFCPH	ETTAE	VTGIP	SHPT	PTDWN	GTVTSS	GDTWSNHT	EALPPGKPKQKNPTKG	237	
	AAL35775	WTHKP	-----	DWNGT	VTSS	GDTWSNHT	EALPPGKPKQKNPTKG	214			
	O54947	QTHKPEITTFYAH	ETTAE	VTET	PSYTP	ADWNGT	VTSS	EAWNHTVRIPLRKPQKNPTKG	235		
20		250	260	270	280	290	300				
	NOV1	FEADN	SEEGPGVGGGAAGVWVG	GHV	SECKAKQSYVR	ALTADAQGRVDWRW	IQGTAC	247			
	Q96K94	IYTCAG	CAGLALALIFGALIF	KWYSHSKEKIQNL	SLISLANLPPSGL	ANAVEGIRSEE	262				
	AAL35776	ITIGV	GVSACGLTLALII	GVILKWY	SCKKKLSSLSLITLANLPPGGL	ANAGAVRIRSEE	253				
	AAL35774	FYVGC	CTAA-LLLLLLVSTVA	ITRYILMKRKSASLS	VVAFRVSKIEALQNA	AAVVHSRAED	296				
25	AAL35775	FYVGC	CTAA-LLLLLLVSTVA	ITRYILMKRKSASLS	VVAFRVSKIEALQNA	AAVVHSRAED	273				
	O54947	FYVGM	SVAAL-LLLLLLASTVVV	TRYIIIRKKMGSL	SFVAFHVS	KSRALQNA	AIIVHPR	AED	294		
30		310	320	330							
	NOV1	VCTLL	SRTGRA	-----	258						
	Q96K94	NIYTI	EEENVYEVEE	PN	EYCYVSSRQQPSQPLGCRFAMP	301					
	AAL35776	NIYTI	EEENVYEVEN	SNEYYCYVNS-QQPS	-----	281					
	AAL35774	NIYI	VEDRP	-----	305						
	AAL35775	NIYI	VEDRP	-----	282						
35	O54947	NIYI	LEDRSRGAE	-----	307						

The presence of identifiable domains in the disclosed NOV1 protein was determined by using Pfam and then determining the Interpro number. The results are listed in Table 1F with the statistics and domain description.

Table 1F. Domain Analysis of NOV1		
PSSMs Producing Significant Alignments	Score (bits)	E Value
NGF: domain 1 of 2, from 133 to 184	70.6	1.5e-19

NGF	epvsrRGELSVCDsVsVWVTnDKttAvDirGkeVtVLgeVninngp.		
NOV1	SPASHQGELAVCDAVSVWVT-DPGTAVDLVVLEVEVLGEVPAAVGSS		
NGF	lKQYFF (SEQ ID NO:129)		
NOV1	LHQHFF (SEQ ID NO:2)		
NGF: domain 2 of 2, from 213 to 258		100.5	2.5e-28
NGF	HWnSeCkttqtYVRALTmdnnklVgWRfIRIDTACVctLsrKtGrT	(SEQ ID NO:130)	
NOV1	HWVSECKAKQSYVRALTADAQGRVDWRWIQIGTACVCTLLSRTGRA	(SEQ ID NO:2)	

Consistent with other known members of the neurotrophin family of proteins, NOV1 contains nerve growth factor domains as illustrated in Table 1F.

The NOV1 nucleic acid, and the encoded polypeptide, according to the invention are useful in a variety of applications and contexts. For example, NOV1 nucleic acids and polypeptides can be used to identify proteins that are members of the neurotrophin family of proteins. The NOV1 nucleic acids and polypeptides can also be used to screen for molecules, which inhibit or enhance NOV1 activity or function. Specifically, the nucleic acids and polypeptides according to the invention may be used as targets for the identification of small molecules that modulate or inhibit, *e.g.*, development and survival of certain sympathetic and sensory neurons in both the central and peripheral nervous systems. These molecules can be used to treat, *e.g.*, proinflammatory disorder, immune disorder, and inflammatory disease.

In addition, the NOV1 nucleic acid and polypeptide according to the invention are useful, *inter alia*, as novel members of the protein families according to the presence of domains and sequence relatedness to previously described proteins. For example, the NOV1 nucleic acid and polypeptide include structural motifs that are characteristic of proteins belonging to the family of nerve growth factors such as the neurotrophin proteins. Nerve growth factor (NGF) is the prototype for the neurotrophin family of polypeptides which are essential in the developments and survival of certain sympathetic and sensory neurons in both the central and peripheral nervous systems. NGF was discovered when mouse sarcoma tissue transplants in chicken embryos caused an increase in the size of spinal ganglia.

The NOV1 nucleic acid and polypeptide, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications in the mediation of the

peripheral and central nervous system. As such the NOV1 nucleic acid and polypeptide, antibodies and related compounds according to the invention may be used to treat immune and nervous system disorders, *e.g.*, proinflammatory disorder, immune disorder, inflammatory disease, septic shock, arthritis, bone pain, or bone deformity.

The NOV1 nucleic acid and polypeptide are useful for detecting specific cell types. For example, expression analysis has demonstrated that a NOV1 nucleic acid is expressed in placenta and uterus.

Additional utilities for the NOV1 nucleic acid and polypeptide according to the invention are disclosed herein.

NOV2

The disclosed NOV2 nucleic acid (alternatively referred to herein as CG56275-01) encodes a novel Guanylate kinase-like protein and includes the 1336 nucleotide sequence (SEQ ID NO:3) shown in Table 2A. The novel NOV2 nucleic acid of the invention maps to chromosome 2.

An open reading frame for the mature protein was identified beginning with an ATG initiation codon at nucleotides 3-5, and ending with a TGA stop codon at nucleotides 1326-1328. Putative untranslated regions, if any, are found upstream from the initiation codon and downstream from the termination codon. The start and stop codons are in bold letters.

Table 2A. NOV2 Nucleotide Sequence (SEQ ID NO:3)

CAATGAGGATTGTTTGTGTTAGTGAAAAACCAACAGCCCCTGGGAGCCACCATCAAGCGCCACGAGATGACAGGGG
ACATCTTGGTGGCCAGGATCATCCACGGTGGGCTGGCGGAGAGAAGTGGGTGCTATATGCTGGAGACAACTGG
TAGAAGTGAATGGAGTTTCAGTTGAGGGACTGGACCCTGAACAAGTGATCCATATTCTGGCCATGTCTCGAGGCA
CAATCATGTTCAAGGTGGTTCCAGTCTCTGACCCCTCCTGTGAATAGCCAGCAGATGGTAAGAATTGTGTACGTCC
GTGCCATGACTGAGTACTGGCCCCAGGAGGATCCCACATCCCCTGCATGGACGCTGGATTGCCTTTCCAGAAGG
GGGACATCCTCCAGATTGTGGACCAGAATGATGCCCTCTGGTGGCAGGCCCGAAAAATCTCAGACCCTGCTACCT
GCGCTGGGCTTGTCCTTCTAACCACCTTCTGAAGAGGAGGAAGCAACGGGAATTCTGGTGGTCTCAGCCGTACC
AGCCTCACACCTGCCTCAAGTCAACCCTACAACCTGAAGGAGGAGTTTGTGGCTACGGTCAGAAGTTCTTTATAG
GTAGGTCTACCTCAGCCCCTGCATGCCAGTGTGTGCTGCACCGGCAGCTGCTACAGTGCAGTGGGTGCCCTT
ACGAGGAGGTGGTGAGGTACCAGCGACGCCCTTCAGACAAGTACCGCCTCATAGTGCTCATGGGTATGTCCTTAG
GACCCCTCTGGTGTGGAGTAAATGAGCTCAGAAGACAACCTATTGAATTTAATCCAGCCATTTTCAAAGTGCTG
TGCCAACTACTCGTACTAAAAAGAGTTACGAAATGAATGGGCGTGAGTATCACTATGTGTCCAAGGAAACATTTG
AAAACCTCATATATAGTCAAGGAGGATGCTGGAGTATGGTGAGTACAAAGGCCACCTGTATGGCACTAGTGTGG
ATGCTGTTCAAACAGTCCTTGTGCAAGGAAAGATCTGTGTCATGGACCTAGAGCCTCAGAATATGAGGTGTATGA
AACATCTCGGAAAAATGCCAAGGTTATTACTGACTACTATGTGGACATGAAGTTCAAGGTAAGAGCAAGTCAAA
AACTAAAGGATGAAGACCTACAAGAGATGGAAAATTTAGCCCAAAGAATGGAACTCAGTTTGGCCAATTTTTTG
ATCATGTGATTGTGAATGACAGCTTGCACGATGCATGTGCCAGTTGTTGTCTGCCATACAGAAGGCTCAGGAGG

AGCCTCAGTGGGTACCAGCAACATGGATTTCTCAGATACTGAGTCTCAATGAGACTTCTT

The NOV2 protein (SEQ ID NO:4) encoded by SEQ ID NO:3 is 441 amino acid residues in length and is presented using the one-letter amino acid code in Table 2B. The SignalP, Psort and/or Hydropathy results indicates that NOV2 has a signal peptide and is likely to be localized in the microbody (peroxisome) with a certainty of 0.3000. Alternatively, a NOV2 polypeptide is located to the nucleus with a certainty of 0.3000, the mitochondrial matrix space with a certainty of 0.1000, or the lysosome (lumen) with a certainty of 0.1000.

Table 2B. Encoded NOV2 Protein Sequence (SEQ ID NO:4)

MRIVCLVKNQQPLGATIKRHEMTGDILVARI IHGGLAERSGLLYAGDKLVEVNGVSVEGLDPEQVIHILAMSRGT
IMFKVVPVSDPPVNSQQMVRI VYVRAMTEYWPQEDPDI PCMDAGLPFQKGDILQIVDQNDALWWQARKISDPATC
AGLVPSNHLLKRRKQREFWWSQPYQPHTCLKSTLQLKEEFVGYGQKFFIGRSHLSPLHASVCCTGSCYSAVGAPY
EEVVRYQRRPSDKYRLIVLMGMSLGP SGVGVNELRRQLIEFNPSHFQSAVPTTRTKKSYEMNGREYHYVSKETFE
NLIYSHRRMLEYGEYKGHLYGTSVDAVQTVLVEGKICVMDLEPQNMRCMKQSRKNAKVITDYYVDMKFKVRASQK
LKDEDLQEMENLAQRMETQFGQFFDHVIVNDSLHDACAQLLSAIQKAQEEPQWVPATWISSDTESQ

Small nucleotide polymorphisms (SNP) variants of NOV2 are disclosed in Example 2.

A search against the Patp database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 2C.

Table 2C. PatP Results for NOV2

Sequences Producing High-Scoring Segment Pairs:		High Score	Smallest Sum Prob P (N)
patp:AAE11774	Human kinase (PKIN)-8 protein	2074	2.1e-214
patp:AAU07123	Human novel human protein, NHP #23	823	7.6e-82
patp:AAU07119	Human novel human protein, NHP #19	775	9.3e-77
patp:AAU07115	Human novel human protein, NHP #15	713	3.5e-70
patp:AAU07111	Human novel human protein, NHP #11	709	9.2e-70

In a BLAST search of public sequence databases, it was found, for example, that the NOV2 nucleic acid sequence of this invention has 313 of 392 bases (79%) identical to a gb:GENBANK-ID:AB030499|acc:AB030499.1 mRNA from Rattus norvegicus (Rattus norvegicus mRNA for DLG6 alpha, complete cds). Further, the full amino acid sequence of the

		
	NOV2	-----	1
	Q96JB8	WLQALLKIYDCLQEFKEKKLVPA ¹³⁰ TPHAQVLSYEVV ¹⁴⁰ ELLRETPTSPEIQELRQMLQAPHFK ¹⁵⁰	120
	Q96Q44	WLQALLKIYDCLQEFKEKKLVPA ¹³⁰ TPHAQVLSYEVV ¹⁴⁰ ELLRETPTSPEIQELRQMLQAPHFK ¹⁵⁰	120
5	Q920P8	-----	1
	Q920P7	-----	1
	Q9QYH1	-----	1
		
10	NOV2	-----	29
	Q96JB8	ALLSAHDTIAQKDFEPLLPPLPDNIPES ¹³⁰ EEAMRIVCLVKNQQPLGATIKRHEMTGDILVA ¹⁴⁰	180
	Q96Q44	ALLSAHDTIAQKDFEPLLPPLPDNIPES ¹³⁰ EEAMRIVCLVKNQQPLGATIKRHEMTGDILVA ¹⁴⁰	180
	Q920P8	-----	29
15	Q920P7	-----	29
	Q9QYH1	-----	29
		
20	NOV2	R ¹⁹⁰ IIHGGLAERSGLLYAGDKLVEVNGVSVEGLDPEQVIHILAMSRGTIMFKVVPVSDPPVN ²⁰⁰	89
	Q96JB8	R ¹⁹⁰ IIHGGLAERSGLLYAGDKLVEVNGVSVEGLDPEQVIHILAMSRGTIMFKVVPVSDPPVN ²⁰⁰	240
	Q96Q44	R ¹⁹⁰ IIHGGLAERSGLLYAGDKLVEVNGVSVEGLDPEQVIHILAMSRGTIMFKVVPVSDPPVN ²⁰⁰	240
	Q920P8	R ¹⁹⁰ IIHGGLAERSGLLYAGDKLVEVNGVSVEGLDPEQVIHILAMSCGTIMFKVVPVSAPPVS ²⁰⁰	89
	Q920P7	R ¹⁹⁰ IIHGGLAERSGLLYAGDKLVEVNGVSVEGLDPEQVIHILAMSCGTIMFKVVPVSAPPVS ²⁰⁰	89
25	Q9QYH1	R ¹⁹⁰ IIHGGLAERSGLLYAGDKLVEVNGV ²⁰⁰ PEGLDPEQVIHILAMSCGTIMFKVVPVSAPPVS ²¹⁰	89
		
30	NOV2	SOQMVRIYVVRAMIDYWPQEDPDIPCMDAGLPFQKGDILQIVDQNDALWWQARKISDPAT ²⁵⁰	149
	Q96JB8	SOQMVRIYVVRAMIDYWPQEDPDIPCMDAGLPFQKGDILQIVDQNDALWWQARKISDPAT ²⁵⁰	297
	Q96Q44	SOQMVRIYVVRAMIDYWPQEDPDIPCMDAGLPFQKGDILQIVDQNDALWWQARKISDPAT ²⁵⁰	284
	Q920P8	SOQKMGVYVVRAMIDYWPQEDPDIPCMDAGLPFLKGDILQIVDQNDALWWQARKISDLTI ²⁵⁰	146
	Q920P7	SOQKMGVYVVRAMIDYWPQEDPDIPCMDAGLPFLKGDILQIVDQNDALWWQARKISDLTI ²⁵⁰	146
35	Q9QYH1	SQTTVYVVRAMIDYWPQEDPDIPCMDAGLPFLKGDILQIVDQNDALWWQARKISDLTI ²⁵⁰	146
		
40	NOV2	CAGLVPSNHLLKR-KQREFWWSQPYQPHTCLKSTLQ-----	185
	Q96JB8	CAGLVPSNHLLKR-KQREFWWSQPYQPHTCLKSTLSISMEEEEDMKIDEKCVEADEETFE	356
	Q96Q44	CAGLVPSNHLLKR-KQREFWWSQPYQPHTCLKSTL-----	318
	Q920P8	CAGLVPSNHLLKR-KQREFWWSQPYQPHTCLKSTRALSMEEEDSMKIDEKCVEADEETFE	205
	Q920P7	CAGLVPSNHLLKR-KQREFWWSQPYQPHTCLKSTR-----EDSMKIDEKCVEADEETFE	199
	Q9QYH1	CAGLVPSNHLLKR-KQREFWWSQPYQPHTCLKSTR-----	180
		
45	NOV2	-----	228
	Q96JB8	SEELSEDKEEFVGYGQKFFIAGFRRSMRLCRRKSHLSPLHASVCCTGSCYSAVGAPYEEV	416
	Q96Q44	-----YKEEFVGYGQKFFIAGFRRSMRLCRRKSHLSPLHASVCCTGSCYSAVGAPYEEV	372
50	Q920P8	SEELAEAKDEFVGDGQKFFIAGFRRSMRLCRRKSHFSQ ³⁷⁰ LHASLCCSCSCYSAVGAPYEEV ³⁸⁰	265
	Q920P7	SEELAEAKDEFVGDGQKFFIAGFRRSMRLCRRKSHFSQ ³⁷⁰ LHASLCCSCSCYSAVGAPYEEV ³⁸⁰	259
	Q9QYH1	-----SKEEFVGDGQKFFIAGFR-----QQHANMRTCTSCYSAVGAPYEEV	221
		
55	NOV2	VRYQRRPSDKYRLIVLMGMSLGP ⁴³⁰ SGVGVNELRRQLIEFNPSHFQSAVP-TTRTKKSYEMN ⁴⁴⁰	287
	Q96JB8	VRYQRRPSDKYRLIVLMGMSLGP ⁴³⁰ SGVGVNELRRQLIEFNPSHFQSAVPHTTTRTKKSYEMN ⁴⁴⁰	472

Q96Q44	VRYQRPSDKYRLIVLM----	GPSGVGVNELRRQLIEFNPSHFQSAVPHTTRTKKSYEMN	428				
Q920P8	VRYQROPADKHRLIVLV----	GPSGVGVNELRRQLIGCNPSCFQSAVPHTTRSPKSYEMD	321				
Q920P7	VRYQROPADKHRLIVLV----	GPSGVGVNELRRQLIGCNPSCFQSAVPHTTRSPKSYEMD	315				
Q9QYH1	VRYQROPADKHRLIVLV----	GPSGVGVNELRRQLIGCNPSCFQSAVPHTTRSPKSYEMD	277				
	490	500	510	520	530	540	
NOV2	GREYHYVSKETFENLIYSHRRM	LEYGEYKGHL	YGTSDAVQTVL	VEGKICVMDLEPQ---			344
Q96JB8	GREYHYVSKETFENLIYSHR-	MLEYGEYKGHL	YGTSDAVQTVL	VEGKICVMDLEPQDIQ			531
Q96Q44	GREYHYVSKETFENLIYSHR-	MLEYGEYKGHL	YGTSDAVQTVL	VEGKICVMDLEPQDIQ			487
Q920P8	GREYHYVSRETFESLMYGHK-	MLEYGEYKGHL	YGTSVNAVH	AVLDEGKICVMDLEPQDIQ			380
Q920P7	GREYHYVSRETFESLMYGHK-	MLEYGEYKGHL	YGTSVNAVH	AVLDEGKICVMDLEPQDIQ			374
Q9QYH1	GREYHYVSRETFESLMYGHK-	MLEYGEYKGHL	YGTSVNAVH	AVLDEGKICVMDLEPQDIQ			336
	550	560	570	580	590	600	
NOV2	-----	NMRCMKQSRKNAKVITDYYVDMKFK	VRASQKLK	DEDLQEMENL			387
Q96JB8	GVRTHLKPYYVIFIKPSNMRCMKQSRKNAKVITDYYVDMKFK	-----	DEDLQEMENL				583
Q96Q44	GVRTHLKPYYVIFIKPSNMRCMKQSRKNAKVITDYYVDMKFK	-----	DEDLQEMENL				539
Q920P8	LARTRDLKPCVIFIKPPNTSSMRHSRKNAKITDYYVDMKFK	-----	DEDLQEMEEL				432
Q920P7	LARTRDLKPCVIFIKPPNTSSMRHSRKNAKITDYYVDMKFK	-----	DEDLQEMEEL				426
Q9QYH1	LARTRELKPYVIFIKPPSMSSMRHSRKNAKITDYYVDMKFK	-----	DEDLQEMEEL				388
	610	620	630	640	650		
NOV2	AQRMETQFGQFFDHVIVND	SLHDACAQLLSAIQKAQE	EPQWVPATWISSD	TESQ			441
Q96JB8	AQRMETQFGQFFDHVIVND	SLHDACAQLLSAIQKAQE	EPQWVPATWISSD	TESQ			637
Q96Q44	AQRMETQFGQFFDHVIVND	SLHDACAQLLSAIQKAQE	EPQWVPATWISSD	TESQ			593
Q920P8	AQKMESQFGQFFDHVIVND	NLODACQLLSAIQRAQE	EELQWVPEAWVSPD	TES-			485
Q920P7	AQKMESQFGQFFDHVIVND	NLODACQLLSAIQRAQE	EELQWVPEAWVSPD	TES-			479
Q9QYH1	AQKMESQFGQFFDHVIVND	NLODARAQLLSAIQKAQE	EELQWVPEAWVSPGAES-				441

The presence of identifiable domains in the disclosed NOV2 protein was determined by using Pfam and then determining the Interpro number. The results are listed in Table 2F with the statistics and domain description.

Table 2F. Domain Analysis of NOV2		
PSSMs Producing Significant Alignments		Score (bits)
Guanylate kin: domain 1 of 1, from 278 to 380		69.5
GK	TRpVpRpgEvdGkdYhFVssrEemekdIaan.eFlEygefqqnyYGT	
NOV2	TRT-KKSYEMNGREYHYVS-KETFENLIYSHrRMLEYGEYKGHL YGT	
GK	sletvrqvakqgKiciLDvepQgvkrlrtaelsNPivvFIaPpSlqelek	
NOV2	SVDAVQTVLVEGKICVMDLEPQNMRCMKQSRKN-AKVI---TDYYVDMKF	

GK	rLegrnkesEes	(SEQ ID NO:136)
	+ + ++ +	
NOV2	KVRASQKLKDED	(SEQ ID NO:4)

Consistent with other known members of the guanylate kinase family of proteins, NOV2 contains guanylate kinase domains as illustrated in Table 2F.

The NOV2 nucleic acid, and the encoded polypeptide, according to the invention are useful in a variety of applications and contexts. For example, NOV2 nucleic acids and polypeptides can be used to identify proteins that are members of the guanylate kinase family of proteins. The NOV2 nucleic acids and polypeptides can also be used to screen for molecules, which inhibit or enhance NOV2 activity or function. Specifically, the nucleic acids and polypeptides according to the invention may be used as targets for the identification of small molecules that modulate or inhibit, *e.g.*, cell signaling pathways, cell junction organization, or transmembrane regulation.. These molecules can be used to treat, *e.g.*, Von Hippel-Lindau (VHL) syndrome, diabetes, and tuberous sclerosis.

In addition, the NOV2 nucleic acid and polypeptide according to the invention are useful, *inter alia*, as novel members of the protein families according to the presence of domains and sequence relatedness to previously described proteins. For example, the NOV2 nucleic acid and polypeptide include structural motifs that are characteristic of proteins belonging to the family of kinases such as the guanylate kinase proteins. Guanylate kinase is a critical enzyme for biosynthesis of GTP and dGTP, and its role in nucleotide metabolism makes it a target for cancer chemotherapy. The structure of mouse guanylate kinase (gmk) includes an N-terminal ATP binding motif and a neighboring guanylate kinase signature sequence (GKSS). The low molecular mass cytosolic forms of guanylate kinase, such as gmk and guk1, are implicated in the regulation of the supply of guanine nucleotides to cell signaling pathways, while the related families of high molecular mass and membrane-associated forms of guanylate kinase, such as MAGUK, CASK, SAP102, ZO-1, and MAGI-1, have roles in cell junction organization and transmembrane regulation.

The NOV2 nucleic acid and polypeptide, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications in the mediation of biosynthesis and nucleotide metabolism. As such the NOV2 nucleic acid and polypeptide,

antibodies and related compounds according to the invention may be used to treat genetic conditions, *e.g.*, Von Hippel-Lindau (VHL) syndrome, diabetes, or tuberous sclerosis.

The NOV2 nucleic acid and polypeptide are useful for detecting specific cell types. For example, expression analysis has demonstrated that a NOV2 nucleic acid is expressed in synovium/synovial membrane.

Additional utilities for the NOV2 nucleic acid and polypeptide according to the invention are disclosed herein.

NOV3

The disclosed NOV3 nucleic acid (alternatively referred to herein as CG53400-01) encodes a novel hypothetical 85.6 kDa-like protein and includes the 3089 nucleotide sequence (SEQ ID NO:5) shown in Table 3A. The novel NOV3 nucleic acid of the invention maps to chromosome 12.

Table 3A. NOV3 Nucleotide Sequence (SEQ ID NO:5)

AGTTCTTACTGGATAACGGTGCAGACCCCTCCCTGCGGGACAGGCAGGGCTACACAGCTGTGCACTATGCAGCCG
CCTATGGCAACAGACAGAACCTCGAACTGCTCTTAGAAATGTCTTTAACTGCCTGGAGGATGTGGAGAGCACCA
TTCCAGTCAGCCCTTTGCACTTAGCTGCCTACAACGGTCACTGTGAAGCCTTGAAGACGCTGGCGGAGACGCTGG
TGAATCTGGACGTAAGGGACCACAAGGGCCGGACCGCACTCTTCTGGCCACGGAGCGCGGCTCTACTGAGTGTG
TGGAGGTGCTTACAGCCACGGCGCCTCTGCCCTCATCAAGGAGCGCAAGCGCAAGTGGACACCCCTGCACGCTG
CTGCTGCCCTCTGGCCACACTGACTCCCTGCACTTGCTGATCGACAGTGGGGAACGAGCTGACATCACAGATGTCA
TGGATGCCTATGGACAGACCCCACTGATGCTGGCCATCATGAATGGCCATGTGGACTGTGTACATCTGCTGCTAG
AGAAAGGATCCACAGCTGATGCTGCTGACCTCCGGGGCCGCACTGCCCTCCACCGCGGGGCACTGACTGGCTGTG
AGGACTGCCTGGCTGCCCTGCTGGACCACGACGCATTTGTGCTGTGCCGAGACTTTAAGGGCCGACGCCCCATT
ACCTGGCCTCAGCCTGTGGCCACACTGCAGTACTGCCGACCCTGCTGCAGGCTGCCCTTTCCACAGATCCCCCTGG
ATGCCGGGTGGATTACAGCGGATACTCGCCCATGCACTGGGCTCCTACACTGGACATGAAGATTGTCTGGAGT
TGTTACTTGAACACAGCCCGTTTTCGTACCTGGAAGGAAACCCCTTCACTCCTTTGCACTGTGCAGTGATTAATA
ACCAAGACAGCACCACAGAGATGCTACTGGGAGCTCTGGGTGCCAAGATTGTGAACAGCCGAGATGCCAAAGGAC
GGACCCCTTACGCGCTGCCTTCGCGGCACTGCGCTCATGACGGCGCTGAGAACGGGCAGACCGCTGCTGTGGAAT
TTCTGCTGTATCGAGGGAAGGCAGACCTTACTGTGTTGGATGAGAACAAAGAACAGGCCCTCCACTTGGCTTGTA
GCAAGGGCCATGAGAAATGTGCCCTCATGATCCTGGCAGAAACCAAGACCTTGGCCTTATCAATGCTACCAACA
GTGCGCTGCAGATGCCACTCCACATTGCTGCCCGGAATGGTCTAGCTTCTGTGGTACAGGCCCTGCTGAGTCATG
GGGCCACAGTGTGGCTGTGGATGAAGAAGGTGGGTGGGTCTGGGGCCCCATGCCTCTCTTGGGTTTGGGGTCA
GGGACATTCTTCAGGAGGTGACTTCTTAATCTTGCTATACATGGGATTTTCTTCCCAAGGGAAGTCTTCAGAGCA
GGGAGCCACACCA

The NOV3 protein (SEQ ID NO:6) encoded by SEQ ID NO:5 is 993 amino acid residues in length and is presented using the one-letter amino acid code in Table 3B. The SignalP, Psort and/or Hydropathy results indicate that NOV3 has no known signal peptide and is likely to be localized in the mitochondrial matrix space with a certainty of 0.5083. Alternatively, a NOV3 polypeptide is located to the nucleus with a certainty of 0.3000, the mitochondrial inner membrane with a certainty of 0.2317, or the mitochondrial intermembrane space with a certainty of 0.2217.

Table 3B. Encoded NOV3 Protein Sequence (SEQ ID NO:6)

MESAGPRSPCSRHSRRLGRSVSPVEPPPPPPGARCGRSPGRAMGILSITDQPPLVQAI FSRDVEEVRSLLSQKE
NINVLQERRTPLHAAAYVDVPILQLLMSGANVNAKDTLWLTPLHRAAASRNETVNLLLNKGASLNVCDKKER
QPLHWAFLGHLEVLKLLVARGADLGCKDRKGYGLLHTAAASGQIEVVKYLLRMGAIEIDEPNAFGNTALHIACYL
GQDAVAIELVNAGANVNQPNKGFTPLHVAAVSTNGALCLELLVNNGADVNYQSKEGKSPHMAA IHGRFTRSQI
LIQNGSEIDCADKFGNTPLHVAARYGHELLISTLMTNGADTARRGIHDMFPLHLAVLFGFSDCCRKLLSSGQLYS
IVSSLSNEHVL SAGFDINTPDNLGR TCLHAAASGGNVECLNLLLSSGADLRRRDKFGRTPLHYAAANGSYQCAVT
LVTAGAGVNEADCKGCSPLHYAAASDTYRRAEPHTPSSHDAEEDEPLKESRRKEAFFCLEFLLDNGADPSLRDRQ
GYTAVHYAAAYGNRQNLLELLEMSFNCLVEDVESTIPVSPLHLAAYNGHCEALKTLAETLVNLDVRDHKGRTALFL
ATERGSTECVEVLTAHGASALIKERKRKWTPLHAAAASGHTDSLHLLIDSGERADITDVM DAYGQTPLMLAIMNG
HVDCVHLLLEKGSTADAADLRGTALHRGAVTGCEDCLAALLDHDAFVLCRDFKGRTP IHLASACGHTAVLRTL
QAALSTDPLDAGVDYSGYSPMHWASYTGHEDCLELLEHSPFSYLEGNPFTPLHCAVINNQDSTTEMLLGALGAK
IVNSRDAKGRTP LHAAAFADNVSGLRMLLQHQA EVNATDHI GRTALMTAAENGQTAAVEFLLYRGKADLTVL DEN
KNTALHLACSKGHEKCALMILAETQDLGLINATNSALQMLPHIAARNGLASVVQALLSHGATVLA VDEEGGWGLG
PHASLGFGVRDILQEVTS

Included in the invention are variants of the parent clone NOV3 as shown below in Table 3C. These novel variants were derived by laboratory cloning of cDNA fragments coding for a domain of the full length form of NOV3 (CG53400-01), between residues 596 and 968.

Table 3C. Variants of NOV3			
NOV3 Variant No.	Alternate Reference	Change in SEQ ID NO:5	Change in SEQ ID NO:6
1	174228169	T → C at bp 2644	I → T at aa 866
2	174228176	T → C at bp 2144; A → G at bp 2227; and T → C at bp 2644	D → G at aa 727; and I → T at aa 866
3	174228191	A → G at bp 2628; and T → C at bp 2644	N → D at aa 861; and I → T at aa 866
4	174228195	A → G at bp 2622; and T → C at bp 2644	E → G at aa 859' and I → T at aa 866
5	174228206	G → A at bp 2118; and T → C at bp 2644	D → N at aa 691; and I → T at aa 866
6	174228213	G → A at bp 1947; G → A at bp 2541; and T → C at bp 2644	A → T at aa 634 A → T at aa 832; and I → T at aa 866

A search against the Patp database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 3D.

Table 3D. PatP Results for NOV3		
Sequences Producing High-Scoring Segment Pairs:		Smallest Sum Prob P (N)
patp:AAM39062 Human polypeptide	High Score 2704	3.6e-281
patp:AAU28174 Novel human secretory protein	1932	2.3e-199
patp:AAM40848 Human polypeptide	1621	2.1e-166

patp:AAU20496 Human secreted protein	1287	5.2e-131
patp:AAU25428 Human mddt protein from clone LG:893050.1:2000Feb18	1045	2.3e-105

In a BLAST search of public sequence databases, it was found, for example, that the NOV3 nucleic acid sequence of this invention has 1552 of 2369 bases (65%) identical to a gb:GENBANK-ID:HSM801363|acc:AL133087.1 mRNA from Homo sapiens mRNA; cDNA DKFZp434D2328 (from clone DKFZp434D2328); partial cds. Further, the full amino acid sequence of the disclosed NOV3 protein of the invention has 498 of 791 amino acid residues (62%) identical to, and 600 of 791 amino acid residues (75%) similar to, the 791 amino acid residue ptnr:SPTREMBL-ACC:Q9UFA4 protein from Human (HYPOTHETICAL 85.6 KDA PROTEIN).

The NOV3 protein of the invention also has homolgy to the proteins shown in the BLASTP data in Table 3E.

Table 3E. NOV3 BLASTP Results

Gene Index/ Identifier	Protein/Organism	Length of aa	Identity (%)	Positives (%)	Expect Value
Q9UFA4	HYPOTHETICAL 85.6 KDA PROTEIN - Human	791	498/791 (62%)	600/791 (75%)	2.9e-263
O15084	Hypothetical protein KIAA0379 - Human	1059	435/917 (47%)	577/917 (62%)	2.9e-199
Q9NCP8	ANKYRIN 2 - Drosophila melanogaster (fruit fly)	1159	243/761 (31%)	357/761 (46%)	3.5e-70
T42714	ankyrin 3, splice form 2 - mouse	1765	231/761 (30%)	342/761 (44%)	8.2e-70
T42715	ankyrin 3, splice form 3 - mouse	1940	231/761 (30%)	342/761 (44%)	1.0e-69

A multiple sequence alignment is given in Table 3F, with the NOV3 protein of the invention being shown in line 1 in a ClustalW analysis comparing NOV3 with related protein sequences of Table 3E.

Table 3F. ClustalW Analysis of NOV3

1. SEQ ID NO.: 6 NOV3 4. SEQ ID NO.: 139 Q9NCP8

2. SEQ ID NO.: 137 Q9UFA4 5. SEQ ID NO.: 140 T42714
3. SEQ ID NO.: 138 O15084 6. SEQ ID NO.: 141 T42715

10055877_012202

5		10	20	30	40	50	60	
	NOV3	MESAGPRSPCSR-----HRSRLGRSVSPVEPPPPPPGARCGRSPGRAMGILSITDQPP	54					
	Q9UFA4	-----	1					
10	O15084	---GAEATAMA-----FLKLRDQPSLVQAI FNGDPDEVRALIFKKEDVNFQDNEK RTP	50					
	Q9NCP8	---MVTEN-----GAQGDGNTSFLRAARACNLERVLEHKKNNIDNTSNANGLNA	47					
	T42714	MSEEPKEKPAKPAHRKRKGKSDANASYLRAARACHLEKALDYIKNGVDVNICNQGLNA	60					
	T42715	MSEEPKEKPAKPAHRKRKGKSDANASYLRAARACHLEKALDYIKNGVDVNICNQGLNA	60					
15		70	80	90	100	110	120	
	NOV3	LIVQAI FSRDVEEVRSLLSOKENINVLDOERRITPLHAAAYVGDVPITLOLLMSGANVNAKD	114					
	Q9UFA4	-----	1					
	O15084	LHAAAYLCDAEITELLILSGARVNAKDSKWLITPLHRAVASCSEEA VOVLKHSADVNAKD	110					
	Q9NCP8	LHLASKDGHIVVSELLRRGAIVDSATKKGN TALHIASLAGQEEVVKLLLEHNASVNVQS	107					
20	T42714	LHLASKEGHVEEVVSELLQREANVDAATKKGN TALHIASLAGQAEVVKVLVTNGANVNAQS	120					
	T42715	LHLASKEGHVEEVVSELLQREANVDAATKKGN TALHIASLAGQAEVVKVLVTNGANVNAQS	120					
25		130	140	150	160	170	180	
	NOV3	TLWLITPLHRAAAS--R-----N-----ETVNL L LNKGA	140					
	Q9UFA4	-----	1					
	O15084	KNWQITPLHIAAANKAVKCAEALVPLLSNVNVS DRAGRTALHHAAFSGHGFVVKLLLSRGA	170					
	Q9NCP8	ONGFTPLVMAAQENHDAVVRLLLSNGANQSLATEDGFTPLAVAMQQGHDKVAVLLES--	165					
	T42714	ONGFTPLVMAAQENHLEVVRFLLDNGASQSLATEDGFTPLAVALQQGHDOVVSLLLEN--	178					
30	T42715	ONGFTPLVMAAQENHLEVVRFLLDNGASQSLATEDGFTPLAVALQQGHDOVVSLLLEN--	178					
35		190	200	210	220	230	240	
	NOV3	SLNVCDIKKERQPLHWA AFLGHLEVLKLLVARGADLGCKDRKGYGLLHTAAASGQIEVVKY	200					
	Q9UFA4	-----	21					
	O15084	NINAFDKKDRRAIHWAA YMGHIEVVVKLLVSHGA EVTCKDKKSYTPLHAAASSGMISVVKY	230					
	Q9NCP8	--DTRGKVR L PALHIAAKKDDVKAATLLLDNDHNP DVTSKSGFTPLHIAASHYGNQNIANL	223					
	T42714	--DTKGKVR L PALHIAARKDDTKAAALLLOND TNADVESKSGFTPLHIAAHYGNIN VATL	236					
40	T42715	--DTKGKVR L PALHIAARKDDTKAAALLLOND TNADVESKSGFTPLHIAAHYGNIN VATL	236					
45		250	260	270	280	290	300	
	NOV3	LLRMGA EIDE PNAFGN TALHTAC YLGQDAVAIELVNAGANVNQPN DKGFTPLHVAAVSTN	260					
	Q9UFA4	LLNLGVEIDEIN VYGN TALHTAC YNGQDAV VNELIDYGANVNQPNNGFTPLHF AA ASTH	81					
	O15084	LLDLGVDMNEPNAYGNITPLHVAC YNGQDVV VNELIDCGAIVNQKNEKGFTPLHF AA ASTH	290					
	Q9NCP8	LLIQKGADVNSAKHNI SPLHVA AKWGKTNMVSL LLEKCGNIEAKTRDGLTPLHCAARS GH	283					
	T42714	LLNRAAAVDFTARNDITPLHVASKRGNANMVKLLDRGAKTDAKTRDGLTPLHCGARS GH	296					
	T42715	LLNRAAAVDFTARNDITPLHVASKRGNANMVKLLDRGAKTDAKTRDGLTPLHCGARS GH	296					
50		310	320	330	340	350	360	
	NOV3	GALCLELLVNNGADVNYQSKGK SPLHMAAIHGRFTRSQILLONGSEIDCADKFGNTPLH	320					
	Q9UFA4	GALCLELLVNNGADVNIQSKDGK SPLHMTAVHGRFTRSQITLIONGGEIDCVDKDKGNTPLH	141					
	O15084	GALCLELLVNGGADVNMKSKDGK TPLHMTALHGRFSRSQITIOSGAVIDCEDKNGNTPLH	350					
55	Q9NCP8	-EQVVDMLLERGAPISAKTKNGLAPLHMAAQGEHVDAARILLYHRAPVDEVTVDYLTALH	342					
	T42714	-EQVVEMLLDRSAPILSKTKNGLSPLHMA TQGDHLNCVQLLQHNVPVDDVTNDYLTALH	355					

T42715 -EQVVEMLLDERSAPILSKTKNGLSPLHMAITQGDHLNCVOILLQHNVPVDDVTNDYLTALH 355

5 NOV3 VAARYGHELLISTLTMTNGADTAREGIHDMFPLHIAVLFGFSDCCRKLSSGQLYSIVSSL 380
 Q9UFA4 VAARYGHELLINTLITSGADTAKCGIHSMFPLHIAALNAHSDCCRKLSSGQKYSIVSLF 201
 O15084 VAARYGHELLINTLITSGADTAKRGIHGMFPLHIAALSGFSDCCRKLSSG----- 401
 Q9NCP8 VAAHCGHVVRVAKLLIDRNADANARALNGFTPLHIAACKNRIRVMELLIRHGCASISATTES 402
 T42714 VAAHCGHYKVAKVLLDKKASPNKALNGFTPLHIAACKNRIRVMELLIRHGCASIQAVTES 415
 10 T42715 VAAHCGHYKVAKVLLDKKASPNKALNGFTPLHIAACKNRIRVMELLIRHGCASIQAVTES 415

15 NOV3 -----SNEHVLISAGFDINTPDLGRITCLHAAASGCVNVECLNLLSSGADL 425
 Q9UFA4 -----SNEHVLISAGFEIDTPDKFGRITCLHAAASGCVNVECLNLLSSGADF 246
 O15084 -----FDIDTPDDFGRTCLHAAASGCVNLECLNELLNTGADF 437
 Q9NCP8 GLTPLHVAAFMGCMNIVIYLLQHDASPDVPTVRGETPLHIAARANQTDIIRILRNQAQV 462
 T42714 GLTPIHVAAFMGHVNIVSOLMHHGASPNNTTIVRGETALHMAARSCQAEVVRVYLQDGAQV 475
 T42715 GLTPIHVAAFMGHVNIVSOLMHHGASPNNTTIVRGETALHMAARSCQAEVVRVYLQDGAQV 475

20 NOV3 RRDKDFGRITPLHYAAANGSYQCAVTLVITAGAGVNEADCKGCSPLHYAAASDYYRRAPHT 485
 Q9UFA4 HKKDKCGRTPLHYAAANCHFHCIETLVTTGANVNETDDWGRTALHYAAASDMRNKTLIG 306
 25 O15084 NKKDKFGRSPLHYAAANCNYQCLFALVGSASVNDLDERGCTPLHYAATSDDTG----- 491
 Q9NCP8 DAAAREQOTPLHIAASRLGNVDIVMLLLQHGAAQVDATTCKMYTALHIAAKEGQDEVAVLI 522
 T42714 EAKAKDDQTPPLHISARLGKADIVQOLLQOGASPNAAATTSGYTPLHIAAREGHEDVAFFL 535
 T42715 EAKAKDDQTPPLHISARLGKADIVQOLLQOGASPNAAATTSGYTPLHIAAREGHEDVAFFL 535

30 NOV3 PS-----SHDAEDEDPIKESRRKEAFFCLEFLLDNGADPSLRDQGYTAVHYAAAYGNRO 540
 Q9UFA4 NA-----HDNSEELERARELKEKEATLCLEFLLDNDANPSIRDKEGYNSIHYAAAYGHRO 361
 O15084 -----KCLEYLLRNDANPGIRDKQGYNAVHYSAAYGHRL 525
 35 Q9NCP8 ENGAALDAATKKGFTPLHLTAKYGHIVKVAQLLLQKEADVDAOGKNGVTPLHVACHYNNQO 582
 T42714 DHGASLSITTKKGFTPLHVAAYKYLEVASLLLOKSASPDAAGKSGLTPLHVAAYHDNQK 595
 T42715 DHGASLSITTKKGFTPLHVAAYKYLEVASLLLOKSASPDAAGKSGLTPLHVAAYHDNQK 595

40 NOV3 NLELLLEMS-----FN--CLEDVESTIPVSPLHIAAYNGHCEALKTLAETLVNLDVR 590
 Q9UFA4 CLELLLLERT-----NSG--FE-ESDSGATKSPHLIAAYNGHHQALEVLLQSLVDLDIR 411
 O15084 CLQLIASETPLDVLMETSGTDLSDSDNRATISPLHIAAYHGHQALEVLLQSLLDLDIR 585
 Q9NCP8 VALLLLEKG-----ASPHATAKNGTPLHIAARKNQMDIATTLLEYGALANAE 630
 45 T42714 VALLLLDQG-----ASPHAAAKNGYTPHLIAAKKNQMDIATSLLEYGADANAV 643
 T42715 VALLLLDQG-----ASPHAAAKNGYTPHLIAAKKNQMDIATSLLEYGADANAV 643

50 NOV3 DHKGRITALFLATERGSTECVEVLTAGASALIKERKRKWTPLHAAAASGHTDSLHLLIDS 650
 Q9UFA4 DEKGRITALDLAAFKGHTCEVALINQASIFVKDNVTKRTPLHASVINGHTLCRLILLEI 471
 O15084 NSSGRITPLDLAAFKGHVECDVLLINQASILVKDYILKRTPLHAAATNGHSECLRLILIGN 645
 Q9NCP8 SKAGFTPLHLSSQEGHAEISNLLTEHKAAVNHPAK-NGLTPMLHCAQEDNVNVAEILLEKN 689
 T42714 TROGIVSVHLAAQEGHVDVMSLLLSRNANVNLSNK-SGLTPLHLAAQEDRVNVAEVLVNQ 702
 55 T42715 TROGIVSVHLAAQEGHVDVMSLLLSRNANVNLSNK-SGLTPLHLAAQEDRVNVAEVLVNQ 702

730 740 750 760 770 780

		
	NOV3	GERADITDVMDAYGOTPLMLAIMNGHVDVHLLLEKGSTADAADLRGRTALHRCGAVTGCE	710
	Q9UFA4	ADNPEAVDVKDAKGOTPLMLAVAYGHIDAVSLLEKEANVDTVDILGCTALHRCGIMTGHE	531
	O15084	AEPQNAVDIQDNGGOTPLMLSVLNGHTDCVYSLINKGANVDAKDKWGRRTALHRCGAVTGHE	705
5	Q9NCP8	G---ANTIDMATKAGYTPLHVASHHGQANMVRFLLONGANVDAATSIGYTPLHQTAAQQGHC	746
	T42714	G---AHVDAQTKMGYTPLHYGCHYCNIKIVNFFLLOHSAKVNAKTKNGYTALHQAAQQGHT	759
	T42715	G---AHVDAQTKMGYTPLHYGCHYCNIKIVNFFLLOHSAKVNAKTKNGYTALHQAAQQGHT	759
		790 800 810 820 830 840	
10		
	NOV3	DCLAALLDHDADFVLCRDFKGRTPHLHSAACGHTAVLRITLLQAALSTDPDA-----	761
	Q9UFA4	ECVOMLLLEQEVSIILCKDSRGRTPLHYAAARGHATWLSELLQMALSEED-CC-----	581
	O15084	ECVDALLQHGAKCLLRDSRGRTPLHLHSAACGHIGVLGALLQSAASMDANPA-----	756
	Q9NCP8	HIVNLLLEHKANANAQTVNGOTPLHTARKLGYISVLDLTKTITKEDETAAPSQAEEKYR	806
15	T42714	HIINVLLQNNASPNELTVNCTALALARRLGYISVVDTLKVVTETIMTTTT---ITEKHK	816
	T42715	HIINVLLQNNASPNELTVNCTALALARRLGYISVVDTLKVVTETIMTTTT---ITEKHK	816
		850 860 870 880 890 900	
20		
	NOV3	-----GVDYS-----	766
	Q9UFA4	-----FKDNQ-----	586
	O15084	-----TADNH-----	761
	Q9NCP8	VVAPEAMHESF-MSDSE-----EEGG-----EDNM	830
	T42714	MNVPETMNEVLDMSDDEVRKASAPEKLSDGGEYISDGEEGDKCTWFKIPKVQEVLVKSEDA	876
25	T42715	MNVPETMNEVLDMSD-----EGDKCTWFKIPKVQEVLVKSEDA	855
		910 920 930 940 950 960	
30		
	NOV3	-----GYSPMHWASYTGHEDELELL	786
	Q9UFA4	-----GYTPLHWACYNGNENCLEVL	606
	O15084	-----GYTALHWACYNGHETCVELL	781
	Q9NCP8	LSDQPYRYLTVDDEMKSGLDSDLPID---VTRDER-----MDSNRMTQSAEYASGVPPT	880
	T42714	ITGDTD KYLGPDQLKELGDDSLPAEGYVGFSLGARSASLRSFSSDRSYTLNRSSYARDSM	936
	T42715	ITGDTD KYLGPDQLKELGDDSLPAEGYVGFSLGARSASLRSFSSDRSYTLNRSSYARDSM	915
35		970 980 990 1000 1010 1020	
		
	NOV3	LEHSPFSYLEGNPFTPLHCAVINNQ-----DSTTEMLLGA LCA	824
	Q9UFA4	LEQKCFRKFIGNPFTPLHCAIINDH-----GNCA SLLGAIDS	644
40	O15084	LEQEVFQKTEGNAFSP LHC AIVINDN-----EGAAEMLLDTLGA	819
	Q9NCP8	LGEEVISPHKTQVYGSSPKATVDGV-YIANGSGHDEPPHVGRKLSWKSFLVSEFLVDARCG	939
	T42714	MIEELLVPSKEQHLTFTREFDSDLRHYSWAADTLDNVNLVSSPVHSGFLVSEFLVDARCG	996
	T42715	MIEELLVPSKEQHLTFTREFDSDLRHYSWAADTLDNVNLVSSPVHSGFLVSEFLVDARCG	975
45		1030 1040 1050 1060 1070 1080	
		
	NOV3	KIVNSRDAKGRTP L HAAAFADNVSGLRMLLQHQAENVATDHI -GRTALMTAAENGQTA AV	883
	Q9UFA4	SIIVSCRDDKGRTP L HAAAFADHVECLQLL LRHSAPVNAVDNS -GKTALMMAAENGQAGAV	703
	O15084	SIIVNATDSKGRTP L HAAAFTHDVECLQLL LSHNAQVNSVDST -GKTPLMMAAENGQNTNTV	878
50	Q9NCP8	AMRGCRHSGVRMIIPSRSTCQPTRVTCRYVKPQRTMHPPQLMEGEALASRVLELGP CSTK	999
	T42714	SMRGSRRHHGMRIIPPRKCTAPTRITCRLVVRHKLANPPPMVEGEGLASRLVEMGPAGAQ	1056
	T42715	SMRGSRRHHGMRIIPPRKCTAPTRITCRLVVRHKLANPPPMVEGEGLASRLVEMGPAGAQ	1035
55		1090 1100 1110 1120 1130 1140	
		
	NOV3	EFLLYRGKADLTVLVDENKNTALHLACSKGHEKCALMILAETQD--LGLINA--TNSALQM	939
	Q9UFA4	DILVN SAQADLT VKDKDLNTPHLACSKGHEKCALLILDKIQD--ESLINE--KNALQI	759

O15084 EMLVSSASAELTLQDNSKNTALHLACSKGHETSALLILEKITD--RNLIINA--TNAALOT 934
 Q9NCP8 FLGPVVMFVPHFASLRGKERETIILRSDNGETWREHTIDNSEEIIHDVLOQCFEPEETAQ 1059
 T42714 FLGPVIVEIPHFGSMRGKERELIVLRSENGETWKEHQFDSKNEDLAEELNG--MDEEDDS 1114
 T42715 FLGPVIVEIPHFGSMRGKERELIVLRSENGETWKEHQFDSKNEDLAEELNG--MDEEDDS 1093

5

1150 1160 1170 1180 1190 1200
 NOV3 PLHVAARNGLASVVQALLSHGATVLADEEGG-----WGL 974
 Q9UFA4 PLHVAARNGLKVVVEELLAKGACVLAVDENG----- 791
 O15084 PLHVAARNGLTMVVOELLGKGASVLAVDENGYPALACAPNKDVADCLALILATMPVSS 994
 Q9NCP8 LEEQAGNHVCRFVYTYDFPQYFAVVSRIROEVHAIG---P-----EGGMVSSTVVPQVOA 1110
 T42714 PEEELGTRICRIITKDFPQYFAVVSRIKQESNQIG---P-----EGGILSSTTVPLVOA 1165
 T42715 PEEELGTRICRIITKDFPQYFAVVSRIKQESNQIG---P-----EGGILSSTTVPLVOA 1144

15

1210 1220 1230 1240 1250 1260
 NOV3 G-PHASLGFGRDILQEVTS----- 993
 Q9UFA4 ----- 791
 O15084 SSPLSSSLTFNAINRYTNTSKT-----VSFEALPIMRNEPSSYCS----- 1033
 Q9NCP8 VFPPQALTKKIKVGLQVN-----LFKPR--K----- 1134
 T42714 SFPEGALTKRIRVGLQAQVPVEETVKKILGNKATFSPIVTVEPRRRKFHKPITMTIPVPP 1225
 T42715 SFPEGALTKRIRVGLQAQVPVEETVKKILGNKATFSPIVTVEPRRRKFHKPITMTIPVPP 1204

20

1270 1280 1290 1300 1310 1320
 NOV3 ----- 993
 Q9UFA4 ----- 791
 O15084 -----FNNIGGEQEYLYTDVD----- 1049
 Q9NCP8 -----G-VAPEKLRKIS----- 1145
 T42714 PSGEGVSNGYKGDATPNLRLRLCSITGGTSPAQWEDITGTTPLTFIKDCVSFTTNVSARFW 1285
 T42715 PSGEGVSNGYKGDATPNLRLRLCSITGGTSPAQWEDITGTTPLTFIKDCVSFTTNVSARFW 1264

25

1330 1340 1350 1360 1370 1380
 NOV3 ----- 993
 Q9UFA4 ----- 791
 O15084 --ELNDSSETY----- 1059
 Q9NCP8 ---VNHVPKKK-----RFSLIW----- 1159
 T42714 LADCHQVLETVGLASQLYRELICVPYMAKFVVFATNDPVESSLRCFCMTDDRVDKTLEQ 1345
 T42715 LADCHQVLETVGLASQLYRELICVPYMAKFVVFATNDPVESSLRCFCMTDDRVDKTLEQ 1324

40

1390 1400 1410 1420 1430 1440
 NOV3 ----- 993
 Q9UFA4 ----- 791
 O15084 ----- 1059
 Q9NCP8 ----- 1159
 T42714 QENFEEVARSKDIEVLEGKPIYVDCYGNLAPLTGGGQQLVFNFYFSENRLPFSIKIRDT 1405
 T42715 QENFEEVARSKDIEVLEGKPIYVDCYGNLAPLTGGGQQLVFNFYFSENRLPFSIKIRDT 1384

50

1450 1460 1470 1480 1490 1500
 NOV3 ----- 993
 Q9UFA4 ----- 791
 O15084 ----- 1059
 Q9NCP8 ----- 1159
 T42714 SQEPCGRSLFLKEPKTTKGLPQTAVCNLNITLPAHKKAEEKADRRQSFASLALRKRYSYLT 1465

55

2022-07-27 10:01:00

T42715 SQEPCGRLSFLKEPKTTKGLPQTAVCNLNITLPAHKKAEEKADRRQSFASLALRKRYSYLT 1444

		1510	1520	1530	1540	1550	1560	
5	NOV3	993					
	Q9UFA4	-----	791					
	O15084	-----	1059					
	Q9NCP8	-----	1159					
10	T42714	EPSMSQPSPCERTDIRMAIVADHLGLSWTELARELNFSVDEINQIRVENPNLSISQSFML	1525					
	T42715	EPSMSQPSPCERTDIRMAIVADHLGLSWTELARELNFSVDEINQIRVENPNLSISQSFML	1504					

		1570	1580	1590	1600	1610	1620	
15	NOV3	993					
	Q9UFA4	-----	791					
	O15084	-----	1059					
	Q9NCP8	-----	1159					
	T42714	LKKWVTRDGKNATTDALTSVLTkinRIDIVTLLEGPIFDYGNISGTRSFADENN VFHDPV	1585					
	T42715	LKKWVTRDGKNATTDALTSVLTkinRIDIVTLLEGPIFDYGNISGTRSFADENN VFHDPV	1564					


		1630	1640	1650	1660	1670	1680	
20	NOV3	993					
	Q9UFA4	-----	791					
25	O15084	-----	1059					
	Q9NCP8	-----	1159					
	T42714	D-----	1586					
	T42715	DGHPSPQVELETPMGLYWTppNPFQDDHFSDISSIESPFRTPSRLSDGLVPSQGNIEHP	1624					

		1690	1700	1710	1720	1730	1740	
30	NOV3	993					
	Q9UFA4	-----	791					
	O15084	-----	1059					
35	Q9NCP8	-----	1159					
	T42714	-----	1586					
	T42715	TGGPPVVTAEEDTSLEDskMDDSVTVTDpadPLDVDESQLKDLcQSECAQCWASVPgIPND	1684					

		1750	1760	1770	1780	1790	1800	
40	NOV3	993					
	Q9UFA4	-----	791					
	O15084	-----	1059					
	Q9NCP8	-----	1159					
45	T42714	-----	1586					
	T42715	GRQAEPLRPQTRKVGMSSEQQEKgKSGPDEEVTEdKVksLFEDIQLEEVeAEEMTEdQGQ	1744					

		1810	1820	1830	1840	1850	1860	
50	NOV3	993					
	Q9UFA4	-----	791					
	O15084	-----	1059					
	Q9NCP8	-----	1159					
	T42714	-----GWQNETPSGSLESpaQARRLTGGLLDRLDDSSDQARDSITSYL	1629					
55	T42715	AMLNRVQRAELAMSSLAGWQNETPSGSLESpaQARRLTGGLLDRLDDSSDQARDSITSYL	1804					

		1870	1880	1890	1900	1910	1920	
--	--	------	------	------	------	------	------	--



The presence of identifiable domains in the disclosed NOV3 protein was determined by using Pfam and then determining the Interpro number. The results are listed in Table 3G with the statistics and domain description.

Table 3G. Domain Analysis of NOV3		
PSSMs Producing Significant Alignments		E Value
ank: domain 2 of 26, from 83 to 115		40.4
ANK	dGrTPLHlAarnGhlevvklLLeaGAdvnardk (SEQ ID NO:142)	
NOV3	ERRTPLHAAAYVGDVPILQLLLMSGANVNAKDT (SEQ ID NO:6)	
ank: domain 11 of 26, from 398 to 430		42.2
ANK	dGrTPLHlAarnGhlevvklLLeaGAdvnardk (SEQ ID NO:143)	
NOV3	LGRTCLHAAASGGNVECLNLLSSGADLRRRDk (SEQ ID NO:6)	

Consistent with other known members of the 85.6kDa family of proteins, NOV3 contains ankyrin domains as illustrated in Table 3G.

The NOV3 nucleic acid, and the encoded polypeptide, according to the invention are useful in a variety of applications and contexts. For example, NOV3 nucleic acids and polypeptides can be used to identify proteins that are members of the ankyrin family of proteins. The NOV3 nucleic acids and polypeptides can also be used to screen for molecules, which inhibit or enhance NOV3 activity or function. Specifically, the nucleic acids and polypeptides according to the invention may be used as targets for the identification of small molecules that modulate or inhibit, *e.g.*, red blood cell formation/organization, or signal transduction/cell activation. These molecules can be used to treat, *e.g.*, spherocytosis.

In addition, the NOV3 nucleic acid and polypeptide according to the invention are useful, *inter alia*, as novel members of the protein families according to the presence of domains and sequence relatedness to previously described proteins. For example, the NOV3 nucleic acid and polypeptide include structural motifs that are characteristic of proteins belonging to the family of transmembrane proteins/membrane skeleton proteins such as the ankyrin proteins. Ankyrin is a globular protein (200 kD) that links spectrin and an integral membrane protein (Band III) in the erythrocyte plasma membrane. Ankyrin belongs to a family of closely related polypeptides associated with the plasma membrane of cells in a variety of cell types (*e.g.* lymphocytes, platelets, fibroblasts and endothelial tissues). Ankyrin has been shown to underlie membrane proteins including CD44, the voltage-dependent sodium channel, Na^+/K^+ ATPase and the anion exchanger protein. Functional diversity between members of the ankyrin family is generated by the expression of multiple genes as well as alternative splicing of pre-mRNA's. The formation of a direct connection between ankyrin and functionally important transmembrane proteins/membrane skeleton may be one of the earliest events to occur during signal transduction and cell activation.

The NOV3 nucleic acid and polypeptide, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications in the mediation of signal transduction or cell activation. As such the NOV3 nucleic acid and polypeptide, antibodies and related compounds according to the invention may be used to treat genetic conditions, *e.g.*, endometriosis, fertility, adrenoleukodystrophy, congenital adrenal hyperplasia, diabetes, Von Hippel-Lindau (vhl) syndrome, pancreatitis, obesity, hyperparathyroidism, hypoparathyroidism, hyperthyroidism, hypothyroidism, SIDS, xerostomia, scleroderma, hypercalcaemia, ulcers, cirrhosis, transplantation, inflammatory bowel disease, diverticular disease, hirschsprung's

105557-0130
2023-04-29 10:55:57
disease, crohn's disease, appendicitis, hemophilia, hypercoagulation, idiopathic
thrombocytopenic purpura, autoimmune disease, allergies, immunodeficiencies, graft vesus
host, anemia, ataxia-telangiectasia, lymphedema, tonsilitis, osteoporosis, hypercalceimia,
arthritis, ankylosing spondylitis, scoliosis, tendinitis, muscular dystrophy, lesch-nyhan syndrome,
5 myasthenia gravis, dental disease and infection, cardiomyopathy, atherosclerosis, hypertension,
congenital heart defects, aortic stenosis, atrial septal defect (asd), atrioventricular (a-v) canal
defect, ductus arteriosus, pulmonary stenosis, subaortic stenosis, ventricular septal defect (vsd),
valve diseases, tuberous sclerosis, aneurysm, fibromuscular dysplasia, stroke, bleeding disorders,
alzheimer's disease, parkinson's disease, huntington's disease, cerebral palsy, epilepsy, multiple
10 sclerosis, ataxia-telangiectasia, leukodystrophies, behavioral disorders, addiction, anxiety, pain,
neuroprotection, endocrine dysfunctions, growth and reproductive disorders, cystitis,
incontinence, renal artery stenosis, interstitial nephritis, glomerulonephritis, polycystic kidney
disease, systemic lupus erythematosus, renal tubular acidosis, iga nephropathy, or vesicoureteral
reflux.

15 The NOV3 nucleic acid and polypeptide are useful for detecting specific cell types. For
example, expression analysis has demonstrated that a NOV3 nucleic acid is expressed in adrenal
gland/suprarenal gland, bone, brain, cartilage, cervix, coronary artery, platelets, kidney, kidney
cortex, liver, mammary gland/breast, pancreas, placenta, salivary glands, spleen,
synovium/synovial membrane, thymus, cerebral medulla/cerebral white matter, and left
20 cerebellum.

Additional utilities for the NOV3 nucleic acid and polypeptide according to the invention
are disclosed herein.

NOV4

25 The NOV4 proteins descibed herein are novel myotonic dystrophy kinase-related CDC-
42 binding kinase (MRCK)-like proteins. The NOV4 nucleic acids disclosed herein map to
chromosome 11q13. Two alternative novel NOV4 nucleic acids and polypeptides are disclosed
herein, namely NOV4a and NOV4b.

NOV4a

30 A NOV4 variant is NOV4a (alternatively referred to herein as CG56209-01), which
encodes the 3835 nucleotide sequence (SEQ ID NO:7) shown in Table 4A. An open reading

frame for the mature protein was identified beginning with an ATG codon at nucleotides 98-100 and ending with a TAG codon at nucleotides 3689-3691. Putative untranslated regions, if any, downstream from the termination codon and upstream from the initiation codon are underlined. The start and stop codons are in bold letters.

5

Table 4A. NOV4a Nucleotide Sequence (SEQ ID NO:7)

CGGACAGAGCCTCAGACGGTTGGGCGGACGGACGGCCCCGACAGGCGGGCATGCGGGCGGCCAGACTGTAGCCGAG
CAGCGAGGCTCCGGCCGAGCC**ATGG**AGCGGCGGCTGCGCGCGCTGGAGCAGCTGGCGCGGGGCGAGGCCGGCGG
CTGCCCGGGGCTCGACGGCTCCTAGATCTGCTGCTGGCGCTGCACCACGAGCTCAGCAGCGGCCCCCTACGGCG
GGAGCGCAGCGTGGCGCAGTTCCTGAGCTGGGCCAGCCCCCTTCGTATCAAAGGTGAAAGAACTGCGTCTGCAGAG
AGATGACTTTGAGATCTTGAAGGTGATCGGCCGAGGAGCCTTTGGGGAGGTACCCGTGGTGAGGCAGAGGGACAC
TGGGCAGATTTTTGCCATGAAAATGCTGCACAAGTGGGAGATGCTGAAGAGGGCTGAGACAGCCTGTTTCCGGGA
GGAGCGGGATGTGCTCGTGAAGGGGACAGCCGTTGGGTGACCACTCTGCACTATGCCTTCCAAGACGAGGAGTA
CCTGTACCTTGTGATGGACTACTATGCTGGTGGGGACCTCCTGACGCTGCTGAGCCGCTTCGAGGACCGTCTCCC
GCCCAGCTGGCCCACTTCTACCTGGCTGAGATGGTGTGCGCCATCCACTCGCTGCACCAGCTGGGTTATGTCCA
CAGGGATGTCAAGCCAGACAACGTCTCTGCTGGATGTGAACGGGCACATTTCGCTGGCTGACTTCGGCTCCTGCCT
GCGTCTCAACACCAACGGCATGGTGGATTTCATCAGTGGCAGTAGGGACGCGGACTATATCTCCCTGAGATCCT
GCAGGCCATGGAGGAGGCAAGGGCCACTACGGCCACAGTGTGACTGGTGGTTCGCTTGGAGTCTGCGCCTATGA
GCTGCTCTTTGGGGAGACGCCCTTCTATGCTGAGTCCTTGGTGGAAACCTACGGCAAGATCATGAACCACGAGGA
CCACCTGCAGTTCCCCCGGACGTGCCTGACGTGCCAGCCAGCGCCCAAGACCTGATCCGCCAGCTGCTGTGTGCG
CCAGGAAGAGCGGCTAGGCCGTGGTGGGCTGGATGACTTCCGGAACCATCCTTTCTTGAAGGCGTGACTGGGA
GCGGCTGGCGAGCAGCACGGCCCCCTATATTCCTGAGCTGCGGGGACCCATGGACACCTCCAACCTTTGATGTGGA
TGACGACACCTCAACCATCCAGGACCCCTGCCACCGCCCTCCACGGGGCCTTCTCCGGCCATCACCTGCCATT
CGTGGGCTTCACCTACACCTCAGCTTGGGCTGCCCTGGAGCGGAAGCTCCAGTGTCTGGAGCAGGAGAAGCTCCC
AGCTGGAGGAAGCCCGCAACTGAGGAAGGAGGTGGCCGCCCTGCGAGAGCAGCTGGAGCAGGCCACAGCCACAG
GCGTCTGCAGGAGGCCGAGAAGCAGAGCAGGCCCTGCAACAGGAGCTCGCCATGCTGCGGGAGGAGCTGGAGCA
GGAGAGCAAGCAGCGGCTGGAGGGTGAAGCGGGGAGACGGAGAGCAACTGGGAGGCCAGCTCGCCGACATCCT
CAGCTGGGTGAATGATGAGAAGGTCTCAAGAGGCTACCTGCAGGCCCTGGCCACCAAGATGGCAGAGGAGCTGGA
GTCCTTGAGGAACGTAGGCACCCAGGACCAACAGTGAAGGCGCGGCGACTGCAGAAGATGGAGGCCTCGGCCAG
GCTGGAGCTGCAGTCAGCGCTGGAGGCCGAGATCCGCGCAAGCAGGGCCTGCAGGAGCGGCTGACACAGGTGCA
GGAGGCCAGCTGCAGGCTGAGGGCTGTCCCCCTCCACAGCCCGGCTCACACAGCTGCGCCCCGGAGCTTCCC
ATCCCCGACCAAGTGTCTCCGCTGCACCTCGCTGATGCTGGGCGCTGGGCGCCAGGGCCTGGGTTGTGATTGCGG
CTACTTTTGTACACAACCTGTGCCCCACAGGCCCAACCTGCCCCGTGCCCCCTGACCTCCTCCGCACAGCCCT
GGGAGTACACCCGAAACAGGCACAGGCACCTGCTATGAGGGCTTTCTGTGAGGTGTCCGGCGGGGCTGGCAGCG
CGTGTGTTGCTGCCCCGAGTGAAGTCAAGCCTGCTGCTGTTTGAAGCCCCCTGACCTGAGGCTCAGCCCGCCAGTGG
GGCCCTCCTGCAGGTCTTAGATCTGAGGGACCCCCAGTTCTCGGCTACCCCTGTCTGGCCTCTGATGTTATCCA
TGCCCAATCCAGGGACCTGCCACGCATCTTAGGGTGACAACCTCCAGCTGGCAGTGCCGCCACACAGTGCAC
TGTGCTGCTGCTGGCAGAGAGCGAGGGGAGCGGGAACGCTGGCTGCAGGTGCTGGGTGAGCTGCAGCGGCTGCT
GCTGGACGCGCGGCCAAGACCCCGGCCCGTGTACACACTCAAGGAGGCTTACGACAACGGGCTGCCGCTGCTGCC
TCACACGCTCTGCGCTGCCATCTCGACCAGGATCGACTTGCCTTGGCACCGAGGAGGGGCTCTTTGTATCCA
TCTGGACATCTTCCAGGTGGGGAGTGCCGGCGCGTGCAGCAGCTGACCTTGAGCCCCAGTGCAGGCCTGCTGGT
CGTGTGTGTGGCCGCGGCCCCAGCGTGCCTCTTTGCCCTGGCGGAGCTGGAGAACATAGAGGTAGCAGGTGC
CAAGATCCCCGAGTCTCGAGGCTGCCAGGTGCTGGCAGCTGGAAGCATCCTGCAGGCCCGCACCCCGGTGCTCTG
TGTAGCCGTCAAGCGCCAGGTGCTCTGCTACCAGCTGGGCCCCGGGCCCTGGGCCCTGGCAGCGCCGCATCCGTGA
GCTGCAGGCACCTGCCACTGTGCAGAGCCTGGGGCTGCTGGGCGACCGGCTATGTGTGGGCGCCGCCGGTGGCTT
TGCACTCTACCCGCTGCTCAACGAGGCTGCGCCGTTGGCGCTGGGGGCCGGTTTGGTGCCTGAGGAGCTGCCACC
ATCCCGCGGGGGCCTGGGTGAGGCACTGGGTGCCGTGGAGCTTAGCCTCAGCGAGTTCTGCTACTCTTACCAC
TGCTGGCATCTACGTGGATGGCGCAGGCCGCAAGTCTCTGTTCAAGGAGAACTCCATCGATGTGTTTACGTGAG
GAGGGCAGAATGGGTGCAGACCGTGCCTCAAGAAGGTGCGGCCCTCAATCCAGAGGGCTCCTGTTCTCTTA
CGGCACCGAGAAGGACGAGTTCGACATCCCGACCTCACCGACAACAGCCGGCGCAGCTGTTCCGCACCAAGAG
CAAGCGCCGCTTCTTTTCCGCGTGTGCGAGGAGCAGCAGAAGCAGCAGCGCAGGGAGATGCTGAAGGACCTTT

TGTGCGCTCCAAGCTCATCTCGCCGCTACCAACTTCAACCACCTAGTACACGTGGGCCCTGCCAACGGGCGGCC
 CGGCGCCAGGACAAAGTCCCCGGTTAGTCTGCTCCAGAATTTGGAAATCCTAGTTTCTCTCTCGTATCCCCG
 AGTCTGGGACACAAAACCTCGCCCCAGCCTATGAGCATCCTGAGCCCCGCCCTCTTCCTGACGAAACTGGCCCC
 GGATCAGAGCAGGACCTCCCTTACGCCACTGCACTCCAGCCTGGCCGACAGCAAGAGTCTGTCTCCCTCCCTCCAC
 TCCCCATGAGCCCTAGGACGGGTCACTCATCTCTCAGAGCCTCAGTTCCCAGCCCTGGAGGGAGATGAGGTTTC
 CCAGCCCCACAGGGCTGTTGTGAGGCTGACGTGCCCTCATGGCCAAGGGCTGTCTGTAGCCTGGCCCCCGTATCC
 TCTTGGGGTT

The NOV4a protein (SEQ ID NO:8) encoded by SEQ ID NO:7 is 1197 amino acid residues in length and is presented using the one-letter amino acid code in Table 4B. The SignalP, Psort and/or Hydropathy results indicate that NOV4a has no known signal peptide and is likely to be localized in the nucleus with a certainty of 0.7600. Alternatively, a NOV4a polypeptide is located to the microbody (peroxisome) with a certainty of 0.3114, the lysosome (lumen) with a certainty of 0.1772, or the mitochondrial matrix space with a certainty of 0.1000.

Table 4B. Encoded NOV4a Protein Sequence (SEQ ID NO:8)

MERRLRALEQLARGEAGGCPGLDGLLDLLALHHELSSGPLRRERSVAQFLSWASPFVSKVKELRLQRDDFEILK
 VIGRGAFGEVTVVRQRDTGQIFAMKMLHKWEMLKRAETACFREERDVLVKGDSRWVTTLHYAFQDEEYLYLVMDY
 YAGGDLTLLSRFEDRLPPELAQFYLAEMVLAIHSLHQLGYVHRDVKPDNVLLDVNGHIRLADFGSCLRLNTNGM
 VDSSVAVGTPDYISPEILQAMEEGKGHYGPQCDWWSLGVCAYELLFGETPFYAESLVETYGKIMNHEDHLQFPD
 VPDVPASAQDLIRQLLCRQEERLGRGGLDDFRNHFFEGVDWERLASSTAPYIPELRGPMDTSNFDVDDDTLNHP
 GTLPPPSHGAFSGHHLFPVGFYTSAWAALERKLQCLEQEKLPAAGSPQLRKEVAALREQLEQAHSHRRLOEAEK
 QSQALQQELAMLREELEQESKQRLEGERRETESNWEAQLADILSWVNDEKVSRYLQALATKMAEELESRLNVGT
 QDHQWKARRLQKMEASARLELQSALEAEIRAKQGLQERLTQVQEAQLQAEPCPPPGSHTLRPRSPFPSPTKCLR
 CTSLMLGLGRQGLGCDGCFHTTTCAPQAPPCVPVPPDLLRTALGVHPETGTGTAYEGFLSGVRRGWQRVFAALSD
 SRRLLFDAPDLRLSPPSGALLQVLDLRDPQFSATPVLASDVIHAQSRDLPRIFRVTTSQLAVPPTTCTVLLLAES
 EGERERWLQVLGELQRLLLDARPRPRPVYTLKEAYDNGLPLLPHTLCAAILDQDRLALGTEEGLFVIHLDIFQVG
 ECRRVQQLTSLSPSAGLLVVLGCRGPSVRLFALAELENI EVAGAKI PESRGCQVLAAGSILQARTPVLCVAVKRQV
 LCYQLGPGPGPWQRRIRELQAPATVQSLGLLDRLCVGAAGGFALYPLLNEAAPLALGAGLVPEELPPSRGGLGE
 ALGAVELSLSEFLLFTTAGIYVDGAGRKSLFSENSIDVFDVRRAEWVQTVPLKKVRPLNPEGSLFLYGTEKDEF
 DIPDLTDNSRRQLFRTKSKRRFFFRVSEEQQKQQRREMLKDPFVRSKLISPTNFNHLVHVG PANGRPGARDKSP
 VSPAPEFGNPSFLSFVSRVWDTKLRPQPMISLSPALFLTCLAPDQSRTSLTPLHSSLADSKSLSPSSSTPHEP

SNP variants of NOV4a are disclosed in Example 2.

NOV4b

Alternatively, a NOV4 variant is NOV4b (alternatively referred to herein as CG56209-02), which includes the 3985 nucleotide sequence (SEQ ID NO:9) shown in Table 4C. An open reading frame for the mature protein was identified beginning with an ATG codon at nucleotides 98-100 and ending with a TAG codon at nucleotides 3839-3841. Putative untranslated regions,

if any, downstream from the termination codon and upstream from the initiation codon are underlined. The start and stop codons are in bold letters.

Table 4C. NOV4b Nucleotide Sequence (SEQ ID NO:9)

CGGACAGAGCCTCAGACGGTTGGGCGGACGGACGGCCCCGACAGGCGGGCATGCGGGCGGCCAGACTGTAGCCGAG
CAGCGAGGCTCCGGCCGACGCC**ATGG**AGCGGCGGCTGCGCGCGCTGGAGCAGCTGGCGCGGGGCGAGGCCGGCGG
CTGCCCCGGGGCTCGACGGCCTCCTAGATCTGCTGCTGGCGCTGCACCACGAGCTCAGCAGCGGCCCCCTACGGCG
GGAGCGCAGCGTGGCGCAGTTCCTGAGCTGGGCCAGCCCCCTTCGTATCAAAGGTGAAAGAACTGCGTCTGCAGAG
AGATGACTTTGAGATCTTGAAGGTGATCGGCCGAGGAGCCTTTGGGGAGGTCACCGTGGTGAGGCAGAGGGACAC
TGGGCAGATTTTTGCCATGAAAATGCTGCACAAGTGGGAGATGCTGAAGAGGGCTGAGACAGCCTGTTTCCGGGA
GGAGCGGGATGTGCTCGTGAAGGGGACAGCCGTTGGGTGACCCTCTGCACTATGCCTTCCAAGACGAGGAGTA
CCTGTACCTTGTGATGGACTACTATGCTGGTGGGGACCTCCTGACGCTGCTGAGCCGCTTCGAGGACCGTCTCCC
GCCCCAGCTGGCCCACTTCTACCTGGCTGAGATGGTGTGGCCATCCACTCGCTGCACCAGCTGGGTTATGTCCA
CAGGGATGTCAAGCCAGACAACGTCCTGCTGGATGTGAACGGGCACATTCCGCTGGCTGACTTCGGCTCCTGCCT
GCGTCTCAACACCAACGGCATGGTGGATTATCATGAGTGGCAGTAGGGACGCCGACTATATCTCCCCTGAGATCCT
GCAGGCCATGGAGGAGGGCAAGGGCCACTACGGCCACAGTGTGACTGGTGGTTCGCTTGGAGTCTGCGCCTATGA
GCTGCTCTTTGGGGAGACGCCCTTCTATGCTGAGTCTTGGTGGAAACCTACGGCAAGATCATGAACCACGAGGA
CCACCTGCAGTTCCCCCGGACGTGCCTGACGTGCCAGCCAGCGCCCAAGACCTGATCCGCCAGCTGCTGTGTCTG
CCAGGAAGAGCGGCTAGGCGGTGGTGGGCTGGATGACTTCCGGAACCATCCTTCTTCGAAGGCGTGGACTGGGA
GCGGCTGGCGAGCAGCAGGCCCCCTATATTCTGAGCTGCGGGGACCCATGGACACCTCCAACCTTGTATGTGGA
TGACGACACCCTCAACCATCCAGGGACCCCTGCCACCGCCCTCCCACGGGGCCTTCTCCGGCCATCACCTGCCATT
CGTGGGCTTCACCTACACCTCAGCTTGGGCTGCCCTGGAGCGGAAGCTCCAGTGTCTGGAGCAGGAGAAGCTCCC
AGCTGGAGGAAGCCCGCAACTGAGGAAGGAGGTGGCCGCCCTGCGAGAGCAGCTGGAGCAGGCCACAGCCACAG
CGCTCTGCAGGAGGCCGAGAAGCAGAGCCAGGCCCTGCAACAGGAGCTCGCCATGCTGCGGGAGAGCTGGAGCA
GGAGAGCAAGCAGCGGCTGGAGGGTGAGCGGCGGGAGACGGAGAGCAACTGGGAGGCCAGCTCGCCGACATCCT
CAGCTGGGTGAATGATGAGAAGGTCTCAAGAGGCTACCTGCAGGCCCTGGCCACCAAGATGGCAGAGGAGCTGGA
GTCTTTGAGGAACGTAGGCACCCAGGACCACAGTGAAGGCGCGGCGACTGCAGAAGATGGAGGCCTCGGCCAG
GCTGGAGCTGCAGTCAAGCTGGAGGCCGAGATCCGCGCAAGCAGGGCCTGCAGGAGCGGCTGACACAGGTGCA
GGAGGCCAGCTGCAGGCTGAGGGCTGTCCCCCTCCCAGCCCGGCTCACACAGCTGCGCCCCCGGAGCTTCCC
ATCCCCGACCAAGTGTCTCCGCTGCACCTCGCTGATGCTGGGCCTGGGCCGCCAGGCCCTGGGTTGTGATTGCGG
CTACTTTTGTACACAACCTGTGCCCCACAGGCCCCACCCTGCCCGTGCCCCCTGACCTCCTCCGCACAGCCCT
GGGAGTACACCCCGAAACAGGCACAGGCACTGCCTATGAGGGCTTTCTGTGAGGTGTCCGGCGGGGCTGGCAGCG
CGTGTGTGCTGCCCTGAGTGACTCACGCCTGCTGCTGTTTGACGCCCCCTGACCTGAGGCTCAGCCCGCCAGTGG
GGCCCTCCTGCAGGTCTTAGATCTGAGGGACCCCCAGTTCTCGGCTACCCCTGTCTGGCCTCTGATGTTATCCA
TGCCCAATCCAGGGACCTGCCACGCATCTTTAGGGTGAGTGCTGGTCCAGCTGGCAGTGCCGCCACACAGTG
CACTGTGCTGCTGCTGGCAGAGAGCGAGGGGAGCGGGAACGCTGGCTGCAGGTGCTGGGTGAGCTGCAGCGGT
GCTGCTGGAGCGCGGCCAAGACCCCGGCCCGTGTACACACTCAAGGAGGTTACGACAACGGGCTGCCGCTGCT
GCCTCACACGCTCTGCGTGCATCCTCGACCAAGATCGACTTGCCTTGGCACCAGGAGGGGCTCTTTGTTCAT
CCATCTGGACATCTCCAGGTGGGGGAGTGCCGGCGCTGCAGCAGCTGACCTTGAGCCCCAGTGCCAGGCCCTGCT
GGTCTGTGCTGTGTGGCCGCGGCCCCAGCGTGCGTCTCTTTGCCCTGGCGGAGCTGGAGAACATAGAGGTAGCAGG
TGCCAAGATCCCCGAGTCTCGAGGCTGCCAGGTGCTGGCAGCTGGAAGCATCTGCAGGCCCGACCCCGGTGCT
CTGTGTAGCCGTCAAGCGCCAGGTGCTCTGCTACCAGCTGGGCCCGGGCCCTGGGCCCTGGCAGCGCCGCATCCG
TGAGCTGCAGGCACCTGCCACTGTGCAGAGCCTGGGGCTGCTGGGCGACCGCTATGTGTGGGCGCCGCCGTGG
CTTTGCACTCTACCCGCTGTCTAACGAGGCTGCGCCGTTGGCGCTGGGGGCCGCTTTGGTGCCTGAGGAGCTGCC
ACCATCCCGCGGGGGCCTGGGTGAGGCACTGGGTGCCGTGGAGCTTAGCCTCAGCGAGTTTCTGCTACTCTTCAC
CACTGCTGGCATCTACGTGGATGGCGCAGGCCGCAAGTCTCGTGGCCACGAGCTGTTGTGGCCAGCAGCGCCCC
TGGCGTGCCCGCAGGGTATGCGGCCCCCTACCTGACAGTGTTTCAGCGAGAACTCCATCGATGTGTTTGACGTGAG
GAGGGCAGAATGGGTGCAGACCGTGCCGCTCAAGAAGGTGAGGGTCCGCCAGAGCCCTGGGCTGCCTCAGGTGCG
GCCCCCTCAATCCAGAGGGCTCCCTGTTCTCTACGGCACCGAGAAGTCCGCCTGACCTACCTCAGGAACAGCT
GGCAGGTGAGGGAGACGAGTTTCGACATCCCGGACCTCACCGACAACAGCCGGCGCCAGCTGTTCCGCACCAAGAG
CAAGCGCCGCTTCTTTTTCCGCGTGTGCGAGGAGCAGCAGAAGCAGCAGCGCAGGGAGATGTGAAGGACCCCTT
TGTGCGCTCCAAGCTCATCTCGCCGCTACCAACTTCAACCACCTAGTACAGTGGGCCCTGCCAACGGCGGCC
CGGCGCCAGGGACAAGTCCCCGGTTAGTCTGCTCCAGAATTGGAAATCCTAGTTTCTCTCTCCTTCGTATCCCCG

AGTCTGGGACACAAACTCCGCCCCCAGCCTATGAGCATCCTGAGCCCCGCCCTCTTCCTGACGAAACTGGCCCC
GGATCAGAGCAGGACCTCCCTTACGCCACTGCACTCCAGCCTGGCCGACAGCAAGAGTCTGTCTCCCTCCTCCAC
TCCCCATGAGCCCTAGGACGGGTCACCTCATCTCTCAGAGCCTCAGTTCCCAGCCCTGGAGGGAGATGAGGTTTC
CCAGCCCCACAGGGCTGTTGTGAGGCTGACGTGCCCTCATGGCCAAGGGCTGTCTGTAGCCTGGCCCCCGTATCC
TCTTGGGGTT

The NOV4b protein (SEQ ID NO:10) encoded by SEQ ID NO:9 is 1247 amino acid residues in length and is presented using the one-letter amino acid code in Table 4D. The SignalP, Psort and/or Hydropathy results indicate that NOV4b has no known signal peptide and is likely to be localized in the nucleus with a certainty of 0.8800. Alternatively, a NOV4b polypeptide is located to the microbody (peroxisome) with a certainty of 0.3226, the lysosome (lumen) with a certainty of 0.1925, or the mitochondrial matrix space with a certainty of 0.1000.

Table 4D. Encoded NOV4b Protein Sequence (SEQ ID NO:10)

MERRLRALEQLARGEAGGCPGLDGLLDLLLLALHHELSSGPLRRERSVAQFLSWASPFVSKVKELRLQRDDFEILK
VIGRGAFGEVTVVRQRTDGTQIFAMKMLHKWEMLKRAETACFREERDVLVKGDSRWVTTLHYAFQDEEYLYLVMDY
YAGGDLTLLSRFEDRLPPELAQFYLAEMVLAHSLHQLGYVHRDVKPDNVLLDVNGHIRLADFGSCLRLNTNGM
VDSSVAVGTPDYISPEILQAMEEGKGHYGPQCDWWSLGVCAYELLFGETPFYAESLVETYGKIMNHEDHLQFPDP
VPDVPASAQDLIRQLLCRQEERLGRGGLDDFRNHPPFEGVDWERLASSTAPYIPELRGPMDTSNFDVDDDTLNHP
GTLPPPSHGAFSGHHLPFVGFYTSAAWALERKLCLEQEKLPAGGSPQLRKEVAALREQLQAHSHRRLQEAKE
QSQALQQLAMLRREELEQESKORLEGERRETESNWEAQLADILSWVNDEKVSRYLQALATKMAEELESRLNVGT
QDHWKARRLOKMEASARLELQSALEAEIRAKQGLQERLTQVQEAQLQAECPFPQPGSHTLRPRSFPSPKCLR
CTSLMLGLGRQGLGDCGYFCHTTCAPQAPPCVPPDLLRTALGVHPETGTGTAYEGFLSGVRRGWQRFVFAALSD
SRLLLFDAPDLRLSPPSGALLQVLDLRDPQFSATPVLASDVIIHAQSRDLPRIFRVSASQLAVPPTTCTVLLLA
SEGERERWLQVLGELQRLLLDARPRPRPVYTLKEAYDNGPLPLPHTLCAAILDQDRLALGTEGLFVIHLDFQV
GECRRVQQLTLSPSAGLLVVLGCRGPSVRLFALAELENIEVAGAKIPESRGCVLAAGSILQARTPVLCAVAKRO
VLCYQLGPGPGPWQRRIRELQAPATVQSLGGLGDRLCVGAAGGFALYPLLNEAAPLALGAGLVPEELPPSRGGLG
EALGAVELSLSEFLLFTTAGIYVDGAGRKSRGHELLWPAAPPVGPAGYAAPYLTVFSENSIDVFDVRRAEWVQT
VPLKKVRVRQSPGLPQVRPLNPEGSFLYGTKEVRLTYLRNQLAGEGDEFDIPDLTDNSRRQLFRTKSKRRFFFR
VSEEQQQQRREMLKDPFVRSKLISPPTNFNHLVHVGPPANGRPGARDKSPVSPAPEFGNPSFLSFVSRVWDTKLR
PQPMISILSPALFLTKLAPDQSRSTLTPLHSSLADSKSLSPSSTPHEP

NOV4 Clones

Unless specifically addressed as NOV4a or NOV4b, any reference to NOV4 is assumed to encompass all variants.

A search against the Patp database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 4E.

Table 4E. PatP Results for NOV4

Smallest

Sequences Producing High-Scoring Segment Pairs:		High Score	Sum Prob P (N)
patp:AAB42069	Human ORFX ORF1833 polypeptide sequence	1516	1.4e-189
patp:AAU17106	Novel signal transduction pathway protein - human	1471	1.6e-150
patp:AAR56979	Human myotonic dystrophy gene protein	1326	8.5e-138
patp:AAR38860	Myotonic dystrophy protein - Human	1314	2.6e-136
patp:AAR41000	Human brain cDNA clone C28 protein kinase	1215	2.2e-123

In a BLAST search of public sequence databases, it was found, for example, that the NOV4a nucleic acid sequence of this invention has 865 of 865 bases (100%) identical to a gb:GENBANK-ID:HSMDPKIN|acc:Y12337.1 mRNA from H.sapiens mRNA for myotonic dystrophy protein kinase like protein. Further, the full amino acid sequence of the disclosed NOV4a protein of the invention has 314 of 572 amino acid residues (54%) identical to, and 418 of 572 amino acid residues (73%) similar to, the 1732 amino acid residue ptnr:SPTREMBL-ACC:O54874 protein from Rattus norvegicus (Rat) (MYTONIC DYSTROPHY KINASE-RELATED CDC42-BINDING KINASE).

Additional BLAST results are shown in Table 4F.

Table 4F. NOV4 BLASTP Results

Gene Index/ Identifier	Protein/Organism	Length of aa	Identity (%)	Positives (%)	Expect Value
Q9W1B0	GEK PROTEIN (LD24220P) - Drosophila melanogaster (fruit fly)	1637	286/553 (51%)	383/553 (69%)	8.0e-225
O44368	GENGHIS KHAN - Drosophila melanogaster (fruit fly)	1613	286/553 (51%)	383/553 (69%)	1.0e-224
O01583	HYPOTHETICAL 180.5 KDA PROTEIN - Caenorhabditis elegans	1590	291/572 (50%)	375/572 (65%)	5.0e-207
O54874	MYTONIC DYSTROPHY KINASE-RELATED CDC42-BINDING KINASE - Rattus norvegicus (Rat)	1732	314/572 (54%)	418/572 (73%)	1.2e-201
O54875	MYOTONIC DYSTROPHY KINASE-RELATED CDC42-BINDING KINASE MRCK-BETA - Rattus norvegicus (Rat)	1702	307/570 (53%)	405/570 (71%)	3.7e-193

A multiple sequence alignment is given in Table 4G, with the NOV4 proteins of the invention being shown in lines 1 and 2 in a ClustalW analysis comparing NOV4 with related protein sequences of Table 4F.

Table 4G. ClustalW Analysis of NOV4

1. SEQ ID NO.: 8	NOV4a	5. SEQ ID NO.: 146	O01583
2. SEQ ID NO.: 10	NOV4b	6. SEQ ID NO.: 147	O54874
3. SEQ ID NO.: 144	Q9W1B0	7. SEQ ID NO.: 148	O54875
4. SEQ ID NO.: 145	O44368		

	10	20	30	40	50	60	
NOV4a	-----MERRLRAL-----EOLARGEAGG-----CPGLDGLLDLILA	31					
NOV4b	-----MERRLRAL-----EOLARGEAGG-----CPGLDGLLDLILA	31					
Q9W1B0	MEYESSEISDITTTGSCCKRLTFLKCILSDTTS	DOKWAAEFGEDTEGHQFSLDYLLDFTFLV	60				
O44368	-----MYSKRHHKRS-----KWAAEFDEDETEGHQFSLDYLLDFTFLV	36					
O01583	---MAEPPPDSDAPVRLKTL-----ENIYMDGPSK-KPEALSFETLLDSLIC	43					
O54874	-----MSGEVRLRQL-----EQFILDGPAQTNGQCFSVETLLDILIC	37					
O54875	-----MSAKVRLKKL-----EQLLLDGPWR-NESSLSVETLLDVLVC	36					

	70	80	90	100	110	120	
NOV4a	LHHELSSGPLRRERSVAQFLSWASPFVSKVKELRLQRDDFEILKVIGRGAFGEVTVVRQR	91					
NOV4b	LHHELSSGPLRRERSVAQFLSWASPFVSKVKELRLQRDDFEILKVIGRGAFGEVTVVRQR	91					
Q9W1B0	LYDECSNSSLRREKGVSDFLKLSKPFVHIVRKLR	LSRDDFDILKTIIGRGAFGEVCVVMQI	120				
O44368	LYDECSNSSLRREKGVSDFLKLSKPFVHIVRKLR	LSRDDFDILKTIIGRGAFGEVCVVMQI	96				
O01583	LYDECCNSTLRKEKCIAEFVESVKTIVISKAKLR	LSRDDFEILKVIGRGAFGEVAVVVRMR	103				
O54874	LYDECNNSPLRREKNILEYLEWAKPFTSKVKQRLHREDFEILKVIGRGAFGEVAVVVKIK	97					
O54875	LYTECSHSALRRDKYVAEFLEWAKPFTQLVKDMQLHREDFEILKVIGRGAFGEVAVVVKMK	96					

	130	140	150	160	170	180	
NOV4a	DTGQIFAMKMLHKWEMLKRAETACFREERDVLVKGDSRWVITLHYAFQDEEYLYLVMDYY	151					
NOV4b	DTGQIFAMKMLHKWEMLKRAETACFREERDVLVKGDSRWVITLHYAFQDEEYLYLVMDYY	151					
Q9W1B0	STEKVYAMKILNKWEMLKRAETACFREERDVLVFGDROWITNLHYAFQDNINLYLVMDYY	180					
O44368	STEKVYAMKILNKWEMLKRAETACFREERDVLVFGDROWITNLHYAFQDNINLYLVMDYY	156					
O01583	GVGEIYAMKILNKWEMLKRAETACFREERDVLVYGDRRWITNLHYAFQDEKNLYLVMDYY	163					
O54874	NADKVFAMKILNKWEMLKRAETACFREERDVLVNGDSKWITLHYAFQDNINLYLVMDYY	157					
O54875	NTERIYAMKILNKWEMLKRAETACFREERDVLVNGDCOWITLHYAFQDENYLYLVMDYY	156					

	190	200	210	220	230	240	
NOV4a	AGGDLTLLSRFEDRLPPELAOFYLAEMVLAIHSLHQLGYVHRDVKPDNVLLDMNGHIRL	211					
NOV4b	AGGDLTLLSRFEDRLPPELAOFYLAEMVLAIHSLHQLGYVHRDVKPDNVLLDMNGHIRL	211					
Q9W1B0	CGGDLTLLSKFEDKLPEDMAKFYITETMLAINSIHQIRYVHRDVKPDNVLLDKRGHVR	240					
O44368	CGGDLTLLSKFEDKLPEDMAKFYITETMLAINSIHQIRYVHRDVKPDNVLLDKRGHVR	216					
O01583	IGGDMTLLSKFEDKLPEDMAKFYITETMLAINSIHQIRYVHRDVKPDNVLLDMOQHIRL	223					
O54874	VGGDLTLLSKFEDRLPEEMARFYLAEMVLAIDSVHQLHYVHRDVKPDNLLDMNGHIRL	217					
O54875	VGGDLTLLSKFEDKLPEEMARFYIGEMVLAIDSIHQHYVHRDVKPDNVLLDMNGHIRL	216					

		250	260	270	280	290	300		
	NOV4a	ADFGSCLRLNTN	GMVDSSVAVGTPDYISPEILOAMEEGKGYGPOCDWWSL	GLVCAYELL				271	
5	NOV4b	ADFGSCLRLNTN	GMVDSSVAVGTPDYISPEILOAMEEGKGYGPOCDWWSL	GLVCAYELL				271	
	Q9W1B0	ADFGSCLRLDKD	GTVOSSNVAVGTPDYISPEILRAMEDGKGRYGTECDWWSL	GLVCMYEMLY				300	
	O44368	ADFGSCLRLDKD	GTVOSSNVAVGTPDYISPEILRAMEDGKGRYGTECDWWSL	GLVCMYEMLY				276	
	O01583	ADFGSCLRLADG	SVASNVAVGTPDYISPEILRAMEDGGRYGRYK	ECDDWWSLGLCMYEMLY				283	
	O54874	ADFGSCLRLMED	GTVOSSVAVGTPDYISPEILOAMEDGKGRYGP	ECDDWWSLGLVCMYEMLY				277	
10	O54875	ADFGSCLKMND	DGTVOSSVAVGTPDYISPEILOAMEDGMGKYGP	ECDDWWSLGLVCMYEMLY				276	
		310	320	330	340	350	360		
	NOV4a	GETPFYAESLV	ETYGKIMNHEDHLQFPDVP---	DVPASADLI	RQLLCRQEERLGRGGI			328	
15	NOV4b	GETPFYAESLV	ETYGKIMNHEDHLQFPDVP---	DVPASADLI	RQLLCRQEERLGRGGI			328	
	Q9W1B0	GETPFYAESLV	ETYGKIMNHONCFNLP	SQETLNYKVSETSQDLLCKLICIPENRLGONGI				360	
	O44368	GETPFYAESLV	ETYGKIMNHONCFNLP	SQETLNYKVSETSQDLLCKLICIPENRLGONGI				336	
	O01583	GETPFYERL	VDTYGKIMSHODMLDFDDEID-WVVSEEA	KDLIRQLICSSDVRFGNGI				342	
	O54874	GETPFYAESLV	ETYGKIMNHKERFQFP	TQVT--DVSENAKDLIRRLIC	SREHRLGONGI			334	
20	O54875	GETPFYAESLV	ETYGKIMNHEERFQFP	SHVT--DVSEEA	KDLIRRLICSRERRLGONGI			333	
		370	380	390	400	410	420		
	NOV4a	DDFRNHPPF	EGVDWERLASSTAPYIPELRG	PMDTSNFDVD--DDTLNHPGTL	PPPSHGAF			386	
25	NOV4b	DDFRNHPPF	EGVDWERLASSTAPYIPELRG	PMDTSNFDVD--DDTLNHPGTL	PPPSHGAF			386	
	Q9W1B0	QDFMDHP	FWFVGIDWKNIRQGPAPYV	PEVSSPTDTSNFDVD--DNDVRLTDS	IPPSANPAF			418	
	O44368	QDFMDHP	FWFVGIDWKNIRQGPAPYV	PEVSSPTDTSNFDVD--DNDVRLTDS	IPPSANPAF			394	
	O01583	SDFQLH	PPFEGIDWNTIRDSNP	PPYVPEVSSPTDTSNFDVDVCE	DDFTPC	ETQPPRVLA	AF	402	
	O54874	EDFKKH	PPFSGIDWNI	RNCEAPYIPEVSSPTDTSNFDVD--	DDCLKN	SETMPPPTHTAF		392	
30	O54875	EDFKKH	AFEGIDWNI	RNLEAPYIPDVSSPSDTSNFDVD--	DDVLRN	IEILPPGSHTGF		391	
		430	440	450	460	470	480		
	NOV4a	SGHHL	PFVGF	TYTIS-----	AWAAL	ERKIQCLE		413	
35	NOV4b	SGHHL	PFVGF	TYTIS-----	AWAAL	ERKIQCLE		413	
	Q9W1B0	SGFHL	PFVGF	TYTIS-----	SS-TLDS	SKNQSSGFG		449	
	O44368	SGFHL	PFVGF	TYTIS-----	SS-TLDS	SKNQSSGFG		425	
	O01583	TCNHL	PFVGF	SYTHG	SLLSDARS	LTDEIRAIAQRCQG-----	DAELMEKS	VDGFMVELE	456
	O54874	SGHHL	PFVGF	TYTIS	SSCVLS	SDRSCLRVTAGPTSLD	LDVNVQRTLDN	NLATEAYERRIKRLE	452
40	O54875	SGHHL	PFVGF	TYTIS	TESCF	SDRGSLKSMIQSNTLT	KDEDVQRDL	ENSLQIEAYERRIKRLE	451
		490	500	510	520	530	540		
	NOV4a	QEKLPAG	-----	GSPQ	-----	LRKEVAALR	-----	433	
45	NOV4b	QEKLPAG	-----	GSPQ	-----	LRKEVAALR	-----	433	
	Q9W1B0	DDTL	DTIS---	SPQLAILPS	NNSE---	TPVDSVQLKALND	QLAALK	489	
	O44368	DDTL	DTIS---	SPQLAILPS	NNSE---	TPVDSVQLKALND	QLAALK	465	
	O01583	NEKAEL	VQKLKEAQ	TI	IAQHVAENPRSEED	RNYESTIAQLKDEI	QILN	504	
	O54874	QEKLEL	TRKLQ	ESTQT	VQALQYSTVDG	PLTASKDLETKSLKEE	EKLRLKQVAE	VNHLEQQ	512
50	O54875	QEKLEL	SRKLQ	ESTQT	VQSLHGSTR-	ALGNSNRDKETKRLNEEL	ERMKSKMAD	SNRLERQ	510
		550	560	570	580	590	600		
	NOV4a	-----	-----	-----	-----	EQLEQAHSR		443	
55	NOV4b	-----	-----	-----	-----	EQLEQAHSR		443	
	Q9W1B0	-----	-----	-----	QEKAELS	KQHNEVFERLKTQD	SELODAISOR	520	
	O44368	-----	-----	-----	QEKAELS	KQHNEVFERLKTQD	SELODAISOR	496	

001583 -----KRLEDEHALAQOOQPKDEIVAASEK 529
 054874 LEEANSVRRELDADFRIKAFKQIKTLQOEREELNKELVQASERLKNOSKELKDAHCR 572
 054875 LEDTVTLRQEHEDSTQRLKGLEKQYRLARQEKEELHKQLVEASERLKSQTKELKDAHQR 570

5 610 620 630 640 650 660
|.....|.....|.....|.....|.....|.....|.....|.....|.....|.....|.....|.....|
 NOV4a R----- 444
 NOV4b R----- 444
 Q9W1B0 NIAMMEYSEVTEKLSSELNRNOKKLSROVRDKEEELDGAMQKNDSLRNELRKSDKTRRELE 580
 10 044368 NIAMMEYSEVTEKLSSELNRNOKKLSROVRDKEEELDGAMQKNDSLRNELRKSDKTRRELE 556
 001583 K-----LKELKERNKOLVMEKSEIORELDNINDHLDQVIVEKATVVQ---QRDDMQAELA 581
 054874 KLAMQEFMEINERLTTELHTOKOKLARHVRDKEEVDLVMOKAESTRQELRRRAERAKKELE 632
 054875 KRALQEFSELNERMAELRSOKQKVSROLRDKKEEEMEVAMOKIDSMRQDIRKSEKSRKELE 630

15 670 680 690 700 710 720
|.....|.....|.....|.....|.....|.....|.....|.....|.....|.....|.....|
 NOV4a ----- 444
 NOV4b ----- 444
 Q9W1B0 LHIEDAVIEAAKEKKLREHAEDCCROLQOMELRK-----GS-SSVETTMPLSISSEMSSYE 634
 20 044368 LHIEDAVIEAAKEKKLREHAEDCCROLQOMELRK-----GS-SSVETTMPLSISSEMSSYE 610
 001583 DVGDSLLEKDSVKRLQDEAEKAKKQVADFEEK-----LKEIETEKIALI 626
 054874 VHTEALIAEASKDRKLREQSRHYSKOLENELEGLKQKQISYSPGICSIEHQOEITKLKTD 692
 054875 ARLEDAVAEASKERKLREHSEFSKQOMERELETCLKVKQGGRGPG-ATLEHQOEISKIRSE 689

25 730 740 750 760 770 780
|.....|.....|.....|.....|.....|.....|.....|.....|.....|.....|.....|
 NOV4a -----LQEAQKQSOALQOELAMLRRELEQ----- 468
 NOV4b -----LQEAQKQSOALQOELAMLRRELEQ----- 468
 Q9W1B0 IERLELQFSEKLSHQQTRHN-MELEALREQFSELENANLALTKELQQTOERLKYTOMESI 693
 30 044368 IERLELQFSEKLSHQQTRHN-MELEALREQFSELENANLALTKELQQTOERLKYTOMESI 669
 001583 KKQEEVTIEARKSVETDDHLSEEVVAAKNTIASLQATNEERETELKKLKORMDEERASHT 686
 054874 LEKKSIFYEEEEISKREGIHA-SEIKNLKKELHDSGQQLALNKEIMVLDKLEKTRRESQ 751
 054875 LEKKVLFYEEELVRRERSHV-LEVKNVKEVHESESHQLALQEVLMLEKDKLEKSKRERH 748

35 790 800 810 820 830 840
|.....|.....|.....|.....|.....|.....|.....|.....|.....|.....|.....|
 NOV4a -----ESKORLEGE-----RR 479
 NOV4b -----ESKORLEGE-----RR 479
 Q9W1B0 TDSAETLLELKKQHDLEKSSWFEEKQRLSSEVNLSKSLKELQAED---DEIFKELRMKR 750
 40 044368 TDSAETLLELKKQHDLEKSSWFEEKQRLSSEVNLSKSLKELQAED---DEIFKELRMKR 726
 001583 AQSEQEMKQLEAHYERAKMLQDNVEQMNVENRGLRDEIEKLS-----QQMAAL 735
 054874 SEREEFENEFKQOYEREKVLLTEENKKLTSELDKLTSLYESLSLRNQHLEEEVKDLADKK 811
 054875 SEMEEAIGAMKDKYERERAMLFDENKKLTANEKLCSEFVDKLTQNRQLEDELQDLASKK 808

45 850 860 870 880 890 900
|.....|.....|.....|.....|.....|.....|.....|.....|.....|.....|.....|
 NOV4a ETESNWEAQAADILSWVNDEKVSRYLQALATKMAEELESRLN-----VGTQDHQW 530
 NOV4b ETESNWEAQAADILSWVNDEKVSRYLQALATKMAEELESRLN-----VGTQDHQW 530
 Q9W1B0 EAITLWBEROMAEIIQWVSDEKDARGYLQALATKMTEELEYLKHVG---TFNNGVDNKNW 807
 50 044368 EAITLWBEROMAEIIQWVSDEKDARGYLQALATKMTEELEYLKHVG---TFNNGVDNKNW 783
 001583 PRGGLNEQOLHEIFNVVSEKATREEMENLTRKITGEVESLKNNSPLTTSNYIQNTPSGW 795
 054874 ESWAHWEAQTETIIQWVSDEKDARGYLQALASKMTEELEALRNS-----SLGTRATMPW 866
 054875 ESWAHWEAQAETIIQWVSDEKDARGYLQALASKMTEELETLRSS-----SLGSRITLPLW 863

55 910 920 930 940 950 960
|.....|.....|.....|.....|.....|.....|.....|.....|.....|.....|.....|
 NOV4a KARRLQKMAASARLELQSALEAEIRAKQGLQERLTQVQEAQLQAE----- 576

	NOV4b	KARRLOKMEASARLELQSALEAEIRAKOGLQERLTOVQEAQLQAEG-----	576
	Q9W1B0	RNRRSQKLDKMELLNQSALEAEIRAKNMISDELQTRSDLISTQKEVRDYKKRYDSILH	867
	O44368	RNRRSQKLDKMELLNQSALEAEIRAKNMISDELQTRSDLISTQKEVRDYKKRYDSILH	843
	O01583	GSRRMNNVARKDGLDLQROLQAEIDAKLKLKAEKNSQEYLTSAARLDDTEKRMASLMR	855
5	O54874	KMRRFAKLDMASARLELQSALEAEIRAKOGLQERLQVKNVKNITECKLKQSEKKNLELLS	926
	O54875	KVRRSQKLDMSARLELQSALEAEIRAKQLVHEIRKVDTSIAFESKLESEAKNRELLE	923
		970 980 990 1000 1010 1020	
10	NOV4a	-----	576
	NOV4b	-----	576
	Q9W1B0	DFQKKETELRDLQKGGLEYSESFLNKSTHHG-LSSAFFRDMSKNSEI IDSAESFGNESGD	926
	O44368	DFQKKETELRDFEKGLEYSESFLNKSTHHG-LSSAFFRDMSKNSEI IDSAESFGNESGD	902
	O01583	EVAMLKQQKNIENS-----SDSAFSSTMGRLMISMNNDYEMSNSSLMRQEMISRQSTP	910
15	O54874	EIEQLIKDTEE-LR-----SEKGVHRDSQH-SFLAFLNTPTDALDQFERSPSCTP-AGK	978
	O54875	EMQSLKKRMEEKFR-----ADTGLKLPDFQD-PIFEYFNTAPLAHDLTFRTSASDQETQ	977
		1030 1040 1050 1060 1070 1080	
20	NOV4a	-----CP-----P--	579
	NOV4b	-----CP-----P--	579
	Q9W1B0	NFTPNFFQSGNSGMLFNIEPKYAGKNNKDHSSMKEASVSDLSREESDQLVKESQKKVP--	984
	O44368	NFTPNFFQSGNSGMLFNIEPKYAGKNNKDHSSMKEASVSDLSREESDQLVKESQKKVP--	960
	O01583	-----SYENAILLHDHQVPRVDDLRYKQKPMKTASGIFSP--	946
25	O54874	-----GRIADSAPLPVHTPT-----LRKKGCPASAGFP--	1007
	O54875	-----ASKLDLSPSVSVATSTEQQEDAARSQQRPS TVPLPNT	1014
		1090 1100 1110 1120 1130 1140	
30	NOV4a	-----PQPGSHTLRPRSFPSPTKCLRCTSLMLGLGRQGLGCD-CGYFCHTTCAPQAPP	631
	NOV4b	-----PQPGSHTLRPRSFPSPTKCLRCTSLMLGLGRQGLGCD-CGYFCHTTCAPQAPP	631
	Q9W1B0	-----GNTAIHQFLVVRTFSSPTKCNHCTSLMVGLTROGVVCEICGFACHTICQKQVPT	1037
	O44368	-----GNTAIHQFLVVRTFSSPTKCNHCTSLMVGLTROGVVCEICGFACHTICQKQVPT	1013
	O01583	---VSISAMERGHNFERMKIKPTKCGHCTSLILGLDRQGLFCQSCQYACHVSCAEVVSQ	1003
35	O54874	-----PKRKTHQFFVKSFPTAPTKCHQCTSLMVGLTROGCSCFVCGFSCHITCNKAPT	1060
	O54875	QALAMAGPKPKAHQESIKSFPSPTCSHCTSLMVGLTROGYACEVCAFSCHVSCKDSAPQ	1074
		1150 1160 1170 1180 1190 1200	
40	NOV4a	-CPVPPDLLRTALGVHPETGTGTAYEGFL-----SGVRRGWQRVFAALSDSRLLLEDAPD	685
	NOV4b	-CPVPPDLLRTALGVHPETGTGTAYEGFL-----SGVRRGWQRVFAALSDSRLLLEDAPD	685
	Q9W1B0	TCPVPMDOTKRPLGIDPTRGIGTAYEGYVVKVPSGVIKRGWIRQFVVVCDKFLFLYDISP	1097
	O44368	TCPVPMDOTKRPLGIDPTRGIGTAYEGYVVKVPSGVIKRGWIRQFVVVCDKFLFLYDISP	1073
	O01583	SCPVP-EEERRPLGIDPTRGVGTAYEGLVKTPRAGGVKRGWQTAYVVVCDKFLFLYDCTV	1062
45	O54874	TCPVPPEQTKPLGIDPQKGVGTAYEGHVRIIPKIPAGVKKGWQALAVVCDKFLFLYDIAE	1120
	O54875	VCPVPPEQSKRPLGVDVQRGIGTAYKGYVVKVPSKPTGVKKGWQRAYAVVCDCKFLFLYDLPE	1134
		1210 1220 1230 1240 1250 1260	
50	NOV4a	LR---LSPPSGALLQVLDLRDPQFSATPVLASDVIHAQSRDLPRIFRVTT-SQLAVPPTT	741
	NOV4b	LR---LSPPSGALLQVLDLRDPQFSATPVLASDVIHAQSRDLPRIFRVSAWSQLAVPPTT	742
	Q9W1B0	DR---CALPSVSVSQVLDLRDPFSVGSVRESVDVIHAAKKDVPCIFKIKT--ALIDGGLS	1152
	O44368	DR---CALPSVSVSQVLDLRDPFSVGSVRESVDVIHAAKKDVPCIFKIKT--ALIDGGLS	1128
	O01583	DRQNMQDVKNETRLVLDLRDPDFVCGVSEADVIHAQKGDIPKIFRVITTTQILNNSSEY	1122
55	O54874	GK---ASQPSVSVSQVLDLRDEEFVSSVVASDVIHASRKDIPCFIRVIA-SQLSAPSDK	1176
	O54875	GK---STOPGVIASQVLDLRDEEFVSSVVASDVIHATRRDIPCFIRVIA-SLLGSPSKI	1190

		1270	1280	1290	1300	1310	1320	
NOV4a	CT-----VLLLAESEGERERWLVQLGELQRLLLDARPRPRPVYTLKEAYDN-GLPLLPHT	795						
NOV4b	CT-----VLLLAESEGERERWLVQLGELQRLLLDARPRPRPVYTLKEAYDN-GLPLLPHT	796						
Q9W1B0	LN-----TLMLADNESEKSKWVIALGELHRLKRNLSLPNTAIFKVNEILDN-TLSLIRNA	1206						
O44368	LN-----TLMLADNESEKSKWVIALGELHRLKRNLSLPNTAIFKVNEILDN-TLSLIRNA	1182						
O01583	SSSSKFYTLFMAETEEBKRWVVALSELKTLIRRSKLADRKAFLVKEVFDVTTLPISIRVA	1182						
O54874	CS-----ILMLADSETERSKWVGVLSELHKVLKKNKFRDRSVYVPKEAYDS-TLPLIKTT	1230						
O54875	SS-----LLILTENENEKRWVGILEGLQAILHKNLRLRSQVVHVAAQAYDS-SLPLIKTV	1244						
		1330	1340	1350	1360	1370	1380	
NOV4a	LCAAILDQDRIALGT-EEGLFVTHLD---IFQVGECCR---VQQLTLSPSAGLLVVLVC	846						
NOV4b	LCAAILDQDRIALGT-EEGLFVTHLD---IFQVGECCR---VQQLTLSPSAGLLVVLVC	847						
Q9W1B0	LCSVIIYPNQILLGT-EDGLFYINLDQYETARIGESKK---ILOLWYIEEEQILVILC	1260						
O44368	LCSVIIYPNQILLGT-EDGLFYINLDQYETARIGESKK---ILOLWYIEEEQILVILC	1236						
O01583	QCCAILDRSKIVIGFSDHGLYCTEISRQLIPVCGEKENKQRCVETVEYDEAEQLMMIV	1242						
O54874	QAAAILDHERVALGN-EEGLFVVHVTKDELIRVGNKK---IHQELIPSDQLVAVIS	1284						
O54875	LAAAILVDGDRILAVGL-EEGLYVIELTRDVIVRAADCKK---VYQELAPKEKLLILLC	1298						
		1390	1400	1410	1420	1430	1440	
NOV4a	G--RGPSVRLFALAELENIEVAGA--KIPESRGCVLAAGSIL--QARTPVLCAVAMKR--	898						
NOV4b	G--RGPSVRLFALAELENIEVAGA--KIPESRGCVLAAGSIL--QARTPVLCAVAMKR--	899						
Q9W1B0	G--KQRNRLRLPIRALEASDVWEI--KVVESKNCISACTGIIRRFNPVYSFIALKRPN	1316						
O44368	G--KQRNRLRLPIRALEASDVWEI--KVVESKNCISACTGIIRGFNPVYSFIALKRPN	1292						
O01583	GPAKDRHVRIIVPSAALDGRDLKWI--KVNDTKGCHLLAVGTNNP--GGRAGFFAVAFKK--	1297						
O54874	G--RNRRVRLFPMSALDGRETDYF--KLAETKGCQTIAAGKVR--HGALSCLCAVAMKR--	1336						
O54875	G--RNHRVHLYPWTISFDGAASNFDIKLPETKGCQLLATGTLR--KSSSTCLFVAMKR--	1352						
		1450	1460	1470	1480	1490	1500	
NOV4a	---QVLCYQLGPGPGPWQRRIRELQAPATVQSLGLLGDR-LCVGAAGGFALYPLLNAAAP	954						
NOV4b	---QVLCYQLGPGPGPWQRRIRELQAPATVQSLGLLGDR-LCVGAAGGFALYPLLNAAAP	955						
Q9W1B0	NHTQIVVYEINR-TRTRHQKTCEFTIGYMAOHLQILSDMRLVVAHQSGFTAYFLRGEATA	1375						
O44368	NHTQIVVYEINR-TRTRHQKTCEFTIGYMAOHLQILSDMRLVVAHQSGFTAYFLRGEATA	1351						
O01583	---SVTIFQIDR-SEKRHKKWKDLAMPGTQSIATFNGR-LYVGFSHSFRSWSLVGVDS	1352						
O54874	---QVLCYELFQ-SKTRHRKFKELQVPCNVQWMAIFSEH-LCVGFQSGFLRYPLNGEGSP	1391						
O54875	---LVLCYELIOR-TKPFHRKFKNEIVAPGHVQWMAFMKDR-LCVGYPSGFSLLSIQGDGP	1407						
		1510	1520	1530	1540	1550	1560	
NOV4a	-----LALGAGLVPEELPPSRGGLGEALGAVELSLS-----EYLLLFITTA	994						
NOV4b	-----LALGAGLVPEELPPSRGGLGEALGAVELSLS-----EYLLLFITTA	995						
Q9W1B0	-----MSLVHPENQLCAFLNYSGV-DAVRVIEILCPSGGNFGEYLLVFQITL	1420						
O44368	-----MSLVHPENQLCAFLNYSGV-DAVRVIEILCPSGGNFGEYLLVFQITL	1396						
O01583	PVGSGDASGAVLQHISLVNMDTSLQFLNQOTSIEAKLIVNVPGSPD-----EYLLVFNMT	1408						
O54874	-----CNMLHSNDHTLAFITHQPM-DALCAVELSNK-----EYLLCFSSI	1430						
O54875	-----LDLVNPADPSLAFLSQQSF-DALCAVELKSE-----EYLLCFSHM	1446						
		1570	1580	1590	1600	1610	1620	
NOV4a	GIYVDGAGRKS-----LFSENSIDVFDVRRAEWVQTVPLKK	1030						
NOV4b	GIYVDGAGRKS-----LFSENSIDVFDVRRAEWVQTVPLKK	1055						
Q9W1B0	AIYVDLQGRKSRDREIMYPAFP--TYITECDGHLLVFSDFTHLDIFNTQTAEWVQSIGLKO	1478						
O44368	AIYVDLQGRKSRDREIMYPAFP--TYITECDGHLLVFSDFTHLDIFNTQTAEWVQSIGLKO	1454						
O01583	GLYVNEMGRRSRLPEVMEPTQA--KYFAYHEPYLCVFSENEVDIFNVTLAEWVQVINLRS	1466						

054874 GIYTDQGRRSRQOELMWPANP--SSCCYNAPYLSLYSENAVDIFDVNSMEWITOTLPLKK 1488
 054875 GLYVDPQGRRSRTQOELMWPAAP--VACSCSSSHVTWSEYGVDFVDMETMEWVQTIGLRR 1504

1630 1640 1650 1660 1670 1680
 5
 NOV4a VR-----PLNPEGSLFLYGTEK-----DEFDIPDLTDNSRRQLFR 1065
 NOV4b VRVRQSPGLPQVRPLNPEGSLFLYGTEKVRITYLRNQLAGEGDEFDIPDLTDNSRRQLFR 1115
 Q9W1B0 SL-----PLNNLGNVVLSSVNDTPLIVYLSN---IHTKGLQYRDGNRKGLPS 1523
 O44368 SL-----PLNNLGNVVLSSVNDTPLIVYLSN---IHTKGLQYRDGNRKGLPS 1499
 10 O01583 AK-----PLSGDGILSTCLCNDSPILFVLLQNVLQDQDSIEVFNLAGSTDGRL 1515
 O54874 VR-----PLNTEGSLNLLGLEITIRLIYFKNKMAE-GDELVVPETSDNSRKQMR 1536
 O54875 IR-----PLNSLGSLNLLGCEPPCLIIYFKNKFS--GTVLNWEDTSDNSKKQMLR 1551

1690 1700 1710 1720 1730 1740
 15
 NOV4a -TKSKRRFFFRVSEEQQKQORREMLKDPFVRSKLISPTNFNHIVHMGFANG----- 1116
 NOV4b -TKSKRRFFFRVSEEQQKQORREMLKDPFVRSKLISPTNFNHIVHMGFANG----- 1166
 Q9W1B0 ---IKRRFSIREINKTIKSDR-----RSKMISAPTNNFNHISHMGPGDGIQ----- 1565
 O44368 ---IKRRFSIREINKTIKSDR-----RSKMISAPTNNFNHISHMGPGDGIQ----- 1541
 20 O01583 --VTRRKFTFRTIGKDDRSASERR-----SHIQISTPSEFMHTVHMGFAP----- 1558
 O54874 NINNKKRRYSFRVPEEERMQQORREMLRDPPEMRNKLISNPTNFNHIAHMGPGDGIQILKDLP 1596
 O54875 -TRSKRRFVEKVPPEERLQORREMLRDPPELRSKMISNPTNFNHIAHMGPGDGLCMQVLM DLP 1610

1750 1760 1770 1780 1790 1800
 25
 NOV4a ---RPGARD-----KSPVSPAPEFGNP-----SFLSFVSRVWDTK 1148
 NOV4b ---RPGARD-----KSPVSPAPEFGNP-----SFLSFVSRVWDTK 1198
 Q9W1B0 -----NQRLLDLPTTLET-----ADQACSPIIHS 1589
 O44368 -----NQRLLDLPTTLET-----ADQACSPIIHS 1565
 30 O01583 -----VMELOQNFI DLQSNHSHSTSSDKDSLNR 1586
 O54874 MNPRPQESRTVFSGSVSIPSITKSRPEPGRSMSASSGLSARSSAQNGSALKREFSGGSYN 1656
 O54875 LSVRPQPRR-----KSRVLPQQASLGS--LPSR---NKPYVSWPSSGGSEP 1651

1810 1820 1830 1840 1850 1860
 35
 NOV4a LRPQPM S ILS-----PAL---FLT KLAPDQSR TSLT PLHSS LADSKSLSPSS 1192
 NOV4b LRPQPM S ILS-----PAL---FLT KLAPDQSR TSLT PLHSS LADSKSLSPSS 1242
 Q9W1B0 LSCIPQSRKS-----N-----FLEQVDANSDDYGNDNIIISRTSPMASSEFMD 1631
 O44368 LSCIPQSRKS-----N-----FLEQVDANSDDYGNDNIIISRTSPMASSEFMD 1607
 40 O01583 -----VMELOQNFI DLQSNHSHSTSSDKDSLNR 1586
 O54874 TKRQPMPSPEGSLSSGGVDQGS DAPVRDYDGE-DSDSPRHSTASNSNLSSPPSPVSPR 1715
 O54875 GVPVPLRSMS-----D--PDQ---DEFDKEPDSSTKHS LRPTAPT LAAPRAPHRT 1697

1870
 45
 NOV4a TPHEP----- 1197
 NOV4b TPHEP----- 1247
 Q9W1B0 GLSNND----- 1637
 O44368 GLSNND----- 1613
 50 O01583 VNND----- 1590
 O54874 KTKSLSLESTDRGSWDP 1732
 O54875 GASSL----- 1702

The presence of identifiable domains in the disclosed NOV4 protein was determined by using Pfam and then determining the Interpro number. The results are listed in Table 4H with the statistics and domain description.

Table 4H. Domain Analysis of NOV4		
PSSMs Producing Significant Alignments	Score (bits)	E Value
pkinese: domain 1 of 1, from 71 to 337	231.5	1.3e-65
PKinase yelleklGeGsfgkVykakhk.tgkivAvKilkkesls.....l ++++++ + ++ + ++ ++++++ + +++++ ++ ++ +		
NOV4 FEILKVIGRGAFGEVTVVRQRdTGQIFAMKMLHKWEMlkraetacFR		
PKinase rEiqilkrslsHpNIvrlIlgvfedtdhlylvmEymegGdLfdylrrng.p ++ + + + + ++++++ ++++++ ++++++ + + +++++ ++		
NOV4 EERDVLVKGDSRWVTTLHYAFQ-DEEYLYLVMDYYAGGDLTLLSRFEdR		
PKinase lsekeakkialQilrGleYLHsngivHRDLKpeNILldengtvKiaDFGL ++++ +++++ +++++ + + + + + + + + ++++++		
NOV4 LPPELAQFYLAEMVLAIHSLHQLGYVHRDVKPDNVLLDVNGHIRLADFGS		
PKinase Arll.....eklTtfvGTpwYmmAPEvileg.....rgysskvDvWSlGv + +++++ + + + + + + + + +++++ ++++++ + +		
NOV4 CLRLntngmVDSSVAVGTPDYI-SPEI-LQAmeeGkGHYGPQCDWWSLGV		
PKinase iLyElItggplfpgadlpftggdevdqliifvklPfsdelpktridpl + ++++ +++++ +++++ +++++ +++++ +++++ +++++ +++++ +++++		
NOV4 CAYELLFG-----ETPFYA-----ESLV		
PKinase eelfrikkr..rlplpsncSee...lkdLlkkcLnkDPskRpGsatakei + + ++ +++++ +++++ +++++ +++++ +++++ +++++ +++++ +++++ +++++		
NOV4 ETYGKIMNHedHLQFPDPDPVpasAQDLIRQLLCRQ-EERLGRGGLDDF		
PKinase lnhpwf (SEQ ID NO:149) +++++		
NOV4 RNHPFF (SEQ ID NO:8)		

Consistent with other known members of the myotonic dystrophy kinase-related Cdc42-binding kinases (MRCKs) family of proteins, NOV4 contains protein kinase domains as illustrated in Table 4H.

NOV4 nucleic acids, and the encoded polypeptides, according to the invention are useful in a variety of applications and contexts. For example, NOV4 nucleic acids and polypeptides can be used to identify proteins that are members of the protein kinase family of proteins. The NOV4 nucleic acids and polypeptides can also be used to screen for molecules, which inhibit or

enhance NOV4 activity or function. Specifically, the nucleic acids and polypeptides according to the invention may be used as targets for the identification of small molecules that modulate or inhibit, *e.g.*, cytoskeletal reorganization or molecular switch mechanisms. These molecules can be used to treat, *e.g.*, myotonic dystrophy, myotonic dystrophy type 2, proximal myotonic myopathy, or proximal myotonic dystrophy.

In addition, various NOV4 nucleic acids and polypeptides according to the invention are useful, *inter alia*, as novel members of the protein families according to the presence of domains and sequence relatedness to previously described proteins. For example, the NOV4 nucleic acids and their encoded polypeptides include structural motifs that are characteristic of proteins belonging to the family of protein kinases such as the MRCK protein. MRCK is a Ser/Thr kinase that is highly related to myotonic dystrophy kinase and ROKs. MRCK contains an N-terminal kinase domain, a coiled-coil region, a cysteine-rich domain (CR), a pleckstrin-like domain (PH), and a C-terminal p21 GTPase-binding domain (GBD). Two different MRCK genes are expressed in rat. MRCKa mRNA is enriched in brain and lung, while MRCKb mRNA is expressed in lung and kidney. MRCKa phosphorylates Ser/Thr residues in myelin basic protein, histone H1, and non-muscle myosin regulatory light chain. In HeLa cells, expression of kinase-dead MRCKa blocks Cdc42-dependent formation of focal complexes and peripheral microspikes, while in PC12 cells MRCKa may act downstream of Cdc42 and Rac1 to promote neurite outgrowth.

The NOV4 nucleic acids and polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications in the mediation of cell migration and differentiation. As such the NOV4 nucleic acids and polypeptides, antibodies and related compounds according to the invention may be used to treat muscle, or cell migration disorders, *e.g.*, myotonic dystrophy, myotonic dystrophy type 2, proximal myotonic myopathy, proximal myotonic dystrophy, neuromuscular diseases associated with cardiomyopathy, multiple endocrine neoplasia type 1(MEN1), insulin dependent diabetes mellitus, familial paraganglioma type 2, spinocerebellar ataxia type 5, Bardet-Biedl syndrome, non-hodgkins lymphoma, cancers such as breast cancer, liver, lung, pancrease, and prostate cancers.

The NOV4 nucleic acids and polypeptides are useful for detecting specific cell types. For example, expression analysis has demonstrated that a NOV4 nucleic acid is expressed in adrenal gland, bone marrow, brain - amygdala, brain - cerebellum, brain - hippocampus, brain -

substantia nigra, brain - thalamus, brain -whole, fetal brain, fetal kidney, fetal liver, fetal lung, heart, kidney, lymphoma - Raji, mammary gland, pancreas, pituitary gland, placenta, prostate, salivary gland, skeletal muscle, small intestine, spinal cord, spleen, stomach, testis, thyroid, trachea, and uterus.

5 Additional utilities for NOV4 nucleic acids and polypeptides according to the invention are disclosed herein.

NOV5

10 The disclosed NOV5 nucleic acid (alternatively referred to herein as CG56288-01) encodes a novel S100 calcium binding-like protein and includes the 332 nucleotide sequence (SEQ ID NO:11) shown in Table 5A. Although SignalP, Psort and/or hydropathy suggest that the S100 Calcium Binding Protein-like protein may be localized in the cytoplasm, the protein predicted here is similar to the S100 Calcium Binding Protein family, some members of which are secreted. Therefore it is likely that this novel S100 Calcium Binding Protein-like protein is available at the same sub-cellular localization and hence accessible to a diagnostic probe and for various therapeutic applications.

15 An open reading frame for the mature protein was identified beginning with an ATG initiation codon at nucleotides 8-10, and ending with a TGA stop codon at nucleotides 320-322. Putative untranslated regions, if any, are found upstream from the initiation codon and downstream from the termination codon. The start and stop codons are in bold letters.

Table 5A. NOV5 Nucleotide Sequence (SEQ ID NO:11)

CTCCAAC ATGG CAAAAATCTCCAGCCCTACAGAGACTGTGCGGTGCATTCAGTCCCTGATTGCTGTTTTCCAGAA GTATGCTGGAAAGGATGGTTACAACCGCAATCTCTCCAAGACGGAGTTCCTAAGCTTCATGAATACAGAGCTGGC TGCCTTTACAAAGAACCAGAAGGACCCCGGTGTCCTTGACCGCATGAAGAACTGGATGTCAGCAGCGATGGGCA GTTAGATTTCCCAAATTTCTTAATCTGATTGGCGGCTAGCTGTGGCTTGCCATGACTCCTTCCTCAAGGCTGT CCCTTCCCAGAAGTGGAAGT GAGGACCCCATG
--

25 The NOV5 protein (SEQ ID NO:12) encoded by SEQ ID NO:11 is 104 amino acid residues in length and is presented using the one-letter amino acid code in Table 5B. The SignalP, Psort and/or Hydropathy results indicate that NOV5 has no known signal peptide and is likely to be localized in the mitochondrial matrix space with a certainty of 0.5964. Alternatively,

a NOV5 polypeptide is located to the mitochondrial inner membrane with a certainty of 0.3037, the mitochondrial intermembrane space with a certainty of 0.3037, or the mitochondrial outer membrane with a certainty of 0.3037.

Table 5B. Encoded NOV5 Protein Sequence (SEQ ID NO:12)

MAKISSPTETVRCIQSLIAVFQKYAGKDGYNRLSKTEFLSFMNTELA AFTKNQKDPGVLD RMKKLDVSSDQGLD
FPKFLNLIIGGLAVACHDSFLKAVPSQKWN

A search against the Patp database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 5C.

Table 5C. PatP Results for NOV5

		High Score	Smallest Sum Prob P (N)
Sequences Producing High-Scoring Segment Pairs:			
patp:AAB58356	Lung cancer associated polypeptide sequence - human	467	4.0e-44
patp:AAB45541	Human S100A11 protein - Homo sapiens	467	4.0e-44
patp:AAU31484	Novel human secreted protein #1975	232	3.2e-19
patp:AAB45531	Human S100A1 protein	167	2.5e-12
patp:AAM40258	Human polypeptide	167	2.5e-12

In a BLAST search of public sequence databases, it was found, for example, that the NOV5 nucleic acid sequence of this invention has 305 of 335 bases (91%) identical to a gb:GENBANK-ID:HUMS100CP1|acc:D49355.1 mRNA from Human mRNA for S100C protein, complete cds. Further, the full amino acid sequence of the disclosed NOV5 protein of the invention has 102 of 103 amino acid residues (99%) identical to, and 102 of 103 amino acid residues (99%) similar to, the 104 amino acid residue ptnr:SPTREMBL-ACC:Q9UDP3 protein from Human (WUGSC:H_NH0456N16.1 PROTEIN).

The NOV5 protein of the invention also has homolgy to the proteins shown in the BLASTP data in Table 5D.

Table 5D. NOV5 BLASTP Results

Gene Index/ Identifier	Protein/Organism	Length of aa	Identity (%)	Positives (%)	Expect Value
---------------------------	------------------	-----------------	--------------	---------------	--------------

Q9UDP3	Putative S100 calcium-binding protein H_NH0456N16.1 - Homo sapiens (Human)	104	102/103 (99%)	102/103 (99%)	6.0e-50
O60417	S100 calcium-binding protein A14 - Homo sapiens (Human)	102	99/102 (97%)	100/102 (98%)	3.8e-48
P31949	Calgizzarin (S100C protein) (MLN 70) - Homo sapiens (Human)	105	93/103 (90%)	97/103 (94%)	5.2e-44
P24480	Calgizzarin (S100C protein) - Oryctolagus cuniculus (Rabbit)	102	83/100 (83%)	92/100 (92%)	3.0e-39
P50543	Calgizzarin (Endothelial monocyte-activating polypeptide) (EMAP) - Mus musculus (Mouse)	98	79/96 (82%)	87/96 (90%)	1.7e-36

A multiple sequence alignment is given in Table 5E, with the NOV5 protein of the invention being shown in line 1 in a ClustalW analysis comparing NOV5 with related protein sequences of Table 5D.

Table 5E. ClustalW Analysis of NOV5

1. SEQ ID NO.: 12	NOV5	4. SEQ ID NO.: 152	P31949
2. SEQ ID NO.: 150	Q9UDP3	5. SEQ ID NO.: 153	P24480
3. SEQ ID NO.: 151	O60417	6. SEQ ID NO.: 154	P50543

		10	20	30	40	50	60	
NOV5	MAKISSPTETVRCISLI	AVFQKYAGKDGYN	RNLSKTEFLSFMNTE	LAAFTKNQKDPGVL	60			
Q9UDP3	MAKISSPTETVRCISLI	AVFQKYAGKDGYN	CNLSKTEFLSFMNTE	LAAFTKNQKDPGVL	60			
O60417	MAKISSPTETERCIESLI	AVFQKYAGKDGYN	RNLSKTEFLSFMNTE	LAAFTKNQKDPGVL	60			
P31949	MAKISSPTETERCIESLI	AVFQKYAGKDGYN	YTLTKTEFLSFMNTE	LAAFTKNQKDPGVL	60			
P24480	---MSRPTETERCIESLI	AVFQKYAGKDGHS	VTLSKTEFLSFMNTE	LAAFTKNQKDPGVL	57			
P50543	-----MPTETERCIESLI	AVFQKYS	SGKDGNN	TQLSKTEFLSFMNTE	LAAFTKNQKDPGVL	55		
		70	80	90	100			
NOV5	DR-MKKLDVSSDGQ	LDFPKFLN	LIGGLAVACHDS	FLKAVPSQKWN	104			
Q9UDP3	DR-MKKLDVSSDGQ	LDFPKFLN	LIGGLAVACHDS	FLKAVPSQKWT	104			

O60417 DH-MKKLDVSSDGQLDFPKFLNLIGGLAVACHDSFLKAVPSQK-- 102
P31949 DRMMKKLDTNSDGQLDFSEFLNLIGGLAMACHDSFLKAVPSQKRT 105
P24480 DRMMKKLDLNSDGQLDFQEFNLIGGLAVACHESFVKAAPPQKRF 102
P50543 DRMMKKLDLNCQDGLDFQEFNLIGGLAMACHDSFLQTS--QKRI 98

The presence of identifiable domains in the disclosed NOV5 protein was determined by using Pfam and then determining the Interpro number. The results are listed in Table 5F with the statistics and domain description.

Table 5F. Domain Analysis of NOV5		
PSSMs Producing Significant Alignments		E Value
S_100: domain 1 of 1, from 10 to 53		8.8e-14
S-100	LEkaietiInvFhqYSgreGdkdtLsKkELKeLlekELpnfLkn + +++ ++ ++ ++ ++++ + + + +++++ + +++++	(SEQ ID NO:155)
NOV5	TVRCIQSLIAVFQKYAGKDGYNRNLSKTEFLSFMNTELAFTKN	(SEQ ID NO:12)

Consistent with other known members of the S100 family of proteins, NOV5 contains S100 calcium binding domains as illustrated in Table 5F.

The NOV5 nucleic acid, and the encoded polypeptide, according to the invention are useful in a variety of applications and contexts. For example, NOV5 nucleic acids and polypeptides can be used to identify proteins that are members of the S100 family of proteins. The NOV5 nucleic acids and polypeptides can also be used to screen for molecules, which inhibit or enhance NOV5 activity or function. Specifically, the nucleic acids and polypeptides according to the invention may be used as targets for the identification of small molecules that modulate or inhibit, *e.g.*, calcium regulation. These molecules can be used to treat, *e.g.*, various cancers like breast, lung, or colorectal.

In addition, the NOV5 nucleic acid and polypeptide according to the invention are useful, *inter alia*, as novel members of the protein families according to the presence of domains and sequence relatedness to previously described proteins. For example, the NOV5 nucleic acid and polypeptide include structural motifs that are characteristic of proteins belonging to the family of S100 proteins. S100 proteins are expressed in a cell-type specific manner in higher organisms, including humans, and are involved in the calcium-regulated control of very diverse cellular

processes. Proteins of the S100 family belong to the large group of EF-hand calcium-binding proteins.

The NOV5 nucleic acid and polypeptide, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications in the mediation of calcium regulation. As such the NOV5 nucleic acid and polypeptide, antibodies and related compounds according to the invention may be used to treat genetic conditions, *e.g.*, various cancers like breast, lung, and colorectal, as well as heart disease such as myocardial ischemia.

The NOV5 nucleic acid and polypeptide are useful for detecting specific cell types. For example, expression analysis has demonstrated that a NOV5 nucleic acid is expressed in elevated levels in colorectal cancers compared with that of normal colorectal mucosa, as well as in breast cancer-derived metastatic axillary lymph nodes, but not in normal lymph nodes or breast fibroadenomas. Accordingly, the NOV5 nucleic acids and polypeptides, antibodies and related compounds according to the invention will have diagnostic and therapeutic applications in the detection of cancer, *e.g.*, breast or colorectal cancer. A NOV5 nucleic acid is also expressed in brain, lung, smooth muscle and keratinocyte tissue.

Additional utilities for the NOV5 nucleic acid and polypeptide according to the invention are disclosed herein.

NOV6

The disclosed NOV6 nucleic acid (alternatively referred to herein as CG56048-01) encodes a novel olfactory receptor-like protein/G-protein coupled receptor (GPCR) protein and includes the 1121 nucleotide sequence (SEQ ID NO:13) shown in Table 6A.

An open reading frame for the mature protein was identified beginning with an ATG initiation codon at nucleotides 30-32, and ending with a TAG stop codon at nucleotides 1119-1121. Putative untranslated regions, if any, are found upstream from the initiation codon and downstream from the termination codon. The start and stop codons are in bold letters.

Table 6A. NOV6 Nucleotide Sequence (SEQ ID NO:13)

TTATTTCAAAAACCTTTTCGATACTGCTCCTATGGCTCCCCATGTCCGAATATGTATGCCCTTGACGGACGGCATTTC
CTTCATTTGAGGACCTCTTGGCTAACAATATCCTCAGAATATTTGTCTGGGTTATAGCTTTCATTACCTGCTTTG
GAAATCTTTTTGTCAATTGGCATGAGATCTTTCATTAAAGCTGAAAATACAACCTACGCTATGTCCATCAAAATCC
TTTGTGTGCTGATTGCCTGATGGGTGTTTACTTGTTCTTTGTTGGCATTTCGATATAAAATACCGAGGGCAGT

ATCAGAAGTATGCCTTGCTGTGGATGGAGAGCGTGCAGTGCCGCCTCATGGGGTTCCCTGGCCATGCTGTCCACCG
AAGTCTCTGTTCTGCTACTGACCTACTTGACTTTGGAGAAGTTCCTGGTCATTGTCTTCCCCCTTCAGTAACATTC
GACCTGGAAAACGGCAGACCTCAGTCATCCTCATTTGCATCTGGATGGCGGGATTTTAAATAGCTGTAATCCAT
TTTGGAATAAGGATTATTTTGGAAACTTTTATGGGAAAAATGGAGTATGTTTCCCAC'TTATTATGACCAAACAG
AAGATATTGGAAGCAAAGGGTATTCTCTTGGAATTTTCTAGGTGTGAAC'TTGCTGGCTTTTCTCGTCATTGTGT
TTTCCTATATTACTATGTTCTGTTCCATTCAAAAAACCGCCTTGACAGACCACAGAAGTAAGGAATTGTTTTGGAA
GAGAGGTGGCTGTTGCAAAATCGTTTCTTTTTTATAGTGTTCTCTGATGCCATCTGCTGGATTCCCTGTATTTGTAG
TTAAAATCCTTTCCCTCTTCCGGGTGGAAATTCAGACACAATGACTTCCTGGATAGTGATTTTTTTCCTTCCAG
TTAACAGTGCTTTGAATCCAATCCTCTATACTCTCACAACCAACTTTTTTAAGGACAAGTTGAAACAGCTGCTGC
ACAAACATCAGAGGAAATCAATTTTCAAAATTAATAAAAAAAGTTTATCTACATCCATTGTGTGGATAGAGGACT
CCTCTTCCCTGAAACTTGGGGTTTGAACAAAATAACACTTGGAGACAGTATAATGAAACCAGTTTCCTAG

The NOV6 protein (SEQ ID NO:14) encoded by SEQ ID NO:13 is 363 amino acid residues in length and is presented using the one-letter amino acid code in Table 6B. The SignalP, Psort and/or Hydropathy results indicate that NOV6 has a signal peptide and is likely to be localized in the plasma membrane with a certainty of 0.6000. Alternatively, a NOV6 polypeptide is located to the Golgi body with a certainty of 0.4000, the endoplasmic reticulum (membrane) with a certainty of 0.3000, or the mitochondrial inner membrane with a certainty of 0.0300. The SignalP indicates a likely cleavage site for a NOV6 polypeptide is between positions 41 and 42, *i.e.*, at the dash in the sequence CFG-NL.

Table 6B. Encoded NOV6 Protein Sequence (SEQ ID NO:14)

MAPHVRICMPLTDGISSFEDLLANNILRIFVWVIAFITCFGNLFVIGMRSFIKAENTHAMSILCCADCLMGV
YLFFVGIFDIKYRGQYQKYALLWMESVQCRLMGFLAMLSTEVSVLLTYLTLEKFLVIVFPFSNIRPGKRQTSVI
LICIWMAGFLIAVIPFWNKDYFGNFYKNGVCFPLYDQTEDIGSKGYSLGIFLGVNLLAFLVIVFSYITMFCSI
QKTALQTEVRNCFGREVAVANRFFFIVFSDAICWIPVFVVKILSLFRVEIPDTMTSWIVIFFLPVNSALNPILY
TLTNNFFKDKLKQLLHKHQKRSIFKIKKSLSTSIVWIEDSSSLKGLVNLKITLGDSIMKPVS

SNP variants of NOV6 are disclosed in Example 2.

A search against the Patp database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 6C.

Table 6C. PatP Results for NOV6

		High Score	Smallest Sum Prob P (N)
Sequences Producing High-Scoring Segment Pairs:			
patp:AAU04370	Human G-protein coupled receptor, hRUP16	1840	1.3e-189
patp:AA42170	Human LGR7 long form protein sequence	1117	5.3e-113
patp:AA42171	Human LGR7 short form protein sequence	1117	5.3e-113

patp:AAE02498	Human CON222 G protein-coupled receptor protein	1117	5.3e-113
patp:AAY57286	Human GPCR protein (HGPRP) sequence (clone ID 2488822)	1111	2.3e-112

In a BLAST search of public sequence databases, it was found, for example, that the NOV6 nucleic acid sequence of this invention has 723 of 1057 bases (68%) identical to a gb:GENBANK-ID:AF190500|acc:AF190500.1 mRNA from Homo sapiens leucine-rich repeat-containing G protein-coupled receptor 7 (LGR7) mRNA, complete cds. Further, the full amino acid sequence of the disclosed NOV6 protein of the invention has 203 of 339 amino acid residues (59%) identical to, and 271 of 339 amino acid residues (79%) similar to, the 757 amino acid residue ptrn:TREMBLNEW-ACC:AAG17167 protein from Human (LEUCINE-RICH REPEAT-CONTAINING G PROTEIN-COUPLED RECEPTOR 7).

The NOV6 protein of the invention also has homolgy to the proteins shown in the BLASTP data in Table 6D.

Table 6D. NOV6 BLASTP Results

Gene Index/ Identifier	Protein/Organism	Length of aa	Identity (%)	Positives (%)	Expect Value
Q91ZZ5	G PROTEIN COUPLED RECEPTOR AFFECTING TESTICULAR DESCENT - Mus musculus (Mouse)	737	304/361 (84%)	326/361 (90%)	3.6e-162
Q9HBX9	LEUCINE-RICH REPEAT-CONTAINING G PROTEIN-COUPLED RECEPTOR 7 - Homo sapiens (Human)	757	203/339 (59%)	271/339 (79%)	6.8e-113
CAC38938	SEQUENCE 15 FROM PATENT WO0131014 - Homo sapiens (Human)	396	203/339 (59%)	271/339 (79%)	6.8e-113
Q9VBP0	CG5042 PROTEIN - Drosophila melanogaster (Fruit fly)	359	136/311 (43%)	194/311 (62%)	3.1e-62
P46023	G-protein coupled receptor GRL101 precursor - Lymnaea stagnalis (Great pond snail)	1115	128/343 (37%)	198/343 (57%)	2.7e-56

A multiple sequence alignment is given in Table 6E, with the NOV6 protein of the invention being shown in line 1 in a ClustalW analysis comparing NOV6 with related protein sequences of Table 6D.

Table 6E. ClustalW Analysis of NOV6

1. SEQ ID NO.: 14	NOV6	4. SEQ ID NO.: 158	CAC38938
2. SEQ ID NO.: 156	Q91ZZ5	5. SEQ ID NO.: 159	Q9VBP0
3. SEQ ID NO.: 157	Q9HBX9	6. SEQ ID NO.: 160	P46023

		10	20	30	40	50	60					
	NOV6	-----						1			
	Q91ZZ5	-----										1
	Q9HBX9	-----										1
	CAC38938	-----										1
	Q9VBP0	-----										1
	P46023	MATMSGTTIVCLIIYLTTMLGNSQGVNLKIESPSPPTLCSVEGTFHCDDGMLQCVLMGSKC										60
		70	80	90	100	110	120					
	NOV6	-----						1			
	Q91ZZ5	-----										1
	Q9HBX9	-----										1
	CAC38938	-----										1
	Q9VBP0	-----										1
	P46023	DGVSDCENGMDSESVETCGCLQSEFQCNHTTCIDKILRCDRNDDCSNGLDERECDIYICPL										120
		130	140	150	160	170	180					
	NOV6	-----						1			
	Q91ZZ5	-----										1
	Q9HBX9	-----										1
	CAC38938	-----										1
	Q9VBP0	-----										1
	P46023	GTHVKWHNHFCVPRDKQCDFLDDCGDNSDEKICERRECVATEFKCNNSQCVAFGNLCDGL										180
		190	200	210	220	230	240					
	NOV6	-----						1			
	Q91ZZ5	-----										1
	Q9HBX9	-----										1
	CAC38938	-----										1
	Q9VBP0	-----										1
	P46023	VDCVDGSDDEDQVACDSDKYFQCAEGSLIKKEFVCDGWVDCKLTFADDELNCKLCDEDDFRC										240
		250	260	270	280	290	300					
	NOV6	-----						1			
	Q91ZZ5	-----										1

5	Q9HBX9	-----	1
	CAC38938	-----	1
	Q9VBP0	-----	1
	P46023	SDTRCIQKSNVCDGYCDCKTCDDEEVCANNTYGCPCMDTKYMCRSIYGEPRCIDKDNVCNM	300
10		310 320 330 340 350 360	
		
	NOV6	-----	1
	Q91ZZ5	-----MWLLLVHVIILLTEVKDFALADS	21
	Q9HBX9	-----MTSGSVFFYILIFGKYFSHG	20
	CAC38938	-----	1
	Q9VBP0	-----	1
15	P46023	INDCRDGNVGTDEYYCSNDSECKNFQAAMGFFYCPEERCLAKHLYCDLHPDCINGEDEQS	360
		370 380 390 400 410 420	
		
	NOV6	-----	1
	Q91ZZ5	SMVAPLCPKGYFPCGNLTCKLPRAFHCDCGVDDCGNGADEDNCGDTSWTTIFGTVHGNVN	81
	Q9HBX9	GGQDVKCSLGYFPCGNITKCLPQLLHCNGVDDCGNQADEDNCGDNNGWSMQFDKYFASY	80
	CAC38938	-----	1
20	Q9VBP0	-----	1
	P46023	CLAPPKCSQDEFQCHHG-KCIPISKRCDSVHDCVDWSDENNCENHQCAANMKSCLSGHCI	419
25		430 440 450 460 470 480	
		
	NOV6	-----	1
	Q91ZZ5	KVT-----LTQECFLS-QYPQHCCYRENELECVKADLKAVPKVSSN---VTLLSLKKN	130
	Q9HBX9	KMTSQYPFEAETPECLVG-SVPVQCLCQGLELDCDETNLRAVPSVSSN---VTAMSLQWN	136
	CAC38938	-----	1
	Q9VBP0	-----	1
30	P46023	EEHKWCNFBHRECPDGSDEKDCDPRPVCEANQFRCKNGQCIDPLQVCVKGDKYDGCADQSH	479
		490 500 510 520 530 540	
		
	NOV6	-----	1
	Q91ZZ5	KIHLRPVKVFSRYTELTKIYLQHNCITHISRRAFLG-----LHNLQIL	173
	Q9HBX9	LIRKLPPDCFKNYHDLQKLYLQNNKITSISIIYAFRG-----LNSLTKL	179
	CAC38938	-----	1
35	Q9VBP0	-----	1
	P46023	LINCSQHICLEGQFRCKRSFCINQTKVCDGTVDCLQGMWDENNCRYWCPHGQAICQCEGV	539
40		550 560 570 580 590 600	
		
	NOV6	-----	1
	Q91ZZ5	YLSHNCITSLRPGIFKDLHQLAWLILDNDNPITRISQKSFMGLNSLFFLPMVGNRLEALP-	232
	Q9HBX9	YLSHNRITFLKPGVFEDLHRLLEWLIIEDNHLRSISPPTYGLNSLILLVLMNNVLTRLPD	239
	CAC38938	-----	1
	Q9VBP0	-----	1
45	P46023	TMDCTGQKLKEMPVQQMEEDLSKLMIGDNLNLTSTTFSATYYDKVTYLDLSRNLHTEIP	599
		610 620 630 640 650 660	
		
	NOV6	-----	1
	Q91ZZ5	ETLCAQMPQLNWVDLANNGIKYITNSTFLTCDSLTVLFLPRNQIGFVPEKTFSSSLKNLGE	292
	Q9HBX9	KPLCQHMPRLHWLDLEGNHIIHNLRLNLTFFISCSNLTVLVMRKNKINHLNENTFAPLQKLDE	299
	CAC38938	-----	1
50	Q9VBP0	-----	1
55			

1005327 "012302"

P46023	IYSFQNMWKLTHLNLADNNITSLKNGSLLGLSNLKQLHINGNKIETIEEDTFSSMIHLTV	659
	670 680 690 700 710 720	
5	NOV6	1
	Q91ZZ5	LDLSSNMITKLPVHLFSDLHLLQKLNLSNPLLYVHKNQFGSLKQLQSLDLERIEIPNIS 352
	Q9HBX9	LDLGSNKIENLPPLIFKDLKELSQNLSYNPIQKIQANQFDYLVKLKSLLEGIEISNIQ 359
	CAC38938	1
	Q9VBP0	1
10	P46023	LDLSNQRLTHVYKNMFKGLKQITVLNISRNQINSIDNGAFNNLANVRLIDLSGNVIKDIG 719
	730 740 750 760 770 780	
15	NOV6	MAPHVRICMPLTDGISSFEDLLANNILRIFVWVIAFIT 38
	Q91ZZ5	TGMFQPMKNLSHTYLRKTFRYCSYVPHVRICMPSTDGISSSEDLLANGILRVSVWVIAFIT 412
	Q9HBX9	QRMRPLMNLSHIYFKKFQYCYAPHVRSCPKNTDGISSLENLLASIIQRFVWVVSAMT 419
	CAC38938	MRPLVNLSHIYFKKFQYCYAPHVRSCPKNTDGISSLENLLASIIQRFVWVVSAMT 58
	Q9VBP0	MTPRVRMCKPSTDGVSSFODLLSKPVLRYSAWVMAFIT 38
20	P46023	QKVFMGPLPRLVELKTDSYRFFCLAPEGVKCSPKQDEFSSCEDLMSNHVLRVSIWVIGVIA 779
	790 800 810 820 830 840	
25	NOV6	CFGNI FVICMRSPFIKAENTTHAMSIKILCCADCLMGVYLFFVGIFDLKYRGQYOKMALLW 98
	Q91ZZ5	CVGNFLVIAVRSLIKAENTTHAMSIKILCCADCLMGVYLFSVGVDIKYRGQYOKMALLW 472
	Q9HBX9	CFGNI FVICMRPYIRSENKLYAMSIISLCCADCLMGVYLFVIGGFDFKRGGEYNKHAQLW 479
	CAC38938	CFGNI FVICMRPYIRSENKLYAMSIISLCCADCLMGVYLFVIGGFDFKRGGEYNKHAQLW 118
	Q9VBP0	IAGNVLVLWGRFIYDENAVVTMVRNLALADMLMGFYLVITIGVDYFYRNEYKVKVLDW 98
	P46023	LVGNFVVI FWRVRDFRGGKVHVSFLITNLAI GDFLMGVYLLIATADTYIRGVYISHDENW 839
30		850 860 870 880 890 900
35	NOV6	MESVQCRIMGFLAMLSTEVSVLLLTFLTLEKELVIVFPFSNLR-PGKRQTSVILICIWMA 157
	Q91ZZ5	MESVPCRIMGFLATLSTEVSVLLLTFLTLEKELVIVFPFSNLR-LGKROTAVALASIWV 531
	Q9HBX9	MESTHCQLVGSIALSTEVSVLLLTFLTLEKYICIVYPFRCVR-PGKCRITITVLILIWIT 538
	CAC38938	MESTHCQLVGSIALSTEVSVLLLTFLTLEKYICIVYPFRCVR-PGKCRITITVLILIWIT 177
	Q9VBP0	ITSWQCTILHGTAVSSSEVSMILAFMSLERFILLIADPFRGHRSIGNRVMWIALICIWIT 158
	P46023	KQSGLCQFACFVSTFSSEL SVLTLSTITLDRILICILFPLRRTR-LGLRQAITVMSCIWVL 898
40		910 920 930 940 950 960
45	NOV6	--GFLIAVLPFWNKDYFCNFIYGKNGVCFPLYDQTEDIGSKGYSLGIFLGVNLLAFLVIV 215
	Q91ZZ5	--GFLIAAVPFTREDYFCNFIYGKNGVCFPLHYDQAEDFGSRGYSLGIFLGVNLLAFLVIV 589
	Q9HBX9	--GFLIAVLPISNKEFFKNYYGTNGVCFPLHSEDTE SIGAQIYSVAIFLGINLAFLIIV 596
	CAC38938	--GFLIAVLPISNKEFFKNYYGTNGVCFPLHSEDTE SIGAQIYSVAIFLGINLAFLIIV 235
	Q9VBP0	GVGLAVAPVLLWRTSTLPPYGSYSGTCFPLHIHEAFPMG-WLYSAFVFLGVNLLLVMTA 217
	P46023	--VFLIAVLPILGFSYFENFIYGRSGVCLALHVT PDRRPG-WEYSVGVFILLNLLSFVILIA 955
50		970 980 990 1000 1010 1020
55	NOV6	FSYITIMFCSIQRTALQTTEVRNCFGREVAVANRFFFI VFSDAICWIPVFVVKILSLFRVE 275
	Q91ZZ5	ISYVIMFCSIHKTALQTAEVRS HIGKEVAVANRFFFI VFSDAICWIPVFVVKILSLLOVE 649
	Q9HBX9	FSYGSMEFYSVHQSATATATEIRNQVKEMILAKRFFFI VFTDALCWIPIFVVKFLSLLOVE 656
	CAC38938	FSYGSMEFYSVHQSATATATEIRNQVKEMILAKRFFFI VFTDALCWIPIFVVKFLSLLOVE 295
	Q9VBP0	MLYTALLISLWRTSATPLT---LLDCEFAVRFFFI VLTDFLCWPIIIVMKIIVFFNYN 273
	P46023	SSYLWIMFSVAKKTRSAVRTAES--KNDNAMARRMTLIVMTDFCCWVPIIIVLGFVSLAGAR 1013
	1030 1040 1050 1060 1070 1080	

Consistent with other known members of the olfactory receptor family of proteins, NOV6 contains 7-transmembrane domains as illustrated in Table 6F.

The NOV6 nucleic acid, and the encoded polypeptide, according to the invention are useful in a variety of applications and contexts. For example, NOV6 nucleic acids and polypeptides can be used to identify proteins that are members of the olfactory receptor family of proteins. The NOV6 nucleic acids and polypeptides can also be used to screen for molecules, which inhibit or enhance NOV6 activity or function. Specifically, the nucleic acids and polypeptides according to the invention may be used as targets for the identification of small molecules that modulate or inhibit, *e.g.*, cellular recognition, or G-protein-mediated transduction of odorant signals. These molecules can be used to treat, *e.g.*, taste and scent detectability disorders, immune diseases, or signal transduction pathways.

In addition, the NOV6 nucleic acid and polypeptide according to the invention are useful, *inter alia*, as novel members of the protein families according to the presence of domains and sequence relatedness to previously described proteins. For example, the NOV6 nucleic acid and polypeptide include structural motifs that are characteristic of proteins belonging to the family of olfactory receptor proteins. Olfactory receptors have great variety, exquisite specificity, high sensitivity and fast response. The human olfactory epithelium contains two to three thousand distinct olfactory receptors, a class of G-protein coupled receptors. The receptors consist of seven hydrophobic segments that span the cell membrane (trans-membrane domains I-VII), separated by hydrophilic segments that project into the intra- or extra-cellular space. Trans-membrane domains II-VII comprise a hypervariable segment that defines the ligand specificity of the receptor.

The NOV6 nucleic acid and polypeptide, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications in the mediation of signal transduction. As such the NOV6 nucleic acid and polypeptide, antibodies and related compounds according to the invention may be used to treat, *e.g.*, developmental diseases, MHC II and III diseases (immune diseases), taste and scent detectability disorders, Burkitt's lymphoma, corticoneurogenic disease, signal transduction pathway disorders, retinal diseases including those involving photoreception, cell growth rate disorders, cell shape disorders, feeding disorders, control of feeding, potential obesity due to over-eating, potential disorders due to starvation (lack of appetite), noninsulin-dependent diabetes mellitus (NIDDM1), bacterial, fungal, protozoal and

viral infections (particularly infections caused by HIV-1 or HIV-2), pain, cancer (including but not limited to neoplasm, adenocarcinoma, lymphoma, prostate cancer, uterus cancer), anorexia, bulimia, asthma, parkinson's disease, acute heart failure, hypotension, hypertension, urinary retention, osteoporosis, crohn's disease, multiple sclerosis, and treatment of albright hereditary

5 ostoeodystrophy, angina pectoris, myocardial infarction, ulcers, asthma, allergies, benign prostatic hypertrophy, and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation, dentatorubro-pallidoluysian atrophy(DRPLA) hypophosphatemic rickets, autosomal dominant (2) acrocallosal syndrome and dyskinesias, such as huntington's disease or gilles de la tourette syndrome.

10 The NOV6 nucleic acid and polypeptide are useful for detecting specific cell types. For example, expression analysis has demonstrated that a NOV6 nucleic acid is predominantly expressed in olfactory epithelium and taste receptor cells of the tongue.

Additional utilities for the NOV6 nucleic acid and polypeptide according to the invention are disclosed herein.

15 **NOV7**

The NOV7 proteins descibed herein are novel carbonate dehydratase-like proteins. The NOV7 nucleic acids disclosed herein map to chromosome 15. Two alternative novel NOV7 nucleic acids and polypeptides are disclosed herein, namely NOV7a and NOV7b.

20 **NOV7a**

A NOV7 variant is NOV7a (alternatively referred to herein as CG50365-01), which encodes the 828 nucleotide sequence (SEQ ID NO:15) shown in Table 7A. An open reading frame for the mature protein was identified beginning with an ATG codon at nucleotides 16-18 and ending with a TAA codon at nucleotides 802-804. Putative untranslated regions, if any,

25 downstream from the termination codon and upstream from the initiation codon are underlined. The start and stop codons are in bold letters.

Table 7A. NOV7a Nucleotide Sequence (SEQ ID NO:15)

CCACCCCGAGGGACCA ATG TCGAGGCTCAGCTGGGGATACCGCGAGCACAA CGG TCTATTCACTGGAAGGAATTT TTCCCTATTGCTGATGGTGATCAGCAATCTCCAATTGAGATTAAAACCAAAGAAGTGAAATATGACTCTTCCCTC CGACCACTTAGTATCAAGTATGACCCAAGCTCAGCTAAAATCATCAGCAACAGCGGCCATTCTTCAATGTTGAC TTTGATGACACAGAGAACAAATCAGTTCTGCGTGGTGGTCCTCTCACTGGAAGCTACAGGTTACGGCAGGTTAC
--

CTTCACTGGGGGTCCGCTGATGACCACGGCTCCGAGCACATAGTAGATGGAGTGAGCTATGCTGCAGAGCTCCAT
 GTTGTTCCTGGAATTCAGACAAATACCCCAGCTTTGTTGAGGCAGCTCATGAACCAGATGGACTGGCTGTCTTG
 GGAGTGTTTTTACAGGTGGGTGAACCTAATCCCAACTGCAAAAGATTACTGACACTTTGGATTCCATTAAAGAA
 AAGGGTAAACAACTCGATTACAAATTTTGACCTATTGTCTCTGCTTCCACCATCCTGGGACTACTGGACATAT
 CCTGGTCTCTTACAGTTCACCTCTTCTTGAGAGTGTACATGGATTGTTTTAAAGCAACCTATAAACATCAGC
 TCTCAACAGCTGGCCAAATTCGCAGTCTCCTGTGCACAGCGGAGGGTGAAGCAGCAGCTTTTCTGGTGAGCAAT
 CACCGCCACACAGCCTCTAAAGGGCCGCAAAGTGAGAGCCTCTTCCAT**TAAAAATTGTCACCAATGAACTCC**
CCC

The NOV7a protein (SEQ ID NO:16) encoded by SEQ ID NO:15 is 262 amino acid residues in length and is presented using the one-letter amino acid code in Table 7B. The SignalP, Psort and/or Hydropathy results indicate that NOV7a has no known signal peptide and is likely to be localized in the microbody (peroxisome) with a certainty of 0.7480. Alternatively, a NOV7a polypeptide is located to the mitochondrial matrix space with a certainty of 0.1000, the lysosome (lumen) with a certainty of 0.1000, or the endoplasmic reticulum (membrane) with a certainty of 0.1000.

Table 7B. Encoded NOV7a Protein Sequence (SEQ ID NO:16)

MSRLSWGIREHNGPIHWKEFFPIADGDQQSPIEIKTKEVKYDSSLRPLSIKYDPSSAKIISNSGHSFNVDFFDTE
 NKSVLRRGGLTGSYRLRQVHLHWGSADHDGSEHIVDGVSYAAELHVHWNNDKYPSFVEAAHEPDGLAVLGVFLO
 VGEPNSQLQKITDLDLSIKEKGKQTRFTNFDLLSLLPPSWDYWTYPGSLTVPPLLESVTWIVLKQPINISSQQLA
 KFRSLLCTAEGEAAFLVSNHRPPQPLKGRKVRASFH

NOV7b

Alternatively, a NOV7 variant is NOV7b (alternatively referred to herein as CG50365-02), which includes the 833 nucleotide sequence (SEQ ID NO:17) shown in Table 7C. An open reading frame for the mature protein was identified beginning with an ATG codon at nucleotides 21-23 and ending with a TAA codon at nucleotides 807-809. Putative untranslated regions, if any, downstream from the termination codon and upstream from the initiation codon are underlined. The start and stop codons are in bold letters.

Table 7C. NOV7b Nucleotide Sequence (SEQ ID NO:17)

ATGTCGAGGCTCAGCTGGGG**ATG**TTCGAGGCTCAGCTGGGGATACCGCGAGCACAAACGGTCCTATTCACTGGAAGG
 AATTTTCCCTATTGCTGATGGTGATCAGCAATCTCCAATTGAGATTAAACCAAAGAAGTGAAATATGACTCTT
 CCCTCCGACCACTTAGTATCAAGTATGACCCAAGCTCAGCTAAATCATCAGCAACAGCGCCATTCTTCAATG
 TTGACTTTGATGACACAGAGAACAAATCAGTTCTGCGTGGTGGTCCCTCACTGGAAGCTACAGGTTACGGCAGG
 TTCACCTTCACTGGGGGTCCGCTGATGACCACGGCTCCGAGCACATAGTAGATGGAGTGAGCTATGCTGCAGAGC
 TCCATGTTGTTCACTGGAATTCAGACAAATACCCCAGCTTTGTTGAGGCAGCTCATGAACCAGATGGACTGGCTG

TCTTGGGAGTGTTTTTACAGATTGGTGAACCTAATTCCTCAACTGCAAAAGATTACTGACACTTTGGATTCCATTA
AAGAAAAGGGTAAACAACTCGATTACAAATTTTGACCTATTGTCTCTGCTTCCACCATCCTGGGACTACTGGA
CATATCCTGGTTCTTACAGTTCCACCTCTTCTTGAGAGTGTACATGGATTGTTTTAAAGCAACCTATAAACA
TCAGCTCTCAACAGCTGGCCAAATTTTCGAGTCTCCTGTGCACAGCGGAGGGTGAAGCAGCAGCTTTTCTGGTGA
GCAATCACCGCCACCACAGCCTCTAAAGGGCCGCAAAGTGAGAGCCTCTTCCATTAAAAATTGTCACCAATGA
ACTCCCCC

The NOV7b protein (SEQ ID NO:18) encoded by SEQ ID NO:17 is 262 amino acid residues in length and is presented using the one-letter amino acid code in Table 7D. The SignalP, Psort and/or Hydropathy results indicate that NOV7b has no known signal peptide and is likely to be localized in the microbody (peroxisome) with a certainty of 0.7480. Alternatively, a NOV7b polypeptide is located to the mitochondrial matrix space with a certainty of 0.1000, the lysosome (lumen) with a certainty of 0.1000, or the endoplasmic reticulum (membrane) with a certainty of 0.1000.

Table 7D. Encoded NOV7b Protein Sequence (SEQ ID NO:18)

MSRLSWG YREHNGPIHWKEFFPIADGDQQSPIEIKTKEVKYDSSLRPLSIKYDPSSAKIISNSGHSFNVDFFDDE
NKS VLRGGPLTGSYRLRQVHLHWGSADHDGSEHIVDGVSYAAELHVHWNNDKYP SFVEAAHEPDGLAVLG VFLQ
IGEPNSQLQKITDTLDSIKEKGKQTRFTNFDLLSLLPSPWDYWTYPGSLTVPPLLESVTWIVLKQPINISSQQLA
KFRSLLCTAEGEAAAF LVSNHRPPQPLKGRKVRASFH

NOV7 Clones

Unless specifically addressed as NOV7a or NOV7b, any reference to NOV7 is assumed to encompass all variants.

A search against the Patp database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 7E.

Table 7E. PatP Results for NOV7

		High Score	Smallest Sum Prob P (N)
Sequences Producing High-Scoring Segment Pairs:			
patp:AAU19418	Human diagnostic and therapeutic polypeptide (DITHP) #4	1296	5.7e-132
patp:AAB63110	Human secreted protein sequence encoded by gene 27	964	8.7e-97
patp:AAG73863	Human colon cancer antigen protein	872	4.9e-87
patp:AAB59588	Human carbonic anhydrase isoform #1	870	8.0e-87
patp:AAW75702	Carbonic anhydrase II protein - Homo sapiens	858	1.5e-85

In a BLAST search of public sequence databases, it was found, for example, that the NOV7a nucleic acid sequence of this invention has 551 of 793 bases (69%) identical to a gb:GENBANK-ID:HUMCAIX|acc:M33987.1 mRNA from Human carbonic anhydrase I (CAI) mRNA, complete cds. Further, the full amino acid sequence of the disclosed NOV7a protein of the invention has 160 of 257 amino acid residues (62%) identical to, and 197 of 257 amino acid residues (76%) similar to, the 260 amino acid residue ptmr:SWISSPROT-ACC:Q92051 protein from Brachydanio rerio (Zebrafish) (Zebra danio) (CARBONIC ANHYDRASE (EC 4.2.1.1) (CARBONATE DEHYDRATASE)).

In a similar BLAST search of public sequence databases, it was found, for example, that the NOV7b nucleic acid sequence of this invention has 549 of 789 bases (69%) identical to a gb:GENBANK-ID:HSCAIR|acc:X05014.1 mRNA from Human cDNA for carbonic anhydrase I. Further, the full amino acid sequence of the disclosed NOV7b protein of the invention has 156 of 261 amino acid residues (59%) identical to, and 202 of 261 amino acid residues (77%) similar to, the 261 amino acid residue ptmr:pir-id:CRHU1 protein from human (carbonate dehydratase (EC 4.2.1.1) I [validated]).

Additional BLAST results are shown in Table 7F.

Table 7F. NOV7 BLASTP Results

Gene Index/ Identifier	Protein/Organism	Length of aa	Identity (%)	Positives (%)	Expect Value
Q9D6N1	CARBONIC ANHYDRASE (EC 4.2.1.1) (CARBONATE DEHYDRATASE) (CARBONIC ANHYDRASE XIII) - Mus musculus (Mouse)	262	238/262 (90%)	250/262 (95%)	1.7e-130
Q92051	Carbonic anhydrase (EC 4.2.1.1) (Carbonate dehydratase) - Brachydanio rerio (Zebrafish) (Zebra danio)	260	160/257 (62%)	197/257 (76%)	3.8e-87
CRHU1	carbonate dehydratase (EC 4.2.1.1) I [validated] - human	261	157/261 (60%)	202/261 (77%)	6.2e-87
JN0836	carbonate dehydratase (EC	261	158/261 (60%)	202/261 (77%)	6.2e-87

	4.2.1.1) I - gorilla				
P00917	Carbonic anhydrase I (EC 4.2.1.1) (Carbonate dehydratase I) (CA-I) - Equus caballus (Horse)	260	160/256 (62%)	196/256 (76%)	1.0e-86

A multiple sequence alignment is given in Table 7G, with the NOV7 proteins of the invention being shown in lines 1 and 2 in a ClustalW analysis comparing NOV7 with related protein sequences of Table 7F.

Table 7G. ClustalW Analysis of NOV7

1. SEQ ID NO.: 16	NOV7a	5. SEQ ID NO.: 164	CRHU1
2. SEQ ID NO.: 18	NOV7b	6. SEQ ID NO.: 165	JN0836
3. SEQ ID NO.: 162	Q9D6N1	7. SEQ ID NO.: 166	P00917
4. SEQ ID NO.: 163	Q92051		

	10	20	30	40	50	60
NOV7a	MSRLSWG	YREHNGPI	IHWKEFF	PIADGDQ	QSPIEIK	TKYDPS
NOV7b	MSRLSWG	YREHNGPI	IHWKEFF	PIADGDQ	QSPIEIK	TKYDPS
Q9D6N1	MARLSWG	YGEHNGPI	IHWNELF	PIADGDQ	QSPIEIK	TKYDPA
Q92051	-MAHAWG	YGPADGPE	SWAESFP	IANGP	ROSPID	IVPTQA
CRHU1	MASPDWG	YDDKNGPE	QWSKLYP	IANGN	NQSPVD	IKTSE
JN0836	MASPDWG	YDDKNGPE	QWSKLYP	IANGN	NQSPVD	IKTSE
P00917	-AHSDWG	YDPSPEGP	ZEWVKLY	PIABGB	BQSPID	IKTSE

	70	80	90	100	110	120
NOV7a	SNSGHSF	NVDFDD	TENKSVL	RGGPLT	GSYRLR	QVHLHW
NOV7b	SNSGHSF	NVDFDD	TENKSVL	RGGPLT	GSYRLR	QVHLHW
Q9D6N1	SNSGHSF	NVDFDD	TENKSVL	RGGPLT	GSYRLR	QVHLHW
Q92051	LNVGHSF	QVDFDD	ENSSITL	AGGPII	TGIYRL	RQFHFW
CRHU1	INVGHSE	FVNFED	NDNRSVL	KGGPFS	DSYRLF	QFHFHW
JN0836	INVGHSE	FVNFED	NDNRSVL	KGGPFS	DSYRLF	QFHFHW
P00917	VNVGHSE	FQVKFED	SDNRSVL	KDGPLP	GSYRLV	QFHFHW

	130	140	150	160	170	180
NOV7a	VVHWNSD	KYPSFVE	AAHEPD	GLAVL	GVFLQV	GEPN
NOV7b	VVHWNSD	KYPSFVE	AAHEPD	GLAVL	GVFLQV	GEPN
Q9D6N1	VVHWNSD	KYPSFVE	AAHEPD	GLAVL	GVFLQV	GEPN
Q92051	VVHWNSD	KYPSFVE	AAHEPD	GLAVL	GVFLQV	GEPN
CRHU1	VAHWNSA	KYSSLA	EAAASK	ADGLAV	IGVLMK	VG
JN0836	VAHWNSA	KYSSLA	EAAASK	ADGLAV	IGVLMK	VG
P00917	VVHWNSD	KYSSFE	AAASK	ADGLAV	IGVLMK	VG

Additional utilities for NOV7 nucleic acids and polypeptides according to the invention are disclosed herein.

NOV8

The NOV8 proteins described herein are novel carboxypeptidase-like proteins. The NOV8 nucleic acids disclosed herein map to chromosome 2. Four alternative novel NOV8 nucleic acids and polypeptides are disclosed herein, namely NOV8a, NOV8b, NOV8c and NOV8d.

NOV8a

A NOV8 variant is NOV8a (alternatively referred to herein as CG55794-01), which encodes the 1196 nucleotide sequence (SEQ ID NO:19) shown in Table 8A. An open reading frame for the mature protein was identified beginning with an ATG codon at nucleotides 16-18 and ending with a TAA codon at nucleotides 1138-1140. Putative untranslated regions, if any, downstream from the termination codon and upstream from the initiation codon are underlined. The start and stop codons are in bold letters.

Table 8A. NOV8a Nucleotide Sequence (SEQ ID NO:19)

TTACTGTGTGGCAGAA**ATGA**AGCCTCTGCTTGAAACCCTTTATCTTTTGGGGATGCTGGTTCTGGAGGGCTGGGA
TATGATAGATCCTTAGCCCAACACAGACAAGAGATTGTGGACAAGTCAGTGAGTCCATGGAGCCTGGAGACGTAT
TCCTATAACATATACCACCCCATGGGAGAGATCAATGAGTGGATGAGAGAGATCAGTGAGAAGTACAAGGAAGTG
GTGACACAGCATTTCTTAGGAGTGACCTATGAGACCCACCCCATATATTATCTGAAGATCAGCCAACCATCTGGT
AATCCCAAGAAAATCATTTGGATGGGCTGTGGAATTCACGCCAGAGAATGGATTGCTCCTGCTTTTTGCCAATGG
TTCGTCAAAGAAATTTCTACAAAACCATAAAGACAACCTCAAGGATACGCAAGCTCCTTAGGAACCTGGACTTCTAT
GTCCTTCCAGTTCTTAACATAGATGGTTATATCTACACTTGGACAACCTGATCGTCTTTGGAGGAAATCCCGTTCA
CCCCATAATAATGGCACATGTTTTGGGACGGATCTCAATCGAAATTTCAATGCATCTTGGTGATATTGGTGCC
TCTAGAACTGCCAAGATCAAACATTCTGTGGGACAGGGCCAGTGTCTGAACCAGAGACTAAAGCTGTTGCCAGC
TTCATAGAGAGCAAGAAGGATGATATTTTGTGCTTCCTGACCATGCACTCTTATGGGCAGTTAATTCTCACACCT
TACGGCTACACCAAAAATAAATCAAGTAACCACCCAGAAAATGATTCAAGTTGGACAGAAGGCAGCAAATGCATTG
AAAGCAAAGTATGGAACCAATTATAGAGTTGGATCGAGTGCAGATATTTTATATGCCTCATCAGGGTCTTCAAGA
GATTGGGCCCCGAGACATTGGGATTCCCTTCTCATATACGTTTGAGCTGAGGGACAGTGGAACATATGGGTTTGT
CTGCCAGAAGCTCAGATCCAGCCACCTGTGAGGAGACCATGGAGGCTGTGCTGTCAGTCCTGGATGATGTGTAT
GCGAAACACTGGCACTCGGACAGTGTGGAAGGGTGACATCTGCCACTATGCTGCTGGGCCTGCTGGTGTCTCTGC
ATGTCTCTTCTCT**TAA**GTGCATCTTGCCAGGCCTGCTCAACCCAGTGGCATGAGTGTGGCTGGAGGAACG

The NOV8a protein (SEQ ID NO:20) encoded by SEQ ID NO:19 is 374 amino acid residues in length and is presented using the one-letter amino acid code in Table 8B. The SignalP, Psort and/or Hydropathy results indicate that NOV8a has a signal peptide and is likely

to be localized extracellularly at the plasma membrane with a certainty of 0.9190. Alternatively, a NOV8a polypeptide is located to the lysosome (membrane) with a certainty of 0.2000, the microbody (peroxisome) with a certainty of 0.1292, or the endoplasmic reticulum (membrane) with a certainty of 0.1000. The SignalP indicates a likely cleavage site for a NOV8a peptide is between positions 20 and 21, *i.e.*, at the dash in the sequence GLG-YD.

Table 8B. Encoded NOV8a Protein Sequence (SEQ ID NO:20)

MKPLLETLYLLGMLVPGGLGYDRSLAQHRQEIVDKSVSPWSLETYSYNIYHPMGEINEWMREISEKYKEVVTQHF
 LGVTYETHPIYYLKISQPSGNPKKIIWMGCGIHAREWIAPAFQWFVKEILQNHKDNSRIRKLLRNLDIFYVLPVL
 NIDGYIYTWTDLRWRKSRSPHNNGTCFGTDLNRNFNASWCSIGASRNCQDQTFCGTGPVSEPETKAVASFIESK
 KDDILCFLTMHSYGQLILTPYGYTKNKSSNHPEMIQVGQKAANALKAKYGTNYRVGSSADILYASSGSSRDWARD
 IGIPFSYTFELRDSGTYGfVLPEAQIQPTCEETMEAVLSVLDDVYAKHWHSDSAGRVTSATMLLGLLVSCMSLL

SNP variants of NOV8a are disclosed in Example 2.

NOV8b

Alternatively, a NOV8 variant is NOV8b (alternatively referred to herein as CG55794-03), which includes the 1222 nucleotide sequence (SEQ ID NO:21) shown in Table 8C. An open reading frame for the mature protein was identified beginning with an ATG codon at nucleotides 41-43 and ending with a TAA codon at nucleotides 1163-1165. Putative untranslated regions, if any, downstream from the termination codon and upstream from the initiation codon are underlined. The start and stop codons are in bold letters.

Table 8C. NOV8b Nucleotide Sequence (SEQ ID NO:21)

CCAGAGAGGCCCAAGATTTTCTAACTTACTGTGTGGCAGAATGAAGCCTCTGCTTGAAACCCCTTTATCTTTTGGG
 GATGCTGGTTCTTGGAGGGCTGGGATATGATAGATCCTTAGCCCAACACAGACAAGAGATTGTGGACAAGTCAGT
 GAGTCCATGGAGCCTGGAGACGTATTCCTATAACATATACCAACCCCATGGGAGAGATCTATGAGTGGATGAGAGA
 GATCAGTGAGAAGTACAAGGAAGTGGTGACACAGCATTTCCCTAGGAGTGACCTATGAGACCCACCCCATATATTA
 TCTGAAGATCAGCCAACCATCTGGTAATCCCAAGAAAATCATTGTGGATGGACTGTGGAATTCACGCCAGAGAATG
 GATTGCTCCTGCTTTTGGCAATGGTTCGTCAAAGAAATCTACAAAACCATAAAGACAACCTCAAGGATACGCAA
 GCTCCTTAGGAACCTGGACTTCTATGTCTTCCAGTTCTTAACATAGATGGTTATATCTACACTTGGACAACCTGA
 TCGTCTTTGGAGGAAATCCCGTTCACCCCATATAATGGCACATGTTTTGGGACGGATCTCAATCGAAATTTCAA
 TGCTTCTTGGTGTAGTATTGGTGCCCTCTAGAACTGCCAAGATCAAACATTCTGTGGGACAGGGCCAGTGTCTGA
 ACCAGAGACTAAAGCTGTTGCCAGCTTCATAGAGAGCAAGAAGGATGATATTTTGTGCTTCTGACCATGCACTC
 TTATGGGCAGTTAATTCTCACACCTTACGGCTACACCAAAATAAATCAAGTAACCAACCCAGAAATGATTCAAGT
 TGGACAGAAGGCAGCAAATGCATTGAAAGCAAAGTATGGAACCAATTATAGAGTTGGATCGAGTGCAGATATTTT
 ATATGCCTCATCAGGGTCTTCAAGAGATTGGGCCCGAGACATTGGGATTCCCTTCTCATATACGTTTGAGCTGAG
 GGACAGTGGAAACATATGGGTTTGTCTGCCAGAAGCTCAGATCCAGCCACCTGTGAGGAGACCATGGAGGCTGT
 GCTGTGAGTCTGGATGATGTGTATGCGAAACACTGGCACTCGGACAGTGCTGGAAGGGTGACATCTGCCACTAT
 GCTGCTGGGCCTGCTGGTGTCTGCATGTCTTCTCTAAGTGCATTCTGCCCAGGCCTGCTCAACCCAGTGGC

ATGAGTGTGGCTTGGAGGAACG

The NOV8b protein (SEQ ID NO:22) encoded by SEQ ID NO:21 is 347 amino acid residues in length and is presented using the one-letter amino acid code in Table 8D. The SignalP, Psort and/or Hydropathy results indicate that NOV8b has a signal peptide and is likely to be localized extracellularly at the plasma membrane with a certainty of 0.9190. Alternatively, a NOV8b polypeptide is located to the lysosome (membrane) with a certainty of 0.2000, the microbody (peroxisome) with a certainty of 0.1345, or the endoplasmic reticulum (membrane) with a certainty of 0.1000. The SignalP indicates a likely cleavage site for a NOV8b peptide is between positions 20 and 21, *i.e.*, at the dash in the sequence GLG-YD.

Table 8D. Encoded NOV8b Protein Sequence (SEQ ID NO:22)

MKPLLETLYLLGMLVPGGLGYDRSLAQHRQEIVDKSVSPWSLETYSYNIYHPMGEIYEWREISEKYKEVVTOHF
LGVTYETHPIYYLKISQPSGNPKKIIMDCGIHAREWIAPFCQWFVKEILQNHKDNSRIRKLLRNLDYFVLPVL
NIDGYIYTWTDLRWRKSRSPHNNGTCFGTDLNRNFNASWCSIGASRNCQDQTFCGTGPVSEPETKAVASFIESK
KDDILCFLTMHSYGQLILTPYGYTKNKSSNHPMIQVGQKAANALKAKYGTNYRVGSSADILYASSGSSRDWARD
IGIPFSYTFELRDSGTYGVLPEAQIQPTCEETMEAVLSVLDDVYAKHWHSDSAGRVT SATMLLGLLVSCMSLL

NOV8c

Alternatively, a NOV8 variant is NOV8c (alternatively referred to herein as CG55794-06), which includes the 977 nucleotide sequence (SEQ ID NO:23) shown in Table 8E. An open reading frame for the mature protein was identified beginning with an ATG codon at nucleotides 41-43 and ending with a TAG codon at nucleotides 671-673. Putative untranslated regions, if any, downstream from the termination codon and upstream from the initiation codon are underlined. The start and stop codons are in bold letters.

Table 8E. NOV8c Nucleotide Sequence (SEQ ID NO:23)

CCAGAGAGGCCAGAAATTTCTAACTTACTGTGTGGCAGAAATGAAGCCTCTGCTTGAAACCCCTTTATCTTTTGGG
GATGCTGGTTCCTGGAGGGCTGGGATATGATAGATCCTTAGCCCAACACAGACAAGAGATTGTGGACAAGTCAGT
GAGTCCATGGAGCCTGGAAACGTATTCCTATAACATATACCAACCCCATGGGAGAGATCTATGAGTGGATGAGAGA
GATCAGTAGAGAAGTACAAGGAAGTGGTGACACAGCATTTTCCTAGGAGTGACCTATGAGACCCACCCCATATATTA
TCTGAAGATCAGCCAACCATCTGGTAATCCCAAGAAAAATCATTTGGATGGACTGTGGAATTCACGCCAGAGAATG
GATTGCTCCTGCTTTTTGCCAATGGTTCGTCAAAGAAATTTCTACAAAACCATAAAGACAACCTCAAGGATACGCAA
GCTCCTTAGGAACCTGGACTTCTATGTCCTTCCAGTTCTTAACATAGATGGTTATATCTACACTTGGACAACCTGA
TCGTCTTTGGAGGAAATCCCGTTCACCCCATATAATGGCACATGTTTTGGGACGGATCTCAATCGAAATTTCAA
TGCTTCTTGGTGTAATTCAGTTGGACAGAAGGCAGCAAATGCATTGAAAGCAAAGTATGGAACCAATTATAGAG

TTGGATCGAGTGCAGATATTTTATATGCCTCATCAGGGTCTTCAAGAGATTGGGCCCAGACATTGGGATTCCCT
TCTCATATACGTTTGAGCTGAGGGACAGTGGAAACATATGGGTTTGTCTGCCAGAAGCTCAGATCCAGCCCACCT
GTGAGGAGACCATGGAGGCTGTGCTGTCAGTCCTGGATGATGTGTATGCGAAACACTGGCACTCGGACAGTGTG
GAAGGGTGACATCTGCCACTATGCTGCTGGGCCTGCTGGTGTCTGTCATGTCTTCTCTAAGTGCATCCTGCCC
AG

The NOV8c protein (SEQ ID NO:24) encoded by SEQ ID NO:23 is 210 amino acid residues in length and is presented using the one-letter amino acid code in Table 8F. The SignalP, Psort and/or Hydropathy results indicate that NOV8c has a signal peptide and is likely to be localized extracellularly at the plasma membrane with a certainty of 0.3700. Alternatively, a NOV8c polypeptide is located to the microbody (peroxisome) with a certainty of 0.2242, the lysosome (lumen) with a certainty of 0.1900, or the endoplasmic reticulum (membrane) with a certainty of 0.1000. The SignalP indicates a likely cleavage site for a NOV8c peptide is between positions 20 and 21, *i.e.*, at the dash in the sequence GLG-YD.

Table 8F. Encoded NOV8c Protein Sequence (SEQ ID NO:24)

MKPLLETLYLLGMLVPGGLGYDRSLAQHRQEIIVDKSVSPWSLETYSYNIYHPMGEIYEWMRISEKYKEVVTQHF
LGVTYETHPIYYLKI SQPSGNPKKI IWMDCGIHAREWIAPAFQWFVKEILQNHKDNSRIRKLLRNLD FYVLPVL
NIDGYIYTWTTDRLWRKSRSPHNNGTCFGTDLNRNFNASWCNSSWTEGSKCIESKVWNQL

NOV8d

Alternatively, a NOV8 variant is NOV8d (alternatively referred to herein as CG55794-07), which includes the 1378 nucleotide sequence (SEQ ID NO:25) shown in Table 8G. An open reading frame for the mature protein was identified beginning with an ATG codon at nucleotides 259-261 and ending with a TAA codon at nucleotides 1225-1227. Putative untranslated regions, if any, downstream from the termination codon and upstream from the initiation codon are underlined. The start and stop codons are in bold letters.

Table 8G. NOV8d Nucleotide Sequence (SEQ ID NO:25)

ACTCACTATAGGGCTCGAGCGGCCGCCCGGGCAGGTGAAAATACATCAGCATGTGGGAAAGAGCAACGTTGATCG
TCTTCACGGAAAGGCTGAGGACCCTGCGCCTACCACATGTTGGCCAGGGTGAGCAAGCAGTGAAAGAGAAAACAC
TTTTTTCAAAAAGCCAAGTATCCTTAGCCCAACACAGACAAGAGATTGTGGACAAGTCAGTGAGTCCATGGAGC
CTGGAGACGTATTCTATAACATATACCACCCCATGGGAGAGATCTATGAGTGGATGAGAGAGATCAGTGAGAAG
TACAAGGAAGTGGTGACACAGCATTTCTAGGAGTGACCTATGAGACCCACCCCATATATTATCTGAAGATCAGC
CAACCATCTGGTAATCCCAAGAAAATCATTTGGATGGACTGTGGAATTCACGCCAGAGAATGGATTGCTCCTGCT
TTTTGCCAATGGTTTCGTCAAAGAAATCTACAAAACCATAAAGACAACCTCAAGGATACGCAAGCTCCTTAGGAAC
CTGGACTTCTATGTCCTTCCAGTTCTTAACATAGATGGTTATATCTACACTTGGACAACCTGATCGTCTTTGGAGG

AAATCCCGTTACCCCATAATAATGGCACATGTTTTGGGACGGATCTCAATCGAAATTTCAATGCTTCTTGGTGT
 AGTATTGGTGCCCTCTAGAACTGCCAAGATCAAACATTCTGTGGGACAGGGCCAGTGTCTGAACCAGAGACTAAA
 GCTGTTGCCAGCTTCATAGAGAGCAAGAAGGATGATATTTTGTGCTTCCTGACCATGCACTCTTATGGGCAGTTA
 ATTCTCACACCTTACGGCTACACCAAAAAATAAATCAAGTAACCAACCCAGAAATGATTCAAGTTGGACAGAAGGCA
 GCAAAATGCATTGAAAGCAAAGTATGGAACCAATTATAGAGTTGGATCGAGTGCAGATATTTTATATGCCTCATCA
 GGGTCTTCAAGAGATTGGGCCCCGAGACATTGGGATTCCCTTCTCATATACGTTTGAGCTGAGGGACAGTGGAAACA
 TATGGGTTTGTCTGCCAGAAGCTCAGATCCAGCCCACCTGTGAGGAGACCATGGAGGCTGTGCTGTCAGTCCTG
 GATGATGTGTATGCGAAACACTGGCACTCGGACAGTGTGGAAGGGTGACATCTGCCACTATGCTGCTGGGCCTG
 CTGGTGTCTGCATGTCTCTCTCTAAGTGCATTCTGCCCAGGCCTGCTCAACCCAGTGGCATGAGTGTGGCTG
 GAGGAACGGTGTGTTATGGTTGTAAAGAAACCAATAATTTAACTAAAAATACTTCCTATTTCAATAAAAAAAAAA
 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA

The NOV8d protein (SEQ ID NO:26) encoded by SEQ ID NO:25 is 322 amino acid residues in length and is presented using the one-letter amino acid code in Table 8H. The SignalP, Psort and/or Hydropathy results indicate that NOV8d has no known signal peptide and is likely to be localized in the cytoplasm at the endoplasmic reticulum (membrane) with a certainty of 0.8500. Alternatively, a NOV8d polypeptide is located to the microbody (peroxisome) with a certainty of 0.4781, the plasma membrane with a certainty of 0.4400, or the mitochondrial inner membrane with a certainty of 0.1000.

Table 8H. Encoded NOV8d Protein Sequence (SEQ ID NO:26)

MGEIYEWMRRISEKYKEVVTQHFLGVTYETHPIYYLKISQPSGNPKKIWMDCGIHAREWIAPAFQWFVKEILQ
 NHKDNSRIRKLLRNLDIFYVLPVLNIDGYIYTWTDRLRKRSRSPHNNGTCFGTDLNRNFNASWCSIGASRNCQDQ
 TFCGTGPVSEPETKAVASFIESKKDDILCFLTMHSYQLILTPYGYTKNKSSNHPEMIQVGQKAANALKAKYGTN
 YRVGSSADILYASSGSSRDWARDIGIPFSYTFELRDSGTYGTVLPEAQIQPTCEETMEAVLSVLDDVYAKHWHSD
 SAGRVTSATMLLGLLVSCMSLL

NOV8 Clones

Unless specifically addressed as NOV8a, NOV8b, NOV8c, or NOV8d any reference to NOV8 is assumed to encompass all variants.

A search against the Patp database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 8I.

Table 8I. PatP Results for NOV8

Sequences Producing High-Scoring Segment Pairs:		
	High Score	Smallest Sum Prob P (N)

patp:AAG66547	Human secreted metallocarboxypeptidase-like polypeptide	2001	1.1e-206
patp:AAG66565	Human secreted metallocarboxypeptidase-like variant polypeptide	1998	2.3e-206
patp:AAB74682	Human protease and protease inhibitor PPIM-15	1932	2.3e-199
patp:AAG66560	Human secreted metallocarboxypeptidase-like polypeptide	1899	7.3e-196
patp:AAG66566	Human secreted metallocarboxypeptidase-like polypeptide	1896	1.5e-195

In a BLAST search of public sequence databases, it was found, for example, that the NOV8a nucleic acid sequence of this invention has 584 of 914 bases (63%) identical to a gb:GENBANK-ID:AF190274|acc:AF190274.1 mRNA from Bothrops jararaca (Bothrops jararaca carboxypeptidase homolog mRNA, complete cds). Further, the full amino acid sequence of the disclosed NOV8a protein of the invention has 151 of 325 amino acid residues (46%) identical to, and 219 of 325 amino acid residues (67%) similar to, the 416 amino acid residue ptnr:SPTREMBL-ACC:Q9PUF2 protein from Bothrops jararaca (Jararaca) (CARBOXYPEPTIDASE HOMOLOG).

In a similar BLAST search of public sequence databases, it was found, for example, that the NOV8b nucleic acid sequence of this invention has 586 of 914 bases (64%) identical to a gb:GENBANK-ID:AF190274|acc:AF190274.1 mRNA from Bothrops jararaca (Bothrops jararaca carboxypeptidase homolog mRNA, complete cds). Further, the full amino acid sequence of the disclosed NOV8b protein of the invention has 152 of 325 amino acid residues (46%) identical to, and 219 of 325 amino acid residues (67%) similar to, the 416 amino acid residue ptnr:SPTREMBL-ACC:Q9PUF2 protein from Bothrops jararaca (Jararaca) (CARBOXYPEPTIDASE HOMOLOG).

In a further BLAST search of public sequence databases, it was found, for example, that the NOV8c nucleic acid sequence of this invention has 621 of 672 bases (92%) identical to a gb:GENBANK-ID:AX083139|acc:AX083139.1 mRNA from Homo sapiens (Sequence 42 from Patent WO0110903). Further, the full amino acid sequence of the disclosed NOV8c protein of the invention has 83 of 176 amino acid residues (47%) identical to, and 122 of 176 amino acid residues (69%) similar to, the 422 amino acid residue ptnr:SPTREMBL-ACC:Q9EQV9 protein from Rattus norvegicus (Rat) (PRE-PROCARBOXYPEPTIDASE R).

In yet a further BLAST search of public sequence databases, it was found, for example, that the NOV8d nucleic acid sequence of this invention has 1073 of 1077 bases (99%) identical to a gb:GENBANK-ID:AX083139|acc:AX083139.1 mRNA from Homo sapiens (Sequence 42 from Patent WO0110903). Further, the full amino acid sequence of the disclosed NOV8d

protein of the invention has 142 of 283 amino acid residues (50%) identical to, and 199 of 283 amino acid residues (70%) similar to, the 416 amino acid residue ptnr:SPTREMBL-ACC:Q9PUF2 protein from Bothrops jararaca (Jararaca) (CARBOXYPEPTIDASE HOMOLOG).

5 Additional BLAST results are shown in Table 8J.

Table 8J. NOV8 BLASTP Results					
Gene Index/ Identifier	Protein/Organism	Length of aa	Identity (%)	Positives (%)	Expect Value
Q9PUF2	CARBOXYPEPTIDASE HOMOLOG - Bothrops jararaca (Jararaca)	416	151/325 (46%)	219/325 (67%)	9.7e-82
CAA03381	SEQUENCE 85 FROM PATENT WO9620011 - unidentified	349	149/311 (47%)	204/311 (65%)	7.9e-80
CAA03380	SEQUENCE 81 FROM PATENT WO9620011 - unidentified	349	148/311 (47%)	204/311 (65%)	1.6e-79
CAA03377	SEQUENCE 68 FROM PATENT WO9620011 - unidentified	349	148/311 (47%)	203/311 (65%)	4.3e-79
Q9JHH6	CARBOXYPEPTIDASE R (THROMBIN- ACTIVATABLE FIBRINOLYSIS INHIBITOR) (1110032P04RIK PROTEIN) - Mus musculus (Mouse)	422	141/313 (45%)	206/313 (65%)	7.1e-79

10 A multiple sequence alignment is given in Table 8K, with the NOV8 proteins of the invention being shown in lines 1 through 4 in a ClustalW analysis comparing NOV8 with related protein sequences of Table 8J.

Table 8K. ClustalW Analysis of NOV8

15	1. SEQ ID NO.: 20	NOV8a	6. SEQ ID NO.: 169	CAA03381
	2. SEQ ID NO.: 22	NOV8b	7. SEQ ID NO.: 170	CAA03380
	3. SEQ ID NO.: 24	NOV8c	8. SEQ ID NO.: 171	CAA03377
	4. SEQ ID NO.: 26	NOV8d	9. SEQ ID NO.: 172	Q9JHH6
	5. SEQ ID NO.: 168	Q9PUF2		

20

		10	20	30	40	50	60	
	NOV8a	1					
	NOV8b	1					
5	NOV8c	1					
	NOV8d	1					
	Q9PUF2	MWPLLFLIGATSAFAETTVHRFDGEKVYRVTPRNEDEVYFLNYLANIVQVDFWRPDSVEL	60					
	CAA03381	1					
	CAA03380	1					
10	CAA03377	1					
	Q9JHH6	MKLHGLGILVAIIILYEQHGFAFQSGQVLSALPRTSRQVQLLQNLTTTYEVVLWQPVTAEF	60					
		70	80	90	100	110	120	
15	NOV8a	MKPLLET-LY-----LLGMLVPGGLGYDRSLAQHROEIVDKSVSPWS---LETYSY	47					
	NOV8b	MKPLLET-LY-----LLGMLVPGGLGYDRSLAQHROEIVDKSVSPWS---LETYSY	47					
	NOV8c	MKPLLET-LY-----LLGMLVPGGLGYDRSLAQHROEIVDKSVSPWS---LETYSY	47					
	NOV8d	1					
	Q9PUF2	VKAEMTVDFRIEADRCSEVESILQOSGLNIE-ILIDNLQAVLDRQLD---NHARTAGYNY	116					
20	CAA03381	-----MKYLLPTAAAG---LILLAAQPAMA-----ATGHSY	28					
	CAA03380	-----MKYLLPTAAAG---LILLAAQPAMA-----ATGHSY	28					
	CAA03377	-----MKYLLPTAAAG---LILLAAQPAMA-----ATGHSY	28					
	Q9JHH6	IEKKKEVHFFVNASDVDSVKAHLNVSRI PFN-VLMNNVEDLLEQQT FNDTVSPRASASY	119					
25		130	140	150	160	170	180	
	NOV8a	NIYHPMGEINEWMREISEKYKEVVTOHFLGVITYETHPIIYLLKISQPSGNPKKIIMWDCGI	107					
	NOV8b	NIYHPMGEIYEWMPREISEKYKEVVTOHFLGVITYETHPIIYLLKISQPSGNPKKIIMWDCGI	107					
	NOV8c	NIYHPMGEIYEWMPREISEKYKEVVTOHFLGVITYETHPIIYLLKISQPSGNPKKIIMWDCGI	107					
30	NOV8d	-----MGEIYEWMPREISEKYKEVVTOHFLGVITYETHPIIYLLKISQPSGNPKKIIMWDCGI	55					
	Q9PUF2	EKYN SWEKIDAWTADIANENPSLVSRLQIGTTFEGRPMPLLKV-GKPGVNKKAIIFMDCGF	175					
	CAA03381	EKYNKWETIEAWTQOVATENPALISRSVIGTTFEGRAIYLLKV-GKAGQNKPAIFMDCGF	87					
	CAA03380	EKYNKWETIEAWTQOVATENPALISRSVIGTTFEGRAIYLLKV-GKAGQNKPAIFMDCGF	87					
	CAA03377	EKYNKWETIEAWTQOVATENPALISRSVIGTTFEGRAIYLLKV-GKAGQNKPAIFMDCGF	87					
35	Q9JHH6	EQVSLNELIYSWIEVITEQHPDMLQKIYIGSSFEKYPIYVLKVSQKEQRIKNAIIMWDCGI	179					
		190	200	210	220	230	240	
40	NOV8a	HAREWISPAFCQWFVKEILQNHKDNSRIKLLRNLDIFYVLPVLNIDGYIYTWT TDRWRK	167					
	NOV8b	HAREWISPAFCQWFVKEILQNHKDNSRIKLLRNLDIFYVLPVLNIDGYIYTWT TDRWRK	167					
	NOV8c	HAREWISPAFCQWFVKEILQNHKDNSRIKLLRNLDIFYVLPVLNIDGYIYTWT TDRWRK	167					
	NOV8d	HAREWISPAFCQWFVKEILQNHKDNSRIKLLRNLDIFYVLPVLNIDGYIYTWT TDRWRK	115					
	Q9PUF2	HAREWISPAFCQWFVREAVRTYGETITMTQLLNKLDIFYL PVLNIDGYIYSWKQSRMWRK	235					
	CAA03381	HAREWISPAFCQWFVREAVRTYGREIQVTELLDKLDFYVLPVLNIDGYIYTWT KSRFWRK	147					
45	CAA03380	HAREWISPAFCQWFVREAVRTYGREIQVTELLDKLDFYVLPVLNIDGYIYTWT KSRFWRK	147					
	CAA03377	HAREWISPAFCQWFVREAVRTYGREIQVTELLDKLDFYVLPVLNIDGYIYTWT KSRFWRK	147					
	Q9JHH6	HAREWISPAFCWFVGYVTQFHGKENLYTRLLRHVDIFYIMPVMNVGDYDTWKKNRMWRK	239					
		250	260	270	280	290	300	
50	NOV8a	SRSPHNNGTCFGTDLNRNFNAS-WCSIGASRNCQDQTECGTGPVSEPETKAVASFIESKK	226					
	NOV8b	SRSPHNNGTCFGTDLNRNFNAS-WCSIGASRNCQDQTECGTGPVSEPETKAVASFIESKK	226					
	NOV8c	SRSPHNNGTCFGTDLNRNFNAS-WCNSSWIE-----GS-----K-----CIESK-	205					
	NOV8d	SRSPHNNGTCFGTDLNRNFNAS-WCSIGASRNCQDQTECGTGPVSEPETKAVASFIESKK	174					
55	Q9PUF2	TRSVNAGSTCIGTDPNRNFDAA-WCSVGASRNPCESETYCGSKPESEKETKALADFIRNR	294					
	CAA03381	TRSTHTGSSCIGTDPNRNFDAG-WCEIGASRNPCESETYCGPAAESEKETKALADFIRNKL	206					
	CAA03380	TRSTHTGSSCIGTDPNRNFDAG-WCEIGASRNPCESETYCGPAAESEKETKALADFIRNKL	206					

CAA03377 TRSTHTGSSCIGTDPNRNFDAG-WCEIGASRNPCDETYCGPAAESEKETKALADFTIRNKL 206
Q9JHH6 NRSAHKNNRCVGTDLNRNFASKHWCEKGASSSSCSETYCGLYPESEPEVKAWADFTIRRN 299

```

      310      320      330      340      350      360
5  NOV8a DDILCFELTMHSYGQILITPYGYTKNKSSNHPEMIQVGQKAANALKAKYG-TNMYRVCSAD 285
   NOV8b DDILCFELTMHSYGQILITPYGYTKNKSSNHPEMIQVGQKAANALKAKYG-TNMYRVCSAD 285
   NOV8c -----VWN-----QL----- 210
   NOV8d DDILCFELTMHSYGQILITPYGYTKNKSSNHPEMIQVGQKAANALKAKYG-TNMYRVCSAD 233
10 Q9PUF2 SIIQAYLTIHSYSOMLLYPYSYTYDLTSNNKKLNSTAKEAIRELKVLFQ-TEYTYGPGAA 353
   CAA03381 SSIKAYLTIHSYSOMMIYPYSYAYKLGENNAELNALAKATVKELASLHG-TKYTYGPGAT 265
   CAA03380 SSIKAYLTIHSYSOMMIYPYSYAYKLGENNAELNALAKATVKELASLHG-TKYTYGPGAT 265
   CAA03377 SSIKAYLTIHSYSOMMIYPYSYAYKLGENNAELNALAKATVKELASLHG-TKYTYGPGAT 265
   Q9JHH6 DHIKAYISMHSYSQQTILFPYSYNRSKSKDHEELSLVASEAVRATESINKNTRYTHSGSE 359

      370      380      390      400      410      420
20 NOV8a ILYASSGSSRDWARDIGIPFSYTFELRDSGTYGFFVLPEAQIOPTCEETMEAVLSVLDDVY 345
   NOV8b ILYASSGSSRDWARDIGIPFSYTFELRDSGTYGFFVLPEAQIOPTCEETMEAVLSVLDDVY 345
   NOV8c ----- 210
   NOV8d ILYASSGSSRDWARDIGIPFSYTFELRDSGTYGFFVLPEAQIOPTCEETMEAVLSVLDDVY 293
   Q9PUF2 TIYPACGSDDWAYDQGIKYAFTFELRDKGRYGFALPESQIKPTCEETMIAVKYLAEYML 413
   CAA03381 TIYPACGSDDWAYDQGIKYSETFELRDTGRYGFLLPESQIRATCEETFLAIKYVASYVL 325
   CAA03380 TIYPACGSDDWAYDQGIKYSETFELRDTGRYGFLLPESQIRATCEETFLAIKYVASYVL 325
   CAA03377 TIYPACGSDDWAYDQGIKYSETFELRDTGRYGFLLPESQIRATCEETFLAIKYVASYVL 325
   Q9JHH6 SEYLAPEGSDDWIYDILGIKYSETFELRDTGRYGFLLPERYIKPTCAEALAAISKIVWHVI 419

      430      440
30 NOV8a AKHWHSDSAGRVTSATMILGLLVSCMSLL 374
   NOV8b AKHWHSDSAGRVTSATMILGLLVSCMSLL 374
   NOV8c ----- 210
   NOV8d AKHWHSDSAGRVTSATMILGLLVSCMSLL 322
   Q9PUF2 S-L----- 416
35 CAA03381 EHLHSHHHHHHEFEEQKLISEEDLN----- 349
   CAA03380 EHLHSHHHHHHEFEEQKLISEEDLN----- 349
   CAA03377 EHLHSHHHHHHEFEEQKLISEEDLN----- 349
   Q9JHH6 RNT----- 422

```

The presence of identifiable domains in the disclosed NOV8 protein was determined by using Pfam and then determining the Interpro number. The results are listed in Table 8L with the statistics and domain description.

Table 8L. Domain Analysis of NOV8		
PSSMs Producing Significant Alignments	Score (bits)	E Value
Zn_carbOpept: domain 1 of 1, from 50 to 332	384.8	8.7e-112
Zn_CarbOpept YhnleeyawlDllvsnfPdLvskvsiGksyeGRdlkvLKisdnpat + +++ ++ ++ ++ + +++ + +++ +++ ++		

NOV8	YHPMGEINEWMREISEKYKEVVTQHFLGVTYETHPIYYLKISQP--S
Zn_CarbOpept	genePevfavagWiHAREwvtsAtllwllkelvanYgsDktitklldgld +++++++ ++ + ++++ +++++ ++++++ ++++++
NOV8	GNPKKIIWMGCG- IHAREWIAPAFQCQWVKEILQNHKDNSRIRKLLRNLD
Zn_CarbOpept	lfyilpvfnpDGyaYsitttSyRmWRKtRspnagsfcvGtDpNRNwyaqw +++++ + ++ ++++ + ++ + ++ + + +++ +
NOV8	-FYVLPVLNIDGYIYTWTDD--RLWRKSRSPHNNGTCFGTDLNRNFNASW
Zn_CarbOpept	ggmgassysPcSetYeGtapfSepEtkavedfirswlgGGkqnIkayItf +++++ + ++++ + + + ++++ ++ + ++ ++++
NOV8	CSIGASR-NCQDQTFCTGTPVSEPETKAVASFIESKDD---DILCFLTM
Zn_CarbOpept	HsYSqlllyPYgydynlnpdandldelsdlkiaadalsarhgtyYtlglp + +++++ +++ ++ ++ + +++ ++++++ ++++++ +++ +
NOV8	HSYGQLILTPYGYTKNKSSNHPEMIQVG--QKAANALKAKYGTNYRVG-S
Zn_CarbOpept	gsstIYpasAGGsdDwaydvgiikyaftfElrpdtdgsyGnPCFllPeeqI +++++ +++ ++ ++ + + ++++++ ++ +++ + ++ + +
NOV8	SADILYASS-GSSRDWARDIG-IPFSYTFELR-DSGTYG---FVLPEAQI
Zn_CarbOpept	iptgsee (SEQ ID NO:173) +++++ +
NOV8	QPTCE-E (SEQ ID NO:20)

Consistent with other known members of the carboxypeptidase family of proteins, NOV8 contains a zinc carboxypeptidase domain as illustrated in Table 8L.

NOV8 nucleic acids, and the encoded polypeptides, according to the invention are useful
5 in a variety of applications and contexts. For example, NOV8 nucleic acids and polypeptides
can be used to identify proteins that are members of the carboxypeptidase family of proteins.
The NOV8 nucleic acids and polypeptides can also be used to screen for molecules, which
inhibit or enhance NOV8 activity or function. Specifically, the nucleic acids and polypeptides
according to the invention may be used as targets for the identification of small molecules that
10 modulate or inhibit, *e.g.*, digestion or hydrolysis of polypeptide chains. These molecules can be
used to treat, *e.g.*, pancreatitis, ulcers, inflammatory bowel disease, diverticular disease, Crohn's
disease, appendicitis, or obesity.

In addition, various NOV8 nucleic acids and polypeptides according to the invention are useful, *inter alia*, as novel members of the protein families according to the presence of domains and sequence relatedness to previously described proteins. For example, the NOV8 nucleic acids and their encoded polypeptides include structural motifs that are characteristic of proteins belonging to the carboxypeptidase family. Carboxypeptidase B, (CPB) like carboxypeptidase A,

is a pancreatic exopeptidase. Unlike carboxypeptidase A, however, carboxypeptidase B catalyzes the hydrolysis of the peptide bonds involving basic amino acids lysine, arginine and ornithine. This hydrolysis occurs at the C-terminal bond in these polypeptides.

The NOV8 nucleic acids and polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications in the mediation of hydrolysis. As such the NOV8 nucleic acids and polypeptides, antibodies and related compounds according to the invention may be used to treat digestive disorders, *e.g.*, xerostomia, hypercalcaemia, ulcers, Von Hippel-Lindau (VHL) syndrome, cirrhosis, transplantation, inflammatory bowel disease, diverticular disease, hirschsprung's disease, crohn's disease, appendicitis, stroke, tuberous sclerosis, anxiety, pain, endocrine dysfunctions, neuroprotection, diabetes, obesity, growth and reproductive disorders, myasthenia gravis.

The NOV8 nucleic acids and polypeptides are useful for detecting specific cell types. For example, expression analysis has demonstrated that a NOV8 nucleic acid is expressed in pooled mammalian tissue, small intestine, and spinal cord.

Additional utilities for NOV8 nucleic acids and polypeptides according to the invention are disclosed herein.

NOV9

The disclosed NOV9 nucleic acid (alternatively referred to herein as CG56463-01) encodes a novel neurotransmitter receptor-like protein and includes the 1142 nucleotide sequence (SEQ ID NO:27) shown in Table 9A. The NOV9 nucleic acid disclosed herein maps to chromosome 6p23.

An open reading frame for the mature protein was identified beginning with an GCT codon at nucleotides 3-5, and ending with a TAA stop codon at nucleotides 1020-1022. Putative untranslated regions, if any, are found upstream from the initiation codon and downstream from the termination codon. The start and stop codons are in bold letters.

Table 9A. NOV9 Nucleotide Sequence (SEQ ID NO:27)	
AGG CT GTGGAGCTGTGTTACAAGAACGTGAACGAATCCTGCATTAAAACTCCTTACTCGCCAGGTCCTCGATCTATCCTCTACGCCGTCCTTGGTTTTGGGGCTGTGCTGGCAGCGTTTGGAAACTTACTGGTCATGATTGCTATCCTTCATTCAAACAACTGCACACACCTACAACTTTCTGATTGCGTCGCTGGCCTGTGCTGACTTCTTGGTGGGAGTCACTGTGATGCCCTTCAGCACAGTGAGGTCTGTGGAGAGCTGTTGGTACTTTGGGGACAGTTACTGTAAATTCCATA	

CATGTTTTGACACATCCTTCTGTTTTGCTTCTTTATTTCAATTTATGCTGTATCTCTGTTGATAGATACATTGCTG
TTACTGATCCTCTGACCTATCCAACCAAGTTTACTGTGTGTCAGTTTCAGGGATATGCATTGTTCTTTCCCTGGTTCT
TTTCTGTGCACATACAGCTTTTCGATCTTTTACACGGGAGCCAACGAAGAAGGAATTGAGGAATTAGTAGTTGCTC
TAACCTGTGTAGGAGGCTGCCAGGCTCCACTGAATCAAACTGGGTCTACTTTGTTTTCTTCTATTCTTTATAC
CCAATGTCGCCATGGTGTATATACAGTAAGATATTTTTGGTGGCCAAGCATCAGGCTAGGAAGATAGAAAGTA
CAGCCAGCCAAGCTCAGTCCTCCTCAGAGAGTTACAAGGAAAGAGTAGCAAAAAGAGAGAGAAAGGCTGCCAAAA
CTTTGGGAATTGCTATGGCAGCATTCTTGTCTCTTGGCTACCATACTCGTTGATGCAGTGATTGATGCTTATA
TGAATTTTATAACTCCTCCTTATGTTTATGAGATTTTAGTTTGGTGTGTTTATTATAATTGAGCTATGAACCCCT
TGATTTATGCTTTCTTTTACCAATGGTTTGGGAAGGCAATAAACTTATTGTAAGCGGCAAGGTCTTAAGGACTG
ATTCGTCAACAATAATTTATTTCTGAAGAAGTAGAGACAGATTAAAAACATTACTGTAGAGACCTCAAACTA
ACTTGAATTAAGGTCAAGTGCAAAAATAAACACTTGGACATAGAGAGGCAAGCATGATCATATGCCAAGTTGTA
GGACAATACATTCAATC

The NOV9 protein (SEQ ID NO:28) encoded by SEQ ID NO:27 is 339 amino acid residues in length and is presented using the one-letter amino acid code in Table 9B. The SignalP, Psort and/or Hydropathy results indicate that NOV9 has a signal peptide and is likely to be localized in the plasma membrane with a certainty of 0.6000. Alternatively, a NOV9 polypeptide is located to the Golgi body with a certainty of 0.4000, the endoplasmic reticulum (membrane) with a certainty of 0.3000, or the mitochondrial inner membrane with a certainty of 0.0300. The SignalP indicates a likely cleavage site for a NOV9 polypeptide is between positions 47 and 48, *i.e.*, at the dash in the sequence MIA-IL.

Table 9B. Encoded NOV9 Protein Sequence (SEQ ID NO:28)

AVELCYKNVNESCIKTPYSPGPRSILYAVLGFGAVLAAFGNLLVMIAILHFKQLHTPTNFLIASLACADFLVGVT
VMPFSTVRSVESWCYFGDSYCKFHTCFDTSFCFASLFHLCCISVDRIYAVTDPLTYPTKFTVSVSGICIVLSWFF
SVTYSFSIFYTGANEIEELVVALTCVGGCQAPLNQNWLLCFLFFIPNVAMVFIYSKIFLVAKHQARKIEST
ASQAQSSSESYKERVAKRERKAAKTLGIAMAAFLVSWLPYLVDAVIDAYMNFITPPYVYEILVWCVYNSAMNPL
IYAFFYQWFGKAIKLIIVSGKVLRTDSSTTNLFSEEVETD

SNP variants of NOV9 are disclosed in Example 2.

A search against the Patp database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 9C.

Table 9C. PatP Results for NOV9

	High Score	Smallest Sum Prob P (N)
Sequences Producing High-Scoring Segment Pairs:		
patp:AAB18764 Amino acid sequence of the human SNORF1 receptor	1782	1.8e-183

patp:AAB18765	Amino acid sequence of the rat SNORF1 receptor	1592	2.5e-163
patp:AAG80970	Human nGPCR40 #2	1307	3.9e-133
patp:AAG72611	Human OR-like polypeptide query sequence	1257	7.8e-128
patp:AAU25611	Human G Protein-Coupled Receptor (GPCR) polypeptide #58	1251	3.4e-127

In a BLAST search of public sequence databases, it was found, for example, that the NOV9 nucleic acid sequence of this invention has 601 of 1000 bases (60%) identical to a gb:GENBANK-ID:AR035954|acc:AR035954.1 mRNA from Unknown. (Sequence 1 from patent
5 US 5871967). Further, the full amino acid sequence of the disclosed NOV9 protein of the invention has 152 of 330 amino acid residues (46%) identical to, and 216 of 330 amino acid residues (65%) similar to, the 337 amino acid residue ptnr:SPTREMBL-ACC:O14804 protein from Human (PUTATIVE NEUROTRANSMITTER RECEPTOR).

The NOV9 protein of the invention also has homolgy to the proteins shown in the
10 BLASTP data in Table 9D.

Table 9D. NOV9 BLASTP Results

Gene Index/ Identifier	Protein/Organism	Length of aa	Identity (%)	Positives (%)	Expect Value
Q96RI9	TRACE AMINE RECEPTOR 3 - Homo sapiens (Human)	348	339/339 (100%)	339/339 (100%)	2.3e-183
Q923Y6	TRACE AMINE RECEPTOR 3 - Rattus norvegicus (Rat)	338	293/334 (87%)	314/334 (94%)	3.2e-163
Q923Y2	TRACE AMINE RECEPTOR 8 - Rattus norvegicus (Rat)	358	241/332 (72%)	285/332 (85%)	4.7e-137
Q923X5	TRACE AMINE RECEPTOR 15 - Rattus norvegicus (Rat)	358	234/334 (70%)	281/334 (84%)	3.4e-134
Q923X8	TRACE AMINE RECEPTOR 12 - Rattus norvegicus (Rat)	333	236/333 (70%)	280/333 (84%)	4.4e-134

A multiple sequence alignment is given in Table 9E, with the NOV9 protein of the
15 invention being shown in line 1 in a ClustalW analysis comparing NOV9 with related protein sequences of Table 9D.

Table 9E. ClustalW Analysis of NOV9

1. SEQ ID NO.: 28 NOV9 4. SEQ ID NO.: 176 Q923Y2
2. SEQ ID NO.: 174 Q96RI9 5. SEQ ID NO.: 177 Q923X5
3. SEQ ID NO.: 175 Q923Y6 6. SEQ ID NO.: 178 Q923X8

10 20 30 40 50 60

NOV9 AVELCYKNVNESCIKTPYSPGPRSTILYAVLGFGLAVL 36
Q96RI9 -----MVNNFSQAEAVELCYKNVNESCIKTPYSPGPRSTILYAVLGFGLAVL 45
Q923Y6 -----MELCYENVNGSCIKSSYSPWPRAILYAVLGLGLAVL 35
Q923Y2 MDKLVDNFLSGQSRTMSDLLSASSPOLCYENINGSCIRSPYSPGPRLLILYAVFGFGAVL 60
Q923X5 MRVDDDRFPWDQDSILSRDLLSASSLQLCYENINRSCVRSPYSPGPRLLILYAVFGFGAVL 60
Q923X8 -----MQLCYEKNRSCVRSPYSPGPRLLILYAVFGFGAVL 35

70 80 90 100 110 120

NOV9 AAFGNLLVMIAILHFKQLHTPTNFLIASLACADFLVGVTVMPFSTVRSVESCWYFGDSYC 96
Q96RI9 AAFGNLLVMIAILHFKQLHTPTNFLIASLACADFLVGVTVMPFSTVRSVESCWYFGDSYC 105
Q923Y6 AVFGNLLVITAILHFKQLHTPTNFLVASLACADFLVGVTVMPFSTVRSVEGCWYFGDIYC 95
Q923Y2 AVCGNLLVMTSILHFRQLHSPANFLVASLACADFLVGLTVMPFSTVRSVEGCWYFGDIYC 120
Q923X5 AVCGNLLVMTSILHFRQLHSPANFLVASLACADFLVGLTVMPFSMVRSEGCWYFGDIYC 120
Q923X8 AVCGNLLVMTSILHFRQLHSPANFLVASLACADFLVGLTVMPFSMVRSEGCWYFGDIYC 95

130 140 150 160 170 180

NOV9 KFHTCFDTSFCFASLFLHLCISVDRIYIAVDPLIYPTKFTVSVSGICIVLSWFFSVITYSF 156
Q96RI9 KFHTCFDTSFCFASLFLHLCISVDRIYIAVDPLIYPTKFTVSVSGICIVLSWFFSVITYSF 165
Q923Y6 KFHTCFDTSFCFASLFLHLCISIDRIYIAVDPLIYPTKFTVSVSGVCIASWFFSVITYSF 155
Q923Y2 KFHSCHFSGFCYSSIFHLCHFISVDRIYIAVSDPLIYPTKFTASVSGKCITFSWLLSIITYCF 180
Q923X5 KLFHTCFDVSFCYCSLFLHCHFISVDRIYIAVSDPLIYPTKFTASVSGKCITFSWLLSIITYCF 180
Q923X8 KFHSSEFDGSCFCYSSIFHLCHFISADRIYIAVSDPLIYPTKFTASVSGKCITFSWLLSIITYSF 155

190 200 210 220 230 240

NOV9 SIFYTGANEBCIEELVVALTCVGGCQAPLNQNWVLLCFLLFFIPNVAMVFITYSKIFLVAK 216
Q96RI9 SIFYTGANEBCIEELVVALTCVGGCQAPLNQNWVLLCFLLFFIPNVAMVFITYSKIFLVAK 225
Q923Y6 SIFYTGANEBCIEELVVALTCVGGCQAPLNQNWVLLCFLLFFIPNVAMVFITYSKIFLVAK 215
Q923Y2 SILYTGANEAGLEDLVSALTCVGGCQIAVNSWVFINFLELFLVPTLVMMTVYSKIFLIAK 240
Q923X5 PLIYTGASEAGLEDLVSALTCVGGCQIPNQKQVFINFLELFLVPTLVMMTVYSKIFLIAK 240
Q923X8 SIFYTCVNEAGLEDLVSALTCVGGCQIAVNSWVFINFLELFLVPTLVMMTVYSKIFLIAK 215

250 260 270 280 290 300

NOV9 HQARKIESTASQAQSSSESYKERVAKRERKAAKTLGIAMAFLVSWLPYLVDIVIDAYMN 276
Q96RI9 HQARKIESTASQAQSSSESYKERVAKRERKAAKTLGIAMAFLVSWLPYLVDIVIDAYMN 285
Q923Y6 QQAARKIEGSANQPAQSSSESYKERVARRERKAAKTLGIAMAFLVSWLPYIIDIVIDAYMN 275
Q923Y2 QQAQNIIEKMSKOTTRASESYKDRVAKRERKAAKTLGIAMAFLVSWLPYFIDSIIIDAFLG 300
Q923X5 QQAQNIIEKMRKOTARASESYKDRVCKRERKAAKTLGIAMAFLVSWLPYFIDSIIIDAFLG 300
Q923X8 QQAQNIIEKMGKOTARASESYKDRVAKRERKAAKTLGIAMAFLVSWLPYFIDSIIIDAFLG 275

310 320 330 340 350 360

7tm_1	lervlptallvtlwLayvNscINPiIY	(SEQ ID NO:180)
	+++++ + +++ + +++ +	
NOV9	---TPPYVYEILVWCYVYNSAMNPLIY	(SEQ ID NO:28)

Consistent with other known members of the neurotransmitter receptor family of proteins, NOV9 contains 7-transmembrane domains as illustrated in Table 9F.

The NOV9 nucleic acid, and the encoded polypeptide, according to the invention are useful in a variety of applications and contexts. For example, NOV9 nucleic acids and polypeptides can be used to identify proteins that are members of the neurotransmitter receptor family of proteins. The NOV9 nucleic acids and polypeptides can also be used to screen for molecules, which inhibit or enhance NOV9 activity or function. Specifically, the nucleic acids and polypeptides according to the invention may be used as targets for the identification of small molecules that modulate or inhibit, *e.g.*, cellular recognition, or G-protein-mediated transduction of neuromuscular/synaptic signals. These molecules can be used to treat, *e.g.*, neurological disorders, immune diseases, or signal transduction pathways.

In addition, the NOV9 nucleic acid and polypeptide according to the invention are useful, *inter alia*, as novel members of the protein families according to the presence of domains and sequence relatedness to previously described proteins. For example, the NOV9 nucleic acid and polypeptide include structural motifs that are characteristic of proteins belonging to the family of neurotransmitter receptor proteins. Nerve cells are highly specialized for cell-to-cell communication. A number of small molecules called neurotransmitters act as the actual signals, released from one nerve cell only to dock on another cell. There are numerous subtypes of receptor for any given neurotransmitter. Docking molecules, or receptors, act as gates, triggered by the neurotransmitter. When a neurotransmitter molecule fits into a receptor, it typically opens the gate, allowing ions to travel through the cell's membrane. The ions, in turn, excite the cell. If the receiving cell is a nerve cell, this excitation can lead to release of its own neurotransmitters.

The vast majority of neurotransmitter receptors belong to a class of proteins known as the serpentine receptors. This class exhibits a characteristic transmembrane structure: spanning the cell membrane, seven times. The link between neurotransmitters and intracellular signaling is carried out by association either with G-proteins (small GTP-binding and hydrolyzing proteins)

or with protein kinases, or by the receptor itself in the form of a ligand-gated ion channel (for example, the acetylcholine receptor). An additional characteristic of neurotransmitter receptors is that they are subject to ligand-induced desensitization: such that they can become unresponsive upon prolonged exposure to their neurotransmitter.

The NOV9 nucleic acid and polypeptide, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications in the mediation of signal transduction. As such the NOV9 nucleic acid and polypeptide, antibodies and related compounds according to the invention may be used to treat, *e.g.*, leukemia, acute nonlymphocytic, spinocerebellar ataxia-1, or neurological disorders.

The NOV9 nucleic acid and polypeptide are useful for detecting specific cell types. For example, expression analysis has demonstrated that a NOV9 nucleic acid is predominantly expressed in skeletal muscle and selected areas of the brain.

Additional utilities for the NOV9 nucleic acid and polypeptide according to the invention are disclosed herein.

NOV10

The disclosed NOV10 nucleic acid (alternatively referred to herein as CG56321-01) encodes a novel proto-oncogene MAF-like protein and includes the 1189 nucleotide sequence (SEQ ID NO:29) shown in Table 10A. The NOV10 nucleic acid disclosed herein maps to chromosome 8.

An open reading frame for the mature protein was identified beginning with an ATG initiation codon at nucleotides 85-87, and ending with a TAG stop codon at nucleotides 1144-1146. Putative untranslated regions, if any, are found upstream from the initiation codon and downstream from the termination codon. The start and stop codons are in bold letters.

Table 10A. NOV10 Nucleotide Sequence (SEQ ID NO:29)

GGGAGCAGGGGGGGGAGAGGCCTGCAGCTCCCCACCACTCCACAGCCCGCCGTCGGGGCGCGGCCGGGCGCGGG CCCCGGGCG AT GGCCGCGGAGCTGGCGATGGGCGCCGAGCTGCCAGCAGCCCGCTGGCCATCGAGTACGTCAAC GACTTCGACCTGATGAAGTTCGAGGTGAAGAAGGAGCCTCCCGAGGCCGAGCGCTTCTGCCACCGCCTGCCGCCA GGCTCGCTGTCTCGACGCCGCTCAGCAGCCCTGCTCCTCCGTGCCCTCCTCGCCAGCTTCTGCGCGCCAGC CCGGGCACCGGCGGGCGGGCGGGCGGGGGGCGGCGGGCTCGTCTCAGGCCGGGGGCGCCCCGGGCGCGCG AGCGGGGGCCCCGGCGCCGTCGGGGGCACCTCGGGGAAGCCGGCGCTGGAGGATCTGTACTGGATGAGCGGCTAC CAGCATCACCTCAACCCGAGGCGCTCAACCTGACGCCCCGAGGACGCGGTGGAGGCGCTCATCGGCAGCGGCCAC CACGGCGCGCACACGGCGCGCACACCCGGCGGCCGCGCAGCCTACGAGGCTTTCCGCGGCCCGGGCTTCGCG

gb:GENBANK-ID:AF034693|acc:AF034693.1 mRNA from Coturnix japonica (Coturnix coturnix japonica bZip transcription factor MafA (mafA) gene, complete cds). Further, the full amino acid sequence of the disclosed NOV10 protein of the invention has 134 of 249 amino acid residues (53%) identical to, and 151 of 249 amino acid residues (60%) similar to, the 311 amino acid residue ptnr:SPTREMBL-ACC:Q90370 protein from Coturnix coturnix japonica (Japanese quail) (MAFB PROTEIN).

The NOV10 protein of the invention also has homolgy to the proteins shown in the BLASTP data in Table 10D.

Table 10D. NOV10 BLASTP Results					
Gene Index/ Identifier	Protein/Organism	Length of aa	Identity (%)	Positives (%)	Expect Value
Q90370	MAFB PROTEIN - Coturnix coturnix japonica (Japanese quail)	311	134/249 (53%)	151/249 (60%)	1.3e-77
Q90888	MAFB - Gallus gallus (Chicken)	311	132/249 (53%)	152/249 (61%)	4.2e-77
Q98UK4	C-MAF - Brachydanio rerio (Zebrafish) (Zebra danio)	327	186/339 (54%)	212/339 (62%)	1.9e-76
Q98UK5	TRANSCRIPTION FACTOR MAFB - Brachydanio rerio (Zebrafish) (Zebra danio)	356	181/353 (51%)	212/353 (60%)	1.1e-71
O73679	TRANSCRIPTION FACTOR VAL - Brachydanio rerio (Zebrafish) (Zebra danio)	356	181/353 (51%)	212/353 (60%)	1.1e-71

A multiple sequence alignment is given in Table 10E, with the NOV10 protein of the invention being shown in line 1 in a ClustalW analysis comparing NOV10 with related protein sequences of Table 10D.

Table 10E. ClustalW Analysis of NOV10

1. SEQ ID NO.: 30	NOV10	4. SEQ ID NO.: 183	Q98UK4
2. SEQ ID NO.: 181	Q90370	5. SEQ ID NO.: 184	Q98UK5
3. SEQ ID NO.: 182	Q90888	6. SEQ ID NO.: 185	O73679

		10	20	30	40	50	60	
5	NOV10	MAAELAMG-AELPSSPLAIEYVNDFDLMKFVVKKEPPEA----	ERFCHRLPP-GSLSSST	53				
	Q90370	MAGELSTIG-AELPTSPLAMEYVNDFDLMKFVVKKEPLGRNDRS-GRHCTRLQOPAGSVSST	58					
	Q90888	MAGELSTIG-AELPTSPLAMEYVNDFDLMKFVVKKEPLGRNDRS-GRHCTRLQOPAGSVSST	58					
	Q98UK4	MASELAMSSSDLPTSPLAMEYVNDFDLMKFVVKKEPVEP-DRS-ISQCSRLIAGGSLSSST	58					
	Q98UK5	MSADLAMG-PELPTSPLAIEYVNDFDLMKFVVKKEAAMAHDRANIRQCNRLOPQGSVSST	59					
10	073679	MSADLAMG-PELPTSPLAIEYVNDFDLMKFVVKKEAAMAHDRANIRQCNRLOPQGSVSST	59					
		70	80	90	100	110	120	
15	NOV10	PISTPCSSVPSSPSFSCAPSPGTGGGGGAGGGGSSQAGGAPGPPSGGPGAVGGTSGKPAAL	113					
	Q90370	PISTPCSSVPSSPSFSP-----	TEQKTHL	82				
	Q90888	PISTPCSSVPSSPSFSP-----	TEQKTHL	82				
	Q98UK4	PMSTPCSSVPSSPSFSAPSPGSG-----	SEOKAHL	88				
	Q98UK5	PISTPCSSVPSSPSFSP-----	TEQKNHL	83				
	073679	PISTPCSSVPSSPSFSP-----	TEQKNHL	83				
20		130	140	150	160	170	180	
	NOV10	EDLYWMSG--YQHHLNPEALNLTPEDAVEALIGS-----	GHHG--	AHHGA	154			
	Q90370	EDLYWMAN--SY-QQNNPEALNLTPEDAVEALIGS-----	HQVSQQLOG--	FESFR-A	129			
	Q90888	EDLYWMAN--SY-QQNNPEALNLTPEDAVEALIGS-----	HQVSQQLOG--	FESFR-A	129			
25	Q98UK4	EDFYWMTG--YQQQLNPEALGFSPEDAVEALISS-----	SHQLQS--	FDGYARG	133			
	Q98UK5	EELYWMPGSGAYPQQIDPQTLSLTPEDAVEALIGATAHGHPPPPHVQQQLQAGAFDGYRGA	143					
	073679	EELYWMPGSGAYPQQIDPQTLSLTPEDAVEALIGATAHGHPPPPHVQQQLQAGAFDGYRGA	143					
30		190	200	210	220	230	240	
	NOV10	HHPAAAA-----	AYEAFRGPCHAGGGG--	ADDMCAG--	HHHGAHHAHHHHAAHHHHH	203		
	Q90370	HHHHHHH-----	HQHHLHQYPAVTH--	EDLAGSG--	HPHHHHHHHHHASP--	TP	172	
	Q90888	HHHHHHH-----	HQHHLHQYPAVTH--	EDLAGSG--	HPHHHHHHHHHQASP--	TP	172	
35	Q98UK4	QQFGSAAG-----	AGGAMAGEEMGSAAAVVSAVIAAAAQNGAPHHHHHHHHHHHPAGHH	187				
	Q98UK5	HHHHGHAAQQQQQQQPQHHLHQYGAIPHHPDDLSCGHPGAHGHHHPHHHHHHHHSQDPDSP	203					
	073679	HHHHGHAAQQQQQQQPQHHLHQYGAIPHHPDDLSCGHPGAHGHHHPHHHHHHHHSQDPDSP	203					
40		250	260	270	280	290	300	
	NOV10	HHHHHGGAGHGGGAGHEV-----	RIEERFSDDQLVMSVRELNRQLRGF	247				
	Q90370	STSSSSSQQLTSHQQHPPSS-----	SVEDRFSDQLVMSVRELNRHLRGF	219				
	Q90888	STSSSSSQQLTSHQQHPPSS-----	SVEDRFSDQLVMSVRELNRHLRGF	219				
	Q98UK4	HHHAAPGAQSN GASAGHP-GH-----	MHLDERFSDEQLVMSVRELNRQLRGV	234				
45	Q98UK5	SPISPEQLHHRHHHHHHHPGHGPGQQGHGVGGGLNVEDRFSDQLVMSVRELNRHLRGF	263					
	073679	SKISPEQXHHHHHHHHHPGHGPGQQGHGVGGGLNVEDRFSDQLVMSVRELNRHLRGF	263					
50		310	320	330	340	350	360	
	NOV10	SKEEVIRLKQKRRTLKNRGYAQSCREKRVQQRHILESEKCOLSQVEQLKLEVGRLAKER	307					
	Q90370	TKDEVIRLKQKRRTLKNRGYAQSCRYKRVQQKHLENEKTQLIQQVEQLKQEVTRLARER	279					
	Q90888	TKDEVIRLKQKRRTLKNRGYAQSCRYKRVQQKHLENEKTQLIQQVEQLKQEVTRLARER	279					
	Q98UK4	SKEEVIRLKQKRRTLKNRGYAQSCRYKRVQQRHMLEGEKTQLMQQVDHLKQELSRILVRER	294					
	Q98UK5	TKDEVIRLKQKRRTLKNRGYAQSCREKRVQQKHLENEKTQLINQVEQLKQELNRLARER	323					
55	073679	TKDEVIRLKQKRRTLKNRGYAQSCREKRVQQKHLENEKTQLINQVEQLKQELNRLARER	323					
		370	380	390	400			

1005537.013300
molecules, which inhibit or enhance NOV10 activity or function. Specifically, the nucleic acids and polypeptides according to the invention may be used as targets for the identification of small molecules that modulate or inhibit, *e.g.*, gene regulation/expression. These molecules can be used to treat, *e.g.*, autoimmune disorders or antioxidant induction of molecules such as NQO1,
5 GST, Ya, or other detoxification enzymes.

In addition, the NOV10 nucleic acid and polypeptide according to the invention are useful, *inter alia*, as novel members of the protein families according to the presence of domains and sequence relatedness to previously described proteins. For example, the NOV10 nucleic acid and polypeptide include structural motifs that are characteristic of proteins belonging to the
10 family of bZip transcription factor proteins. Transcription factors are proteins that bind to the enhancer or promoter regions and interact such that transcription occurs from only a small group of promoters in any cell. Most transcription factors can bind to specific DNA sequences, and these trans-regulatory proteins can be grouped together in families based on similarities in structure. Within such a family, proteins share a common framework structure in their respective
15 DNA-binding sites, and slight differences in the amino acids at the binding site can alter the sequence of the DNA to which it binds. In addition to having this sequence-specific DNA-binding domain, transcription factors contain a domain involved in activating the transcription of the gene whose promoter or enhancer it has bound. Usually, this trans-activating domain enables that transcription factor to interact with proteins involved in binding RNA polymerase. This
20 interaction often enhances the efficiency with which the basal transcriptional complex can be built and bind RNA polymerase II. There are several families of transcription factors.

The bZip transcription factor family of proteins are dimers, each of whose subunits contains a basic DNA-binding domain at the carboxyl end, followed closely by an a helix containing several leucine residues. These leucines are placed in the helix such that they interact
25 with similarly spaced leucine residues on other bZip proteins to form a "leucine zipper" between them, causing dimers to form. This domain is followed by a regulatory domain that can interact with the promoter to stimulate or repress transcription.

The NOV10 nucleic acid and polypeptide, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications in the mediation of gene
30 transcription. As such the NOV10 nucleic acid and polypeptide, antibodies and related compounds according to the invention may be used to treat, *e.g.*, anemia, ataxia-telangiectasia,

autoimmune disease, cancer, immunodeficiencies, hemophilia, hypercoagulation, idiopathic thrombocytopenic purpura, allergies, transplantation, graft versus host disease (GVHD), lymphoedema, systemic lupus erythematosus, asthma, emphysema, scleroderma, ARDS, diabetes, renal artery stenosis, interstitial nephritis, glomerulonephritis, polycystic kidney disease, systemic lupus erythematosus, renal tubular acidosis, IgA nephropathy, hypercalcaemia, or Lesch-Nyhan syndrome.

The NOV10 nucleic acid and polypeptide are useful for detecting specific cell types. For example, expression analysis has demonstrated that a NOV10 nucleic acid is expressed in blood, lymphocyte, whole embryo, lung, pancreas, kidney and eye.

Additional utilities for the NOV10 nucleic acid and polypeptide according to the invention are disclosed herein.

NOV11

The NOV11 proteins described herein are novel lysyl oxidase-like proteins. The NOV11 nucleic acids disclosed herein map to chromosome 10. Two alternative novel NOV11 nucleic acids and polypeptides are disclosed herein, namely NOV11a and NOV11b.

NOV11a

A NOV11 variant is NOV11a (alternatively referred to herein as CG56381-01), which encodes the 2599 nucleotide sequence (SEQ ID NO:31) shown in Table 11A. An open reading frame for the mature protein was identified beginning with an ATG codon at nucleotides 78-80 and ending with a TGA codon at nucleotides 2568-2570. Putative untranslated regions, if any, downstream from the termination codon and upstream from the initiation codon are underlined. The start and stop codons are in bold letters.

Table 11A. NOV11a Nucleotide Sequence (SEQ ID NO:31)

<p>CCGCCGCGGCGCCCGCCAGCCCCGGACTGTCCGCGCTCCATCTGGTATCTTGGCCTCAGCTGTCCTTGAAGTCA CCATGGCGTGGTCCCCACCAGCCACCCTCTTTCTGTTCTGCTGCTGCTAGGCCAGCCCCCTCCAGCAGGCCAC AGTCACTGGGCACCACTAAGCTCCGGCTGGTGGGCCAGAGCAAGCCAGAGGAGGGCCGCCTGGAGGTGCTGC ACCAGGGCCAGTGGGGCACCGTGTGTGATGACAACCTTGTCTATCCAGGAGGCCACAGTGGCTTGCCGCCAGCTGG GCTTCGAAGCTGCCTTGACCTGGGCCACAGTGCCAAGTACGGCCAAGGGGAGGGACCCATCTGGCTGGACAATG TGCGCTGTGTGGGCACAGAGAGCTCCTTGGACCAAGTGCAGGTCTAATGGCTGGGGAGTCAGTGACTGCAGTCACT CAGAAGACGTAGGGGTGATATGCCACCCCGCGGCCATCGTGGCTACCTTTCTGAACTGTCTCCAATGCCCTTG GGCCCCAGGTGAGGAGGCTGGGCCGGCGGCTGGAGGAGGTGCGGCTCAAGCCCATCCTTGCCAGTGCCAAGCAGC ATAGCCAGTGACCGAGGGAGCCGTGGAGGTGAAGTATGAGGGCCACTGGCGGCAGGTGTGTGACCAGGGCTGGA CCATGAACAACAGCAGGGTGGTGTGCGGATGCTGGGCTTCCCAGCGAGGTGCCTGTGACAGCCACTACTACA</p>

SLHTPSCCRYTRYLSLLEPCPSQSPNSEEKGCQCGAPRTCSSLMARSP IQMVLLPQDGS GPAPKGLWPMEYVL
QALLS

SNP variants of NOV11a are disclosed in Example 2.

NOV11b

Alternatively, a NOV11 variant is NOV11b (alternatively referred to herein as CG56381-02), which includes the 2592 nucleotide sequence (SEQ ID NO:33) shown in Table 11C. An open reading frame for the mature protein was identified beginning with an ATG codon at nucleotides 46-48 and ending with a TGA codon at nucleotides 2314-2316. Putative untranslated regions, if any, downstream from the termination codon and upstream from the initiation codon are underlined. The start and stop codons are in bold letters.

Table 11C. NOV11b Nucleotide Sequence (SEQ ID NO:33)

CGCGCTCCATCTGGTATCTTGGCCTCAGCTGTCTTGAAGTCACCATGGCGTGGTCCCCACCAGCCACCCTCTTT
CTGTTCTCTGCTGCTGCTAGGCCAGCCCCCTCCAGCAGGCCACAGTCACTGGGCACCACTAAGCTCCGGCTGGTG
GGCCCAGAGAGCAAGCCAGAGGAGGGCCGCTGGAGGTGCTGCACCAGGGCCAGTGGGGCACCGTGTGTGATGAC
AACTTTGCTATCCAGGAGGCCACAGTGGCTTGCCTCCAGCTGGGCTTCGAAGCTGCCTTGACCTGGGCCCACAGT
GCCAAGTACGGCCAAGGGGAGGGACCCATCTGGCTGGACAATGTGCGCTGTGTGGGCACAGAGAGCTCCTTGGAC
CAGTGCGGGTCTAATGGCTGGGGAGTCACTGACTGCAGTCACTCAGAAGACGTAGGGGTGATATGCCACCCCCG
CGCCATCGTGGCTACCTTTCTGAACTGTCTCAATGCCCTTGGGCCCCAGGGCCAGCGCTGGAGGAGGTGCGG
CTCAAGCCCATCCTTGCCAGTGCCCAAGCAGCATAGCCCCAGTGACCGAGGGAGCCGTGGAGGTGAAGTATGAGGGC
CACTGGCGGCAGGTGTGTGACCAGGGCTGGACCATGAACAACAGCAGGGTGGTGTGCGGGATGCTGGGCTTCCCC
AGCGAGGTGCCTGCCGACAGCCACTACTACAGGAAAGTCTGGGATCTGAAGATGAGGGACCTAAGTCTAGGCTG
AAGAGCCTGACGAATAAGAACTCCTTCTGGATCCACCAGGTACCTGCCTGGGGACAGAGCCCCACATGGCCAAC
TGCCAGGTGCAGGTGGCTCCAGCCCCGGGCAAGCTGCGGCCAGCCTGCCAGGTGGCATGCACGCTGTGGTCAGC
TGTGTGGCAGGGCCTCACTTCCGCCCCACGAAGACAAAGCCACAACGCAAAGGGTCTGGGCAGAGGAGCCGAGG
GTGCGCTGCGCTCCGGGGCCAGGTGGGCGAGGGCCGGGTGGAAGTGCTCATGAACCGCCAGTGGGGCACGGTC
TGTGACCACAGGTGGAACCTCATCTCTGCCAGTGTGCTGTGCTCAGCTGGGCTTTGGCTCTGCTCGGGAGGCC
CTCTTTGGGGCCCCGGCTGGGCCAAGGGCTAGGGCCCATCCACCTGAGTGAGGTGCGCTGCAGGGGATATGAGCGG
ACCCTCAGCGACTGCCCTGCCCTGGAAGGGTCCCAGAATGGTTGCCAATGAGAATGATGCTGCTGTGCTGAGTGC
AATGTCCCTAATATGGGCTTTTCAATCAGGTGCGCTTGGCTGGTGGGCGTATCCCTGAGGAGGGGCTATTGGAG
GTGCAGGTGGAGGTGAACGGGGTCCACGCTGGGGGAGCGTGTGAGTGAAGTGGGGGCTCACCGAAGCCATG
GTGGCCTGCCGACAGCTCGGCCTGGGTTTGGCCATCCATGCCTACAAGGAAACCTGGTTCTGGTGGGGACGCCA
AGGGCCCAGGAGGTGGTGTGAGTGGGGTGGCTGCTCAGGCACAGAGCTGGCCCTGCAGCAGTGCCAGAGGCAC
GGGCGGTGCACTGCTCCACGGTGGCGGGCGCTTCTGGCTGGAGTCTCCTGCATGGACAGTGACACAGACCTG
GTGATGAACGCCAGCTAGTGCAGGAGACGGCTACTTGGAGGACCGCCGCTCAGCCAGCTGTATTGTGCCCCAC
GAGGAGAATGCCTCTCCAAGTCTGCGGATCACATGGACTGGCCCTACGGATAACCGCCGCTATTGCGCTTCTCC
ACACAGATCTACAATCTGGGCCGACTGACTTTTCGTCCAAAGACTGGACGCGATAGCTGGGTTTGGCACCAGTGT
CACAGGCATTACCACAGCATTGAGGTCTTACCCCACTACGACCTCCTCACTCTCAATGGCTCCAAGGTGGCTGAG
GGGCACAAGGCCAGCTTCTGTCTGGAGGACACAACTGCCCCACAGGACTGCAGCGGCGCTACGCATGTGCCAAC
TTTGGAGAACAGGGAGTGAAGTGTAGGCTGTGGGACACCTACCGGCATGACATTGATTGCCAGTGGGTGGATATC
ACAGATGTGGGGCCCCGGGAATTATATCTTCCAGGTGATTGTGAATCCCCACTATGAAGTGGCAGAGTCAGATTTT
TCCAACAATATGCTGCAGTGCCGCTGCAAGTATGATGGGCACCGGGTCTGGCTGCACAAGTCCACACAGGGAAT
TCATACCCAGCCAATGCAGAACTCTCCCTGGAGCAGGAACAGCGTCTCAGGAACAACCTCATCTGAAGCTGTCA
TGCACTCCTAGCTGCTGCCGATACACCAGATACCTCAGCTTATTGGAGCCATGCCCTTTCACAGAGTCCCAACT
CAGAGGAAAAGGGCCAGTGCCAAGGGGCACCAAGAACTGCTCAGGAAGCCTTTTGATGGCAAGATCACCATCC
AGATGGTATTGCTCCCTCAGGATGGCTCTGGGCTGCCCTAAGGGCCTGTGGCCTATGGAATATGTCTCTCAGG
CTTTGCTTAGCTGAGCTCCCCTTCTGTAAGGAAACCCAGTCA

The NOV11b protein (SEQ ID NO:34) encoded by SEQ ID NO:33 is 756 amino acid residues in length and is presented using the one-letter amino acid code in Table 11D. The SignalP, Psort and/or Hydropathy results indicate that NOV11b has a signal peptide and is likely to be localized in the lysosome (lumen) with a certainty of 0.4302. Alternatively, a NOV11b polypeptide is located extracellularly with a certainty of 0.3700, the microbody (peroxisome) with a certainty of 0.1403, or the endoplasmic reticulum (membrane) with a certainty of 0.1000. The SignalP indicates a likely cleavage site for a NOV11b peptide between positions 24 and 25, i.e., at the dash in the sequence SRP-QS.

Table 11D. Encoded NOV11b Protein Sequence (SEQ ID NO:34)	
MAWSPPATLFLFLLLLGQPPPSRPQSLGTTKLRLVGPESKPEEGRLEVLHQGQWGTVCDDNFATQEQATVACRQLG	
FEAALTWAHSAKYGGEGPIWLDNVRCVGTESLDCGSGNGWGVSDCSHSEDVGVICHPRRHRGYLSETVSNALG	
PQGQRLEEVRLLKPIILASAKQHSPVTEGAVEVKYEGHWRQVCDQGTMMNSRVVCGMLGFPSEVPADSHYYRKVWD	
LKMRDPKSRLKSLTNKNSFWIHQVTCLGTEPHMANCQVQVAPARGKLRPACPGMHAVVSCVAGPHFRPPKTKPQ	
RKGSWAEEPRVRLRSGAQVGEGRVEVLMNRQWGTVCDDRWNLIASVVCRLGFGSAREALFGARLGQGLGPIHL	
SEVRCRGYERTLSDCPALEGSQNGCQHENDAAVRCNVPNMGFQNVRLAGGRIPEEGLLEVQVEVNGVPRWGSVC	
SENWGLTEAMVACRQLGLGFAIHAYKETWFWSGTPRAQEVMSGVRCSTELALQQCQRHGPVHCSHGGRFLAG	
VSCMDSAPDLVMNAQLVQETAYLEDRLPSQLYCAHEENCLSKSADHMDWPYGYRLLRFSTQIYNLGRDTRPKT	
GRDSVWVHQCHRHYHSIEVFTHYDLLTLNGSKVAEGHKASFCLEDTNCPTGLQRRYACANFGEQGVTVGCWDTYR	
HDIDCQWVDITDVGPGNYIFQVIVNPHYEVAESDFSNMMLQCRCCKYDGHVRVWLNCHTGNSYPANAELSLEQEQR	
LRNNLI	

NOV11 Clones

Unless specifically addressed as NOV11a or NOV11b, any reference to NOV11 is assumed to encompass all variants.

A search against the Patp database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 11E.

Table 11E. PatP Results for NOV11			
		High Score	Smallest Sum Prob P (N)
Sequences Producing High-Scoring Segment Pairs:			
patp:AAB19127	Polypeptide isolated from lymph node stromal cells of fsn -/- mice	3450	0.0
patp:AAB49534	Clone HOHEC84 #1 - Homo sapiens	2947	6.4e-307
patp:AAB00077	Human lysyl oxidase related protein (Lor)	2281	2.4e-236
patp:AAB00073	Human lysyl oxidase related protein (Lor)-2	2279	3.9e-236

In a BLAST search of public sequence databases, it was found, for example, that the NOV11a nucleic acid sequence of this invention has 1075 of 1078 bases (99%) identical to a gb:GENBANK-ID:AK025542|acc:AK025542.1 mRNA from Homo sapiens cDNA: FLJ21889
 5 fis, clone HEP03178. Further, the full amino acid sequence of the disclosed NOV11a protein of the invention has 404 of 705 amino acid residues (57%) identical to, and 523 of 705 amino acid residues (74%) similar to, the 774 amino acid residue ptmr:SPTREMBL-ACC:Q9Y4K0 protein from Human (LYSYL OXIDASE-RELATED PROTEIN).

In a similar BLAST search of public sequence databases, it was found, for example, that
 10 the NOV11b nucleic acid sequence of this invention has 1070 of 1076 bases (99%) identical to a gb:GENBANK-ID:AK025542|acc:AK025542.1 mRNA from Homo sapiens cDNA: FLJ21889 fis, clone HEP03178. Further, the full amino acid sequence of the disclosed NOV11b protein of the invention has 360 of 616 amino acid residues (58%) identical to, and 456 of 616 amino acid residues (74%) similar to, the 895 amino acid residue ptmr:SPTREMBL-ACC:Q9W6N1 protein
 15 from Perca flavescens (Yellow perch) (LYSYL OXIDASE RELATED PROTEIN HOMOLOG).

Additional BLAST results are shown in Table 11F.

Table 11F. NOV11 BLASTP Results

Gene Index/ Identifier	Protein/Organism	Length of aa	Identity (%)	Positives (%)	Expect Value
Q96JB6	LYSYL OXIDASE-RELATED PROTEIN C - Homo sapiens (Human)	756	722/739 (97%)	723/739 (97%)	0.0
Q96PC0	LYSYL OXIDASE-LIKE 4 - Homo sapiens (Human)	756	718/739 (97%)	720/739 (97%)	0.0
Q96DY1	UNKNOWN (PROTEIN FOR MGC:17373) - Homo sapiens (Human)	756	719/739 (97%)	721/739 (97%)	0.0
Q924C6	LYSYL OXIDASE-RELATED PROTEIN C - Mus musculus (Mouse)	757	624/736 (84%)	665/736 (90%)	0.0
Q9Y4K0	Lysyl oxidase homolog 2 precursor (EC 1.4.3.-) (Lysyl oxidase-like	774	404/705 (57%)	523/705 (74%)	3.1e-236

	protein 2) (Lysyl oxidase related protein 2) (Lysyl oxidase-related protein WS9-14) - Homo sapiens (Human)				
--	--	--	--	--	--

A multiple sequence alignment is given in Table 11G, with the NOV11 proteins of the invention being shown in lines 1 and 2 in a ClustalW analysis comparing NOV11 with related protein sequences of Table 11F.

Table 11G. ClustalW Analysis of NOV11

	1. SEQ ID NO.: 32	NOV11a	5. SEQ ID NO.: 189	Q96DY1
	2. SEQ ID NO.: 34	NOV11b	6. SEQ ID NO.: 190	Q924C6
	3. SEQ ID NO.: 187	Q96JB6	7. SEQ ID NO.: 191	Q9Y4K0
	4. SEQ ID NO.: 188	Q96PC0		
10				
15				
		10 20 30 40 50 60		
	NOV11a	MAWSPPATLFLFLLLLG-QPP-----PSRPQSLGTTKLRL	34	
	NOV11b	MAWSPPATLFLFLLLLG-QPP-----PSRPQSLGTTKLRL	34	
	Q96JB6	MAWSPPATLFLFLLLLG-QPP-----PSRPQSLGTTKLRL	34	
	Q96PC0	MAWSPPATLFLFLLLLG-QPP-----PSRPQSLGTTKLRL	34	
20	Q96DY1	MARSPPATLFLFLLLLG-QPP-----PSRPQSLGTTKLRL	34	
	Q924C6	MMWPQPTFLFLFLLLLSQAP-----SSRPQSSGTTKLRL	35	
	Q9Y4K0	MERPLCSHLCSCIALMLALLSPLSLAQYDSWPHYPEYFQQPAPEYHQPPAPANVAKIQRL	60	
25				
		70 80 90 100 110 120		
	NOV11a	VGPESKPEEGRLEVLHQGWGTVCDDNFATVACRQLGFEEALTWHAHSAKYGGEGP	94	
	NOV11b	VGPESKPEEGRLEVLHQGWGTVCDDNFATVACRQLGFEEALTWHAHSAKYGGEGP	94	
	Q96JB6	VGPESKPEEGRLEVLHQGWGTVCDDNFATVACRQLGFEEALTWHAHSAKYGGEGP	94	
	Q96PC0	VGPESKPEEGRLEVLHQGWGTVCDDNFATVACRQLGFEEALTWHAHSAKYGGEGP	94	
30	Q96DY1	VGPESKPEEGRLEVLHQGWGTVCDDNFATVACRQLGFEEALTWHAHSAKYGGEGP	94	
	Q924C6	VGPADEPPEEGRLEVLHQGWGTVCDDDFALQVATVACRQLGFESALTWHAHSAKYGGEGP	95	
	Q9Y4K0	AGOKRKHSEGRVEVYVDQGWGTVCDDDFSIHAHVVCRELGYVEAKSWTASSYKKGEGP	120	
35				
		130 140 150 160 170 180		
	NOV11a	IWLDNVRCVGTESSLDQCGSNGWGVSDCSHSEDVGVICHPRRHRYGLSETVSNALGPQVR	154	
	NOV11b	IWLDNVRCVGTESSLDQCGSNGWGVSDCSHSEDVGVICHPRRHRYGLSETVSNALGPQ--	152	
	Q96JB6	IWLDNVRCVGTESSLDQCGSNGWGVSDCSHSEDVGVICHPRRHRYGLSETVSNALGPQ--	152	
	Q96PC0	IWLDNVRCVGTESSLDQCGSNGWGVSDCSHSEDVGVICHPRRHRYGLSETVSNALGPQ--	152	
40	Q96DY1	IWLDNVRCVGTESSLDQCGSNGWGVSDCSHSEDVGVICHPRRHRYGLSETVSNALGPQ--	152	
	Q924C6	IWLDNVRCVGTETKLLDQCGSNGWGVSDCRHSEDVGVVCHPRRHRYGLHSEKVSALGPQ--	153	
	Q9Y4K0	IWLDNVRCVGTETKLLDQCGSNGWGVSDCRHSEDVGVVCHPRRHRYGLHSEKVSALGPQ--	153	
		190 200 210 220 230 240		

NOV11a	RLGRRLEEVRLKPIILASAKQHSPVTEGAVEVKYEGHWRQVCDQGWTMNNNSRVVCGMLGFP	214
NOV11b	--GQRLLEEVRLLKPIILASAKQHSPVTEGAVEVKYEGHWRQVCDQGWTMNNNSRVVCGMLGFP	210
Q96JB6	--GRRLEEVRLKPIILASAKQHSPVTEGAVEVKYEGHWRQVCDQGWTMNNNSRVVCGMLGFP	210
Q96PC0	--GRRLEEVRLKPIILASAKQHSPVTEGAVEVKYEGHWRQVCDQGWTMNNNSRVVCGMLGFP	210
Q96DY1	--GRRLEEVRLKPIILASAKQHSPVTEGAVEVKYEGHWRQVCDQGWTMNNNSRVVCGMLGFP	210
Q924C6	--GRRLEEVRLKPIILASAKRHSPVTEGAVEVRYDGHWRQVCDQGWTMNNNSRVVCGMLGFP	211
Q9Y4K0	NLNIOVEDIPRAILLSTYRKRTIPVMEGYVEVKEGKTWKQICDKHWTAKNSRVVCGMFGFP	237
250 260 270 280 290 300		
NOV11a	SEVPVDSHYR-----LKSLTNKNFSFWIHQVTCLGTEPHMANCQVQVAPARG	261
NOV11b	SEVPADSHYRKVWDLKMRDPKSRLKSLTNKNSFWIHQVTCLGTEPHMANCQVQVAPARG	270
Q96JB6	SEVPVDSHYRKVWDLKMRDPKSRLKSLTNKNSFWIHQVTCLGTEPHMANCQVQVAPARG	270
Q96PC0	SEVPVDSHYRKVWDLKMRDPKSRLKSLTNKNSFWIHQVTCLGTEPHMANCQVQVAPARG	270
Q96DY1	SEVPVDSHYRKVWDLKMRDPKSRLKSLTNKNSFWIHQVTCLGTEPHMANCQVQVAPARG	270
Q924C6	SQTSVNSHYRKVWNLKMRDPKSRLNSLTNKNFSFWIHQVTCGTEPHLAKCQVQVAPARG	271
Q9Y4K0	GERTYNTKVYK-----MFASRR--KQRYWPFSSDCTGTEAHTSSCKLGPQVSLD	284
310 320 330 340 350 360		
NOV11a	KLR--PACPGGMHAVVSCVAGPHFRPPKTKPQRKGSWAEPRVRLRSGAQVGEGRVEVLNN	320
NOV11b	KLR--PACPGGMHAVVSCVAGPHFRPPKTKPQRKGSWAEPRVRLRSGAQVGEGRVEVLNN	329
Q96JB6	KLR--PACPGGMHAVVSCVAGPHFRPPKTKPQRKGSWAEPRVRLRSGAQVGEGRVEVLNN	329
Q96PC0	KLR--PACPGGMHAVVSCVAGPHFRPPKTKPQRKGSWAEPRVRLRSGAQVGEGRVEVLNN	329
Q96DY1	KLR--PACPGGMHAVVSCVAGPHFRPPKTKPQRKGSWAEPRVRLRSGAQVGEGRVEVLNN	329
Q924C6	KLR--PACPGGMHAVVSCVAGPHFRQPKPTRKESHAEELKVLRLRSGAQVGEGRVEVLNN	330
Q9Y4K0	PMKNVTCENG--PAVAVSCVPGQVFS--PDGSPSRFRKAYKPEOPLVRLRGGAYTIGEGRVEVLKN	344
370 380 390 400 410 420		
NOV11a	RQWGTVCDDRWNLIASVVCRLQGLFGSAREALFGARLGQGLGPIHLSEVRCRGYERTLSD	380
NOV11b	RQWGTVCDDRWNLIASVVCRLQGLFGSAREALFGARLGQGLGPIHLSEVRCRGYERTLSD	389
Q96JB6	RQWGTVCDDRWNLIASVVCRLQGLFGSAREALFGARLGQGLGPIHLSEVRCRGYERTLSD	389
Q96PC0	RQWGTVCDDRWNLIASVVCRLQGLFGSAREALFGARLGQGLGPIHLSEVRCRGYERTLSD	389
Q96DY1	RQWGTVCDDRWNLIASVVCRLQGLFGSAREALFGARLGQGLGPIHLSEVRCRGYERTLSD	389
Q924C6	RQWGTVCDDRWNLIASVVCRLQGLFGSAREALFGALGQGLGPIHLSEVRCRGYERTLGD	390
Q9Y4K0	GEWGTVCDDKWDLV--SASVVCRLGFGSAREALFGALGQGLGPIHLNELQCTGNEKSID	404
430 440 450 460 470 480		
NOV11a	CPALEGSQNGCQHENDAAVRCNVNPMGFQNOVRLAGGRIPEEGLLEVQVEVNGVPRWGSV	440
NOV11b	CPALEGSQNGCQHENDAAVRCNVNPMGFQNOVRLAGGRIPEEGLLEVQVEVNGVPRWGSV	449
Q96JB6	CPALEGSQNGCQHENDAAVRCNVNPMGFQNOVRLAGGRIPEEGLLEVQVEVNGVPRWGSV	449
Q96PC0	CPALEGSQNGCQHENDAAVRCNVNPMGFQNOVRLAGGRIPEEGLLEVQVEVNGVPRWGSV	449
Q96DY1	CPALEGSQNGCQHENDAAVRCNVNPMGFQNOVRLAGGRIPEEGLLEVQVEVNGVPRWGSV	449
Q924C6	CLALEGSQNGCQHENDAAVRCNTPDMGFQNOVRLAGGRNSEEGVVEVQVEVNGGPRWGIV	450
Q9Y4K0	CKFNAESQ--GCNHEEDA--GVRCNT--PAMGLQKKLR--LNGGRNPEYEGRVEVLVERNGSLVWGMV	463
490 500 510 520 530 540		
NOV11a	CSENWGLTEAMVACRQLGLGFIAHAYKETWFWSGTPRAQEVVMMSGVRCSGTELALQQCOR	500
NOV11b	CSENWGLTEAMVACRQLGLGFIAHAYKETWFWSGTPRAQEVVMMSGVRCSGTELALQQCOR	509
Q96JB6	CSENWGLTEAMVACRQLGLGFIAHAYKETWFWSGTPRAQEVVMMSGVRCSGTELALQQCOR	509
Q96PC0	CSENWGLTEAMVACRQLGLGFIAHAYKETWFWSGTPRAQEVVMMSGVRCSGTELALQQCOR	509
Q96DY1	CSENWGLTEAMVACRQLGLGFIAHAYKETWFWSGTPRAQEVVMMSGVRCSGTELALQQCOR	509
Q924C6	CSDHWGLTEAMVTCRQLGLGFANFALKD--TW--WQGTPEAKEVVMMSGVRCSGTEALQQCOR	510

1005537.01602

Q9Y4K0 CGONWGHVEAMVVCROGLGLGFASNAFOETWYWHGDVNSNKVVMMSGVKCSGTSLAHCRH 523

		550	560	570	580	590	600	
		
5	NOV11a	HG-	PVHCSHGGGRFLAGVSCMDSAPDLVMNAQLVQETAYLEDRLPSQLYCAHEENCLSKS	559				
	NOV11b	HG-	PVHCSHGGGRFLAGVSCMDSAPDLVMNAQLVQETAYLEDRLPSQLYCAHEENCLSKS	568				
	Q96JB6	HG-	PVHCSHGGGRFLAGVSCMDSAPDLVMNAQLVQETAYLEDRLPSQLYCAHEENCLSKS	568				
	Q96PC0	HG-	PVHCSHGGGRFLAGVSCMDSAPDLVMNAQLVQETAYLEDRLPSQLYCAHEENCLSKS	568				
	Q96DY1	HG-	PVHCSHGGGRFLAGVSCMDSAPDLVMNAQLVQETAYLEDRLPSQLYCAHEENCLSKS	568				
10	Q924C6	HG-	PVHCSHGGGRFLAGVSCMDSAPDLVMNAQLVQETAYLEDRLPSQLYCAHEENCLSKS	569				
	Q9Y4K0	DGEDVACPOGGVOYGAGVACSEIAPDLVMNAQLVQETAYLEDRLPSQLYCAHEENCLSKS	583					

		610	620	630	640	650	660	
		
15	NOV11a	ADHMDWPYGYRRLLRFSSTQIYNLGRDTRPKTGRDSWVWHQCHRHYHSIEVFTHYDLLTL	619					
	NOV11b	ADHMDWPYGYRRLLRFSSTQIYNLGRDTRPKTGRDSWVWHQCHRHYHSIEVFTHYDLLTL	628					
	Q96JB6	ADHMDWPYGYRRLLRFSSTQIYNLGRDTRPKTGRDSWVWHQCHRHYHSIEVFTHYDLLTL	628					
	Q96PC0	ADHMDWPYGYRRLLRFSSTQIYNLGRDTRPKTGRDSWVWHQCHRHYHSIEVFTHYDLLTL	628					
	Q96DY1	ADHMDWPYGYRRLLRFSSTQIYNLGRDTRPKTGRDSWVWHQCHRHYHSIEVFTHYDLLTL	628					
20	Q924C6	ADHMDWPYGYRRLLRFSSTQIYNLGRDTRPKTGRDSWVWHQCHRHYHSIEVFTHYDLLTL	629					
	Q9Y4K0	AAQTDPPTGYRRLLRFSSTQIYNLGRDTRPKTGRDSWVWHQCHRHYHSIEVFTHYDLLTL	643					

		670	680	690	700	710	720	
		
25	NOV11a	NGSKVAEGHKASFLEDTCNPTGLQRRYACANFGEQGVTVGCWDTYRHDIDCQWVDITDV	679					
	NOV11b	NGSKVAEGHKASFLEDTCNPTGLQRRYACANFGEQGVTVGCWDTYRHDIDCQWVDITDV	688					
	Q96JB6	NGSKVAEGHKASFLEDTCNPTGLQRRYACANFGEQGVTVGCWDTYRHDIDCQWVDITDV	688					
	Q96PC0	NGSKVAEGHKASFLEDTCNPTGLQRRYACANFGEQGVTVGCWDTYRHDIDCQWVDITDV	688					
	Q96DY1	NGSKVAEGHKASFLEDTCNPTGLQRRYACANFGEQGVTVGCWDTYRHDIDCQWVDITDV	688					
30	Q924C6	NGSKVAEGHKASFLEDTCNPTGLQRRYACANFGEQGVTVGCWDTYRHDIDCQWVDITDV	689					
	Q9Y4K0	NGSKVAEGHKASFLEDTCNPTGLQRRYACANFGEQGVTVGCWDTYRHDIDCQWVDITDV	703					

		730	740	750	760	770	780	
		
35	NOV11a	GPGNYIFQVIVNPHYEVAESDFSNNMLQCRCKYDGHVWLHNCHTGSEFIPSQCRTPGAG	739					
	NOV11b	GPGNYIFQVIVNPHYEVAESDFSNNMLQCRCKYDGHVWLHNCHTGSEFIPSQCRTPGAG	742					
	Q96JB6	GPGNYIFQVIVNPHYEVAESDFSNNMLQCRCKYDGHVWLHNCHTGSEFIPSQCRTPGAG	742					
	Q96PC0	GPGNYIFQVIVNPHYEVAESDFSNNMLQCRCKYDGHVWLHNCHTGSEFIPSQCRTPGAG	742					
	Q96DY1	GPGNYIFQVIVNPHYEVAESDFSNNMLQCRCKYDGHVWLHNCHTGSEFIPSQCRTPGAG	742					
40	Q924C6	GPGNYIFQVIVNPHYEVAESDFSNNMLQCRCKYDGHVWLHNCHTGSEFIPSQCRTPGAG	743					
	Q9Y4K0	GPGNYIFQVIVNPHYEVAESDFSNNMLQCRCKYDGHVWLHNCHTGSEFIPSQCRTPGAG	757					

		790	800	810	820	830	840	
		
45	NOV11a	TASQEQPHLKLSTHTPSCCRYTRYLSLLEPCPSQSPNSEKGCQCAPRTCSGSLLMARS	799					
	NOV11b	LSLEQEQRRLRNLI-----	756					
	Q96JB6	LSLEQEQRRLRNLI-----	756					
	Q96PC0	LSLEQEQRRLRNLI-----	756					
	Q96DY1	LSLEQEQRRLRNLI-----	756					
50	Q924C6	LSLEQEQRRLRNLI-----	757					
	Q9Y4K0	KKFEHFSGLLNNOLSPQ-----	774					

		850	860	870	
		
55	NOV11a	PIQMVLPLPDGSGPAPKGLWPMYEVVLQALLS	830		
	NOV11b	-----	756		
	Q96JB6	-----	756		

Q96PC0 ----- 756
Q96DY1 ----- 756
Q924C6 ----- 757
Q9Y4K0 ----- 774

5
The presence of identifiable domains in the disclosed NOV11 protein was determined by using Pfam and then determining the Interpro number. The results are listed in Table 11H with the statistics and domain description.

Table 11H. Domain Analysis of NOV11		
PSSMs Producing Significant Alignments		Score (bits)
		E Value
Lysyl oxidase: domain 1 of 1, from 524 to 727		511.7
LOX	pDLvldpalVQetaYvedrpLylLrCAaEEEnCLaSSAyraeawdYdh + + +++ +++ ++++ ++ ++ + + ++ ++ +	
NOV11	PDLVMNAQLVQETAYLEDRLSQLYCAHEENCLSKSADHMD-WPYGY	
LOX	RrLLRFssrvkNlGrADFrPkapRhsWeWHsCHqHYHSmdeFtHYDLLda + + ++ + + ++ + ++ + + +++ + ++	
NOV11	RRLRFSTQIYNLGRDTFRPKTGRDSVWHQCHRHYHSIEVFTHYDLLTL	
LOX	ngtkKVAEGHKASFLEDteCdegvlkRYaCtnhGtQGlsvGCyDtYraD ++ + + + + + + + +++ + +++ + + ++	
NOV11	NGS-KVAEGHKASFLEDTNCPTGLQRRYACANFGEQGVTVGCWDTYRHD	
LOX	IDCQWiDITDvkPGnYILkVevNPkyevaESDFtNNvvrCnikYdGhrvy + + + + ++ + +++++ + ++ +++ + ++++	
NOV11	IDCQWVDITDVGPgNYIFQVIVNPHYEVAESDFSNNMLQCRCKYDGHRVW	
LOX	asnChigda (SEQ ID NO:192) ++ + ++	
NOV11	LHNCHTGEF (SEQ ID NO:32)	

Consistent with other known members of the copper-dependent amine oxidase family of proteins, NOV11 contains a lysyl oxidase domain as illustrated in Table 11H.

15 NOV11 nucleic acids, and the encoded polypeptides, according to the invention are useful in a variety of applications and contexts. For example, NOV11 nucleic acids and polypeptides can be used to identify proteins that are members of the copper-dependent amine oxidase family of proteins. The NOV11 nucleic acids and polypeptides can also be used to screen for molecules, which inhibit or enhance NOV11 activity or function. Specifically, the

20 nucleic acids and polypeptides according to the invention may be used as targets for the

identification of small molecules that modulate or inhibit, *e.g.*, crosslinking of extracellular matrix proteins. These molecules can be used to treat, *e.g.*, autoimmune disease, allergies, immunodeficiencies, asthma, psoriasis, acne, or pigmentation disorders.

In addition, various NOV11 nucleic acids and polypeptides according to the invention are useful, *inter alia*, as novel members of the protein families according to the presence of domains and sequence relatedness to previously described proteins. For example, the NOV11 nucleic acids and their encoded polypeptides include structural motifs that are characteristic of proteins belonging to the lysyl oxidase family. Lysyl oxidase (LOX) is a secreted enzyme that cross-links collagen and elastin, and thus is critical for the integrity of the extracellular matrix, the breakdown of which contributes to cancer invasion and metastasis. LOX is also important to the health of connective tissues and arteries. Lysyl oxidase requires a copper co-factor and therefore its activity can be lowered by a dietary deficiency.

The NOV11 nucleic acids and polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications in the mediation of crosslinking and biogenesis of connective tissue matrices. As such the NOV11 nucleic acids and polypeptides, antibodies and related compounds according to the invention may be used to treat digestive disorders, *e.g.*, diabetes, Von Hippel-Lindau (VHL) syndrome, pancreatitis, obesity, endometriosis, fertility, hemophilia, hypercoagulation, idiopathic thrombocytopenic purpura, autoimmune disease, allergies, immunodeficiencies, transplantation, graft versus host disease (GVHD), lymphoedema, osteoporosis, hypercalcaemia, arthritis, ankylosing spondylitis, scoliosis, systemic lupus erythematosus, asthma, emphysema, scleroderma, allergy, ARDS, renal artery stenosis, interstitial nephritis, glomerulonephritis, polycystic kidney disease, systemic lupus erythematosus, renal tubular acidosis, IgA nephropathy, Lesch-Nyhan syndrome, psoriasis, actinic keratosis, tuberous sclerosis, acne, hair growth/loss, alopecia, pigmentation disorders, and endocrine disorders.

The NOV11 nucleic acids and polypeptides are useful for detecting specific cell types. For example, expression analysis has demonstrated that a NOV11 nucleic acid is expressed in kidney, lung, lymphoid tissue, mammary gland/breast, ovary, pancreas, testis, uterus, and bone.

Additional utilities for NOV11 nucleic acids and polypeptides according to the invention are disclosed herein.

NOV12

The NOV12 proteins described herein are novel phosphatase-like proteins. The NOV12 nucleic acids disclosed herein map to chromosome 17. Two alternative novel NOV12 nucleic acids and polypeptides are disclosed herein, namely NOV12a and NOV12b.

NOV12a

A NOV12 variant is NOV12a (alternatively referred to herein as CG56436-01), which encodes the 1002 nucleotide sequence (SEQ ID NO:35) shown in Table 12A. An open reading frame for the mature protein was identified beginning with an ATG codon at nucleotides 101-103 and ending with a TGA codon at nucleotides 902-904. Putative untranslated regions, if any, downstream from the termination codon and upstream from the initiation codon are underlined. The start and stop codons are in bold letters.

Table 12A. NOV12a Nucleotide Sequence (SEQ ID NO:35)

GCCGGGACAGACCTCTGCTGCCGCCGCCGCCACGAACGTGTGACGACGGCTGGAGGCCAACAGAGTCCCTACAGG
TGGTGCTCACGGTAATGCACCGACA**ATG**AGTGGCTGTTTCCAGTTTCTGGCCTCCGCTGCCTATCTAGGGACGG
CAGGATGGCCGCGCAGGGCGCGCCGCGCTTCTCCTGACCTTCGACTTCGACGAGACTATCGTGGACGAAAACAG
CGACGATTTCGATCGTGC GCGCCGCGCCGGGCCAGCGGCTCCCGGAGAGCCTGCGAGCCACCTACCGCGAGGGCTT
CTACAACGAGTACATGCAGCGCGTCTTCAAGTACCTGGGCGAGCAGGGCGTGCGGCCGCGGGACCTGAGCGCCAT
CTACGAAGCCATCCCTTTGTGCGCCAGGCATGAGCGACCTGCTGCAGTTTGTGGCAAAACAGGGCGCCTGCTTCGA
GGTGATTCTCATCTCCGATGCCAACACCTTTGGCGTGAGAGCTCGCTGCGCGCCGCGGCCGCCACACAGCCTGTT
CCGCCGCATCCTCAGCAACCCGTCGGGGCCGGATGCGCGGGGACTGCTGGCTCTGCGGCCGTTCCACACACACAG
CTGCGCGCGCTGCCCCGCCAACATGTGCAAGCACAGGTGCTCAGCGACTACCTGCGCGAGCGGGGCCACGACGG
CGTGCACTTCGAGCGCCTCTTCTACGTGGGCGACGCGCCAACGACTTCTGCCCCATGGGGCTGCTGGCGGGCGG
CGACGTGGCCTTCCCGCGCCGCGGCTACCCCATGCACCGCCTCATTCAGGAGGCCCAGAAGGCCGAGCCCAGCTC
GTTCCGCGCCAGCGTGGTGCCCTGGGAAACGGCTGCAGATGTGCGCCTCCACCTGCAACAGGTGCTGAAGTCGTG
CTGAGTCTGGCCGCTGCAGGGGGGTACCCGGGCCAACGGCGGAGGGGGCGGGGAAGGGAGATTCGGCAAAGACA
GCTTTACTACTCCCTTTTCCCTTTGGC

The NOV12a protein (SEQ ID NO:36) encoded by SEQ ID NO:35 is 267 amino acid residues in length and is presented using the one-letter amino acid code in Table 12B. The SignalP, Psort and/or Hydropathy results indicate that NOV12a has no known signal peptide and is likely to be localized in the mitochondrial matrix space with a certainty of 0.4728. Alternatively, a NOV12a polypeptide is located in the microbody (peroxisome) with a certainty of 0.2224, the lysosome (lumen) with a certainty of 0.1905, or the mitochondrial inner membrane with a certainty of 0.1762.

Table 12B. Encoded NOV12a Protein Sequence (SEQ ID NO:36)

MSGCFPVSGLRCLSRDGRMAAQGAPRFLLTDFDETIVDENSDDSIIVRAAPGQRLPESLRATYREGFYNEYMQRV
FKYLGEQGVPRDLSTAIYEAIPLSPGMSDLLQFVAKQGACFEVILISDANTFGVSSLRAAGHSLFRRILSNPS
GPDARGLLALRPFHTHSCARCPANMCKHKVLSDYLRERAHGCVHFERLFYVGDGANDFCPMGLLAGGDVAFPRRG
YPMHRLIQEAQKAEPSSFRASVVPWETAADVRLHLQOVLSKSC

SNP variants of NOV12a are disclosed in Example 2.

NOV12b

Alternatively, a NOV12 variant is NOV12b (alternatively referred to herein as CG56436-02), which includes the 903 nucleotide sequence (SEQ ID NO:37) shown in Table 12C. An open reading frame for the mature protein was identified beginning with an ATG codon at nucleotides 4-6 and ending with a TGA codon at nucleotides 805-807. Putative untranslated regions, if any, downstream from the termination codon and upstream from the initiation codon are underlined. The start and stop codons are in bold letters.

Table 12C. NOV12b Nucleotide Sequence (SEQ ID NO:37)

ACA**ATG**AGTGGCTGTTTTCCAGTTTCTGGCCTCCGCTGCCTATCTAGGGACGGCAGGATGGCCGCGCAGGGCGCG
CCGCGCTTCTCTGACCTTCGACTTCGACGAGACTATCGTGACGAAAACAGCGACGATTTCGATCGTGCGCGCC
GCGCCGGGCCAGCGGCTCCCGGAGAGCCTGCGAGCCACCTACCGCGAGGGCTTCTACAACGAGTACATGCAGCGC
GTCTTCAAGTACCTGGGCGAGCAGGGCGTGCGGCCGCGGGACCTGAGCGCCATCTACGAAGCCATCCCTTTGTCTG
CCAGGCATGAGCGACCTGCTGCAGTTTGTGGCAAAACAGGGCGCCTGCTTCGAGGTGATTCTCATCTCCGATGCC
AACACCTTTGGCGTGGAGAGCTCGCTGCGCGCCGCGGCCACCACAGCCTGTTCCGCGCGCATCCTCAGCAACCCG
TCGGGGCCGGATGCGCGGGGACTGCTGGCTCTGCGGCCGTTCCACACACACAGCTGCGCGCGCTGCCCCGCCAAC
ATGTGCAAGCACAAGGTGCTCAGCGACTACCTGCGCGAGCGGGCCACGACGGCGTGCACTTCGAGCGCCTCTTC
TACGTGGGCGACGGCGCCAACGACTTCTGCCCCATGGGGCTGCTGGCGGGCGGCGACGTGGCCTTCCCGCGCCGC
GGCTACCCCATGCACCGCCTCATTAGGAGGCCCAGAAGGCCGAGCCAGCTCGTTCCGCGCCAGCGTGGTGCC
TGGGAAACGGCTGCAGATGTGCGCCTCCACCTGCAACAGGTGCTGAAGTCGTGCT**GAGT**CTGGCCGCTGCAGGG
GGGTACCCGGGCCAACGGCGGAGGGGCGGGGAAGGGAGATTCCGGCAAAGACAGCTTTACTACTCCCTTTCCCT
TTG

The NOV12b protein (SEQ ID NO:38) encoded by SEQ ID NO:37 is 267 amino acid residues in length and is presented using the one-letter amino acid code in Table 12D. The SignalP, Psort and/or Hydropathy results predict that NOV12b has no known signal peptide and is likely to be localized in the mitochondrial matrix space with a certainty of 0.4728.

Alternatively, a NOV12b polypeptide is located in the microbody (peroxisome) with a certainty of 0.2224, the lysosome (lumen) with a certainty of 0.1905, or the mitochondrial inner membrane with a certainty of 0.1762.

Table 12D. Encoded NOV12b Protein Sequence (SEQ ID NO:38)

MSGCFPVSGLRCLSRDGRMAAQGAPRFLLTDFDETIVDENSDDSIIVRAAPGQRLPESLRATYREGFYNEYMQRV
FKYLGEQGVPRDLISAIYEAIPLSPGMSDLLQFVAKQGACFEVILISDANTFGVLESSLRAAGHHSIFRRILSNPS
GPDARGLLALRPFHHTHSCARCPANMCKHKVLS DYLRERAHG VHFERLFYVGDGANDFCPMGLLAGGDVAFPRRG
YPMHRLIQEAQKAEPSSFRASVVPWETAADVRLHLQQLKSC

NOV12 Clones

Unless specifically addressed as NOV12a or NOV12b, any reference to NOV12 is assumed to encompass all variants.

A search against the Patp database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 12E.

Table 12E. PatP Results for NOV12

		High Score	Smallest Sum Prob P (N)
Sequences Producing High-Scoring Segment Pairs:			
patp:AAB42487	Human ORFX ORF2251 polypeptide sequence	1409	6.1e-144
patp:AAB52146	Human secreted protein encoded by cDNA #44	738	7.7e-73
patp:AAB52178	Human secreted protein BLAST search protein	706	1.9e-69
patp:AAB52177	Human secreted protein BLAST search protein	475	5.7e-45
patp:AAM93066	Human digestive system antigen	347	2.1e-31

In a BLAST search of public sequence databases, it was found, for example, that the NOV12a nucleic acid sequence of this invention has 609 of 916 bases (66%) identical to a gb:GENBANK-ID:GGA6529|acc:AJ006529.1 mRNA from Gallus gallus (Gallus gallus mRNA for putative phosphatase). Further, the full amino acid sequence of the disclosed NOV12a protein of the invention has 159 of 265 amino acid residues (60%) identical to, and 199 of 265 amino acid residues (75%) similar to, the 268 amino acid residue ptmr:SPTREMBL-ACC:O73884 protein from Gallus gallus (Chicken) (PUTATIVE PHOSPHATASE).

In a similar BLAST search of public sequence databases, it was found, for example, that the NOV12b nucleic acid sequence of this invention has 579 of 865 bases (66%) identical to a gb:GENBANK-ID:GGA6529|acc:AJ006529.1 mRNA from Gallus gallus (Gallus gallus mRNA for putative phosphatase). Further, the full amino acid sequence of the disclosed NOV12b protein of the invention has 159 of 265 amino acid residues (60%) identical to, and 199 of 265

Q9D9M5 -----MKVLLVDFDNTIITDDNSDTWIVQCAPDKKLPIEL 35
Q9VWF0 MSSNQEQSPAATAAAVASCLRLKQQRRLAADFDFDHTIVSQNTDTVVRDLLPTEVTSKV 60
Q9SU92 -----MAK---IVILDFDRTLIDGSDNWWVTEMG---LTEIF 33
Q9FZ62 -----MAKNNNIVIVDFDKTILDVSDNWWVDELG---FTDLF 36

5

70 80 90 100 110 120

NOV12a RATYREGFYNEYMQRVFKYLGEQVVRPRDLISAIYEAIPLSPGMSDLLQFVAKQGACFEVI 119
NOV12b RATYREGFYNEYMQRVFKYLGEQVVRPRDLISAIYEAIPLSPGMSDLLQFVAKQGACFEVI 119
O73884 RQSFREGFYNEYMQRVLAYMGDQGVKMGDFKAVYENIPLSPGMPDLQFLSKNHELFEI 119
Q9D9M5 QDSYQKGLWTEEMGRVFKYLRLDEGVKADELKRAVTSIPFTSGMIELLSFLRMNKDRFDCT 95
Q9VWF0 NELVENDCWTEYMAEVFRLIHEQVSEARIRDTIRGIPEVPGFVRLIKHLAKR-LHYDLI 119
Q9SU92 HQLRFTLPWNRLMDRMMELQSQGRSIDDIKSCLKKMPIDSHITIEAKSAKSS--GCDLK 91
Q9FZ62 NQLLPTMPWNLSLMNRMMKELHDHGKTIEEIKQVLRRIPIHPRVIPAKSAHAL--GCELR 94

10

130 140 150 160 170 180

NOV12a LISDANIFGVESLRAAGHHSIFRRILSNPSGPDARGLLALRPFHHS-----CARCPAN 174
NOV12b LISDANIFGVESLRAAGHHSIFRRILSNPSGPDARGLLALRPFHHS-----CARCPAN 174
O73884 LISDANMFGIECKLRAAGFYSLFRKIFSNPSSFDKRGYFTLGPYHSHK-----CLDCPAN 174
Q9D9M5 IISDSNSIFIDWVLEAAAFHDVDFHVFITNPASFDSSGRLTVKNYHAHS-----CTRCPKN 150
Q9VWF0 IISDSNSVFIDEWLRHNLADCFVAIFTNPAEFDASGRLMVRAHQQSD-----CKLSASN 175
Q9SU92 IISDANOFFIEKILEHHDLVDCFSEIYTNPTSLDDNGNLRILPYHSDALPPHSCNLCPSN 151
Q9FZ62 IISDANILFIETITIEHLGIGEFFSEININPGLVDEQGRLIVSPYHDFIKSSHGCSRCPN 154

20

190 200 210 220 230 240

NOV12a MCKHKVLSDYLRER-AHDGVHFERLFYVGDGANDECPMGLLAGGDVAFPRRGYPMHRLIQ 233
NOV12b MCKHKVLSDYLRER-AHDGVHFERLFYVGDGANDECPMGLLAGGDVAFPRRGYPMHRLIQ 233
O73884 TCKRKILTEYLAER-AQEEVEFERVFFYVGDGANDECPSVTLTSADVAFPRRGYPMHMTQ 233
Q9D9M5 LCKNTVLGEFIDKQ-LQKGVRYTRIVYIGDGGNDVCPVTFLKKNVAMPREGYTLHRTLA 209
Q9VWF0 LCKGRVLEHEFVIEQDLRRSIRYDHVFFYVGDGNNDICPVLQRACDFACARKGEAMEKHLL 235
Q9SU92 LCKGLVMDHLRASS--SNDQIPRRFIYLGDDGGDFCPTLKLRECFVMPRTNYPILWKKIS 209
Q9FZ62 MCKGLIIDRIQASL--TKEGKTSKMIYLGDGAGDYCPSLGLKAEDYMMPRKNPFWDLIS 212

25

250 260 270 280 290 300

NOV12a BAQKAEPSSFRASVVPWETAADVRLHLQOVLKS-C----- 267
NOV12b BAQKAEPSSFRASVVPWETAADVRLHLQOVLKS-C----- 267
O73884 EMEKKQPGTFQATVVPWESATEVARYLQELLKKKC----- 268
Q9D9M5 KMSQN-LEPMESSIVVWSSGVEIISHLOFLIKM----- 241
Q9VWF0 RNRSK--LKLRAQLLIWKSGFDLMDQMLALPOLKTPQVQGDGDQPDQDADTDGKVPEVAR 293
Q9SU92 DN---PLLIIAEVKWSSAEEQQRIILQLVSTITKEEDS----- 245
Q9FZ62 QN---PMLVKATVRDWTIDGEDMERILMEIINEIMSSEEGEENDKMLSSSENCKISVGIVH 268

30

310

NOV12a ----- 267
NOV12b ----- 267
O73884 ----- 268
Q9D9M5 ----- 241
Q9VWF0 RASAVAGPTKSPN 306
Q9SU92 ----- 245
Q9FZ62 EPIQVPLNLVK-- 279

35

40

45

50

55

The presence of identifiable domains in the disclosed NOV12 protein was determined by using Pfam and then determining the Interpro number. The results are listed in Table 12H with the statistics and domain description.

Table 12H. Domain Analysis of NOV12		
PSSMs Producing Significant Alignments	Score (bits)	E Value
Hydrolase: domain 1 of 1, from 26 to 225	-10.8	1.9
Hyd.	ikavvFDkDGTltdgkeppiaeaivealrelglapleevekl1grg1	
	++ + +++ + + +++++ ++ + +++ +++	
NOV12	RFLlTFDFDETIVDEN---SDDSIvRAAPGQR--LPESLRATYREGF	
Hyd.	.gerilleggltaell.ld.evlglial.dklypgarealkaLkerGikv	
	+ +++++ + ++++++ + +++++ +++ +++ +++++ ++ +	
NOV12	yN-EYMQRVFKYLGEQgVRpRDLsAIYEaIPLSPGMSDLLQFvAKQGACF	
Hyd.	ailTngdr.naeallealglal.fdaivdsdevggvgpvvvgKPkpeifl	
	++ +++ + ++ + + ++ ++ ++ ++	
NOV12	EVIL---IsDANTFGVSSLRaAGHSLFRRLS-----NPSGPDAR	
Hyd.	lalerlgvkpeevg.....p.kvlmvGDgi	
	++ + + +++ + + +++ ++ +++ +++ +++ ++ +	
NOV12	GLLALRPFHTHSCArceanmckhkvlsdylrerahdgvhFeRLFYVGdGA	
Hyd.	nD.apalaaAGvgvamngg (SEQ ID NO:198)	
	+ +++ +++ +++	
NOV12	NDfCPMGLLAGGDVAFPRRG (SEQ ID NO:36)	

Consistent with other known members of the protein phosphatase family of proteins, NOV12 contains a hydrolase domain as illustrated in Table 12H.

NOV12 nucleic acids, and the encoded polypeptides, according to the invention are useful in a variety of applications and contexts. For example, NOV12 nucleic acids and polypeptides can be used to identify proteins that are members of the protein phosphatase family of proteins. The NOV12 nucleic acids and polypeptides can also be used to screen for molecules, which inhibit or enhance NOV12 activity or function. Specifically, the nucleic acids and polypeptides according to the invention may be used as targets for the identification of small molecules that modulate or inhibit, *e.g.*, biological processes that control cell growth and homeostasis. These molecules can be used to treat, *e.g.*, hyper/hypothyroidism, endometriosis,

fertility, transplantation, hypogonadism, Alzheimer's disease, Parkinson's disease, neurodegeneration, or growth disorders.

In addition, various NOV12 nucleic acids and polypeptides according to the invention are useful, *inter alia*, as novel members of the protein families according to the presence of domains and sequence relatedness to previously described proteins. For example, the NOV12 nucleic acids and their encoded polypeptides include structural motifs that are characteristic of proteins belonging to the protein phosphatase family. The major protein phosphatases in all cells are highly conserved and widely distributed. They are integrally associated with the regulation of many neuronal functions and have been implicated in the etiology of several neurological disorders. Their involvement in the specific control of individual neuronal functions requires the specific regulation of distinct pools of protein phosphatase inside the cell. This is believed to be mediated by specific proteins which both target the enzyme to specific subcellular locations and modulate its activity towards colocalised substrates.

The NOV12 nucleic acids and polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications in the mediation of cell signaling/signal transduction. As such the NOV12 nucleic acids and polypeptides, antibodies and related compounds according to the invention may be used to treat, *e.g.*, hyperthyroidism, hypothyroidism, endometriosis, fertility, Von Hippel-Lindau (VHL) syndrome, cirrhosis, transplantation, hypogonadism, Alzheimer's disease, stroke, tuberous sclerosis, hypercalcaemia, Parkinson's disease, Huntington's disease, cerebral palsy, epilepsy, Lesch-Nyhan syndrome, multiple sclerosis, ataxia-telangiectasia, leukodystrophies, behavioral disorders, addiction, anxiety, pain, neurodegeneration, endocrine dysfunctions, diabetes, obesity, growth and reproductive disorders, systemic lupus erythematosus, autoimmune disease, asthma, emphysema, scleroderma, allergy, ARDS, renal artery stenosis, interstitial nephritis, glomerulonephritis, polycystic kidney disease, renal tubular acidosis, IgA nephropathy, hemophilia, hypercoagulation, idiopathic thrombocytopenic purpura, immunodeficiencies, and graft versus host disease.

The NOV12 nucleic acids and polypeptides are useful for detecting specific cell types. For example, expression analysis has demonstrated that a NOV12 nucleic acid is expressed in bone marrow, brain, kidney, liver, lung, lung pleura, pituitary gland, placenta, and thyroid.

Additional utilities for NOV12 nucleic acids and polypeptides according to the invention are disclosed herein.

NOV13

The disclosed NOV13 nucleic acid (alternatively referred to herein as CG56441-01) encodes a novel chloride channel protein CLC-KA-like protein and includes the 1991 nucleotide sequence (SEQ ID NO:39) shown in Table 13A.

An open reading frame for the mature protein was identified beginning with an ATG initiation codon at nucleotides 8-10, and ending with a TAG stop codon at nucleotides 1973-1975. Putative untranslated regions, if any, are found upstream from the initiation codon and downstream from the termination codon. The start and stop codons are in bold letters.

Table 13A. NOV13 Nucleotide Sequence (SEQ ID NO:39)

GGGCCTG ATG GAGGAGTTTGTGGGGCTGCGTGAGGGCTTCTCAGGGGACCCTGTGACTCTGCAGGAGCTGTGGGG
CCCCTGTCCCCACATCCGCCGAGCCATCCAAGGTGGCTGGAGTGGCTAAAGCAGAAGGTGTTCCGCCTGGGAGA
AGACTGGTACTTCTGATGACCCTCGGGGTGCTCATGGCCCTGGTCAGCTATGCCATGAACTTTGCCATCGGGTG
TGTGGTCCGAGGCTTCTCCAGAGCATCACGCCCTCCTCTGGAGGTTCTGGAATCCCGGAGCTGAAGACCATGTT
GGCGGGTGTGATCTTGGAGGACTACCTGGATATCAAGAACTTTGGGGCCAAGGTGGTGGGCCTCTCCTGCACCCT
GGCCACCGGCAGCACCTGTTCCTGGGCAAAGTGGGCCCTTTCGTGCACTTGTCTGTAATGATCGCTGCCTACCT
GGCCCGTGTGCGCACCACGACCATCGGGGAGCCTGAGAACAAGAGCAAGCAAAACGAAATGCTGGTGGCAGCGGC
GGCAGTGGGCGTGGCCACAGTCTTTGCAGCTCCCTTCAGCGGCGTCTGTTCAGCATCGAGGTCATGTCTTCCCA
CTTCTCTGTCCGGGATTACTGGAGGGGCTTCTTTGCGGCCACCTGCGGGGCCTTCATATTCCGGCTCCTGGCAGT
CTTCAACAGCGAGCAGGAGACCATCACCTCCCTCTACAAGACCAGTTTCCGGGTGGACGTTCCCTTCGACCTGCC
TGAGATCTTCTTTTTTGTGGCGCTGGGTGGCATCTGCGGCGTCTGAGCTGTGCTTACCTCTTCTGTGAGCGAAC
CTTCTCAGCTTCATCAAGACCAATCGGTACAGCTCCAACTGCTGGCTACTAGCAAGCCTGTGTACTCCGCTCT
GGCCACCTTGCTTCTCGCCTCCATCACCTACCCGCTGGTGTGGGCCACTTCCTAGCTTCTCGGCTGTCCATGAA
GCAGCATCTGGACTCGCTGTTGACAACCACTCCTGGGCGCTGATGACCCAGAACTCCAGCCCACCCTGGCCCGA
GGAGCTCGACCCCCAGCACCTTTGGTGGGAATGGTACCACCCGCGGTTACCATCTTTGGGACCCTTGCCCTTCTT
CCTGGTTATGAAGTTCTGGATGCTGATTCTGGCCACCACCATCCCCATGCCTGCCGGGTACTTCATGCCCATCTT
TATCCTTGGAGCTGCCATCGGGCGCCTCTTGGGAGAGGCTCTTGCCGTCGCCTTCCCTGAGGGGATTGTGACTGG
AGGGGTACCAATCCCATCATGCCCGGGGGTATGCTCTGGCAGGGGCTGCAGCCTTCTCAGGGGCTGTGACCCA
CACCATCTCCACGGCGCTGCTGGCCTTTGAGCTGACCGGCCAGATAGTGCATGCACTGCCCCGTGCTGATGGCGGT
GCTGGCAGCCAACGCCATTGCACAGAGCTGCCAGCCCTCCTTCTATGATGGCACCATCATTGTCAAGAAGCTGCC
ATACCTGCCACGGATTCTGGGCCGCAACATCGGCTCCACCATGTGAGGGTGGAGCACTTCATGAACCACAGCAT
CACCACACTGGCCAAGGACACGCCGCTGGAGGAGGTGGTCAAGGTTGTGACCTCCACAGACGTGACCGAGTATCC
CCTGGTGGAGAGCACAGAGTCCCAGATCCTGGTAGGCATCGTGCAGAGGGCCAGCTGGTGCAGGCCCTCCAGGC
TGAGCCTCCTTCCAGGGCTCCAGGACACCAGCAGCGTCTCCAGGACATCTTGCCAGGGGCTGCCCCACGGAACC
AGTGACCCTGACGCTATTCTCAGAGACCACCTTGCACCAGGCACAAAACCTCTTTAAGCTGTTGAACCTTCAGTC
CCTCTTCGTGACATCGCGGGGCAGAGCTGTGGGCTGCGTGTCTTGGGTGGAGATGAAGAAAGCAATTTCCAACCT
GACAAATCCGCCAGCTCCAAAG TGAG CCGGCCAGCAAGAT

The NOV13 protein (SEQ ID NO:40) encoded by SEQ ID NO:39 is 655 amino acid residues in length and is presented using the one-letter amino acid code in Table 13B. The SignalP, Psort and/or Hydropathy results indicate that NOV13 has a signal peptide and is likely to be localized at the plasma membrane with a certainty of 0.6000. Alternatively, a NOV13 polypeptide is located to the Golgi body with a certainty of 0.4000, the endoplasmic reticulum (membrane) with a certainty of 0.1882, or the microbody (peroxisome) with a certainty of 0.3000. The SignalP indicates a likely cleavage site for a NOV13 peptide between positions 66 and 67, *i.e.*, at the dash in the sequence SYA-MN.

Table 13B. Encoded NOV13 Protein Sequence (SEQ ID NO:40)		
MEEFVGLREGFGSDPVTLQELWGPCPHIRRAIQGGLEWLKQKVFRLEDWYFLMTLGVLMALVSYAMNFAIGCVV RGFSQSITPSSGGSGIPELKTMLAGVILEDYLDIKNFGAKVVGLSCTLATGSTLFLGKVGPFVHLSVMIAAYLGR VRTTTIGEPENKSKQNEMLVAAAAGVATVFAAPFSGVLFSIEVMSSHFVSRDYWRGFFAATCGAFIFRLLAVFN SEQETITSLYKTSFRVDVFPDLPEIFFFVALGGICGVLSCAYLFCQRTFLSFIKTNRYSSKLLATSKPVYSALAT LLASITYPPGVGHFLASRLSMKQHLDSLFDNHSWALMTQNSSPPWPEELDPQHLWWEWYHPRFTIFGTLAFFLV MKFWMLILATTIPMPAGYFMPIFILGAAIGRLLGEALAVAFPEGIVTGGVTNPIMPGGYALAGAAAFSGAVTHTI STALLAFELTGQIVHALPVLMAVLAANAIAQSCQPSFYDGTIIIVKKLPYLPRILGRNIGSHHVRVEHFMNHSITT LAKDTPLEEVVKVVTSTDVTEYPLVESTESQILVGIVQRAQLVQALQAEPSPRAPGHQQRLQDILARGCPTPEPVT LTLFSETTLHQAQNLQSLFVTSRGRAVGCVSWVEMKKAISNLTNPPAPK		

SNP variants of NOV13 are disclosed in Example 2.

A search against the Patp database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 13C.

Table 13C. PatP Results for NOV13			
Sequences Producing High-Scoring Segment Pairs:		High Score	Smallest Sum Prob P (N)
patp:AA13937	Human CLCNKB protein	2754	0.0
patp:AAR60336	C1C-K1 protein - Rattus rattus - Sprague-Dawley	2331	2.3e-273
patp:AA169633	Human gastric chloride channel C1C-2G	1216	1.6e-132
patp:AA169631	Rabbit gastric chloride channel C1C-2G	1211	5.5e-132
patp:AA169632	Rat brain chloride channel C1C-2	1207	1.5e-131

In a BLAST search of public sequence databases, it was found, for example, that the NOV13 nucleic acid sequence of this invention has 1768 of 1779 bases (99%) identical to a gb:GENBANK-ID:HSCLCHPRA|acc:Z30643.1 mRNA from H.sapiens mRNA for chloride

channel (putative) 2139bp. Further, the full amino acid sequence of the disclosed NOV13 protein of the invention has 578 of 579 amino acid residues (99%) identical to, and 578 of 579 amino acid residues (99%) similar to, the 687 amino acid residue ptnr:SWISSPROT-ACC:P51800 protein from Human (CHLORIDE CHANNEL PROTEIN CLC-KA (CLC-K1)).

The NOV13 protein of the invention also has homolgy to the proteins shown in the BLASTP data in Table 13D.

Table 13D. NOV13 BLASTP Results					
Gene Index/ Identifier	Protein/Organism	Length of aa	Identity (%)	Positives (%)	Expect Value
P51800	Chloride channel protein CLC-KA (CLC-K1) - Homo sapiens	687	578/579 (99%)	578/579 (99%)	0.0
P51801	Chloride channel protein CLC-KB (CLC-K2) - Homo sapiens	687	531/579 (91%)	550/579 (94%)	0.0
P51803	Chloride channel protein CLC-K1 - Oryctolagus cuniculus (Rabbit)	687	497/579 (85%)	535/579 (92%)	3.1e-300
P51804	Chloride channel protein CLC-K2 - Oryctolagus cuniculus (Rabbit)	678	486/564 (86%)	522/564 (92%)	2.3e-293
A57713	chloride channel CLC-K1 - rat	687	484/579 (83%)	527/579 (91%)	2.1e-290

A multiple sequence alignment is given in Table 13E, with the NOV13 protein of the invention being shown in line 1 in a ClustalW analysis comparing NOV13 with related protein sequences of Table 13D.

Table 13E. ClustalW Analysis of NOV13

1. SEQ ID NO.: 40	NOV13	4. SEQ ID NO.: 201	P51803
2. SEQ ID NO.: 199	P51800	5. SEQ ID NO.: 202	P51804
3. SEQ ID NO.: 200	P51801	6. SEQ ID NO.: 203	A57713

10 20 30 40 50 60

NOV13 MEEFVGLREGFSGDPVTLOELWGPCPHIRRAIOGGEWLKQKVFRLGEDWYFLMTLGVLM 60

P51800 MEELVGLREGFSGDPVTLOELWGPCPHIRRAIOGGEWLKQKVFRLGEDWYFLMTLGVLM 60

5 P51801 MEEFVGLREGSSGNPVTLOELWGPCPLIRRGIRGGLEWLKQKLFRLGEDWYFLMTLGVLM 60

P51803 MEELVGLREGSSGNPVALRELWGPCPRIRRGIRGGLEWLKQKLFRLGEDWYFLMTLGVLM 60

P51804 MEELVGLREGSSGNPVALRELWSPCPRIIRRGIRGGLEWLKQKLFRLGEDWYFLMTLGVLM 60

A57713 MEELVGLREGSSGKPVTLQELWGPCPRIIRRGVRRGLEWLKQKLFRLGEDWYFLVALGVLM 60

10 70 80 90 100 110 120

NOV13 ALVSYAMNFALGCVVR-----GFSQSITPSSGG 88

P51800 ALVSYAMNFALGCVVRAHQLYREIGDSHLLRYLSWTVPVALVSFSSGFSQSITPSSGG 120

15 P51801 ALVSCAMDLAVESVVRRAHQLYREIGDSHLLRYLSWTVPVALVSFSSGFSQSITPSSGG 120

P51803 ALISYAMNFALGRVVRRAHQLYREIGDSHLLRYLSWTVPVALVSFSSGFSQSITPSSGG 120

P51804 ALISYAMNFALGRVVRRAHQLYREIGDSHLLRYLSWTVPVALVSFSSGFSQSITPSSGG 120

A57713 ALISYAMNFALGRVVRRAHQLYREIGDSHLLRYLSWTVPVALVSFSSGFSQSITPSSGG 120

20 130 140 150 160 170 180

NOV13 SGIPELKTMLAGVILEDYLDIKNFGAKVVGLSCTLATGSTFLGKVGPFVHLSVMIAAYL 148

P51800 SGIPELKTMLAGVILEDYLDIKNFGAKVVGLSCTLATGSTFLGKVGPFVHLSVMIAAYL 180

P51801 SGIPELKTMLAGVILEDYLDIKNFGAKVVGLSCTLATGSTFLGKVGPFVHLSVMIAAYL 180

25 P51803 SGIPELKTMLAGVILEDYLDIKNFGAKVVGLSCTLATGSTFLGKVGPFVHLSVMIAAYL 180

P51804 SGIPELKTMLAGVILEDYLDIKNFGAKVVGLSCTLATGSTFLGKVGPFVHLSVMIAAYL 180

A57713 SGIPELKTMLAGVILEDYLDIKNFGAKVVGLSCTLATGSTFLGKVGPFVHLSVMIAAYL 180

30 190 200 210 220 230 240

NOV13 GRVRTTTIGEPENKSKQNEMLVAAAAGVATVFAAPFSGVLFSEIVMSSHFSVRDYWRGF 208

P51800 GRVRTTTIGEPENKSKQNEMLVAAAAGVATVFAAPFSGVLFSEIVMSSHFSVRDYWRGF 240

P51801 GRVRTTTIGEPENKSKQNEMLVAAAAGVATVFAAPFSGVLFSEIVMSSHFSVWDYWRGF 240

P51803 GRVRTKTIGEAENKSKQNEMLVAAAAGVATVFAAPFSGVLFSEIVMSSHFSVWDYWRGF 240

P51804 GRVRTKTIGEAENKSKQNEMLVAAAAGVATVFAAPFSGVLFSEIVMSSHFSVWDYWRGF 240

35 A57713 GRVRAKTIGETENKSKQNEMLVAAAAGVATVFAAPFSGVLFSEIVMSSHFSVWDYWRGF 240

40 250 260 270 280 290 300

NOV13 FAATCGAFMRLLAVFNSEQETITSLYKTSFRVDVPFDLPEIFFFVALGICGVLSLAYL 268

P51800 FAATCGAFMRLLAVFNSEQETITSLYKTSFRVDVPFDLPEIFFFVALGICGVLSLAYL 300

P51801 FAATCGAFMRLLAVFNSEQETITSLYKTSFRVDVPFDLPEIFFFVALGICGVLSLAYL 300

P51803 FAATCGAFMRLLAVFNSEQETITSLYKTSFRVDVPFDLPEIFFFVALGICGVLSLAYL 300

P51804 FAATCGAFMRLLAVFNSEQETITSLYKTSFRVDVPFDLPEIFFFVALGICGVLSLAYL 300

45 A57713 FAATCGAFMRLLAVFNSEQETITSLYKTSFRVDVPFDLPEIFFFVALGICGVLSLAYL 300

50 310 320 330 340 350 360

NOV13 FCQRTFLSFIKTNRYSSKLLATSKPVYSALATLVLASITYPPGVGHFLASRLSMKQHLDS 328

P51800 FCQRTFLSFIKTNRYSSKLLATSKPVYSALATLVLASITYPPGVGHFLASRLSMKQHLDS 360

P51801 FCQRTFLSFIKTNRYSSKLLATSKPVYSALATLVLASITYPPGVGHFLASRLSMKQHLDS 360

P51803 FCQRTFLSFIKTNRYSSKLLATSKPVYSALATLVLASITYPPGVGHFLASRLSMKQHLDS 360

P51804 FCQRTFLSFIKTNRYSSKLLATSKPVYSALATLVLASITYPPGVGHFLASRLSMKQHLDS 360

A57713 FCQRTFLSFIKTNRYSSKLLATSKPVYSALATLVLASITYPPGVGHFLASRLSMKQHLDS 360

55 370 380 390 400 410 420

NOV13 LFDNHSWALMTNNSPPWPELDPQHLWWEWYHPRFTIRGTLAFFLVMMKFWMLILATTIP 388

5	P51800	LFDNHSWALMTONSSPPWPEELDPQHLWWEWYHPRFTIFGTLAFFLVMKFWMLILATTIP	420
	P51801	LFDNHSWALMTONSSPPWPEELDPQHLWWEWYHPRFTIFGTLAFFLVMKFWMLILATTIP	420
	P51803	LFDNHSWALMTONSSPPWPAEPDPQHLWWEWYHPRFTIFGTLAFFLVMKFWMLILATTIP	420
	P51804	LFDNHSWALMTONSSPPWPAEPDPQHLWWEWYHPRFTIFGTLAFFLVMKFWMLILATTIP	420
	A57713	LFDNHSWALMTONSSPPWPAEPDPQHLWWEWYHPRFTIFGTLAFFLVMKFWMLILATTIP	420
10	NOV13	MPAGYFMPIFII GAAIGRLLGEALAVAFPEGIVTGGVTNPIMPGGYALAGAAAFSGAVTH	448
	P51800	MPAGYFMPIFII GAAIGRLLGEALAVAFPEGIVTGGVTNPIMPGGYALAGAAAFSGAVTH	480
	P51801	MPAGYFMPIFII GAAIGRLLGEALAVAFPEGIVTGGVTNPIMPGGYALAGAAAFSGAVTH	480
	P51803	MPAGYFMPIFII GAAIGRLLGEALAVAFPEGIVTGGVTNPIMPGGYALAGAAAFSGAVTH	480
	P51804	MPAGYFMPIFII GAAIGRLLGEALAVAFPEGIVTGGVTNPIMPGGYALAGAAAFSGAVTH	480
15	A57713	MPAGYFMPIFII GAAIGRLLGEALAVAFPEGIVTGGVTNPIMPGGYALAGAAAFSGAVTH	480
20	NOV13	TISTALLAFELTGQIVHALPVLMAVLAANAIAQSCQPSFYDGTIMVKKLPYLPRIILGRNI	508
	P51800	TISTALLAFELTGQIVHALPVLMAVLAANAIAQSCQPSFYDGTIMVKKLPYLPRIILGRNI	540
	P51801	TISTALLAFELTGQIVHALPVLMAVLAANAIAQSCQPSFYDGTIMVKKLPYLPRIILGRNI	540
	P51803	TISTALLAFELTGQIVHALPVLMAVLAANAIAQSCQPSFYDGTIMVKKLPYLPRIILGRNI	540
	P51804	TISTALLAFELTGQIVHALPVLMAVLAANAIAQSCQPSFYDGTIMVKKLPYLPRIILGRNI	540
	A57713	TISTALLAFELTGQIVHALPVLMAVLAANAIAQSCQPSFYDGTIMVKKLPYLPRIILGRNI	540
25	NOV13	GSHHVRVEHFMMNHSITTLAKDTPLEEVVKVVTSTDVTEYPLVESTESQILVGIVQRAQLV	568
	P51800	GSHHVRVEHFMMNHSITTLAKDTPLEEVVKVVTSTDVTEYPLVESTESQILVGIVQRAQLV	600
	P51801	GSHHVRVEHFMMNHSITTLAKDTPLEEVVKVVTSTDVTEYPLVESTESQILVGIVQRAQLV	600
30	P51803	GSHHVRVEHFMMNHSITTLAKDTPLEEVVKVVTSTDVTEYPLVESTESQILVGIVQRAQLV	600
	P51804	GSHHVRVEHFMMNHSITTLAKDTPLEEVVKVVTSTDVTEYPLVESTESQILVGIVQRAQLV	600
	A57713	GSHHVRVEHFMMNHSITTLAKDTPLEEVVKVVTSTDVTEYPLVESTESQILVGIVQRAQLV	600
35	NOV13	QALQAEPPSRAPGHQOCLQDILARGCPTPEVTLTLFSETLHQAHNLFKLLNLSLFFVTS	628
	P51800	QALQAEPPSRAPGHQOCLQDILARGCPTPEVTLTLFSETLHQAHNLFKLLNLSLFFVTS	660
	P51801	QALQAEPPSRAPGHQOCLQDILARGCPTPEVTLTLFSETLHQAHNLFKLLNLSLFFVTS	660
40	P51803	QALQAEPPSRAPGHQOCLQDILARGCPTPEVTLTLFSETLHQAHNLFKLLNLSLFFVTS	660
	P51804	QALQAEPPSRAPGHQOCLQDILARGCPTPEVTLTLFSETLHQAHNLFKLLNLSLFFVTS	660
	A57713	QALQAEPPSRAPGHQOCLQDILARGCPTPEVTLTLFSETLHQAHNLFKLLNLSLFFVTS	660
45	NOV13	RGRAVGCVSWVEMKKAISNLTNPPAPK	655
	P51800	RGRAVGCVSWVEMKKAISNLTNPPAPK	687
	P51801	RGRAVGCVSWVEMKKAISNLTNPPAPK	687
	P51803	RGRAVGCVSWVEMKKAISNLTNPPAPK	687
	P51804	RGRAVGCVSWVEMKKAISNLTNPPAPK	687
50	A57713	RGRAVGCVSWVEMKKAISNLTNPPAPK	687

The presence of identifiable domains in the disclosed NOV13 protein was determined by using Pfam and then determining the Interpro number. The results are listed in Table 13F with the statistics and domain description.

Table 13F. Domain Analysis of NOV13

PSSMs Producing Significant Alignments		Score (bits)	E Value
voltage_CLC: domain 1 of 1, from 67 to 484		558.6	1.7e-164
CLC	fslglvlllaallvkkfAPaAaGSGIPEiKtiLsGikivgkeylrprt + + + + ++ + + + ++ +++ ++++++		
NOV13	MNFAIGCVVRGFSQSITPSSGGSGIPELKTMLAGVIL--EDYLDIKN		
CLC	lvvKvvGlalslgsG..lslGKEGPfVHiGaciAalLsklgstslrlqfs + + ++ + +++++ ++++ + + ++ ++ + ++++++ +		
NOV13	FGAKVVLGSLCTLATGstLFLGKVGPFVHLSVMIAAYLGRVRTT-----TI		
CLC	lfkyseedrRkdrdllaGaAaGvAaaFgAPiGGVLFslEevssenayf + +++++ + ++++++ + + + ++ ++++ ++		
NOV13	GEPENKSKQ---NEMLVAAAAGVATVFAAPFSGVLFsIEVMSS---HF		
CLC	rvknlwrgLFFasavaafvlrlinsffvsgkcgqFgtglalFdvfsrtdr ++ +++++ ++++++ +++++ ++ ++++++ ++++++		
NOV13	SVRDYWRG-FFAATCGAFIFRLLA---VFNSEQE--TITSLYKTSFRVD-		
CLC	dpftlfELplFillGifgGllGalFnrlnrkvkfrkknkykskifglpp +++++ +++ +++ ++ +++++ ++ ++++++ +++++ +++++ +		
NOV13	VPFDLPEIFFFVALGGICGVLSCAYLFCQRTFLSFIKTNRYSSKLLATSK		
CLC	vlepavglitgvlspfpplllgcaggelvelgrtlnelfdnCtwg.eyn +++++ ++++++ ++++++ + + + ++++++ +		
NOV13	PVYSALATLLLASITYPPGVGHFLASRLSMKQ--HLDLFDNHSWALMTQ		
CLC	dlasllcdtpedavlsldfhwnpgpegdfsafatlLllllliakfilitlft +++++ +++++ +++++ ++++++ +++++ +++++ +		
NOV13	NSSPPWPEELDPQHLWW--EWYH--PRFTIFGTLAFFLVMKFWMLILAT		
CLC	GigvPgGlFvPslviGAavGrlvGiaverlimavlsHdwfpiglfcegfp ++++ + + ++++ ++ +++ + +++ ++++++ + +		
NOV13	TIPMPAGYFMPiFILGAAIGRLLG-----EALAVA---FPEGIVTGGVT		
CLC	dcilePGlYAvvGAAaflgGvvrmTvslaVivfElTGnlsvilPlMvAvl ++++ + ++ + + +++++ +++++ + + ++ + + +++ ++		
NOV13	NPIM-PGGYALAGAAAFSG-AVTHTISTALLAFELTGQIVHALPVLMAVL		
CLC	iakavadslg (SEQ ID NO:204) +++++		
NOV13	AANAIAQSCQ (SEQ ID NO:40)		

Consistent with other known members of the voltage-gated chloride channel family of proteins, NOV13 contains CLC domains as illustrated in Table 13F.

5

The NOV13 nucleic acid, and the encoded polypeptide, according to the invention are useful in a variety of applications and contexts. For example, NOV13 nucleic acids and

polypeptides can be used to identify proteins that are members of the voltage-gated chloride channel family of proteins. The NOV13 nucleic acids and polypeptides can also be used to screen for molecules, which inhibit or enhance NOV13 activity or function. Specifically, the nucleic acids and polypeptides according to the invention may be used as targets for the
5 identification of small molecules that modulate or inhibit, *e.g.*, physiological functions such as cell volume regulation, membrane potential stabilization, signal transduction, or transepithelial transport. These molecules can be used to treat, *e.g.*, diseases associated with the kidney such as renal artery stenosis, diabetes, or renal tubular acidosis.

In addition, the NOV13 nucleic acid and polypeptide according to the invention are
10 useful, *inter alia*, as novel members of the protein families according to the presence of domains and sequence relatedness to previously described proteins. For example, the NOV13 nucleic acid and polypeptide include structural motifs that are characteristic of proteins belonging to the family of voltage-gated chloride channel proteins. All functionally characterized members of the CLC family transport chloride, some in a voltage-regulated process. These channels serve a
15 variety of physiological functions such as cell volume regulation, membrane potential stabilization, signal transduction, and transepithelial transport.

The NOV13 nucleic acid and polypeptide, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications in the mediation of kidney diseases. As such the NOV13 nucleic acid and polypeptide, antibodies and related
20 compounds according to the invention may be used to treat, *e.g.*, diabetes, autoimmune disease, renal artery stenosis, interstitial nephritis, glomerulonephritis, polycystic kidney disease, systemic lupus erythematosus, renal tubular acidosis, IgA nephropathy, hypercalcaemia, or Lesch-Nyhan syndrome.

The NOV13 nucleic acid and polypeptide are useful for detecting specific cell types. For
25 example, expression analysis has demonstrated that a NOV13 nucleic acid is expressed in the kidney.

Additional utilities for the NOV13 nucleic acid and polypeptide according to the invention are disclosed herein.

NOV14

The disclosed NOV14 nucleic acid (alternatively referred to herein as CG56443-01) encodes a novel mast cell function-associated antigen (MAFA)-like protein and includes the 645 nucleotide sequence (SEQ ID NO:41) shown in Table 14A. The NOV14 nucleic acid disclosed herein maps to chromosome 19.

An open reading frame for the mature protein was identified beginning with an ATG initiation codon at nucleotides 31-33, and ending with a TAA stop codon at nucleotides 604-606. Putative untranslated regions, if any, are found upstream from the initiation codon and downstream from the termination codon. The start and stop codons are in bold letters.

Table 14A. NOV14 Nucleotide Sequence (SEQ ID NO:41)

ACTGGAGTGTGCTACAAAGATACCCCAAAATGTGGAAGCAACTGTGGAAC TGGGTAACAGGCCTTCCAGAAAGC
CCCCAATTTGAGTCCCATCAAAGGTTAGTTCTTCTGCCTATTCTTGAAATTCATGTAAACTCAAATCTTACAGA
ATGTATTCATTCTGTTTGGGTTTCTTAACTCTTGTGAGACAGAGTCTTGCTCTGTCACCCAGGCTGGAATGCAGT
GGCGCCATCTCGGCTCACTGCAAGATCTGTGAGCCGTGCCCTACGTCGTGGCTGCCCTTCGGGGGGCTCCTGCTAC
TATTTCTCTGTGCCGAAGACCACGTGGGCAGAGGCGCAGGGCCACTGCGCCGATGCCAGCGCACATCTGGCTGCC
TTCCAGAAAGATAGGAAAGTCGCCTTTTATTCTGTACTTTTGGGTAGGTGCCTCTTCGGAATAGGCCTGGCCAGA
GTGGGTGGGTGGAGGTGGCAGGTGGCACC GGGGACCCAGATAGATGCACCCGAGTAGGACAAGGGGCTGCTTC
TGTCAGGAAAGCATTTCTGGTCTTCCTGCCTCGGAACTCAGGCTGGAAAAGTGGTGGCACTGCTCAAAAACACTG
CAATAACAAACCACAGATGTCTGTTCCAAAGATTACAATCAAAAC

The NOV14 protein (SEQ ID NO:42) encoded by SEQ ID NO:41 is 191 amino acid residues in length and is presented using the one-letter amino acid code in Table 14B. The SignalP, Psort and/or Hydropathy results indicate that NOV14 has a signal peptide and is likely to be localized at the plasma membrane with a certainty of 0.7900. Alternatively, a NOV14 polypeptide is located to the microbody (peroxisome) with a certainty of 0.5804, the Golgi body with a certainty of 0.3000, or the endoplasmic reticulum (membrane) with a certainty of 0.2000. The SignalP indicates a likely cleavage site for a NOV14 peptide between positions 57 and 58, *i.e.*, at the dash in the sequence SLA-LS.

Table 14B. Encoded NOV14 Protein Sequence (SEQ ID NO:42)

MWKQLWNWVTGLPESPQFESHQRLVLLPILEIHVNSKSYRMYSFCLGFLTLVRQSLALSPRLECSGAISAHCKIC
EPCPTSWLPFGGSCYYFVSKTTWAEAQGHCADASAHLAAFPEDRKVAFYSVLLGRCLFGIGLARVGGWRWQVAP
GTQIDAPAVGQGACFCQESISGLPASELRLEKWWHCSKTLQ

A search against the Patp database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 14C.

Table X14C. PatP Results for NOV14

Sequences Producing High-Scoring Segment Pairs:		High Score	Smallest Sum Prob P (N)
patp:AAE11760	Mouse mast cell function associated antigen (MAFA) protein	266	8.1e-23
patp:AAR77033	Mammalian mast cell function-associated antigen (MAFA)	252	2.5e-21
patp:AAW88277	Rat mast cell function-associated antigen (MAFA)	252	2.5e-21
patp:AAE11761	Rat mast cell function associated antigen (MAFA) protein	252	2.5e-21
patp:AAM25760	Human protein sequence	239	5.9e-20

In a BLAST search of public sequence databases, it was found, for example, that the NOV14 nucleic acid sequence of this invention has 109 of 151 bases (72%) identical to a gb:GENBANK-ID:HSA007973|acc:AJ007973.1 mRNA from Homo sapiens LGMD2B gene. Further, the full amino acid sequence of the disclosed NOV14 protein of the invention has 62 of 179 amino acid residues (34%) identical to, and 87 of 179 amino acid residues (48%) similar to, the 188 amino acid residue ptrn:SPTREMBL-ACC:O88713 protein from Mouse (MAST CELL FUNCTION-ASSOCIATED ANTIGEN 2F1 (MAFA)).

The NOV14 protein of the invention also has homolgy to the proteins shown in the BLASTP data in Table 14D.

Table 14D. NOV14 BLASTP Results

Gene Index/ Identifier	Protein/Organism	Length of aa	Identity (%)	Positives (%)	Expect Value
O88713	MAST CELL FUNCTION-ASSOCIATED ANTIGEN 2F1 (MAFA) (KILLER CELL LECTIN-LIKE RECEPTOR G1) - Mus musculus (Mouse)	188	62/179 (34%)	87/179 (48%)	1.0e-22
Q64335	MAFA PROTEIN - Rattus norvegicus (Rat)	188	59/179 (32%)	84/179 (46%)	3.1e-21
O75613	ITIM-CONTAINING RECEPTOR MAFA-L - Homo sapiens (Human)	189	45/149 (30%)	71/149 (47%)	3.8e-16

Q96E93	SIMILAR TO KILLER CELL LECTIN-LIKE RECEPTOR SUBFAMILY G, MEMBER 1 - Homo sapiens (Human)	195	45/149 (30%)	71/149 (47%)	3.8e-16
O43198	MAST CELL FUNCTION- ASSOCIATED ANTIGEN - Homo sapiens (Human)	189	44/149 (29%)	70/149 (46%)	1.2e-14

A multiple sequence alignment is given in Table 14E, with the NOV14 protein of the invention being shown in line 1 in a ClustalW analysis comparing NOV14 with related protein sequences of Table 14D.

Table 14E. ClustalW Analysis of NOV14

1. SEQ ID NO.: 42	NOV14	4. SEQ ID NO.: 207	O75613
2. SEQ ID NO.: 205	O88713	5. SEQ ID NO.: 208	Q96E93
3. SEQ ID NO.: 206	Q64335	6. SEQ ID NO.: 209	O43198

	10	20	30	40	50	60
NOV14	MWKQIWNWVTGLPESPOFESHQRLVLLPILEIHVNSKSYRMYSFCLGFLTIVRQSLALSP	60				
O88713	MADSSIYSTLELPEAPQVODESRWKLKAVLHRPHLS---RFAMVALGLLTVILMSLLMYQ	57				
Q64335	MADNSIYSTLELPAAPRVODDSRWKVKAVLHRPCVS---YLVMAVALGLLTVILMSLLLYQ	57				
O75613	MTDSVIYSMLLELPTATQAONDYGPOQKSSSSSRPSCS---CLVAIALGLLTAVLLSVLLYQ	57				
Q96E93	MTDSVIYSMLLELPTATQAONDYGPOQKSSSSSRPSCS---CLVAIALGLLTAVLLSVLLYQ	57				
O43198	MTDSVIYSMLLELPTATQAONDYGPOQKSSSSSRPSCS---CLVAIALGLLTAVLLSVLLYQ	57				

	70	80	90	100	110	120
NOV14	RLECSGAISAHCKICEPCPTSWLPFGGSCYYFSVPKTTWAEAQGHCADASAHLLAAFPEDR	120				
O88713	RILCCGSKDSTCSHCPCPILWTRNGSHCYFFSMKKDWNSSLKFCADKGSHELLTFPDNQ	117				
Q64335	RTLCCGSKGFMCSQCRCPLWWRNGSHCYFFSMKKDWNSSLKFCADKGSHELLTFPDNQ	117				
O75613	WILCQGSNYSTCASCPCPCPDRWMKYGNHCYYFSVEEKDWNSSLKFCCLARDSHLLVITDNO	117				
Q96E93	WILCQGSNYSTCASCPCPCPDRWMKYGNHCYYFSVEEKDWNSSLKFCCLARDSHLLVITDNO	117				
O43198	WILCQGSNYSTCASCPCPCPDRWMKYGNHCYYFSVEEKDWNSSLKFCCLARDSHLLVITDNO	117				

	130	140	150	160	170	180
NOV14	KVAFYSVLLGRCLFGIGLARVGGWRWQVAPGTQIDAPAVGQACFCQES-ISGLPASELR	179				
O88713	GVKLFGEYLGQDFYWIWGLRNDGWRWEGGPALSLR-ILINSLTORCGAIHRNGLQASSCE	176				
Q64335	GVNLFQCEYVGEDFYWIWGLRNDGWRWEDGPALSLS-ILSNSVQKCGTIHRCGLHASSCE	176				
O75613	EMSILQVELSEAFQWIGLRNNSGWRWEDGSPLNFSRISNSFVOTCGAINKNGLOASSCE	177				
Q96E93	EMSILQVELSEAFQWIGLRNNSGWRWEDGSPLNFSRISNSFVOTCGAINKNGLOASSCE	177				
O43198	EMSILQVELSEAFQWIGLRNNSGWRWEDGSPLNFSRISNSFVOTCGAINKNGLOASSCE	177				

	190
.....	

NOV14 LEKWWHCSTLQ----- 191
 O88713 VALQWICKKVLY----- 188
 Q64335 VALQWICKKVLP----- 188
 O75613 VPLHWVCKKVRL----- 189
 5 Q96E93 VPLHWVCKKCPFADQALF 195
 O43198 VPLHGVCKKVRL----- 189

10 The presence of identifiable domains in the disclosed NOV14 protein was determined by using Pfam and then determining the Interpro number. The results are listed in Table 14F with the statistics and domain description.

Table 14F. Domain Analysis of NOV14		
PSSMs Producing Significant Alignments		E Value
Xlink: domain 1 of 1, from 87 to 114		0.9
Xlink	GeVFhyrapsgRYkltFeEAqaaClrqqAriA (SEQ ID NO:210)	
	++ + + + ++ +	
NOV14	GSCYYFSVPK----TTWAEAQGHCADASAHLA (SEQ ID NO:42)	

15 Consistent with other known members of the MAFA family of proteins, NOV14 contains an extracellular link (Xlink) domains as illustrated in Table 14F.

The NOV14 nucleic acid, and the encoded polypeptide, according to the invention are useful in a variety of applications and contexts. For example, NOV14 nucleic acids and polypeptides can be used to identify proteins that are members of the MAFA family of proteins.

20 The NOV14 nucleic acids and polypeptides can also be used to screen for molecules, which inhibit or enhance NOV14 activity or function. Specifically, the nucleic acids and polypeptides according to the invention may be used as targets for the identification of small molecules that modulate or inhibit, *e.g.*, cellular activation/cascade, allergic response, or the release of mediators such as histamine. These molecules can be used to treat, *e.g.*, atopic disorders such as

25 asthma, allergies, cancers such as lymphoma, or immunological disorders.

In addition, the NOV14 nucleic acid and polypeptide according to the invention are useful, *inter alia*, as novel members of the protein families according to the presence of domains and sequence relatedness to previously described proteins. For example, the NOV14 nucleic acid and polypeptide include structural motifs that are characteristic of proteins belonging to the

family of MAFA proteins. Mast cells are part of the immune system. They carry Fcepsilon type receptors on their surface to which IgE antibodies bind specifically. Crosslinking by multivalent antigens initiates a biochemical cascade which causes the secretion of neurotransmitters and thus allergic reaction of the immediate type. It was recently discovered that this membrane protein carries an Immune Receptor Tyrosine based Inhibition Motif (ITIM).

The NOV14 nucleic acid and polypeptide, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications in the mediation of immune response, cancer, or atopy. As such the NOV14 nucleic acid and polypeptide, antibodies and related compounds according to the invention may be used to treat, *e.g.*, cancer, autoimmune disease, allergies, immunodeficiencies, transplantation, graft versus host disease (GVHD), or lymphoedema.

The NOV14 nucleic acid and polypeptide are useful for detecting specific cell types. For example, expression analysis has demonstrated that a NOV14 nucleic acid is expressed in lymph, testis, liver, breast, melanocyte, heart, uterus, brain, and spleen.

Additional utilities for the NOV14 nucleic acid and polypeptide according to the invention are disclosed herein.

NOV15

The NOV15 proteins described herein are novel murine epidermal growth factor-6 (MEGF6). The NOV15 nucleic acids disclosed herein map to chromosome 1. Six alternative novel NOV15 nucleic acids and polypeptides are disclosed herein, namely NOV15a, NOV15b, NOV15c, NOV15d, NOV15e and NOV15f.

NOV15a

A NOV15 variant is NOV15a (alternatively referred to herein as CG56449-01), which encodes the 7337 nucleotide sequence (SEQ ID NO:43) shown in Table 15A. An open reading frame for the mature protein was identified beginning with an ATG codon at nucleotides 1-3 and ending with a TGA codon at nucleotides 4213-4215. Putative untranslated regions, if any, downstream from the termination codon and upstream from the initiation codon are underlined.

The start and stop codons are in bold letters.

Table 15A. NOV15a Nucleotide Sequence (SEQ ID NO:43)

ATGCCCATGGGACATTCTGACAGGTGGTCTTGGCGTCTCCTGAGGCTGGCACTGCCACTCCCAGTCTGGTTGCCG
GCTGGGGGTGGCCGAGGCGCTGACTCTCCATGTCTCTGTTCAGGCCCCACGTGTGTGCTGAGCAGGAGCTGACC
CTGGTGGGCGCCGCCAGCCGTGCGTGACAGGCTTAAGCCACACGGTGCCGGTGTGGAAGGCCGCTGTGGGTGG
CAGGCGTGGTGCCTGGGTCTATGAGCGGAGGACCGTCTACTACATGGGCTACAGGCAGGTGTATACCACGGAGGCC
CGGACCGTGCTCAGGTGCTGCCGAGGGTGGATGCAGCAGCCCGACGAGGAGGGCTGCCTCTCGGATGTGGGTGAG
TGTGCCAACGCCAACGGGGGCTGTGCGGGTGGTGCCGGGACACCGTGGGGGGCTTCTACTGCCGTGGCCCCC
CCCAGCCACCAGCTGCAGGGTGATGGCGAGACTTGCCAAGATGTGGACGAATGCCGAACCCACAACGGTGGCTGC
CAGACCGGTGCGTGAACACCCAGGCTCCTACCTCTGTGAGTGCAAGCCCGCTTCCGGCTCCACACTGACAGC
AGGACCTGCGCCATTAACCTCTGCGCCCTGGGCAATGGCGGCTGCCAGCACCCTGTGTCCAGCTCACAATCACT
CGGCATCGCTGCCAGTGCCGGCCCGGGTTCCAGCTCCAGGAGGACGGCAGGCATTGTGTCCGTAGAAGCCCGTGT
GCCAACAGGAACGGCAGCTGCATGCACAGGTGCCAGGTGGTCCGGGGCCTCGCCCGCTGTGAGTGCCACGTGGGC
TATCAGCTAGCAGCGGACGGCAAGGCCTGTGAAGATGTGGACGAATGTGCCCGAGGGCTGGCCCAGTGTGCCCAT
GGCTGCCTCAACACCCAGGGGTCTTCAAGTGCGTGTGTACGCGGGCTATGAGCTGGGCGCCGATGGCCGGCAG
TGCTACCGTATTGAGATGAAATCGTGAACAGCTGTGAGGCCAACACGGCGGCTGCTCCCATGGCTGCAGCCAC
ACCAGTGCTGGGCCCCCTGTGCACCTGTCCCCGCGGCTACGAGCTGGACACAGATCAGAGGACCTGCATCAGATGT
CGACGACTGTGCAGACAGCCCGTGTGCAGCAGGTGTGCACCAACAACCTGGCGGGTACGAGTGCGGCTGCTAC
GCCGGCTACCGGCTCAGTGCCGATGGCTGCGGCTGCGAGGATGTGGATGAGTGCGCCTCCAGCCGTGGCGGCTGC
GAGCACCCTGCACCAACCTGGCCGGCTCCTTCCAGTGTCTCCTGCGAGGCCGCTACCGGCTGCACGAGGACCTGT
AGGGGCTGCAGCGCCCTGGAGGAGCCGATGGTGGACCTGGACGCGGAGCTGCCTTTTCGTGCGGCCCTTGCCCCAC
ATTGCCGTGCTCCAGGACGAGCTGCCGCAACTCTTCCAGGATGACGACGTGCGGGCCGATGAGGAAGAGGCAGAG
TTGCGGGGCGAACACACGCTCACAGAGAAGTTTGTCTGCTGGATGACTCCTTTGGCCATGACTGCAGCTTGACC
TGTGATGACTGCAGGAACGGAGGGACCTGCCTCCTGGGCTGGATGGCTGTGATTGCCCGAGGGCTGGACTGGG
CTCATCTGCAATGAGAGTTGTCTCCGGACACCTTTGGGAAGAACTGCAGCTTCTCCTGCAGCTGTGAGAATGGT
GGGACCTGCGACTCTGTACGGGGGCTGCGGCTGCCCCCGGGTGTGAGTGAAGTAACTGTGAGGATGGCTGC
CCCAAGGGCTACTATGGCAAGCACTGTGCAAGAAATGCAACTGTGCCAACCGGGGCGGCTGCCACCGCCTCTAC
GGGGCCTGCCTCTGCGACCCAGGGCTCTACGGCCGCTTCTGCCACCTCGCCTGCCCGCCGTGGGCCCTTTGGGCCG
GGCTGCTCGGAGGAGTGCCAGTGTGTGCAGCCCCACACGAGTCCCTGTGACAAGAGGGATGGCAGCTGCTCCTGC
AAGGCTGGCTTCCGGGGCGAGCGCTGTGAGGCAGAGTGTGAGCCGGGCTACTTTGGGCCGGGGTGTGTCAGGCA
TGACCTGCCAGTGGGCGTGCCCTGTGACTCCGTGAGCGGCGAGTGTGGGAAGCGGTGTCTGCTGGCTTCCAG
GGAGAGGACTGTGGCCAAGAGTGGCCGGTGGGGACCTTTGGCGTGAAGTGTCTGAGCTCCTGCTCCTGTGGGGG
GCCCCCTGCCACGGGTCACGGGGCAGTGCCGGTGTCCGGCGGAGGACTGGGGAAGACTGTGAGGCAGGTGAG
TGTGAGGGCCTCTGGGGGCTGGGCTGCCAGGAGATCTGCCAGCATGCCATAACGCTGCTCGCTGCGACCTGTAG
ACCGGAGCCTGCCTGTGCTCCTTGGCTTTGTGCGGAGCCGCTGCCAGGACTGTGAGGCAGGCTGGTATGGTCCC
AGCTGCCAGACAATGTGCTCTTGTGCCAATGATGGGCACTGCCACCAAGACACGGGACACTGCAGCTGTGCCCC
GGGTGGACCGGCTTTAGCTGCCAGAGAGCCTGTGATACTGGGCACTGGGGACCTGACTGCAGCCACCCCTGCAAC
TGCAGCGCTGGCCACGGGAGCTGTGATGCCATCAGCGGCTGTGTCTGTGTGAGGCTGGCTACGTGGGCCCGCGG
TGCGAGCAGTCAGAGTGTCCCAGGGCCACTTTGGGCCCGGCTGTGAGCAGCGGTGCCAGTGTGAGCATGGAGCA
GCCTGTGACCACGTGAGCGGGCCTGCACCTGCCCGCGCGGCTGGAGGGGACCTTCTGCGAGCATGCTGCCCCG
GCCGGCTTCTTTGGATTGACTGTGCGAGTGCTGCAACTGCACCGCCGGAGCTGCCTGTGATGCCGTGAATGGC
TCCTGCCTCTGCCCCGCTGGCCGCCGGGGCCCCGCTGTGCCGAGAGTGCCTGCCAGCCACACCTACGGGCAC
AATTGCAGCCAGGCTGTGCTGCTTTAACGGGGCTCCTGTGACCCTGTCCAGGGCAGTGCCACTGTGCCCCCT
GGCTGGATGGGGCCCTCCTGCCTGCAGGCCTGCCCTGCCGGCCTGTACGGCGACAAGTGTGCGCATCTCTGCCTC
TGCCAGAACGGAGGGACCTGTGACCTGTCTCAGGCCACTGTGCGTGCCAGAGGGCTGGGCCGGCCTGGCCTGT
GAGGTAGAGTGCCCTCCCCGGGACGTGAGAGCTGGCTGCCGGCACAGCGGCGGTTGCCCTCAACGGGGGCTGTGT
GACCCGCACACGGGGCGCTGCCTCTGCCAGCCGGCTGGACTGGGGACAAGTGTGAGAGCCCTGCAGCCTGTGCC
AAGGGCACATTGGGGCTCACTGTGAGGGGCGTGTGCTGCCGGTGGGGAGGCCCCCTGCCACCTTGCCACCGGG
GCCTGCCTCTGCCCTCCGGGTGGCGGGGGCTCATCTTTCTGCAGCCTGCCTGCGGGGCTGGTTTGGAGAGGCC
TGTGCCAGCGCTGCAGCTGCCCGCTGGCGTGCCTGCCACCAGTCACTGGGGCTGCCGCTGTCCCCCTGGC
TTCACTGGCTCCGGCTGCGAGCAGGCCTGCCACCCGGCAGCTTTGGGGAGGACTGTGCGCAGATGTGCCAGTGT
CCCCGTGAGAACCCGGCCTGCCACCTGCCACCGGGACCTGTGATGTGCTGCTGGCTACCACGGCCCCAGCTGC
CAGCAACGATGTCCGCCCGGGCGGTATGGGCCAGGCTGTGAACAGCTGTGTGGGTGTCTCAACGGGGGCTCCTGT
GATGCGGCCACGGGGGCTGCCGCTGCCCACTGGGTTCTCAGGACGGACTGCAACCTCACCTGTCCGAGGGC
CGCTTCCGGCCCCAAGTGCACCCACGTGTGTGGGTGTGGGCAGGGGGCGGCTGCCACCTGTGACCGGCACCTGC
CTCTGCCCCCGGGGAGAGCCGGCTCCGCTGTGAGCGAGGCTGCCCCAGAACCAGGTTTGGCGTGGGCTGCGAG

CACACCTGCTCCTGCAGAAATGGGGGCTGTGCCACGCCAGCAAGCGGCAGCTGCTCCTGTGGCCTGGGCTGGAC
GGGGCGGCACTGCGAGCTGGCCTGTCCCCCTGGGCGCTACGGAGCCGCTGCCATCTGGAGTGCTCCTGCCACAA
CAACAGCACGTGT**GAGCCTGCCACGGGCACCTGCCGCTGCGGCCCGGCTTCTATGGCCAGGCCTGCGAGCACCC**
CTGTCCCCCTGGCTTCCACGGGGCTGGCTGCCAGGGGTGTGTCTGGTGTCAACATGGAGCCCCCTGCGACCCAT
CAGTGGCCGATGCCTCTGCCCTGCCGGCTTCCACGGCCACTTCTGTGAGAGGGGGTGTGAGCCAGGTTCAATTTGG
AGAGGGCTGCCACCAGCGCTGTGACTGTGACGGGGGGGACCCTGTGACCCTGTACCGGTCTCTGCCTTTGCCC
ACCAGGGCGCTCAGGAGCCACCTGTAACCTGGATTGCAGAAGGGGCCAGTTTGGGCCAGCTGCACCCTGCACTG
TGACTGCGGGGGTGGGGCTGACTGCGACCCTGTGAGTGGGCAGTGTCACTGTGTGGATGGCTACATGGGGCCAC
GTGCCGGGAAGGTGGGCCCCCTCCGGCTCCCCGAGAACCCGTCTTAGCCCAGGGCTCAGCGGGCACACTGCCCGC
CTCCAGCAGACCCACATCCCGGAGCGGTGGACCAGCGAGGCACTAGTAGAGGCAGTCCCGTGGAGCCCGCTCTC
CAGTCCCAGCCAGAGGGGACCCTGGCCTTTGGTGACCACTGAGAAGGACACTTCACGGGCCAGAGCTCCTGGTA
CTGCCCTTCTTTGAGGGCCGTGGAGGGCTGTGGACAGCCAGCAACCTGTGCTCTTGGAGGCTGGTGTGGCCT
TGAGGAGGGAAGCCTCGCATGGCCGCTGGAAGAGAGGCGCCTCCTGGCCTGGCTCTGCAGAACCAGGGGCACGC
TCTGGGCCTGGCTGAGGAAGTCCCGCTCTCCCCGCGCTCTGAGTTGGAAGTGGAGACAGGTGTGGGCGCCAGTG
TGGTGCAGGCGCAGGTGCAGGCACAGGGCCACTGTCTCCAGGCAGGCTTTTGGTGTAGGCCCTGGGACTGG
AAGTCGCCCAGCCCGTATTATGTAAAGGTATTTATGGGCCACTGCACATGCCCGCTGCAGCCCTGGGATCAGCT
GGAAGCTGCCTGTCTCTCTGCCCAATCCCCAGAAACCTGATTTCAGGTCTGCAGGCTCCTGCGGGCTCACCAG
GCTGCTGGCTCCGGTACCATGTAAACCTAGGAAGGTAAAGGAGCAGGCAACCTCCTCGTGGCCTGTGTGTTGCT
GTGTTACGTGGACTCTGTGTGGGCTCCTCCCTGGGGCCCGGCCAGCATAACGGTGCACCCAGGGACCTCCAGTG
CACCCGGGGCCCTTTGCAGGGGTGGGGGTGCCACACAAGTGAAGAAGTTGGGACTCATCTCAGTTCCAGTGCTA
TTGAGGAGAACGCTGGGGTGCATTCAATACCGCTGAGACCCAGAGACTGGCTGTTCCAGAGAATGGCCAGGG
GGAGGAGGGCTGGTGTGGAGGGCAACCTGGACTGAGGCCGAATCCCTTGGGCTCACCCACCCACCCCTACCT
GAGCATCAGCAGTGGGGGAGGGCAGCATCGCAGGGGCAGGGACTCCCTGGGTGAGGACAGACCAGCCTCCCCGA
GCACCTGGCACTCATGGGTGAGGCTGACTTCTCTGGAAGAGGGCCAGAGTGGAAGGAAGAGGCAGAGGGTA
GAGGTGGTGGCTGGGGGCTCCTCTGCAGAGTGGGGTGGCCATGGAGAGGGCTGCACTCACACCGCAACATAGGA
CTCTCTCTCCCTTAAGAAGGCCCCCTTAGGGTCTGGGTGCGGCCCCCATCACCTAAAACCAGCCAAGGTAGCT
GAGGCCCCAGGGCAGACAATTTACCAGCAGGANGAGGAGGAGTCCAGTGAGCTTGGTTGCTCACAGACAGCAAG
GGAGCTGTACAGAGGAAGCTGATGAATGGACCGCTGTGGGGAGACTTTAAAGTAGAACAGTGATAAGGGAGGGC
AGGATGGTGGGGATGCAGAAGCAGCAGCCAGAGAGAGACGGACTGGGGTGCAGACGGAGTGTGGAAAACGCATAC
CTTGAAATGAAGCATCCAGCAGATGGGGTGAAGTGGATACAGCTCAGGAGATTCTCCAGGAATAGCAGGGAGGCG
TAAAGAGAGACAACGTACAGAGATAGATGAATGGAAATGGGTAAAGGAGGTGTTCAATCACATCCATCTAACTGC
AAAAATACAAAAGTAAGAAGTCATTGACATGAAGCAACGACGACCAAGACGTTCTCAGATCTAAAGGTGAATGATC
TCAGTCAGCCTGGAAATGCACAAGGTGGAAAAATAACATAAAAAAGCCATAAGACCTTGAAGAATCAATGTCA
AAGATAAATTCTAAAGTCCAGAGAAAAAAGAATGGGAATCAAATTGACCTCAGACTATACGTGAGAAACACGGA
GAGCCAGAAAATGTGATGTTCCATCCTCAGAGTTTGAAGGAAATATTTGAAGGCTGAATTTTACATCCAGCTAA
ACTATCAAAGGCATGCAAAGTCCATGTTATTCTTAGGCCTTCAAGGCCTCGGCCATTTTTCTACAGAAAAGCCTG
ATTTTAAATGCTCTTAGAGACGTTCTCCAGCCAGAAGAGAAAGAAGCCAGGAGGGTGCTCTGAGATATTAGTC
ACCACAGTTCCCAAATGGCCTAGGAATTACAGAGAGTCAGAATATCACCACTTACTCCCCAATGGGAACCCCCGACA
GTCTCAGCATGGTGTGAGGGTGTGGACGGGGGGCCTGGCAGGTACCAATCACTCATCCGCTCAGTGAAGACACA
GTGTTACAGTACGGAAGCCATAAGGCAGGCCGAGCTTCTGCCCATCCGAGGAAATCTCAGCTATCCAACGGCGG
TCAGGAGCAGAGGAAAAATAAGCAGAATAACTAGAAAACACGCTCACAGATCCTAATGTTAACGGTTACAAATGA
CGACGGAAAAACAACCTCTGACCATATATTATATAGTTTCAAGCAGCAAGAAGGAGGATATTGAACATTCTCAA
CACACATAATAAACGCTTGAGATGATGATGCTCATTACCTGATTTGATCACTAGACATNCCATGTATCAAAA
CATCACTGTGTATCCGATGAATATCTACAATTATTGTCAATTAAAAACATCATTAATAAACAA

The NOV15a protein (SEQ ID NO:44) encoded by SEQ ID NO:43 is 1404 amino acid residues in length and is presented using the one-letter amino acid code in Table 15B. Although the SignalP, Psort and/or Hydropathy results indicate that NOV15a has a signal peptide and is likely to be localized in the mitochondrial matrix space with a certainty of 0.4753, the NOV15a protein disclosed here is similar to the EGF family, some members of which are released

extracellularly. Alternatively, a NOV15a polypeptide is located to the microbody (peroxisome) with a certainty of 0.3000, the mitochondrial inner membrane with a certainty of 0.1802, or the mitochondrial intermembrane space with a certainty of 0.1802. The SignalP indicates a likely cleavage site for a NOV15a peptide is between positions 31 and 32, *i.e.*, at the dash in the sequence GRG-AD.

Table 15B. Encoded NOV15a Protein Sequence (SEQ ID NO:44)

MPMGHSDRWSWRLRLALPLPVWLPAGGGRGADSPCLCSRPHVCAEQELTLVGRRQPCVQALSHTVPVWKAGCGW QAWCVGHERRTVYYMGYRQVYTTEARTVLRCCRGWMQOPDEEGCLSDVGEKANANGGCAGRCRDTVGGFYCRWPP PSHQLQGDGETCQDVDECRTHNGGCQHRVCNTPGSYLCECKPGFRLHTDSRTCAINSCALGNGGCQHHCVQLTIT RHRCQCRPGFQLQEDGRHCVRRSPCANRNGSCMHRCQVVRGLARCECHVGQYLAADGKACEDVDECAAGLAQCAH GCLNTQGSFKVCVCHAGYELGADGRQCYRIEMEIVNSCEANNGGCSHGCSHTSAGPLCTCPRGYELDTDQRTCIRC RRLCRQPVLQQVCTNNPGGYECGYAGYRLSADGCGCEDVDECASSRGGCEHHCTNLAGSFQCSCEAGYRLHEDR RGCSALEEPMVDLDGELPFVRLPHIAVLQDELPLQFQDDDVGADEEEAELRGEHTLTEKFVCLDDSFHDCSLT CDDCRNGGTCLLGLDGCDCPEGWTGLICNESCPDPTFGKNCSFSCSQNGGTCDSVTGACRCPPGVSGTNCEDGC PKGYYGKHCRKKNCANRGRCHRLYGACLCDPGLYGRFCHLACPPWAFGPGCSEECQCVQPHQTQSCDKRDGSCSC KAGFRGERCQAECEPGYFGPGCWQACTCPVGVACDSVSGECGKRCPAGFQGEDCGQECVPVGTGVCNCSSSCSCGG APCHGVTGQCRCPGRTGEDCEAGECEGLWGLGCQETCPACHNAARCDPETGACLCPLPGFVGSRCQDCEAGWYGP SCQTMCSANDGHCHQDTGHCSCAPGWTGFSCQACDTGHWGPDCSHPCNCSAGHGSCDAISGLCLCEAGYVGPR CEQSECPQGHFGPGCEQRCQCGHGAACDHVSGACTCPAGWRGTFCHEACPAGFFGLDCRSACNCTAGAACDAVNG SCLCPAGRRGPRCAESACPAHTYGHNCQACACFNGASCDPVHGQCHCAPGWMGPSCLQACPAGLYGDNCRHSCL CQNGGTCDPVSGHCACPEGWAGLACEVECLPRDVRAGCRHSGGCLNGLCDPHTGRCLCPAGWTGDKCQSPAACA KGTFGPHCEGRACRWGGPCHLATGACLCPPGWRGPHLSAACLRGWFGCAQRCSCPPGAACHHVTGACRCPPG FTGSGCEQACPPGSFGEDCAQMCQCPGENPACHPATGTCSAAGYHGPSCQQRCPGRYGPGEQLCGCLNNGGSC DAATGACRCPTGFLGTDCNLTCPQGRFGPNCTHVCGCGQAACDPVTGTCLCPGRAGVRCERGCPOQNRFGVGC HTCSCRNGGLCHASKRQLLLWPGLDGAALRAGLSPWALRSRLPSGVLLPQQQHV
--

SNP variants of NOV15a are disclosed in Example 2.

NOV15b

Alternatively, a NOV15 variant is NOV15b (alternatively referred to herein as CG56449-02), which includes the 7319 nucleotide sequence (SEQ ID NO:45) shown in Table 15C. An open reading frame for the mature protein was identified beginning with an ATG codon at nucleotides 1-3 and ending with a TGA codon at nucleotides 4195-4197. Putative untranslated regions, if any, downstream from the termination codon and upstream from the initiation codon are underlined. The start and stop codons are in bold letters.

105537425007

Table 15C. NOV15b Nucleotide Sequence (SEQ ID NO:45)

ATGCCCATGGGACATTCTGACAGGTGGTCTTGGCGTCTCCTGAGGCTGGCACTGCCACTCCCAGTCTGGTTGCCG
GCTGGGGGTGGCCGAGGCGCTGACTCTCCATGTCTCTGTTCCAGGCCCCACGTGTGTGCTGAGCAGGAGCTGACC
CTGGTGGGCGCCGCCAGCCGTGCGTGCAGGCCCTTAAGCCACACGGTGCCGGTGTGGAAGGCCGGCTGTGGGTGG
CAGGCGTGGTGCCTGGGTGATGAGCGGAGAACCGTCTACTACATGGGCTACAGGCAGGTGTATACCACGGAGGCC
CGGACCGTGTCTAGGTGCTGCCGAGGGTGGACGCAGCAGCCGACGAGGAGGGCTGCCTCTCGGCTGAATGCAGC
GCCAGCCTCTGTTTTTACGGTGGCCGTTGTGTGCCAGGCTCAGCCCAGCCGTGTCACTGTCCCCCGGCTTCCAG
GGACCCCGCTGTCAATGATGTGGACGAATGCCGAACCCACAACGGTGGCTGCCAGCACCCTGCGTGAACACC
CCAGGCTCCTACCTCTGTGAGTGCAAGCCCGGCTTCCGGCTCCACACTGACAGCAGGACCTGCCTGGCCATTAAC
TCCTGCGCCCTGGGCAATGGCGGCTGCCAGCACCACCTGTGTCCAGCTCACAATCACTCGGCATCGCTGCCAGTGC
CGGCCCCGGTTCCAGCTCCAGGAGGACGGCAGGCATTGTGTCCGTAGAAGCCCGTGTGCCAACAGGAACGGCAGC
TGCATGCACAGGTGCCAGTGGTCCGGGGCCTCGCCCGCTGTGAGTGCCACGTGGGCTATCAGCTAGCAGCGGAC
GGCAAGGCCTGTGAAGATGTGGACGAATGTGCCGCAGGGCTGGCCCACTGTGCCATGGCTGCCTCAACACCCAG
GGGTCTTTCAAGTGCGTGTGTACGCGGGCTATGAGCTGGGCGCCGATGGCCGGCAGTGCTACCGTATTGAGATG
GAAATCGTGAACAGCTGTGAGGCCAACAACGGCGGCTGCTCCCATGGCTGCAGCCACACAGTGCTGGGCCCCCTG
TGCACCTGTCCCCGCGGCTACGAGCTGGACACAGATCAGAGGACCTGCATCAGATGTGACGACTGTGCAGACAG
CCCGTGTGTGACAGGTGTGCACCAACAACCTGGCGGGTACGAGTGCGGCTGTACGCCGGCTACCGGCTCAGT
GCCGATGGCTGCGGCTGCGAGGATGTGGATGAGTGCGCCCTCCAGCCGTGGCGGCTGCGAGCACCACCTGCACCAAC
CTGGCCCGCTCTTCCAGTGTCTCGGAGGCGCGCTACCGGCTGCACGAGGACCGTAGGGGCTGCAGCGCCCTG
GAGGAGCGCATGGTGGACCTGGACGCGGAGCTGCCCTTTCGTGCGGCCCTGCCCCACATTGCCGTGCTCCAGGAC
GAGCTGCCGCAACTCTTCCAGGATGACGACGTGCGGGGCGGATGAGGAAGAGGCAGAGTTGCGGGGCGAACACACG
CTCACAGAGAAGTTTGTCTGCCTGGATGACTCCTTTGGCCATGACTGCAGCTTGACCTGTGATGACTGCAGGAAC
GGAGGGACCTGCCTCCTGGGCTGGATGGCTGTGATTTGCCCCGAGGGCTGGACTGGGCTCATCTGCAATGAGAGT
TGTCTCCGGACACCTTTGGGAAGAACTGCAGCTTCTCCTGCAGCTGTGAGAATGGTGGGACCTGCGACTCTGTC
ACGGGGGCTGCGCTGCCCGGCTGCCCGGCTGTGAGTGAACCTAAGTGTGAGGATGGCTGCCCAAGGGCTACTATGGC
AAGCACTGTGCAAGAAATGCAACTGTGCCAACCAGGGGCGGCTGCCACCGCCTCTACGGGGCCTGCCTCTGCGAC
CCAGGGCTCTACGGCCGCTTCTGCCACCTCGCCTGCCCGCGTGGGCTTTGGGCGGGGCTGCTCGGAGGAGTGC
CAGTGTGTGACGCCCCACACGCAGTCTGTGACAAGAGGGATGGCAGCTGCTCCTGCAAGGCTGGCTTCCGGGGC
GAGCGCTGTGAGGCAGAGTGTGAGCCGGGCTACTTTGGGCGGGGCTGCTGGCAGGCATGCACCTGCCAGTGGG
GTGGCCTGTGACTCCGTGAGCGGCGAGTGTGGGAAGCGGTGTCTGCTGGCTTCCAGGGAGAGGACTGTGGCCAA
GAGTGGCCCGTGGGGACCTTTGGCGTGAACCTGCTCAGCTCCTGCTCCTGTGGGGGGGCCCTGCCACGGGGT
ACGGGGCAGTGCCGCTGTGCCCGGGGAGGACTGGGAAGACTGTGAGGCAGGTGAGTGTGAGGGCTCTGGGG
CTGGGCTGCCAGGAGATCTGCCAGCATGCCATAACGCTGCTCGCTGCGACCTGAGACCGGAGCCTGCCTGTGTC
CTCCCTGGCTTTGTGCGCAGCCGCTGCCAGGACTGTGAGGCAGGCTGGTATGGTCCCAGCTGCCAGACAATGTGC
TCTTGTGCCAATGATGGGCACTGCCACCAAGACACGGGACACTGCAGCTGTGCCCCGGGTGGACCGGCTTTAGC
TGCCAGAGAGCCTGTGATACTGGGCACTGGGGACCTGACTGCAGCCACCCCTGCAACTGCAGCGCTGGCCACGGG
AGCTGTGATGCCATCAGCGCCTGTGTCTGTGTGAGGCTGGCTACGTGGGCGCGGCTGCGAGCAGTCAAGTGT
CCCCAGGGCCACTTTGGGCGCGGCTGTGAGCAGCGGTGCCAGTGTGAGCATGGAGCAGCCTGTGACCACGTGAGC
GGGGCCTGCACCTGCCCGGCGGCTGGAGGGGACCTTCTGCGAGCATGCCTGCCCGGCGGCTTCTTTGGATTG
GACTGTGCGAGTGCCTGCAACTGCACCGCCGGAGCTGCCTGTGATGCCGTGAATGGCTCCTGCCTCTGCCCCGCT
GGCCGCGGGGCCCCGCTGTGCGGAGAGTGCCTGCCAGCCACACCTACGGGCACAATTGCAGCCAGGCCTGT
GCCTGCTTTAACGGGGCTCCTGTGACCCTGTCCACGGGCACTGCCACTGTGCCCTGGCTGGATGGGGCCCTCC
TGCCTGCAGGCCTGCCCTGCCGCGCTGTACGGGCACTGTGCGGATTTCTGCCTCTGCCAGAACGGAGGGACC
TGTGACCCTGTCTCAGGCACTGTGCGTGCCAGAGGGCTGGGCGGCGCTGCGCTGTGAGGTAGAGTGCCTCCCC
CGGGACGTGAGAGCTGGCTGCCGGCACAGCGGCGTTGCCCTAACGGGGGCTGTGTGACCCGCACACGGGCGC
TGCTCTGCCAGCCGCTGGACTGGGGACAAGTGTGAGAGCCCTGCAGCCTGTGCCAAGGGCACATTGGGGCCT
CACTGTGAGGGGCGCTGTGCCTGCCGCTGGGGAGGCCCTGCCACCTTGCCACCGGGGCTGCCTCTGCCCTCCG
GGGTGGCGGGGCTCATCTTTCTGCAGCCTGCCTGCGGGGCTGGTTTGGAGAGGCTGTGCCAGCGCTGCAGC
TGCCCGCTGGCGCTGCCTGCCACACGTCACTGGGGCTGCCGCTGTCCCCCTGGCTTCACTGGCTCCGGCTGC
GAGCAGGCCTGCCACCGGCGAGCTTTGGGGAGGACTGTGCGCAGATGTGCCAGTGTCCGGTGAGAACCGGGC
TGCCACCTGCCACCGGACCTGCTCATGTGCTGCTGGCTACCACGGCCCCAGCTGCCAGCAACGATGTCCGCCC
GGGCGGTATGGGCCAGGCTGTGAACAGCTGTGTGGGTGTCTAACGGGGGCTCCTGTGATGCGGCCACGGGGGCT
TGCCGCTGCCCACTGGGTTCCTCGGGACGAGTGAACCTCACCTGTCCGAGGGCGGCTTCGGCCCCAACTGC
ACCCACGTGTGTGGGTGTGGGCAGGGGGCGGCTGCGACCTGTGACGGGCACCTGCCTCTGCCCCCGGGGAGA
GCCGGCGTCCGCTGTGAGCGAGGCTGCCCCAGAACCGGTTTGGCGTGGGCTGCGAGCACCTGCTCCTGCAGA

AATGGGGGCTGTGCCACGCCAGCAAGCGGCAGCTGCTCCTGTGGCCTGGGCTGGACGGGGCGGCACTGCGAGCT
GGCCTGTCCCCCTGGGCGCTACGGAGCCGCTGCCATCTGGAGTGCTCCTGCCACAACAACAGCACGTGTGAGCC
TGCCACGGGCACCTGCCGCTGCGGCCCCGGCTTCTATGGCCAGGCTGCGAGCACCCCTGTCCCCCTGGCTTCCA
CGGGGCTGGCTGCCAGGGGTGTGTGCTGGTGTCAACATGGAGCCCCCTGCGACCCCATCAGTGGCCGATGCCTCTG
CCCTGCGGGCTTCCACGGCCACTTCTGTGAGAGGGGTGTGAGCCAGGTTCAATTTGGAGAGGGCTGCCACCAGCG
CTGTGACTGTGACGGGGGGGACCCCTGTGACCCTGTACCCGCTCTCTGCCCTTTGCCACCAGGGCGCTCAGGAGC
CACCTGTAACCTGGATTGCAGAAGGGGCCAGTTTGGGCCAGCTGCACCCTGCACTGTGACTGCGGGGGTGGGGC
TGACTGCGACCCTGTCACTGGGCAGTGTCACTGTGTGGATGGCTACATGGGGCCACGTGCCGGGAAGGTGGGCC
CCTCCGGCTCCCCGAGAACCCTCCTTAGCCAGGGCTCAGCGGGCACACTGCCCGCTCCAGCAGACCCACATC
CCGGAGCGGTGGACCAGCGAGGCACTAGTAGAGGCACTCCCGTGGAGCCCGCTCTCCAGTCCAGCCAGAGGGG
ACCCTGGCCTTTGGTGACCACTGAGAAGGACACTTACGGGCCCAGAGCTCCTGGTACTGCCCTTCTTTGAGGG
CCGTGGAGGGCTGTGGACAGCCAGCAACCTGTGCTCTTGGAGGCTGGTGTGGCCTTGAGGAGGGAAGCCTCGC
ATGGCCGCTGGAAGAGAGGCGCTCCTGGCCTGGCTCTGCAGAACCAGGGGCACGCTCTGGGCTGGGCTGAGG
AAGTCCCGCTCTCCCGCGCTCTGAGTTGACTGAGGACAGGTGTGGGCGCCAGTGTGGGTGCAGGCGCAGGTG
CAGGCACAGGGCCACTGTCTCCAGGCAGGCTTTTGGTGTCTAGGCCCTGGGACTGGAAGTCGCCACGCCGTAT
TTATGTAAAGGTATTTATGGGCCACTGCACATGCCCGCTGCAGCCCTGGGATCAGCTGGAAGTCGCTGTCTATCT
CCTGCCCAATCCCCAGAAACCCTGATTAGGTCTGCAGGCTCCTGCGGGCTCACCAGGCTGCTGGCTCCGGTACC
ATGTAAACCTAGGAAGGTAAAGGAGCAGGCAACCTCCTCGTGGCCTGTGTGTTTGTGTGTACGTGGACTCTGT
GTGGGCTCCTCCCTGGGGCCCGCCAGCATAACGGTGCACCCAGGGACCTCCAGTGCACCCGGGGCCCTTTGCA
GGGGTGGGGTGGCCACACAAGTGAAGAAGTTGGGACTCATCTCAGTTCCCACTGCTATTGAGGAGAACGCTGGGG
CTGCATTATTACCGCTGAGACCCAGAGACTGGCTGTTCCAGAGAATGGCCAGGGGGAGGAGGGCTGGTGTGG
AGGGGCAACCTGGACTGAGGCCGAACCTCCTTGGGCTCACCCACCCACCCCTACCTGAGCATCAGCAGTGGGGG
GAGGGCAGCATCGCAGGGGCAGGGACTCCTGGGTGAGGACAGACCAGCCCTCCGAGCACCTGGCACTCATGGG
CTGAGGCTGACTTCTCCTGGAAGAAGGGCCAGAGTGAAGGAAGAGGCAGAGGGTAGAGGTGGTGGCTGGGGG
TCCTCTGCAGAGTGGGGTGGCCAATGGAGAGGGCTGCACTCACACCGCAACATAGGACTCTCTCTCCCTTAAGAA
GGCCCCCTTAGGGTCTGGGCTGCCGCCCCCATCACCTAAACCAGCCAAGGTAGCTGAGGCCCCAGGGCAGACA
ATTTACCAGCAGGANGAGGAGGAGTCCAGTGAGCTTGGTTGCTCACAGACAGCAAGGGAGCTGTACAGAGGAA
GCTGATGAATGGACCGCTGTGGGGAGACTTTAAAGTAGAACAGTGATAAGGGAGGGCAGGATGGTGGGGATGCAG
AAGCAGCAGCCAGAGAGAGACGGACTGGGGTGCAGACGGAGTGTGGAAAACGCATACCTTGAAATGAAGCATCCA
GCAGATGGGGTGAAGTGAATACAGCTCAGGAGATTCTCCAGGAATAGCAGGGAGGCGTAAAGAGAGACAACGTAC
AGAGATAGATGAATGGAATGGGTAAAGGGAGGTGTTTCACTCATCTTAAGTGAATGATCTCAGTCAGCCTGGAAATG
GTCATTGACATGAAGCAACGACGACCAAGACGTTCTCAGATCTAAAGGTGAATGATCTCAGTCAGCCTGGAAATG
CACAAGGTGGAAAAATAACATAAAAAAGCCATAAGACCTTGAAGAACATCAATGTCAAAGATAAATTCTAAAGTC
CCAGAGAAAAAAGAATGGGAATCAAATTGACCTCAGACTATACGTGAGAAACACGGAGAGCCAGAAAACCTGTGAT
GTTCCATCCTCAGAGTTTGAAGGAAATATTTGAAGGCTGAATTTTACATCCAGCTAAACTATCAAAGGCATGCAA
AGTCCATGTTATTCTTAGGCCCTTCAAGGCCTCGGCCATTTTCTACAGAAAAGCCTGATTTTAAATGCTCTTAG
AGACGTTCTCCAGCCAGAAGAGAAAGAAGCCAGGAGGGTGCTCTGAGATATTAGTCACCACAGTTCCCAAATGG
CCTAGGAATTCAGAGAGTCAGAATATCACCATTACTCCCCAATGGGAACCCCGACAGTCTCAGCATGGTGTGAG
GGTGTGGACGGGGGGCTGGCAGGTACCAATCACTCATCCGCTCAGTGAAGACACAGTGTTCAGCTACGGAAGC
CATAAGGCAGGCCGAGCTTCTGCCCATCCGGAGGAAATCTCAGCTATCCAACGGCGGTGAGGAGCAGAGGAAAT
AAAGCAGAATAACTAGAAAACACGCTCACAGATCCTAATGTTAACGGTTACAAATGACGACGGAAAAACAACTC
CTGACCATATATTATATAGTTTCAAGCAGCAAGAAGGAGGATATTGAACATTCTCAACACACATAATAAACGCTT
GAGATGATGATATGCTCATTACCCTGATTTGATCACTAGACATNCCATGTATCAAAACATCACTGTGTATCCGAT
GAATATCTACAATTATTGTCAATTAAAAACATCAATAAAAACAA

The NOV15b protein (SEQ ID NO:46) encoded by SEQ ID NO:45 is 1398 amino acid residues in length and is presented using the one-letter amino acid code in Table 15D. Although the SignalP, Psort and/or Hydropathy results indicate that NOV15b has a signal peptide and is likely to be localized in the mitochondrial matrix space with a certainty of 0.4753, the NOV15b protein disclosed here is similar to the EGF family, some members of which are released

extracellularly. Alternatively, a NOV15b polypeptide is located to the microbody (peroxisome) with a certainty of 0.3000, the mitochondrial inner membrane with a certainty of 0.1802, or the mitochondrial intermembrane space with a certainty of 0.1802. The SignalP indicates a likely cleavage site for a NOV15b peptide is between positions 31 and 32, *i.e.*, at the dash in the sequence GRG-AD.

Table 15D. Encoded NOV15b Protein Sequence (SEQ ID NO:46)

MPMGHSDRWSWRLRLALPLPVWLPAGGGRGADSPCLCSRPHVCAEQELTLVGRRQPCVQALSHTVPVWKAGCGW
QAWCVGHERRTVYYMGYRQVYTTEARTVLRCCRGTQOPDEEGCLSAECSASLCFHGGRCVPGSAQPCHCPPGFG
GPRCQYDVDECRTTHNGGCQHRCVNTPGSYLCECKPGFRLHTDSRTCLAINSCALGNGGCQHHCVQLTITRHRQC
RPGFQLQEDGRHCVRRSPCANRNGSCMHRQVVRGLARCECHVGYYLAADGKACEDVDECAAGLAQCAHGCLNTQ
GSFKVCCHAGYELGADGRQCYRIEMEIVNSCEANNGGCSHGCSHTSAGPLCTCPRGYELDTDQRTCIRCRRLCRQ
PVLQQVCTNNPGGYECGQYAGYRLSADGCGCEDVDECASSRGGCEHHCTNLGSGFQCSCEAGYRLHEDRRGCSAL
EPMVDLDGELPFVVRPLPHIAVLQDELPLQFQDDVGADEEEAELRGEHTLTEKFVCLDDSFQHDGSLTCDDCRN
GGTCLLGLDGCDCPEGWTGLICNESCPDPTFGKNCFSFSCQNGGTCDSVTGACRCPPGVSGTNCEDGCPKGYG
KHCRKKNCANRGRCHRLYGACLCDPGLYGRFCHLACPPWAFGPGCSEECQCVQPHQSCDKRDGSCSKAGFRG
ERCQAECEPGYFGPGCWQACTCPVGVACDSVSGECGKRCPPAGFQGEDCGQECPPVGTGVCNCSGCGAPCHGV
TGQCRCPGRTGEDCEAGECEGLWGLGCQEICPACHNAARCDPETGACLCLPGFVGSRCQDCEAGWYGPSCQTM
SCANDGHCHQDTGHCSCAPGWTGFSQACRACDTGHWGPDCSHPCNCSAGHGSCDAISGLCLCEAGYVGPCEQSEC
PQGHFGPGCEQRCQCGHGAACDHVSGACTCPAGWRGTFCHEACPAFFGLDCRSACNCTAGAACDAVNGSCLCPA
GRRGPRCAESACPAHTYGHNCSSQACACFNGASCDPVHGQCHCAPGWMGPSCLQACPAAGLYGDNCRHSCLCQNGGT
CDPVSGHCACPEGWAGLACEVECLPRDVRAGCRHSGGCLNGLCDPHTGRCLCPAGWTGDKQSPAACAKGTFGP
HCEGRACACRWGGPCHLATGACLCPGWRGPHLSAACLRGWFEACAQRCSPPGAACHHVTGACRCPPGFTGSGC
EQACPPGSFGEDCAQMCQCPGENPACHPATGTCSAAGYHGPPSCQQRCPGRYGPGEQLCGCLNNGGSCDAATGA
CRCPTGFLGTDCNLTCPQGRFGPNCTHVCGCGQAACDPVTGTCLCPPGRAGVRCERGCPPQNRFGVGCEHTCSCR
NGGLCHASKRQLLLWPLDGAALRAGLSPWALRSRLPSGVLLPQQQHV

NOV15c

Alternatively, a NOV15 variant is NOV15c (alternatively referred to herein as CG56449-03), which includes the 4733 nucleotide sequence (SEQ ID NO:47) shown in Table 15E. An open reading frame for the mature protein was identified beginning with an ATG codon at nucleotides 1-3 and ending with a TAG codon at nucleotides 4351-4353. Putative untranslated regions, if any, downstream from the termination codon and upstream from the initiation codon are underlined. The start and stop codons are in bold letters.

Table 15E. NOV15c Nucleotide Sequence (SEQ ID NO:47)

ATGCCCATGGGACATTCTGACAGGTGGTCTTGGCGTCTCCTGAGGCTGGCACTGCCACTCCCAGTCTGGTTGCCG
GCTGGGGGTGGCCGAGGCGCTGACTCTCCATGTCTCTGTTCAGGCCCCACGTGTGTGCTGAGCAGGAGCTGACC
CTGGTGGGCGCCGCCAGCCGTGCGTGACGGCCTTAAGCCACACGGTGCCGGTGTGAAGGCCGGCTGTGGGTGG
CAGGCGTGGTGCCTGGGTGATGAGCGGAGAACCGTCTACTACATGGGCTACAGGCAGGTGTATACACGGAGGCC
CGGACCGTGCTCAGGTGCTGCCGAGGTGGACGCAGCAGCCCCGACGAGGAGGGCTGCCTCTCGGCTGAATGCAGC

GCCAGCCTCTGTTTTACGGTGGCCGTTGTGTGCCAGGCTCAGCCAGCCGTGTCACTGTCCCCCGGCTTCCAG
GGACCCCGCTGTCTAGTATGATGTGGACGAATGCCGAACCCACAACGGTGGCTGCCAGCACCAGGTGCGTGAACACC
CCAGGCTCCTACCTCTGTGAGTGAAGCCCGGCTTCCGGCTCCACACTGACAGCAGGACCTGCCTGGCCATTAAC
TCCTGCGCCCTGGGCAATGGCGGCTGCCAGCACCCTGTGTCCAGCTCACAATCACTCGGCATCGCTGCCAGTGC
CGGCCCGGTTCCAGCTCCAGGAGGACGGCAGGCATTGTGTCCGTAGAAGCCCGTGTGCCAACAGGAACGGCAGC
TGCATGCACAGGTGCCAGGTGGTCCGGGGCTCGCCCGCTGTGAGTGCCACGTGGGCTATCAGCTAGCAGCGGAC
GGCAAGGCCTGTGAAGATGTGGACGAATGTGCCGAGGGCTGGCCAGTGTGCCCATGGCTGCCCTAACACCCAG
GGGTCTTTCAAGTGCCTGTGTACGCGGGCTATGAGCTGGGCGCCGATGGCCGGCAGTGTACCGTATTGAGATG
GAAATCGTGAACAGCTGTGAGGCCAACACGGCGGCTGTCTCCATGGCTGCAGCCACACAGTGTGGGCCCTTG
TGCACCTGTCCCCGCGGTACGAGCTGGACACAGATCAGAGGACCTGCATCAGATGTGACGACTGTGCAGACAG
CCCGTGTGTGCAGCAGGTGTGCACCAACAACCCCTGGCGGGTACGAGTGGCGGTGCTACGCCGGCTACCGGCTCAGT
GCCGATGGCTGCGGCTGCGAGGATGTGGATGAGTGCGCCCTCCAGCCGTGGCGGTGCGAGCACCCTGCACCAAC
CTGGCCGGCTCCTTCCAGTGTCTTGCAGGCGGGCTACCGGCTGCACGAGGACCGTAGGGGCTGCAGCGCCCTG
GAGGAGCCGATGGTGGACCTGGACGGCGAGCTGCCCTTTCGTGCGGCCCTGCCCCACATTGCCGTGTCCAGGAC
GAGCTGCCGCAACTCTTCCAGGATGACGACGTGCGGGCCGATGAGGAAGAGGCAGAGTTGCGGGGCGAACACAGC
CTCACAGAGAAGTTTGTCTGCCTGGATGACTCCTTTGGCCATGACTGCAGCTTGACCTGTGATGACTGCAGAAC
GGAGGGACCTGCCCTCCCTGGGCTGGATGGCTGTGATTGCCCGAGGGCTGGACTGGGCTCATCTGCATGAGAGT
TGTCTCCGGACACCTTTGGGAAGAAGTGCAGCTTCTCCTGCAGCTGTGAGAATGGTGGGACCTGCGACTCTGTG
ACGGGGGCTGCCGCTGCCCGGCTGCTAGTGGAACTAAGTGTGAGGATGGCTGCCCAAGGGCTACTATGGC
AAGCACTGTGCAAGAAATGCAACTGTGCCAACCGGGGCCGTGCCACCGCCTCTACGGGGCTGCCCTGTGCGAC
CCAGGGCTCTACGGCCGCTTCTGCCACCTCGCTGCCCGCGTGGGCTTTGGGCCGGGCTGCTCGGAGGAGTGC
CAGTGTGTGCAGCCCCACACGAGTCTGTGACAAGAGGATGGCAGCTGCTCCTGCAAGGCTGGCTTCCGGGGC
GAGCGCTGTGAGCAGAGTGTGAGCTGGGCTACTTTGGGCCGGGCTGCTGGCAGGCATGCACCTGCCAGTGGG
GTGGCCTGTGACTCCGTGAGCGGCGAGTGTGGGAAGCGGTGTCTGCTGGCTTCCAGGGAGAGGACTGTGGCCAA
GAGTGGCCCGTGGGGACGTTTGGCGTGAAGTGTGCGAGCTCCTGCTCCTGTGGGGGGGCCCCCTGCCACGGGGT
ACGGGGCAGTGGCGGTGCCACCGGGGAGGACTGGGGAAGACTGTGAGGCAGATTGTCCCAGGGGCCGTGGGG
CTGGGCTGCCAGGAGATCTGCCAGCATGCCAGCAGCTGCCCGCTGCGACCCCTGAGACCGGAGCCTGCCTGTGC
CTCCCTGGCTTCGTGCGCAGCCGCTGCCAGGACGTGTGCCAGCAGGCTGGTATGTTCCAGCTGCCAGACAAG
TGCTCTTTGTGCAATGATGGGCACTGCCACCCAGCCAGGACACTGCAGCTGTGCCCGGGTGGACCGGCTTT
AGCTGCCAGAGAGCCCTGTGATACTGGGCACTGGGGACCTGACTGCAGCCACCCCTGCAACTGCAGCCTGGCCAC
GGGAGCTGTGATGCCATCAGCGGCTGTGTCTGTGTGAGGCTGGCTACGTGGGCCCGCGGTGCGAGCAGCAGTGT
CCCCAGGGCCACTTTGGGCCCGGCTGTGAGCAGCTGTGCCAGTGTGAGCATGGAGCAGCCTGTGACCACGTGAGC
GGGGCTGCACCTGCCCGGCCGGCTGGAGGGGACCTTCTGCGAGCATGCCTGCCCGGCCGGCTTCTTTGGATTG
GACTGTCTGTAGTGCCTGCAACTGCACCGCCGGAGCTGCCGTGTGATGCCGTGAATGGCTCCTGCCTCTGCCCGCT
GGCCGCCGGGGCCCCCGCTGTGCCGAGACCTGCCCTGCCGGCCTGTACGGCGACAAGTGTGCGCATTCCTGCCTC
TGCCAGAACGGAGGGACCTGTGACCCTGTCTCAGGCCACTGTGCGTGGCCAGAGGGCTGGGCCGGCTGGCCTGT
GAGAAGGAGTGGCCCCCGGGACGTCAGAGCTGGCTGCCGGCACAGCGGTGGTTGCCCTAACGGGGGCTGTGT
GACCCGCACACGGGCCGCTGCCTCTGCCAGCCGGCTGGGCTGGGGACAAGTGTGAGAGCCCTGCCTGCGGGG
TGGTTTGGAGAGGCTGTGCCAGCACTGCAGCTGCCCGCTGGCGCTGCCTGCCACCAGTCACTGGGGCCTGC
CGCTGTCCCCCTGGCTTCACTGGCTCCGGCTGCGAGCAGGATGTCCGCCCGGGCGGTATGGGCCAGGCTGTGAA
CAGCTGTGTGGGTGTCTCAACGGGGCTCCTGTGATGCGGCCAGGGGGCTGCCGCTGCCCACTGGGTTCTCTC
GGGACGGACTGCAACCTCACTGTCTCCGAGGGCGCTTCCGGCCCCAAGTGCACCCACGTGTGTGGGTGTGGCAG
GGGGCGGCTTGCAGCCCTGTGACCGGCACCTGCCCTCTGCCCGGGGAGAGCCGGCGTCCGCTGTGAGCGAGGC
TGCCCCCAGAACCGGTTTGGCGTGGGCTGCGAGCACACCTGCTCCTGCAGAAATGGGGGCTGTGCCACGCCAGC
AACGGCAGCTGCTCCTGTGGCCTGGGCTGGACGGGGCGGCACTGCGAGCTGGCCTGTCCCCCTGGGCGCTACGGA
GCCGCTGCCATCTGGAGTGTCTTGCACAAACAACAGCAGGGTGAGCCTGCCACGGGCACCTGCCGCTGCGGC
CCCCGCTTCTATGGCCAGGCTGCGAGCACCCCTGTCCCCCTGGCTTCCACGGGGCTGGCTGCCAGGGGTGTGTG
TGGTGTCAACATGGAGCCCCCTGCGACCCCATCAGTGGCCGATGCCCTGTGCCCTGCCGGCTTCCACGGCCACTTC
TGTGAGAGGGGGTGTGAGCCAGGTTCAATTGGAGAGGGTGCCACCAGCGCTGTGACTGTGACGGGGGGGACCC
TGTGACCTGTACCCGCTCTGTGCCCTTTGCCACCAGGGCGCTCAGGAGCCACCTGTAACCTGGATTGCAGAAGG
GGCCAGTTTGGGCCAGCTGCACCTGCAGTGTGACTGCGGGGGTGGGGCTGACTGCGACCCCTGTGAGTGGGAG
TGTCACTGTGTGGATGGCTACATGGGGCCACGTGCCGGGAAGGTGGGGCCCTCCGGCTCCCCGAGAACCGTCC
TTAGCCAGGGCTCAGCGGCGACACTGCCCGCTCCAGCAGACCCACATCCCGAGCGGTGGACCAGCGAGGCAC
TAGTAGAGGAGTCCCGTGGAGCCCGCTCTCCAGTCCAGCCAGAGGGGACCTGGCCTTTGGTGACCACTGAG
AAGGACACTTACGGGGCCAGAGCTCCTGGTACTGCCCTTCTTTGAGGGCCGTGGAGGGCTGTGGACAGCCAG
CAACCTGTGCTCTTGGAGGCTGGTGTGGCCTTGAGGAGGGAAGCCTCGCATGGCCGCTGGAAAGAGAGGCGCTC
CTGGCCTGGCTCTGCAGAACCCAGGGCAGCTCTGGGCTGGGCTGAGGAAGTCCCGCTCTCCCGCGGCTCTG

AGTTGGACTGAGGACAGGTGTGGGCGCCAGTGTGGGTGCAGGCGCAGGTGCAGGCACAGGGCCACTGTCCTCCAG
GCAGGCTT

The NOV15c protein (SEQ ID NO:48) encoded by SEQ ID NO:47 is 1450 amino acid residues in length and is presented using the one-letter amino acid code in Table 15F. Although the SignalP, Psort and/or Hydropathy results indicate that NOV15c has a signal peptide and is likely to be localized in the mitochondrial matrix space with a certainty of 0.4753, the NOV15c protein disclosed here is similar to the EGF family, some members of which are released extracellularly. Alternatively, a NOV15c polypeptide is located to the cytoplasm with a certainty of 0.4500, the mitochondrial inner membrane with a certainty of 0.1802, or the mitochondrial intermembrane space with a certainty of 0.1802. The SignalP indicates a likely cleavage site for a NOV15c peptide is between positions 31 and 32, *i.e.*, at the dash in the sequence GRG-AD.

Table 15F. Encoded NOV15c Protein Sequence (SEQ ID NO:48)

MPMGHSDRWSWRLRLALPLPVWLPAGGGRGADSPCLCSRPHVCAEQELTLVGRRQPCVQALSHTVPVWKAGCGW
QAWCVGHERRTVYYMGYRQVYTTEARTVLRCRGTQPPDEEGCLSAECSASLCFHGGRCVPGSAQPCPCPGFQ
GPRCQYDVDECRTHNGGCQHRVNTPGSYLCECKPGFRLHTDSRTCLAINSCALGNGGCQHHCVQLTITRHRQC
RPGFQLQEDGRHCVRRSPCANRNGSCMHRCQVVRGLARCECHVGYLADGKACEDVDECAAGLAQCAHGCLNTQ
GSFKCVCHAGYELGADGRQCYRIEMEIVNSCEANNGGCSHGCSHTSAGPLCTCPRGYELDTDQRTCIRCRRLCRQ
PVLQQVCTNNPGGYECGYAGYRLSADGCGCEDVDECASSRGGCEHHCTNLGSGFQCSCEAGYRLHEDRRGCSAL
EPPMVDLDGELPFVRPLPHIAVLQDELPLQFQDDVGADEEEAEELRGEHTLTEKFVCLDDSFHDCSLTCDDCRN
GGTCLLGLDGCDCPEGWTGLICNESCPPDTFGKNCSFSCSCQNGGTCDSVTGACRCPPGVSGTNCEDGCPKGYG
KHCRKKNCANRGRCHRLYGACLCDPGLYGRFCHLACPPWAFPGCSEECQCVQPHQTQSCDKRDGSCSCKAGFRG
ERCQAECELGYFGPGCWQACTCPVGVACDSVSGECCGRKCPAGFQGEDCGQECVGTFTGVNCSSSSCGGAPCHGV
TGQCRCPPGRTGEDCEADCPEGRWGLGCQEICPACQHAARCDPETGACLCLPGFVGSRCQDVC PAGWYGPSCQTR
CSCANDGHCHPATGHCSAPGWTGFSCQACDTHGWGPDSCSHPCNCSAGHGS CDAISGLCLCEAGYVGP RCEQQC
PQGHFGPGCEQLCQCQHGAAADHVS GACTCPAGWRGTFCHEACPA GFFGLDCRSACNCTAGAACDAVNGSCLCPA
GRRGPRCAETCPAGLYGDNCRHSCLCQNGGTCDPVSGHCACPEGWAGLACEKECPPRDV RAGCRHSGGCLNGGLC
DPHTGRCLCPAGWAGDKCQSPCLRGWFG EACAQHCS CPPGAACHVVTGACRCP PGFTGSGCEQGCPPGRYGP GCE
QLCGCLNGGSCDAATGACRCPTGFLGTD CNLTCQGRFGPNCTHVC GCGQGAACDPVTGTCLCPPGRAGVRCERG
CPQNRFGVGC EHTCSCRNGGLCHASNGSCSGLGWTGRHCELACPPGRYGAACHLECSCHNNSTGEPATGTCTCRG
PGFYGQACEHPCPPGFHAGCQGLWCQHGAPCDPISGRCLCPAGFHGHFCERGCEPGSFEGEGCHQRCDCDGGAP
CDPVTGLCLCPPGRSGATCNLDCRRGQFGPSCTLHDCGGGADCDPVSGQCHCVDGYMGPTCREGGPLRLPENPS
LAQGSAGTLPASSRPTSRSGGPARH

NOV15d

Alternatively, a NOV15 variant is NOV15d (alternatively referred to herein as CG56449-04), which includes the 877 nucleotide sequence (SEQ ID NO:49) shown in Table 15G. An open reading frame for the mature protein was identified beginning with an ATG codon at nucleotides 25-27 and ending with a TAG codon at nucleotides 535-537. Putative untranslated

regions, if any, downstream from the termination codon and upstream from the initiation codon are underlined. The start and stop codons are in bold letters.

Table 15G. NOV15d Nucleotide Sequence (SEQ ID NO:49)

CCGAGCTGCCTGTGATGCCGTGA**AT**GGCTCCTGCCTCTGCCCCGCTGGCCGCCGGGGCCCCCGCTGTGCCGAGA
CCTGCCCTGCCGGCCTGTACGGCGACA**ACT**GTGGCATTCCTGCCTCTGCCAGAACGGAGGGACCTGTGACCCTG
TCTCAGGCCTGCGAGCACCCTGTCCCCCTGGCTTCCACGGGGCTGGCCGCCAGGGGTGTGCTGGTGTCAACAT
GGAGCCCCCTGCGACCCCATCAGTGGCCGATGCCTCTGCCCTGCCGGCTTCCACGGCCACTTCTGTGAGAGGGAT
TGCAGAAGGGGCCAGTTTGGGCCAGCTGCACCCTGCACTGTGACTGCGGGGTGGGGCTGACTGCGACCCTGTC
AGTGGGCAGTGTCACTGTGTGGATGGCTACATGGGGCCCACGTGCCGGGAAGGTGGGCCCCCTCCGGCTCCCCGAG
AACCCGTCTTAGCCCAGGGCTCAGCGGGCACACTGCCCGCCTCCAGCAGACCCACATCCCGGAGCGGTGGACCA
GCGAGGCAC**TAG**TAGAGGCAGTCCCGTGGAGCCCGCCTCTCCAGTCCAGCCAGAGGGGACCCTGGCCTTTGGTG
ACCACTGAGAAGGACACTTCCAGGGCCCAGAGCTCCTGGTACTGCCCTTCCTTTGAGGGCCGTGGAGGGCTGTGG
ACAGCCCAGCAACCTGTGCTCTTGGAGGCTGGTGTGGCCTTGAGGAGGAAGCCTCGCATGGCCGCTGGAAGAG
AGGCGTCTCCTGGCCTGGCTCTGCAGAACCCAGGGGCACGCTCTGGGCCTGGGCTGAGGAAGTCCCGCTCTCCCG
CGCTCTGAGTTGGACTGAGGACAGGTGTGGGCGCCAGTGTGGGTGCAGGCG

The NOV15d protein (SEQ ID NO:50) encoded by SEQ ID NO:49 is 170 amino acid residues in length and is presented using the one-letter amino acid code in Table 15H. The SignalP, Psort and/or Hydropathy results indicate that NOV15d has no known signal peptide and is likely to be localized in the cytoplasm with a certainty of 0.6500. Alternatively, a NOV15d polypeptide is located to the lysosome (lumen) with a certainty of 0.1853, or the mitochondrial matrix space with a certainty of 0.1000.

Table 15H. Encoded NOV15d Protein Sequence (SEQ ID NO:50)

MAPASAPLAAGAPAVPRPALPACTATTVGIPASARTEGPVTLSQLACEHPCPPGFHAGRQGLCWCQHGA**PCD**PI
GRCLCPAGFHGHFCERDCRRGQFGP**S**CTLHCDCGGGADCDPVSGQCHCVDGYMGPTCREGGPLRLPENPSLAQGS
AGTL**P**ASSRPTSRSGGP**A**RH

NOV15e

Alternatively, a NOV15 variant is NOV15e (alternatively referred to herein as CG56449-06), which includes the 7334 nucleotide sequence (SEQ ID NO:51) shown in Table 15I. An open reading frame for the mature protein was identified beginning with an ATG codon at nucleotides 1-3 and ending with a TGA codon at nucleotides 4210-4212. Putative untranslated regions, if any, downstream from the termination codon and upstream from the initiation codon are underlined. The start and stop codons are in bold letters.

Table 15I. NOV15e Nucleotide Sequence (SEQ ID NO:51)

ATGCCCATGGGACATTCTGACAGGTGGTCTTGGCGTCTCCTGAGGCTGGCACTGCCACTCCAGTCTGGTTGCCG
GCTGGGGGTGGCCGAGGCGCTGACTCTCCATGTCTCTGTTCCAGGCCCCACGTGTGTGCTGAGCAGGAGCTGACC
CTGGTGGGCGCCGCCAGCCGTGCGTGCAGGCCTTAAGCCACACGGTGCCGGTGTGGAAGGCCGGCTGTGGGTGG
CAGGCGTGGTGCCTGGGTGATGAGCGGAGGACCGTCTACTACATGGGCTACAGGCAGGTGTATACCACGGAGGCC
CGGACCGTGTCTAGGTGCTGCCGAGGGTGGATGCAGCAGCCCCGACGAGGAGGGCTGCCTCTCGGATGTGGGTGAG
TGTGCCAACGCCAACGGGGGCTGTGCGGGTGGTGCCGGGACACCGTGGGGGGCTTCTACTGCCGCTGGCCCCC
CCAGCCACCAGCTGCAGGGTGTGGCGAGACTTGCCAAGATGTGGACGAATGCCGAACCCACAACGGTGGCTGC
CAGCACCAGTGCCTGAACACCCAGGCTCCTACCTCTGTGAGTGAAGCCCGCTTCCGGCTCCCACTGACAGC
AGGACCTGCGCCATTAACCTCTGCGCCCTGGGCAATGGCGGCTGCCAGCACCCTGTGTCCAGCTCACAATCACT
CGGCATCGCTGCCAGTGGCGGGCCGGGTTCCAGCTCCAGGAGGACGGCAGGCATTGTGTCCGTAGAAGCCCGTGT
GCCAACAGGAACGGCAGCTGCATGCACAGGTGCCAGGTGGTCCGGGGCCTCGCCCGCTGTGAGTGCCACGTGGGC
TATCAGCTAGCAGCGGACGGCAAGGCCTGTGAAGATGTGGACGAATGTGCCGAGGGCTGGCCAGTGTGCCCAT
GGCTGCCTCAACACCCAGGGGTCTTCAAGTGCCTGTGTACGCGGGCTATGAGCTGGGCGCCGATGGCCGGCAG
TGCTACCGTATTGAGATGGAAATCGTGAACAGCTGTGAGGCCAACACGGCGGCTGTCTCCATGGCTGCAGCCAC
ACAGTGTCTGGGCCCCCTGTGCACCTGTCCCCGCGGCTACGAGCTGGACACAGATCAGAGGACCTGCATCAGATGT
CGACGACTGTGCAGACAGCCCGTGTGCAGCAGGTGTGCACCAACACCTGGCGGGTACGAGTGCCGGCTGTCTAC
GCCGGCTACCGGCTCAGTGCCGATGGCTGCGGCTGCGAGGATGTGGATGAGTGCCTCCAGCCGTGGCGGCTGC
GAGCACCCTGCACCAACCTGGCCGGCTCCTTCCAGTGTCTGCGAGGCGGCTACCGGCTGCACGAGGACCGT
AGGGGTGTCAGCGCCCTGGAGGAGCCGATGGTGGACCTGGACGGCGAGCTGCCTTTCTGCGGGCCCCCTGCCCCAC
ATTGCCGTGTCTCAGGACGAGCTGCCGCAACTCTTCCAGGATGACGACGTGGGGCCGATGAGGAAGAGGCAGAG
TTGCGGGGCGAACACACGCTCAGAGAGAAGTTTGTCTGCTGGATGACTCCTTTGGCCATGACTGCAGCTTGACC
TGTGATGACTGCAGGAACGGAGGGACCTGCCTCCTGGGCTGGATGGCTGTGATTGCCCGAGGGCTGGACTGGG
CTCATCTGCAATGAGAGTTGTCTCCTCCGACACCTTTGGGAAGAACTGCAGCTTCTCCTGCAGCTGTGAGAAATGGT
GGGACCTGCGACTCTGTACGCGGGGCTGCCGCTGCCCCCGGGTGTGAGTGAAGTAACTGTGAGGATGGCTGC
CCCAAGGGCTACTATGGCAAGCACTGTGCAAGAAATGCAACTGTGCCAACCGGGGCGGCTGCCACCGCCTCTAC
GGGGCTGCTCTGCGACCCAGGGCTCTACGGCCGCTTCTGCCACCTCGCCTGCCCGCCGTGGGCCCTTTGGGCCG
GGCTGCTCGGAGGAGTGCCAGTGTGTGCAGCCCCACACGAGTCTGTGACAAGAGGGATGGCAGCTGCTCCTGC
AAGGCTGGCTTCCGGGGCGAGCCTGTGAGGCAGAGTGTGAGCCGGGCTACTTTGGGCCGGGGTGTGGCAGGCA
TGCACCTGCCAGTGGGCGTGGCCTGTGACTCCGTGAGCGGCGAGTGTGGGAAGCGGTGTCTGTGGCTTCCAG
GGAGAGGACTGTGGCCAAGAGTGGCCGGTGGGGACCTTTGGCGTGAAGTGTCTGAGCTCCTGTCTGTGGGGG
GCCCCCTGCCACGGGGTACGGGGCAGTGCCGGTGTCCGCCGGGAGGACTGGGAAGACTGTGAGGCAGGTGAG
TGTGAGGGCTCTGGGGGCTGGGTGCCAGGAGATCTGCCAGCATGCCATAACGCTGCTCGTGCAGACCTGAG
ACCGGAGCCTGCTGTGCTCCTGGCTTTGTGCGGACCGCTGCCACCAAGACACGGGACACTGCAGCTGTGCCCC
AGCTGCCAGACAATGTGCTCTTGTGCCAATGATGGGCACTGCCACCAAGACACGGGACACTGCAGCTGTGCCCC
GGGTGGACCGGCTTTAGCTGCCAGAGAGCCTGTGATACTGGGCACTGGGGACCTGACTGCAGCCACCCCTGCAAC
TGCAGCGTGGCCACGGGAGCTGTGATGCCATCAGCGGCTGTGTCTGTGTGAGGCTGGCTACGTGGGCCCCGG
TGCGAGCAGTCAGAGTGTCCCCAGGGCCACTTTGGGCCCCGGTGTGAGCAGCGGTGCCAGTGTGAGCATGGAGCA
GCCTGTGACCACGTGAGCGGGGCTGCACCTGCCCGGCCGCTGGAGGGGACCTTCTGCGAGCATGCCTGCCCG
GCCGGCTTCTTTGGATTGGACTGTGCGAGTGCCTGCAACTGCACCGCCGGAGCTGCCTGTGATGCCGTGAATGGC
TCCTGCCTCTGCCCCGCTGGCCGCCGGGGCCCCCGCTGTGCCGAGACCTGCCAGCCACACCTACGGGCACAAT
TGCAGCCAGGCTGTGCTGCTTTAACGGGGCTCCTGTGACCTGTCCACGGGCAGTGCCACTGTGCCCTTGGC
TGGATGGGGCCCTCCTGCCTGCAGGCCTGCCCTGCCCGCTGTACGGCGACAAGTGTGGGCATTCTGTGCTGTG
CAGAACGGAGGGACCTGTGACCTGTCTCAGGCCACTGTGCGTGCCAGAGGGCTGGGCGGGCTGGCCTGTGAG
GTAGAGTGCCTCCCCGGGACGTGAGAGTGGCTGCCGGCACAGCGCGGTTGCCTCAACGGGGGCTGTGTGAC
CCGCACACGGGCGCTGCCTCTGCCAGCCGGCTGGACTGGGGACAAGTGTGAGAGCCCTGCAGCCTGTGCCAAG
GGCATTTCGGGCTCACTGTGAGGGGCGCTGTGCTGCCGGTGGGGAGGCCCCCTGCCACCTTGCCACGGGGGCT
TGCCCTGTGCCCTCCGGGGTGGCGGGGGCTCATCTTTCTGCAGCCTGCCTGCGGGCTGGTTTGGAGAGGCTGT
GCCCAGCGCTGCAGCTGCCCGCTGGCGCTGCCCTGCCACCACGTCACTGGGGCTGCCGCTGTGCCAGTGTCCC
ACTGGCTCCGGCTGCGAGCAGGCTGCCACCCGGCAGCTTTGGGGAGGACTGTGCGCAGATGTGCCAGTGTCCC
GGTGAGAACCCGGCTGCCACCTGCCACCGGACCTGCTCATGTGCTGGCTACCACGGCCCCAGCTGCCAG
CAACGATGTCCGCCGGGCGTATGGGCCAGGCTGTGAACAGCTGTGTGGGTGTCTCAACGGGGGCTCCTGTGAT
GCGGCCACGGGGGCTGCCGCTGCCCACTGGGTTCTCGGGACGAGTGAACCTCACCTGTCCGAGGGCCGC
TTCGGCCCCAACTGCACCCACGTGTGTGGGTGTGGGCAGGGGGCGGCTGCGACCTGTGACCGGCACCTGCCTC
TGCCCCCGGGGAGAGCCGGCGTCCGCTGTGAGCGAGGCTGCCCCAGAACCGGTTTGGCGTGGGCTGCGAGCAC

ACCTGCTCCTGCAGAAATGGGGGCTGTGCCACGCCAGCAAGCGGCAGCTGCTCCTGTGGCCTGGGCTGGACGGG
GCGGCACTGCGAGCTGGCCTGTCCCCCTGGGGCGTACGGAGCCGCTGCCATCTGGAGTGCTCCTGCCACAACAA
CAGCACGTGT**GAG**CCTGCCACGGGGCACCTGCCGCTGCGGCCCCGGCTTCTATGGCCAGGCCTGCGAGCACCCCTG
TCCCCCTGGCTTCCACGGGGCTGGCTGCCAGGGGTTGTGTGGTGTCAACATGGAGCCCCCTGCGACCCCATCAG
TGGCCGATGCCTTGCCCTGCCGGCTTCCACGGCCACTTCTGTGAGAGGGGTGTGAGCCAGGTTTATTGGAGA
GGGCTGCCACCAGCGCTGTGACTGTGACGGGGGGGACCCCTGTGACCCTGTCACCGGTCTCTGCCTTTGCCACC
AGGGCGCTCAGGAGCCACCTGTAACCTGGATTGCAGAAGGGGCCAGTTTGGGCCAGCTGCACCCTGCACTGTGA
CTGCGGGGGTGGGGCTGACTGCGACCCCTGTGAGTGGGCAGTGTCACTGTGTGGATGGCTACATGGGGCCACGTG
CCGGGAAGGTGGGGCCCTCCGGCTCCCCGAGAACCCGTCTTAGCCAGGGCTCAGCGGGCACACTGCCCGCCTC
CAGCAGACCCACATCCCGGAGCGGTGGACCAGCGAGGCACTAGTAGAGGAGTCCCGTGGAGCCCGCCTCTCCAG
TCCCAGCCAGAGGGGACCCTGGCCTTTGGTGACCACTGAGAAGGACACTTACGGGGCCAGAGCTCCTGGTACTG
CCCTTCCTTTGAGGGCCGTGGAGGGCTGTGGACAGCCCAACCTGTGCTCTTGGAGGCTGGTGTGGCCTTGA
GGAGGGAAGCCTCGCATGGCCGCTGGAAGAGAGGCGCCTCCTGGCCTGGCTCTGCAGAACCCAGGGGCACGCTCT
GGCCCTGGGCTGAGGAAGTCCCGCTCTCCCCGCGGCTCTGAGTTGGACTGAGGACAGGTGTGGGCGCCAGTGTGG
GTGCAGGCGCAGGTGCAGGCACAGGGCCACTGTCTCCAGGCAGGCTTTTTGGTGCTAGGCCCTGGGACTGGAAG
TCGCCCAGCCCGTATTTATGTAAAGGTATTTATGGGCCACTGCACATGCCCGCTGCAGCCCTGGGATCAGCTGGA
AGCTGCCTGTCTCTCTGCCCAATCCCCAGAAACCCTGATTAGGTCTGCAGGCTCCTGCGGGCTCACCAGGCT
GCTGGCTCCGGTACCATGTAAACCTAGGAAGGTAAAGGAGCAGGCAACCTCCTCGTGGCCTGTGTGTTTGCTGTG
TTACGTGGACTCTGTGTGGGCTCCTCCCTGGGGCCCGCCAGCATAACGGTGCACCCAGGGACCTCCCAGTGCAC
CCGGGGCCCTTTGCAGGGGTGGGGTGGCCACACAAGTGAAGAAGTTGGGACTCATCTCAGTTCCAGTGTCTATTG
AGGAGAACGCTGGGGCTGCATTACCTGCTGAGACCCAGAGACTGGCTGTTCCAGAGAATGGCCCAGGGGGA
GGAGGGCTGGTGTGGAGGGGCAACCTGGACTGAGGCCGAACCTCCCTTGGGCTCACCCACCCACCCCTACCTGAG
CATCAGCAGTGGGGGAGGGCAGCATCGCAGGGGCGAGGACTCCCTGGGTGAGGACAGACCAGCCCTCCCGAGCA
CCTGGCACTCATGGGCTGAGGCTGACTTCTCCTGGAAGAAGGGCCCAGAGTGGGAAGGAAGAGGCAGAGGGTAGAG
GTGGTGGCTGGGGGCTCCTCTGCAGAGTGGGGTGGCCAATGGAGAGGGCTGCACTCACACCGCAACATAGGACTC
TCTCTCCCTTAAGAAGGCCCCCTTAGGGTCTGGGCTGCCGCCCCCATCACCTAAAACAGCCAAGGTAGCTGAG
GCCCCAGGGCAGACAATTTACCAGCAGGANGAGGAGGAGTCCAGTGAGCTTGTTGCTCACAGACAGCAAGGGA
GCTGTACAGAGGAAGCTGATGAATGGACCGCTGTGGGGAGACTTTAAAGTAGAACAGTGATAAGGGAGGGCAGG
ATGGTGGGGATGCAGAAGCAGCAGCCAGAGAGAGACGGACTGGGGTGCAGACGGAGTGTGGAAAACGCATACCTT
GAAATGAAGCATCCAGCAGATGGGGTGAGTGGATACAGCTCAGGAGATTCTCCAGGAATAGCAGGGAGGCGTAA
AGAGAGACAACGTACAGAGATAGATGAATGGAAATGGGTAAAGGGAGGTGTTTATTACATCCATCTAACTGCAAA
ATACAAAAGTAAGAAGTCATTGACATGAAGCAACGACGACCAAGACGTTCTCAGATCTAAAGGTGAATGATCTCA
GTCAGCCTGGAAATGCACAAGGTGGAAAAATAACATAAAAAAGCCATAAGACCTTGAAGAACATCAATGTCAAAG
ATAAATTCTAAAGTCCCAGAGAAAAAAGAAATGGGAATCAAATTGACCTCAGACTATACGTGAGAAACACGGAGAG
CCAGAAAACCTGTGATGTTCCATCCTCAGAGTTTGAAGGAAATATTTGAAGGCTGAATTTTACATCCAGCTAAACT
ATCAAAGGCATGCAAAGTCCATGTTATTCTTAGGCCTTCAAGGCCTCGGCCATTTTTCTACAGAAAAGCCTGATT
TTAAAATGCTCTTAGAGACGTTCTCCAGCCAGAAGAGAAAGAAGCCAGGAGGGTGCTCTGAGATATTAGTCACC
ACAGTTCCCAAATGGCCTAGGAATTCAGAGAGTCAGAATATCACCATTACTCCCCAATGGGAACCCCCGACAGTC
TCAGCATGGTGTGAGGGTGTGGACGGGGGGCCTGGCAGGTACCAATCACTCATCCCGCTCAGTGAAGACACAGTG
TTCAGCTACGGAAGCCATAAGGCAGGCCGAGCTTCTGCCCATCCGGAGGAAATCTCAGCTATCCAACGGCGGTCA
GGAGCAGAGGAAAATAAAGCAGAATAACTAGAAAACACGCTCACAGATCCTAATGTTAACGGTTACAAATGACGA
CGGAAAAACAACTCCTGACCATATATTATATAGTTTCAAGCAGCAAGAAGGAGGATATTGAACATTCTCAACAC
ACATAATAAACGCTTGAGATGATGATATGCTCATTACCCTGATTGATCACTAGACATNCCATGTATCAAAACAT
CACTGTGTATCCGATGAATATCTACAATTATTGTCAATTAAAAACATCATTA AAAACAA

The NOV15e protein (SEQ ID NO:52) encoded by SEQ ID NO:51 is 1403 amino acid residues in length and is presented using the one-letter amino acid code in Table 15J. Although the SignalP, Psort and/or Hydropathy results indicate that NOV15e has a signal peptide and is likely to be localized in the mitochondrial matrix space with a certainty of 0.4753, the NOV15e protein disclosed here is similar to the EGF family, some members of which are released

extracellularly. Alternatively, a NOV15e polypeptide is located to the microbody (peroxisome) with a certainty of 0.3000, the mitochondrial inner membrane with a certainty of 0.1802, or the mitochondrial intermembrane space with a certainty of 0.1802. The SignalP indicates a likely cleavage site for a NOV15e peptide is between positions 31 and 32, *i.e.*, at the dash in the sequence GRG-AD.

Table 15J. Encoded NOV15e Protein Sequence (SEQ ID NO:52)

MPMGHSDRWSRLLRLALPLPVWLPAGGGRGADSPCLCSRPHVCAEQELTLVGRRQPCVQALSHTVPVWKAGCGW QAWCVGHERRTVYYMGYRQVYTTEARTVLRCCRGWMQQPDEEGCLSDVGECANANGGCAGRCRDTVGGFYCRWPP PSHQLQGDGETCQDVDECRTHNGGCQHRCVNTPGSYLCECKPGFRLHTDSRTCAINSCALNGGCQHHCVQLTIT RHRCQCRPGFQLQEDGRHCVRRSPCANRNGSCMHRCQVVRGLARCECHVGYYLAADGKACEDVDECAAGLAQCAH GCLNTQGSFKCVCHAGYELGADGRQCYRIEMEIVNSCEANNGGCSHGCSHTSAGPLCTCPRGYELDTDQRTCIRC RRLCRQPVLLQVCTNNPGGYECGYAGYRLSADGCGCEDVDECASSRGGCEHHCTNLAGSFQCSCEAGYRLHEDR RGCSALEEPMVDLDGELPFVRLPHIAVLQDELQQLFQDDVDGADDEEEAELRGEHTLTEKFVCLDDSFHDCSLT CDDCRNGGTCLLGLDGCDCPEGWTGLICNESCPDPTFGKNCSFSCSCQNGGTCDSVTGACRCPPGVSGTNCEGDC PKGYYGKHCRKCCANRGRCHRLYGACLCDPGLYGRFCHLACPPWAFGPGCSEECQCVQPHQTQSCDKRDGSCSC KAGFRGERCQAECEPGYFGPGCWQACTCPVGVACDSVSGECGKRCFAGFQGEDCGQECFVGTFGVNCSSSCSCGG APCHGVTGQCRCPPGRTGEDCEAGECEGLWGLGCQEICPACHNAARCDPETGACLCPLPGFVGSRCQDCEAGWYGP SCQTMCSANDGHCHQDTGHCSAPGWTGFSCQACDTGHWGPDCSHPCNCSAGHGSCTAISGLCLCEAGYVGP CEQSECPQGHFGPGCEQRCQCGHGAACDHVSGACTCPAGWRGTFCHEACFAGFFGLDCRSACNCTAGAACDAVNG SCLCPAGRRGPRCAETCPAHTYGHNCSQACACFNGASCDPVHGQCHCAPGWMGPSCLQACPAGLYGDNCRHSCLC QNGGTCDPVSGHCACPEGWAGLACEVECLPRDVRAGCRHSGGCLNGLCDPHTGRCLCPAGWTGDKCQSPAACAK GTFPGHCEGRACRWGGPCHLATGACLCPPGWRGPHLSAACLGRWFGEACAQRCSCPPGAACHHVTGACRCPPGF TGSGCEQACPPGSFGEDCAQMCQCPGENPACHPATGTCSAAGYHGPSCQQRCPGRYGPGEQLCGCLNNGGSCD AATGACRCPTGFLGTDCNLTCPQGRFGPNCTHVCGCGQAACDPVTGTCLCPGRAGVRCERGCPQNRFGVGCEH TCSCRNGGLCHASKRQLLLWPLDGAALRAGLSPWALRSRLPSGVLLPQQQHV
--

NOV15f

Alternatively, a NOV15 variant is NOV15f (alternatively referred to herein as CG56449-08), which includes the 4835 nucleotide sequence (SEQ ID NO:53) shown in Table 15K. An open reading frame for the mature protein was identified beginning with an ATG codon at nucleotides 1-3 and ending with a TAG codon at nucleotides 4732-4734. Putative untranslated regions, if any, downstream from the termination codon and upstream from the initiation codon are underlined. The start and stop codons are in bold letters.

Table 15K. NOV15f Nucleotide Sequence (SEQ ID NO:53)

ATG TCGTTCTTGAAGAGGCGAGGGCAGCGGGGCGCGGGTGGTCTCGCGTTGGTGCTGCTGCTGCTCCCCGCC GTGCCCCGTGGGCGCCAGCGTTCCGCCGCGGCCCTGCTCCCGCTGCAGCCCGGCATGCCCCACGTGTGTGCTGAG CAGGAGCTGACCCCTGGTGGGCCGCCAGCCGTGCGTGACGGCCTTAAGCCACACGGTGCCGGTGTGGAAGGCC GGCTGTGGGTGGCAGGCGTGGTGCCTGGGTGATGAGCGGAGGACCGTCTACTACATGGGCTACAGGCAGGTGTAT ACCACGGAGGCCCGGACCGTGCTCAGGTGCTGCCGAGGGTGGATGCAGCAGCCGACGAGGAGGGCTGCCTCTCG

GATGTGGGTGAGTGTGCCAACGCCAACGGGGGCTGTGCGGGTCGGTGCCGGGACACCGTGGGGGGCTTCTACTGC
CGCTGGCCCCCCCCCAGCCACCAGCTGCAGGGTGATGGCGAGACTTGCCAAGATGTGGACGAATGCCGAACCCAC
AACGGTGGCTGCCAGCACCAGGTGCGTGAACACCCAGGCTCCTACCTCTGTGAGTGCAGCCCCGGCTTCCGGCTC
CACACTGACAGCAGGACCTGCGCCATTAACCTCTGCGCCCCGGAATGGCGGCTGCCAGCACCAGTGTGTCCAG
CTACAATCACTCGGCATCGCTGCCAGTGCCGGCCCCGGGTTCAGCTCCAGGAGGACGGCAGGCATTGTGTCCGT
AGAAGCCCGTGTGCCAACAGGAACGGCAGCTGCATGCACAGGTGCCAGGTGGTCCGGGGCTCGCCCGCTGTGAG
TGCCACGTGGGCTATCAGCTAGCAGCGGACGGCAAGGCCTGTGAAGATGTGGACGAATGTGCCGAGGGCTGGCC
CAGTGTGCCCATGGCTGCCTCAACACCCAGGGGTCTTCAAGTGCCTGTGTACGCGGGCTATGAGCTGGGCGCC
GATGGCCGGCAGTGCTACCGTATTGAGATGGAAATCGTGAACAGCTGTGAGGCCAACACGGCGGCTGTCTCCAT
GGCTGCAGCCACACCAGTGCTGGGCCCCCTGTGCACCTGTCCCCGGGCTACGAGCTGGACACAGATCAGAGACC
TGCATCAGATGTGACGACTGTGCAGACAGCCCGTGTGCAGCAGGTGTGCACCAACAACCCCTGGCGGGTACGAG
TGCGGCTGCTACGCCGGCTACCGGCTCAGTGCCGATGGCTGCGGCTGCGAGGATGTGGATGAGTGCCTCCAGC
CGTGGCGGCTGCGAGCACCAGTGCACCAACCTGGCGGCTCCTTCCAGTGCTCCTGCGAGGCGGGCTACCGGCTG
CAGGAGGACCTAGGGGCTGCAGCGCCCTGGAGGAGCCGATGGTGGACCTGGACGGCGAGCTGCCTTTCGTGCGG
CCCCTGCCCCACATTGCCGTGCTCCAGGACGAGCTGCCGCAACTCTTCCAGGATGACGACGTCCGGGGCCGATGAG
GAAGAGGCAGAGTTGCCGGGCGAACACACGCTCACAGAGAAGTTTGTCTGCCCTGGATGACTCCTTTGGCCATGAC
TGCAGCTTGACCTGTGATGACTGCAGGAACGGAGGGACCTGCCTCCTGGGCTGGATGGCTGTGATTGCCCCGAG
GGCTGGACTGGGCTCATCTGCAATGAGAGTTGTCTCCGGACACCTTTGGGAAGAACTGCAGCTTCTCCTGCAGC
TGTGAGAATGGTGGGACCTGCGACTCTGTACGGGGGCTGCCGCTGCCCCCGGGTGTGAGTGGAACTAACTGT
GAGGATGGCTGCCCCAAGGGCTACTATGGCAAGCACTGTGCGAAGAAATGCAACTGTGCCAACCGGGGCGGGTGC
CACCCTCTACGGGGCTGCCTCTGCGACCCAGGGCTCTACGGCCGCTTCTGCCACCTCGCCTGCCCGCCGTGG
GCCTTTGGGCGGGCTGCTCGGAGGAGTGCCAGTGTGTGCAGCCCCACACGAGTCTGTGACAAGAGGGATGGC
AGCTGTCTCTGCAAGGCTGGCTTCCGGGGCGAGCGCTGTGAGGCAGAGTGTGAGCCGGGTACTTTGGGCGGGG
TGCTGGCAGGCATGCACCTGCCAGTGGGCGTGGCCTGTGACTCCGTGAGCGGCGAGTGTGGGAAGCGGTGCTCT
GCTGGCTTCCAGGGAGAGGACTGTGGCCAAGAGTGCCCGGTGGGGACCTTTGGCGTGAACGTCTCGAGCTCCTGC
TCCTGTGGGGGGGCCCCCTGCCACGGGGTACGGGGCAGTGCCGGTGTCCGCCGGGAGGACTGGGGAAGACTGT
GAGGCAGGTGAGTGTGAGGGCTCTGGGGGCTGGGCTGCCAGGAGATCTGCCAGCATGCCATAACGCTGCTCGC
TGCGACCTGAGACCGGAGCCTGCCTGTGCCTCCCTGGCTTTGTGCGGACGCGCTGCCAGGACTGTGAGGCAGGC
TGGTATGGTCCCAGCTGCCAGACAATGTGCTCTTTAGCTGCCAGAGAGCCTGTGATACTGGGCAGTGGGGACCTGACTGCAGC
AGCTGTGCCCCCGGGTGGACCGGCTTTAGCTGCCAGAGAGCCTGTGATACTGGGCAGTGGGGACCTGACTGCAGC
CACCCTTGCAACTGCAGCGCTGCCACGGGAGCTGTGATGCCATCAGCGGCCTGTGTCTGTGTGAGGCTGGCTAC
GTGGGCCCCGCGTGCAGCAGTGCAGAGTGTCCCCAGGGCCACTTTGGGCCCCGGCTGTGAGCAGCGGTGCCAGTGT
CAGCATGGAGCAGCCTGTGACCACGTGCAGCGGGGCTGCACCTGCCCGGCGGCTGGAGGGGCACCTTCTGCGAG
CATGCCTGCCCGCGCGGCTTCTTTGGATGGACTGTGCGAGTGCCTGCAACTGCACCGCGGAGCTGCCTGTGAT
GCCGTGAATGGCTCCTGCCTCTGCCCCGCTGGCGCGGGGCCCCCGCTGTGCGGAGAGTGCCTGCCAGCCAC
ACCTACGGGCACAATTGCAGCCAGGCTGTGCCTGCTTTAACGGGGCCTCCTGTGACCCTGTCCACGGGCAGTGC
CACTGTGCCCCGCTGGTGGATGGGGCCCTCCTGCCTGCAGGCTGCCCTGCCGGCTGTACGGCGACAACGTGCGG
CATTCCTGCCTCTGCCAGAACGGAGGACCTGTGACCCTGTCTCAGGCCACTGTGCGTGGCCAGAGGGCTGGGCC
GGCCTGGCCTGTGAGGTAGAGTGCCCTCCCCGGGACGTGCAGAGTGGCTGCCGGCACAGCGGCGGTTGCCCAAC
GGGGGCTGTGTGACCCGCACACGGGCGCTGCCTCTGCCAGCCGGCTGGACTGGGGACAAGTGTGAGGCCCT
GCAGCCTGTGCCAAGGGCACATTCGGGCTCACTGTGAGGGGCGCTGTGCCTGCCGGTGGGGAGGCCCCCTGCCAC
CTTGCCACCGGGGCTGCCTCTGCCCCCGGGGTGGCGGGGCTCATCTTCTGCAGCCTGCCTGCGGGGCTGG
TTTGGAGAGGCTGTGCCAGCGCTGCAGTGCCTGCGGCTGCCAGCACGTACTGGGGCTGCCG
TGTCCCCCTGGCTTCACTGGCTCCGGCTGCAGCAGGCTGCCACCCGCGAGCTTTGGGGAGGACTGTGCGCAG
ATGTGCCAGTGTCCGGTGAGAACCAGGCTGCCACCTGCCACCGGACCTGCTCATGTGTGCTGGCTACCAC
GGCCCCAGCTGCCAGCAACGATGTCCGCCCGGGCGGTATGGGCCAGGCTGTGAACAGCTGTGTGGGTGTCTAAC
GGGGCTCCTGTGATGCGGCCACGGGGGCTGCCGCTGCCCACTGGGTTCCTCGGGACGAGTGAACCTCACC
TGTCCGACGGGCGCTTCCGGCCCCAAGTGCACCCACGTGTGTGGGTGTGGGACGGGGCGGCTGCGACCTGTG
ACGGGCACCTGCCTCTGCCCCCGGGGAGAGCGGCGTCCGCTGTGAGCGAGGCTGCCCCAGAACCGGTTTGGC
GTGGGCTGCGAGCACCTGCTCCTGCAGAAATGGGGCTGTGCCACGCCAGCAACGGCAGCTGCTCCTGTGGC
CTGGGCTGGACGGGGCGGACTGCGAGCTGGCCTGTCCCCCTGGGCGCTACGGAGCCGCTGCCATCTGGAGTGC
TCCTGCCACAACAACAGCACGTGTGAGCCTGCCACGGGACCTGCCGCTGCGGCCCCGGCTTCTATGGCCAGGCC
TGCGAGCACCCCTGTCCCCCTGGCTTCCACGGGGCTGGCTGCCAGGGGTGTGCTGGTGTCAACATGGAGCCCCC
TGCGACCCCATCAGTGGCCGATGCCTCTGCCCTGCCGGCTTCCACGGCCACTTCTGTGAGAGGGGGTGTGAGCCA
GGTTTCAATTTGGAGAGGGCTGCCACAGCGCTGTGACTGTGACGGGGGGGACCCCTGTGACCCTGTACCGGTCTC
TGCCTTTGCCACAGGGGCGCTCAGGAGCCACCTGTAACCTGGATTGCAGAAGGGGGCAGTTTGGGGCCAGCTGC
ACCCTGCACTGTGACTGCGGGGTGGGGCTGACTGCGACCTGTGAGTGGGACGTGCTGTGTGGATGGCTAC

ATGGGGCCACGTGCCGGGAAGCGGGCACACTGCCCCGCTCCAGCAGACCCACATCCCGGAGCGGTGGACCAGCG
AGGCACTAGTAGAGGCAGTCCCGTGGAGCCCGCTCTCCAGTCCCAGCCAGAGGGGACCCTGGCCTTTGGTGACC
ACTGAGAAGGACACTTCACGGGGCCAGAGCTCCTG

The NOV15f protein (SEQ ID NO:54) encoded by SEQ ID NO:53 is 1577 amino acid residues in length and is presented using the one-letter amino acid code in Table 15L. The SignalP, Psort and/or Hydropathy results indicate that NOV15f has a signal peptide and is likely to be localized extracellularly with a certainty of 0.8200. Alternatively, a NOV15f polypeptide is located to the lysosome (lumen) with a certainty of 0.1900, the endoplasmic reticulum (membrane) with a certainty of 0.1000, or the endoplasmic reticulum (lumen) with a certainty of 0.1000. The SignalP indicates a likely cleavage site for a NOV15f peptide is between positions 30 and 31, *i.e.*, at the dash in the sequence VGA-SV.

Table 15L. Encoded NOV15f Protein Sequence (SEQ ID NO:54)

MSFLEEARAAGRAVVLALVLLLLPAVPVGASVPPRPLLPLQPGMPHVCAEQELTLVGRRQPCVQALSHTVPVWKA
GCGWQAWCVGHERRTVYYMGYRQVYTTEARTVLRCCRGWMQQPDEEGCLSDVGEKANANGGCAGRCRDTVGGFYC
RWPPPSHQQLQGDGETCQDVDECRTNNGGCQHRCVNTPGSYLCECKPGFRLHTDSRTCAINSCALGNGGCQHHCVO
LTIIRHRCQCRPGFQLQEDGRHCVRRSPCANRNGSCMHRCQVVRGLARCECHVGYYQLAADGKACEDVDECAAGLA
QCAHGCLNTQGSFKCVCHAGYELGADGRQCYRIEMEIVNSCEANNGGCSHGCSHTSAGPLCTCPRGYELDTDQRT
CIRCRRLCRQPVLLQQVCTNNPGGYECGYAGYRLSADGCGCEDVDECASSRGGCEHHCTNLAGSFQCSCEAGYRL
HEDRRGCSALEEPMVDLDGELPFVRPLPHIAVLQDELPLQFQDDVGADEEEAELRGEHTLTEKFVCLDDSFHGD
CSLTCDCCRNGGTCLLGLDGCDCEGWTGLICNESCPDPTFGKNCSFSCSCQNGGTCDSVTGACRCPPGVSGTNC
EDGCPKGYGKHKRKKNCANRGRCHRLYGACLCDPGLYGRFCHLACPPWAFGPGCSEECQCVQPHQTQSCDKRDG
SCSKAGFRGERCQAECEPGYFGPGCWQACTCPVGVACDSVSGECGRKCPAGFQGEDCGQCEPVGTFGVNCSSSC
SCGAPCHGVTGQCRCPPGRTGEDCEAGECEGLWGLGCQEICPACHNAARCDPETGACLCPLPGFVGSRCQDCEAG
WYGPSQTMCSANDGHCHQDTGHCSAPGWTGFSCQACDTGHWGPDCHPCNCSAGHGSCTAISGLCLCEAGY
VGPRCEQSECPQGHFGPGCEQRCQCGHAACDHVSGACTCPAGWRGTFCEHACPAFFGLDCRSACNCTAGAACD
AVNGSCLCPAGRRGPRCAESACPAHTYGHNCSQACACFNGASCDPVHGQCHCAPGWMGPSCLQACPAAGLYGDNCR
HSCLCQNGGTCDPVSGHCACPEGWAGLACEVECLPRDVRAGCRHSGGCLNGLCDPHTGRCLCPAGWTGDKCQSP
AACAKGTFGPHCEGRACACRWGGPCHLATGACLCPPGWRGPHLSAACLRGWGEACAQRCSPPGAACHHVTGACR
CPPGFTGSGCEQACPPGSFGEDCAQMCQCPGENPACHPATGTCSAAGYHGPSQQRCPGGRYGPGEQLCGCLN
GGSCDAATGACRCPTGFLGTDNLTCPPQGRFGPNCTHVCGCGQGAACDPVTGTCLCPPGRAGVRCERGCPQNRFG
VGCEHTCSCRNGGLCHASNGSCSGLGWTGRHCELACPPGRYGAACHLECSCHNNSTCEPATGTCTRCGPGFYGQA
CEHPCPPGFHGAGCQGLCWCQHGAAPCDPISGRCLCPAGFHGHFCERGCEPGSFGECHQRCDCDGGAPCDPVTGL
CLCPPGRSGATCNLDCCRQGFPSCTLHCDGGGADCDPVSGQCHCVDGYMGPTCREAGTLPASSRPTSRSGGPA
RH

NOV15 Clones

Unless specifically addressed as NOV15a, NOV15b, NOV15c, NOV15d, NOV15e, or NOV15f any reference to NOV15 is assumed to encompass all variants.

A search against the Patp database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 15M.

Table 15M. PatP Results for NOV15

Sequences Producing High-Scoring Segment Pairs:		High Score	Smallest Sum Prob P (N)
patp:AA72091	Human serine protease #2 encoded by clone HMGBM65	2570	5.8e-267
patp:AAB66267	Human TANGO 272	1416	1.1e-144
patp:AA72715	HFICU08 clone human attractin-like protein	1396	1.5e-142
patp:AAB66269	Rat TANGO 272	1200	8.6e-122
patp:AAG75479	Human colon cancer antigen protein	945	3.4e-94

In a BLAST search of public sequence databases, it was found, for example, that the NOV15a nucleic acid sequence of this invention has 2717 of 3360 bases (80%) identical to a gb:GENBANK-ID:AB011532|acc:AB011532.1 mRNA from Rattus norvegicus mRNA for MEGF6, complete cds. Further, the full amino acid sequence of the disclosed NOV15a protein of the invention has 1060 of 1364 amino acid residues (77%) identical to, and 1147 of 1364 amino acid residues (84%) similar to, the 1574 amino acid residue ptmr:SPTREMBL-ACC:O88281 protein from Rat (MEGF6).

In a similar BLAST search of public sequence databases, it was found, for example, that the NOV15b nucleic acid sequence of this invention has 2624 of 3343 bases (78%) identical to a gb:GENBANK-ID:AB011532|acc:AB011532.1 mRNA from Rattus norvegicus mRNA for MEGF6, complete cds. Further, the full amino acid sequence of the disclosed NOV15b protein of the invention has 1045 of 1363 amino acid residues (76%) identical to, and 1131 of 1363 amino acid residues (82%) similar to, the 1574 amino acid residue ptmr:SPTREMBL-ACC:O88281 protein from Rat (MEGF6).

In a similar BLAST search of public sequence databases, it was found, for example, that the NOV15c nucleic acid sequence of this invention has 3219 of 4514 bases (71%) identical to a gb:GENBANK-ID:AB011532|acc:AB011532.1 mRNA from Rattus norvegicus mRNA for MEGF6, complete cds. Further, the full amino acid sequence of the disclosed NOV15c protein of the invention has 966 of 1426 amino acid residues (67%) identical to, and 1062 of 1426 amino

acid residues (74%) similar to, the 1574 amino acid residue ptrn:SPTREMBL-ACC:O88281 protein from Rat (MEGF6).

In a similar BLAST search of public sequence databases, it was found, for example, that the NOV15d nucleic acid sequence of this invention has 650 of 687 bases (94%) identical to a gb:GENBANK-ID:AB011539|acc:AB011539.1 mRNA from Homo sapiens mRNA for MEGF6, partial cds. Further, the full amino acid sequence of the disclosed NOV15d protein of the invention has 106 of 141 amino acid residues (75%) identical to, and 108 of 141 amino acid residues (76%) similar to, the 153 amino acid residue ptrn:SPTREMBL-ACC:O75095 protein from Human (MEGF6).

In a further BLAST search of public sequence databases, it was found, for example, that the NOV15e nucleic acid sequence of this invention has 1072 of 1072 bases (100%) identical to a gb:GENBANK-ID:AB011539|acc:AB011539.1 mRNA from Homo sapiens mRNA for MEGF6, partial cds. Further, the full amino acid sequence of the disclosed NOV15e protein of the invention has 1059 of 1363 amino acid residues (77%) identical to, and 1147 of 1363 amino acid residues (84%) similar to, the 1574 amino acid residue ptrn:SPTREMBL-ACC:O88281 protein from Rat (MEGF6).

In yet a further BLAST search of public sequence databases, it was found, for example, that the NOV15f nucleic acid sequence of this invention has 2755 of 3390 bases (81%) identical to a gb:GENBANK-ID:AB011532|acc:AB011532.1 mRNA from Rattus norvegicus mRNA for MEGF6, complete cds. Further, the full amino acid sequence of the disclosed NOV15f protein of the invention has 1222 of 1562 amino acid residues (78%) identical to, and 1322 of 1562 amino acid residues (84%) similar to, the 1574 amino acid residue ptrn:SPTREMBL-ACC:O88281 protein from Rat (MEGF6).

Additional BLAST results are shown in Table 15N.

Table 15N. NOV15 BLASTP Results

Gene Index/ Identifier	Protein/Organism	Length of aa	Identity (%)	Positives (%)	Expect Value
O88281	MEGF6 - Rattus norvegicus (Rat)	1574	1060/1364 (77%)	1147/1364 (84%)	0.0
Q9TVQ2	Y64G10A.7 PROTEIN - Caenorhabditis elegans	1664	519/1245 (41%)	673/1245 (54%)	2.3e-293
T27283	hypothetical	1620	461/1272	609/1272	8.5e-225


```

Q96KG6 ----- 1
Q96KG7 -----MVISLNSCLSFICLLCHWIGTASPLNLEDPNVCSHWESYSV 42

      130      140      150      160      170      180
5  ....|....|....|....|....|....|....|....|....|....|
NOV15a EEGCLSDVGECANANGGCAGRCRDTVGGFYCRWPPPSHQLOGDGETCQDVDECRTTHNGGC 175
NOV15b EEGCLS--AECSASLCFHGGRCVPGS-AQPCHCPP-G--FQGP-RCQYDVEDECRTTHNGGC 168
NOV15c EEGCLS--AECSASLCFHGGRCVPGS-AQPCHCPP-G--FQGP-RCQYDVEDECRTTHNGGC 168
NOV15d ----- 1
10 NOV15e EEGCLSDVGECANANGGCAGRCRDTVGGFYCRWPPPSHQLOGDGETCQDVDECRTTHNGGC 175
NOV15f EEGCLSDVGECANANGGCAGRCRDTVGGFYCRWPPPSHQLOGDGETCQDVDECRTTHNGGC 179
O88281 QEGCLSDVDECASANGGCEGPCCNTVGGFYCRCPG-GYQLQGDGKTCQDVDECRAHNGGC 175
Q9TVQ2 GAKCQYDANECMANNGGCEHECVNTIGTYYCRWPG-GFELS GDGNTCSDI DECAVSNGGC 168
T27283 GAKCQYDANECMANNGGCEHECVNTIGTYYCRWPG-GFELS GDGNTCSDI DECAVSNGGC 168
15 Q96KG6 ----- 1
Q96KG7 TVQESYP-----HPFDQIYYTSCTDILN 65

      190      200      210      220      230      240
20 ....|....|....|....|....|....|....|....|....|....|
NOV15a QHRCVNTPGSYLCECKPGFRLHTDSRTC-----AINSCALGNGGCOHHCVQL 222
NOV15b QHRCVNTPGSYLCECKPGFRLHTDSRTCL-----AINSCALGNGGCOHHCVQL 216
NOV15c QHRCVNTPGSYLCECKPGFRLHTDSRTCL-----AINSCALGNGGCOHHCVQL 216
NOV15d ----- 1
25 NOV15e QHRCVNTPGSYLCECKPGFRLHTDSRTC-----AINSCALGNGGCOHHCVQL 222
NOV15f QHRCVNTPGSYLCECKPGFRLHTDSRTC-----AINSCALGNGGCOHHCVQL 226
O88281 QHRCVNTPGSYLCECKPGFRLHTDGRTC-----AISCTLGNGGCOHQCQVQL 223
Q9TVQ2 SDRCVNSPGGERCDPCPSDLYLHADGRTCGSGGFHFENLILIKVTSCSTDNGGCEHECEND 228
T27283 SDRCVNSPGGERCDPCPSDLYLHADGRTCG-----KVTSCSTDNGGCEHECEND 216
Q96KG6 -----MHTPSIR-SITHDAOTSSTGSS----- 21
30 Q96KG7 WFKCTRHRVSYRTAYRHGEKTMYYRKSQ----- 93

      250      260      270      280      290      300
35 ....|....|....|....|....|....|....|....|....|....|
NOV15a TIT-RHRC-CRPGFQLQEDGRHCVRRSPCANRNGSCMHRCQVVRGLARCECHVGQYLAAD 281
NOV15b TIT-RHRC-CRPGFQLQEDGRHCVRRSPCANRNGSCMHRCQVVRGLARCECHVGQYLAAD 275
NOV15c TIT-RHRC-CRPGFQLQEDGRHCVRRSPCANRNGSCMHRCQVVRGLARCECHVGQYLAAD 275
NOV15d ----- 1
40 NOV15e TIT-RHRC-CRPGFQLQEDGRHCVRRSPCANRNGSCMHRCQVVRGLARCECHVGQYLAAD 281
NOV15f TIT-RHRC-CRPGFQLQEDGRHCVRRSPCANRNGSCMHRCQVVRGLARCECHVGQYLAAD 285
O88281 TVT-QHRC-CRPGFQLQEDGRHCVRRSPCAEGNGGCMHICQLRGLAHCGCHPGYLAAD 282
Q9TVQ2 SNGEFVRCRCRVGFRLSENKRSCQPVDPKFNKGGCOHHCTNNHGRACCOCYPGFHLSYD 288
T27283 SNGEFVRCRCRVGFRLSENKRSCQPVDPKFNKGGCOHHCTNNHGRACCOCYPGFHLSYD 276
Q96KG6 -----APG-----TALCTEECVHGRCSVPTCHCEPGWGGPDSSSGCDSDHW 63
45 Q96KG7 -----CCPGFYESGEMCVPHCADKCVHGRCIAPNTCCEPGWGGTNCSSACDGDHW 144

      310      320      330      340      350      360
50 ....|....|....|....|....|....|....|....|....|....|
NOV15a GKACEDVDECAAGLAQCAHGCLNTQGSFKCVCHAGYELGADGROCQYRIEMEIVNSCEANN 341
NOV15b GKACEDVDECAAGLAQCAHGCLNTQGSFKCVCHAGYELGADGROCQYRIEMEIVNSCEANN 335
NOV15c GKACEDVDECAAGLAQCAHGCLNTQGSFKCVCHAGYELGADGROCQYRIEMEIVNSCEANN 335
NOV15d ----- 1
55 NOV15e GKACEDVDECAAGLAQCAHGCLNTQGSFKCVCHAGYELGADGROCQYRIEMEIVNSCEANN 341
NOV15f GKACEDVDECAAGLAQCAHGCLNTQGSFKCVCHAGYELGADGROCQYRIEMEIVNSCEANN 345
O88281 RKTCDVDECALGLAQCAHGCLNTQGSFKCVCHAGYELGADGROCQYRIEMEIVNSCEAGN 342
Q9TVQ2 RRSCVDIDECAK-NNGCEHFCENVKGTIRCKCREGYQLGRDGRTC----EEMLGGCQVGN 343
T27283 RRSCVDIDECAK-NNGCEHFCENVKGTIRCKCREGYQLGRDGRTC----EEMLGGCQVGN 331
Q96KG6 GPHCSNRCCQCN-----GALCNPIIGACVCAAGERG---WR----- 96

```

Q96KG7 GPHCTSRCCKN-----GALCNPIIGACHCAAGERG--WR----- 177

370 380 390 400 410 420

5 NOV15a GGCSHGCSHTSAG-PLCTCPRGYELDTDORTCIR----- 374
 NOV15b GGCSHGCSHTSAG-PLCTCPRGYELDTDORTCIR----- 368
 NOV15c GGCSHGCSHTSAG-PLCTCPRGYELDTDORTCIR----- 368
 NOV15d ----- 1
 NOV15e GGCSHGCSHTSAG-PLCTCPRGYELDTDORTCIR----- 374
 10 NOV15f GGCSHGCSHTSAG-PLCTCPRGYELDTDORTCIR----- 378
 O88281 GGCSHGCSHTSAG-PLCTCPRGYELDEDTKID----- 375
 Q9TVQ2 GGCQHDICYDQPDGGHVCKCRNGYILANDOKLCHD----- 377
 T27283 GGCQHDICYDQPDGGHVCKCRNGYILANDOKLCHDNISTVIHARAPRLWDSYETVTCVTPT 391
 Q96KG6 --CEELCAPGTHG----- 107
 15 Q96KG7 --CEDRCEQGTYG----- 188

430 440 450 460 470 480

20 NOV15a -----CRRLCRQPVLQOVCTNNPGGYECGC 399
 NOV15b -----CRRLCRQPVLQOVCTNNPGGYECGC 393
 NOV15c -----CRRLCRQPVLQOVCTNNPGGYECGC 393
 NOV15d ----- 1
 NOV15e -----CRRLCRQPVLQOVCTNNPGGYECGC 399
 NOV15f -----CRRLCRQPVLQOVCTNNPGGYECGC 403
 25 O88281 -----IDDCANSPPCQOACANTPGGYECSC 400
 Q9TVQ2 -----INECHENNGDCSQCVCNLAGSVECC 403
 T27283 DLTCHKLCMHLD SGHVQCFCDG YELIDSKFCQD INECHENNGDCSQCVCNLAGSVECC 451
 Q96KG6 -----KG-CQLPCQCHGASCDPRAGECLC 131
 Q96KG7 -----ND-CHQRCQCHGATCDHVTGEQRC 212

490 500 510 520 530 540

35 NOV15a YAGYRLSADGGCGCEDVDECASSRGGCEHHCTNLAGSFQCSCEAGYRLHEDRRGCSALEEP 459
 NOV15b YAGYRLSADGGCGCEDVDECASSRGGCEHHCTNLAGSFQCSCEAGYRLHEDRRGCSALEEP 453
 NOV15c YAGYRLSADGGCGCEDVDECASSRGGCEHHCTNLAGSFQCSCEAGYRLHEDRRGCSALEEP 453
 NOV15d ----- 1
 NOV15e YAGYRLSADGGCGCEDVDECASSRGGCEHHCTNLAGSFQCSCEAGYRLHEDRRGCSALEEP 459
 NOV15f YAGYRLSADGGCGCEDVDECASSRGGCEHHCTNLAGSFQCSCEAGYRLHEDRRGCSALEEP 463
 40 O88281 FAGYRLNTDGGCGCEDVDECASGHGGCEHHCSNLAGSFQCFCEAGYRLDEDRRGCTSLEES 460
 Q9TVQ2 KPGFRLMKDRKTCEDISECSSNNGGCEQICSNQEGGYMCSCEPGFELSEDGHSCHDMNEC 463
 T27283 KPGFRLMKDRKTCEDISECSSNNGGCEQICSNQEGGYMCSCEPGFELSEDGHSCHDMNEC 511
 Q96KG6 APGY----TCVYCEELCPPGSHGAHCELRCP----- 158
 Q96KG7 PPGY----TGAFCEELCPPGKHGPQCEQRCP----- 239

550 560 570 580 590 600

45 NOV15a MVDLDGELPFVRP-----LPHIAVLQDELQOLFQDDD---VGADEEEAEELRGEHT 506
 NOV15b MVDLDGELPFVRP-----LPHIAVLQDELQOLFQDDD---VGADEEEAEELRGEHT 500
 NOV15c MVDLDGELPFVRP-----LPHIAVLQDELQOLFQDDD---VGADEEEAEELRGEHT 500
 NOV15d ----- 1
 NOV15e MVDLDGELPFVRP-----LPHIAVLQDELQOLFQDDD---VGADEEEAEELRGEHT 506
 NOV15f MVDLDGELPFVRP-----LPHIAVLQDELQOLFQDDD---VGADEEEAEELRGEHT 510
 50 O88281 VVDLDGRLPFVRP-----LPHIAVLRLDELPRIFQDDYG---AEEEEAAEELRGEHT 508
 Q9TVQ2 LINNGGCAQLCKNRKGSRRQCQFAGYILAHDEKSCVAASDSADIFSNDIEDYSKVPGLDS 523
 55 T27283 LINNGGCAQLCKNRKGSRRQCQFAGYILAHDEKSCVAASDSADIFSNDIEDYSKVPGLDS 571
 Q96KG6 ----- 158
 Q96KG7 ----- 239

		610	620	630	640	650	660	
	NOV15a	LTEKFVCLDDS	-----	-----	-----	-----	-----	F 518
5	NOV15b	LTEKFVCLDDS	-----	-----	-----	-----	-----	F 512
	NOV15c	LTEKFVCLDDS	-----	-----	-----	-----	-----	F 512
	NOV15d	-----	-----	-----	-----	-----	-----	1
	NOV15e	LTEKFVCLDDS	-----	-----	-----	-----	-----	F 518
	NOV15f	LTEKFVCLDDS	-----	-----	-----	-----	-----	F 522
10	O88281	LTEKFVCLDHS	-----	-----	-----	-----	-----	F 520
	Q9TVQ2	IDEVISSIESYPADESPRPLVFGRRRHVKACVNFQGTLSLELFSSEVVRTDPSEKCPNGFF	-----	-----	-----	-----	-----	583
	T27283	IDEVISSIESYPADESPRPLVFGRRRHVKACVNFQGTLSLELFSSEVVRTDPSEKCPNGFF	-----	-----	-----	-----	-----	631
	Q96KG6	-----	-----	-----	-----	-----	-----	158
	Q96KG7	-----	-----	-----	-----	-----	-----	239
15								
		670	680	690	700	710	720	
	NOV15a	GHDCSLTCDCCRNGGTCLLG	-----	LDGCDCEGWTGLICNESCPEDTFGKNCSFSCSCON	-----	-----	-----	574
	NOV15b	GHDCSLTCDCCRNGGTCLLG	-----	LDGCDCEGWTGLICNESCPEDTFGKNCSFSCSCON	-----	-----	-----	568
20	NOV15c	GHDCSLTCDCCRNGGTCLLG	-----	LDGCDCEGWTGLICNESCPEDTFGKNCSFSCSCON	-----	-----	-----	568
	NOV15d	-----	-----	-----	-----	-----	-----	1
	NOV15e	GHDCSLTCDCCRNGGTCLLG	-----	LDGCDCEGWTGLICNESCPEDTFGKNCSFSCSCON	-----	-----	-----	574
	NOV15f	GHDCSLTCDCCRNGGTCLLG	-----	LDGCDCEGWTGLICNESCPEDTFGKNCSFSCSCON	-----	-----	-----	578
	O88281	GHDCSLTCDCCRNGGTCLLG	-----	LDGCDCEGWTGLICNESCPEDTFGKNCSFSCSCON	-----	-----	-----	576
25	Q9TVQ2	GSTCQLSCSDCONGGKCSMRGSGLLSKCDCPSGYTGEKCEQICRNGYWGVDCAHKCSCK	-----	-----	-----	-----	-----	642
	T27283	GSTCQLSCSDCONGGKCSMRGSGLLSKCDCPSGYTGEKCEQICRNGYWGVDCAHKCSCK	-----	-----	-----	-----	-----	690
	Q96KG6	-----	CONGGTCHHITG	-----	ECACPPGWTGAVCAQCPPEGTFGONCSQDCPCHH	-----	-----	204
	Q96KG7	-----	CONGGVCHHVTG	-----	ECSCPSGWMGTVCQPCPEGRFGKNCSQECQCHN	-----	-----	285
30								
		730	740	750	760	770	780	
	NOV15a	GGTCDSVTGACRCPPGVSGTNCEDEG	-----	CPKGYYGKHKCRKKCNCAN	-----	RGRCHRLYGACLCDP	-----	632
	NOV15b	GGTCDSVTGACRCPPGVSGTNCEDEG	-----	CPKGYYGKHKCRKKCNCAN	-----	RGRCHRLYGACLCDP	-----	626
	NOV15c	GGTCDSVTGACRCPPGVSGTNCEDEG	-----	CPKGYYGKHKCRKKCNCAN	-----	RGRCHRLYGACLCDP	-----	626
35	NOV15d	-----	-----	-----	-----	-----	-----	1
	NOV15e	GGTCDSVTGACRCPPGVSGTNCEDEG	-----	CPKGYYGKHKCRKKCNCAN	-----	RGRCHRLYGACLCDP	-----	632
	NOV15f	GGTCDSVTGACRCPPGVSGTNCEDEG	-----	CPKGYYGKHKCRKKCNCAN	-----	RGRCHRLYGACLCDP	-----	636
	O88281	GGTCDSVTGACRCPPGVSGTNCEDEG	-----	CPKGYYGKHKCRKKCNCAN	-----	RGRCHRLYGACLCDP	-----	634
40	Q9TVQ2	--LCDPSTGSCRCED	-----	PEKCSGDPGPDGFGYGSQCNLKCRMDCPNGRCDPVFGYCTCPD	-----	-----	-----	697
	T27283	--LCDPSTGSCRCED	-----	PEKCSGDPGPDGFGYGSQCNLKCRMDCPNGRCDPVFGYCTCPD	-----	-----	-----	745
	Q96KG6	GGQCDHVTGQCHCTAGYMGDRCDDE	-----	CPFGSFGFQCSORCDCHN	-----	GGQCSPTTGACECEP	-----	262
	Q96KG7	GGTCDAATGQCHCTAGYMGDRCDDE	-----	CPVGTGVLCAETCCQVN	-----	GGKCYHVSAGACLCEA	-----	343
45								
		790	800	810	820	830	840	
	NOV15a	GLYG-RFCHLACPPWAFGPGCSEECQCVQPHOTOSCDKRDGSCSCKAGERGERCOAECEPG	-----	-----	-----	-----	-----	691
	NOV15b	GLYG-RFCHLACPPWAFGPGCSEECQCVQPHOTOSCDKRDGSCSCKAGERGERCOAECEPG	-----	-----	-----	-----	-----	685
	NOV15c	GLYG-RFCHLACPPWAFGPGCSEECQCVQPHOTOSCDKRDGSCSCKAGERGERCOAECEPG	-----	-----	-----	-----	-----	685
	NOV15d	-----	-----	-----	-----	-----	-----	1
50	NOV15e	GLYG-RFCHLACPPWAFGPGCSEECQCVQPHOTOSCDKRDGSCSCKAGERGERCOAECEPG	-----	-----	-----	-----	-----	691
	NOV15f	GLYG-RFCHLACPPWAFGPGCSEECQCVQPHOTOSCDKRDGSCSCKAGERGERCOAECEPG	-----	-----	-----	-----	-----	695
	O88281	GLYG-RFCHLACPPWAFGPGCSEECQCVQPHOTOSCDKRDGSCSCKAGERGERCOAECEPG	-----	-----	-----	-----	-----	693
	Q9TVQ2	GLYG-OSCEKPCPHITFGKNCRFPCKCARENSEGCDEITGKCRCKPGYIGHHCCKRMCSFG	-----	-----	-----	-----	-----	756
	T27283	GLYG-OSCEKPCPHITFGKNCRFPCKCARENSEGCDEITGKCRCKPGYIGHHCCKRMCSFG	-----	-----	-----	-----	-----	804
55	Q96KG6	GKGPQRQERLCPEGLHGPCTILPCPCDADNTISCHPVTGACTCPGWSGHHCNESCQVPG	-----	-----	-----	-----	-----	322
	Q96KG7	GFAGERCEARLCPEGLHGPCTILPCPCDADNTISCHPVTGACTCPGWSGHHCNESCQVPG	-----	-----	-----	-----	-----	403

		850	860	870	880	890	900	
	NOV15a	YFGPGCWQACTCPVGVACDSVSGECGKRC	PAGFQGEDCGQEC	VPVGTFGVNCSSSS	CS	CGGA	751	
	NOV15b	YFGPGCWQACTCPVGVACDSVSGECGKRC	PAGFQGEDCGQEC	VPVGTFGVNCSSSS	CS	CGGA	745	
5	NOV15c	YFGPGCWQACTCPVGVACDSVSGECGKRC	PAGFQGEDCGQEC	VPVGTFGVNCSSSS	CS	CGGA	745	
	NOV15d	-MAP-----ASAPLAAGAPAVP----	RPALPA-----	CTATTVGTIPAS	-----		33	
	NOV15e	YFGPGCWQACTCPVGVACDSVSGECGKRC	PAGFQGEDCGQEC	VPVGTFGVNCSSSS	CS	CGGA	751	
	NOV15f	YFGPGCWQACTCPVGVACDSVSGECGKRC	PAGFQGEDCGQEC	VPVGTFGVNCSSSS	CS	CGGA	755	
10	O88281	FFGPGCRHRTCQPGVACDPVSGECRTCCPPG	VOGEDCGQEC	VPVGTFGVNCSSSS	CS	CGGA	753	
	Q9TVQ2	LFGAGCANKCSCPAGITRCDPVITGDCITK	CPAGVQGNL	CDQPCPAGYFGYDCEQKCS	CA	ADV	816	
	T27283	LFGAGCANKCSCPAGITRCDPVITGDCITK	CPAGVQGNL	CDQPCPAGYFGYDCEQKCS	CA	ADV	864	
	Q96KG6	YYGDGCLPCTCQNGADCHSITG--GCT	CAPGFMGEVCAVS	CAACT	CPNCSS	ICSCNNG	380	
	Q96KG7	FYGEACQQICSCQNGADCDSVIG--KCT	CAPGFKGIDCSTP	CPLGT	MC	NCSSRCGCKND	461	
15		910	920	930	940	950	960	
	NOV15a	P-----CHGVTGQCRCPGRTGEDCEAG	-----	ECEGLWGLGQ	785			
	NOV15b	P-----CHGVTGQCRCPGRTGEDCEAG	-----	ECEGLWGLGQ	779			
	NOV15c	P-----CHGVTGQCRCPGRTGEDCEAD	-----	CPEGRWGLGQ	779			
20	NOV15d	-----ART-----	-----	EG	38			
	NOV15e	P-----CHGVTGQCRCPGRTGEDCEAG	-----	ECEGLWGLGQ	785			
	NOV15f	P-----CHGVTGQCRCPGRTGEDCEAG	-----	ECEGLWGLGQ	789			
	O88281	P-----CHRVTECLCPPGKTGEDCGAD	-----	CPEGRWGLGQ	787			
	Q9TVQ2	ASPHKSKVCHHVTGTCTCLPGKTGPLCDQS	-----	CAPNT	GP	NCA	857	
25	T27283	ASPHKSKVCHHVTGTCTCLPGKTGPLCDQ	CLIFVETIEFDIAFS	INVIACAPNT	GP	NCA	924	
	Q96KG6	G-----TCSFVDSCTCKEGWQGLDCTLP	-----	CPSGTWGLN	415			
	Q96KG7	A-----VCSFVDSCTCKAGWHGVDCSIR	-----	CPSGTWGF	496			
30		970	980	990	1000	1010	1020	
	NOV15a	EICPACHNAARCDPETGACLCLPGFVGSRCQD	-CEAGWYGPS	QTMCS	CANDGHCHQD	TG	844	
	NOV15b	EICPACHNAARCDPETGACLCLPGFVGSRCQD	-CEAGWYGPS	QTMCS	CANDGHCHQD	TG	838	
	NOV15c	EICPACHNAARCDPETGACLCLPGFVGSRCQD	VCPAGWYGPS	QTRCS	CANDGHCHPAT	TG	839	
	NOV15d	-----PVT-----	-----				41	
35	NOV15e	EICPACHNAARCDPETGACLCLPGFVGSRCQD	-CEAGWYGPS	QTMCS	CANDGHCHQD	TG	844	
	NOV15f	EICPACHNAARCDPETGACLCLPGFVGSRCQD	-CEAGWYGPS	QTMCS	CANDGHCHQD	TG	848	
	O88281	EICPACHNAARCDPETGACLCLPGFVGSRCQD	TCSAGWYG	TGQIR	CACANDGHCHQD	PTTG	847	
	Q9TVQ2	HTCS-CVNGAKCDESDGSC	CHCTPGFYGATC	SEV	OPTGRFGIDCMQLCK	QNGAICDTSNG	916	
	T27283	HTCS-CVNGAKCDESDGSC	CHCTPGFYGATC	SEV	OPTGRFGIDCMQLCK	QNGAICDTSNG	983	
40	Q96KG6	ESCT-CANGAACSPIDCS	CSCTPGWLGDT	CELPCPDG	TGFLN	CSHDCSHADGCDPVTG	474	
	Q96KG7	LTCQ-CLNGGACNTLDCT	CTCAPGRGEKCEL	PCQDGT	TYGLNCAERCD	CSHADGCHPTTG	555	
45		1030	1040	1050	1060	1070	1080	
	NOV15a	HCSCAPGWTGFSQACDTHWGPDCSHPCNCS	SAGHGS	CDASGLCLCEAGYVGPR	CEQS	904		
	NOV15b	HCSCAPGWTGFSQACDTHWGPDCSHPCNCS	SAGHGS	CDASGLCLCEAGYVGPR	CEQS	898		
	NOV15c	HCSCAPGWTGFSQACDTHWGPDCSHPCNCS	SAGHGS	CDASGLCLCEAGYVGPR	CEQS	899		
	NOV15d	-----LSQA-----	-----	CEHP	49			
	NOV15e	HCSCAPGWTGFSQACDTHWGPDCSHPCNCS	SAGHGS	CDASGLCLCEAGYVGPR	CEQS	904		
50	NOV15f	HCSCAPGWTGFSQACDTHWGPDCSHPCNCS	SAGHGS	CDASGLCLCEAGYVGPR	CEQS	908		
	O88281	RCSCAPGWTGFSQACDTHWGPDCSHPCNCS	SAGHGS	CDASGLCLCEAGYVGPR	CEQS	907		
	Q9TVQ2	SCECAPGWSGKKCDKACAPGTGKDCSKK	CCADG-MHCD	PSDGE	CTCPPGKKGHK	CDET	975	
	T27283	SCECAPGWSGKKCDKACAPGTGKDCSKK	CCADG-MHCD	PSDGE	CTCPPGKKGHK	CDET	1042	
	Q96KG6	HCCCLAGWTGIRCDSTCPPGRWGPNC	SVSC	SCENG-GSC	SPEDGSCECAP	GERGPLCQRI	533	
55	Q96KG7	HCRCLPGWSGVHCDSVCAEGRWGPNC	SLPCYCKNG-ASC	SPDDG	ICECAP	GERGTTTCQRI	614	
		1090	1100	1110	1120	1130	1140	

NOV15a	ECPOGHFGPGCEQRC--QCQHGAACDHVS	GA	CTCPAGWRGTFCEHAC	CPAG	FG	FLD	DCRSAC	962					
NOV15b	ECPOGHFGPGCEQRC--QCQHGAACDHVS	GA	CTCPAGWRGTFCEHAC	CPAG	FG	FLD	DCRSAC	956					
NOV15c	-CPQGHFGPGCEQLC--QCQHGAACDHVS	GA	CTCPAGWRGTFCEHAC	CPAG	FG	FLD	DCRSAC	956					
NOV15d	-CPPGFHGA	GRGLC--WCQHGAPCDPI	SGRCLCPAG	FG	GH	GF	CERD	RR	CF	GP	SCT	LHC	106
NOV15e	ECPOGHFGPGCEQRC--QCQHGAACDHVS	GA	CTCPAGWRGTFCEHAC	CPAG	FG	FLD	DCRSAC	962					
NOV15f	ECPOGHFGPGCEQRC--QCQHGAACDHVS	GA	CTCPAGWRGTFCEHAC	CPAG	FG	FLD	DCRSAC	966					
O88281	-CRQGY	GPSCEQKC--RCEHGAACDHVS	GA	CTCPAGWRGTFCEHAC	CPAG	FG	FLD	CDSAC	964				
Q9TVQ2	-CDSLFGAGCKGIC--SCQNGATCDSVT	GSCECRPGWRGKK	CDRPCDGRFGEGCNAIC	1032									
T27283	-CDSLFGAGCKGIC--SCQNGATCDSVT	GSCECRPGWRGKK	CDRPCDGRFGEGCNAIC	1099									
Q96KG6	-CPPGF	FGHGAQPCPLCVHSSRPCHHIS	GISICECLPGFS	GCALCNQVCAGGY	FG	QDCAQLC	592						
Q96KG7	-CSPGF	FGHRCSTCPQCVHSSGPPCHHITGL	CDCLPGETGALCNEVCPSGRFGKNCAGIC	673									

		1150	1160	1170	1180	1190	1200	
15	NOV15a	NCTAG	-----AACDAVNGSCLCPAGRRGPRCAESACPAHTYGHNC	SOACACFNGA	1012			
	NOV15b	NCTAG	-----AACDAVNGSCLCPAGRRGPRCAESACPAHTYGHNC	SOACACFNGA	1006			
	NOV15c	NCTAG	-----AACDAVNGSCLCPAGRRGPRCAET	-----	985			
	NOV15d	DCGGG	-----ADCDPVSGQCHCVDGYMGPTCREG	-----	135			
20	NOV15e	NCTAG	-----AACDAVNGSCLCPAGRRGPRCAET	CPAHTYGHNC	SOACACFNGA	1011		
	NOV15f	NCTAG	-----AACDAVNGSCLCPAGRRGPRCAESACPAHTYGHNC	SOACACFNGA	1016			
	O88281	NCSAG	-----APCDAVTGSCI	CPAGRWGPRCAQS	CPPLTGLNCSQICTCFNGA	1013		
	Q9TVQ2	DC	TTTNDTSMYNPFVARCDHVTGECRC	PAGWTGPD	CQTS	CPLGRHGEGRCHSCQCSNGA	1091	
	T27283	DC	TTTNDTSMYNPFVARCDHVTGECRC	PAGWTGPD	CQTS	CPLGRHGEGRCHSCQCSNGA	1158	
25	Q96KG6	SCANN	-----GTCSPIDGSCQCFPGWIGKDC	CSQA	CPPGFWGPACFHACSCHNGA	641		
	Q96KG7	TCTNN	-----GTCNPIDRSCQCYPGWIGSD	CSQP	CPPAHWGPNCIHTCNCHNGA	722		

[illegible]

		1270	1280	1290	1300	1310	1320	
	NOV15a	LACEVECLPRDVRAGCRHSGGCLNGGLCDPHTGRCLCPAGWTGDKCOSPAACAKGTGPH	1132					
45	NOV15b	LACEVECLPRDVRAGCRHSGGCLNGGLCDPHTGRCLCPAGWTGDKCOSPAACAKGTGPH	1126					
	NOV15c	LACEKECPPRDVRAGCRHSGGCLNGGLCDPHTGRCLCPAGWAGDKCOSP-----	1071					
	NOV15d	-----TLPASSRPTSRSG-----G-----PARH-----	170					
	NOV15e	LACEVECLPRDVRAGCRHSGGCLNGGLCDPHTGRCLCPAGWTGDKCOSPAACAKGTGPH	1131					
	NOV15f	LACEVECLPRDVRAGCRHSGGCLNGGLCDPHTGRCLCPAGWTGDKCOSPAACAKGTGPH	1136					
50	O88281	LACENECPLPGHYAAGCOLNCSCLGGICDLRTGHCLCPAGWTGDKCOS--SCVSGTGCVH	1131					
	Q9TVQ2	PSCEFLCPFQGQFGRNCAQRNCNKNGASCDRKTRGRCECLPGWSGEHCEK--SCVSHYGAK	1209					
	T27283	PS---LCFPFGQFGRNCAQRNCNKNGASCDRKTRGRCECLPGWSGEHCEK--SCVSHYGAK	1273					
	Q96KG6	QHCEQRCAFGTFGYGCCQLCECMNNSTCDHVTTGTCTCYCSPGFKGIRCDQA-ALMMEELNPY	760					
	Q96KG7	RHCRCCKPSGTGYGCGROI CDLNNSTCDHITGTCTCYCSPGWKGARCDQAGVIIVGNLNLSL	842					

1330 1340 1350 1360 1370 1380

	NOV15a	CEGRCAC-RWGGPCHLATGACLCPPGWRGPHLSAACLRGWFGEACAQRCSPPGAACHHV	1191
	NOV15b	CEGRCAC-RWGGPCHLATGACLCPPGWRGPHLSAACLRGWFGEACAQRCSPPGAACHHV	1185
	NOV15c	-----CLRGWFGEACAQRCSPPGAACHHV	1096
	NOV15d	-----	170
5	NOV15e	CEGRCAC-RWGGPCHLATGACLCPPGWRGPHLSAACLRGWFGEACAQRCSPPGAACHHV	1190
	NOV15f	CEGRCAC-RWGGPCHLATGACLCPPGWRGPHLSAACLRGWFGEACAQRCSPPGAACHHV	1195
	O88281	CEEHCAC-RKGASCHHVITGACFCPPGWRGPHCEQACPRGWFGEACAQRCLCPTNASCHHV	1190
	Q9TVQ2	CEETCEC-ENGALCDPISGHCSQCPGWRGKKCNRPCLKGYFGRHCSQSCRCANSKSCDHI	1268
10	T27283	CEETCEC-ENGALCDPISGHCSQCPGWRGKKCNRPCLKGYFGRHCSQSCRCANSKSCDHI	1332
	Q96KG6	TKISPALGAERHSVGAVTGIMLLFFIVVLLGLFAWHRRRQKEKGRDLAPRVSYTPAMRM	820
	Q96KG7	SRTSTALPADSYQIGAIAGIILVLVLLFLLALFIIYRHKQKGK-ESSMPAVTYTPAMRV	901
		1390 1400 1410 1420 1430 1440	
15	NOV15a	TGACRCPPPGFTGSGCEQACPPGSF-GEDCAQMCQCPGENPACHPATCTCS-----	1240
	NOV15b	TGACRCPPPGFTGSGCEQACPPGSF-GEDCAQMCQCPGENPACHPATCTCS-----	1234
	NOV15c	TGACRCPPPGFTGSGCEQACPPG-----	1118
	NOV15d	-----	170
20	NOV15e	TGACRCPPPGFTGSGCEQACPPGSF-GEDCAQMCQCPGENPACHPATCTCS-----	1239
	NOV15f	TGACRCPPPGFTGSGCEQACPPGSF-GEDCAQMCQCPGENPACHPATCTCS-----	1244
	O88281	TGECRCPPPGFTGLSCEQACQPGTF-GKDCEHLCCQCPGETWACDPASGVCT-----	1239
	Q9TVQ2	SGRCQCPKGYAGHSCTELCPDGTG-FGESCSQKCDCG-ENSMCDAISCKCF-----	1316
	T27283	SGRCQCPKGYAGHSCTELCPDGTG-FGESCSQKCDCG-ENSMCDAISCKCF-----	1380
	Q96KG6	TSTDYSLS-----	828
25	Q96KG7	VNADYTISGTLPHSNGGNANSHYFTNPSYHTLTQCATSPHVNNRDRMTVTKSKNNQLFVN	961
		1450 1460 1470 1480 1490 1500	
30	NOV15a	---CAAGYHG--PSCQQRCP-PGRYGPGEQQLCG-CLNGGSCDAATGACRCPTGFLGTDC	1293
	NOV15b	---CAAGYHG--PSCQQRCP-PGRYGPGEQQLCG-CLNGGSCDAATGACRCPTGFLGTDC	1287
	NOV15c	-----RYGPGEQQLCG-CLNGGSCDAATGACRCPTGFLGTDC	1154
	NOV15d	-----	170
	NOV15e	---CAAGYHG--PSCQQRCP-PGRYGPGEQQLCG-CLNGGSCDAATGACRCPTGFLGTDC	1292
	NOV15f	---CAAGYHG--PSCQQRCP-PGRYGPGEQQLCG-CLNGGSCDAATGACRCPTGFLGTDC	1297
35	O88281	---CAAGYHG--TGCLQRC-PSGRYGPGEHCK-CLNGGTCDPATGACYCPAGFLGADC	1292
	Q9TVQ2	---CKPGHSG--SDCKSGC-VQGRFGPDCNQLCS-CENGVCDSSTGSCVCPGYIGTKC	1369
	T27283	---CKPGHSG--SDCKSGC-VQGRFGPDCNQLCS-CENGVCDSSTGSCVCPGYIGTKC	1433
	Q96KG6	-----GACG-----MDRRQNTYI-----MDKGFKDYMKESVCSSSTC	860
40	Q96KG7	LKNVNPGRKRGVPGDCTGTLPADWKHGGYLNELGAFGLDRSYMGRKSLKDLGKNSEYNSSNC	1021
		1510 1520 1530 1540 1550 1560	
45	NOV15a	NLTCPOGRFGPNCTHVCGCGGGAACDPVTGTCLCPPGRAGVRCERGCPCNRFVGVGCEHTC	1353
	NOV15b	NLTCPOGRFGPNCTHVCGCGGGAACDPVTGTCLCPPGRAGVRCERGCPCNRFVGVGCEHTC	1347
	NOV15c	NLTCPOGRFGPNCTHVCGCGGGAACDPVTGTCLCPPGRAGVRCERGCPCNRFVGVGCEHTC	1214
	NOV15d	-----	170
	NOV15e	NLTCPOGRFGPNCTHVCGCGGGAACDPVTGTCLCPPGRAGVRCERGCPCNRFVGVGCEHTC	1352
	NOV15f	NLTCPOGRFGPNCTHVCGCGGGAACDPVTGTCLCPPGRAGVRCERGCPCNRFVGVGCEHTC	1357
50	O88281	SLACPOGRFGPSCAHVCACRGAACDPVSGACTCSPGKTGVRCEHGCPCDRFGKGCELKC	1352
	Q9TVQ2	EIACQSDRFGPTCEKICNCENGCTCDRLTGQCRCLPGFTGMTCNQVCPEGRFGAGCKEKC	1429
	T27283	EIACQSDRFGPTCEKICNCENGCTCDRLTGQCRCLPGFTGMTCNQVCPEGRFGAGCKEKC	1493
	Q96KG6	SLNSENPNYATIKDPPILTCKLPESYVEMKSPVHMGSPYTDVPSLSTSNKNIYEVEPTV	920
	Q96KG7	SLNSENPNYATIKDPPVLIPKSECGYVEMKSPARRDSPYAEINNSTSANRNVEVEPTV	1081
55		1570 1580 1590 1600 1610 1620	
	NOV15a	SCRNGGLCHASKR-----QLLLWPGLDGAALRAGLSPWALRSRLPSG-----	1395

	NOV15b	SCRNGGLCHASKR-----OLLLWPGLDGAALRAGLSPWALRSRLPSG-----	1389
	NOV15c	SCRNGGLCHASNGSCSCGLGWTGRHCELCACPPGRYGAACHLECSCHNNSTGEPATGTCRC	1274
	NOV15d	-----	170
5	NOV15e	SCRNGGLCHASKR-----OLLLWPGLDGAALRAGLSPWALRSRLPSG-----	1394
	NOV15f	SCRNGGLCHASNGSCSCGLGWTGRHCELCACPPGRYGAACHLECSCHNNSTCEPATGTCRC	1417
	O88281	SCRNGGLCHASNGSCSCPLGWMGPHCEHACPAARYGAACHLECFQNNGSCBPTTGACLC	1412
	Q9TVQ2	RCANG-HCNASSGECKCNLGFTGPSCEQSCPSGKYGLNCTLDCECYQARCDPVQGCCDC	1488
	T27283	RCANG-HCNASSGECKCNLGFTGPSCEQSCPSGKYGLNCTLDCECYQARCDPVQGCCDC	1552
10	Q96KG6	SVVQEGCGHNSYIQ-----NAYDLPRNSHIPGHYDLLPVRQSPAN-----	961
	Q96KG7	SVVQGVFSNNGRLSQ-----DPYDLPRNSHIPCHYDLLPVRDSSESPEKQ---E-	1126
		1630 1640 1650 1660 1670 1680	
	NOV15a	
15	NOV15b	-----VLLPQQQH-----	1404
	NOV15c	-----VLLPQQQH-----	1398
	NOV15d	GPGFYGQACEHPCPPGPHGAGCQGLCWCQHGAPCDPISGRCLCPAGFHGHFCERGCEPGS	1334
	NOV15e	-----VLLPQQQH-----	1403
20	NOV15f	GPGFYGQACEHPCPPGPHGAGCQGLCWCQHGAPCDPISGRCLCPAGFHGHFCERGCEPGS	1477
	O88281	GPGFYGQACEHSCPSGFHGPCQRVCECQAGAPCDPVSGQCLCPAGFHGFCEKGCESGS	1472
	Q9TVQ2	PPGRYGSRCQFSCPNFGFYGWYCSQSCSCQNGAHCDGADGRCLCPAGFQVKLANKKNDLE	1548
	T27283	PPGRYGSRCQFSCPNFGFYGWYCSQSCSCQNGAHCDGADGRCLCPAGFQVKLANKKNDLE	1612
	Q96KG6	-----GPSQDKQS-----	969
25	Q96KG7	-----D--SG---GS--SNSSSSSE-----	1140
		1690 1700 1710 1720 1730 1740	
	NOV15a	
30	NOV15b	-----	1404
	NOV15c	-----	1398
	NOV15d	FGECHQRCDCDGG-----APCDPVTGLCLCPPGRSGATCNLDCCRQGFPGSC	1382
	NOV15e	-----	170
	NOV15f	-----	1403
35	O88281	FGECHQRCDCDGG-----APCDPVTGLCLCPPGRSGATCNLDCCRQGFPGSC	1525
	Q9TVQ2	FGDGCLQQCNCHTG-----VPCDPISGLCLCPPGRTGAACDLDCRRGRFGPGC	1520
	T27283	LVQNIEFF-----	1608
	Q96KG6	-----	1620
40	Q96KG7	-----	969
		1750 1760 1770 1780 1790 1800	
	NOV15a	
45	NOV15b	-----	1404
	NOV15c	-----	1398
	NOV15d	TLHCDCGGGADCDPVSGQCHCVDGYMGPTCREGGPLRLPENPSLAQGSAGTLPASSRPTS	1442
	NOV15e	-----	170
	NOV15f	-----	1403
50	O88281	TLHCDCGGGADCDPVSGQCHCVDGYMGPTCREAG-----TLPASSRPTS	1569
	Q9TVQ2	ALRCDCGGGADCDPISGQCHCVDSYMGPCTREVP-----TQISSSRPAP	1564
	T27283	QNKQCFCNGATCDARTGQCSCSPGWLGPCTQIEMMDP-----NNVANRGDLP	1655
	Q96KG6	-----	1620
55	Q96KG7	-----	969
		1810	
	NOV15a	-----	1404
	NOV15b	-----	1398

NOV15c RSGGPARH-- 1450
NOV15d ----- 170
NOV15e ----- 1403
NOV15f RSGGPARH-- 1577
O88281 QHPSSRAMKH 1574
Q9TVQ2 EDWEWRKKR- 1664
T27283 ----- 1620
Q96KG6 ----- 969
Q96KG7 ----- 1140

The presence of identifiable domains in the disclosed NOV15 protein was determined by using Pfam and then determining the Interpro number. The results are listed in Table 15P with the statistics and domain description.

Table 15P. Domain Analysis of NOV15

PSSMs Producing Significant Alignments		Score (bits)	E Value
EGF: domain 2 of 27, from 168 to 203		38.8	1.2e-07
EGF	Capnn.pCsngGtCvntpggssdnfggytCeCppGdyylsyTGkrC ++++ ++ + +++++ ++ ++ +++++ + ++	(SEQ ID NO:216)	
NOV15	CRTHNgGCQH--RCVNTPG-----SYLCECKPG-FRLHTDSRTC	(SEQ ID NO:44)	
EGF: domain 3 of 27, from 208 to 244		34.2	3e-06
EGF	Capnn.pCsngGtCvntpggssdnfggytCeCppGdyylsyTGkrC +++++ ++ + + + ++ + + +++++ + ++	(SEQ ID NO:217)	
NOV15	CALNGNgGCQH--HCVQLTI-----TRHRCQCRPG-FQLQEDGRHC	(SEQ ID NO:44)	
EGF: domain 4 of 27, from 250 to 285		33.9	3.7e-06
EGF	Capnn.pCsngGtCvntpggssdnfggytCeCppGdyylsyTGkrC + ++ ++ + + +++ + ++ +++++ + +	(SEQ ID NO:218)	
NOV15	CANRNngSCMH--RCQVVRG-----LARCECHVG-YQLAADGKAC	(SEQ ID NO:44)	
EGF: domain 5 of 27, from 291 to 326		29.5	7.9e-05
EGF	Capnn.pCsngGtCvntpggssdnfggytCeCppGdyylsyTGkrC + + + +++ + +++ ++ +++++ + ++	(SEQ ID NO:219)	
NOV15	CAAGLaQCAH--GCLNTQG-----SFKCVCHAG-YELGADGRQC	(SEQ ID NO:44)	

Consistent with other known members of the MEGF6 family of proteins, NOV15 contains an epithelial growth factor (EGF) domain as illustrated in Table 15P.

NOV15 nucleic acids, and the encoded polypeptides, according to the invention are useful in a variety of applications and contexts. For example, NOV15 nucleic acids and

polypeptides can be used to identify proteins that are members of the EGF family of proteins. The NOV15 nucleic acids and polypeptides can also be used to screen for molecules, which inhibit or enhance NOV15 activity or function. Specifically, the nucleic acids and polypeptides according to the invention may be used as targets for the identification of small molecules that modulate or inhibit, *e.g.*, cell adhesion or receptor-ligand interactions. These molecules can be used to treat, *e.g.*, neurodegenerative disorders such as Alzheimers or Parkinson's disease, or connective tissue disorders such as Marfan syndrome, .

In addition, various NOV15 nucleic acids and polypeptides according to the invention are useful, *inter alia*, as novel members of the protein families according to the presence of domains and sequence relatedness to previously described proteins. For example, the NOV15 nucleic acids and their encoded polypeptides include structural motifs that are characteristic of proteins belonging to the MEGF family. Proteins belonging to the MEGF/Fibrillin family of proteins share a common feature of having epidermal growth factor (EGF)-like motifs. Examples of proteins containing EGF-like motifs include the MEGF proteins, which are expressed in the brain and are involved in neural development and function, the fibrillins, which are involved in extracellular matrix structure and maintenance, and the notch proteins (MEGF6), which are thought to be involved in mediating cell-fate decisions during hematopoiesis and neural development. Thus, such proteins play a critical role in a number of extracellular events, including cell adhesion and receptor-ligand interactions. Defects in these proteins can have profound effects on cellular and extracellular physiology and structure. For example, a mutation in fibrillin 1 causes Marfan syndrome, a disease that involves connective tissue, bone and lung manifestations.

The NOV15 nucleic acids and polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications in the mediation of cellular and extracellular physiology. As such the NOV15 nucleic acids and polypeptides, antibodies and related compounds according to the invention may be used to treat, *e.g.*, cancer, trauma, bacterial and viral infections, regeneration (in vitro and in vivo), fertility, endometriosis, cardiomyopathy, atherosclerosis, hypertension, congenital heart defects, aortic stenosis, atrial septal defect (ASD), atrioventricular (A-V) canal defect, ductus arteriosus, pulmonary stenosis, subaortic stenosis, ventricular septal defect (VSD), valve diseases, tuberous sclerosis, scleroderma, obesity, transplantation, anemia, bleeding disorders, transplantation, diabetes,

autoimmune disease, renal artery stenosis, interstitial nephritis, glomerulonephritis, polycystic kidney disease, systemic lupus erythematosus, renal tubular acidosis, IgA nephropathy, hypercalceimia, Lesch-Nyhan syndrome, systemic lupus erythematosus, autoimmune disease, asthma, emphysema, allergy, ARDS, von Hippel-Lindau (VHL) syndrome, Alzheimer's disease, stroke, hypercalceimia, Parkinson's disease, Huntington's disease, cerebral palsy, epilepsy, Lesch-Nyhan syndrome, multiple sclerosis, ataxia-telangiectasia, leukodystrophies, behavioral disorders, addiction, anxiety, pain, neurodegeneration, Hirschsprung's disease , Crohn's Disease, and appendicitis.

The NOV15 nucleic acids and polypeptides are useful for detecting specific cell types.

For example, expression analysis has demonstrated that a NOV15 nucleic acid is expressed in: brain, colon, frontal lobe, heart, kidney, lung, mammary gland/breast, ovary, prostate, and vein.

Additional utilities for NOV15 nucleic acids and polypeptides according to the invention are disclosed herein.

NOV16

The disclosed NOV16 nucleic acid (alternatively referred to herein as AL359846_A_da1) encodes a novel **G-protein coupled receptor (GPCR)**-like protein and includes the 990 nucleotide sequence (SEQ ID NO:55) shown in Table 16A. The NOV16 nucleic acid disclosed herein maps to chromosome 4.

An open reading frame for the mature protein was identified beginning with an ATG initiation codon at nucleotides 3-5, and ending with a TGA stop codon at nucleotides 945-947. Putative untranslated regions, if any, are found upstream from the initiation codon and downstream from the termination codon. The start and stop codons are in bold letters.

Table 16A. NOV16 Nucleotide Sequence (SEQ ID NO:55)

```
ACATGGAGACAAGAAATTACTCTGCCATGACTGAATTCTTTCTGGTGGGGCTTTCCCAATATCCAGAGCTCCAGC
TTTTTCTGTTCTGCTCTGCCTCATCATGTACATGATAATCCTCCTGGGAAATAGCCTCCTCATTATCATCACCA
TCTTGGATTCTCGCCTCCATACTCCCATGTATTTCTTTCTTGGAAACCTCTCATTCTTGGACATCTGTTACACAT
CCTCATCCATTCTCCAATGCTTATTATATTTATGTCTGAGAGAAAATCCATCTCCTTCATTGGCTGTGCTCTGC
AGATGGTTATGTCCCTTGGCTTGGGCTCCACTGAGTGTGTCTCCTGGCTGTGATGGCCTATGACCACTATGTGG
CCATCTGCAACCCACTGAGGTACTCCATCATCATGAACGGAGTGCTGTATGTGCAAATGGCTGCATGGTCCTGGA
TCATAGGCTGTCTGACCTCCCTATTGCACACAGTTCTGACAAATGATGTTGCCCTTTCTGTGGGAATAATGTCATTG
ATCATATTACCTGTGAAATTTTGGCCCTTCTAAACCTTGTTTGTTCAGATATCACCATCAATGTGCTTATCATGA
CAGTGACAAATATTGTTTCACTGGTGATTCTTCTACTGTTAATTTTCATCTCCTATGTGTTTATTCTCTCTTCCA
TCCTGAGAATTAATTGTGCTGAGGGAAGAAAGAAAGCCTTCTCTACCTGTTTCAGCGCACTCGATTGTGGTCATCT
```

TATTCTACGGTTCAGCCCTTTTATGTACATGAAACCCAAGTCAAAGAACACTAATACATCTGATGAGATTATTG
GGCTGTCTTATGGAGTGGTAAGCCCAATGTTAAATCCCATCATCTATAGCCTCAGGAATAAAGAGGTCAAAGAGG
CTGTAAAGAAAGTCCTGAGCAGACATCTGCATTTATTGAAAATGTGAAAAACCTTGGGCATGCGATATCCTCAAT
GGGGCAAGAGAGCTT

The NOV16 protein (SEQ ID NO:56) encoded by SEQ ID NO:55 is 314 amino acid residues in length and is presented using the one-letter amino acid code in Table 16B. The SignalP, Psort and/or Hydropathy results indicate that NOV16 has a signal peptide and is likely to be localized at the plasma membrane with a certainty of 0.6000. Alternatively, a NOV16 polypeptide is located to the Golgi body with a certainty of 0.4000, the endoplasmic reticulum (membrane) with a certainty of 0.3000, or the microbody (peroxisome) with a certainty of 0.3000. The SignalP indicates a likely cleavage site for a NOV16 peptide between positions 43 and 44, *i.e.*, at the dash in the sequence GNS-LL.

Table 16B. Encoded NOV16 Protein Sequence (SEQ ID NO:56)

METRNYSAMTEFFLVGLSQYPELQLFLFLLCLIMYMIILLGNLLIIITILDSRLHTPMYFFLGNL SFLDICYTS
SSIPPMLIIFMSERKSISFIGCALQMVMSLGLGSTECVLLAVMAYDHYVAICNPLRYSIIMNGVLVQMAAWSWI
IGCLTSL LHTVLTMMPLPFCGNNVIDHITCEILALLKLVCS DITINVLIMTVTNIVSLVILL LIFISYVFI LSSI
LRINCAEGRKKAFTCSAHSIVVILFYGSALFMYMKPKSKNTNTSDEIIIGLSYGVVSPMLNP IYSLRNKEVKEA
VKKVLSRHLHLLKM

A search against the Patp database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 16C.

Table 16C. PatP Results for NOV16

		High Score	Smallest Sum Prob P (N)
Sequences Producing High-Scoring Segment Pairs:			
patp:AAU24629	Human olfactory receptor AOLFR123	1575	1.6e-161
patp:AAG71424	Human olfactory receptor polypeptide	1569	6.8e-161
patp:AAG72315	Human olfactory receptor polypeptide	1377	1.5e-140
patp:AAG71954	Human olfactory receptor polypeptide	1028	1.4e-103
patp:AAG72652	Murine OR-like polypeptide query sequence	991	1.2e-99

In a BLAST search of public sequence databases, it was found, for example, that the NOV16 nucleic acid sequence of this invention has 555 of 804 bases (69%) identical to a gb:GENBANK-ID:MMU133424|acc:AJ133424.1 mRNA from Mus musculus or37a gene.

Further, the full amino acid sequence of the disclosed NOV16 protein of the invention has 189 of 313 amino acid residues (60%) identical to, and 246 of 313 amino acid residues (78%) similar to, the 318 amino acid residue ptnr:SPTREMBL-ACC:Q9QZ21 protein from Mouse (OLFACTORY RECEPTOR).

- 5 The NOV16 protein of the invention also has homolgy to the proteins shown in the BLASTP data in Table 16D.

Table 16D. NOV16 BLASTP Results

Gene Index/ Identifier	Protein/Organism	Length of aa	Identity (%)	Positives (%)	Expect Value
Q9QZ21	OLFACTORY RECEPTOR - Mus musculus (Mouse)	318	189/313 (60%)	246/313 (78%)	5.2e-99
Q9QZ22	OLFACTORY RECEPTOR - Mus musculus (Mouse)	319	190/317 (59%)	250/317 (78%)	1.8e-98
Q9QZ20	OLFACTORY RECEPTOR - Mus musculus (Mouse)	318	187/312 (59%)	244/312 (78%)	2.9e-98
Q9QZ19	OLFACTORY RECEPTOR - Mus musculus (Mouse)	319	187/314 (59%)	246/314 (78%)	1.6e-97
Q9NQN1	Olfactory receptor 2S2 - Homo sapiens (Human)	319	187/312 (59%)	245/312 (78%)	3.8e-96

- 10 A multiple sequence alignment is given in Table 16E, with the NOV16 protein of the invention being shown in line 1 in a ClustalW analysis comparing NOV16 with related protein sequences of Table 16D.

Table 16E. ClustalW Analysis of NOV16

- 15 1. SEQ ID NO.: 56 NOV16 4. SEQ ID NO.: 222 Q9QZ20
 2. SEQ ID NO.: 220 Q9QZ21 5. SEQ ID NO.: 223 Q9QZ19
 3. SEQ ID NO.: 221 Q9QZ22 6. SEQ ID NO.: 224 Q9NQN1

	10	20	30	40	50	60	
NOV16	METRNYSA-MTEFFLVGLSQPELQLFLFLCLIMYMIILLGNSLLILITILD SRLHTPM	59					
Q9QZ21	MEGANOST-VAEFVLLGLSDHPKLEKTFVLLILMYLVILLGNGVLILVLSILDSHLHTPM	59					
Q9QZ22	MDRSNETAPLSGFILLGLSAHPKLEKTFVLLILMYLVILLGNGVLILVLSILDSHLHTPM	60					
Q9QZ20	MDVSNQTT-VTEFVLLGLSAHPKLEKTFVLLILSMYLVILLGNGVLILVLSILDSHLHTPM	59					

	Q9QZ19	MERSNKTTPVSSFIILLGLSAHPKLEKTFVFLILMYLVILLGNVVLILVSIILDSHLHTPM	60
	Q9NQ1	MEKANETSPVMGFVLLRLSAHPELEKTFVFLILMYLVILLGNVVLILVSIILDSRLHTPM	60
5		70 80 90 100 110 120	
	NOV16	YFFLGNLISFLDICYTSSSIPLMLIIFMSERKSIISFTGCAIQMVMSLGLCSTECVLLAVMA	119
	Q9QZ21	YFFLGDLISFLDICYTSSSIPLVLDGFLTTPRKTIISFSGCAVQMFLSFAMGATECVLLGMMA	119
	Q9QZ22	YFFLGNLISFLDICYTSSSVPLIILDSFLTTPRKTIISFSGCAVQMFLSFAMGATECVLLSMMA	120
	Q9QZ20	YFFLGNLISFLDICYTSSSVPLVLDGFLTTPRKTIISFSGCAVQMFLSFAMGATECVLLGMMA	119
10	Q9QZ19	YFFLGNLISFLDICYTSSSVPLIILDSFLTTPRKTIISFSGCAVQMFLSFAMGATECVLLGMMA	120
	Q9NQ1	YFFLGNLISFLDICYTSSSVPLVLDGFLTTPRKTIISFSGCAVQMFLSFAMGATECVLLSMMA	120
15		130 140 150 160 170 180	
	NOV16	YDHYVAICNPLRYSIIMNGVLYVQMAAWSWIIIGCLTSLLHTVLTMLPFCGNVIEHTIC	179
	Q9QZ21	FDHYVAICNPLRYPVVMNKSAAYVPMASVSWAGGANSIVQISLAVQLPFCGDNVINHFTIC	179
	Q9QZ22	FDHYVAICNPLRYPVVMNKAAAYVPMASVSWAGGITNSVQVOTSLAMRLPFCGDNVINHFTIC	180
	Q9QZ20	FDHYVAICNPLRYPVVMNKAAAYVPMASVSWAGGANSIVQISLAVQLPFCGDNVINHFTIC	179
	Q9QZ19	FDHYVAICNPLRYPVVMNKAAAYVPMASVSWAGGANSIVQISLAVQLPFCGDNVINHFTIC	180
20	Q9NQ1	FDHYVAICNPLRYSIIMNGVLYVQMAAWSWIIIGCLTSLLHTVLTMLPFCGDNVINHFTIC	180
25		190 200 210 220 230 240	
	NOV16	EILAVLKLVCSDIINIVIMTVINIVSLVILLLIFISYVFILSSILRINCAEGRKKAFS	239
	Q9QZ21	EILAVLKLACADISINVISMGVANVIFLGVPVLFIFVSYVIFILSTILRIPSAEGRKKAFS	239
	Q9QZ22	EILAVLKLACADISINVISMGVANVIFLAVPVLFIFVSYVIFILVITILRIPSAEGRKKAFS	240
	Q9QZ20	EILAVLKLACADISINVISMGVANVIFLGVPVLFIFVSYVIFILSTILRIPSAEGRKKAFS	239
	Q9QZ19	EILAVLKLACADISINVISMGVANVIFLGVPVLFIFVSYVIFILSTILRIPSAEGRKKAFS	240
	Q9NQ1	EILAVLKLACADISINVISMEVINVIFLGVPVLFISFSYVIFILITILRIPSAEGRKKVFS	240
30		250 260 270 280 290 300	
	NOV16	TCSAHSIVVILFYGSALFMYMKPKSKN---T---NTSDEIIGLSYGVVSPMLNPPIIYSLR	293
	Q9QZ21	TCSAHLTVVILFYGTILFMYGKPKSKDPLGADKQDVSDKLISLFYGVITPMLNPPIIYSLR	299
	Q9QZ22	TCSAHLTVVILFYGTILFMYGKPKSKDPLGADKQDLADKLISLFYGVVTPMLNPPIIYSLR	300
	Q9QZ20	TCSAHLTVVILFYGTILFMYGKPKSKDPLGADKQDLADKLISLFYGVITPMLNPPIIYSLR	299
	Q9QZ19	TCSAHLTVVILFYGTILFMYGKPKSKDPLGADKQDLADKLISLFYGVVTPMLNPPIIYSLR	300
	Q9NQ1	TCSAHLTVVILFYGTILFMYGKPKSKDSMGADKEDLSDKLIPLFYGVVTPMLNPPIIYSLR	300
40		310 320	
	NOV16	NKEVKEAVKVLRSRHLHLKLM	314
	Q9QZ21	NKDVKA AVRNLVG-QKCLIQ-	318
	Q9QZ22	NKDVKA AVRNLVG-QKHLTE-	319
45	Q9QZ20	NKDVKA AVRNLAS-HRCLTF-	318
	Q9QZ19	NKDVKA AVTNLVG-QKHFKW-	319
	Q9NQ1	NKDVKA AVRRLIR-PKGFTO-	319

The presence of identifiable domains in the disclosed NOV16 protein was determined by using Pfam and then determining the Interpro number. The results are listed in Table 16F with the statistics and domain description.

Table 16F. Domain Analysis of NOV16

PSSMs Producing Significant Alignments		Score (bits)	E Value
7tm_1: domain 1 of 1, from 41 to 290		132.9	3.7e-41
7tm_1	GNlLVilvilrtkklrtptnifilNLAvADLLflltlppwalyylv GN+L i++ ++ +l+tp+++f++NL++ D++++ + p++l++++		
NOV16	GNSLLIIITILDSRLHTPMYFFLGNSFLDICYTSSSIPPMLIIFMS		
7tm_1	gsedWpfGsalCklvtaldvvnmyaSillltaISiDRYlAIvhPlryrrr e++ ++ ++C l++ + + + + lL+++++D Y+AI++Plry+ +		
NOV16	--ERKSISFIGCALQMVMSLGLGSTEVCVLLAVMAYDHYVAICNPLRYSII		
7tm_1	rtsprrrAkvvillvWvllaillslPpllfswwktveegngtlnvntvCli ++ + + + + W++++l sl++ ++ ++ ++++gn++ ++++C i		
NOV16	MN-GVLYVQMAAWSWIIGCLTSLHTVL-TMMLPFCGNNV--IDHITCEI		
7tm_1	dfpeestasvstwlrsyvllstlvGflPllvilvcYtrIlrtlr..... ++s+ t + + ++ ++v+ ++ ll+i + Y +Il + + +		
NOV16	LALLKLVCSDITINVLIMTVTNIVSLVILLLLIFISYVFILSSILrinca		
7tm_1	...kaaktllvvvvvFvlCWlPyfivllldtlc.lsiimsstCelervlp +++k a+ ++ ++++v++++ ++++++ + +		
NOV16	egrKKAFASTCSAHSIVVILFYGSALFMYMKPKSkNT-----NT		
7tm_1	tallvtlwLayvNsclNPiIY (SEQ ID NO:225) ++ l +++v+++lNPiIY		
NOV16	SDEIIGLSYGVVSPMLNPiIY (SEQ ID NO:56)		

Consistent with other known members of the GPCR family of proteins, NOV16 contains a 7-transmembrane (7tm_1) domain as illustrated in Table 16F.

The NOV16 nucleic acid, and the encoded polypeptide, according to the invention are useful in a variety of applications and contexts. For example, NOV16 nucleic acids and polypeptides can be used to identify proteins that are members of the GPCR family of proteins. The NOV16 nucleic acids and polypeptides can also be used to screen for molecules, which inhibit or enhance NOV16 activity or function. Specifically, the nucleic acids and polypeptides according to the invention may be used as targets for the identification of small molecules that modulate or inhibit, *e.g.*, cell recognition or signal transduction. These molecules can be used to treat, *e.g.*, taste and scent detectability disorders, weight disorders, immune diseases, or signal transduction pathways.

In addition, the NOV16 nucleic acid and polypeptide according to the invention are useful, *inter alia*, as novel members of the protein families according to the presence of domains and sequence relatedness to previously described proteins. For example, the NOV16 nucleic

acid and polypeptide include structural motifs that are characteristic of proteins belonging to the family of GPCR proteins. The human GPCR genes are generally intron-less and belong to four gene subfamilies, displaying great sequence variability. These genes are dominantly expressed in olfactory epithelium. Olfactory receptors (ORs) have been identified as extremely large family of GPCRs in a number of species. As members of the GPCR family, these receptors share a seven transmembrane domain structure with many neurotransmitter and hormone receptors, and are likely to underlie the recognition and G-protein-mediated transduction of odorant signals. Like GPCRs, the ORs they can be expressed in a variety of tissues where they are thought to be involved in recognition and transmission of a variety of signals.

The NOV16 nucleic acid and polypeptide, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications in the mediation of signal transduction. As such the NOV16 nucleic acid and polypeptide, antibodies and related compounds according to the invention may be used to treat, *e.g.*, developmental diseases, MHCII and III diseases (immune diseases), taste and scent detectability disorders, Burkitt's lymphoma, corticoneurogenic disease, signal transduction pathway disorders, retinal diseases including those involving photoreception, cell growth rate disorders, cell shape disorders, feeding disorders, control of feeding, potential obesity due to over-eating, potential disorders due to starvation (lack of appetite), noninsulin-dependent diabetes mellitus (NIDDM1), bacterial, fungal, protozoal and viral infections (particularly infections caused by HIV-1 or HIV-2), pain, cancer (including but not limited to Neoplasm; adenocarcinoma; lymphoma; prostate cancer; uterus cancer), anorexia, bulimia, asthma, Parkinson's disease, acute heart failure, hypotension, hypertension, urinary retention, osteoporosis, Crohn's disease, multiple sclerosis, angina pectoris, myocardial infarction, ulcers, asthma, allergies, benign prostatic hypertrophy, or psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, and severe mental retardation.

The NOV16 nucleic acid and polypeptide are useful for detecting specific cell types. For example, expression analysis has demonstrated that a NOV16 nucleic acid is expressed in olfactory neuroepithelium and the heart.

Additional utilities for the NOV16 nucleic acid and polypeptide according to the invention are disclosed herein.

NOV17

The NOV17 proteins described herein are novel transporter-like proteins. Two alternative novel NOV17 nucleic acids and polypeptides are disclosed herein, namely NOV17a and NOV17b.

- 5 NOV17a is directed to a transporter protein having a hydrophilic amino terminus containing sequences enriched in proline (P), glutamate (E), serine (S), and threonine (T), *i.e.*, PEST-containing transporter. The NOV17a nucleic acid disclosed herein maps to chromosome 6.

- 10 NOV17b is directed to a Na⁺ independent aromatic amino acid transporter. The NOV17b nucleic acid maps to chromosome 5.

NOV17a

- 15 A NOV17 variant is NOV17a (alternatively referred to herein as CG56459-01), which encodes the 1875 nucleotide sequence (SEQ ID NO:57) shown in Table 17A. An open reading frame for the mature protein was identified beginning with an ATG codon at nucleotides 5-7 and ending with a TAA codon at nucleotides 1823-1825. Putative untranslated regions, if any, downstream from the termination codon and upstream from the initiation codon are underlined. The start and stop codons are in bold letters.

Table 17A. NOV17a Nucleotide Sequence (SEQ ID NO:57)

GCT CATG CCTTATGGGCGGGGTGACCCACACATCTGTGCCCTCTCTGAGCAGGAGGAGGCCCCGTCGCAGACGCG CGCGCAGACAGCGTCTGCCGCGGGCACCTGGGGCCGCGCGCCGCGGGGCGCCCCGCTCCGCTCTCCGAGGCCCA ATCATCTGGAGGCTGTGGGGGCACGTCCCGCTCCCGGCCACGCCCCAGCCGGCGGGGCGGGGGCTCGCGTCCCT CGCGCTTCTCCGGCGCCTGAGGGGCCCGCCTCGGGCCATGGTGCTCTCCAGGAGGAGCCGGACTCCGCGCGGGG CAGGAGCGAGGCGCAGCCGCTCGGCCCGCGCCACGGGGGCGGCTCCGCCGCCCGGCCCGGGACCCCTCGGACAG CCCCGAGGCGGGCTGTGAGAAGGTGGAGGTGGAGCTGGCGGGGCGGCGACCGCGGAGCCCCATGAGCCCCCGA ACCCCCGAGGGCGGGCTGGGGCTGGCTGGTGATGCTGGCGGCCATGTGGTGCAACGGGTGGGTGTTTCGGCATCCA GAACGCTTGCGGGGTGCTCTTCGTGTCCATGCTGGAAACCTTCGGCTCCAAAGACGATGACAAGATGGTCTTTAA GACAGCATGGGTAGGTTCTCTCTCCATGGGGATGATTTTCTTTTGCTGCCCAATAGTCAGCGTCTTCACAGACCT ATTTGGTTGTGCGAAAACAGCTGTCTGTGGGTGCTGCTGTTGGATTGTTGGGCTCATGTCCAGTTCTTTTGTAAG TTCCATCGAGCCTCTGTACCTTACCTATGGAATCATATTTGCCGTGCGGCTGCTCCTTTGCATACCAGCCTTCATT GGTCATTTTGGGACACTATTTCAAGAAGCGCCTTGACTGGTGAATGGCATTGTCACTGCTGGCAGCAGTGTCTT CACAATCCTGCTGCCTTTGCTCTTAAGGGTTCTGATTGACAGCGTGGGCCTCTTTTACACATTGAGGGTGCTCTG CATCTTCATGTTTGTCTCTTTCTGGCTGGCTTTACTTACCGACCTCTTGCTACCAGTACCAAAGATAAAGAGAG TGGAGGTAGCGGATCCTCCCTCTTTTCCAGGAAAAAGTTCAGTCCGCCAAAAAAATTTCAATTTGCCATCTT CAAGGTGACAGCTTATGCAGTGTGGGCAGTTGGAATACCACTTGCACCTTTTGGATACTTTGTGCCTTATGTTCA CTTGGTGAGTATGCTCCTTCACAAACATGTAAATGAAAGATTTCAAGATGAAAAAATAAAGAGGTTGTTCTCAT GTGCATTGGCGTCACTTCAGGAGTTGGACGACTGCTCTTTGGCCGATTGCAGATTATGTGCCTGGTGTGAAGAA GGTTTATCTACAGGTACTTTCCTTTTCTTCATTGGTCTGATGTCCATGATGATTCCTCTGTGTAGCATCTTTGG
--

GGCCCTCATTGCTGTGTGCCTCATCATGGGTCTCTTCGATGGATGCTTCATTTCCATTATGGCTCCCATAGCCTT
 TGAGTTAGTTGGTGCCAGGATGTCTCCCAAGCAATTGGATTTCTGCTCGGATTCATGTCTATACCCATGACTGT
 TGGCCACCCATTGCAGGTTTACTTCGTGACAACTGGGCTCCTATGATGTGGCATTTCTACCTCGCTGGAGTCCC
 TCCCTTATTGGAGGTGCTGTGCTTTGTTTTATCCCGTGGATCCATAGTAAGAAGCAAAGAGAGATCAGTAAAC
 CACTGGAAAAGAAAAGATGGAGAAAATGTTGGAAAACCAGAACTCTCTGCTGTCAAGTTCATCTGGAATGTTCAA
 GAAAGAATCTGACTCTATTATTTAATATCTTACATACCTCCACCAGACTGGACTTGCTTTTGAATTTAAGCAA

The NOV17a protein (SEQ ID NO:58) encoded by SEQ ID NO:57 is 606 amino acid residues in length and is presented using the one-letter amino acid code in Table 17B. The SignalP, Psort and/or Hydropathy results indicate that NOV17a has no known signal peptide and is likely to be localized at the plasma membrane with a certainty of 0.8000. Alternatively, a NOV17a polypeptide is located in the Golgi body with a certainty of 0.4000, the endoplasmic reticulum (membrane) with a certainty of 0.3000, or the mitochondrial inner membrane with a certainty of 0.0300.

Table 17B. Encoded NOV17a Protein Sequence (SEQ ID NO:58)

MLMGVTHTSVPLSEQEEAPSQTRAQTASAAGTWGRAPRGAPPLSEAQSSGGCGGTSRSPRPQPAGRGLASLA
 LLRRLRGPPRAMVLSQEEPDSARGTSEAQPLGPAPTGAAPPGPGPSDSPEAAVEKVEVELAGPATAEPHEPPEP
 PEGGWGLVMLAAMWCNGSVFGIQNACGVLFVSMLFTFGSKDDDKMVFKTAWVGSLSMGMIFFCCPIVSVFTDLF
 GCRKTAVVGAAVGFVGLMSSSFVSSIEPLYLTYGIIIFACGCSFAYQPSLVILGHYFKRLGLVNGIIVTAGSSVFT
 ILLPLLLRVLIDSVGLFYTLRVLCIFMFVLFFLAGFTYRPLATSTKDKESGGSGSSLFSRKKFSPPKKIFNFAIFK
 VTAYAVWAVGIPLALFGYFVPYVHLVSMLLHKHVNERFQDEKNKEVVLVCIGVTSGVGRLLFGRIADYVPGVKKV
 YLQVLSFFFIGLMSMMIPLCSIFGALIAVCLIMGLFDGCFISIMAPIAFELVGAQDVSQAIGFLLGFMSIPMTVG
 PPIAGLLRDLKLSYDVAFYLAGVPPLIGGAVLCFIPWIHKKQREISKTTGKEKMEKMLENQNSLLSSSSGMFKK
 ESDSII

SNP variants of NOV17a are disclosed in Example 2.

NOV17b

Alternatively, a NOV17 variant is NOV17b (alternatively referred to herein as CG56459-02), which includes the 1605 nucleotide sequence (SEQ ID NO:59) shown in Table 17C. An open reading frame for the mature protein was identified beginning with an ATG codon at nucleotides 31-33 and ending with a TAA codon at nucleotides 1576-1578. Putative untranslated regions, if any, downstream from the termination codon and upstream from the initiation codon are underlined. The start and stop codons are in bold letters.

Table 17C. NOV17b Nucleotide Sequence (SEQ ID NO:59)

CTCCGGCGCCTGAGGGGCCCGCCTCGGGCCATGGTGCTCTCCAGGAGGAGCCGGACTCCGCGCGGGGCACGAGC
 GAGGCGCAGCCGCTCGGCCCCGCGCCACGGGGGCGGCTCCGCCGCCGGCCGGGACCCTCGGACAGCCCCGAG
 GCGGCTGTGAGAAGGTGGAGGTGGAGCTGGCGGGGCGGCGACCGCGGAGCCCCATGAGCCCCCGAACCCCC
 GAGGGCGGCTGGGGCTGGCTGGTGATGCTGGCGGCCATGTGGTGCAACGGGTCCGTGTTCCGCATCCAGAACGCT
 TCGGGGTGCTCTTCGTGTCCATGCTGGAACCTTCGGCTCCAAAGACGATGACAAGATGGTCTTTAAGACAGCA
 TGGGTAGGTTCTCTCTCCATGGGGATGATTTTCTTTTGCTGCCCAATAGTCAGTGTCTTCACAGACCTATTTGGT
 TGTCCGAAAACAGCTGTGCTGGGTGCTGCTGTTGGATTGTGGGCTCATGTCCAGTCTTTTGTAAAGTTCCATC
 GAGCCTCTGTACCTTACCTATGGAATCATATTTGCCTGCGGCTGCTCCTTTGCATACCAGCCTTCATTGGTCATT
 TTGGGACACTATTTCAAGAAGCGCCTTGGACTGGTGAATGGCATTGTCACTGCTGGCAGCAGTGTCTTCACAATC
 CTGCTGCCTTTGCTCTTAAGGGTTCTGATTGACAGCGTGGGCCTCTTTTACACATTGAGGGTGCTCTGCATCTTC
 ATGTTTGTCTCTTTCTGGCTGGCTTTACTTACCGACCTCTTGCTACCAGTACCAAAGATAAAGAGAGTGGAGGT
 AGCGGATCCTCCCTCTTTTCCAGGAAAAGTTCAAGTCTCCAAAAAAATTTTCAATTTTGCCATCTTCAAGGTG
 ACAGCTTATGCAGTGTGGGCAGTTGGAATACCACTTGCACCTTTTGGATACTTTGTGCCCTTATGTTCACTTGATG
 AAACATGTAAATGAAAGATTTCAAGATGAAAAAATAAAGAGGTTGTTCTCATGTGCATTGGCGTCACTTCAGGA
 GTTGACGACTGCTCTTTGGCCGATTGCAGATTATGTGCTGGTGTGAAGAAGGTTTATCTACAGGTACTCTCC
 TTTTCTTCATTGGTCTGATGTCCATGATGATTCTCTGTGTAGCATCTTTGGGGCCCTCATGTGCTGTGTCCTC
 ATCATGGGTCTCTTCGATGGATGCTTCATTTCCATTATGGCTCCCATAGCCTTTGAGTTAGTTGGTGCCAGGAT
 GTCTCCCAAGCAATTGGATTTCTGCTCGGATTCATGTCTATACCCATGACTGTTGGCCACCATTGCAAGGTTTA
 CTTGCTGACAACTGGGCTCCTATGATGTGGCATTCTACCTCGCTGGAGTCCCTCCCTTATTGGAGGTGCTGTG
 CTTTGTGTTTATCCCGTGGATCCATAGTAAGAAGCAAAGAGAGATCAGTAAACCCTGGAAAAGAAAAGATGGAG
 AAAATGTTGAAAACCAGAACTCTCTGCTGTCAAGTTCATCTGGAATGTTCAAGAAAGAATCTGACTCTATTATT
TAATATCTTACATACCTCCACCAGACTGGA

The NOV17b protein (SEQ ID NO:60) encoded by SEQ ID NO:59 is 515 amino acid residues in length and is presented using the one-letter amino acid code in Table 17D. The SignalP, Psort and/or Hydropathy results indicate that NOV17b has no known signal peptide and is likely to be localized at the plasma membrane with a certainty of 0.8000. Alternatively, a NOV17b polypeptide is located in the Golgi body with a certainty of 0.4000, the endoplasmic reticulum (membrane) with a certainty of 0.3000, or the mitochondrial inner membrane with a certainty of 0.0300.

Table 17D. Encoded NOV17b Protein Sequence (SEQ ID NO:60)

MVLSQEEPD SARGTSEAQPLGPAPTGAAPPPGPGPSDSPEAAVEKVEVELAGPATAEPHEPPEPPEGGWGWL VML
 AAMWCNGSVFGIQNACGVLFVSMLETFGSKDDDKMVFKTAWVGSLSMGMIFFCCPIVSVFTDLFGCRKTA VVGAA
 VGFVGLMSSSFVSSIEPLYLTYGIIIFACGCSFAYQPSLVILGHYFKRLGLVNGIVTAGSSVFTILLPLLLRVLI
 DSVGLFYTLRVLCIFMFVLFAGFTYRPLATSTKD KESGSGSSLSFRKKFSPPKKIFNFAIFKVTAYAVWAVGI
 PLALFGYFVPYVHLMKHVNRFQDEKNKEVVL MCIGVTSVGRLLFGRIADYVPGVKVYLQVLSFFF IGLMSMM
 IPLCSIFGALIAVCLIMGLFDGCFISIMAPIAFELVGAQDV SQAIGFLLGFMSIPMTVGPP IAGLLRDKLGSDV
 AFYLAGVPPLIGGAVLCFIPWIHKKQREISKTTGKEKMEKMLENQNSLLSSSSGMFKKESDSII

NOV17 Clones

Unless specifically addressed as NOV17a or NOV17b, any reference to NOV17 is assumed to encompass all variants.

A search against the Patp database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 17E.

Table 17E. PatP Results for NOV17

Sequences Producing High-Scoring Segment Pairs:	High Score	Smallest Sum Prob P (N)
patp:AAE07068 Human gene 18 encoded secreted protein HKZCK47	712	4.4e-70
patp:AAM93737 Human polypeptide	308	1.5e-41
patp:AAY31642 Human transport-associated protein-4 (TRANP-4)	442	1.8e-41
patp:AAB88570 Human hydrophobic domain containing protein clone HP03612 #34	297	2.5e-25
patp:AAE06594 Human protein having hydrophobic domain, HP03949	162	6.3e-20

In a BLAST search of public sequence databases, it was found, for example, that the NOV17a nucleic acid sequence of this invention has 687 of 711 bases (96%) identical to a gb:GENBANK-ID:AF116652|acc:AF116652.1 mRNA from Homo sapiens PRO0813 mRNA, complete cds. Further, the full amino acid sequence of the disclosed NOV17a protein of the invention was found to have 283 of 564 amino acid residues (50%) identical to, and 363 of 564 amino acid residues (64%) similar to, the 613 amino acid residue ptmr:SWISSPROT-ACC:P36021 protein from Human (X-LINKED PEST-CONTAINING TRANSPORTER).

In a similar BLAST search of public sequence databases, it was found, for example, that the NOV17b nucleic acid sequence of this invention has 1363 of 1605 bases (84%) identical to a gb:GENBANK-ID:AB047324|acc:AB047324.1 mRNA from Rattus norvegicus TAT1 mRNA, complete cds. Further the full amino acid sequence of the disclosed NOV17b protein of the invention was found to have 435 of 515 amino acid residues (84%) identical to, and 463 of 515 amino acid residues (89%) similar to, the 514 amino acid residue ptmr:TREMBLNEW-ACC:BAB55595 protein from Rat (TAT1 PROTEIN).

Additional BLAST results are shown in Table 17F.

Table 17F. NOV17 BLASTP Results

Gene Index/ Identifier	Protein/Organism	Length of aa	Identity (%)	Positives (%)	Expect Value
Q91Y77	TAT1 PROTEIN - Rattus norvegicus (Rat)	514	434/520 (83%)	464/520 (89%)	1.6e-230
P36021	Monocarboxylate transporter 8 (MCT 8) (X-linked PEST- containing transporter) (MCT 7) - Homo sapiens (Human)	613	283/564 (50%)	363/564 (64%)	7.7e-137
O70324	Monocarboxylate transporter 8 (MCT 8) (X-linked PEST- containing transporter) - Mus musculus (Mouse)	565	264/492 (53%)	340/492 (69%)	1.3e-132
Q9P1I2	PRO0813 - Homo sapiens (Human)	201	200/200 (100%)	200/200 (100%)	2.1e-102
AAH17968	HYPOTHETICAL 21.9 KDA PROTEIN - Homo sapiens (Human)	201	198/200 (99%)	199/200 (99%)	2.4e-101

A multiple sequence alignment is given in Table 17G, with the NOV17 proteins of the invention being shown in lines 1 and 2 in a ClustalW analysis comparing NOV17 with related protein sequences of Table 17F.

Table 17G. ClustalW Analysis of NOV17

1. SEQ ID NO.: 58	NOV17a	5. SEQ ID NO.: 228	O70324
2. SEQ ID NO.: 60	NOV17b	6. SEQ ID NO.: 229	Q9P1I2
3. SEQ ID NO.: 226	Q91Y77	7. SEQ ID NO.: 230	AAH17968
4. SEQ ID NO.: 227	P36021		

		10	20	30	40	50	60	
15	NOV17a						54
	NOV17b	-----MLMGGVTHTSVPLSEQEEAPSQTRAQTASAAGTWGRAPRGAPPPLSEAQSSGGC						1
	Q91Y77	-----						1
	P36021	MGRGGGGGLDVGGGEGSRDRLSRDGLASWGAEPGGGGSGSGSSPPSSSSCSSRNKYQPQ						60
20	O70324	-----MALP-----SPASEEAEGPCQEANQEYQEP						25
	Q9P1I2	-----						1
	AAH17968	-----						1
25		70	80	90	100	110	120	
							

NOV17a GGTSRSRPRPQPAGRGLASLALLRRLRGPPRAMVLSEQEEDPSAR-GTSEACP---LGPAP 110
 NOV17b -----MVLSQEEPD SAR-GTSEACP---LGPAP 24
 Q91Y77 -----MVPSLEEPAAAERETNEACP---PGPAP 25
 P36021 SGSSGPPSSHSPPAAMALQSQASEE-AKGPWQEQADQEQQEPVGSPEPESEPEPEPEPEPEPV 119
 O70324 VCS--PVPEPEPEPE-----PEPEPDPEP-VPVPPPEPQPEPEPQPLPDPAP 69
 Q9P1I2 ----- 1
 AAH17968 ----- 1

130 140 150 160 170 180
 NOV17a TGAA-----PPPGPGPSDSPEAAVEKVEVELAGPA---TAEPHEPPEPPEGGFGWLIV 159
 NOV17b TGAA-----PPPGPGPSDSPEAAVEKVEVELAGPA---TAEPHEPPEPPEGGFGWLIV 73
 Q91Y77 SDDA-----PLPVPGPSDVSDGVSVEKVEVELTR---STGNQEPPEPPEGGFGWLIV 72
 P36021 VPPP--EPQPEPQPLPDPAPLPLELEFESERVHEPEPTPTVETIRGTARGFQPPPEGGFGWVV 177
 O70324 LPELGFEAEPEPQPLPDPAPLPLELGFEAEPVQEPPEPTPTVETIRGTARGFQPPPEGGFGWIV 129
 Q9P1I2 ----- 1
 AAH17968 ----- 1

190 200 210 220 230 240
 NOV17a MLAAMWCNGSVFGIQNACGVLEFVSMLETFGSKDDDKMVEKTAWVGSLSMGMIFFCPIVS 219
 NOV17b MLAAMWCNGSVFGIQNACGVLEFVSMLETFGSKDDDKMVEKTAWVGSLSMGMIFFCPIVS 133
 Q91Y77 MLAAMWCNGSVFGIQNACGVLEFVSMLETFGAKDDDNMAFKAAWVGSLSMGMIFFCPIVS 132
 P36021 VFAATWCNGSVFGIHN SVGLYLSMLEEKEKKNR-QVEFQAAWVGALAMGMIFFCSPIVS 236
 O70324 VFAATWCNGSVFGIHN SVGLYLSMLEEKEKKNR-QVEFQAAWVGALAMGMIFFCSPIVS 188
 Q9P1I2 ----- 1
 AAH17968 ----- 1

250 260 270 280 290 300
 NOV17a VFTDLFGCRKTA VVGAAVGFVGLMSSSFVSSI EPLYLT YGIIFACGCSFAYQPSLVILGH 279
 NOV17b VFTDLFGCRKTA VVGAAVGFVGLMSSSFVSSI EPLYLT YGIIFACGCSFAYQPSLVILGH 193
 Q91Y77 VFTDMFGCRRTAVLGA VVGAAVGFVGLMSSSFVSSI EPLYFT YGVVAFACGCSFAYQPSLVILGH 192
 P36021 IFTDRLGCRITATAGAAVAFGLHSSSFTSSLSLRYFTYGIIFGCGCSFAFQPSLVILGH 296
 O70324 IFTDRLGCRITATTGA VAFGLHSSSFTSSLSLRYFTYGIIFGCGCSFAFQPSLVILDH 248
 Q9P1I2 ----- 1
 AAH17968 ----- 1

310 320 330 340 350 360
 NOV17a YFKKRLGLVNGIVTAGSSVFTILLPLLRVLIDSVGLFYTLRVL CTFMFVFLFLAGFTYRP 339
 NOV17b YFKKRLGLVNGIVTAGSSVFTILLPLLRVLIDSVGLFYTLRVL CTFMFVFLFLAGFTYRP 253
 Q91Y77 YFKKRLGLVNGIVTAGSSVFTILLPLLRVLIDSVGLFYTLRVL CTFMFVFLFLAGFTYRP 252
 P36021 YFQRLGLANGVVSAGSSIFSMSPFELIRMLGDKIKLAQTFQVLSTFMFVLM LLSLT YRP 356
 O70324 YFQRLGLANGVVSAGSSIFSMSPFELIKMLGDKIKLAQTFQVLSTFMFVLTLLSLT YRP 308
 Q9P1I2 ----- 1
 AAH17968 ----- 1

370 380 390 400 410 420
 NOV17a LATSTKDKESGGSGSSLSFSRKKFSPPPKIFNFALFKVTAYAVWAVGIPLALFGYFVPYVH 399
 NOV17b LATSTKDKESGGSGSSLSFSRKKFSPPPKIFNFALFKVTAYAVWAVGIPLALFGYFVPYVH 313
 Q91Y77 LVPSSKEKESEDSRSSFFSRRKLSPPPKIFNFALFKETAYAVWAGIPLALFGYFVPYVH 312
 P36021 LLPSSQDTPSK-RGVRTLHQRF LAQLRK YFNMRVFRQRTYRIWAFGIAAAALGYFVPYVH 415
 O70324 LLPSSQDTPSK-RGAHTLRQRFV LQVFRK YFNMRVFRQRTYRIWAFGIAAAALGYFVPYVH 367
 Q9P1I2 ----- 1
 AAH17968 ----- 1

		430	440	450	460	470	480	
	NOV17a	LVSMLLHKHVN	ERFDEKNKEV	LMCIGVTSGVGRLL	FGRIADYV	PGVKKVYLQVLS	FFFF	459
5	NOV17b	LM-----KHVN	ERFDEKNKEV	LMCIGVTSGVGRLL	FGRIADYV	PGVKKVYLQVLS	FFFF	368
	Q91Y77	LMN-----HVKER	FDVNNKEV	LMCIGVTSGVGRLL	FGRIADYV	PGVKKVYLQVLS	FFFF	367
	P36021	LMK-----YVEEEF	SEIKETWVLL	VCIGATSG	GRVLSCHIS	SDSTPG	KKIYQVLS	470
	O70324	LMK-----YVEDKF	KEIKETWVLL	VCIGATSG	GRVLSCHIS	SDSTPG	KKIYQVLS	422
	Q9P1I2	-----MKHVN	ERFDEKNKEV	LMCIGVTSGVGRLL	FGRIADYV	PGVKKVYLQVLS	FFFF	54
10	AAH17968	-----MKHVN	ERFDEKNKEV	LMCIGVTSGVGRLL	FGRIADYV	PGVKKVYLQVLS	FFFF	54
		490	500	510	520	530	540	
	NOV17a	IGLMSMMIPLCS	IFGALIAVCLIMGL	FDGCFISIMAPIA	FELVCAQDV	SQAIGFLLGFMS		519
15	NOV17b	IGLMSMMIPLCS	IFGALIAVCLIMGL	FDGCFISIMAPIA	FELVCAQDV	SQAIGFLLGFMS		428
	Q91Y77	IGLMSMMIPLCS	IFGALIAVCLIMGL	FDGCFISIMAPIA	FELVCAQDV	SQAIGFLLGFMS		427
	P36021	IGLMSMMIPLCR	DFGGLIVVCLFL	GLCDGFFI	IMAPIAFELV	GPMQASQAIG	LLGMM	530
	O70324	IGLMSMMIPLCR	DFGGLIVVCLFL	GLCDGFFI	IMAPIAFELV	GPMQASQAIG	LLGMM	482
	Q9P1I2	IGLMSMMIPLCS	IFGALIAVCLIMGL	FDGCFISIMAPIA	FELVCAQDV	SQAIGFLLGFMS		114
20	AAH17968	IGLMSMMIPLCS	IFGALIAVCLIMGL	FDGCFISIMAPIA	FELVCAQDV	SQAIGFLLGFMS		114
		550	560	570	580	590	600	
	NOV17a	IPMTVGPP	IAGLLRDKLGSYD	VAFYLAGVPP	IGGAVLCFIP	WIHSSKKQRE	ISKTGKEK	579
25	NOV17b	IPMTVGPP	IAGLLRDKLGSYD	VAFYLAGVPP	IGGAVLCFIP	WIHSSKKQRE	ISKTGKEK	488
	Q91Y77	IPMTVGPP	IAGLLRDKLGSYD	VAFYLAGVPP	IGGAVLCFIP	WIHSSKKQRE	ISKTGKEK	487
	P36021	IPMTVGPP	IAGLLRDKLGSYD	VAFYLAGVPP	IGGAVLCFIP	WIHSSKKQRE	ISKTGKEK	590
	O70324	IPMTVGPP	IAGLLRDKLGSYD	VAFYLAGVPP	IGGAVLCFIP	WIHSSKKQRE	ISKTGKEK	542
	Q9P1I2	IPMTVGPP	IAGLLRDKLGSYD	VAFYLAGVPP	IGGAVLCFIP	WIHSSKKQRE	ISKTGKEK	174
30	AAH17968	IPMTVGPP	IAGLLRDKLGSYD	VAFYLAGVPP	IGGAVLCFIP	WIHSSKKQRE	ISKTGKEK	174
		610	620					
	NOV17a	MEKMLENQNS	LLSSSSSGMFK	KESDSII				606
35	NOV17b	MEKMLENQNS	LLSSSSSGMFK	KESDSII				515
	Q91Y77	MEKMLENQNS	LLSSSSSGMFK	KESDSII				514
	P36021	MLAPDPDP	NGELLPGS	--P-NPEEPI-				613
	O70324	MLSHDPDP	NGELLPGS	--P-TPEEPI-				565
	Q9P1I2	MEKMLENQNS	LLSSSSSGMFK	KESDSII				201
40	AAH17968	MEKMLENQNS	LLSSSSSGMFK	KESDSII				201

The presence of identifiable domains in the disclosed NOV17 protein was determined by using Pfam and then determining the Interpro number. The results are listed in Table 17H with the statistics and domain description.

Table 17H. Domain Analysis of NOV17		
PSSMs Producing Significant Alignments	Score (bits)	E Value
sugar_tr: domain 1 of 1, from 155 to 584	-178.6	1.9

[illegible]

Consistent with other known members of the proton-linked monocarboxylate transporter (MCTs) family of proteins, NOV17 contains a transporter domain as illustrated in Table 17H.

NOV17 nucleic acids, and the encoded polypeptides, according to the invention are
5 useful in a variety of applications and contexts. For example, NOV17 nucleic acids and
polypeptides can be used to identify proteins that are members of the MCTs family of proteins.

The NOV17 nucleic acids and polypeptides can also be used to screen for molecules, which inhibit or enhance NOV17 activity or function. Specifically, the nucleic acids and polypeptides according to the invention may be used as targets for the identification of small molecules that modulate or inhibit, *e.g.*, cellular metabolism, or transport of monocarboxylates such as lactate and pyruvate. These molecules can be used to treat, *e.g.*, infantile sialic storage disease.

In addition, various NOV17 nucleic acids and polypeptides according to the invention are useful, *inter alia*, as novel members of the protein families according to the presence of domains and sequence relatedness to previously described proteins. For example, the NOV17 nucleic acids and their encoded polypeptides include structural motifs that are characteristic of proteins belonging to the MCTs family. Monocarboxylates such as lactate and pyruvate play a pivotal role in cellular physiology of most mammalian cells. Lactic acid, in particular, is produced in huge amounts as an end-product of glycolysis. Some tissues, such as white skeletal muscle, red blood cells and tumor cells, rely on this pathway to produce majority of their ATP under normal physiological conditions, while all tissues become dependent on this pathway during hypoxia or ischaemia. Two molecules of lactic acid are generated for every glucose molecule during glycolysis. Lactic acid must be transported out of the cell if high rates of glycolysis are to be maintained. Accumulation of lactic acid leads to a decrease in intracellular pH and cessation of glycolysis. Lactic acid transport is carried out by a recently identified family of proton-linked monocarboxylate transporters (MCTs) located at the plasma membrane. At least 9 MCTs (MCT1-9)-related genes have so far been identified in mammals, each having a different tissue distribution. MCTs also mediate the transport of many other metabolically important monocarboxylates such as pyruvate, the branched-chain oxo acids derived from leucine, valine and isoleucine, and the ketone bodies acetoacetate, -hydroxybutyrate and acetate.

The NOV17 nucleic acids and polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications in the mediation of cellular metabolism and transport. As such the NOV17 nucleic acids and polypeptides, antibodies and related compounds according to the invention may be used to treat, *e.g.*, Salla disease, infantile sialic acid storage disease, cystinosis, or streptozotocin-induced diabetes.

The NOV17 nucleic acids and polypeptides are useful for detecting specific cell types. For example, expression analysis has demonstrated that a NOV17a nucleic acid is expressed in adrenal gland, bone marrow, brain - amygdala, brain - cerebellum, brain - hippocampus, brain -

substantia nigra, brain - thalamus, brain -whole, fetal brain, fetal kidney, fetal liver, fetal lung, heart, kidney, lymphoma - Raji, mammary gland, pancreas, pituitary gland, placenta, prostate, salivary gland, skeletal muscle, small intestine, spinal cord, spleen, stomach, testis, thyroid, trachea, and uterus. Conversely, a NOV17b nucleic acid is expressed in parathyroid gland, liver, colon, muscle, brain, placenta, vulva, testis, lung, kidney, skin, and colon adenocarcinoma.

Additional utilities for NOV17 nucleic acids and polypeptides according to the invention are disclosed herein.

NOV18

The NOV18 proteins described herein are novel olfactory receptor/G-protein coupled receptor (GPCR)-like proteins. Two alternative novel NOV18 nucleic acids and polypeptides are disclosed herein, namely NOV18a and NOV18b.

NOV18a

A NOV18 variant is NOV18a (alternatively referred to herein as CG56510-01), which encodes the 1001 nucleotide sequence (SEQ ID NO:61) shown in Table 18A. An open reading frame for the mature protein was identified beginning with an ATG codon at nucleotides 37-39 and ending with a TGA codon at nucleotides 958-960. Putative untranslated regions, if any, downstream from the termination codon and upstream from the initiation codon are underlined. The start and stop codons are in bold letters.

Table 18A. NOV18a Nucleotide Sequence (SEQ ID NO:61)
GTGTTCCATAGATTATTTTGTCTTTTGTCTGAAGTG ATG CTGAATACAACCTCAGTCACCGAATTTCTCCTCTTG GGAGTGACAGACATTCAAGAACTGCAGCCTTTTCTCTTCGTGGTTTTCTCACCATCTACTTCATCAGTGTGACT GGGAATGGAGCCGTTCTGATGATTGTCATCTCCGATCCTAGACTCCATTCCCTTATGTATTTCTTCCTGGGAAAC CTGTCTACCTGGATATCTGTTACTCTACGGTGACACTGCCAAAAATGCTGCAGAACTTTCTCTCTACACACAAA GCAATTTCTTTCTTGGGATGCATAAGCCAGCTTCATTTCTTCCACTTCCTGGGCAGCACGGAGTCCATGTTGTTT GCCGTGATGGCATTGACCTCTCTGTGGCTATCTGCAAGCCACTTCGCTACACTGTCATCATGAACCTCAGCTC TGTACCCAGATGGCCATCACAATCTGGGTCAATGGTTTTTCCATGCCCTGCTGCACTCCGTAATGACTTCTCGC TTGAACCTCTGTGGTTCCAACCGTATCCATCATTTTCTCTGTGATATTAAGCCATTGCTAAAGCTGGCCTGTGGG AACTGAGCTTAATCAGTGGCTACTCAGTACTGTCACGGGGACAATTGCCATGGGCCCCCTTCTTTCTGACACTT CTCTCCTATTTCTACATTATCACTTATCTCTTCTTCAAGACCCGTTCTTGTAGCATGCTCTGTAAAGCACTGTCC ACTTGTGCCTCCCACCTTCATGGTAGTTATTCTTTTCTATGCACCTGTTCTTTTACCTATATCCATCCTGCGTTA GAGAGCTTCATGGACCAGGACCGGATTGTTGCCATCATGTACACTGTGGTCACTCCTGTACTAAACCCACTGATC TATACTTTGAGGAACAAGGAAGTGAAGGGGCCCTTGGGTAGAGTGATCAGAAGGCTTTG ATT TGAATAAACCAGA GAACTCTACTGAGGCATAAATAACCA

The NOV18a protein (SEQ ID NO:62) encoded by SEQ ID NO:61 is 307 amino acid residues in length and is presented using the one-letter amino acid code in Table 18B. The SignalP, Psort and/or Hydropathy results indicate that NOV18a has a signal peptide and is likely to be localized at the plasma membrane with a certainty of 0.6000. Alternatively, a NOV18a polypeptide is located in the Golgi body with a certainty of 0.4000, the endoplasmic reticulum (membrane) with a certainty of 0.3000, or the microbody (peroxisome) with a certainty of 0.3000. The SignalP indicates a likely cleavage site for a NOV18a peptide between positions 39 and 40, *i.e.*, at the dash in the sequence VTG-NG.

Table 18B. Encoded NOV18a Protein Sequence (SEQ ID NO:62)

MLNTTSVTEFLLLGVTDIQELQPFLFVVFLLTIYFISVTGNGAVLMIVISDPRLHSLMYFFLGNL SYLDICYSTVT
LPKMLQNFLSTHKAI SFLGCISQLHFFHFLGSTESMLFAVMAFDLSVAICKPLRYTVIMNPQLCTQMAITIWVIG
FFHALLHSVMTSRLNFCGSNRIHHFLCDIKPLLKLACGNTELNQWLLSTVTGTIAMGPFFLTLLSYFYIIITYLFF
KTRSCSMLCKALSTCASHFMVVILFYAPVLFTYIHPALESFMDQDRIVAIMYTVVTPVLNPLIYTLRNKEVKGAL
GRVIRRL

SNP variants of NOV18a are disclosed in Example 2.

NOV18b

Alternatively, a NOV18 variant is NOV18b (alternatively referred to herein as CG56510-02), which includes the 1101 nucleotide sequence (SEQ ID NO:63) shown in Table 18C. An open reading frame for the mature protein was identified beginning with an ATG codon at nucleotides 148-150 and ending with a TGA codon at nucleotides 1069-1071. Putative untranslated regions, if any, downstream from the termination codon and upstream from the initiation codon are underlined. The start and stop codons are in bold letters.

Table 18C. NOV18b Nucleotide Sequence (SEQ ID NO:63)

TAAGCTTCTATACAACCTTCTGAGGTTTGGAAAGAAGTACAACAGTACTCTCCTTCCAAGTATCTTTGGCTTGGTGA
GAAAATTCTGAGCCGGAAGGATTCTGATTGCGATTAGTGTTCCATAGATTATTTTGTCTTTTGTCTGAAGTGATG
CTGAATACAACCTCAGTCACCGAATTTCTCCTCTTGGGAGTGACAGACATTCAAGAACTGCAGCCTTTTCTCTTC
GTGGTTTTCTCACCATCTACTTCATCAGTGTGACTGGGAATGGAGCCGTTCTGATGATTGTCTATCTCCGATCCT
AGACTCCATTCCCTTATGTATTTCTTCTGGAACCTGTCTACCTGGATATCTGTTACTCTACGGTGACACTG
CCAAAAATGCTGCAGAACTTTCTCTCTACACACAAAGCAATTTCTTTCTTGGGATGCATAAGCCAGCTTCATTTT
TTCCACTTCTGCGCAGCACGGAGTCCATGTTGTTCGCCGTGATGGCATTGACCTCTCTGTGGCTATCTGCAAG
CCACTTCGCTACACTGTCATCATGAACCCTCAGCTCTGTACCCAGATGGCCATCACAATCTGGGTCATTGGTTTT

```

TTCCATGCCCTGCTGCACTCCGTAATGACTTCTCGCTTGAACCTTCTGTGGTTCCAACCGTATCCATCATTTC
TGTGATATTAAGCCATTGCTAAAGCTGGCCTGTGGGAACACTGAGCTTAATCAGTGGCTACTCAGTACTGTCACG
GGGACAATTGCCATGGGCCCTTCTTTCTGACACTTCTCTCCTATTTCTACATTATCATTATCTCTTCTTCAAG
ACCCGTTCTTGTAGCATGCTCTGTAAAGCACTGTCCACTTGTGCCTCCCACTTCATGGTAGTTATTCTTTCTAT
GCACCTGTTCTTTTCACCTATATCCATCCTGCGTTAGAGAGCTTCATGGACCAGGACCGGATTGTTGCCATCATG
TACACTGTGGTCACTCCTGTACTAAACCACTGATCTATACTTTGAGGAACAAGGAAGTGAAGGGGGCCTTGGGT
AGAGTGATCAGAAGGCTTTGATTTGAATAAACAGAGAACTCTACTGAGGC

```

The NOV18b nucleic acid (SEQ ID NO:63) encodes the NOV18a protein SEQ ID NO:62.

NOV18 Clones

Unless specifically addressed as NOV18a or NOV18b, any reference to NOV18 is assumed to encompass all variants.

A search against the Patp database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 18D.

Table 18D. PatP Results for NOV18

	High Score	Smallest Sum Prob P (N)
Sequences Producing High-Scoring Segment Pairs:		
patp:AAG72203 Human olfactory receptor polypeptide	1590	4.0e-163
patp:AAG72870 Human olfactory receptor data exploratorium sequence	1590	4.0e-163
patp:AAG71661 Human olfactory receptor polypeptide	1344	4.7e-137
patp:AAG72212 Human olfactory receptor polypeptide	1344	4.7e-137
patp:AAG72633 Murine OR-like polypeptide query sequence	1296	5.7e-132

In a BLAST search of public sequence databases, it was found, for example, that the NOV18 nucleic acid sequences of this invention have 590 of 911 bases (64%) identical to a gb:GENBANK-ID:AF101730|acc:AF101730.1 mRNA from Pan troglodytes isolate PTOR1E1 olfactory receptor gene, complete cds. Further, the full amino acid sequence of the disclosed NOV18 protein of the invention has 205 of 306 amino acid residues (66%) identical to, and 251 of 306 amino acid residues (82%) similar to, the 316 amino acid residue ptnr:SPTREMBL-ACC:Q9UGF7 protein from Human (BA150A6.1 (NOVEL 7 TRANSMEMBRANE RECEPTOR (RHODOPSIN FAMILY) (OLFACTORY RECEPTOR LIKE) PROTEIN

(HS6M1-27))). While it has not been annotated as an olfactory receptor, genomic clone Genbank ID AL049739.2 shows 100% homology to NOV18.

Additional BLAST results are shown in Table 18E.

Table 18E. NOV18 BLASTP Results

Gene Index/ Identifier	Protein/Organism	Length of aa	Identity (%)	Positives (%)	Expect Value
P58182	Olfactory receptor 12D2 (Hs6M1-20) - Homo sapiens (Human)	307	307/307 (100%)	307/307 (100%)	5.1e-163
Q920Y9	BM332P19.2 (NOVEL 7 TRANSMEMBRANE RECEPTOR (RHODOPSIN FAMILY) (OLFACTORY RECEPTOR LIKE) PROTEIN (MM17M1- 13), ORTHOLOG OF HUMAN DJ994E9.8 (HS6M1-20)) - Mus musculus (Mouse)	308	245/306 (80%)	268/306 (87%)	7.3e-132
Q920Y8	BM332P19.3 (NOVEL 7 TRANSMEMBRANE RECEPTOR (RHODOPSIN FAMILY) (OLFACTORY RECEPTOR LIKE) PROTEIN (MM17M1- 14)) - Mus musculus (Mouse)	313	240/306 (78%)	267/306 (87%)	8.7e-129
Q920Z0	BM332P19.1 (NOVEL 7 TRANSMEMBRANE RECEPTOR (RHODOPSIN FAMILY) (OLFACTORY RECEPTOR LIKE) PROTEIN (MM17M1- 12)) - Mus musculus (Mouse)	308	240/306 (78%)	263/306 (85%)	9.9e-128
CAC44547	BM332P19.4 (NOVEL 7 TRANSMEMBRANE RECEPTOR (RHODOPSIN FAMILY) (OLFACTORY RECEPTOR LIKE) PROTEIN (MM17M1- 8P)) - Mus musculus (Mouse)	277	206/276 (74%)	243/276 (88%)	2.6e-113

A multiple sequence alignment is given in Table 18F, with the NOV18 protein of the invention being shown in line 1 in a ClustalW analysis comparing NOV18 with related protein sequences of Table 18E.

Table 18F. ClustalW Analysis of NOV18

1. SEQ ID NO.: 62	NOV18	4. SEQ ID NO.: 234	Q920Y8
2. SEQ ID NO.: 232	P58182	5. SEQ ID NO.: 235	Q920Z0
3. SEQ ID NO.: 233	Q920Y9	6. SEQ ID NO.: 236	CAC44547

	10	20	30	40	50	60	
NOV18	MLNTTSVTEFLLLGVTDIQELQPFLLFVVFLLTIYFISVTGNGAVLMIVISDPRLHSLMYFF	60					
P58182	MLNTTSVTEFLLLGVTDIQELQPFLLFVVFLLTIYFISVTGNGAVLMIVISDPRLHSLMYFF	60					
Q920Y9	MSNQTSVTEFLLLGVTDIQELNPILFVIFFTIYFVNITGNGAILMIVILDPRHLHSPMYFF	60					
Q920Y8	MLNQTSVTEFLLLGVTDIQEPQPFLLFAIFFTIYFVNITGNGAILMIVILDPRHLHSPMYFF	60					
Q920Z0	MSNQTSVTEFLLLGVTDIQELNPILFVIFFTIYFVNITGNGAILMIVILDPRHLHSPMYFF	60					
CAC44547	-----MYFVNIVAGNGAILMIVISDPRLHLPMYFF	29					
	70	80	90	100	110	120	
NOV18	LGNLSYLDICYSTVTLPKMLQNLFLSTHK AISFLGCISQLHFFHFLGSTESMLFAVMAFDL	120					
P58182	LGNLSYLDICYSTVTLPKMLQNLFLSTHK AISFLGCISQLHFFHFLGSTESMLFAVMAFDL	120					
Q920Y9	LGNLACLDICYSTVTLPKMLQNLFLSTNKAISFLGCITQLHFFHFLGSTESMLLPVMAFDR	120					
Q920Y8	LGNLACLDISYSTVTVPKMLENLLSTNKAISFLGCITQLHFFHFLGSTESMLLPVMAFDR	120					
Q920Z0	LGNLACLDISYSTVTVPKMLENLLSTNKAISFLGCITQLHFFHFLGSTESMLLPVMAFDR	120					
CAC44547	LGNLACLDICYSTVTVPKMLENFFSTSKAISFLGCITQLHFFHFLGSTESMLLPVMAFDR	89					
	130	140	150	160	170	180	
NOV18	SVAICKPLRYIVIMNPOLCTQMAITIWVIGFFHALLHSVMTSRLNFCGSNRHIFHFLCDIK	180					
P58182	SVAICKPLRYIVIMNPOLCTQMAITIWVIGFFHALLHSVMTSRLNFCGSNRHIFHFLCDIK	180					
Q920Y9	FVAICRPLHYSVIMNHQLCIHMTVTIWTIGFFHALLHSVMTSRLSFCGPNHIVHFFCDIK	180					
Q920Y8	FVAICRPLHYSVIMNWOVCILMAVTIWTIAFLHALLHSVMTSRLSFCGLNHIHFFCDIK	180					
Q920Z0	FVAICRPLHYSVIMNHQLCIHMTVTIWTIGFFHALLHSVMTSRLSFCGPNHIVHFFCDIK	180					
CAC44547	FVAICRPLHYPAIMNSOVCIQVAISIWAIPFLHALVHSLTSQNLFCGSNRHIVHFFCDIK	149					
	190	200	210	220	230	240	
NOV18	PLLELACGNTELNLWLLNTVTGTIATGPFFLTLLSYFYIITYLFFKTRSCSMLCKALSTC	240					
P58182	PLLELACGNTELNLWLLNTVTGTIATGPFFLTLLSYFYIITYLFFKTRSCSMLCKALSTC	240					
Q920Y9	PLLELACGNTELNLWLLNTVTGTIATGPFFLTLLSYFYIITYLFLKTRSCSMLHKAALSTC	240					
Q920Y8	PLLELACGNTELNLWLLNTVTGTIASVPFFLTLLSYFYIITYLFLKTRSCSMLHKAALSTC	240					
Q920Z0	PLLELACGNTELNLWLLNTVTGTIATGPFFLTLLSYFYIITYLFLKTRSCSMLHKAALSTC	240					
CAC44547	PLLELACGNTELNRWLLNTLTGTVAIGLFFLTLLSYFYIITYLFLKTRSCSMLHKAALSTC	209					
	250	260	270	280	290	300	
NOV18	ASHFMVVILFYAPVLFYIHPALESFMDQDRIVAIMYIVVTPVLNPLIYTLRNKEVKGAL	300					
P58182	ASHFMVVILFYAPVLFYIHPALESFMDQDRIVAIMYIVVTPVLNPLIYTLRNKEVKGAL	300					

Q920Y9 ASHFMVVILLVVPVLFYIIRPASGSSLDQDRIIAIMYSVWTPALNPLIYTLRNKEVRSAL 300
Q920Y8 ASHFMVVVLFYAPVLFYIIRPTSGSSLDQDRIIAIMYSVWTPALNPLIYTLRNKEVRSAL 300
Q920Z0 ASHFMVVVLFYAPVLFYIIRPASGSSLDQDRIIAIMYSVWTPALNPLIYTLRNKEVRSAL 300
CAC44547 ASHFMVVMIFYPVLFYIINPDSGSSLEKDRIIAIMYSVWTPALNPLIYTLRNKEVRGAL 269

310
.....|.....|...
NOV18 GRVIRRL----- 307
P58182 GRVIRRL----- 307
Q920Y9 NRKVRRL----- 308
Q920Y8 NRKVRRLCLLEEI 313
Q920Z0 NRKVRRL----- 308
CAC44547 NRKVRRL----- 277

The presence of identifiable domains in the disclosed NOV18 protein was determined by using Pfam and then determining the Interpro number. The results are listed in Table 18G with the statistics and domain description.

Table 18G. Domain Analysis of NOV18

PSSMs Producing Significant Alignments		Score (bits)	E Value
7tm_1: domain 1 of 1, from 39 to 289		68.8	5.6e-21
7tm	GNLLVilvilrtkklrtptnifilNLAvADLLflltppwalyylvg + ++++ +++++ + +++++ ++ ++ ++		
NOV18	GNGAVLMIVISDPRLHSLMYFFLGNL SYLDICYSTVTL PKMLQNFLS		
7tm	gsedWpfGsalCklvtaldvvnmyaSillLtaISiDRyLAivhPlryrrr ++ ++ ++ + ++ + + + ++ +++++ + ++ +++ ++		
NOV18	--THKAISFLGCISQLHFFHFLGSTESMLFAVMAFDLSVAICKPLRYTVI		
7tm	rtsprrrAkvvillvWvlalllslPpllfswwktveegngtlnvnvtvCli ++ +++++ + + + ++++ +++++ ++ ++++++++ + ++ ++		
NOV18	MN-PQLCTQMAITIWVIGFFHALLHSVM-TSRLNFCGSNR--IHHFLCDI		
7tm	dfpeestasvstwlrsyvlstlvGFllPllvilvcYtrIrltr..... +++ + ++ + + +++ + + + ++ +++++		
NOV18	KPLLKLACGNTELNQWLLSTVTGTIAMGPFFLTLLSYFYIITYLFfktrs		
7tmkaaktllvvvvvFvLCWlPyfivllldtlc.lsiimsstCelerv + +++ + + +++++ + + + ++ ++		
NOV18	csmLCALSTCASHFMVVILFYAPVLFYIHPALEsFM-----		
7tm	lptallvtlwLayvNsclNPiY (SEQ ID NO:237) + ++++++++ +++ +		
NOV18	-DQDRIVAIMYTVVTPVLNPLIY (SEQ ID NO:62)		

Consistent with other known members of the olfactory receptor family of proteins, NOV18 contains 7-transmembrane domains as illustrated in Table 18G.

The NOV18 nucleic acids, and the encoded polypeptide, according to the invention are useful in a variety of applications and contexts. For example, NOV18 nucleic acids and polypeptides can be used to identify proteins that are members of the olfactory receptor family of proteins. The NOV18 nucleic acids and polypeptides can also be used to screen for molecules, which inhibit or enhance NOV18 activity or function. Specifically, the nucleic acids and polypeptides according to the invention may be used as targets for the identification of small molecules that modulate or inhibit, *e.g.*, cellular recognition, or G-protein-mediated transduction of odorant signals. These molecules can be used to treat, *e.g.*, taste and scent detectability disorders, immune diseases, or signal transduction pathways.

In addition, the NOV18 nucleic acids and polypeptide according to the invention are useful, *inter alia*, as novel members of the protein families according to the presence of domains and sequence relatedness to previously described proteins. For example, the NOV18 nucleic acids and polypeptide include structural motifs that are characteristic of proteins belonging to the family of olfactory receptor proteins. Olfactory receptors have great variety, exquisite specificity, high sensitivity and fast response. The human olfactory epithelium contains two to three thousand distinct olfactory receptors, a class of G-protein coupled receptors. The receptors consist of seven hydrophobic segments that span the cell membrane (trans-membrane domains I-VII), separated by hydrophilic segments that project into the intra- or extra-cellular space. Trans-membrane domains II-VII comprise a hypervariable segment that defines the ligand specificity of the receptor.

The NOV18 nucleic acids and polypeptide, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications in the mediation of signal transduction. As such the NOV18 nucleic acids and polypeptide, antibodies and related compounds according to the invention may be used to treat, *e.g.*, developmental diseases, MHC II and III diseases (immune diseases), taste and scent detectability disorders, Burkitt's lymphoma, corticoneurogenic disease, signal transduction pathway disorders, retinal diseases including those involving photoreception, cell growth rate disorders, cell shape disorders, feeding disorders, control of feeding, potential obesity due to over-eating, potential disorders due to starvation (lack of appetite), noninsulin-dependent diabetes mellitus (NIDDM1), bacterial, fungal, protozoal and

viral infections (particularly infections caused by HIV-1 or HIV-2), pain, cancer (including but not limited to neoplasm, adenocarcinoma, lymphoma, prostate cancer, uterus cancer), anorexia, bulimia, asthma, parkinson's disease, acute heart failure, hypotension, hypertension, urinary retention, osteoporosis, crohn's disease, multiple sclerosis, and treatment of albright hereditary osteodystrophy, angina pectoris, myocardial infarction, ulcers, asthma, allergies, benign prostatic hypertrophy, and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation, dentatorubro-pallidoluysian atrophy(DRPLA) hypophosphatemic rickets, autosomal dominant (2) acrocallosal syndrome and dyskinesias, such as huntington's disease or gilles de la tourette syndrome.

The NOV18 nucleic acids and polypeptide are useful for detecting specific cell types. For example, expression analysis has demonstrated that a NOV18 nucleic acid is predominantly expressed in olfactory epithelium and taste receptor cells of the tongue. However, it is also expressed in apical microvilli of the retinal pigment epithelium, arterial (aortic), basal forebrain, brain, Burkitt lymphoma cell lines, corpus callosum, cardiac (atria and ventricle), caudate nucleus, CNS and peripheral tissue, cerebellum, cerebral cortex, colon, cortical neurogenic cells, endothelial (coronary artery and umbilical vein) cells, palate epithelia, eye, neonatal eye, frontal cortex, fetal hematopoietic cells, heart, hippocampus, hypothalamus, leukocytes, liver, fetal liver, lung, lung lymphoma cell lines, fetal lymphoid tissue, adult lymphoid tissue, those that express MHC II and III nervous, medulla, subthalamic nucleus, ovary, pancreas, pituitary, placenta, pons, prostate, putamen, serum, skeletal muscle, small intestine, smooth muscle (coronary artery in aortic) spinal cord, spleen, stomach, testis, thalamus, and thymus tissue.

Additional utilities for the NOV18 nucleic acid and polypeptide according to the invention are disclosed herein.

NOV19

A NOV19 polypeptide has been identified as a Major Duchenne Muscular Dystrophy (DP71)-like protein. The novel NOV19 nucleic acid sequences maps to the chromosome Xp21.2. Two alternative novel NOV19, NOV19a and NOV19b, nucleic acids and encoded polypeptides are provided.

NOV19a

A NOV19 variant is the novel NOV19a (alternatively referred to herein as CG56574-01), which includes the 2463 nucleotide sequence (**SEQ ID NO:64**) shown in Table 19A. A NOV19a ORF begins with a TGG initiation codon at nucleotides 3-5 and ends with a TAA codon at nucleotides 2106-2108. Putative untranslated regions upstream from the initiation codon and downstream from the termination codon are underlined in Table 19A, and the start and stop codons are in bold letters.

Table 19A. NOV19a Nucleotide Sequence (SEQ ID NO:64)

GGTGGGCGAGCCGACACACGCCCCGCCCCGTCTGGGGGCAGCGCCCCCTCCCCGGCCCCGCGCGCG
GCTCCTCCGCAGTGCTTTTCAGCTGTGAGCTTGGGCGGCGGCGGCGGCGGCGCTCCACTTTCGGGGAG
CCCGGCGGCTCTGGGAAGCTCACTCCTCCACTCGTACCCACACTCGACCGCGGAGCCCTTGCAGCCA
TGAGGGAACAGCTCAAAGGCCACGAGACTCAAACAACCTTGCTGGGACCATCCCAAAATGACAGAGCT
CTACAGTCTTTAGCTGACCTGAATAATGTCAGATTCTCAGCTTATAGGACTGCCATGAAATCCGA
AGACTGCAGAAGGCCCTTTGCTGGGATCTCTTGAGCCTGTCAGCTGCATGTGATGCCTTGGACCAGC
ACAACCTCAAGCAAAATGACCAGCCCATGGATATCCTGCAGATTATTAATTGTTTGACCACTATTTA
TGACCGCCTGGAGCAAGAGCACACAACATTTGGTCAACGTCCCTCTCTGCGTGGATATGTGTCTGAAC
TGGCTGCTGAATGTTTATGATACGGGACGAACAGGGAGGATCCGTGTCCTGTCTTTTAAACTGGCA
TCATTTCCCTGTGTAAAGCACATTTGGAAGACAAGTACAGAAACCTTTTCAAGCAAGTGGCAAGTTC
AACAGGATTTTGTGACCAGCGCAGGCTGGGCTCCTTCTGCATGATTCTATCCAAATTCGAACAG
TTGGGTGAAGTTGCATCCTTTGGGGGCAGTAACATTGAGCCAAGTGTCCGGAGCTGCTTCCAATTTG
CTAATAATAAGCCAGAGATCGAAGCGGCCCTCTCTAGACTGGATGAGACTGGAACCCCACTCCAT
GGTGTGGCTGCCCCGTCTTGCACAGAGTGGCTGCTGCAGAACTGCCAAGCATCAGGCCAAATGTAAC
ATCTGCAAGAGTGTCCAATCATTGGATTACAGGTACAGGAGTCTAAAGCACTTTAATTATGACATCT
GCCAAAGCTGCTTTTTTCTGGTTCGAGTTGCAAAAGGCCATAAAATGCACTATCCCATGGTGAATA
TTGCACTCCGACTACATCAGGAGAAGATGTTTCGAGACTTTGCCAAGGTACTAAAAACAAATTCGA
ACCAAAAGGTATTTTGGCAAGCATCCCCGAATGGGCTACCTGCCAGTGCAGACTGTCTTAGAGGGGG
ACAACATGGAACTCCCGTTACTCTGATCAACTTCTGGCCAGTAGATTCTGCGCCTGCCTCGTCCCC
TCAGCTTTCACACGATGATACTCATTACGCATTGAACATTATGCTAGCAGGCTAGCAGAAATGGAA
AACAGCAATGGATCTTATCTAAATGATAGCATCTCTCCTAATGAGAGCATAGATGATGAACATTTGT
TAATCCAGCATTTACTGCCAAAGTTTGAACCAGGACTCCCCCTGAGCCAGCCTCGTAGTCTGCCCCA
GATCTTGATTTCTTAGAGAGTGAGGAAAGAGGGGAGCTAGAGAGAATCCTAGCAGATCTTGAGGAA
GAAAACAGGAATCTGCAAGCAGAATATGACCGTCTAAAGCAGCAGCACGAACATAAAGGCCTGTCCC
CACTGCCGTCCCCCTCCTGAAATGATGCCACCTCTCCCCAGAGTCCCCGGGATGCTGAGCTCATTGC
TGAGGCCAAGCTACTGCGTCAACACAAAGGCCGCTGGAAGCCAGGATGCAAATCCTGGAAGACCAC
AATAAACAGCTGGAGTCACAGTTACACAGGCTAAGGCAGCTGCTGGAGCAACCCAGGCAGAGGCCA
AAGTGAATGGCACAACGGTGTCTCTCTCTACCTCTCTACAGAGGTCCGACAGCAGTCAGCCTAT
GCTGCTCCGAGTGGTTGGCAGTCAAACCTTCGACTCCATGGGTGAGGAAGATCTTCTCAGTCCTCCC
CAGGACACAAGCACAGGTTAGAGGAGGTGATGGAGCAACTCAACAACCTCTCCCTAGTTCAAGAG
GACACAATGTAGGAAGTCTTTTCCACATGGCAGATGATTTGGGCAGAGCGATGGAGTCCTTAGTATC
AGTCATGACAGATGAAGAAGGAGCAGAAATAATGTTTTACAACCTCCTGATTCCCGCATGGTTTTTAT
AATATTTCATACAACAAAGAGGATTAGACAGTAAGAGTTTACAAGAAATAAATCTATATTTTTGTGAA
GGGTAGTGGTATTACTGTAGATTTCAAGTCTGTTATTGTTTTGTTAACAATGGCA
GGTTTTACACGTCTATGCAATTGTACAAAAAGTTATAAGAAAACCTACATGTAAAATCTTGATAGCT
AAATAACTTGCCATTTCTTTATATGGAACGCATTTTGGGTGTTTTAAAAATTTATAACAGTTATAAA
GAAAGATTGTAACTAAAGTGTGCTTTATAAAAAAGTTGTTTATAAAAAAC

The NOV19a polypeptide (SEQ ID NO:65) encoded by SEQ ID NO:64 is 701 amino acid residues in length and is presented using the one-letter amino acid code in Table 19B. The Psort profile for the NOV19a predicts that this peptide is likely to be localized at the nucleus with a certainty of 0.9700.

Table 19B. NOV19a protein sequence (SEQ ID NO:65)

WASRHTPAPSGGSAPSPARPRRLRSFAFSCELGRRRRRSTFGEPGGSGKLTPLVPTLDRGALAAM
REQLKGHETQTTTCWDHPKMTELYQSLADLNNVRFSAYRTAMKLRLQKALCWDLLSLSAACDALDQH
NLKQNDQPMIDILQIINCLTTIYDRLEQEHNNLVNVPCLVDMCLNWLNVYDTGRTGRIRVLSFKTGI
ISLCKAHLEDKYRNLFKQVASSTGFCDQRRLLGLLHDSIQIPRQLGEVASFGGSNIEPSVRSCFQFA
NNKPEIEAALFLDWMRLPQSMVWLPVLHRVAAAETAKHQAKCNICKECPIIGFRYRSLKHFNYDIC
QSCFFSGRVAKGHKMHYPMVEYCTPTTSGEDVRDFAKVLKNKFRTKRYFAKHPRMGYLPVQTVLEGD
NMETPVTLINFWPVDAPASSPQLSHDDTHSRIEYASRLAEMENSNGSYLNDISPNEIDDEHLL
IQHYCQSLNQDSPSQPRSPAQILISLESEERGELERILADLEENRNLQAEYDRLKQQHEHKGSLP
LPSPPEMMPTSPQSPRDAELIAEAKLLRQHKGRLEARMQILEDHNKQLESQHLRLRQLLEQPQAEAK
VNGTTVSSPSTSLQRSDDSSQPMLLRVVGSQTSDSMGEDLLSPQDTSTGLEEVMEQLNNSFPSSRG
HNVGSLFHMADDLGRAMESLVSVMTDEEGAE

NOV19b

Alternatively, a NOV19 variant is the novel NOV19b (alternatively referred to herein as CG56574-02), which includes the 2005 nucleotide sequence (SEQ ID NO:66) shown in Table 19C. NOV19b was created by polymerase chain reaction (PCR) using the primers: 5' GAAGCTCACTCCTCCACTCGTACC 3' (SEQ ID NO:237) and 5' ATGAATATTATAAAAACCATGCGGGAA 3' (SEQ ID NO:238). Primers were designed based on *in silico* predictions of the full length or some portion (one or more exons) of the cDNA/protein sequence of the invention. The PCR product derived by exon linking, covering the entire open reading frame, was cloned into the pCR2.1 vector from Invitrogen to provide clone 127720::M18533r3_0_1.698587.P22.

The NOV19b ORF begins with a Kozak consensus ATG initiation codon at nucleotides 53-55 and ends with a TAA codon at nucleotides 1958-1960. Putative untranslated regions upstream from the initiation codon and downstream from the termination codon are underlined in Table 19C, and the start and stop codons are in bold letters.

Table 19C. NOV19b Nucleotide Sequence (SEQ ID NO:66)

GAAGCTCACTCCTCCACTCGTACCCACACTCGACCGCGGAGCCCTTGCAGCCATGAGGGAACAGCTC
AAAGGCCACGAGACTCAAACAACCTTGCTGGGACCATCCCAAATGACAGAGCTCTACCACTCTTTAG
CTGACCTGAATAATGTCAGATTCTCAGCTTATAGGACTGCCATGAAACTCCGAAGACTGCAGAAGGC
CCTTTGCTTGATCTCTTGAGCCTGTCAGCTGCATGTGATGCCTTGGACCAGCACAACTCAAGCAA

AATGACCAGCCCATGGATATCCTGCAGATTATTAATTGTTTGACCACTATTTATGACCGCCTGGAGC
AAGAGCACAACAATTTGGTCAACGTCCCTCTCTGCGTGGATATGTGTCTGAACTGGCTGCTGAATGT
TTATGATACGGGACGAACAGGGAGGATCCGTGTCTGTCTTTTAAACTGGCATCATTTCCCTGTGT
AAAGCACATTTGGAAGACAAGTACAGATACCTTTTCAAGCAAGTGGCAAGTTCAACAGGATTTTGTG
ACCAGCGCAGGCTGGGCCTCCTTCTGCATGATTCTATCCAAATTCAGACAGTTGGGTGAAGTTGC
ATCCTTTGGGGGCGGTAACATTGAGCCAAGTGTCCGAGCTGCTTCCAATTTGCTAATAATAAGCCA
GAGATCGAAGCGGCCCTCTTCTAGACTGGATGAGACTGGAACCCAGTCCATGGTGTGGCTGCCCCG
TCCTGCACAGAGTGGCTGCTGCAGAACTGCCAAGCATCAGGCCAAATGTAACATCTGCAAAGAGTG
TCCAATCATTTGGATTGAGGTACAGGAGTCTAAAGCACTTTAATTATGACATCTGCCAAAGCTGCTTT
TTTTCTGGTTCGAGTTGCAAAAGGCCATAAAATGCACTATCCCATGGTGGAAATATTGCACTCCGACTA
CATCAGGAGAAGATGTTTCGAGACTTTGCCAAGGTACTAAAAAACAAATTTGCAACCAAAAGGTATTT
TGCGAAGCATCCCCGAATGGGCTACCTGCCAGTGCAGACTGTCTTAGAGGGGGACAACATGGAAACT
CCCGTTACTCTGATCAACTTCTGGCCAGTAGATTCTGCGCCTGCCTCGTCCCTCAGCTTTACACAG
ATGATACTCATTACGCATTGAACATTATGCTAGCAGGCTAGCAGAAATGGAAAACAGCAATGGATC
TTATCTAAATGATAGCATCTCTCTAATGAGAGCATAGATGATGAACATTTGTTAATCCAGCATTAC
TGCCAAAGTTTGAACCAGGACTCCCCCTGAGCCAGCCTCGTAGTCCTGCCAGATCTTGATTTCCT
TAGAGAGTGAGGAAAGAGGGGAGCTAGAGAGAATCCTAGCAGATCTTGAGGAAGAAAACAGGAATCT
GCAAGCAGAATATGACCGTCTAAAGCAGCAGCACGAACATAAAGGCCTGTCCCCACTGCCGTCCCCCT
CCTGAAATGATGCCACCTCTCCCCAGAGTCCCCGGGATGCTGAGCTCATTGCTGAGGCCAAGCTAC
TGCGTCAACACAAAGGCCGCTGGAAGCCAGGATGCAATCCTGGAAGACCACAATAAACAGCTGGA
GTCACAGTTACACAGGCTAAGGCAGCTGCTGGAGCAACCCAGGCAGAGGCCAAAGTGAATGGCGCA
ACGGTGTCTCTCTTCTACCTCTCTACAGAGGTCCGACAGCAGTCAGCCTATGCTGCTCCGAGTGG
TTGGCAGTCAAACCTTCGACTCCATGGGTGAGGAAGATCTTCTCAGTCCTCCCAGGACACAAGCAC
AGGGTTAGAGGAGGTGATGGAGCAACTCAACAACCTCTTCCCTAGTTCAAGAGGACACAATGTAGGA
AGTCTTTTCCACATGGCAGATGATTTGGGCAGAGCGATGGAGTCCTTAGTATCAGTCATGACAGATG
AAGAAGGAGCAGAAATAAATGTTTTACAACCTCTGATTCCCGCATGGTTTTTATAATATTCAT

Variant sequences of NOV19b are included in Example 2. A variant sequence can include a single nucleotide polymorphism (SNP). A SNP can, in some instances, be referred to as a "cSNP" to denote that the nucleotide sequence containing the SNP originates as a cDNA.

The NOV19b protein (SEQ ID NO:67) encoded by SEQ ID NO:66 is 635 amino acid residues in length and is presented using the one-letter code in Table 19D. The Psort profile for NOV19b predicts that this sequence is likely to be localized at the cytoplasm with a certainty of 0.4500. The Signal P predicts a likely cleavage site for a NOV19b peptide is between positions 64 and 65, *i.e.*, at the dash in the sequence CDA-LD.

Table 19D. NOV19b protein sequence (SEQ ID NO:67)

MREQLKGHETQTTCDWHPKMTELYQSLADLNNVRFSAYRTAMKLRRRLQKALCLDLLSLSAACDALDQ
HNLKQNDQPMIDILQIINCLTTIYDRLEQEHNNLVNPLCVDMLNWLNNVYDTGRTGRIRVLSFKTG
IISLCKAHLEDKYRYLFKQVASSTGFCDQRRLLGLLHDSIQIPQLGEVASFSGGNI EPSVRSCFQF
ANNKPEIEAALFLDWMRLPQSMVWLPVLHRVAAETA KHQAKCNICKECPIIGFRYRSLKHFNYDI
CQSCFFSGRVAKGHKMHYPMVEYCTPTTSGEDVRDFAKVLKNKFR TKRYFAKHPRMGYLPVQTVLEG
DNMETPVTLINFWPVDSAPASSPQLSHDDTHSR IEHYASRLAEMENSNGSYLNDISPNESIDDEHL
LIQHYCQSLNQDSPLSQPRSPAQILISLESEERGELE RILADLEEENRN LQAEYDR LKQQHEHKGLS
PLPSPPEMMPTSPQSPRDAELIAEAKLLRQHKGRLEARMQ ILEDHNKQLESQ LHRRLRQLLEQPQAEA
KVNGATVSSPSTSLQRSDSSQPMLLRVVGSTSDSMGEEDLLSPQDTSTGLEEVMEQLNNSFPSSR
GHNVGSLFHMADDLGRAMESLVSVM TDEEGAE

NOV19 Clones

Unless specifically addressed as NOV19a or NOV19b, any reference to NOV19 is assumed to encompass all variants. NOV19a polypeptide is longer than the NOV19b polypeptide, having an additional 66 amino acids on the N-terminus. NOV19a also differs from NOV19b at four amino acid residues [aa 119 (W>L); aa 215 (N>Y); aa 255 (S>G); aa 607 (T>A)] as shown Table 19G.

A search against the Patp database, a proprietary database that contains sequences published in patents and patent publications, yielded several homologous proteins shown in Table 19E.

Table 19E. Patp results for NOV19

Sequences producing High-scoring Segment Pairs:	Reading Frame	High Score	Smallest Sum Prob P (N)
>patp:AA59237 A rod shortened dystrophin (deltaDysAx2)	+1	3127	0.0
>patp:AA59238 A rod shortened dystrophin (deltaDysAx11)	+1	3127	0.0
>patp:AA59239 A rod shortened dystrophin (deltaDysAH3)	+1	3127	0.0
>patp:AA59240 A rod shortened dystrophin (deltaDysM3)	+1	3127	0.0
>patp:AA59242 A rod shortened dystrophin (deltaDysH4)	+1	3127	0.0
>patp:AAP90290 Human Duchenne muscular dystrophy gene	+1	3120	0.0

In a BLAST search of public sequence databases, it was found, for example, that the NOV19a nucleic acid sequence of this invention has 1793 of 1798 bases (99%) identical to a gb:GENBANK-ID:HSDMDR|acc:X14298.1 mRNA from *Homo sapiens* (Human mRNA for MAJOR DUCHENNE MUSCULAR DYSTROPHY PROTEIN (DP71)). The NOV19a polypeptide sequence of the invention was found to have 620 of 635 amino acid residues (97%) identical to, and 620 of 635 amino acid residues (97%) similar to, the 622 amino acid residue ptmr:SPTREMBL-ACC:Q02295 protein from *Homo sapiens* (MAJOR DUCHENNE MUSCULAR DYSTROPHY PROTEIN (DP71)).

Similarly, it was found, for example, that the NOV 19b nucleic acid sequence of this invention has 1793 of 1798 bases (99%) identical to a gb:GENBANK-ID:E30218|acc:E30218.1 mRNA from unidentified (Shortened dystrophin). The NOV19b polypeptide sequence of the invention also was found to have 620 of 635 amino acid residues (97%) identical to, and 620 of 635 amino acid residues (97%) similar to, the 622 amino acid residue ptmr:SPTREMBL-ACC:Q02295 protein from *Homo sapiens* (MAJOR DUCHENNE MUSCULAR DYSTROPHY PROTEIN (DP71)).

Additional BLAST results are shown in Table 19F.

Table 19F. BLAST results for NOV19					
Gene Index/ Identifier	Protein/ Organism	Length (aa)	Identity (%)	Positives (%)	Expect
ptnr:SPTREMBL- ACC:Q02295	DMD PROTEIN - <i>Homo sapiens</i>	622	620/635 (97%)	620/635 (97%)	0.0
ptnr:SWISSNEW- ACC:P11532	Dystrophin - <i>Homo sapiens</i>	3685	596/599 (99%)	596/599 (99%)	0.0
ptnr:SPTREMBL- ACC:Q14205	Dystrophin - <i>Homo sapiens</i>	3127	596/599 (99%)	596/599 (99%)	0.0

A multiple sequence alignment is given in Table 19G, with the NOV19 protein of the invention being shown on line 1, in a ClustalW analysis comparing NOV19 with related protein sequences disclosed in Table 19F.

Table 19G. Information for the ClustalW proteins:

1. >NOV19a; SEQ ID NO:65
2. >NOV19b; SEQ ID NO:67
3. >Q02295/DMD PROTEIN [*Homo sapiens*]; SEQ ID NO:239
4. >P11532/ Dystrophin [*Homo sapiens*]; SEQ ID NO:240
5. >Q14205/ Dystrophin [*Homo sapiens*]; SEQ ID NO:241

		2810	2820	2830	2840	2850
NOV19a	WASRHT		PAPSGGSAP	SPAR	
NOV19b	----- ----- ----- ----- ----- ----- -----					
Q02295	----- ----- ----- ----- ----- ----- -----					
P11532	EASSDQWKRLHLSLQELLVWLQKDDLSRQAPIGGDFPAVQKQNDVHRA					
Q14205	EASSDQWKRLHLSLQELLVWLQKDDLSRQAPIGGDFPAVQKQNDVHRA					
		2860	2870	2880	2890	2900
NOV19a				PR	
NOV19b	----- ----- ----- ----- ----- ----- -----					
Q02295	----- ----- ----- ----- ----- ----- -----					
P11532	FKRELKTKPEVIMSTLETVRIFLTEQPLEGLEKLYQBPRELPPPEERAQNV					
Q14205	FKRELKTKPEVIMSTLETVRIFLTEQPLEGLEKLYQBPRELPPPEERAQNV					
		2910	2920	2930	2940	2950
NOV19a	RLLR		SAFSCELGRRRR	RSTFGEPGGS	
NOV19b	----- ----- ----- ----- ----- ----- -----					
Q02295	----- ----- ----- ----- ----- ----- -----					
P11532	TRLRLKQAEVNTWEKLNLSADWQKIDETLERLQELQEATDELDDLKL					
Q14205	TRLRLKQAEVNTWEKLNLSADWQKIDETLERLQELQEATDELDDLKL					
		2960	2970	2980	2990	3000
NOV19a	GKLTTP	LVPITD	RGALAMREQLK		

5

NOV19b -----MREQLK-----
 Q02295 -----MREQLK-----
 P11532 RQAEVIKGSWQPVGDLLIDS LQDHLEKVKALRGEIAPLKENVSHVNDLAR
 Q14205 RQAEVIKGSWQPVGDLLIDS LQDHLEKVKALRGEIAPLKENVSHVNDLAR

3010 3020 3030 3040 3050

10

NOV19a -----
 NOV19b -----
 Q02295 -----
 P11532 QLTTLGIQLSPYNLSTLEDLNTRWKLQVAVEDRVRQLHEAHRDFGPASQ
 Q14205 QLTTLGIQLSPYNLSTLEDLNTRWKLQVAVEDRVRQLHEAHRDFGPASQ

3060 3070 3080 3090 3100

15

NOV19a -----GHETQTTTCWDHPKMTELYQSLADLNN
 NOV19b -----GHETQTTTCWDHPKMTELYQSLADLNN
 Q02295 -----GHETQTTTCWDHPKMTELYQSLADLNN
 P11532 HFLSTSVQGPWERAISPKNVPYYINGHETQTTTCWDHPKMTELYQSLADLNN
 Q14205 HFLSTSVQGPWERAISPKNVPYYINGHETQTTTCWDHPKMTELYQSLADLNN

3110 3120 3130 3140 3150

25

NOV19a VRFSAYRTAMKLRRLOKALCWDLLSLSAACDALDQHNLKQNDQPM DILQI
 NOV19b VRFSAYRTAMKLRRLOKALCWDLLSLSAACDALDQHNLKQNDQPM DILQI
 Q02295 VRFSAYRTAMKLRRLOKALCWDLLSLSAACDALDQHNLKQNDQPM DILQI
 P11532 VRFSAYRTAMKLRRLOKALCWDLLSLSAACDALDQHNLKQNDQPM DILQI
 Q14205 VRFSAYRTAMKLRRLOKALCWDLLSLSAACDALDQHNLKQNDQPM DILQI

3160 3170 3180 3190 3200

30

NOV19a INCLTTIYDRLEQEHNNLVNVPLCVDMLNWLNNVYDTGRTGRIRVLSFK
 NOV19b INCLTTIYDRLEQEHNNLVNVPLCVDMLNWLNNVYDTGRTGRIRVLSFK
 Q02295 INCLTTIYDRLEQEHNNLVNVPLCVDMLNWLNNVYDTGRTGRIRVLSFK
 P11532 INCLTTIYDRLEQEHNNLVNVPLCVDMLNWLNNVYDTGRTGRIRVLSFK
 Q14205 INCLTTIYDRLEQEHNNLVNVPLCVDMLNWLNNVYDTGRTGRIRVLSFK

3210 3220 3230 3240 3250

40

NOV19a TGIISLCKAHLEDKYRNLFKQVASSTGFCDQRRGLLLHDSIQIPROLGE
 NOV19b TGIISLCKAHLEDKYRYLFKQVASSTGFCDQRRGLLLHDSIQIPROLGE
 Q02295 TGIISLCKAHLEDKYRYLFKQVASSTGFCDQRRGLLLHDSIQIPROLGE
 P11532 TGIISLCKAHLEDKYRYLFKQVASSTGFCDQRRGLLLHDSIQIPROLGE
 Q14205 TGIISLCKAHLEDKYRYLFKQVASSTGFCDQRRGLLLHDSIQIPROLGE

3260 3270 3280 3290 3300

45

NOV19a VASFGGSNIEPSVRSCFQFANNKPEIEAALFLDWMRLPQSMVWLPVLHR
 NOV19b VASFGGSNIEPSVRSCFQFANNKPEIEAALFLDWMRLPQSMVWLPVLHR
 Q02295 VASFGGSNIEPSVRSCFQFANNKPEIEAALFLDWMRLPQSMVWLPVLHR
 P11532 VASFGGSNIEPSVRSCFQFANNKPEIEAALFLDWMRLPQSMVWLPVLHR
 Q14205 VASFGGSNIEPSVRSCFQFANNKPEIEAALFLDWMRLPQSMVWLPVLHR

3310 3320 3330 3340 3350

55

NOV19a VAAAETAKHQAKCNICKECPIIGFRYRSLKHFNVDICQSCFFSGRVAKGH
 NOV19b VAAAETAKHQAKCNICKECPIIGFRYRSLKHFNVDICQSCFFSGRVAKGH
 Q02295 VAAAETAKHQAKCNICKECPIIGFRYRSLKHFNVDICQSCFFSGRVAKGH
 P11532 VAAAETAKHQAKCNICKECPIIGFRYRSLKHFNVDICQSCFFSGRVAKGH
 Q14205 VAAAETAKHQAKCNICKECPIIGFRYRSLKHFNVDICQSCFFSGRVAKGH

3360 3370 3380 3390 3400

60

5

NOV19a KMHYPMVEYCTPTTSGEDVRDFAKVLKKNKFRTKRYFAKHPRMGYLPVQTV
NOV19b KMHYPMVEYCTPTTSGEDVRDFAKVLKKNKFRTKRYFAKHPRMGYLPVQTV
Q02295 KMHYPMVEYCTPTTSGEDVRDFAKVLKKNKFRTKRYFAKHPRMGYLPVQTV
P11532 KMHYPMVEYCTPTTSGEDVRDFAKVLKKNKFRTKRYFAKHPRMGYLPVQTV
Q14205 KMHYPMVEYCTPTTSGEDVRDFAKVLKKNKFRTKRYFAKHPRMGYLPVQTV

10

3410 3420 3430 3440 3450
.....|.....|.....|.....|.....|.....|.....|.....|.....|.....|
NOV19a LEGDNMETPVTLINFWPVD SAPASSPQLSHDDTHSR IEHYASRLAEMENS
NOV19b LEGDNMETPVTLINFWPVD SAPASSPQLSHDDTHSR IEHYASRLAEMENS
Q02295 LEGDNMET-----P ASSPQLSHDDTHSR IEHYASRLAEMENS
P11532 LEGDNMETPVTLINFWPVD SAPASSPQLSHDDTHSR IEHYASRLAEMENS
Q14205 LEGDNMETPVTLINFWPVD SAPASSPQLSHDDTHSR IEHYASRLAEMENS

15

3460 3470 3480 3490 3500
.....|.....|.....|.....|.....|.....|.....|.....|.....|.....|
NOV19a NGSYLND SISPNESIDDEHLLIQHYCQSLNQDSPLSQPRSPAQILISLES
NOV19b NGSYLND SISPNESIDDEHLLIQHYCQSLNQDSPLSQPRSPAQILISLES
Q02295 NGSYLND SISPNESIDDEHLLIQHYCQSLNQDSPLSQPRSPAQILISLES
P11532 NGSYLND SISPNESIDDEHLLIQHYCQSLNQDSPLSQPRSPAQILISLES
Q14205 NGSYLND SISPNESIDDEHLLIQHYCQSLNQDSPLSQPRSPAQILISLES

20

3510 3520 3530 3540 3550
.....|.....|.....|.....|.....|.....|.....|.....|.....|.....|
NOV19a EERGELERILADLEEENRN LQAEYDRLKQOHEHKGLSPLSPPEMMPTSP
NOV19b EERGELERILADLEEENRN LQAEYDRLKQOHEHKGLSPLSPPEMMPTSP
Q02295 EERGELERILADLEEENRN LQAEYDRLKQOHEHKGLSPLSPPEMMPTSP
P11532 EERGELERILADLEEENRN LQAEYDRLKQOHEHKGLSPLSPPEMMPTSP
Q14205 EERGELERILADLEEENRN LQAEYDRLKQOHEHKGLSPLSPPEMMPTSP

30

3560 3570 3580 3590 3600
.....|.....|.....|.....|.....|.....|.....|.....|.....|.....|
NOV19a QSPRDAELIAEAKLLRQHKGRLEARMQI LEDHNKQLESQ LHRRLQ LLEQP
NOV19b QSPRDAELIAEAKLLRQHKGRLEARMQI LEDHNKQLESQ LHRRLQ LLEQP
Q02295 QSPRDAELIAEAKLLRQHKGRLEARMQI LEDHNKQLESQ LHRRLQ LLEQP
P11532 QSPRDAELIAEAKLLRQHKGRLEARMQI LEDHNKQLESQ LHRRLQ LLEQP
Q14205 QSPRDAELIAEAKLLRQHKGRLEARMQI LEDHNKQLESQ LHRRLQ LLEQP

35

3610 3620 3630 3640 3650
.....|.....|.....|.....|.....|.....|.....|.....|.....|.....|
NOV19a QAEAKVNGTTVSSPSTSLQRS DSSQPMLLRVVG SQTSDSMGEEDLLSPPQ
NOV19b QAEAKVNGTTVSSPSTSLQRS DSSQPMLLRVVG SQTSDSMGEEDLLSPPQ
Q02295 QAEAKVNGTTVSSPSTSLQRS DSSQPMLLRVVG SQTSDSMGEEDLLSPPQ
P11532 QAEAKVNGTTVSSPSTSLQRS DSSQPMLLRVVG SQTSDSMGEEDLLSPPQ
Q14205 QAEAKVNGTTVSSPSTSLQRS DSSQPMLLRVVG SQTSDSMGEEDLLSPPQ

45

3660 3670 3680 3690 3700
.....|.....|.....|.....|.....|.....|.....|.....|.....|.....|
NOV19a DTSTGLEEVMEQLNNSFPSSRGHNVGSLFHMADDLGRAMESLVSVMTDEE
NOV19b DTSTGLEEVMEQLNNSFPSSRGHNVGSLFHMADDLGRAMESLVSVMTDEE
Q02295 DTSTGLEEVMEQLNNSFPSSRGHNVGSLFHMADDLGRAMESLVSVMTDEE
P11532 DTSTGLEEVMEQLNNSFPSSRGHNT-----P-----GKPMR--EDTM----
Q14205 DTSTGLEEVMEQLNNSFPSSRGHNT-----P-----GKPMR--EDTM----

50

55

NOV19a GAE
NOV19b GAE
Q02295 GAE
P11532 ---
Q14205 ---

60

The NOV19 Clustal W alignment shown in Table 19G was modified to begin at amino residue 2801. The data in Table 19G includes all of the regions overlapping with the NOV19 protein sequences.

The presence of identifiable domains in the protein disclosed herein was determined by searches using algorithms such as PROSITE, Blocks, Pfam, ProDomain, Prints and then determining the Interpro number by crossing the domain match (or numbers) using the Interpro website (<http://www.ebi.ac.uk/interpro/>). Table 19H lists the domain description from DOMAIN analysis results against NOV19.

Table 19H Domain Analysis of NOV19			
Model	Region of Homology	Score (bits)	E value
ZZ zinc finger	305-350	93.3	4.9e-24
Ribosomal L24e	248-308	-25.9	3.4
M Protein Signature	499-519	9.4	38
M Protein Signature	565-585	5.1	1.5e+02

Consistent with other known members of the DP71 family of proteins, NOV19 contains a zinc finger ZZ domain as illustrated in Table19H. NOV19 nucleic acids, and the encoded polypeptides, according to the invention are useful in a variety of applications and contexts. For example, NOV19 nucleic acids and polypeptides can be used to identify proteins that are members of the DP71 family of proteins. The NOV19 nucleic acids and polypeptides can also be used to screen for molecules, which inhibit or enhance NOV19 activity or function. Specifically, the nucleic acids and polypeptides according to the invention may be used as targets for the identification of small molecules that modulate or inhibit, *e.g.*, cellular activation, cellular metabolism and signal transduction. These molecules can be used to treat, *e.g.*, deafness 4, congenital sensorineural, Duchenne muscular dystrophy, Becker muscular dystroph, cardiomyopathy, dilated, X-linked, McLeod phenotype, Lesch-Nyhan syndrome, myasthenia gravis, Adrenal hypoplasia, congenital, with hypogonadotropic hypogonadism, Dosage-sensitive sex reversal, Glycerol kinase deficiency; Gonadal dysgenesis, XY female type, Hyperglycerolemia, diabetes, obesity, and Retinitis pigmentosa-6.

In addition, various NOV19 nucleic acids and polypeptides according to the invention are useful, *inter alia*, as novel members of the protein families according to the presence of domains and sequence relatedness to previously described proteins. For example, the NOV19 nucleic

acids and their encoded polypeptides include structural motifs that are characteristic of proteins belonging to the family of DP71 such as the Major Duchenne Muscular Dystrophy proteins involved in skeletal muscle and nerve physiology.

Duchenne muscular dystrophy (DMD) is an X-linked recessive disorder which manifest
5 as a progressive degeneration of muscles and results in death. A less severe disorder, Becker's muscular dystrophy (BMD), is allelic to DMD. Some 30% of DMD patients also suffer also from mental retardation. The DMD gene is the largest known gene, consisting of almost 0.1% of the human genome (2,500 Kbp). The product of the DMD gene in the muscle, dystrophin, is a 427 kDa protein translated from a 14 kb mRNA. Dystrophin is a rod-shaped protein consisting of an
10 actin binding N-terminal domain, a large domain of spectrin-like repeats, a cystein-rich domain with potential Ca²⁺ binding sites, and a C-terminal domain. A very similar isoform of dystrophin, encoded by the same gene, is found in the brain. The expression of the two isoforms is regulated by two promoters. One is active in muscle cells and glia cells. The other is active mainly in neurons. A 70.8 kDa protein, called Dp71, is the product of a promoter located
15 between exons 62 and 63 of the DMD gene.

Dp71 is of special interest as it consists of the cysteine-rich and C-terminal domains of dystrophin, but lacks the actin binding domain and the spectrin-like repeats. Dp71 is by far the major product of the DMD gene in brain and many other nonmuscle tissues. Analysis of the expression of the DMD gene products during development has shown that Dp71 is already
20 expressed in the embryonic stem cells. The known dystrophins and their mRNAs are detected only after differentiation of specialized cell types.

The NOV19 nucleic acids and polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications in the mediation of muscle and nerve physiology. As such, the NOV19 nucleic acids and polypeptides, antibodies
25 and related compounds according to the invention may be used to treat muscle and nervous system disorders, *e.g.*, Duchenne muscular dystrophy, Becker muscular dystroph, cardiomyopathy, dilated, X-linked, McLeod phenotype, Lesch-Nyhan syndrome, myasthenia gravis.

The NOV19 nucleic acids and polypeptides are useful for detecting specific cell types.
30 For example, expression analysis has demonstrated that a NOV19 nucleic acid is expressed in Adipose, Aorta, Vein, Umbilical Vein, Adrenal Gland/Suprarenal gland, Pancreas, Thyroid,

Parotid Salivary glands, Stomach, Liver, Colon, Bone Marrow, Peripheral Blood, Spleen, Lymph node, Tonsils, Bone, Cartilage, Muscle, Skeletal Muscle, Brain, Cerebellum, Left cerebellum, Thalamus, Pituitary Gland, Temporal Lobe, Amygdala, Substantia Nigra, Hippocampus, Spinal Chord, Cervix, Mammary gland/Breast, Ovary, Placenta, Uterus, Oviduct/Uterine

5 Tube/Fallopian tube, Prostate, Testis, Lung, Kidney, Retina, Cochlea, and Foreskin.

Additional utilities for NOV19 nucleic acids and polypeptides according to the invention are disclosed herein.

NOV20

10 A NOV20 polypeptide has been identified as a G Protein-Coupled Receptor RTA (GPCR)-like protein. The novel NOV20 nucleic acid sequences maps to the chromosome11. Two alternative novel NOV20, NOV20a and NOV20b, nucleic acids and encoded polypeptides are provided.

NOV20a

15 A NOV20 variant is the novel NOV20a (alternatively referred to herein as CG56517-01), which includes the 1219 nucleotide sequence (SEQ ID NO:68) shown in Table 20A. A NOV20a ORF begins with a Kozak onsensus sequence ATG initiation codon at nucleotides 31-33 and ends with a TGA codon at nucleotides1051-1053. Putative untranslated regions upstream from the initiation codon and downstream from the termination codon are underlined in Table 20A, and the start and stop codons are in bold letters.

Table 20A. NOV20a Nucleotide Sequence (SEQ ID NO:68)

AGCAGGGGGCCAGACGCGCCAGGCCTGGAGATGGCTGGAACTGCTCCTGGGAGGCCCCATCCCGGCA
ACAGGAACAAGATGTGCCCTGGCCTGAGCGAGGCCCCGGAACCTCTACAGCCGGGGCTTCCTGACCAT
CGAGCAGATCGCGATGCTGCCGCCTCCGGCCGTATGAACCTACATCTTCCTGCTCCTCTGCCTGTGT
GGCCTGGTGGGCAACGGGCTGGTCTCTGGTTTTTCGGCTTCTCCATCAAGAGGAACCCCTTCTCCA
TCTACTTCCCTGCACCTGGCCAGCGCCGATGTGGGCTACCTCTTCAGCAAGGCGGTGTTCTCCATCCT
GAACACGGGGGGCTTCCTGGGCACGTTTGCCGACTACATCCGCAGCGTGTGCCGGTCTCTGGGGCTC
TGCATGTTCCCTTACCGGCGTGAGCCTCCTGCCGGCCGTGAGCGCGTGCAGCGTGCGCCCTCGGTATCT
TCCCCGCTGGTACTGGCGCCGGCGGCCCAAGCGCCTGTGCGCCGTGGTGTGCGCCCTGCTGTGGGT
CCTGTCCCTCCTGGTCACCTGCCTGCACAACTACTTCTGCGTGTTCCTGGGCCGCGGGGCCCCGGGC
GCGTGTGTCAGGCACATGGACATCTTCCTGGGCATCCTCCTGTTCTGCTCTGCTGCCCGCTCATGG
TGCTGCCCTGCCTGGCCCTCATCCTGCACGTGGAGTGCGGGCCCCGACGGGCCACGCTCTGCCAAGCT
CAAGCAGTCATCCTGGCCATGGTCTCCGTCTTCCTGGTGTCTCCATCTACTTAGGGATCGACTGG
TTCTCTTCTGGGTCTTCAGATCCCCGGCCCCCTTCCCCGAGTACGTCACTGACCTGTGCATCTGCA
TCAACAGCAGCGCCAAGCCATCGTCTACTTCTGGCCGGGAGGACAAGTCGCAGCGGCTGTTGGAG
CCTTAGGGTGGTCTTCAGTGGGGCCTGCGGGACGGCGCTGACTGGGGGATGTGCGGGCAGCACGCTC

AACACAGTCACCATGGAGATGCAGTGTCCCCGGGGGAACGCCTCCT**G**AGACTGCAGCGCCTGGAGGA
GGCAGTGGCAGGAATCGTGCTCCAAGACTCTTCTGCTGTGGACAGGAATGGGCACTAGTTCTGAGTC
CATACAGGAGAGGAAAGATCTGTATGCTCTCCTCGGGCCTTCTTCTCCCTGGGACTGTGGA**A**CTCAG
GTAGTGTCTGGGC

The NOV20a polypeptide (SEQ ID NO:69) encoded by SEQ ID NO:68 is 340 amino acid residues in length and is presented using the one-letter amino acid code in Table 20B. The Psort profile for the NOV20 a and NOV20b proteins predicts that this peptides are likely to be localized at the plasma membrane with a certainty of 0.6000. The Signal P predicts a likely cleavage site for a NOV20 peptide is between positions 67 and 68, *i.e.*, at the dash in the sequenceVLW-FF.

Table 20B. NOV20a protein sequence (SEQ ID NO:69)

MAGNCSWEAHPGNRNKMCPGLSEAPELYSRGFLTIEQIAMLPPPAVMNYIFLLCLCGLVGNGLVLW
FFGFSIKRNPFSIYFLHLASADVGLFSKAVFSILNTGGFLGTFADYIRSVCRVLGLCMFLTGVSL
PAVSASACASVIFPAWYWRRRPKRLSAVVCALLWVLSLLVTCLHNYFCVFLGRGAPGACCRHMDIFL
GILLFLLCCPLMVLPCALILHVECGPDGPRSAKLKHVILAMVSVFLVSSIYLGIDWFLFWVFQIPA
PFPEYVTDLCICINSSAKPIVYFLAGRTSRSGCWSLRVVFSGACGTALTGGCRGSTLNTVTMEMQCP
PGNAS

NOV20b

Alternatively, a NOV20 variant is the novel NOV20b (alternatively referred to herein as CG56517-02), which includes the 1113 nucleotide sequence (SEQ ID NO:70) shown in Table 20C. NOV20b was created by polymerase chain reaction (PCR) using the primers: 5'-ATCAGGACAGCTGCAGGTGGGT-3' (SEQ ID NO:242) and 5'-TCTCCTGTATGGACTCAGAAGAAGGTG-3' (SEQ ID NO:243). Primers were designed based on *in silico* predictions of the full length or some portion (one or more exons) of the cDNA/protein sequence of the invention. The PCR product derived by exon linking, covering the entire open reading frame, was cloned into the pCR2.1 vector from Invitrogen to provide clone CG56517-01.698754.A13.

The NOV20b ORF begins with a Kozak consensus ATG initiation codon at nucleotides 73-75 and ends with a TGA codon at nucleotides 1102-1104. Putative untranslated regions upstream from the initiation codon and downstream from the termination codon are underlined in Table 20C, and the start and stop codons are in bold letters.

Table 20C. NOV20b Nucleotide Sequence (SEQ ID NO:70)

ATCAGGACAGCTGCAGGTGGGTGTGCAGACTGGTGAGCTGCCAGCAGGGGGCCAGACGCGCCAGGCC
 TGGAGATGGCTGGAACTGCTCCTGGGAGGCCCATCCCGGCAACAGGAACAAGATGTGCCCTGGCCT
 GAGCGAGGCCCCGGAACCTACAGCCGGGGCTTCTGACCATCGAGCAGATCGCGATGCTGCCGCCT
 CCGGCCGTCATGAACCTACATCTTCTGCTCCTCTGCCTGTGTGGCCTGGTGGGCAACGGGCTGGTCC
 TCTGGTTTTTCGGCTTCTCCATCAAGAGGAACCCCTTCTCCATCTACTTCTGACCTGGCCAGCGC
 CGATGTGGGCTACCTCTTCCAGCAAGGCGGTGTTCTCCATCCTGAACACGGGGGGCTTCTGGGCACG
 TTTGCCGACTACATCCGCAGCGTGTGCCGGGTCTGGGGCTCTGCATGTTCTTACCGGCGTGAGCC
 TCCTGCCGGCCGTCAGCGCCGAGCGCTGCGCCTCGGTCATCTTCCCCGCTGGTACTGGCGCCGGCG
 GCCCAAGCGCCTGTCGGCCGTGGTGTGCGCCCTGCTGTGGGTCTGTCCCTCCTGGTCACTGCCTG
 CACAACACTTCTGCGTGTTCCTGGTCTGCTGCTGCGCCGCTCATGGTGCTGCCCTGCCTGGCCCTCATCT
 TCCTGGGCATCCTCCTGTTCTGCTGCTGCTGCGCCGCTCATGGTGCTGCCCTGCCTGGCCCTCATCT
 GCACGTGGAGTGCCGGGGCCGACGGCGCCAGCGCTCTGCCAAGCTCAACCACGTCATCCTGGCCATG
 GTCTCCGTCTTCTGGTGTCTCCATCTACTTAGGGATCGACTGGTTCTCTTCTGGGTCTTCCAGA
 TCCCGGCCCCCTTCCCGAGTACGTCACTGACCTGTGCATCTGCATCAACAGCAGCGCCAAGCCCAT
 CGTCTACTTCTGGCCGGGAGGGACAAGTCGCAGCGGTGTGGGAGCCGCTCAGGGTGGTCTTCCAG
 CGGGCCCTGCGGGACGGCGCTGAGCTGGGGGAGGCCGGGGGAGCAGCGCCCAACACAGTCACCATGG
 AGATGCAGTGTCCCCGGGGAACGCCTCCTGAGACTCCAGC

The NOV20b protein (SEQ ID NO:71) encoded by SEQ ID NO:70 is 343 amino acid residues in length and is presented using the one-letter code in Table 20D.

Table 20D. NOV20b protein sequence (SEQ ID NO:71)

MAGNCSWEAHPGNRNMCPGLSEAPELYSRGFLTIEQIAMLPPPAVMNYIFLLCLCLGLVG
 NGLVLWFFGFSIKRNPFSIYFLHLASADVGYLFSKAVFSILNTGGFLGTFFADYIRSVCRVL
 GLCMFLTGVSLLPVSAERCASVIFPAWYWRRRPKRLSAVVCALLWVLSLLVTCLHNYFCV
 FPGRGAPGAACRHMDFLGILLFLLCCPLMVLPCALILHVECRARRRQSAKLNHVILAM
 VSVFLVSSIYLGIDWFLFWVFQIPAPFPEYVTDLCICINSSAKPIVYFLAGRDKSQRLWEP
 LRVVFQRALRDGAELGEAGGSTPNTVTMEMQCPPGNAS

NOV20 Clones

Unless specifically addressed as NOV20a or NOV20b, any reference to NOV20 is assumed to encompass all variants. NOV20b has four frame-shifts at position 762, 959, 986, and 1042 bp, respectively, when compared with NOV20a. These frame-shifts result in numerous amino acid differences between NOV20a and NOV20b.

A search against the Patp database, a proprietary database that contains sequences published in patents and patent publications, yielded several homologous proteins shown in Table 20E and Table 20F.

Table 20E. Patp results for NOV20a

	Reading Frame	High Score	Smallest Sum Prob P(N)
Sequences producing High-scoring Segment Pairs:			
>patp:AAB88477 Human membrane clone PSEC0142	+1	1625	7.9e-167
>patp:AAR97222 Human G-protein coupled receptor	+1	1591	3.2e-163
>patp:AAR96145 G protein coupled receptor protein	+1	1404	2.1e-143

Table 20F. Patp results for NOV20b

	Reading Frame	High Score	Smallest Sum Prob P(N)
Sequences producing High-scoring Segment Pairs:			
>patp:AAB88477 Human membrane clone PSEC0142	+1	1826	3.9e-188
>patp:AAR97222 Human G-protein coupled receptor	+1	1792	1.6e-184
>patp:AAR96145 G protein coupled receptor protein	+1	1589	5.1e-163

In a BLAST search of public sequence databases, it was found, for example, that the NOV20a nucleic acid sequence of this invention has 840 of 1032 bases (81%) identical to a gb:GENBANK-ID:RATRТА|acc:M35297.1 mRNA from *Rattus norvegicus* probable G protein-coupled receptor (RTA) mRNA, complete cds. NOV20a protein of the invention was found to have 265 of 343 amino acid residues (77%) identical to, and 280 of 343 amino acid residues (81%) similar to, the 343 amino acid residue ptmr:SWISSPROT-ACC:P23749 protein from probable *Rattus norvegicus* G protein-coupled receptor RTA.

Similarly, it was found, for example, that the NOV 20b nucleic acid sequence of this invention has 903 of 1086 bases (83%) identical to a gb:GENBANK-ID:RATRТА|acc:M35297.1 mRNA from *Rattus norvegicus* G protein-coupled receptor (RTA) mRNA, complete cds. NOV20b protein of the invention was found to have 291 of 343 amino acid residues (84%) identical to, and 307 of 343 amino acid residues (89%) similar to, the 343 amino acid residue ptmr:SWISSPROT-ACC:P23749 protein from *Rattus norvegicus* probable G protein-coupled receptor RTA.

Additional BLAST results are shown in Table 20G.

The presence of identifiable domains in the protein disclosed herein was determined by searches using algorithms such as PROSITE, Blocks, Pfam, ProDomain, Prints and then determining the Interpro number by crossing the domain match (or numbers) using the Interpro website (<http://www.ebi.ac.uk/interpro/>). The DOMAIN analysis results indicate that the NOV20 protein contains the following protein domain (as defined by Interpro): domain name 7tm_1 7 transmembrane receptor (rhodopsin family). DOMAIN results for NOV20 were collected from the Conserved Domain Database (CDD) with Reverse Position Specific BLAST. This BLAST samples domains found in the Smart and Pfam collections.

As discussed below, the NOV20 protein of the invention contained significant homology to the 7tm_1 domain. This indicates that the NOV20 sequence has properties similar to those of other proteins known to contain this 7tm_1 domain and similar to the properties of these domains. The 254 amino acid domain termed 7tm_1 (SEQ ID NO:248; Pfam Acc. No. 00001) a seven transmembrane receptor (rhodopsin family), is shown in Table 20J.

Table 20J. 7tm_1, 7 transmembrane receptor domain (SEQ ID NO:248)	
GNLLVILVILRTKKLRTPTNIFLLNLAVADLLFLLTLPWALYYLVGGDWVFGDALCKLVGALFVVNGYASILLTALISIDRYL	
AI VHPLRYRRIRTPRRAKVLILLVWVLALLLSLPPLLF SWLRTVEEGNTTVCLIDFPEESVKRSYVLLSTLVGFVLP LLVILVC	
YTRILRTLKRARSQRSLKRRSSSERKAAKMLLVVVVVFLCWLPHYHIVLLDLSLCLLSIWRVLP TALLITLWLAYVNSCLNPI	
IY	

The DOMAIN results are listed in Table 20K and Table 20L with the statistics and domain description. An alignment of NOV20a residues 61-290 (SEQ ID NO:68) with the full 7tm_1 domain, residues 1-254 (SEQ ID NO:248), are shown in Table 20K. A similar alignment of NOV20b residues 61-290 (SEQ ID NO:70), are shown in Table 20L. This indicates that the NOV20 sequences have properties similar to those of other proteins known to contain this domain as well as to the 254 amino acid 7tm domain (SEQ ID NO:248). For Table 20K and Table 20L, fully conserved single residues are indicated by the vertical line and “strong” semi-conserved residues are indicated by the “plus sign.” The “strong” group of conserved amino acid residues may be any one of the following groups of amino acids: STA, NEQK, NHQK, NDEQ, QHRK, MILV, MILF, HY, FYW.

Table 20K Domain Analysis of NOV20a

PSSMs producing significant alignments:

Score E
(bits) value
72.2 4.9e-22

gnl|Pfam|pfam00001 7tm_1, 7 transmembrane receptor (rhodopsin family)

5 NOV20a 61 *->GNLLVilvilrtkkrlrtptnifilNLAvADLLflltltppwalyylv
||+||++ +++ |++|++|+|| || +|++ ++++++ |
GNGLVLWFFGF-SIKRNPFSIYFLHLASADVGYLFSKAVFSILNTGG 106

10 NOV20a 107 gsedWpfGsalCklvtaldvvnmyaSillLtaISiDRYlAivhPlryrrr
+ | ++ + |+++ + +++ || | | + +++ | +|+||
--FLGTFADYIRSVCRVLGLCMFLTGVSLLPVAVSASACASVIFPAWYWRR 154

15 NOV20a 155 rtsprrAkvvillvWvlallslPpllfswvktveegngtlnvnvtvCli
| +|+ +|++| ||+||++ ++ +|+ + + |
RP-KRLSAVVCALLWVLSLLVTCLHNYFCVFLGRGAP-----GACCRH 196

NOV20a 197 dfpeestasvstwlrsyvlstlvGflPllvilvcYtrIlrtlr....
+ ++| +|++ |++ | + | | +|++ ++++++
M-----DIFLGILLFLLCCPLMVLPCALILHVECgpdgp 231

NOV20a 232 ...kaaktllvvvvvFvlCWlPyfivllldtlc.lsiimsstCelervlp
++ | + +++|+ | +|++ + | ++|++++++
rsaKLKHVILAMVSVFLVSSIYLGIDWFLFWVFqIP-----AP 269

NOV20a 270 tallvtlwLayvNsclNPiY<-* (SEQ ID NO:248)
++ +|| ++ +|| ||+ | (SEQ ID NO:69)
FPEYVTDLCICINSSAKPIVY 290

Table 20L Domain Analysis of NOV20b

PSSMs producing significant alignments:

Score E
(bits) value
102.2 1.7e-31

gnl|Pfam|pfam00001 7tm_1, 7 transmembrane receptor (rhodopsin family)

35 NOV20b 61 *->GNLLVilvilrtkkrlrtptnifilNLAvADLLflltltppwalyylv
||+||++ +++ |++|++|+|| || +|++ ++++++ |
GNGLVLWFFGF-SIKRNPFSIYFLHLASADVGYLFSKAVFSILNTGG 106

NOV20b 107 gsedWpfGsalCklvtaldvvnmyaSillLtaISiDRYlAivhPlryrrr
+ | ++ + |+++ + +++ || | | +|+ +++ | +|+||
--FLGTFADYIRSVCRVLGLCMFLTGVSLLPVAVSAERCASVIFPAWYWRR 154

NOV20b 155 rtsprrAkvvillvWvlallslPpllfswvktveegngtlnvnvtvCli
| +|+ +|++| ||+||++ ++ +| + ++ | + +|+
RP-KRLSAVVCALLWVLSLLVTCLHNYF--CVFPGRGAP-----GAACRH 196

NOV20b 197 dfpeestasvstwlrsyvlstlvGflPllvilvcYtrIlrtlr....
+ ++| +|++ |++ | + | | +|++ ++ +++
M-----DIFLGILLFLLCCPLMVLPCALILHVECrarr 231

...kaaktllvvvvvFvlCWlPyfivllldtlc.lsiimsstCelervl

NOV20b 232 ^{+++ | + +++ | + | + | + + + + + + + + +} qrsaKLNHVILAMVSVFLVSSIYLGIDWFLFWVFqIP-----A 269
 5 ptallvtlwLayvNscINPiIY<-* (SEQ ID NO:248)
 NOV20b 270 ^{| + + + | | + + + + | | + |} PFPEYVTDLCLICINSSAKPIVY 291 (SEQ ID NO:71)

Consistent with other known members of the GPCR family of proteins, NOV20 contains
 10 7tm_1 7 transmembrane receptor (rhodopsin family) domain as illustrated in Table 20K and
 Table 20L, as well as homology and cellular localization, *i.e.* plasma membrane.

NOV20 nucleic acids, and the encoded polypeptides, according to the invention are
 useful in a variety of applications and contexts. For example, NOV20 nucleic acids and
 polypeptides can be used to identify proteins that are members of the GPCR family of proteins.

15 The NOV20 nucleic acids and polypeptides can also be used to screen for molecules, which
 inhibit or enhance NOV20 activity or function. Specifically, the nucleic acids and polypeptides
 according to the invention may be used as targets for the identification of small molecules that
 modulate or inhibit, *e.g.*, cellular signal transduction. These molecules can be used to treat, *e.g.*,
 cancer, immune disorders, and endocrine disorders.

20 In addition, various NOV20 nucleic acids and polypeptides according to the invention are
 useful, *inter alia*, as novel members of the protein families according to the presence of domains
 and sequence relatedness to previously described proteins. For example, the NOV20 nucleic
 acids and their encoded polypeptides include 7tm_1 7 transmembrane receptor (rhodopsin
 family) domain and sequence homology that are characteristic of proteins belonging to the
 25 family of GPCR such as the G protein-coupled receptor (RTA). The GPCR1 protein of the
 invention has a high homology to the 7tm_1 domain (PFam Acc. No. pfam00001). The 7tm_1
 domain is from the 7 transmembrane receptor family, which includes a number of different
 proteins, including, for example, serotonin receptors, dopamine receptors, histamine receptors,
 andrenergic receptors, cannabinoid receptors, angiotensin II receptors, chemokine receptors,
 30 opioid receptors, G-protein coupled receptor (GPCR) proteins, olfactory receptors (OR), and the
 like.

G-Protein Coupled Receptor proteins ("GPCRs") have been identified as a large family
 of G protein-coupled receptors in a number of species. These receptors share a seven
 transmembrane domain structure with many neurotransmitter and hormone receptors, and are
 35 likely to underlie the recognition and G-protein-mediated transduction of various signals.

Human GPCR generally do not contain introns and belong to four different gene subfamilies, displaying great sequence variability. These genes are dominantly expressed in olfactory epithelium. See, *e.g.*, Ben-Arie *et al.*, Hum. Mol. Genet. 3:229-235 (1994); and, Online Mendelian Inheritance in Man ("OMIM") entry # 164342 (<http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?>).

The NOV20 nucleic acids and polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications in the mediation of cellular signal transduction. As such the NOV20 nucleic acids and polypeptides, antibodies and related compounds according to the invention may be used to treat a wide range of disorders such as cancer, immune disorders, endocrine disorders and other diseases, *e.g.*, developmental diseases; MHCII and III diseases (immune diseases); taste and scent detectability disorders; Burkitt's lymphoma; corticoneurogenic disease; signal transduction pathway disorders; metabolic pathway disorders; retinal diseases including those involving photoreception; cell growth rate disorders; cell shape disorders; metabolic disorders; feeding disorders; control of feeding; the metabolic syndrome X; wasting disorders associated with chronic diseases; obesity; potential obesity due to over-eating or metabolic disturbances; potential disorders due to starvation (lack of appetite); diabetes; noninsulin-dependent diabetes mellitus (NIDDM); infectious disease; bacterial, fungal, protozoal and viral infections (particularly infections caused by HIV-1 or HIV-2); pain; cancer (including but not limited to neoplasm; adenocarcinoma; lymphoma; prostate cancer; uterus cancer); cancer-associated cachexia; anorexia; bulimia; asthma; Parkinson's disease; acute heart failure; hypotension; hypertension; urinary retention; osteoporosis; Crohn's disease; multiple sclerosis; Albright Hereditary Osteodystrophy; angina pectoris; myocardial infarction; ulcers; allergies; benign prostatic hypertrophy; and psychotic and neurological disorders; including anxiety; schizophrenia; manic depression; delirium; dementia; neurodegenerative disorders; Alzheimer's disease; severe mental retardation; Dentatorubro-pallidoluysian atrophy (DRPLA); Hypophosphatemic rickets; autosomal dominant (2) Acrocallosal syndrome and dyskinesias, such as Huntington's disease or Gilles de la Tourette syndrome; immune disorders; Adrenoleukodystrophy; Congenital Adrenal Hyperplasia; Hemophilia; Hypercoagulation; Idiopathic thrombocytopenic purpura; autoimmune disease; immunodeficiencies; transplantation; Von Hippel-Lindau (VHL) syndrome; Stroke; Tuberous sclerosis; hypercalcaemia; Cerebral palsy; Epilepsy; Lesch-Nyhan syndrome; Ataxia-

telangiectasia; Leukodystrophies; Behavioral disorders; Addiction; Neuroprotection; Cirrhosis; Transplantation; Systemic lupus erythematosus; Emphysema; Scleroderma; ARDS; Renal artery stenosis; Interstitial nephritis; Glomerulonephritis; Polycystic kidney disease; Systemic lupus erythematosus; Renal tubular acidosis; IgA nephropathy; Cardiomyopathy; Atherosclerosis;

5 Congenital heart defects; Aortic stenosis ; Atrial septal defect (ASD); Atrioventricular (A-V) canal defect; Ductus arteriosus; Pulmonary stenosis ; Subaortic stenosis; Ventricular septal defect (VSD); valve diseases; Scleroderma; fertility; Pancreatitis; Endocrine dysfunctions; Growth and reproductive disorders; Inflammatory bowel disease; Diverticular disease; Leukodystrophies; Graft vesus host; Hyperthyroidism; Endometriosis; and hematopoietic

10 disorders.

The NOV20 nucleic acids and polypeptides are useful for detecting specific cell types. For example, expression analysis has demonstrated that a NOV20 nucleic acid is expressed in Brain, Synovium/Synovial membrane.

Additional utilities for NOV20 nucleic acids and polypeptides according to the invention are

15 disclosed herein.

NOV21

A NOV21 polypeptide has been identified as a TFIIC box B-binding subunit-like protein (also referred to as CG56500-01). The disclosed novel NOV21 nucleic acid (**SEQ ID NO:72**) of

20 6921 nucleotides is shown in Table 21A. The cDNA coding for the NOV21 was cloned by polymerase chain reaction (PCR) using the following primers: 5'-CCATGGGCCGACCGGCTC-3' (**SEQ ID NO:249**) and 5'-TGGCGGGCTTCCTCGTCATC-3' (**SEQ ID NO:250**) on the following pools of human cDNAs: Pool 1 - adrenal gland, bone marrow, brain - amygdala, brain - cerebellum, brain - hippocampus, brain - substantia nigra, brain - thalamus, brain -whole, fetal

25 brain, fetal kidney, fetal liver, fetal lung, heart, kidney, lymphoma - Raji, mammary gland, pancreas, pituitary gland, placenta, prostate, salivary gland, skeletal muscle, small intestine, spinal cord, spleen, stomach, testis, thyroid, trachea, uterus. The novel NOV21 nucleic acid sequences maps to the chromosome16p12.

An ORF begins with an ATG initiation codon at nucleotides 61-63 and ends with a TAG

30 codon at nucleotides 6313-6315. A putative untranslated region and/or downstream from the termination codon is underlined in Table 21A, and the start and stop codons are in bold letters.

Table 21A. NOV21 Nucleotide Sequence (SEQ ID NO:72)

ATGGACCAAGGCCCTTGGCGGTGCGTTGCGCACCCCGGGCGCCGCGACTGAAGTAGCAATGGACG
CGCTGGAGTCGTTGTTGGACGAAGTCGCTCTGGAGGGGCTCGATGGCCTGTGTCTGCCAGCGCTGTG
GAGCCGGCTGGAGACGCGAGTGCCGCCCTTCCCGCTGCCTTTGGAACCTGCACGCAGGAGTTTCTC
TGGCGGGCCCTCGCCACGCACCCGGGCATCAGCTTCTATGAGGAGCCTCGGGAGCGACCCGACCTAC
AGCTCCAGGACCGGTATGAAGAAATTGATTGGAACCTGGAATTTTGGAGTCTAGGAGGGACCCGGT
GGCTTTGGAGGATGTCTACCCATTTCATATGATCTTAGAGAATAAGGATGGCATCCAGGGCTCATGC
CGCTACTTTAAGGAGAGGAAAAACATTACCAATGACATCAGAACCAAGTCCTTGCAGCCTCGCTGTA
CAATGGTGAACCTTTGACAGGTGGGGGAAGAACTGATCATCGGTTCCCTCCAGCCCATGCGGT
ACAGGCCCTTGATAGCCAGGAGGGGGATCCCGACCTGAAGCTGCCGACTTCTCTACTGCATCCT
GGAACGGCTAGGCCGGTCCAGGTGCAAGGGGAGCTCCAGCGAGACCTTCACACCACTGCTTTCAAGG
TTGATGCTGGGAAGCTGCACTATCACAGAAAAATTTTGAACAAAAACGGGCTGATTACAATGCAGTC
CCATGTGATCCGATTACCCACTGGAGCCCAGCAACACTCAATCCTCCTCCTACTGAACCGGTTTCAT
GTGGACAGGAGGAGCAAATACGACATCCTCATGGAGAAGCTTTCGGTCATGCTGAGCACACGGACTA
ACCACATAGAGACGCTGGGAAAGCTGAGGGAAGAGCTGGGGCTGTGCGAAAGGACGTTTAAGCGTCT
GTACCAGTATATGCTGAACGCCGGGCTAGCCAAGGTGGTGTCTCTTCGCTTGCAAGAGATCCACCT
GAATGTGGACCTTGTAAGACAAAGAAAGGGACCGACGTCATGGTTCCGTGCCTCAAGCTGCTGAAGG
AATTTAAACGGAATGACCATGATGATGACGAGGACGAGGAGTTCATCTCAAGACAGTGCCTCCAGT
GGACATTGTGTTTCGAGCGGGATATGCTCACACAGACCTACGACCTCATTGAGCGCAGAGGCACGAAA
GGAATTTCCAAGCTGAAATCCGAGTGGCTATGAATGTGGGAAAACTAGAAGCAAGAATGCTGTGCC
GACTTCTTCAAAGATTCAAAGTTGTCAAGGGATTTCATGGAAGACGAAGGTCGGCAGCGAACCCAA
GTACATTTCTGCGTGTGTCAGAGGAGAGCGACCTAAGCCGGCAGTACCAAAGAGAGAAGGCCCGC
AGCGAGCTCTTGACCACCGTGAGCCTGGCGTCTATGCAGGAGGAGTTCGCTTCTGCCTGAAGGCGAGG
ACACCTTCTCTCTGAGTCGGACAGTGAGGAGGAGAGGAGCAGCAGCAAGCGGAGAGGCAGAGGGTC
CCAGAAAAGACACAAGAGCCTCTGCAACCTCCGGCCCAAGACCCAGCCTCATCACTCCACCCCAACC
AAGGGTGGGTGGAAAGTTGTAAACCTACACCCATTGAAAAAGCAGCCGCCCTCCTTCCCAGGAGCTG
CTGAAGAGAGAGCCTGCCAGAGCCTTGCCAGCAGGGACAGCCTCTTAGATACCAGCAGCGTCTCAGA
ACCCAACGTGTCTTTGTCTCCCACTGTGCGGACAGCAACAGTGGTGACATAGCTGTGATCGAGGAG
GTCCGGATGGAACCCAAAGGAGAGTAGCAGTTCCCTGAAGACTGGGAGGCACAGCTCAGGCCAAG
ACAAACCACACGAAACTTACCGACTGCTGAAACGCAGGAATCTGATCATAGAAGCTGTCAACCAATCT
TCGCTTAATCGAGAGTTTATTACGATTACAGAAGATGATCATGGATCAGGAGAAGCAGGAAGGCGTG
TCCACCAAGTGCTGCAAGAAGTCCATTGTCCGCTTGGTGCGGAACCTGTCTGAGGAAGGTCTCTTGC
GATTGTATCGGACCACTGTCAATTCAAGATGGCATCAAGAAGAAGGTGGATCTGGTGGTGACCCGTC
CATGGACCAGAACGACCCTCTAGTGAGAAGTGCCATCGAGCAGGTCCGCTTCCGGATCTCCAATTCA
AGCACAGCCAACAGGGTTAAACTTCCCAGCCTCCAGTGCCCCAAGGGGAGGCAGAAGAAGACAGTC
AAGGAAAAGAGGGCCCAAGTGGATCAGGGGACTCTCAGCTGAGTGCTTCTCTAGATCAGAAAGTGG
ACGGATGAAAAAAGTGATAATAAAATGGGCATAACCCCGCTTAGAAATTATCACCCCATTTGTAGTT
CCCGACTGGGGCGTCTCTAGGATTTCTGCCCAAAATGCCTCGCCTGCGGGTGGTCCACATGTTTC
TGTGGTACCTCATCTACGGGCACCCTGCCAGCAACACCGTGAGAGAAGCCAAGCTTCATCAGTGAACG
GAGAACGATAAAGCAGGAGTCAGGCAGGGCAGGCGTCCGGCCGTCTCTCTGGAAGTGCCTGGGAG
GCCTGCTCTGAAGCCCCATCTAAAGGCAGCCAAGATGGTGTACCTGGGAGGCTGAAGTGGAGCTTG
CCACGGAGACAGTGATGTGACGATGCCTCGTGGATGCGCTACATCCCCCAATCCAGTCCACAG
GGACTTCGGCTTTGGCTGGGCTCTCGTCAGCGACATCCTCCTCTGCCTTCCCTCTCCATCTTCATC
CAGATTGTGCAAGTCAGCTACAAGGTGGACAACCTGGAGGAATTTCTGAACGACCCGCTGAAGAAGC
ACACGCTGATCCGCTTTCTCCCCAGGCCCATTCGGCAGCAGCTTCTGTACAAGAGGCGTTACATTTT
TTCGGTGGTGGAGAACCTTCAGAGGCTGTGCTACATGGGGGTGCTACAGTTTGGTCCCACGGAAAAG
TTTCAGGATAAAGATCAGGTCTTTATCTTCTTGAAGAAGAATGCAGTCATTGTTGACACTACCATCT
GCGACCCACATTACAACCTGGGCCGAGGAGGCGGCCCTTCGAGAGGCGCTCTATGTCTGAACTC
AATGCAGGATGTGAAAACTACTGGTTTGACCTGCAGTGCGTCTGCCTCAACACCCCACTAGGCGTG
GTGCGCTGCCCGCGCGTCAGGAAGAAGCAGCAGCACAGACCAGGGCAGCGACGAGGAGGCGAGCCTGC
AGAAGGAGCAGGAGAGCGCCATGGACAAGCAACCTGGAGCGCAAGTGCGCCATGCTGGAGTACAC
CACTGGAAGCCGTGAGGTGGTGGATGAAGGCTTGATCCCTGGAGATGGGTGGGTGCCCGCAGGGCTC
GATTCAGCTTCTACGGACACCTCAAGCGCAACTGGATCTGGACCAGCTACATCATCAACCAGGCCA
AAAAGGAGAACACTGCCGAGAGAATGGAATCAGTGAAGCTCCAGACATTTCTGTCCAAGCGCCC

AATGCCCCTCAGTGCCAGAGGCAACAGCAGGTTGAATATTTGGGGGAAGCAAGAGTAGGCTCCGAG
CTCTGTGCTGGCTGGGAAGAGCAGTTTGGAGTGGACCGAGAGCCCTCGCTGGACCGAAACCGGAGAG
TGAGGGGTGGGAAAAGCCAGAAGCGGAAGCGGCTGAAGAAGGACCTGGGAAGAAGATCAAGAGAAA
GAAGAAAGGAGAGTTCCAGGAGAAAAAAGCAAAAGGCTGCGCTACCATGATGAAGCCGACCAGAGT
GCCCTGCATCGGATGACGCGGCTTCGTGTACCTGGTCTATGCAGGAGGATGGGCTGCTTGTGCTGT
GCCGCATTGCCAGCAATGTCTCAACACCAAGGTGAAGGGTCCATTTGTACCTGGCAGGTGGTACG
GGACATTTTGCATGCCACGTTTGAAGAGTCTTTGGATAAAACATCTCATTTCCCTTGACGAAGAGCT
CGCTACATAGTCAAAAACCCACAGGCCCTATCTCAACTATAAAGTGTGCCTGGCCGAGGTGTACCAGG
ATAAAGCACTTGTGGAGATTTTCATGAATCGAAGAGGTGACTATGATGACCCAAAGGTTTGTGCCAA
CGAGTTTAAAGAATTTGTGGAGAAGCTTAAAGAAAAGTTTCAGTTTCAGCCCTAAGGAATTTAACTT
GAAATCCCAGACACACTCCAGGAGCTGTTCCGACAGGTACCGAGTTTGGCAATTGGGGATGAAAAAG
ATCAAACCAGGAAAGAGGATGAACCTAACAGCGTGGATGACATCCACTTTCTGGTGCTTCAGAACCT
GATCCAGAGCAGCTGGCCCTCTCAGACAGTCAGATGAAGTCCACAGTCATTTCCAGACTTTCCGC
CTCTATCGGGAGTACAAGGACCAGTTCCTTGTGAAGGCCCTTCATGGAGTGCCAGAAGAGGAGCTTGG
TCAACCGGCGCGGGTCAACCACACGCTGGGCCCCAAGAAGAACCGGGCCCTCCCTTCGTGCCAAT
GTCTTACCAGCTATCCCAGACCTACTACAGGATTTTTACGTGGCGATTTCCAAGCACCATCTGCACG
GAGTCATTCCAGTTTTTGGACAGAATGCGGGCTGCCGGCAAGTTGGACCAGCCTGATCGTTTCTCTT
TCAAAGACCAGGATAATAACGAGCCCAAAACGACATGGTGGCCTTTTCACTGGACGGCCCTGGAGG
AAATTGTGTGGCCGCTCTGACCCTCTTCTCTCTGGGCCTCATTTCTGTGGATGTCAGGATCCCGGAG
CAGATCATCGTGGTAGACAGCTCAATGGTGGAGAATGAGGTCATCAAAGCTTGGGGAAGGACGGCA
GCCTGGAGGATGACGAGGATGAAGAGGATGACTTGGACGAAGGTGTAGGGGGCAAGCGCCGAGCAT
GGAGGTGAAACCTGCGCAAGCCTCCACACCAACTACCTGCTGATGAGGGGCTACTACTCCCCGGC
ATCGTCAGCACCCGCAACCTCAACCCCAACGACAGCATTTGTGGTCAACTCCTGCCAGATGAAGTTCC
AGCTCCGCTGCACCCCTGTGCCCCCGGGCTCAGGCCCGCTGCCGCTCCTCTGGAAGAGCTAACAAT
GGGAACCTCCTGCCTCCCTGATACGTTACCAAGCTGATAAACCCCAAGGAAACACCTGCAGCTTG
GAGGAGTTTGTCTCCAGCTGGAGCTGTCTGGGTATAGTCCCGAAGACCTGACTGCTGCCCTTGGAGA
TCTTGAAGCCATTATAGCCACGGGTGTTTTGGGATTGACAAGGAGGAGCTGCGCAGACGGTTCTC
GGCCTTGGAGAAGGCAGGTGGTGGGCGCACCAGGACATTCGAGATTGCATCCAGGCCCTCCTGGAG
CAGCATCAGGTGCTGGAGGTGCGTGGCAACACTGCGCGCCTGGTAGCCATGGGCTCTGCTTGGCCTT
GGCTCCTGCACTCCGTGCGGCTGAAAGACAGAGACGCGCAGATCCAGAGAGAAGACCCCGAGGC
CAGACCCCTGGAGGGGTCTTCCAGTGAGGACAGCCCCCGAGGGGCAGGCACCTCCTTCTCACAGC
CCCCGGGGCACCAGAGGCGCGCAGCTGGGCGAGTGAGAATGGGGAGACCGACGCGGAGGGCACCC
AGATGACCCCTGCCAAGAGGCCAGCGCTCCAGGACTCAAATTTGGCCCCAGCCTTGGGCCCCGAGC
TGAAGATGGGGCAGAAGCCAGGCCCATCTCCACCCCAAGCTCTTGAAGACACCGCTGCAGCGGGA
GCAGCACAGGAAGACCAAGAGGTGTGCGGTTTACAGAGAGTTTCGGAGCTGCCAACATCTCCAGG
CAGCACGGGAAAGGGACTGTGAGAGTGTCTGCTTCATCGGCCGGCCGTGGCGTGTCTGTGATGGCCA
CCTGAACCTTCTGTATGCAAGGGTATGATGGAGGCCATGCTGTACCACATCATGACCAGGCCTGGC
ATCCCCGAGAGCTCCCTGCTGCGCCACTACCAGGGGTCTGTCAGCCCGTGCCTGTGCTGGAGTTGC
TCCAGGGCCTGGAGTCCCTCGGCTGCATCCGGAAGCGCTGGCTGAGAAAGCCAAGGCCTGTCTCGCT
CTTCTCTACACCCGTGGTGGAAAGAGGTGGAAGTGCCCTCCAGCCTGGACGAGAGCCCCATGGCTTTC
TATGAGCCACCTTGGACTGTACCCTCCGGCTGGGCGGTGTGTTCCCCACGAGGTCAACTGGAACA
AGTGGATCCACCTCTAGGACCCCTGTGGGCGTCCCCTCCCTCCAGCCACCGCCTGCCACACCACTC
CTGCCCTGGTGTCTGGCAGACCCCACTGTGCCCTGGCCTTGGGTCTGCCGAGCCTCCTGCAGCAGGGG
ACGGGTGCTTTGGCCAGAGTCACAGACTGACACGTTTCCCACTGTACTGGAACCTTGGAAGAGGGG
CTCCCCGACCTGCCCATCCCCAGGCTCTTCTGGGCCTTCCCCTTGGGAACCTGGCCTCATCACACTG
GGAGTTGGTGCTTCTGTCTCTGGGTCTCCAGAGTTTGGCCCGCTGTGCACACCTCACATTCCAGA
GTGGGATACACTTTCAGAAATAGGGATCGGTGTGCCCCGCTGCGAGGGGGCCCCCATGGGGGCTGTG
GCCCCCTCCGACGGCAGGACATCCCAACCCCTGGCTGGGACTGAACCACCCAGAGCGGAGCGGCTCCC
TTTTAGCCCTTGTGAGTCACTGGCAGGCCCCAGCTGGGCTGGCTGTCCGTGTCCCTCAGCCTGGCT
GGTGATTCCCTTGCAGGAGGG

The NOV21 protein (SEQ ID NO:73) encoded by SEQ ID NO:72 is 2084 amino acid residues in length and is presented using the one-letter amino acid code in Table 21B. NOV21

has two SNP variants, whose variant positions for its nucleotide and amino acid sequences is numbered according to **SEQ ID NOS:72 and 73**, respectively. A variant sequence can include a single nucleotide polymorphism (SNP). A SNP can, in some instances, be referred to as a "cSNP" to denote that the nucleotide sequence containing the SNP originates as a cDNA.

NOV21 has at least two variants. Variant 13376755 is a G to A SNP at 129 bp of the nucleotide sequence that results in no change in the protein sequence (silent), and variant c100.2613 is an insertion of nucleotide C before 5780 bp of the nucleotide sequence that results in a frameshift with all amino acids after 1907 being discordant with the original protein sequence.

Psort analysis predicts the NOV21 protein of the invention to be localized in the nucleus with a certainty of 0.8000, as expected by a transcription factor subunit. As expected for a member of the TFIIC box B-binding subunit protein family, no identifiable domains with significant score were identified in the NOV21 polypeptide by searches using algorithms such as PROSITE, Blocks, Pfam, ProDomain, Prints.

Table 21B. Encoded NOV21 protein sequence (SEQ ID NO:73)

```
MDALESLLDEVALEGLDGLCLPALWSRLETRVPPFPLPLEPCTQEFLLWRALATHPGISFYEEPFRERPDQLQD
RYEEIDLETGILESRRDPVALEDVYPIHMILENKDGIQSGCRYFKERKNITNDIRTKSLQPRCTMVEPFDRWG
KKLIIGSLPAHAVQALDSPGGGRPEAARLLLLHPGTARPVQVQGEQLQDRLHTTAFKVDAGKLHYHRKILNKN
GLITMQSHVIRLPTGAQQHSILLNLRNFHVDRRSKYDILMEKLSVMLSTRTNHIETLGKLRLEELGLCERTFKR
LYQYMLNAGLAKVVSRLRQEIHPCEGPKCTKKGTDVMVRCLKLLKEFKRNDHDDDEDEEVI SKTVPPVDIVFE
RDMLTQTYDILERRGTGKISQAEIRVAMNVGKLEARMLCRLQLRPFKVVKGFMEDGRQRTTKYISCVFAEESD
LSRQYQREKARSELLTTVSLASMQEESLLPEGEDTFLSESDSEERSSSKRRGRGSQKDRASANLRPKTQPH
HSTPTKGGWKVNLHPLKKQPPSFPGAAERACQSLASRDSLLDTSSVSEPNVSFVSHCADSNSGDI A VIEEV
RMENPKESSSSLKTGRHSSGQDKPHETYRLLKRRNLIIEAVTNLRILIESLFTIQKMIMDQEQEGVSTKCCCK
SIVRLVRNLSEGLLRLYRTTVIQDGIKKKVDLVHPSMDQNDPLVRS AIEQVRFRISNSSTANRVKTSQPPV
PQGEAEEDSQGKEGPGSGSDSQLSASSRSESGRMKSDNKMGITPLRNYHPIVVPGLRSLGFLPKMPRLRVV
HMFLWYLIYGHPASNTVEKPSFISERRTIKQESGRAGVRPSSSGSAWEACSEAPSKGSQDGV TWAEAEVELATE
TVYVDDASWMRYIPIPVHRDFGFGWALVSDILLCLPLSIFIQIVQVSYKVDNLEEF LNDPLK KHTLIRFLPR
PIRQQLLYKRRYIFSVVENLQRLCYMGVLQFGPTEKFQDKDQVFI FLKKN AVI VDTTICDPHYNLGRRRRPFE
RRLYVLNSMQDVENYWF DLQCVCLNTPLGVVRCPRVRKNSSTDQGSDEEGLQKEQESAMD KHNLERKCAMLE
YTTGSREVVDGLIPGDGLGAAGLDSSFYGH LKRNWIWTSYIINQAKKENTAAENGLTVRLQTF LSKRPMPLS
ARGNSRLNIWGEARVSEL CAGWEEQFEVDREPSLDNRNRVRGGKSQKRKRLKDPGKKIKRKKKGFEFPGEKS
KRLRYHDEADQSALHRMTRLRVTWSMQEDGLLVLCRIASNVLNTKVKGPFVTWQVVRDILHATFEESLDKTSH
SLGRRARYIVKNPQAYLNYKVCLAEVYQDKALVGDFMNRGRDYDDPKVCANEFKEFVEKLKEKFSSALRNSNL
EIPDTLQELFARYRVLAIGDEKDQTRKEDELNSVDDIHFLVLQNLIQSTLALSDSQMKSYSQFQTRLYREYK
DHLVLKAFMECQKRSLVNRNRVNHTLGPKNRNLALFPVMSYQLSQTYYRIFTWRFPSTICTESFQFLDRMRAA
GKLDQPD RFSFKDQDNNEPTNDMVAFSLDGP GNCVAVLTFLSLGLISVDVRIPEQIIVVDSSMVENEVIKSL
GKDGSLEDEDEDEDDLDEGVGKKRRSMEV KPAQASHTNYLLMRGYSPGIVSTRNLNPND SIVVNSCQM K FQL
RCTPVPARLRPAAAPLEELTMGTSCLPDTFTKLINPQENTCSLEEFVLQLELSGYSPEDLTAAL EILEAI IAT
GCGFIDKEELRRRFSALEKAGGRTRTFADCIQALLEHQVLEVGGN TARLVAMGSAWPWLLHSVRLKDREDA
DIQREDPQARPLEGSSSEDSPPGEQAPPSHSPRGTKRRASWASENGETDAEGTQMPAKR PALQDSNLAPSLG
PGAEDGAEAAQAPSPPPALEDTAAAGAAQEDQEGVGFTESFGAANISQAARERDCESVCFIGRPWRVVDGHLNL
PVCKGMMEAMLYHIMTRPGIPESSLLRHYQGVLPVAVLELLQGLESLGCIRKRWLRKPRPVSLFSTPVVEEV
EVPSSLDES PMAFYEPTLDCTLR LGRVFPHEVWNWKNKIHL
```

A search against the Patp database, a proprietary database that contains sequences published in patents and patent publications, yielded several homologous proteins shown in Table 21C.

Table 21C. Patp results for NOV21

Sequences producing High-scoring Segment Pairs:	Reading Frame	High Score	Smallest Sum Prob P(N)
>patp:AAM32653 Peptide #6690 encoded by probe	+1	519	5.2e-48
>patp:AAM59814 Human brain expressed single exon probe	+1	519	5.2e-48
>patp:AAM72401 Human bone marrow expressed probe	+1	519	5.2e-48
>patp:AAM34175 Peptide #8212 encoded by probe	+1	491	4.9e-48
>patp:AAM74000 Human bone marrow expressed probe	+1	491	4.9e-48
>patp:AAM60401 Human brain expressed single exon probe	+1	343	2.7e-29
>patp:AAM73037 Human bone marrow expressed probe	+1	343	2.7e-29
>patp:AAM33554 Peptide #7591 encoded by probe	+1	324	2.8e-27
>patp:AAM60680 Human brain expressed single exon probe	+1	324	2.8e-27
>patp:AAM73352 Human bone marrow expressed probe	+1	324	2.8e-27

In a BLAST search of public sequence databases, it was found, for example, that the nucleic acid sequence of this invention has 6006 of 6134 bases (97%) identical to a gb:GENBANK-ID:HSU02619|acc:U02619.1 mRNA from *Homo sapiens* (Human TFIIC Box B-binding subunit mRNA, complete cds). The NOV21 polypeptide was found to have 1937 of 1948 amino acid residues (99%) identical to, and 1939 of 1948 amino acid residues (99%) similar to, the 2109 amino acid residue ptmr:SPTREMBL-ACC:Q12789 protein from *Homo sapiens* (TFIIC BOX B-BINDING SUBUNIT (TRANSCRIPTION FACTOR (TFIIC) ALPHA CHAIN) (3' PARTIAL)). The NOV21 polypeptide lacks 25 internal amino acids, when compared to ptmr:SPTREMBL-ACC:Q12789 protein from *Homo sapiens* (Human) (TFIIC BOX B-BINDING SUBUNIT (TRANSCRIPTION FACTOR (TFIIC) ALPHA CHAIN) (3' PARTIAL)).

NOV21 also has homology to the proteins shown in the BLASTP data in Table 21D.

Table 21D. BLAST results for NOV21

Gene Index/ Identifier	Protein/ Organism	Length (aa)	Identity (%)	Positives (%)	Expect
ptmr:SPTREMBL-ACC:Q12789	TFIIC BOX B-BINDING SUBUNIT (TRANSCRIPTION FACTOR (TFIIC) ALPHA CHAIN) (3' PARTIAL)- <i>Homo sapiens</i>	2109	1937/1948 (99%)	1939/1948 (99%)	0.0

ptnr:SPTREMBL- ACC:Q9Y4W9	TRANSCRIPTION FACTOR (TFIIIC) ALPHA CHAIN, PARTIAL - <i>Homo sapiens</i>	1857	1679/1696 (98%)	1683/1696 (99%)	0.0
ptnr:SPTREMBL- ACC:Q63505	TRANSCRIPTION FACTOR IIIC ALPHA-SUBUNIT - <i>Rattus norvegicus</i>	2148	1506/1933 (77%)	1669/1933 (86%)	0.0
ptnr:SPTREMBL- ACC:Q12838	TFIIIC ALPHA SUBUNIT - <i>Homo sapiens</i>	660	627/658 (95%)	633/658 (96%)	0.0
ptnr:pir-id:B56011	Transcription factor IIIC alpha chain - <i>Homo sapiens</i>	654	623/654 (95%)	629/654 (96%)	0.0

A multiple sequence alignment is given in Table 21E, with the NOV21 protein being shown on line 1 in Table 21E in a ClustalW analysis, and comparing the NOV21 protein with the related protein sequences shown in Table 21D. This BLASTP data is displayed graphically in the ClustalW in Table 21E.

Table 21E. ClustalW Analysis of NOV21

- 1) > NOV21; **SEQ ID NO:73**
- 2) >Q12789/ TFIIIC BOX B-BINDING SUBUNIT (TRANSCRIPTION FACTOR (TFIIIC) ALPHA CHAIN) (3' PARTIAL) [*Homo sapiens*]; **SEQ ID NO:251**
- 3) >Q9Y4W9/ TRANSCRIPTION FACTOR (TFIIIC) ALPHA CHAIN, PARTIAL [*Homo sapiens*]; **SEQ ID NO:252**
- 4) >Q63505/ TRANSCRIPTION FACTOR IIIC ALPHA-SUBUNIT [*Rattus norvegicus*]; **SEQ ID NO:253**
- 5) >Q12838 / TFIIIC ALPHA SUBUNIT [*Homo sapiens*]; **SEQ ID NO:254**
- 6) >O13129/ Transcription factor IIIC alpha chain [*Homo sapiens*]; **SEQ ID NO:255**

		10	20	30	40	50
NOV21	MDALESLLDEVALEGLDGLCLPALWSRLETRVPPFPLPLEPCTQEFWLRA					
Q12789	MDALESLLDEVALEGLDGLCLPALWSRLETRVPPFPLPLEPCTQEFWLRA					
Q9Y4W9	-----					
Q63505	MDALESLLDEVALEGLDGLCLPALWSRLESRSAPFPLPLEPYTQEFWLRA					
Q12838	-----					
B56011	-----					
		60	70	80	90	100
NOV21	LATHPGISFYEEP RERPD LQ LQDRYEEIDLETGILESRRDPVALEDVYPI					
Q12789	LATHPGISFYEEP RERPD LQ LQDRYEEIDLETGILESRRDPVALEDVYPI					
Q9Y4W9	-----					
Q63505	LVTHPGISFYEEP RERPD LQ LQDRYEEIDLETGILESRRDPV TLEDVYPI					
Q12838	-----NSLQDRYEEIDLETGILESRRDPVALEDVYPI					
B56011	-----LQDRYEEIDLETGILESRRDPVALEDVYPI					
		110	120	130	140	150
NOV21	HMILENKDGIQGSCRYFKERKNITNDIRTKSLQPRCTMVEPFDRWGKKLI					
Q12789	HMILENKDGIQGSCRYFKERKNITNDIRTKSLQPRCTMVEPFDRWGKKLI					

Q9Y4W9 -----
 Q63505 HMILENKDGIOGSCRYFKERKDISSIRSKLQPRCTMVEAFSRWGKKLI
 Q12838 HMILENKDGIOGSCRYFKERKNITNDIRTKSLQPRCTMVEAFDRWGKKLI
 B56011 HMILENKDGIOGSCRYFKERKNITNDIRTKSLQPRCTMVEAFDRWGKKLI

160 170 180 190 200
 NOV21 TGS LPAH AVQALDSPG GSRPEAARLLLLHPGTARPVQVQEGELQRLDHTT
 Q12789 TGS LPAH AVQALDSPG GSRPEAARLLLLHPGTARPVQVQEGELQRLDHTT
 Q9Y4W9 -----
 Q63505 IVASQDMRYRALIGLECDPDLKLPDFSYCILERLGRSRWQEGELQRLDHTT
 Q12838 IVASQAMRYRALIQEGCDPDLKLPDFSYCILERLGRSRWQEGELQRLDHTT
 B56011 IVASQAMRYRALIQEGCDPDLKLPDFSYCILERLGRSRWQEGELQRLDHTT

210 220 230 240 250
 NOV21 AFKVDAGKLHYHRKILNKNGLITMQSHVIRLPTGAQQHSILLLLNRFHVD
 Q12789 AFKVDAGKLHYHRKILNKNGLITMQSHVIRLPTGAQQHSILLLLNRFHVD
 Q9Y4W9 -----
 Q63505 AFKVDAGKLHYHRKILNKNGLITMQSHVIRLPTGAQQHSILLLLNRFHVD
 Q12838 AFKVDAGKLHYHRKILNKNGLITMQSHVIRLPTGAQQHSILLLLNRFHVD
 B56011 AFKVDAGKLHYHRKILNKNGLITMQSHVIRLPTGAQQHSILLLLNRFHVD

260 270 280 290 300
 NOV21 RRSKYDILMEKLSVMLSTRTNHIETLGKLR EELGLCERTFKRLYQYMLNA
 Q12789 RRSKYDILMEKLSVMLSTRTNHIETLGKLR EELGLCERTFKRLYQYMLNA
 Q9Y4W9 --SKYDILMEKLSVMLSTRTNHIETLGKLR EELGLCERTFKRLYQYMLNA
 Q63505 RRSKYDILMEKLSMMLSTRSNQIETLGKLR EELGLCERTFKRLYQYMLNA
 Q12838 RRSKYDILMEKLSVMLSTRTNHIETLGKLR EELGLCERTFKRLYQYMLNA
 B56011 RRSKYDILMEKLSVMLSTRTNHIETLGKLR EELGLCERTFKRLYQYMLNA

310 320 330 340 350
 NOV21 GLAKVVSRLRQEIHP ECGPCKTKKGTDMVRCLKLLKEFKR---NDHDDD
 Q12789 GLAKVVSRLRQEIHP ECGPCKTKKGTDMVRCLKLLKEFKR---NDHDDD
 Q9Y4W9 GLAKVVSRLRQEIHP ECGPCKTKKGTDMVRCLKLLKEFKR---NDHDDD
 Q63505 GLAKVVSRLRQEIHP ECGPCKTKKGTDMVRCLKLLKEFKR---NDHDDD
 Q12838 GLAKVVSRLRQEIHP ECGPCKTKKGTDMVRCLKLLKEFKR---NDHDDD
 B56011 GLAKVVSRLRQEIHP ECGPCKTKKGTDMVRCLKLLKEFKR---NDHDDD

360 370 380 390 400
 NOV21 EDEEVISKTVPVDIVFERDMLTQTYDLIERRGTKGISQAEIRVAMNVGK
 Q12789 EDEEVISKTVPVDIVFERDMLTQTYDLIERRGTKGISQAEIRVAMNVGK
 Q9Y4W9 EDEEVISKTVPVDIVFERDMLTQTYDLIERRGTKGISQAEIRVAMNVGK
 Q63505 DDEEAIISKAVPPVDIVFERDMLTQTYDLIERRGTKGISQAEIRVAMNVGK
 Q12838 EDEEVISKTVPVDIVFERDMLTQTYDLIERRGTKGISQAEIRVAMNVGK
 B56011 EDEEVISKTVPVDIVFERDMLTQTYDLIERRGTKGISQAEIRVAMNVGK

410 420 430 440 450
 NOV21 LEARMLCRLLRQFKVVGFM EDEGRQRTTKYISCVFAEESDLSROYQREK
 Q12789 LEARMLCRLLRQFKVVGFM EDEGRQRTTKYISCVFAEESDLSROYQREK
 Q9Y4W9 LEARMLCRLLRQFKVVGFM EDEGRQRTTKYISCVFAEESDLSROYQREK
 Q63505 LEARMLCRLLRQFKVVGFM EDEGRQRTTKYISCVFAEESDLSROYAREK
 Q12838 LEARMLCRLLRQFKVVGFM EDEGRQRTTKYISCVFAEESDLSROYQREK
 B56011 LEARMLCRLLRQFKVVGFM EDEGRQRTTKYISCVFAEESDLSROYQREK

460 470 480 490 500
 NOV21 ARSELLTTVSLASMQEESLLPEGEDTFLSESDSEERSSS-KRRGRGSQK
 Q12789 ARSELLTTVSLASMQEESLLPEGEDTFLSESDSEERSSS-KRRGRGSQK

Q9Y4W9 MPRLRVHMFLLWYLYVGHASPNTVEKPSFISERRTIKQESGRACVVRPSSS
 Q63505 MPRLRVHMFLLWYLYVGHASPNTVEKPSFISERRTIKQESGRACVVRPSSS
 Q12838 -----
 B56011 -----

5
 10
 15
 20
 25
 30
 35
 40
 45
 50
 55
 60

860 870 880 890 900

NOV21 GSAWEACSEAPSKGSQDGVTWAEVELATETVYVDDASWMRYIPPIPVHR
 Q12789 GSAWEACSEAPSKGSQDGVTWAEVELATETVYVDDASWMRYIPPIPVHR
 Q9Y4W9 GSAWEACSEAPSKGSQDGVTWAEVELATETVYVDDASWMRYIPPIPVHR
 Q63505 GDDWDS-SEA--KNSTESSWEAEMLSTERVYVDEISWMRYVPIPIHR
 Q12838 -----
 B56011 -----

910 920 930 940 950

NOV21 DFGFGWALVSDILLCLPLSIFIQIVQVSYKVDNLEEFNDPLKKHTLIRF
 Q12789 DFGFGWALVSDILLCLPLSIFIQIVQVSYKVDNLEEFNDPLKKHTLIRF
 Q9Y4W9 DFGFGWALVSDILLCLPLSIFIQIVQVSYKVDNLEEFNDPLKKHTLIRF
 Q63505 DFGFGWALVSDILLCLPLSIFIQIVQVSYKVDNLEEFNDPLKKHTLIRF
 Q12838 -----
 B56011 -----

960 970 980 990 1000

NOV21 LPRPIRQQLLYKRRYIFSVVENLQRLCYMGVLQFGPTEKFQDKDQVFI FL
 Q12789 LPRPIRQQLLYKRRYIFSVVENLQRLCYMGVLQFGPTEKFQDKDQVFI FL
 Q9Y4W9 LPRPIRQQLLYKRRYIFSVVENLQRLCYMGVLQFGPTEKFQDKDQVFI FL
 Q63505 LPRPIRQQLLYKRRYIFSVVENLQRLCYMGVLQFGPTEKFQDKDQVFI FL
 Q12838 -----
 B56011 -----

1010 1020 1030 1040 1050

NOV21 KKNNAVIVDTTICDPHYNLGRRRRPFERRLYVLNSMQDVENYWFDLQCVCL
 Q12789 KKNNAVIVDTTICDPHYNLGRRRRPFERRLYVLNSMQDVENYWFDLQCVCL
 Q9Y4W9 KKNNAVIVDTTICDPHYNLARSSRPERRLYVLNSMQDVENYWFDLQCVCL
 Q63505 KKNNAVIVDTTICDPHYNLARSSRPERRLYVLNSMQDVESYWFDLQCVCL
 Q12838 -----
 B56011 -----

1060 1070 1080 1090 1100

NOV21 NTPLGVVRCPRVRKNSSTDQGSDEEGSLQKEQESAMDKHNLERKCAMLEY
 Q12789 NTPLGVVRCPRVRKNSSTDQGSDEEGSLQKEQESAMDKHNLERKCAMLEY
 Q9Y4W9 NTPLGVVRCPRVRKNSSTDQGSDEEGSLQKEQESAMDKHNLERKCAMLEY
 Q63505 NTPLGVVRCPCAK-ICDPDPSDEEGSLRKEQESAMDKHNLERKCAMLEY
 Q12838 -----
 B56011 -----

1110 1120 1130 1140 1150

NOV21 TTGSREVVDGLIPGDGLGAAGLDSSFYGHILKRNWIWTSYIINQAKKENT
 Q12789 TTGSREVVDGLIPGDGLGAAGLDSSFYGHILKRNWIWTSYIINQAKKENT
 Q9Y4W9 TTGSREVVDGLIPGDGLGAAGLDSSFYGHILKRNWIWTSYIINQAKKENT
 Q63505 TTGSREVVDGLIPGDGLGAAGLDSSFYAHLKRNWVWTSYIINKARKNNT
 Q12838 -----
 B56011 -----

1160 1170 1180 1190 1200

NOV21 AAENGLTVRLQTFSLKRPMPLSARCNLSRLNIWGEARVGSSELCAGWEEQFE
 Q12789 AAENGLTVRLQTFSLKRPMPLSARCNLSRLNIWGEARVGSSELCAGWEEQFE

Q9Y4W9 AAENGLTVRLQTFLSKRPMPISARCNRLNIWGFEARVGSELCAWEEQFE
Q63505 -SENGLTGRLQTFLSKRPMPLGSGGSGRLPLWSEHGKADAELCADKEEHFE
Q12838 -----
B56011 -----

5 1210 1220 1230 1240 1250

NOV21 VDREPSLDNRNRVRGGKSQKRRLKKDPGKKIKRKKKGFEPPGEKSKRLRY
Q12789 VDREPSLDNRNRVRGGKSQKRRLKKDPGKKIKRKKKGFEPPGEKSKRLRY
Q9Y4W9 VDREPSLDNRNRVRGGKSQKRRLKKDPGKKIKRKKKGFEPPGEKSKRLRY
Q63505 LDREPTPGNRNRKVRGGKSQKRRLKKDPGKKIKRKKKGFEPPGEKSKRLRY
Q12838 -----
B56011 -----

15 1260 1270 1280 1290 1300

NOV21 HDEADQSALHRMTRLRVITWSMQEDGLLVLCRIASNVLNTKVKGPFVTWQV
Q12789 HDEADQSALHRMTRLRVITWSMQEDGLLVLCRIASNVLNTKVKGPFVTWQV
Q9Y4W9 HDEADQSALHRMTRLRVITWSMQEDGLLVLCRIASNVLNTKVKGPFVTWQV
Q63505 QDEADQNALRMTRLRVITWSMQEDGLLVLCRIASNVLNTKVKGPFVTWQV
Q12838 -----
B56011 -----

25 1310 1320 1330 1340 1350

NOV21 VRDILHATFEESLDKTSLSLGRRARYIVKNPQAYLNYKVCLAEVYQDKAL
Q12789 VRDILHATFEESLDKTSLSLGRRARYIVKNPQAYLNYKVCLAEVYQDKAL
Q9Y4W9 VRDILHATFEESLDKTSLSVGRRARYIVKNPQAYLNYKVCLAEVYQDKAL
Q63505 VRDILHATFEESLDKTSLSVGRRARYIVKNPQAFMNYKVCLAEVYQDKAL
Q12838 -----
B56011 -----

35 1360 1370 1380 1390 1400

NOV21 VGDFMNRGRDYDDPKVCANEFKEFVEKLKEKFSSALRNSNLEIPDTLQEL
Q12789 VGDFMNRGRDYDDPKVCANEFKEFVEKLKEKFSSALRNSNLEIPDTLQEL
Q9Y4W9 VGDFMNRGRDYDDPKVCANEFKEFVEKLKEKFSSALRNSNLEIPDTLQEL
Q63505 VGDFMSRKDNVEDPKVCANEFKEFVEKLKEKFSSGLRNPINLEIPDTLQEL
Q12838 -----
B56011 -----

45 1410 1420 1430 1440 1450

NOV21 FARYRVLAIGDEKDQTRKEDELNSVDDIHFLVLQNLIQSTLALSDSOMKS
Q12789 FARYRVLAIGDEKDQTRKEDELNSVDDIHFLVLQNLIQSTLALSDSOMKS
Q9Y4W9 FARYRVLAIGDEKDQTRKEDELNSVDDIHFLVLQNLIQSTLALSDSOMKS
Q63505 FAKYRVLAIGDEKDRVRKEDELNSVEDIHFLVLQNLIQSTLSLSNSQSNS
Q12838 -----
B56011 -----

50 1460 1470 1480 1490 1500

NOV21 YQSFQTFRLYREYKDHVLVKAFMECQKRSLVNRRRVNHTLGPKNRALPF
Q12789 YQSFQTFRLYREYKDHVLVKAFMECQKRSLVNRRRVNHTLGPKNRALPF
Q9Y4W9 YQSFQTFRLYREYKDHVLVKAFMECQKRSLVNRRRVNHTLGPKNRALPF
Q63505 CQSFQTFRLYREFREPVLVRAFMECQKRSLVNRRRVSHSQGPKNRALVPF
Q12838 -----
B56011 -----

60 1510 1520 1530 1540 1550

NOV21 VPMSYQLSQTYRYRIFTWRFPSTICTESFQFLDRMRAAGKLDQPDFSFKD
Q12789 VPMSYQLSQTYRYRIFTWRFPSTICTESFQFLDRMRAAGKLDQPDFSFKD

Q9Y4W9 VPMSYQLSQTYYYRIFTWRFPSTICTESFQFLDRMRAAGKLDQPDHFSFKD
Q63505 VPMSYQLSQSYYYKIFTWRFPSTICTESFQFYDRLRANGILDQPDHFSFKD
Q12838 -----
B56011 -----

5 1560 1570 1580 1590 1600

NOV21 QDNNEPTNDMVAFLDGPGGNCVAVLTFLSLGLISVDVRIPEQIIVVDSS
Q12789 QDNNEPTNDMVAFLDGPGGNCVAVLTFLSLGLISVDVRIPEQIIVVDSS
Q9Y4W9 QDNNEPTNDMVAFLDGPGGNCVAVLTFLSLGLISVDVRIPEQIIVVDSS
Q63505 MDSNDPSSDLVAFSLDSPGGHCVTALALFSLGLISVDVRIPEQIIVVDSS
Q12838 -----
B56011 -----

15 1610 1620 1630 1640 1650

NOV21 MVENEVIKSLGKDGSLDDDEDEEDDLDEGVGGKRRSMEVKPAQASHTNYL
Q12789 MVENEVIKSLGKDGSLDDDEDEEDDLDEGVGGKRRSMEVKPAQASHTNYL
Q9Y4W9 MVENEVIKSLGKDGSLDDDEDEEDDLDEGVGGKRRSMEVKPAQASHTNYL
Q63505 MVESEVMKSLGKDGGL-DDDDEEEDLDEGSGTKRQSEVVKAHQASHTKYL
Q12838 -----
B56011 -----

20 1660 1670 1680 1690 1700

NOV21 LMRGYYS-PCIVSTRNLNPNDISIVVNSQMKFQLRCTFPVPARLR---PAA
Q12789 LMRGYYS-PCIVSTRNLNPNDISIVVNSQMKFQLRCTFPVPARLR---PAA
Q9Y4W9 LMRGYYS-PCIVSTRNLNPNDISIVVNSQMKFQLRCTFPVPARLR---PAA
Q63505 LMRGYITVPCMVSTRNLNPNDISIVVNSQVKFRLNTPAPTHLGPTGPTA
Q12838 -----
B56011 -----

25 1710 1720 1730 1740 1750

NOV21 APLEELTMGTSCLPDFTFKLINPQENTCSLEEFVLQLELSGYSPEDLTAA
Q12789 APLEELTMGTSCLPDFTFKLINPQENTCSLEEFVLQLELSGYSPEDLTAA
Q9Y4W9 APLEELTMGTSCLPDFTFKLINPQENTCSLEEFVLQLELSGYSPEDLTAA
Q63505 TPLEELQAGPSCLPASEFTSLVDPQLHTRCPEEFAHQMAQSGYSPEDVAAS
Q12838 -----
B56011 -----

30 1760 1770 1780 1790 1800

NOV21 LEILEAIIATGCFGIDKEELRRRFSALEKAGGGRTRTFADCIQALLEQHQ
Q12789 LEILEAIIATGCFGIDKEELRRRFSALEKAGGGRTRTFADCIQALLEQHQ
Q9Y4W9 LEILEAIIATGCFGIDKEELRRRFSALEKAGGGRTRTFADCIQALLEQHQ
Q63505 LEILQAVAAADCFGVDRKLSRQFSALEKIADKRTRTFELDYIQLLEQQQ
Q12838 -----
B56011 -----

35 1810 1820 1830 1840 1850

NOV21 VLEVGCNTARLVAMGSAWPWLLHSVRLKDRE-DADIQREDPOARPLEGSS
Q12789 VLEVGCNTARLVAMGSAWPWLLHSVRLKDRE-DADIQREDPOARPLEGSS
Q9Y4W9 VLEVGCNTARLVAMGSAWPWLLHSVRLKDRE-DADIQREDPOARPLEGSS
Q63505 VMEVGGNTVRLVAMASAQPWLLPSVRLKDVEIDTKASGDSQSRLPAGSS
Q12838 -----
B56011 -----

40 1860 1870 1880 1890 1900

NOV21 SEDSPPEGQAPPSHSPRGTKRRASWASENGETDAEGTQMTPAKRPAALQDS
Q12789 SEDSPPEGQAPPSHSPRGTKRRASWASENGETDAEGTQMTPAKRPAALQDS

45 1860 1870 1880 1890 1900

50 1860 1870 1880 1890 1900

55 1860 1870 1880 1890 1900

60 1860 1870 1880 1890 1900

Q9Y4W9 SEDSPPEGQAPPSSHSPRGTKRRASWASENGETDAEGTQMTPAKRPAQDS
Q63505 IEDHTSEGAIPPVSSNGTKKRPYCSIQSPETDAEATRLPAKKPTLQDV
Q12838 -----
B56011 -----

5 1910 1920 1930 1940 1950

NOV21
Q12789
Q9Y4W9
Q63505
Q12838
B56011 -----

15 1960 1970 1980 1990 2000

NOV21
Q12789
Q9Y4W9
Q63505
Q12838
B56011 -----

25 2010 2020 2030 2040 2050

NOV21
Q12789
Q9Y4W9
Q63505
Q12838
B56011 -----

35 2060 2070 2080 2090 2100

NOV21
Q12789
Q9Y4W9
Q63505
Q12838
B56011 -----

45 2110 2120 2130 2140 2150

NOV21
Q12789
Q9Y4W9
Q63505
Q12838
B56011 -----

50 2160

NOV21
Q12789
Q9Y4W9
Q63505
Q12838
B56011 -----

55 SHSCYQSSAQPSTGVATSR

60

Consistent with other known members of the TFIIC box B-binding subunit family of proteins, NOV21 has, for example, homology to other members of the TFIIC box B-binding subunit family and nuclear localization.

NOV21 nucleic acids, and the encoded polypeptides, according to the invention are useful in a variety of applications and contexts. For example, NOV21 nucleic acids and polypeptides can be used to identify proteins that are members of the TFIIC box B-binding subunit family of proteins. The NOV21 nucleic acids and polypeptides can also be used to screen for molecules, which inhibit or enhance NOV21 activity or function. Specifically, the nucleic acids and polypeptides according to the invention may be used as targets for the identification of small molecules that modulate or inhibit, *e.g.*, gene transcription. These molecules can be used to treat, *e.g.*, cancer and viral disease.

In addition, various NOV21 nucleic acids and polypeptides according to the invention are useful, *inter alia*, as novel members of the protein families according to the sequence relatedness to previously described proteins. For example, the NOV20 nucleic acids and their encoded polypeptides show homology to proteins belonging to the family of TFIIC box B-binding subunit proteins such as the α -chain of the Human TFIIC box B-binding subunit.

Transcription factor IIC (TFIIC) is a multisubunit basic TF for RNA polymerase III. It initiates transcription complex assembly on tRNA and related genes by binding to the internal box B promoter element and is also required for transcription of 5S rRNA and other stable nuclear and cytoplasmic RNAs transcribed by polymerase III. In mammalian cells, regulation of TFIIC activity controls overall polymerase III transcription in response to growth factors and viral infection. A full-length cDNA (and genomic DNA from the transcription initiation region) encoding the box B binding subunit of human TFIIC, the 243-kDa alpha subunit has been reported and shown to encode a component of TFIIC. (L'Etoile *et al.*, Proc Natl Acad Sci USA, 91: 1652-6 (1994)).

The NOV21 nucleic acids and polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications in gene regulation. As such the NOV21 nucleic acids and polypeptides, antibodies and related compounds according to the invention may be used to treat cancer and viral infections, *e.g.*, TFIIC box B-binding subunit protein is cleaved and inactivated by the poliovirus-encoded 3C protease during poliovirus infection (Shen *et al.*, Mol. Cell. Biol, 16: 4163-71 (1996)).

The NOV21 nucleic acids and polypeptides are useful for detecting specific cell types. For example, expression analysis has demonstrated that a NOV21 nucleic acid is expressed in adrenal gland, bone marrow, brain - amygdala, brain - cerebellum, brain - hippocampus, brain - substantia nigra, brain - thalamus, brain -whole, fetal brain, fetal kidney, fetal liver, fetal lung, heart, kidney, lymphoma - Raji, mammary gland, pancreas, pituitary gland, placenta, prostate, salivary gland, skeletal muscle, small intestine, spinal cord, spleen, stomach, testis, thyroid, trachea, uterus, Adipose, Aorta, Bone, Bronchus, Cartilage, Cervix, Chorionic Villus, Colon, Coronary Artery, Dermis, Epidermis, Hypothalamus, Liver, Lung, Lymph node, Lymphoid tissue, Myometrium, Ovary, Peripheral Blood, Respiratory Bronchiole, Retina, Right Cerebellum, Synovium/Synovial membrane, Temporal Lobe, Thymus, Tonsils, Umbilical Vein, Vein, Vulva, and Whole Organism.

Additional utilities for NOV21 nucleic acids and polypeptides according to the invention are disclosed herein.

NOV22

A NOV22 polypeptide has been identified as a Nucleoside Diphosphate Kinase B-like protein (also referred to as CG56475-01). The disclosed novel NOV22 nucleic acid (**SEQ ID NO:74**) of 473 nucleotides is shown in Table 22A. The novel NOV22 nucleic acid sequences maps to the chromosome 2.

An ORF begins with an ATG initiation codon at nucleotides 12-14 and ends with a TAA codon at nucleotides 464-466. A putative untranslated region and/or downstream from the termination codon is underlined in Table 22A, and the start and stop codons are in bold letters.

Table 22A. NOV22 Nucleotide Sequence (SEQ ID NO:74)	
ATCCTCAGGCC ATGG CCAACACTGAGAGCATCATTATCAATCCGAGTGCTGTTTCAGCACAGCCTGGT	
GGGTGAAATCATCAAATACTCTGAGCAGAAGGGATTCTACCTGGTGACCATGAAGTTCCTTCGGGCC	
TCTGAGAAACCCCTGAAGGAGCACTACACTAACCTGAAAGACCACCCATTCTTCCCGGACCTTGTGA	
AGTACATGAACTCAGGGCAGGTTGTGGCCATGGTCCCTGGAGGGGCTGAATGTGGCAAAGACAGGGCT	
AAGGATGCTTGGGGAGACCAATTCATTGGGCTCTATGCTAGAGACTATTATTCGCAGGGACTTCTGC	
GCTAAATAGGCGGGAACGTCATTGGTGGCAGTGATTCAATACAAAGTGCTGGCAAAGAAATGGCTA	
AATGGCTTAAAGAAGAAGAACTGGTTGACTACAAATCTCGTGCCTATGACAAGATCTATGAT AAAAA	
<u>GGAG</u>	

The NOV22 protein (SEQ ID NO:75) encoded by SEQ ID NO:74 is 181 amino acid residues in length and is presented using the one-letter amino acid code in Table 22B. Psort analysis predicts the NOV22 protein of the invention to be localized in the cytoplasm with a certainty of 0.6500.

Table 22B. Encoded NOV22 protein sequence (SEQ ID NO:75)

MANTESIIINPSAVQHSLVGEIIKYSEQKGFYLVMTMKFLRASEKPLKEHYTNLKDHPFFDPLVKYMNMSGQVVA
MVLEGLNVAKTGLRMLGETNSLGSMLLETIIIRRDCAKIGGNVIGGSDSLQSAGKEMAKWLKEEELVDYKSRAY
DKIYDKKEVKAAVCLDAVPGSLDTALHPIDLEAIG

A search against the Patp database, a proprietary database that contains sequences published in patents and patent publications, yielded several homologous proteins shown in Table 22C.

Table 22C. Patp results for NOV22

Sequences producing High-scoring Segment Pairs:	Reading Frame	High Score	Smallest Sum Prob P(N)
>patp:AAAY07000 mm23-H2 protein sequence	+1	468	3.2e-44
>patp:AAB14812 Human nm23 protein nm23-H2S	+1	468	3.2e-44

In a BLAST search of public sequence databases, it was found, for example, that the nucleic acid sequence of this invention has 376 of 475 bases (79%) identical to a gb:GENBANK-ID:HUMPUF|acc:L16785.1 mRNA from *Homo sapiens* (c-myc transcription factor (puf) mRNA, complete cds). The NOV22 polypeptide of the invention was found to have 100 of 152 amino acid residues (65%) identical to, and 113 of 152 amino acid residues (74%) similar to, the 152 amino acid residue ptrn:SWISSPROT-ACC:P22392 protein from *Homo sapiens* (NUCLEOSIDE DIPHOSPHATE KINASE B (EC 2.7.4.6) (NDK B) (NDP KINASE B) (NM23-H2) (C-MYC PURINE-BINDING TRANSCRIPTION FACTOR PUF)).

NOV22 also has homology to the proteins shown in the BLASTP data in Table 22D.

Table 22D. BLAST results for NOV22

Gene Index/ Identifier	Protein/ Organism	Length (aa)	Identity (%)	Positives (%)	Expect
ptnr:SWISSPROT- ACC:P22392	Nucleoside diphosphate kinase B (EC 2.7.4.6) - <i>Homo sapiens</i>	152	100/152 (65%)	113/152 (74%)	4.0e- 44
ptnr:SWISSPROT- ACC:P19804	Nucleoside diphosphate kinase B (EC 2.7.4.6) - <i>Rattus norvegicus</i>	152	99/152 (65%)	112/152 (73%)	5.1e- 44
ptnr:SWISSPROT- ACC:Q01768	Nucleoside diphosphate kinase B (EC 2.7.4.6) - <i>Mus musculus</i>	152	99/152 (65%)	112/152 (73%)	8.4e- 44
ptnr:SPTREMBL- ACC:O57535	NUCLEOSIDE DIPHOSPHATE KINASE - <i>Gallus gallus</i>	153	93/151 (61%)	109/151 (72%)	3.7e- 41
ptnr:SWISSPROT- ACC:P15532	Nucleoside diphosphate kinase A (EC 2.7.4.6) - <i>Mus musculus</i>	152	96/152 (63%)	112/152 (73%)	4.8e- 41

A multiple sequence alignment is given in Table 22E, with the NOV22 protein being shown on line 1 in Table 22E in a ClustalW analysis, and comparing the NOV22 protein with the related protein sequences shown in Table 22D. This BLASTP data is displayed graphically in the ClustalW in Table 22E.

Table 22E. ClustalW Analysis of NOV22

- 1) > NOV22; **SEQ ID NO:75**
- 2) > P22392/ Nucleoside diphosphate kinase B (EC 2.7.4.6) [*Homo sapiens*]; **SEQ ID NO:256**
- 3) > P19804/ Nucleoside diphosphate kinase B (EC 2.7.4.6) [*Rattus norvegicus*]; **SEQ ID NO:257**
- 4) > Q01768/ Nucleoside diphosphate kinase B (EC 2.7.4.6) [*Mus musculus*]; **SEQ ID NO:258**
- 5) > O57535/ Nucleoside diphosphate kinase [*Gallus gallus*]; **SEQ ID NO:259**
- 6) > P15532/ Nucleoside diphosphate kinase A (EC 2.7.4.6) [*Mus musculus*]; **SEQ ID NO:260**

		10	20	30	40	50
NOV22	-	MANTES--IIINPSAVQHS	LVGEI	IKYSEQKGFYLV	TMKFLRASEKPLK	
P22392	-	MANBERTFIAIKPDGVQ	RGLVGEI	IKRFEQKGFRLVAMKFLRASEEHLK		
P19804	-	MANBERTFIAIKPDGVQ	RGLVGEI	IKRFEQKGFRLVAMKFLRASEEHLK		
Q01768	-	MANBERTFIAIKPDGVQ	RGLVGEI	IKRFEQKGFRLVAMKFLRASEEHLK		
O57535	MA	ANCERTFIAIKPDGVQ	RGLVGEI	IKRFEQKGFRLVAMKFLVHASEDLK		
P15532	-	MANSERTFIAIKPDGVQ	RGLVGEI	IKRFEQKGFRLVGLKFLQASEDLK		
		60	70	80	90	100
NOV22	E	HYTNLKDHPFFPD	LVKYMNSGQV	VAMVLEGLNVAKTGL	MLGETNSLGS	

P22392 QHYIDLKDRPFFPGLVKYMNSGPVVAMV-EGLNVVKTGRVMLGETNPADS
 P19804 QHYIDLKDRPFFPGLVKYMNSGPVVAMV-EGLNVVKTGRVMLGETNPADS
 Q01768 QHYIDLKDRPFFPGLVKYMNSGPVVAMV-EGLNVVKTGRVMLGETNPADS
 O57535 QHYIDLKDRPFFPGLVKYMNSGPVVAMV-EGLNVVKTGRVMLGETNPADS
 P15532 EHYIDLKDRPFFPGLVKYMNSGPVVAMV-EGLNVVKTGRVMLGETNPADS

110 120 130 140 150
 NOV22 MLETIIRRDFAKIGGNIIGSDSLOSAGKEMAKNLKEELVDYKSRAYD
 P22392 KPGT-IRGDFCIQVGRNIIHGSDSVKSAEKEISLWFKPEELVDYKSCAHD
 P19804 KPGT-IRGDFCIQVGRNIIHGSDSVKSAEKEISLWFKPEELVDYKSCAHD
 Q01768 KPGT-IRGDFCIQVGRNIIHGSDSVKSAEKEISLWFKPEELVDYKSCAHD
 O57535 KPGT-IRGDFCIQVGRNIIHGSDSVKSAEKEISLWFKPEELVDYKSCAHD
 P15532 KPGT-IRGDFCIQVGRNIIHGSDSVKSAEKEISLWFKPEELVDYKSCAHD

160 170 180
 NOV22 KTYDKKEVKAAVCLDAVPGSLDTALHPIDLEAIG
 P22392 WVYE-----
 P19804 WVYE-----
 Q01768 WVYE-----
 O57535 WVYE-----
 P15532 WTYE-----

The presence of identifiable domains in the protein disclosed herein was determined by searches using algorithms such as PROSITE, Blocks, Pfam, ProDomain, Prints and then determining the Interpro number by crossing the domain match (or numbers) using the Interpro website (<http://www.ebi.ac.uk/interpro/>). Table 22F lists the domain description from DOMAIN analysis results against NOV22.

Table 22F Domain Analysis of NOV22			
Model	Region of Homology	Score (bits)	E value
Nucleoside diphosphate kinase (NDK)	7-151	173.6	3.3e-48

Consistent with other known members of the subunit family of proteins, NOV22 has, for example, an Nucleoside Diphosphate Kinase (NDK) signature sequence and homology to other members of the Nucleoside Diphosphate Kinase B family.

NOV22 nucleic acids, and the encoded polypeptides, according to the invention are useful in a variety of applications and contexts. For example, NOV22 nucleic acids and polypeptides can be used to identify proteins that are members of the Nucleoside Diphosphate Kinase B family of proteins. The NOV22 nucleic acids and polypeptides can also be used to screen for molecules, which inhibit or enhance NOV22 activity or function. Specifically, the nucleic acids and polypeptides according to the invention may be used as targets for the

identification of small molecules that modulate or inhibit, *e.g.*, nucleic acid synthesis, CTP for lipid synthesis, UTP for polysaccharide synthesis and GTP for protein elongation, signal transduction and microtubule polymerization. These molecules can be used to treat disorders of metabolism, cellular growth and differentiation, *e.g.*, cancer.

5 In addition, various NOV22 nucleic acids and polypeptides according to the invention are useful, *inter alia*, as novel members of the protein families according to the presence of domains and sequence relatedness to previously described proteins. For example, the NOV20 nucleic acids and their encoded polypeptides show homology to proteins belonging to the family of Nucleoside Diphosphate Kinase B such as human nucleoside diphosphate kinase B (EC 2.7.4.6).

10 Nucleoside diphosphate kinases (EC 2.7.4.6) (NDK) are enzymes required for the synthesis of nucleoside triphosphates (NTP) other than ATP. They provide NTPs for nucleic acid synthesis, CTP for lipid synthesis, UTP for polysaccharide synthesis and GTP for protein elongation, signal transduction and microtubule polymerization (Parks, R. and Agarwal R., In: The enzymes - Group transfer. Boyer P.D. (Ed.) Academic Press, New York, 1973, pp.307-334).

15 In eukaryotes, there is a small family of NDK isozymes each of which acts in a different subcellular compartment and/or has a distinct biological function. Eukaryotic NDK isozymes are hexamers of two highly related chains (A and B) (Gilles, *et al.*, J. Biol. Chem. 266: 8784-8789 (1991)). By random association (A₆, A₅B...A₁B₅, B₆), these two kinds of chain form isoenzymes differing in their isoelectric point.

20 NDK are proteins of 17 Kd that act via a ping-pong mechanism in which a histidine residue is phosphorylated, by transfer of the terminal phosphate group from ATP. In the presence of magnesium, the phosphoenzyme can transfer its phosphate group to any NDP, to produce an NTP.

25 NDK isozymes have been sequenced from prokaryotic and eukaryotic sources. It has also been shown that the *Drosophila* awd (abnormal wing discs) protein, is a microtubule-associated NDK (Biggs *et al.*, Cell 63: 933-940 (1990)). Mammalian NDK is also known as metastasis inhibition factor nm23. The sequence of NDK has been highly conserved through evolution. There is a single histidine residue conserved in all known NDK isozymes within the NDK signature, which is involved in the catalytic mechanism (Gilles, *et al.*, J. Biol. Chem. 266: 8784-30 8789 (1991)).

The NOV22 nucleic acids and polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications in cellular growth and metabolism. As such the NOV22 nucleic acids and polypeptides, antibodies and related compounds according to the invention may be used to treat cancer, *e.g.*, atherosclerosis, aneurysm, hypertension, fibromuscular dysplasia, stroke, scleroderma, obesity, transplantation, myocardial infarction, embolism, cardiovascular disorders, bypass surgery, fertility disorders, myasthenia gravis, leukodystrophies, pain, neuroprotection, systemic lupus erythematosus, autoimmune disease, asthma, emphysema, scleroderma, allergy, ARDS and other diseases, disorders and conditions of the like.

The NOV22 nucleic acids and polypeptides are useful for detecting specific cell types. For example, expression analysis has demonstrated that a NOV22 nucleic acid is expressed in lymphocyte, placental, liver, cardiovascular, nervous, respiratory, and immune systems, and this protein is found in reduced amount in tumor cells of high metastatic potential. Accordingly, the NOV22 nucleic acids, polypeptides, antibodies and related compounds according to the invention will have diagnostic and therapeutic applications in the detection of cancer.

Additional utilities for NOV22 nucleic acids and polypeptides according to the invention are disclosed herein.

NOV23

A NOV23 polypeptide has been identified as a T-cell-like protein (also referred to as CG56352-02). The disclosed novel NOV23 nucleic acid (**SEQ ID NO:76**) of 1326 nucleotides is shown in Table 23A. An ORF begins with an ATG initiation codon at nucleotides 19-21 and ends with a TAG codon at nucleotides 1324-1326. A putative untranslated region and/or downstream from the termination codon is underlined in Table 23A, and the start and stop codons are in bold letters. The NOV23 nucleotide sequence maps to chromosome 5.

Table 23A. NOV23 Nucleotide Sequence (SEQ ID NO:76)	
TGGGGGCGGCTACTGCTC ATG TGATTGTGGAGTAGACAGTTGGAAGAAGTACCCAGTCCATTTGGAG	
AGTTAAACTGTGCCTAACAGAGGTGTCCTCTGACTTTTCTTCTGCAAGCTCCATGTTTTCACATCT	
TCCCTTTGACTGTGTCTCTGCTGCTGCTGCTACTACTTACAACCCTGTTCTCCCGTGTTACAGAATT	
GGGCCACAATTCTCTCCTAGGGCAGTGTCTGAAAGTGAGCAGACAAAATGGGGTAGGGAAACAAT	
CAGATAACGCATTTGTGTCTGGCCAGGGTGACCGCACCGGTAAAGATGAGCTATCAATCTGCATTGC	
ACAGCTGACCAGGAATTTCTTGTGGGCAAAATATGGGGGAGTAGCTTCCTCTTTATTCTGTTAGAC	
ATGGCTTGCAGTTTCTCTGAAATGGAGTTACCTCACTACCGCTTGAGTCTTGGCTCTCCTTCTCTC	

TCTATG CAGGGT CCTCAGAAGT GGAATACAGAGCGGAGGTCGGTCAGAATGCCTATCTGCCCTGCTT
CTACACCCAGCCGCCCCAGGGAACCTCGTGCCCGTCTGCTGGGGCAAAGGAGCCTGTCTGTGTTT
GAATGTGGCAACGTGGTGCTCAGGACTGATGAAAGGGATGTGAATTATTGGACATCCAGATACTGGC
TAAATGGGGATTTCGCAAAGGAGATGTGTCCCTGACCATAGAGAATGTGACTCTAGCAGACAGTGG
GATCTACTGCTGCCGGATCCAAATCCCAGGCATAATGAATGATGAAAAATTTAACCTGAAGTTGGTC
ATCAAACCAGCCAAGGTCACCCCTGCACCGACTCGGCAGAGAGACTTCACTGCAGCCTTTCCAAGGA
TGCTTACCACCAGGGGACATGGCCCATGATGGTGGTTCTTGTCTTTCACTTCCAGATGTAAGACT
CACCCAAATATCCACATTGGCCAATGAGTTACGGGACTCTAGATTGGCCAATGACTTACGGGACTCT
GGAGCAACCATCAGAATAGGCATCTACATCGGAGCAGGGATCTGTGCTGGGCTGGCTCTGGCTCTTA
TCTTCGGCGCTTTAATTTCAAATGTTATTCTCATAGCAAAGAGAAGATACAGAATTTAAGCCTCAT
CTCTTTGGCCAACCTCCCTCCCTCAGGATTGGCAAATGCAGTAGCAGAGGGAATTCGCTCAGAAGAA
AACATCTATACCATTGAAGAGAACGTATATGAAGTGGAGGAGCCCAATGAGTATTATTGCTATGTCA
GCAGCAGGCAGCAACCTCACAACCTTTGGGTTGTGCTTTGCAATGCCATAG

The NOV23 protein (SEQ ID NO:77) encoded by SEQ ID NO:76 is 401 amino acid residues in length and is presented using the one-letter amino acid code in Table 23B. NOV23 has one SNP variants, whose variant positions for its nucleotide and amino acid sequences is numbered according to SEQ ID NOS:76 and 77, respectively. A variant sequence can include a single nucleotide polymorphism (SNP). A SNP can, in some instances, be referred to as a "cSNP" to denote that the nucleotide sequence containing the SNP originates as a cDNA. Variant 13376756 is a G to T SNP at 839 bp of the nucleotide sequence that results in an Arg to Leu change at amino acid 240 of protein sequence.

Psort analysis predicts the NOV23 protein of the invention to be localized in the endoplasmic reticulum (membrane) with a certainty of 0.6850. The Signal P predicts a likely cleavage site for a NOV23 peptide is between positions 26 and 27, *i.e.*, at the dash in the sequence VHR-IG.

Table 23B. Encoded NOV23 protein sequence (SEQ ID NO:77)

MFSLPFD CVLLLLLLLTFLSRVHRIGPQFSPRAVFLKVSQRNGVGKQSDNAFVSGQGDRTGKD
ELSICIAQLTRNFLVGKIWGSSFLFILLDMACSFPEMELPHSPLESWLSFSLYAGSSEVEYRAEV
GQNAYLPCFYTPAAPGNLVPVCWGKGACPVFECCGNVLRDTERDVNYWTSRYWLNDFRKGDVSL
TIENVTLADSGIYCCRIQIPGIMNDEKFNKLVIKPAKVTPAPTRQRDFTAAFPRLTTRGHGPH
DGGSCSLPDVRLTQISTLANELRDSRLANDLRDSGATIRIGIYIGAGICAGLALALIFGALIFK
CYSHSKEKIQNLSLISLANLPPSGLANAVAEGIRSEENIYTIENVEVEEPNEYCYVSSRQQP
SQPLGCRFAMP

A search against the Patp database, a proprietary database that contains sequences published in patents and patent publications, yielded several homologous proteins shown in Table 23C.

Table 23C. Patp results for NOV23

			Smallest Sum
Sequences producing High-scoring Segment Pairs:			Prob P (N)
>patp:AAW01049 Product 200 gene expressed T helper cells	Reading Frame +1	High Score 1420	6.6e-153
>patp:AAV97058 Human T helper cell gene 200 product	+1	1420	6.6e-153
>patp:AAB51104 Human 200 gene product	+1	1420	6.6e-153
>patp:AAB59169 Human 200 gene protein	+1	1420	6.6e-153
>patp:AAB81518 Human TH1 specific 200 gene product	+1	1420	6.6e-153

In a BLAST search of public sequence databases, it was found, for example, that the NOV23 polypeptide of the invention was found to have 274 of 298 amino acid residues (91%) identical to, and 278 of 298 amino acid residues (93%) similar, to the 301 amino acid residue ptr:SPTREMBL-ACC:Q96K94 cDNA FLJ14428 FIS, clone HEMBA1006293 (*Homo sapiens*). NOV23 also has homology to the proteins shown in the BLASTP data in Table 23D.

Table 23D. BLAST results for NOV23

Gene Index/ Identifier	Protein/ Organism	Length (aa)	Identity (%)	Positives (%)	Expect
ptnr:SPTREMBL- ACC:Q96K94	CDNA FLJ14428 FIS, CLONE HEMBA1006293 - <i>Homo sapiens</i>	301	274/298 (91%)	278/298 (93%)	8.4e- 153
ptnr:TREMBLNEW- ACC:AAL35776	TIM3 - <i>Mus musculus</i>	281	168/275 (61%)	195/275 (70%)	1.1e-80
ptnr:SPTREMBL- ACC:O54947	KIDNEY INJURY MOLECULE-1 PRECURSOR (KIM-1) - <i>Rattus norvegicus</i>	307	63/156 (40%)	83/156 (53%)	8.1e-31
ptnr:TREMBLNEW- ACC:AAL35774	TIM1 - <i>Mus musculus</i>	305	60/141 (42%)	77/141 (54%)	2.3e-30
ptnr:SPTREMBL- ACC:O43656	HEPATITIS A VIRUS CELLULAR RECEPTOR 1 - <i>Homo sapiens</i>	359	52/120 (43%)	71/120 (59%)	2.1e-27

A multiple sequence alignment is given in Table 23E, with the NOV23 protein being shown on line 1 in Table 23E in a ClustalW analysis, and comparing the NOV23 protein with the related protein sequences shown in Table 23D. This BLASTP data is displayed graphically in the ClustalW in Table 23E.

Table 23E. ClustalW Analysis of NOV23

- 1) > NOV23; **SEQ ID NO:77**
- 2) > Q96K94/cDNA FLJ14428 FIS [*Homo sapiens*]; **SEQ ID NO:261**
- 3) > AAL35776/ TIM3 [*Mus musculus*]; **SEQ ID NO:262**
- 4) > O54947/ Kidney Injury Molecule-1 Precursor [*Rattus norvegicus*]; **SEQ ID NO:263**
- 5) > AAL35774/ TIM1 [*Mus musculus*]; **SEQ ID NO:264**
- 6) > O43656/ Hepatitis A Virus Cellular Receptor 1; **SEQ ID NO:265**

10 20 30 40 50

```

.....|.....|.....|.....|.....|.....|.....|.....|.....|.....|
NOV23  MFSHLPFDCVLLLLLLLTTTLFSRVHRIGPQFSPRAVFLKVSQRNGVVGKQS
Q96K94  MFSHLPFDCVLLLLLLL-----
AAL35776 MFSGLTLNCVLLLLLOLL-----
O54947  -MVQLQVFISGLLLLP-----
AAL35774 -MNQIQVFISGLLLLP-----
O43656  --MHPQVVILSLILHLAD-----

              60      70      80      90      100
NOV23  DNAFVSGQGDRGTGKDELSICIAQLTRNFLVGKIWGSSFLFILLDMACSF
Q96K94  -----LTR-----
AAL35776 -----LAR-----
O54947  -----
AAL35774 -----
O43656  -----

              110     120     130     140     150
NOV23  EMELPHSPLESWLSFSLYAGSSEVEYRAEVGQONAYLPCFYTPAAPGNLVP
Q96K94  -----SSEVEYRAEVGQONAYLPCFYTPAAPGNLVP
AAL35776 -----SLENAYVFEVGKNAYLPCSYTLSTPGALVP
O54947  -----SVDSYEVVKGVVGHPTIPCTYST--RGGITT
AAL35774 -----TVDSYEVVKGVVGHPTIPCTYST--YRGITT
O43656  -----SVAGSVKVGGEAGPSVTLPCHYS---CAVTS

              160     170     180     190     200
NOV23  VCWGKGACPVFECCNVVLRITDERDVNYWTS-RYWLNCGDFRKGDVSLTIEN
Q96K94  VCWGKGACPVFECCNVVLRITDERDVNYWTS-RYWLNCGDFRKGDVSLTIEN
AAL35776 MCWGKGFCPWSQCTNELLRITDERNVTYQSSRYQLKGDNLKGDVSLTIEN
O54947  TCWGRGQCPYSSCONILIWIWNGYQVTVYRSSRYNLKCHISEGDVSLTIEN
AAL35774 TCWGRGQCPSSACNTLIWIWNGHRVTYQSSRYNLKCHISEGDVSLTIEN
O43656  MCWNRGSCSLFTCONGIVWINGTHVTYRKDTRYKLLGDLSSRDVSLTIEN

              210     220     230     240     250
NOV23  VTLADSGIYCCRIQIPGIMNDEKFNLEKLVIKP-----
Q96K94  VTLADSGIYCCRIQIPGIMNDEKFNLEKLVIKP-----
AAL35776 VTLDDHGTIYCCRIQIPGLMNDKKLELKLIDIK-----
O54947  SVSDSDSGLYCCRVEIPGWENDQKMTFSLEVVKP-----EIPSPPT
AAL35774 SVESDSGLYCCRVEIPGWENDQKVTFSLVQVKP-----EIPTRPPT
O43656  TAVSDSGVYCCRVEHRCWFENDMKITVSLVTPPKVTTPIVTTVPTVTTV

              260     270     280     290     300
NOV23  -----AKVTPAPTRQR-----DFTAAFERMLTTRGHGP-----HDGGSC
Q96K94  -----AKVTPAPTLQR-----DFTAAFERMLTTRGHGP-----AETQTL
AAL35776 -----AKVTPAQTAHG-----DSTTASERTLTTERNG-----SETQTL
O54947  RPTTTRPTTTT-RPTTIS-----TRSTHVPTSTRVSTSTP-----TPEQTQ
AAL35774 RPTTTRPTATGRPTTIS-----TRSTHVPTSIRVSTSTEP-----TSTHTW
O43656  RTSTTVPTTTTVPTTTTVPTTMSIPTTTTVPTTMTVSTTSVPTTTSIPTT

              310     320     330     340     350
NOV23  LSLLEDVR-----
Q96K94  GSLPDIN-----
AAL35776 VTLHNNN-----
O54947  THKPEIT--TFYA-----HETTAEVTETP-----
AAL35774 THKPEPT--TFCP-----HETTAEVTGIP-----
O43656  TSVFVTTTVSTFVPPMPLPRQNHEPVATSPSSPQPAETHPTTLQGAIRRE

              360     370     380     390     400

```

20230704 15:59:07

5

10

15

20

25

```

.....|.....|.....|.....|.....|.....|.....|.....|.....|.....|
NOV23      -----LTQISTLANELRDSRLANDLRDS---GATIRIGIYI
Q96K94     -----LTQISTLANELRDSRLANDLRDS---GATIRIGIYI
AAL35776   -----GTKISTWADEIKDS-----GETIRTAHI
O54947     -----SYTPADWNGTVTSSEE-AWNNHTVRIPLRK--PQRNPTKGFYV
AAL35774   -----SHTPTDWNNGTVTSSTD-TWSNHTAIPPGK--PQKNPTKGFYV
O43656     PTSSPLYSYT-TDGNDTVTESSDGLWNNNQTLFLEHSLLTANTTKGIYA

              410      420      430      440      450
NOV23      GAGTCAGLALALIFGALIFKCYSHSKEKIQNLSLISLANIPPSGLANAVA
Q96K94     GAGTCAGLALALIFGALIFKCYSHSKEKIQNLSLISLANIPPSGLANAVA
AAL35776   GVGVSAGLTLALIIIGVLIIRWYSCKKKLSSLSLITLANIPPGGLANAGA
O54947     GMSVAALLLLLLLASTVVVTRYIIIRK-KMGSLSFVAFHVSKSRALQNAAI
AAL35774   GICIAALLLLLLVSTVAITRYIILMKR-KSASLSVVAFRVSKIEALQNAAV
O43656     GVCISVLVLLALLG-VIIARKYFFKK-EVQQLS-VSFSSLQIKALQNAVE

              460      470      480      490
NOV23      EGIRSEENIYTIENVEVEEPEPNEYCYVSSRQQPSQPLGCRFAMP
Q96K94     EGIRSEENIYTIENVEVEEPEPNEYCYVSSRQQPSQPLGCRFAMP
AAL35776   VRIRSEENIYTIENVEVEENSNEYCYVNS-QQPS-----
O54947     VHPRAEDNIYTIEDSRGAE-----
AAL35774   VHSRAEDNIYIVEDRP-----
O43656     KEVQAEDNIYIENSLYATD-----
```

The presence of identifiable domains in the protein disclosed herein was determined by searches using algorithms such as PROSITE, Blocks, Pfam, ProDomain, Prints and then determining the Interpro number by crossing the domain match (or numbers) using the Interpro website (<http://www.ebi.ac.uk/interpro/>). Table 23F lists the domain description from DOMAIN analysis results against NOV23.

Table 23F Domain Analysis of NOV23			
Model	Region of Homology	Score (bits)	E value
Immunoglobulin	131-212	9.8	0.18
Peptidase S8	42-62	3.3	6.2

35

40

Consistent with other known members of the immunoglobulin superfamily class of proteins, *e.g.*, T-cell proteins, NOV23 has, for example, an immunoglobulin signature sequence and homology to the ‘human gene 200’ protein (W01049), may represent a previously unknown splice variant. NOV23 nucleic acids, and the encoded polypeptides, according to the invention are useful in a variety of applications and contexts. For example, NOV23 nucleic acids and polypeptides can be used to identify proteins that are members of the T-cell family of proteins. The NOV23 nucleic acids and polypeptides can also be used to screen for molecules, which inhibit or enhance NOV23 activity or function. Specifically, the nucleic acids and polypeptides

according to the invention may be used as targets for the identification of small molecules that modulate or inhibit immune function. These molecules can be used to treat inflammation, allergies, and other immune disorders.

In addition, various NOV23 nucleic acids and polypeptides according to the invention are useful, *inter alia*, as novel members of the protein families according to the presence of domains and sequence relatedness to previously described proteins. For example, the NOV23 nucleic acids and their encoded polypeptides show homology to proteins belonging to the immunoglobulin superfamily such as kidney injury molecule-1 (KIM-1). KIM-1 seems to play a role in cell adhesion.

The basic structure of immunoglobulin (Ig) molecules is a tetramer of two light chains and two heavy chains linked by disulfide bonds (Gough, Trends Biochem. Sci. 6: 203-205 (1981)). There are two types of light chains: kappa and lambda, each composed of a constant domain (CL) and a variable domain (VL). There are five types of heavy chains: alpha, delta, epsilon, gamma and mu, all consisting of a variable domain (VH) and three (in alpha, delta and gamma) or four (in epsilon and mu) constant domains (CH1 to CH4). The major histocompatibility complex (MHC) molecules are made of two chains. In class I the alpha chain is composed of three extracellular domains, a transmembrane region and a cytoplasmic tail (Klein and Figueroa, Immunol. Today 7: 41-44 (1986)). The beta chain (beta-2- microglobulin) is composed of a single extracellular domain. In class II (Figueroa and Klein, J. Immunol. Today 7: 78-81 (1986)), both the alpha and the beta chains are composed of two extracellular domains, a transmembrane region and a cytoplasmic tail. It is known that the Ig constant chain domains and a single extracellular domain in each type of MHC chains are related (Orr et al., Nature 282: 266-270 (1979); Cushley and Owen, Immunol. Today 4: 88-92 (1983)).

These homologous domains are approximately one hundred amino acids long and include a conserved intradomain disulfide bond. Members of the immunoglobulin superfamily are found in hundreds of proteins of different functions. Examples include antibodies, the giant muscle kinase titin and receptor tyrosine kinases. Immunoglobulin-like domains may be involved in protein-protein and protein-ligand interactions.

The NOV23 nucleic acids and polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications in cellular growth and metabolism. As such the NOV23 nucleic acids and polypeptides, antibodies and

related compounds according to the invention may be used to immune disorders, *e.g.*, inflammation, allergies, autoimmune disease, and asthma.

The NOV23 nucleic acids and polypeptides are useful for detecting specific cell types. For example, expression analysis has demonstrated that a NOV23 nucleic acid is differentially expressed in mononuclear cells, B and CD4+ lymphocytes, as well as secondary Th1, -2, and Tr1 cells. Accordingly, the NOV23 nucleic acids, polypeptides, antibodies and related compounds according to the invention will have diagnostic and therapeutic applications in the detection of immune disorders and inflammation.

Additional utilities for NOV23 nucleic acids and polypeptides according to the invention are disclosed herein.

NOV24

A NOV24 polypeptide has been identified as a Organin Anion Transporter (OAT)-like protein. The novel NOV24 nucleic acid sequences maps to the chromosome11. Two alternative novel NOV24, NOV24a and NOV24b, nucleic acids and encoded polypeptides are provided.

NOV24a

A NOV24 variant is the novel NOV24a (alternatively referred to herein as CG56062-01), which includes the 1741 nucleotide sequence (**SEQ ID NO:78**) shown in Table 24A. A NOV24a ORF begins with a Kozak onsensus sequence ATG initiation codon at nucleotides 5-7 and ends with a TAA codon at nucleotides 1724-1726. Putative untranslated regions upstream from the initiation codon and downstream from the termination codon are underlined in Table 24A, and the start and stop codons are in bold letters.

Table 24A. NOV24a Nucleotide Sequence (SEQ ID NO:78)	
GCCTATGGCCATGGCCTTCACAGACCTGCTGGATGCTCTGGGCAGCATGGGCCGCTTCCAGCTCAAC CACACAGCCCTGCTGCTGCTGCCCTGCGGCCTGCTGGCCTGCCACAACCTCCTGCAGAACTTCACCG CCGCTGTCCCCCCCCACCACTGCCGGGGCCCTGCCAACCACACTGAGGCCTCCACCAACGACTCGGG GGCCTGGCTGAGGGCCACCATACCCCTGGACCAGCTTGGGGCCCCTGAGCCCTGCCGGCGCTTCACC AAGCCTCAGTGGGGCCCTGCTGAGCCCCAACTCCTCCATCCCGGGCGCGGCCACGGAGGGCTGCAAGG ACGGCTGGGTCTATAACCGCAGTGTTTTCCCGTCCACCATCGTGATGGAGGTCAGAAGGGGCTGGGT GTGTGGGGGGGCTGCTGCCGAGGCCAGTCTGAAGCGCCCATGTCTTCCCTGCAGTGGGATCTGGTG TGTGAGGCCCCGCACTCTCCGAGACCTGGCGCAGTCCGTCTACATTGCCGGGGTGCTGGTGGGGGCTG CCGTGTTTGGCAGCTTGGCAGACAGGCTGGGCTGCAAGGGCCCCCTGGTCTGGTCTTACCTGCAGCT GGCAGCTTCGGGGGCCGCCACAGCGTATTTAGCTCCTTCAGTGCCTATTGCGTCTTCCGGTTCCTG	

ATGGGCATGACCTTCTCTGGCATCGTGGAGTGGATGCCACACGGGGCCGGACTGTGGCGGGTATTT
TGCTGGGGTATTTCCTTACCCTGGGCCAGCTCATCTGGCTGGGGTAGCCTACCTGATTGCCCCCTG
GCGGTGCCTGCAGTTTGGCATCTCTGCTCCTTTCCTGATCTTTTTCCTCTATTCTTGGTGGCTTCCA
GAGTCATCCCGCTGGCTCCTCCTGCATGGCAAAGTCCAGTTAGCTGTACAGAATCTGCAGAAGGTGG
CTGCAATGAACGGGAGGAAGCAGGAAGGGGAAAGGCTGACCAAGGAGGTGATGAGCTCCTACATCCA
AAGCGAGTTTGAAGTGTCTGCACCTCCAACCTCAATCTTGGACCTCTTCCGAACCCCGGCCATCCGC
AAGGTACATGCTGTCTCATGGTGATTGTTTCTCCAACCTCTGTGGCTTACTATGGCCTGGCCATGG
ACCTGCAGAAGTTTGGGCTCAGCCTATACCTGGTGAGGCCCTGTTTGAATCATCAACATCCCGGC
CATGCTGGTGGCCACCGCCACCATGATTACGTGGGCCCGGTGCCACGGTGGCCTCCTTCTCATC
CTGGCCGGGCTCATGGTGATCGCCAAACATGTTTGTGCCAGAAGGTACGCAGATCCTGTGCACAGCCC
AGGCAGCGCTGGGCAAAGGCTGCCAGTGGGCTCCTTCATCTGTGTGTACCTGTTTACCGGCGAGCT
GTACCCACGGAGATCAGGCAGATGGGGATGGGCTTTCCTCTGTCCACGCCCGCCTCGGGGGCCTG
ACGGCGCCCTGGTTTACCACACTTGGGGAATACAGCACCATCCTGCCACCCGTGAGCTTTGGGGCCA
CCGCAATCCTGGCTGGGCTGGCCGTCTGCTTCTGACTGAGACCCGCAACATGCCCCTGGTGGAGAC
CATCGCAGCCATGGAGAGGAGGCTCAAAGAAGGCTCTTCCAAGAAACATGTAGAAGAGAAGAGTGAA
GAAATTTCTCTTACAGCAGCTGAGAGCATCTCCCCTCAAAGAGACCATCTAAGCTGCCTGGAACCTG

The NOV24a polypeptide (SEQ ID NO:79) encoded by SEQ ID NO:78 is 573 amino acid residues in length is presented using the one-letter amino acid code in Table 24B. NOV24a has one SNP variant, whose variant position for its nucleotide and amino acid sequences is numbered according to SEQ ID NOS:78 and 79, respectively. A variant sequence can include a single nucleotide polymorphism (SNP). A SNP can, in some instances, be referred to as a "cSNP" to denote that the nucleotide sequence containing the SNP originates as a cDNA. NOV24b Variant 13374434 is a C to T SNP at 190 bp of the nucleotide sequence that result does not result in a change in the protein sequence (silent).

The Psort profile for the NOV24a and NOV24b proteins predicts that this peptides are likely to be localized at the plasma membrane with a certainty of 0.6000. The Signal P predicts a likely cleavage site for a NOV24a peptide is between positions 34 and 35, *i.e.*, at the dash in the sequence LLA-CH. A similar cleavage sit is predicted between positions 41 and 42 in NOV24b.

Table 24B. NOV24a protein sequence (SEQ ID NO:79)

MAMAFDLLDALGSMGRFQLNHTALLLLPCGLLACHNFLQNFTAAVPPHHCRGPNHTEAS
TND SGAWLRATIPLDQLGAPEPCRRFTKPQWALLSPNSSIPGAATEGCKDGVYNRSVFPS
TI VMEVRRGWVCGGAAAEAQSEAPMSSLQWDLVCEARTLRDLAQSVYIAGVLVGA AVFGSL
ADRLGCKGPLVWSYLQLAASGAATAYFSSFSAYCVFRFLMGMTFSGIVEWMPTRGRTVAGI
LLGYSFTLGQLILAGVAYLIRPWRLQFAISAPFLIFFLYSWWLPESSRWLLLHGKSQ LAV
QNLQKVAAMNGRKQEGERLTKEVMSSYIQSEFASVCTSNSILD LFRTPAIRKVTCCLMVIW
FSNSVAYYGLAMD LQKFGLSLYLVQALFGIINIPAMLVATATMIYVGRRATVASFLILAGL
MVIANMFVPEGTQILCTAQAALGKGCLASSFICVYLFTGELYPT EIRQMGMGFASVHARLG
GLTAPLVTTTLGEYSTILPPVSFGATAILAGLAVCFLTETRN MPLVETIAAMERRVKEGSSK
KHVEEKSEEISLQQLRASPLKETI

NOV24b

Alternatively, a NOV24 variant is the novel NOV24b (alternatively referred to herein as CG56062-02), which includes the 1690 nucleotide sequence (**SEQ ID NO:80**) shown in Table

24C. NOV24b sequence was cloned by the polymerase chain reaction (PCR) using the primers: 5' CATGGCCTTCACAGACCTGCT 3' (**SEQ ID NO:266**) and 5'

CAGGTTCCAGGCAGCTTAGATG 3' (**SEQ ID NO:267**). Primers were designed based on in silico predictions of the full length or some portion (one or more exons) of the cDNA/protein sequence of the invention. These primers were used to amplify a cDNA from a pool containing

expressed human sequences derived from the following tissues: adrenal gland, bone marrow, brain - amygdala, brain - cerebellum, brain - hippocampus, brain - substantia nigra, brain - thalamus, brain -whole, fetal brain, fetal kidney, fetal liver, fetal lung, heart, kidney, lymphoma - Raji, mammary gland, pancreas, pituitary gland, placenta, prostate, salivary gland, skeletal muscle, small intestine, spinal cord, spleen, stomach, testis, thyroid, trachea and uterus.

The NOV24b ORF begins with a Kozak consensus ATG initiation codon at nucleotides 5-7 and ends with a TAA codon at nucleotides 1673-1675. Putative untranslated regions upstream from the initiation codon and downstream from the termination codon are underlined in Table 24C, and the start and stop codons are in bold letters.

Table 24C. NOV24b Nucleotide Sequence (SEQ ID NO:80)

GCCTATGGCCATGGCCTTCACAGACCTGCTCATGGCCTTCACAGACCTGCTGGATGCTCTGGGCAGC
ATGGGCGCGCTTCCAGCTCAACCACACAGCCCTGCTGCTGCTGCCCTGCGGCCTGCTGGCCTGCCACA
ACTTCCTGCAGAACTTCACGGCCGCTGTCCCCCCCCACCACTGCCGGGGCCCTGCCAACCACACTGA
GGACTCCACCAACGACTCGGGGGCCTGGCTGAGGGCCACCATAACCCCTGGACCAGCTTGGGGCCCCCT
AAGCCCTGCCGGCGCTTCACCAAGCCTCAGTGGGCCCCTGCTGAGCCCCAACTCCTCCATCCCGGGCG
CGGCCACGGAGGGCTGCAAGGACGGCTGGGTCTATAACCGCAGTGTTCCTCCGTCCACCATCGTGAT
GGAGTGGGATCTGGTGTGTGAGGCCCGCACTCTCCGAGACCTGGTGCAGTCCGTCTACATGGCCGGG
GTGCTGGTGGGGCTGCCGTGTTTGGCAGCTTGGCAGACAGGCTGGGCTGCAAGGGCCCCCTGGTCT
GGTCTTACCTGCAGCTGGCAGCTTCGGGGGCCGCCACAGCGTATTTTCAGCTCCTTCAGTGCCTATTG
CGTCTTCCGGTTTCTGATGGGCATGACCTTCTCTGGCATCGTGGAGTGGATGCCACACGGGGCCGG
ACTGTGGCGGGTATTTTGTGGGGTATTCTTCACCCCTGGGCCAGCTCATCTGGCTGGGGTAGCCT
ACCTGATTGCCCCCTGGCGGTGCCTGCAGTTTGCCATCTCTGCTCCTTTCTGATCTTTTTCTCTTA
TTCTTGGTGGCTTCCAGAGTCATCCCGCTGGCTCCTCTGCATGGCAAGTCCAGTTAGCTGTACAG
AATCTGCAGAAGGTGGCTGCAATGAACGGGAGGAAGCAGGAAGGGGAAAGGCTGACCAAGGAGGTGA
TGAGCTCCTACATCCAAAGCGAGTTTGCAAGTGTCTGCACCTCCAACCTCAATCTTGGACCTCTTCCG
AACCCCGGCCATCCGCAAGGTACATGCTGTCTCATGGTGATTGGTTCTCCAACCTCTGTGGCTTAC
TATGGCCTGGCCATGGACCTGCAGAAAGTTTGGGCTCAGCCTATACCTGGTGCAGGCCCTGTTTGGAA
TCATCAACATCCCGGCCATGCTGGTGGCCACCGCCACCATGATTTACGTGGGCGCCCGTGCCACGGT
GGCCTCCTTCCTCATCTGGCCGGGCTCATGGTGATCGCCAACATGTTTGTGCCAGAAGGTACGCAG
ATCCTGTGCACAGCCAGGCAGCGCTGGGCAAAGGCTGCCTGGCCAGCTCCTTCATCTGTGTGTACC
TGTTTACCGCGAGCTGTACCCACGGAGATCAGGCAGATGGGGATGGGCTTTGCCTCTGTCCACGC
CCGCTCGGGGGCCTGACGGCGCCCCTGTTACCACACTTGGGGAATACAGCACCATCCTGCCACCC
GTGAGCTTTGGGGCCACCGCAATCCTGGCTGGGCTGGCCGTCTGCTTCTGACTGAGACCCGCAACA
TGCCCCTGGTGGAGACCATCGCAGCCATGGAGAGGAGGGTCAAAGAAGGCTCTTCCAAGAAACATGT
AGAAGAGAAGAGTGAAGAAATTTCTCTTCAGCAGCTGAGAGCATCTCCCTCAAAGAGACCATCTAA
GCTGCCTGGAACCTG

The NOV24b protein (SEQ ID NO:81) encoded by SEQ ID NO:80 is 556 amino acid residues in length and is presented using the one-letter code in Table 24D.

Table 24D. NOV24b protein sequence (SEQ ID NO:81)

MAMAFDILLMAFTDILLDALGSMGRFQLNHTALLLLPCGLLACHNFLQNFTAAVPPPHHCRGPANHTED
STNDGAWLRATIPLDQLGAPKPCRRFTKPQWALLSPNSSIPGAATEGCKDGWVYNRSVFPSTIVME
WDLVCEARTLRDLVQSVYMAGVLVGAAVFGSLADRLGCKGPLVWSYLQLAASGAATAYFSSFSAYCV
FRFLMGMTFSGIVEWMPTRGRTVAGILLGYSFTLGQLILAGVAYLIRPWRCLQFAISAPFLIFFLYS
WWLPESRRWLLHGSQSLAVQNLQKVAAMNGRKQEGERLTKEVMSSYIQSEFASVCTSNSILDLFRT
PAIRKVTCLMVIWFSNSVAYYGLAMDLOKFGLSLYLVQALFGIINIPAMLVATATMIYVGRRATVA
SFLILAGLMVIANMFVPEGTQILCTAQAALGKGCLASSFICVYLFTGELYPTAIRQMGMGFASVHAR
LGGLTAPLVTTLGEYSTILPPVSFGATAILAGLAVCFLETETRNPLVETIAAMERRVKEGSSKKHVE
EKSEEISLQQLRASPLKETI

NOV24 Clones

Unless specifically addressed as NOV24a or NOV24b, any reference to NOV24 is assumed to encompass all variants. NOV24b polypeptide sequence is 17 amino acids shorter than NOV24a polypeptide and also has 13 different amino acids shown in Table 24E.

Table 24E. Information for the ClustalW proteins:

5		10	20	30	40	50
	NOV24aMAMAFTDLLDALGSMGRFQLNHTALLLLPCGLLACHNFLQNFT				
	NOV24b	MAMAFTDLLMAFTDLLDALGSMGRFQLNHTALLLLPCGLLACHNFLQNFT				
10		60	70	80	90	100
	NOV24a	AAVPPHHCRCGPANHTEASTNDSCAWLRATIPLDQ-GAPEPCRRFTKPQWA				
	NOV24b	AAVPPHHCRCGPANHTEDSTNDSCAWLR-TIPLDQLGAPKPCRRFTKPQWA				
15		110	120	130	140	150
	NOV24a	LLSPNSSIPGAATEGCKDGWVYNRSVFPSTIVMEVRRGWVCGAAAEAS				
	NOV24b	LLSPNSSIPGAATEGCKDGWVYNRSVFPSTIVMEWD-LVC-----				
20		160	170	180	190	200
	NOV24a	EAPMSSLQWDLVEARTLRDLAQSVYIAGVLVGAAVFGSLADRLGCKGPLV				
	NOV24b	-----EARTLRDLVQSVYMAC-LVGAAVFGSLADRLGCKGPLV				
25		210	220	230	240	250
	NOV24a	WSYLQLAASGAATAYFSSFSAYCVFRFLMGMTFSGIVEW-PTRGRTVAGI				
	NOV24b	WSYLQLAASGAATAYFSSFSAYCVFRFLMGMTFSGIVEWMPTRGRTVAGI				
30		260	270	280	290	300
	NOV24a	LLGYSFTLGQLILAGVAYLIRPWRCLQFAISAPFLIFFLYSWWLPSSRW				
	NOV24b	LLGYSE-LGQLILAGVAYLIRPWRCLQFAISAPFLIFFLYSWWLPSSRW				
35		310	320	330	340	350
	NOV24a	LLHGSQSLAVQNLOKVA-MNGRKQEGERLTKEVMSSYIQSEFASVCTSN				
	NOV24b	LLHGSQSLAVQNLOKVAAMNGRKQEGERLTKEVSS-YIQSEFASVCTSN				
40		360	370	380	390	400
	NOV24a	SILDLFRTPAIRKVTCCLMVIWFSNSVAYYGLAMDLOKFGLSLYL-QALF				
	NOV24b	SILDLFRTPAIRKVTCCLMVIWFSNSVAYYGLAMDLOKFGLSLYLVQALF				
45		410	420	430	440	450
	NOV24a	GIINIPAMLVATA-TMIYVGRRATVASFLILAGLMVIANMFVPEGTQILCT				
	NOV24b	GIINIPAMLVAT-TMIYVGRRATVASFLILAGLMVIANMFVPEGTQILCT				
50		460	470	480	490	500
	NOV24a	AQAALGKGCLASSFICVYLFTGE-YPTEIRQMGMGFASVHARLGGLTAPL				
	NOV24b	AQAALGKGCLASSFICVYLFTGELYPTTEIRQMGMGFASVH-RLGGLTAPL				
55		510	520	530	540	550
	NOV24a	VTTLGEYSTILPPVSFGATAILAGLAVCFLTETRNMPVETIAAMERRVK				
	NOV24b	VTTLGEYSTILPPVSFGATAILAGLAVCFLTETRNMPVETIAAMERRVK				
60		560	570			
					

NOV24a E-SSKKHVEEKSEEISLQOLRASPLKETI
NOV24b EGSSKKHVEEKSEEISLQ-LRASPLKETI

A search against the Patp database, a proprietary database that contains sequences published in patents and patent publications, yielded several homologous proteins shown in Table 24F and Table 24G.

Table 24F. Patp results for NOV24a

Sequences producing High-scoring Segment Pairs:	Reading Frame	High Score	Smallest Sum Prob P(N)
>patp:AAB36553 Mouse organic anion transporter 5 (OATP5)	+1	978	1.1e-126
>patp:AA92903 Rat cerebral OAT3	+1	1009	6.6e-125
>patp:AAB47274 hOAT3	+1	992	3.2e-123
>patp:AA92902 Human cerebral OAT3	+1	991	4.1e-123
>patp:AAW44195 Mouse osteoclast transporter protein	+1	990	9.7e-122

Table 24G. Patp results for NOV24b

Sequences producing High-scoring Segment Pairs:	Reading Frame	High Score	Smallest Sum Prob P(N)
>patp:AA944278 Human organic anion transporter	+1	1256	1.0e-127
>patp:AAB47271 hOAT1	+1	1256	1.0e-127
>patp:AAW88488 Rat organic anion transporter OAT-1	+1	1254	1.6e-127
>patp:AAW88489 Human organic anion transporter OAT-1	+1	1249	5.5e-127
>patp:AA92903 Rat cerebral OAT3	+1	1239	6.3e-126

In a BLAST search of public sequence databases, it was found, for example, that the NOV24a nucleic acid sequence of this invention has 680 of 1082 bases (62%) identical to a gb:GENBANK-ID:OCU242871|acc:AJ242871.1 mRNA from *Oryctolagus cuniculus* (*Oryctolagus cuniculus* mRNA for renal organic anion transporter 1 (rbOAT1)) (Fig. 3A).

NOV24a polypeptide was found to have 196 of 424 amino acid residues (46%) identical to, and 277 of 424 amino acid residues (65%) similar to, the 536 amino acid residue ptnr:SPTREMBL-ACC:Q9R1U7 protein from *Rattus norvegicus* (ORGANIC ANION TRANSPORTER 3).

Similarly, it was found, for example, that the NOV 24b nucleic acid sequence of this invention has 713 of 1132 bases (62%) identical to a gb:GENBANK-

ID:AF097491|acc:AF097491.1 mRNA from *Homo sapiens* (*Homo sapiens* organic anion transporter 3 (OAT3) mRNA, complete cds). NOV24b was found to have 246 of 522 amino acid residues (47%) identical to, and 328 of 522 amino acid residues (62%) similar to, the 563 amino

acid residue ptnr:SPTREMBL-ACC:O95742 protein from *Homo sapiens* (RENAL ORGANIC ANION TRANSPORT PROTEIN 1).

Additional BLAST results are shown in Table 24H and Table I.

Table 24H. BLAST results for NOV24a					
Gene Index/ Identifier	Protein/ Organism	Length (aa)	Identity (%)	Positives (%)	Expect
gi 17472512 ref XP_061724.1 (XM_061724)	similar to putative renal organic anion transporter 1 [<i>Homo sapiens</i>]	705	338/400 (84%)	341/400 (84%)	0.0
gi 3831566 gb AAC70004.1 (AF057039)	putative renal organic anion transporter 1 [<i>Homo sapiens</i>]	550	236/550 (42%)	314/550 (56%)	1e-119
gi 4759042 ref NP_004781.1 (NM_004790)	solute carrier family 22 (organic anion transporter), member 6; renal organic anion transporter 1 [<i>Homo sapiens</i>]	550	236/550 (42%)	314/550 (56%)	1e-118
gi 4579723 dbj BAA75072.1 (AB009697)	hOAT1-1 [<i>Homo sapiens</i>]	563	236/550 (42%)	314/550 (56%)	1e-118
gi 2687858 emb CAB09724.1 (Z97028)	renal organic anion transporter [<i>Pseudopleuronectes americanus</i>]	562	237/557 (42%)	323/557 (57%)	1e-118

Table 24I. BLAST results for NOV24b					
Gene Index/ Identifier	Protein/ Organism	Length (aa)	Identity (%)	Positives (%)	Expect
gi 17472512 ref XP_061724.1 (XM_061724)	similar to putative renal organic anion transporter 1 [<i>Homo sapiens</i>]	705	308/400 (77%)	314/400 (78%)	1e-165
gi 4579723 dbj BAA75072.1 (AB009697)	hOAT1-1 [<i>Homo sapiens</i>]	563	235/526 (44%)	312/526 (58%)	1e-122

gi 3831566 gb AAC70004.1 (AF057039)	putative renal organic anion transporter 1 [<i>Homo sapiens</i>]	550	235/526 (44%)	312/526 (58%)	1e-122
gi 4759042 ref NP_004781.1 (NM_004790)	solute carrier family 22 (organic anion transporter), member 6; renal organic anion transporter 1 [<i>Homo sapiens</i>]	550	235/526 (44%)	312/526 (58%)	1e-122
gi 8393886 ref NP_058920.1 (NM_017224)	organic cationic transporter-like 1 [<i>Rattus norvegicus</i>]	551	234/526 (44%)	313/526 (59%)	1e-121

A multiple sequence alignment is given in Table 24J, with the NOV24a protein of the invention being shown on line 1, in a ClustalW analysis comparing NOV24a with related protein sequences disclosed in Table 24H.

Table 24J. Information for the ClustalW proteins (NOV24a):

1. >NOV24a; **SEQ ID NO:79**
2. >gi|17472512/ similar to putative renal organic anion transporter [*Homo sapiens*]; **SEQ ID NO:268**
3. >gi|3831566/ putative renal organic anion transporter 1 [*Homo sapiens*]; **SEQ ID NO:269**
4. >gi|4759042/ solute carrier family 22 [*Homo sapiens*]; **SEQ ID NO:270**
5. >gi|4579723/ hOAT1-1 [*Homo sapiens*]; **SEQ ID NO:271**
6. >gi|2687858/ renal organic anion transporter [*Pseudopleuronectes americanus*]; **SEQ ID NO:272**

		10	20	30	40	50
NOV24a					
gi 1747251	MSAVLTPGLFLPLPGPLPASLHKAGGTGPQVRPMAMAFDTLLDALGSMGR					
gi 3831566	----- ----- ----- ----- ----- ----- ----- ----- ----- -----					
gi 4759042	----- ----- ----- ----- ----- ----- ----- ----- ----- -----					
gi 4579723	----- ----- ----- ----- ----- ----- ----- ----- ----- -----					
gi 2687858	----- ----- ----- ----- ----- ----- ----- ----- ----- -----					
		60	70	80	90	100
NOV24a	FQLNHTALLLLPCGLLACHNFTLQNFATAVPPHHCRCGPAN--HTEASTNDS					
gi 1747251	FQLNHTALLLLPCGLLACHNFTLQNFATAVPPHHCRCGPAN--HTEASTNDS					
gi 3831566	FQIQVTLVVLPLLLMASHNTLQNFATAVPPHHCRCPPA---DANLSKNGG					
gi 4759042	FQIQVTLVVLPLLLMASHNTLQNFATAVPPHHCRCPPA---DANLSKNGG					
gi 4579723	FQIQVTLVVLPLLLMASHNTLQNFATAVPPHHCRCPPA---DANLSKNGG					
gi 2687858	FQVLHVTLICIPVLLMASHNLLQNFVATVPSHYCNANLSQARLSLEES					
		110	120	130	140	150
NOV24a					
gi 1747251	GAWLRATIPLDQLGAPEPCRFRTKPQWALLSPN-SSIPG-----A					
gi 3831566	---LEVWLPRDRQGQPECLRFTSPQWGLPFLNGTEANG-----TG					

```

gi|4759042 ---LEVWLEPRDRQGQEPESCLRFTSPQWGLPFLNGTEANG-----TG
gi|4579723 ---LEVWLEPRDRQGQEPESCLRFTSPQWGLPFLNGTEANG-----TG
gi|2687858 ---LLITVPLDGAKEPQRCQRYAAPQWHLGKNGTSGSGDLADATESMDA

5      160      170      180      190      200
      ....|....|....|....|....|....|....|....|....|....|
NOV24a ATEGCKDCGWVYNRSVFPSTIVMEVRRGWVCGAAAEQSEAPMSSLQWDL
gi|1747251 ATEGCKDCGWVYNRSVFPSTIVMEVRRGWVCGAAAEQSEAPMSSLQWDL
gi|3831566 ATEPCTDCGIYDNSTFPSTIVT-----EWDL
gi|4759042 ATEPCTDCGIYDNSTFPSTIVT-----EWDL
gi|4579723 ATEPCTDCGIYDNSTFPSTIVT-----EWDL
gi|2687858 ALQECSDGWSYNSTVRSSTIIS-----EWHL

10     210     220     230     240     250
      ....|....|....|....|....|....|....|....|....|
NOV24a VCEARTLRDLAQSVYIACVLVGAAVFGSLADRLCKGPLVWSYLQLAASG
gi|1747251 VCEARTLRDLAQSVYIACVLVGAAVFGSLADRLCKGPLVWSYLQLAASG
gi|3831566 VCSHRALRQLAQSLYMGVLLGAMVFGYLADRLGRRKVLILNLYLQTAVSG
gi|4759042 VCSHRALRQLAQSLYMGVLLGAMVFGYLADRLGRRKVLILNLYLQTAVSG
gi|4579723 VCSHRALRQLAQSLYMGVLLGAMVFGYLADRLGRRKVLILNLYLQTAVSG
gi|2687858 VCDMHSFKQMGQTIYMGCVLVGALLFGCLSDRYGRRILLISNLLMAVSG

15     260     270     280     290     300
      ....|....|....|....|....|....|....|....|....|
NOV24a AATAYFSSFSAYCVFRFLMCMTFSG-----
gi|1747251 AATAYFSSFSAYCVFRFLMCMTFSGIILNSVSLPPARVLDLGLGSRVVV
gi|3831566 TCAAFAPNFPPIYCAFRLLSCMALAGISLN-----
gi|4759042 TCAAFAPNFPPIYCAFRLLSCMALAGISLN-----
gi|4579723 TCAAFAPNFPPIYCAFRLLSCMALAGISLN-----
gi|2687858 TCAAFSSSFSLFCVFRFGCGLALSCLGLN-----

20     310     320     330     340     350
      ....|....|....|....|....|....|....|....|....|
NOV24a -----IVEWMPTRGRITVAGILLGYFTLGQLILAGVAYLIRPWRCLQFAI
gi|1747251 ALLAVVVEWMPTRGRITVAGILLGYFTLGQLILAGVAYLIRPWRCLQFAI
gi|3831566 -CMTLNVEWMPPIHTRACVGTLLGYVYSLGQFLLAGVAYAVPHWRHLQLLV
gi|4759042 -CMTLNVEWMPPIHTRACVGTLLGYVYSLGQFLLAGVAYAVPHWRHLQLLV
gi|4579723 -CMTLNVEWMPPIHTRACVGTLLGYVYSLGQFLLAGVAYAVPHWRHLQLLV
gi|2687858 -TFSLIVEWIPTRIITAVGTTTGYCYTLGQLILVLLAYFIRDWRWLTAV

25     360     370     380     390     400
      ....|....|....|....|....|....|....|....|....|
NOV24a SAPFLIFFLYSWWLPESSRWLLHCKSQLAVQNLQKVAAMNCRKQEGERL
gi|1747251 SAPFLIFFLYSWWLPESSRWLLHCKSQLAVQNLQKVAAMNCRKQEGERL
gi|3831566 SAPFFAFFIYSWFFIESARWHSSSGRLDLTLRALQVARINCKREEGAKL
gi|4759042 SAPFFAFFIYSWFFIESARWHSSSGRLDLTLRALQVARINCKREEGAKL
gi|4579723 SAPFFAFFIYSWFFIESARWHSSSGRLDLTLRALQVARINCKREEGAKL
gi|2687858 SLPFYVFELIAWWFHESSRWLALSNRTEHALKNLKSVARFNCRHEEAEKL

30     410     420     430     440     450
      ....|....|....|....|....|....|....|....|....|
NOV24a TKEVMSSYIQSEFASVCTSNSILDLEFRTPAIRKVTCCLMVIWF-----
gi|1747251 TKEVMSSYIQSEFASVCTSNSILDLEFRTPAIRKVTCCLMVIWGHSPMEP
gi|3831566 SMEVLRASLOKELTMGKQASAMELLRCPTLRHLFLCLSMLEWF-----
gi|4759042 SMEVLRASLOKELTMGKQASAMELLRCPTLRHLFLCLSMLEWF-----
gi|4579723 SMEVLRASLOKELTMGKQASAMELLRCPTLRHLFLCLSMLEWF-----
gi|2687858 DIKMLHESMKKEMSCTQGSYSILDLENTPAMRKRTLCLSAVWL-----

35     460     470     480     490     500
      ....|....|....|....|....|....|....|....|....|
NOV24a TRPAQSCPGNRRFGSRTPLANRTRKIGAMSKCFASLPAGSRAGLAPGIN
gi|1747251 TRPAQSCPGNRRFGSRTPLANRTRKIGAMSKCFASLPAGSRAGLAPGIN
gi|3831566 -----

```

```

gi|4759042 -----
gi|4579723 -----
gi|2687858 -----

```

5 A similar multiple sequence alignment is given in Table 24K, with the NOV24b protein of the invention being shown on line 1, in a ClustalW analysis comparing NOV24b with related protein sequences disclosed in Table 24I.

Table 24K. Information for the ClustalW proteins (NOV24b):

- 10 1. >NOV24b; **SEQ ID NO:81**
2. >gi|17472512/ similar to putative renal organic anion transporter 1 [*Homo sapiens*]; **SEQ ID NO:273**
3. >gi|4579723/ hOAT1-1 [*Homo sapiens*]; **SEQ ID NO:274**
4. >gi|3831566/ putative renal organic anion transporter 1 [*Homo sapiens*]; **SEQ ID NO:275**
5. >gi|4759042/ solute carrier family 22 [*Homo sapiens*]; **SEQ ID NO:276**
15 6. >gi|8393886/ organic cationic transporter-like 1 [*Rattus norvegicus*]; **SEQ ID NO:277**

```

      10      20      30      40      50
NOV24b  MAMAFTDLLMAFTDLLDALGSMGRFQLNHTALLLPCLLACHNELQNFT
gi|4579723  -----MAFNDLLQQVGGVGRFQQIQVTLVVLPPLLLMASHNTLQNFT
gi|3831566  -----MAFNDLLQQVGGVGRFQQIQVTLVVLPPLLLMASHNTLQNFT
gi|4759042  -----MAFNDLLQQVGGVGRFQQIQVTLVVLPPLLLMASHNTLQNFT
gi|8393886  -----MAFNDLLQQVGGVGRFQLIQVTMVAAPLLLMASHNTLQNFT

      60      70      80      90     100
NOV24b  AAVPPHHCRGPANHTEDSTNDSGAWLRATIPLDQLCAPKPCRRFTKQWA
gi|4579723  AAIPTTHHCRPPADANLSKNGGLEVWL----PRDRQGPESCLRFTSPQWG
gi|3831566  AAIPTTHHCRPPADANLSKNGGLEVWL----PRDRQGPESCLRFTSPQWG
gi|4759042  AAIPTTHHCRPPADANLSKNGGLEVWL----PRDRQGPESCLRFTSPQWG
gi|8393886  AAIPTTHHCRPPANANLSKNGGLEAWL----PLDKQGPESCLRFTSPQWG

     110     120     130     140     150
NOV24b  LLSPNSSIPG--AATEGCKDGVVYNRSVFPSTIVMEWDLVCEARTLRDLV
gi|4579723  LPFLNGTEANGTGATEPCTDGIYDNSTFPSTIVTEWDLVCSHRALRQLA
gi|3831566  LPFLNGTEANGTGATEPCTDGIYDNSTFPSTIVTEWDLVCSHRALRQLA
gi|4759042  LPFLNGTEANGTGATEPCTDGIYDNSTFPSTIVTEWDLVCSHRALRQLA
gi|8393886  PPFYNGTEANGTRVTEPCTDGVVYDNSTFPSTIVTEWNLVCSHRAFRQLA

     160     170     180     190     200
NOV24b  QSVYMAGVLYGAAVFGSLADRLGCKGPIVWSYLOLAASGAATAYFSSFSA
gi|4579723  QSLYMGVLLGAMVFGYLADRLGRRKVLILNYLQTAVSGTCAAFAPNFPPI
gi|3831566  QSLYMGVLLGAMVFGYLADRLGRRKVLILNYLQTAVSGTCAAFAPNFPPI
gi|4759042  QSLYMGVLLGAMVFGYLADRLGRRKVLILNYLQTAVSGTCAAFAPNFPPI
gi|8393886  QSLYMGVLLGAMVFGYLADRLGRRKVLILNYLQTAVSGTCAAVAPNYTV

     210     220     230     240     250
NOV24b  YCVFRFLMGMTFSGI-----VEWMPTRGRTVAGIILGYSFILGQLIL
gi|4579723  YCAFRLLSGMALAGISLNCMTLNVEWMPIHTRACVGTILIGVYSLGQFLI
gi|3831566  YCAFRLLSGMALAGISLNCMTLNVEWMPIHTRACVGTILIGVYSLGQFLI
gi|4759042  YCAFRLLSGMALAGISLNCMTLNVEWMPIHTRACVGTILIGVYSLGQFLI
gi|8393886  YCVFRLLSGMSLASIAINCMTLNVEWMPIHTRAVVGTILIGVYSLGQFLI

```

			260	270	280	290	300
	NOV24b		AGVAYLIRPWRC	LQFATSAPFLIF	FLYSWWLPES	SRWLLHCK	SQAVQN
5	gi 4579723		AGVAYAVPHWRHL	QLLVSAFFAFFI	YSWFFIESAR	WHSSSGRLD	LTTLRA
	gi 3831566		AGVAYAVPHWRHL	QLLVSAFFAFFI	YSWFFIESAR	WHSSSGRLD	LTTLRA
	gi 4759042		AGVAYAVPHWRHL	QLLVSAFFAFFI	YSWFFIESAR	WHSSSGRLD	LTTLRA
	gi 8393886		AGIAYAVPHWRHL	QLVSVPPFFIA	FIYSWFFIESAR	WYSSSGRLD	LTTLRA
10	NOV24b		310	320	330	340	350
			LQKVAAMNGRKQ	EGERTTKEVMSS	YIOSEFASVCT	SNISILDLE	RTTPAIRK
	gi 4579723		LQRVARINGKREE	GAKLSMEVLRAS	LQKELTMGKQ	QASAMELLRC	PTLRH
	gi 3831566		LQRVARINGKREE	GAKLSMEVLRAS	LQKELTMGKQ	QASAMELLRC	PTLRH
15	gi 4759042		LQRVARINGKREE	GAKLSMEVLRAS	LQKELTMGKQ	QASAMELLRC	PTLRH
	gi 8393886		LQRVARINGKQEE	GAKLSIEVLR	TSLQKELT	LSKQASAMELL	RCPTLRH
20	NOV24b		360	370	380	390	400
			VTCCLMVIWFS	NSVAYYGLAMD	LQKFCLSLYLV	QALFGIINI	PAMLVATA
	gi 4579723		LFLCLSMWFATS	FAYYGLVMDLQ	GFGVSIYLIQ	VIFGAVDLPA	KLVGF
	gi 3831566		LFLCLSMWFATS	FAYYGLVMDLQ	GFGVSIYLIQ	VIFGAVDLPA	KLVGF
	gi 4759042		LFLCLSMWFATS	FAYYGLVMDLQ	GFGVSIYLIQ	VIFGAVDLPA	KLVGF
25	gi 8393886		LFLCLSMWFATS	FAYYGLVMDLQ	GFGVSMYLIQ	VIFGAVDLPA	KLVCF
30	NOV24b		410	420	430	440	450
			TMIYVGRRA	TVASFLLI	LAGLMVIAN	MEVPEGTQ	ILCTAQAALGKGC
	gi 4579723		VINSLGRRPAQ	MAALLLAGI	CILLNGVIPQ	DQSIVRTSLAV	LKGKCLAAS
	gi 3831566		VINSLGRRPAQ	MAALLLAGI	CILLNGVIPQ	DQSIVRTSLAV	LKGKCLAAS
	gi 4759042		VINSLGRRPAQ	MAALLLAGI	CILLNGVIPQ	DQSIVRTSLAV	LKGKCLAAS
	gi 8393886		VINSMGRRPAQ	MAALLLAGI	CILVNCIL	PKSHTI	IRTSLAVLKGKCLASS
35	NOV24b		460	470	480	490	500
			FICVYLF	TGELYPT	ETIRQMCMGF	ASVHARLGGL	TAPLVTTLGEYSTILPP
	gi 4579723		FNCIFLYT	TGELYPT	MIRO	TGMGMGST	MARVGSIVSPLVSMTAELYP
	gi 3831566		FNCIFLYT	TGELYPT	MIRO	TGMGMGST	MARVGSIVSPLVSMTAELYP
	gi 4759042		FNCIFLYT	TGELYPT	MIRO	TGMGMGST	MARVGSIVSPLVSMTAELYP
40	gi 8393886		FNCIFLYT	TGELYPT	VIRO	TGLGMGST	MARVGSIVSPLVSMTAELYP
45	NOV24b		510	520	530	540	550
			VSFGATAIL	AGLAVCF	ETETRNMP	LVETIAAMERR	-----VK---EGSS
	gi 4579723		FIYGAVPVA	ASAVTVLL	PETLGQPL	PDTVQDLES	RWAPTQKEAGIYPRKG
	gi 3831566		FIYGAVPVA	ASAVTVLL	PETLGQPL	PDTVQDLES	-----RKG
	gi 4759042		FIYGAVPVA	ASAVTVLL	PETLGQPL	PDTVQDLES	-----RKG
	gi 8393886		FIFGAVPV	VASAVTALL	PETLGQPL	PDTVQDLKSR	-----SRG
50	NOV24b		560	570			
			KKHVEEK	SEEISLQQL	RASPLKETI		
	gi 4579723		KQTRQQQ	EHQYMPV	PLQASAEK	KNGL	
	gi 3831566		KQTRQQQ	EHQYMPV	PLQASAEK	KNGL	
	gi 4759042		KQTRQQQ	EHQYMPV	PLQASAEK	KNGL	
55	gi 8393886		KQNQQQQ	EQQKQMP	PLQASTQ	KNGL	

The presence of identifiable domains in the NOV24 proteins disclosed herein was determined by searches using algorithms such as PROSITE, Blocks, Pfam, ProDomain, Prints

and then determining the Interpro number by crossing the domain match (or numbers) using the Interpro website (<http://www.ebi.ac.uk/interpro/>). The DOMAIN results are listed in Table 24L and Table 24M with the statistics and domain description. This indicates that the NOV24 sequences have properties similar to those of other proteins known to contain these domains.

5

Table 24L Domain Analysis of NOV24a			
Model	Region of Homology	Score (bits)	E value
Sugar transporter	123-537	6.5	2.8e-08
Reduced folate carrier	130-498	-221.7	0.9
Cell cycle protein	277-529	-241.8	0.95

Table 24M Domain Analysis of NOV24b			
Model	Region of Homology	Score (bits)	E value
Sugar transporter	107-520	8.1	2.5e-08
Reduced folate carrier	118-481	-220.8	0.81
Cell cycle protein	260-512	-242.8	0.95

Consistent with other known members of the OAT family of proteins, NOV24 has, for example, sugar transporter domain and homology to other members of the OAT Protein family. NOV24 nucleic acids, and the encoded polypeptides, according to the invention are useful in a variety of applications and contexts. For example, NOV24 nucleic acids and polypeptides can be used to identify proteins that are members of the OAT family of proteins. The NOV24 nucleic acids and polypeptides can also be used to screen for molecules, which inhibit or enhance NOV24 activity or function. Specifically, the nucleic acids and polypeptides according to the invention may be used as targets for the identification of small molecules that modulate or inhibit, *e.g.*, molecular transport. These molecules can be used to treat, *e.g.*, cancer, immune disorders, and kidney disorders.

In addition, various NOV24 nucleic acids and polypeptides according to the invention are useful, *inter alia*, as novel members of the protein families according to the presence of domains and sequence relatedness to previously described proteins. It is known that many members of the organic anion transporter (OAT), organic cation transporter (OCT), and organic anion-transporting polypeptide (oatp) gene families mediate the transport of diverse organic anions and

cations. It has also been suggested that ATP-dependent primary active transporters such as MDR1/P-glycoprotein and the multidrug resistance-associated protein (MRP) gene family function as efflux pumps of renal tubular cells for more hydrophobic molecules and anionic conjugates.

5 A number transporters, such as the p-aminohippurate/dicarboxylate exchanger OAT1, the anion/sulfate exchanger SAT1, the peptide transporters PEPT1 and PEPT2, and the nucleoside transporters CNT1 and CNT2, are key proteins in organic anion handling that possess the same characteristics as has been predicted from previous physiological studies. The role of other cloned transporters, such as MRP1, MRP2, OATP1, OAT-K1, and OAT-K2, is still poorly
10 characterized, whereas the only information that is available on the homologs OAT2, OAT3, OATP3, and MRP3-6 is that they are expressed in the kidney, but their localization, not to mention their function, remains to be elucidated.

The organic anion transporter 3 belongs to sugar transporter family. The sugar
15 transporters belong to a family of membrane proteins responsible for the transport of various sugars in a wide range of prokaryotic and eukaryotic organisms. These integral membrane proteins are predicted to comprise twelve membrane spanning domains. It is likely that the transporters have evolved from an ancient protein present in living organisms before the divergence into prokaryotes and eukaryotes. In mammals, these proteins are expressed in a number of organs.

20 The NOV24 nucleic acids and polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications in the mediation of molecular transport. As such the NOV24 nucleic acids and polypeptides, antibodies and related compounds according to the invention may be used to treat a wide range of disorders such as cancer, kidney disorders, immune disorders and other diseases, *e.g.*, Von Hippel-Lindau (VHL)
25 syndrome, Cirrhosis, Transplantation, Osteoporosis, Hypercalcaemia, Arthritis, Ankylosing spondylitis, Scoliosis, Diabetes, Autoimmune disease, Renal artery stenosis, Interstitial nephritis, Glomerulonephritis, Polycystic kidney disease, Systemic lupus erythematosus, Renal tubular acidosis, IgA nephropathy, Lesch-Nyhan syndrome renal malfunction, nephrotoxicity, disease associated with cytotoxic drug, osteoporosis, osteopetrosis resistance, liver diseases, and heart
30 diseases.

The NOV24 nucleic acids and polypeptides are useful for detecting specific cell types. For example, expression analysis has demonstrated that a NOV24 nucleic acid is expressed in Bone Marrow, Kidney, Intestine, Liver membrane, adrenal gland, bone marrow, brain - amygdala, brain - cerebellum, brain - hippocampus, brain - substantia nigra, brain - thalamus, brain -whole, fetal brain, fetal kidney, fetal liver, fetal lung, heart, kidney, lymphoma - Raji, mammary gland, pancreas, pituitary gland, placenta, prostate, salivary gland, skeletal muscle, small intestine, spinal cord, spleen, stomach, testis, thyroid, trachea and uterus.

Additional utilities for NOV24 nucleic acids and polypeptides according to the invention are disclosed herein.

NOV25

A NOV25 polypeptide has been identified as a Ficolin-like protein. Eight alternative novel NOV25, NOV25a, NOV25b, NOV25c, NOV25d, NOV25e, NOV25f, NOV25g, and NOV25h, nucleic acids and encoded polypeptides are provided. The novel NOV25 nucleic acid sequences maps to the chromosome 9q34.

NOV25a

A NOV25 variant is the novel NOV25a (alternatively referred to herein as 152736829), which includes the 1082 nucleotide sequence (**SEQ ID NO:82**) shown in Table 25A. NOV25a sequence was cloned by polymerase chain reaction (PCR) using the following primers: GCTCGCTGTCCTGCTAGTCTTGTT (**SEQ ID NO:278**) and AGAAACATAATTCTCCCTCTGGTGAGG (**SEQ ID NO:279**) on the following pool of human cDNAs: Pool 1 - Adrenal gland, bone marrow, brain - amygdala, brain - cerebellum, brain - hippocampus, brain - substantia nigra, brain - thalamus, brain -whole, fetal brain, fetal kidney, fetal liver, fetal lung, heart, kidney, lymphoma - Raji, mammary gland, pancreas, pituitary gland, placenta, prostate, salivary gland, skeletal muscle, small intestine, spinal cord, spleen, stomach, testis, thyroid, trachea, uterus. A NOV25a ORF begins with a ATG initiation codon at nucleotides 16-18 and ends with a TAG codon at nucleotides 928-930. Putative untranslated regions upstream from the initiation codon and downstream from the termination codon are underlined in Table 25A, and the start and stop codons are in bold letters.

Table 25A. NOV25a Nucleotide Sequence (SEQ ID NO:82)

CTGAGTGGAGCCACCATGGCCCCGGGGGCTCGCTGTCTGCTAGTCTTGTTCTGTCATATCAAGAACC
TGCCTGCCCAGGCTGCGGACACATGTCCAGAGGTGAAGGTGGTGGGCTGGAGGGCTCTGACAAGCT
CACCATTCTCCGAGGCTGCCCGGGGCTGCCCGGGGCCCCAGGGCCAAAGGGAGAGGCAGGTGTCATT
GGAGAGAGAGGAGAACGCGGTCTCCCTGGAGCCCCCTGGAAAGGCAGGACCAGTGGGGCCCCAAAGGAG
ACCGAGGAGAGAAGGGGATGCGTGGAGAGAAAGGAGACGCTGGGCAGTCTCAGTCGTGTGCGACAGG
CCCACGCAACTGCAAGGACCTGCTAGACCGGGGTATTTCTGAGCGGCTGGCACACCATCTACCTG
CCCGACTGCCGGCCCCCTGACTGTGCTCTGTGACATGGACACGGACGGAGGGGGCTGGACCGTTTTCC
AGCGGAGGATGGATGGCTCTGTGGACTTCTATCGGGACTGGGCCGCATACAAGCAGGGCTTCGGCAG
TCAGCTGGGGGAGTTCTGGCTGGGGAACGACAACATCCACGCCCTGACTGCCCAGGGAAGCAGCGAG
CTCCGTGTAGACCTGGTGGACTTTGAGGGCAACCACAGTTTGCTAAGTACAAATCATTCAAGGTGG
CTGACGAGGCAGAGAAGTACAAGCTGGTACTGGGAGCCTTTGTGCGGGGCAGTGGCGACCAAGACAA
TGATGTGAGTTCTTCAATTGTGCTGAGAAGTTCCAGGGAGCCTGGTGGTACGCCGACTGTCATGCT
TCAAACCTCAATGGTCTCTACCTCATGGGACCCCATGAGAGCCATGCCAATGGTATCAACTGGAGTG
CGGCGAAGGGGTACAAATATAGCTACAAGGTGTCAGAGATGAAGGTGCGGCCCCGCTAGACGGGCCA
GGACCCCTCCACATGCACCTGCTAGTGGGGAGGCCACCCACAAGCGCTGCGTCGTGGAAGTCACC
CCATTTCCCCAGCCAGACACACTCCCATGACGCCACAGCTGCCCTTTGCCCCCAGCTCAGTCAAG
CCGCCACATG

The NOV25a polypeptide (SEQ ID NO:83) encoded by SEQ ID NO:82 is 304 amino acid residues in length and is presented using the one-letter amino acid code in Table 25B.

NOV25a has one SNP variant, whose variant position for its nucleotide and amino acid sequences is numbered according to SEQ ID NOS:82 and 83, respectively. A variant sequence can include a single nucleotide polymorphism (SNP). A SNP can, in some instances, be referred to as a "cSNP" to denote that the nucleotide sequence containing the SNP originates as a cDNA. NOV25a Variant 13374708 is a G to A SNP at 774 bp of the nucleotide sequence that results in no change in the protein sequence (silent).

The Psort profile for the NOV25a predicts that this peptide is likely to be localized extracellularly with a certainty of 0.0.4944. The Signal P predicts a likely cleavage site for a NOV25a peptide is between positions 22 and 23, *i.e.*, at the dash in the sequence AQA-AD.

Table 25B. NOV25a protein sequence (SEQ ID NO:83)

MARGLA VLLVLF LHIKNLPAQAADTCPEVKVVGLEGS DKLTI LRGCPLPGAPGPKGEAGVIGERGE
RGLPGAPGKAGPVGPKGDRGEKGMERGEKDAGQSQSCATGPRNCKDLLDRGYFLSGWHTIYLPDCRP
LTVLCDMDTDGGGWTVFQRRMDGSVDFYRDWAAYKQGFSQLGEFWLGNDNIHALTAQGSSELRVDL
VDFEGNHQFAKYKSFKVADEAEKYKLVLGAFVGG SADQDNDVSSNCAEFQGAWWYADCHASN LMG
LYLMGP HESHANGINWSAAKGYKYSYKVSEMKVRPA

NOV25b

Alternatively, a NOV25 variant is the novel NOV25b (alternatively referred to herein as CG56653-02), which includes the 1332 nucleotide sequence (**SEQ ID NO:84**) shown in Table

25C. NOV25b was cloned by polymerase chain reaction (PCR) using the following primers:

GCTCGCTGTCCTGCTAGTCTTGTT (**SEQ ID NO:280**) and

AGAAACATAATTCTCCCTCTGGTGAGG (**SEQ ID NO:281**) on the following pool of

human cDNAs: Pool 1 - Adrenal gland, bone marrow, brain - amygdala, brain - cerebellum, brain - hippocampus, brain - substantia nigra, brain - thalamus, brain - whole, fetal brain, fetal

kidney, fetal liver, fetal lung, heart, kidney, lymphoma - Raji, mammary gland, pancreas, pituitary gland, placenta, prostate, salivary gland, skeletal muscle, small intestine, spinal cord, spleen, stomach, testis, thyroid, trachea, uterus. The NOV25b ORF begins with a Kozak

consensus ATG initiation codon at nucleotides 183-185 and ends with a TAG codon at nucleotides 1107-1109. Putative untranslated regions upstream from the initiation codon and

downstream from the termination codon are underlined in Table 25C, and the start and stop codons are in bold letters.

Table 25C. NOV25b Nucleotide Sequence (SEQ ID NO:84)

TTTTAGGTCTGTTTGTGTCGTAGGCAGATGGAGCTTGTATAATTATGCCTCATAGGGATAGTACAAGG
AAGGGTAGGCTATGTGTTTTGTCAGGGAGTTGAGAACTGTGGCACAAGCGAGAGCTGGTTTCCT
CTGCCCTGTTAGAGCTGGGGGACTCTTCAGAGTCAAAGGCCAGAGAGCATGGAGCTGAGTGGAGCCA
CCATGGCCCCGGGGCTCGCTGTCTGTAGTCTTGTTCCTGCATATCAAGAACCTGCCTGCCCAGGC
TGCGGACACATGTCCAGAGGTGAAGGTGGTGGGCCCTGGAGGGCTCTGGCAAGCTCACCATTCTCCGA
GGCTGCCCCGGGGCTGCCCCGGGGCCCCAGGGCCAAAGGGAGAGGCAGGTGTCATTGGAGAGAGAGGAG
ACCGAGGAGAGAAGGGGATGCGTGGAGAGAAAGGAGACGCTGGGCAGTCTCAGTCGTGTGCGACAGG
CCCACGCAACTGCAAGGACCTGCTAGACCGGGGGTATTTCTGAGCGGCTGGCACACCATCTACCTG
CCCCACTGCCGGCCCCCTGACTGTGCTCTGTGACATGGACACGACGAGGGGGCTGGACCGTTTTCC
AGCGGAGGATGGATGGCTCTGTGGACTTCTATCGGGACTGGGCCGCATACAAGCAGGGCTTCGGCAG
TCAGCTGGGGGAGTTCTGGCTGGGGAATGACAACATCCACGCCCTGACTGCCCAGGGAAGCAGCGAG
CTCCGTGTAGACCTGGTGGACTTTGAGGGCAACCACAGTTTGCTAAGTACAAATCATTCAAGGTGG
CTGACGAGGCAGAGAAGTACAAGCTGGTACTGGGAGCCTTTGTGCGGGGCAGTGCGGGTAATTCTCT
AACGGGCCACAACAACAACTTCTTCTCCACCAAAGACCAAGACAATGATGTGAGTCTTTCGAATTGT
GCTGAGAAGTTCCAAGGAGCCTGGTGGTACGCCGACTGTCATGCTTCAAACCTCAATGGTCTCTACC
TCATGGGACCCCATGAGAGCTATGCCAATGGTATCAACTGGAGTGCGGCGAAGGGGTACAAATATAG
CTACAAGGTGTGAGAGTGAAGGTGCGGCCCGCCTAGACGGGCCAGGACCCCTCCACATGCACCTGC
TAGTGGGGAGGCCACACCCACAAGCGCTGCGTCTGGAAGTCACCCCATTTCCCCAGCCAGACACAC
TCCCATGACGCCCACAGCTGCCCCCTTTGCCCCAGCTCAGTCAAGCCGCCACATGCCCACAACCTCA
CCAGAGGGAGAATTATGTTTCTAAATATGTTTACTTTTGGGGACAGAAAAAAAAAAAA

The NOV25b protein (**SEQ ID NO:85**) encoded by **SEQ ID NO:84** is 308 amino acid residues in length is presented using the one-letter code in Table 25D. The Psort profile for NOV25b predicts that this sequence is likely to be localized extracellularly with a certainty of 0.4500. The Signal P predicts a likely cleavage site for a NOV25b peptide is between positions 29 and 30, *i.e.*, at the dash in the sequence AQA-AD.

Table 25D. NOV25b protein sequence (SEQ ID NO:85)

MELSGATMARGLAVLLVFLHLIKNLPAQAADTCPEVKVVGLESGSKLTILRGCPGLPGAPGPKGEAG VIGERGDRGEKGMERGEKGDAGQSQSCATGPRNCKDLLDRGYFLSGWHTIYLPDCRPLTVLCDMDTDG GGWTVFQRRMDGSVDFYRDWAAKQGFSGQLGEFWLGNDNIHALTAQGSSELRVLDLVDFEGNHQFAK YKSFKVADEAEKYKLVLGAFVGGSGAGNSLTGHNNNFSTKDQDNDVSSNCAEKFQGAWWYADCHAS NLNGLYLMGPHEGYANGINWSAAKGYKYSYKVSEMKVRPA
--

NOV25c

Alternatively, a NOV25 variant is the novel NOV25c (alternatively referred to herein as CG56653-03), which includes the 728 nucleotide sequence (**SEQ ID NO:86**) shown in Table 25E. NOV25c was cloned by the polymerase chain reaction (PCR) using the primers: 5' GCTCGCTGTCCTGCTAGTCTTGTT 3' (**SEQ ID NO:282**) and 5' AGAAACATAATTCTCCCTCTGGTGAGG 3' (**SEQ ID NO:283**). Primers were designed based on in silico predictions of the full length or some portion (one or more exons) of the cDNA/protein sequence of the invention. These primers were used to amplify a cDNA from a pool containing expressed human sequences derived from the following tissues: adrenal gland, bone marrow, brain - amygdala, brain - cerebellum, brain - hippocampus, brain - substantia nigra, brain - thalamus, brain -whole, fetal brain, fetal kidney, fetal liver, fetal lung, heart, kidney, lymphoma - Raji, mammary gland, pancreas, pituitary gland, placenta, prostate, salivary gland, skeletal muscle, small intestine, spinal cord, spleen, stomach, testis, thyroid, trachea and uterus. The NOV25c ORF begins with an ORF identified at nucleotides 1-2 and ends with a TAG codon at nucleotides 574-576. Putative untranslated regions upstream from the initiation codon and downstream from the termination codon are underlined in Table 25E, and the start and stop codons are in bold letters.

Table 25E. NOV25c Nucleotide Sequence (SEQ ID NO:86)

CTGCATATCAAGAACCTGCCTGCCCAGGCTGCGGACACATGTCCAGAGGTGAAGGTGGTGGGCCTGG

AGGGCTCTGACAAGCTCACCATTCTCCGAGGCTGCCCGGGGCTGCCCGGGGCCCCAGGGCCAAAGGG
AGAGGCAGGTGTCATTGGAGAGAGAGGAGAACGCGGTCTCCCTGGAGCCCCCTGGAAAGGCAGGACCA
GTGGGGCCCCAAAGGAGACCGAGGAGAGAAGGGGATGCGTGGAGAGAAAGGAGACGCTGGGCAGTCTC
AGTCGTGTGCGACAGGCCCCACGCAACTGCAAGGACCTGCTAGACCGGGGTATTTCTGAGCGGCTG
GCACACCATCTACCTGCCCCACTGCCGGCCCCCTGACTGTGCTCTGTGACATGGACACGGACGGAGGG
GGCTGGACCGTTTTCAGGGAGCCTGGTGGTACGCCGACTGTCATGCTTCAAACCTCAATGGTCTCT
ACCTCATGGGACCCCATGAGAGCTATGCCAATGGTATCAACTGGAGTGC GGCGAAGGGGTACAAATA
TAGCTACAAGGTGTCAGAGATGAAGGTGCGGCCCGCTAGACGGGCCAGGACCCCTCCACATGCACC
TGCTAGTGGGGAGGCCACACCCACAAGCGCTGCGTCGTGGAAGTCACCCATTTCCTCCAGCCAGACA
CACTCCCATGACGCCACAGCTGCCCCCTTTGCCCCAGCTCAGTCAAGCCGCCACATG

The NOV25c protein (SEQ ID NO:87) encoded by SEQ ID NO:86 is 191 amino acid residues in length is presented using the one-letter code in Table 25F. The Psort profile for NOV25c predicts that this sequence is likely to be localized in the cytoplasm with a certainty of 0.4500.

Table 25F. NOV25c protein sequence (SEQ ID NO:87)

LHIKNLPAQAADTCPEVKVVGLEGSDKLTILRGCPGLPGAPGPKGEAGVIGERGERGLPGAPGKAGP
VGPKGDRGEKGMERGEKGDAGSQSCATGPRNCKDLLDRGYFLSGWHTIYLPDCRPLTVLCDMDTDGG
GWTVFQGAWWYADCHASNLNGLYLMGPHE SYANGINWSAAKG YKYSYKVSEMKVRPA

NOV25d

Alternatively, a NOV25 variant is the novel NOV25d (alternatively referred to herein as CG56653-04), which includes the 1104 nucleotide sequence (SEQ ID NO:88) shown in Table 25G. NOV25d was cloned by the polymerase chain reaction (PCR). Primers were designed based on in silico predictions of the full length or some portion (one or more exons) of the cDNA/protein sequence of the invention. These primers were used to amplify a cDNA from a pool containing expressed human sequences derived from the following tissues: adrenal gland, bone marrow, brain - amygdala, brain - cerebellum, brain - hippocampus, brain - substantia nigra, brain - thalamus, brain -whole, fetal brain, fetal kidney, fetal liver, fetal lung, heart, kidney, lymphoma - Raji, mammary gland, pancreas, pituitary gland, placenta, prostate, salivary gland, skeletal muscle, small intestine, spinal cord, spleen, stomach, testis, thyroid, trachea and uterus. The NOV25d ORF begins with a Kozak consensus ATG initiation codon at nucleotides 16-18 and ends with a TAG codon at nucleotides 883-885. Putative untranslated regions

upstream from the initiation codon and downstream from the termination codon are underlined in Table 25G, and the start and stop codons are in bold letters.

Table 25G. NOV25d Nucleotide Sequence (SEQ ID NO:88)
CTGAGTGGAGCCACCATGGCCCGGGGGCTCGCTGTCCTGCTAGTCTTGTTCTGTCATATCACGAACC TGCCTGCCAGGCTGCGGACACATGTCCAGAGGTGAAGGTGGTGGGCCTGGAGGGCTCTGACAAGCT CACCATTCTCCGAGGCTGCCCCGGGGCTGCCCGGGGCCCCAGGACCAAGGGAGAGGCAGGTGTCAATT GGAGAGAAAGGAGACGCTGGGCAGTCTCAGTCGTGTGCGACAGGCCACGCAACTGCAAGGACCTGC TAGACCGAGGGTATTTCTGAGCGGCTGGCACACCATCTACCTGCCCCGACTGCCGGCCCCCTTACTGT GCTCTGTGACATGGATACGGACGGAGGGGGCTGGACCGTTTTCCAGCGGAGGATGGATGGCTCTGTG GACTTCTATCGGGACTGGGCCGCATACAAGCAGGGCTTCGGCAGTCAGCTGGGGGAGTTCTGGCTGG GGAATGACAACATCCACGCCCTGACTGCCCAGGGAAGCAGCGAGCTCCGTGTAGACCTGGTGGACTT TGAGGGCAACCACCAGTTTGTCTAAGTACAAATCATTCAAGGTGGCTGACGAGGCAGAGAAGTACAAG CTGGTACTGGGAGCCTTTGTGCGGGGCGAGTGCGGGTAATTCTCTAACGGGCCACAACAACAATTCT TCTCCACCAAAGACCAAGACAATGATGTGAGTTCCTCGAATTGTGCTGAGAAGTTCCAGGGAGCCTG GTGGTACGCCGACTGTCATGCTTCAAACCTCAATGGTCTCTACCTCATGGGACCCCATGAGAGCTAT GCCAATGGTATCAACTGGAGTGCGGCGAAGGGGTACAAATATAGCTACAAGGTGTCAGAGATGAAGG TGCGGCCCGCC TAG ACGGGCCAGGACCCCTCCACATGCACCTGCTAGTGGGGAGGCCACACCCACAA GCGCTGCGTCGTGGAAGTCACCCCATTTCCCCAGCCAGACACACTCCCATGACGCCCACAGCTGCCC CTTTGCCCCAGCTCAGTCAAGCCGCCACATGCCACCAACCTCACCAGAGGGAGAATTATGTTTCTA AATATGTTTACTTTGGGACAGAAAAAAAAAAAA

The NOV25d protein (SEQ ID NO:89) encoded by SEQ ID NO:88 is 289 amino acid residues in length is presented using the one-letter code in Table 25H. The Psort profile for NOV25d predicts that this sequence is likely to be localized extracellularly with a certainty of 0.6472. The Signal P predicts a likely cleavage site for a NOV25d peptide is between positions 22 and 23, *i.e.*, at the dash in the sequence AQA-AD.

Table 25H. NOV25d protein sequence (SEQ ID NO:89)
MARGLAVLLVLF L HITNLPQAADTCPEVKVVGLEGSDKLTILRGCPGLPGAPGPKGEAGVIGEKGD AGQSQSCATGPRNCKDLLDRGYFLSGWHTIYLPDCRPLTVLCDMDTDGGGWTVFQRRMDGSVDFYRD WAAYKQGF GS QLGEFWLGNDNIHALTAQSSSELRV LD LVDFEGNHQFAKYKSFKVADAEKYKLV L GA FVGGSAGNSLTGHNNNFFSTKDQDNDVSSNCAEK F QGAWWYADCHASN L NGLYLMGP H ESYANGIN WSAAKGYKY S YKVSEMKVRPA

NOV25e

Alternatively, a NOV25 variant is the novel NOV25e (alternatively referred to herein as CG56653-06), which includes the 988 nucleotide sequence (SEQ ID NO:90) shown in Table 25I. NOV25e was cloned by the polymerase chain reaction (PCR) using the primers: 5'GTTTTGTGTCAGGGAGTTGAGAACTGTG 3' (SEQ ID NO:284) and 5'

GAAATGGGGTGACTTCCACGAC 3' (SEQ ID NO:285). Primers were designed based on in silico predictions of the full length or some portion (one or more exons) of the cDNA/protein sequence of the invention. These primers were used to amplify a cDNA from a pool containing expressed human sequences derived from the following tissues: adrenal gland, bone marrow, brain - amygdala, brain - cerebellum, brain - hippocampus, brain - substantia nigra, brain - thalamus, brain -whole, fetal brain, fetal kidney, fetal liver, fetal lung, heart, kidney, lymphoma - Raji, mammary gland, pancreas, pituitary gland, placenta, prostate, salivary gland, skeletal muscle, small intestine, spinal cord, spleen, stomach, testis, thyroid, trachea and uterus. The NOV25e ORF begins with a Kozak consensus ATG initiation codon at nucleotides 56-58 and ends with a TAG codon at nucleotides 905-907. Putative untranslated regions upstream from the initiation codon and downstream from the termination codon are underlined in Table 25I, and the start and stop codons are in bold letters.

Table 25I. NOV25e Nucleotide Sequence (SEQ ID NO:90)

<p> GTTTCCTCTGCCCTGTTAGAGCTGGGGGACTCTTCAGAGTCAAAGGCCAGAGAGCATGGAGCTGAGT GGAGCCACCATGGCCCCGGGGGCTCGCTGTCCTGCTAGTCTTGTTCCCTGCATATCAAGAACCTGCCTG CCCAGGCTGCGGACACATGTCCAGAGGTGAAGGTGGTGGGCCTGGAGGGCTCTGACAAGCTCACCAT TCTCCGAGGCTGCCCGGGGCTGCCCGGGGCCCCAGGCCAAAGGGAGAGGCAGGTGTCAATTGGAGAG AGAGGAGAACGCGGTCTCCCTGGAGCCCCCTGGAAAGGCAGGACCAGTGGGGCCCCAAAGGAGACCGAG GAGAGAAGGGGATGCGTGGAGAGAAAGGAGACGCTGGGCAGTCTCAGTCGTGTGCGACAGGTCCACG CAACTGCAAGGACCTGCTAGACCGGGGGTATTTCTGAGCGGCTGGCACACCATCTACCTGCCCCGAC TGCCGGCCCCCTGACTGTGCTCTGTGACATGGACACGGACGGAGGGGGCTGGACCGTTTTCCAGCGGA GGATGGATGGCTCTGTGGACTTTGAGGGCAACCACCAAGTTTGCTAAGTACAAATCATTCAAGGTGGC TGACGAGGCAGAGAAGTACAAGCTGGTACTGGGAGCCTTTGTCTGGGGGCAGTGGCGGTAATTCTCTA ACGGGCCACAACAACAATTCTTCTCCACCAAGACCAAGACAATGATGTGAGTTCTTCGAATTGTG CTGAGAAGTTCCAAGGAGCCTGGTGGTACGCCGACTGTCTGCTTCAAACCTCAATGGTCTCTACCT CATGGGACCCCATGAGAGCTATGCCAATGGTATCAACTGCAGTGCGGCGAAGGGGTACAAATATAGC TACAAGGTGTGAGAGATGAAGGTGCGGCCCGCTTAGACGGGCCAGGACCCCTCCACATGCACCTGCT AGTGGGGAGGCCACACCCACAAGCGCTGCGTCGTGGAAGTCACCCATTTC </p>

The NOV25e protein (SEQ ID NO:91) encoded by SEQ ID NO:90 is 283 amino acid residues in length is presented using the one-letter code in Table 25J. A variant sequence can include a single nucleotide polymorphism (SNP). A SNP can, in some instances, be referred to as a "cSNP" to denote that the nucleotide sequence containing the SNP originates as a cDNA. A NOV24b Variant is a G to T SNP at 89 bp of the nucleotide sequence.

The Psort profile for NOV25e predicts that this sequence is likely to be localized extracellularly with a certainty of 0.6711. The Signal P predicts a likely cleavage site for a NOV25e peptide is between positions 29 and 30, *i.e.*, at the dash in the sequence AQA-AD.

Table 25J. NOV25e protein sequence (SEQ ID NO:91)

MELSGATMARGLAVLLVLFLHIKNLPAQAADTCPEVKVVGLEGS DKL TILRGCPGLPGAPGPKGEAG
VIGERGERGLPGAPGKAGPVGPKGDRGEKGMERGEKGDAGSQSCATGPRNCKDLLDRGYFLSGWHTI
YLPDCRPLTVLCDMDTDGGGWTVFQRRMDGSVDFEGNHQFAKYKSFKVADEAEKYKLVLGAFVGGSA
GNSLTGHNNNFSTKDQDNDVSSNCAEKFQGAWWYADCHASNLNGLYLMGPHE SYANGINCSAAKG
YKYSYKVSEMKVRPA

NOV25f

Alternatively, a NOV25 variant is the novel NOV25f (alternatively referred to herein as CG56653-01), which includes the 1194 nucleotide sequence (SEQ ID NO:92) shown in Table 25K. The NOV25f ORF begins with a Kozak consensus ATG initiation codon at nucleotides 15-18 and ends with a TAG codon at nucleotides 973-975. Putative untranslated regions upstream from the initiation codon and downstream from the termination codon are underlined in Table 25K, and the start and stop codons are in bold letters.

Table 25K. NOV25f Nucleotide Sequence (SEQ ID NO:92)

CTGAGTGGAGCCACCATGGGCCCGGGGCTCGCTGTCCTGCTAGTCTTGTTCTGTCATATCAAGAACCT
TGCCTGCCCAGGCTGCGGACACATGTCCAGAGGTGAAGGTGGTGGGCCTGGAGGGCTCTGACAAGCT
CACCATTCTCCGAGGCTGCCCGGGGCTGCCCGGGGCCCCAGGGCCAAAGGGAGAGGCAGGTGTCATT
GGAGAGAGAGGAGAACGCGGTCTCCCTGGAGCCCTGGAAAGGCAGGACCAGTGGGGCCCCAAAGGAG
ACCGAGGAGAGAAGGGGATGCGTGGAGAGAAAGGAGACGCTGGGCAGTCTCAGTCGTGTGCGACAGG
CCCACGCAACTGCAAGGACCTGCTAGACCGGGGGTATTTCTGAGCGGCTGGCACACCATCTACCTG
CCCGACTGCCGGCCCCCTGACTGTGCTCTGTGACATGGACACGGACGGAGGGGGCTGGACCGTTTTC
AGCGGAGGATGGATGGCTCTGTGGACTTCTATCGGGACTGGGCGGCATACAAGCAGGGCTTCGGCAG
TCAGCTGGGGGAGTTCTGGCTGGGGAACGACAACATCCACGCCCTGACTGCCAGGGAAGCAGCGAG
CTCCGTGTAGACCTGGTGGACTTTGAGGGCAACCACCAGTTTGCTAAGTACAAATCATTCAAGGTGG
CTGACGAGGCAGAGAAGTACAAGCTGGTACTGGGAGCCTTTGTGCGGGGCAGTGCGGGTAATTCTCT
AACGGGCCACAACAACAACCTTCTTCCACCAAAGACCAAGACAATGATGTGAGTTCTTCGAATTGT
GCTGAGAAGTTCCAGGGAGCCTGGTGGTACGCCGACTGTCATGCTTCAAACCTCAATGGTCTCTACC
TCATGGGACCCCATGAGAGCTATGCCAATGGTATCAACTGGAGTGCGGCGAAGGGGTACAAATATAG
CTACAAGGTGTCAGAGATGAAGGTGCGGCCCGCCTAGACGGGGCCAGGACCCCTCCACATGCACCTGC
TAGTGGGAGGCCACACCCACAAGCGCTGCGTCGTGGAAAGTCACCCCATTTCCCCAGCCAGACACAC
TCCCATGACGCCCACAGCTGCCCCTTTGCCCCAGCTCAGTCAAGCCGCCACATGCCCAACCTCA
CCAGAGGGAGAATTATGTTTCTAAATATGTTTACTTTGGGACAGAAAAA

The NOV25f protein (SEQ ID NO:93) encoded by SEQ ID NO:92 is 319 amino acid residues in length is presented using the one-letter code in Table 25L. The Psort profile for

NOV25f predicts that this sequence is likely to be localized extracellularly with a certainty of 0.4944.

Table 25L. NOV25f protein sequence (SEQ ID NO:93)
MARGLAVLLVFLHLIKNLPAQAADTCPEVKVVGLEGSDKLTILRGCPGLPGAPGPKGEAGVIGERGE RGLPGAPGKAGPVGPKGDRGEKGMERGEKGDAGQSQSCATGPRNCKDLLDRGYFLSGWHTIYLPDCRP LTVLCDMDTDGGGWTVFQRRMDGSVDFYRDWAAYKQGFSQLGEFWLGNDNIHALTAQGSSELRVDL VDFEGNHQFAKYKSFKVADEAEKYKLVLGAFAVGGGAGNSLTGHNNFFSTKDQDNDVSSSNCAEKFQ GAWWYADCHASNLNGLYLMGPHESYANGINWSAAKGKYSYKVSEMKVRPA

5 **NOV25g**

Alternatively, a NOV25 variant is the novel NOV25g (alternatively referred to herein as CG56653-09), which includes the 1144 nucleotide sequence (**SEQ ID NO:94**) shown in Table 25M. NOV25g was derived by laboratory cloning of cDNA fragments, by *in silico* prediction of the sequence. cDNA fragments covering either the full length of the DNA sequence, or part of the sequence, or both, were cloned. In silico prediction was based on sequences available in Curagen's proprietary sequence databases or in the public human sequence databases, and provided either the full length DNA sequence, or some portion thereof. The NOV25g ORF begins with a Kozak consensus ATG initiation codon at nucleotides 183-185 and ends with a TAG codon at nucleotides 981-983. Putative untranslated regions upstream from the initiation codon and downstream from the termination codon are underlined in Table 25M, and the start and stop codons are in bold letters.

Table 25M. NOV25g Nucleotide Sequence (SEQ ID NO:94)
<u>TTT</u> <u>TAGG</u> <u>TCTG</u> <u>TTTGT</u> <u>CGTAGG</u> <u>CAGATGGAGCTT</u> <u>GTTATAATTATGCCTCATAGGGATAGTACAAGG</u> <u>AAGGGTAGGCTATGTGTTTGT</u> <u>CAGGGAGTTGAGAACTGTGGCACAAGGCGAGAGCTGGTTTCCT</u> <u>CTGCCCTGTTAGAGCTGGGGGACTCTT</u> <u>CAGAGTCAAAGGCCAGAGAGCATGGAGCTGAGTGGAGCCA</u> <u>CCATGGCCCCGGGGGCTCGCTGTCCTGTAGTCTTGTTCCTGCATATCAAGAACCTGCCTGCCCAGGC</u> <u>TGCGGACACATGTCCAGAGGTGAAGGTGGTGGGCCTGGAGGGCTCTGACAAGCTCACCATTCTCCGA</u> <u>GGCTGCCCGGGGCTGCCCGGGGCCCCAGGGCCAAAGGGAGAGGCAGGTGTCATTGGAGAGAGAGGAG</u> <u>AACGCGGTCTCCCTGGAGCCCCCTGGAAAGGCAGGACCAAGTGGGGCCCAAGGAGACCGAGGAGAGAA</u> <u>GGGGATGCGTGGAGAGAAAGGAGACGCTGGGCAGTCTCAGTCGTGTGCGACAGGCCCACGCAACTGC</u> <u>AAGGACCTGCTAGACCGGGGTATTTCTGAGCGGCTGGCACACCATCTACCTGCCCCGACTGCCGGC</u> <u>CCCTGACTGTGCTCTGTGACATGGACACGACGAGGGGGCTGGACCGTTTTCCAGCGGAGGATGGA</u> <u>TGGCTCTGTGACTTCTATCGGGACTGGGCCGCATACAAGCAGGGCTTCGGCAGTCAGCTGGGGGGT</u> <u>AATTCTCTAACGGGCCACAACAACACTTCTTCTCCACCAAAGACCAAGACAATGATGTGAGTTCTT</u> <u>CGAATTGTGCTGAGAAGTTCCAAGGAGCCTGGTGGTACGCCGACTGTGCATGCTTCAAACCTCAATGG</u> <u>TCTCTACCTCATGGGACCCCATGAGAGCTATGCCAATGGTATCAACTGGAGTGCGGCGAAGGGGTAC</u> <u>AAATATAGCTACAAGGTGTGAGAGATGAAGGTGCGGCCCGCC</u> TAG <u>ACGGGCCAGGACCCCTCCACAT</u> <u>GCACCTGCTAGTGGGGAGGCCACACCCACAAGCGCTGCGTCGTGGAAGTCACCCCATTTCCCGAGCC</u> <u>AGACACACTCCCATGACGCCCACAGCTGCCCTTTGCCCCAGCTCAGTCAAGCCGCCACATGCCCA</u>

The NOV25g protein (SEQ ID NO:95) encoded by SEQ ID NO:94 is 266 amino acid residues in length is presented using the one-letter code in Table 25N. The Psort profile for NOV25g predicts that this sequence is likely to be localized extracellularly with a certainty of 0.6711. The Signal P predicts a likely cleavage site for a NOV25g peptide is between positions 29 and 30, *i.e.*, at the dash in the sequence AQA-AD.

Table 25N. NOV25g protein sequence (SEQ ID NO:95)

MELSGATMARGLAVLLVFLHITKNLPAQAADTCPEVKVVGLEGSCLKLTILRGCPGLPGAPGPKGEAG
VIGERGERGLPGAPGKAGPVGPKGDRGEKGMERGEKGDAGQSQSCATGPRNCKDLLDRGYFLSGWHTI
YLPDCRPLTVLCDMDTDGGGWTFQRRMDGSVDFYRDWAAYKQGFQSQLGGNSLTGHNNNFSTKDQ
DNDVSSSNCAEFQGAWWYADCHASNGLNYLMGPHESYANGINWSAAKGYKYSYKVSEMKVRPA

NOV25h

Alternatively, a NOV25 variant is the novel NOV25h (alternatively referred to herein as CG56653-01 & CG56653-02 assembly 169319361), which includes the 900 nucleotide sequence (SEQ ID NO:96) shown in Table 25O. The NOV25h ORF begins at nucleotides 1-2 and ends with a TAG codon at nucleotides 898.

Table 25O. NOV25h Nucleotide Sequence (SEQ ID NO:96)

GGATCCGCGGACACATGTCCAGAGGTGAAGGTGGTGGGCTGGAGGGCTCTGACAAGCTCACCATTCTCCGAGGCTGCCCGGGGCTGCCCGGGGCCCCAGGGCCAAAGGAGAGGCAGGTGTCTATTGGAGAGAGAGGAGAACGCGGTCTCCCTGGAGCCCCCTGGAAAGGCAGGACCAGTGGGGCCCCAAAGGAGACCGAGGAGAGAAGGGGATGCGTGGAGAGAAAGGAGACGCTGGGCAGTCTCAGTCGTGTGCGACAGGCCCCACGCACTGCAAGGACCTGCTAGACCGGGGGTATTTCTGAGCGGCTGGCACACCATCTACCTGCCCCGACTGCCGGCCCCCTGACTGTGCTCTGTGACATGGACACGGACGGAGGGGGCTGGACCGTTTTCCAGCGGAGGATGGATGGCTCTGTGGACTTCTATCGGGACTGGGCGGCATACAAGCAGGGCTTCGGCAGTCAGCTGGGGAGTTCTGGCTGGGGAACGACAACATCCACGCCCTGACTGCCCAGGGAAGCAGCGAGCTCCGTGTAGACCTGGTGGACTTTGAGGGCAACCACAGTTTGCTAAGTACAAATCATTCAGGTGGCTGACGAGGCAGAGAAGTACAAGCTGGTACTGGGAGCCTTTGTGCGGGGCAGTGCGGGTAATCTCTAACGGGCCACAACAACAACCTTCTTCTCCACCAAAGACCAAGACAATGATGTGAGTTCTTCGAATTGTGCTGAGAA GTTCCAGGGAGCCTGGTGGTACGCCGACTGTCATGCTTCAAACCTCAATGGTCTCTACCTCATGGGACCCATGAGAGCTATGCCAATGGTATCAACTGGAGTGCGGCAAGGGGTACAAATATAGCTACAAGGTGTGAGATGAAGGGGCCCCGCCCTCGAG

The NOV25h protein (SEQ ID NO:97) encoded by SEQ ID NO:96 is 300 amino acid residues in length is presented using the one-letter code in Table 25P. The Psort profile for

NOV25h predicts that this sequence is likely to be localized extracellularly with a certainty of 0.4500.

Table 25P. NOV25h protein sequence (SEQ ID NO:97)
GSADTCPEVKVVGLEGS DKL TILRGCPGLPGAPGPKGEAGVIGERGERGLPGAPGKAGPVGPKGDRG EKGMRGEKGDAGQS QSCATGPRNCKDLLDRGYFLSGWHTIYLPDCRPLTVLCDMDTDGGGWTVFQRR MDGSVDFYRDWAAYKQGF GSQLGEFWLGNDNIHALTAQGSSELRVLDLVDFEGNHQFAKYKSKVVADE AEKYKLVLGAFVGG SAGNSLTGHNNNFSTKQDNDVSSNCAEKFQGAWWYADCHASNGLNGLYLMG PHESYANGINWSAAKG YKYSYKVSEMKGPALE

NOV25 Clones

Unless specifically addressed as NOV25a, NOV25b, NOV25c, NOV25d, NOV25e, NOV25f, NOV25g, or NOV25h , any reference to NOV25 is assumed to encompass all variants. Further, Patp, BLAST, and DOMAIN analyses are presented for NOV25b, the longest NOV25 polypeptide sequence.

A search against the Patp database, a proprietary database that contains sequences published in patents and patent publications, yielded several homologous proteins shown in Table 25Q.

Table 25Q. Patp results for NOV25			
Sequences producing High-scoring Segment Pairs:			Smallest Sum
	Reading Frame	High Score	Prob P (N)
>patp:AAR94183 Human 35 kDa opsonin protein P35	+1	1272	2.0e-129
>patp:AAR94179 Human 35 kDa opsonin protein P35 fragment	+1	1225	1.9e-124
>patp:AAR30971 TGF-beta-1 binding protein	+1	1200	8.6e-122
>patp:AAR94178 Human 35 kDa opsonin protein P35 fragment	+1	1022	6.2e-103
>patp:AAB29658 Human membrane-associated protein HUMAP-15	+1	746	1.1e-73

NOV25 polypeptides are ficolin-like proteins with sequence homology to the Fibrinogen protein family. In a BLAST search of public sequence databases, it was found, for example, that the NOV25b nucleic sequence of this invention has 956 of 982 bases (97%) identical to a gb:GENBANK-ID:S80990|acc:S80990.1 mRNA from *Homo sapiens* [ficolin (human, uterus, mRNA, 1736 nt)]. The full NOV25b polypeptide sequence was found to have 252 of 276 amino acid residues (91%) identical to, and 258 of 276 amino acid residues (93%) similar to, the 319 amino acid residue ptnr:SPTREMBL-ACC:Q92596 protein from *Homo sapiens*.

Additional BLAST results are shown in Table 25R.

Table 25R. BLAST results for NOV25					
Gene Index/ Identifier	Protein/ Organism	Length (aa)	Identity (%)	Positives (%)	Expect
GI 8051584 REF NP_01994.2 (NM_002003)	FICOLIN 1 PRECURSOR [<i>Homo sapiens</i>]	326	307/326 (94%)	307/326 (94%)	1e-174
GI 13124165 SP O00602	FCN1_HUMAN FICOLIN 1 PRECURSOR (COLLAGEN/FIBRINO GEN DOMAIN- CONTAINING PROTEIN 1) [<i>Homo sapiens</i>]	326	305/326 (93%)	306/326 (93%)	1e-172
GI 2135117 PIR JC4942	FICOLIN-1 PRECURSOR [<i>Homo sapiens</i>]	319	300/319 (94%)	300/319 (94%)	1e-170
GI 423207 PIR B47172	FICOLIN-BETA - [<i>Sus scrofa</i>]	326	238/324 (73%)	264/324 (81%)	1e-133
GI 16758442 REF NP_446086.1 (NM_053634)	FICOLIN B [<i>Rattus norvegicus</i>]	319	229/317 (72%)	255/317 (80%)	1e-131

A multiple sequence alignment is given in Table 25S, with the NOV25 protein of the invention being shown on line 1, in a ClustalW analysis comparing NOV25 with related protein sequences disclosed in Table 25R.

Table 25S. Information for the ClustalW proteins:

1. >NOV25a; SEQ ID NO:83
2. >NOV25b; SEQ ID NO:85
3. >NOV25c; SEQ ID NO:87
4. >NOV25d; SEQ ID NO:89
5. >NOV25e; SEQ ID NO:91
6. >NOV25f; SEQ ID NO:93
7. >NOV25g; SEQ ID NO:95
8. >NOV25h; SEQ ID NO:97
9. >GI|8051584/ FICOLIN 1 PRECURSOR [*Homo sapiens*]; SEQ ID NO:286
10. >GI|1312416/ FCN1_HUMAN FICOLIN 1 PRECURSOR [*Homo sapiens*]; SEQ ID NO:287
11. >GI|2135117/ FICOLIN-1 PRECURSOR [*Homo sapiens*]; SEQ ID NO:288
12. >GI|423207/ FICOLIN-BETA [*Sus scrofa*]; SEQ ID NO:289
13. >GI|1675844/ FICOLIN B [*Rattus norvegicus*]; SEQ ID NO:290

.....|.....|.....|.....|.....|.....|.....|.....|.....|.....|.....|

NOV25a	-----MARGLAVLLVFLFLHIKNLPAQAADTCPEVKVVGLEGSDKLTIL
NOV25b	MELSGATMARGLAVLLVFLFLHIKNLPAQAADTCPEVKVVGLEGSDKLTIL
NOV25c	-----LHIKNLPAQAADTCPEVKVVGLEGSDKLTIL
NOV25d	-----MARGLAVLLVFLFLHIKNLPAQAADTCPEVKVVGLEGSDKLTIL
NOV25e	MELSGATMARGLAVLLVFLFLHIKNLPAQAADTCPEVKVVGLEGSDKLTIL
NOV25f	-----MARGLAVLLVFLFLHIKNLPAQAADTCPEVKVVGLEGSDKLTIL
NOV25g	MELSGATMARGLAVLLVFLFLHIKNLPAQAADTCPEVKVVGLEGSDKLTIL
NOV25h	-----GSADTCPEVKVVGLEGSDKLTIL
GI 8051584	MELSGATMARGLAVLLVFLFLHIKNLPAQAADTCPEVKVVGLEGSDKLTIL
GI 1312416	MELSGATMARGLAVLLVFLFLHIKNLPAQAADTCPEVKVVGLEGSDKLTIL
GI 2135117	-----MARGLAVLLVFLFLHIKNLPAQAADTCPEVKVVGLEGSDKLTIL
GI 423207	MELSRVAVALGPTGQLLFLSFQTLAQAADTCPEVKVVGLEGSDKLSIL
GI 1675844	-----MVLGSAALFVLSLCVTELTTLHAADTCPEVKVLDLEGSNKLTIL
	60 70 80 90 100
NOV25a	RGCPGLPGAPGPKGEAGVIGERGERGLPGAPGKAGPVGPKGDRGEKGMRG
NOV25b	RGCPGLPGAPGPKGEAGVIGERG-----DRGEKGMRG
NOV25c	RGCPGLPGAPGPKGEAGVIGERGERGLPGAPGKAGPVGPKGDRGEKGMRG
NOV25d	RGCPGLPGAPGPKGEAGVIG-----
NOV25e	RGCPGLPGAPGPKGEAGVIGERGERGLPGAPGKAGPVGPKGDRGEKGMRG
NOV25f	RGCPGLPGAPGPKGEAGVIGERGERGLPGAPGKAGPVGPKGDRGEKGMRG
NOV25g	RGCPGLPGAPGPKGEAGVIGERGERGLPGAPGKAGPVGPKGDRGEKGMRG
NOV25h	RGCPGLPGAPGPKGEAGVIGERGERGLPGAPGKAGPVGPKGDRGEKGMRG
GI 8051584	RGCPGLPGAPGPKGEAGVIGERGERGLPGAPGKAGPVGPKGDRGEKGMRG
GI 1312416	RGCPGLPGAPGPKGEAGVIGERGERGLPGAPGKAGPVGPKGDRGEKGMRG
GI 2135117	RGCPGLPGAPGPKGEAGVIGERGERGLPGAPGKAGPVGPKGDRGEKGMRG
GI 423207	RGCPGLPGAAGPKGEAGANGPKGERGSPGVVGKAGEAGPKGDRGEKAGRG
GI 1675844	QGCPGLPGAALGPKGEAGAKGDRGESGLPGHFGKAGFTGPKGDRGEKGVRG
	110 120 130 140 150
NOV25a	EKGDAGQSQSCATGPRNCKDLLDRGYFLSGWHTIYLPDCRPLTVLCDMDT
NOV25b	EKGDAGQSQSCATGPRNCKDLLDRGYFLSGWHTIYLPDCRPLTVLCDMDT
NOV25c	EKGDAGQSQSCATGPRNCKDLLDRGYFLSGWHTIYLPDCRPLTVLCDMDT
NOV25d	-KGDAGQSQSCATGPRNCKDLLDRGYFLSGWHTIYLPDCRPLTVLCDMDT
NOV25e	EKGDAGQSQSCATGPRNCKDLLDRGYFLSGWHTIYLPDCRPLTVLCDMDT
NOV25f	EKGDAGQSQSCATGPRNCKDLLDRGYFLSGWHTIYLPDCRPLTVLCDMDT
NOV25g	EKGDAGQSQSCATGPRNCKDLLDRGYFLSGWHTIYLPDCRPLTVLCDMDT
NOV25h	EKGDAGQSQSCATGPRNCKDLLDRGYFLSGWHTIYLPDCRPLTVLCDMDT
GI 8051584	EKGDAGQSQSCATGPRNCKDLLDRGYFLSGWHTIYLPDCRPLTVLCDMDT
GI 1312416	EKGDAGQSQSCATGPRNCKDLLDRGYFLSGWHTIYLPDCRPLTVLCDMDT
GI 2135117	EKGDAGQSQSCATGPRNCKDLLDRGYFLSGWHTIYLPDCRPLTVLCDMDT
GI 423207	EKGEFPGQLQSCATGPRITCKELLTRGFHFLSGWHTIYLPDCRPLTVLCDMDT
GI 1675844	EKGLTGPQSQSCATGPRITCKELLTRGYFLTGWYTIYLPDCRPLTVLCDMDT
	160 170 180 190 200
NOV25a	DGGGWTVFQRRMDGSVDFYRDWAAYKQGFGSQLGEFWLGNDNIHALTAQG
NOV25b	DGGGWTVFQRRMDGSVDFYRDWAAYKQGFGSQLGEFWLGNDNIHALTAQG
NOV25c	DGGGWTVFQ-----
NOV25d	DGGGWTVFQRRMDGSVDFYRDWAAYKQGFGSQLGEFWLGNDNIHALTAQG
NOV25e	DGGGWTVFQRRMDGSVDFE-----
NOV25f	DGGGWTVFQRRMDGSVDFYRDWAAYKQGFGSQLGEFWLGNDNIHALTAQG
NOV25g	DGGGWTVFQRRMDGSVDFY-----
NOV25h	DGGGWTVFQRRMDGSVDFYRDWAAYKQGFGSQLGEFWLGNDNIHALTAQG
GI 8051584	DGGGWTVFQRRMDGSVDFYRDWAAYKQGFGSQLGEFWLGNDNIHALTAQG
GI 1312416	DGGGWTVFQRRMDGSVDFYRDWAAYKQGFGSQLGEFWLGNDNIHALTAQG
GI 2135117	DGGGWTVFQRRMDGSVDFYRDWAAYKQGFGSQLGEFWLGNDNIHALTAQG
GI 423207	DGGGWTVFQRRSDGSVDFYRDWAAYKRQFGSQLGEFWLGNDNIHALTAQG
GI 1675844	DGGGWTVFQRRIDGTVDFFRDWTSYKQGFGSQLGEFWLGNDNIHALTAQG
	210 220 230 240 250

45

The presence of identifiable domains in the protein disclosed herein was determined by searches using algorithms such as PROSITE, Blocks, Pfam, ProDomain, Prints and then determining the Interpro number by crossing the domain match (or numbers) using the Interpro website (<http://www.ebi.ac.uk/interpro/>). Table 25T lists the domain description from DOMAIN analysis results against NOV25.

242

Collagen triple helix repeat	38-96	6.0	7.8e-05
Fibrinogen beta and gamma chains, C-terminal globular domain	96-308	325.6	3e-95

Consistent with other known members of the Fibrinogen family of proteins, *e.g.*, ficolins, NOV25 contains fibrinogen and collagen domains as illustrated in Table 25T (Ohashi and Erickson, J. Biol. Chem., 272: 14220-6 (1997)). NOV25 nucleic acids, and the encoded polypeptides, according to the invention are useful in a variety of applications and contexts. For example, NOV25 nucleic acids and polypeptides can be used to identify proteins that are members of the Fibrinogen family of proteins. The NOV25 nucleic acids and polypeptides can also be used to screen for molecules, which inhibit or enhance NOV25 activity or function. Specifically, the nucleic acids and polypeptides according to the invention may be used as targets for the identification of small molecules that modulate or inhibit, *e.g.*, cellular activation, cellular metabolism, host defense and signal transduction. These molecules can be used to treat, *e.g.*, arthritis, autoimmune disease, immunodeficiencies, anemia, ataxia-telangiectasia, hemophilia, hypercoagulation, idiopathic thrombocytopenic purpura, graft versus host disease, endometriosis, fertility, systemic lupus erythematosus, asthma, emphysema, scleroderma, allergies, ARDS, hypercoagulation, as well as other diseases, disorders and conditions.

In addition, various NOV25 nucleic acids and polypeptides according to the invention are useful, *inter alia*, as novel members of the protein families according to the presence of domains and sequence relatedness to previously described proteins. For example, the NOV25 nucleic acids and their encoded polypeptides include structural motifs that are characteristic of proteins belonging to the ficolin family of proteins involved in cytokine and steroid physiology (Ohashi and Erickson, J. Biol. Chem., 272: 14220-6 (1997)).

Ficolin was originally isolated as a protein from pig uterus membrane extracts that bound transforming growth factor- (Ichijo *et al.*, J. Biol. Chem., 266: 22459-64 91991)). Ficolins have also been identified from human blood as a corticosteroid binding protein, termed hucolin (Edgar, FEBS Lett., 375: 159-61 (1995)), an elastin binding protein, termed EBP-37 (Harumiya *et al.*, J. Biochem., 117: 1029-35 (1995)), and a GlcNAc binding lectin, termed P35 (Matsushita *et al.*, J. Biol. Chem. 271: 2448-54 (1996)). Ficolin cDNAs, are termed human ficolin (Lu *et al.*, Biochem. J., 313: 473-8 (1996)), ficolin-1 (Harumiya *et al.*, J. Biochem., 120: 745-51 (1996)), and P35-related gene (Endo *et al.*, Genomics, 36: 515-21, (1996)) have been cloned.

The amino acid sequence of ficolins consist of a short N-terminal domain, a middle collagen-like domain, and aC-terminal fibrinogen-like (fbg)1 domain (Ohashi and Erickson, J. Biol. Chem., 272: 14220-6 (1997)). The collagen domains assemble these proteins into trimers, and electron microscopy shows that four or six trimers are connected together by the N-terminal domain, leaving the C-terminal lectin domains to project in a multimeric array (13-17). Like C1q and collectins play roles in immune defense, ficolins have been implicated in a similar role, in that human plasma ficolin (P35) is a lectin that binds to the carbohydrate of bacterial surface (Lu *et al.*, Immunology, 89: 289-94 (1996)) and enhances opsonic activity of white blood cells, *e.g.*, polymorphonuclear neutrophils (Matsushita *et al.*, J. Biol. Chem., 271: 2448-54 (1996)). Ficolin may play a role in alleviating inflammation in joints and other sites of inflammation.

Indeed, experiments comparing the gene expression levels of matched white blood cell fraction, *e.g.*, peripheral blood lymphocytes (PBLs), and synovial fluid from three Rheumatoid Arthritis (RA) patients showed significantly lower level of NOV25f of the present invention in the RA patients. Specifically, the NOV25f gene was found to be upregulated 26-fold The presence of this ficolin in the PBLs was, on average, 26-fold over the level found in the synoviocytes of these RA patients.

Based on the surprising result from GeneCalling that Ficolin is upregulated to such a high extent in PBLs vs synoviocytes in RA patients, and coupling this knowledge with the TaqMan profiles presented below, ficolin may be useful as a protein therapeutic in RA patients and other patients with autoimmune diseases. Ficolin, or pharmaceutically active portions thereof, may be administered to RA patients directly into the joint space of the knee or other joint space to alleviate inflammation and promote healing.

Protein therapeutics designed with the protein encoded for by NOV25 could function as an opsinin to target and eliminate bacteria by complement –mediated destruction. These proteins could be important for the treatment of bacterial septicemia. Ficolins may also have the ability to bind to elastins. Elastins are functionally important for lung alveolar development and inactivation of these proteins can lead to emphysema-like disease. Antibodies against NOV25 may prevent tissue destruction mediated by ficolin activity during emphysema, asthma and arthritis

The NOV25 nucleic acids and polypeptides are useful for detecting specific cell types. For example, expression analysis has demonstrated that a NOV25 nucleic acid is expressed in

white blood cells, Aorta, Colon, Bone Marrow, Joints, Peripheral Blood, Spleen, Pituitary Gland, Mammary gland/Breast, Uterus, Prostate, Lung, and Kidney. .

Additional utilities for NOV25 nucleic acids and polypeptides according to the invention are disclosed herein.

NOV26

A NOV26 polypeptide has been identified as a ficolin-like protein (also referred to as 152736833). The disclosed novel NOV26 nucleic acid (SEQ ID NO:98) of 779 nucleotides is shown in Table 26A. The cDNA coding for the NOV26 was cloned by polymerase chain reaction (PCR) using the following primers: GCTCGCTGTCCTGCTAGTCTTGTT (SEQ ID NO:291) and AGAAACATAATTCTCCCTCTGGTGAGG (SEQ ID NO:292) on the following pool of human cDNAs: Pool 1 - Adrenal gland, bone marrow, brain - amygdala, brain - cerebellum, brain - hippocampus, brain - substantia nigra, brain - thalamus, brain - whole, fetal brain, fetal kidney, fetal liver, fetal lung, heart, kidney, lymphoma - Raji, mammary gland, pancreas, pituitary gland, placenta, prostate, salivary gland, skeletal muscle, small intestine, spinal cord, spleen, stomach, testis, thyroid, trachea, uterus. The novel NOV26 nucleic acid sequences maps to the chromosome 9.

An ORF begins with an Kozak consensus ATG initiation codon at nucleotides 16-18 and ends with a TAG codon at nucleotides 625-627. A putative untranslated region and/or downstream from the termination codon is underlined in Table 26A, and the start and stop codons are in bold letters.

Table 26A. NOV26 Nucleotide Sequence (SEQ ID NO:98)

CTGAGTGGAGCCACCA**ATG**CCCCGGGGGCTCGCTGTCCTGCTAGTCTTGTTCTGCATATCAAGAACC
TGCTTGCCAGGCTGCGGACACATGTCCAGAGGTGAAGGTGGTGGCCTGGAGGGCTCTGACAAGCT
CACCATTCTCCGAGGCTGCCCCGGGGCTGCCCCGGGGCCCCAGGGCCAAAGGGAGAGGCAGGTGTCATT
GGAGAGAGAGGAGAACGCGGTCTCCCTGGAGCCCCCTGGAAAGGCAGGACCAGTGGGGCCCCAAAGGAG
ACCGAGGAGAGAAGGGGATGCGTGAGAGAGAAAGGAGACGCTGGGCAGTCTCAGTCGTGTGCGACAGG
CCCACGCAACTGCAAGGACCTGCTAGACCGGGGGTATTTCTGAGCGGCTGGCACACCATCTACCTG
CCCGACTGCCGGCCCCCTGACTGTGCTCTGTGACATGGACACGGACGGAGGGGGCTGGACCGTTTTC
AGGGAGCCTGGTGGTACGCCGACTGTCATGCTTCAAACCTCAATGGTCTCTACCTCATGGGACCCCA
TGAGAGCTATGCCAATGGTATCAACTGGAGTGCGGCGAAGGGGTACAAATATAGCTACAAGGTGTCA
GAGATGAAGGTGCGGCCCGCT**TAG**ACGGGGCCAGGACCCCTCCACATGCACCTGCTAGTGGGGAGGCC
ACACCCACAAGCGCTGCGTTCGTGGAAGTCACCCCATTTCCCCAGCCAGACACACTCCCATGACGCCC
ACAGTGCCCCCTTGCCCCCAGCTCAGTCAAGCCGCCACATG

The NOV26 protein (SEQ ID NO:99) encoded by SEQ ID NO:98 is 203 amino acid residues in length and is presented using the one-letter amino acid code in Table 26B. Psort analysis predicts the NOV26 protein of the invention to be localized extracellularly with a certainty of 0.4944. The Signal P predicts a likely cleavage site for a NOV26 peptide is between positions 22 and 23, *i.e.*, at the dash in the sequence AQA-AD.

Table 26B. Encoded NOV26 protein sequence (SEQ ID NO:99)

MARGLAVLLVLFLLHIKNLPAQAADTCPEVKVVGLEGSDKLTILRGCPGLPGAPGPKGEAGVIGER
GERGLPGAPGKAGPVGPKGDRGEKGMERGEKGDAGQSQSCATGPRNCKDLLDRGYFLSGWHTIYLP
DCRPLTVLCMDTDGGGWTVFQGAWWYADCHASNLNGLYLMGPHESEYANGINWSAAKGKYSYKYV
SEMKVRPA

A search against the Patp database, a proprietary database that contains sequences published in patents and patent publications, yielded several homologous proteins shown in Table 26C.

Table 26C. Patp results for NOV26

Sequences producing High-scoring Segment Pairs:	Reading Frame	High Score	Smallest Sum Prob P(N)
>patp:AAR94183 Human 35 kDa opsonin protein P35	+1	560	2.9e-78
>patp:AAR30971 TGF-beta-1 binding protein	+1	582	7.7e-78
>patp:AAR94179 Human 35 kDa opsonin P35 fragment (III)	+1	539	5.4e-75
>patp:AAB19732 Human SECX Clone 4437909.0.4	+1	200	9.7e-27
>patp:AAB19733 Human SECX Clone 4437909.0.55	+1	200	9.7e-27

In a BLAST search of public sequence databases, it was found, for example, that the nucleic acid sequence of this invention has 487 of 496 bases (98%) identical to a gb:GENBANK-ID:D83920|acc:D83920.1 mRNA from *Homo sapiens* (Human uterus mRNA for human ficolin-1, complete cds). The full amino acid sequence of the protein of the invention was found to have 152 of 152 amino acid residues (100%) identical to, and 152 of 152 amino acid residues (100%) similar to, the 319 amino acid residue ptmr:SPTREMBL-ACC:Q92596 protein from *Homo sapiens* (FICOLIN).

NOV26 also has homology to the proteins shown in the BLASTP data in Table 26D.

Table 26D. BLAST results for NOV26

Gene Index/ Identifier	Protein/ Organism	Length (aa)	Identity (%)	Positives (%)	Expect
gi 8051584 ref NP_001994.2 (NM_002003)	ficolin 1 precursor [<i>Homo sapiens</i>]	326	136/152 (89%)	136/152 (89%)	1e-72
gi 2135117 pir JC4942	ficolin-1 precursor - human	319	136/152 (89%)	136/152 (89%)	1e-72
gi 13124165 sp O00602	FCN1_HUMAN FICOLIN 1 PRECURSOR (COLLAGEN/FIBRINOGEN DOMAIN-CONTAINING PROTEIN 1) (FICOLIN-A) (FICOLIN A) (M-FICOLIN)	326	135/152 (88%)	135/152 (88%)	4e-72
gi 1669354 dbj BAA09707.1 (D63394)	P35-related protein [<i>Homo sapiens</i>]	187	129/152 (84%)	130/152 (84%)	2e-64
gi 423207 pir B47172	ficolin-beta - pig	326	109/152 (71%)	118/152 (76%)	1e-55

A multiple sequence alignment is given in Table 26E, with the NOV26 protein being shown on line 1 in Table 26E in a ClustalW analysis, and comparing the NOV26 protein with the related protein sequences shown in Table 26D. This BLASTP data is displayed graphically in the ClustalW in Table 26E.

Table 26E. ClustalW Analysis of NOV26

- 1) > NOV26; SEQ ID NO:99
- 2) > gi|8051584/ ficolin 1 precursor [*Homo sapiens*]; SEQ ID NO:293
- 3) > gi|2135117/ ficolin 1 precursor [*Homo sapiens*]; SEQ ID NO:294
- 4) > gi|1312416/ FCN1_Human Ficolin 1 precursor; SEQ ID NO:295
- 5) > gi|1669354/ P35-related protein [*Homo sapiens*]; SEQ ID NO:296
- 6) > gi|423207/ ficolin-beta [Pig]; SEQ ID NO:297

		10	20	30	40	50
NOV26	-----	MARGLAVLLVFLFLHIKNLPAQAADTCPEVKVVGLEGSDKLTIL			
gi 8051584	MELSGATMARGLAVLLVFLFLHIKNLPAQAADTCPEVKVVGLEGSDKLTIL					
gi 2135117	-----	MARGLAVLLVFLFLHIKNLPAQAADTCPEVKVVGLEGSDKLTIL				
gi 1312416	MELSGATMARGLAVLLVFLFLHIKNLPAQAADTCPEVKVVGLEGSDKLTIL					
gi 1669354	MELSGATMARGLAVLLVFLFLHIKNLPAQAADTCPEVKVVGLEGSDKLTIL					
gi 423207	MELSRVAVALGPTGQLLFLSFQTLAAQAADTCPEVKVVGLEGSDKLSIL					
		60	70	80	90	100
NOV26	RGCPGLPGAPGPKGEAGVIGERGERGLPGAPGKAGPVGPKGDRGEKGMRG					
gi 8051584	RGCPGLPGAPGPKGEAGVIGERGERGLPGAPGKAGPVGPKGDRGEKGMRG					
gi 2135117	RGCPGLPGAPGPKGEAGVIGERGERGLPGAPGKAGPVGPKGDRGEKGMRG					
gi 1312416	RGCPGLPGAPGPKGEAGVIGERGERGLPGAPGKAGPVGPKGDRGEKGMRG					

gi 1669354	RGCPGLPGAGPKGEAGVIGERGERGLPGAPGKAGPVGP-----
gi 423207	RGCPGLPGAAGPKGEAGANGPKGERGSPGVVGKAGPAGPKGDRGEKCARC
	110 120 130 140 150
NOV26	EKGDAGQSQSCATGPRNCKDLLDRGYFLSGWHTIYLPDCRPLTVLCDMDT
gi 8051584	EKGDAGQSQSCATGPRNCKDLLDRGYFLSGWHTIYLPDCRPLTVLCDMDT
gi 2135117	EKGDAGQSQSCATGPRNCKDLLDRGYFLSGWHTIYLPDCRPLTVLCDMDT
gi 1312416	EKGDAGQSQSCATGPRNCKDLLDRGYFLSGWHTIYLPDCRPLTVLCDMDT
gi 1669354	-KGDAGQSQSCATGPRNCKDLLDRGYFLSGWHTIYLPDCRPLTVLCDMDT
gi 423207	EKGEFGQLQSCATGPRITCKELLTRGHFLSGWHTIYLPDCQPLTVLCDMDT
	160 170 180 190 200
NOV26	DGGGWTVFQ-----
gi 8051584	DGGGWTVFQRRMDGSVDFYRDWAAYKQGFGSQLGEFWLGNDNIHALTAQG
gi 2135117	DGGGWTVFQRRMDGSVDFYRDWAAYKQGFGSQLGEFWLGNDNIHALTAQG
gi 1312416	DGGGWTVFQRRMDGSVDFYRDWAAYKQGFGSQLGEFWLGNDNIHALTAQG
gi 1669354	DGGGWTVFQ-----
gi 423207	DGGGWTVFQRRSDGSVDFYRDWAAYKRGFGSQLGEFWLGNDNIHALTAQG
	210 220 230 240 250
NOV26	-----
gi 8051584	SSELRVLDLDFEGNHQFAKYKSFKVADEAEKYKLVLCAFVGGSSACNSLTG
gi 2135117	SSELRVLDLDFEGNHQFAKYKSFKVADEAEKYKLVLCAFVGGSSACNSLTG
gi 1312416	SSELRVLDLDFEGNHQFAKYKSFKVADEAEKYKLVLCAFVGGSSACNSLTG
gi 1669354	-----
gi 423207	TSELRVLDLDFEGNHQFAKYRSFQVAGEAEKYKLVLCGFLEGNAGDSLSS
	260 270 280 290 300
NOV26	-----GAWWYADCHASNNG-LYLMGPHESS
gi 8051584	HNNNFFSTKDQDNDVSSSNCAEKFGQAWWYADCHASNNG-LYLMGPHESS
gi 2135117	HNNNFFSTKDQDNDVSSSNCAEKFGQAWWYADCHASNNG-LYLMGPHESS
gi 1312416	HNNNFFSTKDQDNDVSSSNCAEKFGQAWWYADCHASNNG-LYLMGPHESS
gi 1669354	-----RMDGSVDFYRDWAA
gi 423207	HRDQFFSTKDQDNDNHSNCAEQYHGAWWYNACHSSNLNG-RYLRCLHTS
	310 320
NOV26	YANGINWSAAKGKYSYKVSEMKVRPA
gi 8051584	YANGINWSAAKGKYSYKVSEMKVRPA
gi 2135117	YANGINWSAAKGKYSYKVSEMKVRPA
gi 1312416	YANGINWSAAKGKYSYKVSEMKVRPA
gi 1669354	YKQCFGSQLEFWLGNDNIHALTAQ--
gi 423207	YANGVNWRSRGYNYSYQVSEMKVRLT

The presence of identifiable domains in the protein disclosed herein was determined by searches using algorithms such as PROSITE, Blocks, Pfam, ProDomain, Prints and then determining the Interpro number by crossing the domain match (or numbers) using the Interpro website (<http://www.ebi.ac.uk/interpro/>). Table 26F lists the domain description from DOMAIN analysis results against NOV26.

Table 26F Domain Analysis of NOV26

Model	Region of Homology	Score (bits)	E value
Collagen triple helix repeat (20 copies)	43-101	44.1	1.6e-10
Fibrinogen beta and gamma chains, C-terminal globular domain	107-152	49.6	1.6e-14
Fibrinogen beta and gamma chains, C-terminal globular domain	153-203	50.8	7.5e-15

Consistent with other known members of the Fibrinogen family of proteins, *e.g.*, ficolin, NOV26 contains fibrinogen and collagen domains as illustrated in Table 25T (Ohashi and

Erickson, J. Biol. Chem., 272: 14220-6 (1997)). NOV26 nucleic acids, and the encoded polypeptides, according to the invention are useful in a variety of applications and contexts. For example, NOV26 nucleic acids and polypeptides can be used to identify proteins that are members of the Fibrinogen family of proteins. The NOV26 nucleic acids and polypeptides can also be used to screen for molecules, which inhibit or enhance NOV26 activity or function.

Specifically, the nucleic acids and polypeptides according to the invention may be used as targets for the identification of small molecules that modulate or inhibit, *e.g.*, cellular activation, cellular metabolism, host defense and signal transduction. These molecules can be used to treat, *e.g.*, arthritis, autoimmune disease, immunodeficiencies, anemia, ataxia-telangiectasia, hemophilia, emphysema, hypercoagulation, idiopathic thrombocytopenic purpura, graft versus host disease, endometriosis, fertility, systemic lupus erythematosus, asthma, emphysema, scleroderma, allergies, ARDS, hypercoagulation, as well as other diseases, disorders and conditions.

In addition, various NOV26 nucleic acids and polypeptides according to the invention are useful, *inter alia*, as novel members of the protein families according to the presence of domains and sequence relatedness to previously described proteins. For example, the NOV26 nucleic acids and their encoded polypeptides include structural motifs that are characteristic of proteins belonging to the ficolin family of proteins involved in cytokine and steroid physiology (Ohashi and Erickson, J. Biol. Chem., 272: 14220-6 (1997)).

Ficolin was originally isolated as a protein from pig uterus membrane extracts that bound transforming growth factor- (Ichijo *et al.*, J. Biol. Chem., 266: 22459-64 91991)). Ficolins have also been identified from human blood as a corticosteroid binding protein, termed hucolin (Edgar, FEBS Lett., 375: 159-61 (1995)), an elastin binding protein, termed EBP-37 (Harumiya

et al., J. Biochem., 117: 1029-35 (1995)), and a GlcNAc binding lectin, termed P35 (Matsushita *et al.*, J. Biol. Chem. 271: 2448-54 (1996)). Ficolin cDNAs, are termed human ficolin (Lu *et al.*, Biochem. J., 313: 473-8 (1996)), ficolin-1 (Harumiya *et al.*, J. Biochem., 120: 745-51 (1996)), and P35-related gene (Endo *et al.*, Genomics, 36: 515-21, (1996)) have been cloned.

5 The amino acid sequence of ficolins consist of a short N-terminal domain, a middle collagen-like domain, and a C-terminal fibrinogen-like (fbg)1 domain (Ohashi and Erickson, J. Biol. Chem., 272: 14220-6 (1997)). The collagen domains assemble these proteins into trimers, and electron microscopy shows that four or six trimers are connected together by the N-terminal domain, leaving the C-terminal lectin domains to project in a multimeric array (13-17). Like C1q
10 and collectins play roles in immune defense, ficolins have been implicated in a similar role, in that human plasma ficolin (P35) is a lectin that binds to the carbohydrate of bacterial surface (Lu *et al.*, Immunology, 89: 289-94 (1996)) and enhances opsonic activity of white blood cells, *e.g.*, polymorphonuclear neutrophils (Matsushita *et al.*, J. Biol. Chem., 271: 2448-54 (1996)). Ficolin may play a role in alleviating inflammation in joints and other sites of inflammation.

15 Protein therapeutics designed with the protein encoded for by NOV26 could function as an opsinin to target and eliminate bacteria by complement –mediated destruction. These proteins could be important for the treatment of bacterial septicemia. Ficolins may also have the ability to bind to elastins. Elastins are functionally important for lung alveolar development and inactivation of these proteins can lead to emphysema-like disease. Antibodies against NOV26
20 may prevent tissue destruction mediated by ficolin activity during emphysema, asthma and arthritis

 The NOV26 nucleic acids and polypeptides are useful for detecting specific cell types. For example, expression analysis has demonstrated that a NOV25 nucleic acid is expressed in peripheral blood leukocytes, uterus, spleen, lung, and thymus.

25 Additional utilities for NOV26 nucleic acids and polypeptides according to the invention are disclosed herein.

NOV27

A NOV27 polypeptide has been identified as a peroxisomal Ca-dependent solute carrier-like protein (also referred to as CG56262-01). The disclosed novel NOV27 nucleic acid (**SEQ ID NO:100**) of 1551 nucleotides is shown in Table 27A. An ORF begins with a Kozak consensus ATG initiation codon at nucleotides 108-110 and ends with a TGA codon at nucleotides 1512-1514. A putative untranslated region and/or downstream from the termination codon is underlined in Table 27A, and the start and stop codons are in bold letters. The novel NOV27 nucleic acid sequences maps to the chromosome 19.

Table 27A. NOV27 Nucleotide Sequence (SEQ ID NO:100)

GCGGCCGCGGGAGCTGACCCTGCGGGGTCCC GGGGGGGAGGGGGAGCCGCGAAGCCCCACTGAGG
 CCGCCGCTGCCGGGCCTCCCCTCCCCCGGGCGGGCGCCATGCGGGGGAGCCGGGGCGACGCGGAG
 CGGCGGCAGCGCTGGGGTCGCCTGTTTCGAGGAGCTGGACAGTAACAAGGATGGCCGCGTGGACGTGC
 ACGAGTTGCGCCAGGGGCTGGCCAGGCTGGGCGGGGGCAACCCAGACCCCGGCGCCCAACAGGGTAT
 CTCTCTGAGGGTGATGCTGACCCAGATGGCGGGCTCGACCTGGAGGAATTTTCCCGCTATCTGCAG
 GAGCGGGAACAGCGTCTGCTGCTCATGTTTCACAGTCTTGACCGGAACCAGGATGGTCACATTGATG
 TCTCTGAGATCCAACAGAGTTTCCGAGCTCTGGGCATTTCCATCTCGCTGGAGCAGGCTGAGAAAAT
 TTTGCACAGCATGGACCGAGACGGCACAATGACCATTGACTGGCAAGAATGGCGCGACCACTTCCTG
 TTGCATTGCTGGAAAATGTGGAGGACGTGCTGTATTTCTGGAAGCATTCACGGTCTTGGACATTG
 GCGAGTGCCTGACAGTGCCGGACGAGTTCTCAAAGCAAGAGAAGCTGACGGGCATGTGGTGGAACA
 GCTGGTGGCCGGCGCAGTGCCAGGTGCCGTGTACGGACAGGCACGGCCCCCTCTGGACCGCCTCAAG
 GTCTTCATTACAGTCCATGCCTCAAAGACCAACCGGCTGAACATCCTTGGGGGGCTTCGAAGCATGG
 TCCTTGAGGGAGGCATCCGCTGCCTGTGGCGCGGCAATGGTATTAATGTACTCAAGATTGCCCCCGA
 GTCAGCTATCAAGTTCATGGCCTATGAACAGGTGAGGAGGGCCATCCTGGGGCAGCAGGAGACACTG
 CATGTGCAGGAGCGCTTCGTGGCTGGCTCCCTGGCTGGTGCCACAGCCCAAACCATCATTACCTTA
 TGGAGGTGCTGAAGACGCGGCTGACCTTGCGCCGACGGGCCAGTATAAGGGGCTGCTGGACTGCGC
 CAGGCGTATCCTGGAGAGGGAGGGGCCCCGTGCCTTCTACGCGGCTACCTCCCCAACGTGCTGGGC
 ATCATCCCCTATGCGGGCATCGACCTGGCCGTCTACGAGGTCTGAAGAACTGGTGGCTTCAGCAGT
 ACAGCCACGACTCGGCAGACCCAGGCATCCTCGTGCTCCTGGCCTGCGGTACCATATCCAGCACCTG
 CGGCCAGATAGCCAGTTACCCGCTGGCCCTGGTCCGGACCCGCATGCAGGCACAAGCCTCCATCGAG
 GGTGGCCCCCAGCTGTCCATGCTGGGTCTGCTACGTACATCCTGTCCCAGGAGGGCATGCGGGGCC
 TCTACCGGGGGATCGCCCCCAACTTCATGAAGGTTATTCCAGCTGTGAGCATCTCCTATGTGGTCTA
 CGAGAACATGAAGCAGGCCTTGGGGGTACGTCCAGGT**GAGGG**ACCCGAGCCCGTCCCCCAATCC
 CTCACCCCCC

The NOV27 protein (**SEQ ID NO:101**) encoded by **SEQ ID NO:100** is 468 amino acid residues in length and is presented using the one-letter amino acid code in Table 27B. Psort analysis predicts the NOV27 protein of the invention to be localized in the cytoplasm with a certainty of 0.4500.

NOV27 has a SNP variant, whose variant position for its nucleotide and amino acid sequence is numbered according to **SEQ ID NOS:100 and 101**, respectively. A variant sequence can include a single nucleotide polymorphism (SNP). A SNP can, in some instances, be referred to as a "cSNP" to denote that the nucleotide sequence containing the SNP originates as a cDNA.

NOV27 has at least one variant. NOV27 variant 13376757 is a G to A SNP at 1529 bp of the nucleotide sequence that results in no change in the protein sequence since the SNP is not in the amino acid coding region.

Table 27B. Encoded NOV27 protein sequence (SEQ ID NO:101)

```
MRGSPGDAERRQRWGRLEELDSNKDGRVDVHELROGLARLGGGNPDPGAQQGISSEGDADPDGG
LDLEEFSSRYLQEREQRLLLLMFHSLDRNQDGHIDVSEIQQSFRALGISISLEQAEKILHSMRDRGT
MTIDWQEWDRDHFLHLSLENVEDVLYFWKHSTVLDIGECLTVPDEFKQEKLTGMWWKQLVAGAVA
GAVSRTGTAPLDRLKVFIQVHASKTNRLNILGGLRSMVLEGGIRCLWRGNGINVLKIAPESAIFK
MAYEQVRRAILGQOETLHVQERFVAGSLAGATAQTIIYPMEVLKTRLTTLRRTGQYKGLLDCARRI
LREGPRAFYRGYLPNVLGIIIPYAGIDLAVYEVLKNWWLQQYSHDSADPGILVLLACGTISSTCG
QIASYPLALVRTRMQAQASIEGGPQLSMLGLLRHILSQEGMRGLYRGIAPNFMKVI PAVSISYVV
YENMKQALGVTSR
```

A search against the Patp database, a proprietary database that contains sequences published in patents and patent publications, yielded several homologous proteins shown in Table 27C.

Table 27C. Patp results for NOV27

Sequences producing High-scoring Segment Pairs:	Reading Frame	High Score	Smallest Sum Prob P(N)
>patp:AAU27697 Human full-length polypeptide sequence #22	+1	2403	2.8e-249
>patp:AAU27869 Human contig polypeptide sequence #22	+1	2403	2.8e-249
>patp:AAM79077 Human protein	+1	1543	3.8e-158
>patp:AAV66718 Membrane-bound protein PRO1106	+1	1536	2.1e-157
>patp:AAB65241 Human PRO1106 (UNQ549)	+1	1536	2.1e-157

In a BLAST search of public sequence databases, it was found, for example, that the nucleic acid sequence of this invention has 886 of 1379 bases (64%) identical to a gb:GENBANK-ID:AF123303|acc:AF123303.1 mRNA from *Homo sapiens* (calcium-binding transporter mRNA, partial cds). The full amino acid sequence of the protein of the invention was found to have 280 of 461 amino acid residues (60%) identical to, and 365 of 461 amino acid residues (79%) similar to, the 475 amino acid residue ptnr:SPTREMBL-ACC:O18757 protein from *Oryctolagus cuniculus* (PEROXISOMAL CA-DEPENDENT SOLUTE CARRIER).

NOV27 also has homology to the proteins shown in the BLASTP data in Table 27D.

Table 27D. BLAST results for NOV27

Gene Index/ Identifier	Protein/ Organism	Length (aa)	Identity (%)	Positives (%)	Expect
gi 13430868 ref NP_077008.1 (NM 024103)	hypothetical protein MGC2615 [<i>Homo sapiens</i>]	482	392/454 (86%)	395/454 (86%)	0.0
gi 16549529 dbj BAB70825.1 (AK054901)	unnamed protein product [<i>Homo sapiens</i>]	384	379/384 (98%)	382/384 (98%)	0.0
gi 15620851 dbj BAB67789.1 (AB067483)	KIAA1896 protein [<i>Homo sapiens</i>]	568	298/480 (62%)	352/480 (73%)	1e-168
gi 11360341 pir T50686	peroxisomal Ca- dependent solute carrier [imported] [<i>Oryctolagus cuniculus</i>]	475	277/464 (59%)	358/464 (76%)	1e-165
gi 18043565 gb AAH19978.1 (BC019978)	Unknown (protein for MGC:28954) [<i>Mus musculus</i>]	366	261/365 (71%)	308/365 (83%)	1e-156

A multiple sequence alignment is given in Table 27E, with the NOV27 protein being shown on line 1 in Table 27E in a ClustalW analysis, and comparing the NOV27 protein with the related protein sequences shown in Table 27D. This BLASTP data is displayed graphically in the ClustalW in Table 27E.

Table 27E. ClustalW Analysis of NOV27

- 1) > NOV27; **SEQ ID NO:101**
- 2) > gi|1343086/ hypothetical protein MGC2615 [*Homo sapiens*]; **SEQ ID NO:298**
- 3) > gi|1654952/ unnamed protein product [*Homo sapiens*]; **SEQ ID NO:299**
- 4) > gi|1562085/ KIAA1896 protein [*Homo sapiens*]; **SEQ ID NO:300**
- 5) > gi|1136034/ peroxisomal Ca-dependent solute carrier [*Oryctolagus cuniculus*]; **SEQ ID NO:301**
- 6) > gi|1804356/ Unknown (protein for MGC:28954) [*Mus musculus*]; **SEQ ID NO:302**

		10	20	30	40	50
NOV27					
gi 1343086	-----					
gi 1654952	-----					
gi 1562085	SELLLRPGTTAVLAHLKKQETAPACRASSLRTPGQSSQQLCSQRALVLWS					
gi 1136034	-----					
gi 1804356	-----					
		60	70	80	90	100
NOV27					
gi 1343086	-----MRGSPGDAEROR-----					
gi 1654952	-----MRGSPGDAEROR-----					
gi 1562085	HPSKVNRSRHRRLLEETVMLQMLWHFLASFFPRAGCHGSREGDDREVRGTP					
gi 1136034	-----MLRWLRGFVLPTAACQGAEPPT-----					
gi 1804356	-----					

110 120 130 140 150
 NOV27 ---WGRLFEELEDSNKDGRVDVHELRLQGLARLGGGNPDPGAQQCISSEGLA
 gi|1343086 ---WGRLFEELEDSNKDGRVDVHELRLQGLARLGGGNPDPGAQQCISSEGLA
 gi|1654952 -----
 gi|1562085 APAWRDQMASFLGKQDGRAEATEKRPTILLVVG--PAEQFPKKIVQAGDK
 gi|1136034 ---YETLTFQALDRNGDGVVDIRELQEGLKSLGIP-LGQDAEEKIFTTGDV
 gi|1804356 -----
 160 170 180 190 200
 NOV27 DPDGGLDLEEFSSRYLQERERQLLLMFHSLDRNODGHIDVSEIQOSFRALG
 gi|1343086 DPDGGLDLEEFSSRYLQERERQLLLMFHSLDRNODGHIDVSEIQOSFRALG
 gi|1654952 -----MFHSLDRNODGHIDVSEIQOSFRALG
 gi|1562085 DLDGQLDLEEFVHYLQDHEKKLRLLVFKSLDKKNDGRIDAQEIWQSLRDLG
 gi|1136034 NKDGKLDLEEFMKYLLKDHKKMKLAKKSLDKKNDGKIEASEIVQSLQTLG
 gi|1804356 -----MQSLRDLG
 210 220 230 240 250
 NOV27 ISISLEQAEEKILHS-----MDRDGMTIDWQEWDRDHFLLHSLE
 gi|1343086 ISISLEQAEEKILHS-----MDRDGMTIDWQEWDRDHFLLHSLE
 gi|1654952 ISISLEQAEEKILHS-----MDRDGMTIDWQEWDRDHFLLHSLE
 gi|1562085 VKISEQQAEEKILKRIRTGHFWGPVYMDKNGTMTIDWNEWDRYHLLHPVE
 gi|1136034 LTISEQQAELILQS-----IDADGMTIDWNEWDRYFLFNPA
 gi|1804356 VKISEQQAEEKILK--S-----MDKNGTMTIDWNEWDRYHLLHPVE
 260 270 280 290 300
 NOV27 NVEDVLYFWKHST-----
 gi|1343086 NVEDVLYFWKHSTLSSAGFSAWIKDSTAEQNRSKTTVLARRSGSHLKSQH
 gi|1654952 NVEDVLYFWKHST-----
 gi|1562085 NIPEIILYWKHST-----
 gi|1136034 DIEEIRFWKHSTG-----
 gi|1804356 NIPEIILYWKHST-----
 310 320 330 340 350
 NOV27 -----VLDIGECLTVPDEFSSQEKLTGMWWKQLVAGAVAGAVSRT
 gi|1343086 FGRPKWADHEVDIGECLTVPDEFSSQEKLTGMWWKQLVAGAVAGAVSRT
 gi|1654952 -----VLDIGECLTVPDEFSSQEKLTGMWWKQLVAGAVAGAVSRT
 gi|1562085 -----IDVGENLTVPDEFTVBERQTGMWWRLVAGGAGAVSRT
 gi|1136034 -----IDIGDSLTIPTDEFTEERKSQWWRQLLAGGIAGAVSRT
 gi|1804356 -----IDVGENLTVPDEFTVBERQTGMWWRLVAGGAGAVSRT
 360 370 380 390 400
 NOV27 GTAPLDRLKVFIOVHASKTNRLNILGGLRSMVLEGGIRSLWRGNGINVLK
 gi|1343086 GTAPLDRLKVFIOVHASKTNRLNILGGLRSMVLEGGIRSLWRGNGINVLK
 gi|1654952 GTAPLDRLKVFIOVHASKTNRLNILGGLRSMVLEGGIRSLWRGNGINVLK
 gi|1562085 CTAPLDRLKVLMOVHASRSNNMGIVGFTOMIREGGARSLWRGNGINVLK
 gi|1136034 STAPLDRLKVLMOVHGSKS--MNIFGCFROMIREGGVRSLSWRGNGINVLK
 gi|1804356 CTAPLDRLKVLMOVHASRSNNMCIVGFTOMIREGGAKSLWRGNGINVLK
 410 420 430 440 450
 NOV27 IAPESAIFMAYEQVRRAILGQOETLHVQERFVAGSLAGATAQTIIYPME
 gi|1343086 IAPESAIFMAYEQIKRAILGQOETLHVQERFVAGSLAGATAQTIIYPME
 gi|1654952 IAPESAIFMAYEQIKRAILGQOETLHVQERFVAGSLAGATAQTIIYPME
 gi|1562085 IAPESAIFMAYEQIKRLVGSQOETLRIHERLVAGSLAGATAQSSIIYPME
 gi|1136034 IAPETAIVKFWVYEQYKLLTEEGQKIGTFERFISGSMAGATAQTIIYPME
 gi|1804356 IAPESAIFMAYEQMKRLVGSQOETLRIHERLVAGSLAGATAQSSIIYPME

```

5          460      470      480      490      500
NOV27      . . . . . | . . . . . | . . . . . | . . . . . | . . . . .
gi|1343086 VLKTRLTLRRRTGQYKGLLDLCARRILEREGPRAFYRGYLPNVLGIIPIYAGI
gi|1654952 VLKTRLTLRRRTGQYKGLLDLCARRILEREGPRAFYRGYLPNVLGIIPIYAGI
gi|1562085 VLKTRMALRKRTGQYSGMLDCARRILAREGVAAAFYKGYVPNMLGIIPIYAGI
gi|1136034 VMKTRLAVGKTGQYSGIYDCAKKILKYEGFGAFYKGYVPNMLGIIPIYAGI
gi|1804356 VLKTRMALRKRTGQYSGMLDCARRILAREGVAAAFYKGYIPNMLGIIPIYAGI

10          510      520      530      540      550
NOV27      . . . . . | . . . . . | . . . . . | . . . . . | . . . . .
gi|1343086 DLAVYEVLNKNWNLQOYSHDSADPGILVLLACGTISSTCGQIASYPLALVR
gi|1654952 DLAVYETLNKNWNLQOYSHDSADPGILVLLACGTISSTCGQIASYPLALVR
gi|1562085 DLAVYETLNKNWNLQOYSHDSADPGILVLLACGTISSTCGQIASYPLALVR
gi|1136034 DLAVYETLNKNWNLQOYSHDSADPGILVLLACGTISSTCGQIASYPLALVR
gi|1804356 DLAVYETLNKNWNLQOYSHDSADPGILVLLACGTISSTCGQIASYPLALVR

15          560      570      580      590      600
NOV27      . . . . . | . . . . . | . . . . . | . . . . . | . . . . .
gi|1343086 TRMQAQASIEGGEQLSMLGLLRHILSQEGMRGLYRGIIAPNFMKVIPAVSI
gi|1654952 TRMQAQAG-----WSTVARFQITATSAFQV
gi|1562085 TRMQAQASIEGGEQLSMLGLLRHILSQEGMRGLYRGIIAPNFMKVIPAVSI
gi|1136034 TRMQAQASIEGAEVITMSSIFKHILRTEGAFGLYRGIIAPNFMKVIPAVSI
gi|1804356 TRMQAQAMLEGAPEQLNMVCLFRRIISKEGLPGLYRGITPNFMKVLPAVGI
TRMQAQASIEGAEVITMSSIFKQILRTEGAFGLYRGIIAPNFMKVIPAVSI

20          610
NOV27      . . . . . | . . . . . | . . . . .
gi|1343086 SYVYENMKQALGVTSR
gi|1654952 QAILLPQPPE-----
gi|1562085 SYVYENMKQALGVTSR
gi|1136034 SYVYENLKITLGVSQR
gi|1804356 SYVYENLKITLGVSQR

```

The presence of identifiable domains in the protein disclosed herein was determined by searches using algorithms such as PROSITE, Blocks, Pfam, ProDomain, Prints and then determining the Interpro number by crossing the domain match (or numbers) using the Interpro website (<http://www.ebi.ac.uk/interpro/>). Table 27F lists the domain description from DOMAIN analysis results against NOV27.

Table 27F Domain Analysis of NOV27			
Model	Region of Homology	Score (bits)	E value
EF hand	13-41	28.0	1.1e-05
EF hand	81-109	22.4	0.00055
Poly A polymerase regulatory subunit	103-111	1.3	0.94
EF hand	117-145	12.6	0.072
Mitochondrial carrier protein	184-276	93.5	2.1e-25
Mitochondrial carrier protein	278-369	120.1	2.2e-33
Mitochondrial	375-468	90.7	1.5e-24

carrier protein			
-----------------	--	--	--

Consistent with other known members of the mitochondrial carrier proteins, e.g., peroxisomal Ca-dependent solute carrier family of proteins, NOV27 contains EF hand calcium binding domains and mitochondrial carrier transport signature domains as illustrated in Table 27F. NOV27 nucleic acids, and the encoded polypeptides, according to the invention are useful in a variety of applications and contexts. For example, NOV27 nucleic acids and polypeptides can be used to identify proteins that are members of the peroxisomal Ca-dependent solute carrier family of proteins. The NOV27 nucleic acids and polypeptides can also be used to screen for molecules, which inhibit or enhance NOV27 activity or function. Specifically, the NOV27 nucleic acids and polypeptides according to the invention may be used as targets for the identification of small molecules that modulate or inhibit, e.g., transport facilitation. These molecules can be used to treat, e.g., cancer, trauma, regeneration (*in vitro* and *in vivo*), viral/bacterial/parasitic infections, atherosclerosis, aneurysm, hypertension, fibromuscular dysplasia, stroke, scleroderma, obesity, Von Hippel-Lindau (VHL) syndrome, Alzheimer's disease, stroke, tuberous sclerosis, hypercalcaemia, Parkinson's disease, Huntington's disease, cerebral palsy, epilepsy, Lesch-Nyhan syndrome, multiple sclerosis, ataxia-telangiectasia, leukodystrophies, behavioral disorders, addiction, anxiety, pain, diabetes, autoimmune disease, renal artery stenosis, interstitial nephritis, glomerulonephritis, polycystic kidney disease, systemic lupus erythematosus, renal tubular acidosis, IgA nephropathy, hypercalcaemia, muscular dystrophy, Lesch-Nyhan syndrome, myasthenia gravis and other diseases, disorders and conditions of the like.

In addition, various NOV27 nucleic acids and polypeptides according to the invention are useful, *inter alia*, as novel members of the protein families according to the presence of domains and sequence relatedness to previously described proteins. For example, the NOV27 nucleic acids and their encoded polypeptides include structural motifs and homology that are characteristic of proteins belonging to the family of mitochondrial carrier proteins such as the peroxisomal Ca-dependent solute carrier proteins.

Many calcium-binding proteins belong to the same evolutionary family and share a type of calcium-binding domain known as the EF-hand. This type of domain consists of a twelve residue loop flanked on both side by a twelve residue alpha-helical domain. Different types of substrate carrier proteins involved in energy transfer are found in the inner mitochondrial

membrane such as the ADP, ATP carrier protein (AAC) (ADP/ATP translocase), the 2-oxoglutarate/malate carrier protein (OGCP), the phosphate carrier protein, which transports phosphate groups from the cytosol into the mitochondrial matrix all share a common carrier protein motif. NOV27 also resembles the peroxisomal Ca-dependent solute carrier from rabbit.

- 5 Although the Psort suggests that this is a cytosolic protein rather than mitochondrial, it is hypothesized that it might function in the uncoupling of ATP translocation and play a role in metabolic disease.

The NOV27 nucleic acids and polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications for the treatment of
10 metabolic disorders. As such the NOV27 nucleic acids and polypeptides, antibodies and related compounds according to the invention may be used to treat metabolic disorders, *e.g.*, cancer, trauma, regeneration (*in vitro* and *in vivo*), viral/bacterial/parasitic infections, atherosclerosis, aneurysm, hypertension, fibromuscular dysplasia, stroke, scleroderma, obesity, Von Hippel-Lindau (VHL) syndrome, Alzheimer's disease, stroke, tuberous sclerosis, hypercalcaemia,
15 Parkinson's disease, Huntington's disease, cerebral palsy, epilepsy, Lesch-Nyhan syndrome, multiple sclerosis, ataxia-telangiectasia, leukodystrophies, behavioral disorders, addiction, anxiety, pain, diabetes, autoimmune disease, renal artery stenosis, interstitial nephritis, glomerulonephritis, polycystic kidney disease, systemic lupus erythematosus, renal tubular acidosis, IgA nephropathy, hypercalcaemia, muscular dystrophy, Lesch-Nyhan syndrome, and
20 myasthenia gravis.

The NOV27 nucleic acids and polypeptides are useful for detecting specific cell types. For example, expression analysis has demonstrated that a NOV27 nucleic acid is expressed in Adrenal Gland/Suprarenal gland, Amygdala, Aorta, Brain, Bronchus, Cerebral Medulla/Cerebral white matter, Cervix, Coronary Artery, Frontal Lobe, Heart, Kidney, Liver, Lung, Mammary
25 gland/Breast, Ovary, Oviduct/Uterine Tube/Fallopian tube, Parietal Lobe, Peripheral Blood, Pituitary Gland, Prostate, Retina, Skeletal Muscle, Spinal Chord, Spleen, Substantia Nigra, Temporal Lobe, Testis, Thalamus, Thymus, Thyroid, and Vein .

Additional utilities for NOV27 nucleic acids and polypeptides according to the invention are disclosed herein.

NOV28

A NOV28 polypeptide has been identified as a Sodium-glucose cotransporter (SGLT)-like protein (also referred to as CG56559-01). The disclosed novel NOV28 nucleic acid (**SEQ ID NO:102**) of 1900 nucleotides is shown in Table 28A. The novel NOV28 nucleic acid sequences maps to the chromosome 17.

An ORF begins with a Kozak consensus ATG initiation codon at nucleotides 51-53 and ends with a TGA codon at nucleotides 1851-1853. A putative untranslated region and/or downstream from the termination codon is underlined in Table 28A, and the start and stop codons are in bold letters.

Table 28A. NOV28 Nucleotide Sequence (SEQ ID NO:102)

TTGCCCTCAGTCCCTCGGGCTCATACCTAGTGCCTGCGGCAGGACAGCC**ATGGCCGCCAACTCCAC**
CAGCGACCTCCACACTCCCGGGACGCAGCTGAGCGTGGCTGACATCATCGTCATCACTGTGTATTTT
GCTCTGAACGTGGCCGTGGGCATATGGTCTCTTGTGCGGGCCAGTAGGAACACGGTGAATGGCTACT
TCCTGGCAGGCCGGGACATGACGTGGTGGCCGATTGGAGCCTCCCTCTTCGCCAGCAGCGAGGGCTC
TGGCCTCTTCATTGGACTGGCGGGCTCAGGCGCGGCAGGAGGTCTGGCCGTGGCAGGCTTCGAGTGG
AATGCCACGTACGTGCTGCTGGCACTGGCATGGGTGTTTCGTGCCCATCTACATCTCCTCAGAGATCG
TCACCTTACCTGAGTACATTGAGAAGCGCTACGGGGGCCAGCGGATCCGCATGTACCTGTCTGTCTCT
GTCCCTGCTACTGTCTGTCTTCACCAAGATATCGGCCCTGGACCTGTACGCGGGGGCTCTGTTTGTG
CACATCTGCCTGGGCTGGAACCTTCTACCTCTCCACCATCTCAGCTCGGCATCACAGCCCTGTACA
CCATCGCAGGTACTGGCGGCCCTGGCTGCTGTAATCTACACGGACGCCCTGCAGACGCTCATCATGGT
GGTGGGGGCTGTATCTCTGACAATCAAAGCTTTTGACCAGATCGGTGGTTACGGGCAGCTGGAGGCA
GCCTACGCCCAGGCCATTCCCTCCAGGACCATTGCCAACACCACCTGCCACCTGCCACGTACAGACG
CCATGCACATGTTTTCGAGACCCCCACACAGGGGACCTGCCGTGGACCGGGATGACCTTTGGCCTGAC
CATCATGGCCACCTGGTACTGGTGCACCGACCAGGTGATCGTGCAGCGATCACTGTGAGCCCGGGAC
CTGAACCATGCCAAGGCGGGCTCCATCCTGGCCAGCTACCTCAAGATGCTCCCCATGGGCCTGATCA
TCATGCCGGGCATGATCAGCCGCGCATTGTTCCAGATGATGTGGGCTGCGTGGTGCCGTCCGAGTG
CCTGCGGGCCTGCGGGGCCGAGGTGCGCTGCTCCAACATCGCCTACCCCAAGCTGGTCATGGAAGT
ATGCCCATCGGTCTGCGGGGGCTGATGATCGCAGTGATGTGGCGGCGCTCATGTGCTGCTGACCT
CCATCTTCAACAGCAGCAGCACCTCTTCACTATGGACATCTGGAGGCGGCTGCGTCCCCGCTCCGG
CGAGCGGGAGCTCCTGCTGGTGGGACGGTTGGTCATAGTGGCACTCATCGGCGTGAGTGTGGCCTGG
ATCCCCGTCCTGCAGGACTCCAACAGCGGGCAACTCTTCATCTACATGCAGTCAGTGACCAGCTCCC
TGGCCCCACCAAGTGAAGTGCAGTCTTTGTCTGGGCGTCTTCTGGCGACGTGCCAACGAGCAGCAGGG
GGCCTTCTGGGGCCTGATAGCAGGGCTGGTGGTGGGGGCCACGAGGCTGGTCCTGGAATTCTGAAC
CCAGCCCCACCGTGCGGAGAGCCAGACACGCGCCAGCCGTCTTGGGGAGCATCCACTACCTGCACT
TCGCTGTGCGCCCTCTTGTCACTCAGTGGTGTCTTGTGGTGGCTGGAAGCCTGCTGACCCACCCCC
ACAGAGTGTCCAGATTGAGAACCCTTACCTGGTGGACCTGGCTCAGGATGTGCCCTTGGGAACATAA
GCAGGTGATGGCCAAACACCCAGAAACACGCCTTCTGGGCGCGTGTCTGTGGCTTCAATGCCATCC
TCCTCATGTGTGTCAACATATTCTTTTATGCCTACTTCGCCTG**ACTG**CCATCCTGGACAGAAAGG
CAGGAGCTCTGAGTCCTCAGGTCC

The NOV28 protein (**SEQ ID NO:103**) encoded by **SEQ ID NO:102** is 600 amino acid residues in length and is presented using the one-letter amino acid code in Table 28B. NOV28 has at least five SNP variants, whose variant positions for its nucleotides and amino acids sequences is numbered according to **SEQ ID NOS:102 and 103**, respectively. A variant

sequence can include a single nucleotide polymorphism (SNP). A SNP can, in some instances, be referred to as a "cSNP" to denote that the nucleotide sequence containing the SNP originates as a cDNA.

NOV28 variant 13376762 is an A to T SNP at 158 bp of the nucleotide sequence that results in no change in the protein sequence (silent), variant 13376761 is a C to T SNP at 491 bp of the nucleotide sequence that results in no change in the protein sequence (silent), variant 13376760 is a T to C SNP at 565 bp of the nucleotide sequence that results in a Leu to Pro change at amino acid 172 of protein sequence, variant 13376759 is a C to T SNP at 867 bp of the nucleotide sequence that results in no change in the protein sequence (silent), and variant 13376758 is a C to T SNP at 1762 bp of the nucleotide sequence that results in a Pro to Leu change at amino acid 571 of protein sequence.

Psort analysis predicts the NOV28 protein of the invention to be localized to the plasma membrane with a certainty of 0.8200. The Signal P predicts a likely cleavage site for a NOV28 peptide is between positions 42 and 43, *i.e.*, at the dash in the sequence CRA-SR.

Table 28B. Encoded NOV28 protein sequence (SEQ ID NO:103)

```
MAANSTSDLHTPGTQLSVADIIVITVYFALNVAVGWSSCRASRNTVNGYFLAGRDMTWWPIGASLFASSEGS
GLFIGLAGSGAAGGLAVAGFEWNATYVLLALAWVFVPIYISSEIVTLPEYIQKRYGGQIRMYLSVLSLLLSV
FTKISALDLYAGALFVHICLGWNFYLSITLTLGITALYTIAGTGGLAAVIYTDALQTLIMVVGAVILTIKAFD
QIGGYGQLEAAYAQAIPSRITANTTCHLPRTDAMHMRDPHTGDLPTGTMFGLTIMATWYWCTDQVIVQRS
SARDLNHAKAGSILASYLKMLPMGLIIMPGMISRALFPDDVGCVPVSECLRACGAEVGCSNIAYPKLVMEIMP
IGLRGLMIAVMLAALMSSLTSIFNSSSTLFTMDIWRRLRPRSGERELLLVGRLLVIVALIGVSVAWIPVLQDSN
SGQLFIYMQSVTSSLAPPVTAFFVLGVFWRRANEQQGAFWGLIAGLVVGATRLVLEFLNPAPPCGEPDTRPAV
LGSIHYLHFAVALFALSGAVVAGSLLTPPPQSVQIENLTWWTLAQDVPLGKAGDGQTPQKHAFWARVCGFN
AILLMCVNIFFYAYFA
```

A search against the Patp database, a proprietary database that contains sequences published in patents and patent publications, yielded several homologous proteins shown in Table 28C.

Table 28C. Patp results for NOV28

Sequences producing High-scoring Segment Pairs:	Reading Frame	High Score	Smallest Sum Prob P(N)
>patp:AAE06614 Human protein	+1	3051	6.1e-318
>patp:AAE08088 Human transporter-related protein #35	+1	3051	6.1e-318
>patp:AAR73595 Cotransporter protein SGLT1	+1	1669	5.2e-177
>patp:AAR73593 Cotransporter protein SNST1	+1	1655	4.2e-175
>patp:AAB60093 Human transport protein TPPT-13	+1	1622	3.1e-168

In a BLAST search of public sequence databases, it was found, for example, that the nucleic acid sequence of this invention has 1451 of 1839 bases (78%) identical to a gb:GENBANK-ID:OCU08813|acc:U08813.1 mRNA from *Oryctolagus cuniculus* (Na⁺/glucose cotransporter-related protein mRNA, complete cds). NOV28 polypeptide of the invention was found to have 532 of 600 amino acid residues (88%) identical to, and 560 of 600 amino acid residues (93%) similar to, the 597 amino acid residue ptrn:SPTREMBL-ACC:Q28610 protein from *Oryctolagus cuniculus* (NA⁺/GLUCOSE COTRANSPORTER-RELATED PROTEIN).

NOV28 also has homology to the proteins shown in the BLASTP data in Table 28D.

Table 28D. BLAST results for NOV28					
Gene Index/ Identifier	Protein/ Organism	Length (aa)	Identity (%)	Positives (%)	Expect
gi 520469 gb AAA660 65.1 (U08813)	597 aa protein related to Na/glucose cotransporters [<i>Oryctolagus cuniculus</i>]	597	486/600 (81%)	513/600 (85%)	0.0
gi 16553933 dbj BAB 71619.1 (AK057946)	unnamed protein product [<i>Homo sapiens</i>]	517	425/459 (92%)	425/459 (92%)	0.0
gi 9588428 emb CAC0 0574.1 (AL109659)	dJ1024N4.1 (novel Sodium:solute symporter family member similar to SLC5A1 (SGLT1)) [<i>Homo sapiens</i>]	552	303/526 (57%)	380/526 (71%)	1e-159
gi 631592 pir S488 57	glucose transport protein - sheep	664	275/541 (50%)	370/541 (67%)	1e-152
gi 1709219 sp P5379 1	SL51_SHEEP SODIUM/GLUCOSE COTRANSPORTER 1 (NA(+)/GLUCOSE COTRANSPORTER 1) (HIGH AFFINITY SODIUM-GLUCOSE COTRANSPORTER)	664	275/541 (50%)	371/541 (67%)	1e-151

A multiple sequence alignment is given in Table 28E, with the NOV28 protein being shown on line 1 in Table 28E in a ClustalW analysis, and comparing the NOV28 protein with the

related protein sequences shown in Table 28D. This BLASTP data is displayed graphically in the ClustalW in Table 28E.

Table 28E. ClustalW Analysis of NOV28

- 1) > NOV28; **SEQ ID NO:103**
5 2) > gi|520469| 597 aa protein related to Na/glucose cotransporters [*Oryctolagus cuniculus*]; **SEQ ID NO:303**
3) > gi|1655393|unnamed protein product [*Homo sapiens*]; **SEQ ID NO:304**
4) > gi|9588428| dJ1024N4.1 (novel Sodium:solute symporter family member similar to SLC5A1 (SGLT1) [*Homo sapiens*]; **SEQ ID NO:305**
10 5) > gi|631592| glucose transport protein [sheep]; **SEQ ID NO:306**
6) > gi|1709219| SL51_sheep sodium/glucose cotransporter 1 Na⁺/glucose cotransporter 1) (high affinity sodium-glucose cotransporter); **SEQ ID NO:307**

15		10	20	30	40	50
	NOV28	MAANSTSDLHTPGTQLS--VADITIVITVYFALNVAVGIWSSC			
	gi 520469	----- ----- ----- ----- ----- ----- -----	MVADNSTSDPHAPGPQLS--VTDIVVITVYFALNVAVGIWSSC			
	gi 1655393	----- ----- ----- ----- ----- ----- -----	MPRTCCWHWH----- ----- ----- ----- ----- -----			
20	gi 9588428	MGPASGDGVRTETAPHIALDSRVGLHAYDISVVIYFVFVIAVGIWSSI				
	gi 631592	MDS-STLSPPAIDTAEPQAYERIR-NAADISVIVYFVVVMAVGLWHMF				
	gi 1709219	MDS-STWSPPATATAEPQAYERIR-NAADISVIVYFVVVMAVGLWAMF				
25		60	70	80	90	100
	NOV28	RASRNTVNGYFLAGRDMTWWPIGASLEFASSEGSGLEIFGLAGSGAAGGLAV			
	gi 520469	RASRNTVSGYFLAGRDMTWWPIGASLEFSGSEGSGLEIFGLAGSGAAGGLAV			
	gi 1655393	PS---TS----- ----- ----- ----- ----- -----	PQRSSPYLSTFRS--ATGASGS-ACTCLSC			
	gi 9588428	RASRGTIGCYFLAGRSMVWVPIGASLMSSNVGSGLEIFGLAGTGAAGGLAV				
	gi 631592	STNRGTVGGEFFLAGRSMVWVPIGASLEFASNIGSGHEFVGLAGTGAAGGIAT				
	gi 1709219	STNRGTVGGEFFLAGRSMVWVPIGASLEFASNIGSGHEFVGLAGTGAAGGIAT				
30		110	120	130	140	150
	NOV28	AGFEWNATYVLLALAWVFVPIYISSEIVTLPEYIQKRYGGQRIRMVLSVL			
	gi 520469	AGFDWNATYVLLALAWVFVPIYISSEIVTLAEYIQKRFGGQRIRMVLSVL			
	gi 1655393	P----- ----- ----- ----- ----- -----	---CYCLS--S----- ----- ----- ----- -----			
	gi 9588428	GGFEWNATWLLALGWVFVPIYIAAGVVTMPQYLRKRFGGQRIQVYMSVL				
	gi 631592	GGFEWNALILVLLGWVFVPIYIKAGVVTMPYLRKRFGGQRIQVYLSVL				
	gi 1709219	GGFEWNALILVLLGWVFVPIYIKAGVVTMPYLRKRFGGQRIQVYLSVL				
35		160	170	180	190	200
	NOV28	SLLLSVFTKISALDLYAGALEVHICLGWNFYLSLTILTLGITALYTTIAGTG			
	gi 520469	SLLLSVFTKIS-LDLYAGALEVHICLGWNFYLSLTILTLGITALYTTITG--			
	gi 1655393	----- ----- ----- ----- ----- ----- -----	WTCTR----- ----- ----- ----- ----- -----			
	gi 9588428	SLLLYIFTKIS-TDIFSGALEIQMALGWNLYLSTGILLVVTAVYTTIAG--				
	gi 631592	SLVLYIFTKIS-ADIFSGAIFINLALGLDLYLAIFILLAITALYTTITG--				
	gi 1709219	SLVLYIFTKIS-ADIFSGAIFINLALGLDLYLAIFILLAITALYTTITG--				
40		210	220	230	240	250
	NOV28	GLAAVIYTDALQTLIMVVGAVILTIFAFDQICGGYGQLEAAYAQAIPSRITI			
	gi 520469	GLVAVIYTDALQTLIMVVGAVILAIKAFHQIDGYGQMEAAAYARAIPSRTIV			
	gi 1655393	GLAAVIYTDALQTLIMVVGAVILTIFAFDQICGGYGQLEAAYAQAIPSRITI				
	gi 9588428	GLMAVIYTDALQTVIMVGGALVLMFLGFQDVGWYPGLEQRYRQAIPNVTV				
	gi 631592	GLAAVIYTDTLQTVIMLLGSFILTGFAPHEVGGYSAFVTKYMNNAIPTVTS				
45		210	220	230	240	250
	NOV28	GLAAVIYTDALQTLIMVVGAVILTIFAFDQICGGYGQLEAAYAQAIPSRITI			
	gi 520469	GLVAVIYTDALQTLIMVVGAVILAIKAFHQIDGYGQMEAAAYARAIPSRTIV			
	gi 1655393	GLAAVIYTDALQTLIMVVGAVILTIFAFDQICGGYGQLEAAYAQAIPSRITI				
	gi 9588428	GLMAVIYTDALQTVIMVGGALVLMFLGFQDVGWYPGLEQRYRQAIPNVTV				
	gi 631592	GLAAVIYTDTLQTVIMLLGSFILTGFAPHEVGGYSAFVTKYMNNAIPTVTS				
50		210	220	230	240	250
	NOV28	GLAAVIYTDALQTLIMVVGAVILTIFAFDQICGGYGQLEAAYAQAIPSRITI			
	gi 520469	GLVAVIYTDALQTLIMVVGAVILAIKAFHQIDGYGQMEAAAYARAIPSRTIV			
	gi 1655393	GLAAVIYTDALQTLIMVVGAVILTIFAFDQICGGYGQLEAAYAQAIPSRITI				
	gi 9588428	GLMAVIYTDALQTVIMVGGALVLMFLGFQDVGWYPGLEQRYRQAIPNVTV				
	gi 631592	GLAAVIYTDTLQTVIMLLGSFILTGFAPHEVGGYSAFVTKYMNNAIPTVTS				
55		210	220	230	240	250
	NOV28	GLAAVIYTDALQTLIMVVGAVILTIFAFDQICGGYGQLEAAYAQAIPSRITI			
	gi 520469	GLVAVIYTDALQTLIMVVGAVILAIKAFHQIDGYGQMEAAAYARAIPSRTIV			
	gi 1655393	GLAAVIYTDALQTLIMVVGAVILTIFAFDQICGGYGQLEAAYAQAIPSRITI				
	gi 9588428	GLMAVIYTDALQTVIMVGGALVLMFLGFQDVGWYPGLEQRYRQAIPNVTV				
	gi 631592	GLAAVIYTDTLQTVIMLLGSFILTGFAPHEVGGYSAFVTKYMNNAIPTVTS				

```

gi|1709219 GLAAVIYTDLQTVIMLLGSFILTGFHFHEVGGYSAFVTKYMNAIPTVLS
      260      270      280      290      300
5  NOV28 ANTT-----CHLPRTDAMHMFDRDPHTGDLPTGCMTFGLTIMATWYWCTDQ
   gi|520469| ANTT-----CHLPRADAMHMFDRPYTGDLPTGCMTFGLTIMATWYWCTDQ
   gi|1655393| ANTT-----CHLPRTDAMHMFDRDPHTGDLPTGCMTFGLTIMATWYWCTDQ
   gi|9588428| PNTT-----CHLPRPDADFHLRDPVSGDIPWPGLIFGLTIVLATWCWCTDQ
   gi|631592| YGNTITVKKECYTPRADSFHIFRDPLKGDLPWPGLIFGLTIISLWYWCTDQ
   gi|1709219 YGNTITVKKECYTPRADSFHIFRDPLKGDLPWPGLIFGLTIISLWYWCTDQ
      310      320      330      340      350
15 NOV28 VIVQRSLSARDLNHAKAGSILASYLKMLPMGLIIMPGMISRALFP-----
   gi|520469| VIVQRSLSARNLNHAKAGSILASYLKMLPMGLIIMPGMISRALFP-----
   gi|1655393| VIVQRSLSARDLNHAKAGSILASYLKMLPMGLIIMPGMISRALFPGAHVY
   gi|9588428| VIVQRSLSAKSLSHAKGGSVLGGYLKILPMFFIVMPGMISRALFP-----
   gi|631592| VIVQRCLSAKNMSHVKAGCIMCGYMKLLPMFLMVMPGMISRILFT-----
   gi|1709219 VIVQRCLSAKNMSHVKAGCIMCGYMKLLPMFLMVMPGMISRILFT-----
      360      370      380      390      400
20 NOV28 -----DDVGCVPSECLRACGAEVGCSNIAYPKLVMELMPIGLR
   gi|520469| -----DEVGCVVPSECLRACGAEIGCSNIAYPKLVMELMPVGLR
   gi|1655393| EERHQVSVSRTDDVGCVPSECLRACGAEVGCSNIAYPKLVMELMPIGLR
   gi|9588428| -----DEVGCVDPDVCQRTCGARVGCNIAYPKLVMALMPVGLR
   gi|631592| -----EKVACTVPSECEKYCGTKVGCTNIAYPTLVVELMPNGLR
   gi|1709219 -----EKVACTVPSECEKYCGTKVGCTNIAYPTLVVELMPNGLR
      410      420      430      440      450
25 NOV28 GLMIAVMLAALMSSSLTSIFNSSSTLFTMDIWRRLRPRSGERELLVGRVLV
   gi|520469| GLMIAVMPALMSSSLTSIFNSSSTLFTMDIWRRLRPCASERELLVGRVLV
   gi|1655393| GLMIAVMLAALMSSSLTSIFNSSSTLFTMDIWRRLRPRSGERELLVGRVLV
   gi|9588428| GLMIAVMAALMSSSLTSIFNSSSTLFTIDVWQRFRRKSTEQELMVVGRVF
   gi|631592| GLMLSVMLASLMSSSLTSIFNSASTLFTMDIYTKIRKKASEKELMIAGRIF
   gi|1709219 GLMLSVMLASLMSSSLTSIFNSASTLFTMDIYTKIRKKASEKELMIAGRIF
      460      470      480      490      500
30 NOV28 IVALIGVSVAVIPVLQDSNSGQLFIYMQSVTSSLAPPVTAFFVLGVFWRR
   gi|520469| IVVLIGVSVAVIPVLQDSNSGQLFIYMQSVTSSLAPPVTAFFLGLFWQR
   gi|1655393| IVALIGVSVAVIPVLQDSNSGQLFIYMQSVTSSLAPPVTAFFVLGVFWRR
   gi|9588428| VVFLVVISIILWIPITIQSSNSGQLFDYICAVTSYLAPPITALFLLAIFCKR
   gi|631592| MLVLIGVSIWVPIVQSAQSGQLFDYIQSITSYLGPPIAAVFLLAIFCKR
   gi|1709219 MLVLIGVSIWVPIVQSAQSGQLFDYIQSITSYLGPPIAAVFLLAIFCKR
      510      520      530      540      550
35 NOV28 ANEQQGAFWGLIAGLVVGCATRLVLEFLNPAPPCEPDTRPAVLGSIHYLH
   gi|520469| ANEQ-GAFWGLLAGLVAVGCATRLVLEFLHPAPPCCAADTRPAVLSQLHYLH
   gi|1655393| ANEQ-GAFWGLIAGLVVGCATRLVLEFLNPAPPCEPDTRPAVLGSIHYLH
   gi|9588428| VTEP-GAFWGLVFGVLGVCLLRMILEFSYPAPACGEVDRRPAVLKDFHYLY
   gi|631592| VNEP-GAFWGLIIGFLICVSRMITEFAYGTGSCMEFSNCPTIICGVHYLY
   gi|1709219 VNEP-GAFWGLIIGFLICVSRMITEFAYGTGSCMEFSNCPTIICGVHYLY
      560      570      580      590      600
40 NOV28 FAVALFALSGAVVAGSLLTPPPQSVQIENLTWWT---LAQDVPLGTKAG
   gi|520469| FAVALFVLTGAVAVGGSLLTPPPRRHQIENLTWWT---LTRDLSLGAKAG
   gi|1655393| FAVALFALSGAVVAGSLLTPPPQSVQIENLTWWT---LAQDVPLGTKAG
   gi|9588428| FAILLCGLTAIVIVIVSLCTPIPEEQ-----
   gi|631592| FAILLFVITIIIVILAISLFTKPIADVHLRYRLCWSLRNSKEERIDDAEDE

```


105587 "042302
sodium:solute symporter family of proteins. The NOV28 nucleic acids and polypeptides can also be used to screen for molecules, which inhibit or enhance NOV28 activity or function. Specifically, the nucleic acids and polypeptides according to the invention may be used as targets for the identification of small molecules that modulate or inhibit, *e.g.*, cellular activation and cellular metabolism. These molecules can be used to treat, *e.g.*, for metabolic diseases such as cancer, trauma, regeneration (in vitro and in vivo), viral/bacterial/parasitic infections, diabetes, autoimmune disease, renal artery stenosis, interstitial nephritis, glomerulonephritis, polycystic kidney disease, systemic lupus erythematosus, renal tubular acidosis, IgA nephropathy, hypercalcaemia, Lesch-Nyhan syndrome, cardiomyopathy, atherosclerosis, hypertension, congenital heart defects, aortic stenosis, atrial septal defect (ASD), atrioventricular (A-V) canal defect, ductus arteriosus, pulmonary stenosis, subaortic stenosis, ventricular septal defect (VSD), valve diseases, tuberous sclerosis, scleroderma, obesity, transplantation and other diseases, disorders and conditions of the like.

In addition, various NOV28 nucleic acids and polypeptides according to the invention are useful, *inter alia*, as novel members of the protein families according to the presence of domains and sequence relatedness to previously described proteins. For example, the NOV28 nucleic acids and their encoded polypeptides include structural motifs that are characteristic of proteins belonging to the SSF family such as the Na⁺/glucose transporter proteins involved in renal transport and metabolism. (Ohashi and Erickson, J. Biol. Chem., 272: 14220-6 (1997)).

Integral membrane proteins that mediate the intake of a wide variety of molecules with the concomitant uptake of sodium ions are grouped into a number of distinct families. One of these families, known as the SSF, consists of integral membrane proteins that are predicted to comprise at least ten membrane spanning domains. Members of the SSF catalyze solute:Na⁺ symport (Reizer *et al.*, Biochem. Biophys. Acta, 1197: 133-166 (1994)) can transport sugars, amino acids, nucleosides, inositols, vitamins, urea or anions, depending on the system. Members of the SSF family have been identified in bacteria, archaea and animals, and all functionally well characterized members catalyze solute uptake via Na⁺ symport.

The NOV28 nucleic acids and polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications in the mediation of metabolism and immune function and renal physiology. As such, the NOV28 nucleic acids and polypeptides, antibodies and related compounds according to the invention may be used to treat

metabolic, immune and renal disorders, *e.g.*, metabolic diseases such as diabetes and hypertension, or cancer, trauma, regeneration (*in vitro* and *in vivo*), viral/bacterial/parasitic infections, diabetes, autoimmune disease, renal artery stenosis, interstitial nephritis, glomerulonephritis, polycystic kidney disease, systemic lupus erythematosus, renal tubular acidosis, IgA nephropathy, hypercalcaemia, Lesch-Nyhan syndrome, cardiomyopathy, atherosclerosis, hypertension, congenital heart defects, aortic stenosis, atrial septal defect (ASD), atrioventricular (A-V) canal defect, ductus arteriosus, pulmonary stenosis, subaortic stenosis, ventricular septal defect (VSD), valve diseases, tuberous sclerosis, scleroderma, obesity, transplantation and other diseases, disorders and conditions of the like. The NOV28 nucleic acids and polypeptides are useful for detecting specific cell types. For example, expression analysis has demonstrated that a NOV28 nucleic acid is expressed in Kidney and Heart .

Additional utilities for NOV28 nucleic acids and polypeptides according to the invention are disclosed herein.

NOV29

A NOV29 polypeptide has been identified as a Na⁺/glucose transporter-like protein. Six alternative novel NOV29, NOV29a, NOV29b, NOV29c, NOV29d, NOV29e, and NOV29f, nucleic acids and encoded polypeptides are provided. The novel NOV29 nucleic acid sequences maps to the chromosome 1.

NOV29a

A NOV29 variant is the novel NOV29a (alternatively referred to herein as CG56557-01), which includes the 2147 nucleotide sequence (**SEQ ID NO:104**) shown in Table 29A. A NOV29a ORF begins with a Kozak consensus ATG initiation codon at nucleotides 66-68 and ends with a TGA codon at nucleotides 2118-2120. Putative untranslated regions upstream from the initiation codon and downstream from the termination codon are underlined in Table 29A, and the start and stop codons are in bold letters.

Table 29A. NOV29a Nucleotide Sequence (SEQ ID NO:104)

<u>TTAAAGGAAAGGAATGAAGCCAGGAGCGCCTCAAAGTCCAGCCTGCTGTTGACCAACACTAACAGAT</u> <u>GAGCAAGGAGCTGGCAGCAATGGGGCCTGGAGCTTCAGGGGACGGGGTCAGGACTGAGACAGCTCCA</u> <u>CACATAGCACTGGACTCCAGAGTTGGTCTGCACGCCACGACATCAGCGTGGTGGTCATCTACTTTG</u> <u>TCTTCGTCATTGCTGTGGGGATCTGGTCGTCATCCGTGCAAGTCGAGGGACCATTTGGCGGCTATTT</u> <u>CCTGGCCGGGAGGTCCATGAGCTGGTGGCCAGTGGGAGCATCTCTGATGTCCAGCAATGTGGGCAGT</u>

GGCTTGTTTCATCGGCCTGGCTGGGACAGGGGCTGCCGAGGCCTTGCCGTAGGTGGCTTCGAGTGGA
 ACGTAAGGAAGCTGGCCTGGTTTCTCGTCTTCGTCCCTGTGTACATCGCAGCAGGTGTGGTCACAAT
 GCCGCAGTATCTGAAGAAGCGATTTGGGGGCCAGAGGATCCAGGTGTACATGTCTGTCTGTCTCTC
 ATCCTCTACATCTTCACCAAGATCTCGGTAGACATCTTCTCTGGAGCCCTCTTCATCCAGATGGCAT
 TGGGCTGGAACCTGTACCTCTCCACAGGGATCCTGCTGGTGGTGACTGCCGTCTACACCATTGCAGG
 TGGCCTCATGGCCGTGATCTACACAGATGCTCTGCAGACGGTGATCATGGTAGGGGGAGCCCTGGTC
 CTCATGTTTTAGGACGTGGGCTGGTACCCAGGCCCTGGAGCAGCGGTACAGGCAGGCCATCCCTAATG
 TCACAGTCCCCAACACCACCTGTACCTCCCACGGCCCCGATGCTTTCCACATTCTTCGGGACCCTGT
 GAGCGGGGACATCCCTTGGCCAGGTCTCATTTTCGGGCTCACAGTGCTGGCCACCTGGTGTGGTGTC
 ACAGACCAGGTCAATTGTGCAGCGGTCTCTCTCGGCCAAGAGTCTGTCTCATGCCAAGGGAGGCTCCG
 TGCTGGGGGGCTACCTGAAGATCCTCCCATGTTCTTCATCGTCATGCCTGGCATGATCAGCCGGGC
 CCTGTTCCCAGACGAGGTGGGCTGCGTGGACCCTGATGTCTGCCAAAGAATCTGTGGGGGGCTGATGA
 GGATGTTCCAACATTGCCCTACCCTAAGTTGGTTCATGGCCCTCATGCCTGTTGGTGGGGGGCTGATGA
 TTGCCGTGATCATGGCCGCTCTCATGAGCTCACTCACCTCCATCTTCAACAGCAGCAGCACCTGTT
 CACCATTGATGTGTGGCAGCGCTTCCGCAGGAAGTCAACAGAGCAGGAGCTGATGGTGGTGGGCAGG
 GTGTTTGTGGTGTTCCTGGTTGTCTATCAGCATCCTCTGGATCCCCATCATCAAAGCTCCAACAGTG
 GGCAGCTCTTCGACTACATCCAGGCTGTACCCAGTTACCTGGCCCCACCCATCACCGCTCTCTTCCT
 GCTGGCCATCTTCTGCAAGAGGGTCCACAGAGCAGGGAGCTTCTGGGGCCTCGTGTTCGGCTGGGA
 GTGGGGCTTCTGCGTATGATCCTGGAGTTCTCATACCCAGCGCCAGCCTGTGGGGAGGTGGACCGGA
 GGCCAGCAGTGCTGAAGGACTTCCACTACCTGTACTTTGCAATCCTCTCTGCGGGCTCACTGCCAT
 CGTCATTGTCTATTGTCTAGCCTCTGTACAACCTCCCATCCCTGAGGAACAGGCAAGTCGCCTCACATGG
 TGGACTCGGAACCTGCCCCCTCTCTGAGCTGGAGAAGGAGGCCCCCATACTTTCCATCAGTATCTC
 ACCATCTCTCTCCCTCCCTACTCTCTATCACTTTCTCTTCTCCAATCTTCTTTGCTCTCCCCCTC
 CTGCTCTCTCTTGTCTTCTGGCTTTGTCCCTCCAGCCCCAAGCAGGTCTTGGGGAAAGTTGCTCTGG
 AGCTGGTTCTGTGGGCTCTCTGGAACACCGGAGCAGGCCCTGAGCCAGCAGAGAAGGCTGCGCTAG
 AACAGAAGCTGACAAGCATTGAGGAGGAGCCACTCTGGAGACATGTCTGCAACATCAATGCTGTCTCT
 TTTGCTGGCCATCAACATCTTCTCTGGGGCTATTTTGGCTGATCCACAGACCTGGCTTCAGTGTA
 GAC

The NOV29a polypeptide (SEQ ID NO:105) encoded by SEQ ID NO:104 is 684 amino acid residues in length and is presented using the one-letter amino acid code in Table 29B.

NOV29a has two SNP variants, whose variant positions for their nucleotide and amino acid

sequences is numbered according to SEQ ID NOS:104 and 105, respectively. A variant sequence can include a single nucleotide polymorphism (SNP). A SNP can, in some instances,

be referred to as a "cSNP" to denote that the nucleotide sequence containing the SNP originates

as a cDNA. NOV29a Variant 13374708 is a G to A SNP at 774 bp of the nucleotide sequence

that results in no change in the protein sequence (silent). NOV29a variant 13375611 is a T to C

SNP at 1572 bp of the nucleotide sequence that results in a Ser to Pro change at amino acid 503

of protein sequence, and NOV29a variant 13375610 is a T to C SNP at 1684 bp of the nucleotide

sequence that results in a Val to Ala change at amino acid 540 of protein sequence.

The Psort profile for the NOV29a predicts that this peptide is likely to be localized at the plasma membrane with a certainty of 0.8000. The Signal P predicts a likely cleavage site for a

NOV29a peptide is between positions 59 and 60, *i.e.*, at the dash in the sequence IRA-SR.

Table 29B. NOV29a protein sequence (SEQ ID NO:105)

MSKELAAMGPGASGDGVRTETAPHIALDSRVGLHAYDISVVVIYFVFVIAVGIWSSIRASRGITIGGY
 FLAGRSMWWPVGASLMSSNVGSLFIGLAGTGAAGGLAVGGFEWNRKLAWFLVFPVYIAAGVVT
 MPQYLKKRFGGQRIQVYMSVLSLILYIFTKISVDIFSGALFIQMALGWNLYLSTGILLVVTAVYTIA
 GGLMAVIYTDALQTVIMVGGALVLMFQDVGWYPGLEQRYRQAIPNVTVPNTTCHLPRPDAFHILRDP
 VSGDIPWPGLIFGLTVLATWCWCTDQVIVQSRSLSAKSLSHAKGGSVLGGYLKILPMFFIVMPGMISR
 ALFPDEVGCVDPDVCQRICGARVGCSNIAYPKLVLMALMPVGRGLMIAVIMAALMSSLTSIFNSSSTL
 FTIDVWQRFRRKSTEQELMVVGRVFVFLVVISILWIPIIQSSNSGQLFDYIQAVTSYLAPPITALF
 LLAIFCKRVTEQGAFWGLVFGLGVLLRMILEFSYPAPACGEVDRRPAVLKDFHYLYFAILLCGLTA
 IVIVIVSLCTTPIPEEQASRLTWTRNCPLSELEKEAPPYFPSVSHHLSPTSLLSLSFLQSSLPLP
 SCSPLSSGFVPPAPSRSWGKLLWSWFCGLSGTPEQALSPA EKAALEQKLTSEEEPLWRHVCNINAV
 LLLAINIFLWGYFA

NOV29b

Alternatively, a NOV29 variant is the novel NOV29b (alternatively referred to herein as CG56557-02), which includes the 797 nucleotide sequence (**SEQ ID NO:106**) shown in Table 29C. NOV29b was cloned by polymerase chain reaction (PCR) using the primers: 5' GTCAGGACTGAGACAGCTCCACAC 3' (**SEQ ID NO:308**) and 5' CTGAAGCCAGGTCTGTGGAATCAC 3' (**SEQ ID NO:309**). Primers were designed based on in silico predictions of the full length or some portion (one or more exons) of the cDNA/protein sequence of the invention. These primers were used to amplify a cDNA from a pool containing expressed human sequences derived from the following tissues: adrenal gland, bone marrow, brain - amygdala, brain - cerebellum, brain - hippocampus, brain - substantia nigra, brain - thalamus, brain -whole, fetal brain, fetal kidney, fetal liver, fetal lung, heart, kidney, lymphoma - Raji, mammary gland, pancreas, pituitary gland, placenta, prostate, salivary gland, skeletal muscle, small intestine, spinal cord, spleen, stomach, testis, thyroid, trachea and uterus. The PCR product derived by exon linking, covering the entire open reading frame, was cloned into the pCR2.1 vector from Invitrogen to provide clone 57808::ba252a4.698037.N15.

The NOV29b ORF begins with a Kozak consensus ATG initiation codon at nucleotides 19-21 and ends with a TGA codon at nucleotides 775-777. Putative untranslated regions upstream from the initiation codon and downstream from the termination codon are underlined in Table 29C, and the start and stop codons are in bold letters.

Table 29C. NOV29b Nucleotide Sequence (SEQ ID NO:106)

AGCAAGGAGCTGGCAGCA**AT**GGGGCCTGGAGCTTCAGGGACGGGGTCAGGACTGAGACAGCTCCAC

ACATAGCACTGGACTCCAGAGTTGGTCTGCACGCCTACGACATCAGCGTGGTGGTCATCTACTTTGT
 CTTTCGTATTGCTGTGGGGATCTGGTCTCCATCTTCTGCAAGAGGGTCACAGAGCCCGGAGCTTTC
 TGGGGCCTCGTGTGGGCTGGGAGTGGGGCTTCTGCGTATGATCCTGGAGTTCTCATACCCAGCGC
 CAGCCTGTGGGGAGGTGGACCGGAGGCCAGCAGTGTGAAGGACTTCCACTACCTGTACTTTGCAAT
 CCTCCTCTGCGGGCTCACTGCCATCGTCATTGTCTGAGCCTCTGTACAACCTCCCATCCCTGAG
 GAACAGCTCACACGCCTCACATGGTGGACTCGGAACTGCCCCCTCTCTGAGCTGGAGAAGGAGGCC
 ACGAGAGCACACCGGAGATATCCGAGAGGCCAGCCGGGGAGTGCCCTGCAGGAGGTGGAGCGGCAGA
 GAACTCGAGCCTGGGCCAGGAGCAGCCTGAAGCCCCAAGCAGGTCTGGGGAAAGTTGCTCTGGAGC
 TGGTTCTGTGGGCTCTCTGGAACACCGGAGCAGGCCCTGAGCCCAGCAGAGAAGGCTGCGCTAGAAC
 AGAAGCTGACAAGCATTGAGGAGGAGCCACTCTGGAGACATGTCTGCAACATCAATGCTGTCTTTT
 GCTGGCCATCAACATCTTCTCTGGGGCTATTTTGGCTGATTCCACAGACCTGGCTTCAG

The NOV29b protein (SEQ ID NO:107) encoded by SEQ ID NO:106 is 252 amino acid residues in length is presented using the one-letter code in Table 29D. The Psort profile for NOV29b predicts that this sequence is likely to be localized at the plasma membrane with a certainty of 0.6000. The Signal P predicts a likely cleavage site for a NOV29b peptide is between positions 52 and 53, *i.e.*, at the dash in the sequence IFC-KR.

Table 29D. NOV29b protein sequence (SEQ ID NO:107)

MGPASGDGVRTETAPHIALDSRVGLHAYDISVVVIYFVFVIAVGIWSSIFCKRVTEPGAFWGLVFG
 LGVGLLRMLEFSYPAPACGEVDRRPAVLKDFHYLYFAILLCGLTAIVIVIVSLCTTPIPEEQLTRL
 TWWTRNCPLSELEKEAHESTPEISERPAGECPAGGGAAENSSLGQEPEAPSRSWGKLLWSWFCGLS
 GTPEQALSPA EKAAL EQKLTSIEEEPLWRHVCNINAVLLLLAINIFLWGYFA

NOV29c

Alternatively, a NOV29 variant is the novel NOV29c (alternatively referred to herein as CG56557-03), which includes the 2278 nucleotide sequence (SEQ ID NO:108) shown in Table 29E. The NOV29c ORF begins with a Kozak consensus sequence ATG identified at nucleotides 20-22 and ends with a TGA codon at nucleotides 2248-2250. Putative untranslated regions upstream from the initiation codon and downstream from the termination codon are underlined in Table 29E, and the start and stop codons are in bold letters.

Table 29E. NOV29c Nucleotide Sequence (SEQ ID NO:108)

GAGCAAGGAGCTGGCAGCAATGGGGCCTGGAGCTTCAGGGGACGGGGTCAGGACTGAGACAGCTCCA
CACATAGCACTGGACTCCGGAGTTGGTCTGCACGCCTACGACATCAGCGTGGTGGTCATCTACTTTG
TCTTCGTCAATGCTGTGGGGATCTGGTCTGTCATCCGTGCAAGTCGAGGGACCATTGGCGGCTATTT
CCTGGCCGGGAGGTCCATGAGCTGGTGGCCAATTGGAGCATCTCTGATGTCCAGCAATGTGGGCAGT
GGCTTGTTTCATCGGCCTGGCTGGGACAGGGGCTGCCGGAGGCCTTGCCGTAGGTGGCTTCGAGTGA
ACATGAGGAAATCAAGGTCTGGAGGAGACAGAGGGATCCATCCAAGGTCACACGGGAGGACTGGGGT

CAGGTCCCAGGTCTCTTATTTCTCTGTTCTGGGGGCTCCACAGCACAGCACTGCCTCTGGGTGGGA
 AGCCGCCCCCTCTGTCTACATCCAGGACCTGGATACCTTCTTCTTCTCCCCACTCTCCCAGGCAACCT
 GGCTGCTCCTGGCCCTTGGCTGGGTCTTCGTCCTGTGTACATCGCAGCAGGTGTGGTCACAATGCC
 GCAGTATCTGAAGAAGCGATTTGGGGGCCAGAGGATCCAGGTGTACATGTCTGTCTGTCTCTCATC
 CTCTACATCTTCACCAAGATCTCGACTGACATCTTCTCTGGAGCCCCCTTCATCCAGATGGCATTGG
 GCTGGAACCTGTACCTCTCCACAGGGATCCTGCTGGTGGTGAAGTCCGTCTACACCATTGCAGGTGG
 CCTCATGGCCGTGATCTACACAGATGCTCTGCAGACGGTGATCATGGTAGGGGGAGCCCTGGTCCTC
 ATGTTTCAGGACGTGGGCTGGTACCCAGGCCTGGAGCAGCGGTACAGGCAGGCCATCCCTAATGTCA
 CAGTCCCCAACACCACCTGTACCTCCCACGGCCCGATGCTTTCACATTCTTCGGGACCCTGTGAG
 CGGGGACATCCCTTGGCCAGGTCTCATTTCGGGCTCACAGTGTGGCCACCTGGTGTGGTGACA
 GACCAGGTCAATTGTGACGCGGTCTCTCTCGGCCAAGAGTCTGTCTCATGCCAAGGGAGGCTCCGTGC
 TGGGGGGCTACCTGAAGATCCTCCCATGTTCTTTCATCGTCATGCCAAGGGAGGCTCCGTGC
 GTTCCCAGACGAGGTGGGCTGCGTGGACCTTGATGTCTGCCAAAGAATCTGTGGGGCCCGAGTGGGA
 TGTTCACACATTGCCTACCTAAGTTGGTCATGGCCCTCATGCCTGTTGGTGGGGGCTGATGATTG
 CCGTGATCATGGCCGCTCTCATGAGCTCACTCACCTCCATCTTCAACAGCAGCAGCACCCTGTTTAC
 CATTGATGTGTGGCAGCGCTTCCGCAGGAAGTCAACAGAGCAGGAGCTGATGGTGGTGGGCAGGGTG
 TTTGTGGTGTCTCTGGTTGTCTATCAGCATCCTCTGGATCCCCATCATCAAAGCTCAAACAGTGGGC
 AGCTCTTCGACTACATCCAGGCTGTACCAGTTACCTGGCCCCACCCATCACCGCTCTCTTCTGCT
 GGCCATCTTCTGCAAGAGGGTACAGAGCAGGGAGCTTCTGGGGCCTCGTGTCTGGCCTGGGAGTG
 GGGCTTCTGCGTATGATCCTGGAGTTCTCATACCCAGCGCCAGCCTGTGGGGAGGTGGACCGGAGGC
 CAGCAGTGTGAAGGACTTCCACTACCTGTACTTTGCAATCCTCTCTGCGGGCTCACTGCCATCGT
 CATTGTCAATTGTGAGCCTCTGTACAACCTCCATCCCTGAGGAACAGGCAAGTCGCCTCACATGGTGG
 ACTCGGAAGTGGCCCCCTCTCTGAGCTGGAGAAGGAGGCCCCCCCCATACTTTCCATCAGTATCTCACC
 ATCTCTCTCCCTCCCTACTCTCCTATCACTTTCTCTTCTCCAATCTTCTTTGCCTCTCCCTCCTG
 CTCTCCTTTGTCTTCTGGCTTTGTCCCTCCAGCCCCAAGCAGGTCTTGGGGAAAGTTGCTCTGGAGC
 TGGTTCTGTGGGCTCTCTGGAACACCGGAGCAGGCCCTGAGCCCAGCAGAGAAGGCTGCGCTAGAAC
 AGAAGCTGACAAGCATTGAGGAGGAGCCACTCTGGAGACATGTCTGCAACATCAATGCTGTCTTTT
 GCTGGCCATCAACATCTTCTCTGGGCTATTTTGGTGTATCCACAGACCTGGCTTCAGTGTAGAC

The NOV29c protein (SEQ ID NO:109) encoded by SEQ ID NO:108 is 743 amino acid residues in length is presented using the one-letter code in Table 29F. The Psort profile for NOV29c predicts that this sequence is likely to be localized in the cytoplasm with a certainty of 0.8000. The Signal P predicts a likely cleavage site for a NOV29c peptide is between positions 52 and 53, *i.e.*, at the dash in the sequence IRA-SR.

Table 29F. NOV29c protein sequence (SEQ ID NO:109)

MGPASGDGVRTETAPHIALDSVGLHAYDISVVVIYFVFVIAVGIWSSIRASRGTIGGYFLAGRSM
 SWWPIGASLMSSNVGSGLFIGLAGTGAAGGLAVGGFEWNMRKSRSGDRGIHPRSHGRTGVR SQVSY
 FSVRGPPTAQHCLWVGSRPSVYIQDLDTFFFSPLSQATWLLLALGWVFPVYIAAGVVTMPQYLKKR
 FGGQRIQVYMSVLSLILYIFTKISTDIFSGAPFIQMALGWNLYLSTGILLVVTAVYTIAGGLMAVIY
 TDALQTVIMVGGALVLMFQDVGWYPGLEQRYRQAI PNVTVPNTTCHLPRPDAFHILRDPVSGDIPWP
 GLIFGLTVLATWCWCTDQVIVQRSLSAKSLSHAKGGSVLGGYLKILPMFFIVMPGMISRALFPDEVG
 CVDPDVCQRICGARVGCSNIAYPKLVMALMPVGRGLMIAVIMAALMSSLTSIFNSSSTLFTIDVWQR
 FRRKSTEQELMVVGRVVFVFLVVISILWIPIIQSSNSGQLFDYIQAVTSYLAPPITALFLLAIFCKR
 VTEQGAFWGLVFGLVGLLRMILEFSYPAPACGEVDRRPAVLKDFHYLYFAILLCGLTAIVIVIVSL
 CTTPIPEEQASRLTWWRNCP LSELEKEAPPYFPSVSHHLSPTSPTLLSLSLFLQSSLP LPSCSPLSSG
 FVPPAPSRSWGKLLWSWFCGLSGTPEQALSPA EKAAL EQKLT SIEEEPLWRHVCNINAVLLLAINIF
 LWGYFA

NOV29d

Alternatively, a NOV29 variant is the novel NOV29d (alternatively referred to herein as CG56653-04), which includes the 1969 nucleotide sequence (**SEQ ID NO:110**) shown in Table 29G. The NOV29d ORF begins with a Kozak consensus ATG initiation codon at nucleotides 18-20 and ends with a TGA codon at nucleotides 847-849. Putative untranslated regions upstream from the initiation codon and downstream from the termination codon are underlined in Table 29G, and the start and stop codons are in bold letters.

Table 29G. NOV29d Nucleotide Sequence (SEQ ID NO:110)

AGCAAGGAGCTGGCAGCA**AT**GGGGCCTGGAGCTTCAGGGGACGGGGTCAGGACTGAGACAGCTCCAC
ACATAGCACTGGACTCCAGAGTTGGTCTGCACGCCCTACGACATCAGCGTGGTGGTCATCTACTTTGT
CTTCGTCATTGTTGTGGGGATCTGGTCGTCCATCCGTGCAAGTCGAGGGACCATTGGCGGCTATTTT
CTGGCCCCACCCATCACCGCTCTCTTCTGCTGGCCATCTTCTGCAAGAGGGTCACAGAGCCCGGAG
CTTTCTGGGGCCTCGTGTGTTGGCCTGGGAGTGGGGCTTCTGCGTATGATCCTGGAGTTCTCATACCC
AGCGCCAGCCTGTGGGGAGGTGGACCGGAGGCCAGCAGTGTGAAGGACTTCCACTACCTGTACTTT
GCAATCCTCCTCTGCGGGCTCACTGCCATCGTCATTGTGTCAGCCTCTGTACAACCTCCCATCC
CTGAGGAACAGCTCACACGCCCTCACATGGTGGACTCGGAAGTGGCCCCCTCTCTGAGCTGGAGAAGGA
GGCCACGAGAGCACACCGGAGATATCCGAGAGGCCAGCCGGGGAGTGCCCTGCAGGAGGTGGAGCG
GCAGAGAACTCGAGCCTGGGGCAGGAGCAGCCTGAAGCCCCAAGCAGGTCCTGGGGAAAGTTGCTCT
GGAGCTGGTTCTGTGGGGCTCTCTGGAACACCGGAGCAGGCCCTGAGCCCAGCAGAGAAGGCTGCGCT
AGAACAGAAGCTGACAAGCATTGAGGAGGAGCCACTCTGGAGACATGTCTGCAACATCAATGCTGTC
CTTTTGTCTGGCCATCAACATCTTCTCTGGGGCTATTTTGC**GTG**ATTCCACAGACCTGGCTTCAGTG
TAGACAGATTAAACAAAGCCCCAAGCCTGTGAGCCACAGAAACAGGCTCTCCTCTTACTTTGCTGTCT
AAACTGGAGATCACAGAAGTCAAGACTGCAAGCTCCCCTGAAGAGAATCCAACCTCAACCTGCACACT
TGACAAGTGGAGAAACAGAAGCTCAGAGAGAGCACTGGGTTTGTTCAGGACCACCCAGAAGGTGTCA
CACGGGGTTTCCCCACTCTTTCTGATATATTGCCTTACAGACCTACCTCAAACACACTGTTTCCACC
CTCTTCTTGAATGTATTTCAGTAGCCTTTACTGAATGTGTGTCTTGAGAGTAGAAAAATGGAGGATAC
AAGAAAAGGAGCAGGAAGAAATTTGCAAAAATCCAAGAGCACCTTTGCTCCCCCTTATCCTCCTTCC
TCTTCCCCCTTTCTAGTTCCCCCTACCTCTCTATCTTTCTATTCTCACCAATAATCTCTTTGTTGCATG
AATTTACCCAGGAGAGTCCTATATTTCCATTGGTGGCTCCACAGTGGTGGCTGTCAGACCCGAAGGG
GTGGGGAGCCAAGGGTGGACTTTAAGCATGGTGACAGATGGTATTTTGGGCAGAAAGCTCTTAGACA
ATGGACTATCCAAAGCACTATTTAAATTCTGCCTCTTCTACTCTCTAACCCTCAAGGAATCAAGACATGTT
CTCTATGGCCTTGAGAAGCAGTTGGAGAGACATGACTTGTAAAACCTCAAGGAATCAAGACATGTT
ACTCTGTATTTAAGGGTAAGCCCCACAGCGGGCAGCACAAACAGCCTGGGAGCCACTGTGCCTGTGC
TTCTCTGTCTTCTCCCTTTGCTTGCCATGAATCCGCATACCTTGGAATACACTGTGACCCCAAGTTA
AGTGTCCCTTCGCCAGGAAGCTGCCGCAACGTCCAGACCTGGGTCAAGTTCCCACTCCTGCTCCCAT
AGCCTTGACCTGCTTCTGTACAGCACTGATCACACTGAGATGGAAGACTCCAGGGGGCAAGGACCA
AGGGCCATATCCCAAGTGACTTTGTACCCAGAAAATAACAGCTGTTCAATAAATGTGTATTGAGTTA
ATTAGTTAAAAA

The NOV29d protein (SEQ ID NO:111) encoded by SEQ ID NO:110 is 276 amino acid residues in length is presented using the one-letter code in Table 29H. The Psort profile for NOV29d predicts that this sequence is likely to be localized at the plasma membrane with a certainty of 0.6000. The Signal P predicts a likely cleavage site for a NOV29d peptide is between positions 52 and 53, *i.e.*, at the dash in the sequence IRA-SR.

Table 29H. NOV29d protein sequence (SEQ ID NO:111)

MGPASGDGVRTETAPHIALDSRVGLHAYDISVVVIYFVFVIVVGIWSSIRASRGTIGGYFLAPPIT
ALFLLAIFCKRVTEPGAFWGLVFGGLVGLLRMILEFSYPAPACGEVDRRPAVLKDFHYLYFAILLCG
LTAIVIVIVSLCTTPIPEEQLTRLTWTRNCPLSELEKEAHESSTPEISERPAGECPAGGGAAENSSL
GQEQPEAPSRSWGKLLWSWFCGLSGTPEQALSPAEEAALEQKLTSEEEPLWRHVCNINAVLLLLAIN
IFLWGYFA

NOV29e

Alternatively, a NOV29 variant is the novel NOV29e (alternatively referred to herein as CG56557-05), which includes the 2162 nucleotide sequence (SEQ ID NO:112) shown in Table 29I. The NOV29e ORF begins with a Kozak consensus ATG initiation codon at nucleotides 21-23 and ends with a TAG codon at nucleotides 2133-2135. Putative untranslated regions upstream from the initiation codon and downstream from the termination codon are underlined in Table 29I, and the start and stop codons are in bold letters.

Table 29I. NOV29e Nucleotide Sequence (SEQ ID NO:112)

TGAGCAAGGAGCTGGCAGCA**AT**GGGGCCTGGAGCTTCAGGGGACGGGGTCAGGACTGAGACAGCTCC
ACACATAGCACTGGACTCCAGAGTTGGTCTGCACGCCACGACATCAGCGTGGTGGTCATCTACTTT
GTCTTCGTCATTGCTGTGGGGATCTGGTCTGCCATCCGTGCAAGTCGAGGGACCATTGGCGGCTATT
TCCTGGCCGGGAGGTCCATGAGCTGGCGGCCAATTGGAGCATCTCTGATGTCCAGCAATGTGGGCAG
TGGCTTGTTTCATCGGCCTGGCTGGGACAGGGGCTGCCGGAGGCCCTTGCCGTAGGTGGCTTCGAGTGG
AACATGAGGAAATCAAGGTCTGGAGGAGACAGAGGGATCCATCCAAGGTCACACGGGAGGACTGGGG
TCAGGTCCCAGGCAACCTGGCTGCTCCTGGCCCTTGGCTGGGTCTTCGTCCCTGTGTACATCGCAGC
AGGTGTGGTCACAATGCCGAGTATCTGAAGAAGCGATTTGGGGGCCAGAGGATCCAGGTGTACATG
TCTGTCTGTCTCTCATCTCTACATCTTCACCAAGATCTCGACTGACATCTTCTCTGGAGCCCTCT
TCATCCAGATGGCATTGGGCTGGAACCTGTACCTCTCCACAGGGATCCTGCTGGTGGTGACTGCCGT
CTACACCATTGCAGGTGGCCTCATGGCCGTGATCTACACAGATGCTCTGCAGACGGTGATCATGGTA
GGGGGAGCCCTGGTCCTCATGTTTCAGGACGTGGGCTGGTACCCAGGCCTGGAGCAGCGGTACAGGC
AGGCCATCCCTAATGTACAGTCCCCAACACCACCTGTACCTCCACGGCCCGATGCTTTCACAT
TCTTCGGGACCCTGTGAGCGGGGACATCCCTTGGCCAGGTCTCATTTTCGGGCTCACAGTGTCTGGCC
ACCTGGTGTGGTGCACAGACCAGGTCAATTGTGCAGCGGTCTCTCTCGGCCAAGAGTCTGTCTCATG
CCAAGGGAGGCTCCGTGCTGGGGGCTACCTGAAGATCCTCCCATGTTCTTCATCGTCATGCCTGG
CATGATCAGCCGGGCCCTGTTCCAGACAGGTGGGCTGCGTGGACCCGTATGTCTGCCAAAGAATC
TGTGGGGCCCGAGTGGGATGTTTCCAACATTGCCTACCCTAAGTTGGTCATGGCCCTCATGCCTGTTG
GTCGGGGGCTGATGATTGCCGTGATCATGGCCGCTCTCATGAGCTCACTCACCTCCATCTTCAACAG
CAGCAGCACCCCTGTTTACCATTGATGTGTGGCAGCGCTTCCGCAGGAAGTCAACAGAGCAGGAGCTG

ATGGTGGTGGGCAGGGTGTGTTGTGGTGTTCCTGGTTGTCATCAGCATCCTCTGGATCCCCATCATCC
AAAGCTCCAACAGTGGGCAGCTCTTCGACTACATCCAGGCTGTACCAGTTACCTGGCCCCACCCAT
CACCGCTCTCTTCCTGCTGGCCATCTTCTGCAAGAGGGTCACAGAGCAGGGAGCTTTCTGGGGCCTC
GTGTTTGGCCTGGGAGTGGGGCTTCTGCGTATGATCCTGGAGTTCTCATACCCAGCGCCAGCCTGTG
GGGAGGTGGACCGGAGGCCAGCAGTGTGAAGGACTTCCACTACCTGTACTTTGCAATCCTCCTCTG
CGGGCTCACTGCCATCGTCATTGTGTCATTGTGAGCCTCTGTACAACTCCCATCCCTGAGGAACAGGCA
AGTCGCCTCACATGGTGGACTCGGAAGTGGCCCCCTCTCTGAGCTGGAGAAGGAGGCCCCCCCCATACT
TTCCATCAGTATCTCACCATCTCTCTCCCTCCCCCTACTCTCCTATCACTTTCCTTTCTCCAATCTTC
TTTGCTCTCCCCCTCCTGCTCTCCTTTGTCTTCTGGCTTTGTCCCTCCAGCCCCAAGCAGGTCTTG
GGAAAGTTGCTCTGGAGCTGGTCTGTGGGCTCTCTGGAACACCGGAGCAGGCCCTGAGCCCAGCAG
AGAAGGCTGCGCTAGAACAGAAGCTGACAAGCATTGAGGAGGAGCCACTCTGGAGACATGTCTGCAA
CATCAATGCTGTCTTTTGGCTGGCCATCAACATCTTCTCTGGGGCTATTTTGCCTGATTCCACAGA
CCTGGCTTCAGTGTAGAC

The NOV29e protein (SEQ ID NO:113) encoded by SEQ ID NO:112 is 704 amino acid residues in length is presented using the one-letter code in Table 29J. The Psort profile for NOV29e predicts that this sequence is likely to be localized at the plasma membrane with a certainty of 0.8000. The Signal P predicts a likely cleavage site for a NOV29e peptide is between positions 52 and 53, *i.e.*, at the dash in the sequence IRA-SR.

Table 29J. NOV29e protein sequence (SEQ ID NO:113)

MGPASGDGVRTETAPHIALDSRVGLHAYDISVVVIYFVFVIAVGIWSSIRASRGITGGYFLAGRSM
SWRPIGASLMSSNVGSLFIFLAGTGAAGGLAVGGFEWNMRKSRSGDRGIHPRSHGRTGVRSQATW
LLLALGWVFPVYIAAGVVTMPQYLKKRFGGQRIQVMSVLSLILYIFTKISTDIFSGALFIQMALG
WNLYLSTGILLVVTAVYTIAGGLMAVIYTDALQTVIMVGALVLMFQDVGWYPGLEQRYRQAI PNVT
VPNTTCHLPRPDAFHILRDPVSGDIPWPGLIFGLTVLATWCWCTDQVIVQRSLSAKSLSHAKGGSVL
GGYLKILPMFFIVMPGMISRALFPDEVGCVDPDVCQRICGARVGCNIAYPKLVMALMPVGRGLMIA
VIMAALMSSLTSIFNSSSTLFTIDVWQRFRRKSTEQELMVVGRVFVFLVVISILWIPIIQSSNSGQ
LFDYIQAVTSYLAPPITALFLLAIFCKRVTEQGAFWGLVFGGLVGLLRMILEFSYPAPACGEVDRRP
AVLKDFHYLYFAILLCGLTAIVIVIVSLCTTPIPEEQASRLTWTRNCPLSELEKEAPPYFPSVSHH
LSPSPPTLLSLFLQSSLPLPSCSPLSSGFVPPAPSRSWGKLLWSWFCGLSGTPEQALSPA EKAAL EQ
KLTSIEEEPLWRHVCNINAVLLLLAINIFLWG YFA

NOV29f

Alternatively, a NOV29 variant is the novel NOV29f (alternatively referred to herein as CG56557-06), which includes the 875 nucleotide sequence (SEQ ID NO:114) shown in Table 29K. NOV25e was cloned by the polymerase chain reaction (PCR) using the primers: 5' GTCAGGACTGAGACAGCTCCACAC 3' (SEQ ID NO:310) and 5'

CTGAAGCCAGGTCTGTGGAATCAC 3' (SEQ ID NO:311). Primers were designed based on in silico predictions of the full length or some portion (one or more exons) of the cDNA/protein sequence of the invention. These primers were used to amplify a cDNA from a pool containing

expressed human sequences derived from the following tissues: adrenal gland, bone marrow, brain - amygdala, brain - cerebellum, brain - hippocampus, brain - substantia nigra, brain - thalamus, brain -whole, fetal brain, fetal kidney, fetal liver, fetal lung, heart, kidney, lymphoma - Raji, mammary gland, pancreas, pituitary gland, placenta, prostate, salivary gland, skeletal muscle, small intestine, spinal cord, spleen, stomach, testis, thyroid, trachea and uterus. The PCR product derived by exon linking, covering the entire open reading frame, was cloned into the pCR2.1 vector from Invitrogen to provide clone 57808::ba252a4.698037.N1.

The NOV29f ORF begins with a Kozak consensus ATG initiation codon at nucleotides 19-21 and ends with a TGA codon at nucleotides 847-849. Putative untranslated regions upstream from the initiation codon and downstream from the termination codon are underlined in Table 29K, and the start and stop codons are in bold letters.

Table 29K. NOV29f Nucleotide Sequence (SEQ ID NO:114)

AGCAAGGAGCTGGCAGCAATGGGGCCTGGAGCTTCAGGGGACGGGGTCAGGACTGAGACAGCTCCAC
ACATAGCACTGGACTCCAGAGTTGGTCTGCACGCCACGACATCAGCGTGGTGGTCATCTACTTTGT
CTTCGTCATTGTTGTGGGGATCTGGTTCGTCATCCGTGCAAGTCGAGGGACCATTGGCGGCTATTTTC
CTGGCCCCACCCATCACCGCTCTCTTCCTGCTGGCCATCTTCTGCAAGAGGGTCACAGAGCCCGGAG
CTTCTGGGGCCTCGTGTGTTGGCCTGGGAGTGGGGCTTCTGCGTATGATCCTGGAGTTCTCATACCC
AGCGCCAGCCTGTGGGGAGGTGGACCGGAGGCCAGCAGTGCTGAAGGACTTCCACTACCTGTACTTT
GCAATCCTCCTCTGCGGGCTCACTGCCATCGTCATTGTTCATTGTCAGCCTCTGTACAACTCCCATCC
CTGAGGAACAGCTCACACGCCCTACATGGTGGACTCGGAACGCCCCCTCTCTGAGCTGGAGAAGGA
GGCCACGAGAGCACACCGGAGATATCCGAGAGGCCAGCCGGGGAGTGCCCTGCAGGAGGTGGAGCG
GCAGAGAACTCGAGCCTGGGCCAGGAGCAGCCTGAAGCCCCAAGCAGGTCTGGGGAAAGTTGCTCT
GGAGCTGGTTCTGTGGGCTCTCTGGAACACCGGAGCAGGTCTGAGCCCAGCAGAGAAGGCTGCGCT
AGAACAGAAGCTGACAAGCATTGAGGAGGAGCCACTCTGGAGACATGTCTGCAACATCAATGCTGTC
CTTTTGCTGGCCATCAACATCTTCCTCTGGGGCTATTTTGCGT**GATTCCACAGACCTGGCTTCAGTG**
TAGA

Variant sequences of NOV29f are included in Example 2. A variant sequence can include a single nucleotide polymorphism (SNP).

The NOV29f protein (SEQ ID NO:115) encoded by SEQ ID NO:114 is 319 amino acid residues in length is presented using the one-letter code in Table 29L. The Psort profile for NOV29f predicts that this sequence is likely to be localized at the plasma membrane with a certainty of 0.6000. The Signal P predicts a likely cleavage site for a NOV29f peptide is between positions 52 and 53, *i.e.*, at the dash in the sequence IRA-SR.

Table 29L. NOV29f protein sequence (SEQ ID NO:115)

MGPASGDGVRTETAPHIALDSRVGLHAYDISVVVIYFVFVIVVGIWSSIRASRGITIGGYFLAPPIT
ALFLLAIFCKRVTEPGAFWGLVFGLGVLLRMILEFSYPAPACGEVDRRPAVLKDFHYLYFAILLCG
LTAIVIVIVSLCTTPIPEEQLTRLTWWTRNCPLSELEKEAHSTPEISERPAGGCPAGGGAAENSSL
GQEQPEAPSRSWGKLLWSWFCGLSGTPEQVLSPAEEAALQKLTSEEEPLWRHVCNINAVLLLLAIN
IFLWGYFA

NOV29 Clones

Unless specifically addressed as NOV29a, NOV29b, NOV29c, NOV29d, NOV29e, or NOV29f, any reference to NOV29 is assumed to encompass all variants. Further, Patp, BLAST, and DOMAIN analyses are presented for NOV29c, the longest NOV29 polypeptide sequence.

A search against the Patp database, a proprietary database that contains sequences published in patents and patent publications, yielded several homologous proteins shown in Table29M.

Table 29M. Patp results for NOV29

Sequences producing High-scoring Segment Pairs:	Reading Frame	High Score	Smallest Sum Prob P(N)
>patp:AAE06614 Human protein	+1	1567	1.4e-199
>patp:AAE08088 Human transporter-related protein #35	+1	1567	1.4e-199
>patp:AAR73595 Cotransporter protein SGLT1	+1	1474	4.1e-196
>patp:AAR73593 Cotransporter protein SNST1	+1	1508	1.1e-185
>patp:AAB60093 Human transport protein TPPT-13	+1	1531	2.7e-184

NOV29 polypeptides are ficolin-like proteins with sequence homology to the Fibrinogen protein family. In a BLAST search of public sequence databases, it was found, for example, that the NOV29c nucleic sequence of this invention has 660 of 938 bases (70%) identical to a gb:GENBANK-ID:RNU03120|acc:U03120.1 *Rattus norvegicus* (Sprague-Dawley sodium-glucose cotransporter 1 mRNA, complete cds - *Rattus norvegicus*, 2627 bp). The full NOV29c polypeptide sequence was found to have 401 of 446 amino acid residues (89%) identical to, and 401 of 446 amino acid residues (91%) similar to, the 552 amino acid residue gi|9588428|emb|CAC00574.1| (AL109659) dJ1024N4.1 (novel Sodium:solute symporter family member similar to SLC5A1 (SGLT1)) from *Homo sapiens*.

Additional BLAST results are shown in Table 25N.

Table 29N. BLAST results for NOV29

Gene Index/ Identifier	Protein/ Organism	Length (aa)	Identity (%)	Positives (%)	Expect
gi 9588428 emb CAC00574.1 (AL109659)	dJ1024N4.1 (novel Sodium:solute symporter family member similar to SLC5A1 (SGLT1)) [<i>Homo sapiens</i>]	552	401/446 (89%)	401/446 (89%)	0.0
gi 631592 pir S48857	glucose transport protein - sheep	530	285/579 (49%)	367/579 (63%)	1e-149
gi 1709219 sp P53791	SL51_SHEEP SODIUM/GLUCOSE COTRANSPORTER 1 (NA(+)/GLUCOSE COTRANSPORTER 1) (HIGH AFFINITY SODIUM-GLUCOSE COTRANSPORTER)	664	285/579 (49%)	367/579 (63%)	1e-148
gi 631593 pir S48858	glucose transport protein homolog - sheep	664	284/579 (49%)	368/579 (63%)	1e-148
gi 6563312 gb AAF17249.1 AF208031_1 (AF208031)	SGLT1 protein [<i>Mus musculus</i>]	665	282/579 (48%)	367/579 (62%)	1e-144

A multiple sequence alignment is given in Table 29O, with the NOV29 protein of the invention being shown on line 1, in a ClustalW analysis comparing NOV29 with related protein sequences disclosed in Table 25N.

Table 29O. Information for the ClustalW proteins:

1. >NOV29a; SEQ ID NO:105
2. >NOV29b; SEQ ID NO:107
3. >NOV29c; SEQ ID NO:109
4. >NOV29d; SEQ ID NO:111
5. >NOV29e; SEQ ID NO:113
6. >NOV29f; SEQ ID NO:115
7. >GI9588428/ dJ1022N4.1 (sodium:solute symporter family member) [*Homo sapiens*]; SEQ ID NO:312
8. >GI631592/ glucose transport protein [sheep]; SEQ ID NO:313
9. >GI1709219/ SL51_Sheep sodium/glucose cotransporter 1 [sheep]; SEQ ID NO:314
10. >GI631593/ glucose transport protein homologue [sheep]; SEQ ID NO:315
11. >GI6563312/SGLT1 protein [*Mus musculus*]; SEQ ID NO:316

	10	20	30	40	50
NOV29a	MSKELAA	MGPGASGDGVRTETAPHIALDS	RVGLHAYDISVVVIYFVFVIA		
NOV29b	-----	MGPGASGDGVRTETAPHIALDS	RVGLHAYDISVVVIYFVFVIA		
NOV29c	-----	MGPGASGDGVRTETAPHIALDS	RVGLHAYDISVVVIYFVFVIA		

5	NOV29d	-----MGPASGDGVRTETAPHIALDSRVGLHAYDISVVVIYFVFVIV
	NOV29e	-----MGPASGDGVRTETAPHIALDSRVGLHAYDISVVVIYFVFVIA
	NOV29f	-----MGPASGDGVRTETAPHIALDSRVGLHAYDISVVVIYFVFVIV
	gi 9588428	-----MGPASGDGVRTETAPHIALDSRVGLHAYDISVVVIYFVFVIA
	gi 631592	-----MDSSTLSPPATDTAEPLQAYERIR--NAADISVIVVIYFVVVMA
	gi 1709219	-----MDSSTWSPPATATAEPLQAYERIR--NAADISVIVVIYFVVVMA
10	gi 631593	-----MDSSTWSPPATATAEPLQAYERIR--NAADISVIVVIYFVVVMA
	gi 6563312	-----MDSSTLSPAVTATDAPIPSAYERIR--NAADISVIVVIYFVVVMA
15		60 70 80 90 100
	NOV29a
	NOV29b	VGIWSSIRASRGTIGGYFLAGRSMSSWWPIGASLMSSNVGSGLFI GLAGTG
	NOV29c	VGIWSSIRASRGTIGGYFLAGRSMSSWWPIGASLMSSNVGSGLFI GLAGTG
	NOV29d	VGIWSSIRASRGTIGGYFLA-----
	NOV29e	VGIWSSIRASRGTIGGYFLAGRSMSSWWPIGASLMSSNVGSGLFI GLAGTG
20	NOV29f	VGIWSSIRASRGTIGGYFLA-----
	gi 9588428	VGIWSSIRASRGTIGGYFLAGRSMSSWWPIGASLMSSNVGSGLFI GLAGTG
	gi 631592	VGLWHMFSTNRGTIVGGFFLAGRSMVWWPIGASLFASNIGSCHFVGLAGTG
	gi 1709219	VGLWAMFSTNRGTIVGGFFLAGRSMVWWPIGASLFASNIGSCHFVGLAGTG
	gi 631593	VGLWAMFSTNRGTIVGGFFLAGRSMVWWPIGASLFASNIGSCHFVGLAGTG
	gi 6563312	VGLWAMFSTNRGTIVGGFFLAGRSMVWWPIGASLFASNIGSCHFVGLAGTG
25		110 120 130 140 150
	NOV29a
	NOV29b	AACGLAVGGFEWNVRK-----
	NOV29c	AACGLAVGGFEWNMRKSRSGGDRGIHPRSHGRTGVR SQVS YFSVRGPPTA
	NOV29d	-----
	NOV29e	AACGLAVGGFEWNMRKSRSGGDRGIHPRSHGRTGVR-----
30	NOV29f	-----
	gi 9588428	AACGLAVGGFEWN-----
	gi 631592	AAAGIATGGFEWN-----
	gi 1709219	AAAGIATGGFEWN-----
	gi 631593	AAAGIATGGFEWN-----
	gi 6563312	AAAGIAMGGFEWN-----
35		160 170 180 190 200
	NOV29a
	NOV29b	-----LAWFLVFPVPIYIAAGVVT
	NOV29c	QHCLWVGSRPVYIQDLDTFFFSPLSQATWLLALGWVFPVPIYIAAGVVT
	NOV29d	-----P-----
	NOV29e	-----SQATWLLALGWVFPVPIYIAAGVVT
40	NOV29f	-----P-----
	gi 9588428	-----ATWLLALGWVFPVPIYIAAGVVT
	gi 631592	-----ALILVVLLGWVFPVPIYIKAGVVT
	gi 1709219	-----ALILVVLLGWVFPVPIYIKAGVVT
	gi 631593	-----ALILVVLLGWVFPVPIYIKAGVVT
	gi 6563312	-----ALVILVVVLLGWIFVPIYIKAGVVT
45		210 220 230 240 250
	NOV29a
	NOV29b	MPQYLKKRFGGQRIQVYMSVLSLILYIFTKISVDIFSGALFIQMALGWNL
	NOV29c	MPQYLKKRFGGQRIQVYMSVLSLILYIFTKISTDIFSGALFIQMALGWNL
	NOV29d	-----
	NOV29e	MPQYLKKRFGGQRIQVYMSVLSLILYIFTKISTDIFSGALFIQMALGWNL
50	NOV29f	-----
	gi 9588428	MPQYLKKRFGGQRIQVYMSVLSLILYIFTKISTDIFSGALFIQMALGWN-
	gi 631592	MPEYLRKRFGGQRIQVYLSVLSLVLYIFTKISADIFSGAIFINLALG---
	gi 1709219	MPEYLRKRFGGQRIQVYLSVLSLVLYIFTKISADIFSGAIFINLALG---
	gi 631593	MPEYLRKRFGGQRIQVYLSVLSLVLYIFTKISADIFSGAIFINLALG---
	gi 631593	MPEYLRKRFGGQRIQVYLSVLSLVLYIFTKISADIFSGAIFINLALG---
55		
	NOV29a	MPQYLKKRFGGQRIQVYMSVLSLILYIFTKISVDIFSGALFIQMALGWNL
	NOV29b	MPQYLKKRFGGQRIQVYMSVLSLILYIFTKISTDIFSGALFIQMALGWNL
	NOV29c	MPQYLKKRFGGQRIQVYMSVLSLILYIFTKISTDIFSGALFIQMALGWNL
	NOV29d	-----
	NOV29e	MPQYLKKRFGGQRIQVYMSVLSLILYIFTKISTDIFSGALFIQMALGWNL
60	NOV29f	-----
	gi 9588428	MPQYLKKRFGGQRIQVYMSVLSLILYIFTKISTDIFSGALFIQMALGWN-
	gi 631592	MPEYLRKRFGGQRIQVYLSVLSLVLYIFTKISADIFSGAIFINLALG---
	gi 1709219	MPEYLRKRFGGQRIQVYLSVLSLVLYIFTKISADIFSGAIFINLALG---
	gi 631593	MPEYLRKRFGGQRIQVYLSVLSLVLYIFTKISADIFSGAIFINLALG---
	gi 631593	MPEYLRKRFGGQRIQVYLSVLSLVLYIFTKISADIFSGAIFINLALG---

```

gi|6563312 MPEYLRKRFGGKRIQIVLSVLSLLLYIFTKISADIFSGAIFINLALG---
                260      270      280      290      300
5      NOV29a  ....|....|....|....|....|....|....|....|....|....|
      NOV29b  YLSTG-----IILLVVTAVYTIAGGLMAVIYTDALQTVI
      NOV29c  -----
      NOV29d  YLSTG-----IILLVVTAVYTIAGGLMAVIYTDALQTVI
      NOV29e  -----
      NOV29f  YLSTG-----IILLVVTAVYTIAGGLMAVIYTDALQTVI
10      gi|9588428 -----
      gi|631592| -----
      gi|1709219 -----
      gi|631593| -----
      gi|6563312 -----

                310      320      330      340      350
20      NOV29a  ....|....|....|....|....|....|....|....|....|....|
      NOV29b  MVGGALVLMFQDVGWYPGLEQRYRQAI PNVTVPNTTCHLPRPDAFHILRD
      NOV29c  -----
      NOV29d  MVGGALVLMFQDVGWYPGLEQRYRQAI PNVTVPNTTCHLPRPDAFHILRD
      NOV29e  -----
      NOV29f  MVGGALVLMFQDVGWYPGLEQRYRQAI PNVTVPNTTCHLPRPDAFHILRD
25      gi|9588428 -----
      gi|631592| -----
      gi|1709219 -----
      gi|631593| -----
      gi|6563312 -----

                360      370      380      390      400
35      NOV29a  ....|....|....|....|....|....|....|....|....|....|
      NOV29b  PVSGDIPWPGLIFGLTVLATWCWCTDQVIVQRSLSAKSLSHAKGGSVLGG
      NOV29c  -----
      NOV29d  PVSGDIPWPGLIFGLTVLATWCWCTDQVIVQRSLSAKSLSHAKGGSVLGG
      NOV29e  -----
      NOV29f  PVSGDIPWPGLIFGLTVLATWCWCTDQVIVQRSLSAKSLSHAKGGSVLGG
40      gi|9588428 -----
      gi|631592| -----
      gi|1709219 -----
      gi|631593| -----
      gi|6563312 -----

                410      420      430      440      450
45      NOV29a  ....|....|....|....|....|....|....|....|....|....|
      NOV29b  YLKILPMFFIIVMPGMISRALFPDEVGCVDPDVCQRICGARVGCSNIAYPK
      NOV29c  -----
      NOV29d  YLKILPMFFIIVMPGMISRALFPDEVGCVDPDVCQRICGARVGCSNIAYPK
      NOV29e  -----
      NOV29f  YLKILPMFFIIVMPGMISRALFPDEVGCVDPDVCQRICGARVGCSNIAYPK
50      gi|9588428 -----
      gi|631592| -----
      gi|1709219 -----
      gi|631593| -----
      gi|6563312 -----

                460      470      480      490      500
60      NOV29a  ....|....|....|....|....|....|....|....|....|....|
      NOV29b  LVMALMPVGRGLMIAVIMAALMSSLTSIFNSSSTLFTIDVWQRFRRKSTE
      NOV29c  -----

```

5

10

15

20

25

30

35

40

45

50

55

60

```

NOV29d -----
NOV29e LVMALMPVGRGLMIAVIMAALMSSLTSIFNSSSTLFTIDVWQRFRRKSTE
NOV29f -----
gi|9588428 -----
gi|631592| -----
gi|1709219 -----
gi|631593| -----
gi|6563312 -----

                    510      520      530      540      550
NOV29a QELMVVGRVFVVFLVVISILWIPITIQSSNSGQLFDYIQAVTSYLAPPITA
NOV29b -----
NOV29c QELMVVGRVFVVFLVVISILWIPITIQSSNSGQLFDYIQAVTSYLAPPITA
NOV29d -----PITA
NOV29e QELMVVGRVFVVFLVVISILWIPITIQSSNSGQLFDYIQAVTSYLAPPITA
NOV29f -----PITA
gi|9588428 -----LYLS
gi|631592| -----LDLYLA
gi|1709219 -----LDLYLA
gi|631593| -----LDLYLA
gi|6563312 -----LDIYLA

                    560      570      580      590      600
NOV29a LELLAI FCKRVTEQCAFWGLVFG-----LGVGLLRMILEFS---YP
NOV29b -----SIFCKRVTEPCAFWGLVFG-----LGVGLLRMILEFS---YP
NOV29c LELLAI FCKRVTEQCAFWGLVFG-----LGVGLLRMILEFS---YP
NOV29d LELLAI FCKRVTEPCAFWGLVFG-----LGVGLLRMILEFS---YP
NOV29e LELLAI FCKRVTEQCAFWGLVFG-----LGVGLLRMILEFS---YP
NOV29f LELLAI FCKRVTEPCAFWGLVFG-----LGVGLLRMILEFS---YP
gi|9588428 TGILLVVTAVYTIAGGLMAVIYTDALQTVIMVGGALVIMFLGFQDVGWYP
gi|631592| IELLAI TALTALYITITGGLAAVIYDTLQTVIMLLGSFILTGFAPHEVGGYS
gi|1709219 IELLAI TALTALYITITGGLAAVIYDTLQTVIMLLGSFILTGFAPHEVGGYS
gi|631593| IELLAI TALTALYITITGGLAAVIYDTLQTVIMLLGSFILTGFAPHEVGGYS
gi|6563312 IELLAI TALTALYITITGGLAAVIYDTLQTAIMLVGSFILTGFAPHEVGGYE

                    610      620      630      640      650
NOV29a -----APACGEVDR-----RP---AVLKD-----F
NOV29b -----APACGEVDR-----RP---AVLKD-----F
NOV29c -----APACGEVDR-----RP---AVLKD-----F
NOV29d -----APACGEVDR-----RP---AVLKD-----F
NOV29e -----APACGEVDR-----RP---AVLKD-----F
NOV29f -----APACGEVDR-----RP---AVLKD-----F
gi|9588428 GLEQRYRQAI PNVTVP-----NTTCHLPREDAFHILRDPVSGDIPWPGLI
gi|631592| AFVTKYMNAIPTVTSYGNTTVKKECYTPRADSFHIFRDPLKGDLPWPGLI
gi|1709219 AFVTKYMNAIPTVTSYGNTTVKKECYTPRADSFHIFRDPLKGDLPWPGLI
gi|631593| AFVTKYMNAIPTVTSYGNTTVKKECYTPRADSFHIFRDPLKGDLPWPGLI
gi|6563312 AFMDKYMKAIPTKVSNNGNFTAKEECYTPRADSFHIFRDPI TGDMWPWPGLI

                    660      670      680      690      700
NOV29a HYLYFAILLCGLTAIVIVIVISLCTTPIPEEQ-----ASRLTWWTTRNC
NOV29b HYLYFAILLCGLTAIVIVIVISLCTTPIPEEQ-----LTRLTWWTTRNC
NOV29c HYLYFAILLCGLTAIVIVIVISLCTTPIPEEQ-----ASRLTWWTTRNC
NOV29d HYLYFAILLCGLTAIVIVIVISLCTTPIPEEQ-----LTRLTWWTTRNC
NOV29e HYLYFAILLCGLTAIVIVIVISLCTTPIPEEQ-----ASRLTWWTTRNC
NOV29f HYLYFAILLCGLTAIVIVIVISLCTTPIPEEQ-----LTRLTWWTTRNC
gi|9588428 FGLTVLATWCWCTDQVIVQRCLSAKSLSHAKGGSVLGGYKLIPMFFFIVM
gi|631592| FGLTIISLWYWCCTDQVIVQRCLSAKNMSHVKAGCIMCGYMKLLPMFLMVM
gi|1709219 FGLTIISLWYWCCTDQVIVQRCLSAKNMSHVKAGCIMCGYMKLLPMFLMVM
gi|631593| FGLTIISLWYWCCTDQVIVQRCLSAKNMSHVKAGCIMCGYMKLLPMFLMVM

```

	gi 6563312	FGLAILA[]WYWC[]DQVIVQRC[]SAKNMSHVKAGCTLCGYLKL[]PMFLMVM
		710 720 730 740 750
5	NOV29a	P---LSELEKEAPPYF[]SVSHHLS[]P---TLLSL-
	NOV29b	P---LSELEKEAHESTPEISERPAC[]E---PACGG-
	NOV29c	P---LSELEKEAPPYF[]SVSHHLS[]P---TLLSL-
	NOV29d	P---LSELEKEAHESTPEISERPAC[]E---PACGG-
10	NOV29e	P---LSELEKEAPPYF[]SVSHHLS[]P---TLLSL-
	NOV29f	P---LSELEKEAHESTPEISERPAC[]E---PACGG-
	gi 9588428	PGMISRALFPD[]EVGCVDP[]DVCQRIC[]GARVGC[]SNIAYP[]KLVMA[]LMPVGLRG
	gi 631592	PGMISRILFTEKVACTV[]PSECEKYC[]GTVGCT[]NIAYP[]TLVVEL[]MPLNGLRG
	gi 1709219	PGMISRILFTEKVACTV[]PSECEKYC[]GTVGCT[]NIAYP[]TLVVEL[]MPLNGLRG
15	gi 631593	PGMISRILFTEKVACTV[]PSECEKYC[]GTVGCT[]NIAYP[]TLVVEL[]MPLNGLRG
	gi 6563312	PGMISRILYTEK[]IACVL[]PEECQKYC[]GTPVGC[]TNIAYP[]TLVVEL[]MPLNGLRG
		760 770 780 790 800
20	NOV29a	-----SFLQSSLP-----LPSCSP-LSSG
	NOV29b	-----AAENSSLG-----QE-----
	NOV29c	-----SFLQSSLP-----LPSCSP-LSSG
	NOV29d	-----AAENSSLG-----QE-----
	NOV29e	-----SFLQSSLP-----LPSCSP-LSSG
25	NOV29f	-----AAENSSLG-----QE-----
	gi 9588428	LMI[]AVIMA[]ALMSS[]LTSIF[]NSSTL[]FTIDV[]WQFR[]RRKST[]EQEL[]MVVGR[]VVFV
	gi 631592	LML[]SVML[]ASL[]MSS[]LTSIF[]NSAST[]LFTMDI[]YTKIR[]KKASE[]KELMI[]AGRL[]FM
	gi 1709219	LML[]SVML[]ASL[]MSS[]LTSIF[]NSAST[]LFTMDI[]YTKIR[]KKASE[]KELMI[]AGRL[]FM
	gi 631593	LML[]SVML[]ASL[]MSS[]LTSIF[]NSAST[]LFTMDI[]YTKIR[]KKASE[]KELMI[]AGRL[]FM
30	gi 6563312	LML[]SVMM[]ASL[]MSS[]LTSIF[]NSAST[]LFTMDI[]YTKIR[]KKASE[]KELMI[]AGRL[]FI
		810 820 830 840 850
35	NOV29a	FVPPAPSR[]SWGKL[]LWSWFCC[]----LSGTPEQALS[]PAEKA[]ALEQK[]LTSIE
	NOV29b	-QPEAPSR[]SWGKL[]LWSWFCC[]----LSGTPEQALS[]PAEKA[]ALEQK[]LTSIE
	NOV29c	FVPPAPSR[]SWGKL[]LWSWFCC[]----LSGTPEQALS[]PAEKA[]ALEQK[]LTSIE
	NOV29d	-QPEAPSR[]SWGKL[]LWSWFCC[]----LSGTPEQALS[]PAEKA[]ALEQK[]LTSIE
	NOV29e	FVPPAPSR[]SWGKL[]LWSWFCC[]----LSGTPEQALS[]PAEKA[]ALEQK[]LTSIE
40	NOV29f	-QPEAPSR[]SWGKL[]LWSWFCC[]----LSGTPEQVLS[]PAEKA[]ALEQK[]LTSIE
	gi 9588428	VFLVVISI[]LWPI[]IQSS[]NSCQ[]LFDYI[]QAVTS[]YLAPP[]ITALF[]LLAIF[]CKRV
	gi 631592	LVLIGVSI[]AWPI[]VQSA[]QSCQ[]LFDYI[]QISIT[]SYLGP[]PIAAV[]FLLAIF[]CKRV
	gi 1709219	LVLIGVSI[]AWPI[]VQSA[]QSCQ[]LFDYI[]QISIT[]SYLGP[]PIAAV[]FLLAIF[]CKRV
	gi 631593	LVLIGVSI[]AWPI[]VQSA[]QSCQ[]LFDYI[]QISIT[]SYLGP[]PMRAV[]FLLAIF[]CKRV
	gi 6563312	LVLIGISI[]AWPI[]VQSA[]QSCQ[]LFDYI[]QISIT[]SYLGP[]PIAAV[]FLLAIF[]CKRV
45		860 870 880 890 900
	NOV29a	E[]EP--LWRHVCNINAV[]LL[]LAINIFLWG-----YFA
	NOV29b	E[]EP--LWRHVCNINAV[]LL[]LAINIFLWG-----YFA
	NOV29c	E[]EP--LWRHVCNINAV[]LL[]LAINIFLWG-----YFA
50	NOV29d	E[]EP--LWRHVCNINAV[]LL[]LAINIFLWG-----YFA
	NOV29e	E[]EP--LWRHVCNINAV[]LL[]LAINIFLWG-----YFA
	NOV29f	E[]EP--LWRHVCNINAV[]LL[]LAINIFLWG-----YFA
	gi 9588428	TEPGAFWGLV[]FGLGVGL[]LRMLE[]FSYP[]APACGE[]VDRR[]PAVLK[]DFHYLYFA
	gi 631592	NEPGAFWGLI[]IGFLIGVSR[]MITEFAY[]GTGSCME[]PSNCPTI[]ICGVHYLYFA
55	gi 1709219	NEPGAFWGLI[]IGFLIGVSR[]MITEFAY[]GTGSCME[]PSNCPTI[]ICGVHYLYFA
	gi 631593	NEPGAFWGLI[]IGFLIGVSR[]MITEFAY[]GTGSCME[]PSNCPTI[]ICGVHYLYFA
	gi 6563312	NEQGAFWGLI[]LIGFLIGISR[]MITEFAY[]GTGSCME[]PSNCPI[]ICGVHYLYFA

The NOV29 Clustal W alignment shown in Table 29O was modified to end at amino

residue 900. The data in Table 29O includes all of the regions overlapping with the NOV29 protein sequences.

The presence of identifiable domains in the protein disclosed herein was determined by searches using algorithms such as PROSITE, Blocks, Pfam, ProDomain, Prints and then determining the Interpro number by crossing the domain match (or numbers) using the Interpro website (<http://www.ebi.ac.uk/interpro/>). Table 29P lists the domain description from DOMAIN analysis results against NOV29c.

Table 25P Domain Analysis of NOV29			
Model	Region of Homology	Score (bits)	E value
Sodium:solute symporter family	60-549	608.2	2.6e-180
Integral membrane protein DUF6	427-559	-28.7	0.87
36KDa capillovirus serine protease (S35)	429-441	2.2	0.36

Consistent with other known members of the sodium:solute symporter family (SSF), the NOV29 Na⁺/glucose transporter-like protein contains the sodium:solute symporter family domain and an integral membrane domain as illustrated in Table 25T (Ohashi and Erickson, J. Biol. Chem., 272: 14220-6 (1997)). NOV29 nucleic acids, and the encoded polypeptides, according to the invention are useful in a variety of applications and contexts. For example, NOV29 nucleic acids and polypeptides can be used to identify proteins that are members of the sodium:solute symporter family of proteins. The NOV29 nucleic acids and polypeptides can also be used to screen for molecules, which inhibit or enhance NOV29 activity or function. Specifically, the nucleic acids and polypeptides according to the invention may be used as targets for the identification of small molecules that modulate or inhibit, *e.g.*, cellular activation and cellular metabolism. These molecules can be used to treat, *e.g.*, for metabolic diseases such as diabetes and hypertension, or cancer, trauma, regeneration (*in vitro* and *in vivo*), viral/bacterial/parasitic infections, diabetes, autoimmune disease, renal artery stenosis, interstitial nephritis, glomerulonephritis, polycystic kidney disease, systemic lupus erythematosus, renal tubular acidosis, IgA nephropathy, hypercalcaemia, Lesch-Nyhan syndrome, cirrhosis, transplantation, infertility and other diseases, disorders and conditions of the like.

In addition, various NOV29 nucleic acids and polypeptides according to the invention are useful, *inter alia*, as novel members of the protein families according to the presence of domains and sequence relatedness to previously described proteins. For example, the NOV29 nucleic acids and their encoded polypeptides include structural motifs that are characteristic of proteins belonging to the SSF family such as the Na⁺/glucose transporter proteins involved in renal transport and metabolism. (Ohashi and Erickson, J. Biol. Chem., 272: 14220-6 (1997)).

Integral membrane proteins that mediate the intake of a wide variety of molecules with the concomitant uptake of sodium ions are grouped into a number of distinct families. One of these families, known as the SSF, consists of integral membrane proteins that are predicted to comprise at least ten membrane spanning domains. Members of the SSF catalyze solute:Na⁺ symport (Reizer *et al.*, Biochem. Biophys. Acta, 1197: 133-166 (1994)) can transport sugars, amino acids, nucleosides, inositols, vitamins, urea or anions, depending on the system. Members of the SSF family have been identified in bacteria, archaea and animals, and all functionally well characterized members catalyze solute uptake via Na⁺ symport.

The NOV29 nucleic acids and polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications in the mediation of metabolism and immune function and renal physiology. As such, the NOV29 nucleic acids and polypeptides, antibodies and related compounds according to the invention may be used to treat metabolic, immune and renal disorders, *e.g.*, metabolic diseases such as diabetes and hypertension, or cancer, trauma, regeneration (*in vitro* and *in vivo*), viral/bacterial/parasitic infections, diabetes, autoimmune disease, renal artery stenosis, interstitial nephritis, glomerulonephritis, polycystic kidney disease, systemic lupus erythematosus, renal tubular acidosis, IgA nephropathy, hypercalcaemia, Lesch-Nyhan syndrome, cirrhosis, transplantation, or infertility. The NOV29 nucleic acids and polypeptides are useful for detecting specific cell types. For example, expression analysis has demonstrated that a NOV29 nucleic acid is expressed in Kidney, Liver, Testis, Whole Organism. .

Additional utilities for NOV29 nucleic acids and polypeptides according to the invention are disclosed herein.

A NOV30 polypeptide has been identified as a Sodium-glucose cotransporter (SGLT)-like protein (also referred to as CG56398-01). The disclosed novel NOV30 nucleic acid (**SEQ ID NO:116**) of 2105 nucleotides is shown in Table 30A. The novel NOV30 nucleic acid sequences maps to the chromosome 16.

5 An ORF begins with a Kozak consensus ATG initiation codon at nucleotides 31-33 and ends with a TAA codon at nucleotides 2056-2058. A putative untranslated region and/or downstream from the termination codon is underlined in Table 30A, and the start and stop codons are in bold letters.

Table 30A. NOV30 Nucleotide Sequence (SEQ ID NO:116)

CCTCAGGATCCAGAGGTCTCGTTTCAGGACC**ATG**GAGAGCGGCACCAGCAGCCCTCAGCCTCCACAGT
TAGATCCCCTGGATGCGTTTCCCCAGAAGGGCTTGGAGCCTGGGGACATCGCGGTGCTAGTTCTGTGTA
CTTCCTCTTTGTCCTGGCTGTTGGACTATGGTCCACAGTGAAGACAAAAGAGACACAGTGAAAGGC
TACTTCCTGGCTGGAGGGGACATGGTGTGGTGGCCAGTGGGTGCATCCTTGTGTTGCCAGCAATGTTG
GAAGTGGACATTTTATTGGCCTGGCAGGGTCAGGTGCTGCTACGGGCATTTCTGTATCAGCTTATGA
ACTTAATGGCTTGTCTTCTGTGCTGATGTTGGCCTGGATCTTCTACCCATCTACATTGCTGGTCAG
GTGACCACGATGCCAGAATACCTACGGAAGCGCTTCGGTGGCATCAGAATCCCCATCATCCTGGCTG
TACTCTACCTATTTATCTACATCTTCACCAAGATCTCGGTAGACATGTATGCAGGTGCCATCTTCAT
CCAGCAGTCTTTGCACCTGGATCTGTACCTGGCCATAGTTGGGCTACTGGCCATCACTGCTGTATAC
ACGGTTGCTGGTGGCCTGGCTGCTGTGATCTACACGGATGCCCTGCAGACGCTGATCATGCTTATAG
GAGCGCTCACCTTGATGGGCTACAGTTTCGCCGCGGTTGGTGGGATGGAAGGACTGAAGGAGAAGTA
CTTCTTGGCCCTGGCTAGCAACCGGAGTGAGAACAGCAGCTGCGGGCTGCCCCGGAAGATGCCTTC
CATATTTTCCGAGATCCGCTGACATCTGATCTCCCGTGGCCGGGGTCTTATTTGGAATGTCCATCC
CATCCCTCTGGTACTGGTGCACGGATCAGGTAATTGTCCAGCGGACTCTGGCTGCCAAGAACCTGTC
CCATGCCAAAGGAGGTGCTCTGATGGCTGCATACCTGAAGGTGCTGCCCCCTTTCATAATGGTGTTC
CCTGGGATGGTCAAGCCCTCAGGCTGTTTCGGACATCGCGTATCCCAAACCTCGTGCTGGAACCTCGCC
AGATCTGCAGCAACCCCTCAGGCTGTTTCGGACATCGCGTATCCCAAACCTCGTGCTGGAACCTCGCC
CACAGGTCTCCGTGGGCTGATGATGGCTGTGATGGTGGCGGCTCTCATGTCTCCCTCACCTCCATC
TTTAACAGTGCCAGCACCATCTTCACCATGGACCTCTGGAATCACCTCCGGCCTCGGGCATCTGAGA
AGGAGCTCATGATTGTGGGCAGGGTGTGTTGTGCTGCTGCTGGTCCTGGTCTCCATCCTCTGGATCCC
TGTGGTCCAGGCCAGCCAGGGCGGCCAGCTCTTCATCTATATCCAGTCCATCAGCTCCTACCTGCAG
CCGCTGTGGCGGTGGTCTTCATCATGGGATGTTTCTGGAAGAGGACCAATGAAAAGGGTGCCTTCT
GGGGCCTGATCTCGGGCCTGCTCCTGGGCTTGGTTAGGCTGGTCCTGGACTTTATTTACGTGCAGCC
TCGATGCGACCAGCCAGATGAGCGCCCGGTCTGGTGAAGAGCATTCACTACCTCTACTTCTCCATG
ATCCTGTCCACGGTCACCCCTCATCACTGTCTCCACCGTGAGCTGGTTCACAGAGCCACCCTCCAAGG
AGATGGTCAGCCACCTGACCTGGTTTACTCGTCACGACCCCGTGGTCCAGAAGGAACAAGCACCACC
AGCAGCTCCCTTGTCTCTTACCCTCTCTCAGAACGGGATGCCAGAGGCCAGCAGCAGCAGCGCTC
CAGTTCGAGATGGTTCAAGAAAACAGCTCTAAAACCCACAGCGGTGACATGACCCCAAAGCAGTCCA
AAGTGGTGAAGGCCATCCTGTGGCTCTGTGGAATACAGGAGAAGGGCAAGGAAGAGCTCCCGGCCAG
AGCAGAAGCCATCATAGTTTCCCTGGAAGAAAACCCCTTGGTGAAGACCTCCTGGACGTCAACCTC
ATTTTCTGCGTGAGCTGCGCCATCTTTATCTGGGGCTATTTTGTCT**AGT**GTGGGGTGAACCCAGGGG
TCCAAACTCTGTTCTCTTCAGTGCTCC

10 The NOV30 protein (**SEQ ID NO:117**) encoded by **SEQ ID NO:116** is 675 amino acid residues in length and is presented using the one-letter amino acid code in Table 30B. Psort

analysis predicts the NOV30 protein of the invention to be localized to the plasma membrane with a certainty of 0.8000. The Signal P predicts a likely cleavage site for a NOV30 peptide is between positions 50 and 51, *i.e.*, at the dash in the sequenceVKT-KR.

Table 30B. Encoded NOV30 protein sequence (SEQ ID NO:117)

```
MESGTSSPQPPQLDPLDAFPQKGLEPGDIAVLVLYFLFVLAVGLWSTVKT-KRDTVKGYFLAGGDM
VWWPVGASLFASNVGSGHFIFLAGSGAATGISVSAYELNGLFSVLMWIFLPIYIAGQVTTMPE
YLRKRFGGIRIPILAVLYLFIYIFTKISVDMYAGAFIQQSLHLDLYLAIVGLLAITAVYTVAG
GLAAVIYTDALQTLIMLIGALTLMGYSFSAVGGMEGLKEKYFLALASNRSENSSCGLPREDAFHI
FRDPLTSDLWPVGVLFGMSIPSLWYWCTDQVIVQRTLAAKNLSHAKGGALMAAYLKVLPLFIMVF
PGMVSRIILFPDQVACADPEICQKICSNPSGCSDIAYPKLVLELLPTGLRGLMMAMVVAALMSSLT
SIFNSASTIFTMDLWNHLRPRASEKELMIVGRVFVLLLVLSILWIPVVQASQGGQLFIYIQSIS
SYLQPPVAVVFIMGCFWKRTNEKGAFWGLISGLLLGLVRLVLDFIYVQPRCDQDERPVLVKSIIH
YLYFSMILSTVTLITVSTVSWFTEPPSKEMVSHLTWFTRHDPVVQKEQAPPAAPLSLTLSQNGMP
EASSSSSVQFEMVQENTSKTHSGDMTPKQSKVVKAILWLCGIQEKGEELPARAEAIIVSLEENP
LVKTLTLLDVNLIFCVSCAIFIWGYFA
```

A search against the Patp database, a proprietary database that contains sequences published in patents and patent publications, yielded several homologous proteins shown in Table 30C.

Table 30C. Patp results for NOV30

Sequences producing High-scoring Segment Pairs:	Reading Frame	High Score	Smallest Sum Prob P(N)
>patp:AAB60093 Human transport protein TPPT-13	+1	3461	0.0
>patp:AAB85102 Novel human transporter protein (NHP)	+1	3455	0.0
>patp:AAR73595 Cotransporter protein SGLT1	+1	1729	2.1e-184
>patp:AAR73593 Cotransporter protein SNST1	+1	1726	1.6e-177
>patp:AAV31221 Human SAAT1 protein	+1	1629	2.9e-174

In a BLAST search of public sequence databases, it was found, for example, that the NOV30 nucleic acid sequence of this invention has 1764 of 2068 bases (85%) identical to a gb:GENBANK-ID:RABSGCTP|acc:D16226.1 mRNA from *Oryctolagus cuniculus* (Rabbit mRNA for sodium-glucose cotransporter, complete cds). NOV30 polypeptide was found to have 568 of 675 amino acid residues (84%) identical to, and 624 of 675 amino acid residues (92%) similar to, the 674 amino acid residue ptnr:SPTREMBL-ACC:Q28728 protein from *Oryctolagus cuniculus* (ONE OF THE MEMBERS OF SODIUM-GLUCOSE COTRANSPORTER FAMILY).

NOV30 also has homology to the proteins shown in the BLASTP data in Table 30D.

Table 30D. BLAST results for NOV30					
Gene Index/ Identifier	Protein/ Organism	Length (aa)	Identity (%)	Positives (%)	Expect
gi 17941285 ref NP_443176.2 (NM_052944)	putative sodium-coupled cotransporter RKST1 [<i>Homo sapiens</i>]	675	597/675 (88%)	597/675 (88%)	0.0
gi 15419543 gb AAK97053.1 AF292385_1 (AF292385)	putative sodium-coupled cotransporter RKST1 [<i>Homo sapiens</i>]	675	596/675 (88%)	596/675 (88%)	0.0
gi 473969 dbj BAA03753.1 (D16226)	one of the members of sodium-glucose cotransporter family [<i>Oryctolagus cuniculus</i>]	674	503/675 (74%)	550/675 (80%)	0.0
gi 16165175 ref XP_056259.1 (XM_056259)	putative sodium-coupled cotransporter RKST1 [<i>Homo sapiens</i>]	548	483/548 (88%)	483/548 (88%)	0.0
gi 2564063 dbj BAA22950.1 (AB008225)	Na ⁺ -glucose cotransporter type 1 (SGLT-1)-like protein [<i>Xenopus laevis</i>]	673	791 bits (2042)	409/679 (60%)	0.0

A multiple sequence alignment is given in Table 30E, with the NOV30 protein being shown on line 1 in Table 30E in a ClustalW analysis, and comparing the NOV30 protein with the related protein sequences shown in Table 30D. This BLASTP data is displayed graphically in the ClustalW in Table 30E.

Table 30E. ClustalW Analysis of NOV30

- 1) > NOV30; SEQ ID NO:117
- 2) > gi|1794128/ putative sodium-coupled cotransporter RKST1 [*Homo sapiens*]; SEQ ID NO:317
- 3) > gi|1541954/ putative sodium-coupled cotransporter RSTK1 [*Homo sapiens*]; SEQ ID NO:318
- 4) > gi|473969/ member of sodium-glucose cotransporter family [*Oryctolagus cuniculus*]; SEQ ID NO:319
- 5) > gi|1616517/ putative sodium-coupled cotransporter RKST1 [*Homo sapiens*]; SEQ ID NO:320
- 6) > gi|2564063/ Na⁺-glucose cotransporter type 1 (SGLT-1)-like protein [*Xenopus laevis*]; SEQ ID NO:321

5

10

15

20

25

30

35

40

45

50

55

60

```

NOV30      MESGTSSPQPPQLDPLDAFPQKGLEPGDIAVLVLYFLFVLAVGLWSTVKT
gi|1794128 MESGTSSPQPPQLDPLDAFPQKGLEPGDIAVLVLYFLFVLAVGLWSTVKT
gi|1541954 MESGTSSPQPPQLDPLDAFPQKGLEPGDIAVLVLYFLFVLAVGLWSTVKT
gi|473969| MESSTSSPQPPLSDPLDFFPQRSLEPGDIAVLVLYFLFVLAVGLWSTVKT
gi|1616517 -----
gi|2564063 METSSQSS-PQTTPGMBAFPKKSLDTTIDIVVLVLYFVFVLAVGLLSMCRT

          60          70          80          90         100
NOV30      KRDTVKGYFLAGGDMVWWPVGASLFASNVGSGHFVGLAGSGAATGISVSA
gi|1794128 KRDTVKGYFLAGGDMVWWPVGASLFASNVGSGHFVGLAGSGAATGISVSA
gi|1541954 KRDTVKGYFLAGGDMVWWPVGASLFASNVGSGHFVGLAGSGAATGISVSA
gi|473969| KRDTVKGYFLAGGDMVWWPVGASLFASNVGSGHFVGLAGSGAATGISVAA
gi|1616517 -----
gi|2564063 KRCTVKGYFLAGKDMAWVPVGASLFASNVGSGHFVGLAGSCAASGIAVTA

          110         120         130         140         150
NOV30      YELNGLFSVLMIAWIFLPIYIAGQVTTMPEYLRKRFGGIRIPIILAVLYL
gi|1794128 YELNGLFSVLMIAWIFLPIYIAGQVTTMPEYLRKRFGGIRIPIILAVLYL
gi|1541954 YELNGLFSVLMIAWIFLPIYIAGQVTTMPEYLRKRFGGIRIPIILAVLYL
gi|473969| YEFNGMFVSVLMIAWIFLPIYIAGQVTTMPEYLRKRFGGIRIPIILAVLYL
gi|1616517 -----MPEYLRKRFGGIRIPIILAVLYL
gi|2564063 YEWNGLFCVIALAWLFLPIYISAGVTTMPEYLQRFGGKRIQIFLAAILYL

          160         170         180         190         200
NOV30      FIYIFTKISVDMYAGAIFIQOSLHLDLYLAIVGLLAIITAVYTVAGGLAAV
gi|1794128 FIYIFTKISVDMYAGAIFIQOSLHLDLYLAIVGLLAIITAVYTVAGGLAAV
gi|1541954 FIYIFTKISVDMYAGAIFIQOSLHLDLYLAIVGLLAIITAVYTVAGGLAAV
gi|473969| FIYIFTKISVDMYTGAIFIQOSLHLDLYLSVVGLLAVTALYTVAGGLAAV
gi|1616517 FIYIFTKISVDMYAGAIFIQOSLHLDLYLAIVGLLAIITAVYTVAGGLAAV
gi|2564063 FIYIFTKISVDMYAGALFIQQALOWDLYVAVIGLLVITAIYTVAGGLAAV

          210         220         230         240         250
NOV30      IYTDALQTLIMLIGALTLMGYSF AAVGGMEGLKEKYFLALASNRSENSSC
gi|1794128 IYTDALQTLIMLIGALTLMGYSF AAVGGMEGLKEKYFLALASNRSENSSC
gi|1541954 IYTDALQTLIMLIGALTLMGYSF AAVGGMEGLKEKYFLALASNRSENSSC
gi|473969| IYTDALQTLIMLVGALTLMGYSF AAVGGMEGLQEKYFLALPSNRSENSSC
gi|1616517 IYTDALQTLIMLIGALTLMGYSF AAVGGMEGLKEKYFLALASNRSENSSC
gi|2564063 IYTDLTQTVIMLIGALTLMGYSFIEIGFEALQEKYFHAIPNTHSGNSTC

          260         270         280         290         300
NOV30      GLPREDAFHI FRDPLTSDLWPVGVLF GMSIPSLWYWCTDQVIVQRTLAAK
gi|1794128 GLPREDAFHI FRDPLTSDLWPVGVLF GMSIPSLWYWCTDQVIVQRTLAAK
gi|1541954 GLPREDAFHI FRDPLTSDLWPVGVLF GMSIPSLWYWCTDQVIVQRTLAAK
gi|473969| GLPREDAFHI FRDPLTSDLWPVGVLF GMSIPSLWYWCTDQVIVQRTSLAAK
gi|1616517 GLPREDAFHI FRDPLTSDLWPVGVLF GMSIPSLWYWCTDQVIVQRTLAAK
gi|2564063 GLPREDAFHI FRDPLTSDLWPVGVLF GMSIPSLWYWCTDQVIVQRTSLAAK

          310         320         330         340         350
NOV30      NLSHAKGGALMAAYLKVLP L FIMVFPGMVSRILFPDQVACADPEICQKIC
gi|1794128 NLSHAKGGALMAAYLKVLP L FIMVFPGMVSRILFPDQVACADPEICQKIC
gi|1541954 NLSHAKGGALMAAYLKVLP L FIMVFPGMVSRILFPDQVACADPEICQKIC
gi|473969| NLSHAKGGSLMAAYLKVLP L FIMVFPGMVSRILFPDQVACADPETCQRVC
gi|1616517 NLSHAKGGALMAAYLKVLP L FIMVFPGMVSRILFPDQVACADPEICQKIC
gi|2564063 NLSHAKAGSLAASLKVLP L FIMVLP GMISRVLF T DQVACADPELCKEIC

          360         370         380         390         400

```

5

```

.....|.....|.....|.....|.....|.....|.....|.....|.....|.....|
NOV30      SNPSGCSDIAYPKLVLELLPTGLRGLMMAVMVAALMSSLTSIFNSASTIF
gi|1794128 SNPSGCSDIAYPKLVLELLPTGLRGLMMAVMVAALMSSLTSIFNSASTIF
gi|1541954 SNPSGCSDIAYPKLVLELLPTGLRGLMMAVMVAALMSSLTSIFNSASTIF
gi|473969| NNPSGCSDIAYPKLVLELLPTGLRGLMMAVMVAALMSSLTSIFNSASTIF
gi|1616517 SNPSGCSDIAYPKLVLELLPTGLRGLMMAVMVAALMSSLTSIFNSASTIF
gi|2564063 GNPSGCSDIAYPKLVLELLPTGLRGLMMAVMVAALMSSLTSIFNSASTIF

```

10

```

              410      420      430      440      450
.....|.....|.....|.....|.....|.....|.....|.....|.....|.....|
NOV30      TMDLWNHLRPRASEKELMIVGRVFVLLLVLSILWIPVVQASQGGQLFIY
gi|1794128 TMDLWNHLRPRASEKELMIVGRVFVLLLVLSILWIPVVQASQGGQLFIY
gi|1541954 TMDLWNHLRPRASEKELMIVGRVFVLLLVLSILWIPVVQASQGGQLFIY
gi|473969| TMDLWNHLRPRASEKELMIVGRVFVLLLVLSILWIPVVQASQGGQLFIY
gi|1616517 TMDLWNHLRPRASEKELMIVGRVFVLLLVLSILWIPVVQASQGGQLFIY
gi|2564063 TMDLWNHLRPRASEKELMIVGRVFVLLLVLSILWIPVVQASQGGQLFIY

```

15

```

              460      470      480      490      500
.....|.....|.....|.....|.....|.....|.....|.....|.....|.....|
NOV30      IQSISSYLQPPVAVVFIMGCFWKRTNEKGAFWGLISGLLLGLVRLVLDIFI
gi|1794128 IQSISSYLQPPVAVVFIMGCFWKRTNEKGAFWGLISGLLLGLVRLVLDIFI
gi|1541954 IQSISSYLQPPVAVVFIMGCFWKRTNEKGAFWGLISGLLLGLVRLVLDIFI
gi|473969| IQSISSYLQPPVAVVFIMGCFWKRTNEKGAFWGLISGLLLGLVRLVLDIFI
gi|1616517 IQSISSYLQPPVAVVFIMGCFWKRTNEKGAFWGLISGLLLGLVRLVLDIFI
gi|2564063 IQSISSYLQPPVAVVFIMGCFWKRTNEKGAFWGLISGLLLGLVRLVLDIFI

```

20

```

              510      520      530      540      550
.....|.....|.....|.....|.....|.....|.....|.....|.....|.....|
NOV30      YVQPRCDQDQDERPVLVKSIIHYLYFSMILSTVTLITVSTVSWFTEPPSKEM
gi|1794128 YVQPRCDQDQDERPVLVKSIIHYLYFSMILSTVTLITVSTVSWFTEPPSKEM
gi|1541954 YVQPRCDQDQDERPVLVKSIIHYLYFSMILSTVTLITVSTVSWFTEPPSKEM
gi|473969| YVQPRCDQDQDERPVLVKSIIHYLYFSMILSTVTLITVSTVSWFTEPPSKEM
gi|1616517 YVQPRCDQDQDERPVLVKSIIHYLYFSMILSTVTLITVSTVSWFTEPPSKEM
gi|2564063 YVQPRCDQDQDERPVLVKSIIHYLYFSMILSTVTLITVSTVSWFTEPPSKEM

```

30

```

              560      570      580      590      600
.....|.....|.....|.....|.....|.....|.....|.....|.....|.....|
NOV30      VSHLTWFTTRHDPVVQKEQAPPAAPLSLTLSQNGMPEASSSSSVQFEMVQE
gi|1794128 VSHLTWFTTRHDPVVQKEQAPPAAPLSLTLSQNGMPEASSSSSVQFEMVQE
gi|1541954 VSHLTWFTTRHDPVVQKEQAPPAAPLSLTLSQNGMPEASSSSSVQFEMVQE
gi|473969| VSHLTWFTTRHDPVVQKEQAPPAAPLSLTLSQNGMPEASSSSSVQFEMVQE
gi|1616517 VSHLTWFTTRHDPVVQKEQAPPAAPLSLTLSQNGMPEASSSSSVQFEMVQE
gi|2564063 VSHLTWFTTRHDPVVQKEQAPPAAPLSLTLSQNGMPEASSSSSVQFEMVQE

```

40

```

              610      620      630      640      650
.....|.....|.....|.....|.....|.....|.....|.....|.....|.....|
NOV30      NTSKTHSGDMTPKQSKVVKAILWLCGIQ----EKGKEELPARAEAIIVSL
gi|1794128 NTSKTHSGDMTPKQSKVVKAILWLCGIQ----EKGKEELPARAEAIIVSL
gi|1541954 NTSKTHSGDMTPKQSKVVKAILWLCGIQ----EKGKEELPARAEAIIVSL
gi|473969| GASKAHSSDTPKQSRVVRAILWLCGME----GKSTEQAPRPAPVPLASI
gi|1616517 NTSKTHSGDMTPKQSKVVKAILWLCGIQ----EKGKEELPARAEAIIVSL
gi|2564063 ATYNDTDDNPSSSSLLKKTILWLCGMDSRKGDKHDQAPPAPLEPABVLL

```

45

50

55

```

              660      670
.....|.....|.....|.....|.....|.....|.....|.....|.....|.....|
NOV30      EENPLVKTLTLLDVNLIFCVSCAIFIWGYFA
gi|1794128 EENPLVKTLTLLDVNLIFCVSCAIFIWGYFA
gi|1541954 EENPLVKTLTLLDVNLIFCVSCAIFIWGYFA
gi|473969| EENPLVKTLTLLDVNLIFCVSCAIFIWGYFA
gi|1616517 EENPLVKTLTLLDVNLIFCVSCAIFIWGYFA
gi|2564063 YERPLILKQVLTAVILCMSAGVELWAYFG

```

60

The presence of identifiable domains in the protein disclosed herein was determined by searches using algorithms such as PROSITE, Blocks, Pfam, ProDomain, Prints and then determining the Interpro number by crossing the domain match (or numbers) using the Interpro website (<http://www.ebi.ac.uk/interpro/>). Table 30F lists the domain description from DOMAIN analysis results against NOV30.

Table 30F Domain Analysis of NOV30			
Model	Region of Homology	Score (bits)	E value
Sodium:solute symporter family	58-487	676.0	1e-200
Phosphotransferase system, EIIC	29-277	-161.4	0.88
Amino acid permease	71-474	-358.2	0.97
60Kd inner membrane protein	106-234	-136.8	0.78

Consistent with other known members of the sodium:solute symporter family (SSF), the NOV30 Na⁺/glucose transporter-like protein contains the sodium:solute symporter family domain and an integral membrane domain as illustrated in Table 30F (Ohashi and Erickson, J. Biol. Chem., 272: 14220-6 (1997)). NOV30 nucleic acids, and the encoded polypeptides, according to the invention are useful in a variety of applications and contexts. For example, NOV30 nucleic acids and polypeptides can be used to identify proteins that are members of the sodium:solute symporter family of proteins. The NOV30 nucleic acids and polypeptides can also be used to screen for molecules, which inhibit or enhance NOV30 activity or function. Specifically, the nucleic acids and polypeptides according to the invention may be used as targets for the identification of small molecules that modulate or inhibit, *e.g.*, cellular activation and cellular metabolism. These molecules can be used to treat, *e.g.*, for metabolic diseases such as cancer, trauma, regeneration (in vitro and in vivo), viral/bacterial/parasitic infections, hyperparathyroidism, hypoparathyroidism, inflammatory bowel disease, diverticular disease, Von Hippel-Lindau (VHL) syndrome, Alzheimer's disease, stroke, tuberous sclerosis, hypercalcaemia, Parkinson's disease, Huntington's disease, cerebral palsy, epilepsy, Lesch-Nyhan syndrome, multiple sclerosis, ataxia-telangiectasia, leukodystrophies, behavioral disorders, addiction, anxiety, pain, neurodegeneration, systemic lupus erythematosus, autoimmune disease, asthma, emphysema, scleroderma, allergy, ARDS, diabetes, autoimmune disease, renal artery stenosis, interstitial nephritis, glomerulonephritis, polycystic kidney disease, systemic lupus

erythematosus, renal tubular acidosis, IgA nephropathy, hypercalceimia, inflammatory bowel disease, diverticular disease and other diseases, disorders and conditions of the like.

In addition, various NOV30 nucleic acids and polypeptides according to the invention are useful, *inter alia*, as novel members of the protein families according to the presence of domains and sequence relatedness to previously described proteins. For example, the NOV30 nucleic acids and their encoded polypeptides include structural motifs that are characteristic of proteins belonging to the SSF family such as the Na⁺/glucose transporter proteins involved in renal transport and metabolism. (Ohashi and Erickson, J. Biol. Chem., 272: 14220-6 (1997)).

Integral membrane proteins that mediate the intake of a wide variety of molecules with the concomitant uptake of sodium ions are grouped into a number of distinct families. One of these families, known as the SSF, consists of integral membrane proteins that are predicted to comprise at least ten membrane spanning domains. Members of the SSF catalyze solute:Na⁺ symport (Reizer *et al.*, Biochem. Biophys. Acta, 1197: 133-166 (1994)) can transport sugars, amino acids, nucleosides, inositols, vitamins, urea or anions, depending on the system. Members of the SSF family have been identified in bacteria, archaea and animals, and all functionally well characterized members catalyze solute uptake via Na⁺ symport.

The NOV30 nucleic acids and polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications in the mediation of metabolism and immune function and renal physiology. As such, the NOV30 nucleic acids and polypeptides, antibodies and related compounds according to the invention may be used to treat metabolic, immune and renal disorders, *e.g.*, metabolic diseases such as diabetes and hypertension, cancer, trauma, regeneration (in vitro and in vivo), viral/bacterial/parasitic infections, hyperparathyroidism, hypoparathyroidism, inflammatory bowel disease, diverticular disease, Von Hippel-Lindau (VHL) syndrome, Alzheimer's disease, stroke, tuberous sclerosis, hypercalceimia, Parkinson's disease, Huntington's disease, cerebral palsy, epilepsy, Lesch-Nyhan syndrome, multiple sclerosis, ataxia-telangiectasia, leukodystrophies, behavioral disorders, addiction, anxiety, pain, neurodegeneration, systemic lupus erythematosus, autoimmune disease, asthma, emphysema, scleroderma, allergy, ARDS, diabetes, autoimmune disease, renal artery stenosis, interstitial nephritis, glomerulonephritis, polycystic kidney disease, systemic lupus erythematosus, renal tubular acidosis, IgA nephropathy, hypercalceimia, inflammatory bowel disease, diverticular disease and other diseases, disorders and conditions of the like. For

example, expression analysis has demonstrated that a NOV30 nucleic acid is expressed in Kidney, Parathyroid, Brain, Hippocampus, Hypothalamus, Lung, Small Intestine, Spinal Chord, Substantia Nigra, Whole Organism.

Additional utilities for NOV30 nucleic acids and polypeptides according to the invention are disclosed herein.

NOV31

A NOV31 polypeptide has been identified as a Olfactory Receptor (GPCR)-like protein (also referred to as CG56616-01). The disclosed novel NOV31 nucleic acid (**SEQ ID NO:118**) of 1201 nucleotides is shown in Table 31A. An ORF begins with Kozak consensus ATG initiation codon at nucleotides 86-88 and ends with a TAA codon at nucleotides 1040-1042. A putative untranslated region and/or downstream from the termination codon is underlined in Table 31A, and the start and stop codons are in bold letters.

Table 31A. NOV31 Nucleotide Sequence (SEQ ID NO:118)

<p>TCATTGACACATGCTTGAAAGTAATCAGAGTAAGATAAAATATTTGTCTTAACATGCTCTGTCTTACA AGCTAAAGAGGGAGTAAATATGGAATGGGAAAACCACACCATTCCTGGTGGAATTTTTCTGAAGGGAC TTTCTGGTCACCCAAGACTTGAGTTACTCTTTTTTGTGCTCATCTTCATAATGTATGTGGTCATCCT TCTGGGGAATGGTACTCTCATTTTAATCAGCATCTTGGACCCTCACCTTCACACCCCTATGTACTTC TTTCTGGGGAACCTCTCCTTCTTGGACATCTGCTACACCACCACCTCTATTCCCTCCACGCTAGTGA GCTTCCTTTTCAGAAAGAAAGACCATTTCCTTTCTGGCTGTGCAGTGCAGATGTTCCCTCAGCTTGGC CATGGGGAACAAGAGTGTGTGCTTCTGGGCGTGATGGCCTTTGACCGCTATGTGGCTATCTGCAAC CCTCTGAGATATCCCATCATCATGAGTAAGGATGCCATATGTACCCATGGCAGCTGGGTCCCTGGATCA TAGGAGCTGTCAATTCTGCAGTACAAACAGTGTTTGTGGTACAATTGCCTTTCTGCAGGAATAACAT CATCAATCATTTACCTGTGAAATTCTAGCTGTGCATGAACTGGCCTGTGCTGACATCTCAGGCAAT GAGTTCATCCTGCTTGTGACCACAACATTGTTCCCTATTGACACCTTTGTTATTAATTATTGTCTCTT ACACGTTAATCATTTTGTGAGCATCTTCAAAATTAGCTCTTCGGAGGGGAGAGCAAACTTCCTCTAC CTGCTCAGCTCGTCTGACTGTGGTGATAACATTCTGTGGGACCATCTTCCTCATGTACATGAAGCCC AAGTCTCAAGAGACACTTAATTCAGATGACTTGGATGCCACTGACAACTTATATTCATATTCTACA GGGTGATGACTCCCATGATGAATCCTTTAATCTACAGTCTTAGAAACAAGGATGTGAAGGAGGCAGT AAAACACCTACTGAGAAGAAAAAATTTAACAAGTAAATGAGAAAGGTGAGAGTAATTTTATAATCA CAATATGGAAATCAATTAGAGAAACCAAGGTTAAACAGATAGGTTCTCGTTGCTGTTTCACATTCAT CTCTCGAAGTTCTAAAGCTCCAAATACACTTCTCTGATTGCGATACATAATGAAAAGAAGT</p>
--

The NOV31 protein (**SEQ ID NO:119**) encoded by **SEQ ID NO:118** is 318 amino acid residues in length and is presented using the one-letter amino acid code in Table 31B. NOV31 has at least 10 SNP variants, whose variant positions for its nucleotide and amino acid sequences

is numbered according to **SEQ ID NOS:118 and 119**, respectively. A variant sequence can include a single nucleotide polymorphism (SNP). A SNP can, in some instances, be referred to as a "cSNP" to denote that the nucleotide sequence containing the SNP originates as a cDNA. Variant sequences of NOV31 are included in Example 2.

Psort analysis predicts the NOV31 protein of the invention to be localized to the plasma membrane with a certainty of 0.6000. The Signal P predicts a likely cleavage site for a NOV29b peptide is between positions 41 and 42, *i.e.*, at the dash in the sequence LLG-NG.

Table 31B. Encoded NOV31 protein sequence (SEQ ID NO:119)

MEWENHTILVEFFLKGLSGHPRLELLFFVLIFIMYVILLGNGTLILISILDPHLHTPMYFFLGN
LSFLDICYTTTSTLVSFLSERKTISLSCAVQMFLSLAMGTTECVLLGVMAFDYVAICNPL
RYPIMSKDAYVPMAGSWIIGAVNSAVQTVFVVQLPFCRNNIINHFTCEILAVMKLACADISGN
EFILLVTTTLFLLTPLLIIIVSYTLIILSIFKISSSEGRSKPSSTCSARLTVVITFCGTIFLMYM
KPKSQETLNSDDL DATDKLIFIFYRVMT PMMNPLIYSLRNKDVKEAVKHLRRKNFNK

A search against the Patp database, a proprietary database that contains sequences published in patents and patent publications, yielded several homologous proteins shown in Table 31C.

Table 31C. Patp results for NOV31

Sequences producing High-scoring Segment Pairs:	Reading Frame	High Score	Smallest Sum Prob P(N)
>patp:AAG71953 Human olfactory receptor polypeptide	+1	1620	2.7e-166
>patp:AAU24703 Human olfactory receptor AOLFR202	+1	1620	2.7e-166
>patp:AAG71431 Human olfactory receptor polypeptide	+1	1504	5.2e-154
>patp:AAU24702 Human olfactory receptor AOLFR201	+1	1504	5.2e-154
>patp:AAG72024 Human olfactory receptor polypeptide	+1	1399	7.0e-143

In a BLAST search of public sequence databases, it was found, for example, that the NOV31 nucleic acid sequence of this invention has 702 of 991 bases (70%) identical to a gb:GENBANK-ID:MMU133426|acc:AJ133426.1 mRNA from *Mus musculus* (or37c gene). The full amino acid sequence of the protein of the invention was found to have 209 of 314 amino acid residues (66%) identical to, and 246 of 314 amino acid residues (78%) similar to, the 318 amino acid residue ptnr:SPTREMBL-ACC:Q9QZ21 protein from *Mus musculus* (OLFACTORY RECEPTOR). Also 100% similarity to Genbank_AL450426.3 sequence that is not annotated.

NOV31 also has homology to the proteins shown in the BLASTP data in Table 31D.

Table 31D. BLAST results for NOV31

Gene Index/ Identifier	Protein/ Organism	Length (aa)	Identity (%)	Positives (%)	Expect
gi 17452276 ref XP_071094.1 (XM_071094)	similar to olfactory receptor 37b [<i>Homo sapiens</i>]	318	291/318 (91%)	291/318 (91%)	1e-150
gi 17452271 ref XP_071093.1 (XM_071093)	similar to olfactory receptor 37b [<i>Homo sapiens</i>]	318	272/318 (85%)	279/318 (87%)	1e-137
gi 17452269 ref XP_071092.1 (XM_071092)	similar to olfactory receptor 37b [<i>Homo sapiens</i>]	318	255/318 (80%)	268/318 (84%)	1e-127
gi 11276077 ref NP_062347.1 (NM_019474)	olfactory receptor 37b [<i>Mus musculus</i>]	318	200/314 (63%)	230/314 (72%)	1e-101
gi 11276079 ref NP_062348.1 (NM_019475)	olfactory receptor 37c [<i>Mus musculus</i>]	318	198/310 (63%)	224/310 (71%)	8e-99

A multiple sequence alignment is given in Table 31E, with the NOV31 protein being shown on line 1 in Table 31E in a ClustalW analysis, and comparing the NOV31 protein with the related protein sequences shown in Table 31D. This BLASTP data is displayed graphically in the ClustalW in Table 31E.

Table 31E. ClustalW Analysis of NOV31

- 1) > NOV31; **SEQ ID NO:119**
- 2) > gi|1745227/ similar to Olfactory receptor 37b [*Homo sapiens*] ; **SEQ ID NO:322**
- 3) > gi|1745227/ similar to olfactory receptor 37b [*Homo sapiens*] ; **SEQ ID NO:323**
- 4) > gi|1745226/ similar to olfactory receptor 37b [*Homo sapiens*] ; **SEQ ID NO:324**
- 5) > gi|1127607/ olfactory receptor 37b [*Mus musculus*] ; **SEQ ID NO:325**
- 6) > gi|1127607/ olfactory receptor 37c [*Mus musculus*] ; **SEQ ID NO:326**

		10	20	30	40	50
NOV31	MEWENHTILVEFFLKGLSCHPRLELLFFVLIFIMYVVILLGNGTLILISI					
gi 1745227	MEWENHTILVEFFLKGLSCHPRLELLFFVLIFIMYVVILLGNGTLILISI					
gi 1745227	MEWENHTILVEFFLKGLSCHPRLELLFFVLIFIMYVVILLGNGTLILISI					
gi 1745226	MEWENHTILVEFFLKGLSCHPRLELLFFVLIFIMYVVILLGNGTLILISI					
gi 1127607	MEGANQSTVAEFVLLGLSDHPKLEKTFVLLILLMYLVILLGNGVLIIVSI					
gi 1127607	MDVSNQTTVTTEFVLLGLSAHPKLEKTFVLLILLMYLVILLGNGVLIIVSI					
		60	70	80	90	100
NOV31	LDPHLHTPMYFFLGNLISFLDICYTTTSIPSTLVSFSLSERKTISLSGCAVQ					
gi 1745227	LDPHLHTPMYFFLGNLISFLDICYTTTSIPSTLVSFSLSERKTISLSGCAVQ					
gi 1745227	LDPHLHTPMYFFLGNLISFLDICYTTTSIPSTLVSFSLSERKTISLSGCAVQ					
gi 1745226	LDPHLHTPMYFFLGNLISFLDICYTTTSIPSTLVSFSLSERKTISLSGCAVQ					
gi 1127607	LDLHLHTPMYFFLGDLISFLDICYTTSSIPLVLDGFLTPRKTISFSGCAVQ					
gi 1127607	LDLHLHTPMYFFLGDLISFLDICYTTSSIPLVLDGFLTPRKTISFSGCAVQ					

		110	120	130	140	150
5	NOV31	MFLSLAMGTTECVLLGVMAFD	RYVAICNPLRYPIIMSKDAYV	PMAAGSWI		
	gi 1745227	MFLSLAMGTTECVLLGVMAFD	RYVAICNPLRYPIIMSKDAYV	PMAAGSWI		
	gi 1745227	MFLGLAMGTTECVLLGVMAFD	RYVAICNPLRYPIIMSKDAYV	PMAAGSWI		
	gi 1745226	MFLGLAMGTTECVLLGVMAFD	RYVAICNPLRYPIIMSKNAYV	PMAVGSWF		
	gi 1127607	MFLSFAMGATECVLLGVMAFD	RYVAICNPLRYPVVMNKSA	YVMAVSSWV		
10	gi 1127607	MFLSFAMGATECVLLGVMAFD	RYVAICNPLRYPVVMNKA	AYVMAVSSWV		
		160	170	180	190	200
	NOV31	IGAVNSAVQTVFVVQLPFCRN	NIINHFTCEILAVMKLACADIS	CNEFILL		
	gi 1745227	IGAVNSAVQTVFVVQLPFCRN	NIINHFTCEILAVMKLACADIS	CNEFILL		
15	gi 1745227	IGAVNSAVQSVFVVQLPFCRN	NIINHFTCEILAVMKLACADIS	CNEFIML		
	gi 1745226	AGIVNSAVQTVFVVQLPFCRN	VINHFSCEILAVMKLACADIS	CNEFLML		
	gi 1127607	AGGANSLVQISLAVQLPFCG	DNVINHFTCEILAVLKLACADIS	INVISMG		
	gi 1127607	AGGANSLVQISLAVQLPFCG	DNVINHFTCEILAVLKLACADIS	INVISMG		
20		210	220	230	240	250
	NOV31	VTTTLFLLTPLLLIIVSYTLI	ILSIFKISSSEGRSKPSS	TCSARLTVVIT		
	gi 1745227	VTTTLFLLTPLLLIIVSYTLI	ILSIFKISSSEGRSKPSS	TCSARLTVVIT		
	gi 1745227	VATTLFLLTPLLLIIVSYTLI	IVSIFKISSSEGRSKAS	TCSAHLTVVII		
25	gi 1745226	VATILFTMPLLLIIVISYSLI	ISSILKIHSEGRSKAF	STCSAHLTVVII		
	gi 1127607	VANVIFLGVEVLFIFVSYIF	ILSTILRIPSAEGRKKA	FSTCSAHLTVVLV		
	gi 1127607	VANVIFLGVEVLFIFVSYIF	ILSTILRIPSAEGRKKA	FSTCSAHLTVVII		
		260	270	280	290	300
	NOV31	FCGTIFLMYMKPKSQETLNS	DDLDATDKLIFIFYRVMT	PMNPLIYSLRN		
	gi 1745227	FCGTIFLMYMKPKSQETLNS	DDLDATDKLIFIFYRVMT	PMNPLIYSLRN		
	gi 1745227	FYGTIFLMYMKPKSKETLNS	DDLDATDKIISMFGVMT	PMNPLIYSLRN		
	gi 1745226	FYGTIFLMYMKPKSKETLNS	DDLDATDKIISMFGVMT	PMNPLIYSLRN		
35	gi 1127607	FYGTIFLMYCKPKSKDPLG	ADKQDVSDKLISLFYGL	TPMLNP	IYSLRN	
	gi 1127607	FYGTIFLMYCKPKSKDPLG	ADKQDLADKLISLFYGL	TPMLNP	IYSLRN	
		310				
40	NOV31	KDVKEAVKHLLRRKNFNK				
	gi 1745227	KDVKEAVKHLLRRKNFNK				
	gi 1745227	KDVKEAVKHLLNRRFFSK				
	gi 1745226	KDVKEAVKHLPNRRFFSK				
	gi 1127607	KDVKAAVRNLVGQKCLIQ				
45	gi 1127607	KDVKAAVRNLA	SHRCLTF			

The presence of identifiable domains in the protein disclosed herein was determined by
 searches using algorithms such as PROSITE, Blocks, Pfam, ProDomain, Prints and then
 determining the Interpro number by crossing the domain match (or numbers) using the Interpro
 website (<http://www.ebi.ac.uk/interpro/>). The DOMAIN analysis results indicate that the NOV31
 protein contains the following protein domain (as defined by Interpro): domain name 7tm_1 7
 transmembrane receptor (rhodopsin family). DOMAIN results for NOV31 were collected from

the Conserved Domain Database (CDD) with Reverse Position Specific BLAST. This BLAST samples domains found in the Smart and Pfam collections.

As discussed below, the NOV31 protein of the invention contained significant homology to the 7tm_1 domain. This indicates that the NOV31 sequence has properties similar to those of other proteins known to contain this 7tm_1 domain and similar to the properties of these domains. The 254 amino acid domain termed 7tm_1 (SEQ ID NO:327; Pfam Acc. No. 00001) a seven transmembrane receptor (rhodopsin family), is shown in Table 31F.

Table 31F. 7tm_1, 7 transmembrane receptor domain (SEQ ID NO:327)	
GNLLVILVILRTKKLRTPTNIFLLNLAVADLLFLLTLPWALYYLVGGDWVFGDALCKLVGALFVVNGYASILLTTAISIDRYL	
AIVHPLRYRRIRTPRRAKVLILLVWVLALLSLPPLLFSLWRTVEEGNTTVCLIDFPEESVKRSYVLLSTLVGFVLPPLLVILVC	
YTRILRTLKRARSQSLKRRSSSERKAAKMLLVVVVFLCWLPHYHIVLLDLSLCLLSIWRVLP TALLITLWLAYVNSCLNPI	
IY	

The DOMAIN results are listed in Table 31G with the statistics and domain description. An alignment of NOV31 residues 41-296 (SEQ ID NO:119) with the full 7tm_1 domain, residues 1-254 (SEQ ID NO:327), are shown in Table 31G. This indicates that the NOV31 sequences have properties similar to those of other proteins known to contain this domain as well as to the 254 amino acid 7tm domain (SEQ ID NO:327). For Table 31G, fully conserved single residues are indicated by the vertical line and “strong” semi-conserved residues are indicated by the “plus sign.” The “strong” group of conserved amino acid residues may be any one of the following groups of amino acids: STA, NEQK, NHQK, NDEQ, QHRK, MILV, MILF, HY, FYW.

Table 31G Domain Analysis of NOV31
PSSMs producing significant alignments:

		Score	E
		(bits)	value
gnl Pfam pfam00001	7tm_1, 7 transmembrane receptor (rhodopsin family)	128.7	7.9e-40

		*->GNLLVilvilrtkklrtptnifilNLAvADLLflltlppwalyylv	
		+ + ++ + + +++ ++ ++ +++++ + + ++	
NOV31	41	GNGTLILISILDPHLHTPMYFFLGNSFLDICYTTTTSIPSTLVSFSL 87	
		gsedWpfGsalCklvtaldvvnmyaSilllLtaISiDRYlAivhPlryrrr	
		++ ++ + ++++ ++ +++ + ++++ + ++ + +	

NOV31 88 --ERKTISLSGCAVQMFLSLAMGTTTECVLLGVMAFDRYVAICNPLRYPII 135

5 NOV31 136 MS-KDAYVPMAGSWIIGAVNSAVQTVF-VVQLPFCRNNI--INHFTCEI 181

10 NOV31 182 LAVMKLACAdISGN-EFILLVTTTLFLLTPLLLIIVSYTLIILSIFkiss 230

NOV31 231 segsrskpsSTCSARLTVVITFC-----GTIFLMYMKpKS---QETLNS 270

15 NOV31 271 DDLDATDKLIFIFYRVMTMPMNPLIY 296 (SEQ ID NO:119)

Consistent with other known members of the GPCR family of proteins, NOV31 contains 7tm_1 7 transmembrane receptor (rhodopsin family) domain as illustrated in Table 31G as well as homology and cellular localization, *i.e.* plasma membrane.

NOV31 nucleic acids, and the encoded polypeptides, according to the invention are useful in a variety of applications and contexts. For example, NOV31 nucleic acids and polypeptides can be used to identify proteins that are members of the GPCR family of proteins. The NOV31 nucleic acids and polypeptides can also be used to screen for molecules, which inhibit or enhance NOV31 activity or function. Specifically, the nucleic acids and polypeptides according to the invention may be used as targets for the identification of small molecules that modulate or inhibit, *e.g.*, cellular signal transduction. These molecules can be used to treat, *e.g.*, cancer, immune disorders, and endocrine disorders.

In addition, various NOV31 nucleic acids and polypeptides according to the invention are useful, *inter alia*, as novel members of the protein families according to the presence of domains and sequence relatedness to previously described proteins. For example, the NOV31 nucleic acids and their encoded polypeptides include 7tm_1 7 transmembrane receptor (rhodopsin family) domain and sequence homology that are characteristic of proteins belonging to the family of GPCR such as the G protein-coupled olfactory receptor. The NOV31 protein of the invention has a high homology to the 7tm_1 domain (PFam Acc. No. pfam00001). The 7tm_1 domain is from the 7 transmembrane receptor family, which includes a number of different proteins, including, for example, serotonin receptors, dopamine receptors, histamine receptors, andadrenergic receptors, cannabinoid receptors, angiotensin II receptors, chemokine receptors,

opioid receptors, G-protein coupled receptor (GPCR) proteins, olfactory receptors (OR), and the like.

G-Protein Coupled Receptor proteins ("GPCRs") have been identified as a large family of G protein-coupled receptors in a number of species. These receptors share a seven transmembrane domain structure with many neurotransmitter and hormone receptors, and are likely to underlie the recognition and G-protein-mediated transduction of various signals. Human GPCR generally do not contain introns and belong to four different gene subfamilies, displaying great sequence variability. These genes are dominantly expressed in olfactory epithelium. See, *e.g.*, Ben-Arie *et al.*, Hum. Mol. Genet. 3:229-235 (1994); and, Online Mendelian Inheritance in Man ("OMIM") entry # 164342 (<http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?>).

The NOV31 nucleic acids and polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications in the mediation of cellular signal transduction. As such the NOV31 nucleic acids and polypeptides, antibodies and related compounds according to the invention may be used to treat a wide range of disorders such as cancer, immune disorders, endocrine disorders and other diseases, *e.g.*, developmental diseases; MHCII and III diseases (immune diseases); taste and scent detectability disorders; Burkitt's lymphoma; corticoneurogenic disease; signal transduction pathway disorders; metabolic pathway disorders; retinal diseases including those involving photoreception; cell growth rate disorders; cell shape disorders; metabolic disorders; feeding disorders; control of feeding; the metabolic syndrome X; wasting disorders associated with chronic diseases; obesity; potential obesity due to over-eating or metabolic disturbances; potential disorders due to starvation (lack of appetite); diabetes; noninsulin-dependent diabetes mellitus (NIDDM); infectious disease; bacterial, fungal, protozoal and viral infections (particularly infections caused by HIV-1 or HIV-2); pain; cancer (including but not limited to neoplasm; adenocarcinoma; lymphoma; prostate cancer; uterus cancer); cancer-associated cachexia; anorexia; bulimia; asthma; Parkinson's disease; acute heart failure; hypotension; hypertension; urinary retention; osteoporosis; Crohn's disease; multiple sclerosis; Albright Hereditary Osteodystrophy; angina pectoris; myocardial infarction; ulcers; allergies; benign prostatic hypertrophy; and psychotic and neurological disorders; including anxiety; schizophrenia; manic depression; delirium; dementia; neurodegenerative disorders; Alzheimer's disease; severe mental retardation; Dentatorubro-

pallidoluisian atrophy (DRPLA); Hypophosphatemic rickets; autosomal dominant (2)
 Acrocallosal syndrome and dyskinesias, such as Huntington's disease or Gilles de la Tourette
 syndrome; immune disorders; Adrenoleukodystrophy; Congenital Adrenal Hyperplasia;
 Hemophilia; Hypercoagulation; Idiopathic thrombocytopenic purpura; autoimmune disease;
 5 immunodeficiencies; transplantation; Von Hippel-Lindau (VHL) syndrome; Stroke; Tuberous
 sclerosis; hypercalcaemia; Cerebral palsy; Epilepsy; Lesch-Nyhan syndrome; Ataxia-
 telangiectasia; Leukodystrophies; Behavioral disorders; Addiction; Neuroprotection; Cirrhosis;
 Transplantation; Systemic lupus erythematosus; Emphysema; Scleroderma; ARDS; Renal artery
 stenosis; Interstitial nephritis; Glomerulonephritis; Polycystic kidney disease; Systemic lupus
 10 erythematosus; Renal tubular acidosis; IgA nephropathy; Cardiomyopathy; Atherosclerosis;
 Congenital heart defects; Aortic stenosis ; Atrial septal defect (ASD); Atrioventricular (A-V)
 canal defect; Ductus arteriosus; Pulmonary stenosis ; Subaortic stenosis; Ventricular septal
 defect (VSD); valve diseases; Scleroderma; fertility; Pancreatitis; Endocrine dysfunctions;
 Growth and reproductive disorders; Inflammatory bowel disease; Diverticular disease;
 15 Leukodystrophies; Graft versus host; Hyperthyroidism; Endometriosis; and hematopoietic
 disorders.

The NOV31 nucleic acids and polypeptides are useful for detecting specific cell types.
 For example, expression analysis has demonstrated that a NOV31 nucleic acid is expressed in
 Apical microvilli of the retinal pigment epithelium, arterial (aortic), basal forebrain, brain,
 20 Burkitt lymphoma cell lines, corpus callosum, cardiac (atria and ventricle), caudate nucleus,
 CNS and peripheral tissue, cerebellum, cerebral cortex, colon, cortical neurogenic cells,
 endothelial (coronary artery and umbilical vein) cells, palate epithelia, eye, neonatal eye, frontal
 cortex, fetal hematopoietic cells, heart, hippocampus, hypothalamus, leukocytes, liver, fetal
 liver, lung, lung lymphoma cell lines, fetal lymphoid tissue, adult lymphoid tissue, Those that
 25 express MHC II and III nervous, medulla, subthalamic nucleus, ovary, pancreas, pituitary,
 placenta, pons, prostate, putamen, serum, skeletal muscle, small intestine, smooth muscle
 (coronary artery in aortic) spinal cord, spleen, stomach, taste receptor cells of the tongue, testis,
 thalamus, and thymus tissue.

Additional utilities for NOV31 nucleic acids and polypeptides according to the invention are
 30 disclosed herein.

NOV32

A NOV32 polypeptide has been identified as a Phosphoenolpyruvate Carboxykinase (PCK)-like protein (also referred to as 153065222). The disclosed novel NOV32 nucleic acid (**SEQ ID NO:120**) of 2069 nucleotides is shown in Table 32A. The cDNA coding for the

5 NOV32 was cloned by polymerase chain reaction (PCR) using the following primers:
CCTTCCATACCTCCCCGGCTC (**SEQ ID NO:328**) and
TGTGGGAAGGTCTATGGCACATTGA (**SEQ ID NO:329**) on the following pools of human
cDNAs: Pool 1 - adrenal gland, bone marrow, brain - amygdala, brain - cerebellum, brain -
hippocampus, brain - substantia nigra, brain - thalamus, brain -whole, fetal brain, fetal kidney,
10 fetal liver, fetal lung, heart, kidney, lymphoma - Raji, mammary gland, pancreas, pituitary gland,
placenta, prostate, salivary gland, skeletal muscle, small intestine, spinal cord, spleen, stomach,
testis, thyroid, trachea, uterus.

15 An ORF begins with Kozak consensus ATG initiation codon at nucleotides 67-69 and
ends with a TGA codon at nucleotides 1891-1893. A putative untranslated region and/or
downstream from the termination codon is underlined in Table 32A, and the start and stop
codons are in bold letters.

Table 32A. NOV32 Nucleotide Sequence (SEQ ID NO:120)

CCCGCCTTCCATACCTCCCCGGCTCCGCTCGGTTCTGGCCACCCCGCAGCCCCTGCCCAGGTGCCA TGGCCGCATTGTACCGCCCTGGCCTGCGGCTTAAGTGGCATGGGCTGAGCCCCTTGGGCTGGCCATC ATGCCGTAGCATCCAGACCCTGCGAGTGCTTAGTGGAGATCTGGGCCAGCTTCCCACTGGCATTGCA GATTTTGTAGAGCACAGTGGCCGCTGTGCCAACAGAGGGCATCCACATCTGTGATGGAAGTGAAGG CTGAGAATACTGCCACACTGACCTGCTGGAGCAGCAGGGCCTCATCCGAAAGCTCCCCAAGTACAA TAACTGCTGGCTGGCCCGCACAGACCCCAAGGATGTGGCACGAGTAGAGAGCAAGACGGTGATTGTA ACTCCTTCTCAGCGGGACACGGTACCACTCCCGCCTGGTGGGGCCTGTGGGCAGCTGGGCAACTGGA TGTCCCCAGCTGATTTCCAGCGAGCTGTGGATGAGAGGTTTCCAGGCTGCATGCAGGGCCGCACCAT GTATGTGCTTCCATTGAGCATGGGTCTGTGGGCTCCCGCTGTCCCGCATCGGGGTGCAGCTCACT GACTCAGCCTATGTGGTGGCAAGCATGCGTATTATGACCCGACTGGGGACACCTGTGCTTCAGGCCC TGGGAGATGGTGACTTTGTCAAGTGTCTGCACTCCGTGGGCCAGCCCCTGACAGGACAAGGGGAGCC AGTGAGCCAGTGGCCGTGCAACCCAGAGAAAACCTGATTGGCCACGTGCCCCAGCAGCGGGAGATC ATCTCCTTCCGCGAGCGGCTATGGTGGCAACTCCCTGCTGGGCAAGAAGTGCTTTGCCCTACGCATCG CCTCTCGGCTGGCCCGGGATGAGGGCTGGCTGGCAGAGCACATGCTGATCCTGGGCATCACCAGCCC TGCAGGGAAGAAGGCGCTATGTGCAGCCGCTTCCCTAGTGCCTGTGGCAAGACCAACCTGGCTATG ATGCGGCTGCACTGCCAGGCTGGAAAGTGGAGTGTGTGGGGGATGATATTGCTTGGATGAGGTTTG ACAGTGAAGGTCGACTCCGGGCCATCAACCCTGAGAACGGCTTCTTTGGGGTTGCCCCCTGGTACCTC TGCCACCACCAATCCCAACGCCATGGCTACAATCCAGAGTAACACTATTTTACCAATGTGGCTGAG ACCAGTGATGGTGGCGTGTACTGGGAGGGCATTGACCAGCCTCTTCCACCTGGTGTTACTGTGACCT CCTGGCTGGGCAAAACCTGGAAACCTGGTGACAAGGAGCCCTGTGCACATCCCAACTCTCGATTTTG TGCCCCGGCTCGCCAGTGCCCCATCATGGACCCAGCCTGGGAGGGCCCCAGAGGGTGTCCCCATTGAC GCCATCATCTTTGGTGGCCGCAGACCCAAAGGAAGATCATCATGCACGACCCATTTGCCATGCGGC CCTTTTTTGGCTACAACCTCGGGCACTACCTGGAACACTGGCTGAGCATGGAAGGGCGCAAGGGGGC CCAGCTGCCCCGTATCTTCATGTCAACTGGTTCGGCGTGACGAGGCAGGGCACTTCTGTGGCCA
--

GGCTTTGGGGAGAATGCTCGGGTGCTAGACTGGATCTGCCGGCGGTTAGAGGGGGAGGACAGTGCCC
 GAGAGACACCCATTGGGCTGGTGCCAAAGGAAGGAGCCTTGGATCTCAGCGGCCTCAGAGCTATAGA
 CACCACCTCAGCTGTTCTCCCTCCCAAGGACTTCTGGGAACAGGAGGTTTCGTGACATTCGGAGCTAC
 CTGACAGAGCAGGTCAACCAGGATCTGCCCCAAGAGGTGTTGGCTGAGCTTGAGGCCCTGGAGAGAC
 GTGTGCACAAAATGTGACCTGAGGCCTAGTCTAGCAAGAGGACATAGCACCCCTCATCTGGGAATAGG
 GAAGGCACCTTGACAGAAAATATGAGCAATTGATATTAACATAACATCTTCAATGTGCCATAGACCTTC
 CCACAAAGACTGTCCAATAATAAGAGATGCTTATCTATTTTAAAAAAAAAAAAAAAAAAAAA

The NOV32 protein (SEQ ID NO:121) encoded by SEQ ID NO:120 is 608 amino acid residues in length and is presented using the one-letter amino acid code in Table 32B. NOV32 has two SNP variants, whose variant positions for its nucleotide and amino acid sequences is numbered according to SEQ ID NOS:120 and 121, respectively. A variant sequence can include a single nucleotide polymorphism (SNP). A SNP can, in some instances, be referred to as a "cSNP" to denote that the nucleotide sequence containing the SNP originates as a cDNA.

NOV32 variant 13376584 is a G to A SNP at 116 bp of the nucleotide sequence that results in a Ser to Asn change at amino acid 17 of protein sequence, and variant 13376583 is a C to T SNP at 1297 bp of the nucleotide sequence that results in a Pro to Ser change at amino acid 411 of protein sequence.

Psort analysis predicts the NOV32 protein of the invention to be localized in the mitochondria with a certainty of 0.5801.

Table 32B. Encoded NOV32 protein sequence (SEQ ID NO:121)

MAALYRPGLRLNWHGLSPLGWPSRCSIQTLRVLSGDLGQLPTGIRDFVEHSARLCQPEGIHIICDGTEAENTAT
 LTLEQQGLIRKLPKYNNCWLARTDPKDVARVESKTVIVTPSQRDVPLPPGGACGQLGNWMSPADFQRAVDE
 RFPGCMQGRMTMYVLPFSMGPVGSPLSRIGVQLTDSAYVVASMRIMTRLGTPVLQALGDGDFVKCLHVSQGPLT
 GQGEVPSQWPCNPEKTLIGHVPDQREIISFGSGYGGNSLLGKKCFALRIASRLARDEGWLAEHMLILGITSPA
 GKALCAAAPFSACGKTNLAMMRPALPGWKVECVGDDIAWMRFDSEGRRLRAINPENGFFGVAPGTSATTNPNA
 MATIQSNTIFTNVAETSDGGVWEGIDQPLPPGVTVTSWLGKPKWPGDKEPCAHPNSRFCAPARQCPIMDPAW
 EAPEGVPIDAIIFGRRPKGKIIMHDPFAMRPFPGYNFGHYLEHWLSMEGRKGAQLPRI FHVNWFRDEAGHF
 LWPGFGENARVLDWICRRLEGEDSARETPIGLVPKEGALDLSGLRAIDTTQLFSLPKDFWEQEVRDIRSYLTE
 QVNQDLPKVELAELEALERRVHKM

A search against the Patp database, a proprietary database that contains sequences published in patents and patent publications, yielded several homologous proteins shown in Table 32C.

Table 32C. Patp results for NOV32

Sequences producing High-scoring Segment Pairs:	Reading Frame	High Score	Smallest Sum Prob P(N)
>patp:AAV80296 Human mitochondrial PEPCK	+1	2494	0.0
>patp:AAB71890 Mouse PCK-cytosolic protein	+1	1765	3.9e-238
>patp:AAB71880 Human PCK-cytosolic protein	+1	1763	1.4e-235
>patp:AAR15144 <i>Haemonchus contortus</i> PEPCK	+1	1410	1.2e-194
>patp:AAV35500 <i>Chlamydia pneumoniae</i> transmembrane protein	+1	1251	1.4e-161

In a BLAST search of public sequence databases, it was found, for example, that the NOV32 nucleic acid sequence of this invention has 1557 of 1636 bases (95%) identical to a gb:GENBANK-ID:HSPPPCK|acc:X92720.1 mRNA from *Homo sapiens* (mRNA for phosphoenolpyruvate carboxykinase). The full amino acid sequence of the protein of the invention was found to have 459 of 469 amino acid residues (97%) identical to, and 463 of 469 amino acid residues (98%) similar to, the 640 amino acid residue ptmr:SWISSPROT-ACC:Q16822 protein from *Homo sapiens* (PHOSPHOENOLPYRUVATE CARBOXYKINASE, MITOCHONDRIAL PRECURSOR [GTP] (EC 4.1.1.32) (PHOSPHOENOLPYRUVATE CARBOXYLASE) (PEPCK-M)).

NOV32 also has homology to the proteins shown in the BLASTP data in Table 32D.

Table 32D. BLAST results for NOV32

Gene Index/ Identifier	Protein/ Organism	Length (aa)	Identity (%)	Positives (%)	Expect
gi 14750965 ref XP_033337.1 (XM_033337)	phosphoenolpyruvate carboxykinase 2 (mitochondrial) [<i>Homo sapiens</i>]	640	577/640 (90%)	577/640 (90%)	0.0
gi 3287892 sp Q16822	PPCM_HUMAN PHOSPHOENOLPYRUVATE CARBOXYKINASE, MITOCHONDRIAL PRECURSOR [GTP] (PHOSPHOENOLPYRUVATE CARBOXYLASE) (PEPCK-M)	640	581/640 (90%)	581/640 (90%)	0.0

gi 16307539 gb AAH10318.1 AAH10318 (BC010318)	Similar to phosphoenolpyruvate carboxykinase 2 (mitochondrial) [<i>Mus musculus</i>]	640	530/624 (84%)	549/624 (87%)	0.0
gi 12655193 gb AAH01454.1 AAH01454 (BC001454)	phosphoenolpyruvate carboxykinase 2 (mitochondrial) [<i>Homo sapiens</i>]	640	578/640 (90%)	578/640 (90%)	0.0
gi 4758886 ref NP_004554.1 (NM_004563)	phosphoenolpyruvate carboxykinase 2 (mitochondrial) [<i>Homo sapiens</i>]	640	582/640 (90%)	582/640 (90%)	0.0

A multiple sequence alignment is given in Table 32E, with the NOV32 protein being shown on line 1 in Table 32E in a ClustalW analysis, and comparing the NOV32 protein with the related protein sequences shown in Table 32D. This BLASTP data is displayed graphically in the ClustalW in Table 32E.

Table 32E. ClustalW Analysis of NOV32

- 1) > NOV32; **SEQ ID NO:121**
- 2) > gi|1475096/ Phosphoenolpyruvate carboxykinase 2 (mitochondrial) [*Homo sapiens*]; **SEQ ID NO:330**
- 3) > gi|3287892/ PPCM_human phosphoenolpyruvate carboxykinase, mitochondrial precursor [GTP]; **SEQ ID NO:331**
- 4) > gi|1630753/ Similar to phosphoenolpyruvate carboxykinase 2 (mitochondrial) [*Mus musculus*]; **SEQ ID NO:332**
- 5) > gi|1265519/ phosphoenolpyruvate carboxykinase 2 (mitochondrial) [*Homo sapiens*]; **SEQ ID NO:333**
- 6) > gi|4758886/ phosphoenolpyruvate carboxykinase 2 (mitochondrial) [*Homo sapiens*]; **SEQ ID NO:334**

		10	20	30	40	50
NOV32	MAALYRPGRLRNWHGLSPLGWPCRSIQTLRVLSGDLGQLPTGIRDFVEH					
gi 1475096	MAALYRPGRLRNWHGLSPLGWPCRSIQTLRVLSGDLGQLPTGIRDFVEH					
gi 3287892	MAALYRPGRLRNWHGLSPLGWPCRSIQTLRVLSGDLGQLPTGIRDFVEH					
gi 1630753	MAAMYLPGRLRSRHGLRPWCWSPCRSIQTLRVLSGDMSQLPAGVRDFVAR					
gi 1265519	MAALYRPGRLRNWHGLSPLGWPCRSIQTLRVLSGDLGQLPTGIRDFVEH					
gi 4758886	MAALYRPGRLRNWHGLSPLGWPCRSIQTLRVLSGDLGQLPTGIRDFVEH					
		60	70	80	90	100
NOV32	SARLCQPEGIHI CDGTEAENTATLTLEQQGLIRKLPKYNNCW LARTDPK					
gi 1475096	SARLCQPEGIHI CDGTEAENTATLTLEQQGLIRKLPKYNNCW LARTDPK					
gi 3287892	SARLCQPEGIHI CDGTEAENTATLTLEQQGLIRKLPKYNNCW LARTDPK					
gi 1630753	SARLCQPEGIHI CDGTEAENTATLTLEQQGLIRKLPKYNNCW LARTDPK					
gi 1265519	SARLCQPEGIHI CDGTEAENTATLTLEQQGLIRKLPKYNNCW LARTDPK					
gi 4758886	SARLCQPEGIHI CDGTEAENTATLTLEQQGLIRKLPKYNNCW LARTDPK					
		110	120	130	140	150
NOV32	DVARVESKTVIVTPSQRDVPLPPGGACGQLGNWMSPADFQRAVDERFPG					
gi 1475096	DVARVESKTVIVTPSQRDVPLPPGGARGQLGNWMSPADF-----					
gi 3287892	DVARVESKTVIVTPSQRDVPLPPGGARGQLGNWMSPADF-----					
gi 1630753	DVARVESKTVIVTPSQRDVPLPPGGARGQLGNWMSPADF-----					
gi 1265519	DVARVESKTVIVTPSQRDVPLPPGGARGQLGNWMSPADF-----					
gi 4758886	DVARVESKTVIVTPSQRDVPLPPGGACGQLGNWMSPADF-----					

The NOV32 Clustal W alignment shown in Table 32E was modified to end at amino residue 150. The data in Table 32E includes all of the regions overlapping with the NOV32 protein sequences.

The presence of identifiable domains in the protein disclosed herein was determined by searches using algorithms such as PROSITE, Blocks, Pfam, ProDomain, Prints and then determining the Interpro number by crossing the domain match (or numbers) using the Interpro website (<http://www.ebi.ac.uk/interpro/>). Table 32F lists the domain description from DOMAIN analysis results against NOV32.

Table 32F Domain Analysis of NOV32			
Model	Region of Homology	Score (bits)	E value
Phosphoenolpyruvate carboxykinase	46-456	1193.2	0
Phosphoenolpyruvate carboxykinase	457-608	381.5	4.5e-112

Consistent with other known members of the PCK family of proteins, NOV32 contains phosphoenolpyruvate carboxykinase domains as illustrated in Table32F. NOV32 nucleic acids, and the encoded polypeptides, according to the invention are useful in a variety of applications and contexts. For example, NOV32 nucleic acids and polypeptides can be used to identify proteins that are members of the PCK family of proteins. The NOV32 nucleic acids and polypeptides can also be used to screen for molecules, which inhibit or enhance NOV32 activity or function. Specifically, the nucleic acids and polypeptides according to the invention may be used as targets for the identification of small molecules that modulate or inhibit, *e.g.*, gluconeogenesis. These molecules can be used to treat, *e.g.*, hypoglycemia and other diseases, disorders and conditions of the like.

In addition, various NOV32 nucleic acids and polypeptides according to the invention are useful, *inter alia*, as novel members of the protein families according to the presence of domains and sequence relatedness to previously described proteins. For example, the NOV32 nucleic acids and their encoded polypeptides include structural motifs and homology that are characteristic of proteins belonging to the family of PCK proteins which

Phosphoenolpyruvate carboxykinase (GTP) (PCK; EC 4.1.1.32) catalyzes the formation of phosphoenolpyruvate by decarboxylation of oxaloacetate while hydrolyzing GTP, a rate

limiting step in gluconeogenesis (the biosynthesis of glucose). In vertebrates there are two isozymes: a cytosolic form whose activity is affected by hormones regulating this metabolic process (such as glucagon, or insulin) and a mitochondrial form. The activity is about equally distributed between cytosol and mitochondria in human liver. In contrast, PCK is essentially a cytosolic enzyme in rat liver. See also PCK1 (261680), the human cytosolic PCK enzyme. Modaresi *et al.* (1996) cloned and sequenced the cDNA of the mitochondrial form of hepatic PCK (Biochem J., 315 (Pt 3):807-14 (1996)). The gene encodes a 640-amino acid polypeptide. The gene has an overall 68% DNA sequence identity and a 70% deduced amino acid sequence identity with human cytosolic PCK cDNA. Expression studies were also reported.

Deficiencies in PKC2 (PEPCK2) have been documented. In 2 unrelated children, Hommes *et al.* (1976) observed hypoglycemia and liver impairment, with deficiency of PEPCK in liver tissue taken immediately after death (Acta Paediatr Scand., 65(2):233-40 (1976)). Massive fatty deposition in liver and kidneys was found at autopsy. Fiser *et al.* (1974) also observed hypoglycemia caused by deficiency of PEPCK (Am J Obstet Gynecol., 120(7):944-50 (1974)). Other enzymatic causes of hypoglycemia include deficiency of glucose-6-phosphatase (232200), fructose-1,6-diphosphatase (229700), and pyruvate carboxylase (266150). Vidnes and Sovik (1976) described a case of persistent neonatal hypoglycemia in which only the extramitochondrial (i.e., cytosolic) form of hepatic phosphoenolpyruvate carboxykinase (PCK1) was deficient (Acta Paediatr Scand., 65(3):307-12 (1976)). Phosphoenolpyruvate carboxykinase can be measured in fibroblasts, which are said to contain only mitochondrial PEPCK (Clayton *et al.*, Eur J Pediatr., 145(1-2):46-50 (1986)). Clayton *et al.* (1986) reported this disorder in a female child who died of liver failure at 6 months and probably in her brother who died a crib death at 4 weeks (Eur J Pediatr., 145(1-2):46-50 (1986)). Leonard *et al.* (1991) studied the next child in this family, a boy who developed a similar illness with liver failure (Eur J Pediatr., 150(3):198-9 (1991)). PEPCK activity in leukocytes and fibroblasts was normal, however, leading Leonard *et al.* (1991) to conclude that the primary defect in this family does not reside in this enzyme (Eur J Pediatr., 150(3):198-9 (1991)). Subsequent studies of a third affected child in this family by Bodnar *et al.* (1993) suggested that the sibs suffered from the mitochondrial DNA depletion syndrome (251880) and that this depletion is controlled by the nuclear genome (Am J Hum Genet., 53(3):663-9 (1993)).

The NOV32 nucleic acids and polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications in regulating glucose metabolism. As such the NOV32 nucleic acids and polypeptides, antibodies and related compounds according to the invention may be used to treat metabolic disorders, *e.g.*,

hypoglycemia.

The NOV32 nucleic acids and polypeptides are useful for detecting specific cell types. For example, expression analysis has demonstrated that a NOV32 nucleic acid is expressed in Liver, Adipose, Adrenal Gland/Suprarenal gland, Bone, Bone Marrow, Brain, Brown adipose, Cartilage, Cervix, Colon, Duodenum, Heart, Kidney, Kidney Cortex, Left cerebellum, Lung, Lymphoid tissue, Mammary gland/Breast, Ovary, Pancreas, Placenta, Prostate, Retina, Skin, Small Intestine, Spinal Chord, Stomach, Substantia Nigra, Synovium/Synovial membrane, Testis, Tonsils, Uterus, Vulva, Whole Organism.

Additional utilities for NOV32 nucleic acids and polypeptides according to the invention are disclosed herein.

NOV33

A NOV33 polypeptide has been identified as a G Protein-Coupled Receptor (GPCR)-like protein (also referred to as CG56610-01). The disclosed novel NOV33 nucleic acid (**SEQ ID NO:122**) of 924 nucleotides is shown in Table 33A. An ORF begins with an AAA codon which codes for the amino acid lysine at nucleotides 3-5 and ends with a TGA codon at nucleotides 912-914. A putative untranslated region and/or downstream from the termination codon is underlined in Table 33A, and the start and stop codons are in bold letters.

Table 33A. NOV33 Nucleotide Sequence (SEQ ID NO:122)

<p>CTAAATTTCCAACCTTCTTGTTGACCGGCATTCTGGCCTAGAGTCTGCCCATGTCTGGATCTCCAT TCCTTTCTGTTGTTTTATGCCATTGCCCTCTCTGGGAACAGCGTGATCCTGTTTGTTCATCATTACC CAGCAGAGTCTCCATGAACCCATGTATTATTTCTCTTCAGGCTATCAGCCACTGATCTGGACTTGA CTGTTTCTTCATTGTCAACAACATTAGGTATTCTCTGGTTTGAGGCACGTGAAATCAGTCTATATAG CTGCATTGTCCAGATGTTTTTCTTCATGGATTCACTTTTATGGAATCTGGAGTGCTGGTGGCTACA GCCTTTGACCGTTATGCGGCCATCTGTGACCCTCTGAGGTACACTACCATTCTACTAATTCCAGAA TCATTCAAATGGGTCTTCTGATGATTACACGTGCTATAGTACTAATATTGCCACTACTTTTGCTCCT TAAGCCTCTCTATTTCTGTAGAATGAATGCCCTTTCTCACTCCTATTGTTACCATCCAGATGTGATT CAATTAGCATGTTTCAGACATTCGGGCAAATAGCATCTGTGGATTAAGTATCTCATCCTGACCACTG GAATAGATACACCATGCATTGTCCTGTCATATATCTTAATTATTCACCTCTGTCTCAGAATTGCCTC CCCTGAAGAATGGCACAAGGTCTTCAGCACCTGTGTCTCCCATGTGGGAGCAGTTGCTTTCTTCTAC ATCCACATGCTGAGCCTGTCTTGGTGTATCGCTATGGTCGGTCAGCCCCAGAGTAGTCCATTTCAG</p>

NOV33 also has homology to the proteins shown in the BLASTP data in Table 33D.

Table 33D. BLAST results for NOV33					
Gene Index/ Identifier	Protein/ Organism	Length (aa)	Identity (%)	Positives (%)	Expect
gi 17456801 ref XP_061626.1 (XM_061626)	similar to OLFACTORY RECEPTOR 51I2 (HOR5BETA12) [<i>Homo sapiens</i>]	342	159/299 (53%)	197/299 (65%)	2e-72
gi 17456767 ref XP_061618.1 (XM_061618)	similar to prostate specific G-protein coupled receptor [<i>Homo sapiens</i>]	879	128/290 (44%)	172/290 (59%)	2e-56
gi 17456777 ref XP_061621.1 (XM_061621)	similar to olfactory receptor-like protein COR3beta [<i>Homo sapiens</i>]	327	132/299 (44%)	172/299 (57%)	2e-55
gi 11991863 gb AAG42364.1 (AF289204)	odorant receptor HOR3'beta1 [<i>Homo sapiens</i>]	321	136/300 (45%)	178/300 (59%)	3e-55
gi 17472781 ref XP_061811.1 (XM_061811)	similar to OLFACTORY RECEPTOR 51I2 (HOR5BETA12) [<i>Homo sapiens</i>]	312	128/295 (43%)	169/295 (56%)	1e-54

A multiple sequence alignment is given in Table 33E, with the NOV33 protein being shown on line 1 in Table 33E in a ClustalW analysis, and comparing the NOV33 protein with the related protein sequences shown in Table 33D. This BLASTP data is displayed graphically in the ClustalW in Table 33E.

Table 33E. ClustalW Analysis of NOV33

- 1) > NOV33; **SEQ ID NO:123**
- 2) > gi|1745680/ similar to olfactory receptor 51I2 [*Homo sapiens*]; **SEQ ID NO:335**
- 3) > gi|1745676/ similar to prostate specific G-protein coupled receptor [*Homo sapiens*]; **SEQ ID NO:336**
- 4) > gi|1745677/ similar to olfactory receptor-like protein COR3beta [*Homo sapiens*]; **SEQ ID NO:337**
- 5) > gi|1199186/ odorant receptor HOR3'beta1 [*Homo sapiens*]; **SEQ ID NO:338**
- 6) > gi|1747278/ similar to olfactory receptor 51I2 [*Homo sapiens*]; **SEQ ID NO:339**

```

                    560      570      580      590      600
NOV33              .....|.....|.....|.....|.....|.....|.....|.....|.....|.....|
                  -----KFPT-----FLLTGIPGLESATVWISIP
gi|1745680        -----MTETSLSSQCFPMS-VLNNTIAEPLIFLLMGIPGLKATQYWISIP
gi|1745676        QDFGGHPPSPPLSPHTMTLGLSLGNSSSSVSATFLLSGIPGLERMHWISIP

```

gi	1745677	-----MAIFNNTTSSSSN-----FLLTAFFPGLECAHVWISIP
gi	1199186	-----MFLSSRMITS---VSPSTSTNSSFLLTGFGSCMEQQYPWFSSIP
gi	1747278	-----MGLFNVTHPAFLLTGIPGLESSHWSLSGP
5		610 620 630 640 650
	NOV33
	gi	1745680 FCCFYAIALSCNSVILFVLIITQOSLHEPMPYYFLFRLSATDLDITVSSLSLST
	gi	1745676 FCLLYVVAVSGNSMILFVVLCEKSLHKKPMYYFLSMLSATDLSLSLCTLST
10	gi	1745677 LCFMYLVSIIPGNCITILFIITKTERSLHEPMPYFLSMLALIDLGLSLCTLPT
	gi	1745677 VCCLYTIALLGNSMIFLVIITKRRLLHKKPMYYFLSMLAAVDLCITITLPT
	gi	1199186 FSSIYAMVLLGNCMVLFVLIWTEPSLHQPMFYFLSMLALDLCMLSTVYT
	gi	1747278 LCVMYAVALLGNTVILQAVRVEPSLHEPMPYFLSMLSFSDDVAISMATLPT
15		660 670 680 690 700
	NOV33
	gi	1745680 TLGILWFBAREISLYSCIVOMFFLHCFTFMESGVLVATAFDRYAAICDPL
	gi	1745676 TLGVFWFBAREINLNACIAQMFFLHCFTFMESGVLLAMAFDRFVAICYPL
	gi	1745677 VLGIWVGAREISHDACAQLFFIHCFSFLESSVLLSMAFDRFVAICHPPL
20	gi	1745677 VLGVLWFBAREISFKACFIOMFFVHAFSLLESSVLLVAMAFDRFVAICNPL
	gi	1199186 VLGILWRIIREISLDSICIAQSYFIHGLSFMESSVLLTMAFDRYTAICNPL
	gi	1747278 VLRTFCLNARNITFDACLITOMFLIHFSMMESGILLAMSFDRYVAICDPL
25		710 720 730 740 750
	NOV33
	gi	1745680 RYTTILTNSRTIIQMGLMITRAIVLILPILLLLKPLYFCRMNALSHSYCY
	gi	1745676 RYTTILTNRITAKIGMSMLIRNAVMLFVMLFVKRLSFCSSMVLSHSYCY
	gi	1745677 HYVSILTNTVIGRIGLVSLGRSVALIFPLPFMLKRPYCGSPVLSHSYCL
	gi	1745677 NYATILTDRMVLVIGLVICIRPAVFLPLLVAINTVSFHGGHLSHPFCY
	gi	1199186 RYSSILTNSRTIIKIGLTIIGRSFFFITPPIICLKFFNYCHFHILSHSFCL
30	gi	1747278 RYATVLTTEVIAAMGLGAAARSFITLPLPFLIKRLPICRSNVLSHSYCL
35		760 770 780 790 800
	NOV33
	gi	1745680 HPDVIQLACSDIRANSICGLTDLILITGIDTPCTVLSYILIIHSLVRIAS
	gi	1745676 HVDLIQLSCIDNRINSILGLEALLSTGFDCCPCILLSYILIIHRSVLSTAS
	gi	1745677 HQEVMKLACADMKANSIYGMFVIVSTVIGIDSLILFESYALILRLVLSIAS
	gi	1745677 HPEVIKYTYSKPWISSFWGLELQLYLNGTDVLFILFSYVLILRLVIGIVA
	gi	1199186 HODLLRLACSDIRFNSYYALMLVICILLDDAILILFSYILILKSVLAVAS
40	gi	1747278 HPDMRLACADISINSIYGLEVLVSTFCMDLFFIFLSYVLILRSMVATAS
45		810 820 830 840 850
	NOV33
	gi	1745680 PEEWHKVFSTCVSHVGAVAFFYIHMLSLSLVYRYGRSAPRVVHSMANVY
	gi	1745676 SEERRKAFNTCTSHISAVSIFYLPLISLSLVHRYCHSAPPFVHIIMANVF
	gi	1745677 RAERFKALNTCVSHICAVLLFYTPMIGLSVIHFRFGKQAPHLVQVVMGFMY
	gi	1745677 RKKQOKALSTCVCHICAVTIFYVPLISLSLAHRLFHSTPRVLCSTLANIY
	gi	1199186 QEERHKLFTCTSHICAVLVFYIPIIISLTMVHRFGKHLSPVAHVLIIGNIY
	gi	1747278 REERLKAALNTCVSHILAVLAFYVPMIGVSTVHRFGKHVPCYIHVLMNSVY
50		860 870 880 890
	NOV33
	gi	1745680 LLIPPVNLNPIIDSVKTKQIRKAMLSLLLTK-----
	gi	1745676 LLIPPVNLNPIIYSVKIKQIQKAIKVLIQKHKSNSHQFLIRDKAIYE
	gi	1745677 LLIPPVNMNPIIYSVKTKQIRDRVTHAFCY-----
55	gi	1745677 LLIPPVNLNPIIYSLKTKTIROAMFQLLOSKGSGWGFNVRLGRWD---
	gi	1199186 ILFPPLNMNPIIYSVKTQQIHTRMLRLFLSKRY-----
	gi	1747278 LFVPPVNLNPIIYSAKTKETIRRAIFRMFHHIKI-----

60 The NOV33 Clustal W alignment shown in Table 33E was modified to begin at amino residue 551. The data in Table 33E includes all of the regions overlapping with the NOV33

protein sequences.

The presence of identifiable domains in the protein disclosed herein was determined by searches using algorithms such as PROSITE, Blocks, Pfam, ProDomain, Prints and then determining the Interpro number by crossing the domain match (or numbers) using the Interpro website (<http://www.ebi.ac.uk/interpro/>). The DOMAIN analysis results indicate that the NOV33 protein contains the following protein domain (as defined by Interpro): domain name 7tm_1 7 transmembrane receptor (rhodopsin family). DOMAIN results for NOV33 were collected from the Conserved Domain Database (CDD) with Reverse Position Specific BLAST. This BLAST samples domains found in the Smart and Pfam collections.

As discussed below, the NOV33 protein of the invention contained significant homology to the 7tm_1 domain. This indicates that the NOV33 sequence has properties similar to those of other proteins known to contain this 7tm_1 domain and similar to the properties of these domains. The 254 amino acid domain termed 7tm_1 (SEQ ID NO:340; Pfam Acc. No. 00001) a seven transmembrane receptor (rhodopsin family), is shown in Table 33F.

Table 33F. 7tm_1, 7 transmembrane receptor domain (SEQ ID NO:340)

GNLLVILVILRTKRLTPTNIFLLNLAVADLLFLLTLPWPALYYLVGGDWVFGDALCKLVGALFVVNGYASILLTAAISIDRYL
AIVHPLRYRRIRTPRRAKVLILLVWVLALLLSLPPLLFSWLRTVEEGNTTVCLIDFPEESVKRSYVLLSTLVGFVLPPLLVLVC
YTRILRTLKRARSQRSLKRRSSSERKAAKMLLVVVVFVLCWLPYHIVLLLDLCLLSIWRVLP TALLITLWLAYVNSCLNP I
IY

The DOMAIN results are listed in Table 33G with the statistics and domain description.

An alignment of NOV33 residues 34-133 (SEQ ID NO:123) with the full 7tm_1 domain, residues 1-254 (SEQ ID NO:340), are shown in Table 33G. This indicates that the NOV33 sequences have properties similar to those of other proteins known to contain this domain as well as to the 254 amino acid 7tm domain (SEQ ID NO:340). For Table 33G, fully conserved single residues are indicated by the vertical line and “strong” semi-conserved residues are indicated by the “plus sign.” The “strong” group of conserved amino acid residues may be any one of the following groups of amino acids: STA, NEQK, NHQK, NDEQ, QHRK, MILV, MILF, HY, FYW.

Table 33G Domain Analysis of NOV33

PSSMs producing significant alignments:

Score E
(bits) value
42.1 1.5e-12

gnl|Pfam|pfam00001 7tm_1, 7 transmembrane receptor (rhodopsin family)

5 NOV33 34 *->GNLLVilvilrtkklrtptnifilNLAvADLLflltlppwalyylv
GN++++vi+ +++l+ p+++f++ L+ +DL +++++ + +l +l++
GNSVILFVIITQQLHEPMYYFLFRLSATDLDLTVSSSLSTTLGILWF 80
gsedWpfGsalCklvtaldvvnmyaSillLtaISiDRYlAIvhPlryrrr
e ++ + C +++++ +++++ L+a ++DRY AI++Plry ++
10 NOV33 81 --EAREISLYSCIVQMFFLHGFTFMESGVLVATAFDRYAAICDPLRYTTI 128
rtspr<-* (SEQ ID NO:340)
t r
NOV33 129 LT-NSR 133 (SEQ ID NO:123)

15 Consistent with other known members of the GPCR family of proteins, NOV33 contains 7tm_1 7 transmembrane receptor (rhodopsin family) domain as illustrated in Table 33G as well as homology and cellular localization, *i.e.* plasma membrane.

20 NOV33 nucleic acids, and the encoded polypeptides, according to the invention are useful in a variety of applications and contexts. For example, NOV33 nucleic acids and polypeptides can be used to identify proteins that are members of the GPCR family of proteins. The NOV33 nucleic acids and polypeptides can also be used to screen for molecules, which inhibit or enhance NOV33 activity or function. Specifically, the nucleic acids and polypeptides according to the invention may be used as targets for the identification of small molecules that
25 modulate or inhibit, *e.g.*, cellular signal transduction. These molecules can be used to treat, *e.g.*, cancer, immune disorders, and endocrine disorders.

In addition, various NOV33 nucleic acids and polypeptides according to the invention are useful, *inter alia*, as novel members of the protein families according to the presence of domains and sequence relatedness to previously described proteins. For example, the NOV33 nucleic
30 acids and their encoded polypeptides include 7tm_1 7 transmembrane receptor (rhodopsin family) domain and sequence homology that are characteristic of proteins belonging to the family of GPCR such as the G protein-coupled olfactory receptor. The NOV33 protein of the invention has a high homology to the 7tm_1 domain (PFam Acc. No. pfam00001). The 7tm_1 domain is from the 7 transmembrane receptor family, which includes a number of different
35 proteins, including, for example, serotonin receptors, dopamine receptors, histamine receptors, andrenergic receptors, cannabinoid receptors, angiotensin II receptors, chemokine receptors,

opioid receptors, G-protein coupled receptor (GPCR) proteins, olfactory receptors (OR), and the like.

G-Protein Coupled Receptor proteins ("GPCRs") have been identified as a large family of G protein-coupled receptors in a number of species. These receptors share a seven transmembrane domain structure with many neurotransmitter and hormone receptors, and are likely to underlie the recognition and G-protein-mediated transduction of various signals. Human GPCR generally do not contain introns and belong to four different gene subfamilies, displaying great sequence variability. These genes are dominantly expressed in olfactory epithelium. See, *e.g.*, Ben-Arie *et al.*, Hum. Mol. Genet. 3:229-235 (1994); and, Online Mendelian Inheritance in Man ("OMIM") entry # 164342 (<http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?>).

The NOV33 nucleic acids and polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications in the mediation of cellular signal transduction. As such the NOV33 nucleic acids and polypeptides, antibodies and related compounds according to the invention may be used to treat a wide range of disorders such as cancer, immune disorders, endocrine disorders and other diseases, *e.g.*, developmental diseases; MHCII and III diseases (immune diseases); taste and scent detectability disorders; Burkitt's lymphoma; corticoneurogenic disease; signal transduction pathway disorders; metabolic pathway disorders; retinal diseases including those involving photoreception; cell growth rate disorders; cell shape disorders; metabolic disorders; feeding disorders; control of feeding; the metabolic syndrome X; wasting disorders associated with chronic diseases; obesity; potential obesity due to over-eating or metabolic disturbances; potential disorders due to starvation (lack of appetite); diabetes; noninsulin-dependent diabetes mellitus (NIDDM); infectious disease; bacterial, fungal, protozoal and viral infections (particularly infections caused by HIV-1 or HIV-2); pain; cancer (including but not limited to neoplasm; adenocarcinoma; lymphoma; prostate cancer; uterus cancer); cancer-associated cachexia; anorexia; bulimia; asthma; Parkinson's disease; acute heart failure; hypotension; hypertension; urinary retention; osteoporosis; Crohn's disease; multiple sclerosis; Albright Hereditary Osteodystrophy; angina pectoris; myocardial infarction; ulcers; allergies; benign prostatic hypertrophy; and psychotic and neurological disorders; including anxiety; schizophrenia; manic depression; delirium; dementia; neurodegenerative disorders; Alzheimer's disease; severe mental retardation; Dentatorubro-

pallidolusian atrophy (DRPLA); Hypophosphatemic rickets; autosomal dominant (2)
Acrocallosal syndrome and dyskinesias, such as Huntington's disease or Gilles de la Tourette
syndrome; immune disorders; Adrenoleukodystrophy; Congenital Adrenal Hyperplasia;
Hemophilia; Hypercoagulation; Idiopathic thrombocytopenic purpura; autoimmune disease;
5 immunodeficiencies; transplantation; Von Hippel-Lindau (VHL) syndrome; Stroke; Tuberous
sclerosis; hypercalcaemia; Cerebral palsy; Epilepsy; Lesch-Nyhan syndrome; Ataxia-
telangiectasia; Leukodystrophies; Behavioral disorders; Addiction; Neuroprotection; Cirrhosis;
Transplantation; Systemic lupus erythematosus; Emphysema; Scleroderma; ARDS; Renal artery
stenosis; Interstitial nephritis; Glomerulonephritis; Polycystic kidney disease; Systemic lupus
10 erythematosus; Renal tubular acidosis; IgA nephropathy; Cardiomyopathy; Atherosclerosis;
Congenital heart defects; Aortic stenosis ; Atrial septal defect (ASD); Atrioventricular (A-V)
canal defect; Ductus arteriosus; Pulmonary stenosis ; Subaortic stenosis; Ventricular septal
defect (VSD); valve diseases; Scleroderma; fertility; Pancreatitis; Endocrine dysfunctions;
Growth and reproductive disorders; Inflammatory bowel disease; Diverticular disease;
15 Leukodystrophies; Graft versus host; Hyperthyroidism; Endometriosis; and hematopoietic
disorders.

The NOV33 nucleic acids and polypeptides are useful for detecting specific cell types.
For example, expression analysis has demonstrated that a NOV33 nucleic acid is expressed in
MHC II and III nervous, medulla, subthalamic nucleus, ovary, pancreas, pituitary, placenta,
20 pons, prostate, putamen, serum, skeletal muscle, small intestine, smooth muscle (coronary artery
in aortic) spinal cord, spleen, stomach, taste receptor cells of the tongue, testis, thalamus, and
thymus tissue.

Additional utilities for NOV33 nucleic acids and polypeptides according to the invention
are disclosed herein.

NOVX Nucleic Acids and Polypeptides

One aspect of the invention pertains to isolated nucleic acid molecules that encode
NOVX polypeptides or biologically active portions thereof. Also included in the invention are
nucleic acid fragments sufficient for use as hybridization probes to identify NOVX-encoding
30 nucleic acids (*e.g.*, NOVX mRNAs) and fragments for use as PCR primers for the amplification

and/or mutation of NOVX nucleic acid molecules. As used herein, the term “nucleic acid molecule” is intended to include DNA molecules (*e.g.*, cDNA or genomic DNA), RNA molecules (*e.g.*, mRNA), analogs of the DNA or RNA generated using nucleotide analogs, and derivatives, fragments and homologs thereof. The nucleic acid molecule may be single-stranded or double-stranded, but preferably is comprised double-stranded DNA.

A NOVX nucleic acid can encode a mature NOVX polypeptide. As used herein, a “mature” form of a polypeptide or protein disclosed in the present invention is the product of a naturally occurring polypeptide or precursor form or proprotein. The naturally occurring polypeptide, precursor or proprotein includes, by way of nonlimiting example, the full-length gene product, encoded by the corresponding gene. Alternatively, it may be defined as the polypeptide, precursor or proprotein encoded by an ORF described herein. The product “mature” form arises, again by way of nonlimiting example, as a result of one or more naturally occurring processing steps as they may take place within the cell, or host cell, in which the gene product arises. Examples of such processing steps leading to a “mature” form of a polypeptide or protein include the cleavage of the N-terminal methionine residue encoded by the initiation codon of an ORF, or the proteolytic cleavage of a signal peptide or leader sequence. Thus a mature form arising from a precursor polypeptide or protein that has residues 1 to N, where residue 1 is the N-terminal methionine, would have residues 2 through N remaining after removal of the N-terminal methionine. Alternatively, a mature form arising from a precursor polypeptide or protein having residues 1 to N, in which an N-terminal signal sequence from residue 1 to residue M is cleaved, would have the residues from residue M+1 to residue N remaining. Further as used herein, a “mature” form of a polypeptide or protein may arise from a step of post-translational modification other than a proteolytic cleavage event. Such additional processes include, by way of non-limiting example, glycosylation, myristoylation or phosphorylation. In general, a mature polypeptide or protein may result from the operation of only one of these processes, or a combination of any of them.

The term “probes”, as utilized herein, refers to nucleic acid sequences of variable length, preferably between at least about 10 nucleotides (nt), 100 nt, or as many as approximately, *e.g.*, 6,000 nt, depending upon the specific use. Probes are used in the detection of identical, similar, or complementary nucleic acid sequences. Longer length probes are generally obtained from a natural or recombinant source, are highly specific, and much slower to hybridize than shorter-

length oligomer probes. Probes may be single- or double-stranded and designed to have specificity in PCR, membrane-based hybridization technologies, or ELISA-like technologies.

The term "isolated" nucleic acid molecule, as utilized herein, is one, which is separated from other nucleic acid molecules which are present in the natural source of the nucleic acid.

5 Preferably, an "isolated" nucleic acid is free of sequences which naturally flank the nucleic acid (*i.e.*, sequences located at the 5'- and 3'-termini of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. For example, in various embodiments, the isolated NOVX nucleic acid molecules can contain less than about 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb or 0.1 kb of nucleotide sequences which naturally flank the nucleic acid molecule in
10 genomic DNA of the cell/tissue from which the nucleic acid is derived (*e.g.*, brain, heart, liver, spleen, etc.). Moreover, an "isolated" nucleic acid molecule, such as a cDNA molecule, can be substantially free of other cellular material or culture medium when produced by recombinant techniques, or of chemical precursors or other chemicals when chemically synthesized.

A nucleic acid molecule of the invention, *e.g.*, a nucleic acid molecule having the
15 nucleotide sequence SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, and 122, or a complement of this aforementioned nucleotide sequence, can be isolated using standard molecular biology techniques and the sequence information provided herein. Using all or a
20 portion of the nucleic acid sequence of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, and 122 as a hybridization probe, NOVX molecules can be isolated using standard hybridization and cloning techniques (*e.g.*, as described in Sambrook, *et al.*, (eds.), MOLECULAR CLONING: A
25 LABORATORY MANUAL 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989; and Ausubel, *et al.*, (eds.), CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, NY, 1993.)

A nucleic acid of the invention can be amplified using cDNA, mRNA or alternatively, genomic DNA, as a template and appropriate oligonucleotide primers according to standard PCR
30 amplification techniques. The nucleic acid so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis. Furthermore, oligonucleotides corresponding to

NOVX nucleotide sequences can be prepared by standard synthetic techniques, *e.g.*, using an automated DNA synthesizer.

As used herein, the term “oligonucleotide” refers to a series of linked nucleotide residues, which oligonucleotide has a sufficient number of nucleotide bases to be used in a PCR reaction.

5 A short oligonucleotide sequence may be based on, or designed from, a genomic or cDNA sequence and is used to amplify, confirm, or reveal the presence of an identical, similar or complementary DNA or RNA in a particular cell or tissue. Oligonucleotides comprise portions of a nucleic acid sequence having about 10 nt, 50 nt, or 100 nt in length, preferably about 15 nt to 30 nt in length. In one embodiment of the invention, an oligonucleotide comprising a nucleic
10 acid molecule less than 100 nt in length would further comprise at least 6 contiguous nucleotides SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, and 122, or a complement thereof. Oligonucleotides may be chemically synthesized and may also be used as probes.

15 In another embodiment, an isolated nucleic acid molecule of the invention comprises a nucleic acid molecule that is a complement of the nucleotide sequence shown in SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, and 122, or a portion of this nucleotide sequence (*e.g.*, a
20 fragment that can be used as a probe or primer or a fragment encoding a biologically-active portion of an NOVX polypeptide). A nucleic acid molecule that is complementary to the nucleotide sequence shown SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, and 122 is
25 one that is sufficiently complementary to the nucleotide sequence shown SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, and 122 that it can hydrogen bond with little or no mismatches to the nucleotide sequence shown SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21,
30 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 64, 66, 68, 70, 72,

74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, and 122 thereby forming a stable duplex.

As used herein, the term “complementary” refers to Watson-Crick or Hoogsteen base pairing between nucleotides units of a nucleic acid molecule, and the term “binding” means the physical or chemical interaction between two polypeptides or compounds or associated polypeptides or compounds or combinations thereof. Binding includes ionic, non-ionic, van der Waals, hydrophobic interactions, and the like. A physical interaction can be either direct or indirect. Indirect interactions may be through or due to the effects of another polypeptide or compound. Direct binding refers to interactions that do not take place through, or due to, the effect of another polypeptide or compound, but instead are without other substantial chemical intermediates.

Fragments provided herein are defined as sequences of at least 6 (contiguous) nucleic acids or at least 4 (contiguous) amino acids, a length sufficient to allow for specific hybridization in the case of nucleic acids or for specific recognition of an epitope in the case of amino acids, respectively, and are at most some portion less than a full length sequence. Fragments may be derived from any contiguous portion of a nucleic acid or amino acid sequence of choice. Derivatives are nucleic acid sequences or amino acid sequences formed from the native compounds either directly or by modification or partial substitution. Analogs are nucleic acid sequences or amino acid sequences that have a structure similar to, but not identical to, the native compound but differs from it in respect to certain components or side chains. Analogs may be synthetic or from a different evolutionary origin and may have a similar or opposite metabolic activity compared to wild type. Homologs are nucleic acid sequences or amino acid sequences of a particular gene that are derived from different species.

Derivatives and analogs may be full length or other than full length, if the derivative or analog contains a modified nucleic acid or amino acid, as described below. Derivatives or analogs of the nucleic acids or proteins of the invention include, but are not limited to, molecules comprising regions that are substantially homologous to the nucleic acids or proteins of the invention, in various embodiments, by at least about 70%, 80%, or 95% identity (with a preferred identity of 80-95%) over a nucleic acid or amino acid sequence of identical size or when compared to an aligned sequence in which the alignment is done by a computer homology program known in the art, or whose encoding nucleic acid is capable of hybridizing to the

complement of a sequence encoding the aforementioned proteins under stringent, moderately stringent, or low stringent conditions. See e.g. Ausubel, *et al.*, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, NY, 1993, and below.

A "homologous nucleic acid sequence" or "homologous amino acid sequence," or variations thereof, refer to sequences characterized by a homology at the nucleotide level or amino acid level as discussed above. Homologous nucleotide sequences encode those sequences coding for isoforms of NOVX polypeptides. Isoforms can be expressed in different tissues of the same organism as a result of, for example, alternative splicing of RNA. Alternatively, isoforms can be encoded by different genes. In the invention, homologous nucleotide sequences include nucleotide sequences encoding for an NOVX polypeptide of species other than humans, including, but not limited to: vertebrates, and thus can include, e.g., frog, mouse, rat, rabbit, dog, cat, cow, horse, and other organisms. Homologous nucleotide sequences also include, but are not limited to, naturally occurring allelic variations and mutations of the nucleotide sequences set forth herein. A homologous nucleotide sequence does not, however, include the exact nucleotide sequence encoding human NOVX protein. Homologous nucleic acid sequences include those nucleic acid sequences that encode conservative amino acid substitutions (see below) in SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, and 122, as well as a polypeptide possessing NOVX biological activity. Various biological activities of the NOVX proteins are described below.

An NOVX polypeptide is encoded by the open reading frame ("ORF") of an NOVX nucleic acid. An ORF corresponds to a nucleotide sequence that could potentially be translated into a polypeptide. A stretch of nucleic acids comprising an ORF is uninterrupted by a stop codon. An ORF that represents the coding sequence for a full protein begins with an ATG "start" codon and terminates with one of the three "stop" codons, namely, TAA, TAG, or TGA. For the purposes of this invention, an ORF may be any part of a coding sequence, with or without a start codon, a stop codon, or both. For an ORF to be considered as a good candidate for coding for a *bona fide* cellular protein, a minimum size requirement is often set, e.g., a stretch of DNA that would encode a protein of 50 amino acids or more.

The nucleotide sequences determined from the cloning of the human NOVX genes allows for the generation of probes and primers designed for use in identifying and/or cloning NOVX homologues in other cell types, *e.g.* from other tissues, as well as NOVX homologues from other vertebrates. The probe/primer typically comprises substantially purified oligonucleotide. The

5 oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12, 25, 50, 100, 150, 200, 250, 300, 350 or 400 consecutive sense strand nucleotide sequence SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, and 122;
10 or an anti-sense strand nucleotide sequence of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, and 122; or of a naturally occurring mutant of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, and 122.

Probes based on the human NOVX nucleotide sequences can be used to detect transcripts or genomic sequences encoding the same or homologous proteins. In various embodiments, the probe further comprises a label group attached thereto, *e.g.* the label group can be a radioisotope, a fluorescent compound, an enzyme, or an enzyme co-factor. Such probes can be used as a part
20 of a diagnostic test kit for identifying cells or tissues which mis-express an NOVX protein, such as by measuring a level of an NOVX-encoding nucleic acid in a sample of cells from a subject *e.g.*, detecting NOVX mRNA levels or determining whether a genomic NOVX gene has been mutated or deleted.

25 "A polypeptide having a biologically-active portion of an NOVX polypeptide" refers to polypeptides exhibiting activity similar, but not necessarily identical to, an activity of a polypeptide of the invention, including mature forms, as measured in a particular biological assay, with or without dose dependency. A nucleic acid fragment encoding a "biologically-active portion of NOVX" can be prepared by isolating a portion SEQ ID NOS:1, 3, 5, 7, 9, 11,
30 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110,

112, 114, 116, 118, 120, and 122, that encodes a polypeptide having an NOVX biological activity (the biological activities of the NOVX proteins are described below), expressing the encoded portion of NOVX protein (*e.g.*, by recombinant expression *in vitro*) and assessing the activity of the encoded portion of NOVX.

5 NOVX Nucleic Acid and Polypeptide Variants

The invention further encompasses nucleic acid molecules that differ from the nucleotide sequences shown in SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, and 122 due to

10 degeneracy of the genetic code and thus encode the same NOVX proteins as that encoded by the nucleotide sequences shown in SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, and 122.

In another embodiment, an isolated nucleic acid molecule of the invention has a nucleotide
15 sequence encoding a protein having an amino acid sequence shown in SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, and 123.

In addition to the human NOVX nucleotide sequences shown in SEQ ID NOS:1, 3, 5, 7,
20 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, and 122, it will be appreciated by those skilled in the art that DNA sequence polymorphisms that lead to changes in the amino acid sequences of the NOVX polypeptides may exist within a population (*e.g.*, the human population). Such genetic
25 polymorphism in the NOVX genes may exist among individuals within a population due to natural allelic variation. As used herein, the terms "gene" and "recombinant gene" refer to nucleic acid molecules comprising an open reading frame (ORF) encoding an NOVX protein, preferably a vertebrate NOVX protein. Such natural allelic variations can typically result in 1-5% variance in the nucleotide sequence of the NOVX genes. Any and all such nucleotide
30 variations and resulting amino acid polymorphisms in the NOVX polypeptides, which are the

result of natural allelic variation and that do not alter the functional activity of the NOVX polypeptides, are intended to be within the scope of the invention.

Moreover, nucleic acid molecules encoding NOVX proteins from other species, and thus that have a nucleotide sequence that differs from the human SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, and 122 are intended to be within the scope of the invention. Nucleic acid molecules corresponding to natural allelic variants and homologues of the NOVX cDNAs of the invention can be isolated based on their homology to the human NOVX nucleic acids disclosed herein using the human cDNAs, or a portion thereof, as a hybridization probe according to standard hybridization techniques under stringent hybridization conditions.

Accordingly, in another embodiment, an isolated nucleic acid molecule of the invention is at least 6 nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, and 122. In another embodiment, the nucleic acid is at least 10, 25, 50, 100, 250, 500, 750, 1000, 1500, or 2000 or more nucleotides in length. In yet another embodiment, an isolated nucleic acid molecule of the invention hybridizes to the coding region. As used herein, the term "hybridizes under stringent conditions" is intended to describe conditions for hybridization and washing under which nucleotide sequences at least 60% homologous to each other typically remain hybridized to each other.

Homologs (*i.e.*, nucleic acids encoding NOVX proteins derived from species other than human) or other related sequences (*e.g.*, paralogs) can be obtained by low, moderate or high stringency hybridization with all or a portion of the particular human sequence as a probe using methods well known in the art for nucleic acid hybridization and cloning.

As used herein, the phrase "stringent hybridization conditions" refers to conditions under which a probe, primer or oligonucleotide will hybridize to its target sequence, but to no other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures than shorter sequences. Generally, stringent conditions are selected to be about 5 °C lower than the thermal

melting point (T_m) for the specific sequence at a defined ionic strength and pH. The T_m is the temperature (under defined ionic strength, pH and nucleic acid concentration) at which 50% of the probes complementary to the target sequence hybridize to the target sequence at equilibrium. Since the target sequences are generally present at excess, at T_m, 50% of the probes are occupied at equilibrium. Typically, stringent conditions will be those in which the salt concentration is less than about 1.0 M sodium ion, typically about 0.01 to 1.0 M sodium ion (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30°C for short probes, primers or oligonucleotides (e.g., 10 nt to 50 nt) and at least about 60°C for longer probes, primers and oligonucleotides. Stringent conditions may also be achieved with the addition of destabilizing agents, such as formamide.

Stringent conditions are known to those skilled in the art and can be found in Ausubel, *et al.*, (eds.), CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. Preferably, the conditions are such that sequences at least about 65%, 70%, 75%, 85%, 90%, 95%, 98%, or 99% homologous to each other typically remain hybridized to each other. A non-limiting example of stringent hybridization conditions are hybridization in a high salt buffer comprising 6X SSC, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 mg/ml denatured salmon sperm DNA at 65°C, followed by one or more washes in 0.2X SSC, 0.01% BSA at 50°C. An isolated nucleic acid molecule of the invention that hybridizes under stringent conditions to the sequences SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, and 122, corresponds to a naturally-occurring nucleic acid molecule. As used herein, a "naturally-occurring" nucleic acid molecule refers to an RNA or DNA molecule having a nucleotide sequence that occurs in nature (e.g., encodes a natural protein).

In a second embodiment, a nucleic acid sequence that is hybridizable to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, and 122, or fragments, analogs or derivatives thereof, under conditions of moderate stringency is provided. A non-limiting example of moderate stringency hybridization conditions

are hybridization in 6X SSC, 5X Denhardt's solution, 0.5% SDS and 100 mg/ml denatured salmon sperm DNA at 55°C, followed by one or more washes in 1X SSC, 0.1% SDS at 37°C. Other conditions of moderate stringency that may be used are well-known within the art. *See, e.g., Ausubel, et al. (eds.), 1993, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, NY, and Kriegler, 1990; GENE TRANSFER AND EXPRESSION, A LABORATORY MANUAL, Stockton Press, NY.*

In a third embodiment, a nucleic acid that is hybridizable to the nucleic acid molecule comprising the nucleotide sequences SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, and 122, or fragments, analogs or derivatives thereof, under conditions of low stringency, is provided. A non-limiting example of low stringency hybridization conditions are hybridization in 35% formamide, 5X SSC, 50 mM Tris-HCl (pH 7.5), 5 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.2% BSA, 100 mg/ml denatured salmon sperm DNA, 10% (wt/vol) dextran sulfate at 40°C, followed by one or more washes in 2X SSC, 25 mM Tris-HCl (pH 7.4), 5 mM EDTA, and 0.1% SDS at 50°C. Other conditions of low stringency that may be used are well known in the art (*e.g., as employed for cross-species hybridizations*). *See, e.g., Ausubel, et al. (eds.), 1993, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, NY, and Kriegler, 1990, GENE TRANSFER AND EXPRESSION, A LABORATORY MANUAL, Stockton Press, NY; Shilo and Weinberg, 1981. Proc Natl Acad Sci USA 78: 6789-6792.*

Conservative Mutations

In addition to naturally-occurring allelic variants of NOVX sequences that may exist in the population, the skilled artisan will further appreciate that changes can be introduced by mutation into the nucleotide sequences SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, and 122, thereby leading to changes in the amino acid sequences of the encoded NOVX proteins, without altering the functional ability of said NOVX proteins. For example, nucleotide substitutions leading to amino acid substitutions at "non-essential" amino acid residues can be made in the sequence SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34,

36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, and 123. A

"non-essential" amino acid residue is a residue that can be altered from the wild-type sequences of the NOVX proteins without altering their biological activity, whereas an "essential" amino acid residue is required for such biological activity. For example, amino acid residues that are conserved among the NOVX proteins of the invention are predicted to be particularly non-amenable to alteration. Amino acids for which conservative substitutions can be made are well-known within the art.

Another aspect of the invention pertains to nucleic acid molecules encoding NOVX proteins that contain changes in amino acid residues that are not essential for activity. Such NOVX proteins differ in amino acid sequence from SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, and 122 yet retain biological activity. In one embodiment, the isolated nucleic acid molecule comprises a nucleotide sequence encoding a protein, wherein the protein comprises an amino acid sequence at least about 45% homologous to the amino acid sequences SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, and 123. Preferably, the protein encoded by the nucleic acid molecule is at least about 60% homologous to SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, and 123; more preferably at least about 70% homologous SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, and 123; still more preferably at least about 80% homologous to SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, and 123; even more preferably at least about 90% homologous to SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 65, 67, 69, 71, 73, 75,

77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, and 123; and most preferably at least about 95% homologous to SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, and 123.

An isolated nucleic acid molecule encoding an NOVX protein homologous to the protein of SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, and 123 can be created by introducing one or more nucleotide substitutions, additions or deletions into the nucleotide sequence of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, and 122, such that one or more amino acid substitutions, additions or deletions are introduced into the encoded protein.

Mutations can be introduced into SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, and 122 by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis. Preferably, conservative amino acid substitutions are made at one or more predicted, non-essential amino acid residues. A "conservative amino acid substitution" is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined within the art. These families include amino acids with basic side chains (*e.g.*, lysine, arginine, histidine), acidic side chains (*e.g.*, aspartic acid, glutamic acid), uncharged polar side chains (*e.g.*, glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (*e.g.*, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (*e.g.*, threonine, valine, isoleucine) and aromatic side chains (*e.g.*, tyrosine, phenylalanine, tryptophan, histidine). Thus, a predicted non-essential amino acid residue in the NOVX protein is replaced with another amino acid residue from the same side chain family. Alternatively, in another embodiment, mutations can be introduced randomly along all or part of an NOVX coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened

for NOVX biological activity to identify mutants that retain activity. Following mutagenesis SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, and 122, the encoded protein can be expressed by any recombinant technology known in the art and the activity of the protein can be determined.

The relatedness of amino acid families may also be determined based on side chain interactions. Substituted amino acids may be fully conserved "strong" residues or fully conserved "weak" residues. The "strong" group of conserved amino acid residues may be any one of the following groups: STA, NEQK, NHQK, NDEQ, QHRK, MILV, MILF, HY, FYW, wherein the single letter amino acid codes are grouped by those amino acids that may be substituted for each other. Likewise, the "weak" group of conserved residues may be any one of the following: CSA, ATV, SAG, STNK, STPA, SGND, SNDEQK, NDEQHK, NEQHRK, VLIM, HFY, wherein the letters within each group represent the single letter amino acid code.

In one embodiment, a mutant NOVX protein can be assayed for (i) the ability to form protein:protein interactions with other NOVX proteins, other cell-surface proteins, or biologically-active portions thereof, (ii) complex formation between a mutant NOVX protein and an NOVX ligand; or (iii) the ability of a mutant NOVX protein to bind to an intracellular target protein or biologically-active portion thereof; (e.g. avidin proteins).

In yet another embodiment, a mutant NOVX protein can be assayed for the ability to regulate a specific biological function (e.g., regulation of insulin release).

Antisense Nucleic Acids

Another aspect of the invention pertains to isolated antisense nucleic acid molecules that are hybridizable to or complementary to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, and 122, or fragments, analogs or derivatives thereof. An "antisense" nucleic acid comprises a nucleotide sequence that is complementary to a "sense" nucleic acid encoding a protein (e.g., complementary to the coding strand of a double-stranded cDNA molecule or complementary to an mRNA sequence). In specific aspects, antisense nucleic acid molecules are provided that comprise a sequence

complementary to at least about 10, 25, 50, 100, 250 or 500 nucleotides or an entire NOVX coding strand, or to only a portion thereof. Nucleic acid molecules encoding fragments, homologs, derivatives and analogs of an NOVX protein of SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, and 123, or antisense nucleic acids complementary to an NOVX nucleic acid sequence of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, and 122, are additionally provided.

In one embodiment, an antisense nucleic acid molecule is antisense to a "coding region" of the coding strand of a nucleotide sequence encoding an NOVX protein. The term "coding region" refers to the region of the nucleotide sequence comprising codons which are translated into amino acid residues. In another embodiment, the antisense nucleic acid molecule is antisense to a "noncoding region" of the coding strand of a nucleotide sequence encoding the NOVX protein. The term "noncoding region" refers to 5' and 3' sequences which flank the coding region that are not translated into amino acids (*i.e.*, also referred to as 5' and 3' untranslated regions).

Given the coding strand sequences encoding the NOVX protein disclosed herein, antisense nucleic acids of the invention can be designed according to the rules of Watson and Crick or Hoogsteen base pairing. The antisense nucleic acid molecule can be complementary to the entire coding region of NOVX mRNA, but more preferably is an oligonucleotide that is antisense to only a portion of the coding or noncoding region of NOVX mRNA. For example, the antisense oligonucleotide can be complementary to the region surrounding the translation start site of NOVX mRNA. An antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 nucleotides in length. An antisense nucleic acid of the invention can be constructed using chemical synthesis or enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (*e.g.*, an antisense oligonucleotide) can be chemically synthesized using naturally-occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability

of the duplex formed between the antisense and sense nucleic acids (*e.g.*, phosphorothioate derivatives and acridine substituted nucleotides can be used).

Examples of modified nucleotides that can be used to generate the antisense nucleic acid include: 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine. Alternatively, the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (*i.e.*, RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).

The antisense nucleic acid molecules of the invention are typically administered to a subject or generated *in situ* such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding an NOVX protein to thereby inhibit expression of the protein (*e.g.*, by inhibiting transcription and/or translation). The hybridization can be by conventional nucleotide complementarity to form a stable duplex, or, for example, in the case of an antisense nucleic acid molecule that binds to DNA duplexes, through specific interactions in the major groove of the double helix. An example of a route of administration of antisense nucleic acid molecules of the invention includes direct injection at a tissue site. Alternatively, antisense nucleic acid molecules can be modified to target selected cells and then administered systemically. For example, for systemic administration, antisense molecules can be modified such that they specifically bind to receptors or antigens expressed on a selected cell surface (*e.g.*, by linking the antisense nucleic acid molecules to peptides or antibodies that bind to cell surface receptors or antigens). The antisense nucleic acid molecules can also be delivered to cells using the vectors

described herein. To achieve sufficient nucleic acid molecules, vector constructs in which the antisense nucleic acid molecule is placed under the control of a strong pol II or pol III promoter are preferred.

In yet another embodiment, the antisense nucleic acid molecule of the invention is an α -anomeric nucleic acid molecule. An α -anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual β -units, the strands run parallel to each other. See, e.g., Gaultier, *et al.*, 1987. *Nucl. Acids Res.* **15**: 6625-6641. The antisense nucleic acid molecule can also comprise a 2'-o-methylribonucleotide (See, e.g., Inoue, *et al.* 1987. *Nucl. Acids Res.* **15**: 6131-6148) or a chimeric RNA-DNA analogue (See, e.g., Inoue, *et al.*, 1987. *FEBS Lett.* **215**: 327-330).

Ribozymes and PNA Moieties

Nucleic acid modifications include, by way of non-limiting example, modified bases, and nucleic acids whose sugar phosphate backbones are modified or derivatized. These modifications are carried out at least in part to enhance the chemical stability of the modified nucleic acid, such that they may be used, for example, as antisense binding nucleic acids in therapeutic applications in a subject.

In one embodiment, an antisense nucleic acid of the invention is a ribozyme. Ribozymes are catalytic RNA molecules with ribonuclease activity that are capable of cleaving a single-stranded nucleic acid, such as an mRNA, to which they have a complementary region. Thus, ribozymes (e.g., hammerhead ribozymes as described in Haselhoff and Gerlach 1988. *Nature* 334: 585-591) can be used to catalytically cleave NOVX mRNA transcripts to thereby inhibit translation of NOVX mRNA. A ribozyme having specificity for an NOVX-encoding nucleic acid can be designed based upon the nucleotide sequence of an NOVX cDNA disclosed herein (*i.e.*, SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, and 122). For example, a derivative of a *Tetrahymena* L-19 IVS RNA can be constructed in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in an NOVX-encoding mRNA. See, e.g., U.S. Patent 4,987,071 to Cech, *et al.* and U.S. Patent 5,116,742 to Cech, *et al.* NOVX mRNA can also be used to select a catalytic RNA having a

specific ribonuclease activity from a pool of RNA molecules. *See, e.g., Bartel et al., (1993) Science* 261:1411-1418.

Alternatively, NOVX gene expression can be inhibited by targeting nucleotide sequences complementary to the regulatory region of the NOVX nucleic acid (*e.g., the NOVX promoter and/or enhancers*) to form triple helical structures that prevent transcription of the NOVX gene in target cells. *See, e.g., Helene, 1991. Anticancer Drug Des. 6: 569-84; Helene, et al. 1992. Ann. N.Y. Acad. Sci. 660: 27-36; Maher, 1992. Bioassays 14: 807-15.*

In various embodiments, the NOVX nucleic acids can be modified at the base moiety, sugar moiety or phosphate backbone to improve, *e.g., the stability, hybridization, or solubility of the molecule.* For example, the deoxyribose phosphate backbone of the nucleic acids can be modified to generate peptide nucleic acids. *See, e.g., Hyrup, et al., 1996. Bioorg Med Chem 4: 5-23.* As used herein, the terms "peptide nucleic acids" or "PNAs" refer to nucleic acid mimics (*e.g., DNA mimics*) in which the deoxyribose phosphate backbone is replaced by a pseudopeptide backbone and only the four natural nucleobases are retained. The neutral backbone of PNAs has been shown to allow for specific hybridization to DNA and RNA under conditions of low ionic strength. The synthesis of PNA oligomers can be performed using standard solid phase peptide synthesis protocols as described in Hyrup, *et al., 1996. supra;* Perry-O'Keefe, *et al., 1996. Proc. Natl. Acad. Sci. USA 93: 14670-14675.*

PNAs of NOVX can be used in therapeutic and diagnostic applications. For example, PNAs can be used as antisense or antigene agents for sequence-specific modulation of gene expression by, *e.g., inducing transcription or translation arrest or inhibiting replication.* PNAs of NOVX can also be used, for example, in the analysis of single base pair mutations in a gene (*e.g., PNA directed PCR clamping; as artificial restriction enzymes when used in combination with other enzymes, e.g., S₁ nucleases (See, Hyrup, et al., 1996. supra); or as probes or primers for DNA sequence and hybridization (See, Hyrup, et al., 1996, supra; Perry-O'Keefe, et al., 1996. supra).*

In another embodiment, PNAs of NOVX can be modified, *e.g., to enhance their stability or cellular uptake, by attaching lipophilic or other helper groups to PNA, by the formation of PNA-DNA chimeras, or by the use of liposomes or other techniques of drug delivery known in the art.* For example, PNA-DNA chimeras of NOVX can be generated that may combine the advantageous properties of PNA and DNA. Such chimeras allow DNA recognition enzymes

(e.g., RNase H and DNA polymerases) to interact with the DNA portion while the PNA portion would provide high binding affinity and specificity. PNA-DNA chimeras can be linked using linkers of appropriate lengths selected in terms of base stacking, number of bonds between the nucleobases, and orientation (see, Hyrup, et al., 1996. *supra*). The synthesis of PNA-DNA
5 chimeras can be performed as described in Hyrup, *et al.*, 1996. *supra* and Finn, *et al.*, 1996. *Nucl Acids Res* 24: 3357-3363. For example, a DNA chain can be synthesized on a solid support using standard phosphoramidite coupling chemistry, and modified nucleoside analogs, e.g., 5'-(4-methoxytrityl)amino-5'-deoxy-thymidine phosphoramidite, can be used between the PNA and the 5' end of DNA. See, e.g., Mag, *et al.*, 1989. *Nucl Acid Res* 17: 5973-5988. PNA
10 monomers are then coupled in a stepwise manner to produce a chimeric molecule with a 5' PNA segment and a 3' DNA segment. See, e.g., Finn, *et al.*, 1996. *supra*. Alternatively, chimeric molecules can be synthesized with a 5' DNA segment and a 3' PNA segment. See, e.g., Petersen, *et al.*, 1975. *Bioorg. Med. Chem. Lett.* 5: 1119-11124.

In other embodiments, the oligonucleotide may include other appended groups such as
15 peptides (e.g., for targeting host cell receptors *in vivo*), or agents facilitating transport across the cell membrane (see, e.g., Letsinger, *et al.*, 1989. *Proc. Natl. Acad. Sci. U.S.A.* 86: 6553-6556; Lemaitre, *et al.*, 1987. *Proc. Natl. Acad. Sci.* 84: 648-652; PCT Publication No. WO88/09810) or the blood-brain barrier (see, e.g., PCT Publication No. WO 89/10134). In addition, oligonucleotides can be modified with hybridization triggered cleavage agents (see, e.g., Krol, *et al.*, 1988. *BioTechniques* 6:958-976) or intercalating agents (see, e.g., Zon, 1988. *Pharm. Res.* 5: 539-549). To this end, the oligonucleotide may be conjugated to another molecule, e.g., a
20 peptide, a hybridization triggered cross-linking agent, a transport agent, a hybridization-triggered cleavage agent, and the like.

25 NOVX Polypeptides

A polypeptide according to the invention includes a polypeptide including the amino acid sequence of NOVX polypeptides whose sequences are provided in SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111,
30 113, 115, 117, 119, 121, and 123. The invention also includes a mutant or variant protein any of whose residues may be changed from the corresponding residues shown in SEQ ID NOS:2, 4, 6,

8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, and 123 while still encoding a protein that maintains its NOVX activities and physiological functions, or a functional fragment thereof.

5 In general, an NOVX variant that preserves NOVX-like function includes any variant in which residues at a particular position in the sequence have been substituted by other amino acids, and further include the possibility of inserting an additional residue or residues between two residues of the parent protein as well as the possibility of deleting one or more residues from the parent sequence. Any amino acid substitution, insertion, or deletion is encompassed by the invention. In favorable circumstances, the substitution is a conservative substitution as defined above.

One aspect of the invention pertains to isolated NOVX proteins, and biologically-active portions thereof, or derivatives, fragments, analogs or homologs thereof. Also provided are polypeptide fragments suitable for use as immunogens to raise anti-NOVX antibodies. In one embodiment, native NOVX proteins can be isolated from cells or tissue sources by an appropriate purification scheme using standard protein purification techniques. In another embodiment, NOVX proteins are produced by recombinant DNA techniques. Alternative to recombinant expression, an NOVX protein or polypeptide can be synthesized chemically using standard peptide synthesis techniques.

20 An "isolated" or "purified" polypeptide or protein or biologically-active portion thereof is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the NOVX protein is derived, or substantially free from chemical precursors or other chemicals when chemically synthesized. The language "substantially free of cellular material" includes preparations of NOVX proteins in which the protein is separated from cellular components of the cells from which it is isolated or recombinantly-produced. In one embodiment, the language "substantially free of cellular material" includes preparations of NOVX proteins having less than about 30% (by dry weight) of non-NOVX proteins (also referred to herein as a "contaminating protein"), more preferably less than about 20% of non-NOVX proteins, still more preferably less than about 10% of non-NOVX proteins, and most preferably less than about 5% of non-NOVX proteins. When the NOVX protein or biologically-active portion thereof is recombinantly-produced, it is also preferably substantially free of

culture medium, *i.e.*, culture medium represents less than about 20%, more preferably less than about 10%, and most preferably less than about 5% of the volume of the NOVX protein preparation.

The language "substantially free of chemical precursors or other chemicals" includes preparations of NOVX proteins in which the protein is separated from chemical precursors or other chemicals that are involved in the synthesis of the protein. In one embodiment, the language "substantially free of chemical precursors or other chemicals" includes preparations of NOVX proteins having less than about 30% (by dry weight) of chemical precursors or non-NOVX chemicals, more preferably less than about 20% chemical precursors or non-NOVX chemicals, still more preferably less than about 10% chemical precursors or non-NOVX chemicals, and most preferably less than about 5% chemical precursors or non-NOVX chemicals.

Biologically-active portions of NOVX proteins include peptides comprising amino acid sequences sufficiently homologous to or derived from the amino acid sequences of the NOVX proteins (*e.g.*, the amino acid sequence shown in SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, and 123) that include fewer amino acids than the full-length NOVX proteins, and exhibit at least one activity of an NOVX protein. Typically, biologically-active portions comprise a domain or motif with at least one activity of the NOVX protein. A biologically-active portion of an NOVX protein can be a polypeptide which is, for example, 10, 25, 50, 100 or more amino acid residues in length.

Moreover, other biologically-active portions, in which other regions of the protein are deleted, can be prepared by recombinant techniques and evaluated for one or more of the functional activities of a native NOVX protein.

In an embodiment, the NOVX protein has an amino acid sequence shown SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, and 123. In other embodiments, the NOVX protein is substantially homologous to SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 65, 67, 69, 71, 73, 75, 77, 79,

81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, and 123, and retains the functional activity of the protein of SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, and 123, yet differs in amino acid sequence due to natural allelic variation or mutagenesis, as described in detail, below. Accordingly, in another embodiment, the NOVX protein is a protein that comprises an amino acid sequence at least about 45% homologous to the amino acid sequence SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, and 123, and retains the functional activity of the NOVX proteins of SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, and 123.

Determining Homology Between Two or More Sequences

To determine the percent homology of two amino acid sequences or of two nucleic acids, the sequences are aligned for optimal comparison purposes (*e.g.*, gaps can be introduced in the sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second amino or nucleic acid sequence). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are homologous at that position (*i.e.*, as used herein amino acid or nucleic acid "homology" is equivalent to amino acid or nucleic acid "identity").

The nucleic acid sequence homology may be determined as the degree of identity between two sequences. The homology may be determined using computer programs known in the art, such as GAP software provided in the GCG program package. *See*, Needleman and Wunsch, 1970. *J Mol Biol* 48: 443-453. Using GCG GAP software with the following settings for nucleic acid sequence comparison: GAP creation penalty of 5.0 and GAP extension penalty of 0.3, the coding region of the analogous nucleic acid sequences referred to above exhibits a degree of identity preferably of at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99%, with the

CDS (encoding) part of the DNA sequence shown in SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, and 122. The term "sequence identity" refers to the degree to which two polynucleotide or polypeptide sequences are identical on a residue-by-residue basis over a particular region of comparison. The term "percentage of sequence identity" is calculated by comparing two optimally aligned sequences over that region of comparison, determining the number of positions at which the identical nucleic acid base (*e.g.*, A, T, C, G, U, or I, in the case of nucleic acids) occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the region of comparison (*i.e.*, the window size), and multiplying the result by 100 to yield the percentage of sequence identity. The term "substantial identity" as used herein denotes a characteristic of a polynucleotide sequence, wherein the polynucleotide comprises a sequence that has at least 80 percent sequence identity, preferably at least 85 percent identity and often 90 to 95 percent sequence identity, more usually at least 99 percent sequence identity as compared to a reference sequence over a comparison region.

Chimeric and Fusion Proteins

The invention also provides NOVX chimeric or fusion proteins. As used herein, an NOVX "chimeric protein" or "fusion protein" comprises an NOVX polypeptide operatively-linked to a non-NOVX polypeptide. An "NOVX polypeptide" refers to a polypeptide having an amino acid sequence corresponding to an NOVX protein SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, and 123, whereas a "non-NOVX polypeptide" refers to a polypeptide having an amino acid sequence corresponding to a protein that is not substantially homologous to the NOVX protein, *e.g.*, a protein that is different from the NOVX protein and that is derived from the same or a different organism. Within an NOVX fusion protein the NOVX polypeptide can correspond to all or a portion of an NOVX protein. In one embodiment, an NOVX fusion protein comprises at least one biologically-active portion of an NOVX protein. In another

embodiment, an NOVX fusion protein comprises at least two biologically-active portions of an NOVX protein. In yet another embodiment, an NOVX fusion protein comprises at least three biologically-active portions of an NOVX protein. Within the fusion protein, the term "operatively-linked" is intended to indicate that the NOVX polypeptide and the non-NOVX polypeptide are fused in-frame with one another. The non-NOVX polypeptide can be fused to the N-terminus or C-terminus of the NOVX polypeptide.

In one embodiment, the fusion protein is a GST-NOVX fusion protein in which the NOVX sequences are fused to the C-terminus of the GST (glutathione S-transferase) sequences. Such fusion proteins can facilitate the purification of recombinant NOVX polypeptides.

In another embodiment, the fusion protein is an NOVX protein containing a heterologous signal sequence at its N-terminus. In certain host cells (*e.g.*, mammalian host cells), expression and/or secretion of NOVX can be increased through use of a heterologous signal sequence.

In yet another embodiment, the fusion protein is an NOVX-immunoglobulin fusion protein in which the NOVX sequences are fused to sequences derived from a member of the immunoglobulin protein family. The NOVX-immunoglobulin fusion proteins of the invention can be incorporated into pharmaceutical compositions and administered to a subject to inhibit an interaction between an NOVX ligand and an NOVX protein on the surface of a cell, to thereby suppress NOVX-mediated signal transduction *in vivo*. The NOVX-immunoglobulin fusion proteins can be used to affect the bioavailability of an NOVX cognate ligand. Inhibition of the NOVX ligand/NOVX interaction may be useful therapeutically for both the treatment of proliferative and differentiative disorders, as well as modulating (*e.g.* promoting or inhibiting) cell survival. Moreover, the NOVX-immunoglobulin fusion proteins of the invention can be used as immunogens to produce anti-NOVX antibodies in a subject, to purify NOVX ligands, and in screening assays to identify molecules that inhibit the interaction of NOVX with an NOVX ligand.

An NOVX chimeric or fusion protein of the invention can be produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different polypeptide sequences are ligated together in-frame in accordance with conventional techniques, *e.g.*, by employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation. In another

embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers that give rise to complementary overhangs between two consecutive gene fragments that can subsequently be annealed and reamplified to generate a chimeric gene sequence (*see, e.g.*, Ausubel, *et al.* (eds.) CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, 1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety (*e.g.*, a GST polypeptide). An NOVX-encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the NOVX protein.

NOVX Agonists and Antagonists

The invention also pertains to variants of the NOVX proteins that function as either NOVX agonists (*i.e.*, mimetics) or as NOVX antagonists. Variants of the NOVX protein can be generated by mutagenesis (*e.g.*, discrete point mutation or truncation of the NOVX protein). An agonist of the NOVX protein can retain substantially the same, or a subset of, the biological activities of the naturally occurring form of the NOVX protein. An antagonist of the NOVX protein can inhibit one or more of the activities of the naturally occurring form of the NOVX protein by, for example, competitively binding to a downstream or upstream member of a cellular signaling cascade which includes the NOVX protein. Thus, specific biological effects can be elicited by treatment with a variant of limited function. In one embodiment, treatment of a subject with a variant having a subset of the biological activities of the naturally occurring form of the protein has fewer side effects in a subject relative to treatment with the naturally occurring form of the NOVX proteins.

Variants of the NOVX proteins that function as either NOVX agonists (*i.e.*, mimetics) or as NOVX antagonists can be identified by screening combinatorial libraries of mutants (*e.g.*, truncation mutants) of the NOVX proteins for NOVX protein agonist or antagonist activity. In one embodiment, a variegated library of NOVX variants is generated by combinatorial mutagenesis at the nucleic acid level and is encoded by a variegated gene library. A variegated library of NOVX variants can be produced by, for example, enzymatically ligating a mixture of synthetic oligonucleotides into gene sequences such that a degenerate set of potential NOVX

sequences is expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (*e.g.*, for phage display) containing the set of NOVX sequences therein. There are a variety of methods which can be used to produce libraries of potential NOVX variants from a degenerate oligonucleotide sequence. Chemical synthesis of a degenerate gene sequence can be performed in an automatic DNA synthesizer, and the synthetic gene then ligated into an appropriate expression vector. Use of a degenerate set of genes allows for the provision, in one mixture, of all of the sequences encoding the desired set of potential NOVX sequences. Methods for synthesizing degenerate oligonucleotides are well-known within the art. *See, e.g.*, Narang, 1983. *Tetrahedron* 39: 3; Itakura, *et al.*, 1984. *Annu. Rev. Biochem.* 53: 323; Itakura, *et al.*, 1984. *Science* 198: 1056; Ike, *et al.*, 1983. *Nucl. Acids Res.* 11: 477.

Polypeptide Libraries

In addition, libraries of fragments of the NOVX protein coding sequences can be used to generate a variegated population of NOVX fragments for screening and subsequent selection of variants of an NOVX protein. In one embodiment, a library of coding sequence fragments can be generated by treating a double stranded PCR fragment of an NOVX coding sequence with a nuclease under conditions wherein nicking occurs only about once per molecule, denaturing the double stranded DNA, renaturing the DNA to form double-stranded DNA that can include sense/antisense pairs from different nicked products, removing single stranded portions from reformed duplexes by treatment with S₁ nuclease, and ligating the resulting fragment library into an expression vector. By this method, expression libraries can be derived which encodes N-terminal and internal fragments of various sizes of the NOVX proteins.

Various techniques are known in the art for screening gene products of combinatorial libraries made by point mutations or truncation, and for screening cDNA libraries for gene products having a selected property. Such techniques are adaptable for rapid screening of the gene libraries generated by the combinatorial mutagenesis of NOVX proteins. The most widely used techniques, which are amenable to high throughput analysis, for screening large gene libraries typically include cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates isolation

of the vector encoding the gene whose product was detected. Recursive ensemble mutagenesis (REM), a new technique that enhances the frequency of functional mutants in the libraries, can be used in combination with the screening assays to identify NOVX variants. *See, e.g.,* Arkin and Yourvan, 1992. *Proc. Natl. Acad. Sci. USA* 89: 7811-7815; Delgrave, *et al.*, 1993. *Protein Engineering* 6:327-331.

Anti-NOVX Antibodies

The term "antibody" as used herein refers to immunoglobulin molecules and immunologically active portions of immunoglobulin (Ig) molecules, i.e., molecules that contain an antigen binding site that specifically binds (immunoreacts with) an antigen. Such antibodies include, but are not limited to, polyclonal, monoclonal, chimeric, single chain, F_{ab}, F_{ab'} and F_{(ab')₂} fragments, and an F_{ab} expression library. In general, antibody molecules obtained from humans relates to any of the classes IgG, IgM, IgA, IgE and IgD, which differ from one another by the nature of the heavy chain present in the molecule. Certain classes have subclasses as well, such as IgG₁, IgG₂, and others. Furthermore, in humans, the light chain may be a kappa chain or a lambda chain. Reference herein to antibodies includes a reference to all such classes, subclasses and types of human antibody species.

An isolated protein of the invention intended to serve as an antigen, or a portion or fragment thereof, can be used as an immunogen to generate antibodies that immunospecifically bind the antigen, using standard techniques for polyclonal and monoclonal antibody preparation. The full-length protein can be used or, alternatively, the invention provides antigenic peptide fragments of the antigen for use as immunogens. An antigenic peptide fragment comprises at least 6 amino acid residues of the amino acid sequence of the full length protein, such as an amino acid sequence shown in SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, and 123, and encompasses an epitope thereof such that an antibody raised against the peptide forms a specific immune complex with the full length protein or with any fragment that contains the epitope. Preferably, the antigenic peptide comprises at least 10 amino acid residues, or at least 15 amino acid residues, or at least 20 amino acid residues, or at least 30 amino acid residues.

Preferred epitopes encompassed by the antigenic peptide are regions of the protein that are located on its surface; commonly these are hydrophilic regions.

In certain embodiments of the invention, at least one epitope encompassed by the antigenic peptide is a region of SECX that is located on the surface of the protein, *e.g.*, a hydrophilic region. A hydrophobicity analysis of the human SECX protein sequence will indicate which regions of a SECX polypeptide are particularly hydrophilic and, therefore, are likely to encode surface residues useful for targeting antibody production. As a means for targeting antibody production, hydropathy plots showing regions of hydrophilicity and hydrophobicity may be generated by any method well known in the art, including, for example, the Kyte Doolittle or the Hopp Woods methods, either with or without Fourier transformation. See, *e.g.*, Hopp and Woods, 1981, *Proc. Nat. Acad. Sci. USA* 78: 3824-3828; Kyte and Doolittle 1982, *J. Mol. Biol.* 157: 105-142, each incorporated herein by reference in their entirety. Antibodies that are specific for one or more domains within an antigenic protein, or derivatives, fragments, analogs or homologs thereof, are also provided herein.

A protein of the invention, or a derivative, fragment, analog, homolog or ortholog thereof, may be utilized as an immunogen in the generation of antibodies that immunospecifically bind these protein components.

Various procedures known within the art may be used for the production of polyclonal or monoclonal antibodies directed against a protein of the invention, or against derivatives, fragments, analogs homologs or orthologs thereof (see, for example, *Antibodies: A Laboratory Manual*, Harlow E, and Lane D, 1988, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, incorporated herein by reference). Some of these antibodies are discussed below.

1. Polyclonal Antibodies

For the production of polyclonal antibodies, various suitable host animals (*e.g.*, rabbit, goat, mouse or other mammal) may be immunized by one or more injections with the native protein, a synthetic variant thereof, or a derivative of the foregoing. An appropriate immunogenic preparation can contain, for example, the naturally occurring immunogenic protein, a chemically synthesized polypeptide representing the immunogenic protein, or a recombinantly expressed immunogenic protein. Furthermore, the protein may be conjugated to a second protein known to be immunogenic in the mammal being immunized. Examples of such

immunogenic proteins include but are not limited to keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. The preparation can further include an adjuvant. Various adjuvants used to increase the immunological response include, but are not limited to, Freund's (complete and incomplete), mineral gels (e.g., aluminum hydroxide), surface active substances (e.g., lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, dinitrophenol, etc.), adjuvants usable in humans such as Bacille Calmette-Guerin and Corynebacterium parvum, or similar immunostimulatory agents. Additional examples of adjuvants which can be employed include MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolate).

The polyclonal antibody molecules directed against the immunogenic protein can be isolated from the mammal (e.g., from the blood) and further purified by well known techniques, such as affinity chromatography using protein A or protein G, which provide primarily the IgG fraction of immune serum. Subsequently, or alternatively, the specific antigen which is the target of the immunoglobulin sought, or an epitope thereof, may be immobilized on a column to purify the immune specific antibody by immunoaffinity chromatography. Purification of immunoglobulins is discussed, for example, by D. Wilkinson (The Scientist, published by The Scientist, Inc., Philadelphia PA, Vol. 14, No. 8 (April 17, 2000), pp. 25-28).

2. Monoclonal Antibodies

The term "monoclonal antibody" (MAb) or "monoclonal antibody composition", as used herein, refers to a population of antibody molecules that contain only one molecular species of antibody molecule consisting of a unique light chain gene product and a unique heavy chain gene product. In particular, the complementarity determining regions (CDRs) of the monoclonal antibody are identical in all the molecules of the population. MAbs thus contain an antigen binding site capable of immunoreacting with a particular epitope of the antigen characterized by a unique binding affinity for it.

Monoclonal antibodies can be prepared using hybridoma methods, such as those described by Kohler and Milstein, Nature, 256:495 (1975). In a hybridoma method, a mouse, hamster, or other appropriate host animal, is typically immunized with an immunizing agent to

elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes can be immunized in vitro.

The immunizing agent will typically include the protein antigen, a fragment thereof or a fusion protein thereof. Generally, either peripheral blood lymphocytes are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired. The lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell [Goding, Monoclonal Antibodies: Principles and Practice, Academic Press, (1986) pp. 59-103]. Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine and human origin. Usually, rat or mouse myeloma cell lines are employed. The hybridoma cells can be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine ("HAT medium"), which substances prevent the growth of HGPRT-deficient cells.

Preferred immortalized cell lines are those that fuse efficiently, support stable high level expression of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. More preferred immortalized cell lines are murine myeloma lines, which can be obtained, for instance, from the Salk Institute Cell Distribution Center, San Diego, California and the American Type Culture Collection, Manassas, Virginia. Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies [Kozbor, J. Immunol., 133:3001 (1984); Brodeur et al., Monoclonal Antibody Production Techniques and Applications, Marcel Dekker, Inc., New York, (1987) pp. 51-63].

The culture medium in which the hybridoma cells are cultured can then be assayed for the presence of monoclonal antibodies directed against the antigen. Preferably, the binding specificity of monoclonal antibodies produced by the hybridoma cells is determined by immunoprecipitation or by an in vitro binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA). Such techniques and assays are known in the art. The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson and Pollard, Anal. Biochem., 107:220 (1980). It is an objective,

especially important in therapeutic applications of monoclonal antibodies, to identify antibodies having a high degree of specificity and a high binding affinity for the target antigen.

After the desired hybridoma cells are identified, the clones can be subcloned by limiting dilution procedures and grown by standard methods (Goding, 1986). Suitable culture media for this purpose include, for example, Dulbecco's Modified Eagle's Medium and RPMI-1640 medium. Alternatively, the hybridoma cells can be grown in vivo as ascites in a mammal.

The monoclonal antibodies secreted by the subclones can be isolated or purified from the culture medium or ascites fluid by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.

The monoclonal antibodies can also be made by recombinant DNA methods, such as those described in U.S. Patent No. 4,816,567. DNA encoding the monoclonal antibodies of the invention can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). The hybridoma cells of the invention serve as a preferred source of such DNA. Once isolated, the DNA can be placed into expression vectors, which are then transfected into host cells such as simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. The DNA also can be modified, for example, by substituting the coding sequence for human heavy and light chain constant domains in place of the homologous murine sequences (U.S. Patent No. 4,816,567; Morrison, Nature 368, 812-13 (1994)) or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide. Such a non-immunoglobulin polypeptide can be substituted for the constant domains of an antibody of the invention, or can be substituted for the variable domains of one antigen-combining site of an antibody of the invention to create a chimeric bivalent antibody.

3. Humanized Antibodies

The antibodies directed against the protein antigens of the invention can further comprise humanized antibodies or human antibodies. These antibodies are suitable for administration to humans without engendering an immune response by the human against the administered

immunoglobulin. Humanized forms of antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab')₂ or other antigen-binding subsequences of antibodies) that are principally comprised of the sequence of a human immunoglobulin, and contain minimal sequence derived from a non-human immunoglobulin.

Humanization can be performed following the method of Winter and co-workers (Jones et al., Nature, 321:522-525 (1986); Riechmann et al., Nature, 332:323-327 (1988); Verhoeyen et al., Science, 239:1534-1536 (1988)), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. (See also U.S. Patent No. 5,225,539.) In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies can also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the framework regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin (Jones et al., 1986; Riechmann et al., 1988; and Presta, Curr. Op. Struct. Biol., 2:593-596 (1992)).

4. Human Antibodies

Fully human antibodies essentially relate to antibody molecules in which the entire sequence of both the light chain and the heavy chain, including the CDRs, arise from human genes. Such antibodies are termed "human antibodies", or "fully human antibodies" herein. Human monoclonal antibodies can be prepared by the trioma technique; the human B-cell hybridoma technique (see Kozbor, et al., 1983 Immunol Today 4: 72) and the EBV hybridoma technique to produce human monoclonal antibodies (see Cole, et al., 1985 In: MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inc., pp. 77-96). Human monoclonal antibodies may be utilized in the practice of the present invention and may be produced by using human hybridomas (see Cote, et al., 1983. Proc Natl Acad Sci USA 80: 2026-2030) or by transforming human B-cells with Epstein Barr Virus in vitro (see Cole, et al., 1985 In: MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inc., pp. 77-96).

In addition, human antibodies can also be produced using additional techniques, including phage display libraries (Hoogenboom and Winter, J. Mol. Biol., 227:381 (1991); Marks et al., J. Mol. Biol., 222:581 (1991)). Similarly, human antibodies can be made by introducing human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire. This approach is described, for example, in U.S. Patent Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in Marks et al. (Bio/Technology 10, 779-783 (1992)); Lonberg et al. (Nature 368 856-859 (1994)); Morrison (Nature 368, 812-13 (1994)); Fishwild et al. (Nature Biotechnology 14, 845-51 (1996)); Neuberger (Nature Biotechnology 14, 826 (1996)); and Lonberg and Huszar (Intern. Rev. Immunol. 13 65-93 (1995)).

Human antibodies may additionally be produced using transgenic nonhuman animals which are modified so as to produce fully human antibodies rather than the animal's endogenous antibodies in response to challenge by an antigen. (See PCT publication WO94/02602). The endogenous genes encoding the heavy and light immunoglobulin chains in the nonhuman host have been incapacitated, and active loci encoding human heavy and light chain immunoglobulins are inserted into the host's genome. The human genes are incorporated, for example, using yeast artificial chromosomes containing the requisite human DNA segments. An animal which provides all the desired modifications is then obtained as progeny by crossbreeding intermediate transgenic animals containing fewer than the full complement of the modifications. The preferred embodiment of such a nonhuman animal is a mouse, and is termed the XenomouseTM as disclosed in PCT publications WO 96/33735 and WO 96/34096. This animal produces B cells which secrete fully human immunoglobulins. The antibodies can be obtained directly from the animal after immunization with an immunogen of interest, as, for example, a preparation of a polyclonal antibody, or alternatively from immortalized B cells derived from the animal, such as hybridomas producing monoclonal antibodies. Additionally, the genes encoding the immunoglobulins with human variable regions can be recovered and expressed to obtain the antibodies directly, or can be further modified to obtain analogs of antibodies such as, for example, single chain Fv molecules.

An example of a method of producing a nonhuman host, exemplified as a mouse, lacking expression of an endogenous immunoglobulin heavy chain is disclosed in U.S. Patent No. 5,939,598. It can be obtained by a method including deleting the J segment genes from at least one endogenous heavy chain locus in an embryonic stem cell to prevent rearrangement of the locus and to prevent formation of a transcript of a rearranged immunoglobulin heavy chain locus, the deletion being effected by a targeting vector containing a gene encoding a selectable marker; and producing from the embryonic stem cell a transgenic mouse whose somatic and germ cells contain the gene encoding the selectable marker.

A method for producing an antibody of interest, such as a human antibody, is disclosed in U.S. Patent No. 5,916,771. It includes introducing an expression vector that contains a nucleotide sequence encoding a heavy chain into one mammalian host cell in culture, introducing an expression vector containing a nucleotide sequence encoding a light chain into another mammalian host cell, and fusing the two cells to form a hybrid cell. The hybrid cell expresses an antibody containing the heavy chain and the light chain.

In a further improvement on this procedure, a method for identifying a clinically relevant epitope on an immunogen, and a correlative method for selecting an antibody that binds immunospecifically to the relevant epitope with high affinity, are disclosed in PCT publication WO 99/53049.

5. F_{ab} Fragments and Single Chain Antibodies

According to the invention, techniques can be adapted for the production of single-chain antibodies specific to an antigenic protein of the invention (see e.g., U.S. Patent No. 4,946,778). In addition, methods can be adapted for the construction of F_{ab} expression libraries (see e.g., Huse, et al., 1989 Science 246: 1275-1281) to allow rapid and effective identification of monoclonal F_{ab} fragments with the desired specificity for a protein or derivatives, fragments, analogs or homologs thereof. Antibody fragments that contain the idiotypes to a protein antigen may be produced by techniques known in the art including, but not limited to: (i) an F_{(ab)²} fragment produced by pepsin digestion of an antibody molecule; (ii) an F_{ab} fragment generated by reducing the disulfide bridges of an F_{(ab)²} fragment; (iii) an F_{ab} fragment generated by the treatment of the antibody molecule with papain and a reducing agent and (iv) F_v fragments.

6. Bispecific Antibodies

Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens. In the present case, one of the binding specificities is for an antigenic protein of the invention. The second binding target is any other antigen, and advantageously is a cell-surface protein or receptor or receptor subunit.

Methods for making bispecific antibodies are known in the art. Traditionally, the recombinant production of bispecific antibodies is based on the co-expression of two immunoglobulin heavy-chain/light-chain pairs, where the two heavy chains have different specificities (Milstein and Cuello, Nature, 305:537-539 (1983)). Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture of ten different antibody molecules, of which only one has the correct bispecific structure. The purification of the correct molecule is usually accomplished by affinity chromatography steps. Similar procedures are disclosed in WO 93/08829, published 13 May 1993, and in Traunecker et al., EMBO J., 10:3655-3659 (1991).

Antibody variable domains with the desired binding specificities (antibody-antigen combining sites) can be fused to immunoglobulin constant domain sequences. The fusion preferably is with an immunoglobulin heavy-chain constant domain, comprising at least part of the hinge, CH2, and CH3 regions. It is preferred to have the first heavy-chain constant region (CH1) containing the site necessary for light-chain binding present in at least one of the fusions. DNAs encoding the immunoglobulin heavy-chain fusions and, if desired, the immunoglobulin light chain, are inserted into separate expression vectors, and are co-transfected into a suitable host organism. For further details of generating bispecific antibodies see, for example, Suresh et al., Methods in Enzymology, 121:210 (1986).

According to another approach described in WO 96/27011, the interface between a pair of antibody molecules can be engineered to maximize the percentage of heterodimers which are recovered from recombinant cell culture. The preferred interface comprises at least a part of the CH3 region of an antibody constant domain. In this method, one or more small amino acid side chains from the interface of the first antibody molecule are replaced with larger side chains (e.g. tyrosine or tryptophan). Compensatory "cavities" of identical or similar size to the large side chain(s) are created on the interface of the second antibody molecule by replacing large amino

acid side chains with smaller ones (e.g. alanine or threonine). This provides a mechanism for increasing the yield of the heterodimer over other unwanted end-products such as homodimers.

Bispecific antibodies can be prepared as full length antibodies or antibody fragments (e.g. F(ab')₂ bispecific antibodies). Techniques for generating bispecific antibodies from antibody fragments have been described in the literature. For example, bispecific antibodies can be prepared using chemical linkage. Brennan et al., Science 229:81 (1985) describe a procedure wherein intact antibodies are proteolytically cleaved to generate F(ab')₂ fragments. These fragments are reduced in the presence of the dithiol complexing agent sodium arsenite to stabilize vicinal dithiols and prevent intermolecular disulfide formation. The Fab' fragments generated are then converted to thionitrobenzoate (TNB) derivatives. One of the Fab'-TNB derivatives is then reconverted to the Fab'-thiol by reduction with mercaptoethylamine and is mixed with an equimolar amount of the other Fab'-TNB derivative to form the bispecific antibody. The bispecific antibodies produced can be used as agents for the selective immobilization of enzymes.

Additionally, Fab' fragments can be directly recovered from *E. coli* and chemically coupled to form bispecific antibodies. Shalaby et al., J. Exp. Med. 175:217-225 (1992) describe the production of a fully humanized bispecific antibody F(ab')₂ molecule. Each Fab' fragment was separately secreted from *E. coli* and subjected to directed chemical coupling in vitro to form the bispecific antibody. The bispecific antibody thus formed was able to bind to cells overexpressing the ErbB2 receptor and normal human T cells, as well as trigger the lytic activity of human cytotoxic lymphocytes against human breast tumor targets.

Various techniques for making and isolating bispecific antibody fragments directly from recombinant cell culture have also been described. For example, bispecific antibodies have been produced using leucine zippers. Kostelny et al., J. Immunol. 148(5):1547-1553 (1992). The leucine zipper peptides from the Fos and Jun proteins were linked to the Fab' portions of two different antibodies by gene fusion. The antibody homodimers were reduced at the hinge region to form monomers and then re-oxidized to form the antibody heterodimers. This method can also be utilized for the production of antibody homodimers. The "diabody" technology described by Hollinger et al., Proc. Natl. Acad. Sci. USA 90:6444-6448 (1993) has provided an alternative mechanism for making bispecific antibody fragments. The fragments comprise a heavy-chain variable domain (V_H) connected to a light-chain variable domain (V_L) by a linker

which is too short to allow pairing between the two domains on the same chain. Accordingly, the V_H and V_L domains of one fragment are forced to pair with the complementary V_L and V_H domains of another fragment, thereby forming two antigen-binding sites. Another strategy for making bispecific antibody fragments by the use of single-chain Fv (sFv) dimers has also been reported. See, Gruber et al., J. Immunol. 152:5368 (1994).

Antibodies with more than two valencies are contemplated. For example, trispecific antibodies can be prepared. Tutt et al., J. Immunol. 147:60 (1991).

Exemplary bispecific antibodies can bind to two different epitopes, at least one of which originates in the protein antigen of the invention. Alternatively, an anti-antigenic arm of an immunoglobulin molecule can be combined with an arm which binds to a triggering molecule on a leukocyte such as a T-cell receptor molecule (e.g. CD2, CD3, CD28, or B7), or Fc receptors for IgG (FcγR), such as FcγRI (CD64), FcγRII (CD32) and FcγRIII (CD16) so as to focus cellular defense mechanisms to the cell expressing the particular antigen. Bispecific antibodies can also be used to direct cytotoxic agents to cells which express a particular antigen. These antibodies possess an antigen-binding arm and an arm which binds a cytotoxic agent or a radionuclide chelator, such as EOTUBE, DPTA, DOTA, or TETA. Another bispecific antibody of interest binds the protein antigen described herein and further binds tissue factor (TF).

7. Heteroconjugate Antibodies

Heteroconjugate antibodies are also within the scope of the present invention. Heteroconjugate antibodies are composed of two covalently joined antibodies. Such antibodies have, for example, been proposed to target immune system cells to unwanted cells (U.S. Patent No. 4,676,980), and for treatment of HIV infection (WO 91/00360; WO 92/200373; EP 03089). It is contemplated that the antibodies can be prepared in vitro using known methods in synthetic protein chemistry, including those involving crosslinking agents. For example, immunotoxins can be constructed using a disulfide exchange reaction or by forming a thioether bond. Examples of suitable reagents for this purpose include iminothiolate and methyl-4-mercaptoputyrimidate and those disclosed, for example, in U.S. Patent No. 4,676,980.

8. Effector Function Engineering

It can be desirable to modify the antibody of the invention with respect to effector function, so as to enhance, e.g., the effectiveness of the antibody in treating cancer. For example, cysteine residue(s) can be introduced into the Fc region, thereby allowing interchain disulfide bond formation in this region. The homodimeric antibody thus generated can have improved internalization capability and/or increased complement-mediated cell killing and antibody-dependent cellular cytotoxicity (ADCC). See Caron et al., *J. Exp Med.*, 176: 1191-1195 (1992) and Shopes, *J. Immunol.*, 148: 2918-2922 (1992). Homodimeric antibodies with enhanced anti-tumor activity can also be prepared using heterobifunctional cross-linkers as described in Wolff et al. *Cancer Research*, 53: 2560-2565 (1993). Alternatively, an antibody can be engineered that has dual Fc regions and can thereby have enhanced complement lysis and ADCC capabilities. See Stevenson et al., *Anti-Cancer Drug Design*, 3: 219-230 (1989).

9. Immunoconjugates

The invention also pertains to immunoconjugates comprising an antibody conjugated to a cytotoxic agent such as a chemotherapeutic agent, toxin (e.g., an enzymatically active toxin of bacterial, fungal, plant, or animal origin, or fragments thereof), or a radioactive isotope (i.e., a radioconjugate).

Chemotherapeutic agents useful in the generation of such immunoconjugates have been described above. Enzymatically active toxins and fragments thereof that can be used include diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from *Pseudomonas aeruginosa*), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins, Phytolaca americana proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, croton, saponaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and the tricothecenes. A variety of radionuclides are available for the production of radioconjugated antibodies. Examples include ^{212}Bi , ^{131}I , ^{131}In , ^{90}Y , and ^{186}Re .

Conjugates of the antibody and cytotoxic agent are made using a variety of bifunctional protein-coupling agents such as N-succinimidyl-3-(2-pyridyldithiol) propionate (SPDP), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutaraldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as

bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as tolyene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). For example, a ricin immunotoxin can be prepared as described in Vitetta et al., Science, 238: 1098 (1987). Carbon-14-labeled 1-isothiocyanatobenzyl-3-methyldiethylene triaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugation of radionucleotide to the antibody. See WO94/11026.

In another embodiment, the antibody can be conjugated to a "receptor" (such as streptavidin) for utilization in tumor pretargeting wherein the antibody-receptor conjugate is administered to the patient, followed by removal of unbound conjugate from the circulation using a clearing agent and then administration of a "ligand" (e.g., avidin) that is in turn conjugated to a cytotoxic agent.

10. Immunoliposomes

The antibodies disclosed herein can also be formulated as immunoliposomes. Liposomes containing the antibody are prepared by methods known in the art, such as described in Epstein et al., Proc. Natl. Acad. Sci. USA, 82: 3688 (1985); Hwang et al., Proc. Natl. Acad. Sci. USA, 77: 4030 (1980); and U.S. Pat. Nos. 4,485,045 and 4,544,545. Liposomes with enhanced circulation time are disclosed in U.S. Patent No. 5,013,556.

Particularly useful liposomes can be generated by the reverse-phase evaporation method with a lipid composition comprising phosphatidylcholine, cholesterol, and PEG-derivatized phosphatidylethanolamine (PEG-PE). Liposomes are extruded through filters of defined pore size to yield liposomes with the desired diameter. Fab' fragments of the antibody of the present invention can be conjugated to the liposomes as described in Martin et al., J. Biol. Chem., 257: 286-288 (1982) via a disulfide-interchange reaction. A chemotherapeutic agent (such as Doxorubicin) is optionally contained within the liposome. See Gabizon et al., J. National Cancer Inst., 81(19): 1484 (1989).

11. Diagnostic Applications of Antibodies Directed Against the Proteins of the Invention

Antibodies directed against a protein of the invention may be used in methods known within the art relating to the localization and/or quantitation of the protein (e.g., for use in measuring levels of the protein within appropriate physiological samples, for use in diagnostic

methods, for use in imaging the protein, and the like). In a given embodiment, antibodies against the proteins, or derivatives, fragments, analogs or homologs thereof, that contain the antigen binding domain, are utilized as pharmacologically-active compounds (see below).

An antibody specific for a protein of the invention can be used to isolate the protein by standard techniques, such as immunoaffinity chromatography or immunoprecipitation. Such an antibody can facilitate the purification of the natural protein antigen from cells and of recombinantly produced antigen expressed in host cells. Moreover, such an antibody can be used to detect the antigenic protein (e.g., in a cellular lysate or cell supernatant) in order to evaluate the abundance and pattern of expression of the antigenic protein. Antibodies directed against the protein can be used diagnostically to monitor protein levels in tissue as part of a clinical testing procedure, e.g., to, for example, determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling (i.e., physically linking) the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β -galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include ^{125}I , ^{131}I , ^{35}S or ^3H .

12. Antibody Therapeutics

Antibodies of the invention, including polyclonal, monoclonal, humanized and fully human antibodies, may be used as therapeutic agents. Such agents will generally be employed to treat or prevent a disease or pathology in a subject. An antibody preparation, preferably one having high specificity and high affinity for its target antigen, is administered to the subject and will generally have an effect due to its binding with the target. Such an effect may be one of two kinds, depending on the specific nature of the interaction between the given antibody molecule and the target antigen in question. In the first instance, administration of the antibody may

abrogate or inhibit the binding of the target with an endogenous ligand to which it naturally binds. In this case, the antibody binds to the target and masks a binding site of the naturally occurring ligand, wherein the ligand serves as an effector molecule. Thus the receptor mediates a signal transduction pathway for which ligand is responsible.

Alternatively, the effect may be one in which the antibody elicits a physiological result by virtue of binding to an effector binding site on the target molecule. In this case the target, a receptor having an endogenous ligand which may be absent or defective in the disease or pathology, binds the antibody as a surrogate effector ligand, initiating a receptor-based signal transduction event by the receptor.

A therapeutically effective amount of an antibody of the invention relates generally to the amount needed to achieve a therapeutic objective. As noted above, this may be a binding interaction between the antibody and its target antigen that, in certain cases, interferes with the functioning of the target, and in other cases, promotes a physiological response. The amount required to be administered will furthermore depend on the binding affinity of the antibody for its specific antigen, and will also depend on the rate at which an administered antibody is depleted from the free volume other subject to which it is administered. Common ranges for therapeutically effective dosing of an antibody or antibody fragment of the invention may be, by way of nonlimiting example, from about 0.1 mg/kg body weight to about 50 mg/kg body weight. Common dosing frequencies may range, for example, from twice daily to once a week.

13. Pharmaceutical Compositions of Antibodies

Antibodies specifically binding a protein of the invention, as well as other molecules identified by the screening assays disclosed herein, can be administered for the treatment of various disorders in the form of pharmaceutical compositions. Principles and considerations involved in preparing such compositions, as well as guidance in the choice of components are provided, for example, in Remington : The Science And Practice Of Pharmacy 19th ed. (Alfonso R. Gennaro, et al., editors) Mack Pub. Co., Easton, Pa. : 1995; Drug Absorption Enhancement : Concepts, Possibilities, Limitations, And Trends, Harwood Academic Publishers, Langhorne, Pa., 1994; and Peptide And Protein Drug Delivery (Advances In Parenteral Sciences, Vol. 4), 1991, M. Dekker, New York.

10055877 "012302
2022-03-07 10:05:58
If the antigenic protein is intracellular and whole antibodies are used as inhibitors, internalizing antibodies are preferred. However, liposomes can also be used to deliver the antibody, or an antibody fragment, into cells. Where antibody fragments are used, the smallest inhibitory fragment that specifically binds to the binding domain of the target protein is preferred. For example, based upon the variable-region sequences of an antibody, peptide molecules can be designed that retain the ability to bind the target protein sequence. Such peptides can be synthesized chemically and/or produced by recombinant DNA technology. See, e.g., Marasco et al., Proc. Natl. Acad. Sci. USA, 90: 7889-7893 (1993). The formulation herein can also contain more than one active compound as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other. Alternatively, or in addition, the composition can comprise an agent that enhances its function, such as, for example, a cytotoxic agent, cytokine, chemotherapeutic agent, or growth-inhibitory agent. Such molecules are suitably present in combination in amounts that are effective for the purpose intended.

15 The active ingredients can also be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methylmethacrylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nanoparticles, and nanocapsules) or in macroemulsions.

20 The formulations to be used for in vivo administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes.

Sustained-release preparations can be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, e.g., films, or microcapsules.

25 Examples of sustained-release matrices include polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylate), or poly(vinylalcohol)), polylactides (U.S. Pat. No. 3,773,919), copolymers of L-glutamic acid and γ ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as the LUPRON DEPOTTM (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid. While polymers such as ethylene-vinyl acetate and lactic acid-

30

glycolic acid enable release of molecules for over 100 days, certain hydrogels release proteins for shorter time periods.

ELISA Assay

5

10 An agent for detecting an analyte protein is an antibody capable of binding to an analyte protein, preferably an antibody with a detectable label. Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (*e.g.*, F_{ab} or F_{(ab)2}) can be used. The term "labeled", with regard to the probe or antibody, is intended to encompass direct

15 labeling of the probe or antibody by coupling (*i.e.*, physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently-labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently-labeled streptavidin. The term

20 "biological sample" is intended to include tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject. Included within the usage of the term "biological sample", therefore, is blood and a fraction or component of blood including blood serum, blood plasma, or lymph. That is, the detection method of the invention can be used to detect an analyte mRNA, protein, or genomic DNA in a biological sample *in vitro* as well as

25 *in vivo*. For example, *in vitro* techniques for detection of an analyte mRNA include Northern hybridizations and *in situ* hybridizations. *In vitro* techniques for detection of an analyte protein include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations, and immunofluorescence. *In vitro* techniques for detection of an analyte genomic DNA include Southern hybridizations. Procedures for conducting immunoassays are described, for example in

30 "ELISA: Theory and Practice: Methods in Molecular Biology", Vol. 42, J. R. Crowther (Ed.) Human Press, Totowa, NJ, 1995; "Immunoassay", E. Diamandis and T. Christopoulos, Academic Press, Inc., San Diego, CA, 1996; and "Practice and Theory of Enzyme Immunoassays", P. Tijssen, Elsevier Science Publishers, Amsterdam, 1985. Furthermore, *in vivo* techniques for detection of an analyte protein include introducing into a subject a labeled anti-analyte protein antibody. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.

NOVX Recombinant Expression Vectors and Host Cells

Another aspect of the invention pertains to vectors, preferably expression vectors, containing a nucleic acid encoding an NOVX protein, or derivatives, fragments, analogs or homologs thereof. As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid", which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (*e.g.*, bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (*e.g.*, non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively-linked. Such vectors are referred to herein as "expression vectors". In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. In the present specification, "plasmid" and "vector" can be used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors, such as viral vectors (*e.g.*, replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.

The recombinant expression vectors of the invention comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory sequences, selected on the basis of the host cells to be used for expression, that is operatively-linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, "operably-linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner that allows for expression of the nucleotide sequence (*e.g.*, in an *in vitro* transcription/translation system or in a host cell when the vector is introduced into the host cell).

The term "regulatory sequence" is intended to include promoters, enhancers and other expression control elements (*e.g.*, polyadenylation signals). Such regulatory sequences are described, for example, in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN

10055877 "0122002
ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990). Regulatory sequences include those that direct constitutive expression of a nucleotide sequence in many types of host cell and those that direct expression of the nucleotide sequence only in certain host cells (*e.g.*, tissue-specific regulatory sequences). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, etc. The expression vectors of the invention can be introduced into host cells to thereby produce proteins or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein (*e.g.*, NOVX proteins, mutant forms of NOVX proteins, fusion proteins, etc.).

10 The recombinant expression vectors of the invention can be designed for expression of NOVX proteins in prokaryotic or eukaryotic cells. For example, NOVX proteins can be expressed in bacterial cells such as *Escherichia coli*, insect cells (using baculovirus expression vectors) yeast cells or mammalian cells. Suitable host cells are discussed further in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990). Alternatively, the recombinant expression vector can be transcribed and translated *in vitro*, for example using T7 promoter regulatory sequences and T7 polymerase.

15 Expression of proteins in prokaryotes is most often carried out in *Escherichia coli* with vectors containing constitutive or inducible promoters directing the expression of either fusion or non-fusion proteins. Fusion vectors add a number of amino acids to a protein encoded therein, usually to the amino terminus of the recombinant protein. Such fusion vectors typically serve three purposes: (i) to increase expression of recombinant protein; (ii) to increase the solubility of the recombinant protein; and (iii) to aid in the purification of the recombinant protein by acting as a ligand in affinity purification. Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase. Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith and Johnson, 1988. *Gene* 67: 31-40), pMAL (New England Biolabs, Beverly, Mass.) and pRIT5 (Pharmacia, Piscataway, N.J.) that fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein.

Examples of suitable inducible non-fusion *E. coli* expression vectors include pTrc (Amrann *et al.*, (1988) *Gene* 69:301-315) and pET 11d (Studier *et al.*, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990) 60-89).

5 One strategy to maximize recombinant protein expression in *E. coli* is to express the protein in a host bacteria with an impaired capacity to proteolytically cleave the recombinant protein. See, e.g., Gottesman, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990) 119-128. Another strategy is to alter the nucleic acid sequence of the nucleic acid to be inserted into an expression vector so that the individual codons
10 for each amino acid are those preferentially utilized in *E. coli* (see, e.g., Wada, *et al.*, 1992. *Nucl. Acids Res.* 20: 2111-2118). Such alteration of nucleic acid sequences of the invention can be carried out by standard DNA synthesis techniques.

In another embodiment, the NOVX expression vector is a yeast expression vector. Examples of vectors for expression in yeast *Saccharomyces cerevisiae* include pYepSec1
15 (Baldari, *et al.*, 1987. *EMBO J.* 6: 229-234), pMFa (Kurjan and Herskowitz, 1982. *Cell* 30: 933-943), pJRY88 (Schultz *et al.*, 1987. *Gene* 54: 113-123), pYES2 (Invitrogen Corporation, San Diego, Calif.), and picZ (InVitrogen Corp, San Diego, Calif.).

Alternatively, NOVX can be expressed in insect cells using baculovirus expression vectors. Baculovirus vectors available for expression of proteins in cultured insect cells (e.g.,
20 SF9 cells) include the pAc series (Smith, *et al.*, 1983. *Mol. Cell. Biol.* 3: 2156-2165) and the pVL series (Lucklow and Summers, 1989. *Virology* 170: 31-39).

In yet another embodiment, a nucleic acid of the invention is expressed in mammalian cells using a mammalian expression vector. Examples of mammalian expression vectors include pCDM8 (Seed, 1987. *Nature* 329: 840) and pMT2PC (Kaufman, *et al.*, 1987. *EMBO J.* 6:
25 187-195). When used in mammalian cells, the expression vector's control functions are often provided by viral regulatory elements. For example, commonly used promoters are derived from polyoma, adenovirus 2, cytomegalovirus, and simian virus 40. For other suitable expression systems for both prokaryotic and eukaryotic cells see, e.g., Chapters 16 and 17 of Sambrook, *et al.*, MOLECULAR CLONING: A LABORATORY MANUAL. 2nd ed., Cold Spring Harbor Laboratory,
30 Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989.

In another embodiment, the recombinant mammalian expression vector is capable of directing expression of the nucleic acid preferentially in a particular cell type (*e.g.*, tissue-specific regulatory elements are used to express the nucleic acid). Tissue-specific regulatory elements are known in the art. Non-limiting examples of suitable tissue-specific promoters include the albumin promoter (liver-specific; Pinkert, *et al.*, 1987. *Genes Dev.* 1: 268-277), lymphoid-specific promoters (Calame and Eaton, 1988. *Adv. Immunol.* 43: 235-275), in particular promoters of T cell receptors (Winoto and Baltimore, 1989. *EMBO J.* 8: 729-733) and immunoglobulins (Banerji, *et al.*, 1983. *Cell* 33: 729-740; Queen and Baltimore, 1983. *Cell* 33: 741-748), neuron-specific promoters (*e.g.*, the neurofilament promoter; Byrne and Ruddle, 1989. *Proc. Natl. Acad. Sci. USA* 86: 5473-5477), pancreas-specific promoters (Edlund, *et al.*, 1985. *Science* 230: 912-916), and mammary gland-specific promoters (*e.g.*, milk whey promoter; U.S. Pat. No. 4,873,316 and European Application Publication No. 264,166). Developmentally-regulated promoters are also encompassed, *e.g.*, the murine hox promoters (Kessel and Gruss, 1990. *Science* 249: 374-379) and the α -fetoprotein promoter (Campes and Tilghman, 1989. *Genes Dev.* 3: 537-546).

The invention further provides a recombinant expression vector comprising a DNA molecule of the invention cloned into the expression vector in an antisense orientation. That is, the DNA molecule is operatively-linked to a regulatory sequence in a manner that allows for expression (by transcription of the DNA molecule) of an RNA molecule that is antisense to NOVX mRNA. Regulatory sequences operatively linked to a nucleic acid cloned in the antisense orientation can be chosen that direct the continuous expression of the antisense RNA molecule in a variety of cell types, for instance viral promoters and/or enhancers, or regulatory sequences can be chosen that direct constitutive, tissue specific or cell type specific expression of antisense RNA. The antisense expression vector can be in the form of a recombinant plasmid, phagemid or attenuated virus in which antisense nucleic acids are produced under the control of a high efficiency regulatory region, the activity of which can be determined by the cell type into which the vector is introduced. For a discussion of the regulation of gene expression using antisense genes *see, e.g.*, Weintraub, *et al.*, "Antisense RNA as a molecular tool for genetic analysis," *Reviews-Trends in Genetics*, Vol. 1(1) 1986.

Another aspect of the invention pertains to host cells into which a recombinant expression vector of the invention has been introduced. The terms "host cell" and "recombinant

host cell" are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but also to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.

A host cell can be any prokaryotic or eukaryotic cell. For example, NOVX protein can be expressed in bacterial cells such as *E. coli*, insect cells, yeast or mammalian cells (such as Chinese hamster ovary cells (CHO) or COS cells). Other suitable host cells are known to those skilled in the art.

Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. As used herein, the terms "transformation" and "transfection" are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid (*e.g.*, DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, or electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook, *et al.* (MOLECULAR CLONING: A LABORATORY MANUAL. 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989), and other laboratory manuals.

For stable transfection of mammalian cells, it is known that, depending upon the expression vector and transfection technique used, only a small fraction of cells may integrate the foreign DNA into their genome. In order to identify and select these integrants, a gene that encodes a selectable marker (*e.g.*, resistance to antibiotics) is generally introduced into the host cells along with the gene of interest. Various selectable markers include those that confer resistance to drugs, such as G418, hygromycin and methotrexate. Nucleic acid encoding a selectable marker can be introduced into a host cell on the same vector as that encoding NOVX or can be introduced on a separate vector. Cells stably transfected with the introduced nucleic acid can be identified by drug selection (*e.g.*, cells that have incorporated the selectable marker gene will survive, while the other cells die).

A host cell of the invention, such as a prokaryotic or eukaryotic host cell in culture, can be used to produce (*i.e.*, express) NOVX protein. Accordingly, the invention further provides methods for producing NOVX protein using the host cells of the invention. In one embodiment,

the method comprises culturing the host cell of invention (into which a recombinant expression vector encoding NOVX protein has been introduced) in a suitable medium such that NOVX protein is produced. In another embodiment, the method further comprises isolating NOVX protein from the medium or the host cell.

5 Transgenic NOVX Animals

The host cells of the invention can also be used to produce non-human transgenic animals. For example, in one embodiment, a host cell of the invention is a fertilized oocyte or an embryonic stem cell into which NOVX protein-coding sequences have been introduced. Such host cells can then be used to create non-human transgenic animals in which exogenous NOVX sequences have been introduced into their genome or homologous recombinant animals in which endogenous NOVX sequences have been altered. Such animals are useful for studying the function and/or activity of NOVX protein and for identifying and/or evaluating modulators of NOVX protein activity. As used herein, a "transgenic animal" is a non-human animal, preferably a mammal, more preferably a rodent such as a rat or mouse, in which one or more of the cells of the animal includes a transgene. Other examples of transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens, amphibians, etc. A transgene is exogenous DNA that is integrated into the genome of a cell from which a transgenic animal develops and that remains in the genome of the mature animal, thereby directing the expression of an encoded gene product in one or more cell types or tissues of the transgenic animal. As used herein, a "homologous recombinant animal" is a non-human animal, preferably a mammal, more preferably a mouse, in which an endogenous NOVX gene has been altered by homologous recombination between the endogenous gene and an exogenous DNA molecule introduced into a cell of the animal, *e.g.*, an embryonic cell of the animal, prior to development of the animal.

A transgenic animal of the invention can be created by introducing NOVX-encoding nucleic acid into the male pronuclei of a fertilized oocyte (*e.g.*, by microinjection, retroviral infection) and allowing the oocyte to develop in a pseudopregnant female foster animal. The human NOVX cDNA sequences SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, and 122 can be introduced as a transgene into the genome of a non-human animal. Alternatively, a non-human homologue of the human NOVX gene, such as a mouse NOVX gene, can be isolated

based on hybridization to the human NOVX cDNA (described further *supra*) and used as a transgene. Intronic sequences and polyadenylation signals can also be included in the transgene to increase the efficiency of expression of the transgene. A tissue-specific regulatory sequence(s) can be operably-linked to the NOVX transgene to direct expression of NOVX protein to particular cells. Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are described, for example, in U.S. Patent Nos. 4,736,866; 4,870,009; and 4,873,191; and Hogan, 1986. In: MANIPULATING THE MOUSE EMBRYO, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. Similar methods are used for production of other transgenic animals. A transgenic founder animal can be identified based upon the presence of the NOVX transgene in its genome and/or expression of NOVX mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying a transgene-encoding NOVX protein can further be bred to other transgenic animals carrying other transgenes.

To create a homologous recombinant animal, a vector is prepared which contains at least a portion of an NOVX gene into which a deletion, addition or substitution has been introduced to thereby alter, *e.g.*, functionally disrupt, the NOVX gene. The NOVX gene can be a human gene (*e.g.*, the cDNA of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, and 122), but more preferably, is a non-human homologue of a human NOVX gene. For example, a mouse homologue of human NOVX gene of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, and 122 can be used to construct a homologous recombination vector suitable for altering an endogenous NOVX gene in the mouse genome. In one embodiment, the vector is designed such that, upon homologous recombination, the endogenous NOVX gene is functionally disrupted (*i.e.*, no longer encodes a functional protein; also referred to as a "knock out" vector).

Alternatively, the vector can be designed such that, upon homologous recombination, the endogenous NOVX gene is mutated or otherwise altered but still encodes functional protein (*e.g.*, the upstream regulatory region can be altered to thereby alter the expression of the

endogenous NOVX protein). In the homologous recombination vector, the altered portion of the NOVX gene is flanked at its 5'- and 3'-termini by additional nucleic acid of the NOVX gene to allow for homologous recombination to occur between the exogenous NOVX gene carried by the vector and an endogenous NOVX gene in an embryonic stem cell. The additional flanking NOVX nucleic acid is of sufficient length for successful homologous recombination with the endogenous gene. Typically, several kilobases of flanking DNA (both at the 5'- and 3'-termini) are included in the vector. *See, e.g., Thomas, et al., 1987. Cell 51: 503* for a description of homologous recombination vectors. The vector is then introduced into an embryonic stem cell line (*e.g., by electroporation*) and cells in which the introduced NOVX gene has homologously-recombined with the endogenous NOVX gene are selected. *See, e.g., Li, et al., 1992. Cell 69: 915.*

The selected cells are then injected into a blastocyst of an animal (*e.g., a mouse*) to form aggregation chimeras. *See, e.g., Bradley, 1987. In: TERATOCARCINOMAS AND EMBRYONIC STEM CELLS: A PRACTICAL APPROACH, Robertson, ed. IRL, Oxford, pp. 113-152.* A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term. Progeny harboring the homologously-recombined DNA in their germ cells can be used to breed animals in which all cells of the animal contain the homologously-recombined DNA by germline transmission of the transgene. Methods for constructing homologous recombination vectors and homologous recombinant animals are described further in Bradley, 1991. *Curr. Opin. Biotechnol. 2: 823-829*; PCT International Publication Nos.: WO 90/11354; WO 91/01140; WO 92/0968; and WO 93/04169.

In another embodiment, transgenic non-humans animals can be produced that contain selected systems that allow for regulated expression of the transgene. One example of such a system is the cre/loxP recombinase system of bacteriophage P1. For a description of the cre/loxP recombinase system, *See, e.g., Lakso, et al., 1992. Proc. Natl. Acad. Sci. USA 89: 6232-6236.* Another example of a recombinase system is the FLP recombinase system of *Saccharomyces cerevisiae*. *See, O'Gorman, et al., 1991. Science 251:1351-1355.* If a cre/loxP recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the Cre recombinase and a selected protein are required. Such animals can be provided through the construction of "double" transgenic animals, *e.g., by mating two transgenic animals,*

one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase.

Clones of the non-human transgenic animals described herein can also be produced according to the methods described in Wilmut, *et al.*, 1997. *Nature* 385: 810-813. In brief, a cell (e.g., a somatic cell) from the transgenic animal can be isolated and induced to exit the growth cycle and enter G₀ phase. The quiescent cell can then be fused, e.g., through the use of electrical pulses, to an enucleated oocyte from an animal of the same species from which the quiescent cell is isolated. The reconstructed oocyte is then cultured such that it develops to morula or blastocyte and then transferred to pseudopregnant female foster animal. The offspring borne of this female foster animal will be a clone of the animal from which the cell (e.g., the somatic cell) is isolated.

Pharmaceutical Compositions

The NOVX nucleic acid molecules, NOVX proteins, and anti-NOVX antibodies (also referred to herein as "active compounds") of the invention, and derivatives, fragments, analogs and homologs thereof, can be incorporated into pharmaceutical compositions suitable for administration. Such compositions typically comprise the nucleic acid molecule, protein, or antibody and a pharmaceutically acceptable carrier. As used herein, "pharmaceutically acceptable carrier" is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. Suitable carriers are described in the most recent edition of Remington's Pharmaceutical Sciences, a standard reference text in the field, which is incorporated herein by reference. Preferred examples of such carriers or diluents include, but are not limited to, water, saline, finger's solutions, dextrose solution, and 5% human serum albumin. Liposomes and non-aqueous vehicles such as fixed oils may also be used. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.

A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (*i.e.*, topical),

transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid (EDTA); buffers such as acetates, citrates or phosphates, and agents for the adjustment of tonicity such as sodium chloride or dextrose. The pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringeability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions can be prepared by incorporating the active compound (*e.g.*, an NOVX protein or anti-NOVX antibody) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered

sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, methods of preparation are vacuum drying and freeze-drying that yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

For administration by inhalation, the compounds are delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, *e.g.*, a gas such as carbon dioxide, or a nebulizer.

Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.

The compounds can also be prepared in the form of suppositories (*e.g.*, with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.

In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811.

It is especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.

The nucleic acid molecules of the invention can be inserted into vectors and used as gene therapy vectors. Gene therapy vectors can be delivered to a subject by, for example, intravenous injection, local administration (*see, e.g.*, U.S. Patent No. 5,328,470) or by stereotactic injection (*see, e.g.*, Chen, *et al.*, 1994. *Proc. Natl. Acad. Sci. USA* 91: 3054-3057). The pharmaceutical preparation of the gene therapy vector can include the gene therapy vector in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery vector can be produced intact from recombinant cells, *e.g.*, retroviral vectors, the pharmaceutical preparation can include one or more cells that produce the gene delivery system.

The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.

Screening and Detection Methods

5 The isolated nucleic acid molecules of the invention can be used to express NOVX protein (*e.g.*, via a recombinant expression vector in a host cell in gene therapy applications), to detect NOVX mRNA (*e.g.*, in a biological sample) or a genetic lesion in an NOVX gene, and to modulate NOVX activity, as described further, below. In addition, the NOVX proteins can be used to screen drugs or compounds that modulate the NOVX protein activity or expression as well as to treat disorders characterized by insufficient or excessive production of NOVX protein or production of NOVX protein forms that have decreased or aberrant activity compared to NOVX wild-type protein (*e.g.*; diabetes (regulates insulin release); obesity (binds and transport lipids); metabolic disturbances associated with obesity, the metabolic syndrome X as well as anorexia and wasting disorders associated with chronic diseases and various cancers, and infectious disease (possesses anti-microbial activity) and the various dyslipidemias. In addition, the anti-NOVX antibodies of the invention can be used to detect and isolate NOVX proteins and modulate NOVX activity. In yet a further aspect, the invention can be used in methods to influence appetite, absorption of nutrients and the disposition of metabolic substrates in both a positive and negative fashion.

20 The invention further pertains to novel agents identified by the screening assays described herein and uses thereof for treatments as described, *supra*.

Screening Assays

The invention provides a method (also referred to herein as a "screening assay") for identifying modulators, *i.e.*, candidate or test compounds or agents (*e.g.*, peptides, peptidomimetics, small molecules or other drugs) that bind to NOVX proteins or have a stimulatory or inhibitory effect on, *e.g.*, NOVX protein expression or NOVX protein activity. The invention also includes compounds identified in the screening assays described herein.

In one embodiment, the invention provides assays for screening candidate or test compounds which bind to or modulate the activity of the membrane-bound form of an NOVX protein or polypeptide or biologically-active portion thereof. The test compounds of the

invention can be obtained using any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries; spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the "one-bead one-compound" library method; and synthetic library methods using affinity chromatography selection. The biological library approach is limited to peptide libraries, while the other four approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds. See, e.g., Lam, 1997. *Anticancer Drug Design* 12: 145.

A "small molecule" as used herein, is meant to refer to a composition that has a molecular weight of less than about 5 kD and most preferably less than about 4 kD. Small molecules can be, e.g., nucleic acids, peptides, polypeptides, peptidomimetics, carbohydrates, lipids or other organic or inorganic molecules. Libraries of chemical and/or biological mixtures, such as fungal, bacterial, or algal extracts, are known in the art and can be screened with any of the assays of the invention.

Examples of methods for the synthesis of molecular libraries can be found in the art, for example in: DeWitt, *et al.*, 1993. *Proc. Natl. Acad. Sci. U.S.A.* 90: 6909; Erb, *et al.*, 1994. *Proc. Natl. Acad. Sci. U.S.A.* 91: 11422; Zuckermann, *et al.*, 1994. *J. Med. Chem.* 37: 2678; Cho, *et al.*, 1993. *Science* 261: 1303; Carrell, *et al.*, 1994. *Angew. Chem. Int. Ed. Engl.* 33: 2059; Carell, *et al.*, 1994. *Angew. Chem. Int. Ed. Engl.* 33: 2061; and Gallop, *et al.*, 1994. *J. Med. Chem.* 37: 1233.

Libraries of compounds may be presented in solution (e.g., Houghten, 1992. *Biotechniques* 13: 412-421), or on beads (Lam, 1991. *Nature* 354: 82-84), on chips (Fodor, 1993. *Nature* 364: 555-556), bacteria (Ladner, U.S. Patent No. 5,223,409), spores (Ladner, U.S. Patent 5,233,409), plasmids (Cull, *et al.*, 1992. *Proc. Natl. Acad. Sci. USA* 89: 1865-1869) or on phage (Scott and Smith, 1990. *Science* 249: 386-390; Devlin, 1990. *Science* 249: 404-406; Cwirla, *et al.*, 1990. *Proc. Natl. Acad. Sci. U.S.A.* 87: 6378-6382; Felici, 1991. *J. Mol. Biol.* 222: 301-310; Ladner, U.S. Patent No. 5,233,409.).

In one embodiment, an assay is a cell-based assay in which a cell which expresses a membrane-bound form of NOVX protein, or a biologically-active portion thereof, on the cell surface is contacted with a test compound and the ability of the test compound to bind to an NOVX protein determined. The cell, for example, can be of mammalian origin or a yeast cell. Determining the ability of the test compound to bind to the NOVX protein can be accomplished,

for example, by coupling the test compound with a radioisotope or enzymatic label such that binding of the test compound to the NOVX protein or biologically-active portion thereof can be determined by detecting the labeled compound in a complex. For example, test compounds can be labeled with ^{125}I , ^{35}S , ^{14}C , or ^3H , either directly or indirectly, and the radioisotope detected by direct counting of radioemission or by scintillation counting. Alternatively, test compounds can be enzymatically-labeled with, for example, horseradish peroxidase, alkaline phosphatase, or luciferase, and the enzymatic label detected by determination of conversion of an appropriate substrate to product. In one embodiment, the assay comprises contacting a cell which expresses a membrane-bound form of NOVX protein, or a biologically-active portion thereof, on the cell surface with a known compound which binds NOVX to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with an NOVX protein, wherein determining the ability of the test compound to interact with an NOVX protein comprises determining the ability of the test compound to preferentially bind to NOVX protein or a biologically-active portion thereof as compared to the known compound.

In another embodiment, an assay is a cell-based assay comprising contacting a cell expressing a membrane-bound form of NOVX protein, or a biologically-active portion thereof, on the cell surface with a test compound and determining the ability of the test compound to modulate (*e.g.*, stimulate or inhibit) the activity of the NOVX protein or biologically-active portion thereof. Determining the ability of the test compound to modulate the activity of NOVX or a biologically-active portion thereof can be accomplished, for example, by determining the ability of the NOVX protein to bind to or interact with an NOVX target molecule. As used herein, a "target molecule" is a molecule with which an NOVX protein binds or interacts in nature, for example, a molecule on the surface of a cell which expresses an NOVX interacting protein, a molecule on the surface of a second cell, a molecule in the extracellular milieu, a molecule associated with the internal surface of a cell membrane or a cytoplasmic molecule. An NOVX target molecule can be a non-NOVX molecule or an NOVX protein or polypeptide of the invention. In one embodiment, an NOVX target molecule is a component of a signal transduction pathway that facilitates transduction of an extracellular signal (*e.g.* a signal generated by binding of a compound to a membrane-bound NOVX molecule) through the cell membrane and into the cell. The target, for example, can be a second intercellular protein that

has catalytic activity or a protein that facilitates the association of downstream signaling molecules with NOVX.

Determining the ability of the NOVX protein to bind to or interact with an NOVX target molecule can be accomplished by one of the methods described above for determining direct binding. In one embodiment, determining the ability of the NOVX protein to bind to or interact with an NOVX target molecule can be accomplished by determining the activity of the target molecule. For example, the activity of the target molecule can be determined by detecting induction of a cellular second messenger of the target (*i.e.* intracellular Ca^{2+} , diacylglycerol, IP_3 , etc.), detecting catalytic/enzymatic activity of the target an appropriate substrate, detecting the induction of a reporter gene (comprising an NOVX-responsive regulatory element operatively linked to a nucleic acid encoding a detectable marker, *e.g.*, luciferase), or detecting a cellular response, for example, cell survival, cellular differentiation, or cell proliferation.

In yet another embodiment, an assay of the invention is a cell-free assay comprising contacting an NOVX protein or biologically-active portion thereof with a test compound and determining the ability of the test compound to bind to the NOVX protein or biologically-active portion thereof. Binding of the test compound to the NOVX protein can be determined either directly or indirectly as described above. In one such embodiment, the assay comprises contacting the NOVX protein or biologically-active portion thereof with a known compound which binds NOVX to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with an NOVX protein, wherein determining the ability of the test compound to interact with an NOVX protein comprises determining the ability of the test compound to preferentially bind to NOVX or biologically-active portion thereof as compared to the known compound.

In still another embodiment, an assay is a cell-free assay comprising contacting NOVX protein or biologically-active portion thereof with a test compound and determining the ability of the test compound to modulate (*e.g.* stimulate or inhibit) the activity of the NOVX protein or biologically-active portion thereof. Determining the ability of the test compound to modulate the activity of NOVX can be accomplished, for example, by determining the ability of the NOVX protein to bind to an NOVX target molecule by one of the methods described above for determining direct binding. In an alternative embodiment, determining the ability of the test compound to modulate the activity of NOVX protein can be accomplished by determining the

ability of the NOVX protein further modulate an NOVX target molecule. For example, the catalytic/enzymatic activity of the target molecule on an appropriate substrate can be determined as described, *supra*.

In yet another embodiment, the cell-free assay comprises contacting the NOVX protein or biologically-active portion thereof with a known compound which binds NOVX protein to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with an NOVX protein, wherein determining the ability of the test compound to interact with an NOVX protein comprises determining the ability of the NOVX protein to preferentially bind to or modulate the activity of an NOVX target molecule.

The cell-free assays of the invention are amenable to use of both the soluble form or the membrane-bound form of NOVX protein. In the case of cell-free assays comprising the membrane-bound form of NOVX protein, it may be desirable to utilize a solubilizing agent such that the membrane-bound form of NOVX protein is maintained in solution. Examples of such solubilizing agents include non-ionic detergents such as n-octylglucoside, n-dodecylglucoside, n-dodecylmaltoside, octanoyl-N-methylglucamide, decanoyl-N-methylglucamide, Triton[®] X-100, Triton[®] X-114, Thesit[®], Isotridecypoly(ethylene glycol ether)_n, N-dodecyl--N,N-dimethyl-3-ammonio-1-propane sulfonate, 3-(3-cholamidopropyl) dimethylamminiol-1-propane sulfonate (CHAPS), or 3-(3-cholamidopropyl)dimethylamminiol-2-hydroxy-1-propane sulfonate (CHAPSO).

In more than one embodiment of the above assay methods of the invention, it may be desirable to immobilize either NOVX protein or its target molecule to facilitate separation of complexed from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay. Binding of a test compound to NOVX protein, or interaction of NOVX protein with a target molecule in the presence and absence of a candidate compound, can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtiter plates, test tubes, and micro-centrifuge tubes. In one embodiment, a fusion protein can be provided that adds a domain that allows one or both of the proteins to be bound to a matrix. For example, GST-NOVX fusion proteins or GST-target fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, MO) or glutathione derivatized microtiter plates, that are then combined with the test compound or the test compound and either the non-adsorbed target protein or NOVX protein, and the mixture is

incubated under conditions conducive to complex formation (*e.g.*, at physiological conditions for salt and pH). Following incubation, the beads or microtiter plate wells are washed to remove any unbound components, the matrix immobilized in the case of beads, complex determined either directly or indirectly, for example, as described, *supra*. Alternatively, the complexes can be dissociated from the matrix, and the level of NOVX protein binding or activity determined using standard techniques.

Other techniques for immobilizing proteins on matrices can also be used in the screening assays of the invention. For example, either the NOVX protein or its target molecule can be immobilized utilizing conjugation of biotin and streptavidin. Biotinylated NOVX protein or target molecules can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques well-known within the art (*e.g.*, biotinylation kit, Pierce Chemicals, Rockford, Ill.), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical). Alternatively, antibodies reactive with NOVX protein or target molecules, but which do not interfere with binding of the NOVX protein to its target molecule, can be derivatized to the wells of the plate, and unbound target or NOVX protein trapped in the wells by antibody conjugation. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with the NOVX protein or target molecule, as well as enzyme-linked assays that rely on detecting an enzymatic activity associated with the NOVX protein or target molecule.

In another embodiment, modulators of NOVX protein expression are identified in a method wherein a cell is contacted with a candidate compound and the expression of NOVX mRNA or protein in the cell is determined. The level of expression of NOVX mRNA or protein in the presence of the candidate compound is compared to the level of expression of NOVX mRNA or protein in the absence of the candidate compound. The candidate compound can then be identified as a modulator of NOVX mRNA or protein expression based upon this comparison. For example, when expression of NOVX mRNA or protein is greater (*i.e.*, statistically significantly greater) in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of NOVX mRNA or protein expression. Alternatively, when expression of NOVX mRNA or protein is less (statistically significantly less) in the presence of the candidate compound than in its absence, the candidate compound is identified as an inhibitor of NOVX mRNA or protein expression. The level of NOVX mRNA or

protein expression in the cells can be determined by methods described herein for detecting NOVX mRNA or protein.

In yet another aspect of the invention, the NOVX proteins can be used as "bait proteins" in a two-hybrid assay or three hybrid assay (*see, e.g.*, U.S. Patent No. 5,283,317; Zervos, *et al.*, 1993. *Cell* 72: 223-232; Madura, *et al.*, 1993. *J. Biol. Chem.* 268: 12046-12054; Bartel, *et al.*, 1993. *Biotechniques* 14: 920-924; Iwabuchi, *et al.*, 1993. *Oncogene* 8: 1693-1696; and Brent WO 94/10300), to identify other proteins that bind to or interact with NOVX ("NOVX-binding proteins" or "NOVX-bp") and modulate NOVX activity. Such NOVX-binding proteins are also likely to be involved in the propagation of signals by the NOVX proteins as, for example, upstream or downstream elements of the NOVX pathway.

The two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. Briefly, the assay utilizes two different DNA constructs. In one construct, the gene that codes for NOVX is fused to a gene encoding the DNA binding domain of a known transcription factor (*e.g.*, GAL-4). In the other construct, a DNA sequence, from a library of DNA sequences, that encodes an unidentified protein ("prey" or "sample") is fused to a gene that codes for the activation domain of the known transcription factor. If the "bait" and the "prey" proteins are able to interact, *in vivo*, forming an NOVX-dependent complex, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (*e.g.*, LacZ) that is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected and cell colonies containing the functional transcription factor can be isolated and used to obtain the cloned gene that encodes the protein which interacts with NOVX.

The invention further pertains to novel agents identified by the aforementioned screening assays and uses thereof for treatments as described herein.

Detection Assays

Portions or fragments of the cDNA sequences identified herein (and the corresponding complete gene sequences) can be used in numerous ways as polynucleotide reagents. By way of example, and not of limitation, these sequences can be used to: (i) map their respective genes on a chromosome; and, thus, locate gene regions associated with genetic disease; (ii) identify an

individual from a minute biological sample (tissue typing); and (iii) aid in forensic identification of a biological sample. Some of these applications are described in the subsections, below.

Chromosome Mapping

5 Once the sequence (or a portion of the sequence) of a gene has been isolated, this sequence can be used to map the location of the gene on a chromosome. This process is called chromosome mapping. Accordingly, portions or fragments of the NOVX sequences, SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, and 122, or fragments or derivatives thereof, 10 can be used to map the location of the NOVX genes, respectively, on a chromosome. The mapping of the NOVX sequences to chromosomes is an important first step in correlating these sequences with genes associated with disease.

 Briefly, NOVX genes can be mapped to chromosomes by preparing PCR primers 15 (preferably 15-25 bp in length) from the NOVX sequences. Computer analysis of the NOVX, sequences can be used to rapidly select primers that do not span more than one exon in the genomic DNA, thus complicating the amplification process. These primers can then be used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the NOVX sequences will yield an 20 amplified fragment.

 Somatic cell hybrids are prepared by fusing somatic cells from different mammals (e.g., human and mouse cells). As hybrids of human and mouse cells grow and divide, they gradually lose human chromosomes in random order, but retain the mouse chromosomes. By using media in which mouse cells cannot grow, because they lack a particular enzyme, but in which human 25 cells can, the one human chromosome that contains the gene encoding the needed enzyme will be retained. By using various media, panels of hybrid cell lines can be established. Each cell line in a panel contains either a single human chromosome or a small number of human chromosomes, and a full set of mouse chromosomes, allowing easy mapping of individual genes to specific human chromosomes. See, e.g., D'Eustachio, *et al.*, 1983. *Science* 220: 919-924.

Somatic cell hybrids containing only fragments of human chromosomes can also be produced by using human chromosomes with translocations and deletions.

PCR mapping of somatic cell hybrids is a rapid procedure for assigning a particular sequence to a particular chromosome. Three or more sequences can be assigned per day using a single thermal cycler. Using the NOVX sequences to design oligonucleotide primers, sub-localization can be achieved with panels of fragments from specific chromosomes.

Fluorescence *in situ* hybridization (FISH) of a DNA sequence to a metaphase chromosomal spread can further be used to provide a precise chromosomal location in one step. Chromosome spreads can be made using cells whose division has been blocked in metaphase by a chemical like colcemid that disrupts the mitotic spindle. The chromosomes can be treated briefly with trypsin, and then stained with Giemsa. A pattern of light and dark bands develops on each chromosome, so that the chromosomes can be identified individually. The FISH technique can be used with a DNA sequence as short as 500 or 600 bases. However, clones larger than 1,000 bases have a higher likelihood of binding to a unique chromosomal location with sufficient signal intensity for simple detection. Preferably 1,000 bases, and more preferably 2,000 bases, will suffice to get good results at a reasonable amount of time. For a review of this technique, see, Verma, *et al.*, HUMAN CHROMOSOMES: A MANUAL OF BASIC TECHNIQUES (Pergamon Press, New York 1988).

Reagents for chromosome mapping can be used individually to mark a single chromosome or a single site on that chromosome, or panels of reagents can be used for marking multiple sites and/or multiple chromosomes. Reagents corresponding to noncoding regions of the genes actually are preferred for mapping purposes. Coding sequences are more likely to be conserved within gene families, thus increasing the chance of cross hybridizations during chromosomal mapping.

Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found, *e.g.*, in McKusick, MENDELIAN INHERITANCE IN MAN, available on-line through Johns Hopkins University Welch Medical Library). The relationship between genes and disease, mapped to the same chromosomal region, can then be identified through linkage analysis (co-inheritance of physically adjacent genes), described in, *e.g.*, Egeland, *et al.*, 1987. *Nature*, 325: 783-787.

Moreover, differences in the DNA sequences between individuals affected and unaffected with a disease associated with the NOVX gene, can be determined. If a mutation is observed in some or all of the affected individuals but not in any unaffected individuals, then the mutation is likely to be the causative agent of the particular disease. Comparison of affected and unaffected individuals generally involves first looking for structural alterations in the chromosomes, such as deletions or translocations that are visible from chromosome spreads or detectable using PCR based on that DNA sequence. Ultimately, complete sequencing of genes from several individuals can be performed to confirm the presence of a mutation and to distinguish mutations from polymorphisms.

Tissue Typing

The NOVX sequences of the invention can also be used to identify individuals from minute biological samples. In this technique, an individual's genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for identification. The sequences of the invention are useful as additional DNA markers for RFLP ("restriction fragment length polymorphisms," described in U.S. Patent No. 5,272,057).

Furthermore, the sequences of the invention can be used to provide an alternative technique that determines the actual base-by-base DNA sequence of selected portions of an individual's genome. Thus, the NOVX sequences described herein can be used to prepare two PCR primers from the 5'- and 3'-termini of the sequences. These primers can then be used to amplify an individual's DNA and subsequently sequence it.

Panels of corresponding DNA sequences from individuals, prepared in this manner, can provide unique individual identifications, as each individual will have a unique set of such DNA sequences due to allelic differences. The sequences of the invention can be used to obtain such identification sequences from individuals and from tissue. The NOVX sequences of the invention uniquely represent portions of the human genome. Allelic variation occurs to some degree in the coding regions of these sequences, and to a greater degree in the noncoding regions. It is estimated that allelic variation between individual humans occurs with a frequency of about once per each 500 bases. Much of the allelic variation is due to single nucleotide polymorphisms (SNPs), which include restriction fragment length polymorphisms (RFLPs).

Each of the sequences described herein can, to some degree, be used as a standard against which DNA from an individual can be compared for identification purposes. Because greater numbers of polymorphisms occur in the noncoding regions, fewer sequences are necessary to differentiate individuals. The noncoding sequences can comfortably provide positive individual identification with a panel of perhaps 10 to 1,000 primers that each yield a noncoding amplified sequence of 100 bases. If predicted coding sequences, such as those in SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, and 122 are used, a more appropriate number of primers for positive individual identification would be 500-2,000.

Predictive Medicine

The invention also pertains to the field of predictive medicine in which diagnostic assays, prognostic assays, pharmacogenomics, and monitoring clinical trials are used for prognostic (predictive) purposes to thereby treat an individual prophylactically. Accordingly, one aspect of the invention relates to diagnostic assays for determining NOVX protein and/or nucleic acid expression as well as NOVX activity, in the context of a biological sample (*e.g.*, blood, serum, cells, tissue) to thereby determine whether an individual is afflicted with a disease or disorder, or is at risk of developing a disorder, associated with aberrant NOVX expression or activity. The disorders include metabolic disorders, diabetes, obesity, infectious disease, anorexia, cancer-associated cachexia, cancer, neurodegenerative disorders, Alzheimer's Disease, Parkinson's Disorder, immune disorders, and hematopoietic disorders, and the various dyslipidemias, metabolic disturbances associated with obesity, the metabolic syndrome X and wasting disorders associated with chronic diseases and various cancers. The invention also provides for prognostic (or predictive) assays for determining whether an individual is at risk of developing a disorder associated with NOVX protein, nucleic acid expression or activity. For example, mutations in an NOVX gene can be assayed in a biological sample. Such assays can be used for prognostic or predictive purpose to thereby prophylactically treat an individual prior to the onset of a disorder characterized by or associated with NOVX protein, nucleic acid expression, or biological activity.

Another aspect of the invention provides methods for determining NOVX protein, nucleic acid expression or activity in an individual to thereby select appropriate therapeutic or prophylactic agents for that individual (referred to herein as "pharmacogenomics").

Pharmacogenomics allows for the selection of agents (*e.g.*, drugs) for therapeutic or prophylactic treatment of an individual based on the genotype of the individual (*e.g.*, the genotype of the individual examined to determine the ability of the individual to respond to a particular agent.)

Yet another aspect of the invention pertains to monitoring the influence of agents (*e.g.*, drugs, compounds) on the expression or activity of NOVX in clinical trials.

These and other agents are described in further detail in the following sections.

Diagnostic Assays

An exemplary method for detecting the presence or absence of NOVX in a biological sample involves obtaining a biological sample from a test subject and contacting the biological sample with a compound or an agent capable of detecting NOVX protein or nucleic acid (*e.g.*, mRNA, genomic DNA) that encodes NOVX protein such that the presence of NOVX is detected in the biological sample. An agent for detecting NOVX mRNA or genomic DNA is a labeled nucleic acid probe capable of hybridizing to NOVX mRNA or genomic DNA. The nucleic acid probe can be, for example, a full-length NOVX nucleic acid, such as the nucleic acid of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, and 37, or a portion thereof, such as an oligonucleotide of at least 15, 30, 50, 100, 250 or 500 nucleotides in length and sufficient to specifically hybridize under stringent conditions to NOVX mRNA or genomic DNA. Other suitable probes for use in the diagnostic assays of the invention are described herein.

An agent for detecting NOVX protein is an antibody capable of binding to NOVX protein, preferably an antibody with a detectable label. Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (*e.g.*, Fab or F(ab')₂) can be used. The term "labeled", with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling (*i.e.*, physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently-labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently-labeled streptavidin. The term

"biological sample" is intended to include tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject. That is, the detection method of the invention can be used to detect NOVX mRNA, protein, or genomic DNA in a biological sample *in vitro* as well as *in vivo*. For example, *in vitro* techniques for detection of NOVX mRNA include Northern hybridizations and *in situ* hybridizations. *In vitro* techniques for detection of NOVX protein include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations, and immunofluorescence. *In vitro* techniques for detection of NOVX genomic DNA include Southern hybridizations. Furthermore, *in vivo* techniques for detection of NOVX protein include introducing into a subject a labeled anti-NOVX antibody. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.

In one embodiment, the biological sample contains protein molecules from the test subject. Alternatively, the biological sample can contain mRNA molecules from the test subject or genomic DNA molecules from the test subject. A preferred biological sample is a peripheral blood leukocyte sample isolated by conventional means from a subject.

In another embodiment, the methods further involve obtaining a control biological sample from a control subject, contacting the control sample with a compound or agent capable of detecting NOVX protein, mRNA, or genomic DNA, such that the presence of NOVX protein, mRNA or genomic DNA is detected in the biological sample, and comparing the presence of NOVX protein, mRNA or genomic DNA in the control sample with the presence of NOVX protein, mRNA or genomic DNA in the test sample.

The invention also encompasses kits for detecting the presence of NOVX in a biological sample. For example, the kit can comprise: a labeled compound or agent capable of detecting NOVX protein or mRNA in a biological sample; means for determining the amount of NOVX in the sample; and means for comparing the amount of NOVX in the sample with a standard. The compound or agent can be packaged in a suitable container. The kit can further comprise instructions for using the kit to detect NOVX protein or nucleic acid.

Prognostic Assays

The diagnostic methods described herein can furthermore be utilized to identify subjects having or at risk of developing a disease or disorder associated with aberrant NOVX expression or activity. For example, the assays described herein, such as the preceding diagnostic assays or

the following assays, can be utilized to identify a subject having or at risk of developing a disorder associated with NOVX protein, nucleic acid expression or activity. Alternatively, the prognostic assays can be utilized to identify a subject having or at risk for developing a disease or disorder. Thus, the invention provides a method for identifying a disease or disorder associated with aberrant NOVX expression or activity in which a test sample is obtained from a subject and NOVX protein or nucleic acid (*e.g.*, mRNA, genomic DNA) is detected, wherein the presence of NOVX protein or nucleic acid is diagnostic for a subject having or at risk of developing a disease or disorder associated with aberrant NOVX expression or activity. As used herein, a "test sample" refers to a biological sample obtained from a subject of interest. For example, a test sample can be a biological fluid (*e.g.*, serum), cell sample, or tissue.

Furthermore, the prognostic assays described herein can be used to determine whether a subject can be administered an agent (*e.g.*, an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate) to treat a disease or disorder associated with aberrant NOVX expression or activity. For example, such methods can be used to determine whether a subject can be effectively treated with an agent for a disorder. Thus, the invention provides methods for determining whether a subject can be effectively treated with an agent for a disorder associated with aberrant NOVX expression or activity in which a test sample is obtained and NOVX protein or nucleic acid is detected (*e.g.*, wherein the presence of NOVX protein or nucleic acid is diagnostic for a subject that can be administered the agent to treat a disorder associated with aberrant NOVX expression or activity).

The methods of the invention can also be used to detect genetic lesions in an NOVX gene, thereby determining if a subject with the lesioned gene is at risk for a disorder characterized by aberrant cell proliferation and/or differentiation. In various embodiments, the methods include detecting, in a sample of cells from the subject, the presence or absence of a genetic lesion characterized by at least one of an alteration affecting the integrity of a gene encoding an NOVX-protein, or the misexpression of the NOVX gene. For example, such genetic lesions can be detected by ascertaining the existence of at least one of: (i) a deletion of one or more nucleotides from an NOVX gene; (ii) an addition of one or more nucleotides to an NOVX gene; (iii) a substitution of one or more nucleotides of an NOVX gene, (iv) a chromosomal rearrangement of an NOVX gene; (v) an alteration in the level of a messenger RNA transcript of an NOVX gene, (vi) aberrant modification of an NOVX gene, such as of the

methylation pattern of the genomic DNA, (vii) the presence of a non-wild-type splicing pattern of a messenger RNA transcript of an NOVX gene, (viii) a non-wild-type level of an NOVX protein, (ix) allelic loss of an NOVX gene, and (x) inappropriate post-translational modification of an NOVX protein. As described herein, there are a large number of assay techniques known in the art which can be used for detecting lesions in an NOVX gene. A preferred biological sample is a peripheral blood leukocyte sample isolated by conventional means from a subject. However, any biological sample containing nucleated cells may be used, including, for example, buccal mucosal cells.

In certain embodiments, detection of the lesion involves the use of a probe/primer in a polymerase chain reaction (PCR) (*see, e.g.*, U.S. Patent Nos. 4,683,195 and 4,683,202), such as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR) (*see, e.g.*, Landegran, *et al.*, 1988. *Science* 241: 1077-1080; and Nakazawa, *et al.*, 1994. *Proc. Natl. Acad. Sci. USA* 91: 360-364), the latter of which can be particularly useful for detecting point mutations in the NOVX-gene (*see*, Abravaya, *et al.*, 1995. *Nucl. Acids Res.* 23: 675-682). This method can include the steps of collecting a sample of cells from a patient, isolating nucleic acid (*e.g.*, genomic, mRNA or both) from the cells of the sample, contacting the nucleic acid sample with one or more primers that specifically hybridize to an NOVX gene under conditions such that hybridization and amplification of the NOVX gene (if present) occurs, and detecting the presence or absence of an amplification product, or detecting the size of the amplification product and comparing the length to a control sample. It is anticipated that PCR and/or LCR may be desirable to use as a preliminary amplification step in conjunction with any of the techniques used for detecting mutations described herein.

Alternative amplification methods include: self sustained sequence replication (*see*, Guatelli, *et al.*, 1990. *Proc. Natl. Acad. Sci. USA* 87: 1874-1878), transcriptional amplification system (*see*, Kwok, *et al.*, 1989. *Proc. Natl. Acad. Sci. USA* 86: 1173-1177); Q β Replicase (*see*, Lizardi, *et al.*, 1988. *BioTechnology* 6: 1197), or any other nucleic acid amplification method, followed by the detection of the amplified molecules using techniques well known to those of skill in the art. These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers.

In an alternative embodiment, mutations in an NOVX gene from a sample cell can be identified by alterations in restriction enzyme cleavage patterns. For example, sample and

control DNA is isolated, amplified (optionally), digested with one or more restriction endonucleases, and fragment length sizes are determined by gel electrophoresis and compared. Differences in fragment length sizes between sample and control DNA indicates mutations in the sample DNA. Moreover, the use of sequence specific ribozymes (*see, e.g.*, U.S. Patent No. 5,493,531) can be used to score for the presence of specific mutations by development or loss of a ribozyme cleavage site.

In other embodiments, genetic mutations in NOVX can be identified by hybridizing a sample and control nucleic acids, *e.g.*, DNA or RNA, to high-density arrays containing hundreds or thousands of oligonucleotides probes. *See, e.g.*, Cronin, *et al.*, 1996. *Human Mutation* 7: 244-255; Kozal, *et al.*, 1996. *Nat. Med.* 2: 753-759. For example, genetic mutations in NOVX can be identified in two dimensional arrays containing light-generated DNA probes as described in Cronin, *et al.*, *supra*. Briefly, a first hybridization array of probes can be used to scan through long stretches of DNA in a sample and control to identify base changes between the sequences by making linear arrays of sequential overlapping probes. This step allows the identification of point mutations. This is followed by a second hybridization array that allows the characterization of specific mutations by using smaller, specialized probe arrays complementary to all variants or mutations detected. Each mutation array is composed of parallel probe sets, one complementary to the wild-type gene and the other complementary to the mutant gene.

In yet another embodiment, any of a variety of sequencing reactions known in the art can be used to directly sequence the NOVX gene and detect mutations by comparing the sequence of the sample NOVX with the corresponding wild-type (control) sequence. Examples of sequencing reactions include those based on techniques developed by Maxim and Gilbert, 1977. *Proc. Natl. Acad. Sci. USA* 74: 560 or Sanger, 1977. *Proc. Natl. Acad. Sci. USA* 74: 5463. It is also contemplated that any of a variety of automated sequencing procedures can be utilized when performing the diagnostic assays (*see, e.g.*, Naeve, *et al.*, 1995. *Biotechniques* 19: 448), including sequencing by mass spectrometry (*see, e.g.*, PCT International Publication No. WO 94/16101; Cohen, *et al.*, 1996. *Adv. Chromatography* 36: 127-162; and Griffin, *et al.*, 1993. *Appl. Biochem. Biotechnol.* 38: 147-159).

Other methods for detecting mutations in the NOVX gene include methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA or RNA/DNA heteroduplexes. *See, e.g.*, Myers, *et al.*, 1985. *Science* 230: 1242. In general, the art technique

of "mismatch cleavage" starts by providing heteroduplexes of formed by hybridizing (labeled) RNA or DNA containing the wild-type NOVX sequence with potentially mutant RNA or DNA obtained from a tissue sample. The double-stranded duplexes are treated with an agent that cleaves single-stranded regions of the duplex such as which will exist due to basepair

5 mismatches between the control and sample strands. For instance, RNA/DNA duplexes can be treated with RNase and DNA/DNA hybrids treated with S₁ nuclease to enzymatically digesting the mismatched regions. In other embodiments, either DNA/DNA or RNA/DNA duplexes can be treated with hydroxylamine or osmium tetroxide and with piperidine in order to digest mismatched regions. After digestion of the mismatched regions, the resulting material is then
10 separated by size on denaturing polyacrylamide gels to determine the site of mutation. *See, e.g.,* Cotton, *et al.*, 1988. *Proc. Natl. Acad. Sci. USA* 85: 4397; Saleeba, *et al.*, 1992. *Methods Enzymol.* 217: 286-295. In an embodiment, the control DNA or RNA can be labeled for detection.

In still another embodiment, the mismatch cleavage reaction employs one or more
15 proteins that recognize mismatched base pairs in double-stranded DNA (so called "DNA mismatch repair" enzymes) in defined systems for detecting and mapping point mutations in NOVX cDNAs obtained from samples of cells. For example, the mutY enzyme of *E. coli* cleaves A at G/A mismatches and the thymidine DNA glycosylase from HeLa cells cleaves T at G/T mismatches. *See, e.g.,* Hsu, *et al.*, 1994. *Carcinogenesis* 15: 1657-1662. According to an
20 exemplary embodiment, a probe based on an NOVX sequence, *e.g.*, a wild-type NOVX sequence, is hybridized to a cDNA or other DNA product from a test cell(s). The duplex is treated with a DNA mismatch repair enzyme, and the cleavage products, if any, can be detected from electrophoresis protocols or the like. *See, e.g.,* U.S. Patent No. 5,459,039.

In other embodiments, alterations in electrophoretic mobility will be used to identify
25 mutations in NOVX genes. For example, single strand conformation polymorphism (SSCP) may be used to detect differences in electrophoretic mobility between mutant and wild type nucleic acids. *See, e.g.,* Orita, *et al.*, 1989. *Proc. Natl. Acad. Sci. USA*: 86: 2766; Cotton, 1993. *Mutat. Res.* 285: 125-144; Hayashi, 1992. *Genet. Anal. Tech. Appl.* 9: 73-79. Single-stranded DNA fragments of sample and control NOVX nucleic acids will be denatured and allowed to renature.
30 The secondary structure of single-stranded nucleic acids varies according to sequence, the resulting alteration in electrophoretic mobility enables the detection of even a single base change.

The DNA fragments may be labeled or detected with labeled probes. The sensitivity of the assay may be enhanced by using RNA (rather than DNA), in which the secondary structure is more sensitive to a change in sequence. In one embodiment, the subject method utilizes heteroduplex analysis to separate double stranded heteroduplex molecules on the basis of changes in

5 electrophoretic mobility. *See, e.g., Keen, et al., 1991. Trends Genet. 7: 5.*

In yet another embodiment, the movement of mutant or wild-type fragments in polyacrylamide gels containing a gradient of denaturant is assayed using denaturing gradient gel electrophoresis (DGGE). *See, e.g., Myers, et al., 1985. Nature 313: 495.* When DGGE is used as the method of analysis, DNA will be modified to insure that it does not completely denature, 10 for example by adding a GC clamp of approximately 40 bp of high-melting GC-rich DNA by PCR. In a further embodiment, a temperature gradient is used in place of a denaturing gradient to identify differences in the mobility of control and sample DNA. *See, e.g., Rosenbaum and Reissner, 1987. Biophys. Chem. 265: 12753.*

Examples of other techniques for detecting point mutations include, but are not limited 15 to, selective oligonucleotide hybridization, selective amplification, or selective primer extension. For example, oligonucleotide primers may be prepared in which the known mutation is placed centrally and then hybridized to target DNA under conditions that permit hybridization only if a perfect match is found. *See, e.g., Saiki, et al., 1986. Nature 324: 163; Saiki, et al., 1989. Proc. Natl. Acad. Sci. USA 86: 6230.* Such allele specific oligonucleotides are hybridized to PCR 20 amplified target DNA or a number of different mutations when the oligonucleotides are attached to the hybridizing membrane and hybridized with labeled target DNA.

Alternatively, allele specific amplification technology that depends on selective PCR amplification may be used in conjunction with the instant invention. Oligonucleotides used as primers for specific amplification may carry the mutation of interest in the center of the molecule 25 (so that amplification depends on differential hybridization; *see, e.g., Gibbs, et al., 1989. Nucl. Acids Res. 17: 2437-2448*) or at the extreme 3'-terminus of one primer where, under appropriate conditions, mismatch can prevent, or reduce polymerase extension (*see, e.g., Prossner, 1993. Tibtech. 11: 238*). In addition it may be desirable to introduce a novel restriction site in the region of the mutation to create cleavage-based detection. *See, e.g., Gasparini, et al., 1992. Mol. 30 Cell Probes 6: 1.* It is anticipated that in certain embodiments amplification may also be performed using *Taq* ligase for amplification. *See, e.g., Barany, 1991. Proc. Natl. Acad. Sci.*

USA 88: 189. In such cases, ligation will occur only if there is a perfect match at the 3'-terminus of the 5' sequence, making it possible to detect the presence of a known mutation at a specific site by looking for the presence or absence of amplification.

The methods described herein may be performed, for example, by utilizing pre-packaged diagnostic kits comprising at least one probe nucleic acid or antibody reagent described herein, which may be conveniently used, *e.g.*, in clinical settings to diagnose patients exhibiting symptoms or family history of a disease or illness involving an NOVX gene.

Furthermore, any cell type or tissue, preferably peripheral blood leukocytes, in which NOVX is expressed may be utilized in the prognostic assays described herein. However, any biological sample containing nucleated cells may be used, including, for example, buccal mucosal cells.

Pharmacogenomics

Agents, or modulators that have a stimulatory or inhibitory effect on NOVX activity (*e.g.*, NOVX gene expression), as identified by a screening assay described herein can be administered to individuals to treat (prophylactically or therapeutically) disorders (The disorders include metabolic disorders, diabetes, obesity, infectious disease, anorexia, cancer-associated cachexia, cancer, neurodegenerative disorders, Alzheimer's Disease, Parkinson's Disorder, immune disorders, and hematopoietic disorders, and the various dyslipidemias, metabolic disturbances associated with obesity, the metabolic syndrome X and wasting disorders associated with chronic diseases and various cancers.) In conjunction with such treatment, the pharmacogenomics (*i.e.*, the study of the relationship between an individual's genotype and that individual's response to a foreign compound or drug) of the individual may be considered. Differences in metabolism of therapeutics can lead to severe toxicity or therapeutic failure by altering the relation between dose and blood concentration of the pharmacologically active drug. Thus, the pharmacogenomics of the individual permits the selection of effective agents (*e.g.*, drugs) for prophylactic or therapeutic treatments based on a consideration of the individual's genotype. Such pharmacogenomics can further be used to determine appropriate dosages and therapeutic regimens. Accordingly, the activity of NOVX protein, expression of NOVX nucleic acid, or mutation content of NOVX genes in an individual can be determined to thereby select appropriate agent(s) for therapeutic or prophylactic treatment of the individual.

Pharmacogenomics deals with clinically significant hereditary variations in the response to drugs due to altered drug disposition and abnormal action in affected persons. See *e.g.*, Eichelbaum, 1996. *Clin. Exp. Pharmacol. Physiol.*, 23: 983-985; Linder, 1997. *Clin. Chem.*, 43: 254-266. In general, two types of pharmacogenetic conditions can be differentiated. Genetic conditions transmitted as a single factor altering the way drugs act on the body (altered drug action) or genetic conditions transmitted as single factors altering the way the body acts on drugs (altered drug metabolism). These pharmacogenetic conditions can occur either as rare defects or as polymorphisms. For example, glucose-6-phosphate dehydrogenase (G6PD) deficiency is a common inherited enzymopathy in which the main clinical complication is hemolysis after ingestion of oxidant drugs (anti-malarials, sulfonamides, analgesics, nitrofurans) and consumption of fava beans.

As an illustrative embodiment, the activity of drug metabolizing enzymes is a major determinant of both the intensity and duration of drug action. The discovery of genetic polymorphisms of drug metabolizing enzymes (*e.g.*, N-acetyltransferase 2 (NAT 2) and cytochrome P450 enzymes CYP2D6 and CYP2C19) has provided an explanation as to why some patients do not obtain the expected drug effects or show exaggerated drug response and serious toxicity after taking the standard and safe dose of a drug. These polymorphisms are expressed in two phenotypes in the population, the extensive metabolizer (EM) and poor metabolizer (PM). The prevalence of PM is different among different populations. For example, the gene coding for CYP2D6 is highly polymorphic and several mutations have been identified in PM, which all lead to the absence of functional CYP2D6. Poor metabolizers of CYP2D6 and CYP2C19 quite frequently experience exaggerated drug response and side effects when they receive standard doses. If a metabolite is the active therapeutic moiety, PM show no therapeutic response, as demonstrated for the analgesic effect of codeine mediated by its CYP2D6-formed metabolite morphine. At the other extreme are the so called ultra-rapid metabolizers who do not respond to standard doses. Recently, the molecular basis of ultra-rapid metabolism has been identified to be due to CYP2D6 gene amplification.

Thus, the activity of NOVX protein, expression of NOVX nucleic acid, or mutation content of NOVX genes in an individual can be determined to thereby select appropriate agent(s) for therapeutic or prophylactic treatment of the individual. In addition, pharmacogenetic studies can be used to apply genotyping of polymorphic alleles encoding drug-metabolizing enzymes to

the identification of an individual's drug responsiveness phenotype. This knowledge, when applied to dosing or drug selection, can avoid adverse reactions or therapeutic failure and thus enhance therapeutic or prophylactic efficiency when treating a subject with an NOVX modulator, such as a modulator identified by one of the exemplary screening assays described herein.

Monitoring of Effects During Clinical Trials

Monitoring the influence of agents (*e.g.*, drugs, compounds) on the expression or activity of NOVX (*e.g.*, the ability to modulate aberrant cell proliferation and/or differentiation) can be applied not only in basic drug screening, but also in clinical trials. For example, the effectiveness of an agent determined by a screening assay as described herein to increase NOVX gene expression, protein levels, or upregulate NOVX activity, can be monitored in clinical trails of subjects exhibiting decreased NOVX gene expression, protein levels, or downregulated NOVX activity. Alternatively, the effectiveness of an agent determined by a screening assay to decrease NOVX gene expression, protein levels, or downregulate NOVX activity, can be monitored in clinical trails of subjects exhibiting increased NOVX gene expression, protein levels, or upregulated NOVX activity. In such clinical trials, the expression or activity of NOVX and, preferably, other genes that have been implicated in, for example, a cellular proliferation or immune disorder can be used as a "read out" or markers of the immune responsiveness of a particular cell.

By way of example, and not of limitation, genes, including NOVX, that are modulated in cells by treatment with an agent (*e.g.*, compound, drug or small molecule) that modulates NOVX activity (*e.g.*, identified in a screening assay as described herein) can be identified. Thus, to study the effect of agents on cellular proliferation disorders, for example, in a clinical trial, cells can be isolated and RNA prepared and analyzed for the levels of expression of NOVX and other genes implicated in the disorder. The levels of gene expression (*i.e.*, a gene expression pattern) can be quantified by Northern blot analysis or RT-PCR, as described herein, or alternatively by measuring the amount of protein produced, by one of the methods as described herein, or by measuring the levels of activity of NOVX or other genes. In this manner, the gene expression pattern can serve as a marker, indicative of the physiological response of the cells to the agent. Accordingly, this response state may be determined before, and at various points during, treatment of the individual with the agent.

In one embodiment, the invention provides a method for monitoring the effectiveness of treatment of a subject with an agent (*e.g.*, an agonist, antagonist, protein, peptide, peptidomimetic, nucleic acid, small molecule, or other drug candidate identified by the screening assays described herein) comprising the steps of (i) obtaining a pre-administration sample from a subject prior to administration of the agent; (ii) detecting the level of expression of an NOVX protein, mRNA, or genomic DNA in the preadministration sample; (iii) obtaining one or more post-administration samples from the subject; (iv) detecting the level of expression or activity of the NOVX protein, mRNA, or genomic DNA in the post-administration samples; (v) comparing the level of expression or activity of the NOVX protein, mRNA, or genomic DNA in the pre-administration sample with the NOVX protein, mRNA, or genomic DNA in the post administration sample or samples; and (vi) altering the administration of the agent to the subject accordingly. For example, increased administration of the agent may be desirable to increase the expression or activity of NOVX to higher levels than detected, *i.e.*, to increase the effectiveness of the agent. Alternatively, decreased administration of the agent may be desirable to decrease expression or activity of NOVX to lower levels than detected, *i.e.*, to decrease the effectiveness of the agent.

Methods of Treatment

The invention provides for both prophylactic and therapeutic methods of treating a subject at risk of (or susceptible to) a disorder or having a disorder associated with aberrant NOVX expression or activity. The disorders include cardiomyopathy, atherosclerosis, hypertension, congenital heart defects, aortic stenosis, atrial septal defect (ASD), atrioventricular (A-V) canal defect, ductus arteriosus, pulmonary stenosis, subaortic stenosis, ventricular septal defect (VSD), valve diseases, tuberous sclerosis, scleroderma, obesity, transplantation, adrenoleukodystrophy, congenital adrenal hyperplasia, prostate cancer, neoplasm; adenocarcinoma, lymphoma, uterus cancer, fertility, hemophilia, hypercoagulation, idiopathic thrombocytopenic purpura, immunodeficiencies, graft versus host disease, AIDS, bronchial asthma, Crohn's disease; multiple sclerosis, treatment of Albright Hereditary Osteodystrophy, and other diseases, disorders and conditions of the like.

These methods of treatment will be discussed more fully, below.

Disease and Disorders

Diseases and disorders that are characterized by increased (relative to a subject not suffering from the disease or disorder) levels or biological activity may be treated with Therapeutics that antagonize (*i.e.*, reduce or inhibit) activity. Therapeutics that antagonize activity may be administered in a therapeutic or prophylactic manner. Therapeutics that may be utilized include, but are not limited to: (i) an aforementioned peptide, or analogs, derivatives, fragments or homologs thereof; (ii) antibodies to an aforementioned peptide; (iii) nucleic acids encoding an aforementioned peptide; (iv) administration of antisense nucleic acid and nucleic acids that are "dysfunctional" (*i.e.*, due to a heterologous insertion within the coding sequences of coding sequences to an aforementioned peptide) that are utilized to "knockout" endogenous function of an aforementioned peptide by homologous recombination (*see, e.g.*, Capecchi, 1989. *Science* 244: 1288-1292); or (v) modulators (*i.e.*, inhibitors, agonists and antagonists, including additional peptide mimetic of the invention or antibodies specific to a peptide of the invention) that alter the interaction between an aforementioned peptide and its binding partner.

Diseases and disorders that are characterized by decreased (relative to a subject not suffering from the disease or disorder) levels or biological activity may be treated with Therapeutics that increase (*i.e.*, are agonists to) activity. Therapeutics that upregulate activity may be administered in a therapeutic or prophylactic manner. Therapeutics that may be utilized include, but are not limited to, an aforementioned peptide, or analogs, derivatives, fragments or homologs thereof; or an agonist that increases bioavailability.

Increased or decreased levels can be readily detected by quantifying peptide and/or RNA, by obtaining a patient tissue sample (*e.g.*, from biopsy tissue) and assaying it *in vitro* for RNA or peptide levels, structure and/or activity of the expressed peptides (or mRNAs of an aforementioned peptide). Methods that are well-known within the art include, but are not limited to, immunoassays (*e.g.*, by Western blot analysis, immunoprecipitation followed by sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis, immunocytochemistry, etc.) and/or hybridization assays to detect expression of mRNAs (*e.g.*, Northern assays, dot blots, *in situ* hybridization, and the like).

Prophylactic Methods

In one aspect, the invention provides a method for preventing, in a subject, a disease or condition associated with an aberrant NOVX expression or activity, by administering to the subject an agent that modulates NOVX expression or at least one NOVX activity. Subjects at risk for a disease that is caused or contributed to by aberrant NOVX expression or activity can be identified by, for example, any or a combination of diagnostic or prognostic assays as described herein. Administration of a prophylactic agent can occur prior to the manifestation of symptoms characteristic of the NOVX aberrancy, such that a disease or disorder is prevented or, alternatively, delayed in its progression. Depending upon the type of NOVX aberrancy, for example, an NOVX agonist or NOVX antagonist agent can be used for treating the subject. The appropriate agent can be determined based on screening assays described herein. The prophylactic methods of the invention are further discussed in the following subsections.

Therapeutic Methods

Another aspect of the invention pertains to methods of modulating NOVX expression or activity for therapeutic purposes. The modulatory method of the invention involves contacting a cell with an agent that modulates one or more of the activities of NOVX protein activity associated with the cell. An agent that modulates NOVX protein activity can be an agent as described herein, such as a nucleic acid or a protein, a naturally-occurring cognate ligand of an NOVX protein, a peptide, an NOVX peptidomimetic, or other small molecule. In one embodiment, the agent stimulates one or more NOVX protein activity. Examples of such stimulatory agents include active NOVX protein and a nucleic acid molecule encoding NOVX that has been introduced into the cell. In another embodiment, the agent inhibits one or more NOVX protein activity. Examples of such inhibitory agents include antisense NOVX nucleic acid molecules and anti-NOVX antibodies. These modulatory methods can be performed *in vitro* (e.g., by culturing the cell with the agent) or, alternatively, *in vivo* (e.g., by administering the agent to a subject). As such, the invention provides methods of treating an individual afflicted with a disease or disorder characterized by aberrant expression or activity of an NOVX protein or nucleic acid molecule. In one embodiment, the method involves administering an agent (e.g., an agent identified by a screening assay described herein), or combination of agents that modulates (e.g., up-regulates or down-regulates) NOVX expression or activity. In another

embodiment, the method involves administering an NOVX protein or nucleic acid molecule as therapy to compensate for reduced or aberrant NOVX expression or activity.

Stimulation of NOVX activity is desirable *in situations* in which NOVX is abnormally downregulated and/or in which increased NOVX activity is likely to have a beneficial effect.

- 5 One example of such a situation is where a subject has a disorder characterized by aberrant cell proliferation and/or differentiation (*e.g.*, cancer or immune associated disorders). Another example of such a situation is where the subject has a gestational disease (*e.g.*, preclampsia).

Determination of the Biological Effect of the Therapeutic

- 10 In various embodiments of the invention, suitable *in vitro* or *in vivo* assays are performed to determine the effect of a specific Therapeutic and whether its administration is indicated for treatment of the affected tissue.

In various specific embodiments, *in vitro* assays may be performed with representative cells of the type(s) involved in the patient's disorder, to determine if a given Therapeutic exerts the desired effect upon the cell type(s). Compounds for use in therapy may be tested in suitable animal model systems including, but not limited to rats, mice, chicken, cows, monkeys, rabbits, and the like, prior to testing in human subjects. Similarly, for *in vivo* testing, any of the animal model system known in the art may be used prior to administration to human subjects.

Prophylactic and Therapeutic Uses of the Compositions of the Invention

- 20 The NOVX nucleic acids and proteins of the invention are useful in potential prophylactic and therapeutic applications implicated in a variety of disorders including, but not limited to: metabolic disorders, diabetes, obesity, infectious disease, anorexia, cancer-associated cancer, neurodegenerative disorders, Alzheimer's Disease, Parkinson's Disorder, immune disorders, hematopoietic disorders, and the various dyslipidemias, metabolic disturbances
25 associated with obesity, the metabolic syndrome X and wasting disorders associated with chronic diseases and various cancers.

- As an example, a cDNA encoding the NOVX protein of the invention may be useful in gene therapy, and the protein may be useful when administered to a subject in need thereof. By way of non-limiting example, the compositions of the invention will have efficacy for treatment
30 of patients suffering from: metabolic disorders, diabetes, obesity, infectious disease, anorexia,

cancer-associated cachexia, cancer, neurodegenerative disorders, Alzheimer's Disease, Parkinson's Disorder, immune disorders, hematopoietic disorders, and the various dyslipidemias.

Both the novel nucleic acid encoding the NOVX protein, and the NOVX protein of the invention, or fragments thereof, may also be useful in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed. A further use could be as an anti-bacterial molecule (*i.e.*, some peptides have been found to possess anti-bacterial properties). These materials are further useful in the generation of antibodies, which immunospecifically-bind to the novel substances of the invention for use in therapeutic or diagnostic methods.

The invention will be further described in the following examples, which do not limit the scope of the invention described in the claims.

Examples

Example 1. Quantitative expression analysis of clones in various cells and tissues

The quantitative expression of various clones was assessed using microtiter plates containing RNA samples from a variety of normal and pathology-derived cells, cell lines and tissues using real time quantitative PCR (RTQ PCR). RTQ PCR was performed on an Applied Biosystems ABI PRISM® 7700 or an ABI PRISM® 7900 HT Sequence Detection System.

Various collections of samples are assembled on the plates, and referred to as Panel 1 (containing normal tissues and cancer cell lines), Panel 2 (containing samples derived from tissues from normal and cancer sources), Panel 3 (containing cancer cell lines), Panel 4 (containing cells and cell lines from normal tissues and cells related to inflammatory conditions), Panel 5D/5I (containing human tissues and cell lines with an emphasis on metabolic diseases), AI_comprehensive_panel (containing normal tissue and samples from autoimmune diseases), Panel CNSD.01 (containing central nervous system samples from normal and diseased brains) and CNS_neurodegeneration_panel (containing samples from normal and Alzheimer's diseased brains).

RNA integrity from all samples is controlled for quality by visual assessment of agarose gel electropherograms using 28S and 18S ribosomal RNA staining intensity ratio as a guide (2:1

to 2.5:1 28s:18s) and the absence of low molecular weight RNAs that would be indicative of degradation products. Samples are controlled against genomic DNA contamination by RTQ PCR reactions run in the absence of reverse transcriptase using probe and primer sets designed to amplify across the span of a single exon.

5 First, the RNA samples were normalized to reference nucleic acids such as constitutively expressed genes (for example, β -actin and GAPDH). Normalized RNA (5 μ l) was converted to cDNA and analyzed by RTQ-PCR using One Step RT-PCR Master Mix Reagents (Applied Biosystems; Catalog No. 4309169) and gene-specific primers according to the manufacturer's instructions.

10 In other cases, non-normalized RNA samples were converted to single strand cDNA (sscDNA) using Superscript II (Invitrogen Corporation; Catalog No. 18064-147) and random hexamers according to the manufacturer's instructions. Reactions containing up to 10 μ g of total RNA were performed in a volume of 20 μ l and incubated for 60 minutes at 42°C. This reaction can be scaled up to 50 μ g of total RNA in a final volume of 100 μ l. sscDNA samples are then
15 normalized to reference nucleic acids as described previously, using 1X TaqMan® Universal Master mix (Applied Biosystems; catalog No. 4324020), following the manufacturer's instructions.

Probes and primers were designed for each assay according to Applied Biosystems
Primer Express Software package (version I for Apple Computer's Macintosh Power PC) or a
20 similar algorithm using the target sequence as input. Default settings were used for reaction conditions and the following parameters were set before selecting primers: primer concentration = 250 nM, primer melting temperature (T_m) range = 58°-60°C, primer optimal T_m = 59°C, maximum primer difference = 2°C, probe does not have 5'G, probe T_m must be 10°C greater than primer T_m , amplicon size 75bp to 100bp. The probes and primers selected (see below) were
25 synthesized by Synthegen (Houston, TX, USA). Probes were double purified by HPLC to remove uncoupled dye and evaluated by mass spectroscopy to verify coupling of reporter and quencher dyes to the 5' and 3' ends of the probe, respectively. Their final concentrations were: forward and reverse primers, 900nM each, and probe, 200nM.

PCR conditions: When working with RNA samples, normalized RNA from each tissue and each cell line was spotted in each well of either a 96 well or a 384-well PCR plate (Applied Biosystems). PCR cocktails included either a single gene specific probe and primers set, or two multiplexed probe and primers sets (a set specific for the target clone and another gene-specific set multiplexed with the target probe). PCR reactions were set up using TaqMan® One-Step RT-PCR Master Mix (Applied Biosystems, Catalog No. 4313803) following manufacturer's instructions. Reverse transcription was performed at 48°C for 30 minutes followed by amplification/PCR cycles as follows: 95°C 10 min, then 40 cycles of 95°C for 15 seconds, 60°C for 1 minute. Results were recorded as CT values (cycle at which a given sample crosses a threshold level of fluorescence) using a log scale, with the difference in RNA concentration between a given sample and the sample with the lowest CT value being represented as 2 to the power of delta CT. The percent relative expression is then obtained by taking the reciprocal of this RNA difference and multiplying by 100.

When working with sscDNA samples, normalized sscDNA was used as described previously for RNA samples. PCR reactions containing one or two sets of probe and primers were set up as described previously, using 1X TaqMan® Universal Master mix (Applied Biosystems; catalog No. 4324020), following the manufacturer's instructions. PCR amplification was performed as follows: 95°C 10 min, then 40 cycles of 95°C for 15 seconds, 60°C for 1 minute. Results were analyzed and processed as described previously.

Panels 1, 1.1, 1.2, and 1.3D

The plates for Panels 1, 1.1, 1.2 and 1.3D include 2 control wells (genomic DNA control and chemistry control) and 94 wells containing cDNA from various samples. The samples in these panels are broken into 2 classes: samples derived from cultured cell lines and samples derived from primary normal tissues. The cell lines are derived from cancers of the following types: lung cancer, breast cancer, melanoma, colon cancer, prostate cancer, CNS cancer, squamous cell carcinoma, ovarian cancer, liver cancer, renal cancer, gastric cancer and pancreatic cancer. Cell lines used in these panels are widely available through the American Type Culture Collection (ATCC), a repository for cultured cell lines, and were cultured using the conditions recommended by the ATCC. The normal tissues found on these panels are comprised

of samples derived from all major organ systems from single adult individuals or fetuses. These samples are derived from the following organs: adult skeletal muscle, fetal skeletal muscle, adult heart, fetal heart, adult kidney, fetal kidney, adult liver, fetal liver, adult lung, fetal lung, various regions of the brain, the spleen, bone marrow, lymph node, pancreas, salivary gland, pituitary gland, adrenal gland, spinal cord, thymus, stomach, small intestine, colon, bladder, trachea, breast, ovary, uterus, placenta, prostate, testis and adipose.

In the results for Panels 1, 1.1, 1.2 and 1.3D, the following abbreviations are used:

ca. = carcinoma,
* = established from metastasis,
met = metastasis,
s cell var = small cell variant,
non-s = non-sm = non-small,
squam = squamous,
pl. eff = pl effusion = pleural effusion,
glio = glioma,
astro = astrocytoma, and
neuro = neuroblastoma.

General_screening_panel_v1.4

The plates for Panel 1.4 include 2 control wells (genomic DNA control and chemistry control) and 94 wells containing cDNA from various samples. The samples in Panel 1.4 are broken into 2 classes: samples derived from cultured cell lines and samples derived from primary normal tissues. The cell lines are derived from cancers of the following types: lung cancer, breast cancer, melanoma, colon cancer, prostate cancer, CNS cancer, squamous cell carcinoma, ovarian cancer, liver cancer, renal cancer, gastric cancer and pancreatic cancer. Cell lines used in Panel 1.4 are widely available through the American Type Culture Collection (ATCC), a repository for cultured cell lines, and were cultured using the conditions recommended by the ATCC. The normal tissues found on Panel 1.4 are comprised of pools of samples derived from all major organ systems from 2 to 5 different adult individuals or fetuses. These samples are derived from the following organs: adult skeletal muscle, fetal skeletal muscle, adult heart, fetal heart, adult kidney, fetal kidney, adult liver, fetal liver, adult lung, fetal lung, various regions of the brain, the spleen, bone marrow, lymph node, pancreas, salivary gland, pituitary gland, adrenal gland, spinal

cord, thymus, stomach, small intestine, colon, bladder, trachea, breast, ovary, uterus, placenta, prostate, testis and adipose. Abbreviations are as described for Panels 1, 1.1, 1.2, and 1.3D.

Panels 2D and 2.2

The plates for Panels 2D and 2.2 generally include 2 control wells and 94 test samples composed of RNA or cDNA isolated from human tissue procured by surgeons working in close cooperation with the National Cancer Institute's Cooperative Human Tissue Network (CHTN) or the National Disease Research Initiative (NDRI). The tissues are derived from human malignancies and in cases where indicated many malignant tissues have "matched margins" obtained from noncancerous tissue just adjacent to the tumor. These are termed normal adjacent tissues and are denoted "NAT" in the results below. The tumor tissue and the "matched margins" are evaluated by two independent pathologists (the surgical pathologists and again by a pathologist at NDRI or CHTN). This analysis provides a gross histopathological assessment of tumor differentiation grade. Moreover, most samples include the original surgical pathology report that provides information regarding the clinical stage of the patient. These matched margins are taken from the tissue surrounding (i.e. immediately proximal) to the zone of surgery (designated "NAT", for normal adjacent tissue, in Table RR). In addition, RNA and cDNA samples were obtained from various human tissues derived from autopsies performed on elderly people or sudden death victims (accidents, etc.). These tissues were ascertained to be free of disease and were purchased from various commercial sources such as Clontech (Palo Alto, CA), Research Genetics, and Invitrogen.

Panel 3D

The plates of Panel 3D are comprised of 94 cDNA samples and two control samples. Specifically, 92 of these samples are derived from cultured human cancer cell lines, 2 samples of human primary cerebellar tissue and 2 controls. The human cell lines are generally obtained from ATCC (American Type Culture Collection), NCI or the German tumor cell bank and fall into the following tissue groups: Squamous cell carcinoma of the tongue, breast cancer, prostate cancer, melanoma, epidermoid carcinoma, sarcomas, bladder carcinomas, pancreatic cancers, kidney cancers, leukemias/lymphomas, ovarian/uterine/cervical, gastric, colon, lung and CNS cancer cell lines. In addition, there are two independent samples of cerebellum. These cells are all

cultured under standard recommended conditions and RNA extracted using the standard procedures. The cell lines in panel 3D and 1.3D are of the most common cell lines used in the scientific literature.

Panels 4D, 4R, and 4.1D

Panel 4 includes samples on a 96 well plate (2 control wells, 94 test samples) composed of RNA (Panel 4R) or cDNA (Panels 4D/4.1D) isolated from various human cell lines or tissues related to inflammatory conditions. Total RNA from control normal tissues such as colon and lung (Stratagene, La Jolla, CA) and thymus and kidney (Clontech) was employed. Total RNA from liver tissue from cirrhosis patients and kidney from lupus patients was obtained from BioChain (Biochain Institute, Inc., Hayward, CA). Intestinal tissue for RNA preparation from patients diagnosed as having Crohn's disease and ulcerative colitis was obtained from the National Disease Research Interchange (NDRI) (Philadelphia, PA).

Astrocytes, lung fibroblasts, dermal fibroblasts, coronary artery smooth muscle cells, small airway epithelium, bronchial epithelium, microvascular dermal endothelial cells, microvascular lung endothelial cells, human pulmonary aortic endothelial cells, human umbilical vein endothelial cells were all purchased from Clonetics (Walkersville, MD) and grown in the media supplied for these cell types by Clonetics. These primary cell types were activated with various cytokines or combinations of cytokines for 6 and/or 12-14 hours, as indicated. The following cytokines were used; IL-1 beta at approximately 1-5ng/ml, TNF alpha at approximately 5-10ng/ml, IFN gamma at approximately 20-50ng/ml, IL-4 at approximately 5-10ng/ml, IL-9 at approximately 5-10ng/ml, IL-13 at approximately 5-10ng/ml. Endothelial cells were sometimes starved for various times by culture in the basal media from Clonetics with 0.1% serum.

Mononuclear cells were prepared from blood of employees at CuraGen Corporation, using Ficoll. LAK cells were prepared from these cells by culture in DMEM 5% FCS (Hyclone), 100μM non essential amino acids (Gibco/Life Technologies, Rockville, MD), 1mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10^{-5} M (Gibco), and 10mM Hepes (Gibco) and Interleukin 2 for 4-6 days. Cells were then either activated with 10-20ng/ml PMA and 1-2μg/ml ionomycin, IL-12 at 5-10ng/ml, IFN gamma at 20-50ng/ml and IL-18 at 5-10ng/ml for 6 hours.

In some cases, mononuclear cells were cultured for 4-5 days in DMEM 5% FCS (Hyclone), 100μM non essential amino acids (Gibco), 1mM sodium pyruvate (Gibco), mercaptoethanol 5.5x10⁻⁵M (Gibco), and 10mM Hepes (Gibco) with PHA (phytohemagglutinin) or PWM (pokeweed mitogen) at approximately 5μg/ml. Samples were taken at 24, 48 and 72 hours for RNA preparation. MLR (mixed lymphocyte reaction) samples were obtained by taking blood from two donors, isolating the mononuclear cells using Ficoll and mixing the isolated mononuclear cells 1:1 at a final concentration of approximately 2x10⁶ cells/ml in DMEM 5% FCS (Hyclone), 100μM non essential amino acids (Gibco), 1mM sodium pyruvate (Gibco), mercaptoethanol (5.5x10⁻⁵M) (Gibco), and 10mM Hepes (Gibco). The MLR was cultured and samples taken at various time points ranging from 1- 7 days for RNA preparation.

Monocytes were isolated from mononuclear cells using CD14 Miltenyi Beads, +ve VS selection columns and a Vario Magnet according to the manufacturer's instructions. Monocytes were differentiated into dendritic cells by culture in DMEM 5% fetal calf serum (FCS) (Hyclone, Logan, UT), 100μM non essential amino acids (Gibco), 1mM sodium pyruvate (Gibco), mercaptoethanol 5.5x10⁻⁵M (Gibco), and 10mM Hepes (Gibco), 50ng/ml GMCSF and 5ng/ml IL-4 for 5-7 days. Macrophages were prepared by culture of monocytes for 5-7 days in DMEM 5% FCS (Hyclone), 100μM non essential amino acids (Gibco), 1mM sodium pyruvate (Gibco), mercaptoethanol 5.5x10⁻⁵M (Gibco), 10mM Hepes (Gibco) and 10% AB Human Serum or MCSF at approximately 50ng/ml. Monocytes, macrophages and dendritic cells were stimulated for 6 and 12-14 hours with lipopolysaccharide (LPS) at 100ng/ml. Dendritic cells were also stimulated with anti-CD40 monoclonal antibody (Pharmingen) at 10μg/ml for 6 and 12-14 hours.

CD4 lymphocytes, CD8 lymphocytes and NK cells were also isolated from mononuclear cells using CD4, CD8 and CD56 Miltenyi beads, positive VS selection columns and a Vario Magnet according to the manufacturer's instructions. CD45RA and CD45RO CD4 lymphocytes were isolated by depleting mononuclear cells of CD8, CD56, CD14 and CD19 cells using CD8, CD56, CD14 and CD19 Miltenyi beads and positive selection. CD45RO beads were then used to isolate the CD45RO CD4 lymphocytes with the remaining cells being CD45RA CD4 lymphocytes. CD45RA CD4, CD45RO CD4 and CD8 lymphocytes were placed in DMEM 5% FCS (Hyclone), 100μM non essential amino acids (Gibco), 1mM sodium pyruvate (Gibco), mercaptoethanol 5.5x10⁻⁵M (Gibco), and 10mM Hepes (Gibco) and plated at 10⁶ cells/ml onto

Falcon 6 well tissue culture plates that had been coated overnight with 0.5µg/ml anti-CD28 (Pharmingen) and 3ug/ml anti-CD3 (OKT3, ATCC) in PBS. After 6 and 24 hours, the cells were harvested for RNA preparation. To prepare chronically activated CD8 lymphocytes, we activated the isolated CD8 lymphocytes for 4 days on anti-CD28 and anti-CD3 coated plates and then

5 harvested the cells and expanded them in DMEM 5% FCS (Hyclone), 100µM non essential amino acids (Gibco), 1mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10^{-5} M (Gibco), and 10mM Hepes (Gibco) and IL-2. The expanded CD8 cells were then activated again with plate bound anti-CD3 and anti-CD28 for 4 days and expanded as before. RNA was isolated 6 and 24 hours after the second activation and after 4 days of the second expansion culture. The isolated

10 NK cells were cultured in DMEM 5% FCS (Hyclone), 100µM non essential amino acids (Gibco), 1mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10^{-5} M (Gibco), and 10mM Hepes (Gibco) and IL-2 for 4-6 days before RNA was prepared.

To obtain B cells, tonsils were procured from NDRI. The tonsil was cut up with sterile dissecting scissors and then passed through a sieve. Tonsil cells were then spun down and resuspended at

15 10^6 cells/ml in DMEM 5% FCS (Hyclone), 100µM non essential amino acids (Gibco), 1mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10^{-5} M (Gibco), and 10mM Hepes (Gibco). To activate the cells, we used PWM at 5µg/ml or anti-CD40 (Pharmingen) at approximately 10µg/ml and IL-4 at 5-10ng/ml. Cells were harvested for RNA preparation at 24, 48 and 72 hours.

20 To prepare the primary and secondary Th1/Th2 and Tr1 cells, six-well Falcon plates were coated overnight with 10µg/ml anti-CD28 (Pharmingen) and 2µg/ml OKT3 (ATCC), and then washed twice with PBS. Umbilical cord blood CD4 lymphocytes (Poietic Systems, German Town, MD) were cultured at 10^5 - 10^6 cells/ml in DMEM 5% FCS (Hyclone), 100µM non essential amino acids (Gibco), 1mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10^{-5} M (Gibco), 10mM

25 Hepes (Gibco) and IL-2 (4ng/ml). IL-12 (5ng/ml) and anti-IL4 (1µg/ml) were used to direct to Th1, while IL-4 (5ng/ml) and anti-IFN gamma (1µg/ml) were used to direct to Th2 and IL-10 at 5ng/ml was used to direct to Tr1. After 4-5 days, the activated Th1, Th2 and Tr1 lymphocytes were washed once in DMEM and expanded for 4-7 days in DMEM 5% FCS (Hyclone), 100µM non essential amino acids (Gibco), 1mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10^{-5} M

30 (Gibco), 10mM Hepes (Gibco) and IL-2 (1ng/ml). Following this, the activated Th1, Th2 and

Tr1 lymphocytes were re-stimulated for 5 days with anti-CD28/OKT3 and cytokines as described above, but with the addition of anti-CD95L (1µg/ml) to prevent apoptosis. After 4-5 days, the Th1, Th2 and Tr1 lymphocytes were washed and then expanded again with IL-2 for 4-7 days. Activated Th1 and Th2 lymphocytes were maintained in this way for a maximum of three cycles. RNA was prepared from primary and secondary Th1, Th2 and Tr1 after 6 and 24 hours following the second and third activations with plate bound anti-CD3 and anti-CD28 mAbs and 4 days into the second and third expansion cultures in Interleukin 2.

The following leukocyte cells lines were obtained from the ATCC: Ramos, EOL-1, KU-812. EOL cells were further differentiated by culture in 0.1mM dbcAMP at 5×10^5 cells/ml for 8 days, changing the media every 3 days and adjusting the cell concentration to 5×10^5 cells/ml. For the culture of these cells, we used DMEM or RPMI (as recommended by the ATCC), with the addition of 5% FCS (Hyclone), 100µM non essential amino acids (Gibco), 1mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10^{-5} M (Gibco), 10mM Hepes (Gibco). RNA was either prepared from resting cells or cells activated with PMA at 10ng/ml and ionomycin at 1µg/ml for 6 and 14 hours. Keratinocyte line CCD106 and an airway epithelial tumor line NCI-H292 were also obtained from the ATCC. Both were cultured in DMEM 5% FCS (Hyclone), 100µM non essential amino acids (Gibco), 1mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10^{-5} M (Gibco), and 10mM Hepes (Gibco). CCD1106 cells were activated for 6 and 14 hours with approximately 5 ng/ml TNF alpha and 1ng/ml IL-1 beta, while NCI-H292 cells were activated for 6 and 14 hours with the following cytokines: 5ng/ml IL-4, 5ng/ml IL-9, 5ng/ml IL-13 and 25ng/ml IFN gamma.

For these cell lines and blood cells, RNA was prepared by lysing approximately 10^7 cells/ml using Trizol (Gibco BRL). Briefly, 1/10 volume of bromochloropropane (Molecular Research Corporation) was added to the RNA sample, vortexed and after 10 minutes at room temperature, the tubes were spun at 14,000 rpm in a Sorvall SS34 rotor. The aqueous phase was removed and placed in a 15ml Falcon Tube. An equal volume of isopropanol was added and left at -20°C overnight. The precipitated RNA was spun down at 9,000 rpm for 15 min in a Sorvall SS34 rotor and washed in 70% ethanol. The pellet was redissolved in 300µl of RNase-free water and 35µl buffer (Promega) 5µl DTT, 7µl RNasin and 8µl DNase were added. The tube was incubated at 37°C for 30 minutes to remove contaminating genomic DNA, extracted once with phenol

chloroform and re-precipitated with 1/10 volume of 3M sodium acetate and 2 volumes of 100% ethanol. The RNA was spun down and placed in RNase free water. RNA was stored at -80°C.

AI_comprehensive panel_v1.0

The plates for AI_comprehensive panel_v1.0 include two control wells and 89 test samples comprised of cDNA isolated from surgical and postmortem human tissues obtained from the Backus Hospital and Clinomics (Frederick, MD). Total RNA was extracted from tissue samples from the Backus Hospital in the Facility at CuraGen. Total RNA from other tissues was obtained from Clinomics.

Joint tissues including synovial fluid, synovium, bone and cartilage were obtained from patients undergoing total knee or hip replacement surgery at the Backus Hospital. Tissue samples were immediately snap frozen in liquid nitrogen to ensure that isolated RNA was of optimal quality and not degraded. Additional samples of osteoarthritis and rheumatoid arthritis joint tissues were obtained from Clinomics. Normal control tissues were supplied by Clinomics and were obtained during autopsy of trauma victims.

Surgical specimens of psoriatic tissues and adjacent matched tissues were provided as total RNA by Clinomics. Two male and two female patients were selected between the ages of 25 and 47. None of the patients were taking prescription drugs at the time samples were isolated.

Surgical specimens of diseased colon from patients with ulcerative colitis and Crohns disease and adjacent matched tissues were obtained from Clinomics. Bowel tissue from three female and three male Crohn's patients between the ages of 41-69 were used. Two patients were not on prescription medication while the others were taking dexamethasone, phenobarbital, or tylenol. Ulcerative colitis tissue was from three male and four female patients. Four of the patients were taking lebid and two were on phenobarbital.

Total RNA from post mortem lung tissue from trauma victims with no disease or with emphysema, asthma or COPD was purchased from Clinomics. Emphysema patients ranged in age from 40-70 and all were smokers, this age range was chosen to focus on patients with cigarette-linked emphysema and to avoid those patients with alpha-1anti-trypsin deficiencies.

Asthma patients ranged in age from 36-75, and excluded smokers to prevent those patients that could also have COPD. COPD patients ranged in age from 35-80 and included both smokers and non-smokers. Most patients were taking corticosteroids, and bronchodilators.

In the labels employed to identify tissues in the AI_comprehensive panel_v1.0 panel, the following abbreviations are used:

AI = Autoimmunity
 Syn = Synovial
 Normal = No apparent disease
 Rep22 /Rep20 = individual patients
 RA = Rheumatoid arthritis
 Backus = From Backus Hospital
 OA = Osteoarthritis
 (SS) (BA) (MF) = Individual patients
 Adj = Adjacent tissue
 Match control = adjacent tissues
 -M = Male
 -F = Female
 COPD = Chronic obstructive pulmonary disease

Panels 5D and 5I

The plates for Panel 5D and 5I include two control wells and a variety of cDNAs isolated from human tissues and cell lines with an emphasis on metabolic diseases. Metabolic tissues were obtained from patients enrolled in the Gestational Diabetes study. Cells were obtained during different stages in the differentiation of adipocytes from human mesenchymal stem cells. Human pancreatic islets were also obtained.

In the Gestational Diabetes study subjects are young (18 - 40 years), otherwise healthy women with and without gestational diabetes undergoing routine (elective) Caesarean section. After delivery of the infant, when the surgical incisions were being repaired/closed, the obstetrician removed a small sample (<1 cc) of the exposed metabolic tissues during the closure of each surgical level. The biopsy material was rinsed in sterile saline, blotted and fast frozen within 5 minutes from the time of removal. The tissue was then flash frozen in liquid nitrogen and stored, individually, in sterile screw-top tubes and kept on dry ice for shipment to or to be picked up by CuraGen. The metabolic tissues of interest include uterine wall (smooth muscle), visceral adipose, skeletal muscle (rectus) and subcutaneous adipose. Patient descriptions are as follows:

Patient 2: Diabetic Hispanic, overweight, not on insulin
Patient 7-9: Nondiabetic Caucasian and obese (BMI>30)
Patient 10: Diabetic Hispanic, overweight, on insulin
Patient 11: Nondiabetic African American and overweight
Patient 12: Diabetic Hispanic on insulin

Adipocyte differentiation was induced in donor progenitor cells obtained from Osirus (a division of Clonetics/BioWhittaker) in triplicate, except for Donor 3U which had only two replicates. Scientists at Clonetics isolated, grew and differentiated human mesenchymal stem cells (HuMSCs) for CuraGen based on the published protocol found in Mark F. Pittenger, et al., Multilineage Potential of Adult Human Mesenchymal Stem Cells Science Apr 2 1999: 143-147. Clonetics provided Trizol lysates or frozen pellets suitable for mRNA isolation and ds cDNA production. A general description of each donor is as follows:

Donor 2 and 3 U: Mesenchymal Stem cells, Undifferentiated Adipose
Donor 2 and 3 AM: Adipose, AdiposeMidway Differentiated
Donor 2 and 3 AD: Adipose, Adipose Differentiated

Human cell lines were generally obtained from ATCC (American Type Culture Collection), NCI or the German tumor cell bank and fall into the following tissue groups: kidney proximal convoluted tubule, uterine smooth muscle cells, small intestine, liver HepG2 cancer cells, heart primary stromal cells, and adrenal cortical adenoma cells. These cells are all cultured under standard recommended conditions and RNA extracted using the standard procedures. All samples were processed at CuraGen to produce single stranded cDNA.

Panel 5I contains all samples previously described with the addition of pancreatic islets from a 58 year old female patient obtained from the Diabetes Research Institute at the University of Miami School of Medicine. Islet tissue was processed to total RNA at an outside source and delivered to CuraGen for addition to panel 5I.

In the labels employed to identify tissues in the 5D and 5I panels, the following abbreviations are used:

GO Adipose = Greater Omentum Adipose
SK = Skeletal Muscle
UT = Uterus
PL = Placenta

AD = Adipose Differentiated
AM = Adipose Midway Differentiated
U = Undifferentiated Stem Cells

Panel CNSD.01

5 The plates for Panel CNSD.01 include two control wells and 94 test samples comprised of cDNA isolated from postmortem human brain tissue obtained from the Harvard Brain Tissue Resource Center. Brains are removed from calvaria of donors between 4 and 24 hours after death, sectioned by neuroanatomists, and frozen at -80°C in liquid nitrogen vapor. All brains are sectioned and examined by neuropathologists to confirm diagnoses with clear associated
10 neuropathology.

15 Disease diagnoses are taken from patient records. The panel contains two brains from each of the following diagnoses: Alzheimer's disease, Parkinson's disease, Huntington's disease, Progressive Supranuclear Palsy, Depression, and "Normal controls". Within each of these brains, the following regions are represented: cingulate gyrus, temporal pole, globus palladus, substantia nigra, Brodman Area 4 (primary motor strip), Brodman Area 7 (parietal cortex), Brodman Area 9 (prefrontal cortex), and Brodman area 17 (occipital cortex). Not all brain regions are represented in all cases; e.g., Huntington's disease is characterized in part by neurodegeneration in the globus palladus, thus this region is impossible to obtain from confirmed Huntington's cases. Likewise Parkinson's disease is characterized by degeneration of the substantia nigra making this region
20 more difficult to obtain. Normal control brains were examined for neuropathology and found to be free of any pathology consistent with neurodegeneration.

In the labels employed to identify tissues in the CNS panel, the following abbreviations are used:

25 PSP = Progressive supranuclear palsy
 Sub Nigra = Substantia nigra
 Glob Palladus= Globus palladus
 Temp Pole = Temporal pole
 Cing Gyr = Cingulate gyrus
 BA 4 = Brodman Area 4

Panel CNS_Neurodegeneration_V1.0

The plates for Panel CNS_Neurodegeneration_V1.0 include two control wells and 47 test samples comprised of cDNA isolated from postmortem human brain tissue obtained from the Harvard Brain Tissue Resource Center (McLean Hospital) and the Human Brain and Spinal Fluid Resource Center (VA Greater Los Angeles Healthcare System). Brains are removed from calvaria of donors between 4 and 24 hours after death, sectioned by neuroanatomists, and frozen at -80°C in liquid nitrogen vapor. All brains are sectioned and examined by neuropathologists to confirm diagnoses with clear associated neuropathology.

Disease diagnoses are taken from patient records. The panel contains six brains from Alzheimer's disease (AD) patients, and eight brains from "Normal controls" who showed no evidence of dementia prior to death. The eight normal control brains are divided into two categories: Controls with no dementia and no Alzheimer's like pathology (Controls) and controls with no dementia but evidence of severe Alzheimer's like pathology, (specifically senile plaque load rated as level 3 on a scale of 0-3; 0 = no evidence of plaques, 3 = severe AD senile plaque load). Within each of these brains, the following regions are represented: hippocampus, temporal cortex (Brodmann Area 21), parietal cortex (Brodmann area 7), and occipital cortex (Brodmann area 17). These regions were chosen to encompass all levels of neurodegeneration in AD. The hippocampus is a region of early and severe neuronal loss in AD; the temporal cortex is known to show neurodegeneration in AD after the hippocampus; the parietal cortex shows moderate neuronal death in the late stages of the disease; the occipital cortex is spared in AD and therefore acts as a "control" region within AD patients. Not all brain regions are represented in all cases.

In the labels employed to identify tissues in the CNS_Neurodegeneration_V1.0 panel, the following abbreviations are used:

AD = Alzheimer's disease brain; patient was demented and showed AD-like pathology upon autopsy

Control = Control brains; patient not demented, showing no neuropathology

Control (Path) = Control brains; patient not demented but showing severe AD-like pathology

SupTemporal Ctx = Superior Temporal Cortex

Inf Temporal Ctx = Inferior Temporal Cortex

NOV1: CG56181-01: Neurotrophin – isoform 1

Expression of gene CG56181-01 was assessed using the primer-probe set Ag2943, described in Table AA.

Table AA. Probe Name Ag2943

Primers	Sequences	Length	Start Position
Forward	5'-gactgctgtggacttggtg-3' (SEQ ID NO:341)	20	465
Probe	TET-5'-gaggtggaggtgttggcgaggt-3'-TAMRA (SEQ ID NO:342)	23	490
Reverse	5'-aaagaagtgttggtggaggg-3' (SEQ ID NO:343)	20	533

CNS_neurodegeneration_v1.0 Summary: Ag2943 Expression of the CG56181-01 gene is low/undetectable in all samples on this panel (CTs>35).

Panel 1.3D Summary: Ag2943 Expression of the CG56181-01 gene is low/undetectable in all samples on this panel (CTs>35).

Panel 4D Summary: Ag2943 Expression of the CG56181-01 gene is low/undetectable in all samples on this panel (CTs>35).

NOV2: CG56275-01: guanylate kinase

Expression of gene CG56275-01 was assessed using the primer-probe set Ag2944, described in Table BA. Results of the RTQ-PCR runs are shown in Tables BB, BC, BD and BE.

Table BA. Probe Name Ag2944

Primers	Sequences	Length	Start Position
Forward	5'-ccttaggaccctctggtggt-3' (SEQ ID NO:344)	20	745
Probe	TET-5'-caacttattgaatttaatcccagcca-3'-TAMRA (SEQ ID NO:345)	26	786
Reverse	5'-tagttggcacagcactttga-3' (SEQ ID NO:346)	20	815

Table BB. Panel 1.3D

Tissue Name	Rel. Exp.(%) Ag2944, Run 162293950	Rel. Exp.(%) Ag2944, Run 165701957	Tissue Name	Rel. Exp.(%) Ag2944, Run 162293950	Rel. Exp.(%) Ag2944, Run 165701957
Liver adenocarcinoma	6.7	1.9	Kidney (fetal)	0.0	4.4
Pancreas	0.0	0.0	Renal ca. 786- 0	0.0	0.0

Pancreatic ca. CAPAN 2	0.0	0.0	Renal ca. A498	4.4	6.0
Adrenal gland	0.0	0.0	Renal ca. RXF 393	1.1	0.0
Thyroid	0.5	0.0	Renal ca. ACHN	0.3	0.0
Salivary gland	0.5	0.0	Renal ca. UO- 31	5.1	12.5
Pituitary gland	0.0	0.0	Renal ca. TK- 10	0.0	0.0
Brain (fetal)	1.8	0.7	Liver	0.0	0.0
Brain (whole)	1.7	6.1	Liver (fetal)	0.0	0.0
Brain (amygdala)	1.2	4.2	Liver ca. (hepatoblast) HepG2	0.0	0.0
Brain (cerebellum)	11.0	17.3	Lung	0.6	0.0
Brain (hippocampus)	3.4	7.2	Lung (fetal)	1.0	2.4
Brain (substantia nigra)	1.6	2.9	Lung ca. (small cell) LX-1	0.0	0.0
Brain (thalamus)	0.0	11.6	Lung ca. (small cell) NCI-H69	6.3	4.9
Cerebral Cortex	8.8	1.8	Lung ca. (s.cell var.) SHP-77	0.0	0.0
Spinal cord	0.7	0.0	Lung ca. (large cell)NCI-H460	1.7	4.1
glio/astro U87-MG	100.0	35.1	Lung ca. (non- sm. cell) A549	0.0	0.0
glio/astro U-118- MG	36.9	100.0	Lung ca. (non- s.cell) NCI- H23	0.7	0.0
astrocytoma SW1783	43.5	12.4	Lung ca. (non- s.cell) HOP-62	0.0	0.0
neuro*; met SK-N- AS	0.7	1.1	Lung ca. (non- s.cl) NCI-H522	0.0	0.0
astrocytoma SF- 539	0.8	2.3	Lung ca. (squam.) SW 900	0.0	0.0
astrocytoma SNB- 75	2.9	11.0	Lung ca. (squam.) NCI-	0.9	0.0

			H596		
glioma SNB-19	3.9	6.7	Mammary gland	1.3	1.2
glioma U251	0.3	2.4	Breast ca.* (pl.ef) MCF-7	0.0	0.0
glioma SF-295	0.3	1.0	Breast ca.* (pl.ef) MDA-MB-231	0.7	4.6
Heart (fetal)	0.7	0.0	Breast ca.* (pl.ef) T47D	0.0	0.0
Heart	0.0	1.1	Breast ca. BT-549	0.3	7.6
Skeletal muscle (fetal)	4.6	1.4	Breast ca. MDA-N	0.0	1.4
Skeletal muscle	0.8	3.3	Ovary	0.0	0.0
Bone marrow	0.0	0.0	Ovarian ca. OVCAR-3	0.0	0.0
Thymus	0.0	0.0	Ovarian ca. OVCAR-4	0.3	0.0
Spleen	3.9	4.8	Ovarian ca. OVCAR-5	0.3	0.0
Lymph node	1.2	0.0	Ovarian ca. OVCAR-8	0.0	0.8
Colorectal	2.3	0.9	Ovarian ca. IGROV-1	1.9	2.4
Stomach	0.0	0.0	Ovarian ca.* (ascites) SK-OV-3	0.4	3.5
Small intestine	0.0	0.0	Uterus	0.6	0.0
Colon ca. SW480	0.9	1.4	Placenta	0.0	0.0
Colon ca.* SW620(SW480 met)	0.0	0.0	Prostate	0.0	0.0
Colon ca. HT29	0.0	0.0	Prostate ca.* (bone met)PC-3	0.0	0.9
Colon ca. HCT-116	0.0	0.8	Testis	0.8	1.6
Colon ca. CaCo-2	2.9	1.1	Melanoma Hs688(A).T	4.3	1.6
Colon ca. tissue(ODO3866)	0.8	0.0	Melanoma* (met)	3.1	0.0

			Hs688(B).T		
Colon ca. HCC-2998	0.0	0.0	Melanoma UACC-62	1.1	0.0
Gastric ca.* (liver met) NCI-N87	0.5	3.9	Melanoma M14	0.0	0.0
Bladder	1.9	0.0	Melanoma LOX IMVI	46.3	21.5
Trachea	0.0	0.0	Melanoma* (met) SK-MEL-5	0.0	1.1
Kidney	0.9	0.0	Adipose	1.1	1.1

Table BC. Panel 2D

Tissue Name	Rel. Exp.(%) Ag2944, Run 162373958	Tissue Name	Rel. Exp.(%) Ag2944, Run 162373958
Normal Colon	30.6	Kidney Margin 8120608	0.0
CC Well to Mod Diff (ODO3866)	16.3	Kidney Cancer 8120613	0.0
CC Margin (ODO3866)	8.7	Kidney Margin 8120614	0.0
CC Gr.2 rectosigmoid (ODO3868)	0.0	Kidney Cancer 9010320	10.7
CC Margin (ODO3868)	0.0	Kidney Margin 9010321	0.0
CC Mod Diff (ODO3920)	0.0	Normal Uterus	5.1
CC Margin (ODO3920)	0.0	Uterus Cancer 064011	10.8
CC Gr.2 ascend colon (ODO3921)	0.0	Normal Thyroid	4.9
CC Margin (ODO3921)	7.6	Thyroid Cancer 064010	3.8
CC from Partial Hepatectomy (ODO4309) Mets	5.8	Thyroid Cancer A302152	8.5
Liver Margin (ODO4309)	25.0	Thyroid Margin A302153	0.0
Colon mets to lung (OD04451-01)	5.6	Normal Breast	11.5
Lung Margin (OD04451-02)	0.0	Breast Cancer (OD04566)	0.0

Normal Prostate 6546-1	13.0	Breast Cancer (OD04590-01)	7.1
Prostate Cancer (OD04410)	13.9	Breast Cancer Mets (OD04590-03)	0.0
Prostate Margin (OD04410)	25.0	Breast Cancer Metastasis (OD04655-05)	50.7
Prostate Cancer (OD04720-01)	3.4	Breast Cancer 064006	30.8
Prostate Margin (OD04720-02)	22.7	Breast Cancer 1024	50.3
Normal Lung 061010	29.7	Breast Cancer 9100266	16.8
Lung Met to Muscle (ODO4286)	12.4	Breast Margin 9100265	4.8
Muscle Margin (ODO4286)	0.0	Breast Cancer A209073	5.1
Lung Malignant Cancer (OD03126)	0.0	Breast Margin A2090734	32.1
Lung Margin (OD03126)	25.7	Normal Liver	13.3
Lung Cancer (OD04404)	0.0	Liver Cancer 064003	9.8
Lung Margin (OD04404)	0.0	Liver Cancer 1025	11.5
Lung Cancer (OD04565)	4.5	Liver Cancer 1026	0.0
Lung Margin (OD04565)	5.3	Liver Cancer 6004-T	4.2
Lung Cancer (OD04237-01)	19.2	Liver Tissue 6004-N	15.9
Lung Margin (OD04237-02)	0.0	Liver Cancer 6005-T	0.0
Ocular Mel Met to Liver (ODO4310)	100.0	Liver Tissue 6005-N	0.0
Liver Margin (ODO4310)	6.4	Normal Bladder	35.1
Melanoma Mets to Lung (OD04321)	43.2	Bladder Cancer 1023	13.0
Lung Margin (OD04321)	4.1	Bladder Cancer A302173	11.5
Normal Kidney	7.4	Bladder Cancer (OD04718-01)	6.9
Kidney Ca, Nuclear grade 2 (OD04338)	0.0	Bladder Normal Adjacent (OD04718-03)	19.3
Kidney Margin	2.6	Normal Ovary	0.0

(OD04338)			
Kidney Ca Nuclear grade 1/2 (OD04339)	0.0	Ovarian Cancer 064008	47.3
Kidney Margin (OD04339)	3.2	Ovarian Cancer (OD04768-07)	0.0
Kidney Ca, Clear cell type (OD04340)	0.0	Ovary Margin (OD04768-08)	29.5
Kidney Margin (OD04340)	5.5	Normal Stomach	54.0
Kidney Ca, Nuclear grade 3 (OD04348)	0.0	Gastric Cancer 9060358	0.0
Kidney Margin (OD04348)	7.5	Stomach Margin 9060359	3.3
Kidney Cancer (OD04622-01)	9.1	Gastric Cancer 9060395	10.0
Kidney Margin (OD04622-03)	0.0	Stomach Margin 9060394	59.5
Kidney Cancer (OD04450-01)	6.9	Gastric Cancer 9060397	12.9
Kidney Margin (OD04450-03)	3.1	Stomach Margin 9060396	9.3
Kidney Cancer 8120607	0.0	Gastric Cancer 064005	47.6

Table BD. Panel 3D

Tissue Name	Rel. Exp.(%) Ag2944, Run 164843788	Tissue Name	Rel. Exp.(%) Ag2944, Run 164843788
Daoy- Medulloblastoma	0.6	Ca Ski- Cervical epidermoid carcinoma (metastasis)	0.0
TE671- Medulloblastoma	0.3	ES-2- Ovarian clear cell carcinoma	100.0
D283 Med- Medulloblastoma	0.9	Ramos- Stimulated with PMA/ionomycin 6h	0.0
PFSK-1- Primitive Neuroectodermal	0.0	Ramos- Stimulated with PMA/ionomycin 14h	0.2
XF-498- CNS	1.7	MEG-01- Chronic myelogenous leukemia (megokaryoblast)	0.2
SNB-78- Glioma	3.4	Raji- Burkitt's lymphoma	0.0
SF-268- Glioblastoma	6.7	Daudi- Burkitt's lymphoma	0.0
T98G- Glioblastoma	1.0	U266- B-cell plasmacytoma	0.4

SK-N-SH- Neuroblastoma (metastasis)	7.9	CA46- Burkitt's lymphoma	0.0
SF-295- Glioblastoma	2.0	RL- non-Hodgkin's B-cell lymphoma	0.0
Cerebellum	8.1	JM1- pre-B-cell lymphoma	0.0
Cerebellum	1.2	Jurkat- T cell leukemia	0.0
NCI-H292- Mucoepidermoid lung carcinoma	1.1	TF-1- Erythroleukemia	1.0
DMS-114- Small cell lung cancer	1.3	HUT 78- T-cell lymphoma	0.0
DMS-79- Small cell lung cancer	0.0	U937- Histiocytic lymphoma	0.0
NCI-H146- Small cell lung cancer	0.0	KU-812- Myelogenous leukemia	0.0
NCI-H526- Small cell lung cancer	0.0	769-P- Clear cell renal carcinoma	0.0
NCI-N417- Small cell lung cancer	0.0	Caki-2- Clear cell renal carcinoma	0.0
NCI-H82- Small cell lung cancer	0.6	SW 839- Clear cell renal carcinoma	1.1
NCI-H157- Squamous cell lung cancer (metastasis)	0.0	G401- Wilms' tumor	17.3
NCI-H1155- Large cell lung cancer	0.0	Hs766T- Pancreatic carcinoma (LN metastasis)	0.6
NCI-H1299- Large cell lung cancer	24.0	CAPAN-1- Pancreatic adenocarcinoma (liver metastasis)	0.0
NCI-H727- Lung carcinoid	0.0	SU86.86- Pancreatic carcinoma (liver metastasis)	3.5
NCI-UMC-11- Lung carcinoid	1.7	BxPC-3- Pancreatic adenocarcinoma	1.2
LX-1- Small cell lung cancer	0.0	HPAC- Pancreatic adenocarcinoma	0.5
Colo-205- Colon cancer	0.0	MIA PaCa-2- Pancreatic carcinoma	0.0
KM12- Colon cancer	0.0	CFPAC-1- Pancreatic ductal adenocarcinoma	0.8
KM20L2- Colon cancer	0.0	PANC-1- Pancreatic epithelioid ductal carcinoma	0.0

NCI-H716- Colon cancer	0.0	T24- Bladder carcinma (transitional cell)	1.0
SW-48- Colon adenocarcinoma	0.0	5637- Bladder carcinoma	0.7
SW1116- Colon adenocarcinoma	0.0	HT-1197- Bladder carcinoma	0.3
LS 174T- Colon adenocarcinoma	0.0	UM-UC-3- Bladder carcinma (transitional cell)	1.0
SW-948- Colon adenocarcinoma	0.0	A204- Rhabdomyosarcoma	0.0
SW-480- Colon adenocarcinoma	0.0	HT-1080- Fibrosarcoma	18.9
NCI-SNU-5- Gastric carcinoma	0.0	MG-63- Osteosarcoma	7.4
KATO III- Gastric carcinoma	0.0	SK-LMS-1- Leiomyosarcoma (vulva)	21.6
NCI-SNU-16- Gastric carcinoma	16.0	SJRH30- Rhabdomyosarcoma (met to bone marrow)	0.0
NCI-SNU-1- Gastric carcinoma	0.0	A431- Epidermoid carcinoma	0.0
RF-1- Gastric adenocarcinoma	0.0	WM266-4- Melanoma	4.0
RF-48- Gastric adenocarcinoma	0.0	DU 145- Prostate carcinoma (brain metastasis)	0.0
MKN-45- Gastric carcinoma	0.0	MDA-MB-468- Breast adenocarcinoma	0.0
NCI-N87- Gastric carcinoma	0.0	SCC-4- Squamous cell carcinoma of tongue	1.0
OVCAR-5- Ovarian carcinoma	0.0	SCC-9- Squamous cell carcinoma of tongue	0.4
RL95-2- Uterine carcinoma	0.0	SCC-15- Squamous cell carcinoma of tongue	0.0
HelaS3- Cervical adenocarcinoma	0.0	CAL 27- Squamous cell carcinoma of tongue	0.0

Table BE. Panel 4D

Tissue Name	Rel. Exp.(%) Ag2944, Run 159843300	Tissue Name	Rel. Exp.(%) Ag2944, Run 159843300
Secondary Th1 act	0.0	HUVEC IL-1beta	32.5
Secondary Th2 act	0.0	HUVEC IFN gamma	9.8

Secondary Tr1 act	0.0	HUVEC TNF alpha + IFN gamma	28.3
Secondary Th1 rest	0.0	HUVEC TNF alpha + IL4	43.2
Secondary Th2 rest	0.0	HUVEC IL-11	9.0
Secondary Tr1 rest	0.0	Lung Microvascular EC none	11.9
Primary Th1 act	0.0	Lung Microvascular EC TNFalpha + IL-1beta	23.7
Primary Th2 act	0.0	Microvascular Dermal EC none	16.5
Primary Tr1 act	0.0	Microvascular Dermal EC TNFalpha + IL-1beta	22.4
Primary Th1 rest	0.0	Bronchial epithelium TNFalpha + IL1beta	0.3
Primary Th2 rest	0.0	Small airway epithelium none	1.2
Primary Tr1 rest	0.0	Small airway epithelium TNFalpha + IL-1beta	2.8
CD45RA CD4 lymphocyte act	0.0	Coronary artery SMC rest	27.4
CD45RO CD4 lymphocyte act	0.0	Coronary artery SMC TNFalpha + IL-1beta	0.0
CD8 lymphocyte act	0.4	Astrocytes rest	8.2
Secondary CD8 lymphocyte rest	0.0	Astrocytes TNFalpha + IL-1beta	8.7
Secondary CD8 lymphocyte act	0.0	KU-812 (Basophil) rest	0.0
CD4 lymphocyte none	0.0	KU-812 (Basophil) PMA/ionomycin	0.3
2ry Th1/Th2/Tr1_anti-CD95 CH11	0.0	CCD1106 (Keratinocytes) none	1.8
LAK cells rest	0.0	CCD1106 (Keratinocytes) TNFalpha + IL-1beta	0.0
LAK cells IL-2	0.0	Liver cirrhosis	0.9
LAK cells IL-2+IL-12	0.0	Lupus kidney	0.0
LAK cells IL-2+IFN gamma	0.0	NCI-H292 none	0.3
LAK cells IL-2+ IL-18	0.0	NCI-H292 IL-4	0.7
LAK cells PMA/ionomycin	0.0	NCI-H292 IL-9	0.3
NK Cells IL-2 rest	0.0	NCI-H292 IL-13	0.0

Two Way MLR 3 day	0.3	NCI-H292 IFN gamma	0.0
Two Way MLR 5 day	0.0	HPAEC none	16.7
Two Way MLR 7 day	0.0	HPAEC TNF alpha + IL-1 beta	45.1
PBMC rest	0.0	Lung fibroblast none	2.5
PBMC PWM	0.0	Lung fibroblast TNF alpha + IL-1 beta	0.9
PBMC PHA-L	0.0	Lung fibroblast IL-4	1.5
Ramos (B cell) none	0.0	Lung fibroblast IL-9	4.2
Ramos (B cell) ionomycin	0.0	Lung fibroblast IL-13	0.0
B lymphocytes PWM	0.0	Lung fibroblast IFN gamma	1.1
B lymphocytes CD40L and IL-4	0.7	Dermal fibroblast CCD1070 rest	22.8
EOL-1 dbcAMP	0.7	Dermal fibroblast CCD1070 TNF alpha	36.6
EOL-1 dbcAMP PMA/ionomycin	0.0	Dermal fibroblast CCD1070 IL-1 beta	14.0
Dendritic cells none	0.3	Dermal fibroblast IFN gamma	2.4
Dendritic cells LPS	0.0	Dermal fibroblast IL-4	3.0
Dendritic cells anti-CD40	0.6	IBD Colitis 2	0.6
Monocytes rest	0.0	IBD Crohn's	0.0
Monocytes LPS	0.3	Colon	0.0
Macrophages rest	0.5	Lung	1.7
Macrophages LPS	0.8	Thymus	0.3
HUVEC none	67.4	Kidney	0.6
HUVEC starved	100.0		

Panel 1.3D Summary: Ag2944 Two experiments with the same probe and primer set produce results that are in excellent agreement, with significant expression of the CG56275-01 gene restricted to cancer cell lines. Highest expression of this gene is seen in a cluster of brain cancer lines (CTs=32-34). Moderate levels of expression are also detected in a melanoma cell line.

- 5 Thus, expression of this gene could be used to differentiate these samples from other samples on this panel and as a marker to detect the presence of these cancers. The protein encoded by this gene is homologous to guanylate kinase, an important enzyme in nucleotide metabolic pathways.

This molecule is a known target for several chemotherapeutic agents. Therefore, therapeutic modulation of the expression or function of this novel gene could be effective in the treatment of brain cancer and melanoma.

References:

- 5 Stolworthy TS, Black ME. The mouse guanylate kinase double mutant E72Q/D103N is a functional adenylate kinase. *Protein Eng* 2001 Nov;14(11):903-909.

Guanylate kinase catalyzes the phosphorylation of either GMP to GDP or dGMP to dGDP and is an important enzyme in nucleotide metabolic pathways. Because of its essential intracellular role, guanylate kinase is a target for a number of cancer chemotherapeutic agents such as 6-thioguanine and 8-azaguanine and is involved in antiviral drug activation. Guanylate kinase shares a similarity in function and structure to other nucleoside monophosphate kinases especially with that of the well-studied adenylate kinase. Amino acid substitutions were made within the GMP binding site of mouse guanylate kinase to alter the polarity of the side chains that interact with GMP as a means of evaluating the role that these residues play on substrate interaction. One of these mutants, E72Q/D103N, was shown by functional complementation and enzyme assays to embody both guanylate kinase activity and a novel adenylate kinase activity.

PMID: 11742110

- 20 Hoover KB, Liao SY, Bryant PJ. Loss of the tight junction MAGUK ZO-1 in breast cancer: relationship to glandular differentiation and loss of heterozygosity. *Am J Pathol* 1998 Dec;153(6):1767-73

Membrane-associated guanylate kinase homologs (MAGUKs) may play a role in cellular functions preventing tumorigenesis as indicated by the neoplastic phenotype caused by genetic loss of the MAGUK Dlg in *Drosophila*. To test this possibility, we examined the expression and subcellular localization of the tight junction MAGUK ZO-1, as well as the cell adhesion molecule E-cadherin, in paraffin-embedded breast cancer samples, using immunohistochemistry and confocal microscopy. As expected, normal tissue showed intense staining for ZO-1 at the position of the epithelial tight junctions, but this staining was reduced or lost in 69% of breast cancers analyzed (n = 48). In infiltrating ductal carcinomas (n = 38) there was a reduction in

staining in 42% of well differentiated, in 83% of moderately differentiated and 93% of poorly differentiated tumors. ZO-1 staining was positively correlated with tumor differentiation ($P = .011$) and more specifically with the glandular differentiation of tumors ($P = .0019$). Reduction in ZO-1 staining was strongly correlated with reduced E-cadherin staining ($P = 4.9 \times 10^{-5}$). The results suggest that down-regulation of ZO-1 expression and its failure to accumulate at cell junctions may be causally related to cancer progression. To detect loss of heterozygosity, the ZO-1 gene *tjp-1* was mapped relative to other markers in 15q13 and polymorphic markers flanking *tjp-1* were identified. The marker D15S1019 showed loss of heterozygosity in 23% of informative tumors ($n = 13$). Loss of a *tjp-1*-linked marker suggests that genetic loss may, in some cases, be responsible for the reduction in ZO-1 expression in breast cancer.

PMID: 9846967

Panel 2D Summary: Ag2944 Significant expression of the CG56275-01 gene is restricted to a sample derived from an ocular melanoma metastasis to the liver (CT=34). Thus, expression of this gene could be used to differentiate between this sample and other samples on this panel and as a marker to detect this form of cancer.

Panel 3D Summary: Ag2944 Highest expression of the CG56275-01 gene in this panel is seen in an ovarian cancer cell line (CT=30.10). Significant expression is also seen in a gastric cancer cell line and a lung cancer cell line. Thus, expression of this gene could be used to differentiate between these samples and other samples on this panel.

Panel 4D Summary: Ag2944 The CG56275-01 transcript is expressed in fibroblasts and endothelial cells regardless of treatment. This transcript encodes a putative guanylate kinase that may be needed for the normal function of the cells that express this protein. Thus, the transcript or the protein it encodes could be used to identify endothelium or fibroblasts. Furthermore, regulation of the transcript or the protein it encodes could be important in maintaining normal cellular homeostasis and in the treatment of inflammation, asthma, emphysema, arthritis, IBD or psoriasis.

NOV3a: CG53400-01: Hypothetical 85.6 kDa human protein

Expression of gene CG53400-01 was assessed using the primer-probe set Ag2579, described in Table CA. Results of the RTQ-PCR runs are shown in Tables CB, CC, CD and CE.

Table CA. Probe Name Ag2579

Primers	Sequences	Length	Start Position
Forward	5'-gccttatcaatgctaccaacag-3' (SEQ ID NO:347)	22	2830
Probe	TET-5'-ctgcagatgccactccacattgct-3'-TAMRA (SEQ ID NO:348)	24	2856
Reverse	5'-gcctgtaccacagaagctagac-3' (SEQ ID NO:349)	22	2890

5 Table CB. CNS_neurodegeneration_v1.0

Tissue Name	Rel. Exp.(%) Ag2579, Run 208777161	Tissue Name	Rel. Exp.(%) Ag2579, Run 208777161
AD 1 Hippo	17.2	Control (Path) 3 Temporal Ctx	4.4
AD 2 Hippo	28.3	Control (Path) 4 Temporal Ctx	31.2
AD 3 Hippo	10.7	AD 1 Occipital Ctx	13.8
AD 4 Hippo	9.5	AD 2 Occipital Ctx (Missing)	0.0
AD 5 hippo	92.7	AD 3 Occipital Ctx	7.4
AD 6 Hippo	95.3	AD 4 Occipital Ctx	24.8
Control 2 Hippo	28.7	AD 5 Occipital Ctx	8.7
Control 4 Hippo	12.9	AD 6 Occipital Ctx	40.9
Control (Path) 3 Hippo	7.3	Control 1 Occipital Ctx	5.4
AD 1 Temporal Ctx	22.2	Control 2 Occipital Ctx	63.7
AD 2 Temporal Ctx	31.2	Control 3 Occipital Ctx	16.4
AD 3 Temporal Ctx	10.7	Control 4 Occipital Ctx	9.0
AD 4 Temporal Ctx	26.4	Control (Path) 1 Occipital Ctx	100.0
AD 5 Inf Temporal Ctx	91.4	Control (Path) 2 Occipital Ctx	7.1
AD 5 SupTemporal	42.9	Control (Path) 3	4.6

Ctx		Occipital Ctx	
AD 6 Inf Temporal Ctx	69.3	Control (Path) 4 Occipital Ctx	18.4
AD 6 Sup Temporal Ctx	80.7	Control 1 Parietal Ctx	6.4
Control 1 Temporal Ctx	5.1	Control 2 Parietal Ctx	41.2
Control 2 Temporal Ctx	46.3	Control 3 Parietal Ctx	22.1
Control 3 Temporal Ctx	15.5	Control (Path) 1 Parietal Ctx	92.0
Control 4 Temporal Ctx	10.9	Control (Path) 2 Parietal Ctx	20.7
Control (Path) 1 Temporal Ctx	73.7	Control (Path) 3 Parietal Ctx	6.7
Control (Path) 2 Temporal Ctx	40.1	Control (Path) 4 Parietal Ctx	39.2

Table CC. Panel 1.3D

Tissue Name	Rel. Exp.(%) Ag2579, Run 166190504	Tissue Name	Rel. Exp.(%) Ag2579, Run 166190504
Liver adenocarcinoma	64.2	Kidney (fetal)	13.4
Pancreas	7.1	Renal ca. 786-0	39.2
Pancreatic ca. CAPAN 2	20.0	Renal ca. A498	39.8
Adrenal gland	13.9	Renal ca. RXF 393	34.9
Thyroid	3.8	Renal ca. ACHN	27.0
Salivary gland	14.0	Renal ca. UO-31	40.6
Pituitary gland	15.9	Renal ca. TK-10	10.4
Brain (fetal)	28.5	Liver	1.1
Brain (whole)	79.0	Liver (fetal)	8.9
Brain (amygdala)	43.8	Liver ca. (hepatoblast) HepG2	18.7
Brain (cerebellum)	55.1	Lung	2.6
Brain (hippocampus)	34.4	Lung (fetal)	15.4
Brain (substantia nigra)	17.8	Lung ca. (small cell) LX-1	26.6
Brain (thalamus)	78.5	Lung ca. (small cell) NCI-H69	17.2
Cerebral Cortex	58.6	Lung ca. (s.cell var.)	21.8

		SHP-77	
Spinal cord	17.0	Lung ca. (large cell)NCI-H460	11.4
glio/astro U87-MG	51.8	Lung ca. (non-sm. cell) A549	12.2
glio/astro U-118-MG	60.7	Lung ca. (non-s.cell) NCI-H23	24.5
astrocytoma SW1783	36.3	Lung ca. (non-s.cell) HOP-62	17.3
neuro*; met SK-N-AS	30.8	Lung ca. (non-s.cl) NCI-H522	14.2
astrocytoma SF-539	48.0	Lung ca. (squam.) SW 900	22.5
astrocytoma SNB-75	30.6	Lung ca. (squam.) NCI-H596	7.7
glioma SNB-19	35.8	Mammary gland	10.7
glioma U251	22.5	Breast ca.* (pl.ef) MCF-7	35.1
glioma SF-295	17.8	Breast ca.* (pl.ef) MDA-MB-231	35.6
Heart (fetal)	12.7	Breast ca.* (pl.ef) T47D	13.5
Heart	6.3	Breast ca. BT-549	13.5
Skeletal muscle (fetal)	11.2	Breast ca. MDA-N	7.5
Skeletal muscle	22.8	Ovary	12.1
Bone marrow	5.7	Ovarian ca. OVCAR-3	19.2
Thymus	14.1	Ovarian ca. OVCAR-4	31.4
Spleen	11.1	Ovarian ca. OVCAR-5	13.4
Lymph node	10.2	Ovarian ca. OVCAR-8	12.3
Colorectal	14.6	Ovarian ca. IGROV-1	17.7
Stomach	9.5	Ovarian ca.* (ascites) SK-OV-3	100.0
Small intestine	13.8	Uterus	5.2
Colon ca. SW480	27.5	Placenta	29.7
Colon ca.* SW620(SW480 met)	18.9	Prostate	4.5
Colon ca. HT29	1.7	Prostate ca.* (bone	29.9

		met)PC-3	
Colon ca. HCT-116	14.1	Testis	11.8
Colon ca. CaCo-2	13.8	Melanoma Hs688(A).T	9.9
Colon ca. tissue(ODO3866)	16.0	Melanoma* (met) Hs688(B).T	16.6
Colon ca. HCC-2998	15.2	Melanoma UACC-62	49.3
Gastric ca.* (liver met) NCI-N87	14.0	Melanoma M14	11.7
Bladder	14.5	Melanoma LOX IMVI	11.4
Trachea	6.7	Melanoma* (met) SK-MEL-5	17.3
Kidney	8.7	Adipose	3.1

Table CD. Panel 2.2

Tissue Name	Rel. Exp.(%) Ag2579, Run 174923041	Tissue Name	Rel. Exp.(%) Ag2579, Run 174923041
Normal Colon	27.2	Kidney Margin (OD04348)	90.1
Colon cancer (OD06064)	51.1	Kidney malignant cancer (OD06204B)	20.2
Colon Margin (OD06064)	20.7	Kidney normal adjacent tissue (OD06204E)	43.8
Colon cancer (OD06159)	7.9	Kidney Cancer (OD04450-01)	52.5
Colon Margin (OD06159)	22.2	Kidney Margin (OD04450-03)	29.3
Colon cancer (OD06297- 04)	12.3	Kidney Cancer 8120613	2.2
Colon Margin (OD06297-015)	48.0	Kidney Margin 8120614	36.1
CC Gr.2 ascend colon (ODO3921)	13.5	Kidney Cancer 9010320	16.8
CC Margin (ODO3921)	12.4	Kidney Margin 9010321	18.0
Colon cancer metastasis (OD06104)	6.4	Kidney Cancer 8120607	37.4
Lung Margin (OD06104)	12.8	Kidney Margin 8120608	15.7
Colon mets to lung	20.4	Normal Uterus	28.3

(OD04451-01)			
Lung Margin (OD04451-02)	11.9	Uterine Cancer 064011	15.4
Normal Prostate	16.8	Normal Thyroid	7.3
Prostate Cancer (OD04410)	100.0	Thyroid Cancer 064010	17.6
Prostate Margin (OD04410)	11.9	Thyroid Cancer A302152	34.2
Normal Ovary	36.3	Thyroid Margin A302153	8.2
Ovarian cancer (OD06283-03)	35.8	Normal Breast	26.4
Ovarian Margin (OD06283-07)	18.4	Breast Cancer (OD04566)	6.8
Ovarian Cancer 064008	9.9	Breast Cancer 1024	62.4
Ovarian cancer (OD06145)	7.0	Breast Cancer (OD04590-01)	40.9
Ovarian Margin (OD06145)	18.6	Breast Cancer Mets (OD04590-03)	25.3
Ovarian cancer (OD06455-03)	34.4	Breast Cancer Metastasis (OD04655-05)	46.7
Ovarian Margin (OD06455-07)	10.6	Breast Cancer 064006	20.3
Normal Lung	17.4	Breast Cancer 9100266	62.0
Invasive poor diff. lung adeno (ODO4945-01)	13.8	Breast Margin 9100265	21.9
Lung Margin (ODO4945-03)	14.8	Breast Cancer A209073	15.9
Lung Malignant Cancer (OD03126)	15.5	Breast Margin A2090734	27.7
Lung Margin (OD03126)	9.1	Breast cancer (OD06083)	53.6
Lung Cancer (OD05014A)	27.5	Breast cancer node metastasis (OD06083)	33.4
Lung Margin (OD05014B)	26.4	Normal Liver	18.7
Lung cancer (OD06081)	29.3	Liver Cancer 1026	23.8
Lung Margin (OD06081)	4.5	Liver Cancer 1025	18.4
Lung Cancer (OD04237-01)	12.6	Liver Cancer 6004-T	15.6

Lung Margin (OD04237-02)	25.2	Liver Tissue 6004-N	5.4
Ocular Melanoma Metastasis	26.6	Liver Cancer 6005-T	44.8
Ocular Melanoma Margin (Liver)	2.2	Liver Tissue 6005-N	16.8
Melanoma Metastasis	33.2	Liver Cancer 064003	20.4
Melanoma Margin (Lung)	10.8	Normal Bladder	17.8
Normal Kidney	25.5	Bladder Cancer 1023	24.3
Kidney Ca, Nuclear grade 2 (OD04338)	57.4	Bladder Cancer A302173	35.1
Kidney Margin (OD04338)	25.9	Normal Stomach	48.6
Kidney Ca Nuclear grade 1/2 (OD04339)	31.2	Gastric Cancer 9060397	14.7
Kidney Margin (OD04339)	20.2	Stomach Margin 9060396	18.2
Kidney Ca, Clear cell type (OD04340)	9.3	Gastric Cancer 9060395	22.1
Kidney Margin (OD04340)	21.8	Stomach Margin 9060394	35.6
Kidney Ca, Nuclear grade 3 (OD04348)	15.6	Gastric Cancer 064005	20.6

Table CE. Panel 4D

Tissue Name	Rel. Exp.(%) Ag2579, Run 164331536	Tissue Name	Rel. Exp.(%) Ag2579, Run 164331536
Secondary Th1 act	28.9	HUVEC IL-1beta	14.9
Secondary Th2 act	42.9	HUVEC IFN gamma	23.2
Secondary Tr1 act	29.9	HUVEC TNF alpha + IFN gamma	22.4
Secondary Th1 rest	4.2	HUVEC TNF alpha + IL4	22.7
Secondary Th2 rest	10.5	HUVEC IL-11	11.1
Secondary Tr1 rest	8.2	Lung Microvascular EC none	24.0
Primary Th1 act	39.0	Lung Microvascular EC TNFalpha + IL-1beta	24.8
Primary Th2 act	23.3	Microvascular Dermal EC	23.7

		none	
Primary Tr1 act	33.4	Microsvascular Dermal EC TNFalpha + IL-1beta	19.6
Primary Th1 rest	41.8	Bronchial epithelium TNFalpha + IL1beta	16.6
Primary Th2 rest	23.5	Small airway epithelium none	7.5
Primary Tr1 rest	19.2	Small airway epithelium TNFalpha + IL-1beta	49.0
CD45RA CD4 lymphocyte act	19.9	Coronary artery SMC rest	24.1
CD45RO CD4 lymphocyte act	31.2	Coronary artery SMC TNFalpha + IL-1beta	9.9
CD8 lymphocyte act	14.3	Astrocytes rest	42.6
Secondary CD8 lymphocyte rest	22.1	Astrocytes TNFalpha + IL- 1beta	28.9
Secondary CD8 lymphocyte act	14.9	KU-812 (Basophil) rest	5.1
CD4 lymphocyte none	3.6	KU-812 (Basophil) PMA/ionomycin	18.8
2ry Th1/Th2/Tr1_anti- CD95 CH11	12.1	CCD1106 (Keratinocytes) none	22.8
LAK cells rest	14.1	CCD1106 (Keratinocytes) TNFalpha + IL-1beta	15.2
LAK cells IL-2	20.3	Liver cirrhosis	1.5
LAK cells IL-2+IL-12	21.2	Lupus kidney	3.9
LAK cells IL-2+IFN gamma	33.7	NCI-H292 none	27.7
LAK cells IL-2+ IL-18	22.2	NCI-H292 IL-4	26.1
LAK cells PMA/ionomycin	3.4	NCI-H292 IL-9	61.1
NK Cells IL-2 rest	13.3	NCI-H292 IL-13	34.6
Two Way MLR 3 day	11.8	NCI-H292 IFN gamma	27.9
Two Way MLR 5 day	16.7	HPAEC none	13.1
Two Way MLR 7 day	13.2	HPAEC TNF alpha + IL-1 beta	17.4
PBMC rest	3.6	Lung fibroblast none	12.9
PBMC PWM	94.6	Lung fibroblast TNF alpha + IL-1 beta	10.6
PBMC PHA-L	28.1	Lung fibroblast IL-4	44.8
Ramos (B cell) none	15.0	Lung fibroblast IL-9	29.5

Ramos (B cell) ionomycin	67.8	Lung fibroblast IL-13	18.7
B lymphocytes PWM	49.3	Lung fibroblast IFN gamma	42.0
B lymphocytes CD40L and IL-4	23.7	Dermal fibroblast CCD1070 rest	89.5
EOL-1 dbcAMP	8.8	Dermal fibroblast CCD1070 TNF alpha	100.0
EOL-1 dbcAMP PMA/ionomycin	7.2	Dermal fibroblast CCD1070 IL-1 beta	33.0
Dendritic cells none	12.0	Dermal fibroblast IFN gamma	13.1
Dendritic cells LPS	13.2	Dermal fibroblast IL-4	29.7
Dendritic cells anti- CD40	15.4	IBD Colitis 2	0.7
Monocytes rest	5.5	IBD Crohn's	0.6
Monocytes LPS	11.1	Colon	13.5
Macrophages rest	19.9	Lung	9.7
Macrophages LPS	9.0	Thymus	21.8
HUVEC none	24.3	Kidney	21.0
HUVEC starved	50.0		

CNS_neurodegeneration_v1.0 Summary: Ag2579 Expression of the CG53400-01 gene does not appear to show an association with Alzheimer's disease in this panel. However, this panel confirms the expression of this gene in the brain. Please see Panel 1.3D for discussion of utility of this gene in the central nervous system.

- 5 **Panel 1.3D Summary:** Ag2579 Expression of the CG53400-01 gene is ubiquitous in this panel, with highest expression in the ascites derived ovarian cancer cell line SK-OV-3 (CT=28.5). There is also significant expression of this gene in a cluster of cell lines derived from renal cancer and melanoma. The widespread expression of this gene suggests that the gene product may be involved in cell differentiation and growth. Thus, expression of this gene could be used
- 10 to differentiate between the samples mentioned above and other samples on this panel. Expression of this gene could also potentially be used as a marker for ascites derived ovarian cancer, ascites derived tissue samples, melanoma and renal cancer. Furthermore, therapeutic modulation of the expression or function of this gene may be effective in the treatment of these cancers.

This gene is also widely expressed among tissues with metabolic function, including adipose, adult and fetal skeletal muscle and heart, the pancreas, fetal liver, and the adrenal, thyroid, and pituitary glands. This expression profile suggests that this gene product may also be involved in metabolic function and that therapeutic modulation of the expression or function of this gene may be effective in the treatment of metabolic disorders, such as obesity and diabetes.

In addition, this gene appears to be expressed at much higher levels in fetal liver (CT=32) than in adult liver (CT=35). Thus, expression of this gene could be used to differentiate between adult and fetal sources of liver tissue.

The expression profile of this gene also shows widespread expression of this gene in the brain. This suggests that the protein encoded by this gene may be important for normal neurological function. Therefore, modulation of the function or expression of this gene may be effective in the treatment of neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease.

Panel 2.2 Summary: Ag2579 Expression of the CG53400-01 gene is widespread in this panel, with highest expression in prostate cancer (CT=30.6). Furthermore, expression in prostate cancer is significantly higher than expression in the corresponding normal adjacent tissue. Conversely, expression of this gene is higher in normal kidney than in adjacent kidney tumor. Thus, expression of this gene could be used as a marker for kidney or prostate cancer. In addition, therapeutic modulation of the expression or function of this gene could be used in the treatment of kidney or prostate cancer.

Panel 4D Summary: Ag2579 The CG53400-01 gene is ubiquitously expressed in this panel, with highest in dermal fibroblasts treated with TNF-alpha (CT=26.3). Significant expression is also seen in untreated dermal fibroblasts and PBMC treated with the B cell mitogen, PWM. The expression of this gene in activated dermal fibroblast combined with moderate expression in the mucoepidermoid cell line H292, often used as a model for airway epithelium, suggest that therapeutic modulation of this gene might also be useful in the treatment of asthma and emphysema. In addition, the high levels of expression of this gene in activated B cells are significant because B cells represent a principle component of immunity and contribute to the

immune response in a number of important functional roles, including antibody production. Furthermore, production of antibodies against self-antigens is a major component in autoimmune disorders

Since B cells play an important role in autoimmunity, inflammatory processes and inflammatory cascades, therapeutic modulation of this gene product may therefore, reduce or eliminate the symptoms of patients suffering from asthma, allergies, chronic obstructive pulmonary disease, emphysema, Crohn's disease, ulcerative colitis, rheumatoid arthritis, psoriasis, osteoarthritis, and other autoimmune disorders including systemic lupus erythematosus.

NOV4a: CG56209-01: MYTONIC DYSTROPHY KINASE-RELATED CDC42-BINDING KINASE

Expression of gene CG56209-01 was assessed using the primer-probe set Ag4976, described in Table DA.

Table DA. Probe Name Ag4976

Primers	Sequences	Length	Start Position
Forward	5'-agcttagcctcagcgagttc-3' (SEQ ID NO:350)	20	3039
Probe	TET-5'-ctgctactcttcaccactgctggcat-3'-TAMRA (SEQ ID NO:351)	26	3059
Reverse	5'-gttctcgctgaacagagacttg-3' (SEQ ID NO:352)	22	3106

CNS_neurodegeneration_v1.0 Summary: Ag4976 Expression of the CG56209-01 gene is low/undetectable in all samples on this panel. (CTs>35). (Data not shown.) The amp plot indicates that there is a high probability of a probe failure in this experiment.

General_screening_panel_v1.5 Summary: Ag4976 Expression of the CG56209-01 gene is low/undetectable in all samples on this panel. (CTs>35). (Data not shown.) The amp plot indicates that there is a high probability of a probe failure in this experiment.

Panel 4.1D Summary: Ag4976 Expression of the CG56209-01 gene is low/undetectable in all samples on this panel. (CTs>35). (Data not shown.) The amp plot indicates that there is a high probability of a probe failure in this experiment.

NOV7a and NOV7b: CG50365-01 and CG50365-02: Carbonate Dehydratase

Expression of gene CG50365-01 and variant CG50365-02 was assessed using the primer-probe sets Ag2644 and Ag2575, described in Tables EA and EB. Results of the RTQ-PCR runs are shown in Tables EC, ED, EE, EF, and EG.

5 Table EA. Probe Name Ag2644

Primers	Sequences	Length	Start Position
Forward	5'-tcagcaatctccaattgagatt-3' (SEQ ID NO:353)	22	96
Probe	TET-5'-tgaaatatgactcttcctccgacca-3'-TAMRA (SEQ ID NO:354)	26	131
Reverse	5'-ttttagctgagcttgggtcata-3' (SEQ ID NO:355)	22	169

Table EB. Probe Name Ag2575

Primers	Sequences	Length	Start Position
Forward	5'-tcagcaatctccaattgagatt-3' (SEQ ID NO:356)	22	96
Probe	TET-5'-tgaaatatgactcttcctccgacca-3'-TAMRA (SEQ ID NO:357)	26	131
Reverse	5'-ttttagctgagcttgggtcata-3' (SEQ ID NO:358)	22	169

Table EC. CNS_neurodegeneration_v1.0

Tissue Name	Rel. Exp.(%) Ag2644, Run 208393899	Tissue Name	Rel. Exp.(%) Ag2644, Run 208393899
AD 1 Hippo	10.9	Control (Path) 3 Temporal Ctx	4.3
AD 2 Hippo	22.4	Control (Path) 4 Temporal Ctx	30.1
AD 3 Hippo	6.7	AD 1 Occipital Ctx	12.3
AD 4 Hippo	3.9	AD 2 Occipital Ctx (Missing)	60.7
AD 5 hippo	84.1	AD 3 Occipital Ctx	11.3
AD 6 Hippo	51.8	AD 4 Occipital Ctx	11.0
Control 2 Hippo	22.7	AD 5 Occipital Ctx	69.3
Control 4 Hippo	10.7	AD 6 Occipital Ctx	70.7
Control (Path) 3 Hippo	5.7	Control 1 Occipital Ctx	4.6

AD 1 Temporal Ctx	25.5	Control 2 Occipital Ctx	44.8
AD 2 Temporal Ctx	28.9	Control 3 Occipital Ctx	16.0
AD 3 Temporal Ctx	6.4	Control 4 Occipital Ctx	7.1
AD 4 Temporal Ctx	14.3	Control (Path) 1 Occipital Ctx	79.6
AD 5 Inf Temporal Ctx	100.0	Control (Path) 2 Occipital Ctx	14.5
AD 5 Sup Temporal Ctx	72.7	Control (Path) 3 Occipital Ctx	0.0
AD 6 Inf Temporal Ctx	46.3	Control (Path) 4 Occipital Ctx	20.6
AD 6 Sup Temporal Ctx	66.9	Control 1 Parietal Ctx	4.9
Control 1 Temporal Ctx	10.8	Control 2 Parietal Ctx	69.7
Control 2 Temporal Ctx	50.0	Control 3 Parietal Ctx	17.3
Control 3 Temporal Ctx	15.9	Control (Path) 1 Parietal Ctx	62.4
Control 4 Temporal Ctx	8.8	Control (Path) 2 Parietal Ctx	31.0
Control (Path) 1 Temporal Ctx	63.3	Control (Path) 3 Parietal Ctx	0.0
Control (Path) 2 Temporal Ctx	20.4	Control (Path) 4 Parietal Ctx	54.3

Table ED. Panel 1.3D

Tissue Name	Rel. Exp.(%) Ag2575, Run 162430827	Rel. Exp.(%) Ag2575, Run 162431039	Tissue Name	Rel. Exp.(%) Ag2575, Run 162430827	Rel. Exp.(%) Ag2575, Run 162431039
Liver adenocarcinoma	0.4	0.4	Kidney (fetal)	6.0	6.0
Pancreas	0.4	0.4	Renal ca. 786-0	13.5	13.5
Pancreatic ca. CAPAN 2	4.0	4.0	Renal ca. A498	11.2	11.2
Adrenal gland	1.5	1.5	Renal ca. RXF 393	1.0	1.0

Thyroid	5.4	5.4	Renal ca. ACHN	2.9	2.9
Salivary gland	0.9	0.9	Renal ca. UO-31	5.8	5.8
Pituitary gland	4.8	4.8	Renal ca. TK-10	6.9	6.9
Brain (fetal)	1.2	1.2	Liver	0.9	0.9
Brain (whole)	1.2	1.2	Liver (fetal)	3.7	3.7
Brain (amygdala)	3.1	3.1	Liver ca. (hepatoblast) HepG2	10.0	10.0
Brain (cerebellum)	5.6	5.6	Lung	6.3	6.3
Brain (hippocampus)	5.4	5.4	Lung (fetal)	6.7	6.7
Brain (substantia nigra)	0.3	0.3	Lung ca. (small cell) LX-1	0.0	0.0
Brain (thalamus)	1.7	1.7	Lung ca. (small cell) NCI-H69	6.7	6.7
Cerebral Cortex	21.2	21.2	Lung ca. (s.cell var.) SHP-77	21.2	21.2
Spinal cord	2.8	2.8	Lung ca. (large cell) NCI-H460	4.4	4.4
glio/astro U87-MG	25.9	25.9	Lung ca. (non-sm. cell) A549	2.7	2.7
glio/astro U-118-MG	9.5	9.5	Lung ca. (non-s.cell) NCI-H23	3.0	3.0
astrocytoma SW1783	17.4	17.4	Lung ca. (non-s.cell) HOP-62	4.8	4.8
neuro*; met SK-N-AS	0.0	0.0	Lung ca. (non-s.cl) NCI-H522	0.4	0.4
astrocytoma SF-539	12.9	12.9	Lung ca. (squam.) SW 900	3.4	3.4
astrocytoma SNB-75	2.8	2.8	Lung ca. (squam.) NCI-H596	2.7	2.7
glioma SNB-19	27.0	27.0	Mammary gland	4.0	4.0
glioma U251	4.6	4.6	Breast ca.*	0.0	0.0

			(pl.ef) MCF-7		
glioma SF-295	5.2	5.2	Breast ca.* (pl.ef) MDA-MB-231	7.5	7.5
Heart (fetal)	2.1	2.1	Breast ca.* (pl.ef) T47D	0.7	0.7
Heart	3.1	3.1	Breast ca. BT-549	0.5	0.5
Skeletal muscle (fetal)	3.6	3.6	Breast ca. MDA-N	8.2	8.2
Skeletal muscle	0.0	0.0	Ovary	2.7	2.7
Bone marrow	0.8	0.8	Ovarian ca. OVCAR-3	5.9	5.9
Thymus	6.8	6.8	Ovarian ca. OVCAR-4	0.5	0.5
Spleen	1.6	1.6	Ovarian ca. OVCAR-5	35.1	35.1
Lymph node	1.4	1.4	Ovarian ca. OVCAR-8	12.8	12.8
Colorectal	5.7	5.7	Ovarian ca. IGROV-1	0.0	0.0
Stomach	2.6	2.6	Ovarian ca.* (ascites) SK-OV-3	2.0	2.0
Small intestine	8.8	8.8	Uterus	1.4	1.4
Colon ca. SW480	0.0	0.0	Placenta	0.0	0.0
Colon ca.* SW620(SW480 met)	0.0	0.0	Prostate	0.8	0.8
Colon ca. HT29	8.4	8.4	Prostate ca.* (bone met)PC-3	7.0	7.0
Colon ca. HCT-116	5.7	5.7	Testis	2.2	2.2
Colon ca. CaCo-2	84.1	84.1	Melanoma Hs688(A).T	2.3	2.3
Colon ca. tissue(ODO3866)	40.3	40.3	Melanoma* (met) Hs688(B).T	2.8	2.8
Colon ca. HCC-2998	14.7	14.7	Melanoma UACC-62	1.5	1.5
Gastric ca.* (liver	100.0	100.0	Melanoma	4.3	4.3

met) NCI-N87			M14		
Bladder	11.2	11.2	Melanoma LOX IMVI	7.6	7.6
Trachea	9.9	9.9	Melanoma* (met) SK- MEL-5	13.0	13.0
Kidney	8.9	8.9	Adipose	11.0	11.0

Table EE. Panel 2D

Tissue Name	Rel. Exp.(%) Ag2644, Run 162423326	Tissue Name	Rel. Exp.(%) Ag2644, Run 162423326
Normal Colon	36.1	Kidney Margin 8120608	2.9
CC Well to Mod Diff (ODO3866)	27.9	Kidney Cancer 8120613	4.0
CC Margin (ODO3866)	11.1	Kidney Margin 8120614	3.7
CC Gr.2 rectosigmoid (ODO3868)	19.1	Kidney Cancer 9010320	10.2
CC Margin (ODO3868)	2.2	Kidney Margin 9010321	8.0
CC Mod Diff (ODO3920)	21.0	Normal Uterus	0.0
CC Margin (ODO3920)	18.3	Uterus Cancer 064011	12.2
CC Gr.2 ascend colon (ODO3921)	37.9	Normal Thyroid	12.8
CC Margin (ODO3921)	7.8	Thyroid Cancer 064010	53.2
CC from Partial Hepatectomy (ODO4309) Mets	74.7	Thyroid Cancer A302152	33.7
Liver Margin (ODO4309)	15.7	Thyroid Margin A302153	13.6
Colon mets to lung (OD04451-01)	5.0	Normal Breast	27.7
Lung Margin (OD04451- 02)	8.2	Breast Cancer (OD04566)	1.7
Normal Prostate 6546-1	21.5	Breast Cancer (OD04590-01)	2.7
Prostate Cancer (OD04410)	10.7	Breast Cancer Mets (OD04590-03)	2.8

Prostate Margin (OD04410)	4.0	Breast Cancer Metastasis (OD04655-05)	35.1
Prostate Cancer (OD04720-01)	8.7	Breast Cancer 064006	13.2
Prostate Margin (OD04720-02)	12.1	Breast Cancer 1024	7.0
Normal Lung 061010	24.8	Breast Cancer 9100266	2.9
Lung Met to Muscle (ODO4286)	15.4	Breast Margin 9100265	4.8
Muscle Margin (ODO4286)	1.5	Breast Cancer A209073	18.6
Lung Malignant Cancer (OD03126)	7.9	Breast Margin A2090734	14.4
Lung Margin (OD03126)	22.4	Normal Liver	6.2
Lung Cancer (OD04404)	3.8	Liver Cancer 064003	1.8
Lung Margin (OD04404)	10.6	Liver Cancer 1025	3.4
Lung Cancer (OD04565)	2.2	Liver Cancer 1026	3.6
Lung Margin (OD04565)	5.5	Liver Cancer 6004-T	4.8
Lung Cancer (OD04237-01)	14.7	Liver Tissue 6004-N	1.8
Lung Margin (OD04237-02)	18.0	Liver Cancer 6005-T	3.3
Ocular Mel Met to Liver (ODO4310)	1.0	Liver Tissue 6005-N	2.1
Liver Margin (ODO4310)	5.4	Normal Bladder	10.7
Melanoma Mets to Lung (OD04321)	4.3	Bladder Cancer 1023	1.3
Lung Margin (OD04321)	18.7	Bladder Cancer A302173	4.6
Normal Kidney	35.4	Bladder Cancer (OD04718-01)	7.2
Kidney Ca, Nuclear grade 2 (OD04338)	26.6	Bladder Normal Adjacent (OD04718-03)	10.2
Kidney Margin (OD04338)	14.6	Normal Ovary	2.0
Kidney Ca Nuclear grade 1/2 (OD04339)	23.7	Ovarian Cancer 064008	23.3
Kidney Margin	30.4	Ovarian Cancer	48.3

(OD04339)		(OD04768-07)	
Kidney Ca, Clear cell type (OD04340)	19.3	Ovary Margin (OD04768-08)	2.7
Kidney Margin (OD04340)	22.7	Normal Stomach	21.0
Kidney Ca, Nuclear grade 3 (OD04348)	1.4	Gastric Cancer 9060358	3.8
Kidney Margin (OD04348)	20.3	Stomach Margin 9060359	15.8
Kidney Cancer (OD04622-01)	13.9	Gastric Cancer 9060395	17.0
Kidney Margin (OD04622-03)	2.7	Stomach Margin 9060394	15.8
Kidney Cancer (OD04450-01)	16.6	Gastric Cancer 9060397	49.0
Kidney Margin (OD04450-03)	17.8	Stomach Margin 9060396	12.2
Kidney Cancer 8120607	2.9	Gastric Cancer 064005	100.0

Table EF. Panel 3D

Tissue Name	Rel. Exp.(%) Ag2644, Run 164886194	Tissue Name	Rel. Exp.(%) Ag2644, Run 164886194
Daoy- Medulloblastoma	5.5	Ca Ski- Cervical epidermoid carcinoma (metastasis)	16.5
TE671- Medulloblastoma	0.0	ES-2- Ovarian clear cell carcinoma	24.7
D283 Med- Medulloblastoma	15.3	Ramos- Stimulated with PMA/ionomycin 6h	0.0
PFSK-1- Primitive Neuroectodermal	1.6	Ramos- Stimulated with PMA/ionomycin 14h	2.2
XF-498- CNS	4.9	MEG-01- Chronic myelogenous leukemia (megokaryoblast)	30.8
SNB-78- Glioma	8.8	Raji- Burkitt's lymphoma	3.4
SF-268- Glioblastoma	1.7	Daudi- Burkitt's lymphoma	3.6
T98G- Glioblastoma	0.0	U266- B-cell plasmacytoma	5.9
SK-N-SH- Neuroblastoma (metastasis)	0.0	CA46- Burkitt's lymphoma	3.2
SF-295- Glioblastoma	10.3	RL- non-Hodgkin's B-cell	0.0

		lymphoma	
Cerebellum	8.1	JM1- pre-B-cell lymphoma	0.0
Cerebellum	2.0	Jurkat- T cell leukemia	3.3
NCI-H292- Mucoepidermoid lung carcinoma	22.2	TF-1- Erythroleukemia	28.3
DMS-114- Small cell lung cancer	1.1	HUT 78- T-cell lymphoma	1.8
DMS-79- Small cell lung cancer	100.0	U937- Histiocytic lymphoma	4.4
NCI-H146- Small cell lung cancer	4.9	KU-812- Myelogenous leukemia	2.2
NCI-H526- Small cell lung cancer	6.9	769-P- Clear cell renal carcinoma	3.8
NCI-N417- Small cell lung cancer	6.2	Caki-2- Clear cell renal carcinoma	1.8
NCI-H82- Small cell lung cancer	0.0	SW 839- Clear cell renal carcinoma	4.1
NCI-H157- Squamous cell lung cancer (metastasis)	30.6	G401- Wilms' tumor	0.0
NCI-H1155- Large cell lung cancer	14.9	Hs766T- Pancreatic carcinoma (LN metastasis)	26.2
NCI-H1299- Large cell lung cancer	33.9	CAPAN-1- Pancreatic adenocarcinoma (liver metastasis)	14.4
NCI-H727- Lung carcinoid	1.2	SU86.86- Pancreatic carcinoma (liver metastasis)	39.8
NCI-UMC-11- Lung carcinoid	4.1	BxPC-3- Pancreatic adenocarcinoma	3.3
LX-1- Small cell lung cancer	0.0	HPAC- Pancreatic adenocarcinoma	1.4
Colo-205- Colon cancer	1.4	MIA PaCa-2- Pancreatic carcinoma	2.1
KM12- Colon cancer	31.9	CFPAC-1- Pancreatic ductal adenocarcinoma	32.8
KM20L2- Colon cancer	15.1	PANC-1- Pancreatic epithelioid ductal carcinoma	22.4
NCI-H716- Colon cancer	17.1	T24- Bladder carcinma (transitional cell)	2.8
SW-48- Colon adenocarcinoma	28.5	5637- Bladder carcinoma	11.4

SW1116- Colon adenocarcinoma	13.5	HT-1197- Bladder carcinoma	0.0
LS 174T- Colon adenocarcinoma	56.3	UM-UC-3- Bladder carcinoma (transitional cell)	1.9
SW-948- Colon adenocarcinoma	2.9	A204- Rhabdomyosarcoma	0.0
SW-480- Colon adenocarcinoma	10.9	HT-1080- Fibrosarcoma	4.5
NCI-SNU-5- Gastric carcinoma	0.0	MG-63- Osteosarcoma	2.2
KATO III- Gastric carcinoma	59.0	SK-LMS-1- Leiomyosarcoma (vulva)	13.3
NCI-SNU-16- Gastric carcinoma	29.5	SJRH30- Rhabdomyosarcoma (met to bone marrow)	5.6
NCI-SNU-1- Gastric carcinoma	15.8	A431- Epidermoid carcinoma	0.0
RF-1- Gastric adenocarcinoma	4.8	WM266-4- Melanoma	7.4
RF-48- Gastric adenocarcinoma	6.8	DU 145- Prostate carcinoma (brain metastasis)	0.0
MKN-45- Gastric carcinoma	1.8	MDA-MB-468- Breast adenocarcinoma	0.0
NCI-N87- Gastric carcinoma	24.7	SCC-4- Squamous cell carcinoma of tongue	0.0
OVCAR-5- Ovarian carcinoma	19.9	SCC-9- Squamous cell carcinoma of tongue	0.0
RL95-2- Uterine carcinoma	0.0	SCC-15- Squamous cell carcinoma of tongue	0.0
HelaS3- Cervical adenocarcinoma	0.0	CAL 27- Squamous cell carcinoma of tongue	4.0

Table EG. Panel 4D

Tissue Name	Rel. Exp.(%) Ag2644, Run 158664089	Tissue Name	Rel. Exp.(%) Ag2644, Run 158664089
Secondary Th1 act	0.5	HUVEC IL-1beta	3.3
Secondary Th2 act	0.4	HUVEC IFN gamma	14.4
Secondary Tr1 act	0.4	HUVEC TNF alpha + IFN gamma	27.7
Secondary Th1 rest	0.9	HUVEC TNF alpha + IL4	12.2
Secondary Th2 rest	0.7	HUVEC IL-11	1.0

Secondary Tr1 rest	0.9	Lung Microvascular EC none	1.1
Primary Th1 act	0.6	Lung Microvascular EC TNFalpha + IL-1beta	6.2
Primary Th2 act	1.6	Microvascular Dermal EC none	1.9
Primary Tr1 act	1.4	Microvascular Dermal EC TNFalpha + IL-1beta	2.0
Primary Th1 rest	4.6	Bronchial epithelium TNFalpha + IL1beta	3.3
Primary Th2 rest	1.0	Small airway epithelium none	2.4
Primary Tr1 rest	1.8	Small airway epithelium TNFalpha + IL-1beta	33.9
CD45RA CD4 lymphocyte act	1.9	Coronary artery SMC rest	6.1
CD45RO CD4 lymphocyte act	2.4	Coronary artery SMC TNFalpha + IL-1beta	2.4
CD8 lymphocyte act	1.0	Astrocytes rest	3.9
Secondary CD8 lymphocyte rest	1.4	Astrocytes TNFalpha + IL-1beta	2.1
Secondary CD8 lymphocyte act	0.8	KU-812 (Basophil) rest	1.3
CD4 lymphocyte none	0.8	KU-812 (Basophil) PMA/ionomycin	17.8
2ry Th1/Th2/Tr1_anti-CD95 CH11	0.6	CCD1106 (Keratinocytes) none	9.2
LAK cells rest	2.0	CCD1106 (Keratinocytes) TNFalpha + IL-1beta	6.0
LAK cells IL-2	5.4	Liver cirrhosis	2.1
LAK cells IL-2+IL-12	0.8	Lupus kidney	4.2
LAK cells IL-2+IFN gamma	3.5	NCI-H292 none	35.8
LAK cells IL-2+ IL-18	6.6	NCI-H292 IL-4	52.9
LAK cells PMA/ionomycin	7.4	NCI-H292 IL-9	45.1
NK Cells IL-2 rest	4.4	NCI-H292 IL-13	25.7
Two Way MLR 3 day	3.4	NCI-H292 IFN gamma	42.9
Two Way MLR 5 day	1.4	HPAEC none	5.2
Two Way MLR 7 day	0.8	HPAEC TNF alpha + IL-1 beta	16.3

PBMC rest	2.6	Lung fibroblast none	6.3
PBMC PWM	14.5	Lung fibroblast TNF alpha + IL-1 beta	3.3
PBMC PHA-L	6.2	Lung fibroblast IL-4	25.3
Ramos (B cell) none	4.9	Lung fibroblast IL-9	7.6
Ramos (B cell) ionomycin	10.7	Lung fibroblast IL-13	11.3
B lymphocytes PWM	9.1	Lung fibroblast IFN gamma	75.8
B lymphocytes CD40L and IL-4	4.6	Dermal fibroblast CCD1070 rest	9.2
EOL-1 dbcAMP	0.0	Dermal fibroblast CCD1070 TNF alpha	11.0
EOL-1 dbcAMP PMA/ionomycin	1.5	Dermal fibroblast CCD1070 IL-1 beta	4.3
Dendritic cells none	1.4	Dermal fibroblast IFN gamma	17.8
Dendritic cells LPS	1.1	Dermal fibroblast IL-4	10.0
Dendritic cells anti-CD40	0.9	IBD Colitis 2	2.5
Monocytes rest	5.3	IBD Crohn's	15.8
Monocytes LPS	10.5	Colon	100.0
Macrophages rest	0.9	Lung	14.1
Macrophages LPS	1.1	Thymus	55.5
HUVEC none	7.3	Kidney	17.6
HUVEC starved	4.2		

CNS_neurodegeneration_v1.0 Summary: Ag2644 This panel does not show differential expression of the CG50365-01 gene in Alzheimer's disease. However, this expression profile confirms the presence of this gene in the brain. Please see Panel 1.3D for discussion of utility of this gene in the central nervous system.

- 5 **Panel 1.3D Summary:** Ag2575 The expression of the CG50365-01 gene was assessed in two independent runs on panel 1.3D with excellent concordance between runs. The expression of this gene appears to be highest in a sample derived from a gastric cancer cell line (NCI-H87)(CTs=31). In addition, there is substantial expression in several colon cancer cell lines, ovarian cancer cell lines and brain cancer cell lines. Thus, the expression of this gene could be used to distinguish NCI-H87 cells from other samples in the panel. Moreover, therapeutic
- 10

modulation of this gene, through the use of small molecule drugs, antibodies or protein therapeutics might be of benefit in the treatment of colon cancer, brain cancer or ovarian cancer.

In addition, this gene is expressed at low levels in the cerebral cortex. Carbonate dehydratase may play an important role in modulating excitatory synaptic transmission in brain. Therefore, this molecule may be of use in the treatment of schizophrenia, epilepsy, Alzheimer's disease, bipolar disorder, depression, or any clinical condition associated with impaired or altered neurotransmission.

References:

Parkkila S, Parkkila AK, Rajaniemi H, Shah GN, Grubb JH, Waheed A, Sly WS. Expression of membrane-associated carbonic anhydrase XIV on neurons and axons in mouse and human brain. Proc Natl Acad Sci U S A 2001 Feb 13;98(4):1918-23

Although long suspected from histochemical evidence for carbonic anhydrase (CA) activity on neurons and observations that CA inhibitors enhance the extracellular alkaline shifts associated with synaptic transmission, an extracellular CA in brain had not been identified. A candidate for this CA was suggested by the recent discovery of membrane CA (CA XIV) whose mRNA is expressed in mouse and human brain and in several other tissues. For immunolocalization of CA XIV in mouse and human brain, we developed two antibodies, one against a secretory form of enzymatically active recombinant mouse CA XIV, and one against a synthetic peptide corresponding to the 24 C-terminal amino acids in the human enzyme. Immunostaining for CA XIV was found on neuronal membranes and axons in both mouse and human brain. The highest expression was seen on large neuronal bodies and axons in the anterolateral part of pons and medulla oblongata. Other CA XIV-positive sites included the hippocampus, corpus callosum, cerebellar white matter and peduncles, pyramidal tract, and choroid plexus. Mouse brain also showed a positive reaction in the molecular layer of the cerebral cortex and granular cellular layer of the cerebellum. These observations make CA XIV a likely candidate for the extracellular CA postulated to have an important role in modulating excitatory synaptic transmission in brain.

Panel 2D Summary: Ag2644 The expression of the CG50365-01 gene appears to be highest in a sample derived from a gastric cancer. In addition there is substantial expression associated with

other gastric cancers, when compared to their adjacent normal tissues, as well as expression associated with ovarian cancer, breast cancer, thyroid cancer and colon cancer. This expression conforms with expression in Panel 1.3D. Thus, the expression of this gene could be used to distinguish this gastric cancer sample from other samples in the panel. Moreover, therapeutic modulation of this gene, through the use of small molecule drugs, antibodies or protein therapeutics might be of benefit in the treatment of colon cancer, breast cancer, ovarian cancer, gastric cancer or thyroid cancer.

Panel 3D Summary: Ag2644 The expression of the CG50365-01 gene appears to be highest in a sample derived from a lung cancer cell line (DMS-79). In addition there appears to be expression associated with a colon cancer cell line, a gastric cancer cell line and a pancreatic cancer cell line. Thus, the expression of this gene could be used to distinguish DMS-79 cells from other samples in the panel. Moreover, therapeutic modulation of this gene, through the use of small molecule drugs, antibodies or protein therapeutics might be of benefit in the treatment of colon cancer, pancreatic cancer, gastric cancer or lung cancer.

Panel 4D Summary: Ag2644 The CG50365-01 transcript is expressed in lung fibroblasts treated with gamma interferon, NCI-H292 cells regardless of treatment, activated basophil cell line, and gamma interferon treated HUVECs. It is also expressed in normal colon and thymus. The regulation of the transcript expression in fibroblasts and HUVECs suggests that the protein encoded by this transcript may be contribute to the inflammatory changes due to gamma interferon. Therefore, therapies designed with the protein encoded by this transcript could be important for the treatment of emphysema, psoriasis, arthritis and IBD.

Panel 5 Islet Summary: Ag2575 Expression of the CG50365-01 gene is low/undetectable in all samples on this panel (CTs>35).

NOV8a, NOV8b, and NOV8c: CG55794-01 and CG55794-03 and CG55794-06: Carboxypeptidase

Expression of gene CG55794-01, variant CG55794-03, and splice variant CG55794-06 was assessed using the primer-probe sets Ag2622, Ag3953 and Ag6049, described in Tables FA, FB and FC. Results of the RTQ-PCR runs are shown in Tables FD, FE, FF,

FG, FH, FI, FJ and FK. Please note that the probe/primer set Ag6049 matches only the CG55794-06 variant. This does not change the results presented below.

Table FA. Probe Name Ag2622

Primers	Sequences	Length	Start Position
Forward	5'-catcaggggtcttcaagagattg-3' (SEQ ID NO:359)	22	706
Probe	TET-5'-ccgagacattgggattcccttctcat-3'-TAMRA (SEQ ID NO:360)	26	731
Reverse	5'-acaaacccatatgttccactgt-3' (SEQ ID NO:361)	22	775

Table FB. Probe Name Ag3953

Primers	Sequences	Length	Start Position
Forward	5'-acagtggaacatatgggtttgt-3' (SEQ ID NO:362)	22	775
Probe	TET-5'-agaagctcagatccagcccactgt-3'-TAMRA (SEQ ID NO:363)	25	803
Reverse	5'-catacacatcatccaggactga-3' (SEQ ID NO:364)	22	852

5 Table FC. Probe Name Ag6049

Primers	Sequences	Length	Start Position
Forward	5'-gcttcttgggtgtaattcaagttg-3' (SEQ ID NO:365)	23	602
Probe	TET-5'-acagaaggcagcaaattgcattgaaag-3'-TAMRA (SEQ ID NO:366)	26	626
Reverse	5'-ccaactctataattggttcatactt-3' (SEQ ID NO:367)	26	654

Table FD. CNS_neurodegeneration_v1.0

Tissue Name	Rel. Exp.(%) Ag2622, Run 206942830	Tissue Name	Rel. Exp.(%) Ag2622, Run 206942830
AD 1 Hippo	8.6	Control (Path) 3 Temporal Ctx	9.0
AD 2 Hippo	31.2	Control (Path) 4 Temporal Ctx	54.0
AD 3 Hippo	18.2	AD 1 Occipital Ctx	18.0
AD 4 Hippo	5.4	AD 2 Occipital Ctx (Missing)	0.0
AD 5 hippo	63.3	AD 3 Occipital Ctx	7.0

AD 6 Hippo	27.0	AD 4 Occipital Ctx	21.6
Control 2 Hippo	35.6	AD 5 Occipital Ctx	15.3
Control 4 Hippo	17.7	AD 6 Occipital Ctx	51.1
Control (Path) 3 Hippo	9.2	Control 1 Occipital Ctx	0.0
AD 1 Temporal Ctx	13.8	Control 2 Occipital Ctx	33.7
AD 2 Temporal Ctx	53.6	Control 3 Occipital Ctx	24.5
AD 3 Temporal Ctx	4.5	Control 4 Occipital Ctx	9.0
AD 4 Temporal Ctx	24.1	Control (Path) 1 Occipital Ctx	87.1
AD 5 Inf Temporal Ctx	84.7	Control (Path) 2 Occipital Ctx	10.2
AD 5 Sup Temporal Ctx	28.1	Control (Path) 3 Occipital Ctx	9.3
AD 6 Inf Temporal Ctx	70.2	Control (Path) 4 Occipital Ctx	18.4
AD 6 Sup Temporal Ctx	100.0	Control 1 Parietal Ctx	2.3
Control 1 Temporal Ctx	2.9	Control 2 Parietal Ctx	58.2
Control 2 Temporal Ctx	13.6	Control 3 Parietal Ctx	10.9
Control 3 Temporal Ctx	8.7	Control (Path) 1 Parietal Ctx	65.5
Control 4 Temporal Ctx	19.5	Control (Path) 2 Parietal Ctx	17.1
Control (Path) 1 Temporal Ctx	47.0	Control (Path) 3 Parietal Ctx	3.6
Control (Path) 2 Temporal Ctx	54.3	Control (Path) 4 Parietal Ctx	27.5

Table FE. General_screening_panel_v1.4

Tissue Name	Rel. Exp.(%) Ag3953, Run 213856130	Tissue Name	Rel. Exp.(%) Ag3953, Run 213856130
Adipose	9.3	Renal ca. TK-10	24.3
Melanoma* Hs688(A).T	0.0	Bladder	13.6

Melanoma* Hs688(B).T	11.1	Gastric ca. (liver met.) NCI-N87	39.5
Melanoma* M14	0.0	Gastric ca. KATO III	0.0
Melanoma* LOXIMVI	6.4	Colon ca. SW-948	8.5
Melanoma* SK- MEL-5	0.0	Colon ca. SW480	0.0
Squamous cell carcinoma SCC-4	4.1	Colon ca.* (SW480 met) SW620	0.0
Testis Pool	3.0	Colon ca. HT29	0.0
Prostate ca.* (bone met) PC-3	0.0	Colon ca. HCT-116	40.6
Prostate Pool	18.4	Colon ca. CaCo-2	0.0
Placenta	0.0	Colon cancer tissue	0.0
Uterus Pool	5.8	Colon ca. SW1116	5.2
Ovarian ca. OVCAR- 3	0.0	Colon ca. Colo-205	0.0
Ovarian ca. SK-OV- 3	100.0	Colon ca. SW-48	0.0
Ovarian ca. OVCAR- 4	0.0	Colon Pool	21.3
Ovarian ca. OVCAR- 5	25.5	Small Intestine Pool	13.8
Ovarian ca. IGROV- 1	0.0	Stomach Pool	8.0
Ovarian ca. OVCAR- 8	0.0	Bone Marrow Pool	2.6
Ovary	16.0	Fetal Heart	0.0
Breast ca. MCF-7	8.5	Heart Pool	1.7
Breast ca. MDA- MB-231	3.7	Lymph Node Pool	14.2
Breast ca. BT 549	4.8	Fetal Skeletal Muscle	0.0
Breast ca. T47D	26.1	Skeletal Muscle Pool	31.0
Breast ca. MDA-N	0.0	Spleen Pool	7.9
Breast Pool	7.2	Thymus Pool	12.2
Trachea	0.0	CNS cancer (glio/astro) U87-MG	0.0
Lung	18.6	CNS cancer (glio/astro) U-118-MG	5.9
Fetal Lung	3.3	CNS cancer (neuro;met) SK-N-AS	6.2

Lung ca. NCI-N417	5.4	CNS cancer (astro) SF-539	4.8
Lung ca. LX-1	0.0	CNS cancer (astro) SNB-75	39.2
Lung ca. NCI-H146	4.1	CNS cancer (glio) SNB-19	9.5
Lung ca. SHP-77	11.3	CNS cancer (glio) SF-295	3.6
Lung ca. A549	0.0	Brain (Amygdala) Pool	53.6
Lung ca. NCI-H526	4.2	Brain (cerebellum)	0.0
Lung ca. NCI-H23	13.4	Brain (fetal)	15.9
Lung ca. NCI-H460	10.3	Brain (Hippocampus) Pool	25.5
Lung ca. HOP-62	6.7	Cerebral Cortex Pool	47.3
Lung ca. NCI-H522	26.6	Brain (Substantia nigra) Pool	42.6
Liver	0.0	Brain (Thalamus) Pool	58.2
Fetal Liver	4.7	Brain (whole)	9.5
Liver ca. HepG2	0.0	Spinal Cord Pool	46.0
Kidney Pool	40.1	Adrenal Gland	0.0
Fetal Kidney	17.1	Pituitary gland Pool	12.9
Renal ca. 786-0	12.2	Salivary Gland	3.3
Renal ca. A498	6.7	Thyroid (female)	11.5
Renal ca. ACHN	0.0	Pancreatic ca. CAPAN2	0.0
Renal ca. UO-31	3.1	Pancreas Pool	26.6

Table FF. Panel 1.3D

Tissue Name	Rel. Exp.(%) Ag2622, Run 162554681	Rel. Exp.(%) Ag2622, Run 165672349	Tissue Name	Rel. Exp.(%) Ag2622, Run 162554681	Rel. Exp.(%) Ag2622, Run 165672349
Liver adenocarcinoma	0.0	0.0	Kidney (fetal)	10.5	0.0
Pancreas	0.0	0.0	Renal ca. 786-0	0.0	0.0
Pancreatic ca. CAPAN 2	0.0	10.3	Renal ca. A498	7.0	22.2
Adrenal gland	7.4	33.7	Renal ca. RXF 393	0.0	8.5
Thyroid	46.7	7.7	Renal ca. ACHN	0.0	0.0

Salivary gland	0.0	21.2	Renal ca. UO-31	0.0	0.0
Pituitary gland	14.8	40.9	Renal ca. TK-10	0.0	0.0
Brain (fetal)	13.8	0.0	Liver	0.0	0.0
Brain (whole)	60.3	75.3	Liver (fetal)	6.8	0.0
Brain (amygdala)	61.6	28.9	Liver ca. (hepatoblast) HepG2	0.0	0.0
Brain (cerebellum)	6.2	0.0	Lung	19.8	10.8
Brain (hippocampus)	47.3	97.9	Lung (fetal)	23.2	48.6
Brain (substantia nigra)	28.5	82.9	Lung ca. (small cell) LX-1	0.0	0.0
Brain (thalamus)	54.0	100.0	Lung ca. (small cell) NCI-H69	0.0	0.0
Cerebral Cortex	0.0	27.7	Lung ca. (s.cell var.) SHP-77	0.0	0.0
Spinal cord	77.4	28.7	Lung ca. (large cell) NCI-H460	0.0	0.0
glio/astro U87-MG	0.0	0.0	Lung ca. (non-sm. cell) A549	0.0	0.0
glio/astro U-118-MG	6.5	10.7	Lung ca. (non-s.cell) NCI-H23	0.0	23.7
astrocytoma SW1783	8.3	0.0	Lung ca. (non-s.cell) HOP-62	0.0	10.2
neuro*; met SK-N-AS	0.0	0.0	Lung ca. (non-s.cl) NCI-H522	0.0	14.8
astrocytoma SF-539	0.0	0.0	Lung ca. (squam.) SW 900	0.0	26.4
astrocytoma SNB-75	7.6	19.8	Lung ca. (squam.) NCI-H596	0.0	0.0
glioma SNB-19	13.2	14.4	Mammary gland	13.0	0.0
glioma U251	7.5	0.0	Breast ca.* (pl.ef) MCF-7	0.0	0.0
glioma SF-295	0.0	0.0	Breast ca.*	0.0	0.0

			(pl.ef) MDA-MB-231		
Heart (fetal)	0.0	0.0	Breast ca.* (pl.ef) T47D	0.0	0.0
Heart	0.0	0.0	Breast ca. BT-549	2.6	27.2
Skeletal muscle (fetal)	7.1	11.3	Breast ca. MDA-N	0.0	0.0
Skeletal muscle	84.7	57.0	Ovary	24.1	0.0
Bone marrow	0.0	0.0	Ovarian ca. OVCAR-3	0.0	5.8
Thymus	19.6	0.0	Ovarian ca. OVCAR-4	0.0	0.0
Spleen	0.0	13.2	Ovarian ca. OVCAR-5	0.0	0.0
Lymph node	0.0	0.0	Ovarian ca. OVCAR-8	0.0	0.0
Colorectal	5.8	28.3	Ovarian ca. IGROV-1	0.0	0.0
Stomach	0.0	0.0	Ovarian ca.* (ascites) SK-OV-3	11.3	62.9
Small intestine	7.6	24.5	Uterus	0.0	33.9
Colon ca. SW480	0.0	0.0	Placenta	0.0	0.0
Colon ca.* SW620(SW480 met)	0.0	10.2	Prostate	13.3	0.0
Colon ca. HT29	0.0	0.0	Prostate ca.* (bone met)PC-3	0.0	0.0
Colon ca. HCT-116	19.9	0.0	Testis	22.2	23.0
Colon ca. CaCo-2	0.0	0.0	Melanoma Hs688(A).T	0.0	0.0
Colon ca. tissue(ODO3866)	16.8	9.0	Melanoma* (met) Hs688(B).T	0.0	0.0
Colon ca. HCC-2998	12.5	0.0	Melanoma UACC-62	0.0	0.0
Gastric ca.* (liver met) NCI-N87	27.0	13.3	Melanoma M14	0.0	0.0
Bladder	28.9	12.4	Melanoma	0.0	0.0

			LOX IMVI		
Trachea	13.6	0.0	Melanoma* (met) SK-MEL-5	0.0	0.0
Kidney	100.0	28.5	Adipose	14.0	9.7

Table FG. Panel 2D

Tissue Name	Rel. Exp.(%) Ag2622, Run 163578215	Rel. Exp.(%) Ag2622, Run 165910584	Tissue Name	Rel. Exp.(%) Ag2622, Run 163578215	Rel. Exp.(%) Ag2622, Run 165910584
Normal Colon	7.3	20.4	Kidney Margin 8120608	0.8	0.0
CC Well to Mod Diff (ODO3866)	0.4	0.0	Kidney Cancer 8120613	0.0	1.4
CC Margin (ODO3866)	2.7	2.7	Kidney Margin 8120614	1.6	3.3
CC Gr.2 rectosigmoid (ODO3868)	3.3	0.0	Kidney Cancer 9010320	0.9	1.9
CC Margin (ODO3868)	0.5	6.6	Kidney Margin 9010321	5.2	12.4
CC Mod Diff (ODO3920)	0.0	0.0	Normal Uterus	0.5	0.0
CC Margin (ODO3920)	3.4	10.4	Uterus Cancer 064011	4.6	9.4
CC Gr.2 ascend colon (ODO3921)	2.8	4.7	Normal Thyroid	8.2	9.7
CC Margin (ODO3921)	1.9	5.5	Thyroid Cancer 064010	1.2	10.2
CC from Partial Hepatectomy (ODO4309) Mets	1.2	2.0	Thyroid Cancer A302152	2.8	2.1
Liver Margin (ODO4309)	1.0	4.5	Thyroid Margin A302153	7.4	19.2
Colon mets to lung (OD04451- 01)	0.0	0.0	Normal Breast	1.9	4.7
Lung Margin (OD04451-02)	0.7	1.8	Breast Cancer (OD04566)	4.7	6.1

Normal Prostate 6546-1	30.4	27.7	Breast Cancer (OD04590-01)	1.3	5.2
Prostate Cancer (OD04410)	7.9	15.9	Breast Cancer Mets (OD04590-03)	100.0	4.0
Prostate Margin (OD04410)	13.9	47.3	Breast Cancer Metastasis (OD04655-05)	17.3	33.9
Prostate Cancer (OD04720-01)	5.5	8.7	Breast Cancer 064006	16.6	14.3
Prostate Margin (OD04720-02)	9.2	37.6	Breast Cancer 1024	8.2	39.8
Normal Lung 061010	4.6	5.3	Breast Cancer 9100266	1.0	2.4
Lung Met to Muscle (ODO4286)	0.7	2.6	Breast Margin 9100265	0.5	2.0
Muscle Margin (ODO4286)	5.3	19.6	Breast Cancer A209073	0.0	17.0
Lung Malignant Cancer (OD03126)	2.4	3.7	Breast Margin A2090734	2.3	5.3
Lung Margin (OD03126)	4.6	7.2	Normal Liver	3.1	9.3
Lung Cancer (OD04404)	1.2	1.7	Liver Cancer 064003	0.3	0.0
Lung Margin (OD04404)	1.5	3.6	Liver Cancer 1025	0.8	0.0
Lung Cancer (OD04565)	0.0	0.0	Liver Cancer 1026	0.0	0.0
Lung Margin (OD04565)	0.0	1.5	Liver Cancer 6004-T	0.4	4.6
Lung Cancer (OD04237-01)	3.9	17.4	Liver Tissue 6004-N	0.0	0.0
Lung Margin (OD04237-02)	0.6	6.5	Liver Cancer 6005-T	0.5	0.0
Ocular Mel Met to Liver (ODO4310)	0.0	2.4	Liver Tissue 6005-N	0.0	0.0
Liver Margin (ODO4310)	1.4	1.3	Normal Bladder	2.0	10.0
Melanoma Mets	1.0	2.5	Bladder	0.6	0.0

to Lung (OD04321)			Cancer 1023		
Lung Margin (OD04321)	0.9	8.5	Bladder Cancer A302173	6.9	9.0
Normal Kidney	34.4	100.0	Bladder Cancer (OD04718-01)	1.0	1.7
Kidney Ca, Nuclear grade 2 (OD04338)	4.8	16.5	Bladder Normal Adjacent (OD04718-03)	3.1	10.2
Kidney Margin (OD04338)	3.9	27.4	Normal Ovary	1.6	4.2
Kidney Ca Nuclear grade 1/2 (OD04339)	10.8	26.4	Ovarian Cancer 064008	2.2	8.3
Kidney Margin (OD04339)	21.8	55.1	Ovarian Cancer (OD04768-07)	0.0	0.0
Kidney Ca, Clear cell type (OD04340)	0.8	1.8	Ovary Margin (OD04768-08)	0.0	3.2
Kidney Margin (OD04340)	11.8	41.2	Normal Stomach	2.1	0.0
Kidney Ca, Nuclear grade 3 (OD04348)	0.0	0.0	Gastric Cancer 9060358	0.0	0.0
Kidney Margin (OD04348)	17.9	28.3	Stomach Margin 9060359	0.0	4.5
Kidney Cancer (OD04622-01)	1.9	2.3	Gastric Cancer 9060395	2.0	0.0
Kidney Margin (OD04622-03)	4.6	2.4	Stomach Margin 9060394	3.4	10.8
Kidney Cancer (OD04450-01)	2.1	6.5	Gastric Cancer 9060397	1.3	0.0
Kidney Margin (OD04450-03)	16.5	47.3	Stomach Margin 9060396	0.0	2.7
Kidney Cancer 8120607	0.6	0.0	Gastric Cancer 064005	1.8	13.6

Table FH. Panel 4D

Tissue Name	Rel. Exp.(%) Ag2622, Run 162554700	Rel. Exp.(%) Ag2622, Run 165806297	Tissue Name	Rel. Exp.(%) Ag2622, Run 162554700	Rel. Exp.(%) Ag2622, Run 165806297
Secondary Th1 act	0.0	0.1	HUVEC IL-1beta	0.0	0.0
Secondary Th2 act	0.1	0.0	HUVEC IFN gamma	0.3	0.0
Secondary Tr1 act	0.0	0.0	HUVEC TNF alpha + IFN gamma	0.0	0.0
Secondary Th1 rest	0.0	0.0	HUVEC TNF alpha + IL4	0.0	0.0
Secondary Th2 rest	0.0	0.0	HUVEC IL-11	0.0	0.0
Secondary Tr1 rest	0.0	0.0	Lung Microvascular EC none	0.4	0.1
Primary Th1 act	0.0	0.0	Lung Microvascular EC TNFalpha + IL- 1beta	0.0	0.0
Primary Th2 act	0.2	0.0	Microvascular Dermal EC none	0.0	0.0
Primary Tr1 act	0.0	0.0	Microvascular Dermal EC TNFalpha + IL- 1beta	0.1	0.0
Primary Th1 rest	0.0	0.0	Bronchial epithelium TNFalpha + IL1beta	0.0	0.1
Primary Th2 rest	0.1	0.0	Small airway epithelium none	0.0	0.1
Primary Tr1 rest	0.2	0.0	Small airway epithelium TNFalpha + IL- 1beta	1.1	0.4
CD45RA CD4 lymphocyte act	0.0	0.0	Coronary artery SMC rest	0.0	0.0
CD45RO CD4 lymphocyte act	0.1	0.1	Coronary artery SMC TNFalpha +	0.0	0.0

			IL-1beta		
CD8 lymphocyte act	0.0	0.0	Astrocytes rest	0.0	0.0
Secondary CD8 lymphocyte rest	0.0	0.0	Astrocytes TNFalpha + IL-1beta	0.2	0.2
Secondary CD8 lymphocyte act	0.0	0.0	KU-812 (Basophil) rest	0.0	0.0
CD4 lymphocyte none	0.2	0.0	KU-812 (Basophil) PMA/ionomycin	0.1	0.0
2ry Th1/Th2/Tr1_anti-CD95 CH11	0.0	0.0	CCD1106 (Keratinocytes) none	0.0	0.0
LAK cells rest	0.0	0.0	CCD1106 (Keratinocytes) TNFalpha + IL-1beta	0.0	0.1
LAK cells IL-2	0.0	0.0	Liver cirrhosis	0.8	0.6
LAK cells IL-2+IL-12	0.0	0.0	Lupus kidney	0.2	0.4
LAK cells IL-2+IFN gamma	0.1	0.1	NCI-H292 none	0.0	0.0
LAK cells IL-2+IL-18	0.1	0.0	NCI-H292 IL-4	0.0	0.0
LAK cells PMA/ionomycin	0.0	0.0	NCI-H292 IL-9	0.0	0.1
NK Cells IL-2 rest	0.1	0.0	NCI-H292 IL-13	0.0	0.0
Two Way MLR 3 day	0.0	0.0	NCI-H292 IFN gamma	0.1	0.0
Two Way MLR 5 day	0.0	0.0	HPAEC none	0.1	0.0
Two Way MLR 7 day	0.0	0.0	HPAEC TNF alpha + IL-1 beta	0.0	0.0
PBMC rest	0.0	0.0	Lung fibroblast none	0.1	0.0
PBMC PWM	0.3	0.1	Lung fibroblast TNF alpha + IL-1 beta	0.1	0.0
PBMC PHA-L	0.1	0.0	Lung fibroblast IL-4	0.0	0.1
Ramos (B cell) none	0.0	0.0	Lung fibroblast IL-9	0.4	0.1

Ramos (B cell) ionomycin	0.0	0.0	Lung fibroblast IL- 13	0.1	0.0
B lymphocytes PWM	0.1	0.0	Lung fibroblast IFN gamma	0.5	0.1
B lymphocytes CD40L and IL-4	0.0	0.0	Dermal fibroblast CCD1070 rest	0.1	0.1
EOL-1 dbcAMP	0.0	0.0	Dermal fibroblast CCD1070 TNF alpha	0.0	0.0
EOL-1 dbcAMP PMA/ionomycin	0.2	0.1	Dermal fibroblast CCD1070 IL-1 beta	0.0	0.0
Dendritic cells none	0.0	0.0	Dermal fibroblast IFN gamma	0.1	0.0
Dendritic cells LPS	0.0	0.1	Dermal fibroblast IL-4	0.0	0.1
Dendritic cells anti- CD40	0.0	0.0	IBD Colitis 2	0.0	0.0
Monocytes rest	0.0	0.0	IBD Crohn's	1.0	2.2
Monocytes LPS	0.0	0.0	Colon	100.0	100.0
Macrophages rest	0.0	0.0	Lung	0.2	0.0
Macrophages LPS	0.0	0.0	Thymus	1.3	0.9
HUVEC none	0.0	0.0	Kidney	0.5	0.0
HUVEC starved	0.0	0.0			

Table FI. Panel 5 Islet

Tissue Name	Rel. Exp.(%) Ag3953, Run 223846464	Tissue Name	Rel. Exp.(%) Ag3953, Run 223846464
97457_Patient- 02go_adipose	0.0	94709_Donor 2 AM - A_adipose	0.0
97476_Patient- 07sk_skeletal muscle	0.0	94710_Donor 2 AM - B_adipose	0.0
97477_Patient- 07ut_uterus	0.0	94711_Donor 2 AM - C_adipose	0.0
97478_Patient- 07pl_placenta	0.0	94712_Donor 2 AD - A_adipose	0.0
99167_Bayer Patient 1	0.0	94713_Donor 2 AD - B_adipose	0.0
97482_Patient- 08ut_uterus	0.0	94714_Donor 2 AD - C_adipose	0.0

97483_Patient-08pl_placenta	3.7	94742_Donor 3 U - A_Mesenchymal Stem Cells	0.0
97486_Patient-09sk_skeletal muscle	0.0	94743_Donor 3 U - B_Mesenchymal Stem Cells	0.0
97487_Patient-09ut_uterus	3.8	94730_Donor 3 AM - A_adipose	4.4
97488_Patient-09pl_placenta	0.0	94731_Donor 3 AM - B_adipose	0.0
97492_Patient-10ut_uterus	0.0	94732_Donor 3 AM - C_adipose	0.0
97493_Patient-10pl_placenta	0.0	94733_Donor 3 AD - A_adipose	0.0
97495_Patient-11go_adipose	0.0	94734_Donor 3 AD - B_adipose	0.0
97496_Patient-11sk_skeletal muscle	3.3	94735_Donor 3 AD - C_adipose	3.6
97497_Patient-11ut_uterus	0.0	77138_Liver_HepG2untreated	0.0
97498_Patient-11pl_placenta	4.0	73556_Heart_Cardiac stromal cells (primary)	0.0
97500_Patient-12go_adipose	4.2	81735_Small Intestine	100.0
97501_Patient-12sk_skeletal muscle	3.5	72409_Kidney_Proximal Convoluted Tubule	0.0
97502_Patient-12ut_uterus	0.0	82685_Small intestine_Duodenum	0.0
97503_Patient-12pl_placenta	0.0	90650_Adrenal_Adrenocortical adenoma	0.0
94721_Donor 2 U - A_Mesenchymal Stem Cells	0.0	72410_Kidney_HRCE	0.0
94722_Donor 2 U - B_Mesenchymal Stem Cells	4.0	72411_Kidney_HRE	0.0
94723_Donor 2 U - C_Mesenchymal Stem Cells	0.0	73139_Uterus_Uterine smooth muscle cells	0.0

CNS_neurodegeneration_v1.0 Summary: Ag2622 This panel confirms the expression of the CG55794-01 gene in the CNS; See panel 1.3d for a discussion of utility. Ag6049 Results from

one experiment with the CG55794-06 gene are not included. The amp plot indicates that there were experimental difficulties with this run.

General_screening_panel_v1.4 Summary: Ag3953 Highest expression of the CG55794-01 gene is seen in an ovarian cancer cell line (CT=33.1). Thus, expression of this gene could be used to differentiate between this sample and other samples on this panel. Please see Panel 1.3D for further discussion of the utility of this gene in cancer.

As in the previous panel, this gene is also expressed in the brain, including the cerebral cortex, substantia nigra and thalamus. Please see Panel 1.3D for discussion of utility of this gene in the central nervous system.

General_screening_panel_v1.5 Summary: Ag6049 Results from one experiment with the CG55794-06 gene are not included. The amp plot indicates that there were experimental difficulties with this run.

Panel 1.3D Summary: Ag2622 Two experiments with the same probe and primer sets produce results that are in reasonable agreement, with highest expression of the CG55794-01 gene in the brain and the kidney. Interestingly, there is significantly lower expression in the brain cancer cell lines than normal brain samples. This suggests that absence of this gene might be involved in cell proliferation. Hence this might be used as a diagnostic marker for brain cancer.

As seen in previous panels, the CG55794-01 gene is also expressed at low levels in the CNS. Carboxypeptidase is believed to have a role in the degradation of APP and A-beta, the major component of senile plaques in Alzheimer's disease. Therapeutic upregulation of this gene or its protein product may therefore be of benefit in the treatment of Alzheimer's disease.

References:

Matsumoto A, Itoh K, Matsumoto R. A novel carboxypeptidase B that processes native beta-amyloid precursor protein is present in human hippocampus. Eur J Neurosci 2000 Jan;12(1):227-

The processing of beta-amyloid precursor protein (APP) and generation of beta-amyloid (Abeta) are associated with the pathophysiology of Alzheimer's disease (AD). As the proteases responsible for the process in the human brain have yet to be clarified, we have searched for activities capable of cleaving native brain APP in the human hippocampus. A 40-kDa protein with proteolytic activity that degrades native brain APP in vitro was purified and characterized; molecular analysis identified it as a novel protease belonging to the carboxypeptidase B (CPB) family. PC12 cells overexpressing the cDNA encoding this protease generate a major 12-kDa beta-amyloid-bearing peptide in cytosol, a peptide which has also been detected in a cell-free system using purified brain APP as substrate. Although the protease is homologous to plasma CPB synthesized in liver, it has specific domains such as C-terminal 14 amino acid residues. Western analysis, cDNA-cloning process and Northern analysis suggested a brain-specific expression of this protease. An immunohistochemical study showed that the protease is expressed in various neuronal perikarya, including those of pyramidal neurons of the hippocampus and ependymal-choroid plexus cells, and in a portion of the microglia of normal brains. In brains of patients with sporadic AD, there is decreased neuronal expression of the protease, and clusters of microglia with protease immunoreactivity associated with its extracellular deposition are detected. These findings suggest that brain CPB has a physiological function in APP processing and may have significance in AD pathophysiology.

Panel 2D Summary: Ag2622 The CG55794-01 gene is expressed at low levels in the tissues used for panel 2D, with reasonable concordance between the runs. There is increased expression in normal prostate and kidney compared to the adjacent tumor tissues. There is also increased expression in breast cancer tissues compared to normal breast tissue. Hence, expression of this gene can be used as a diagnostic marker in breast, prostate and kidney cancer. Furthermore, therapeutic modulation of the gene product might be of use in the treatment of these cancers.

Panel 3D Summary: Ag2622 Expression of the CG55794-01 gene is low/undetectable in all samples on this panel (CTs>35).

Panel 4D Summary: Ag2622 The CG55794-01 gene, which encodes a putative carboxypeptidase, is expressed in the colon and down regulated in colon tissue isolated from Crohn's and colitis patients. The carboxypeptidase family of enzymes has been found in the

colon and is associated with colon disease (ref. below). Thus, the expression of the transcript or the protein it encodes could be used to detect normal colon tissue. Furthermore, therapeutics designed with the protein encoded for by this transcript could be important in the treatment of IBD. Ag6049 Results from one experiment with the CG55794-06 gene showed low/undetectable in all samples on Panel 4.1D. (CTs>35).

References:

Sommer H, Schweisfurth H, Schulz M. Serum angiotensin-I-converting enzyme and carboxypeptidase N in Crohn's disease and ulcerative colitis. *Enzyme* 1986;35(4):181-8

Angiotensin-I-converting enzyme (ACE) and carboxypeptidase N1 and N2 (CPN1, CPN2) inactivate kinins and might therefore play a role in the development of inflammatory reactions via an influence on the release of prostaglandins and inactivation of anaphylatoxic peptides of the complement system. In the present study, the serum activity of these enzymes was determined in 60 patients with Crohn's disease, 18 patients with ulcerative colitis and 70 healthy control subjects. ACE was significantly lowered in active Crohn's disease (CDAI greater than 150) and in ulcerative colitis (p less than 0.01), as long as the ileum or cecum was affected. Since ACE was detected in high concentrations in the human intestinal mucosa, decreased values may be explained by damage to the site of its production. CPN1 and CPN2 were raised in both diseases (p less than 0.005), irrespective of their activity and location. These alterations in the activity of the kininases investigated may play a role in the pathogenesis of inflammatory bowel diseases.

Panel 5 Islet Summary: Ag3953 The CG55794-01 gene, a carboxypeptidase homolog, has little to no expression in any of the endocrine/metabolically-related tissues except for small intestine. This expression profile is in agreement with the results from Panel 4D. Carboxypeptidase-B processing of GI peptides (e.g. GLP-2 and CCK) is critical for bioactivity. Thus, a therapeutic modulator of this gene and/or gene-product may prove useful in treating diseases associated with the GI tract and metabolism.

References:

Orskov C, Buhl T, Rabenhøj L, Kofod H, Holst JJ. Carboxypeptidase-B-like processing of the C-terminus of glucagon-like peptide-2 in pig and human small intestine.

FEBS Lett 1989 Apr 24;247(2):193-6

We developed specific, C-terminal radioimmunoassays for three proglucagon (PG) fragments:

- 5 PG 151-158, PG 151-160 and PG 126-159 (glucagon-like peptide-2 (GLP-2] in order to determine the exact C-terminal sequence of the newly isolated GLP-2 in man and pig. The antigens and the antisera showed no mutual cross-reactivity. By gel filtration of extracts of pig and human small intestine, the immunoreactivity eluting at the position of GLP-2 was identified by the radioimmunoassays for glucagon-like peptide-2 (PG 126-159) and for PG 151-158, 10 whereas the assay for PG 151-160 was completely negative. We conclude that the C-terminal amino acid residue of pig and human ileal GLP-2 is PG 158. Thus the basic residues, PG 159 and 160 are removed during its processing in the small intestine.

PMID: 2714431

- 15 Blanke SE, Johnsen AH, Rehfeld JF. N-terminal fragments of intestinal cholecystokinin: evidence for release of CCK-8 by cleavage on the carboxyl side of Arg74 of proCCK. Regul Pept 1993 Jul 23;46(3):575-82

- From porcine duodenal mucosa we have identified three major procholecystokinin (proCCK) fragments: desoctaCCK-33, desnonaCCK-33 and desnonaCCK-39. (DesoctaCCK-33 means CCK-33 devoid of the 8 C-terminal amino acids, etc.). The fragments were purified by 20 immunoaffinity chromatography and three steps of reverse phase HPLC monitored by a radioimmunoassay specific for the N-terminal part of CCK-33. The structures could be deduced from the proCCK sequence by N-terminal sequence determination and mass spectrometry. Whereas desnona-fragments of CCK have been described before, this is the first finding of a desoctaCCK, and it indicates that CCK-8 is released from the longer forms by endogenous 25 cleavage of the Arg-Asp-bond. A carboxypeptidase B-like exopeptidase subsequently must produce the desnona-fragments by removing the arginine residue.

NOV8d: CG55794-07: Splice variant of CG55794-01

Expression of gene CG55794-07 was assessed using the primer-probe sets Ag2622, Ag6050 and Ag3953, described in Tables GA, GB and GC. Results of the RTQ-PCR runs are shown in Tables GD, GE, GF, GG, GH, GI, GJ and GK.

Table GA. Probe Name Ag2622

Primers	Sequences	Length	Start Position
Forward	5'-catcaggggtcttcaagagattg-3' (SEQ ID NO:368)	22	971
Probe	TET-5'-ccgagacattgggattcccttctcat-3'-TAMRA (SEQ ID NO:369)	26	996
Reverse	5'-acaaaccccatatgttccactgt-3' (SEQ ID NO:370)	22	1040

5 Table GB. Probe Name Ag6050

Primers	Sequences	Length	Start Position
Forward	5'-gttgatcggtcttcacggaaag-3' (SEQ ID NO:371)	21	68
Probe	TET-5'-cctaccacatgttggccagggtg-3'-TAMRA (SEQ ID NO:372)	23	104
Reverse	5'-aagtgttttctctttcactgcttg-3' (SEQ ID NO:373)	24	129

Table GC. Probe Name Ag3953

Primers	Sequences	Length	Start Position
Forward	5'-acagtggaacatatgggtttgt-3' (SEQ ID NO:374)	22	1040
Probe	TET-5'-agaagctcagatccagcccactgt-3'-TAMRA (SEQ ID NO:375)	25	1068
Reverse	5'-catacacatcatccaggactga-3' (SEQ ID NO:376)	22	1117

Table GD. CNS_neurodegeneration_v1.0

Tissue Name	Rel. Exp.(%) Ag2622, Run 206942830	Rel. Exp.(%) Ag6050, Run 226208787	Tissue Name	Rel. Exp.(%) Ag2622, Run 206942830	Rel. Exp.(%) Ag6050, Run 226208787
AD 1 Hippo	8.6	18.3	Control (Path) 3 Temporal Ctx	9.0	14.7
AD 2 Hippo	31.2	40.6	Control (Path) 4	54.0	70.7

			Temporal Ctx		
AD 3 Hippo	18.2	18.4	AD 1 Occipital Ctx	18.0	31.6
AD 4 Hippo	5.4	6.5	AD 2 Occipital Ctx (Missing)	0.0	0.0
AD 5 hippo	63.3	87.7	AD 3 Occipital Ctx	7.0	14.5
AD 6 Hippo	27.0	60.7	AD 4 Occipital Ctx	21.6	30.1
Control 2 Hippo	35.6	26.4	AD 5 Occipital Ctx	15.3	20.7
Control 4 Hippo	17.7	18.0	AD 6 Occipital Ctx	51.1	54.0
Control (Path) 3 Hippo	9.2	13.8	Control 1 Occipital Ctx	0.0	5.5
AD 1 Temporal Ctx	13.8	35.1	Control 2 Occipital Ctx	33.7	50.3
AD 2 Temporal Ctx	53.6	52.5	Control 3 Occipital Ctx	24.5	29.1
AD 3 Temporal Ctx	4.5	24.0	Control 4 Occipital Ctx	9.0	6.1
AD 4 Temporal Ctx	24.1	52.9	Control (Path) 1 Occipital Ctx	87.1	100.0
AD 5 Inf Temporal Ctx	84.7	97.3	Control (Path) 2 Occipital Ctx	10.2	34.9
AD 5 SupTemporal	28.1	43.5	Control (Path) 3	9.3	4.4

Ctx			Occipital Ctx		
AD 6 Inf Temporal Ctx	70.2	77.4	Control (Path) 4 Occipital Ctx	18.4	26.4
AD 6 Sup Temporal Ctx	100.0	98.6	Control 1 Parietal Ctx	2.3	11.4
Control 1 Temporal Ctx	2.9	10.3	Control 2 Parietal Ctx	58.2	99.3
Control 2 Temporal Ctx	13.6	34.9	Control 3 Parietal Ctx	10.9	25.7
Control 3 Temporal Ctx	8.7	29.9	Control (Path) 1 Parietal Ctx	65.5	79.0
Control 4 Temporal Ctx	19.5	16.0	Control (Path) 2 Parietal Ctx	17.1	34.4
Control (Path) 1 Temporal Ctx	47.0	85.9	Control (Path) 3 Parietal Ctx	3.6	6.2
Control (Path) 2 Temporal Ctx	54.3	67.8	Control (Path) 4 Parietal Ctx	27.5	57.8

Table GE. General_screening_panel_v1.4

Tissue Name	Rel. Exp.(%) Ag3953, Run 213856130	Tissue Name	Rel. Exp.(%) Ag3953, Run 213856130
Adipose	9.3	Renal ca. TK-10	24.3
Melanoma* Hs688(A).T	0.0	Bladder	13.6
Melanoma* Hs688(B).T	11.1	Gastric ca. (liver met.) NCI-N87	39.5
Melanoma* M14	0.0	Gastric ca. KATO III	0.0
Melanoma* LOXIMVI	6.4	Colon ca. SW-948	8.5
Melanoma* SK-MEL-5	0.0	Colon ca. SW480	0.0
Squamous cell carcinoma SCC-4	4.1	Colon ca.* (SW480 met) SW620	0.0
Testis Pool	3.0	Colon ca. HT29	0.0

Prostate ca.* (bone met) PC-3	0.0	Colon ca. HCT-116	40.6
Prostate Pool	18.4	Colon ca. CaCo-2	0.0
Placenta	0.0	Colon cancer tissue	0.0
Uterus Pool	5.8	Colon ca. SW1116	5.2
Ovarian ca. OVCAR-3	0.0	Colon ca. Colo-205	0.0
Ovarian ca. SK-OV-3	100.0	Colon ca. SW-48	0.0
Ovarian ca. OVCAR-4	0.0	Colon Pool	21.3
Ovarian ca. OVCAR-5	25.5	Small Intestine Pool	13.8
Ovarian ca. IGROV-1	0.0	Stomach Pool	8.0
Ovarian ca. OVCAR-8	0.0	Bone Marrow Pool	2.6
Ovary	16.0	Fetal Heart	0.0
Breast ca. MCF-7	8.5	Heart Pool	1.7
Breast ca. MDA-MB-231	3.7	Lymph Node Pool	14.2
Breast ca. BT 549	4.8	Fetal Skeletal Muscle	0.0
Breast ca. T47D	26.1	Skeletal Muscle Pool	31.0
Breast ca. MDA-N	0.0	Spleen Pool	7.9
Breast Pool	7.2	Thymus Pool	12.2
Trachea	0.0	CNS cancer (glio/astro) U87-MG	0.0
Lung	18.6	CNS cancer (glio/astro) U-118-MG	5.9
Fetal Lung	3.3	CNS cancer (neuro;met) SK-N-AS	6.2
Lung ca. NCI-N417	5.4	CNS cancer (astro) SF-539	4.8
Lung ca. LX-1	0.0	CNS cancer (astro) SNB-75	39.2
Lung ca. NCI-H146	4.1	CNS cancer (glio) SNB-19	9.5
Lung ca. SHP-77	11.3	CNS cancer (glio) SF-295	3.6
Lung ca. A549	0.0	Brain (Amygdala) Pool	53.6
Lung ca. NCI-H526	4.2	Brain (cerebellum)	0.0

Lung ca. NCI-H23	13.4	Brain (fetal)	15.9
Lung ca. NCI-H460	10.3	Brain (Hippocampus) Pool	25.5
Lung ca. HOP-62	6.7	Cerebral Cortex Pool	47.3
Lung ca. NCI-H522	26.6	Brain (Substantia nigra) Pool	42.6
Liver	0.0	Brain (Thalamus) Pool	58.2
Fetal Liver	4.7	Brain (whole)	9.5
Liver ca. HepG2	0.0	Spinal Cord Pool	46.0
Kidney Pool	40.1	Adrenal Gland	0.0
Fetal Kidney	17.1	Pituitary gland Pool	12.9
Renal ca. 786-0	12.2	Salivary Gland	3.3
Renal ca. A498	6.7	Thyroid (female)	11.5
Renal ca. ACHN	0.0	Pancreatic ca. CAPAN2	0.0
Renal ca. UO-31	3.1	Pancreas Pool	26.6

Table GF. General_screening_panel_v1.5

Tissue Name	Rel. Exp.(%) Ag6050, Run 228746661	Tissue Name	Rel. Exp.(%) Ag6050, Run 228746661
Adipose	9.2	Renal ca. TK-10	11.0
Melanoma* Hs688(A).T	3.0	Bladder	13.0
Melanoma* Hs688(B).T	2.1	Gastric ca. (liver met.) NCI-N87	47.6
Melanoma* M14	0.0	Gastric ca. KATO III	0.0
Melanoma* LOXIMVI	0.0	Colon ca. SW-948	1.5
Melanoma* SK- MEL-5	0.7	Colon ca. SW480	2.0
Squamous cell carcinoma SCC-4	2.4	Colon ca.* (SW480 met) SW620	4.2
Testis Pool	18.0	Colon ca. HT29	0.0
Prostate ca.* (bone met) PC-3	0.5	Colon ca. HCT-116	28.3
Prostate Pool	31.6	Colon ca. CaCo-2	3.3
Placenta	1.8	Colon cancer tissue	4.0
Uterus Pool	15.4	Colon ca. SW1116	2.1
Ovarian ca. OVCAR- 3	2.9	Colon ca. Colo-205	0.0

Ovarian ca. SK-OV-3	100.0	Colon ca. SW-48	1.0
Ovarian ca. OVCAR-4	1.3	Colon Pool	14.0
Ovarian ca. OVCAR-5	17.4	Small Intestine Pool	16.0
Ovarian ca. IGROV-1	1.8	Stomach Pool	11.8
Ovarian ca. OVCAR-8	0.0	Bone Marrow Pool	8.1
Ovary	12.6	Fetal Heart	3.8
Breast ca. MCF-7	5.3	Heart Pool	14.3
Breast ca. MDA-MB-231	5.9	Lymph Node Pool	21.5
Breast ca. BT 549	7.6	Fetal Skeletal Muscle	3.5
Breast ca. T47D	0.0	Skeletal Muscle Pool	36.9
Breast ca. MDA-N	1.0	Spleen Pool	9.7
Breast Pool	27.4	Thymus Pool	10.7
Trachea	11.1	CNS cancer (glio/astro) U87-MG	1.0
Lung	13.6	CNS cancer (glio/astro) U-118-MG	5.3
Fetal Lung	18.3	CNS cancer (neuro;met) SK-N-AS	2.7
Lung ca. NCI-N417	0.0	CNS cancer (astro) SF-539	1.3
Lung ca. LX-1	4.4	CNS cancer (astro) SNB-75	14.9
Lung ca. NCI-H146	4.2	CNS cancer (glio) SNB-19	1.4
Lung ca. SHP-77	1.0	CNS cancer (glio) SF-295	12.2
Lung ca. A549	2.0	Brain (Amygdala) Pool	27.5
Lung ca. NCI-H526	0.6	Brain (cerebellum)	16.4
Lung ca. NCI-H23	12.1	Brain (fetal)	14.5
Lung ca. NCI-H460	31.9	Brain (Hippocampus) Pool	24.0
Lung ca. HOP-62	8.9	Cerebral Cortex Pool	47.0
Lung ca. NCI-H522	8.5	Brain (Substantia nigra) Pool	24.5
Liver	1.5	Brain (Thalamus) Pool	62.0

Fetal Liver	7.5	Brain (whole)	20.9
Liver ca. HepG2	0.6	Spinal Cord Pool	20.3
Kidney Pool	23.2	Adrenal Gland	15.3
Fetal Kidney	58.2	Pituitary gland Pool	19.2
Renal ca. 786-0	3.0	Salivary Gland	5.8
Renal ca. A498	7.7	Thyroid (female)	7.8
Renal ca. ACHN	1.8	Pancreatic ca. CAPAN2	0.5
Renal ca. UO-31	2.9	Pancreas Pool	21.0

Table GG. Panel 1.3D

Tissue Name	Rel. Exp.(%) Ag2622, Run 162554681	Rel. Exp.(%) Ag2622, Run 165672349	Tissue Name	Rel. Exp.(%) Ag2622, Run 162554681	Rel. Exp.(%) Ag2622, Run 165672349
Liver adenocarcinoma	0.0	0.0	Kidney (fetal)	10.5	0.0
Pancreas	0.0	0.0	Renal ca. 786- 0	0.0	0.0
Pancreatic ca. CAPAN 2	0.0	10.3	Renal ca. A498	7.0	22.2
Adrenal gland	7.4	33.7	Renal ca. RXF 393	0.0	8.5
Thyroid	46.7	7.7	Renal ca. ACHN	0.0	0.0
Salivary gland	0.0	21.2	Renal ca. UO- 31	0.0	0.0
Pituitary gland	14.8	40.9	Renal ca. TK- 10	0.0	0.0
Brain (fetal)	13.8	0.0	Liver	0.0	0.0
Brain (whole)	60.3	75.3	Liver (fetal)	6.8	0.0
Brain (amygdala)	61.6	28.9	Liver ca. (hepatoblast) HepG2	0.0	0.0
Brain (cerebellum)	6.2	0.0	Lung	19.8	10.8
Brain (hippocampus)	47.3	97.9	Lung (fetal)	23.2	48.6
Brain (substantia nigra)	28.5	82.9	Lung ca. (small cell) LX-1	0.0	0.0
Brain (thalamus)	54.0	100.0	Lung ca. (small cell)	0.0	0.0

			NCI-H69		
Cerebral Cortex	0.0	27.7	Lung ca. (s.cell var.) SHP-77	0.0	0.0
Spinal cord	77.4	28.7	Lung ca. (large cell) NCI-H460	0.0	0.0
glio/astro U87-MG	0.0	0.0	Lung ca. (non-sm. cell) A549	0.0	0.0
glio/astro U-118-MG	6.5	10.7	Lung ca. (non-s.cell) NCI-H23	0.0	23.7
astrocytoma SW1783	8.3	0.0	Lung ca. (non-s.cell) HOP-62	0.0	10.2
neuro*; met SK-N-AS	0.0	0.0	Lung ca. (non-s.cl) NCI-H522	0.0	14.8
astrocytoma SF-539	0.0	0.0	Lung ca. (squam.) SW 900	0.0	26.4
astrocytoma SNB-75	7.6	19.8	Lung ca. (squam.) NCI-H596	0.0	0.0
glioma SNB-19	13.2	14.4	Mammary gland	13.0	0.0
glioma U251	7.5	0.0	Breast ca.* (pl.ef) MCF-7	0.0	0.0
glioma SF-295	0.0	0.0	Breast ca.* (pl.ef) MDA-MB-231	0.0	0.0
Heart (fetal)	0.0	0.0	Breast ca.* (pl.ef) T47D	0.0	0.0
Heart	0.0	0.0	Breast ca. BT-549	2.6	27.2
Skeletal muscle (fetal)	7.1	11.3	Breast ca. MDA-N	0.0	0.0
Skeletal muscle	84.7	57.0	Ovary	24.1	0.0
Bone marrow	0.0	0.0	Ovarian ca. OVCAR-3	0.0	5.8
Thymus	19.6	0.0	Ovarian ca. OVCAR-4	0.0	0.0
Spleen	0.0	13.2	Ovarian ca. OVCAR-5	0.0	0.0
Lymph node	0.0	0.0	Ovarian ca. OVCAR-8	0.0	0.0

Colorectal	5.8	28.3	Ovarian ca. IGROV-1	0.0	0.0
Stomach	0.0	0.0	Ovarian ca.* (ascites) SK- OV-3	11.3	62.9
Small intestine	7.6	24.5	Uterus	0.0	33.9
Colon ca. SW480	0.0	0.0	Placenta	0.0	0.0
Colon ca.* SW620(SW480 met)	0.0	10.2	Prostate	13.3	0.0
Colon ca. HT29	0.0	0.0	Prostate ca.* (bone met)PC- 3	0.0	0.0
Colon ca. HCT- 116	19.9	0.0	Testis	22.2	23.0
Colon ca. CaCo-2	0.0	0.0	Melanoma Hs688(A).T	0.0	0.0
Colon ca. tissue(ODO3866)	16.8	9.0	Melanoma* (met) Hs688(B).T	0.0	0.0
Colon ca. HCC- 2998	12.5	0.0	Melanoma UACC-62	0.0	0.0
Gastric ca.* (liver met) NCI-N87	27.0	13.3	Melanoma M14	0.0	0.0
Bladder	28.9	12.4	Melanoma LOX IMVI	0.0	0.0
Trachea	13.6	0.0	Melanoma* (met) SK- MEL-5	0.0	0.0
Kidney	100.0	28.5	Adipose	14.0	9.7

Table GH. Panel 2D

Tissue Name	Rel. Exp.(%) Ag2622, Run 163578215	Rel. Exp.(%) Ag2622, Run 165910584	Tissue Name	Rel. Exp.(%) Ag2622, Run 163578215	Rel. Exp.(%) Ag2622, Run 165910584
Normal Colon	7.3	20.4	Kidney Margin 8120608	0.8	0.0
CC Well to Mod Diff (ODO3866)	0.4	0.0	Kidney Cancer 8120613	0.0	1.4
CC Margin (ODO3866)	2.7	2.7	Kidney Margin 8120614	1.6	3.3

CC Gr.2 rectosigmoid (ODO3868)	3.3	0.0	Kidney Cancer 9010320	0.9	1.9
CC Margin (ODO3868)	0.5	6.6	Kidney Margin 9010321	5.2	12.4
CC Mod Diff (ODO3920)	0.0	0.0	Normal Uterus	0.5	0.0
CC Margin (ODO3920)	3.4	10.4	Uterus Cancer 064011	4.6	9.4
CC Gr.2 ascend colon (ODO3921)	2.8	4.7	Normal Thyroid	8.2	9.7
CC Margin (ODO3921)	1.9	5.5	Thyroid Cancer 064010	1.2	10.2
CC from Partial Hepatectomy (ODO4309) Mets	1.2	2.0	Thyroid Cancer A302152	2.8	2.1
Liver Margin (ODO4309)	1.0	4.5	Thyroid Margin A302153	7.4	19.2
Colon mets to lung (OD04451- 01)	0.0	0.0	Normal Breast	1.9	4.7
Lung Margin (OD04451-02)	0.7	1.8	Breast Cancer (OD04566)	4.7	6.1
Normal Prostate 6546-1	30.4	27.7	Breast Cancer (OD04590-01)	1.3	5.2
Prostate Cancer (OD04410)	7.9	15.9	Breast Cancer Mets (OD04590-03)	100.0	4.0
Prostate Margin (OD04410)	13.9	47.3	Breast Cancer Metastasis (OD04655-05)	17.3	33.9
Prostate Cancer (OD04720-01)	5.5	8.7	Breast Cancer 064006	16.6	14.3
Prostate Margin (OD04720-02)	9.2	37.6	Breast Cancer 1024	8.2	39.8
Normal Lung 061010	4.6	5.3	Breast Cancer 9100266	1.0	2.4
Lung Met to Muscle (ODO4286)	0.7	2.6	Breast Margin 9100265	0.5	2.0

Muscle Margin (ODO4286)	5.3	19.6	Breast Cancer A209073	0.0	17.0
Lung Malignant Cancer (OD03126)	2.4	3.7	Breast Margin A2090734	2.3	5.3
Lung Margin (OD03126)	4.6	7.2	Normal Liver	3.1	9.3
Lung Cancer (OD04404)	1.2	1.7	Liver Cancer 064003	0.3	0.0
Lung Margin (OD04404)	1.5	3.6	Liver Cancer 1025	0.8	0.0
Lung Cancer (OD04565)	0.0	0.0	Liver Cancer 1026	0.0	0.0
Lung Margin (OD04565)	0.0	1.5	Liver Cancer 6004-T	0.4	4.6
Lung Cancer (OD04237-01)	3.9	17.4	Liver Tissue 6004-N	0.0	0.0
Lung Margin (OD04237-02)	0.6	6.5	Liver Cancer 6005-T	0.5	0.0
Ocular Mel Met to Liver (ODO4310)	0.0	2.4	Liver Tissue 6005-N	0.0	0.0
Liver Margin (ODO4310)	1.4	1.3	Normal Bladder	2.0	10.0
Melanoma Mets to Lung (OD04321)	1.0	2.5	Bladder Cancer 1023	0.6	0.0
Lung Margin (OD04321)	0.9	8.5	Bladder Cancer A302173	6.9	9.0
Normal Kidney	34.4	100.0	Bladder Cancer (OD04718-01)	1.0	1.7
Kidney Ca, Nuclear grade 2 (OD04338)	4.8	16.5	Bladder Normal Adjacent (OD04718-03)	3.1	10.2
Kidney Margin (OD04338)	3.9	27.4	Normal Ovary	1.6	4.2
Kidney Ca Nuclear grade 1/2 (OD04339)	10.8	26.4	Ovarian Cancer 064008	2.2	8.3

Kidney Margin (OD04339)	21.8	55.1	Ovarian Cancer (OD04768-07)	0.0	0.0
Kidney Ca, Clear cell type (OD04340)	0.8	1.8	Ovary Margin (OD04768-08)	0.0	3.2
Kidney Margin (OD04340)	11.8	41.2	Normal Stomach	2.1	0.0
Kidney Ca, Nuclear grade 3 (OD04348)	0.0	0.0	Gastric Cancer 9060358	0.0	0.0
Kidney Margin (OD04348)	17.9	28.3	Stomach Margin 9060359	0.0	4.5
Kidney Cancer (OD04622-01)	1.9	2.3	Gastric Cancer 9060395	2.0	0.0
Kidney Margin (OD04622-03)	4.6	2.4	Stomach Margin 9060394	3.4	10.8
Kidney Cancer (OD04450-01)	2.1	6.5	Gastric Cancer 9060397	1.3	0.0
Kidney Margin (OD04450-03)	16.5	47.3	Stomach Margin 9060396	0.0	2.7
Kidney Cancer 8120607	0.6	0.0	Gastric Cancer 064005	1.8	13.6

Table GI. Panel 4.1D

Tissue Name	Rel. Exp.(%) Ag6050, Run 226202118	Tissue Name	Rel. Exp.(%) Ag6050, Run 226202118
Secondary Th1 act	0.6	HUVEC IL-1beta	0.4
Secondary Th2 act	1.7	HUVEC IFN gamma	1.8
Secondary Tr1 act	0.7	HUVEC TNF alpha + IFN gamma	1.2
Secondary Th1 rest	1.6	HUVEC TNF alpha + IL4	1.2
Secondary Th2 rest	0.0	HUVEC IL-11	1.1
Secondary Tr1 rest	0.8	Lung Microvascular EC none	5.9
Primary Th1 act	0.6	Lung Microvascular EC TNFalpha + IL-1beta	1.6

Primary Th2 act	2.2	Microvascular Dermal EC none	1.5
Primary Tr1 act	1.2	Microvascular Dermal EC TNFalpha + IL-1beta	0.3
Primary Th1 rest	0.4	Bronchial epithelium TNFalpha + IL1beta	3.6
Primary Th2 rest	0.0	Small airway epithelium none	1.0
Primary Tr1 rest	0.3	Small airway epithelium TNFalpha + IL-1beta	8.5
CD45RA CD4 lymphocyte act	1.7	Coronary artery SMC rest	0.4
CD45RO CD4 lymphocyte act	5.1	Coronary artery SMC TNFalpha + IL-1beta	0.0
CD8 lymphocyte act	2.1	Astrocytes rest	1.0
Secondary CD8 lymphocyte rest	5.8	Astrocytes TNFalpha + IL-1beta	3.1
Secondary CD8 lymphocyte act	0.4	KU-812 (Basophil) rest	0.0
CD4 lymphocyte none	0.3	KU-812 (Basophil) PMA/ionomycin	1.3
2ry Th1/Th2/Tr1_anti-CD95 CH11	0.6	CCD1106 (Keratinocytes) none	2.0
LAK cells rest	0.8	CCD1106 (Keratinocytes) TNFalpha + IL-1beta	1.5
LAK cells IL-2	1.8	Liver cirrhosis	1.2
LAK cells IL-2+IL-12	1.1	NCI-H292 none	0.3
LAK cells IL-2+IFN gamma	4.2	NCI-H292 IL-4	0.7
LAK cells IL-2+ IL-18	2.6	NCI-H292 IL-9	3.1
LAK cells PMA/ionomycin	0.3	NCI-H292 IL-13	0.7
NK Cells IL-2 rest	2.0	NCI-H292 IFN gamma	1.7
Two Way MLR 3 day	1.4	HPAEC none	1.2
Two Way MLR 5 day	2.5	HPAEC TNF alpha + IL-1 beta	2.3
Two Way MLR 7 day	0.4	Lung fibroblast none	1.3
PBMC rest	0.6	Lung fibroblast TNF alpha + IL-1 beta	1.6
PBMC PWM	2.5	Lung fibroblast IL-4	4.4
PBMC PHA-L	2.4	Lung fibroblast IL-9	5.4

Ramos (B cell) none	0.0	Lung fibroblast IL-13	4.0
Ramos (B cell) ionomycin	0.0	Lung fibroblast IFN gamma	3.4
B lymphocytes PWM	1.6	Dermal fibroblast CCD1070 rest	1.1
B lymphocytes CD40L and IL-4	1.8	Dermal fibroblast CCD1070 TNF alpha	0.7
EOL-1 dbcAMP	8.4	Dermal fibroblast CCD1070 IL-1 beta	0.3
EOL-1 dbcAMP PMA/ionomycin	8.2	Dermal fibroblast IFN gamma	3.0
Dendritic cells none	0.5	Dermal fibroblast IL-4	1.9
Dendritic cells LPS	1.7	Dermal Fibroblasts rest	1.7
Dendritic cells anti-CD40	0.9	Neutrophils TNFa+LPS	0.0
Monocytes rest	2.0	Neutrophils rest	2.2
Monocytes LPS	0.3	Colon	2.5
Macrophages rest	1.7	Lung	1.6
Macrophages LPS	0.0	Thymus	19.9
HUVEC none	0.3	Kidney	100.0
HUVEC starved	1.2		

Table GJ. Panel 4D

Tissue Name	Rel. Exp.(%) Ag2622, Run 162554700	Rel. Exp.(%) Ag2622, Run 165806297	Tissue Name	Rel. Exp.(%) Ag2622, Run 162554700	Rel. Exp.(%) Ag2622, Run 165806297
Secondary Th1 act	0.0	0.1	HUVEC IL-1beta	0.0	0.0
Secondary Th2 act	0.1	0.0	HUVEC IFN gamma	0.3	0.0
Secondary Tr1 act	0.0	0.0	HUVEC TNF alpha + IFN gamma	0.0	0.0
Secondary Th1 rest	0.0	0.0	HUVEC TNF alpha + IL4	0.0	0.0
Secondary Th2 rest	0.0	0.0	HUVEC IL-11	0.0	0.0
Secondary Tr1 rest	0.0	0.0	Lung Microvascular EC none	0.4	0.1

Primary Th1 act	0.0	0.0	Lung Microvascular EC TNFalpha + IL- 1beta	0.0	0.0
Primary Th2 act	0.2	0.0	Microvascular Dermal EC none	0.0	0.0
Primary Tr1 act	0.0	0.0	Microvascular Dermal EC TNFalpha + IL- 1beta	0.1	0.0
Primary Th1 rest	0.0	0.0	Bronchial epithelium TNFalpha + IL1beta	0.0	0.1
Primary Th2 rest	0.1	0.0	Small airway epithelium none	0.0	0.1
Primary Tr1 rest	0.2	0.0	Small airway epithelium TNFalpha + IL- 1beta	1.1	0.4
CD45RA CD4 lymphocyte act	0.0	0.0	Coronary artery SMC rest	0.0	0.0
CD45RO CD4 lymphocyte act	0.1	0.1	Coronary artery SMC TNFalpha + IL-1beta	0.0	0.0
CD8 lymphocyte act	0.0	0.0	Astrocytes rest	0.0	0.0
Secondary CD8 lymphocyte rest	0.0	0.0	Astrocytes TNFalpha + IL- 1beta	0.2	0.2
Secondary CD8 lymphocyte act	0.0	0.0	KU-812 (Basophil) rest	0.0	0.0
CD4 lymphocyte none	0.2	0.0	KU-812 (Basophil) PMA/ionomycin	0.1	0.0
2ry Th1/Th2/Tr1_anti- CD95 CH11	0.0	0.0	CCD1106 (Keratinocytes) none	0.0	0.0
LAK cells rest	0.0	0.0	CCD1106 (Keratinocytes) TNFalpha + IL- 1beta	0.0	0.1
LAK cells IL-2	0.0	0.0	Liver cirrhosis	0.8	0.6
LAK cells IL-2+IL-	0.0	0.0	Lupus kidney	0.2	0.4

12					
LAK cells IL-2+IFN gamma	0.1	0.1	NCI-H292 none	0.0	0.0
LAK cells IL-2+IL-18	0.1	0.0	NCI-H292 IL-4	0.0	0.0
LAK cells PMA/ionomycin	0.0	0.0	NCI-H292 IL-9	0.0	0.1
NK Cells IL-2 rest	0.1	0.0	NCI-H292 IL-13	0.0	0.0
Two Way MLR 3 day	0.0	0.0	NCI-H292 IFN gamma	0.1	0.0
Two Way MLR 5 day	0.0	0.0	HPAEC none	0.1	0.0
Two Way MLR 7 day	0.0	0.0	HPAEC TNF alpha + IL-1 beta	0.0	0.0
PBMC rest	0.0	0.0	Lung fibroblast none	0.1	0.0
PBMC PWM	0.3	0.1	Lung fibroblast TNF alpha + IL-1 beta	0.1	0.0
PBMC PHA-L	0.1	0.0	Lung fibroblast IL-4	0.0	0.1
Ramos (B cell) none	0.0	0.0	Lung fibroblast IL-9	0.4	0.1
Ramos (B cell) ionomycin	0.0	0.0	Lung fibroblast IL-13	0.1	0.0
B lymphocytes PWM	0.1	0.0	Lung fibroblast IFN gamma	0.5	0.1
B lymphocytes CD40L and IL-4	0.0	0.0	Dermal fibroblast CCD1070 rest	0.1	0.1
EOL-1 dbcAMP	0.0	0.0	Dermal fibroblast CCD1070 TNF alpha	0.0	0.0
EOL-1 dbcAMP PMA/ionomycin	0.2	0.1	Dermal fibroblast CCD1070 IL-1 beta	0.0	0.0
Dendritic cells none	0.0	0.0	Dermal fibroblast IFN gamma	0.1	0.0
Dendritic cells LPS	0.0	0.1	Dermal fibroblast IL-4	0.0	0.1
Dendritic cells anti-CD40	0.0	0.0	IBD Colitis 2	0.0	0.0
Monocytes rest	0.0	0.0	IBD Crohn's	1.0	2.2

Monocytes LPS	0.0	0.0	Colon	100.0	100.0
Macrophages rest	0.0	0.0	Lung	0.2	0.0
Macrophages LPS	0.0	0.0	Thymus	1.3	0.9
HUVEC none	0.0	0.0	Kidney	0.5	0.0
HUVEC starved	0.0	0.0			

Table GK. Panel 5 Islet

Tissue Name	Rel. Exp.(%) Ag3953, Run 223846464	Tissue Name	Rel. Exp.(%) Ag3953, Run 223846464
97457_Patient-02go_adipose	0.0	94709_Donor 2 AM - A_adipose	0.0
97476_Patient-07sk_skeletal muscle	0.0	94710_Donor 2 AM - B_adipose	0.0
97477_Patient-07ut_uterus	0.0	94711_Donor 2 AM - C_adipose	0.0
97478_Patient-07pl_placenta	0.0	94712_Donor 2 AD - A_adipose	0.0
99167_Bayer Patient 1	0.0	94713_Donor 2 AD - B_adipose	0.0
97482_Patient-08ut_uterus	0.0	94714_Donor 2 AD - C_adipose	0.0
97483_Patient-08pl_placenta	3.7	94742_Donor 3 U - A_Mesenchymal Stem Cells	0.0
97486_Patient-09sk_skeletal muscle	0.0	94743_Donor 3 U - B_Mesenchymal Stem Cells	0.0
97487_Patient-09ut_uterus	3.8	94730_Donor 3 AM - A_adipose	4.4
97488_Patient-09pl_placenta	0.0	94731_Donor 3 AM - B_adipose	0.0
97492_Patient-10ut_uterus	0.0	94732_Donor 3 AM - C_adipose	0.0
97493_Patient-10pl_placenta	0.0	94733_Donor 3 AD - A_adipose	0.0
97495_Patient-11go_adipose	0.0	94734_Donor 3 AD - B_adipose	0.0
97496_Patient-11sk_skeletal muscle	3.3	94735_Donor 3 AD - C_adipose	3.6
97497_Patient-11ut_uterus	0.0	77138_Liver_HepG2untreated	0.0
97498_Patient-	4.0	73556_Heart_Cardiac stromal cells	0.0

11pl_placenta		(primary)	
97500_Patient-12go_adipose	4.2	81735_Small Intestine	100.0
97501_Patient-12sk_skeletal muscle	3.5	72409_Kidney_Proximal Convoluted Tubule	0.0
97502_Patient-12ut_uterus	0.0	82685_Small intestine_Duodenum	0.0
97503_Patient-12pl_placenta	0.0	90650_Adrenal_Adrenocortical adenoma	0.0
94721_Donor 2 U - A_Mesenchymal Stem Cells	0.0	72410_Kidney_HRCE	0.0
94722_Donor 2 U - B_Mesenchymal Stem Cells	4.0	72411_Kidney_HRE	0.0
94723_Donor 2 U - C_Mesenchymal Stem Cells	0.0	73139_Uterus_Uterine smooth muscle cells	0.0

CNS_neurodegeneration_v1.0 Summary: Ag2622/Ag6050 Two experiments with two different probe and primer sets confirm the expression of the CG55794-07 gene in the CNS; See panel 1.3d for a discussion of utility of this gene in the central nervous system.

General_screening_panel_v1.4 Summary/General_screening_panel_v1.5

5 **Summary:** Ag3953/Ag6050 Two experiments with two different probe and primer sets show highest expression of the CG55794-07 gene is seen in an ovarian cancer cell line (CT=33.1). Thus, expression of this gene could be used to differentiate between this sample and other samples on this panel. Please see Panel 1.3D for further discussion of the utility of this gene in cancer.

10 As in the previous panel, this gene is also expressed in the brain, including the cerebral cortex, substantia nigra and thalamus. Please see Panel 1.3D for discussion of utility of this gene in the central nervous system.

15 **Panel 1.3D Summary:** Ag2622 Two experiments with the same probe and primer sets produce results that are in reasonable agreement, with highest expression of the CG55794-07 gene in the brain and the kidney. Interestingly, there is significantly lower expression in the brain cancer cell

lines than normal brain samples. This suggests that absence of this gene might be involved in cell proliferation. Hence this might be used as a diagnostic marker for brain cancer.

As seen in previous panels, the CG55794-07 gene is also expressed at low levels in the CNS. Carboxypeptidase is believed to have a role in the degradation of APP and A-beta, the major component of senile plaques in Alzheimer's disease. Therapeutic upregulation of this gene or its protein product may therefore be of benefit in the treatment of Alzheimer's disease.

References:

Matsumoto A, Itoh K, Matsumoto R. A novel carboxypeptidase B that processes native beta-amyloid precursor protein is present in human hippocampus. *Eur J Neurosci* 2000 Jan;12(1):227-38

The processing of beta-amyloid precursor protein (APP) and generation of beta-amyloid (A β) are associated with the pathophysiology of Alzheimer's disease (AD). As the proteases responsible for the process in the human brain have yet to be clarified, we have searched for activities capable of cleaving native brain APP in the human hippocampus. A 40-kDa protein with proteolytic activity that degrades native brain APP in vitro was purified and characterized; molecular analysis identified it as a novel protease belonging to the carboxypeptidase B (CPB) family. PC12 cells overexpressing the cDNA encoding this protease generate a major 12-kDa beta-amyloid-bearing peptide in cytosol, a peptide which has also been detected in a cell-free system using purified brain APP as substrate. Although the protease is homologous to plasma CPB synthesized in liver, it has specific domains such as C-terminal 14 amino acid residues. Western analysis, cDNA-cloning process and Northern analysis suggested a brain-specific expression of this protease. An immunohistochemical study showed that the protease is expressed in various neuronal perikarya, including those of pyramidal neurons of the hippocampus and ependymal-choroid plexus cells, and in a portion of the microglia of normal brains. In brains of patients with sporadic AD, there is decreased neuronal expression of the protease, and clusters of microglia with protease immunoreactivity associated with its extracellular deposition are detected. These findings suggest that brain CPB has a physiological function in APP processing and may have significance in AD pathophysiology.

Panel 2D Summary: Ag2622 The CG55794-07 gene is expressed at low levels in the tissues used for panel 2D, with reasonable concordance between the runs. There is increased expression in normal prostate and kidney compared to the adjacent tumor tissues. There is also increased expression in breast cancer tissues compared to normal breast tissue. Hence, expression of this gene can be used as a diagnostic marker in breast, prostate and kidney cancer. Furthermore, therapeutic modulation of the gene product might be of use in the treatment of these cancers.

Panel 3D Summary: Ag2622 Expression of the CG55794-07 gene is low/undetectable in all samples on this panel (CTs>35).

Panel 4.1D Summary: Ag6050 The CG55794-07 transcript is expressed in EOL cells, fibroblasts and in normal kidney, thymus and colon. Low expression is noted in T cells, LAK cells, and B cells. The expression pattern with this set of primers and probe, which is specific to this gene, is different than that seen with the Ag2622 probe and primers, particularly in the colon, where expression of the transcript is comparatively low. Thus, this transcript or the protein it encodes could be used to identify the tissues where it is expressed, including kidney, and thymus.

Panel 4D Summary: Ag 2622 In two experiments with the same probe and primer set, the CG55794-07 gene, which encodes a putative carboxypeptidase, is expressed in the colon and down regulated in colon tissue isolated from Crohn's and colitis patients. The carboxypeptidase family of enzymes has been found in the colon and is associated with colon disease (ref. below). Thus, the expression of the transcript or the protein it encodes could be used to detect normal colon tissue. Furthermore, therapeutics designed with the protein encoded for by this transcript could be important in the treatment of IBD.

References:

Sommer H, Schweisfurth H, Schulz M. Serum angiotensin-I-converting enzyme and carboxypeptidase N in Crohn's disease and ulcerative colitis. *Enzyme* 1986;35(4):181-8

Angiotensin-I-converting enzyme (ACE) and carboxypeptidase N1 and N2 (CPN1, CPN2) inactivate kinins and might therefore play a role in the development of inflammatory reactions

via an influence on the release of prostaglandins and inactivation of anaphylatoxic peptides of the complement system. In the present study, the serum activity of these enzymes was determined in 60 patients with Crohn's disease, 18 patients with ulcerative colitis and 70 healthy control subjects. ACE was significantly lowered in active Crohn's disease (CDAI greater than 150) and in ulcerative colitis (p less than 0.01), as long as the ileum or cecum was affected. Since ACE was detected in high concentrations in the human intestinal mucosa, decreased values may be explained by damage to the site of its production. CPN1 and CPN2 were raised in both diseases (p less than 0.005), irrespective of their activity and location. These alterations in the activity of the kininases investigated may play a role in the pathogenesis of inflammatory bowel diseases.

Panel 5 Islet Summary: Ag3953 The CG55794-07 gene, a carboxypeptidase homolog, has little to no expression in any of the endocrine/metabolically-related tissues except for small intestine. This expression profile is in agreement with the results from Panel 4D.

Carboxypeptidase-B processing of GI peptides (e.g. GLP-2 and CCK) is critical for bioactivity.

Thus, a therapeutic modulator of this gene and/or gene-product may prove useful in treating diseases associated with the GI tract and metabolism.

References:

Orskov C, Buhl T, Rabenhoj L, Kofod H, Holst JJ. Carboxypeptidase-B-like processing of the C-terminus of glucagon-like peptide-2 in pig and human small intestine.

FEBS Lett 1989 Apr 24;247(2):193-6

We developed specific, C-terminal radioimmunoassays for three proglucagon (PG) fragments: PG 151-158, PG 151-160 and PG 126-159 (glucagon-like peptide-2 (GLP-2] in order to determine the exact C-terminal sequence of the newly isolated GLP-2 in man and pig. The antigens and the antisera showed no mutual cross-reactivity. By gel filtration of extracts of pig and human small intestine, the immunoreactivity eluting at the position of GLP-2 was identified by the radioimmunoassays for glucagon-like peptide-2 (PG 126-159) and for PG 151-158, whereas the assay for PG 151-160 was completely negative. We conclude that the C-terminal

amino acid residue of pig and human ileal GLP-2 is PG 158. Thus the basic residues, PG 159 and 160 are removed during its processing in the small intestine.

PMID: 2714431

Blanke SE, Johnsen AH, Rehfeld JF. N-terminal fragments of intestinal cholecystokinin:

- 5 evidence for release of CCK-8 by cleavage on the carboxyl side of Arg74 of proCCK. Regul Pept 1993 Jul 23;46(3):575-82

From porcine duodenal mucosa we have identified three major procholecystokinin (proCCK) fragments: desoctaCCK-33, desnonaCCK-33 and desnonaCCK-39. (DesoctaCCK-33 means CCK-33 devoid of the 8 C-terminal amino acids, etc.). The fragments were purified by
10 immunoaffinity chromatography and three steps of reverse phase HPLC monitored by a radioimmunoassay specific for the N-terminal part of CCK-33. The structures could be deduced from the proCCK sequence by N-terminal sequence determination and mass spectrometry. Whereas desnona-fragments of CCK have been described before, this is the first finding of a desoctaCCK, and it indicates that CCK-8 is released from the longer forms by endogenous
15 cleavage of the Arg-Asp-bond. A carboxypeptidase B-like exopeptidase subsequently must produce the desnona-fragments by removing the arginine residue.

NOV10: CG56321-01: novel human MAF-like protein

Expression of gene CG56321-01 was assessed using the primer-probe set Ag3095, described in Table HA. Results of the RTQ-PCR runs are shown in Tables HB, HC, HD and HE.

- 20 Table HA. Probe Name Ag3095

Primers	Sequences	Length	Start Position
Forward	5'-agaagtgccaaactccagagc-3' (SEQ ID NO:377)	20	938
Probe	TET-5'-aggtggagcagctgaagctggaggt-3'-TAMRA (SEQ ID NO:378)	25	959
Reverse	5'-cttgtacaggtcccgcctctt-3' (SEQ ID NO:379)	20	998

Table HB. Panel 1.3D

Tissue Name	Rel. Exp.(%) Ag3095, Run 167985248	Tissue Name	Rel. Exp.(%) Ag3095, Run 167985248
Liver adenocarcinoma	0.0	Kidney (fetal)	0.0
Pancreas	9.3	Renal ca. 786-0	0.0
Pancreatic ca. CAPAN 2	0.0	Renal ca. A498	1.3
Adrenal gland	0.0	Renal ca. RXF 393	0.8
Thyroid	0.5	Renal ca. ACHN	0.0
Salivary gland	0.0	Renal ca. UO-31	0.0
Pituitary gland	0.0	Renal ca. TK-10	1.3
Brain (fetal)	0.0	Liver	0.0
Brain (whole)	0.0	Liver (fetal)	0.0
Brain (amygdala)	6.3	Liver ca. (hepatoblast) HepG2	1.0
Brain (cerebellum)	0.0	Lung	0.0
Brain (hippocampus)	0.0	Lung (fetal)	0.0
Brain (substantia nigra)	0.0	Lung ca. (small cell) LX-1	0.0
Brain (thalamus)	0.0	Lung ca. (small cell) NCI-H69	12.0
Cerebral Cortex	1.6	Lung ca. (s.cell var.) SHP-77	1.6
Spinal cord	0.0	Lung ca. (large cell)NCI-H460	0.0
glio/astro U87-MG	0.0	Lung ca. (non-sm. cell) A549	1.0
glio/astro U-118-MG	0.0	Lung ca. (non-s.cell) NCI-H23	9.2
astrocytoma SW1783	0.0	Lung ca. (non-s.cell) HOP-62	0.0
neuro*; met SK-N-AS	0.0	Lung ca. (non-s.cl) NCI-H522	14.6
astrocytoma SF-539	0.8	Lung ca. (squam.) SW 900	0.0
astrocytoma SNB-75	0.4	Lung ca. (squam.) NCI-H596	2.2
glioma SNB-19	0.0	Mammary gland	0.0
glioma U251	2.0	Breast ca.* (pl.ef) MCF-7	2.2
glioma SF-295	0.0	Breast ca.* (pl.ef) MDA-MB-231	0.0

Heart (fetal)	0.0	Breast ca.* (pl.ef) T47D	6.5
Heart	0.0	Breast ca. BT-549	0.0
Skeletal muscle (fetal)	100.0	Breast ca. MDA-N	0.0
Skeletal muscle	61.1	Ovary	0.0
Bone marrow	0.0	Ovarian ca. OVCAR-3	0.0
Thymus	0.0	Ovarian ca. OVCAR-4	4.2
Spleen	0.0	Ovarian ca. OVCAR-5	9.5
Lymph node	0.0	Ovarian ca. OVCAR-8	5.7
Colorectal	2.6	Ovarian ca. IGROV-1	0.0
Stomach	0.0	Ovarian ca.* (ascites) SK-OV-3	1.6
Small intestine	0.0	Uterus	0.0
Colon ca. SW480	1.9	Placenta	2.6
Colon ca.* SW620(SW480 met)	0.0	Prostate	0.0
Colon ca. HT29	0.0	Prostate ca.* (bone met)PC-3	0.0
Colon ca. HCT-116	0.9	Testis	6.9
Colon ca. CaCo-2	0.6	Melanoma Hs688(A).T	0.6
Colon ca. tissue(ODO3866)	0.0	Melanoma* (met) Hs688(B).T	0.0
Colon ca. HCC-2998	0.0	Melanoma UACC-62	1.3
Gastric ca.* (liver met) NCI-N87	2.1	Melanoma M14	0.0
Bladder	4.1	Melanoma LOX IMVI	0.0
Trachea	0.0	Melanoma* (met) SK-MEL-5	0.4
Kidney	1.0	Adipose	2.9

Table HC. Panel 2.2

Tissue Name	Rel. Exp.(%) Ag3095, Run 174268954	Tissue Name	Rel. Exp.(%) Ag3095, Run 174268954
-------------	--	-------------	--

Normal Colon	0.0	Kidney Margin (OD04348)	0.0
Colon cancer (OD06064)	0.0	Kidney malignant cancer (OD06204B)	0.0
Colon Margin (OD06064)	0.0	Kidney normal adjacent tissue (OD06204E)	4.3
Colon cancer (OD06159)	0.0	Kidney Cancer (OD04450-01)	0.0
Colon Margin (OD06159)	0.0	Kidney Margin (OD04450-03)	3.9
Colon cancer (OD06297-04)	0.0	Kidney Cancer 8120613	0.0
Colon Margin (OD06297-015)	0.0	Kidney Margin 8120614	0.0
CC Gr.2 ascend colon (ODO3921)	0.0	Kidney Cancer 9010320	0.0
CC Margin (ODO3921)	2.1	Kidney Margin 9010321	0.0
Colon cancer metastasis (OD06104)	0.0	Kidney Cancer 8120607	0.0
Lung Margin (OD06104)	0.0	Kidney Margin 8120608	0.0
Colon mets to lung (OD04451-01)	0.0	Normal Uterus	0.0
Lung Margin (OD04451-02)	3.7	Uterine Cancer 064011	0.0
Normal Prostate	0.0	Normal Thyroid	0.0
Prostate Cancer (OD04410)	0.0	Thyroid Cancer 064010	0.0
Prostate Margin (OD04410)	3.2	Thyroid Cancer A302152	0.0
Normal Ovary	0.0	Thyroid Margin A302153	3.4
Ovarian cancer (OD06283-03)	0.0	Normal Breast	0.0
Ovarian Margin (OD06283-07)	0.0	Breast Cancer (OD04566)	0.0
Ovarian Cancer 064008	4.0	Breast Cancer 1024	0.0
Ovarian cancer (OD06145)	0.0	Breast Cancer (OD04590-01)	0.0
Ovarian Margin (OD06145)	0.0	Breast Cancer Mets (OD04590-03)	0.0
Ovarian cancer	0.0	Breast Cancer	0.0

(OD06455-03)		Metastasis (OD04655-05)	
Ovarian Margin (OD06455-07)	0.0	Breast Cancer 064006	0.0
Normal Lung	0.0	Breast Cancer 9100266	0.0
Invasive poor diff. lung adeno (ODO4945-01)	0.0	Breast Margin 9100265	0.0
Lung Margin (ODO4945-03)	0.0	Breast Cancer A209073	3.1
Lung Malignant Cancer (OD03126)	0.0	Breast Margin A2090734	0.0
Lung Margin (OD03126)	0.0	Breast cancer (OD06083)	4.4
Lung Cancer (OD05014A)	4.2	Breast cancer node metastasis (OD06083)	4.3
Lung Margin (OD05014B)	0.0	Normal Liver	0.0
Lung cancer (OD06081)	3.4	Liver Cancer 1026	31.6
Lung Margin (OD06081)	0.0	Liver Cancer 1025	0.0
Lung Cancer (OD04237-01)	2.6	Liver Cancer 6004-T	0.0
Lung Margin (OD04237-02)	9.8	Liver Tissue 6004-N	0.0
Ocular Melanoma Metastasis	0.0	Liver Cancer 6005-T	97.3
Ocular Melanoma Margin (Liver)	0.0	Liver Tissue 6005-N	0.0
Melanoma Metastasis	0.0	Liver Cancer 064003	100.0
Melanoma Margin (Lung)	0.0	Normal Bladder	0.0
Normal Kidney	0.0	Bladder Cancer 1023	0.0
Kidney Ca, Nuclear grade 2 (OD04338)	0.0	Bladder Cancer A302173	0.0
Kidney Margin (OD04338)	0.0	Normal Stomach	0.0
Kidney Ca Nuclear grade 1/2 (OD04339)	0.0	Gastric Cancer 9060397	0.0
Kidney Margin (OD04339)	4.6	Stomach Margin 9060396	4.5
Kidney Ca, Clear cell type (OD04340)	0.0	Gastric Cancer 9060395	0.0

Kidney Margin (OD04340)	4.0	Stomach Margin 9060394	0.0
Kidney Ca, Nuclear grade 3 (OD04348)	0.0	Gastric Cancer 064005	0.0

Table HD. Panel 4D

Tissue Name	Rel. Exp.(%) Ag3095, Run 164392099	Tissue Name	Rel. Exp.(%) Ag3095, Run 164392099
Secondary Th1 act	4.7	HUVEC IL-1beta	0.0
Secondary Th2 act	2.6	HUVEC IFN gamma	0.0
Secondary Tr1 act	0.5	HUVEC TNF alpha + IFN gamma	0.0
Secondary Th1 rest	2.5	HUVEC TNF alpha + IL4	0.0
Secondary Th2 rest	6.6	HUVEC IL-11	0.0
Secondary Tr1 rest	4.2	Lung Microvascular EC none	0.0
Primary Th1 act	9.5	Lung Microvascular EC TNFalpha + IL-1beta	0.0
Primary Th2 act	4.8	Microvascular Dermal EC none	1.0
Primary Tr1 act	3.2	Microvascular Dermal EC TNFalpha + IL-1beta	0.8
Primary Th1 rest	3.1	Bronchial epithelium TNFalpha + IL1beta	0.0
Primary Th2 rest	5.8	Small airway epithelium none	0.5
Primary Tr1 rest	0.0	Small airway epithelium TNFalpha + IL-1beta	0.0
CD45RA CD4 lymphocyte act	0.0	Coronary artery SMC rest	0.0
CD45RO CD4 lymphocyte act	3.0	Coronary artery SMC TNFalpha + IL-1beta	0.0
CD8 lymphocyte act	0.0	Astrocytes rest	0.0
Secondary CD8 lymphocyte rest	2.2	Astrocytes TNFalpha + IL- 1beta	0.0
Secondary CD8 lymphocyte act	3.4	KU-812 (Basophil) rest	0.0
CD4 lymphocyte none	0.0	KU-812 (Basophil) PMA/ionomycin	7.0

2ry Th1/Th2/Tr1_anti-CD95 CH11	18.4	CCD1106 (Keratinocytes) none	0.0
LAK cells rest	0.9	CCD1106 (Keratinocytes) TNFalpha + IL-1beta	0.7
LAK cells IL-2	0.8	Liver cirrhosis	4.2
LAK cells IL-2+IL-12	1.1	Lupus kidney	0.0
LAK cells IL-2+IFN gamma	2.7	NCI-H292 none	0.0
LAK cells IL-2+ IL-18	2.0	NCI-H292 IL-4	2.1
LAK cells PMA/ionomycin	100.0	NCI-H292 IL-9	0.0
NK Cells IL-2 rest	1.5	NCI-H292 IL-13	0.6
Two Way MLR 3 day	0.6	NCI-H292 IFN gamma	0.9
Two Way MLR 5 day	0.7	HPAEC none	0.0
Two Way MLR 7 day	2.8	HPAEC TNF alpha + IL-1 beta	0.0
PBMC rest	0.0	Lung fibroblast none	0.0
PBMC PWM	1.9	Lung fibroblast TNF alpha + IL-1 beta	0.3
PBMC PHA-L	0.8	Lung fibroblast IL-4	0.7
Ramos (B cell) none	0.0	Lung fibroblast IL-9	0.0
Ramos (B cell) ionomycin	1.1	Lung fibroblast IL-13	0.0
B lymphocytes PWM	52.5	Lung fibroblast IFN gamma	0.0
B lymphocytes CD40L and IL-4	62.4	Dermal fibroblast CCD1070 rest	0.0
EOL-1 dbcAMP	17.1	Dermal fibroblast CCD1070 TNF alpha	1.4
EOL-1 dbcAMP PMA/ionomycin	56.6	Dermal fibroblast CCD1070 IL-1 beta	0.0
Dendritic cells none	1.8	Dermal fibroblast IFN gamma	0.0
Dendritic cells LPS	0.9	Dermal fibroblast IL-4	0.0
Dendritic cells anti-CD40	3.1	IBD Colitis 2	0.0
Monocytes rest	0.0	IBD Crohn's	0.0
Monocytes LPS	54.3	Colon	26.2
Macrophages rest	1.0	Lung	9.2
Macrophages LPS	0.0	Thymus	0.0

HUVEC none	0.0	Kidney	3.1
HUVEC starved	3.5		

Table HE. Panel 5D

Tissue Name	Rel. Exp.(%) Ag3095, Run 172171202	Tissue Name	Rel. Exp.(%) Ag3095, Run 172171202
97457_Patient-02go_adipose	0.0	94709_Donor 2 AM - A_adipose	0.0
97476_Patient-07sk_skeletal muscle	3.5	94710_Donor 2 AM - B_adipose	0.0
97477_Patient-07ut_uterus	0.0	94711_Donor 2 AM - C_adipose	0.0
97478_Patient-07pl_placenta	5.3	94712_Donor 2 AD - A_adipose	0.0
97481_Patient-08sk_skeletal muscle	14.5	94713_Donor 2 AD - B_adipose	0.0
97482_Patient-08ut_uterus	0.0	94714_Donor 2 AD - C_adipose	0.0
97483_Patient-08pl_placenta	0.0	94742_Donor 3 U - A_Mesenchymal Stem Cells	2.9
97486_Patient-09sk_skeletal muscle	14.7	94743_Donor 3 U - B_Mesenchymal Stem Cells	0.0
97487_Patient-09ut_uterus	0.0	94730_Donor 3 AM - A_adipose	0.0
97488_Patient-09pl_placenta	3.7	94731_Donor 3 AM - B_adipose	0.0
97492_Patient-10ut_uterus	0.0	94732_Donor 3 AM - C_adipose	0.0
97493_Patient-10pl_placenta	11.9	94733_Donor 3 AD - A_adipose	0.0
97495_Patient-11go_adipose	0.0	94734_Donor 3 AD - B_adipose	0.0
97496_Patient-11sk_skeletal muscle	8.1	94735_Donor 3 AD - C_adipose	0.0
97497_Patient-11ut_uterus	0.0	77138_Liver_HepG2untreated	0.0
97498_Patient-11pl_placenta	2.3	73556_Heart_Cardiac stromal cells (primary)	0.0
97500_Patient-12go_adipose	0.0	81735_Small Intestine	0.0

97501_Patient-12sk_skeletal muscle	100.0	72409_Kidney_Proximal Convoluted Tubule	2.5
97502_Patient-12ut_uterus	0.0	82685_Small intestine_Duodenum	0.0
97503_Patient-12pl_placenta	6.2	90650_Adrenal_Adrenocortical adenoma	4.2
94721_Donor 2 U - A_Mesenchymal Stem Cells	0.0	72410_Kidney_HRCE	0.0
94722_Donor 2 U - B_Mesenchymal Stem Cells	0.0	72411_Kidney_HRE	0.0
94723_Donor 2 U - C_Mesenchymal Stem Cells	1.3	73139_Uterus_Uterine smooth muscle cells	3.8

Panel 1.3D Summary: Ag3095 The CG56321-01 gene is expressed predominantly in skeletal muscle and pancreas (CTs=30-33) as well as in several lung and ovarian cancer cell lines. MAF-like proteins are known to be involved in regulating differentiation. Thus, expression of this gene could be used to differentiate between these samples and other samples on this panel.

- 5 Furthermore, therapeutic modulation of the expression or function of this gene product may be effective in the treatment of cancers that affects these tissues.

Panel 2.2 Summary: Ag3095 Expression of the CG56321-01 gene is restricted to samples derived from liver cancer cell lines (CT=34.4). Thus, expression of this gene could be used to differentiate between this sample and other samples on this panel and as a marker to detect the presence of liver cancer. Furthermore, therapeutic modulation of the expression or function of this gene may be effective in the treatment of liver cancer.

- 10

Panel 4D Summary: Ag3095 Highest expression of the CG56321-01 gene is seen in LAK cells stimulated with PMA/ionomycin (CT=31.3). Significant levels of expression are also seen in activated B lymphocytes and eosinophils. Owing to the importance of eosinophils and T cells in lung pathology, inflammatory bowel disease and autoimmune disorders, including rheumatoid arthritis, antibody or small molecule therapies designed with the protein encoded by this gene could block or inhibit inflammation or tissue damage due to lung conditions including asthma, allergies, hypersensitivity reactions, inflammatory bowel disease, viral infections and

- 15

autoimmune disease. Detection of this gene product in LAK cells also suggests that modulation of the function of this gene product with a small molecule drug or antibody may lead to improvement of symptoms associated with tumor immunology and tumor cell clearance, as well as removal of virally and bacterial infected cells.

- 5 **Panel 5D Summary:** Ag3095 The CG56321-01 gene is expressed exclusively in skeletal muscle of an individual who is diagnosed with gestational diabetes and is being treated with insulin (CT=33). Thus, the physiological role of this gene product may extend beyond regulating differentiation and also include regulating the physiology of skeletal muscle under conditions of metabolic stress.

10 **NOV11a and NOV11b: CG56381-01 and CG56381-02: lysyl oxidase**

Expression of gene CG56381-01 and variant CG56381-02 was assessed using the primer-probe sets Ag2916 and Ag2921, described in Tables IA and IB. Results of the RTQ-PCR runs are shown in Tables IC, ID and IE.

Table IA. Probe Name Ag2916

Primers	Sequences	Length	Start Position
Forward	5'-cattgaggtcttcacccactac-3' (SEQ ID NO:380)	22	1898
Probe	TET-5'-ctcctcactctcaatggctccaaggt-3'-TAMRA (SEQ ID NO:381)	26	1923
Reverse	5'-gtttgtgtcctccagacagaag-3' (SEQ ID NO:382)	22	1970

15 Table IB. Probe Name Ag2921

Primers	Sequences	Length	Start Position
Forward	5'-cattgaggtcttcacccactac-3' (SEQ ID NO:383)	22	1898
Probe	TET-5'-ctcctcactctcaatggctccaaggt-3'-TAMRA (SEQ ID NO:384)	26	1923
Reverse	5'-gtttgtgtcctccagacagaag-3' (SEQ ID NO:385)	22	1970

Table IC. Panel 1.3D

Tissue Name	Rel. Exp.(%) Ag2916, Run	Rel. Exp.(%) Ag2921, Run	Tissue Name	Rel. Exp.(%) Ag2916, Run	Rel. Exp.(%) Ag2921, Run
-------------	-----------------------------	-----------------------------	-------------	-----------------------------	-----------------------------

	167649470	167862040		167649470	167862040
Liver adenocarcinoma	31.6	23.7	Kidney (fetal)	4.5	3.2
Pancreas	1.8	1.4	Renal ca. 786-0	0.3	0.2
Pancreatic ca. CAPAN 2	100.0	100.0	Renal ca. A498	0.1	0.1
Adrenal gland	0.4	0.2	Renal ca. RXF 393	8.8	6.4
Thyroid	2.2	0.7	Renal ca. ACHN	25.3	16.0
Salivary gland	1.7	0.9	Renal ca. UO-31	3.6	3.2
Pituitary gland	0.5	0.1	Renal ca. TK-10	0.6	0.4
Brain (fetal)	0.3	0.1	Liver	0.4	0.3
Brain (whole)	0.3	0.2	Liver (fetal)	6.4	6.1
Brain (amygdala)	0.0	0.3	Liver ca. (hepatoblast) HepG2	5.1	3.7
Brain (cerebellum)	0.7	0.3	Lung	1.3	0.6
Brain (hippocampus)	0.1	0.2	Lung (fetal)	0.9	0.4
Brain (substantia nigra)	0.4	0.2	Lung ca. (small cell) LX-1	0.7	0.7
Brain (thalamus)	0.5	0.1	Lung ca. (small cell) NCI-H69	0.4	0.1
Cerebral Cortex	0.1	0.1	Lung ca. (s.cell var.) SHP-77	2.6	2.1
Spinal cord	0.3	0.2	Lung ca. (large cell) NCI-H460	6.0	0.1
glio/astro U87-MG	0.4	0.1	Lung ca. (non-sm. cell) A549	2.0	1.2
glio/astro U-118-MG	0.5	0.2	Lung ca. (non-s.cell) NCI-H23	0.9	0.5
astrocytoma SW1783	0.3	0.2	Lung ca. (non-s.cell) HOP-62	2.8	1.7
neuro*; met SK-N-AS	0.1	0.2	Lung ca. (non-s.cl) NCI-H522	0.2	0.2

astrocytoma SF-539	8.9	8.2	Lung ca. (squam.) SW 900	3.6	2.4
astrocytoma SNB-75	2.1	1.8	Lung ca. (squam.) NCI-H596	1.9	1.2
glioma SNB-19	3.6	2.7	Mammary gland	5.1	3.7
glioma U251	29.9	28.5	Breast ca.* (pl.ef) MCF-7	0.7	0.3
glioma SF-295	0.4	0.4	Breast ca.* (pl.ef) MDA-MB-231	9.0	6.0
Heart (fetal)	0.9	0.4	Breast ca.* (pl.ef) T47D	0.6	1.1
Heart	0.4	0.2	Breast ca. BT-549	0.1	0.1
Skeletal muscle (fetal)	4.9	2.9	Breast ca. MDA-N	1.1	0.8
Skeletal muscle	2.5	3.2	Ovary	2.0	1.4
Bone marrow	0.1	0.0	Ovarian ca. OVCAR-3	0.3	0.3
Thymus	0.9	0.3	Ovarian ca. OVCAR-4	0.7	0.5
Spleen	0.2	0.2	Ovarian ca. OVCAR-5	27.5	18.7
Lymph node	0.4	0.5	Ovarian ca. OVCAR-8	0.4	0.2
Colorectal	0.9	0.7	Ovarian ca. IGROV-1	0.2	0.2
Stomach	0.4	0.5	Ovarian ca.* (ascites) SK-OV-3	2.6	2.1
Small intestine	0.9	1.4	Uterus	2.3	1.4
Colon ca. SW480	5.3	3.5	Placenta	0.2	0.1
Colon ca.* SW620(SW480 met)	5.9	5.0	Prostate	0.6	0.3
Colon ca. HT29	0.8	0.7	Prostate ca.* (bone met)PC-3	2.8	1.4
Colon ca. HCT-	0.3	0.3	Testis	1.8	2.7

116					
Colon ca. CaCo-2	0.8	0.7	Melanoma Hs688(A).T	2.7	2.4
Colon ca. tissue(ODO3866)	0.2	0.1	Melanoma* (met) Hs688(B).T	3.1	2.7
Colon ca. HCC- 2998	0.3	0.3	Melanoma UACC-62	0.3	0.4
Gastric ca.* (liver met) NCI-N87	43.5	37.6	Melanoma M14	1.0	1.0
Bladder	2.1	1.6	Melanoma LOX IMVI	0.5	0.4
Trachea	2.0	1.5	Melanoma* (met) SK- MEL-5	0.3	0.2
Kidney	1.6	0.9	Adipose	1.5	1.3

Table ID. Panel 2.2

Tissue Name	Rel. Exp.(%) Ag2916, Run 175119162	Rel. Exp.(%) Ag2921, Run 175119364	Tissue Name	Rel. Exp.(%) Ag2916, Run 175119162	Rel. Exp.(%) Ag2921, Run 175119364
Normal Colon	15.4	13.1	Kidney Margin (OD04348)	79.6	59.0
Colon cancer (OD06064)	5.9	1.7	Kidney malignant cancer (OD06204B)	3.6	5.1
Colon Margin (OD06064)	5.8	5.7	Kidney normal adjacent tissue (OD06204E)	18.8	9.9
Colon cancer (OD06159)	1.1	0.0	Kidney Cancer (OD04450-01)	16.8	10.7
Colon Margin (OD06159)	15.6	8.3	Kidney Margin (OD04450-03)	12.9	12.9
Colon cancer (OD06297-04)	0.9	1.8	Kidney Cancer 8120613	0.0	0.8
Colon Margin (OD06297-015)	22.8	15.2	Kidney Margin 8120614	12.8	3.9
CC Gr.2 ascend colon (ODO3921)	0.3	0.9	Kidney Cancer 9010320	3.7	1.7

CC Margin (ODO3921)	2.6	6.6	Kidney Margin 9010321	10.5	8.4
Colon cancer metastasis (OD06104)	0.9	1.0	Kidney Cancer 8120607	6.9	8.7
Lung Margin (OD06104)	2.1	2.1	Kidney Margin 8120608	7.4	5.1
Colon mets to lung (OD04451-01)	4.5	1.7	Normal Uterus	51.4	37.4
Lung Margin (OD04451-02)	11.0	4.7	Uterine Cancer 064011	5.4	8.8
Normal Prostate	6.0	6.1	Normal Thyroid	2.9	6.5
Prostate Cancer (OD04410)	5.1	4.7	Thyroid Cancer 064010	8.6	5.5
Prostate Margin (OD04410)	5.6	7.3	Thyroid Cancer A302152	7.4	15.0
Normal Ovary	20.3	24.0	Thyroid Margin A302153	6.1	1.0
Ovarian cancer (OD06283-03)	3.7	2.6	Normal Breast	35.1	28.1
Ovarian Margin (OD06283-07)	6.1	3.6	Breast Cancer (OD04566)	0.0	0.0
Ovarian Cancer 064008	18.0	30.1	Breast Cancer 1024	18.3	15.1
Ovarian cancer (OD06145)	0.7	3.2	Breast Cancer (OD04590-01)	6.5	4.8
Ovarian Margin (OD06145)	19.1	30.1	Breast Cancer Mets (OD04590-03)	7.0	12.1
Ovarian cancer (OD06455-03)	2.2	1.3	Breast Cancer Metastasis (OD04655-05)	3.0	3.4
Ovarian Margin (OD06455-07)	9.5	7.0	Breast Cancer 064006	2.1	3.3
Normal Lung	7.7	8.2	Breast Cancer 9100266	6.8	5.6
Invasive poor diff. lung adeno (ODO4945-01)	0.9	0.0	Breast Margin 9100265	5.9	5.8
Lung Margin (ODO4945-03)	11.3	10.4	Breast Cancer A209073	8.5	3.9

Lung Malignant Cancer (OD03126)	5.0	1.2	Breast Margin A2090734	21.9	15.0
Lung Margin (OD03126)	2.6	1.5	Breast cancer (OD06083)	11.3	8.1
Lung Cancer (OD05014A)	5.0	2.3	Breast cancer node metastasis (OD06083)	1.7	9.3
Lung Margin (OD05014B)	12.6	3.4	Normal Liver	5.6	8.4
Lung cancer (OD06081)	13.7	6.6	Liver Cancer 1026	59.9	48.0
Lung Margin (OD06081)	4.6	6.5	Liver Cancer 1025	11.3	15.5
Lung Cancer (OD04237-01)	3.4	2.3	Liver Cancer 6004-T	7.9	9.9
Lung Margin (OD04237-02)	18.4	8.1	Liver Tissue 6004-N	2.6	2.7
Ocular Melanoma Metastasis	12.9	14.2	Liver Cancer 6005-T	100.0	100.0
Ocular Melanoma Margin (Liver)	13.7	11.6	Liver Tissue 6005-N	15.0	8.4
Melanoma Metastasis	1.1	1.4	Liver Cancer 064003	7.1	12.4
Melanoma Margin (Lung)	12.4	9.6	Normal Bladder	5.6	8.5
Normal Kidney	9.8	5.3	Bladder Cancer 1023	1.6	0.0
Kidney Ca, Nuclear grade 2 (OD04338)	45.1	33.4	Bladder Cancer A302173	2.0	3.4
Kidney Margin (OD04338)	4.9	12.2	Normal Stomach	13.4	15.6
Kidney Ca Nuclear grade 1/2 (OD04339)	43.5	29.1	Gastric Cancer 9060397	1.2	0.5
Kidney Margin (OD04339)	6.9	4.6	Stomach Margin 9060396	1.0	3.0
Kidney Ca, Clear cell type	22.4	11.5	Gastric Cancer 9060395	12.2	5.8

(OD04340)					
Kidney Margin (OD04340)	24.8	14.0	Stomach Margin 9060394	13.3	7.5
Kidney Ca, Nuclear grade 3 (OD04348)	3.6	2.0	Gastric Cancer 064005	5.2	3.1

Table IE. Panel 4D

Tissue Name	Rel. Exp.(%) Ag2916, Run 164310645	Rel. Exp.(%) Ag2921, Run 164310646	Tissue Name	Rel. Exp.(%) Ag2916, Run 164310645	Rel. Exp.(%) Ag2921, Run 164310646
Secondary Th1 act	1.3	0.7	HUVEC IL-1beta	0.3	1.7
Secondary Th2 act	2.7	1.5	HUVEC IFN gamma	0.8	0.8
Secondary Tr1 act	1.2	1.5	HUVEC TNF alpha + IFN gamma	0.5	0.7
Secondary Th1 rest	0.8	0.4	HUVEC TNF alpha + IL4	0.8	0.8
Secondary Th2 rest	0.8	1.1	HUVEC IL-11	0.9	0.8
Secondary Tr1 rest	0.8	0.6	Lung Microvascular EC none	1.6	3.3
Primary Th1 act	3.5	1.3	Lung Microvascular EC TNFalpha + IL- 1beta	1.6	1.5
Primary Th2 act	1.0	1.3	Microvascular Dermal EC none	1.2	0.6
Primary Tr1 act	3.2	2.3	Microvascular Dermal EC TNFalpha + IL- 1beta	0.7	0.5
Primary Th1 rest	4.5	3.2	Bronchial epithelium TNFalpha + IL1beta	1.6	1.3
Primary Th2 rest	2.3	1.5	Small airway epithelium none	0.9	1.0
Primary Tr1 rest	1.5	2.3	Small airway	2.5	3.4

			epithelium TNFalpha + IL- 1beta		
CD45RA CD4 lymphocyte act	2.4	3.0	Coronary artery SMC rest	9.7	8.0
CD45RO CD4 lymphocyte act	1.4	1.6	Coronary artery SMC TNFalpha + IL-1beta	4.5	3.1
CD8 lymphocyte act	0.7	0.7	Astrocytes rest	12.6	11.7
Secondary CD8 lymphocyte rest	1.0	0.7	Astrocytes TNFalpha + IL- 1beta	49.0	30.8
Secondary CD8 lymphocyte act	0.9	0.7	KU-812 (Basophil) rest	0.5	0.6
CD4 lymphocyte none	1.2	0.9	KU-812 (Basophil) PMA/ionomycin	1.1	1.3
2ry Th1/Th2/Tr1_anti- CD95 CH11	1.2	1.4	CCD1106 (Keratinocytes) none	1.3	0.7
LAK cells rest	1.6	1.7	CCD1106 (Keratinocytes) TNFalpha + IL- 1beta	0.4	0.8
LAK cells IL-2	1.3	2.0	Liver cirrhosis	2.6	2.4
LAK cells IL-2+IL- 12	1.3	1.4	Lupus kidney	1.0	1.7
LAK cells IL- 2+IFN gamma	4.4	3.0	NCI-H292 none	1.5	2.8
LAK cells IL-2+ IL-18	1.7	1.4	NCI-H292 IL-4	8.0	7.5
LAK cells PMA/ionomycin	0.4	0.8	NCI-H292 IL-9	1.6	4.2
NK Cells IL-2 rest	1.6	1.1	NCI-H292 IL-13	5.3	3.1
Two Way MLR 3 day	2.5	2.1	NCI-H292 IFN gamma	0.6	1.3
Two Way MLR 5 day	1.2	1.0	HPAEC none	0.8	0.4
Two Way MLR 7 day	1.4	0.6	HPAEC TNF alpha + IL-1 beta	0.5	0.6
PBMC rest	0.6	1.2	Lung fibroblast none	17.7	15.4

PBMC PWM	6.7	2.5	Lung fibroblast TNF alpha + IL-1 beta	4.2	3.3
PBMC PHA-L	0.8	2.1	Lung fibroblast IL- 4	20.6	11.7
Ramos (B cell) none	2.0	2.4	Lung fibroblast IL- 9	25.5	17.8
Ramos (B cell) ionomycin	5.8	4.9	Lung fibroblast IL- 13	9.0	7.7
B lymphocytes PWM	2.5	2.6	Lung fibroblast IFN gamma	15.8	13.2
B lymphocytes CD40L and IL-4	2.2	2.4	Dermal fibroblast CCD1070 rest	14.2	10.1
EOL-1 dbcAMP	0.7	1.1	Dermal fibroblast CCD1070 TNF alpha	12.2	15.4
EOL-1 dbcAMP PMA/ionomycin	2.4	1.4	Dermal fibroblast CCD1070 IL-1 beta	8.2	4.7
Dendritic cells none	1.9	0.7	Dermal fibroblast IFN gamma	100.0	100.0
Dendritic cells LPS	0.7	1.3	Dermal fibroblast IL-4	55.5	38.2
Dendritic cells anti- CD40	1.3	0.8	IBD Colitis 2	0.0	0.1
Monocytes rest	2.0	1.7	IBD Crohn's	0.4	0.2
Monocytes LPS	2.3	1.7	Colon	2.7	1.8
Macrophages rest	0.9	1.4	Lung	4.6	2.4
Macrophages LPS	0.8	0.5	Thymus	5.6	2.8
HUVEC none	0.8	1.4	Kidney	3.6	2.6
HUVEC starved	2.6	2.4			

Panel 1.3D Summary: Ag2916/Ag2921 The expression of the CG56381-01 gene was assessed in two independent runs with the same probe and primer set, with good concordance between the runs. Highest expression is seen in a pancreatic cancer cell line CAPAN2 (CTs=26).

Additionally, moderate expression is seen in a liver cell line as well as brain, colon, gastric,

- 5 renal, lung, ovarian cancer cell lines as well as some melanoma cell lines. Thus, the expression of this gene might be associated with these forms of cancer and therapeutic modulation of this gene might be of use in the treatment of these cancers.

References:

Csiszar K.; Lysyl oxidases: a novel multifunctional amine oxidase family. *Prog Nucleic Acid Res Mol Biol* 2001;70:1-32.

Lysyl oxidase (LOX), a copper-containing amine oxidase, belongs to a heterogeneous family of enzymes that oxidize primary amine substrates to reactive aldehydes. LOX has been traditionally known for one function, the extracellular catalysis of lysine-derived cross-links in fibrillar collagens and elastin. More recently, diverse roles have been attributed to lysyl oxidase and these novel activities cover a spectrum of diverse biological functions such as developmental regulation, tumor suppression, cell motility, and cellular senescence. Lysyl oxidase has also been shown to have both intracellular and intranuclear locations. The multifunctional properties of lysyl oxidase (LOX) and our recent discovery of three novel members of this amine oxidase family, LOX-like (LOXL), LOXL2, and LOXL3, indicate the possibility that these varied functions are performed in both intracellular and extracellular environments by individual novel members of the LOX amine-oxidase family. Structural similarities of the highly conserved copper-binding and lysyl-tyrosylquinone cofactor sites among the LOX and LOX-like proteins may result in similar amine oxidase activities. However, specific novel functions, such as a potential role in cell adhesion and cell growth control, will be determined by other, conserved domains such as the cytokine receptor-like domain that is shared by all LOXs and by multiple scavenger receptor cysteine-rich (SRCR) domains present in LOXL2 and LOXL3. Furthermore, these functions may be carried out in a temporally and spatially regulated fashion.

PMID: 11642359

Panel 2.2 Summary: Ag2916/Ag2921 Two experiments with the same probe and primer set produce results that are in excellent agreement, with highest expression of the CG56381-01 gene in liver cancer (CTs=30). In addition, liver cancers express this gene at a higher level than the normal adjacent liver tissue. Conversely normal ovary and colon tissue express higher level of this gene than the adjacent tumor tissue. Thus, expresseion of this gene can be used as a diagnostic marker for the presence of these cancers. Furthermore, therapetic modulation of this gene using antibodies and small molecule may be useful in the treatment of liver cancer.

Panel 4D Summary: Ag2916/Ag2921 Two experiments with the same probe and primer set produce results that are in excellent agreement, with highest expression of the CG56381-01 gene dermal fibroblasts treated with the proinflammatory cytokines IL-4 and gamma interferon (CTs=26). The transcript, which encodes a putative lysyl oxidase, is expressed at low levels in most tissues in the panel. This enzyme is associated with dermal fibroblasts and is increased in scleroderma. Thus, the transcript or the protein it encodes could be used to identify activated dermal fibroblasts and as a diagnostic reagent for scleroderma. In addition, therapeutics designed with the protein encoded by this transcript could be important for the treatment of scleroderma and other skin diseases such as psoriasis.

10 References:

Chanoki M, Ishii M, Kobayashi H, Fushida H, Yashiro N, Hamada T, Ooshima A. Increased expression of lysyl oxidase in skin with scleroderma. *Br J Dermatol* 1995 Nov;133(5):710-5

Lysyl oxidase initiates cross-linkage of collagen and elastin by catalysing the formation of a lysine-derived aldehyde. In order to study cross-linking in scleroderma, we used monoclonal antibodies to lysyl oxidase to determine the localization of this enzyme in systemic and localized scleroderma, and compared the distributions obtained with that in normal skin. Using an indirect immunofluorescent antibody method and an avidin-biotinylated enzyme complex method, 11 cases of diffuse type of systemic scleroderma and seven cases of localized scleroderma were studied. In the oedematous stage of systemic scleroderma, intracellular and extracellular lysyl oxidase were remarkably increased in the dermis, particularly in groups around blood vessels. In the sclerotic stage of systemic scleroderma, lysyl oxidase was detected intracellularly in fibroblasts and extracellularly among collagen bundles between the lower dermis and the subcutaneous fat tissue. In localized scleroderma, a marked increase in lysyl oxidase was observed in mononuclear cells and fibroblasts near blood vessels in the lower dermis and in the subcutaneous fat tissue, in addition to the extracellular deposits between collagen bundles. The increase in lysyl oxidase in localized scleroderma was much more common than in the oedematous stage of systemic scleroderma. These findings indicated that intracellular and extracellular expression of lysyl oxidase expression was greater in sclerodermatous skin than in normal skin.

NOV12a and NOV12b: CG56436-01 and CG56436-02: Phosphatase like

Expression of gene CG56436-01 and variant CG56436-02 was assessed using the primer-probe set Ag2927, described in Table JA. Results of the RTQ-PCR runs are shown in Tables JB and JC.

5 Table JA. Probe Name Ag2927

Primers	Sequences	Length	Start Position
Forward	5'-ctatctagggacggcaggat-3' (SEQ ID NO:386)	20	137
Probe	TET-5'-ctcctgaccttcgacttcgacgaga-3'-TAMRA (SEQ ID NO:387)	25	182
Reverse	5'-gctgttttcgtccacgatag-3' (SEQ ID NO:388)	20	207

Table JB. Panel 1.3D

Tissue Name	Rel. Exp.(%) Ag2927, Run 167862124	Tissue Name	Rel. Exp.(%) Ag2927, Run 167862124
Liver adenocarcinoma	1.1	Kidney (fetal)	11.0
Pancreas	0.1	Renal ca. 786-0	0.1
Pancreatic ca. CAPAN 2	0.1	Renal ca. A498	0.4
Adrenal gland	0.3	Renal ca. RXF 393	0.2
Thyroid	0.0	Renal ca. ACHN	0.0
Salivary gland	0.1	Renal ca. UO-31	0.0
Pituitary gland	0.1	Renal ca. TK-10	0.4
Brain (fetal)	0.0	Liver	0.1
Brain (whole)	0.9	Liver (fetal)	29.1
Brain (amygdala)	0.0	Liver ca. (hepatoblast) HepG2	0.0
Brain (cerebellum)	0.5	Lung	0.6
Brain (hippocampus)	0.1	Lung (fetal)	0.3
Brain (substantia nigra)	0.6	Lung ca. (small cell) LX-1	0.1
Brain (thalamus)	1.6	Lung ca. (small cell) NCI-H69	0.0
Cerebral Cortex	1.5	Lung ca. (s.cell var.) SHP-77	0.1
Spinal cord	0.4	Lung ca. (large	0.0

		cell)NCI-H460	
glio/astro U87-MG	0.4	Lung ca. (non-sm. cell) A549	0.2
glio/astro U-118-MG	0.2	Lung ca. (non-s.cell) NCI-H23	0.1
astrocytoma SW1783	0.4	Lung ca. (non-s.cell) HOP-62	0.0
neuro*; met SK-N-AS	0.0	Lung ca. (non-s.cl) NCI-H522	0.1
astrocytoma SF-539	0.0	Lung ca. (squam.) SW 900	0.2
astrocytoma SNB-75	0.3	Lung ca. (squam.) NCI-H596	0.0
glioma SNB-19	0.0	Mammary gland	0.2
glioma U251	0.0	Breast ca.* (pl.ef) MCF-7	0.0
glioma SF-295	1.7	Breast ca.* (pl.ef) MDA-MB-231	0.0
Heart (fetal)	100.0	Breast ca.* (pl.ef) T47D	0.0
Heart	0.1	Breast ca. BT-549	0.0
Skeletal muscle (fetal)	1.3	Breast ca. MDA-N	0.0
Skeletal muscle	0.2	Ovary	0.1
Bone marrow	6.6	Ovarian ca. OVCAR-3	0.1
Thymus	0.3	Ovarian ca. OVCAR-4	3.8
Spleen	0.9	Ovarian ca. OVCAR-5	0.6
Lymph node	0.7	Ovarian ca. OVCAR-8	0.3
Colorectal	0.0	Ovarian ca. IGROV-1	0.0
Stomach	0.2	Ovarian ca.* (ascites) SK-OV-3	0.5
Small intestine	0.3	Uterus	0.2
Colon ca. SW480	0.1	Placenta	0.4
Colon ca.* SW620(SW480 met)	0.0	Prostate	0.4
Colon ca. HT29	0.0	Prostate ca.* (bone met)PC-3	1.5
Colon ca. HCT-116	0.5	Testis	6.6

Colon ca. CaCo-2	0.8	Melanoma Hs688(A).T	0.1
Colon ca. tissue(ODO3866)	0.1	Melanoma* (met) Hs688(B).T	0.0
Colon ca. HCC-2998	0.0	Melanoma UACC-62	0.3
Gastric ca.* (liver met) NCI-N87	0.0	Melanoma M14	0.0
Bladder	0.2	Melanoma LOX IMVI	0.0
Trachea	0.0	Melanoma* (met) SK-MEL-5	0.3
Kidney	0.3	Adipose	0.0

Table JC. Panel 4D

Tissue Name	Rel. Exp.(%) Ag2927, Run 164306316	Tissue Name	Rel. Exp.(%) Ag2927, Run 164306316
Secondary Th1 act	1.5	HUVEC IL-1beta	3.6
Secondary Th2 act	5.4	HUVEC IFN gamma	7.7
Secondary Tr1 act	9.0	HUVEC TNF alpha + IFN gamma	5.4
Secondary Th1 rest	4.6	HUVEC TNF alpha + IL4	0.6
Secondary Th2 rest	9.0	HUVEC IL-11	3.5
Secondary Tr1 rest	4.5	Lung Microvascular EC none	6.9
Primary Th1 act	2.1	Lung Microvascular EC TNFalpha + IL-1beta	2.7
Primary Th2 act	2.0	Microvascular Dermal EC none	4.2
Primary Tr1 act	2.1	Microvascular Dermal EC TNFalpha + IL-1beta	4.8
Primary Th1 rest	9.7	Bronchial epithelium TNFalpha + IL1beta	0.0
Primary Th2 rest	11.8	Small airway epithelium none	0.9
Primary Tr1 rest	7.3	Small airway epithelium TNFalpha + IL-1beta	0.0
CD45RA CD4 lymphocyte act	1.7	Coronary artery SMC rest	0.0
CD45RO CD4	2.0	Coronary artery SMC	0.0

lymphocyte act		TNFalpha + IL-1beta	
CD8 lymphocyte act	7.8	Astrocytes rest	0.0
Secondary CD8 lymphocyte rest	7.1	Astrocytes TNFalpha + IL-1beta	1.0
Secondary CD8 lymphocyte act	5.8	KU-812 (Basophil) rest	5.5
CD4 lymphocyte none	1.6	KU-812 (Basophil) PMA/ionomycin	7.8
2ry Th1/Th2/Tr1_anti-CD95 CH11	3.6	CCD1106 (Keratinocytes) none	0.0
LAK cells rest	17.4	CCD1106 (Keratinocytes) TNFalpha + IL-1beta	0.0
LAK cells IL-2	13.3	Liver cirrhosis	6.3
LAK cells IL-2+IL-12	4.3	Lupus kidney	0.9
LAK cells IL-2+IFN gamma	3.4	NCI-H292 none	0.0
LAK cells IL-2+ IL-18	8.0	NCI-H292 IL-4	0.0
LAK cells PMA/ionomycin	4.6	NCI-H292 IL-9	0.0
NK Cells IL-2 rest	24.5	NCI-H292 IL-13	0.0
Two Way MLR 3 day	6.6	NCI-H292 IFN gamma	0.0
Two Way MLR 5 day	2.2	HPAEC none	2.1
Two Way MLR 7 day	8.7	HPAEC TNF alpha + IL-1 beta	5.4
PBMC rest	12.6	Lung fibroblast none	0.9
PBMC PWM	4.5	Lung fibroblast TNF alpha + IL-1 beta	0.0
PBMC PHA-L	6.4	Lung fibroblast IL-4	1.0
Ramos (B cell) none	3.3	Lung fibroblast IL-9	0.0
Ramos (B cell) ionomycin	8.0	Lung fibroblast IL-13	2.4
B lymphocytes PWM	3.1	Lung fibroblast IFN gamma	0.0
B lymphocytes CD40L and IL-4	4.3	Dermal fibroblast CCD1070 rest	2.2
EOL-1 dbcAMP	14.3	Dermal fibroblast CCD1070 TNF alpha	21.3
EOL-1 dbcAMP PMA/ionomycin	43.5	Dermal fibroblast CCD1070 IL-1 beta	0.4
Dendritic cells none	22.2	Dermal fibroblast IFN gamma	0.0

Dendritic cells LPS	54.0	Dermal fibroblast IL-4	0.0
Dendritic cells anti-CD40	100.0	IBD Colitis 2	2.9
Monocytes rest	29.5	IBD Crohn's	1.8
Monocytes LPS	0.8	Colon	13.2
Macrophages rest	18.0	Lung	19.5
Macrophages LPS	2.3	Thymus	2.4
HUVEC none	4.7	Kidney	3.4
HUVEC starved	3.3		

Panel 1.3D Summary: Ag2927 Highest expression of the CG56436-01 gene is seen in the fetal heart (CT=27). Significant levels of expression are also seen in fetal liver and kidney (CTs=29-30). Furthermore, the levels of expression in fetal tissue are much higher than the expression in their adult counterparts. This gene encodes a putative phosphatase and could potentially be used to differentiate between fetal and adult liver, kidney and heart tissue. Furthermore, the higher levels of expression in fetal tissue suggests that this gene may be involved in regulating phosphorylation states in proteins involved in cell growth and proliferation. This conclusion is further supported by the low expression in the tissues originating in the central nervous system, which are primarily composed of post-mitotic cells. Thus, this gene play a role in the cell cycle or possibly in the inhibition of cell differentiation. Therefore, this gene may be of use in stem cell research or therapy intended to control the fate of the stem cells.

Panel 4D Summary: Ag2927 The CG56436-01 transcript is highly expressed in dendritic cells (DC) and is upregulated in response to LPS or CD40 (CT=30). This gene, which encodes a phosphatase homolog, is also expressed in activated EOL cells and TNFalpha induced dermal fibroblasts. Thus, this putative phosphatase may be involved in signalling important in cellular differentiation. This is consistant with the low expression in monocytes, monocytes differentiated into dendritic cells, and monocytes differentiated into macrophages and the upregulation of this transcript in dendritic cells after activation with CD40. Furthermore, phosphatase involvement in DC maturation has been documented (see reference). In addition, colon and lung expression of the transcript is may also result from dendritic cells present in these tissue. Therefore, therapeutic utilization of the protein encoded by this transcript may be important in immune modulation, organ/bone marrow transplantation, and the treatment of

diseases where antigen presentation, a function of mature dendritic cells, plays an important role such as asthma, rheumatoid arthritis, IBD, and psoriasis.

References:

- 5 Faries MB, Bedrosian I, Xu S, Koski G, Roros JG, Moise MA, Nguyen HQ, Engels FH, Cohen PA, Czerwiecki BJ. Calcium signaling inhibits interleukin-12 production and activates CD83(+) dendritic cells that induce Th2 cell development. *Blood* 2001 Oct 15;98(8):2489-97

10 Mature dendritic cells (DCs), in addition to providing costimulation, can define the Th1, in contrast to the Th2, nature of a T-cell response through the production of cytokines and chemokines. Because calcium signaling alone causes rapid DC maturation of both normal and transformed myeloid cells, it was evaluated whether calcium-mobilized DCs polarize T cells toward a Th1 or a Th2 phenotype. After human monocytes were cultured for 24 hours in serum-free medium and granulocyte-macrophage colony-stimulating factor to produce immature DCs, additional overnight culture with either calcium ionophore (CI) or interferon gamma (IFN-gamma), tumor necrosis factor-alpha (TNF-alpha), and soluble CD40L resulted in

15 phenotypically mature DCs that produced interleukin-8 (IL-8) and displayed marked expression of CD80, CD86, CD40, CD54, CD83, DC-LAMP, and RelB. DCs matured by IFN-gamma, TNF-alpha, and soluble CD40L were additionally distinguished by undetectable CD4 expression, marked secretion of IL-12, IL-6, and MIP-1beta, and preferential ability to promote Th1/Tc1 characteristics during T-cell sensitization. In contrast, DCs matured by CI treatment were

20 distinguished by CD4 expression, modest or absent levels of IL-12, IL-6, and MIP-1beta, and preferential ability to promote Th2/Tc2 characteristics. Calcium signaling selectively antagonized IL-12 production by mature DCs activated with IFN-gamma, TNF-alpha, and soluble CD40L. Although the activation of DCs by calcium signals is largely mediated through calcineurin phosphatase, the inhibition of IL-12 production by calcium signaling was

25 independent of this enzyme. Naturally occurring calcium fluxes in immature DCs, therefore, negatively regulate Dc1 differentiation while promoting Dc2 characteristics and Th2/Tc2 polarization. Calcium-mobilized DCs may have clinical usefulness in treating disease states with excessive Th1/Tc1 activity, such as graft-versus-host disease or autoimmunity.

PMID: 11588047

**NOV14: CG56443-01: MAST CELL FUNCTION-ASSOCIATED
ANTIGEN-like protein**

Expression of gene CG56443-01 was assessed using the primer-probe set Ag2928, described in Table KA.

Table KA. Probe Name Ag2928

Primers	Sequences	Length	Start Position
Forward	5'-ctgcttctgtcaggaaagca-3' (SEQ ID NO:389)	20	519
Probe	TET-5'-tttctggtcttctgcctcggaact-3'-TAMRA (SEQ ID NO:390)	25	539
Reverse	5'-tgtgggtttgttattgcagtgtt-3' (SEQ ID NO:391)	22	594

CNS_neurodegeneration_v1.0 Summary: Ag2928 Expression of the CG56443-01 gene is low/undetectable in all samples on this panel (CTs>35).

Panel 1.3D Summary: Ag2928 Expression of the CG56443-01 gene is low/undetectable in all samples on this panel (CTs>35).

Panel 4D Summary: Ag2928 Expression of the CG56443-01 gene is low/undetectable in all samples on this panel (CTs>35).

NOV15a, NOV15b, NOV15c, NOV15e, and NOV15f: CG56449-01, CG56449-02, CG56449-03, CG56449-06, and CG56449-08: MEGF6

Expression of gene CG56449-02 and variants CG56449-01, CG56449-03, CG56449-06, and CG56449-08 was assessed using the primer-probe sets Ag252, Ag252b, Ag422, Ag1513 and Ag1937, described in Tables LA, LB, LC, LD and LE. Results of the RTQ-PCR runs are shown in Tables LF, LG, LH, LI, and LJ. Please note that the probe/primer set Aga422 does not correspond to the CG56449-01, CG56449-06, and CG56449-08 variants. This does not impact the results presented below.

Table LA. Probe Name Ag252

Primers	Sequences	Length	Start Position
Forward	5'-gagctgccgcaactcttcc-3' (SEQ ID NO:392)	19	1426
Probe	TET-5'-cgcaactctgcctcttctcatcgg-3'-TAMRA (SEQ ID NO:393)	25	1463

	NO:393)		
Reverse	5'-gacaaacttctctgtgagcgtgtg-3' (SEQ ID NO:394)	24	1495

Table LB. Probe Name Ag252b

Primers	Sequences	Length	Start Position
Forward	5'-aactcttccaggatgacgacgt-3' (SEQ ID NO:395)	22	1436
Probe	TET-5'-cgcaactctgcctcttctcatcgg-3'-TAMRA (SEQ ID NO:396)	25	1463
Reverse	5'-cttctctgtgagcgtgtgttcg-3' (SEQ ID NO:397)	22	1491

Table LC. Probe Name Ag422

Primers	Sequences	Length	Start Position
Forward	5'-tgaacacccccaggctcctac-3' (SEQ ID NO:398)	20	518
Probe	TET-5'-cggtctccggctccacactgac-3'-TAMRA (SEQ ID NO:399)	22	555
Reverse	5'-taatggccaggcaggtcct-3' (SEQ ID NO:400)	19	580

Table LD. Probe Name Ag1513

Primers	Sequences	Length	Start Position
Forward	5'-acacacgctcacagagaagttt-3' (SEQ ID NO:401)	22	1494
Probe	TET-5'-ctggatgactcctttggccatgact-3'-TAMRA (SEQ ID NO:402)	25	1522
Reverse	5'-ctgcagtcacacaggtcaag-3' (SEQ ID NO:403)	21	1551

Table LE. Probe Name Ag1937

Primers	Sequences	Length	Start Position
Forward	5'-ctgcagtcacacaggtcaag-3' (SEQ ID NO:404)	21	1551
Probe	TET-5'-ccaaaggagtcacccaggcagacaaa-3'-TAMRA (SEQ ID NO:405)	26	1513
Reverse	5'-gaacacacgctcacagagaag-3' (SEQ ID NO:406)	21	1492

5 Table LF. Panel 1

Tissue Name	Rel. Exp.(%) Ag252, Run	Rel. Exp.(%) Ag252, Run	Rel. Exp.(%) Ag252b, Run	Rel. Exp.(%) Ag422, Run
-------------	----------------------------	----------------------------	-----------------------------	----------------------------

	87586417	87588539	91519613	90996078
Endothelial cells	0.8	17.3	9.6	0.4
Endothelial cells (treated)	0.6	5.1	10.6	0.9
Pancreas	7.9	13.0	10.8	1.0
Pancreatic ca. CAPAN 2	2.3	10.7	6.1	0.0
Adrenal gland	0.7	4.3	8.7	0.1
Thyroid	0.1	6.6	5.7	0.1
Salivary gland	5.4	15.6	13.3	1.4
Pituitary gland	0.6	2.3	5.7	0.1
Brain (fetal)	0.0	1.1	7.7	0.0
Brain (whole)	0.0	0.1	1.5	0.0
Brain (amygdala)	0.0	0.2	4.3	0.0
Brain (cerebellum)	0.0	6.7	14.0	0.0
Brain (hippocampus)	0.0	0.0	4.1	0.0
Brain (substantia nigra)	0.0	0.3	5.1	0.0
Brain (thalamus)	0.1	0.5	3.3	0.0
Brain (hypothalamus)	1.2	1.1	5.3	0.0
Spinal cord	0.8	1.7	5.1	0.1
glio/astro U87-MG	0.0	0.0	0.0	0.0
glio/astro U-118-MG	16.2	33.2	19.1	19.2
astrocytoma SW1783	19.1	37.4	19.8	16.3
neuro*; met SK-N-AS	0.0	0.0	0.0	0.0
astrocytoma SF-539	0.9	3.5	5.1	0.3
astrocytoma SNB-75	0.0	4.1	5.7	0.2
glioma SNB-19	0.0	0.0	1.0	0.0
glioma U251	0.0	0.2	0.9	0.0
glioma SF-295	9.7	15.7	11.0	4.1
Heart	2.7	15.2	8.8	0.2
Skeletal muscle	0.3	0.3	3.5	0.0
Bone marrow	6.3	6.3	9.7	0.0
Thymus	25.9	56.6	39.2	19.3

Spleen	2.9	9.1	9.2	0.7
Lymph node	33.2	32.1	22.4	5.8
Colon (ascending)	0.0	0.2	4.9	0.0
Stomach	12.4	18.8	19.2	10.2
Small intestine	3.5	9.0	10.4	0.3
Colon ca. SW480	0.0	0.0	3.7	0.1
Colon ca.* SW620 (SW480 met)	0.0	0.0	1.5	0.0
Colon ca. HT29	0.2	0.9	3.8	0.0
Colon ca. HCT-116	0.2	2.5	13.5	0.0
Colon ca. CaCo-2	0.4	3.9	5.5	0.1
Colon ca. HCT-15	0.2	4.6	7.6	0.2
Colon ca. HCC- 2998	4.3	11.6	5.1	0.2
Gastric ca. * (liver met) NCI-N87	68.8	85.9	55.5	47.3
Bladder	10.4	29.3	12.3	7.9
Trachea	7.6	32.1	11.0	1.8
Kidney	0.8	8.7	4.9	0.0
Kidney (fetal)	10.3	32.1	13.2	1.7
Renal ca. 786-0	10.1	28.1	13.8	3.9
Renal ca. A498	32.8	40.9	24.3	20.0
Renal ca. RXF 393	9.5	18.8	10.4	2.1
Renal ca. ACHN	0.1	5.8	5.6	0.2
Renal ca. UO-31	7.6	17.3	17.7	6.8
Renal ca. TK-10	1.7	8.8	8.0	0.3
Liver	2.7	12.0	9.1	0.2
Liver (fetal)	0.0	2.3	4.4	0.0
Liver ca. (hepatoblast) HepG2	0.0	0.0	0.3	0.0
Lung	30.1	42.9	9.5	56.6
Lung (fetal)	29.3	100.0	42.6	16.3
Lung ca. (small cell) LX-1	7.6	11.3	11.7	2.3
Lung ca. (small cell) NCI-H69	0.0	0.0	0.3	0.0
Lung ca. (s.cell var.) SHP-77	0.0	0.0	0.8	0.0
Lung ca. (large	0.0	0.4	0.8	0.0

cell)NCI-H460				
Lung ca. (non-sm. cell) A549	0.0	0.8	4.0	0.0
Lung ca. (non-s.cell) NCI-H23	0.7	2.4	5.3	0.3
Lung ca. (non-s.cell) HOP-62	0.2	1.3	5.4	0.0
Lung ca. (non-s.cl) NCI-H522	16.0	15.3	13.3	0.4
Lung ca. (squam.) SW 900	4.7	17.1	16.5	3.7
Lung ca. (squam.) NCI-H596	0.0	0.0	0.3	0.0
Mammary gland	66.0	55.1	37.6	53.6
Breast ca.* (pl.ef) MCF-7	0.2	4.2	9.4	0.9
Breast ca.* (pl.ef) MDA-MB-231	0.0	0.8	2.7	0.1
Breast ca.* (pl. ef) T47D	4.0	8.7	11.2	1.9
Breast ca. BT-549	100.0	97.9	100.0	100.0
Breast ca. MDA-N	0.0	0.0	0.1	0.0
Ovary	4.8	15.0	14.5	5.7
Ovarian ca. OVCAR-3	0.4	1.2	5.8	0.3
Ovarian ca. OVCAR-4	0.0	1.0	3.1	0.0
Ovarian ca. OVCAR-5	11.7	36.1	24.0	4.8
Ovarian ca. OVCAR-8	4.1	13.6	11.7	1.3
Ovarian ca. IGROV-1	3.8	13.7	10.0	1.6
Ovarian ca. (ascites) SK-OV-3	1.1	3.9	5.2	0.2
Uterus	2.1	19.1	7.4	0.5
Placenta	0.3	5.0	9.2	0.5
Prostate	40.9	47.0	34.4	11.3
Prostate ca.* (bone met) PC-3	1.0	7.9	9.3	0.2
Testis	1.7	17.2	20.9	3.5

Melanoma Hs688(A).T	34.9	44.4	33.0	19.9
Melanoma* (met) Hs688(B).T	17.7	38.7	23.0	10.8
Melanoma UACC-62	0.0	0.0	0.4	0.0
Melanoma M14	0.1	1.1	5.0	0.1
Melanoma LOX IMVI	0.0	0.0	0.0	0.0
Melanoma* (met) SK-MEL-5	0.0	0.1	1.3	0.0
Melanoma SK-MEL-28	0.1	11.9	6.7	0.1

Table LG. Panel 1.3D

Tissue Name	Rel. Exp.(%) Ag252, Run 165628866	Tissue Name	Rel. Exp.(%) Ag252, Run 165628866
Liver adenocarcinoma	13.9	Kidney (fetal)	22.8
Pancreas	4.7	Renal ca. 786-0	0.0
Pancreatic ca. CAPAN 2	4.1	Renal ca. A498	19.5
Adrenal gland	6.7	Renal ca. RXF 393	53.2
Thyroid	5.1	Renal ca. ACHN	2.4
Salivary gland	13.6	Renal ca. UO-31	1.4
Pituitary gland	5.5	Renal ca. TK-10	1.4
Brain (fetal)	28.5	Liver	3.2
Brain (whole)	43.8	Liver (fetal)	1.4
Brain (amygdala)	32.3	Liver ca. (hepatoblast) HepG2	100.0
Brain (cerebellum)	42.9	Lung	6.3
Brain (hippocampus)	44.1	Lung (fetal)	10.2
Brain (substantia nigra)	4.1	Lung ca. (small cell) LX-1	2.8
Brain (thalamus)	14.8	Lung ca. (small cell) NCI-H69	64.2
Cerebral Cortex	25.5	Lung ca. (s.cell var.) SHP-77	5.9
Spinal cord	2.6	Lung ca. (large cell) NCI-H460	6.4
glio/astro U87-MG	2.0	Lung ca. (non-sm. cell) A549	3.3

glio/astro U-118-MG	10.2	Lung ca. (non-s.cell) NCI-H23	21.6
astrocytoma SW1783	10.6	Lung ca. (non-s.cell) HOP-62	11.9
neuro*; met SK-N-AS	1.7	Lung ca. (non-s.cl) NCI-H522	40.9
astrocytoma SF-539	4.9	Lung ca. (squam.) SW 900	1.7
astrocytoma SNB-75	10.1	Lung ca. (squam.) NCI-H596	23.3
glioma SNB-19	6.6	Mammary gland	6.9
glioma U251	8.4	Breast ca.* (pl.ef) MCF-7	6.8
glioma SF-295	1.4	Breast ca.* (pl.ef) MDA-MB-231	47.0
Heart (fetal)	11.8	Breast ca.* (pl.ef) T47D	0.0
Heart	7.6	Breast ca. BT-549	22.4
Skeletal muscle (fetal)	7.4	Breast ca. MDA-N	3.1
Skeletal muscle	0.0	Ovary	0.6
Bone marrow	1.8	Ovarian ca. OVCAR-3	7.1
Thymus	12.1	Ovarian ca. OVCAR-4	9.5
Spleen	0.0	Ovarian ca. OVCAR-5	2.2
Lymph node	15.7	Ovarian ca. OVCAR-8	20.6
Colorectal	0.0	Ovarian ca. IGROV-1	0.0
Stomach	4.9	Ovarian ca.* (ascites) SK-OV-3	9.7
Small intestine	13.7	Uterus	6.1
Colon ca. SW480	12.0	Placenta	4.9
Colon ca.* SW620(SW480 met)	2.9	Prostate	21.2
Colon ca. HT29	2.3	Prostate ca.* (bone met)PC-3	15.7
Colon ca. HCT-116	2.9	Testis	5.0
Colon ca. CaCo-2	2.9	Melanoma Hs688(A).T	1.6
Colon ca.	2.9	Melanoma* (met)	4.9

tissue(ODO3866)		Hs688(B).T	
Colon ca. HCC-2998	2.8	Melanoma UACC-62	2.7
Gastric ca.* (liver met) NCI-N87	12.9	Melanoma M14	3.2
Bladder	4.1	Melanoma LOX IMVI	3.0
Trachea	34.2	Melanoma* (met) SK-MEL-5	1.3
Kidney	4.7	Adipose	0.0

Table LH. Panel 2D

Tissue Name	Rel. Exp.(%) Ag252, Run 144791435	Tissue Name	Rel. Exp.(%) Ag252, Run 144791435
Normal Colon	11.3	Kidney Margin 8120608	8.7
CC Well to Mod Diff (ODO3866)	11.0	Kidney Cancer 8120613	1.2
CC Margin (ODO3866)	1.6	Kidney Margin 8120614	6.1
CC Gr.2 rectosigmoid (ODO3868)	9.7	Kidney Cancer 9010320	12.5
CC Margin (ODO3868)	2.5	Kidney Margin 9010321	9.9
CC Mod Diff (ODO3920)	20.9	Normal Uterus	18.9
CC Margin (ODO3920)	3.0	Uterus Cancer 064011	15.6
CC Gr.2 ascend colon (ODO3921)	3.2	Normal Thyroid	3.3
CC Margin (ODO3921)	1.8	Thyroid Cancer 064010	6.9
CC from Partial Hepatectomy (ODO4309) Mets	18.7	Thyroid Cancer A302152	10.9
Liver Margin (ODO4309)	2.3	Thyroid Margin A302153	5.7
Colon mets to lung (OD04451-01)	14.0	Normal Breast	42.3
Lung Margin (OD04451- 02)	17.1	Breast Cancer (OD04566)	26.6
Normal Prostate 6546-1	20.6	Breast Cancer (OD04590-01)	21.8

Prostate Cancer (OD04410)	30.1	Breast Cancer Mets (OD04590-03)	36.3
Prostate Margin (OD04410)	18.4	Breast Cancer Metastasis (OD04655-05)	14.9
Prostate Cancer (OD04720-01)	36.9	Breast Cancer 064006	21.5
Prostate Margin (OD04720-02)	24.0	Breast Cancer 1024	42.0
Normal Lung 061010	15.3	Breast Cancer 9100266	11.0
Lung Met to Muscle (ODO4286)	1.5	Breast Margin 9100265	10.8
Muscle Margin (ODO4286)	11.1	Breast Cancer A209073	14.9
Lung Malignant Cancer (OD03126)	23.5	Breast Margin A2090734	13.0
Lung Margin (OD03126)	19.5	Normal Liver	6.4
Lung Cancer (OD04404)	10.5	Liver Cancer 064003	0.0
Lung Margin (OD04404)	53.2	Liver Cancer 1025	1.1
Lung Cancer (OD04565)	12.9	Liver Cancer 1026	19.6
Lung Margin (OD04565)	23.8	Liver Cancer 6004-T	10.0
Lung Cancer (OD04237-01)	4.9	Liver Tissue 6004-N	6.0
Lung Margin (OD04237-02)	32.5	Liver Cancer 6005-T	15.3
Ocular Mel Met to Liver (ODO4310)	2.0	Liver Tissue 6005-N	3.3
Liver Margin (ODO4310)	5.4	Normal Bladder	19.2
Melanoma Mets to Lung (OD04321)	0.7	Bladder Cancer 1023	5.6
Lung Margin (OD04321)	24.5	Bladder Cancer A302173	3.4
Normal Kidney	8.3	Bladder Cancer (OD04718-01)	7.6
Kidney Ca, Nuclear grade 2 (OD04338)	22.5	Bladder Normal Adjacent (OD04718-03)	9.3
Kidney Margin (OD04338)	4.1	Normal Ovary	2.4
Kidney Ca Nuclear grade 1/2 (OD04339)	10.9	Ovarian Cancer 064008	11.8

Kidney Margin (OD04339)	6.5	Ovarian Cancer (OD04768-07)	2.9
Kidney Ca, Clear cell type (OD04340)	26.8	Ovary Margin (OD04768-08)	31.4
Kidney Margin (OD04340)	10.4	Normal Stomach	5.6
Kidney Ca, Nuclear grade 3 (OD04348)	3.7	Gastric Cancer 9060358	0.0
Kidney Margin (OD04348)	6.0	Stomach Margin 9060359	1.9
Kidney Cancer (OD04622-01)	100.0	Gastric Cancer 9060395	5.9
Kidney Margin (OD04622-03)	6.5	Stomach Margin 9060394	2.4
Kidney Cancer (OD04450-01)	4.5	Gastric Cancer 9060397	18.6
Kidney Margin (OD04450-03)	7.4	Stomach Margin 9060396	2.8
Kidney Cancer 8120607	3.5	Gastric Cancer 064005	1.5

Table LI. Panel 4D

Tissue Name	Rel. Exp.(%) Ag1513, Run 163478079	Rel. Exp.(%) Ag1937, Run 161702009	Rel. Exp.(%) Ag422, Run 138056654	Tissue Name	Rel. Exp.(%) Ag1513, Run 163478079	Rel. Exp.(%) Ag1937, Run 161702009	Rel. Exp.(%) Ag422, Run 138056654
Secondary Th1 act	0.7	0.0	0.0	HUVEC IL-1beta	2.9	2.0	3.5
Secondary Th2 act	0.8	0.0	0.0	HUVEC IFN gamma	27.2	18.4	25.9
Secondary Tr1 act	0.5	0.0	4.0	HUVEC TNF alpha + IFN gamma	8.5	9.9	2.0
Secondary Th1 rest	1.7	0.0	5.6	HUVEC TNF alpha + IL4	7.9	5.9	13.7
Secondary Th2 rest	14.0	10.0	15.2	HUVEC IL-11	15.6	15.9	17.8
Secondary Tr1 rest	6.2	0.0	5.7	Lung Microvascular EC none	27.7	25.7	23.8
Primary Th1 act	1.9	2.1	1.1	Lung	24.0	22.5	19.1

				Microvascular EC TNFalpha + IL-1beta			
Primary Th2 act	2.1	2.3	9.9	Microvascular Dermal EC none	14.2	15.9	17.4
Primary Tr1 act	0.2	0.6	4.5	Microsvascular Dermal EC TNFalpha + IL- 1beta	8.2	9.4	25.3
Primary Th1 rest	16.3	10.0	15.7	Bronchial epithelium TNFalpha + IL1beta	4.0	2.2	1.3
Primary Th2 rest	7.4	9.1	21.9	Small airway epithelium none	1.9	1.6	1.5
Primary Tr1 rest	11.6	11.0	13.9	Small airway epithelium TNFalpha + IL- 1beta	0.5	6.4	2.6
CD45RA CD4 lymphocyte act	13.7	9.4	16.6	Coronary artery SMC rest	23.2	29.7	33.9
CD45RO CD4 lymphocyte act	1.1	0.6	3.1	Coronary artery SMC TNFalpha + IL-1beta	33.4	19.5	13.5
CD8 lymphocyte act	1.5	0.9	1.1	Astrocytes rest	0.0	26.6	17.2
Secondary CD8 lymphocyte rest	4.0	3.3	5.0	Astrocytes TNFalpha + IL- 1beta	100.0	100.0	100.0
Secondary CD8 lymphocyte act	0.0	0.0	0.0	KU-812 (Basophil) rest	0.6	0.0	0.0
CD4 lymphocyte none	19.8	18.6	30.8	KU-812 (Basophil) PMA/ionomycin	0.0	0.5	0.0
2ry Th1/Th2/Tr1_anti- CD95 CH11	6.2	4.1	19.9	CCD1106 (Keratinocytes) none	1.9	0.6	3.5
LAK cells rest	8.4	8.7	17.4	CCD1106 (Keratinocytes) TNFalpha + IL- 1beta	0.5	2.1	3.8
LAK cells IL-2	1.6	6.2	5.8	Liver cirrhosis	9.1	12.2	13.0
LAK cells IL-	4.3	4.0	8.4	Lupus kidney	3.0	2.6	3.8

2+IL-12							
LAK cells IL-2+IFN gamma	1.0	8.1	4.1	NCI-H292 none	30.1	41.8	25.7
LAK cells IL-2+IL-18	1.3	8.3	1.3	NCI-H292 IL-4	16.8	35.1	16.5
LAK cells PMA/ionomycin	2.6	1.2	2.5	NCI-H292 IL-9	21.9	28.5	32.8
NK Cells IL-2 rest	1.2	4.8	6.8	NCI-H292 IL-13	37.6	28.1	33.7
Two Way MLR 3 day	8.1	13.5	3.7	NCI-H292 IFN gamma	20.3	23.5	22.5
Two Way MLR 5 day	1.3	5.0	1.4	HPAEC none	36.1	23.5	31.6
Two Way MLR 7 day	1.0	2.0	2.6	HPAEC TNF alpha + IL-1 beta	22.7	11.1	24.5
PBMC rest	3.0	3.7	7.8	Lung fibroblast none	10.7	15.0	14.4
PBMC PWM	5.2	2.3	3.6	Lung fibroblast TNF alpha + IL-1 beta	1.9	2.6	1.2
PBMC PHA-L	1.0	1.9	2.6	Lung fibroblast IL-4	11.0	9.7	7.7
Ramos (B cell) none	0.0	0.0	0.0	Lung fibroblast IL-9	11.3	9.3	13.2
Ramos (B cell) ionomycin	0.0	0.0	0.0	Lung fibroblast IL-13	7.3	4.5	17.4
B lymphocytes PWM	1.1	1.4	1.4	Lung fibroblast IFN gamma	7.1	10.6	9.4
B lymphocytes CD40L and IL-4	2.1	3.7	8.1	Dermal fibroblast CCD1070 rest	33.2	51.4	45.4
EOL-1 dbcAMP	4.7	3.4	4.3	Dermal fibroblast CCD1070 TNF alpha	24.0	31.9	21.3
EOL-1 dbcAMP PMA/ionomycin	3.6	1.3	10.7	Dermal fibroblast CCD1070 IL-1 beta	34.6	34.4	46.3
Dendritic cells none	1.7	1.9	3.3	Dermal fibroblast IFN	30.6	27.0	32.3

				gamma			
Dendritic cells LPS	0.0	0.0	1.2	Dermal fibroblast IL-4	34.4	29.7	33.9
Dendritic cells anti-CD40	1.6	0.6	1.8	IBD Colitis 2	1.7	1.4	3.0
Monocytes rest	5.0	4.8	6.3	IBD Crohn's	0.7	0.0	1.3
Monocytes LPS	0.4	0.6	1.4	Colon	12.9	9.2	25.0
Macrophages rest	12.3	9.0	13.8	Lung	25.7	55.5	42.9
Macrophages LPS	0.5	0.6	0.0	Thymus	12.2	18.0	18.3
HUVEC none	4.2	22.5	15.6	Kidney	26.8	39.2	25.3
HUVEC starved	17.3	22.7	17.1				

Table LJ. Panel 4R

Tissue Name	Rel. Exp.(%) Ag422, Run 138232477	Tissue Name	Rel. Exp.(%) Ag422, Run 138232477
Secondary Th1 act	0.8	HUVEC IL-1beta	37.4
Secondary Th2 act	1.4	HUVEC IFN gamma	9.5
Secondary Tr1 act	0.2	HUVEC TNF alpha + IFN gamma	4.2
Secondary Th1 rest	2.1	HUVEC TNF alpha + IL4	6.4
Secondary Th2 rest	6.1	HUVEC IL-11	17.1
Secondary Tr1 rest	4.1	Lung Microvascular EC none	17.8
Primary Th1 act	2.2	Lung Microvascular EC TNFalpha + IL-1beta	28.5
Primary Th2 act	3.6	Microvascular Dermal EC none	17.8
Primary Tr1 act	1.3	Microvascular Dermal EC TNFalpha + IL-1beta	9.9
Primary Th1 rest	8.1	Bronchial epithelium TNFalpha + IL1beta	2.1
Primary Th2 rest	5.1	Small airway epithelium none	3.3
Primary Tr1 rest	1.1	Small airway epithelium TNFalpha + IL-1beta	8.5
CD45RA CD4 lymphocyte act	7.5	Coronary artery SMC rest	40.6
CD45RO CD4 lymphocyte act	4.6	Coronary artery SMC TNFalpha + IL-1beta	17.2

CD8 lymphocyte act	1.4	Astrocytes rest	19.2
Secondary CD8 lymphocyte rest	5.9	Astrocytes TNFalpha + IL-1beta	56.3
Secondary CD8 lymphocyte act	0.0	KU-812 (Basophil) rest	0.3
CD4 lymphocyte none	27.0	KU-812 (Basophil) PMA/ionomycin	1.6
2ry Th1/Th2/Tr1_anti-CD95 CH11	17.0	CCD1106 (Keratinocytes) none	1.6
LAK cells rest	10.9	CCD1106 (Keratinocytes) TNFalpha + IL-1beta	13.8
LAK cells IL-2	6.9	Liver cirrhosis	26.6
LAK cells IL-2+IL-12	11.8	Lupus kidney	7.2
LAK cells IL-2+IFN gamma	16.8	NCI-H292 none	47.6
LAK cells IL-2+ IL-18	6.2	NCI-H292 IL-4	94.6
LAK cells PMA/ionomycin	3.7	NCI-H292 IL-9	62.4
NK Cells IL-2 rest	4.6	NCI-H292 IL-13	11.9
Two Way MLR 3 day	9.5	NCI-H292 IFN gamma	8.1
Two Way MLR 5 day	3.4	HPAEC none	27.7
Two Way MLR 7 day	1.7	HPAEC TNF alpha + IL-1 beta	21.6
PBMC rest	5.7	Lung fibroblast none	12.6
PBMC PWM	9.2	Lung fibroblast TNF alpha + IL-1 beta	2.8
PBMC PHA-L	4.5	Lung fibroblast IL-4	12.3
Ramos (B cell) none	0.0	Lung fibroblast IL-9	10.2
Ramos (B cell) ionomycin	0.0	Lung fibroblast IL-13	2.6
B lymphocytes PWM	3.5	Lung fibroblast IFN gamma	13.5
B lymphocytes CD40L and IL-4	12.8	Dermal fibroblast CCD1070 rest	63.3
EOL-1 dbcAMP	5.3	Dermal fibroblast CCD1070 TNF alpha	100.0
EOL-1 dbcAMP PMA/ionomycin	5.0	Dermal fibroblast CCD1070 IL-1 beta	20.0
Dendritic cells none	3.3	Dermal fibroblast IFN gamma	25.9
Dendritic cells LPS	1.3	Dermal fibroblast IL-4	18.6

Dendritic cells anti-CD40	1.8	IBD Colitis 1	3.6
Monocytes rest	6.7	IBD Colitis 2	1.5
Monocytes LPS	2.9	IBD Crohn's	2.0
Macrophages rest	12.1	Colon	8.5
Macrophages LPS	0.6	Lung	64.2
HUVEC none	15.7	Thymus	12.9
HUVEC starved	73.7	Kidney	48.3

Panel 1 Summary: Ag252/252b/Ag422 Multiple experiments with three different probe and primer sets produce results that are in excellent agreement, with highest expression of the CG56449-02 gene in a breast cancer cell line BT-549 (CTs=24) and the fetal lung. Based on homology, the protein encoded by this gene contains numerous EGF-motifs and may be required for cell growth and proliferation. The expression profile suggests that this gene product may be involved in brain, colon, renal, lung, ovarian and prostate cancer as well as melanomas. Thus, expression of this gene could be used as a diagnostic marker for the presence of these cancers. Furthermore, therapeutic inhibition of the expression or function of this gene product through the use of antibodies or small molecule drugs might be of use in the treatment of these cancers.

Among tissues with metabolic function, this gene is expressed at moderate to low levels in pancreas, adrenal, thyroid, pituitary, heart, skeletal muscle, and adult and fetal liver. This widespread expression suggests that this gene product may be important for the pathogenesis, diagnosis, and/or treatment of metabolic and endocrine diseases, including obesity and Types 1 and 2 diabetes.

In addition, this gene shows consistent low/moderate levels of expression in the brain. Please see Panel 1.3D for discussion of utility of this gene in the central nervous system.

Panel 1.3D Summary: Ag252 Highest levels of expression of the CG56449-02 gene are seen in a liver cell line HepG2 (CT=30.27). Based on expression in this panel, this gene may be involved in brain, colon, renal, lung, ovarian and prostate cancer as well as melanomas. Thus, expression of this gene could be used as a diagnostic marker for the presence of these cancers. Furthermore, therapeutic inhibition using antibodies or small molecule drugs might be of use in the treatment of these cancers.

This gene product also shows low but significant levels of expression in pancreas, adrenal, thyroid, pituitary, adult and fetal heart, and adult and fetal liver. This widespread expression in tissues with metabolic function is in agreement with results from Panel 1 and suggests that this gene product may be important for the pathogenesis, diagnosis, and/or treatment of metabolic and endocrine diseases, including obesity and Types 1 and 2 diabetes. Furthermore, this gene is more highly expressed in fetal (CT=34) skeletal muscle when compared to expression in the adult (CT=40) and may be useful for the differentiation of the fetal and adult sources of this tissue.

In addition, this gene is expressed at moderate levels in the CNS, again consistent with Panel 1.

This gene encodes a mouse epidermal growth factor homolog, and thus may increase axonal or dendritic outgrowth and synaptogenesis. Therefore, this gene may be of use in the treatment of clinical conditions associated with neuron loss such as head or spinal cord trauma, stroke, or any neurodegenerative disease.

Panel 2D Summary: Ag252 The CG56449-02 gene is expressed at low levels in all the samples on this panel, with highest expression in a kidney cancer sample (CT=31.1). Gastric, liver and colon cancers express this gene at a higher level than the normal adjacent tissue from these organs. There also appears to be increased expression in normal lung and ovarian tissue when compared to the adjacent tumor samples. These data indicate that the expression of this gene might be associated with gastric, liver and colon cancer and thus, therapeutic modulation of this gene product might be of use in the treatment of these cancers. Conversely, absence of expression is associated with ovarian and lung cancer and could potentially be used as a diagnostic marker for the presence of these cancers. Furthermore, therapeutic modulation of this gene might be of use in the treatment of these cancers.

Panel 3D Summary: Ag252 Data from one experiment with this probe and primer and the CG56449-02 gene is not included because the amp plot suggests that there were experimental difficulties with this run.

Panels 4D/4R Summary: Ag1513/Ag1937/Ag422 Multiple experiments with different probe and primer sets produce results that are in excellent agreement. The CG56449-02 transcript is

expressed at low levels in T cells, fibroblasts, endothelium, smooth muscle cells and T cells regardless of treatment. The transcript is also expressed in normal colon, lung and thymus. However, TNFalpha and IL-1beta induce the expression of the transcript in astrocytes. Thus, the transcript encodes a Notch like protein which may function in astrocyte differentiation and activation. Therefore, therapeutic regulation of this transcript or the design of therapeutics with the encoded protein could be important in the treatment of multiple sclerosis or other inflammatory diseases of the CNS.

References:

Tanigaki K, Nogaki F, Takahashi J, Tashiro K, Kurooka H, Honjo T. Notch1 and Notch3 instructively restrict bFGF-responsive multipotent neural progenitor cells to an astroglial fate. Neuron 2001 Jan;29(1):45-55

Notch1 has been shown to induce glia in the peripheral nervous system. However, it has not been known whether Notch can direct commitment to glia from multipotent progenitors of the central nervous system. Here we present evidence that activated Notch1 and Notch3 promotes the differentiation of astroglia from the rat adult hippocampus-derived multipotent progenitors (AHPs). Quantitative clonal analysis indicates that the action of Notch is likely to be instructive. Transient activation of Notch can direct commitment of AHPs irreversibly to astroglia. Astroglial induction by Notch signaling was shown to be independent of STAT3, which is a key regulatory transcriptional factor when ciliary neurotrophic factor (CNTF) induces astroglia. These data suggest that Notch provides a CNTF-independent instructive signal of astroglia differentiation in CNS multipotent progenitor cells.

PMID: 11182080

Irvin DK, Zurcher SD, Nguyen T, Weinmaster G, Kornblum HI. Expression patterns of Notch1, Notch2, and Notch3 suggest multiple functional roles for the Notch-DSL signaling system during brain development. J Comp Neurol 2001 Jul 23;436(2):167-81

The Notch-DSL signaling system consists of multiple receptors and ligands, and plays many roles in development. The function of Notch receptors and ligands in mammalian brain,

however, is poorly understood. In the current study, we examined the expression patterns for three receptors of this system, Notch1, 2, and 3, in late embryonic and postnatal rat brain by in situ hybridization. The three receptors have overlapping but different patterns of expression. Messenger RNA for all three proteins is found in postnatal central nervous system (CNS) germinal zones and, in early postnatal life, within numerous cells throughout the CNS. Within zones of cellular proliferation of the postnatal brain, Notch1 mRNA is found in both the subventricular and the ventricular germinal zones, whereas Notch2 and Notch3 mRNAs are more highly localized to the ventricular zones. Both Notch1 and Notch3 mRNAs are expressed along the inner aspect of the dentate gyrus, a site of adult neurogenesis. Notch2 mRNA is expressed in the external granule cell layer of the developing cerebellum. In several brain areas, Notch1 and Notch2 mRNAs are relatively concentrated in white matter, whereas Notch3 mRNA is not. Neurosphere cultures (which contain CNS stem cells), purified astrocyte cultures, and striatal neuron-enriched cultures express Notch1 mRNA. However, in these latter cultures, Notch1 mRNA is produced by nestin-containing cells, rather than by postmitotic neurons. Taken together, these results support multiple roles for Notch1, 2, and 3 receptor activation during CNS development, particularly during gliogenesis. Copyright 2001 Wiley-Liss, Inc.

PMID: 11438922

Colombatti M, Moretto G, Tommasi M, Fiorini E, Poffe O, Colombara M, Tanel R, Tridente G, Ramarli D. Human MBP-specific T cells regulate IL-6 gene expression in astrocytes through cell-cell contacts and soluble factors. *Glia* 2001 Sep;35(3):224-33

One of the distinctive features of multiple sclerosis (MS) attacks is homing to the CNS of activated T cells able to orchestrate humoral and cell-based events, resulting in immune-mediated injury to myelin and oligodendrocytes. Of the complex interplay occurring between T cells and CNS constituents, we have examined some aspects of T-cell interactions with astrocytes, the major components of the glial cells. Specifically, we focused on the ability of T cells to regulate the gene expression of interleukin-6 (IL-6) in astrocytes, based on previous evidence showing the involvement of this cytokine in CNS disorders. We found that T-cell adhesion and T-cell soluble factors induce IL-6 gene expression in U251 astrocytes through distinct signaling pathways, respectively, resulting in the activation of NF-kappaB and IRF-1

transcription factors. In a search for effector molecules at the astrocyte surface, we found that alpha3beta1 integrins play a role in NF-kappaB activation induced by T-cell contact, whereas interferon-gamma (IFN-gamma) receptors dominate in IRF-1 induction brought about by T-cell-derived soluble factors. Similar phenomena were observed also in normal fetal astrocyte cultures.

- 5 We therefore propose that through astrocyte induction, T cells may indirectly regulate the availability of a cytokine which is crucial in modulating fate and behavior of cell populations involved in the pathogenesis of MS inflammatory lesions.

PMID: 11494413

NOV16: AL359846_A_da1: GPCR

- 10 Expression of gene AL359846_A_da1 was assessed using the primer-probe sets Ag1851, Ag2544 and Ag1706, described in Tables MA, MB and MC. Results of the RTQ-PCR runs are shown in Tables MD, ME, MF, MG and MH.

Table MA. Probe Name Ag1851

Primers	Sequences	Length	Start Position
Forward	5'-ttaattgtgctgaggaagaaa-3' (SEQ ID NO:407)	22	685
Probe	TET-5'-cttctctacctgttcagcgcaactcga-3'-TAMRA (SEQ ID NO:408)	26	713
Reverse	5'-aagggtgaaccgtagaataag-3' (SEQ ID NO:409)	22	749

Table MB. Probe Name Ag2544

Primers	Sequences	Length	Start Position
Forward	5'-ttattctacggttcagcccttt-3' (SEQ ID NO:410)	22	750
Probe	TET-5'-tgtacatgaaaccaagtcaaagaaca-3'-TAMRA (SEQ ID NO:411)	27	775
Reverse	5'-cactccataagacagcccaata-3' (SEQ ID NO:412)	22	821

- 15 Table MC. Probe Name Ag1706

Primers	Sequences	Length	Start Position
Forward	5'-ttaattgtgctgaggaagaaa-3' (SEQ ID NO:413)	22	685

Probe	TET-5'-cttctctacctgttcagcgactcga-3'-TAMRA (SEQ ID NO:414)	26	713
Reverse	5'-aagggtgaaccgtagaataag-3' (SEQ ID NO:415)	22	749

Table MD. CNS_neurodegeneration_v1.0

Tissue Name	Rel. Exp.(%) Ag1851, Run 207926307	Rel. Exp.(%) Ag2544, Run 206974241	Tissue Name	Rel. Exp.(%) Ag1851, Run 207926307	Rel. Exp.(%) Ag2544, Run 206974241
AD 1 Hippo	14.1	16.3	Control (Path) 3 Temporal Ctx	2.1	14.0
AD 2 Hippo	57.4	35.6	Control (Path) 4 Temporal Ctx	55.9	34.2
AD 3 Hippo	12.3	9.9	AD 1 Occipital Ctx	24.3	13.0
AD 4 Hippo	8.6	18.9	AD 2 Occipital Ctx (Missing)	0.0	0.0
AD 5 hippo	56.6	28.1	AD 3 Occipital Ctx	7.6	10.0
AD 6 Hippo	54.3	87.7	AD 4 Occipital Ctx	45.1	33.2
Control 2 Hippo	16.8	33.4	AD 5 Occipital Ctx	8.5	8.1
Control 4 Hippo	21.2	20.4	AD 6 Occipital Ctx	34.2	9.7
Control (Path) 3 Hippo	11.1	7.0	Control 1 Occipital Ctx	8.4	0.0
AD 1 Temporal Ctx	36.3	31.9	Control 2 Occipital Ctx	26.1	24.7
AD 2 Temporal Ctx	57.4	38.4	Control 3 Occipital	21.2	35.4

			Ctx		
AD 3 Temporal Ctx	10.8	9.2	Control 4 Occipital Ctx	2.7	12.9
AD 4 Temporal Ctx	24.8	26.8	Control (Path) 1 Occipital Ctx	73.7	77.4
AD 5 Inf Temporal Ctx	100.0	76.3	Control (Path) 2 Occipital Ctx	26.1	17.8
AD 5 Sup Temporal Ctx	62.0	54.3	Control (Path) 3 Occipital Ctx	5.4	3.2
AD 6 Inf Temporal Ctx	33.9	57.0	Control (Path) 4 Occipital Ctx	35.1	7.6
AD 6 Sup Temporal Ctx	47.3	69.7	Control 1 Parietal Ctx	8.7	9.9
Control 1 Temporal Ctx	15.8	8.5	Control 2 Parietal Ctx	42.9	66.0
Control 2 Temporal Ctx	12.7	25.2	Control 3 Parietal Ctx	49.0	16.3
Control 3 Temporal Ctx	49.7	36.9	Control (Path) 1 Parietal Ctx	51.8	59.9
Control 4 Temporal Ctx	17.3	16.2	Control (Path) 2 Parietal Ctx	55.5	37.1
Control (Path) 1 Temporal Ctx	87.1	74.2	Control (Path) 3 Parietal Ctx	2.6	8.8
Control (Path) 2 Temporal Ctx	83.5	100.0	Control (Path) 4 Parietal Ctx	69.3	56.6

Table ME. Panel 1.3D

Tissue Name	Rel. Exp.(%)	Rel. Exp.(%)	Rel. Exp.(%)	Tissue Name	Rel. Exp.(%)	Rel. Exp.(%)	Rel. Exp.(%)
-------------	--------------	--------------	--------------	-------------	--------------	--------------	--------------

	Ag1706, Run 165532719	Ag1851, Run 165974829	Ag2544, Run 165639972		Ag1706, Run 165532719	Ag1851, Run 165974829	Ag2544, Run 165639972
Liver adenocarcinoma	0.0	0.0	0.0	Kidney (fetal)	14.3	0.0	11.1
Pancreas	0.0	0.0	21.2	Renal ca. 786-0	14.1	11.2	7.7
Pancreatic ca. CAPAN 2	0.0	6.8	8.4	Renal ca. A498	33.9	17.0	26.8
Adrenal gland	0.0	0.0	4.9	Renal ca. RXF 393	0.0	0.0	0.0
Thyroid	12.5	7.2	17.3	Renal ca. ACHN	7.0	8.8	0.0
Salivary gland	25.2	0.0	0.0	Renal ca. UO-31	0.0	15.0	13.3
Pituitary gland	46.0	63.7	13.1	Renal ca. TK-10	0.0	0.0	8.4
Brain (fetal)	25.5	22.2	37.1	Liver	15.5	8.3	100.0
Brain (whole)	100.0	43.2	46.3	Liver (fetal)	6.7	0.0	5.2
Brain (amygdala)	40.1	34.4	71.2	Liver ca. (hepatoblast) HepG2	0.0	7.5	11.7
Brain (cerebellum)	0.0	31.9	24.8	Lung	0.0	0.0	0.0
Brain (hippocampus)	28.5	100.0	55.1	Lung (fetal)	6.7	33.7	8.2
Brain (substantia nigra)	21.8	0.0	5.0	Lung ca. (small cell) LX-1	0.0	0.0	0.0
Brain (thalamus)	20.9	5.6	34.4	Lung ca. (small cell) NCI-H69	0.0	0.0	0.0
Cerebral Cortex	6.5	13.8	12.2	Lung ca. (s.cell var.) SHP-77	13.2	7.9	0.0
Spinal cord	21.5	30.1	10.7	Lung ca. (large cell)NCI- H460	0.0	0.0	0.0
glio/astro U87- MG	18.0	7.7	0.0	Lung ca. (non-sm. cell) A549	0.0	0.0	0.0

glio/astro U-118-MG	6.9	0.0	11.6	Lung ca. (non-s.cell) NCI-H23	9.5	0.0	11.0
astrocytoma SW1783	20.6	7.2	13.1	Lung ca. (non-s.cell) HOP-62	7.4	0.0	0.0
neuro*; met SK-N-AS	0.0	0.0	0.0	Lung ca. (non-s.cl) NCI-H522	9.9	0.0	0.0
astrocytoma SF-539	17.1	8.8	19.8	Lung ca. (squam.) SW 900	0.0	6.1	7.6
astrocytoma SNB-75	0.0	0.0	17.2	Lung ca. (squam.) NCI-H596	8.0	0.0	0.0
glioma SNB-19	9.3	0.0	9.3	Mammary gland	0.0	0.0	11.0
glioma U251	12.8	4.5	0.0	Breast ca.* (pl.ef) MCF-7	0.0	0.0	0.0
glioma SF-295	5.2	0.0	0.0	Breast ca.* (pl.ef) MDA-MB-231	0.0	8.1	9.4
Heart (fetal)	0.0	0.0	0.0	Breast ca.* (pl.ef) T47D	6.3	0.0	0.0
Heart	0.0	15.7	36.6	Breast ca. BT-549	17.8	0.0	40.3
Skeletal muscle (fetal)	0.0	0.0	0.0	Breast ca. MDA-N	0.0	0.0	0.0
Skeletal muscle	6.3	15.4	14.4	Ovary	0.0	0.0	10.2
Bone marrow	37.6	0.0	45.1	Ovarian ca. OVCAR-3	25.9	31.6	46.0
Thymus	0.0	28.7	33.4	Ovarian ca. OVCAR-4	11.3	19.1	6.1
Spleen	1.7	0.0	24.8	Ovarian ca. OVCAR-5	6.3	11.3	36.3
Lymph node	21.2	33.0	35.8	Ovarian ca. OVCAR-8	0.0	0.0	0.0
Colorectal	11.1	0.0	0.0	Ovarian ca. IGROV-1	0.0	0.0	0.0
Stomach	9.4	8.9	28.5	Ovarian ca.*	0.0	10.7	0.0

				(ascites) SK-OV-3			
Small intestine	0.0	0.0	0.0	Uterus	0.0	15.0	7.4
Colon ca. SW480	7.1	0.0	0.0	Placenta	0.0	9.9	0.0
Colon ca.* SW620(SW480 met)	13.1	0.0	0.0	Prostate	6.3	0.0	0.0
Colon ca. HT29	0.0	0.0	0.0	Prostate ca.* (bone met)PC-3	9.4	15.4	4.1
Colon ca. HCT-116	6.7	0.0	0.0	Testis	25.3	23.5	52.5
Colon ca. CaCo-2	18.0	5.5	5.7	Melanoma Hs688(A).T	0.0	8.1	0.0
Colon ca. tissue(ODO3866)	0.0	0.0	0.0	Melanoma* (met) Hs688(B).T	0.0	7.9	0.0
Colon ca. HCC-2998	0.0	0.0	0.0	Melanoma UACC-62	0.0	2.5	0.0
Gastric ca.* (liver met) NCI-N87	48.6	9.3	40.1	Melanoma M14	0.0	0.0	0.0
Bladder	9.0	18.2	0.0	Melanoma LOX IMVI	0.0	0.0	0.0
Trachea	0.0	7.9	14.8	Melanoma* (met) SK-MEL-5	8.3	0.0	0.0
Kidney	0.0	38.4	31.6	Adipose	13.9	15.5	9.1

Table MF. Panel 2.2

Tissue Name	Rel. Exp.(%) Ag1706, Run 173750214	Rel. Exp.(%) Ag1851, Run 174148763	Tissue Name	Rel. Exp.(%) Ag1706, Run 173750214	Rel. Exp.(%) Ag1851, Run 174148763
Normal Colon	4.7	10.0	Kidney Margin (OD04348)	19.3	69.3
Colon cancer (OD06064)	0.0	8.2	Kidney malignant cancer (OD06204B)	4.8	0.0
Colon Margin (OD06064)	2.5	0.0	Kidney normal adjacent tissue (OD06204E)	0.0	0.0

Colon cancer (OD06159)	0.0	0.0	Kidney Cancer (OD04450-01)	49.7	35.4
Colon Margin (OD06159)	11.6	0.0	Kidney Margin (OD04450-03)	12.5	48.0
Colon cancer (OD06297-04)	0.0	0.0	Kidney Cancer 8120613	0.0	0.0
Colon Margin (OD06297-015)	0.0	0.0	Kidney Margin 8120614	0.0	0.0
CC Gr.2 ascend colon (ODO3921)	0.0	0.0	Kidney Cancer 9010320	0.0	0.0
CC Margin (ODO3921)	4.0	8.8	Kidney Margin 9010321	0.0	0.0
Colon cancer metastasis (OD06104)	0.0	0.0	Kidney Cancer 8120607	0.0	0.0
Lung Margin (OD06104)	0.0	0.0	Kidney Margin 8120608	0.0	9.9
Colon mets to lung (OD04451-01)	0.0	0.0	Normal Uterus	11.0	33.4
Lung Margin (OD04451-02)	11.4	11.1	Uterine Cancer 064011	0.0	7.2
Normal Prostate	19.1	9.9	Normal Thyroid	15.1	0.0
Prostate Cancer (OD04410)	0.0	0.0	Thyroid Cancer 064010	9.5	0.0
Prostate Margin (OD04410)	0.0	0.0	Thyroid Cancer A302152	11.6	27.5
Normal Ovary	0.0	0.0	Thyroid Margin A302153	5.3	24.7
Ovarian cancer (OD06283-03)	4.8	0.0	Normal Breast	30.6	36.1
Ovarian Margin (OD06283-07)	2.8	22.1	Breast Cancer (OD04566)	0.0	0.0
Ovarian Cancer 064008	79.6	9.9	Breast Cancer 1024	4.9	0.0
Ovarian cancer (OD06145)	6.8	10.4	Breast Cancer (OD04590-01)	0.0	9.2
Ovarian Margin (OD06145)	0.0	15.5	Breast Cancer Mets (OD04590-03)	42.0	26.2
Ovarian cancer	5.8	25.3	Breast Cancer	17.3	42.0

(OD06455-03)			Metastasis (OD04655-05)		
Ovarian Margin (OD06455-07)	11.8	11.7	Breast Cancer 064006	0.0	0.0
Normal Lung	4.8	11.0	Breast Cancer 9100266	0.0	0.0
Invasive poor diff. lung adeno (ODO4945-01)	25.0	12.1	Breast Margin 9100265	12.8	0.0
Lung Margin (ODO4945-03)	10.7	26.2	Breast Cancer A209073	11.8	7.5
Lung Malignant Cancer (OD03126)	0.0	7.7	Breast Margin A2090734	10.2	28.1
Lung Margin (OD03126)	0.0	0.0	Breast cancer (OD06083)	21.3	31.0
Lung Cancer (OD05014A)	5.5	0.0	Breast cancer node metastasis (OD06083)	35.8	31.9
Lung Margin (OD05014B)	11.9	8.2	Normal Liver	100.0	100.0
Lung cancer (OD06081)	19.5	0.0	Liver Cancer 1026	0.0	0.0
Lung Margin (OD06081)	5.3	0.0	Liver Cancer 1025	37.6	24.7
Lung Cancer (OD04237-01)	5.8	0.0	Liver Cancer 6004-T	5.3	11.3
Lung Margin (OD04237-02)	0.0	0.0	Liver Tissue 6004-N	6.4	0.0
Ocular Melanoma Metastasis	0.0	9.5	Liver Cancer 6005-T	0.0	5.1
Ocular Melanoma Margin (Liver)	0.0	8.1	Liver Tissue 6005-N	0.0	21.3
Melanoma Metastasis	0.0	0.0	Liver Cancer 064003	14.3	3.9
Melanoma Margin (Lung)	5.5	0.0	Normal Bladder	0.0	0.0
Normal Kidney	0.0	23.8	Bladder Cancer 1023	5.6	0.0
Kidney Ca,	28.1	57.0	Bladder Cancer	0.0	0.0

Nuclear grade 2 (OD04338)			A302173		
Kidney Margin (OD04338)	39.5	15.1	Normal Stomach	11.3	12.9
Kidney Ca Nuclear grade 1/2 (OD04339)	71.2	78.5	Gastric Cancer 9060397	0.0	0.0
Kidney Margin (OD04339)	0.0	20.9	Stomach Margin 9060396	9.2	0.0
Kidney Ca, Clear cell type (OD04340)	0.0	0.0	Gastric Cancer 9060395	48.0	0.0
Kidney Margin (OD04340)	22.4	36.3	Stomach Margin 9060394	7.6	0.0
Kidney Ca, Nuclear grade 3 (OD04348)	5.7	0.0	Gastric Cancer 064005	0.0	0.0

Table MG. Panel 4D

Tissue Name	Rel. Exp.(%) Ag1706, Run 164729527	Rel. Exp.(%) Ag1851, Run 165831440	Rel. Exp.(%) Ag2544, Run 164392487	Tissue Name	Rel. Exp.(%) Ag1706, Run 164729527	Rel. Exp.(%) Ag1851, Run 165831440	Rel. Exp.(%) Ag2544, Run 164392487
Secondary Th1 act	0.0	0.0	0.0	HUVEC IL- 1beta	0.0	0.0	0.0
Secondary Th2 act	0.8	2.6	5.2	HUVEC IFN gamma	5.4	5.5	9.4
Secondary Tr1 act	0.0	7.9	0.0	HUVEC TNF alpha + IFN gamma	0.0	0.0	3.1
Secondary Th1 rest	4.9	5.0	0.0	HUVEC TNF alpha + IL4	2.8	0.8	0.0
Secondary Th2 rest	0.0	5.5	0.0	HUVEC IL-11	4.5	1.5	0.0
Secondary Tr1 rest	4.2	4.4	7.1	Lung Microvascular EC none	1.4	2.8	14.4
Primary Th1 act	3.3	1.2	0.0	Lung Microvascular EC TNFalpha + IL-1beta	2.8	4.4	9.0

Primary Th2 act	1.1	4.0	0.0	Microvascular Dermal EC none	1.1	1.6	13.5
Primary Tr1 act	4.3	0.8	0.0	Microvascular Dermal EC TNFalpha + IL- 1beta	0.0	2.6	0.0
Primary Th1 rest	13.4	22.1	36.9	Bronchial epithelium TNFalpha + IL1beta	9.3	5.5	7.7
Primary Th2 rest	15.5	13.6	41.2	Small airway epithelium none	3.4	2.1	0.0
Primary Tr1 rest	6.6	12.1	10.4	Small airway epithelium TNFalpha + IL- 1beta	10.0	24.8	60.7
CD45RA CD4 lymphocyte act	0.7	0.4	8.7	Coronary artery SMC rest	1.3	1.6	3.4
CD45RO CD4 lymphocyte act	13.2	4.9	2.8	Coronary artery SMC TNFalpha + IL-1beta	3.5	2.2	0.0
CD8 lymphocyte act	10.3	8.2	13.4	Astrocytes rest	0.0	9.5	0.0
Secondary CD8 lymphocyte rest	1.9	7.1	16.7	Astrocytes TNFalpha + IL- 1beta	2.8	19.9	13.0
Secondary CD8 lymphocyte act	3.5	6.7	0.0	KU-812 (Basophil) rest	5.4	11.8	17.0
CD4 lymphocyte none	6.0	4.3	13.1	KU-812 (Basophil) PMA/ionomycin	18.4	23.8	36.6
2ry Th1/Th2/Tr1_anti- CD95 CH11	5.6	18.7	13.0	CCD1106 (Keratinocytes) none	10.4	26.1	46.7
LAK cells rest	7.9	7.1	14.0	CCD1106 (Keratinocytes) TNFalpha + IL- 1beta	9.7	100.0	10.7
LAK cells IL-2	0.0	15.5	4.2	Liver cirrhosis	6.1	18.4	10.0
LAK cells IL- 2+IL-12	8.0	15.9	11.3	Lupus kidney	2.7	27.9	13.6
LAK cells IL- 2+IFN gamma	21.2	20.7	77.9	NCI-H292 none	11.6	5.1	20.0

LAK cells IL-2+ IL-18	66.9	22.5	25.9	NCI-H292 IL-4	8.8	14.0	27.4
LAK cells PMA/ionomycin	1.4	0.0	0.0	NCI-H292 IL-9	4.5	6.9	39.8
NK Cells IL-2 rest	9.7	7.1	11.7	NCI-H292 IL-13	0.0	6.9	0.0
Two Way MLR 3 day	10.4	20.2	40.3	NCI-H292 IFN gamma	2.8	5.0	7.8
Two Way MLR 5 day	3.8	7.0	0.0	HPAEC none	5.7	3.2	4.0
Two Way MLR 7 day	0.0	0.8	3.7	HPAEC TNF alpha + IL-1 beta	0.0	2.6	0.0
PBMC rest	0.1	2.5	2.9	Lung fibroblast none	4.5	6.1	0.0
PBMC PWM	20.6	6.0	19.2	Lung fibroblast TNF alpha + IL-1 beta	0.0	3.9	0.0
PBMC PHA-L	11.6	1.5	4.1	Lung fibroblast IL-4	0.0	2.9	0.0
Ramos (B cell) none	10.4	25.9	61.6	Lung fibroblast IL-9	1.3	3.3	8.1
Ramos (B cell) ionomycin	100.0	28.9	100.0	Lung fibroblast IL-13	6.5	0.0	0.0
B lymphocytes PWM	14.1	4.1	13.5	Lung fibroblast IFN gamma	5.0	3.1	15.9
B lymphocytes CD40L and IL-4	31.0	6.0	18.6	Dermal fibroblast CCD1070 rest	27.9	3.6	14.0
EOL-1 dbcAMP	2.0	0.0	0.0	Dermal fibroblast CCD1070 TNF alpha	17.0	9.6	11.2
EOL-1 dbcAMP PMA/ionomycin	0.0	0.0	0.0	Dermal fibroblast CCD1070 IL-1 beta	1.4	0.0	6.3
Dendritic cells none	4.2	3.9	24.7	Dermal fibroblast IFN gamma	6.8	1.6	9.4
Dendritic cells LPS	1.2	3.7	17.6	Dermal fibroblast IL-4	3.9	5.1	14.5

Dendritic cells anti-CD40	2.9	1.4	3.1	IBD Colitis 2	1.7	11.7	3.1
Monocytes rest	0.7	4.9	0.0	IBD Crohn's	0.0	3.1	0.0
Monocytes LPS	2.6	15.9	16.0	Colon	9.1	8.0	10.0
Macrophages rest	6.6	11.0	21.9	Lung	1.4	3.2	8.7
Macrophages LPS	1.4	2.1	0.0	Thymus	31.4	30.6	50.0
HUVEC none	1.6	2.3	0.0	Kidney	10.4	40.9	55.1
HUVEC starved	2.2	4.6	21.6				

Table MH. Panel CNS_1

Tissue Name	Rel. Exp.(%) Ag1851, Run 171628439	Tissue Name	Rel. Exp.(%) Ag1851, Run 171628439
BA4 Control	31.9	BA17 PSP	18.7
BA4 Control2	62.9	BA17 PSP2	7.3
BA4 Alzheimer's2	0.0	Sub Nigra Control	10.2
BA4 Parkinson's	75.8	Sub Nigra Control2	26.4
BA4 Parkinson's2	100.0	Sub Nigra Alzheimer's2	6.9
BA4 Huntington's	13.3	Sub Nigra Parkinson's2	12.6
BA4 Huntington's2	0.0	Sub Nigra Huntington's	34.6
BA4 PSP	26.8	Sub Nigra Huntington's2	32.8
BA4 PSP2	40.9	Sub Nigra PSP2	8.2
BA4 Depression	39.8	Sub Nigra Depression	17.1
BA4 Depression2	8.2	Sub Nigra Depression2	16.0
BA7 Control	38.7	Glob Palladus Control	15.8
BA7 Control2	0.0	Glob Palladus Control2	15.9
BA7 Alzheimer's2	22.8	Glob Palladus Alzheimer's	0.0
BA7 Parkinson's	18.8	Glob Palladus Alzheimer's2	0.0
BA7 Parkinson's2	55.1	Glob Palladus Parkinson's	57.8

BA7 Huntington's	32.1	Glob Palladus Parkinson's2	8.7
BA7 Huntington's2	10.8	Glob Palladus PSP	21.3
BA7 PSP	54.0	Glob Palladus PSP2	0.0
BA7 PSP2	9.1	Glob Palladus Depression	0.0
BA7 Depression	8.3	Temp Pole Control	0.0
BA9 Control	0.0	Temp Pole Control2	41.2
BA9 Control2	8.7	Temp Pole Alzheimer's	0.0
BA9 Alzheimer's	0.0	Temp Pole Alzheimer's2	8.3
BA9 Alzheimer's2	17.1	Temp Pole Parkinson's	32.3
BA9 Parkinson's	17.9	Temp Pole Parkinson's2	14.8
BA9 Parkinson's2	32.5	Temp Pole Huntington's	7.4
BA9 Huntington's	11.7	Temp Pole PSP	11.2
BA9 Huntington's2	0.0	Temp Pole PSP2	0.0
BA9 PSP	15.8	Temp Pole Depression2	8.9
BA9 PSP2	0.0	Cing Gyr Control	35.8
BA9 Depression	0.0	Cing Gyr Control2	16.8
BA9 Depression2	18.4	Cing Gyr Alzheimer's	7.5
BA17 Control	17.3	Cing Gyr Alzheimer's2	23.3
BA17 Control2	40.6	Cing Gyr Parkinson's	15.7
BA17 Alzheimer's2	0.0	Cing Gyr Parkinson's2	17.9
BA17 Parkinson's	43.8	Cing Gyr Huntington's	40.1
BA17 Parkinson's2	15.9	Cing Gyr Huntington's2	20.9
BA17 Huntington's	37.1	Cing Gyr PSP	30.4
BA17	6.5	Cing Gyr PSP2	18.7

Huntington's2			
BA17 Depression	0.0	Cing Gyr Depression	24.1
BA17 Depression2	8.7	Cing Gyr Depression2	17.6

CNS_neurodegeneration_v1.0 Summary: Ag1851/Ag2544 Two experiments with two different probe and primer sets both show significant expression of the AL359846_A_da1 gene in the brain. While no specific association with Alzheimer's disease is evident from the results of these experiments, the expression of this GPCR homolog in the brain is confirmed. Please see Panel 1.3D for discussion of potential utility in the central nervous system.

Panel 1.3D Summary: Ag1706/Ag1851/Ag2544 Three experiments with two different probe and primer sets show significant expression of the AL359846_A_da1 gene, which encodes a novel G-protein coupled receptor (GPCR), in the brain. The GPCR family of receptors contains a large number of neurotransmitter receptors, including the dopamine, serotonin, α and β -adrenergic, acetylcholine muscarinic, histamine, peptide, and metabotropic glutamate receptors. GPCRs are excellent drug targets in various neurologic and psychiatric diseases. All antipsychotics have been shown to act at the dopamine D2 receptor; similarly novel antipsychotics also act at the serotonergic receptor, and often the muscarinic and adrenergic receptors as well. While the majority of antidepressants can be classified as selective serotonin reuptake inhibitors, blockade of the 5-HT_{1A} and α ₂ adrenergic receptors increases the effects of these drugs. The GPCRs are also of use as drug targets in the treatment of stroke. Blockade of the glutamate receptors may decrease the neuronal death resulting from excitotoxicity; furthermore the purinergic receptors have also been implicated as drug targets in the treatment of cerebral ischemia. The β -adrenergic receptors have been implicated in the treatment of ADHD with Ritalin, while the α -adrenergic receptors have been implicated in memory. Therefore this gene may be of use as a small molecule target for the treatment of any of the described diseases.

References:

El Yacoubi M, Ledent C, Parmentier M, Bertorelli R, Ongini E, Costentin J, Vaugeois JM. Adenosine A_{2A} receptor antagonists are potential antidepressants: evidence based on pharmacology and A_{2A} receptor knockout mice. Br J Pharmacol 2001 Sep;134(1):68-77

1. Adenosine, an ubiquitous neuromodulator, and its analogues have been shown to produce 'depressant' effects in animal models believed to be relevant to depressive disorders, while adenosine receptor antagonists have been found to reverse adenosine-mediated 'depressant' effect. 2. We have designed studies to assess whether adenosine A2A receptor antagonists, or genetic inactivation of the receptor would be effective in established screening procedures, such as tail suspension and forced swim tests, which are predictive of clinical antidepressant activity. 3. Adenosine A2A receptor knockout mice were found to be less sensitive to 'depressant' challenges than their wildtype littermates. Consistently, the adenosine A2A receptor blockers SCH 58261 (1 - 10 mg kg⁻¹, i.p.) and KW 6002 (0.1 - 10 mg kg⁻¹, p.o.) reduced the total immobility time in the tail suspension test. 4. The efficacy of adenosine A2A receptor antagonists in reducing immobility time in the tail suspension test was confirmed and extended in two groups of mice. Specifically, SCH 58261 (1 - 10 mg kg⁻¹) and ZM 241385 (15 - 60 mg kg⁻¹) were effective in mice previously screened for having high immobility time, while SCH 58261 at 10 mg kg⁻¹ reduced immobility of mice that were selectively bred for their spontaneous 'helplessness' in this assay. 5. Additional experiments were carried out using the forced swim test. SCH 58261 at 10 mg kg⁻¹ reduced the immobility time by 61%, while KW 6002 decreased the total immobility time at the doses of 1 and 10 mg kg⁻¹ by 75 and 79%, respectively. 6. Administration of the dopamine D2 receptor antagonist haloperidol (50 - 200 microg kg⁻¹ i.p.) prevented the antidepressant-like effects elicited by SCH 58261 (10 mg kg⁻¹ i.p.) in forced swim test whereas it left unaltered its stimulant motor effects. 7. In conclusion, these data support the hypothesis that A2A receptor antagonists prolong escape-directed behaviour in two screening tests for antidepressants. Altogether the results support the hypothesis that blockade of the adenosine A2A receptor might be an interesting target for the development of effective antidepressant agents.

Blier P. Pharmacology of rapid-onset antidepressant treatment strategies. Clin Psychiatry 2001;62 Suppl 15:12-7

Although selective serotonin reuptake inhibitors (SSRIs) block serotonin (5-HT) reuptake rapidly, their therapeutic action is delayed. The increase in synaptic 5-HT activates feedback mechanisms mediated by 5-HT_{1A} (cell body) and 5-HT_{1B} (terminal) autoreceptors, which, respectively, reduce the firing in 5-HT neurons and decrease the amount of 5-HT released per

action potential resulting in attenuated 5-HT neurotransmission. Long-term treatment desensitizes the inhibitory 5-HT₁ autoreceptors, and 5-HT neurotransmission is enhanced. The time course of these events is similar to the delay of clinical action. The addition of pindolol, which blocks 5-HT_{1A} receptors, to SSRI treatment decouples the feedback inhibition of 5-HT neuron firing and accelerates and enhances the antidepressant response. The neuronal circuitry of the 5-HT and norepinephrine (NE) systems and their connections to forebrain areas believed to be involved in depression has been dissected. The firing of 5-HT neurons in the raphe nuclei is driven, at least partly, by alpha₁-adrenoceptor-mediated excitatory inputs from NE neurons. Inhibitory alpha₂-adrenoceptors on the NE neuroterminals form part of a feedback control mechanism. Mirtazapine, an antagonist at alpha₂-adrenoceptors, does not enhance 5-HT neurotransmission directly but disinhibits the NE activation of 5-HT neurons and thereby increases 5-HT neurotransmission by a mechanism that does not require a time-dependent desensitization of receptors. These neurobiological phenomena may underlie the apparently faster onset of action of mirtazapine compared with the SSRIs.

Tranquillini ME, Reggiani A. Glycine-site antagonists and stroke. *Expert Opin Investig Drugs* 1999 Nov;8(11):1837-1848

The excitatory amino acid, (S)-glutamic acid, plays an important role in controlling many neuronal processes. Its action is mediated by two main groups of receptors: the ionotropic receptors (which include NMDA, AMPA and kainic acid subtypes) and the metabotropic receptors (mGluR(1-8)) mediating G-protein coupled responses. This review focuses on the strychnine insensitive glycine binding site located on the NMDA receptor channel, and on the possible use of selective antagonists for the treatment of stroke. Stroke is a devastating disease caused by a sudden vascular accident. Neurochemically, a massive release of glutamate occurs in neuronal tissue; this overactivates the NMDA receptor, leading to increased intracellular calcium influx, which causes neuronal cell death through necrosis. NMDA receptor activation strongly depends upon the presence of glycine as a co-agonist. Therefore, the administration of a glycine antagonist can block overactivation of NMDA receptors, thus preserving neurones from damage. The glycine antagonists currently identified can be divided into five main categories depending on their chemical structure: indoles, tetrahydroquinolines, benzoazepines, quinoxalinediones and pyrida-zinoquinolines.

Monopoli A, Lozza G, Forlani A, Mattavelli A, Ongini E. Blockade of adenosine A2A receptors by SCH 58261 results in neuroprotective effects in cerebral ischaemia in rats. *Neuroreport* 1998 Dec 1;9(17):3955-9 Related Articles, Books, LinkOut

Blockade of adenosine receptors can reduce cerebral infarct size in the model of global ischaemia. Using the potent and selective A2A adenosine receptor antagonist, SCH 58261, we assessed whether A2A receptors are involved in the neuronal damage following focal cerebral ischaemia as induced by occluding the left middle cerebral artery. SCH 58261 (0.01 mg/kg either i.p. or i.v.) administered to normotensive rats 10 min after ischaemia markedly reduced cortical infarct volume as measured 24 h later (30% vs controls, $p < 0.05$). Similar effects were observed when SCH 58261 (0.01 mg/kg, i.p.) was administered to hypertensive rats (28% infarct volume reduction vs controls, $p < 0.05$). Neuroprotective properties of SCH 58261 administered after ischaemia indicate that blockade of A2A adenosine receptors is a potentially useful biological target for the reduction of brain injury.

Panel 2.2 Summary: Ag1706/Ag1851 Results from two experiments using the identical probe/primer set are in reasonable agreement. Expression of the AL359846_A_da1 gene is highest in a normal liver sample. Lower levels of expression are also seen in several kidney and breast samples, both from tumor and normal adjacent tissue. Therefore, expression of this gene may be used to distinguish liver, kidney and breast from the other samples on this panel.

Panel 4D Summary: Ag1706/1851/2544: Results from three experiments are in reasonable agreement. Expression of the AL359846_A_da1 gene is detected in LAK cells, Ramos B cells, thymus and kidney. Expression does not appear to be dependent upon activation in the cell types tested. The expression of the transcript may be dependent upon the proliferation status of cells, since it is expressed in specific types of proliferating cells including LAK cells, B cells and cells in the thymus and kidney. Thus, the transcript or the protein it encodes may be important for detecting LAK cells or thymic and kidney tissue.

Panel CNS_1 Summary: Ag1851 The results of this experiment further confirm the expression of the AL359846_A_da1 gene in the brain. Please see Panel 1.3D for discussion of potential utility in the central nervous system.

NOV19 a and NOV19b: CG56574-01 and CG56574-02: Dystrophin

Expression of gene CG56574-01 and variant CG565724-02 was assessed using the primer-probe set Ag1409, described in Table NA. Results of the RTQ-PCR runs are shown in Table NB.

Table NA. Probe Name Ag1409

Primers	Sequences	Length	Start Position
Forward	5'-agcattactgccaaagtgttgaa-3' (SEQ ID NO:416)	22	1414
Probe	TET-5'-cctcgtagtcctgcccagatcttgat-3'-TAMRA (SEQ ID NO:417)	26	1458
Reverse	5'-ccccctctttcctcactctcttaa-3' (SEQ ID NO:418)	22	1488

5 Table NB. Panel 1.2

Tissue Name	Rel. Exp.(%) Ag1409, Run 138249588	Tissue Name	Rel. Exp.(%) Ag1409, Run 138249588
Endothelial cells	0.4	Renal ca. 786-0	0.7
Heart (Fetal)	4.3	Renal ca. A498	0.6
Pancreas	0.9	Renal ca. RXF 393	0.4
Pancreatic ca. CAPAN 2	0.0	Renal ca. ACHN	1.1
Adrenal Gland	8.8	Renal ca. UO-31	0.9
Thyroid	0.1	Renal ca. TK-10	0.7
Salivary gland	12.9	Liver	13.4
Pituitary gland	0.3	Liver (fetal)	2.0
Brain (fetal)	0.2	Liver ca. (hepatoblast) HepG2	5.1
Brain (whole)	0.7	Lung	0.1
Brain (amygdala)	1.8	Lung (fetal)	0.6
Brain (cerebellum)	0.8	Lung ca. (small cell) LX-1	0.4
Brain (hippocampus)	5.2	Lung ca. (small cell) NCI-H69	0.7
Brain (thalamus)	2.6	Lung ca. (s.cell var.) SHP-77	1.2
Cerebral Cortex	12.0	Lung ca. (large cell) NCI-H460	1.4
Spinal cord	0.7	Lung ca. (non-sm. cell) A549	0.0

glio/astro U87-MG	0.1	Lung ca. (non-s.cell) NCI-H23	6.7
glio/astro U-118-MG	0.3	Lung ca. (non-s.cell) HOP-62	2.0
astrocytoma SW1783	1.1	Lung ca. (non-s.cl) NCI-H522	0.0
neuro*; met SK-N-AS	0.4	Lung ca. (squam.) SW 900	0.0
astrocytoma SF-539	0.3	Lung ca. (squam.) NCI-H596	1.3
astrocytoma SNB-75	1.2	Mammary gland	1.7
glioma SNB-19	4.3	Breast ca.* (pl.ef) MCF-7	0.4
glioma U251	2.4	Breast ca.* (pl.ef) MDA-MB-231	0.0
glioma SF-295	0.1	Breast ca.* (pl. ef) T47D	0.6
Heart	57.4	Breast ca. BT-549	1.3
Skeletal Muscle	100.0	Breast ca. MDA-N	0.7
Bone marrow	0.3	Ovary	4.7
Thymus	0.1	Ovarian ca. OVCAR- 3	1.0
Spleen	0.2	Ovarian ca. OVCAR- 4	1.4
Lymph node	0.1	Ovarian ca. OVCAR- 5	1.2
Colorectal Tissue	1.1	Ovarian ca. OVCAR- 8	1.2
Stomach	0.9	Ovarian ca. IGROV-1	0.0
Small intestine	6.8	Ovarian ca. (ascites) SK-OV-3	0.4
Colon ca. SW480	0.0	Uterus	2.5
Colon ca.* SW620 (SW480 met)	0.0	Placenta	0.2
Colon ca. HT29	0.0	Prostate	3.7
Colon ca. HCT-116	0.0	Prostate ca.* (bone met) PC-3	0.0
Colon ca. CaCo-2	3.1	Testis	0.2
Colon ca. Tissue (ODO3866)	0.4	Melanoma Hs688(A).T	0.2
Colon ca. HCC-2998	0.0	Melanoma* (met)	1.0

		Hs688(B).T	
Gastric ca.* (liver met) NCI-N87	0.0	Melanoma UACC-62	0.5
Bladder	7.9	Melanoma M14	0.4
Trachea	0.3	Melanoma LOX IMVI	0.0
Kidney	6.1	Melanoma* (met) SK-MEL-5	3.9
Kidney (fetal)	1.0		

Panel 1.2 Summary: Ag1409 The CG56574-01 gene has moderate levels of expression (CT values = 28-31) in pancreas, thyroid and pituitary. This gene is highly expressed (CT values = 22-27) in adult and fetal heart, adult and fetal liver, and adrenal gland. This widespread expression in tissues with metabolic function suggests that this putative cytoskeletal protein may be important for the pathogenesis, diagnosis, and/or treatment of metabolic diseases including obesity and Types 1 and 2 diabetes.

This gene is also expressed at moderate to high levels in most cancer cells in this panel. Thus, this gene may be involved in cell structure, binding to glycoproteins associated with the cell membrane. Hence, this gene would be required for cell survival and proliferation.

In addition, this gene, a homolog of dystrophin, is expressed at high levels in the CNS and skeletal muscle. Dystrophin is associated with major Duchenne muscular dystrophy. Thus, therapeutic modulation of this gene or its protein product may be of clinical benefit in the treatment of muscular dystrophy.

NOV21: CG56500-01: TFIIC BOX B-BINDING SUBUNIT

Expression of gene CG56500-01 was assessed using the primer-probe set Ag4856, described in Table OA. Results of the RTQ-PCR runs are shown in Table OB.

Table OA. Probe Name Ag4856

Primers	Sequences	Length	Start Position
Forward	5'-ctgctgatgaggggctactac-3' (SEQ ID NO:419)	21	4996
Probe	TET-5'-aacctcaacccaacgacagcattgt-3'-TAMRA (SEQ ID	26	5041

	NO:420)		
Reverse	5'-gaacttcacatctggcaggagtt-3' (SEQ ID NO:421)	21	5071

Table OB. General_screening_panel_v1.5

Tissue Name	Rel. Exp.(%) Ag4856, Run 228888064	Tissue Name	Rel. Exp.(%) Ag4856, Run 228888064
Adipose	7.6	Renal ca. TK-10	35.4
Melanoma* Hs688(A).T	33.7	Bladder	16.5
Melanoma* Hs688(B).T	39.0	Gastric ca. (liver met.) NCI-N87	71.7
Melanoma* M14	59.5	Gastric ca. KATO III	82.4
Melanoma* LOXIMVI	36.9	Colon ca. SW-948	14.4
Melanoma* SK- MEL-5	28.5	Colon ca. SW480	68.3
Squamous cell carcinoma SCC-4	27.2	Colon ca.* (SW480 met) SW620	61.6
Testis Pool	14.3	Colon ca. HT29	16.4
Prostate ca.* (bone met) PC-3	47.6	Colon ca. HCT-116	100.0
Prostate Pool	27.4	Colon ca. CaCo-2	49.0
Placenta	13.4	Colon cancer tissue	25.2
Uterus Pool	11.2	Colon ca. SW1116	16.8
Ovarian ca. OVCAR- 3	41.5	Colon ca. Colo-205	13.0
Ovarian ca. SK-OV- 3	68.8	Colon ca. SW-48	16.4
Ovarian ca. OVCAR- 4	57.8	Colon Pool	21.3
Ovarian ca. OVCAR- 5	56.3	Small Intestine Pool	18.0
Ovarian ca. IGROV- 1	18.3	Stomach Pool	11.2
Ovarian ca. OVCAR- 8	27.0	Bone Marrow Pool	10.6
Ovary	15.3	Fetal Heart	16.6
Breast ca. MCF-7	44.4	Heart Pool	13.3
Breast ca. MDA- MB-231	32.8	Lymph Node Pool	29.1

Breast ca. BT 549	34.6	Fetal Skeletal Muscle	11.4
Breast ca. T47D	21.9	Skeletal Muscle Pool	28.7
Breast ca. MDA-N	21.9	Spleen Pool	7.9
Breast Pool	22.5	Thymus Pool	27.2
Trachea	16.3	CNS cancer (glio/astro) U87-MG	20.2
Lung	3.4	CNS cancer (glio/astro) U-118-MG	59.5
Fetal Lung	45.7	CNS cancer (neuro;met) SK-N-AS	49.7
Lung ca. NCI-N417	9.8	CNS cancer (astro) SF- 539	47.6
Lung ca. LX-1	56.3	CNS cancer (astro) SNB-75	91.4
Lung ca. NCI-H146	18.2	CNS cancer (glio) SNB- 19	25.7
Lung ca. SHP-77	29.1	CNS cancer (glio) SF- 295	95.3
Lung ca. A549	27.7	Brain (Amygdala) Pool	16.3
Lung ca. NCI-H526	24.1	Brain (cerebellum)	40.3
Lung ca. NCI-H23	48.0	Brain (fetal)	33.4
Lung ca. NCI-H460	27.5	Brain (Hippocampus) Pool	17.7
Lung ca. HOP-62	21.6	Cerebral Cortex Pool	23.5
Lung ca. NCI-H522	36.3	Brain (Substantia nigra) Pool	15.5
Liver	2.0	Brain (Thalamus) Pool	29.3
Fetal Liver	16.8	Brain (whole)	28.3
Liver ca. HepG2	26.1	Spinal Cord Pool	4.3
Kidney Pool	33.9	Adrenal Gland	27.9
Fetal Kidney	16.6	Pituitary gland Pool	16.0
Renal ca. 786-0	57.4	Salivary Gland	6.1
Renal ca. A498	23.2	Thyroid (female)	20.7
Renal ca. ACHN	51.1	Pancreatic ca. CAPAN2	40.9
Renal ca. UO-31	54.0	Pancreas Pool	28.7

General_screening_panel_v1.5 Summary: Ag4856 This gene, which represents a novel transcription factor, is expressed ubiquitously in this panel, with highest expression in a colon

cancer cell line (CT=26). This expression profile suggests that the gene product may be required for cell growth and proliferation and is required for tumor growth.

This gene is also expressed at low-to-moderate levels in many metabolic tissues including adipose, adult and fetal liver, heart, and skeletal muscle, adrenal, pituitary, and pancreas. This gene product represents a novel transcription factor and is an excellent drug target for metabolic and endocrine diseases, including obesity and Types 1 and 2 diabetes.

Among tissues originating in the CNS, this gene is expressed at moderate levels. Because this gene encodes a putative transcription factor, this gene is an excellent drug target for neurological diseases in which transcription of a disease protein (e.g., Huntington's disease) is believed to be central to the progression of the disease.

NOV22: CG56475-01: NUCLEOSIDE DIPHOSPHATE KINASE B

Expression of gene CG56475-01 was assessed using the primer-probe set Ag2946, described in Table PA. Results of the RTQ-PCR runs are shown in Table PB.

Table PA. Probe Name Ag2946

Primers	Sequences	Length	Start Position
Forward	5'-gaccaattcattgggctctat-3' (SEQ ID NO:422)	21	284
Probe	TET-5'-ctattattcgcagggacttctgcgct-3'-TAMRA (SEQ ID NO:423)	26	313
Reverse	5'-atgacgttcccgctatatt-3' (SEQ ID NO:424)	19	340

Table PB. Panel 4D

Tissue Name	Rel. Exp.(%) Ag2946, Run 164403318	Tissue Name	Rel. Exp.(%) Ag2946, Run 164403318
Secondary Th1 act	0.1	HUVEC IL-1beta	0.0
Secondary Th2 act	0.0	HUVEC IFN gamma	0.0
Secondary Tr1 act	0.0	HUVEC TNF alpha + IFN gamma	0.0
Secondary Th1 rest	0.1	HUVEC TNF alpha + IL4	0.0
Secondary Th2 rest	0.0	HUVEC IL-11	0.0

Secondary Tr1 rest	0.0	Lung Microvascular EC none	0.0
Primary Th1 act	0.0	Lung Microvascular EC TNFalpha + IL-1beta	0.0
Primary Th2 act	0.0	Microvascular Dermal EC none	0.0
Primary Tr1 act	0.0	Microvascular Dermal EC TNFalpha + IL-1beta	0.0
Primary Th1 rest	0.1	Bronchial epithelium TNFalpha + IL1beta	0.0
Primary Th2 rest	0.0	Small airway epithelium none	0.0
Primary Tr1 rest	0.0	Small airway epithelium TNFalpha + IL-1beta	0.0
CD45RA CD4 lymphocyte act	0.0	Coronary artery SMC rest	0.1
CD45RO CD4 lymphocyte act	0.1	Coronary artery SMC TNFalpha + IL-1beta	0.0
CD8 lymphocyte act	0.0	Astrocytes rest	0.0
Secondary CD8 lymphocyte rest	0.0	Astrocytes TNFalpha + IL- 1beta	0.0
Secondary CD8 lymphocyte act	0.0	KU-812 (Basophil) rest	0.0
CD4 lymphocyte none	0.0	KU-812 (Basophil) PMA/ionomycin	0.0
2ry Th1/Th2/Tr1_anti- CD95 CH11	0.0	CCD1106 (Keratinocytes) none	0.0
LAK cells rest	0.3	CCD1106 (Keratinocytes) TNFalpha + IL-1beta	0.0
LAK cells IL-2	0.0	Liver cirrhosis	0.7
LAK cells IL-2+IL-12	0.0	Lupus kidney	0.0
LAK cells IL-2+IFN gamma	0.0	NCI-H292 none	0.0
LAK cells IL-2+ IL-18	0.0	NCI-H292 IL-4	0.0
LAK cells PMA/ionomycin	0.4	NCI-H292 IL-9	0.0
NK Cells IL-2 rest	0.0	NCI-H292 IL-13	0.0
Two Way MLR 3 day	0.0	NCI-H292 IFN gamma	0.0
Two Way MLR 5 day	0.0	HPAEC none	0.0
Two Way MLR 7 day	0.0	HPAEC TNF alpha + IL-1 beta	0.2

PBMC rest	0.0	Lung fibroblast none	0.0
PBMC PWM	0.3	Lung fibroblast TNF alpha + IL-1 beta	0.2
PBMC PHA-L	0.3	Lung fibroblast IL-4	0.0
Ramos (B cell) none	36.3	Lung fibroblast IL-9	0.0
Ramos (B cell) ionomycin	100.0	Lung fibroblast IL-13	0.0
B lymphocytes PWM	2.2	Lung fibroblast IFN gamma	0.0
B lymphocytes CD40L and IL-4	14.0	Dermal fibroblast CCD1070 rest	0.0
EOL-1 dbcAMP	0.1	Dermal fibroblast CCD1070 TNF alpha	0.0
EOL-1 dbcAMP PMA/ionomycin	0.0	Dermal fibroblast CCD1070 IL-1 beta	0.0
Dendritic cells none	0.0	Dermal fibroblast IFN gamma	0.0
Dendritic cells LPS	0.0	Dermal fibroblast IL-4	0.0
Dendritic cells anti-CD40	0.0	IBD Colitis 2	0.0
Monocytes rest	0.0	IBD Crohn's	0.0
Monocytes LPS	0.0	Colon	0.3
Macrophages rest	0.0	Lung	0.0
Macrophages LPS	0.0	Thymus	0.4
HUVEC none	0.0	Kidney	0.3
HUVEC starved	0.0		

CNS_neurodegeneration_v1.0 Summary: Ag2946 Expression of the CG56475-01 gene is low/undetectable in all samples on this panel (CTs>35).

Panel 1.3D Summary: Ag2946 Expression of the CG56475-01 gene is low/undetectable in all samples on this panel (CTs>35).

- 5 **Panel 4D Summary:** Ag2946 Expression of the CG56475-01 transcript is exclusive to B cells and a B cell line (Ramos). Activation of RAMOS cells with PMA and ionomycin increases the expression level of the transcript. The gene encodes a putative nucleoside diphosphate kinase B like protein. These proteins may be involved in inducing transcription and preferentially bind single strand DNA. Thus, the protein encoded by this transcript may play a role in B cell differentiation and/or isotype switching. Thus, expression of this gene or the encoded protein

could be used to identify B cells. Furthermore, therapeutics could be designed with the protein encoded by this transcript that might regulate B cell function, and potentially reduce symptoms in diseases where B cells play an important role, including systemic lupus erythematosus and rheumatoid arthritis.

5 References:

Agou F, Raveh S, Mesnildrey S, Veron M. Single strand DNA specificity analysis of human nucleoside diphosphate kinase B. J Biol Chem 1999 Jul 9;274(28):19630-8

Nucleoside diphosphate kinases (NDP kinases) form a family of oligomeric enzymes present in all organisms. Eukaryotic NDP kinases are hexamers composed of identical subunits

10 (approximately 17 kDa). A distinctive property of human NDPK-B encoded by the gene nm23-H2 is its ability to stimulate the gene transcription. This property is independent of its catalytic activity and is possibly related to the role of this protein in cellular events including differentiation and tumor metastasis. In this paper, we report the first characterization of human NDPK-B.DNA complex formation using a filter-binding assay and fluorescence spectroscopy.

15 We analyzed the binding of several oligonucleotides mimicking the promoter region of the c-myc oncogene including variants in sequence, structure, and length of both strands. We show that NDPK-B binds to single-stranded oligonucleotides in a nonsequence specific manner, but that it exhibits a poor binding activity to double-stranded oligonucleotides. This indicates that the specificity of recognition to DNA is a function of the structural conformation of DNA rather than

20 of its specific sequence. Moreover, competition experiments performed with all nucleotides provide evidence for the contribution of the six active sites in the DNA.protein complex formation. We propose a mechanism through which human NDPK-B could stimulate transcription of c-myc or possibly other genes involved in cellular differentiation.

PMID: 10391900

25 NOV23: CG56352-02: T-cell-Immunoglobulin

Expression of gene CG56352-02 was assessed using the primer-probe sets Ag3865, Ag3864 and Ag2918, described in Tables QA, QB and QC. Results of the RTQ-PCR runs are shown in Tables QD, QE, QF and QG.

Table QA. Probe Name Ag3865

Primers	Sequences	Length	Start Position
Forward	5'-attctgttagacatggcttgca-3' (SEQ ID NO:425)	22	391
Probe	TET-5'-cctcactcaccgcttgagtcttg-3'-TAMRA (SEQ ID NO:426)	24	433
Reverse	5'-ctgtattccacttctgaggacc-3' (SEQ ID NO:427)	22	479

Table QB. Probe Name Ag3864

Primers	Sequences	Length	Start Position
Forward	5'-aacctcgtgcccgtctgc-3' (SEQ ID NO:428)	18	559
Probe	TET-5'-ctgtcctgtgtttgaatgtggcaacgt-3'-TAMRA (SEQ ID NO:429)	27	591
Reverse	5'-attcacatccctttcatcag-3' (SEQ ID NO:430)	20	629

Table QC. Probe Name Ag2918

Primers	Sequences	Length	Start Position
Forward	5'-aaatgcagtagcagaggaatt-3' (SEQ ID NO:431)	22	1173
Probe	TET-5'-cgctcagaagaaaacatctataccattga-3'-TAMRA (SEQ ID NO:432)	29	1195
Reverse	5'-ggctcctccacttcatatacgt-3' (SEQ ID NO:433)	22	1229

Table QD. CNS_neurodegeneration_v1.0

Tissue Name	Rel. Exp.(%) Ag3865, Run 212188106	Tissue Name	Rel. Exp.(%) Ag3865, Run 212188106
AD 1 Hippo	8.8	Control (Path) 3 Temporal Ctx	0.0
AD 2 Hippo	0.0	Control (Path) 4 Temporal Ctx	10.7
AD 3 Hippo	0.0	AD 1 Occipital Ctx	6.5
AD 4 Hippo	0.0	AD 2 Occipital Ctx (Missing)	0.0
AD 5 hippo	12.5	AD 3 Occipital Ctx	2.0
AD 6 Hippo	100.0	AD 4 Occipital Ctx	6.6
Control 2 Hippo	10.1	AD 5 Occipital Ctx	21.2
Control 4 Hippo	1.1	AD 6 Occipital Ctx	12.5

Control (Path) 3 Hippo	0.0	Control 1 Occipital Ctx	0.0
AD 1 Temporal Ctx	9.0	Control 2 Occipital Ctx	6.9
AD 2 Temporal Ctx	10.2	Control 3 Occipital Ctx	3.9
AD 3 Temporal Ctx	0.0	Control 4 Occipital Ctx	6.5
AD 4 Temporal Ctx	4.3	Control (Path) 1 Occipital Ctx	16.7
AD 5 Inf Temporal Ctx	25.5	Control (Path) 2 Occipital Ctx	1.7
AD 5 SupTemporal Ctx	5.4	Control (Path) 3 Occipital Ctx	1.6
AD 6 Inf Temporal Ctx	56.3	Control (Path) 4 Occipital Ctx	10.6
AD 6 Sup Temporal Ctx	85.3	Control 1 Parietal Ctx	2.8
Control 1 Temporal Ctx	0.0	Control 2 Parietal Ctx	10.7
Control 2 Temporal Ctx	9.6	Control 3 Parietal Ctx	0.0
Control 3 Temporal Ctx	0.0	Control (Path) 1 Parietal Ctx	15.5
Control 4 Temporal Ctx	0.0	Control (Path) 2 Parietal Ctx	8.7
Control (Path) 1 Temporal Ctx	18.0	Control (Path) 3 Parietal Ctx	0.0
Control (Path) 2 Temporal Ctx	17.7	Control (Path) 4 Parietal Ctx	4.9

Table QE. General_screening_panel_v1.4

Tissue Name	Rel. Exp.(%) Ag3864, Run 217310197	Rel. Exp.(%) Ag3865, Run 219025099	Tissue Name	Rel. Exp.(%) Ag3864, Run 217310197	Rel. Exp.(%) Ag3865, Run 219025099
Adipose	22.7	27.5	Renal ca. TK-10	2.1	2.2
Melanoma* Hs688(A).T	0.2	2.3	Bladder	87.1	61.1
Melanoma* Hs688(B).T	0.0	2.8	Gastric ca. (liver met.) NCI-N87	1.2	2.7
Melanoma*	0.0	0.0	Gastric ca. KATO	0.2	0.0

M14			III		
Melanoma* LOXIMVI	0.3	0.0	Colon ca. SW-948	0.1	0.0
Melanoma* SK-MEL-5	0.6	0.0	Colon ca. SW480	2.0	17.9
Squamous cell carcinoma SCC-4	0.1	0.0	Colon ca.* (SW480 met) SW620	0.1	2.3
Testis Pool	7.0	8.8	Colon ca. HT29	0.0	2.3
Prostate ca.* (bone met) PC-3	0.6	0.0	Colon ca. HCT-116	0.1	1.9
Prostate Pool	4.0	6.2	Colon ca. CaCo-2	3.6	44.4
Placenta	9.0	19.9	Colon cancer tissue	68.3	42.9
Uterus Pool	1.6	8.2	Colon ca. SW1116	0.0	0.0
Ovarian ca. OVCAR-3	0.1	8.8	Colon ca. Colo-205	0.0	3.6
Ovarian ca. SK-OV-3	0.7	0.0	Colon ca. SW-48	0.0	0.0
Ovarian ca. OVCAR-4	0.0	1.7	Colon Pool	17.1	28.9
Ovarian ca. OVCAR-5	1.0	11.1	Small Intestine Pool	8.0	9.5
Ovarian ca. IGROV-1	0.1	2.0	Stomach Pool	9.3	11.3
Ovarian ca. OVCAR-8	0.0	0.0	Bone Marrow Pool	5.6	9.0
Ovary	8.7	2.0	Fetal Heart	3.9	4.9
Breast ca. MCF-7	0.4	15.2	Heart Pool	4.6	10.3
Breast ca. MDA-MB-231	0.5	0.0	Lymph Node Pool	9.6	25.2
Breast ca. BT 549	1.0	13.2	Fetal Skeletal Muscle	4.6	9.0
Breast ca. T47D	1.6	10.5	Skeletal Muscle Pool	4.7	10.2
Breast ca. MDA-N	0.1	0.0	Spleen Pool	100.0	41.8
Breast Pool	13.4	10.9	Thymus Pool	23.8	31.0

Trachea	15.5	21.3	CNS cancer (glio/astro) U87-MG	0.6	8.7
Lung	2.4	0.0	CNS cancer (glio/astro) U-118-MG	0.9	4.8
Fetal Lung	36.6	100.0	CNS cancer (neuro;met) SK-N-AS	0.2	1.2
Lung ca. NCI-N417	0.0	1.7	CNS cancer (astro) SF-539	0.8	1.7
Lung ca. LX-1	0.7	2.3	CNS cancer (astro) SNB-75	3.1	19.3
Lung ca. NCI-H146	0.0	0.0	CNS cancer (glio) SNB-19	0.1	4.3
Lung ca. SHP-77	0.1	1.8	CNS cancer (glio) SF-295	0.7	1.7
Lung ca. A549	0.2	1.3	Brain (Amygdala) Pool	29.5	15.0
Lung ca. NCI-H526	0.0	0.0	Brain (cerebellum)	18.0	9.1
Lung ca. NCI-H23	1.4	0.0	Brain (fetal)	7.6	18.6
Lung ca. NCI-H460	0.0	0.0	Brain (Hippocampus) Pool	37.6	20.7
Lung ca. HOP-62	0.2	2.3	Cerebral Cortex Pool	24.0	5.8
Lung ca. NCI-H522	0.2	4.7	Brain (Substantia nigra) Pool	27.7	9.5
Liver	5.7	0.0	Brain (Thalamus) Pool	43.5	21.9
Fetal Liver	10.7	11.4	Brain (whole)	21.6	6.8
Liver ca. HepG2	1.4	4.8	Spinal Cord Pool	73.7	27.9
Kidney Pool	15.6	39.5	Adrenal Gland	25.7	37.6
Fetal Kidney	17.3	47.0	Pituitary gland Pool	0.8	2.1
Renal ca. 786-0	5.7	10.7	Salivary Gland	4.0	2.5
Renal ca. A498	0.4	2.4	Thyroid (female)	2.7	8.3

Renal ca. ACHN	0.1	0.0	Pancreatic ca. CAPAN2	0.1	0.0
Renal ca. UO-31	0.8	0.0	Pancreas Pool	16.2	21.0

Table QF. Panel 2.2

Tissue Name	Rel. Exp.(%) Ag3864, Run 174448455	Tissue Name	Rel. Exp.(%) Ag3864, Run 174448455
Normal Colon	4.7	Kidney Margin (OD04348)	31.2
Colon cancer (OD06064)	20.4	Kidney malignant cancer (OD06204B)	0.7
Colon Margin (OD06064)	2.5	Kidney normal adjacent tissue (OD06204E)	18.7
Colon cancer (OD06159)	1.0	Kidney Cancer (OD04450-01)	17.0
Colon Margin (OD06159)	1.7	Kidney Margin (OD04450-03)	11.1
Colon cancer (OD06297-04)	1.3	Kidney Cancer 8120613	0.0
Colon Margin (OD06297-015)	4.9	Kidney Margin 8120614	25.9
CC Gr.2 ascend colon (ODO3921)	1.3	Kidney Cancer 9010320	9.6
CC Margin (ODO3921)	2.3	Kidney Margin 9010321	18.8
Colon cancer metastasis (OD06104)	7.3	Kidney Cancer 8120607	5.3
Lung Margin (OD06104)	20.0	Kidney Margin 8120608	19.9
Colon mets to lung (OD04451-01)	20.6	Normal Uterus	2.8
Lung Margin (OD04451-02)	21.6	Uterine Cancer 064011	3.7
Normal Prostate	0.5	Normal Thyroid	0.2
Prostate Cancer (OD04410)	0.6	Thyroid Cancer 064010	2.0
Prostate Margin (OD04410)	0.8	Thyroid Cancer A302152	5.0
Normal Ovary	2.4	Thyroid Margin A302153	1.2
Ovarian cancer	12.9	Normal Breast	4.3

(OD06283-03)			
Ovarian Margin (OD06283-07)	4.7	Breast Cancer (OD04566)	4.0
Ovarian Cancer 064008	3.4	Breast Cancer 1024	3.9
Ovarian cancer (OD06145)	8.3	Breast Cancer (OD04590-01)	10.6
Ovarian Margin (OD06145)	2.3	Breast Cancer Mets (OD04590-03)	14.5
Ovarian cancer (OD06455-03)	1.1	Breast Cancer Metastasis (OD04655-05)	6.1
Ovarian Margin (OD06455-07)	1.8	Breast Cancer 064006	8.2
Normal Lung	9.9	Breast Cancer 9100266	2.4
Invasive poor diff. lung adeno (ODO4945-01)	10.0	Breast Margin 9100265	2.4
Lung Margin (ODO4945-03)	29.3	Breast Cancer A209073	0.5
Lung Malignant Cancer (OD03126)	7.1	Breast Margin A2090734	2.2
Lung Margin (OD03126)	7.4	Breast cancer (OD06083)	13.8
Lung Cancer (OD05014A)	13.1	Breast cancer node metastasis (OD06083)	16.0
Lung Margin (OD05014B)	35.4	Normal Liver	3.1
Lung cancer (OD06081)	3.6	Liver Cancer 1026	2.5
Lung Margin (OD06081)	12.9	Liver Cancer 1025	10.6
Lung Cancer (OD04237-01)	5.9	Liver Cancer 6004-T	4.5
Lung Margin (OD04237-02)	32.1	Liver Tissue 6004-N	1.2
Ocular Melanoma Metastasis	0.4	Liver Cancer 6005-T	8.1
Ocular Melanoma Margin (Liver)	4.1	Liver Tissue 6005-N	20.7
Melanoma Metastasis	1.5	Liver Cancer 064003	2.4
Melanoma Margin (Lung)	11.0	Normal Bladder	7.3
Normal Kidney	3.7	Bladder Cancer 1023	2.5
Kidney Ca, Nuclear	23.0	Bladder Cancer	6.0

grade 2 (OD04338)		A302173	
Kidney Margin (OD04338)	100.0	Normal Stomach	5.2
Kidney Ca Nuclear grade 1/2 (OD04339)	24.5	Gastric Cancer 9060397	4.1
Kidney Margin (OD04339)	16.0	Stomach Margin 9060396	5.5
Kidney Ca, Clear cell type (OD04340)	4.9	Gastric Cancer 9060395	5.6
Kidney Margin (OD04340)	6.8	Stomach Margin 9060394	9.6
Kidney Ca, Nuclear grade 3 (OD04348)	3.4	Gastric Cancer 064005	2.6

Table QG. Panel 4.1D

Tissue Name	Rel. Exp.(%) Ag3864, Run 172209244	Rel. Exp.(%) Ag3865, Run 170128795	Tissue Name	Rel. Exp.(%) Ag3864, Run 172209244	Rel. Exp.(%) Ag3865, Run 170128795
Secondary Th1 act	100.0	0.0	HUVEC IL-1beta	0.0	0.0
Secondary Th2 act	39.0	100.0	HUVEC IFN gamma	0.1	0.0
Secondary Tr1 act	36.6	0.5	HUVEC TNF alpha + IFN gamma	0.0	0.0
Secondary Th1 rest	14.0	0.1	HUVEC TNF alpha + IL4	0.0	0.1
Secondary Th2 rest	3.3	0.3	HUVEC IL-11	0.0	3.9
Secondary Tr1 rest	4.9	0.1	Lung Microvascular EC none	0.0	4.9
Primary Th1 act	8.3	0.0	Lung Microvascular EC TNFalpha + IL-1beta	0.0	5.0
Primary Th2 act	4.8	0.0	Microvascular Dermal EC none	0.0	12.9
Primary Tr1 act	7.1	0.3	Microsvascular Dermal EC TNFalpha + IL-1beta	0.0	4.5

Primary Th1 rest	5.5	0.0	Bronchial epithelium TNFalpha + IL1beta	0.0	5.1
Primary Th2 rest	3.6	0.0	Small airway epithelium none	0.0	6.1
Primary Tr1 rest	2.9	0.1	Small airway epithelium TNFalpha + IL-1beta	0.0	3.3
CD45RA CD4 lymphocyte act	7.6	2.1	Coronary artery SMC rest	0.0	0.0
CD45RO CD4 lymphocyte act	12.8	0.0	Coronary artery SMC TNFalpha + IL-1beta	0.0	0.1
CD8 lymphocyte act	6.5	0.2	Astrocytes rest	0.0	4.5
Secondary CD8 lymphocyte rest	10.4	0.1	Astrocytes TNFalpha + IL-1beta	0.0	0.0
Secondary CD8 lymphocyte act	11.4	0.2	KU-812 (Basophil) rest	0.1	0.0
CD4 lymphocyte none	0.5	0.0	KU-812 (Basophil) PMA/ionomycin	0.7	2.6
2ry Th1/Th2/Tr1_anti-CD95 CH11	6.7	0.2	CCD1106 (Keratinocytes) none	0.0	14.2
LAK cells rest	17.7	0.0	CCD1106 (Keratinocytes) TNFalpha + IL-1beta	0.0	2.3
LAK cells IL-2	31.0	0.0	Liver cirrhosis	1.3	8.1
LAK cells IL-2+IL-12	35.4	0.0	NCI-H292 none	0.0	3.5
LAK cells IL-2+IFN gamma	12.6	0.0	NCI-H292 IL-4	0.0	6.0
LAK cells IL-2+IL-18	15.7	0.1	NCI-H292 IL-9	0.0	6.4
LAK cells PMA/ionomycin	24.1	0.0	NCI-H292 IL-13	0.0	20.4
NK Cells IL-2 rest	24.7	0.0	NCI-H292 IFN gamma	0.0	9.0

Two Way MLR 3 day	11.2	0.0	HPAEC none	0.0	32.1
Two Way MLR 5 day	13.3	2.3	HPAEC TNF alpha + IL-1 beta	0.0	7.6
Two Way MLR 7 day	15.8	0.9	Lung fibroblast none	0.1	3.0
PBMC rest	1.7	0.0	Lung fibroblast TNF alpha + IL-1 beta	0.4	0.7
PBMC PWM	15.4	0.0	Lung fibroblast IL-4	0.1	0.3
PBMC PHA-L	7.6	0.9	Lung fibroblast IL-9	0.3	7.4
Ramos (B cell) none	0.0	0.1	Lung fibroblast IL-13	0.1	4.2
Ramos (B cell) ionomycin	0.3	0.0	Lung fibroblast IFN gamma	0.5	2.5
B lymphocytes PWM	5.4	0.1	Dermal fibroblast CCD1070 rest	0.6	3.7
B lymphocytes CD40L and IL-4	0.3	0.0	Dermal fibroblast CCD1070 TNF alpha	16.0	2.1
EOL-1 dbcAMP	0.1	0.0	Dermal fibroblast CCD1070 IL-1 beta	0.0	1.1
EOL-1 dbcAMP PMA/ionomycin	2.8	0.0	Dermal fibroblast IFN gamma	0.0	1.8
Dendritic cells none	25.0	0.0	Dermal fibroblast IL-4	0.0	2.4
Dendritic cells LPS	13.7	0.1	Dermal Fibroblasts rest	0.0	4.8
Dendritic cells anti-CD40	29.5	0.0	Neutrophils TNFa+LPS	0.3	1.1
Monocytes rest	4.9	0.0	Neutrophils rest	0.0	2.1
Monocytes LPS	7.2	0.2	Colon	0.3	1.4
Macrophages rest	41.5	0.0	Lung	3.5	0.6
Macrophages LPS	8.8	0.0	Thymus	1.6	2.5
HUVEC none	0.0	0.0	Kidney	2.8	17.3
HUVEC starved	0.0	0.0			

CNS_neurodegeneration_v1.0 Summary: Ag3865 This panel confirms the expression of the CG56352-02 gene in the CNS. See General_screening_panel_v1.4 for a discussion of utility. Ag2918 Expression of the CG56352-02 gene is low/undetectable in all samples on this panel (CTs>35).

5 **General_screening_panel_v1.4 Summary:** Ag3864/Ag3865 Two experiments produce results that are in very good agreement, with highest expression of the CG56352-02 gene in fetal lung and spleen (CT=28-32). Furthermore, expression of this gene is higher in fetal lung (CTs=28-30) when compared to expression in the adult (CTs=33-40). Thus, expression of this gene could be used to differentiate between fetal and adult lung tissue.

10 Low, but significant expression of this gene is also seen in colon, breast, renal and CNS cancer cell lines on this panel. Thus, expression of this gene may be associated with these cancers and modulation of expression might be used for treatment of colon, breast, renal and brain cancers.

Among tissues with metabolic function, this gene is expressed at low levels in adipose, adult and fetal liver, adult and fetal heart, adult and fetal skeletal muscle, adrenal, thyroid and pancreas.

15 Based on its tissue distribution, this gene product may be important for the pathogenesis, diagnosis, and/or treatment of endocrine and metabolic disease, including obesity and Types 1 and 2 diabetes.

This gene is expressed at moderate levels in the CNS. Therapeutic modulation of this gene or its protein product may be of use in controlling the inflammatory response and be of benefit in any clinical condition associated with neuroinflammation, such as stroke, head or spinal cord trauma, multiple sclerosis, Alzheimer's disease, and viral infections of the CNS.

Panel 1.3D Summary: Ag2918 Expression of the CG56352-02 gene is low/undetectable in all samples on this panel (CTs>35).

25 **Panel 2.2 Summary:** Ag3864 The CG56352-02 gene is expressed at low level in the tissues used for panel 2.2. The highest expression is seen in a normal kidney sample (CT= 29.7). In addition, there appears to be increased expression in 5 of 6 samples of normal lung tissue when compared to lung cancers and in 7 of 9 samples of normal kidney compared to the adjacent

kidney cancer tissue. Thus, loss of expression of this gene may be associated with these cancers and therapeutic modulation of this gene may therefore be of use in the treatment of these cancers.

Panel 2D Summary: Ag2918 Expression of the CG56352-02 gene is low/undetectable in all samples on this panel (CTs>35).

Panel 4.1D Summary: Ag 3864 The CG56352-02 transcript is found in T cells, particularly chronically activated Th1, Th2 and Tr1 cells. LAK cells, macrophages and dendritic cells also express the transcript. The only non-hematopoietic cell type that expresses the transcript detected by these primers and probe are dermal fibroblasts. Lung, thymus and kidney also express low levels of the transcript. Thus, this transcript or the protein it encodes could be used to detect hematopoietically-derived cells. Furthermore, therapeutics designed with the protein encoded by this transcript could be important in the regulation the function of antigen presenting cells (macrophages and dendritic cells) or T cells and be important in the treatment of asthma, emphysema, psoriasis, arthritis, and IBD.

Ag3865 The CG56352-02 transcript is expressed at low levels in many tissues and at high levels in Th2 cells. The expression profile in this panel using this probe and primer set differs from the Ag3864 results in the expression seen in many nonhematopoietic tissues. Therapeutics designed with the protein encoded by this transcript could be important in the regulation of T cell function.

Panel 4D Summary: Ag2918 Expression of the CG56352-02 gene is low/undetectable in all samples on this panel (CTs>35).

NOV24a and NOV24b: CG56062-01 and CG56062-02: Organic Anion Transporter 3

Expression of gene CG56062-01 and variant CG56062-02 was assessed using the primer-probe sets Ag3948, Ag2874 and Ag3532, described in Tables RA, RB and RC. Results of the RTQ-PCR runs are shown in Tables RD, RE, RF, RG, RH, RI and RJ.

Table RA. Probe Name Ag3948

Primers	Sequences	Length	Start Position
Forward	5'-ctctattcttggtggtccca-3' (SEQ ID NO:434)	21	851
Probe	TET-5'-ctcctgcatggcaagtcccagttag-3'-TAMRA (SEQ ID	25	890

	NO:435)		
Reverse	5'-ccaccttctgcagattctgtac-3' (SEQ ID NO:436)	22	917

Table RB. Probe Name Ag2874

Primers	Sequences	Length	Start Position
Forward	5'-ccaactcaatcttggacctctt-3' (SEQ ID NO:437)	22	1032
Probe	TET-5'-atccgcaagggtcacatgctgtctcat-3'-TAMRA (SEQ ID NO:438)	26	1067
Reverse	5'-cagagttggagaaccaaatacac-3' (SEQ ID NO:439)	22	1094

Table RC. Probe Name Ag3532

Primers	Sequences	Length	Start Position
Forward	5'-ccaactcaatcttggacctctt-3' (SEQ ID NO:440)	22	1032
Probe	TET-5'-atccgcaagggtcacatgctgtctcat-3'-TAMRA (SEQ ID NO:441)	26	1067
Reverse	5'-cagagttggagaaccaaatacac-3' (SEQ ID NO:442)	22	1094

Table RD. CNS_neurodegeneration_v1.0

Tissue Name	Rel. Exp.(%) Ag3948, Run 212345604	Tissue Name	Rel. Exp.(%) Ag3948, Run 212345604
AD 1 Hippo	0.0	Control (Path) 3 Temporal Ctx	0.0
AD 2 Hippo	57.0	Control (Path) 4 Temporal Ctx	33.4
AD 3 Hippo	32.5	AD 1 Occipital Ctx	67.8
AD 4 Hippo	0.0	AD 2 Occipital Ctx (Missing)	5.3
AD 5 Hippo	47.0	AD 3 Occipital Ctx	0.0
AD 6 Hippo	20.3	AD 4 Occipital Ctx	0.0
Control 2 Hippo	0.0	AD 5 Occipital Ctx	18.4
Control 4 Hippo	0.0	AD 6 Occipital Ctx	39.2
Control (Path) 3 Hippo	0.0	Control 1 Occipital Ctx	0.0
AD 1 Temporal Ctx	0.0	Control 2 Occipital Ctx	79.6
AD 2 Temporal Ctx	16.7	Control 3 Occipital Ctx	42.0

AD 3 Temporal Ctx	14.9	Control 4 Occipital Ctx	0.0
AD 4 Temporal Ctx	0.0	Control (Path) 1 Occipital Ctx	46.0
AD 5 Inf Temporal Ctx	100.0	Control (Path) 2 Occipital Ctx	0.0
AD 5 Sup Temporal Ctx	0.0	Control (Path) 3 Occipital Ctx	0.0
AD 6 Inf Temporal Ctx	65.1	Control (Path) 4 Occipital Ctx	11.7
AD 6 Sup Temporal Ctx	91.4	Control 1 Parietal Ctx	10.3
Control 1 Temporal Ctx	0.0	Control 2 Parietal Ctx	49.3
Control 2 Temporal Ctx	0.0	Control 3 Parietal Ctx	0.0
Control 3 Temporal Ctx	0.0	Control (Path) 1 Parietal Ctx	67.8
Control 3 Temporal Ctx	18.0	Control (Path) 2 Parietal Ctx	14.4
Control (Path) 1 Temporal Ctx	32.1	Control (Path) 3 Parietal Ctx	0.0
Control (Path) 2 Temporal Ctx	9.7	Control (Path) 4 Parietal Ctx	20.4

Table RE. General_screening_panel_v1.4

Tissue Name	Rel. Exp.(%) Ag3948, Run 219279808	Tissue Name	Rel. Exp.(%) Ag3948, Run 219279808
Adipose	0.3	Renal ca. TK-10	2.1
Melanoma* Hs688(A).T	0.5	Bladder	2.8
Melanoma* Hs688(B).T	0.2	Gastric ca. (liver met.) NCI-N87	22.2
Melanoma* M14	0.2	Gastric ca. KATO III	4.0
Melanoma* LOXIMVI	0.0	Colon ca. SW-948	0.1
Melanoma* SK-MEL-5	0.1	Colon ca. SW480	10.5
Squamous cell carcinoma SCC-4	2.4	Colon ca.* (SW480 met) SW620	1.6
Testis Pool	0.3	Colon ca. HT29	1.5

Prostate ca.* (bone met) PC-3	0.9	Colon ca. HCT-116	2.3
Prostate Pool	0.3	Colon ca. CaCo-2	0.7
Placenta	0.2	Colon cancer tissue	0.2
Uterus Pool	0.1	Colon ca. SW1116	0.1
Ovarian ca. OVCAR-3	11.5	Colon ca. Colo-205	0.6
Ovarian ca. SK-OV-3	1.3	Colon ca. SW-48	0.8
Ovarian ca. OVCAR-4	0.4	Colon Pool	0.6
Ovarian ca. OVCAR-5	8.0	Small Intestine Pool	0.4
Ovarian ca. IGROV-1	1.9	Stomach Pool	0.1
Ovarian ca. OVCAR-8	0.5	Bone Marrow Pool	0.4
Ovary	0.4	Fetal Heart	0.1
Breast ca. MCF-7	3.2	Heart Pool	0.3
Breast ca. MDA-MB-231	2.3	Lymph Node Pool	0.7
Breast ca. BT 549	0.2	Fetal Skeletal Muscle	0.6
Breast ca. T47D	9.6	Skeletal Muscle Pool	0.4
Breast ca. MDA-N	0.2	Spleen Pool	0.2
Breast Pool	0.7	Thymus Pool	0.3
Trachea	0.6	CNS cancer (glio/astro) U87-MG	0.5
Lung	0.2	CNS cancer (glio/astro) U-118-MG	0.1
Fetal Lung	1.7	CNS cancer (neuro;met) SK-N-AS	0.4
Lung ca. NCI-N417	0.1	CNS cancer (astro) SF-539	0.1
Lung ca. LX-1	100.0	CNS cancer (astro) SNB-75	0.1
Lung ca. NCI-H146	1.0	CNS cancer (glio) SNB-19	0.9
Lung ca. SHP-77	0.1	CNS cancer (glio) SF-295	9.3
Lung ca. A549	2.2	Brain (Amygdala) Pool	0.1
Lung ca. NCI-H526	0.1	Brain (cerebellum)	5.1

Lung ca. NCI-H23	0.9	Brain (fetal)	2.3
Lung ca. NCI-H460	0.2	Brain (Hippocampus) Pool	0.0
Lung ca. HOP-62	0.5	Cerebral Cortex Pool	0.0
Lung ca. NCI-H522	1.1	Brain (Substantia nigra) Pool	0.2
Liver	0.3	Brain (Thalamus) Pool	0.0
Fetal Liver	0.8	Brain (whole)	0.8
Liver ca. HepG2	0.2	Spinal Cord Pool	0.0
Kidney Pool	0.7	Adrenal Gland	0.2
Fetal Kidney	0.7	Pituitary gland Pool	0.0
Renal ca. 786-0	0.2	Salivary Gland	0.1
Renal ca. A498	0.2	Thyroid (female)	0.7
Renal ca. ACHN	0.2	Pancreatic ca. CAPAN2	3.8
Renal ca. UO-31	1.6	Pancreas Pool	0.6

Table RF. Panel 1.3D

Tissue Name	Rel. Exp.(%) Ag2874, Run 161973724	Rel. Exp.(%) Ag2874, Run 165721687	Tissue Name	Rel. Exp.(%) Ag2874, Run 161973724	Rel. Exp.(%) Ag2874, Run 165721687
Liver adenocarcinoma	4.9	5.6	Kidney (fetal)	0.0	0.0
Pancreas	0.0	0.0	Renal ca. 786- 0	0.0	0.0
Pancreatic ca. CAPAN 2	0.0	0.0	Renal ca. A498	0.0	0.0
Adrenal gland	0.0	0.0	Renal ca. RXF 393	0.0	0.0
Thyroid	0.0	6.3	Renal ca. ACHN	0.0	0.0
Salivary gland	0.0	0.0	Renal ca. UO- 31	0.0	0.0
Pituitary gland	0.0	0.0	Renal ca. TK- 10	0.0	0.0
Brain (fetal)	0.0	3.8	Liver	0.0	3.1
Brain (whole)	3.1	6.1	Liver (fetal)	0.0	0.0
Brain (amygdala)	4.3	0.0	Liver ca. (hepatoblast) HepG2	0.0	0.0
Brain (cerebellum)	1.8	7.6	Lung	0.0	0.0

Brain (hippocampus)	0.0	0.0	Lung (fetal)	4.5	4.1
Brain (substantia nigra)	0.0	3.5	Lung ca. (small cell) LX-1	100.0	100.0
Brain (thalamus)	0.0	0.0	Lung ca. (small cell) NCI-H69	0.0	3.2
Cerebral Cortex	2.3	0.0	Lung ca. (s.cell var.) SHP-77	0.0	0.0
Spinal cord	0.0	0.0	Lung ca. (large cell) NCI-H460	0.0	0.0
glio/astro U87-MG	0.0	0.0	Lung ca. (non-sm. cell) A549	0.0	0.0
glio/astro U-118-MG	0.0	0.0	Lung ca. (non-s.cell) NCI-H23	0.0	0.0
astrocytoma SW1783	0.0	0.0	Lung ca. (non-s.cell) HOP-62	0.0	0.0
neuro*; met SK-N-AS	0.0	0.0	Lung ca. (non-s.cl) NCI-H522	1.7	0.0
astrocytoma SF-539	3.8	0.0	Lung ca. (squam.) SW 900	2.1	0.0
astrocytoma SNB-75	0.0	0.0	Lung ca. (squam.) NCI-H596	0.0	0.0
glioma SNB-19	0.0	0.0	Mammary gland	0.0	0.0
glioma U251	0.0	0.0	Breast ca.* (pl.ef) MCF-7	13.9	0.0
glioma SF-295	10.7	12.5	Breast ca.* (pl.ef) MDA-MB-231	2.6	0.0
Heart (fetal)	0.0	0.0	Breast ca.* (pl.ef) T47D	3.2	4.7
Heart	0.0	0.0	Breast ca. BT-549	0.0	0.0
Skeletal muscle (fetal)	0.0	5.3	Breast ca. MDA-N	0.0	0.0
Skeletal muscle	0.0	0.0	Ovary	0.0	0.0
Bone marrow	17.9	6.1	Ovarian ca.	24.1	4.7

			OVCAR-3		
Thymus	18.7	0.0	Ovarian ca. OVCAR-4	4.7	0.0
Spleen	0.0	0.0	Ovarian ca. OVCAR-5	4.8	4.8
Lymph node	10.5	0.0	Ovarian ca. OVCAR-8	0.0	0.0
Colorectal	4.9	3.1	Ovarian ca. IGROV-1	3.0	0.0
Stomach	0.0	0.0	Ovarian ca.* (ascites) SK- OV-3	0.0	3.4
Small intestine	0.0	0.0	Uterus	0.0	6.5
Colon ca. SW480	2.7	0.0	Placenta	0.0	0.0
Colon ca.* SW620(SW480 met)	0.0	0.0	Prostate	10.8	2.7
Colon ca. HT29	0.0	0.0	Prostate ca.* (bone met)PC- 3	0.0	0.0
Colon ca. HCT- 116	0.0	0.0	Testis	0.0	0.0
Colon ca. CaCo-2	0.0	0.0	Melanoma Hs688(A).T	0.0	0.0
Colon ca. tissue(ODO3866)	8.8	0.0	Melanoma* (met) Hs688(B).T	0.0	0.0
Colon ca. HCC- 2998	17.1	2.7	Melanoma UACC-62	0.0	0.0
Gastric ca.* (liver met) NCI-N87	28.9	13.4	Melanoma M14	0.0	0.0
Bladder	13.6	0.0	Melanoma LOX IMVI	0.0	0.0
Trachea	6.7	5.6	Melanoma* (met) SK- MEL-5	0.0	0.0
Kidney	2.6	0.0	Adipose	0.0	0.0

Table RG. Panel 2D

Tissue Name	Rel. Exp.(%) Ag2874, Run	Tissue Name	Rel. Exp.(%) Ag2874, Run
-------------	-----------------------------	-------------	-----------------------------

	161973958		161973958
Normal Colon	24.3	Kidney Margin 8120608	0.0
CC Well to Mod Diff (ODO3866)	0.0	Kidney Cancer 8120613	0.0
CC Margin (ODO3866)	26.2	Kidney Margin 8120614	21.3
CC Gr.2 rectosigmoid (ODO3868)	0.0	Kidney Cancer 9010320	0.0
CC Margin (ODO3868)	13.8	Kidney Margin 9010321	0.0
CC Mod Diff (ODO3920)	11.7	Normal Uterus	0.0
CC Margin (ODO3920)	0.0	Uterus Cancer 064011	10.8
CC Gr.2 ascend colon (ODO3921)	65.1	Normal Thyroid	20.2
CC Margin (ODO3921)	0.0	Thyroid Cancer 064010	42.6
CC from Partial Hepatectomy (ODO4309) Mets	27.9	Thyroid Cancer A302152	24.1
Liver Margin (ODO4309)	0.0	Thyroid Margin A302153	0.0
Colon mets to lung (OD04451-01)	7.5	Normal Breast	0.0
Lung Margin (OD04451- 02)	0.0	Breast Cancer (OD04566)	0.0
Normal Prostate 6546-1	13.0	Breast Cancer (OD04590-01)	49.7
Prostate Cancer (OD04410)	0.0	Breast Cancer Mets (OD04590-03)	18.8
Prostate Margin (OD04410)	0.0	Breast Cancer Metastasis (OD04655- 05)	58.2
Prostate Cancer (OD04720-01)	59.5	Breast Cancer 064006	40.9
Prostate Margin (OD04720-02)	28.7	Breast Cancer 1024	100.0
Normal Lung 061010	0.0	Breast Cancer 9100266	9.7
Lung Met to Muscle (ODO4286)	0.0	Breast Margin 9100265	43.5
Muscle Margin	0.0	Breast Cancer	32.5

(ODO4286)		A209073	
Lung Malignant Cancer (OD03126)	0.0	Breast Margin A2090734	13.4
Lung Margin (OD03126)	11.3	Normal Liver	0.0
Lung Cancer (OD04404)	0.0	Liver Cancer 064003	0.0
Lung Margin (OD04404)	0.0	Liver Cancer 1025	0.0
Lung Cancer (OD04565)	16.3	Liver Cancer 1026	0.0
Lung Margin (OD04565)	0.0	Liver Cancer 6004-T	0.0
Lung Cancer (OD04237-01)	0.0	Liver Tissue 6004-N	0.0
Lung Margin (OD04237-02)	0.0	Liver Cancer 6005-T	0.0
Ocular Mel Met to Liver (ODO4310)	0.0	Liver Tissue 6005-N	0.0
Liver Margin (ODO4310)	0.0	Normal Bladder	58.2
Melanoma Mets to Lung (OD04321)	0.0	Bladder Cancer 1023	0.0
Lung Margin (OD04321)	0.0	Bladder Cancer A302173	16.6
Normal Kidney	16.5	Bladder Cancer (OD04718-01)	66.0
Kidney Ca, Nuclear grade 2 (OD04338)	16.0	Bladder Normal Adjacent (OD04718-03)	0.0
Kidney Margin (OD04338)	14.1	Normal Ovary	0.0
Kidney Ca Nuclear grade 1/2 (OD04339)	13.9	Ovarian Cancer 064008	85.9
Kidney Margin (OD04339)	13.0	Ovarian Cancer (OD04768-07)	0.0
Kidney Ca, Clear cell type (OD04340)	0.0	Ovary Margin (OD04768-08)	0.0
Kidney Margin (OD04340)	0.0	Normal Stomach	14.7
Kidney Ca, Nuclear grade 3 (OD04348)	14.8	Gastric Cancer 9060358	0.0
Kidney Margin (OD04348)	0.0	Stomach Margin 9060359	0.0
Kidney Cancer (OD04622-01)	0.0	Gastric Cancer 9060395	0.0
Kidney Margin	0.0	Stomach Margin	14.0

(OD04622-03)		9060394	
Kidney Cancer (OD04450-01)	0.0	Gastric Cancer 9060397	17.2
Kidney Margin (OD04450-03)	19.2	Stomach Margin 9060396	0.0
Kidney Cancer 8120607	23.5	Gastric Cancer 064005	20.3

Table RH. Panel 3D

Tissue Name	Rel. Exp.(%) Ag2874, Run 164543575	Tissue Name	Rel. Exp.(%) Ag2874, Run 164543575
Daoy- Medulloblastoma	0.0	Ca Ski- Cervical epidermoid carcinoma (metastasis)	0.0
TE671- Medulloblastoma	0.0	ES-2- Ovarian clear cell carcinoma	0.0
D283 Med- Medulloblastoma	0.0	Ramos- Stimulated with PMA/ionomycin 6h	0.0
PFSK-1- Primitive Neuroectodermal	0.0	Ramos- Stimulated with PMA/ionomycin 14h	0.0
XF-498- CNS	0.0	MEG-01- Chronic myelogenous leukemia (megokaryoblast)	0.0
SNB-78- Glioma	0.0	Raji- Burkitt's lymphoma	3.3
SF-268- Glioblastoma	0.0	Daudi- Burkitt's lymphoma	0.0
T98G- Glioblastoma	0.0	U266- B-cell plasmacytoma	0.0
SK-N-SH- Neuroblastoma (metastasis)	0.0	CA46- Burkitt's lymphoma	0.0
SF-295- Glioblastoma	0.0	RL- non-Hodgkin's B-cell lymphoma	0.0
Cerebellum	0.5	JM1- pre-B-cell lymphoma	0.0
Cerebellum	2.3	Jurkat- T cell leukemia	0.0
NCI-H292- Mucoepidermoid lung carcinoma	16.8	TF-1- Erythroleukemia	0.0
DMS-114- Small cell lung cancer	0.0	HUT 78- T-cell lymphoma	8.2
DMS-79- Small cell lung cancer	4.2	U937- Histiocytic lymphoma	0.0
NCI-H146- Small cell lung cancer	0.0	KU-812- Myelogenous leukemia	0.0

NCI-H526- Small cell lung cancer	0.0	769-P- Clear cell renal carcinoma	0.0
NCI-N417- Small cell lung cancer	0.0	Caki-2- Clear cell renal carcinoma	0.0
NCI-H82- Small cell lung cancer	0.0	SW 839- Clear cell renal carcinoma	2.9
NCI-H157- Squamous cell lung cancer (metastasis)	0.0	G401- Wilms' tumor	0.0
NCI-H1155- Large cell lung cancer	0.0	Hs766T- Pancreatic carcinoma (LN metastasis)	3.6
NCI-H1299- Large cell lung cancer	16.6	CAPAN-1- Pancreatic adenocarcinoma (liver metastasis)	4.4
NCI-H727- Lung carcinoid	0.0	SU86.86- Pancreatic carcinoma (liver metastasis)	100.0
NCI-UMC-11- Lung carcinoid	0.0	BxPC-3- Pancreatic adenocarcinoma	0.0
LX-1- Small cell lung cancer	48.0	HPAC- Pancreatic adenocarcinoma	3.6
Colo-205- Colon cancer	9.9	MIA PaCa-2- Pancreatic carcinoma	0.0
KM12- Colon cancer	0.0	CFPAC-1- Pancreatic ductal adenocarcinoma	4.4
KM20L2- Colon cancer	0.0	PANC-1- Pancreatic epithelioid ductal carcinoma	0.0
NCI-H716- Colon cancer	0.0	T24- Bladder carcinma (transitional cell)	3.9
SW-48- Colon adenocarcinoma	0.0	5637- Bladder carcinoma	0.0
SW1116- Colon adenocarcinoma	0.0	HT-1197- Bladder carcinoma	0.0
LS 174T- Colon adenocarcinoma	8.3	UM-UC-3- Bladder carcinma (transitional cell)	0.0
SW-948- Colon adenocarcinoma	5.1	A204- Rhabdomyosarcoma	0.0
SW-480- Colon adenocarcinoma	0.0	HT-1080- Fibrosarcoma	0.0
NCI-SNU-5- Gastric carcinoma	13.5	MG-63- Osteosarcoma	0.0
KATO III- Gastric carcinoma	0.0	SK-LMS-1- Leiomyosarcoma (vulva)	4.1

NCI-SNU-16- Gastric carcinoma	0.0	SJRH30- Rhabdomyosarcoma (met to bone marrow)	0.0
NCI-SNU-1- Gastric carcinoma	0.0	A431- Epidermoid carcinoma	0.0
RF-1- Gastric adenocarcinoma	0.0	WM266-4- Melanoma	0.0
RF-48- Gastric adenocarcinoma	0.0	DU 145- Prostate carcinoma (brain metastasis)	0.0
MKN-45- Gastric carcinoma	0.0	MDA-MB-468- Breast adenocarcinoma	6.5
NCI-N87- Gastric carcinoma	0.0	SCC-4- Squamous cell carcinoma of tongue	0.0
OVCAR-5- Ovarian carcinoma	10.2	SCC-9- Squamous cell carcinoma of tongue	0.0
RL95-2- Uterine carcinoma	0.0	SCC-15- Squamous cell carcinoma of tongue	0.0
HelaS3- Cervical adenocarcinoma	0.0	CAL 27- Squamous cell carcinoma of tongue	21.6

Table RI. Panel 4.1D

Tissue Name	Rel. Exp.(%) Ag3948, Run 170684837	Tissue Name	Rel. Exp.(%) Ag3948, Run 170684837
Secondary Th1 act	1.6	HUVEC IL-1beta	3.1
Secondary Th2 act	8.6	HUVEC IFN gamma	7.4
Secondary Tr1 act	4.4	HUVEC TNF alpha + IFN gamma	2.7
Secondary Th1 rest	0.3	HUVEC TNF alpha + IL4	0.9
Secondary Th2 rest	3.9	HUVEC IL-11	6.0
Secondary Tr1 rest	1.6	Lung Microvascular EC none	7.3
Primary Th1 act	0.3	Lung Microvascular EC TNFalpha + IL-1beta	2.7
Primary Th2 act	1.6	Microvascular Dermal EC none	0.0
Primary Tr1 act	0.0	Microvascular Dermal EC TNFalpha + IL-1beta	0.5
Primary Th1 rest	0.0	Bronchial epithelium TNFalpha + IL1beta	15.5
Primary Th2 rest	1.6	Small airway epithelium none	6.3

Primary Tr1 rest	0.4	Small airway epithelium TNFalpha + IL-1beta	20.4
CD45RA CD4 lymphocyte act	0.0	Coronary artery SMC rest	6.0
CD45RO CD4 lymphocyte act	1.2	Coronary artery SMC TNFalpha + IL-1beta	1.6
CD8 lymphocyte act	2.8	Astrocytes rest	0.3
Secondary CD8 lymphocyte rest	2.0	Astrocytes TNFalpha + IL- 1beta	1.5
Secondary CD8 lymphocyte act	1.2	KU-812 (Basophil) rest	3.4
CD4 lymphocyte none	1.6	KU-812 (Basophil) PMA/ionomycin	6.3
2ry Th1/Th2/Tr1_anti- CD95 CH11	4.6	CCD1106 (Keratinocytes) none	14.6
LAK cells rest	1.6	CCD1106 (Keratinocytes) TNFalpha + IL-1beta	20.6
LAK cells IL-2	1.7	Liver cirrhosis	0.0
LAK cells IL-2+IL-12	3.6	NCI-H292 none	49.7
LAK cells IL-2+IFN gamma	0.0	NCI-H292 IL-4	79.6
LAK cells IL-2+ IL-18	1.7	NCI-H292 IL-9	92.7
LAK cells PMA/ionomycin	0.0	NCI-H292 IL-13	58.2
NK Cells IL-2 rest	4.9	NCI-H292 IFN gamma	50.0
Two Way MLR 3 day	3.1	HPAEC none	8.6
Two Way MLR 5 day	1.4	HPAEC TNF alpha + IL-1 beta	3.5
Two Way MLR 7 day	4.1	Lung fibroblast none	2.7
PBMC rest	2.5	Lung fibroblast TNF alpha + IL-1 beta	2.9
PBMC PWM	2.3	Lung fibroblast IL-4	2.9
PBMC PHA-L	0.4	Lung fibroblast IL-9	4.0
Ramos (B cell) none	0.0	Lung fibroblast IL-13	5.5
Ramos (B cell) ionomycin	0.0	Lung fibroblast IFN gamma	5.8
B lymphocytes PWM	0.0	Dermal fibroblast CCD1070 rest	16.2
B lymphocytes CD40L and IL-4	7.6	Dermal fibroblast CCD1070 TNF alpha	4.7
EOL-1 dbcAMP	1.9	Dermal fibroblast	1.8

		CCD1070 IL-1 beta	
EOL-1 dbcAMP PMA/ionomycin	5.5	Dermal fibroblast IFN gamma	6.7
Dendritic cells none	1.6	Dermal fibroblast IL-4	4.1
Dendritic cells LPS	0.0	Dermal Fibroblasts rest	12.2
Dendritic cells anti- CD40	0.7	Neutrophils TNFa+LPS	0.7
Monocytes rest	2.8	Neutrophils rest	1.5
Monocytes LPS	9.3	Colon	5.5
Macrophages rest	0.0	Lung	11.6
Macrophages LPS	0.8	Thymus	40.6
HUVEC none	0.3	Kidney	100.0
HUVEC starved	9.9		

Table RJ. Panel 4D

Tissue Name	Rel. Exp.(%) Ag2874, Run 159776813	Rel. Exp.(%) Ag3532, Run 166444749	Tissue Name	Rel. Exp.(%) Ag2874, Run 159776813	Rel. Exp.(%) Ag3532, Run 166444749
Secondary Th1 act	0.0	0.0	HUVEC IL-1beta	0.0	0.0
Secondary Th2 act	0.0	0.0	HUVEC IFN gamma	4.4	5.5
Secondary Tr1 act	0.0	7.2	HUVEC TNF alpha + IFN gamma	0.0	0.0
Secondary Th1 rest	0.0	0.0	HUVEC TNF alpha + IL4	0.0	0.0
Secondary Th2 rest	0.0	0.0	HUVEC IL-11	0.0	0.0
Secondary Tr1 rest	0.0	3.3	Lung Microvascular EC none	0.0	9.0
Primary Th1 act	0.0	0.0	Lung Microvascular EC TNFalpha + IL- 1beta	0.0	0.0
Primary Th2 act	0.0	0.0	Microvascular Dermal EC none	0.0	0.0
Primary Tr1 act	0.0	0.0	Microsvascular Dermal EC TNFalpha + IL-	0.0	0.0

			1beta		
Primary Th1 rest	0.0	6.4	Bronchial epithelium TNFalpha + IL1beta	0.0	0.0
Primary Th2 rest	5.6	0.0	Small airway epithelium none	5.2	21.2
Primary Tr1 rest	8.6	0.0	Small airway epithelium TNFalpha + IL-1beta	25.5	19.6
CD45RA CD4 lymphocyte act	0.0	0.0	Coronary artery SMC rest	0.0	2.1
CD45RO CD4 lymphocyte act	0.0	0.0	Coronary artery SMC TNFalpha + IL-1beta	0.0	0.0
CD8 lymphocyte act	0.0	0.0	Astrocytes rest	0.0	0.0
Secondary CD8 lymphocyte rest	0.0	0.0	Astrocytes TNFalpha + IL-1beta	0.0	5.8
Secondary CD8 lymphocyte act	0.0	0.0	KU-812 (Basophil) rest	0.0	0.0
CD4 lymphocyte none	4.1	6.9	KU-812 (Basophil) PMA/ionomycin	0.0	3.0
2ry Th1/Th2/Tr1_anti-CD95 CH11	0.0	0.0	CCD1106 (Keratinocytes) none	13.5	6.7
LAK cells rest	0.0	0.0	CCD1106 (Keratinocytes) TNFalpha + IL-1beta	0.0	69.3
LAK cells IL-2	0.0	0.0	Liver cirrhosis	0.0	0.0
LAK cells IL-2+IL-12	0.0	0.0	Lupus kidney	0.0	4.2
LAK cells IL-2+IFN gamma	0.0	3.5	NCI-H292 none	71.7	85.9
LAK cells IL-2+IL-18	0.0	0.0	NCI-H292 IL-4	53.6	100.0
LAK cells PMA/ionomycin	0.0	0.0	NCI-H292 IL-9	100.0	68.8
NK Cells IL-2 rest	0.0	3.4	NCI-H292 IL-13	36.9	60.3

Two Way MLR 3 day	0.0	0.0	NCI-H292 IFN gamma	8.1	64.2
Two Way MLR 5 day	0.0	7.0	HPAEC none	0.0	0.0
Two Way MLR 7 day	0.0	0.9	HPAEC TNF alpha + IL-1 beta	0.0	0.0
PBMC rest	0.0	0.0	Lung fibroblast none	0.0	0.0
PBMC PWM	8.2	6.9	Lung fibroblast TNF alpha + IL-1 beta	4.0	4.9
PBMC PHA-L	0.0	0.0	Lung fibroblast IL-4	0.0	0.0
Ramos (B cell) none	0.0	0.0	Lung fibroblast IL-9	4.6	0.0
Ramos (B cell) ionomycin	0.0	0.0	Lung fibroblast IL-13	0.0	0.0
B lymphocytes PWM	0.0	3.4	Lung fibroblast IFN gamma	5.0	0.0
B lymphocytes CD40L and IL-4	0.0	5.0	Dermal fibroblast CCD1070 rest	4.6	3.0
EOL-1 dbcAMP	0.0	0.0	Dermal fibroblast CCD1070 TNF alpha	0.0	0.0
EOL-1 dbcAMP PMA/ionomycin	3.7	0.0	Dermal fibroblast CCD1070 IL-1 beta	0.0	0.0
Dendritic cells none	0.0	0.0	Dermal fibroblast IFN gamma	4.6	6.6
Dendritic cells LPS	0.0	0.0	Dermal fibroblast IL-4	0.0	6.5
Dendritic cells anti-CD40	0.0	2.1	IBD Colitis 2	0.0	0.0
Monocytes rest	4.5	0.0	IBD Crohn's	0.0	0.0
Monocytes LPS	8.6	2.7	Colon	12.0	13.7
Macrophages rest	0.0	0.0	Lung	0.0	0.0
Macrophages LPS	0.0	0.0	Thymus	0.0	7.6
HUVEC none	0.0	0.0	Kidney	4.0	17.6
HUVEC starved	0.0	3.5			

CNS_neurodegeneration_v1.0 Summary: Ag3948 This panel does not show differential expression of the CG56062-01 gene in Alzheimer's disease. However, this expression profile confirms the presence of this gene in the brain. Please see Panel General_screening_panel_v1.4 for discussion of utility of this gene in the central nervous system. Ag3532 Expression of the CG56062-01 gene is low/undetectable in all samples on this panel (CTs>35).

General_screening_panel_v1.4 Summary: Ag3948 The expression of the CG56062-01 gene, an organic anion transporter homolog, is highest in a small cell lung cancer line LX-1 (CT=28.2). This gene is also expressed in some ovarian, breast, CNS, gastric, pancreatic, renal and colon cancer cell lines. Therefore, expression of this gene may be associated with these forms of cancer and therapeutic modulation of this gene might be of use in the treatment or diagnosis of these cancers.

This gene is also expressed at low levels in the cerebellum and fetal brain. The organic anion transporters are involved in transport across the blood brain barrier. This gene may therefore be of use in drug delivery to the CNS, specifically for compounds such as nerve growth factors protein therapeutics which are believed to have numerous uses in the CNS, but lack a delivery system. Ag3532 Results from one experiment with this gene are not included. The amp plot indicates that there were instrumental difficulties with this run.

References:

Sugiyama D, Kusuhara H, Shitara Y, Abe T, Meier PJ, Sekine T, Endou H, Suzuki H, Sugiyama Y. Characterization of the efflux transport of 17beta-estradiol-D-17beta-glucuronide from the brain across the blood-brain barrier. J Pharmacol Exp Ther 2001 Jul;298(1):316-22

The contribution of organic anion transporters to the total efflux of 17beta-estradiol-D-17beta-glucuronide (E(2)17betaG) through the blood-brain barrier (BBB) was investigated using the Brain Efflux Index method by examining the inhibitory effects of probenecid, taurocholate (TCA), p-aminohippurate (PAH), and digoxin. E(2)17betaG was eliminated through the BBB with a rate constant of 0.037 min(-1) after the microinjection into the brain. Probenecid and TCA inhibited this elimination with an IC50 value of 34 and 1.8 nmol/0.5 microl of injectate, respectively, whereas PAH and digoxin reduced the total efflux to about 80 and 60% of the

control value, respectively. The selectivity of these inhibitors was confirmed by examining their inhibitory effects on the transport via organic anion transporting polypeptide 1 (Oatp1), Oatp2, organic anion transporter 1 (Oat1), and Oat3 transfectants using LLC-PK1 cells as hosts. Digoxin specifically inhibited the transport via Oatp2 ($K(i) = 0.037 \text{ microM}$). The $K(i)$ values of TCA for Oatp1 and Oatp2 (11 and 39 microM, respectively) were about 20 times lower than those for Oat1 and Oat3 (2.8 and 0.8 mM, respectively). PAH did not affect the transport via the Oatp family, but had a similar affinity for Oat1 and Oat3 (85 and 300 microM, respectively). Probenecid had a similar affinity for these transporters (Oatp1, Oatp2, Oat1, and Oat3) examined in this study. Taking the selectivity of these inhibitors into consideration, the maximum contribution made by the Oatp2 and Oat family to the total efflux of E(2)17betaG from the brain appears to be about 40 and 20%, respectively.

Panel 1.3D Summary: Ag2874 The expression of the CG56062-01 gene was assessed in two independent runs on this panel with reasonable concordance between the runs. The highest expression is seen in a small cell lung cancer line LX-1 (CTs=31-32), consistent with expression in Panel 1.3D. This gene is also expressed in some ovarian, breast, CNS, gastric and colon cancer cell lines. Therefore, expression of this gene might be associated with these forms of cancer and therapeutic modulation of this gene might be of use in the treatment or diagnosis of these cancers.

Panel 2D Summary: Ag2874 The CG56062-01 gene is expressed at low levels in the tissues used for panel 2D. The highest expression is seen in a breast cancer sample (CT=34.2). Significant expression is also seen in single samples of ovarian, bladder, prostate and colon cancers compared with the normal adjacent tissue. This indicates that the expression of this gene might be associated with these forms of cancer and therapeutic modulation of this gene might be of use in the treatment or diagnosis of these cancers.

Panel 3D Summary: Ag2874 Highest expression of the CG56062-01 gene is seen in a pancreatic cancer cell line (CT=31.6). Thus, expression of this gene could be used to differentiate between this sample and other samples on this panel.

Panels 4D and 4.1D Summary: Ag2874/Ag3498 The highest expression of the CG56062-01 transcript is found in the kidney and in the pulmonary muco-epidermoid cell line NCI-H292. The expression of this transcript, although constitutive in the H292 cell line, is up regulated upon treatment with IL-4, IL-9 and IL-13, cytokines that have been linked to the pathogenesis of asthma and/or COPD. This transcript is also found in small airway epithelium and keratinocytes treated with the inflammatory cytokines TNF-a and IL-1b. Therefore, modulation of the expression or activity of the protein encoded by this transcript through the application of small molecule therapeutics may be useful in the treatment of asthma, COPD, emphysema, psoriasis and wound healing.

NOV25f, NOV25b, NOV25e, NOV25g, NOV25a, and NOV26: CG56653-01, CG56653-02, CG56653-06, CG56653-09, 152736829, and 152736833: Ficolin

Expression of gene CG56653-01 and CG56653-02 and CG56653-06 and CG56653-09 and 152736829 and 152736833 was assessed using the primer-probe sets Ag1446, Ag5126 and Ag4934, described in Tables SA, SB and SC. Results of the RTQ-PCR runs are shown in Tables SD, SE, SF, SG, SH and SI. Please note that CG56653-09, a splice variant of CG56653-01, is the only variant that corresponds to the Ag5126 probe/primer set. This does not impact the results presented below.

Table SA. Probe Name Ag1446

Primers	Sequences	Length	Start Position
Forward	5'-cgctgtcctgctagttcttgggtt-3' (SEQ ID NO:443)	21	218
Probe	TET-5'-atatcaagaacctgacctgccaggct-3'-TAMRA (SEQ ID NO:444)	26	244
Reverse	5'-ccttcacctctggacatgtg-3' (SEQ ID NO:445)	20	275

Table SB. Probe Name Ag5126

Primers	Sequences	Length	Start Position
Forward	5'-cagctggggggtaattctc-3' (SEQ ID NO:446)	19	726
Probe	TET-5'-caacttcttctccaccaagaccaagaca-3'-TAMRA (SEQ ID NO:447)	29	761
Reverse	5'-gcacaattcgaagaactcacat-3' (SEQ ID NO:448)	22	793

Table SC. Probe Name Ag4934

Primers	Sequences	Length	Start Position
Forward	5'-cgctgtcctgctagtcctgtt-3' (SEQ ID NO:449)	21	218
Probe	TET-5'-atatcaagaacctgcctgccaggt-3'-TAMRA (SEQ ID NO:450)	26	244
Reverse	5'-ccttcacctctggacatgtg-3' (SEQ ID NO:451)	20	275

Table SD. AI_comprehensive panel_v1.0

Tissue Name	Rel. Exp.(%) Ag1446, Run 211195015	Rel. Exp.(%) Ag1446, Run 212650184	Tissue Name	Rel. Exp.(%) Ag1446, Run 211195015	Rel. Exp.(%) Ag1446, Run 212650184
110967 COPD-F	3.3	1.4	112427 Match Control Psoriasis-F	11.0	2.1
110980 COPD-F	4.8	1.0	112418 Psoriasis-M	2.9	1.1
110968 COPD-M	3.5	0.5	112723 Match Control Psoriasis-M	0.9	0.4
110977 COPD-M	14.9	6.3	112419 Psoriasis-M	5.5	2.6
110989 Emphysema-F	7.4	2.8	112424 Match Control Psoriasis-M	1.8	0.9
110992 Emphysema-F	3.6	2.2	112420 Psoriasis-M	10.2	3.3
110993 Emphysema-F	6.0	1.9	112425 Match Control Psoriasis-M	5.6	1.8
110994 Emphysema-F	3.3	1.6	104689 (MF) OA Bone- Backus	62.0	20.3
110995 Emphysema-F	4.3	2.1	104690 (MF) Adj "Normal" Bone-Backus	23.7	6.0
110996 Emphysema-F	1.6	1.2	104691 (MF) OA Synovium- Backus	10.2	5.2
110997 Asthma-M	7.6	2.6	104692 (BA) OA Cartilage-	0.8	0.0

			Backus		
111001 Asthma-F	15.6	8.3	104694 (BA) OA Bone- Backus	49.0	16.0
111002 Asthma-F	20.3	6.7	104695 (BA) Adj "Normal" Bone-Backus	19.9	7.9
111003 Atopic Asthma-F	10.7	3.7	104696 (BA) OA Synovium- Backus	16.3	5.2
111004 Atopic Asthma-F	7.2	0.0	104700 (SS) OA Bone- Backus	100.0	100.0
111005 Atopic Asthma-F	3.7	1.0	104701 (SS) Adj "Normal" Bone-Backus	29.7	7.0
111006 Atopic Asthma-F	0.0	0.0	104702 (SS) OA Synovium- Backus	27.7	9.3
111417 Allergy-M	4.1	1.7	117093 OA Cartilage Rep7	3.3	0.0
112347 Allergy-M	0.4	0.0	112672 OA Bone5	23.3	5.1
112349 Normal Lung-F	0.5	0.0	112673 OA Synovium5	7.1	2.6
112357 Normal Lung-F	6.7	2.8	112674 OA Synovial Fluid cells5	9.1	3.7
112354 Normal Lung-M	0.5	0.4	117100 OA Cartilage Rep14	2.4	1.3
112374 Crohns- F	2.7	0.0	112756 OA Bone9	3.9	0.7
112389 Match Control Crohns- F	3.5	1.7	112757 OA Synovium9	2.3	2.7
112375 Crohns- F	0.0	0.2	112758 OA Synovial Fluid Cells9	14.3	3.6
112732 Match Control Crohns- F	10.2	2.8	117125 RA Cartilage Rep2	3.6	1.0
112725 Crohns-	11.0	2.4	113492 Bone2	45.4	11.2

M			RA		
112387 Match Control Crohns- M	4.9	2.3	113493 Synovium2 RA	13.9	3.5
112378 Crohns- M	0.0	0.3	113494 Syn Fluid Cells RA	29.7	10.7
112390 Match Control Crohns- M	0.8	0.3	113499 Cartilage4 RA	14.9	6.8
112726 Crohns- M	5.1	2.2	113500 Bone4 RA	16.0	5.4
112731 Match Control Crohns- M	3.1	3.3	113501 Synovium4 RA	11.7	5.2
112380 Ulcer Col-F	1.8	0.5	113502 Syn Fluid Cells4 RA	7.7	4.2
112734 Match Control Ulcer Col-F	40.6	19.1	113495 Cartilage3 RA	26.6	12.5
112384 Ulcer Col-F	10.7	3.8	113496 Bone3 RA	34.6	8.5
112737 Match Control Ulcer Col-F	2.0	1.5	113497 Synovium3 RA	15.4	6.4
112386 Ulcer Col-F	4.0	2.5	113498 Syn Fluid Cells3 RA	33.7	12.8
112738 Match Control Ulcer Col-F	54.3	12.0	117106 Normal Cartilage Rep20	0.5	0.6
112381 Ulcer Col-M	0.0	0.0	113663 Bone3 Normal	0.0	0.3
112735 Match Control Ulcer Col-M	3.4	1.8	113664 Synovium3 Normal	0.0	0.0
112382 Ulcer Col-M	4.9	1.0	113665 Syn Fluid Cells3 Normal	0.8	0.0
112394 Match Control Ulcer Col-M	3.7	1.4	117107 Normal Cartilage Rep22	2.4	1.4
112383 Ulcer	11.2	3.0	113667 Bone4	0.8	0.5

Col-M			Normal		
112736 Match Control Ulcer Col-M	4.6	0.5	113668 Synovium4 Normal	0.6	0.9
112423 Psoriasis-F	23.3	11.7	113669 Syn Fluid Cells4 Normal	2.4	0.4

Table SE. CNS_neurodegeneration_v1.0

Tissue Name	Rel. Exp.(%) Ag1446, Run 206992271	Rel. Exp.(%) Ag5126, Run 226203926	Tissue Name	Rel. Exp.(%) Ag1446, Run 206992271	Rel. Exp.(%) Ag5126, Run 226203926
AD 1 Hippo	13.7	0.0	Control (Path) 3 Temporal Ctx	1.7	0.0
AD 2 Hippo	28.7	0.0	Control (Path) 4 Temporal Ctx	27.2	29.3
AD 3 Hippo	0.0	0.0	AD 1 Occipital Ctx	12.4	0.0
AD 4 Hippo	0.0	0.0	AD 2 Occipital Ctx (Missing)	0.0	0.0
AD 5 Hippo	34.6	17.9	AD 3 Occipital Ctx	6.9	0.0
AD 6 Hippo	87.1	0.0	AD 4 Occipital Ctx	8.4	0.0
Control 2 Hippo	0.0	0.0	AD 5 Occipital Ctx	22.5	26.4
Control 4 Hippo	3.3	13.5	AD 6 Occipital Ctx	20.0	0.0
Control (Path) 3 Hippo	4.6	0.0	Control 1 Occipital Ctx	88.9	100.0
AD 1 Temporal Ctx	15.2	0.0	Control 2 Occipital Ctx	14.4	9.9
AD 2 Temporal Ctx	6.6	0.0	Control 3 Occipital Ctx	14.8	0.0

AD 3 Temporal Ctx	8.8	0.0	Control 4 Occipital Ctx	13.4	0.0
AD 4 Temporal Ctx	2.0	0.0	Control (Path) 1 Occipital Ctx	18.0	0.0
AD 5 Inf Temporal Ctx	28.9	0.0	Control (Path) 2 Occipital Ctx	0.0	0.0
AD 5 Sup Temporal Ctx	38.7	0.0	Control (Path) 3 Occipital Ctx	6.8	0.0
AD 6 Inf Temporal Ctx	64.6	0.0	Control (Path) 4 Occipital Ctx	20.7	38.4
AD 6 Sup Temporal Ctx	100.0	34.9	Control 1 Parietal Ctx	87.1	30.8
Control 1 Temporal Ctx	57.8	27.5	Control 2 Parietal Ctx	28.7	0.0
Control 2 Temporal Ctx	8.0	0.0	Control 3 Parietal Ctx	1.5	0.0
Control 3 Temporal Ctx	3.4	14.5	Control (Path) 1 Parietal Ctx	7.6	0.0
Control 3 Temporal Ctx	15.7	10.9	Control (Path) 2 Parietal Ctx	12.2	24.3
Control (Path) 1 Temporal Ctx	26.2	13.9	Control (Path) 3 Parietal Ctx	3.8	0.0
Control (Path) 2 Temporal Ctx	0.0	14.4	Control (Path) 4 Parietal Ctx	24.5	54.3

Table SF. General_screening_panel_v1.5

Tissue Name	Rel. Exp.(%) Ag4934, Run	Rel. Exp.(%) Ag5126, Run	Tissue Name	Rel. Exp.(%) Ag4934, Run	Rel. Exp.(%) Ag5126, Run
-------------	-----------------------------	-----------------------------	-------------	-----------------------------	-----------------------------

	228843453	228783295		228843453	228783295
Adipose	48.6	29.9	Renal ca. TK-10	0.0	0.0
Melanoma* Hs688(A).T	0.0	0.0	Bladder	6.4	6.2
Melanoma* Hs688(B).T	0.0	0.0	Gastric ca. (liver met.) NCI-N87	0.0	0.0
Melanoma* M14	0.0	0.0	Gastric ca. KATO III	0.0	0.0
Melanoma* LOXIMVI	0.0	0.0	Colon ca. SW- 948	0.0	0.0
Melanoma* SK-MEL-5	4.8	0.0	Colon ca. SW480	0.0	0.0
Squamous cell carcinoma SCC-4	0.0	0.0	Colon ca.* (SW480 met) SW620	0.0	0.0
Testis Pool	1.4	0.0	Colon ca. HT29	0.0	0.0
Prostate ca.* (bone met) PC-3	0.0	0.0	Colon ca. HCT- 116	0.0	0.0
Prostate Pool	9.3	6.8	Colon ca. CaCo-2	0.0	0.0
Placenta	26.8	32.5	Colon cancer tissue	35.6	23.3
Uterus Pool	12.4	0.0	Colon ca. SW1116	0.0	0.0
Ovarian ca. OVCAR-3	0.0	0.0	Colon ca. Colo- 205	0.0	0.0
Ovarian ca. SK-OV-3	0.0	0.0	Colon ca. SW-48	0.0	0.0
Ovarian ca. OVCAR-4	0.0	0.0	Colon Pool	68.8	33.0
Ovarian ca. OVCAR-5	0.0	0.0	Small Intestine Pool	9.4	3.7
Ovarian ca. IGROV-1	0.0	0.0	Stomach Pool	7.5	0.0
Ovarian ca. OVCAR-8	0.0	0.0	Bone Marrow Pool	8.5	9.1
Ovary	4.6	10.0	Fetal Heart	5.4	4.9
Breast ca. MCF-7	0.0	0.0	Heart Pool	9.9	4.6
Breast ca. MDA-MB- 231	0.0	0.0	Lymph Node Pool	8.9	8.1

Breast ca. BT 549	0.0	0.0	Fetal Skeletal Muscle	7.2	12.6
Breast ca. T47D	0.0	0.0	Skeletal Muscle Pool	17.4	8.5
Breast ca. MDA-N	0.0	0.0	Spleen Pool	84.7	95.3
Breast Pool	25.3	15.4	Thymus Pool	16.8	10.6
Trachea	24.3	20.3	CNS cancer (glio/astro) U87-MG	0.0	0.0
Lung	0.7	0.0	CNS cancer (glio/astro) U-118-MG	0.0	0.0
Fetal Lung	100.0	100.0	CNS cancer (neuro;met) SK-N-AS	0.0	0.0
Lung ca. NCI-N417	0.0	0.0	CNS cancer (astro) SF-539	0.0	0.0
Lung ca. LX-1	0.0	0.0	CNS cancer (astro) SNB-75	0.0	0.0
Lung ca. NCI-H146	0.0	0.0	CNS cancer (glio) SNB-19	0.0	0.0
Lung ca. SHP-77	0.0	0.0	CNS cancer (glio) SF-295	0.0	0.0
Lung ca. A549	0.0	0.0	Brain (Amygdala) Pool	1.8	0.0
Lung ca. NCI-H526	0.0	0.0	Brain (cerebellum)	1.4	6.3
Lung ca. NCI-H23	0.0	0.0	Brain (fetal)	3.6	0.0
Lung ca. NCI-H460	0.0	0.0	Brain (Hippocampus) Pool	2.0	0.0
Lung ca. HOP-62	0.0	0.0	Cerebral Cortex Pool	1.9	0.0
Lung ca. NCI-H522	0.0	0.0	Brain (Substantia nigra) Pool	1.7	0.0
Liver	2.2	5.4	Brain (Thalamus) Pool	1.4	0.0
Fetal Liver	28.5	21.0	Brain (whole)	3.7	4.1
Liver ca. HepG2	0.0	0.0	Spinal Cord Pool	3.1	0.0

Kidney Pool	18.6	12.2	Adrenal Gland	6.0	8.8
Fetal Kidney	7.5	8.2	Pituitary gland Pool	0.7	0.0
Renal ca. 786-0	0.0	0.0	Salivary Gland	5.9	3.9
Renal ca. A498	0.0	0.0	Thyroid (female)	15.0	15.1
Renal ca. ACHN	0.0	0.0	Pancreatic ca. CAPAN2	0.0	0.0
Renal ca. UO-31	0.0	0.0	Pancreas Pool	27.9	22.8

Table SG. Panel 1.2

Tissue Name	Rel. Exp.(%) Ag1446, Run 140179219	Tissue Name	Rel. Exp.(%) Ag1446, Run 140179219
Endothelial cells	0.0	Renal ca. 786-0	0.0
Heart (Fetal)	0.7	Renal ca. A498	0.0
Pancreas	0.1	Renal ca. RXF 393	0.0
Pancreatic ca. CAPAN 2	0.0	Renal ca. ACHN	0.0
Adrenal Gland	1.4	Renal ca. UO-31	0.0
Thyroid	0.1	Renal ca. TK-10	0.0
Salivary gland	1.1	Liver	3.7
Pituitary gland	0.1	Liver (fetal)	2.5
Brain (fetal)	0.0	Liver ca. (hepatoblast) HepG2	0.0
Brain (whole)	0.0	Lung	1.2
Brain (amygdala)	0.1	Lung (fetal)	0.4
Brain (cerebellum)	0.0	Lung ca. (small cell) LX-1	0.0
Brain (hippocampus)	0.1	Lung ca. (small cell) NCI-H69	0.0
Brain (thalamus)	0.1	Lung ca. (s.cell var.) SHP-77	0.0
Cerebral Cortex	0.1	Lung ca. (large cell) NCI-H460	0.0
Spinal cord	0.1	Lung ca. (non-sm. cell) A549	0.0
glio/astro U87-MG	0.0	Lung ca. (non-s.cell) NCI-H23	0.0

glio/astro U-118-MG	0.0	Lung ca. (non-s.cell) HOP-62	0.0
astrocytoma SW1783	0.0	Lung ca. (non-s.cl) NCI-H522	0.0
neuro*; met SK-N-AS	0.0	Lung ca. (squam.) SW 900	0.0
astrocytoma SF-539	0.0	Lung ca. (squam.) NCI-H596	0.0
astrocytoma SNB-75	0.0	Mammary gland	0.2
glioma SNB-19	0.0	Breast ca.* (pl.ef) MCF-7	0.0
glioma U251	0.0	Breast ca.* (pl.ef) MDA-MB-231	0.0
glioma SF-295	0.0	Breast ca.* (pl. ef) T47D	0.0
Heart	1.7	Breast ca. BT-549	0.0
Skeletal Muscle	0.9	Breast ca. MDA-N	0.0
Bone marrow	100.0	Ovary	0.8
Thymus	0.2	Ovarian ca. OVCAR- 3	0.0
Spleen	3.5	Ovarian ca. OVCAR- 4	0.0
Lymph node	0.2	Ovarian ca. OVCAR- 5	0.0
Colorectal Tissue	0.2	Ovarian ca. OVCAR- 8	0.0
Stomach	0.1	Ovarian ca. IGROV-1	0.0
Small intestine	0.3	Ovarian ca. (ascites) SK-OV-3	0.0
Colon ca. SW480	0.0	Uterus	0.2
Colon ca.* SW620 (SW480 met)	0.0	Placenta	2.4
Colon ca. HT29	0.0	Prostate	0.4
Colon ca. HCT-116	0.0	Prostate ca.* (bone met) PC-3	0.0
Colon ca. CaCo-2	0.0	Testis	0.0
Colon ca. Tissue (ODO3866)	0.2	Melanoma Hs688(A).T	0.0
Colon ca. HCC-2998	0.0	Melanoma* (met) Hs688(B).T	0.0
Gastric ca.* (liver met)	0.0	Melanoma UACC-62	0.0

NCI-N87			
Bladder	0.7	Melanoma M14	0.0
Trachea	0.1	Melanoma LOX IMVI	0.0
Kidney	0.8	Melanoma* (met) SK-MEL-5	0.0
Kidney (fetal)	0.7		

Table SH. Panel 4.1D

Tissue Name	Rel. Exp.(%) Ag4934, Run 223597255	Rel. Exp.(%) Ag5126, Run 225784392	Tissue Name	Rel. Exp.(%) Ag4934, Run 223597255	Rel. Exp.(%) Ag5126, Run 225784392
Secondary Th1 act	0.0	0.0	HUVEC IL-1beta	0.0	0.0
Secondary Th2 act	0.0	0.0	HUVEC IFN gamma	0.0	0.0
Secondary Tr1 act	0.0	0.0	HUVEC TNF alpha + IFN gamma	0.0	0.0
Secondary Th1 rest	0.0	0.0	HUVEC TNF alpha + IL4	0.0	0.0
Secondary Th2 rest	0.0	0.0	HUVEC IL-11	0.0	0.0
Secondary Tr1 rest	0.0	0.0	Lung Microvascular EC none	0.0	0.0
Primary Th1 act	0.0	0.0	Lung Microvascular EC TNFalpha + IL- 1beta	0.0	0.0
Primary Th2 act	0.0	0.0	Microvascular Dermal EC none	0.0	0.0
Primary Tr1 act	0.0	0.0	Microsvascular Dermal EC TNFalpha + IL- 1beta	0.0	0.0
Primary Th1 rest	0.0	0.0	Bronchial epithelium TNFalpha + IL1beta	0.0	0.0
Primary Th2 rest	0.0	0.0	Small airway epithelium none	0.0	0.0

Primary Tr1 rest	0.0	0.0	Small airway epithelium TNFalpha + IL-1beta	0.0	0.0
CD45RA CD4 lymphocyte act	0.0	0.0	Coronary artery SMC rest	0.0	0.0
CD45RO CD4 lymphocyte act	0.0	0.0	Coronary artery SMC TNFalpha + IL-1beta	0.0	0.0
CD8 lymphocyte act	0.0	0.0	Astrocytes rest	0.0	0.0
Secondary CD8 lymphocyte rest	0.0	0.0	Astrocytes TNFalpha + IL-1beta	0.0	0.0
Secondary CD8 lymphocyte act	0.0	0.0	KU-812 (Basophil) rest	0.0	0.0
CD4 lymphocyte none	0.5	0.5	KU-812 (Basophil) PMA/ionomycin	0.0	0.0
2ry Th1/Th2/Tr1_anti-CD95 CH11	0.0	0.0	CCD1106 (Keratinocytes) none	0.0	0.0
LAK cells rest	6.9	8.5	CCD1106 (Keratinocytes) TNFalpha + IL-1beta	0.0	0.0
LAK cells IL-2	0.0	0.0	Liver cirrhosis	0.2	0.0
LAK cells IL-2+IL-12	0.0	0.0	NCI-H292 none	0.0	0.0
LAK cells IL-2+IFN gamma	0.0	0.1	NCI-H292 IL-4	0.0	0.0
LAK cells IL-2+IL-18	0.0	0.1	NCI-H292 IL-9	0.0	0.0
LAK cells PMA/ionomycin	8.2	9.5	NCI-H292 IL-13	0.0	0.0
NK Cells IL-2 rest	0.0	0.0	NCI-H292 IFN gamma	0.0	0.0
Two Way MLR 3 day	1.0	1.1	HPAEC none	0.0	0.0
Two Way MLR 5 day	0.1	0.2	HPAEC TNF alpha + IL-1 beta	0.0	0.0
Two Way MLR 7 day	0.0	0.0	Lung fibroblast none	0.0	0.0

PBMC rest	19.2	19.3	Lung fibroblast TNF alpha + IL-1 beta	0.0	0.0
PBMC PWM	0.0	0.0	Lung fibroblast IL- 4	0.0	0.0
PBMC PHA-L	0.0	0.0	Lung fibroblast IL- 9	0.0	0.0
Ramos (B cell) none	0.0	0.0	Lung fibroblast IL- 13	0.0	0.0
Ramos (B cell) ionomycin	0.0	0.0	Lung fibroblast IFN gamma	0.0	0.0
B lymphocytes PWM	0.0	0.0	Dermal fibroblast CCD1070 rest	0.0	0.0
B lymphocytes CD40L and IL-4	0.0	0.0	Dermal fibroblast CCD1070 TNF alpha	0.0	0.0
EOL-1 dbcAMP	3.5	3.2	Dermal fibroblast CCD1070 IL-1 beta	0.1	0.0
EOL-1 dbcAMP PMA/ionomycin	0.5	0.3	Dermal fibroblast IFN gamma	0.1	0.1
Dendritic cells none	1.0	1.7	Dermal fibroblast IL-4	0.3	0.3
Dendritic cells LPS	0.1	0.1	Dermal Fibroblasts rest	0.1	0.2
Dendritic cells anti- CD40	0.6	0.7	Neutrophils TNFa+LPS	1.8	2.4
Monocytes rest	100.0	100.0	Neutrophils rest	3.8	5.5
Monocytes LPS	4.8	3.6	Colon	0.0	0.0
Macrophages rest	4.1	4.1	Lung	0.3	0.3
Macrophages LPS	1.8	2.1	Thymus	0.2	0.1
HUVEC none	0.0	0.0	Kidney	0.1	0.1
HUVEC starved	0.0	0.0			

Table SI. Panel 4D

Tissue Name	Rel. Exp.(%) Ag1446, Run 162699707	Tissue Name	Rel. Exp.(%) Ag1446, Run 162699707
Secondary Th1 act	0.0	HUVEC IL-1beta	0.0
Secondary Th2 act	0.0	HUVEC IFN gamma	0.0

Secondary Tr1 act	0.0	HUVEC TNF alpha + IFN gamma	0.0
Secondary Th1 rest	0.0	HUVEC TNF alpha + IL4	0.0
Secondary Th2 rest	0.0	HUVEC IL-11	0.0
Secondary Tr1 rest	0.0	Lung Microvascular EC none	0.0
Primary Th1 act	0.0	Lung Microvascular EC TNFalpha + IL-1beta	0.0
Primary Th2 act	0.0	Microvascular Dermal EC none	0.0
Primary Tr1 act	0.0	Microvascular Dermal EC TNFalpha + IL-1beta	0.0
Primary Th1 rest	0.0	Bronchial epithelium TNFalpha + IL1beta	0.0
Primary Th2 rest	0.0	Small airway epithelium none	0.0
Primary Tr1 rest	0.0	Small airway epithelium TNFalpha + IL-1beta	0.0
CD45RA CD4 lymphocyte act	0.0	Coronary artery SMC rest	0.0
CD45RO CD4 lymphocyte act	0.0	Coronary artery SMC TNFalpha + IL-1beta	0.0
CD8 lymphocyte act	0.0	Astrocytes rest	0.0
Secondary CD8 lymphocyte rest	0.0	Astrocytes TNFalpha + IL-1beta	0.0
Secondary CD8 lymphocyte act	0.0	KU-812 (Basophil) rest	0.0
CD4 lymphocyte none	0.4	KU-812 (Basophil) PMA/ionomycin	0.0
2ry Th1/Th2/Tr1_anti-CD95 CH11	0.0	CCD1106 (Keratinocytes) none	0.0
LAK cells rest	9.4	CCD1106 (Keratinocytes) TNFalpha + IL-1beta	0.0
LAK cells IL-2	0.0	Liver cirrhosis	0.1
LAK cells IL-2+IL-12	0.0	Lupus kidney	0.0
LAK cells IL-2+IFN gamma	0.0	NCI-H292 none	0.0
LAK cells IL-2+ IL-18	0.1	NCI-H292 IL-4	0.0
LAK cells PMA/ionomycin	8.1	NCI-H292 IL-9	0.0
NK Cells IL-2 rest	0.0	NCI-H292 IL-13	0.0

Two Way MLR 3 day	0.8	NCI-H292 IFN gamma	0.0
Two Way MLR 5 day	0.1	HPAEC none	0.0
Two Way MLR 7 day	0.0	HPAEC TNF alpha + IL-1 beta	0.0
PBMC rest	14.8	Lung fibroblast none	0.0
PBMC PWM	0.0	Lung fibroblast TNF alpha + IL-1 beta	0.0
PBMC PHA-L	0.0	Lung fibroblast IL-4	0.0
Ramos (B cell) none	0.0	Lung fibroblast IL-9	0.0
Ramos (B cell) ionomycin	0.0	Lung fibroblast IL-13	0.0
B lymphocytes PWM	0.0	Lung fibroblast IFN gamma	0.0
B lymphocytes CD40L and IL-4	0.0	Dermal fibroblast CCD1070 rest	0.0
EOL-1 dbcAMP	2.5	Dermal fibroblast CCD1070 TNF alpha	0.0
EOL-1 dbcAMP PMA/ionomycin	0.7	Dermal fibroblast CCD1070 IL-1 beta	0.0
Dendritic cells none	1.2	Dermal fibroblast IFN gamma	0.0
Dendritic cells LPS	0.1	Dermal fibroblast IL-4	0.0
Dendritic cells anti-CD40	0.5	IBD Colitis 2	0.0
Monocytes rest	100.0	IBD Crohn's	0.0
Monocytes LPS	2.1	Colon	0.1
Macrophages rest	3.6	Lung	0.4
Macrophages LPS	0.9	Thymus	0.1
HUVEC none	0.0	Kidney	0.2
HUVEC starved	0.0		

AI_comprehensive panel_v1.0 Summary: Ag 1446 Two experiments with the same probe and primer set produce results that are in excellent agreement, with expression of the CG56653-01 gene essentially limited to bone from OA and RA patients. Low to undetectable expression is found in normal bone. Low expression is also found in colon. This transcript encodes a putative

5 ficolin 1 precursor. Ficolins are multimeric lectins that are capable of binding to bacteria. It has been reported to function as a monocyte cell surface molecule important for binding to bacteria, elastin and monocyte adhesion. Therefore, ficolin may play a role in the inflammation of joints

in patients suffering from osteoarthritis (OA) and/or rheumatoid arthritis (RA). Antibodies against proteins encoded by this transcript may thus prevent tissue destruction mediated by ficolin activity during osteoarthritis and arthritis.

CNS_neurodegeneration_v1.0 Summary: Ag1446/Ag5126 Expression of the CG56653-01 gene is low/undetectable in all samples on this panel (CTs>35).

General_screening_panel_v1.5 Summary: Ag4934/Ag5126 Two experiments with different probe and primer sets show highest expression of the CG56653-01 gene in the fetal lung (CTs=31-34). Expression of this gene is also higher in fetal lung and fetal liver (CT=33) than in their adult counterparts (CTs=38-40). Thus expression of this gene could be used to differentiate between the two sources of lung and liver tissue. In addition, low but significant levels of expression in adipose, heart, skeletal muscle, thyroid and pancreas suggest that modulation of this gene product may be a treatment for metabolic or endocrine disease including obesity and Types 1 and 2 diabetes.

Panel 1.2 Summary: Ag1446 The CG56653-01 gene is most highly expressed in bone marrow (CT=22). Thus, expression of this gene could be used to differentiate between this sample and other samples on this panel. In addition, this gene has low-to-moderate levels of expression (CT values = 27-33) in many metabolic tissues including liver, heart, skeletal muscle, thyroid, pancreas, adrenal and pituitary, as seen in General_screening_panel_v1.5. Thus, modulation of this gene product may be a treatment for metabolic or endocrine disease including obesity and Types 1 and 2 diabetes.

Panel 4D/4.1D Summary: Ag1446/Ag4934/Ag5126 Multiple experiments show the CG56653-01 gene highly and selectively expressed in resting monocytes and to a lesser extent in macrophages and granulocytes (neutrophils and EOL cell line), in agreement with published expression profiles. This transcript encodes a putative ficolin 1 precursor. Ficolins are multimeric lectins that are capable of binding to bacteria. It has been reported to function as a monocyte cell surface molecule that is important for binding to bacteria, elastin and monocyte adhesion. Ficolin may also play a role in alleviating inflammation in joints and other sites of inflammation. Therefore, protein therapeutics designed with the protein encoded by this transcript could function as an opsinin to target and eliminate bacteria by complement-mediated destruction.

These proteins could also be important for the treatment of bacterial septicemia. In addition, ficolins may have the ability to bind to elastins. Elastins are functionally important for lung alveolar development and inactivation of these proteins can lead to emphysema-like disease. Therefore, antibodies against proteins encoded by this transcript may prevent tissue destruction mediated by ficolin activity during emphysema, asthma and arthritis.

References:

Harumiya S, Takeda K, Sugiura T, Fukumoto Y, Tachikawa H, Miyazono K, Fujimoto D, Ichijo H. Characterization of ficolins as novel elastin-binding proteins and molecular cloning of human ficolin-1 J Biochem (Tokyo) 1996 Oct;120(4):745-51

A novel elastin-binding protein, EBP-37, was recently identified and purified from human plasma. Its partial amino acid sequences showed significant homology to porcine ficolins, which were originally purified from porcine uterus membranes as multimeric proteins with fibrinogen- and collagen-like domains. Here we report the presence of ficolins in an elastin-binding fraction of porcine plasma and the direct binding of recombinant porcine ficolin-alpha to elastin. In addition, a cDNA encoding a human counterpart of porcine ficolins that is composed of 319 amino acids and is different from EBP-37 was cloned and named human ficolin-1. Northern blotting of various human tissues revealed that human ficolin-1 mRNA is highly expressed in peripheral blood leukocytes. These data suggested that there are at least two kinds of ficolin-related proteins in both pig and human, and they may function as plasma proteins with elastin-binding activities.

PMID: 8947836

Teh C, Le Y, Lee SH, Lu J. Immunology 2000 Oct;101(2):225-32 M-ficolin is expressed on monocytes and is a lectin binding to N-acetyl-D-glucosamine and mediates monocyte adhesion and phagocytosis of Escherichia coli.

Ficolins are a group of multimeric proteins that contain collagen-like and fibrinogen-like (FBG) sequences. Three types of ficolins have been characterized: H-, L- and M-ficolins. Both H- and L-ficolins have demonstrated lectin activities. In the present study, the FBG domain of M-ficolin

was expressed and shown to bind to N-acetyl-D-glucosamine. M-ficolin mRNA was expressed in monocytes but not in the more differentiated macrophages and dendritic cells. By flow cytometry, surface biotinylation and immunoprecipitation, we showed that M-ficolin was associated with the surface of promonocytic U937 cells. M-ficolin transiently expressed in COS-7 cells was also clearly detected on the cell surface by immunoprecipitation. By flow cytometry, M-ficolin was detected on peripheral blood monocytes but not on lymphocytes or granulocytes. Immobilized rabbit anti-M-ficolin F(ab')₂ mediated U937 cell adhesion, and the antibody also inhibited phagocytosis of Escherichia coli K-12 by U937 cells. Therefore, M-ficolin might act as a phagocytic receptor or adaptor on circulating monocytes for micro-organism recognition and may potentially mediate monocyte adhesion.

PMID: 11012776

NOV27: CG56262-01: Ca-binding transporter

Expression of gene CG56262-01 was assessed using the primer-probe sets Ag2896 and Ag2920, described in Tables TA and TB. Results of the RTQ-PCR runs are shown in Tables TC, TD, TE and TF.

Table TA. Probe Name Ag2896

Primers	Sequences	Length	Start Position
Forward	5'-gtcagcttctcttgctttgaga-3' (SEQ ID NO:452)	22	900
Probe	TET-5'-cactgtcaggcactcgccaatgt-3'-TAMRA (SEQ ID NO:453)	23	932
Reverse	5'-ctgtatttctggaagcattcca-3' (SEQ ID NO:454)	22	964

Table TB. Probe Name Ag2920

Primers	Sequences	Length	Start Position
Forward	5'-ttgatgtctctgagatccaaca-3' (SEQ ID NO:455)	22	1134
Probe	TET-5'-agtttccgagctctgggcatttccat-3'-TAMRA (SEQ ID NO:456)	26	1107
Reverse	5'-catgctgtgcaaaattttctc-3' (SEQ ID NO:457)	21	1070

Table TC. CNS_neurodegeneration_v1.0

Tissue Name	Rel. Exp.(%) Ag2896, Run 209734744	Rel. Exp.(%) Ag2920, Run 209779301	Tissue Name	Rel. Exp.(%) Ag2896, Run 209734744	Rel. Exp.(%) Ag2920, Run 209779301
AD 1 Hippo	17.7	21.6	Control (Path) 3 Temporal Ctx	11.0	15.3
AD 2 Hippo	41.5	40.3	Control (Path) 4 Temporal Ctx	41.2	36.9
AD 3 Hippo	13.9	18.2	AD 1 Occipital Ctx	10.7	13.1
AD 4 Hippo	10.7	11.3	AD 2 Occipital Ctx (Missing)	0.0	0.0
AD 5 Hippo	65.1	54.7	AD 3 Occipital Ctx	8.1	9.2
AD 6 Hippo	62.4	73.2	AD 4 Occipital Ctx	23.5	25.3
Control 2 Hippo	45.4	51.8	AD 5 Occipital Ctx	45.4	15.7
Control 4 Hippo	15.8	19.8	AD 6 Occipital Ctx	14.7	44.4
Control (Path) 3 Hippo	10.6	12.9	Control 1 Occipital Ctx	6.8	8.4
AD 1 Temporal Ctx	17.6	18.9	Control 2 Occipital Ctx	52.1	57.4
AD 2 Temporal Ctx	41.5	41.8	Control 3 Occipital Ctx	14.3	18.8
AD 3 Temporal Ctx	10.1	12.9	Control 4 Occipital Ctx	11.0	12.3
AD 4 Temporal Ctx	29.9	27.5	Control (Path) 1 Occipital Ctx	80.7	100.0
AD 5 Inf Temporal	78.5	79.6	Control (Path) 2	11.1	11.5

Ctx			Occipital Ctx		
AD 5 Sup Temporal Ctx	47.0	43.5	Control (Path) 3 Occipital Ctx	5.3	7.0
AD 6 Inf Temporal Ctx	48.0	47.6	Control (Path) 4 Occipital Ctx	14.2	12.3
AD 6 Sup Temporal Ctx	47.3	55.5	Control 1 Parietal Ctx	13.8	15.4
Control 1 Temporal Ctx	14.8	16.6	Control 2 Parietal Ctx	40.6	40.6
Control 2 Temporal Ctx	53.6	66.9	Control 3 Parietal Ctx	2.8	17.8
Control 3 Temporal Ctx	24.3	22.8	Control (Path) 1 Parietal Ctx	100.0	100.0
Control 3 Temporal Ctx	18.0	15.8	Control (Path) 2 Parietal Ctx	25.0	23.2
Control (Path) 1 Temporal Ctx	86.5	88.3	Control (Path) 3 Parietal Ctx	7.1	9.7
Control (Path) 2 Temporal Ctx	45.1	50.0	Control (Path) 4 Parietal Ctx	46.3	47.6

Table TD. Panel 1.3D

Tissue Name	Rel. Exp.(%) Ag2896, Run 167660338	Rel. Exp.(%) Ag2920, Run 167646813	Tissue Name	Rel. Exp.(%) Ag2896, Run 167660338	Rel. Exp.(%) Ag2920, Run 167646813
Liver adenocarcinoma	36.6	40.1	Kidney (fetal)	23.2	21.6
Pancreas	4.2	7.4	Renal ca. 786-0	15.5	19.6
Pancreatic ca. CAPAN 2	10.1	9.3	Renal ca. A498	9.5	9.4
Adrenal gland	3.3	2.8	Renal ca. RXF	17.3	16.6

			393		
Thyroid	11.8	18.9	Renal ca. ACHN	10.5	14.5
Salivary gland	6.7	6.6	Renal ca. UO- 31	7.7	9.9
Pituitary gland	2.2	2.7	Renal ca. TK- 10	12.4	14.7
Brain (fetal)	27.0	27.7	Liver	4.3	3.5
Brain (whole)	81.2	74.2	Liver (fetal)	1.8	2.6
Brain (amygdala)	40.1	40.3	Liver ca. (hepatoblast) HepG2	4.7	4.9
Brain (cerebellum)	30.8	33.0	Lung	5.4	3.2
Brain (hippocampus)	44.8	42.0	Lung (fetal)	4.8	4.7
Brain (substantia nigra)	23.0	21.5	Lung ca. (small cell) LX-1	6.7	6.2
Brain (thalamus)	25.5	31.6	Lung ca. (small cell) NCI-H69	0.0	0.1
Cerebral Cortex	100.0	100.0	Lung ca. (s.cell var.) SHP-77	26.1	31.9
Spinal cord	12.6	12.9	Lung ca. (large cell) NCI-H460	1.2	1.4
glio/astro U87-MG	2.2	2.4	Lung ca. (non- sm. cell) A549	10.4	8.9
glio/astro U-118- MG	9.9	8.1	Lung ca. (non- s.cell) NCI- H23	11.0	12.7
astrocytoma SW1783	8.8	10.1	Lung ca. (non- s.cell) HOP-62	4.9	4.7
neuro*; met SK-N- AS	4.2	3.3	Lung ca. (non- s.cl) NCI-H522	11.4	11.4
astrocytoma SF- 539	5.8	5.4	Lung ca. (squam.) SW 900	7.9	8.6
astrocytoma SNB- 75	10.2	10.5	Lung ca. (squam.) NCI- H596	0.3	0.4
glioma SNB-19	10.1	11.0	Mammary gland	8.3	8.5

glioma U251	14.1	15.8	Breast ca.* (pl.ef) MCF-7	7.5	8.1
glioma SF-295	6.0	5.9	Breast ca.* (pl.ef) MDA- MB-231	6.6	7.1
Heart (fetal)	38.7	40.1	Breast ca.* (pl.ef) T47D	16.2	17.0
Heart	10.7	9.9	Breast ca. BT- 549	5.8	5.1
Skeletal muscle (fetal)	16.0	11.8	Breast ca. MDA-N	19.5	22.5
Skeletal muscle	31.2	28.7	Ovary	10.4	10.3
Bone marrow	0.4	0.6	Ovarian ca. OVCAR-3	11.5	9.2
Thymus	2.5	2.5	Ovarian ca. OVCAR-4	35.6	32.5
Spleen	1.1	1.4	Ovarian ca. OVCAR-5	31.0	34.2
Lymph node	2.6	1.7	Ovarian ca. OVCAR-8	5.4	5.5
Colorectal	14.0	12.3	Ovarian ca. IGROV-1	10.3	10.2
Stomach	4.4	4.0	Ovarian ca.* (ascites) SK- OV-3	13.8	18.0
Small intestine	4.4	4.9	Uterus	6.3	8.4
Colon ca. SW480	5.1	5.3	Placenta	0.0	0.0
Colon ca.* SW620(SW480 met)	14.9	18.7	Prostate	3.2	3.8
Colon ca. HT29	6.8	7.2	Prostate ca.* (bone met)PC- 3	16.5	18.3
Colon ca. HCT- 116	10.7	10.4	Testis	1.4	1.3
Colon ca. CaCo-2	17.0	21.9	Melanoma Hs688(A).T	2.8	2.6
Colon ca. tissue(ODO3866)	2.4	2.4	Melanoma* (met) Hs688(B).T	2.6	3.8
Colon ca. HCC- 2998	9.3	7.6	Melanoma UACC-62	10.9	11.2

Gastric ca.* (liver met) NCI-N87	5.7	5.5	Melanoma M14	8.6	5.8
Bladder	5.1	5.1	Melanoma LOX IMVI	12.2	10.8
Trachea	1.9	2.8	Melanoma* (met) SK-MEL-5	24.0	25.2
Kidney	12.4	17.0	Adipose	6.1	6.4

Table TE. Panel 4D

Tissue Name	Rel. Exp.(%) Ag2896, Run 164401737	Rel. Exp.(%) Ag2920, Run 164403312	Tissue Name	Rel. Exp.(%) Ag2896, Run 164401737	Rel. Exp.(%) Ag2920, Run 164403312
Secondary Th1 act	5.6	7.3	HUVEC IL-1beta	4.9	4.3
Secondary Th2 act	6.8	6.0	HUVEC IFN gamma	19.6	19.8
Secondary Tr1 act	7.4	7.7	HUVEC TNF alpha + IFN gamma	7.8	8.9
Secondary Th1 rest	6.4	6.7	HUVEC TNF alpha + IL4	6.1	7.9
Secondary Th2 rest	7.6	7.1	HUVEC IL-11	10.4	11.8
Secondary Tr1 rest	12.2	9.7	Lung Microvascular EC none	7.5	9.8
Primary Th1 act	12.7	14.5	Lung Microvascular EC TNFalpha + IL-1beta	5.5	6.1
Primary Th2 act	16.0	15.1	Microvascular Dermal EC none	13.7	12.6
Primary Tr1 act	26.4	22.1	Microsvascular Dermal EC TNFalpha + IL-1beta	5.7	6.6
Primary Th1 rest	31.6	33.4	Bronchial epithelium TNFalpha + IL1beta	15.9	11.9
Primary Th2 rest	19.3	18.7	Small airway	4.7	5.3

			epithelium none		
Primary Tr1 rest	14.7	16.5	Small airway epithelium TNFalpha + IL-1beta	35.6	37.1
CD45RA CD4 lymphocyte act	6.2	5.1	Coronary artery SMC rest	7.1	6.7
CD45RO CD4 lymphocyte act	11.2	12.3	Coronary artery SMC TNFalpha + IL-1beta	4.6	5.9
CD8 lymphocyte act	11.6	10.8	Astrocytes rest	27.0	23.8
Secondary CD8 lymphocyte rest	8.2	9.9	Astrocytes TNFalpha + IL-1beta	30.8	28.1
Secondary CD8 lymphocyte act	3.0	3.3	KU-812 (Basophil) rest	8.2	6.3
CD4 lymphocyte none	2.8	3.4	KU-812 (Basophil) PMA/ionomycin	22.5	19.9
2ry Th1/Th2/Tr1_anti-CD95 CH11	7.3	7.4	CCD1106 (Keratinocytes) none	11.1	11.7
LAK cells rest	7.1	6.7	CCD1106 (Keratinocytes) TNFalpha + IL-1beta	6.8	6.3
LAK cells IL-2	14.7	17.0	Liver cirrhosis	3.0	3.0
LAK cells IL-2+IL-12	6.9	7.0	Lupus kidney	6.5	6.2
LAK cells IL-2+IFN gamma	12.8	11.0	NCI-H292 none	63.3	72.7
LAK cells IL-2+IL-18	6.7	9.0	NCI-H292 IL-4	57.4	69.7
LAK cells PMA/ionomycin	0.9	0.6	NCI-H292 IL-9	57.0	65.5
NK Cells IL-2 rest	7.2	6.5	NCI-H292 IL-13	30.8	35.6
Two Way MLR 3 day	6.3	6.8	NCI-H292 IFN gamma	29.3	34.4
Two Way MLR 5 day	3.5	3.0	HPAEC none	10.8	11.7
Two Way MLR 7 day	4.2	4.5	HPAEC TNF alpha + IL-1 beta	6.9	6.4

PBMC rest	2.0	1.6	Lung fibroblast none	16.8	17.4
PBMC PWM	27.9	26.2	Lung fibroblast TNF alpha + IL-1 beta	7.4	8.0
PBMC PHA-L	27.5	26.8	Lung fibroblast IL-4	30.6	34.6
Ramos (B cell) none	16.8	16.0	Lung fibroblast IL-9	24.8	24.1
Ramos (B cell) ionomycin	100.0	100.0	Lung fibroblast IL-13	19.6	21.8
B lymphocytes PWM	36.6	22.8	Lung fibroblast IFN gamma	31.4	37.6
B lymphocytes CD40L and IL-4	13.5	14.9	Dermal fibroblast CCD1070 rest	10.7	12.0
EOL-1 dbcAMP	14.5	15.5	Dermal fibroblast CCD1070 TNF alpha	20.6	21.3
EOL-1 dbcAMP PMA/ionomycin	7.1	6.3	Dermal fibroblast CCD1070 IL-1 beta	6.5	5.9
Dendritic cells none	0.8	1.5	Dermal fibroblast IFN gamma	10.1	11.3
Dendritic cells LPS	0.1	0.2	Dermal fibroblast IL-4	23.0	23.2
Dendritic cells anti-CD40	0.9	0.7	IBD Colitis 2	2.0	2.3
Monocytes rest	0.1	0.0	IBD Crohn's	3.4	4.8
Monocytes LPS	0.2	0.0	Colon	41.5	50.7
Macrophages rest	4.0	3.4	Lung	15.8	17.2
Macrophages LPS	0.5	0.4	Thymus	57.8	55.5
HUVEC none	12.2	12.8	Kidney	5.0	8.5
HUVEC starved	21.6	20.4			

Table TF. Panel CNS_1

Tissue Name	Rel. Exp.(%) Ag2896, Run 171688452	Tissue Name	Rel. Exp.(%) Ag2896, Run 171688452
BA4 Control	22.1	BA17 PSP	22.4
BA4 Control2	41.8	BA17 PSP2	6.5
BA4	5.2	Sub Nigra Control	21.3

Alzheimer's2			
BA4 Parkinson's	39.2	Sub Nigra Control2	18.3
BA4 Parkinson's2	68.8	Sub Nigra Alzheimer's2	7.2
BA4 Huntington's	28.1	Sub Nigra Parkinson's2	27.7
BA4 Huntington's2	13.9	Sub Nigra Huntington's	25.5
BA4 PSP	9.9	Sub Nigra Huntington's2	13.6
BA4 PSP2	25.5	Sub Nigra PSP2	3.4
BA4 Depression	22.7	Sub Nigra Depression	6.3
BA4 Depression2	6.7	Sub Nigra Depression2	6.1
BA7 Control	34.9	Glob Palladus Control	18.9
BA7 Control2	27.7	Glob Palladus Control2	19.9
BA7 Alzheimer's2	6.2	Glob Palladus Alzheimer's	7.2
BA7 Parkinson's	18.3	Glob Palladus Alzheimer's2	9.8
BA7 Parkinson's2	38.2	Glob Palladus Parkinson's	100.0
BA7 Huntington's	51.1	Glob Palladus Parkinson's2	20.9
BA7 Huntington's2	38.7	Glob Palladus PSP	13.8
BA7 PSP	44.4	Glob Palladus PSP2	12.4
BA7 PSP2	18.9	Glob Palladus Depression	7.5
BA7 Depression	10.5	Temp Pole Control	20.0
BA9 Control	27.9	Temp Pole Control2	66.9
BA9 Control2	83.5	Temp Pole Alzheimer's	6.1
BA9 Alzheimer's	4.7	Temp Pole Alzheimer's2	6.6
BA9 Alzheimer's2	12.6	Temp Pole Parkinson's	34.6
BA9 Parkinson's	22.5	Temp Pole	24.0

		Parkinson's2	
BA9 Parkinson's2	45.4	Temp Pole Huntington's	33.4
BA9 Huntington's	39.2	Temp Pole PSP	8.4
BA9 Huntington's2	20.0	Temp Pole PSP2	6.4
BA9 PSP	12.1	Temp Pole Depression2	6.7
BA9 PSP2	3.9	Cing Gyr Control	53.6
BA9 Depression	8.5	Cing Gyr Control2	34.6
BA9 Depression2	9.2	Cing Gyr Alzheimer's	15.9
BA17 Control	25.3	Cing Gyr Alzheimer's2	12.2
BA17 Control2	34.6	Cing Gyr Parkinson's	24.5
BA17 Alzheimer's2	4.3	Cing Gyr Parkinson's2	30.8
BA17 Parkinson's	20.0	Cing Gyr Huntington's	48.0
BA17 Parkinson's2	28.3	Cing Gyr Huntington's2	16.4
BA17 Huntington's	24.1	Cing Gyr PSP	15.2
BA17 Huntington's2	12.1	Cing Gyr PSP2	6.0
BA17 Depression	8.7	Cing Gyr Depression	7.3
BA17 Depression2	16.6	Cing Gyr Depression2	11.7

CNS_neurodegeneration_v1.0 Summary: Ag2896/Ag2920 This panel does not show differential expression of the CG56153-01 gene in Alzheimer's disease. However, this expression profile confirms the presence of this gene in the brain. Please see Panel 1.3D for discussion of utility of this gene in the central nervous system.

- Panel 1.3D Summary:** Ag2896/Ag2920 Two experiments produce results that are in excellent agreement, with highest expression of the CG56262-01 gene in the brain. This gene encodes a Ca binding transporter. Ca++ is critical for synaptic vesicle release. Thus, this gene would be an

excellent small molecule target for any disease believed to result from altered/inappropriate synaptic transmission such as epilepsy, schizophrenia, bipolar disorder, depression, and mania.

This gene also has moderate levels of expression adult and fetal heart, skeletal muscle and liver, and adipose. This gene product is homologous to a mitochondrial calcium-dependent transporter.

- 5 Since intracellular calcium homeostasis is critically important for energy metabolism and signal transduction, modulation of this gene product may therefore be a therapeutic for metabolic and endocrine diseases.

Moderate expression is also seen in almost all cell lines on this panel. This suggests that expression of this gene product is required for cell growth and proliferation in almost all cell types.

10

References:

Kovacs I, Szarics E, Nyitrai G, Blandl T, Kardos J. Matching kinetics of synaptic vesicle recycling and enhanced neurotransmitter influx by Ca^{2+} in brain plasma membrane vesicles. *Neurochem Int* 1998 Nov;33(5):399-405

- 15 Using native plasma membrane vesicle suspensions from the rat cerebral cortex under conditions designed to alter intravesicular $[\text{Ca}^{2+}]$, we found that Ca^{2+} induced 47 +/- 5% more influx of $[\text{3H}]\text{GABA}$, $[\text{3H}]\text{D-aspartate}$ and $[\text{3H}]\text{glycine}$ at 37 degrees C with half-times 1.7 +/- 0.5, 1.3 +/- 0.4 and 1.3 +/- 0.4 min, respectively. We labelled GABA transporter sites with the uptake inhibitor, $[\text{3H}]\text{-(R,S)-N-[4,4-bis(3-methyl-2-thienyl)but-3-en-1-yl]nipecotic acid}$ and found that
- 20 Ca^{2+} induced a partial dissociation of the bound inhibitor from GABA transporter sites with a similar half-time. By means of rapid kinetic techniques applied to native plasma membrane vesicle suspensions, containing synaptic vesicles stained with the amphipathic fluorescent styryl membrane probe $\text{N-(3-triethylammoniumpropyl)-4-[4-(dibutylamino)styryl]pyridinium dibromide}$, we have measured the progress of the release and reuptake of synaptic vesicles in
- 25 response to Ca^{2+} and high- $[\text{K}^{+}]$ depolarization in the 0.0004-100 s range of time. Synaptic vesicle exocytosis, strongly influenced by external $[\text{Ca}^{2+}]$, appeared with the kinetics accelerated by depolarization. These results are consistent with the potential involvement of Ca^{2+} in taking low-affinity transporters to the plasma membrane surface via exocytosis.

Panel 4D Summary: Ag2896/Ag2920 Two experiments show moderate to low expression of the CG56262-01 transcript across a wide range of cells of this panel including epithelium, fibroblasts, and endothelial cells. Lower but still significant levels of expression are also seen in the key players of innate and adaptive immunity: monocytes/macrophages, T and B cells.

- 5 However, the expression of this transcript is highest in the B lymphoma cell line, and NCI H292, a mucoepidermoid cell line (CTs=26.4-27). Thus, inhibition of the function of the protein encoded by this transcript with a small molecule drug, could lead to improvement of the symptoms of patients suffering from autoimmune and inflammatory diseases such as asthma, COPD, emphysema, psoriasis, inflammatory bowel disease, lupus erythematosus, or rheumatoid
- 10 arthritis.

Panel CNS_1 Summary: Ag2896 This expression profile confirms the presence of this gene in the brain. Please see Panel 1.3D for discussion of utility of this gene in the central nervous system.

NOV28: CG56559-01: Na(+)/glucose cotransporter

- 15 Expression of gene CG56559-01 was assessed using the primer-probe sets Ag2950 and Ag2966, described in Tables UA and UB. Results of the RTQ-PCR runs are shown in Tables UC, UD, UE and UF.

Table UA. Probe Name Ag2950

Primers	Sequences	Length	Start Position
Forward	5'-ttggtcatagtggcactcatc-3' (SEQ ID NO:458)	21	1302
Probe	TET-5'-aggactccaacagcgggcaactctt-3'-TAMRA (SEQ ID NO:459)	25	1354
Reverse	5'-ggtcactgactgcatgtagatg-3' (SEQ ID NO:460)	22	1379

Table UB. Probe Name Ag2966

Primers	Sequences	Length	Start Position
Forward	5'-agcgggcaactcttcatcta-3' (SEQ ID NO:461)	20	1365
Probe	TET-5'-atgcagtcagtgaccagctccctg-3'-TAMRA (SEQ ID NO:462)	24	1386

Reverse	5'-caggacaaagactgcagtcact-3' (SEQ ID NO:463)	22	1418
---------	--	----	------

Table UC. Panel 1.3D

Tissue Name	Rel. Exp.(%) Ag2950, Run 167907051	Rel. Exp.(%) Ag2966, Run 160658385	Rel. Exp.(%) Ag2966, Run 165701959	Tissue Name	Rel. Exp.(%) Ag2950, Run 167907051	Rel. Exp.(%) Ag2966, Run 160658385	Rel. Exp.(%) Ag2966, Run 165701959
Liver adenocarcinoma	0.0	0.0	0.0	Kidney (fetal)	0.0	1.0	0.0
Pancreas	0.0	0.2	1.3	Renal ca. 786-0	0.0	0.2	0.0
Pancreatic ca. CAPAN 2	0.0	0.0	0.0	Renal ca. A498	0.0	0.0	0.3
Adrenal gland	0.0	0.2	0.0	Renal ca. RXF 393	0.0	0.0	0.5
Thyroid	0.0	0.3	0.0	Renal ca. ACHN	0.0	0.3	0.0
Salivary gland	0.0	0.1	0.4	Renal ca. UO-31	0.0	0.0	0.0
Pituitary gland	0.0	0.0	0.0	Renal ca. TK-10	0.0	0.0	0.0
Brain (fetal)	0.0	0.0	0.0	Liver	0.0	0.6	0.9
Brain (whole)	0.0	0.0	0.3	Liver (fetal)	0.0	0.4	0.0
Brain (amygdala)	0.0	0.0	0.0	Liver ca. (hepatoblast) HepG2	0.0	0.3	0.0
Brain (cerebellum)	0.0	0.0	0.0	Lung	0.0	0.8	0.6
Brain (hippocampus)	0.0	0.5	0.3	Lung (fetal)	0.0	1.4	1.4
Brain (substantia nigra)	0.0	0.0	0.0	Lung ca. (small cell) LX-1	0.0	0.6	0.0
Brain (thalamus)	0.0	0.0	0.5	Lung ca. (small cell) NCI-H69	0.0	0.0	0.0
Cerebral Cortex	0.0	0.0	0.0	Lung ca. (s.cell var.) SHP-77	0.0	0.3	0.4
Spinal cord	0.0	0.2	0.2	Lung ca.	0.0	0.2	0.0

				(large cell)NCI-H460			
glio/astro U87-MG	0.0	0.0	0.0	Lung ca. (non-sm. cell) A549	0.0	0.8	0.7
glio/astro U-118-MG	0.0	0.0	0.0	Lung ca. (non-s.cell) NCI-H23	0.0	0.0	0.0
astrocytoma SW1783	0.0	0.0	0.0	Lung ca. (non-s.cell) HOP-62	0.0	1.6	2.2
neuro*; met SK-N-AS	0.0	0.0	0.4	Lung ca. (non-s.cl) NCI-H522	0.0	0.5	0.0
astrocytoma SF-539	0.0	0.0	0.0	Lung ca. (squam.) SW 900	0.0	0.0	0.0
astrocytoma SNB-75	0.0	0.0	0.0	Lung ca. (squam.) NCI-H596	0.0	0.0	0.0
glioma SNB-19	0.0	0.0	0.4	Mammary gland	0.0	0.3	0.7
glioma U251	0.0	0.0	0.4	Breast ca.* (pl.ef) MCF-7	0.0	0.2	0.0
glioma SF-295	0.0	0.0	0.0	Breast ca.* (pl.ef) MDA-MB-231	0.0	0.0	0.0
Heart (fetal)	0.0	0.0	0.0	Breast ca.* (pl.ef) T47D	0.0	0.0	0.0
Heart	0.0	0.0	0.0	Breast ca. BT-549	0.0	0.2	0.0
Skeletal muscle (fetal)	0.0	3.9	0.3	Breast ca. MDA-N	0.0	0.0	0.0
Skeletal muscle	0.0	0.0	0.0	Ovary	0.0	0.5	0.0
Bone marrow	0.0	6.9	2.5	Ovarian ca. OVCAR-3	0.0	0.0	0.0
Thymus	0.0	1.9	0.9	Ovarian ca. OVCAR-4	0.0	0.0	0.4
Spleen	0.0	4.2	1.0	Ovarian ca. OVCAR-5	0.0	0.3	0.0

Lymph node	0.0	3.0	5.4	Ovarian ca. OVCAR-8	0.0	0.0	0.0
Colorectal	0.0	0.5	0.0	Ovarian ca. IGROV-1	0.0	0.0	0.0
Stomach	0.0	0.9	0.0	Ovarian ca.* (ascites) SK- OV-3	0.0	0.0	0.0
Small intestine	0.0	1.5	0.5	Uterus	0.0	0.0	0.5
Colon ca. SW480	0.0	0.8	0.0	Placenta	0.0	0.0	0.0
Colon ca.* SW620(SW480 met)	0.0	0.0	0.0	Prostate	0.0	0.0	0.0
Colon ca. HT29	0.0	0.0	0.0	Prostate ca.* (bone met)PC-3	0.0	0.0	0.0
Colon ca. HCT- 116	0.0	0.0	0.0	Testis	0.0	1.6	0.8
Colon ca. CaCo- 2	0.0	0.0	0.0	Melanoma Hs688(A).T	0.0	0.0	0.0
Colon ca. tissue(ODO3866)	0.0	0.3	0.3	Melanoma* (met) Hs688(B).T	0.0	0.0	0.0
Colon ca. HCC- 2998	0.0	0.3	0.0	Melanoma UACC-62	0.0	0.0	0.0
Gastric ca.* (liver met) NCI- N87	0.0	0.2	0.7	Melanoma M14	0.0	0.0	0.0
Bladder	0.0	0.2	0.3	Melanoma LOX IMVI	0.0	0.0	0.0
Trachea	0.0	0.6	0.0	Melanoma* (met) SK- MEL-5	0.0	0.0	0.0
Kidney	100.0	100.0	100.0	Adipose	0.0	0.1	0.6

Table UD. Panel 2D

Tissue Name	Rel. Exp.(%) Ag2966, Run 160658389	Tissue Name	Rel. Exp.(%) Ag2966, Run 160658389
Normal Colon	0.2	Kidney Margin 8120608	91.4
CC Well to Mod Diff	0.1	Kidney Cancer	0.1

(ODO3866)		8120613	
CC Margin (ODO3866)	0.3	Kidney Margin 8120614	100.0
CC Gr.2 rectosigmoid (ODO3868)	0.3	Kidney Cancer 9010320	0.4
CC Margin (ODO3868)	0.1	Kidney Margin 9010321	66.9
CC Mod Diff (ODO3920)	0.6	Normal Uterus	0.2
CC Margin (ODO3920)	0.4	Uterus Cancer 064011	0.4
CC Gr.2 ascend colon (ODO3921)	0.4	Normal Thyroid	0.1
CC Margin (ODO3921)	0.3	Thyroid Cancer 064010	0.0
CC from Partial Hepatectomy (ODO4309) Mets	0.4	Thyroid Cancer A302152	0.0
Liver Margin (ODO4309)	0.2	Thyroid Margin A302153	0.5
Colon mets to lung (OD04451-01)	0.5	Normal Breast	0.8
Lung Margin (OD04451- 02)	0.1	Breast Cancer (OD04566)	0.3
Normal Prostate 6546-1	0.0	Breast Cancer (OD04590-01)	0.8
Prostate Cancer (OD04410)	0.2	Breast Cancer Mets (OD04590-03)	0.8
Prostate Margin (OD04410)	0.0	Breast Cancer Metastasis (OD04655- 05)	0.9
Prostate Cancer (OD04720-01)	0.1	Breast Cancer 064006	0.2
Prostate Margin (OD04720-02)	0.2	Breast Cancer 1024	0.4
Normal Lung 061010	1.5	Breast Cancer 9100266	0.1
Lung Met to Muscle (ODO4286)	0.2	Breast Margin 9100265	0.0
Muscle Margin (ODO4286)	0.0	Breast Cancer A209073	0.2
Lung Malignant Cancer (OD03126)	0.2	Breast Margin A2090734	0.3
Lung Margin (OD03126)	0.4	Normal Liver	0.1

Lung Cancer (OD04404)	0.4	Liver Cancer 064003	0.1
Lung Margin (OD04404)	0.4	Liver Cancer 1025	0.2
Lung Cancer (OD04565)	0.2	Liver Cancer 1026	0.0
Lung Margin (OD04565)	0.4	Liver Cancer 6004-T	0.1
Lung Cancer (OD04237-01)	0.1	Liver Tissue 6004-N	0.1
Lung Margin (OD04237-02)	0.0	Liver Cancer 6005-T	0.0
Ocular Mel Met to Liver (ODO4310)	1.8	Liver Tissue 6005-N	0.0
Liver Margin (ODO4310)	0.0	Normal Bladder	0.2
Melanoma Mets to Lung (OD04321)	0.1	Bladder Cancer 1023	0.1
Lung Margin (OD04321)	0.4	Bladder Cancer A302173	0.1
Normal Kidney	29.9	Bladder Cancer (OD04718-01)	0.1
Kidney Ca, Nuclear grade 2 (OD04338)	9.4	Bladder Normal Adjacent (OD04718-03)	0.1
Kidney Margin (OD04338)	26.2	Normal Ovary	0.0
Kidney Ca Nuclear grade 1/2 (OD04339)	1.3	Ovarian Cancer 064008	0.1
Kidney Margin (OD04339)	75.8	Ovarian Cancer (OD04768-07)	0.0
Kidney Ca, Clear cell type (OD04340)	29.5	Ovary Margin (OD04768-08)	0.0
Kidney Margin (OD04340)	27.5	Normal Stomach	0.1
Kidney Ca, Nuclear grade 3 (OD04348)	0.7	Gastric Cancer 9060358	0.1
Kidney Margin (OD04348)	11.4	Stomach Margin 9060359	0.1
Kidney Cancer (OD04622-01)	0.9	Gastric Cancer 9060395	0.1
Kidney Margin (OD04622-03)	9.6	Stomach Margin 9060394	0.1
Kidney Cancer (OD04450-01)	0.8	Gastric Cancer 9060397	0.1
Kidney Margin	8.2	Stomach Margin	0.0

(OD04450-03)		9060396	
Kidney Cancer 8120607	0.6	Gastric Cancer 064005	0.3

Table UE. Panel 3D

Tissue Name	Rel. Exp.(%) Ag2966, Run 164886340	Tissue Name	Rel. Exp.(%) Ag2966, Run 164886340
Daoy- Medulloblastoma	0.0	Ca Ski- Cervical epidermoid carcinoma (metastasis)	0.0
TE671- Medulloblastoma	0.0	ES-2- Ovarian clear cell carcinoma	0.0
D283 Med- Medulloblastoma	0.0	Ramos- Stimulated with PMA/ionomycin 6h	0.1
PFSK-1- Primitive Neuroectodermal	0.2	Ramos- Stimulated with PMA/ionomycin 14h	0.3
XF-498- CNS	0.0	MEG-01- Chronic myelogenous leukemia (megokaryoblast)	0.0
SNB-78- Glioma	0.0	Raji- Burkitt's lymphoma	0.5
SF-268- Glioblastoma	0.0	Daudi- Burkitt's lymphoma	1.7
T98G- Glioblastoma	0.1	U266- B-cell plasmacytoma	0.0
SK-N-SH- Neuroblastoma (metastasis)	0.0	CA46- Burkitt's lymphoma	0.1
SF-295- Glioblastoma	0.0	RL- non-Hodgkin's B-cell lymphoma	0.0
Cerebellum	0.0	JM1- pre-B-cell lymphoma	0.4
Cerebellum	0.1	Jurkat- T cell leukemia	0.1
NCI-H292- Mucoepidermoid lung carcinoma	0.0	TF-1- Erythroleukemia	0.1
DMS-114- Small cell lung cancer	0.0	HUT 78- T-cell lymphoma	0.1
DMS-79- Small cell lung cancer	0.0	U937- Histiocytic lymphoma	0.1
NCI-H146- Small cell lung cancer	0.0	KU-812- Myelogenous leukemia	0.0
NCI-H526- Small cell lung cancer	0.0	769-P- Clear cell renal carcinoma	0.0
NCI-N417- Small cell lung cancer	0.0	Caki-2- Clear cell renal carcinoma	0.0

NCI-H82- Small cell lung cancer	0.0	SW 839- Clear cell renal carcinoma	0.2
NCI-H157- Squamous cell lung cancer (metastasis)	0.0	G401- Wilms' tumor	0.0
NCI-H1155- Large cell lung cancer	0.0	Hs766T- Pancreatic carcinoma (LN metastasis)	0.0
NCI-H1299- Large cell lung cancer	0.0	CAPAN-1- Pancreatic adenocarcinoma (liver metastasis)	0.0
NCI-H727- Lung carcinoid	0.1	SU86.86- Pancreatic carcinoma (liver metastasis)	0.1
NCI-UMC-11- Lung carcinoid	0.0	BxPC-3- Pancreatic adenocarcinoma	0.2
LX-1- Small cell lung cancer	0.1	HPAC- Pancreatic adenocarcinoma	0.0
Colo-205- Colon cancer	100.0	MIA PaCa-2- Pancreatic carcinoma	0.0
KM12- Colon cancer	0.0	CFPAC-1- Pancreatic ductal adenocarcinoma	0.1
KM20L2- Colon cancer	0.0	PANC-1- Pancreatic epithelioid ductal carcinoma	0.0
NCI-H716- Colon cancer	0.0	T24- Bladder carcinma (transitional cell)	0.0
SW-48- Colon adenocarcinoma	0.0	5637- Bladder carcinoma	0.0
SW1116- Colon adenocarcinoma	0.0	HT-1197- Bladder carcinoma	0.0
LS 174T- Colon adenocarcinoma	0.0	UM-UC-3- Bladder carcinma (transitional cell)	0.0
SW-948- Colon adenocarcinoma	0.0	A204- Rhabdomyosarcoma	0.0
SW-480- Colon adenocarcinoma	0.1	HT-1080- Fibrosarcoma	0.0
NCI-SNU-5- Gastric carcinoma	0.0	MG-63- Osteosarcoma	0.0
KATO III- Gastric carcinoma	0.3	SK-LMS-1- Leiomyosarcoma (vulva)	0.0
NCI-SNU-16- Gastric carcinoma	0.1	SJRH30- Rhabdomyosarcoma (met to bone marrow)	0.0
NCI-SNU-1- Gastric carcinoma	0.0	A431- Epidermoid carcinoma	0.0

RF-1- Gastric adenocarcinoma	0.3	WM266-4- Melanoma	0.0
RF-48- Gastric adenocarcinoma	0.1	DU 145- Prostate carcinoma (brain metastasis)	0.0
MKN-45- Gastric carcinoma	0.0	MDA-MB-468- Breast adenocarcinoma	0.0
NCI-N87- Gastric carcinoma	0.0	SCC-4- Squamous cell carcinoma of tongue	0.0
OVCAR-5- Ovarian carcinoma	0.0	SCC-9- Squamous cell carcinoma of tongue	0.0
RL95-2- Uterine carcinoma	0.1	SCC-15- Squamous cell carcinoma of tongue	0.0
HelaS3- Cervical adenocarcinoma	0.2	CAL 27- Squamous cell carcinoma of tongue	0.0

Table UF. Panel 4D

Tissue Name	Rel. Exp.(%) Ag2950, Run 164306341	Rel. Exp.(%) Ag2966, Run 160660646	Tissue Name	Rel. Exp.(%) Ag2950, Run 164306341	Rel. Exp.(%) Ag2966, Run 160660646
Secondary Th1 act	0.0	0.0	HUVEC IL-1beta	0.0	0.3
Secondary Th2 act	0.0	0.0	HUVEC IFN gamma	0.0	0.9
Secondary Tr1 act	0.0	0.7	HUVEC TNF alpha + IFN gamma	0.0	0.3
Secondary Th1 rest	0.0	0.2	HUVEC TNF alpha + IL4	0.0	0.5
Secondary Th2 rest	0.0	1.6	HUVEC IL-11	0.0	0.8
Secondary Tr1 rest	0.0	1.5	Lung Microvascular EC none	0.0	2.0
Primary Th1 act	0.0	0.3	Lung Microvascular EC TNFalpha + IL- 1beta	0.0	0.8
Primary Th2 act	0.0	0.0	Microvascular Dermal EC none	0.0	1.9
Primary Tr1 act	0.0	0.3	Microsvascular Dermal EC TNFalpha + IL-	0.0	1.7

			1beta		
Primary Th1 rest	0.0	4.8	Bronchial epithelium TNFalpha + IL1beta	0.0	0.0
Primary Th2 rest	0.0	2.1	Small airway epithelium none	0.0	0.0
Primary Tr1 rest	0.0	3.4	Small airway epithelium TNFalpha + IL-1beta	0.0	0.3
CD45RA CD4 lymphocyte act	0.0	0.6	Coronary artery SMC rest	0.0	0.0
CD45RO CD4 lymphocyte act	0.0	1.1	Coronary artery SMC TNFalpha + IL-1beta	0.0	0.3
CD8 lymphocyte act	0.0	0.3	Astrocytes rest	0.0	0.0
Secondary CD8 lymphocyte rest	0.0	1.3	Astrocytes TNFalpha + IL-1beta	0.0	0.3
Secondary CD8 lymphocyte act	0.0	0.0	KU-812 (Basophil) rest	0.0	0.3
CD4 lymphocyte none	0.0	1.7	KU-812 (Basophil) PMA/ionomycin	0.0	0.0
2ry Th1/Th2/Tr1_anti-CD95 CH11	0.0	0.8	CCD1106 (Keratinocytes) none	0.0	0.1
LAK cells rest	0.0	2.1	CCD1106 (Keratinocytes) TNFalpha + IL-1beta	0.0	0.0
LAK cells IL-2	0.0	0.4	Liver cirrhosis	0.0	0.4
LAK cells IL-2+IL-12	0.0	0.3	Lupus kidney	0.0	1.0
LAK cells IL-2+IFN gamma	0.0	0.6	NCI-H292 none	0.0	0.6
LAK cells IL-2+IL-18	0.0	0.6	NCI-H292 IL-4	0.0	0.0
LAK cells PMA/ionomycin	0.0	0.0	NCI-H292 IL-9	0.0	0.0
NK Cells IL-2 rest	0.0	0.6	NCI-H292 IL-13	0.0	0.0

Two Way MLR 3 day	0.0	1.1	NCI-H292 IFN gamma	0.0	0.0
Two Way MLR 5 day	0.0	1.0	HPAEC none	0.0	0.6
Two Way MLR 7 day	0.0	0.5	HPAEC TNF alpha + IL-1 beta	0.0	0.0
PBMC rest	0.0	0.6	Lung fibroblast none	0.0	0.0
PBMC PWM	0.0	1.1	Lung fibroblast TNF alpha + IL-1 beta	0.0	0.0
PBMC PHA-L	0.0	0.2	Lung fibroblast IL-4	0.0	0.0
Ramos (B cell) none	0.0	1.7	Lung fibroblast IL-9	0.0	0.0
Ramos (B cell) ionomycin	0.0	1.1	Lung fibroblast IL-13	0.0	0.0
B lymphocytes PWM	0.0	1.4	Lung fibroblast IFN gamma	0.0	0.2
B lymphocytes CD40L and IL-4	0.0	4.7	Dermal fibroblast CCD1070 rest	0.0	0.0
EOL-1 dbcAMP	0.0	0.0	Dermal fibroblast CCD1070 TNF alpha	0.0	1.4
EOL-1 dbcAMP PMA/ionomycin	0.0	0.1	Dermal fibroblast CCD1070 IL-1 beta	0.0	0.0
Dendritic cells none	0.0	0.5	Dermal fibroblast IFN gamma	0.0	0.0
Dendritic cells LPS	0.0	0.0	Dermal fibroblast IL-4	0.0	0.0
Dendritic cells anti-CD40	0.0	0.5	IBD Colitis 2	0.0	0.2
Monocytes rest	0.0	1.2	IBD Crohn's	0.0	0.0
Monocytes LPS	0.0	0.0	Colon	0.0	4.9
Macrophages rest	0.0	0.2	Lung	0.0	3.1
Macrophages LPS	0.0	0.0	Thymus	100.0	100.0
HUVEC none	0.0	0.5	Kidney	0.0	4.6
HUVEC starved	0.0	0.3			

Panel 1.3D Summary: Ag2950/Ag2966 Three experiments both show expression of the CG56559-01 gene, a sodium-glucose cotransporter homolog, limited to the kidney (CTs=29).

This restricted expression is in agreement with published data that shows secondary active transport of glucose in the kidney is mediated by sodium glucose cotransporter. (See ref. 1).

- 5 Thus, expression of this gene could be used as a marker for kidney tissue. Furthermore, the protein product may be important for normal function of the kidney. Thus, therapeutic modulation of the expression or function of this protein may be useful in treating diseases that affect the kidney, including diabetes.

References:

- 10 Bissonnette P, Noel J, Coady MJ, Lapointe JY. Functional expression of tagged human Na⁺-glucose cotransporter in *Xenopus laevis* oocytes. *J Physiol* 1999 Oct 15;520 Pt 2:359-71
- 15 1. High-affinity, secondary active transport of glucose in the intestine and kidney is mediated by an integral membrane protein named SGLT1 (sodium glucose cotransporter). Though basic properties of the transporter are now defined, many questions regarding the structure- function relationship of the protein, its biosynthesis and targeting remain unanswered. In order to better address these questions, we produced a functional hSGLT1 protein (from human) containing a reporter tag. 2. Six constructs, made from three tags (myc, haemagglutinin and poly-His) inserted at both the C- and N-terminal positions, were thus tested using the *Xenopus* oocyte expression system via electrophysiology and immunohistochemistry. Of these, only the hSGLT1 construct
- 20 with the myc tag inserted at the N-terminal position proved to be of interest, all other constructs showing no or little transport activity. A systematic comparison of transport properties was therefore performed between the myc-tagged and the untagged hSGLT1 proteins. 3. On the basis of both steady-state (affinities for substrate (glucose) and inhibitor (phlorizin) as well as expression levels) and presteady-state parameters (transient currents) we conclude that the two
- 25 proteins are functionally indistinguishable, at least under these criteria. Immunological detection confirmed the appropriate targeting of the tagged protein to the plasma membrane of the oocyte with the epitope located at the extracellular side. 4. The myc-tagged hSGLT1 was also successfully expressed in polarized MDCK cells. alpha-Methylglucose uptake studies on transfected cells showed an exclusively apical uptake pathway, thus indicating that the expressed

protein was correctly targeted to the apical domain of the cell. 5. These comparative studies demonstrate that the myc epitope inserted at the N-terminus of hSGLT1 produces a fully functional protein while other epitopes of similar size inserted at either end of the protein inactivated the final protein.

5 PMID: 10523405

Panel 2D Summary: Ag2966 Expression of the CG56559-01 gene is predominantly limited to the kidney. This result is in agreement with the expression seen in Panel 1.3D. Thus, expression of this gene might be used as a marker of normal kidney tissue.

Panel 3D Summary: Ag2966 Results from one experiment with the CG56559-01 gene are not included. The amp plot indicates that there were experimental difficulties with this run.

Panel 4D Summary: Ag2950/Ag2966 Expression of the CG56559-01 gene is predominantly found in normal tissue from thymus, lung, colon and kidney. This expression profile suggests that the protein product may be involved in glucose transport and normal homeostasis in these tissues. Therefore, therapeutic modulation of the expression or function of this protein may be useful in for maintaining or restoring normal function to these organs during inflammation.

NOV29a: CG56557-01: Na(+)/glucose cotransporter

Expression of gene CG56557-01 was assessed using the primer-probe set Ag2931, described in Table VA. Results of the RTQ-PCR runs are shown in Table VB.

Table VA. Probe Name Ag2931

Primers	Sequences	Length	Start Position
Forward	5'-cagaggatccaggtgtacatgt-3' (SEQ ID NO:464)	22	501
Probe	TET-5'-tcctctacatcttcaccaagatctcgg-3'-TAMRA (SEQ ID NO:465)	27	538
Reverse	5'-agggtccagagaagatgtcta-3' (SEQ ID NO:466)	22	565

20 Table VB. Panel 4D

Tissue Name	Rel. Exp.(%)	Tissue Name	Rel. Exp.(%)
-------------	--------------	-------------	--------------

	Ag2931, Run 165871866		Ag2931, Run 165871866
Secondary Th1 act	0.0	HUVEC IL-1beta	0.0
Secondary Th2 act	0.0	HUVEC IFN gamma	0.0
Secondary Tr1 act	0.0	HUVEC TNF alpha + IFN gamma	0.7
Secondary Th1 rest	0.0	HUVEC TNF alpha + IL4	0.0
Secondary Th2 rest	0.0	HUVEC IL-11	6.0
Secondary Tr1 rest	0.0	Lung Microvascular EC none	0.7
Primary Th1 act	0.0	Lung Microvascular EC TNFalpha + IL-1beta	23.0
Primary Th2 act	0.0	Microvascular Dermal EC none	0.0
Primary Tr1 act	0.0	Microvascular Dermal EC TNFalpha + IL-1beta	12.4
Primary Th1 rest	0.0	Bronchial epithelium TNFalpha + IL1beta	30.1
Primary Th2 rest	0.0	Small airway epithelium none	5.7
Primary Tr1 rest	0.0	Small airway epithelium TNFalpha + IL-1beta	100.0
CD45RA CD4 lymphocyte act	0.5	Coronary artery SMC rest	0.0
CD45RO CD4 lymphocyte act	0.0	Coronary artery SMC TNFalpha + IL-1beta	0.0
CD8 lymphocyte act	0.0	Astrocytes rest	0.0
Secondary CD8 lymphocyte rest	0.0	Astrocytes TNFalpha + IL- 1beta	2.0
Secondary CD8 lymphocyte act	0.0	KU-812 (Basophil) rest	0.0
CD4 lymphocyte none	0.0	KU-812 (Basophil) PMA/ionomycin	0.0
2ry Th1/Th2/Tr1_anti- CD95 CH11	0.0	CCD1106 (Keratinocytes) none	0.0
LAK cells rest	0.0	CCD1106 (Keratinocytes) TNFalpha + IL-1beta	46.3
LAK cells IL-2	0.0	Liver cirrhosis	90.1
LAK cells IL-2+IL-12	0.0	Lupus kidney	0.0
LAK cells IL-2+IFN gamma	0.0	NCI-H292 none	0.0

LAK cells IL-2+ IL-18	0.0	NCI-H292 IL-4	0.0
LAK cells PMA/ionomycin	0.0	NCI-H292 IL-9	0.0
NK Cells IL-2 rest	0.0	NCI-H292 IL-13	0.0
Two Way MLR 3 day	0.0	NCI-H292 IFN gamma	0.0
Two Way MLR 5 day	0.0	HPAEC none	0.0
Two Way MLR 7 day	0.0	HPAEC TNF alpha + IL-1 beta	0.6
PBMC rest	0.0	Lung fibroblast none	0.0
PBMC PWM	0.0	Lung fibroblast TNF alpha + IL-1 beta	6.3
PBMC PHA-L	0.0	Lung fibroblast IL-4	0.0
Ramos (B cell) none	0.0	Lung fibroblast IL-9	0.0
Ramos (B cell) ionomycin	0.0	Lung fibroblast IL-13	0.0
B lymphocytes PWM	0.0	Lung fibroblast IFN gamma	0.0
B lymphocytes CD40L and IL-4	0.0	Dermal fibroblast CCD1070 rest	0.0
EOL-1 dbcAMP	0.0	Dermal fibroblast CCD1070 TNF alpha	2.7
EOL-1 dbcAMP PMA/ionomycin	0.0	Dermal fibroblast CCD1070 IL-1 beta	0.4
Dendritic cells none	0.0	Dermal fibroblast IFN gamma	0.0
Dendritic cells LPS	0.0	Dermal fibroblast IL-4	0.0
Dendritic cells anti- CD40	0.0	IBD Colitis 2	2.8
Monocytes rest	0.0	IBD Crohn's	0.0
Monocytes LPS	0.0	Colon	13.8
Macrophages rest	0.0	Lung	0.0
Macrophages LPS	0.0	Thymus	0.0
HUVEC none	0.0	Kidney	0.0
HUVEC starved	0.0		

CNS_neurodegeneration_v1.0 Summary: Ag2931 Data from one experiment with this probe and primer set and the CG56557-01 gene show low/undetectable levels of expression in all samples on this panel. (CTs>35). (Data not shown.) The amp plot indicates that there is a high probability of a probe failure in this experiment.

Panel 1.3D Summary: Ag2931 Data from one experiment with this probe and primer set and the CG56557-01 gene show low/undetectable levels of expression in all samples on this panel. (CTs>35). (Data not shown.) The amp plot indicates that there is a high probability of a probe failure in this experiment.

- 5 **Panel 2D Summary:** Ag2931 Data from one experiment with this probe and primer set and the CG56557-01 gene show low/undetectable levels of expression in all samples on this panel. (CTs>35). (Data not shown.) The amp plot indicates that there is a high probability of a probe failure in this experiment.

- 10 **Panel 4D Summary:** Ag2931 This CG56557-01 transcript, a Na/glucose cotransporter homolog, is expressed at low levels in small airway epithelium, bronchial epithelium, keratinocytes and lung microvasculature. Furthermore, expression of this transcript is up-regulated by the proinflammatory cytokines TNF-a and IL-1b in all these samples. Modulation of the expression and/or activity of this putative protein by antibodies or small molecules may reduce or eliminate inflammatory reactions that occurs in the lung or skin as a result of asthyma,
- 15 COPD, emphysema, psoriasis or other skin inflammatory diseases. Ag2931 Data from one experiment on this panel with the CG56557-01 gene, designated Run 164300130, is not included. The amp plot indicates that there were experimental difficulties with this run.

NOV29d and NOV29f: CG56557-04 and CG56557-06: Na(+)/glucose cotransporter

- 20 Expression of gene CG56557-04 and variant CG56557-06 was assessed using the primer-probe set Ag6054, described in Table WA. Please note that CG56557-04 is a splice variant of CG56557-01 (presented in section V above)

Table WA. Probe Name Ag6054

Primers	Sequences	Length	Start Position
Forward	5'-tcgtccatccgtgcaa-3' (SEQ ID NO:467)	16	160
Probe	TET-5'-cgagggaccattggcggtca-3'-TAMRA (SEQ ID NO:468)	20	178
Reverse	5'-gggtggggccagga-3' (SEQ ID NO:469)	14	200

CNS_neurodegeneration_v1.0 Summary: Ag6054 Expression of the CG56557-06 gene is low/undetectable in all samples on this panel (CTs>35).

General_screening_panel_v1.5 Summary: Ag6054 Expression of the CG56557-06 gene is low/undetectable in all samples on this panel (CTs>35).

- 5 **Panel 4.1D Summary:** Ag6054 Expression of the CG56557-06 gene is low/undetectable in all samples on this panel (CTs>35).

NOV29c: CG56557-03: splice variant of CG56557-01

Expression of gene CG56557-03 was assessed using the primer-probe set Ag6053, described in Table XA. Results of the RTQ-PCR runs are shown in Tables XB and XC.

10 Table XA. Probe Name Ag6053

Primers	Sequences	Length	Start Position
Forward	5' -caggtctcttatttctctgttcg-3' (SEQ ID NO:470)	23	410
Probe	TET-5' -cctccacagcacagcactgc-3' -TAMRA (SEQ ID NO:471)	21	437
Reverse	5' -acagagggcggtt-3' (SEQ ID NO:472)	15	469

Table XB General_screening_panel_v1.5

Tissue Name	Rel. Exp.(%) Ag6053, Run 228745661	Tissue Name	Rel. Exp.(%) Ag6053, Run 228745661
Adipose	1.2	Renal ca. TK-10	37.9
Melanoma* Hs688(A).T	0.2	Bladder	23.5
Melanoma* Hs688(B).T	0.1	Gastric ca. (liver met.) NCI-N87	16.8
Melanoma* M14	0.7	Gastric ca. KATO III	0.2
Melanoma* LOXIMVI	0.0	Colon ca. SW-948	0.2
Melanoma* SK-MEL-5	0.0	Colon ca. SW480	0.0
Squamous cell carcinoma SCC-4	0.0	Colon ca.* (SW480 met) SW620	0.3
Testis Pool	1.7	Colon ca. HT29	5.1
Prostate ca.* (bone met) PC-3	0.4	Colon ca. HCT-116	2.3

Prostate Pool	5.4	Colon ca. CaCo-2	100.0
Placenta	0.7	Colon cancer tissue	5.8
Uterus Pool	6.0	Colon ca. SW1116	0.0
Ovarian ca. OVCAR-3	0.9	Colon ca. Colo-205	0.5
Ovarian ca. SK-OV-3	3.8	Colon ca. SW-48	2.1
Ovarian ca. OVCAR-4	0.0	Colon Pool	4.2
Ovarian ca. OVCAR-5	10.7	Small Intestine Pool	5.7
Ovarian ca. IGROV-1	4.2	Stomach Pool	3.3
Ovarian ca. OVCAR-8	2.5	Bone Marrow Pool	2.5
Ovary	6.2	Fetal Heart	2.9
Breast ca. MCF-7	0.0	Heart Pool	2.8
Breast ca. MDA-MB-231	0.0	Lymph Node Pool	6.7
Breast ca. BT 549	0.7	Fetal Skeletal Muscle	3.6
Breast ca. T47D	0.0	Skeletal Muscle Pool	1.9
Breast ca. MDA-N	1.4	Spleen Pool	7.9
Breast Pool	5.0	Thymus Pool	4.3
Trachea	4.2	CNS cancer (glio/astro) U87-MG	2.5
Lung	2.1	CNS cancer (glio/astro) U-118-MG	1.2
Fetal Lung	51.4	CNS cancer (neuro;met) SK-N-AS	3.9
Lung ca. NCI-N417	0.0	CNS cancer (astro) SF-539	0.0
Lung ca. LX-1	0.3	CNS cancer (astro) SNB-75	3.8
Lung ca. NCI-H146	0.0	CNS cancer (glio) SNB-19	4.4
Lung ca. SHP-77	2.0	CNS cancer (glio) SF-295	6.9
Lung ca. A549	2.8	Brain (Amygdala) Pool	1.0
Lung ca. NCI-H526	0.0	Brain (cerebellum)	1.6
Lung ca. NCI-H23	4.5	Brain (fetal)	0.0

Lung ca. NCI-H460	11.2	Brain (Hippocampus) Pool	1.7
Lung ca. HOP-62	0.5	Cerebral Cortex Pool	1.5
Lung ca. NCI-H522	3.0	Brain (Substantia nigra) Pool	1.0
Liver	1.3	Brain (Thalamus) Pool	1.0
Fetal Liver	61.6	Brain (whole)	1.3
Liver ca. HepG2	63.7	Spinal Cord Pool	2.5
Kidney Pool	16.2	Adrenal Gland	3.5
Fetal Kidney	40.3	Pituitary gland Pool	1.9
Renal ca. 786-0	4.8	Salivary Gland	1.9
Renal ca. A498	1.3	Thyroid (female)	0.5
Renal ca. ACHN	0.2	Pancreatic ca. CAPAN2	0.4
Renal ca. UO-31	0.3	Pancreas Pool	12.4

Table XC Panel 4.1D

Tissue Name	Rel. Exp.(%) Ag6053, Run 226202129	Tissue Name	Rel. Exp.(%) Ag6053, Run 226202129
Secondary Th1 act	0.0	HUVEC IL-1beta	0.1
Secondary Th2 act	0.0	HUVEC IFN gamma	0.0
Secondary Tr1 act	0.0	HUVEC TNF alpha + IFN gamma	0.0
Secondary Th1 rest	0.0	HUVEC TNF alpha + IL4	0.0
Secondary Th2 rest	0.0	HUVEC IL-11	0.0
Secondary Tr1 rest	0.0	Lung Microvascular EC none	1.0
Primary Th1 act	0.0	Lung Microvascular EC TNFalpha + IL-1beta	1.0
Primary Th2 act	0.0	Microvascular Dermal EC none	0.0
Primary Tr1 act	0.0	Microvascular Dermal EC TNFalpha + IL-1beta	0.0
Primary Th1 rest	0.0	Bronchial epithelium TNFalpha + IL1beta	0.6
Primary Th2 rest	0.0	Small airway epithelium none	0.7
Primary Tr1 rest	0.0	Small airway epithelium TNFalpha + IL-1beta	0.0
CD45RA CD4	0.0	Coronary artery SMC rest	0.0

lymphocyte act			
CD45RO CD4 lymphocyte act	0.9	Coronary artery SMC TNFalpha + IL-1beta	0.0
CD8 lymphocyte act	0.0	Astrocytes rest	1.0
Secondary CD8 lymphocyte rest	0.0	Astrocytes TNFalpha + IL-1beta	0.5
Secondary CD8 lymphocyte act	0.0	KU-812 (Basophil) rest	0.0
CD4 lymphocyte none	0.0	KU-812 (Basophil) PMA/ionomycin	0.0
2ry Th1/Th2/Tr1_anti-CD95 CH11	0.0	CCD1106 (Keratinocytes) none	0.0
LAK cells rest	0.5	CCD1106 (Keratinocytes) TNFalpha + IL-1beta	0.0
LAK cells IL-2	0.5	Liver cirrhosis	5.5
LAK cells IL-2+IL-12	0.0	NCI-H292 none	0.0
LAK cells IL-2+IFN gamma	0.5	NCI-H292 IL-4	0.0
LAK cells IL-2+ IL-18	0.5	NCI-H292 IL-9	0.0
LAK cells PMA/ionomycin	0.0	NCI-H292 IL-13	0.0
NK Cells IL-2 rest	0.3	NCI-H292 IFN gamma	0.0
Two Way MLR 3 day	0.4	HPAEC none	0.5
Two Way MLR 5 day	0.5	HPAEC TNF alpha + IL-1 beta	0.0
Two Way MLR 7 day	0.0	Lung fibroblast none	2.0
PBMC rest	1.5	Lung fibroblast TNF alpha + IL-1 beta	0.4
PBMC PWM	0.0	Lung fibroblast IL-4	1.6
PBMC PHA-L	0.0	Lung fibroblast IL-9	0.0
Ramos (B cell) none	0.0	Lung fibroblast IL-13	1.1
Ramos (B cell) ionomycin	0.0	Lung fibroblast IFN gamma	0.0
B lymphocytes PWM	0.0	Dermal fibroblast CCD1070 rest	0.5
B lymphocytes CD40L and IL-4	0.0	Dermal fibroblast CCD1070 TNF alpha	0.5
EOL-1 dbcAMP	0.0	Dermal fibroblast CCD1070 IL-1 beta	0.0
EOL-1 dbcAMP PMA/ionomycin	0.0	Dermal fibroblast IFN gamma	0.4

Dendritic cells none	0.0	Dermal fibroblast IL-4	1.1
Dendritic cells LPS	0.0	Dermal Fibroblasts rest	0.5
Dendritic cells anti-CD40	1.3	Neutrophils TNFa+LPS	0.8
Monocytes rest	2.8	Neutrophils rest	0.8
Monocytes LPS	1.2	Colon	19.1
Macrophages rest	0.4	Lung	8.2
Macrophages LPS	0.0	Thymus	15.8
HUVEC none	0.2	Kidney	100.0
HUVEC starved	0.0		

CNS_neurodegeneration_v1.0 Summary: Ag6053 Expression of the CG56557-03 gene is low/undetectable in all samples on this panel.

General_screening_panel_v1.5 Summary: Ag6053 The CG56557-03 gene is expressed at low levels in most samples in this panel, with highest expression in CaCo-2 colon cancer cells (CT=30). Significant expression is also seen in some ovarian, colon, renal, CNS cancer cell lines. Hence, expression of this gene could be used as a diagnostic marker and/or for treatment of similar cancers.

In addition, this gene is expressed at low levels in pancreas and adrenal (CT values = 33-34). Thus, this gene product may be a small molecule target for the treatment of metabolic diseases including obesity and Types 1 and 2 diabetes. Furthermore, this gene is expressed at higher levels in fetal liver (CT value = 31) when compared to expression in adult liver (CT value = 36) and may be useful for the differentiation between the two sources of liver tissue.

Panel 4.1D Summary: Ag6053 The CG56557-03 transcript is mostly expressed in kidney (CT=29.5). Low expression of this transcript is also found in colon and thymus. The protein encoded by this transcript may thus be involved in normal tissue/cellular functions in the kidney and colon. Therefore, therapeutics designed with the protein encoded by this transcript may be important in maintaining or restoring normal function to these organs during inflammation.

NOV29e: CG56557-05: splice variant of CG56557-01

Expression of gene CG56557-05 was assessed using the primer-probe set Ag6055, described in Table YA. Results of the RTQ-PCR runs are shown in Tables YB and YC.

Table YA. Probe Name Ag6055

Primers	Sequences	Length	Start Position
Forward	5'-tcaaggtctggaggagacaga-3' (SEQ ID NO:473)	21	348
Probe	TET-5'-ccatccaaggtcacacgggagg-3'-TAMRA (SEQ ID NO:474)	22	374
Reverse	5'-caggttgcttgggacct-3' (SEQ ID NO:475)	17	405

Table YB General_screening_panel_v1.5

Tissue Name	Rel. Exp.(%) Ag6055, Run 228745663	Tissue Name	Rel. Exp.(%) Ag6055, Run 228745663
Adipose	0.0	Renal ca. TK-10	38.7
Melanoma* Hs688(A).T	0.0	Bladder	9.8
Melanoma* Hs688(B).T	0.0	Gastric ca. (liver met.) NCI-N87	3.7
Melanoma* M14	0.0	Gastric ca. KATO III	0.0
Melanoma* LOXIMVI	0.0	Colon ca. SW-948	0.0
Melanoma* SK-MEL-5	0.0	Colon ca. SW480	0.0
Squamous cell carcinoma SCC-4	0.0	Colon ca.* (SW480 met) SW620	0.0
Testis Pool	1.4	Colon ca. HT29	2.6
Prostate ca.* (bone met) PC-3	0.0	Colon ca. HCT-116	0.0
Prostate Pool	0.3	Colon ca. CaCo-2	35.4
Placenta	0.0	Colon cancer tissue	5.7
Uterus Pool	0.2	Colon ca. SW1116	0.5
Ovarian ca. OVCAR-3	0.3	Colon ca. Colo-205	0.0
Ovarian ca. SK-OV-3	1.3	Colon ca. SW-48	3.8
Ovarian ca. OVCAR-4	0.0	Colon Pool	1.2
Ovarian ca. OVCAR-5	0.8	Small Intestine Pool	0.7
Ovarian ca. IGROV-1	0.7	Stomach Pool	1.5
Ovarian ca. OVCAR-	0.0	Bone Marrow Pool	0.5

8			
Ovary	0.4	Fetal Heart	0.6
Breast ca. MCF-7	0.0	Heart Pool	0.4
Breast ca. MDA-MB-231	0.0	Lymph Node Pool	0.6
Breast ca. BT 549	0.0	Fetal Skeletal Muscle	1.7
Breast ca. T47D	0.0	Skeletal Muscle Pool	1.5
Breast ca. MDA-N	0.0	Spleen Pool	1.2
Breast Pool	0.0	Thymus Pool	1.1
Trachea	2.6	CNS cancer (glio/astro) U87-MG	0.0
Lung	1.3	CNS cancer (glio/astro) U-118-MG	0.0
Fetal Lung	17.8	CNS cancer (neuro;met) SK-N-AS	1.2
Lung ca. NCI-N417	0.0	CNS cancer (astro) SF-539	0.0
Lung ca. LX-1	0.0	CNS cancer (astro) SNB-75	1.4
Lung ca. NCI-H146	0.0	CNS cancer (glio) SNB-19	0.0
Lung ca. SHP-77	0.0	CNS cancer (glio) SF-295	1.0
Lung ca. A549	5.9	Brain (Amygdala) Pool	0.0
Lung ca. NCI-H526	0.0	Brain (cerebellum)	0.0
Lung ca. NCI-H23	0.0	Brain (fetal)	0.5
Lung ca. NCI-H460	3.4	Brain (Hippocampus) Pool	0.4
Lung ca. HOP-62	0.0	Cerebral Cortex Pool	0.2
Lung ca. NCI-H522	0.4	Brain (Substantia nigra) Pool	0.0
Liver	2.2	Brain (Thalamus) Pool	0.5
Fetal Liver	100.0	Brain (whole)	0.4
Liver ca. HepG2	77.4	Spinal Cord Pool	0.9
Kidney Pool	1.8	Adrenal Gland	1.6
Fetal Kidney	6.9	Pituitary gland Pool	0.7
Renal ca. 786-0	1.1	Salivary Gland	1.6
Renal ca. A498	0.0	Thyroid (female)	0.0
Renal ca. ACHN	0.0	Pancreatic ca. CAPAN2	0.0
Renal ca. UO-31	0.0	Pancreas Pool	1.8

Table YC. Panel 4.1D

Tissue Name	Rel. Exp.(%) Ag6055, Run 226160573	Tissue Name	Rel. Exp.(%) Ag6055, Run 226160573
Secondary Th1 act	0.0	HUVEC IL-1beta	0.0
Secondary Th2 act	0.0	HUVEC IFN gamma	0.0
Secondary Tr1 act	0.0	HUVEC TNF alpha + IFN gamma	0.0
Secondary Th1 rest	0.0	HUVEC TNF alpha + IL4	4.2
Secondary Th2 rest	0.0	HUVEC IL-11	0.0
Secondary Tr1 rest	0.0	Lung Microvascular EC none	0.0
Primary Th1 act	0.0	Lung Microvascular EC TNFalpha + IL-1beta	0.0
Primary Th2 act	0.0	Microvascular Dermal EC none	0.0
Primary Tr1 act	0.0	Microsvascular Dermal EC TNFalpha + IL-1beta	0.0
Primary Th1 rest	0.0	Bronchial epithelium TNFalpha + IL1beta	0.7
Primary Th2 rest	0.0	Small airway epithelium none	0.0
Primary Tr1 rest	0.0	Small airway epithelium TNFalpha + IL-1beta	0.0
CD45RA CD4 lymphocyte act	0.0	Coronary artery SMC rest	0.0
CD45RO CD4 lymphocyte act	0.0	Coronary artery SMC TNFalpha + IL-1beta	0.0
CD8 lymphocyte act	0.0	Astrocytes rest	0.0
Secondary CD8 lymphocyte rest	0.0	Astrocytes TNFalpha + IL- 1beta	0.0
Secondary CD8 lymphocyte act	0.0	KU-812 (Basophil) rest	0.0
CD4 lymphocyte none	0.0	KU-812 (Basophil) PMA/ionomycin	0.0
2ry Th1/Th2/Tr1_anti- CD95 CH11	0.0	CCD1106 (Keratinocytes) none	0.0
LAK cells rest	0.0	CCD1106 (Keratinocytes) TNFalpha + IL-1beta	0.0
LAK cells IL-2	0.0	Liver cirrhosis	0.8

LAK cells IL-2+IL-12	0.0	NCI-H292 none	0.0
LAK cells IL-2+IFN gamma	0.0	NCI-H292 IL-4	0.0
LAK cells IL-2+ IL-18	0.0	NCI-H292 IL-9	0.0
LAK cells PMA/ionomycin	0.0	NCI-H292 IL-13	0.0
NK Cells IL-2 rest	2.5	NCI-H292 IFN gamma	0.0
Two Way MLR 3 day	0.0	HPAEC none	0.0
Two Way MLR 5 day	0.0	HPAEC TNF alpha + IL-1 beta	0.0
Two Way MLR 7 day	0.0	Lung fibroblast none	0.0
PBMC rest	0.0	Lung fibroblast TNF alpha + IL-1 beta	0.0
PBMC PWM	0.0	Lung fibroblast IL-4	0.0
PBMC PHA-L	0.0	Lung fibroblast IL-9	0.0
Ramos (B cell) none	0.0	Lung fibroblast IL-13	5.0
Ramos (B cell) ionomycin	0.0	Lung fibroblast IFN gamma	0.0
B lymphocytes PWM	0.0	Dermal fibroblast CCD1070 rest	0.0
B lymphocytes CD40L and IL-4	0.0	Dermal fibroblast CCD1070 TNF alpha	0.0
EOL-1 dbcAMP	0.0	Dermal fibroblast CCD1070 IL-1 beta	0.0
EOL-1 dbcAMP PMA/ionomycin	0.0	Dermal fibroblast IFN gamma	0.0
Dendritic cells none	0.0	Dermal fibroblast IL-4	0.0
Dendritic cells LPS	0.0	Dermal Fibroblasts rest	0.0
Dendritic cells anti-CD40	0.7	Neutrophils TNFa+LPS	0.0
Monocytes rest	0.0	Neutrophils rest	4.8
Monocytes LPS	0.0	Colon	100.0
Macrophages rest	0.0	Lung	0.8
Macrophages LPS	0.0	Thymus	4.5
HUVEC none	0.0	Kidney	79.0
HUVEC starved	0.0		

CNS_neurodegeneration_v1.0 Summary: Ag6055 Expression of the CG56557-05 gene is low/undetectable in all samples on this panel (CTs>35).

General_screening_panel_v1.5 Summary: Ag6055 Highest expression of the CG56557-05 gene is in fetal liver (CT value=31). Furthermore, this gene is expressed at much higher levels in the fetal liver when compared to expression in the adult liver (CT=36). Thus, this gene product may be useful for the differentiation of between the adult and fetal sources of this tissue.

- 5 Significant expression is also seen in CaCo-2 colon cancer cells, TK-10 renal cells and HepG2 liver cells. Hence, expression of this gene can be used as a diagnostic marker and/or as treatment for related kidney and colon cancers.

10 **Panel 4.1D Summary:** Ag6055 The CG56557-05 transcript is selectively expressed at low levels in colon (CT=32.7) and kidney. Thus, the protein encoded for this transcript may be involved in normal tissue/cellular functions. Therefore, therapeutics designed with the protein encoded by this transcript may be important for maintaining or restoring normal function to these organs during inflammation.

NOV30: CG56398-01: Na/glucose cotransporter

15 Expression of gene CG56398-01 was assessed using the primer-probe set Ag2925, described in Table ZA. Results of the RTQ-PCR runs are shown in Tables ZB, ZC, ZD, ZE and ZF.

Table ZA. Probe Name Ag2925

Primers	Sequences	Length	Start Position
Forward	5'-ctccctcacctccatctttaac-3' (SEQ ID NO:476)	22	1191
Probe	TET-5'-ccatcttcacccatggacctctggaat-3'-TAMRA (SEQ ID NO:477)	26	1223
Reverse	5'-atcatgagctccttctcagatg-3' (SEQ ID NO:478)	22	1265

Table ZB. CNS_neurodegeneration_v1.0

Tissue Name	Rel. Exp.(%) Ag2925, Run 209777392	Tissue Name	Rel. Exp.(%) Ag2925, Run 209777392
AD 1 Hippo	16.8	Control (Path) 3 Temporal Ctx	0.4
AD 2 Hippo	17.2	Control (Path) 4 Temporal Ctx	5.8
AD 3 Hippo	6.5	AD 1 Occipital Ctx	36.1
AD 4 Hippo	1.4	AD 2 Occipital Ctx	0.0

		(Missing)	
AD 5 hippo	48.3	AD 3 Occipital Ctx	10.4
AD 6 Hippo	17.6	AD 4 Occipital Ctx	15.9
Control 2 Hippo	24.8	AD 5 Occipital Ctx	12.4
Control 4 Hippo	2.6	AD 6 Occipital Ctx	33.2
Control (Path) 3 Hippo	2.1	Control 1 Occipital Ctx	2.3
AD 1 Temporal Ctx	37.9	Control 2 Occipital Ctx	57.0
AD 2 Temporal Ctx	24.3	Control 3 Occipital Ctx	6.7
AD 3 Temporal Ctx	2.5	Control 4 Occipital Ctx	11.6
AD 4 Temporal Ctx	10.5	Control (Path) 1 Occipital Ctx	53.6
AD 5 Inf Temporal Ctx	100.0	Control (Path) 2 Occipital Ctx	8.3
AD 5 SupTemporal Ctx	34.2	Control (Path) 3 Occipital Ctx	4.6
AD 6 Inf Temporal Ctx	24.5	Control (Path) 4 Occipital Ctx	5.2
AD 6 Sup Temporal Ctx	15.4	Control 1 Parietal Ctx	6.2
Control 1 Temporal Ctx	0.5	Control 2 Parietal Ctx	37.6
Control 2 Temporal Ctx	20.0	Control 3 Parietal Ctx	12.4
Control 3 Temporal Ctx	4.8	Control (Path) 1 Parietal Ctx	15.1
Control 4 Temporal Ctx	1.3	Control (Path) 2 Parietal Ctx	16.2
Control (Path) 1 Temporal Ctx	11.9	Control (Path) 3 Parietal Ctx	0.5
Control (Path) 2 Temporal Ctx	5.8	Control (Path) 4 Parietal Ctx	13.7

Table ZC. Panel 1.3D

Tissue Name	Rel. Exp.(%) Ag2925, Run 158046924	Tissue Name	Rel. Exp.(%) Ag2925, Run 158046924
Liver adenocarcinoma	0.4	Kidney (fetal)	1.2

Pancreas	0.0	Renal ca. 786-0	0.0
Pancreatic ca. CAPAN 2	0.0	Renal ca. A498	0.1
Adrenal gland	0.3	Renal ca. RXF 393	0.0
Thyroid	0.0	Renal ca. ACHN	0.0
Salivary gland	0.0	Renal ca. UO-31	0.0
Pituitary gland	0.4	Renal ca. TK-10	0.0
Brain (fetal)	0.3	Liver	0.2
Brain (whole)	19.5	Liver (fetal)	3.8
Brain (amygdala)	10.5	Liver ca. (hepatoblast) HepG2	0.6
Brain (cerebellum)	4.6	Lung	0.2
Brain (hippocampus)	100.0	Lung (fetal)	0.0
Brain (substantia nigra)	22.2	Lung ca. (small cell) LX-1	0.0
Brain (thalamus)	45.4	Lung ca. (small cell) NCI-H69	0.0
Cerebral Cortex	13.0	Lung ca. (s.cell var.) SHP-77	0.0
Spinal cord	25.9	Lung ca. (large cell) NCI-H460	0.0
glio/astro U87-MG	0.0	Lung ca. (non-sm. cell) A549	0.8
glio/astro U-118-MG	0.4	Lung ca. (non-s.cell) NCI-H23	0.0
astrocytoma SW1783	0.1	Lung ca. (non-s.cell) HOP-62	0.0
neuro*; met SK-N-AS	0.0	Lung ca. (non-s.cl) NCI-H522	0.0
astrocytoma SF-539	0.1	Lung ca. (squam.) SW 900	0.0
astrocytoma SNB-75	0.1	Lung ca. (squam.) NCI-H596	0.0
glioma SNB-19	0.0	Mammary gland	0.1
glioma U251	0.0	Breast ca.* (pl.ef) MCF-7	0.0
glioma SF-295	0.0	Breast ca.* (pl.ef) MDA-MB-231	0.5
Heart (fetal)	0.1	Breast ca.* (pl.ef) T47D	0.0
Heart	0.0	Breast ca. BT-549	0.3

Skeletal muscle (fetal)	0.1	Breast ca. MDA-N	0.2
Skeletal muscle	0.0	Ovary	0.1
Bone marrow	0.0	Ovarian ca. OVCAR-3	0.0
Thymus	0.0	Ovarian ca. OVCAR-4	0.0
Spleen	0.1	Ovarian ca. OVCAR-5	0.0
Lymph node	0.1	Ovarian ca. OVCAR-8	0.3
Colorectal	0.1	Ovarian ca. IGROV-1	0.0
Stomach	0.0	Ovarian ca.* (ascites) SK-OV-3	0.0
Small intestine	1.0	Uterus	0.0
Colon ca. SW480	0.2	Placenta	0.4
Colon ca.* SW620(SW480 met)	84.7	Prostate	0.2
Colon ca. HT29	0.2	Prostate ca.* (bone met)PC-3	0.0
Colon ca. HCT-116	0.0	Testis	0.3
Colon ca. CaCo-2	0.2	Melanoma Hs688(A).T	0.0
Colon ca. tissue(ODO3866)	0.1	Melanoma* (met) Hs688(B).T	0.0
Colon ca. HCC-2998	0.7	Melanoma UACC-62	0.1
Gastric ca.* (liver met) NCI-N87	0.0	Melanoma M14	0.0
Bladder	0.0	Melanoma LOX IMVI	0.0
Trachea	0.0	Melanoma* (met) SK-MEL-5	0.0
Kidney	2.6	Adipose	0.0

Table ZD. Panel 2D

Tissue Name	Rel. Exp.(%) Ag2925, Run 158047169	Tissue Name	Rel. Exp.(%) Ag2925, Run 158047169
Normal Colon	2.6	Kidney Margin 8120608	63.7
CC Well to Mod Diff	0.6	Kidney Cancer	0.0

(ODO3866)		8120613	
CC Margin (ODO3866)	0.5	Kidney Margin 8120614	100.0
CC Gr.2 rectosigmoid (ODO3868)	0.0	Kidney Cancer 9010320	0.4
CC Margin (ODO3868)	0.4	Kidney Margin 9010321	14.2
CC Mod Diff (ODO3920)	2.0	Normal Uterus	0.9
CC Margin (ODO3920)	0.7	Uterus Cancer 064011	0.7
CC Gr.2 ascend colon (ODO3921)	0.0	Normal Thyroid	0.0
CC Margin (ODO3921)	1.2	Thyroid Cancer 064010	0.0
CC from Partial Hepatectomy (ODO4309) Mets	1.5	Thyroid Cancer A302152	0.0
Liver Margin (ODO4309)	0.7	Thyroid Margin A302153	0.4
Colon mets to lung (OD04451-01)	0.0	Normal Breast	0.6
Lung Margin (OD04451- 02)	0.9	Breast Cancer (OD04566)	0.9
Normal Prostate 6546-1	0.6	Breast Cancer (OD04590-01)	1.2
Prostate Cancer (OD04410)	1.2	Breast Cancer Mets (OD04590-03)	0.5
Prostate Margin (OD04410)	1.2	Breast Cancer Metastasis (OD04655- 05)	0.9
Prostate Cancer (OD04720-01)	0.9	Breast Cancer 064006	0.0
Prostate Margin (OD04720-02)	1.1	Breast Cancer 1024	0.9
Normal Lung 061010	0.4	Breast Cancer 9100266	1.4
Lung Met to Muscle (ODO4286)	0.0	Breast Margin 9100265	0.0
Muscle Margin (ODO4286)	0.0	Breast Cancer A209073	44.1
Lung Malignant Cancer (OD03126)	1.4	Breast Margin A2090734	1.4
Lung Margin (OD03126)	0.0	Normal Liver	0.0

Lung Cancer (OD04404)	0.8	Liver Cancer 064003	0.0
Lung Margin (OD04404)	0.0	Liver Cancer 1025	0.6
Lung Cancer (OD04565)	0.0	Liver Cancer 1026	1.2
Lung Margin (OD04565)	0.4	Liver Cancer 6004-T	0.3
Lung Cancer (OD04237-01)	0.0	Liver Tissue 6004-N	3.3
Lung Margin (OD04237-02)	0.0	Liver Cancer 6005-T	0.3
Ocular Mel Met to Liver (ODO4310)	0.0	Liver Tissue 6005-N	0.4
Liver Margin (ODO4310)	0.1	Normal Bladder	1.2
Melanoma Mets to Lung (OD04321)	0.0	Bladder Cancer 1023	0.9
Lung Margin (OD04321)	0.1	Bladder Cancer A302173	0.4
Normal Kidney	48.3	Bladder Cancer (OD04718-01)	0.7
Kidney Ca, Nuclear grade 2 (OD04338)	0.9	Bladder Normal Adjacent (OD04718-03)	0.0
Kidney Margin (OD04338)	3.8	Normal Ovary	0.0
Kidney Ca Nuclear grade 1/2 (OD04339)	0.4	Ovarian Cancer 064008	0.1
Kidney Margin (OD04339)	70.7	Ovarian Cancer (OD04768-07)	1.6
Kidney Ca, Clear cell type (OD04340)	3.0	Ovary Margin (OD04768-08)	0.0
Kidney Margin (OD04340)	11.7	Normal Stomach	1.0
Kidney Ca, Nuclear grade 3 (OD04348)	0.2	Gastric Cancer 9060358	0.0
Kidney Margin (OD04348)	2.1	Stomach Margin 9060359	0.0
Kidney Cancer (OD04622-01)	0.0	Gastric Cancer 9060395	0.4
Kidney Margin (OD04622-03)	2.3	Stomach Margin 9060394	0.7
Kidney Cancer (OD04450-01)	0.0	Gastric Cancer 9060397	2.4
Kidney Margin	5.0	Stomach Margin	0.4

(OD04450-03)		9060396	
Kidney Cancer 8120607	0.3	Gastric Cancer 064005	0.6

Table ZE. Panel 4D

Tissue Name	Rel. Exp.(%) Ag2925, Run 158047348	Tissue Name	Rel. Exp.(%) Ag2925, Run 158047348
Secondary Th1 act	1.7	HUVEC IL-1beta	0.0
Secondary Th2 act	0.0	HUVEC IFN gamma	0.0
Secondary Tr1 act	0.6	HUVEC TNF alpha + IFN gamma	0.0
Secondary Th1 rest	0.0	HUVEC TNF alpha + IL4	0.0
Secondary Th2 rest	0.8	HUVEC IL-11	0.6
Secondary Tr1 rest	0.0	Lung Microvascular EC none	0.2
Primary Th1 act	0.6	Lung Microvascular EC TNFalpha + IL-1beta	0.0
Primary Th2 act	0.7	Microvascular Dermal EC none	0.0
Primary Tr1 act	0.6	Microvascular Dermal EC TNFalpha + IL-1beta	0.0
Primary Th1 rest	0.8	Bronchial epithelium TNFalpha + IL1beta	0.0
Primary Th2 rest	1.9	Small airway epithelium none	0.0
Primary Tr1 rest	1.6	Small airway epithelium TNFalpha + IL-1beta	0.0
CD45RA CD4 lymphocyte act	0.5	Coronary artery SMC rest	0.0
CD45RO CD4 lymphocyte act	0.6	Coronary artery SMC TNFalpha + IL-1beta	0.0
CD8 lymphocyte act	0.5	Astrocytes rest	0.0
Secondary CD8 lymphocyte rest	0.3	Astrocytes TNFalpha + IL- 1beta	0.0
Secondary CD8 lymphocyte act	0.0	KU-812 (Basophil) rest	0.0
CD4 lymphocyte none	0.1	KU-812 (Basophil) PMA/ionomycin	0.0
2ry Th1/Th2/Tr1_anti- CD95 CH11	1.2	CCD1106 (Keratinocytes) none	0.0

LAK cells rest	1.1	CCD1106 (Keratinocytes) TNFalpha + IL-1beta	0.0
LAK cells IL-2	1.1	Liver cirrhosis	2.8
LAK cells IL-2+IL-12	1.1	Lupus kidney	1.2
LAK cells IL-2+IFN gamma	0.0	NCI-H292 none	0.5
LAK cells IL-2+ IL-18	0.4	NCI-H292 IL-4	0.2
LAK cells PMA/ionomycin	1.4	NCI-H292 IL-9	1.1
NK Cells IL-2 rest	0.7	NCI-H292 IL-13	0.6
Two Way MLR 3 day	2.3	NCI-H292 IFN gamma	0.6
Two Way MLR 5 day	0.8	HPAEC none	1.3
Two Way MLR 7 day	0.5	HPAEC TNF alpha + IL-1 beta	0.1
PBMC rest	0.0	Lung fibroblast none	0.7
PBMC PWM	1.1	Lung fibroblast TNF alpha + IL-1 beta	0.0
PBMC PHA-L	0.0	Lung fibroblast IL-4	0.3
Ramos (B cell) none	0.0	Lung fibroblast IL-9	0.0
Ramos (B cell) ionomycin	0.0	Lung fibroblast IL-13	0.0
B lymphocytes PWM	0.6	Lung fibroblast IFN gamma	0.0
B lymphocytes CD40L and IL-4	0.4	Dermal fibroblast CCD1070 rest	0.0
EOL-1 dbcAMP	0.0	Dermal fibroblast CCD1070 TNF alpha	0.0
EOL-1 dbcAMP PMA/ionomycin	0.0	Dermal fibroblast CCD1070 IL-1 beta	0.0
Dendritic cells none	1.1	Dermal fibroblast IFN gamma	0.0
Dendritic cells LPS	1.0	Dermal fibroblast IL-4	0.0
Dendritic cells anti- CD40	1.1	IBD Colitis 2	0.0
Monocytes rest	0.6	IBD Crohn's	2.9
Monocytes LPS	0.0	Colon	100.0
Macrophages rest	2.2	Lung	2.1
Macrophages LPS	0.0	Thymus	85.3
HUVEC none	0.8	Kidney	2.9
HUVEC starved	1.6		

Table ZF. Panel CNS_1

Tissue Name	Rel. Exp.(%) Ag2925, Run 171688481	Tissue Name	Rel. Exp.(%) Ag2925, Run 171688481
BA4 Control	3.3	BA17 PSP	3.1
BA4 Control2	14.6	BA17 PSP2	1.8
BA4 Alzheimer's2	3.1	Sub Nigra Control	66.0
BA4 Parkinson's	11.3	Sub Nigra Control2	43.2
BA4 Parkinson's2	24.5	Sub Nigra Alzheimer's2	25.3
BA4 Huntington's	7.7	Sub Nigra Parkinson's2	85.3
BA4 Huntington's2	5.3	Sub Nigra Huntington's	100.0
BA4 PSP	1.5	Sub Nigra Huntington's2	64.2
BA4 PSP2	15.2	Sub Nigra PSP2	14.4
BA4 Depression	3.6	Sub Nigra Depression	19.2
BA4 Depression2	6.6	Sub Nigra Depression2	15.0
BA7 Control	3.3	Glob Palladus Control	31.2
BA7 Control2	12.6	Glob Palladus Control2	5.3
BA7 Alzheimer's2	0.0	Glob Palladus Alzheimer's	12.3
BA7 Parkinson's	5.2	Glob Palladus Alzheimer's2	5.4
BA7 Parkinson's2	12.2	Glob Palladus Parkinson's	28.1
BA7 Huntington's	4.8	Glob Palladus Parkinson's2	10.2
BA7 Huntington's2	53.2	Glob Palladus PSP	6.1
BA7 PSP	4.7	Glob Palladus PSP2	0.0
BA7 PSP2	4.0	Glob Palladus Depression	13.7
BA7 Depression	7.4	Temp Pole Control	0.0
BA9 Control	0.0	Temp Pole Control2	13.3

BA9 Control2	41.8	Temp Pole Alzheimer's	0.0
BA9 Alzheimer's	0.0	Temp Pole Alzheimer's2	0.0
BA9 Alzheimer's2	1.5	Temp Pole Parkinson's	3.2
BA9 Parkinson's	10.2	Temp Pole Parkinson's2	4.7
BA9 Parkinson's2	29.1	Temp Pole Huntington's	8.7
BA9 Huntington's	10.1	Temp Pole PSP	0.0
BA9 Huntington's2	7.2	Temp Pole PSP2	1.4
BA9 PSP	4.7	Temp Pole Depression2	3.3
BA9 PSP2	3.5	Cing Gyr Control	29.3
BA9 Depression	2.8	Cing Gyr Control2	19.1
BA9 Depression2	2.6	Cing Gyr Alzheimer's	21.8
BA17 Control	18.7	Cing Gyr Alzheimer's2	0.9
BA17 Control2	8.5	Cing Gyr Parkinson's	28.3
BA17 Alzheimer's	0.0	Cing Gyr Parkinson's2	30.1
BA17 Parkinson's	16.0	Cing Gyr Huntington's	45.1
BA17 Parkinson's2	31.4	Cing Gyr Huntington's2	64.6
BA17 Huntington's	13.1	Cing Gyr PSP	17.8
BA17 Huntington's2	13.6	Cing Gyr PSP2	4.4
BA17 Depression	4.7	Cing Gyr Depression	6.1
BA17 Depression2	12.0	Cing Gyr Depression2	25.9

CNS_neurodegeneration_v1.0 Summary: Ag2925 This panel does not show differential expression of the CG56398-01 gene in Alzheimer's disease. However, this expression profile

confirms the presence of this gene in the brain. Please see Panel 1.3D for discussion of utility of this gene in the central nervous system.

Panel 1.3D Summary: Ag2925 Expression of the CG56398-01 gene appears to be brain-specific. Highest expression is detected in the hippocampus (CT=28) a region that degenerates in Alzheimer's disease. Thus, this gene would be useful for distinguishing brain tissue from non-neural tissue, and may be beneficial as a drug target in neurodegenerative disease.

Panel 2D Summary: Ag2925 The CG56398-01 gene is most highly expressed in a normal kidney sample (CT= 28.95). Interestingly, expression of this gene is lost in the adjacent cancer samples. Hence, the loss of expression could potentially be used as a diagnostic marker for kidney cancer. This gene is also expressed at low levels in breast and bladder cancer samples and is absent or extremely low in normal adjacent tissue. Therefore, therapeutic inhibition of the activity of this protein product, through the use of small molecule drugs or antibodies, may be useful in the treatment of breast and bladder cancer or as a diagnostic marker for the presence of these cancers.

Panel 4D Summary: Ag2925 Expression of the CG56398-01 transcript is almost exclusively restricted to colon and thymus, with highest expression in normal colon (CT=29). Furthermore, it is expressed at much lower levels in IBD colon. Therefore, the protein encoded by this transcript may be involved in normal tissue/cellular functions in the kidney and colon. Loss-of-expression of this protein may serve as a diagnostic marker for lupus or IBD.

Panel CNS_1 Summary: Ag2925 This panel confirms expression of the CG56398-01 gene in the brain. Please see Panel 1.3D for discussion of utility of this gene in the central nervous system.

NOV31: CG56616-01: Olfactory Receptor

Expression of gene CG56616-01 was assessed using the primer-probe sets Ag1371 and Ag2014, described in Tables AAA, AAB, and AAC. Results of the RTQ-PCR runs are shown in Tables AAD, AAE, AAF and AAG.

Table AAA. Probe Name Ag1371

Primers	Sequences	Length	Start Position
Forward	5'-ctcaccttcacacccctatgta-3' (SEQ ID NO:479)	22	938
Probe	TET-5'-ctttctggggaacctctccttcttgg-3'-TAMRA (SEQ ID NO:480)	26	909
Reverse	5'-gaatagagggtggtggtgtagca-3' (SEQ ID NO:481)	22	882

Table AAB. Probe Name Ag1656

Primers	Sequences	Length	Start Position
Forward	5'-tgataacattctgtgggacccat-3' (SEQ ID NO:482)	22	353
Probe	TET-5'-cctcatgtacatgaagcccaagtctca-3'-TAMRA (SEQ ID NO:483)	27	323
Reverse	5'-ggcatccaagtcattctgaatta-3' (SEQ ID NO:484)	22	292

Table AAC. Probe Name Ag2014

Primers	Sequences	Length	Start Position
Forward	5'-ctcaccttcacacccctatgta-3' (SEQ ID NO:485)	22	938
Probe	TET-5'-ctttctggggaacctctccttcttgg-3'-TAMRA (SEQ ID NO:486)	26	909
Reverse	5'-gaatagagggtggtggtgtagca-3' (SEQ ID NO:487)	22	882

Table AAD. Panel 1.2

Tissue Name	Rel. Exp.(%) Ag1371, Run 133713412	Tissue Name	Rel. Exp.(%) Ag1371, Run 133713412
Endothelial cells	0.0	Renal ca. 786-0	0.0
Heart (Fetal)	0.8	Renal ca. A498	11.7
Pancreas	0.0	Renal ca. RXF 393	0.0
Pancreatic ca. CAPAN 2	0.0	Renal ca. ACHN	0.1
Adrenal Gland	1.2	Renal ca. UO-31	0.3
Thyroid	5.3	Renal ca. TK-10	0.0
Salivary gland	0.0	Liver	16.0
Pituitary gland	35.6	Liver (fetal)	1.3
Brain (fetal)	3.0	Liver ca. (hepatoblast) HepG2	0.0
Brain (whole)	3.7	Lung	0.1
Brain (amygdala)	15.9	Lung (fetal)	0.0

Brain (cerebellum)	1.8	Lung ca. (small cell) LX-1	0.0
Brain (hippocampus)	24.1	Lung ca. (small cell) NCI-H69	18.2
Brain (thalamus)	13.9	Lung ca. (s.cell var.) SHP-77	0.3
Cerebral Cortex	100.0	Lung ca. (large cell)NCI-H460	0.0
Spinal cord	6.4	Lung ca. (non-sm. cell) A549	2.8
glio/astro U87-MG	0.8	Lung ca. (non-s.cell) NCI-H23	0.0
glio/astro U-118-MG	0.1	Lung ca. (non-s.cell) HOP-62	4.5
astrocytoma SW1783	0.0	Lung ca. (non-s.cl) NCI-H522	0.0
neuro*; met SK-N-AS	0.7	Lung ca. (squam.) SW 900	1.6
astrocytoma SF-539	1.4	Lung ca. (squam.) NCI-H596	2.6
astrocytoma SNB-75	0.0	Mammary gland	0.1
glioma SNB-19	4.4	Breast ca.* (pl.ef) MCF-7	0.0
glioma U251	0.0	Breast ca.* (pl.ef) MDA-MB-231	0.0
glioma SF-295	0.8	Breast ca.* (pl. ef) T47D	1.8
Heart	0.0	Breast ca. BT-549	2.0
Skeletal Muscle	1.6	Breast ca. MDA-N	0.5
Bone marrow	0.4	Ovary	4.1
Thymus	1.0	Ovarian ca. OVCAR- 3	14.2
Spleen	2.0	Ovarian ca. OVCAR- 4	3.5
Lymph node	0.3	Ovarian ca. OVCAR- 5	14.9
Colorectal Tissue	8.0	Ovarian ca. OVCAR- 8	3.7
Stomach	0.0	Ovarian ca. IGROV-1	2.0
Small intestine	1.6	Ovarian ca. (ascites) SK-OV-3	0.0

Colon ca. SW480	0.0	Uterus	0.0
Colon ca.* SW620 (SW480 met)	0.0	Placenta	0.0
Colon ca. HT29	1.2	Prostate	0.0
Colon ca. HCT-116	0.0	Prostate ca.* (bone met) PC-3	11.7
Colon ca. CaCo-2	3.5	Testis	1.4
Colon ca. Tissue (ODO3866)	30.6	Melanoma Hs688(A).T	0.0
Colon ca. HCC-2998	0.0	Melanoma* (met) Hs688(B).T	1.2
Gastric ca.* (liver met) NCI-N87	0.1	Melanoma UACC-62	0.0
Bladder	5.0	Melanoma M14	8.2
Trachea	0.1	Melanoma LOX IMVI	0.0
Kidney	0.2	Melanoma* (met) SK-MEL-5	0.0
Kidney (fetal)	18.0		

Table AAE. Panel 1.3D

Tissue Name	Rel. Exp.(%) Ag2014, Run 147837460	Tissue Name	Rel. Exp.(%) Ag2014, Run 147837460
Liver adenocarcinoma	0.0	Kidney (fetal)	7.0
Pancreas	0.0	Renal ca. 786-0	9.9
Pancreatic ca. CAPAN 2	0.0	Renal ca. A498	66.9
Adrenal gland	0.0	Renal ca. RXF 393	0.0
Thyroid	9.9	Renal ca. ACHN	0.0
Salivary gland	0.0	Renal ca. UO-31	0.0
Pituitary gland	74.7	Renal ca. TK-10	0.0
Brain (fetal)	9.5	Liver	0.0
Brain (whole)	43.8	Liver (fetal)	0.0
Brain (amygdala)	15.0	Liver ca. (hepatoblast) HepG2	6.7
Brain (cerebellum)	17.8	Lung	0.0
Brain (hippocampus)	31.9	Lung (fetal)	9.6
Brain (substantia nigra)	0.0	Lung ca. (small cell) LX-1	17.3

Brain (thalamus)	6.9	Lung ca. (small cell) NCI-H69	0.0
Cerebral Cortex	89.5	Lung ca. (s.cell var.) SHP-77	7.4
Spinal cord	25.2	Lung ca. (large cell)NCI-H460	0.0
glio/astro U87-MG	5.4	Lung ca. (non-sm. cell) A549	0.0
glio/astro U-118-MG	0.0	Lung ca. (non-s.cell) NCI-H23	11.0
astrocytoma SW1783	5.8	Lung ca. (non-s.cell) HOP-62	3.8
neuro*; met SK-N-AS	8.5	Lung ca. (non-s.cl) NCI-H522	0.0
astrocytoma SF-539	5.5	Lung ca. (squam.) SW 900	15.5
astrocytoma SNB-75	0.0	Lung ca. (squam.) NCI-H596	0.0
glioma SNB-19	0.0	Mammary gland	0.0
glioma U251	0.0	Breast ca.* (pl.ef) MCF-7	0.0
glioma SF-295	0.0	Breast ca.* (pl.ef) MDA-MB-231	0.0
Heart (fetal)	0.0	Breast ca.* (pl.ef) T47D	0.0
Heart	0.0	Breast ca. BT-549	5.8
Skeletal muscle (fetal)	79.0	Breast ca. MDA-N	0.0
Skeletal muscle	0.0	Ovary	4.5
Bone marrow	0.0	Ovarian ca. OVCAR- 3	100.0
Thymus	11.8	Ovarian ca. OVCAR- 4	0.0
Spleen	9.1	Ovarian ca. OVCAR- 5	10.6
Lymph node	8.2	Ovarian ca. OVCAR- 8	0.0
Colorectal	60.7	Ovarian ca. IGROV-1	0.0
Stomach	0.0	Ovarian ca.* (ascites) SK-OV-3	28.7
Small intestine	0.0	Uterus	0.0
Colon ca. SW480	0.0	Placenta	0.0

Colon ca.* SW620(SW480 met)	0.0	Prostate	0.0
Colon ca. HT29	0.0	Prostate ca.* (bone met)PC-3	7.4
Colon ca. HCT-116	0.0	Testis	31.0
Colon ca. CaCo-2	9.2	Melanoma Hs688(A).T	0.0
Colon ca. tissue(ODO3866)	4.6	Melanoma* (met) Hs688(B).T	37.6
Colon ca. HCC-2998	6.8	Melanoma UACC-62	0.0
Gastric ca.* (liver met) NCI-N87	22.1	Melanoma M14	0.0
Bladder	0.0	Melanoma LOX IMVI	0.0
Trachea	42.9	Melanoma* (met) SK-MEL-5	0.0
Kidney	7.3	Adipose	0.0

Table AAF. Panel 2.2

Tissue Name	Rel. Exp.(%) Ag2014, Run 174232805	Tissue Name	Rel. Exp.(%) Ag2014, Run 174232805
Normal Colon	11.0	Kidney Margin (OD04348)	34.6
Colon cancer (OD06064)	0.0	Kidney malignant cancer (OD06204B)	9.7
Colon Margin (OD06064)	0.0	Kidney normal adjacent tissue (OD06204E)	0.0
Colon cancer (OD06159)	0.0	Kidney Cancer (OD04450-01)	29.5
Colon Margin (OD06159)	0.0	Kidney Margin (OD04450-03)	31.4
Colon cancer (OD06297- 04)	15.1	Kidney Cancer 8120613	0.0
Colon Margin (OD06297-015)	0.0	Kidney Margin 8120614	0.0
CC Gr.2 ascend colon (ODO3921)	0.0	Kidney Cancer 9010320	0.0
CC Margin (ODO3921)	0.0	Kidney Margin 9010321	12.3
Colon cancer metastasis (OD06104)	0.0	Kidney Cancer 8120607	0.0

Lung Margin (OD06104)	0.0	Kidney Margin 8120608	0.0
Colon mets to lung (OD04451-01)	0.0	Normal Uterus	0.0
Lung Margin (OD04451-02)	0.0	Uterine Cancer 064011	54.7
Normal Prostate	0.0	Normal Thyroid	0.0
Prostate Cancer (OD04410)	0.0	Thyroid Cancer 064010	8.5
Prostate Margin (OD04410)	0.0	Thyroid Cancer A302152	95.9
Normal Ovary	54.3	Thyroid Margin A302153	0.0
Ovarian cancer (OD06283-03)	0.0	Normal Breast	35.6
Ovarian Margin (OD06283-07)	13.9	Breast Cancer (OD04566)	0.0
Ovarian Cancer 064008	70.2	Breast Cancer 1024	16.4
Ovarian cancer (OD06145)	0.0	Breast Cancer (OD04590-01)	0.0
Ovarian Margin (OD06145)	30.6	Breast Cancer Mets (OD04590-03)	21.3
Ovarian cancer (OD06455-03)	0.0	Breast Cancer Metastasis (OD04655-05)	12.7
Ovarian Margin (OD06455-07)	2.7	Breast Cancer 064006	0.0
Normal Lung	0.0	Breast Cancer 9100266	0.0
Invasive poor diff. lung adeno (OD04945-01)	2.7	Breast Margin 9100265	17.8
Lung Margin (OD04945-03)	0.0	Breast Cancer A209073	0.0
Lung Malignant Cancer (OD03126)	0.0	Breast Margin A2090734	36.1
Lung Margin (OD03126)	0.0	Breast cancer (OD06083)	21.0
Lung Cancer (OD05014A)	0.0	Breast cancer node metastasis (OD06083)	20.3
Lung Margin (OD05014B)	0.0	Normal Liver	85.9
Lung cancer (OD06081)	0.0	Liver Cancer 1026	0.0
Lung Margin (OD06081)	14.3	Liver Cancer 1025	85.9

Lung Cancer (OD04237-01)	0.0	Liver Cancer 6004-T	31.9
Lung Margin (OD04237-02)	0.0	Liver Tissue 6004-N	0.0
Ocular Melanoma Metastasis	0.0	Liver Cancer 6005-T	0.0
Ocular Melanoma Margin (Liver)	0.0	Liver Tissue 6005-N	35.6
Melanoma Metastasis	0.0	Liver Cancer 064003	0.0
Melanoma Margin (Lung)	0.0	Normal Bladder	0.0
Normal Kidney	12.8	Bladder Cancer 1023	0.0
Kidney Ca, Nuclear grade 2 (OD04338)	37.6	Bladder Cancer A302173	0.0
Kidney Margin (OD04338)	18.6	Normal Stomach	14.1
Kidney Ca Nuclear grade 1/2 (OD04339)	100.0	Gastric Cancer 9060397	0.0
Kidney Margin (OD04339)	0.0	Stomach Margin 9060396	17.2
Kidney Ca, Clear cell type (OD04340)	0.0	Gastric Cancer 9060395	0.0
Kidney Margin (OD04340)	21.5	Stomach Margin 9060394	0.0
Kidney Ca, Nuclear grade 3 (OD04348)	0.0	Gastric Cancer 064005	0.0

Table AAG. Panel 4D

Tissue Name	Rel. Exp.(%) Ag2014, Run 158961232	Tissue Name	Rel. Exp.(%) Ag2014, Run 158961232
Secondary Th1 act	0.0	HUVEC IL-1beta	0.0
Secondary Th2 act	0.0	HUVEC IFN gamma	0.0
Secondary Tr1 act	0.0	HUVEC TNF alpha + IFN gamma	0.0
Secondary Th1 rest	0.0	HUVEC TNF alpha + IL4	0.0
Secondary Th2 rest	0.0	HUVEC IL-11	0.0
Secondary Tr1 rest	0.0	Lung Microvascular EC none	0.0
Primary Th1 act	0.0	Lung Microvascular EC	0.0

		TNFalpha + IL-1beta	
Primary Th2 act	0.0	Microvascular Dermal EC none	0.0
Primary Tr1 act	0.0	Microvasular Dermal EC TNFalpha + IL-1beta	0.0
Primary Th1 rest	0.0	Bronchial epithelium TNFalpha + IL1beta	0.0
Primary Th2 rest	0.0	Small airway epithelium none	0.0
Primary Tr1 rest	0.0	Small airway epithelium TNFalpha + IL-1beta	0.0
CD45RA CD4 lymphocyte act	0.0	Coronery artery SMC rest	0.0
CD45RO CD4 lymphocyte act	0.0	Coronery artery SMC TNFalpha + IL-1beta	0.0
CD8 lymphocyte act	0.0	Astrocytes rest	0.0
Secondary CD8 lymphocyte rest	0.0	Astrocytes TNFalpha + IL-1beta	0.0
Secondary CD8 lymphocyte act	0.0	KU-812 (Basophil) rest	0.0
CD4 lymphocyte none	0.0	KU-812 (Basophil) PMA/ionomycin	0.0
2ry Th1/Th2/Tr1_anti-CD95 CH11	0.0	CCD1106 (Keratinocytes) none	0.0
LAK cells rest	0.0	CCD1106 (Keratinocytes) TNFalpha + IL-1beta	0.0
LAK cells IL-2	0.0	Liver cirrhosis	0.0
LAK cells IL-2+IL-12	0.0	Lupus kidney	0.0
LAK cells IL-2+IFN gamma	0.0	NCI-H292 none	0.0
LAK cells IL-2+ IL-18	0.0	NCI-H292 IL-4	0.0
LAK cells PMA/ionomycin	0.0	NCI-H292 IL-9	100.0
NK Cells IL-2 rest	0.0	NCI-H292 IL-13	0.0
Two Way MLR 3 day	0.0	NCI-H292 IFN gamma	0.0
Two Way MLR 5 day	0.0	HPAEC none	0.0
Two Way MLR 7 day	0.0	HPAEC TNF alpha + IL-1 beta	0.0
PBMC rest	0.0	Lung fibroblast none	0.0
PBMC PWM	0.0	Lung fibroblast TNF alpha + IL-1 beta	0.0

PBMC PHA-L	0.0	Lung fibroblast IL-4	0.0
Ramos (B cell) none	0.0	Lung fibroblast IL-9	0.0
Ramos (B cell) ionomycin	0.0	Lung fibroblast IL-13	0.0
B lymphocytes PWM	0.0	Lung fibroblast IFN gamma	0.0
B lymphocytes CD40L and IL-4	0.0	Dermal fibroblast CCD1070 rest	0.0
EOL-1 dbcAMP	0.0	Dermal fibroblast CCD1070 TNF alpha	0.0
EOL-1 dbcAMP PMA/ionomycin	0.0	Dermal fibroblast CCD1070 IL-1 beta	0.0
Dendritic cells none	0.0	Dermal fibroblast IFN gamma	0.0
Dendritic cells LPS	0.0	Dermal fibroblast IL-4	0.0
Dendritic cells anti-CD40	0.0	IBD Colitis 2	0.0
Monocytes rest	0.0	IBD Crohn's	0.0
Monocytes LPS	0.0	Colon	0.0
Macrophages rest	0.0	Lung	0.0
Macrophages LPS	0.0	Thymus	0.0
HUVEC none	0.0	Kidney	0.0
HUVEC starved	0.0		

Panel 1.2 Summary: Ag1371 Expression of the CG56616-01 gene in this panel is seen in a number of normal tissues including colon, small intestine, bone marrow, thymus, spleen, lymph node, bladder, fetal kidney, ovary, and testis.

In addition, the CG56616-01 transcript is present in a number of metabolically relevant tissues, with low expression in adrenal gland (CT = 33) and skeletal muscle (CT = 32.6), and moderate expression in thyroid (CT = 30.8), pituitary (CT = 28) and liver (CT = 29.2). Therefore, this gene product may be involved in signal transduction pathways in thyroid, pituitary and liver, and may be a drug target for any disease involving one or more of these tissues. For example, this GPCR shows high expression in the pituitary, which controls much endocrine secretion through response to hypophysiotrophic hormones (such as thyrotropin-releasing hormone, somatostatin, somatocrinin, gonadotropin-releasing hormone, corticotropin-releasing hormone) in the posterior pituitary, and response to peripheral hormones (e.g., estrogen, testosterone, etc) in the anterior

pituitary. There are a number of diseases associated with pituitary pathophysiology, including hyper- and hypothyroidism, gigantism, dwarfism, acromegaly, Addison's disease, Cushing's disease, diabetes insipidus. Therefore, therapeutic modulation, blockade, treatment with antagonists, or stimulation of the GPCR encoded by the CG56616-01 gene may be useful in the treatment of one or more of these diseases.

The CG56616-01 gene is expressed at low to moderate levels throughout the CNS, including in amygdala, cerebellum, hippocampus, thalamus, spinal cord and developing brain, with highest expression in cerebral cortex (CT = 26.6). The CG56616-01 gene encodes a putative GPCR. Several neurotransmitter receptors are GPCRs, including the dopamine receptor family, the serotonin receptor family, the GABAB receptor, muscarinic acetylcholine receptors, and others; thus this GPCR may represent a novel neurotransmitter receptor. Targeting various neurotransmitter receptors (dopamine, serotonin) has proven to be an effective therapy in psychiatric illnesses such as schizophrenia, bipolar disorder and depression. Furthermore, the cerebral cortex and hippocampus are regions of the brain that are known to play critical roles in Alzheimer's disease, seizure disorders, and in the normal process of memory formation. Therefore, therapeutic modulation of the CG56616-01 gene or its protein product may be beneficial in the treatment of one or more of these diseases, as may stimulation and/or blockade of the receptor coded for by the gene. Levels of this gene are high, however, in areas outside of the central nervous system (such as the liver), suggesting the possibility of a wider role in intercellular signaling.

Interestingly, the CG56616-01 gene appears to be expressed by a cluster of cell lines derived from melanoma, prostate cancer, lung cancer and ovarian cancer. In addition, this gene seems to be more highly expressed by adult liver when compared to fetal liver and expressed more highly in fetal kidney when compared to adult kidney. Thus, these data indicate that expression of the CG56616-01 gene might be useful in the distinction of adult vs. fetal liver or kidney tissue. Therapeutic application of the CG56616-01 protein might be of use in the treatment of diseases involving the liver in which the diseased state resembles fetal liver. In contrast this gene seems to be expressed by fetal kidney when compared to adult kidney. Thus, application of the CG56616-01 protein might be useful in the treatment of kidney disorders that require tissue regeneration. Also, therapeutic modulation of the CG56616-01 gene product, through the use of small

molecule drugs or antibodies might be of use in the treatment of ovarian cancer, prostate cancer, lung cancer or melanoma.

Panel 1.3D Summary: Ag2014 Significant expression of the CG56616-01 gene is detected in pituitary gland (CT = 34.7), cerebral cortex (CT = 34.5), fetal skeletal muscle (CT = 34.6), and an ovarian cancer cell line (CT = 34.3). These results are consistent with what is observed in other panels and the potential implications are discussed above and below. A second experiment with the probe/primer set Ag1656 shows low/undetectable levels of expression in all the samples on this panel (CTs>35).

Panel 2.2 Summary: Ag2014 Expression of the CG56616-01 gene in panel 2.2 is generally low. However, there is significant expression in samples from kidney cancer, thyroid cancer, liver derived tissue (both normal and malignant) and ovarian derived tissue (both normal and malignant). Of particular interest is the comparison of CG56616-01 gene expression between samples of kidney and thyroid cancers and their respective normal adjacent tissue samples. In both cases the CG56616-01 gene is overexpressed in the malignant tissue when compared to the normal adjacent tissue. Thus, based on these data, therapeutic modulation of the activity of the CG56616-01 gene product, through the use of small molecule drugs or antibodies, may be of use in the treatment of kidney or thyroid cancer. A second experiment with the probe/primer set Ag1656 shows low/undetectable levels of expression in all the samples on this panel (CTs>35).

Panel 4D Summary: Ag2014 The H292 lung epithelial cell line expresses the CG56616-01 gene after IL-9-stimulation. Therefore, the putative GPCR encoded by the CG56616-01 gene may be involved in lung inflammation and mucus secretion (ref. 1). Antibodies or small molecule therapeutics that block the function of this membrane protein may thus be useful as anti-inflammatory therapeutics for the treatment of asthma and emphysema. Very low expression is also detected in a number of other samples including IBD colitis 2 (CT = 34.1), Crohn's (CT = 34.9), thymus (CT = 34.8), kidney (CT = 34.8), monocytes treated with LPS (CT = 34.7) and astrocytes treated with TNFalpha + IL-1beta (CT = 34). A second experiment with the probe/primer set Ag1656 shows low/undetectable levels of expression in all the samples on this panel (CTs>35).

References:

1. Louahed J., Toda M., Jen J., Hamid Q., Renauld J.C., Levitt R.C., Nicolaides N.C. (2000) Interleukin-9 upregulates mucus expression in the airways. Am. J. Respir. Cell. Mol. Biol. 22: 649-656.

2. Interleukin (IL)-9 has recently been shown to play an important role in allergic disease because its expression is strongly associated with the degree of airway responsiveness and the asthmatic-like phenotype. IL-9 is a pleiotropic cytokine that is active on many cell types involved in the allergic immune response. Mucus hypersecretion is a clinical feature of chronic airway diseases; however, the mechanisms underlying the induction of mucin are poorly understood. In this report, we show that IL-9 regulates the expression of a subset of mucin genes in lung cells both in vivo and in vitro. In vivo, the constitutive expression of IL-9 in transgenic mice results in elevated MUC2 and MUC5AC gene expression in airway epithelial cells and periodic acid-Schiff-positive staining (reflecting mucous glycogenates). Similar results were observed in C57BL/6J mice after IL-9 intratracheal instillation. In contrast, instillation of the Thelper 1-associated cytokine interferon gamma failed to induce mucin production. In vitro, our studies showed that IL-9 also induces expression of MUC2 and MUC5AC in human primary lung cultures and in the human mucocoeptidermoid NCI-H292 cell line, indicating a direct effect of IL-9 on inducing mucin expression in these cells. Altogether, these results suggest that upregulation of mucin by IL-9 might contribute to the pathogenesis of human inflammatory airway disorders, such as asthma. These data extend the role of the biologic processes that IL-9 has on regulating the many clinical features of asthma and further supports the IL-9 pathway as a key mediator of the asthmatic response.

NOV32: 153065222/CG56234-02: Splice variant of PCK2

Expression of gene CG56234-02 was assessed using the primer-probe set Ag5111, described in Table ABA. Results of the RTQ-PCR runs are shown in Tables ABB and ABC.

Table ABA. Probe Name Ag5111

Primers	Sequences	Length	Start Position
---------	-----------	--------	----------------

Forward	5'-ctgggaggccccaga-3' (SEQ ID NO:488)	15	1377
Probe	TET-5'-tgtcccatgtgacgccatcatc-3'-TAMRA (SEQ ID NO:489)	22	1395
Reverse	5'-gatgatcttcccttgggtct-3' (SEQ ID NO:490)	21	1429

Table ABB. General_screening_panel_v1.5

Tissue Name	Rel. Exp.(%) Ag5111, Run 228980587	Tissue Name	Rel. Exp.(%) Ag5111, Run 228980587
Adipose	2.0	Renal ca. TK-10	29.1
Melanoma* Hs688(A).T	31.9	Bladder	12.1
Melanoma* Hs688(B).T	28.3	Gastric ca. (liver met.) NCI-N87	31.4
Melanoma* M14	9.9	Gastric ca. KATO III	28.1
Melanoma* LOXIMVI	4.5	Colon ca. SW-948	17.9
Melanoma* SK- MEL-5	39.8	Colon ca. SW480	14.9
Squamous cell carcinoma SCC-4	4.7	Colon ca.* (SW480 met) SW620	29.5
Testis Pool	1.6	Colon ca. HT29	8.6
Prostate ca.* (bone met) PC-3	55.1	Colon ca. HCT-116	11.0
Prostate Pool	0.5	Colon ca. CaCo-2	44.4
Placenta	0.3	Colon cancer tissue	9.7
Uterus Pool	0.6	Colon ca. SW1116	1.4
Ovarian ca. OVCAR- 3	13.6	Colon ca. Colo-205	6.6
Ovarian ca. SK-OV- 3	5.3	Colon ca. SW-48	14.4
Ovarian ca. OVCAR- 4	7.1	Colon Pool	0.1
Ovarian ca. OVCAR- 5	34.6	Small Intestine Pool	0.6
Ovarian ca. IGROV- 1	22.5	Stomach Pool	1.1
Ovarian ca. OVCAR- 8	100.0	Bone Marrow Pool	0.5
Ovary	0.0	Fetal Heart	0.0
Breast ca. MCF-7	87.7	Heart Pool	0.0

Breast ca. MDA-MB-231	12.6	Lymph Node Pool	0.8
Breast ca. BT 549	75.8	Fetal Skeletal Muscle	0.6
Breast ca. T47D	10.1	Skeletal Muscle Pool	0.4
Breast ca. MDA-N	16.4	Spleen Pool	1.7
Breast Pool	0.5	Thymus Pool	0.4
Trachea	4.3	CNS cancer (glio/astro) U87-MG	18.8
Lung	0.0	CNS cancer (glio/astro) U-118-MG	9.3
Fetal Lung	2.0	CNS cancer (neuro;met) SK-N-AS	7.5
Lung ca. NCI-N417	1.8	CNS cancer (astro) SF-539	11.3
Lung ca. LX-1	8.2	CNS cancer (astro) SNB-75	48.6
Lung ca. NCI-H146	11.1	CNS cancer (glio) SNB-19	31.0
Lung ca. SHP-77	11.3	CNS cancer (glio) SF-295	32.5
Lung ca. A549	11.4	Brain (Amygdala) Pool	0.4
Lung ca. NCI-H526	1.8	Brain (cerebellum)	0.3
Lung ca. NCI-H23	83.5	Brain (fetal)	0.3
Lung ca. NCI-H460	27.0	Brain (Hippocampus) Pool	2.5
Lung ca. HOP-62	1.0	Cerebral Cortex Pool	0.4
Lung ca. NCI-H522	67.4	Brain (Substantia nigra) Pool	0.0
Liver	6.3	Brain (Thalamus) Pool	1.0
Fetal Liver	6.7	Brain (whole)	0.7
Liver ca. HepG2	24.7	Spinal Cord Pool	1.1
Kidney Pool	0.8	Adrenal Gland	1.6
Fetal Kidney	1.0	Pituitary gland Pool	0.4
Renal ca. 786-0	8.7	Salivary Gland	0.9
Renal ca. A498	1.5	Thyroid (female)	0.7
Renal ca. ACHN	9.3	Pancreatic ca. CAPAN2	12.8
Renal ca. UO-31	1.9	Pancreas Pool	0.8

Table ABC. Panel 4.1D

Tissue Name	Rel. Exp.(%) Ag5111, Run 226444761	Tissue Name	Rel. Exp.(%) Ag5111, Run 226444761
Secondary Th1 act	90.8	HUVEC IL-1beta	18.7
Secondary Th2 act	40.9	HUVEC IFN gamma	2.8
Secondary Tr1 act	57.4	HUVEC TNF alpha + IFN gamma	5.0
Secondary Th1 rest	27.2	HUVEC TNF alpha + IL4	23.2
Secondary Th2 rest	6.0	HUVEC IL-11	2.3
Secondary Tr1 rest	7.2	Lung Microvascular EC none	3.2
Primary Th1 act	32.8	Lung Microvascular EC TNFalpha + IL-1beta	6.4
Primary Th2 act	49.0	Microvascular Dermal EC none	6.6
Primary Tr1 act	50.0	Microvascular Dermal EC TNFalpha + IL-1beta	0.0
Primary Th1 rest	6.0	Bronchial epithelium TNFalpha + IL1beta	8.7
Primary Th2 rest	6.4	Small airway epithelium none	2.2
Primary Tr1 rest	18.0	Small airway epithelium TNFalpha + IL-1beta	11.8
CD45RA CD4 lymphocyte act	95.9	Coronary artery SMC rest	18.3
CD45RO CD4 lymphocyte act	95.3	Coronary artery SMC TNFalpha + IL-1beta	9.4
CD8 lymphocyte act	77.4	Astrocytes rest	2.1
Secondary CD8 lymphocyte rest	90.1	Astrocytes TNFalpha + IL- 1beta	0.0
Secondary CD8 lymphocyte act	21.0	KU-812 (Basophil) rest	25.9
CD4 lymphocyte none	0.0	KU-812 (Basophil) PMA/ionomycin	26.8
2ry Th1/Th2/Tr1_anti- CD95 CH11	5.4	CCD1106 (Keratinocytes) none	15.2
LAK cells rest	43.5	CCD1106 (Keratinocytes) TNFalpha + IL-1beta	9.0
LAK cells IL-2	52.1	Liver cirrhosis	8.3
LAK cells IL-2+IL-12	33.7	NCI-H292 none	15.3
LAK cells IL-2+IFN	57.0	NCI-H292 IL-4	13.5

gamma			
LAK cells IL-2+ IL-18	46.0	NCI-H292 IL-9	14.2
LAK cells PMA/ionomycin	43.5	NCI-H292 IL-13	29.1
NK Cells IL-2 rest	60.7	NCI-H292 IFN gamma	44.8
Two Way MLR 3 day	32.1	HPAEC none	2.0
Two Way MLR 5 day	53.2	HPAEC TNF alpha + IL-1 beta	7.2
Two Way MLR 7 day	23.5	Lung fibroblast none	21.2
PBMC rest	6.1	Lung fibroblast TNF alpha + IL-1 beta	11.5
PBMC PWM	23.5	Lung fibroblast IL-4	2.4
PBMC PHA-L	35.8	Lung fibroblast IL-9	17.6
Ramos (B cell) none	58.6	Lung fibroblast IL-13	13.4
Ramos (B cell) ionomycin	71.7	Lung fibroblast IFN gamma	11.6
B lymphocytes PWM	21.6	Dermal fibroblast CCD1070 rest	99.3
B lymphocytes CD40L and IL-4	29.7	Dermal fibroblast CCD1070 TNF alpha	74.7
EOL-1 dbcAMP	32.3	Dermal fibroblast CCD1070 IL-1 beta	29.9
EOL-1 dbcAMP PMA/ionomycin	10.6	Dermal fibroblast IFN gamma	13.3
Dendritic cells none	66.0	Dermal fibroblast IL-4	12.2
Dendritic cells LPS	31.4	Dermal Fibroblasts rest	0.0
Dendritic cells anti- CD40	48.3	Neutrophils TNFa+LPS	0.0
Monocytes rest	29.1	Neutrophils rest	0.0
Monocytes LPS	37.6	Colon	32.3
Macrophages rest	100.0	Lung	3.5
Macrophages LPS	28.1	Thymus	12.1
HUVEC none	7.9	Kidney	83.5
HUVEC starved	17.4		

CNS_neurodegeneration_v1.0 Summary: Ag5111 Expression of the CG56234-02 gene is low/undetectable in all samples on this panel (CTs>35).

General_screening_panel_v1.5 Summary: Ag5111 Highest expression of the CG56234-02 gene is seen in an ovarian cancer cell line (CT=30). This gene encodes a splice variant of

PEPCK2, the rate-limiting enzyme in gluconeogenesis that has been shown to be regulated in response to hormones and environmental stress. In addition, to the ovarian cancer cell line, this gene is expressed at a moderate level in most of the cancer cell lines used in this panel.

Therefore, modulation of the gene product using small molecule drugs may affect the growth and survival of cancer cells. Expression of this gene could potentially be used as a diagnostic marker of the metabolic status of cells and inhibition of activity of this gene product might be used for therapeutic treatment of cancers.

This gene is also moderately expressed (CT values = 34) in adult and fetal liver. Inhibition of this enzyme could potentially decrease hepatic glucose production and thus serve as an effective treatment for Type 2 diabetes, which is characterized by excess hepatic glucose production.

Panel 4.1D Summary: Ag 5111 The CG56234-02 transcript is expressed at low levels in a wide range of cell across this panel (CTs=33.3-34.4), including CD4 T cells (naive and memory T cells), CD8 T cells, B cells and macrophages. Expression of this transcript is also found in dermal fibroblasts and kidney. This transcript encodes a homolog of a key enzyme in glucogenesis and therefore may be important for the metabolic status of all these cell types that contribute to the inflammatory response. Therefore, modulation of the activity or expression of this putative protein by small molecules could affect the activity of these cells and be useful for the treatment of autoimmune diseases such as inflammatory bowel diseases, rheumatoid arthritis, asthma, COPD, psoriasis and lupus.

Example 2. SNP analysis of NOVX clones

SeqCalling™ Technology: cDNA was derived from various human samples representing multiple tissue types, normal and diseased states, physiological states, and developmental states from different donors. Samples were obtained as whole tissue, cell lines, primary cells or tissue cultured primary cells and cell lines. Cells and cell lines may have been treated with biological or chemical agents that regulate gene expression for example, growth factors, chemokines, steroids. The cDNA thus derived was then sequenced using CuraGen's proprietary SeqCalling technology. Sequence traces were evaluated manually and edited for corrections if appropriate. cDNA sequences from all samples were assembled with themselves and with public ESTs using bioinformatics programs to generate CuraGen's human SeqCalling

database of SeqCalling assemblies. Each assembly contains one or more overlapping cDNA sequences derived from one or more human samples. Fragments and ESTs were included as components for an assembly when the extent of identity with another component of the assembly was at least 95% over 50 bp. Each assembly can represent a gene and/or its variants such as splice forms and/or single nucleotide polymorphisms (SNPs) and their combinations.

Variant sequences are included in this application. A variant sequence can include a single nucleotide polymorphism (SNP). A SNP can, in some instances, be referred to as a "cSNP" to denote that the nucleotide sequence containing the SNP originates as a cDNA. A SNP can arise in several ways. For example, a SNP may be due to a substitution of one nucleotide for another at the polymorphic site. Such a substitution can be either a transition or a transversion. A SNP can also arise from a deletion of a nucleotide or an insertion of a nucleotide, relative to a reference allele. In this case, the polymorphic site is a site at which one allele bears a gap with respect to a particular nucleotide in another allele. SNPs occurring within genes may result in an alteration of the amino acid encoded by the gene at the position of the SNP. Intragenic SNPs may also be silent, however, in the case that a codon including a SNP encodes the same amino acid as a result of the redundancy of the genetic code. SNPs occurring outside the region of a gene, or in an intron within a gene, do not result in changes in any amino acid sequence of a protein but may result in altered regulation of the expression pattern for example, alteration in temporal expression, physiological response regulation, cell type expression regulation, intensity of expression, stability of transcribed message.

Method of novel SNP Identification: SNPs are identified by analyzing sequence assemblies using CuraGen's proprietary SNPTool algorithm. SNPTool identifies variation in assemblies with the following criteria: SNPs are not analyzed within 10 base pairs on both ends of an alignment; Window size (number of bases in a view) is 10; The allowed number of mismatches in a window is 2; Minimum SNP base quality (PHRED score) is 23; Minimum number of changes to score an SNP is 2/assembly position. SNPTool analyzes the assembly and displays SNP positions, associated individual variant sequences in the assembly, the depth of the assembly at that given position, the putative assembly allele frequency, and the SNP sequence variation. Sequence traces are then selected and brought into view for manual validation. The consensus assembly sequence is imported into CuraTools along with variant sequence changes to

identify potential amino acid changes resulting from the SNP sequence variation. Comprehensive SNP data analysis is then exported into the SNPCalling database.

Method of novel SNP Confirmation:

SNPs are confirmed employing a validated method known as Pyrosequencing

(Pyrosequencing, Westborough, MA). Detailed protocols for Pyrosequencing can be found in: Alderborn et al. Determination of Single Nucleotide Polymorphisms by Real-time

Pyrophosphate DNA Sequencing. (2000). *Genome Research*. 10, Issue 8, August. 1249-1265.

In brief, Pyrosequencing is a real time primer extension process of genotyping. This protocol takes double-stranded, biotinylated PCR products from genomic DNA samples and binds them

to streptavidin beads. These beads are then denatured producing single stranded bound DNA.

SNPs are characterized utilizing a technique based on an indirect bioluminometric assay of pyrophosphate (PPi) that is released from each dNTP upon DNA chain elongation. Following

Klenow polymerase-mediated base incorporation, PPi is released and used as a substrate,

together with adenosine 5'-phosphosulfate (APS), for ATP sulfurylase, which results in the

formation of ATP. Subsequently, the ATP accomplishes the conversion of luciferin to its oxidized derivative by the action of luciferase. The ensuing light output becomes proportional to the

number of added bases, up to about four bases. To allow processivity of the method dNTP excess

is degraded by apyrase, which is also present in the starting reaction mixture, so that only dNTPs

are added to the template during the sequencing. The process has been fully automated and

adapted to a 96-well format, which allows rapid screening of large SNP panels. The DNA and

protein sequences for the novel single nucleotide polymorphic variants are reported. Variants are

reported individually but any combination of all or a select subset of variants are also included.

In addition, the positions of the variant bases and the variant amino acid residues are underlined.

RESULTS

Variants are reported individually but any combination of all or a select subset of variants are also included as contemplated NOVX embodiments of the invention.

NOV4a SNP data

The DNA and protein sequences for the novel single nucleotide polymorphic variants of the Myotonic dystrophy kinase-related CDC42-binding kinase-like gene of NOV4a are reported in Table 4I. Variants are reported individually but any combination of all or a select subset of variants are also included. In summary, there are 4 variants reported .

Table 4I. cSNP and Coding Variants for NOV4a				
Variant	Base Position of cSNP	Wild Type	Variant	Amino Acid Change
13376286	204	T	C	Leu → Pro at aa 36
13376289	351	T	C	Val → Ala at aa 85
13376290	467	G	A	Val → Met at aa 124
13376281	3331	G	A	no change (silent)

NOV6 SNP data

The DNA and protein sequences for the novel single nucleotide polymorphic variants of the GPCR-like gene of NOV6 are reported in Table 6H. Variants are reported individually but any combination of all or a select subset of variants are also included. In summary, there are 2 variants reported .

Table 6H. cSNP and Coding Variants for NOV6				
Variant	Base Position of cSNP	Wild Type	Variant	Amino Acid Change
13376566	217	T	C	Ile → Thr at aa 63
13376567	1036	T	C	Val → Ala at aa 336

NOV8a SNP data

The DNA and protein sequences for the novel single nucleotide polymorphic variants of the Carboxypeptidase-like gene of NOV8a are reported in Table 8M. Variants are reported

individually but any combination of all or a select subset of variants are also included. In summary, there are 14 variants reported.

Table 8M. cSNP and Coding Variants for NOV8a

Variant	Base Position of cSNP	Wild Type	Variant	Amino Acid Change
13375069	116	A	G	Asp → Gly at aa 34
13375068	125	T	C	Val → Ala at aa 37
13375363	270	A	G	Ile → Met at aa 85
13375364	417	G	T	Arg → Ser at aa 134
13375365	579	A	T	silent
13375366	658	A	G	Thr → Ala at aa 215
13375367	674	G	A	Ser → Asn at aa 220
13375368	925	C	T	Pro → Ser at aa 304
13375063	953	A	G	Asp → Gly at aa 313
13375064	955	A	T	Ser → Cys at aa 314
13375369	963	A	G	silent
13375065	983	A	G	Glu → Gly at aa 323
13375370	1037	T	C	Leu → pro at aa 341
13375371	1083	G	A	silent

NOV8b SNP data:

- 5 In the following positions, one or more consensus positions (Cons. Pos.) of the nucleotide sequence have been identified as SNPs. NOV8b has 7 SNP variants, whose variant positions for its nucleotide and amino acid sequences is numbered according to **SEQ ID NOS:21 and 22**, respectively. The nucleotide sequence of the NOV8b variant differs as shown in **Table 8N**.

Table 8N. cSNP and Coding Variants for NOV8b

NT Position of cSNP	Wild Type NT	Variant NT
240	A	G
295	A	G

442	G	T
950	C	T
988	A	G
1062	T	C
1108	G	A

NOV9 SNP data

The DNA and protein sequences for the novel single nucleotide polymorphic variants of the Neurotransmitter Receptor-like gene of NOV9 are reported in Table 9G. Variants are reported individually but any combination of all or a select subset of variants are also included. In summary, there is 1 variant reported.

Table 9G. cSNP and Coding Variants for NOV9				
Variant	Base Position of cSNP	Wild Type	Variant	Amino Acid Change
13376754	752	T	C	silent

NOV11a SNP data

The DNA and protein sequences for the novel single nucleotide polymorphic variants of the Lysyl oxidase-like gene of NOV11a are reported in Table 11I. Variants are reported individually but any combination of all or a select subset of variants are also included. In summary, there are 3 variants reported.

Table 11I. cSNP and Coding Variants for NOV11a				
Variant	Base Position of cSNP	Wild Type	Variant	Amino Acid Change
13376750	1880	C	T	silent
13376749	2150	C	T	silent
13376748	2576	T	C	silent

NOV11b SNP data:

In the following positions, one or more consensus positions (Cons. Pos.) of the nucleotide sequence have been identified as SNPs. NOV11b has 11 SNP variants, whose variant positions for its nucleotide and amino acid sequences is numbered according to **SEQ ID NOS:33 and 34**, respectively. The nucleotide sequence of the NOV11b variant differs as shown in **Table 11J**.

Table 11J. cSNP and Coding Variants for NOV29f		
NT Position of cSNP	Wild Type NT	Variant NT
753	A	T
758	A	T
762	G	A
778	G	A
780	T	C
1711	G	C
1786	G	A
1894	T	C
2170	T	C
2589	T	C
2601	T	C

NOV12a SNP data

The DNA and protein sequences for the novel single nucleotide polymorphic variants of the Phosphatase-like gene of NOV12a are reported in Table 12 I. Variants are reported individually but any combination of all or a select subset of variants are also included. In summary, there is 1 variant reported.

Table 12I. cSNP and Coding Variants for NOV12a				
Variant	Base Position of cSNP	Wild Type	Variant	Amino Acid Change
13376751	185	C	T	silent

NOV13 SNP data

The DNA and protein sequences for the novel single nucleotide polymorphic variants of the Chloride Channel Protein CLC-KA-like gene of NOV13 are reported in Table 13G. Variants

are reported individually but any combination of all or a select subset of variants are also included. In summary, there is 1 variant reported.

In Figure 3, the positions of the variant bases and the variant amino acid residues are underlined. in figure 3. Variant is a T to C SNP at 425 bp of the nucleotide sequence that results in no change in the protein sequence (silent).

Table 13G. cSNP and Coding Variants for NOV13

Variant	Base Position of cSNP	Wild Type	Variant	Amino Acid Change
13376442	425	T	C	silent

NOV15a SNP data

The DNA and protein sequences for the novel single nucleotide polymorphic variants of the MEGF6-like gene of NOV15a are reported in Table 15Q. Variants are reported individually but any combination of all or a select subset of variants are also included. In summary, there are 4 variants reported.

Table 15Q. cSNP and Coding Variants for NOV15a

Variant	Base Position of cSNP	Wild Type	Variant	Amino Acid Change
13374463	522	C	T	silent
13374464	712	C	T	Gln → End at aa 238
13376752	6567	A	G	silent
13376753	7184	A	G	silent

NOV16 SNP data:

In the following positions, one or more consensus positions (Cons. Pos.) of the nucleotide sequence have been identified as SNPs. NOV16 has 3 SNP variants, whose variant positions for its nucleotide and amino acid sequences is numbered according to SEQ ID NOS:55 and 56, respectively. The nucleotide sequence of the NOV16 variant differs as shown in Table 16G.

Table 16G. cSNP and Coding Variants for NOV16		
NT Position of cSNP	Wild Type NT	Variant NT
485	A	C
742	T	C
831	G	T

NOV17a SNP data

- 5 The DNA and protein sequences for the novel single nucleotide polymorphic variants of the PEST-containing transporter-like gene of NOV17a are reported in Table 17I. Variants are reported individually but any combination of all or a select subset of variants are also included. In summary, there are 2 variants reported.

Table 17I. cSNP and Coding Variants for NOV17a				
Variant	Base Position of cSNP	Wild Type	Variant	Amino Acid Change
13374524	between 554 and 555		insertion of T	frameshift with all amino acids after 184 discordant
13374525	661	C	T	silent

NOV18a SNP data

- 15 The DNA and protein sequences for the novel single nucleotide polymorphic variants of the GPCR-like gene of NOV18a are reported in Table 18H. Variants are reported individually but any combination of all or a select subset of variants are also included. In summary, there are 1 variants reported.

Table 18H. cSNP and Coding Variants for NOV18a				
Variant	Base Position of cSNP	Wild Type	Variant	Amino Acid Change
13374523	477	G	A	Trp → End at aa 147

NOV18b SNP data:

In the following positions, one or more consensus positions (Cons. Pos.) of the nucleotide sequence have been identified as SNPs. NOV18b has 1 SNP variants, whose variant positions for its nucleotide and amino acid sequences is numbered according to **SEQ ID NOS:63 and 62**, respectively. The nucleotide sequence of the NOV18b variant differs as shown in **Table 18I**.

Table 18I. cSNP and Coding Variants for NOV29f		
NT Position of cSNP	Wild Type NT	Variant NT
627	G	A

NOV19b SNP data:

In the following positions, one or more consensus positions (Cons. Pos.) of the nucleotide sequence have been identified as SNPs. NOV19b has one SNP variant, whose variant positions for its nucleotide and amino acid sequences is numbered according to **SEQ ID NOS:66 and 67**, respectively. The nucleotide sequence of the NOV19b variant differs as shown in **Table 19I**.

Table 19I. cSNP and Coding Variants for NOV19b		
NT Position of cSNP	Wild Type NT	Variant NT
1682	A	G

NOV29f SNP data:

In the following positions, one or more consensus positions (Cons. Pos.) of the nucleotide sequence have been identified as SNPs. NOV29f has nine SNP variants, whose variant positions for its nucleotide and amino acid sequences is numbered according to **SEQ ID NOS:114 and 115**, respectively. The nucleotide sequence of the NOV29f variant differs as shown in **Table 29Q**.

Table 29Q. cSNP and Coding Variants for NOV29f		
NT Position of cSNP	Wild Type NT	Variant NT
135	T	C
209	G	A
258	G	A
265	T	C
273	C	T
278	A	G
436	A	G
551	A	G
735	G	A

NOV31 SNP data:

In the following positions, one or more consensus positions (Cons. Pos.) of the nucleotide sequence have been identified as SNPs. NOV31 has ten SNP variants, whose variant positions for its nucleotide and amino acid sequences is numbered according to **SEQ ID NOS:118 and 119**, respectively. The nucleotide sequence of the NOV31 variant differs as shown in **Table 31H**.

Table 31H. cSNP and Coding Variants for NOV31		
NT Position of cSNP	Wild Type NT	Variant NT
260	G	A
650	C	T
651	T	C
777	C	G
787	C	T
789	A	G
790	G	C
798	A	G
828	T	A
982	A	G

Example 3. Identification of NOVX clones

The novel NOVX target sequences identified in the present invention were subjected to the exon linking process to confirm the sequence. PCR primers were designed by starting at the

most upstream sequence available, for the forward primer, and at the most downstream sequence available for the reverse primer. Table 34A shows the sequences of the PCR primers used for obtaining different clones for NOV1-18, if any. PCR primers for NOV19-33, if any, are disclosed separately within their respective section above. In each case, the sequence was examined, walking inward from the respective termini toward the coding sequence, until a suitable sequence that is either unique or highly selective was encountered, or, in the case of the reverse primer, until the stop codon was reached. Such primers were designed based on *in silico* predictions for the full length cDNA, part (one or more exons) of the DNA or protein sequence of the target sequence, or by translated homology of the predicted exons to closely related human sequences from other species. These primers were then employed in PCR amplification based on the following pool of human cDNAs: adrenal gland, bone marrow, brain - amygdala, brain - cerebellum, brain - hippocampus, brain - substantia nigra, brain - thalamus, brain -whole, fetal brain, fetal kidney, fetal liver, fetal lung, heart, kidney, lymphoma - Raji, mammary gland, pancreas, pituitary gland, placenta, prostate, salivary gland, skeletal muscle, small intestine, spinal cord, spleen, stomach, testis, thyroid, trachea, uterus.

Table 34A. PCR Primer Sequences

NOVX Clone	Forward Primer (5' → 3')	Reverse Primer (5' → 3')
NOV3 variants	AGATCTAAGGGCCGGACCGCACTCTTCCTGGCCACG (SEQ ID NO:491)	CTCGAGTTCATCCACAGCCAGCACTGTGGCCCCATG (SEQ ID NO:492)
NOV4a	CATGGAGCGGCGGCTGC (SEQ ID NO:493)	GCACAAAAGGGTCCTTCAGCATCTC (SEQ ID NO:494)
NOV5	CTCCAACATGGCAAAAATCTCC (SEQ ID NO:495)	CAAGGGGTCCTCAGTTCCACTT (SEQ ID NO:496)
NOV7b	ATGTCGAGGCTCAGCTGGGGATAC (SEQ ID NO:497)	GGGGGAGTTCATTGGTGACAATTTTTTA (SEQ ID NO:498)
NOV8b	GATGCATTCATTCTCAAGGACACTTGA (SEQ ID NO:499)	CCTGGGCAGAATGCACTTAGAGAAGAG (SEQ ID NO:500)
NOV9	CAATGGTGAACAATTTCTCC (SEQ ID NO:501)	TCAAGTTAGTTTTGAGGTCTCTACA (SEQ ID NO:502)
NOV11b	CGCGCTCCATCTGGTATCTTG (SEQ ID NO:503)	TGACTGGGTTTCCTTACAGAAGAGGAG (SEQ ID NO:504)
NOV12b	GGAGGCCAACAGAGTCCCTACAG (SEQ ID NO:505)	CAAAGGGAAAAGGGAGTAGTAAAGCTG (SEQ ID NO:506)
NOV13	GGGCCTGATGGAGGAGTTTGTG (SEQ ID NO:507)	ATCTTGCTGGGCCGGCTCACTT (SEQ ID NO:508)
NOV16	CATGGAGACAAGAAATTACTCTGCCA (SEQ ID NO:509)	AAGCTCTCTTGCCCCATTGAGGATAT (SEQ ID NO:510)
NOV17a	GAGGCGGCTGTCGAGAAGGT (SEQ ID NO:511)	ATAATAGAGTCAGATTCTTTCTTGAACATTCCAG (SEQ ID NO:512)

Usually the resulting amplicons were gel purified, cloned and sequenced to high redundancy. The PCR product derived from exon linking was cloned into the pCR2.1 vector from Invitrogen. The resulting bacterial clone has an insert covering the entire open reading frame cloned into the pCR2.1 vector. Table 34B shows a list of these bacterial clones for NOV1-18, if any. Bacterial clones for NOV19-33, if any, are treated in their respective sections above. The resulting sequences from all clones were assembled with themselves, with other fragments in CuraGen Corporation's database and with public ESTs. Fragments and ESTs were included as components for an assembly when the extent of their identity with another component of the assembly was at least 95% over 50 bp. In addition, sequence traces were evaluated manually and edited for corrections if appropriate. These procedures provide the sequence reported herein.

Table 34B. Bacterial Clones

NOVX Clone	Bacterial Clone (Physical clone)
NOV5	AC027667.698177.A5
NOV6	117832::GM432e15_A.698346.H10 FLC EL
NOV7b	SC133786449_A.698496.E5
NOV8b	CG55794-01.698509.A5
NOV9	111169::sggc_draft_ba435e4_20000825.698301.A18
NOV11b	127289::CG56319-01.698563.B13
NOV12b	CG56436-01.698590.I11
NOV13	sggc_draft_ba254i4_20000907.698365.M10
NOV15d	121848::SC111823923_2.642041.P7
NOV16	AL359846_A.698352.F6
NOV18b	117869::sggc_draft_dj824k2_20000907.698336.H1

OTHER EMBODIMENTS

Although particular embodiments have been disclosed herein in detail, this has been done by way of example for purposes of illustration only, and is not intended to be limiting with respect to the scope of the appended claims, which follow. In particular, it is contemplated by the

5 inventors that various substitutions, alterations, and modifications may be made to the invention without departing from the spirit and scope of the invention as defined by the claims. The choice of nucleic acid starting material, clone of interest, or library type is believed to be a matter of routine for a person of ordinary skill in the art with knowledge of the embodiments described herein. Other aspects, advantages, and modifications considered to be within the scope of the
10 following claims.